<SEC-DOCUMENT>0001610618-24-000041.txt : 20240422
<SEC-HEADER>0001610618-24-000041.hdr.sgml : 20240422
<ACCEPTANCE-DATETIME>20240422165644
ACCESSION NUMBER:		0001610618-24-000041
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240422
DATE AS OF CHANGE:		20240422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		24861831

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cdtx-20231231.htm
<DESCRIPTION>CIDARA THERAPEUTICS, INC. 2023 FORM 10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fa590d2e-4039-4000-bdf7-5fb59710602c,g:d0764763-c16c-45c9-82e5-80b88e590043,d:b00951007fb342d8a49dba10256b8485-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:cdtx="http://cidara.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdtx-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0001610618</ix:nonNumeric><ix:nonNumeric contextRef="c-64" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-404">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-535">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-369" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="f-2597">0.05</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdtx-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-04-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cdtx:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="obligation"><xbrli:measure>cdtx:obligation</xbrli:measure></xbrli:unit><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdtx:JanssenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-03</xbrli:startDate><xbrli:endDate>2016-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-07</xbrli:startDate><xbrli:endDate>2023-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-12</xbrli:startDate><xbrli:endDate>2020-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-12</xbrli:startDate><xbrli:endDate>2020-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>cdtx:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-03</xbrli:startDate><xbrli:endDate>2019-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:RDFundingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponTransferOfLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponTransferOfLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponTransferOfLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>cdtx:claim</xbrli:measure></xbrli:unit><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-20</xbrli:startDate><xbrli:endDate>2023-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>cdtx:option</xbrli:measure></xbrli:unit><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-12</xbrli:startDate><xbrli:endDate>2024-04-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib00951007fb342d8a49dba10256b8485_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark&#160;One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:5.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:5.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36912</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:22pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">CIDARA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.707%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:126.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:18.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:13.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:115.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:135.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">46-1537286</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">6310 Nancy Ridge Drive,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 101</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">San Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">CA</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">92121</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">(858)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">752-6170</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:40.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Trading symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Name of each exchange on which is registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 Par Value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">&#8220;CDTX&#8221;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the Registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-true" id="f-28">&#253;</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtRestatementRecoveryAnalysisFlag" format="ixt:fixed-false" id="f-29">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-30">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Capital Market on June 30, 2023, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-31">100.2</ix:nonFraction> million.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares of Registrant&#8217;s common stock outstanding as of April&#160;12, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">91,235,020</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.326%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_22">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_52">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_52">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;1C.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_1568">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_1568">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_55">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_55">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_58">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_58">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_61">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_61">70</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART&#160;II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_67">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_70">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_70">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_73">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_91">88</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_94">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_94">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_151">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_151">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_154">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_154">133</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_157">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_157">134</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_160">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_157">134</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART&#160;III</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_166">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_166">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_169">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_169">145</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_172">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_172">161</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_175">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_175">162</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_178">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_178">164</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">PART&#160;IV</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_184">Exhibit and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_184">165</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Form 10-K Summary</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_190">167</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">SIGNATURES</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements. We may, in some cases, use words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our anticipated timing for preclinical development, regulatory submissions, commencement and completion of clinical trials and product approvals;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our plans to research, develop and commercialize our product candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to fund our working capital requirements;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our expected clinical trial designs and regulatory pathways;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to obtain and maintain regulatory approval of our product candidates and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to, our product candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the rate and degree of market acceptance of our products that are approved;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to develop sales and marketing capabilities, whether alone or with collaborators;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulatory developments in the United States, or U.S., and foreign countries;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the performance of our third-party suppliers and manufacturers;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our expectations for the attributes of our product and development candidates, including pharmaceutical properties, efficacy, safety and dosing regimens;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to use our Cloudbreak platform to identify development candidates, or to expand our Cloudbreak platform to other areas of infective disease;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to identify and develop new product candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential for prophylactic use of any of our product candidates;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to retain and recruit key personnel;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our financial performance;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">developments and projections relating to our competitors or our industry; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential impact of broader macroeconomic conditions, including global pandemics, high inflation, bank failures, labor shortages, supply chain disruptions, recession risks and potential disruptions from the ongoing Russia-Ukraine conflict and related sanctions and the Israel-Hamas war.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These forward-looking statements reflect our management&#8217;s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Annual Report on Form 10-K and are subject to risks and uncertainties. We discuss many of these risks in greater detail under &#8220;Risk Factors.&#8221; Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we reference and have filed as exhibits to the Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in this Annual Report on Form 10-K by these cautionary statements. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We need substantial additional funding to complete the development of rezafungin and to advance CD388, CBO421 and our other Cloudbreak programs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We depend heavily on the success of rezafungin and CD388, which is currently in Phase 1 and Phase 2a clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we experience delays or difficulties in enrolling patients in our clinical trials our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If clinical trials for rezafungin, CD388, CBO421 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Any of our product candidates that receive marketing approval may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We may not be successful in our efforts to identify, discover, and develop potential product candidates through our Cloudbreak platform or otherwise.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We are dependent on our collaboration partners to provide funding to continue the development of rezafungin and CD388; for the commercialization of rezafungin outside Japan; and for the late-stage development, manufacturing, registration and commercialization of CD388. If the collaborations are not successful, we may not be able to complete the development of rezafungin and CD388, or capitalize on the full market potential for rezafungin and CD388.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be forced to suspend or terminate one or more of our preclinical Cloudbreak programs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_1598"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restatement of Consolidated Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As described in our Current Report on Form 8-K filed on April 16, 2024, with the United States, or U.S., Securities and Exchange Commission, or the SEC, our Audit Committee of the Board of Directors, or the Audit Committee, determined on April 11 and April 15, 2024, based on management&#8217;s recommendation, that our previously issued audited consolidated financial statements for the fiscal years ended December 31, 2021 and 2022 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and each of our previously issued unaudited condensed consolidated financial statements included in our Quarterly Reports on Form 10-Q for each of the quarterly periods in 2022 and 2023, or collectively the Prior Financial Statements, filed with the SEC, should no longer be relied upon and should be restated due to the matters described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with preparing our audited consolidated financial statements for the year ended December 31, 2023, and through our financial control processes of evaluating indirect taxation consequences upon the first commercial sale of REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (rezafungin for injection) in 2023, we determined that we had a legal obligation for indirect taxation in various tax jurisdictions outside of the U.S. based on our supply chain activities in 2023 and prior years. As a result, the Audit Committee concluded that in prior years we did not appropriately account for indirect taxes which led to understatements of accrued liabilities and operating expenses during the impacted periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a result, we are restating the Prior Financial Statements in this Annual Report on Form 10-K for the fiscal year ended December 31, 2023. In addition, the following items of this Annual Report on Form 10-K include restated financial data: (i) Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and (ii) Part II, Item 8. Consolidated Financial Statements and Supplementary Data. Note 1 and Note 12 to our consolidated financial statements set forth, in a comparative presentation, the previously reported, restatement adjustments and restated amounts for those line items in the relevant periods affected by the restatement. This Annual Report on Form 10-K also includes disclosures regarding the impact of the restatement on the effectiveness of our internal control over financial reporting and disclosure controls and procedures in Part II, Item 9A. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have not amended our previously filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods noted above. Instead, such financial statements are superseded by the audited consolidated financial statements for the years ended December 31, 2022 and 2023 and the quarterly unaudited condensed consolidated financial statements for the 2022 and 2023 quarters contained in this Annual Report on Form 10-K, which give effect to the restatements noted above.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART I</span></div><div id="ib00951007fb342d8a49dba10256b8485_19"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 1. Business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our first commercially approved product in the United States, or U.S., is REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. On July 31, 2023, Melinta Therapeutics, LLC, or Melinta, our commercial partner in the U.S., initiated the commercial launch of REZZAYO in the U.S. On October 2, 2023, Melinta announced receipt from the Centers for Medicare &amp; Medicaid Services, or CMS, of both a product-specific J-Code and a new technology add-on payment, or NTAP, for REZZAYO. Outside the U.S. and Japan, our development and commercial partner for REZZAYO is Mundipharma Medical Company, or Mundipharma. In December 2023, the European Medicines Agency, or EMA, granted approval for REZZAYO in the European Union, or EU, for the treatment of invasive candidiasis in adults. In January 2024, the United Kingdom, or UK, Medicines and Healthcare products Regulatory Agency, or MHRA, granted approval for REZZAYO for the treatment of invasive candidiasis in adults.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we have shifted our primary research focus to our proprietary Cloudbreak</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> platform, we continue to execute on the ongoing ReSPECT Phase 3 pivotal clinical trial for the prevention of invasive fungal infections in adult allogeneic blood and marrow transplant recipients. A significant portion of our future royalties and milestones to be received under both Melinta and Mundipharma licensing agreements are tied to the successful completion of the ReSPECT Phase 3 trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our proprietary Cloudbreak platform enables development of novel drug-Fc conjugates, or DFCs, that inhibit specific disease targets while simultaneously engaging the immune system. Our most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting multiple oncology and autoimmune indications.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe our Cloudbreak platform has the potential to offer a fundamentally new approach to treat and prevent serious diseases such as solid tumor cancers and viral infections, by developing product candidates designed to provide potent disease targeting activity and immune system engagement in a single long-acting molecule. Because serious disease often results when a pathogen or cancer cell evades or overcomes the host immune system, our Cloudbreak DFC candidates are designed to counter diseases in two ways: prevention of disease proliferation and immune evasion by directly targeting and, where applicable, by focusing the immune system on a pathogen or infected cell. We believe this is a potentially transformative approach, distinct from current therapies, including antibody drug conjugates, or ADCs, monoclonal or multispecific antibodies and vaccines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, DFCs are designed to have several advantages, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Multivalent binding which has the potential to increase potency;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Ability to engage different targets to serve as a &#8220;drug cocktail&#8221; in a single molecule, which may improve response to treatment and prevention; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential advantages over vaccines irrespective of the immune status of patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">DFCs are fundamentally different from ADCs: DFCs are biologically stable drug-Fc conjugates designed to engage extracellular targets, while ADCs are designed to enter target cells to deliver and release cytotoxic small molecule drugs. In contrast to ADCs and monoclonal antibodies, DFCs are smaller, providing the potential for better tissue penetration and are designed to target multiple sites. Unlike small molecules, we believe DFC optimization can be focused primarily on potency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lead Cloudbreak candidate for the prevention of influenza is CD388, a DFC in Phase 1 and Phase 2a clinical trials. Our lead oncology DFC is CBO421, a development candidate targeting CD73 for the treatment of solid tumors, which is in investigational new drug application, or IND, -enabling studies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Cloudbreak Influenza Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2020, we nominated CD388, our influenza DFC, as a development candidate. We submitted an IND for CD388 in December 2021 and initiated a Phase 1 trial (NCT05285137) in March 2022. The Phase 1 trial is a randomized, double-blind, dose-escalation study to determine the safety, tolerability and pharmacokinetics of intramuscular and subcutaneous administration of CD388 in healthy subjects. Enrollment of all six planned cohorts has been completed. In addition, a separate Phase 1 Japanese bridging study (NCT05619536) has been initiated and enrollment has been completed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2022, we initiated a Phase 2a trial (NCT05523089) to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. The Phase 2a trial, which dosed its first healthy volunteer in September 2022, is a single-center, randomized, double-blind, placebo-controlled, proof-of-concept study to assess the prophylactic antiviral activity, safety, tolerability and pharmacokinetics of CD388 against influenza via a human viral challenge (influenza) model. Multiple dose levels of CD388 will be evaluated in volunteers who will receive a single administration of CD388 or placebo prior to influenza viral challenge. Enrollment has now been completed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022, we received the first U.S. patent for CD388. The patent includes claims directed to the composition of matter of CD388. The patent is projected to expire in 2039 plus any available patent term extension.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In June 2023, the U.S. Food and Drug Administration, or FDA, granted Fast Track designation to CD388 for the prevention of influenza A and B infection in adults who are at high risk of influenza complications due to underlying immunodeficiency and may not mount an adequate response to influenza vaccine or are at high risk of severe influenza despite influenza vaccination, including those for whom vaccines are contraindicated. Fast Track designation aims to facilitate the development and expedite the review of drugs to treat serious conditions with unmet medical needs. The purpose is to get important new drugs to patients earlier. Companies that are granted this designation are given the opportunity for more frequent interactions with the FDA, and, if relevant criteria are met, eligibility for Priority Review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Final CD388 Phase 2a Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In our recent R&amp;D Day, on September 21, 2023, we announced efficacy and safety data from our Phase 1 and Phase 2a trials evaluating the pre-exposure prophylactic activity of CD388 against an H3N2 influenza A virus strain.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 was well-tolerated up to 900 milligrams, or mg:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.660%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of participants that received one dose of CD388 in Phase 1 and Phase 2a trials</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">First in Human Study (Phase 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Japanese Bridging Study (Phase 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Human Challenge Study (Phase 2a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">50 mg</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">27</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">150 mg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">53</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">450 mg</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">900 mg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">All Doses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:700;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">114</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Safety Summary:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No treatment-emergent serious adverse events, or SAEs, and no discontinuation of study drug or withdrawals due to safety findings.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No consistent adverse event, or AE, patterns. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No hypersensitivity reactions.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Most treatment-emergent adverse events, or TEAEs, were Grade 1 (90%), few Grade 2, all resolved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Incidence of TEAE not dose-dependent.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Few injection site events (pain, intramuscular, or IM, route mainly), Grade 1, all resolved spontaneously.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No clinically relevant electrocardiogram, or ECG, vital signs or physical exam abnormalities.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 pharmacokinetics, or PK, profile is that of a long-acting compound, potentially enabling seasonal pre-exposure prophylaxis, or PrEP:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g1.jpg" alt="cdtx-2023-12-31_g01.jpg" style="height:243px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 demonstrates prophylactic reduction of viral replication in the upper respiratory tract, or URT, and the incidence of PCR-confirmed influenza infection:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Phase 2a prophylactic efficacy results are based on 56 subjects enrolled in the trial, with 28 subjects receiving a single dose of CD388 (150 mg) and 28 subjects receiving a placebo.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Placebo (n=28)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">CD388 150 mg (n=28)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">P-value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:700;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Quantitative reverse transcriptase polymerase chain reaction, or qRT-PCR, confirmed influenza infection </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(&#8220;attack rate&#8221; see Placebo data)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14 (50%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6 (21%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.0248</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">qRT-PCR confirmed symptomatic influenza infection</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9 (32%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4 (14%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.1023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">qRT-PCR confirmed moderately to severe symptomatic influenza infection</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7 (25%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3 (11%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.1477</span></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Statistical significance was pre-determined using a Wilcoxon rank-sum test with a one-sided type-1 error rate of 0.025.</span></div></td></tr></table></div><div style="margin-top:9pt"><img src="cdtx-20231231_g2.jpg" alt="cdtx-2023-12-31_g02.jpg" style="height:387px;margin-bottom:5pt;vertical-align:text-bottom;width:326px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As shown above, despite the small sample size in this analysis, a decrease in viral replication in the URT and influenza infection was observed in participants receiving a single dose of CD388 when compared to placebo. No treatment emergent adverse events leading to study discontinuation or SAEs were reported in the analysis. All participants included in the analysis received either CD388 or placebo and were then challenged with influenza five days later.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Viral culture data confirmed efficacy seen in early analyses:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g3.jpg" alt="cdtx-2023-12-31_g03.jpg" style="height:336px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/><img src="cdtx-20231231_g4.jpg" alt="cdtx-2023-12-31_g04.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we entered into an exclusive, worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize one or more DFCs based on our Cloudbreak platform for the prevention and treatment of influenza.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the Janssen Collaboration Agreement, we are collaborating in the research, preclinical and early clinical development of CD388, under a mutually-agreed research plan with the objective of advancing development through Phase 1 clinical trials and the first Phase 2a clinical trial. We are responsible for performing all IND-enabling nonclinical studies and early-stage clinical trials under the research plan. Both parties are responsible for conducting certain specified chemistry, manufacturing and controls, or CMC, development activities under the research plan. Janssen is solely responsible, and reimburses us for internal personnel and out-of-pocket costs incurred in performing the research plan activities in accordance with an agreed budget. As part of a recent prioritization of its R&amp;D business, in July 2023 Janssen disclosed its intention to discontinue internal development of multiple product candidates in its infectious disease pipeline, including CD388. However, in September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen will assume the future development, manufacturing and commercialization activities of CD388 but intends to transfer its rights and obligations under the Janssen Collaboration Agreement to another transferee. We continue to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following Janssen&#8217;s Election to Proceed Notice, Janssen, or any third-party transferee, is obligated at its sole expense to diligently continue development and commercialization either itself or through the transferee to whom it sublicenses or assigns the rights. If Janssen sublicenses or assigns the rights to a transferee, then all terms under the current Janssen Collaboration Agreement will survive without modification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid us an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, we were eligible for reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting research plan activities. As of December&#160;31, 2023, we have received the $27.0&#160;million up-front payment, $44.5&#160;million in research and development reimbursements, and $10.0&#160;million in milestone payments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to an additional $230.0&#160;million in development and regulatory milestone payments from Janssen for successful completion of certain activities over the next several years, including but not limited to Janssen&#8217;s decision whether to proceed with clinical development and initiation of Phase 2b and Phase 3 trials. In addition, we may be eligible to receive approximately $455.0&#160;million in commercial milestones as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Cloudbreak Oncology Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have expanded the Cloudbreak platform beyond infectious diseases, to discover and develop highly potent DFCs that can target multiple immune checkpoint pathways within a single DFC for oncologic diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Immune checkpoint antagonists have generated durable responses in cancers with improved side effect profiles compared to conventional chemotherapy. However, to date, improved outcomes from existing therapies have been limited to a relatively small subset of patients. To broaden the response rate to more patients, targeting additional mechanisms of tumor immune evasion will be critical.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cloudbreak Oncology seeks to develop a new generation of immunotherapies targeting the tumor microenvironment. Our lead oncology DFC candidate, CBO421, is a potential best-in-class CD73 inhibitor that combines the strengths of small molecules and monoclonal antibodies targeting CD73. CBO421 targets CD73 in the adenosine pathway, which contributes to immune evasion in solid cancers by flooding the tumor microenvironment with adenosine, a potent immune cell suppressor. The CD73 pathway is clinically validated in early/mid-stage clinical studies to reduce tumor growth in combination with PD-1/ PD-L1 inhibitors in disease areas that do not historically respond to checkpoint inhibition alone, such as advanced colorectal cancer, or CRC, and non-small cell lung cancer, or NSCLC. As a monotherapy and in combination with PD-1 inhibitors, CBO421 has demonstrated formation of immunologic memory in multiple murine tumor models, along with potential best-in-class activity in T-cell reactivation assays and tumor penetration compared with the most advanced CD73 antibody therapeutics in clinical development. We are currently advancing CBO421 through IND-enabling studies and expect to file an IND in mid-2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In February 2023, we expanded our existing collaboration with WuXi XDC, a leading global contract manufacturing organization dedicated to end-to-end bioconjugates services, under which WuXi XDC will provide IND-enabling CMC development services for our Cloudbreak Oncology program.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CBO421 demonstrates outstanding preclinical performance:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g5.jpg" alt="cdtx-2023-12-31_g05.jpg" style="height:304px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CBO421 enhances anti-tumor activity of PD-1 inhibitors:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CBO421 and Anti-PD-1 combination improves response rates versus monotherapies.</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g6.jpg" alt="cdtx-2023-12-31_g06.jpg" style="height:348px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CBO421 exhibits a second mechanism of action that differentiates it from small molecule CD73 inhibitors:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g7.jpg" alt="cdtx-2023-12-31_g12.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD73/PD-1 DFC potently inhibits both PD-1 and CD73 receptors:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g8.jpg" alt="cdtx-2023-12-31_g07.jpg" style="height:296px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Enhancement of activity in preclinical models observed when CBO421 was combined with PD-1 inhibition inspired the development of a first in class multispecific CD73/PD-1 targeting DFC that potently inhibits both targets simultaneously. Emerging preclinical data is promising. The multispecific DFC retains the full activity of the monotherapy components in functional binding and activity assays. In a murine colorectal carcinoma efficacy model, the multispecific DFC exhibited superior activity compared with CBO421 and the marketed PD-1 inhibitor, pembrolizumab, validating the concept. Optimization and preclinical development of our CD73/PD-1 targeting DFCs is ongoing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD73/PD-1 DFC outperforms monotherapies in humanized tumor models:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g9.jpg" alt="cdtx-2023-12-31_g08.jpg" style="height:363px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CCRs are a historically difficult-to-drug receptor family:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The DFC platform is also being expanded to include a validated, but difficult class of targets to drug, the chemokine receptors, or CCRs. CCR5 is a validated oncology target that can be a major driver in cancers that rely on the CCL5/CCR5 signaling pathway (e.g., breast, pancreatic and renal cell carcinomas). In several cancers, tumors secrete chemokine CCR5 agonists that promote tumor growth, metastasis and chemoresistance, while simultaneously recruiting immuno-suppressive macrophages and myeloid derived suppressor cells, or MDSCs, to the tumor microenvironment. We have rapidly been able to advance highly potent lead DFC CCR5-antagonist drug candidates that demonstrate robust activity as monotherapies in murine colorectal carcinoma models. Further optimization and preclinical characterization of our CCR5-DFC lead candidates including combination therapy studies, is ongoing.</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g10.jpg" alt="cdtx-2023-12-31_g09.jpg" style="height:335px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CCR5-DFC shows strong tumor control in preclinical model:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g11.jpg" alt="cdtx-2023-12-31_g10.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Rezafungin</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin is a novel molecule in the echinocandin class of antifungals. We are developing rezafungin for the treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">FDA Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2023, the FDA approved REZZAYO for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over 15 years, and is the only available once-weekly echinocandin.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">EMA and UK MHRA Approval of Rezafungin for the Treatment of Invasive Candidiasis in Adults</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the EMA granted approval for REZZAYO in the EU for the treatment of invasive candidiasis in adults. In January 2024, the UK MHRA granted approval for REZZAYO for the treatment of invasive candidiasis in adults.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">REZZAYO Commercialization in the U.S. by Melinta</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 31, 2023, Melinta initiated the commercial launch of REZZAYO in the U.S.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSTORE Phase 3 clinical trial in China</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, enrollment in the ReSTORE Phase 3 trial in China, evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis, was completed. The portion of the trial conducted in China included 52 patients diagnosed with candidemia and/or invasive candidiasis. ReSTORE (NCT03667690) is a global, randomized, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin, the current standard of care, to treat patients with candidemia and/or invasive candidiasis. Data from this study are expected in the second quarter of 2024.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSPECT Phase 3 clinical trial</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are currently conducting the ReSPECT, single, global, randomized, double-blind, controlled Phase 3 pivotal clinical trial (NCT04368559) in patients undergoing allogeneic blood and marrow transplant to assess rezafungin in a 90-day prophylaxis regimen to prevent infections due to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Candida, Aspergillus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Pneumocystis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Rezafungin, dosed at 400 mg for the first week followed by 200 mg once weekly out to 90 days, is being compared to a regimen containing two drugs (an azole and Bactrim) dosed once daily for 90 days. The primary efficacy outcome for this trial for the FDA and EMA is fungal-free survival at Day 90. We expect this trial to enroll approximately 462 patients. A blinded interim analysis is planned in the second quarter of 2024 which will inform the current fungal free survival rates, or FFS. The FFS will determine if the 462 patients planned to be enrolled will be sufficient to power the trial to detect non-inferiority. The study is currently enrolling in the EU, Canada and the U.S.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, we entered into a License Agreement with Melinta, or the Melinta License Agreement, under which we granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin in the U.S.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Melinta is solely responsible for the commercialization of rezafungin in the U.S., at its sole expense. We are responsible for conducting an agreed upon development plan that includes, among other activities, completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prevention of invasive fungal infections in adult allogeneic blood and marrow transplant recipients. We will initially remain the holder of the rezafungin IND and new drug application, or NDA. Both regulatory applications will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated supplemental NDA, or sNDA, for the prophylaxis indication. Following the transfer date, we will remain financially responsible for post-marketing commitments and other remaining development obligations and the costs for those will be deducted from royalties owed to us by Melinta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The total potential transaction value of the Melinta License Agreement is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestones. In addition, we are eligible to receive tiered royalties on U.S. sales in the low double digits to mid-teens. As of December&#160;31, 2023, we have received the $30.0&#160;million up-front payment and a $20.0&#160;million milestone payment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we announced a strategic partnership with Mundipharma to develop and commercialize rezafungin in an intravenous formulation for the treatment and prevention of invasive fungal infections. Under the terms of the Collaboration and License Agreement with Mundipharma, or the Mundipharma Collaboration Agreement, we granted Mundipharma an exclusive, royalty-bearing license to develop, register and commercialize rezafungin outside the U.S. and Japan. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. We are also eligible to receive double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we have received $9.0&#160;million from the sale of our equity to Mundipharma, a $30.0&#160;million up-front payment, $31.2&#160;million in global development funding, and $25.1&#160;million in milestone payments (including an $11.1&#160;million milestone payment creditable against future royalties payable to us). In December 2023, we achieved a milestone of $11.1&#160;million under the Mundipharma Collaboration Agreement for which we have received payment in February 2024. In January 2024, we achieved a milestone of $2.8&#160;million under the Mundipharma Collaboration Agreement for which we have received payment in April 2024.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OUR STRATEGY</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our objective is to become the leading biotechnology company in the discovery, development and commercialization of targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases. Key elements of our strategy include:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:14.68pt">Develop product candidates from our Cloudbreak platform.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> In December 2021, we submitted an IND for CD388 for seasonal and pandemic influenza prevention and treatment, which is in Phase 1 and Phase 2a clinical trials, and are developing new product candidates targeting the prevention and treatment of other life-threatening viral diseases. In addition, we have expanded the Cloudbreak platform beyond infectious diseases, to discover and develop highly potent DFCs that can target multiple immune checkpoint pathways with a single DFC for oncologic diseases. Our lead oncology development candidate, CBO421, targets CD73 in the adenosine pathway. We have expanded our existing collaboration with WuXi XDC under which WuXi XDC provides IND-enabling CMC development services for our Cloudbreak oncology program. We may fund these programs alone, with grant or government contract funding or through new partnerships we may consider. We will also continue to establish intellectual property related to the Cloudbreak platform, its applications and development candidates.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:14.68pt">Advance rezafungin to further approval.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> We are continuing to develop rezafungin, a once-weekly echinocandin antifungal, to address serious fungal infections, including, but not limited to those considered urgent and serious threats by the U.S. Centers for Disease Control and Prevention, or CDC. We successfully completed our ReSTORE Phase 3 treatment clinical trial, which served as the basis for the FDA&#8217;s approval of REZZAYO for the treatment indication, and we are currently enrolling our ReSPECT Phase 3 prophylaxis clinical trial. Approvals in these indications would enable our licensing partners to target two distinct and commercially-attractive market segments with significant unmet needs from the current standard of care: the treatment of candidemia and invasive candidiasis, for which it is currently approved, and the prevention of invasive fungal infections in a highly vulnerable population, adults undergoing allogeneic blood and marrow transplantation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CLOUDBREAK PLATFORM</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe our Cloudbreak platform has the potential to offer a fundamentally new approach to treat and prevent serious diseases such as solid tumor cancers and viral infections, by developing product candidates designed to provide potent disease targeting activity and immune system engagement in a single long-acting molecule. Because serious disease often results when a pathogen or cancer cell evades or overcomes the host immune system, our Cloudbreak DFC candidates are designed to counter diseases in two ways: prevention of disease proliferation or immune evasion by directly targeting and, where applicable, by focusing the immune system on a pathogen or infected cell. We believe this is a potentially transformative approach, distinct from current therapies, including ADCs, monoclonal or multispecific antibodies and vaccines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, DFCs are designed to have several advantages, including:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Multivalent binding which has the potential to increase potency;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Ability to engage different targets to serve as a &#8220;drug cocktail&#8221; in a single molecule, which may improve response to treatment and prevention; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential advantages over vaccines irrespective of the immune status of patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">DFCs are fundamentally different from ADCs: DFCs are biologically stable drug-Fc conjugates designed to engage extracellular targets, while ADCs are designed to enter target cells to deliver and release cytotoxic small molecule drugs. In contrast to ADCs and monoclonal antibodies, DFCs are smaller, providing the potential for better tissue penetration and are designed to target multiple sites. Unlike small molecules, we believe DFC optimization can be focused primarily on potency.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Cloudbreak platform has enabled us to expand the development of DFCs to target other life-threatening diseases. We have expanded the Cloudbreak platform beyond infectious diseases to discover and develop highly potent DFCs that can target multiple immune checkpoint pathways within a single DFC for oncologic indications.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cloudbreak candidates targeting solid tumor cancers and viral infections are called DFCs, single molecules consisting of two distinct moieties with discrete, yet complementary mechanisms of action:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Targeting Moiety (TM):&#160;A highly potent small molecule and/or peptide that binds surface targets on the pathogen or host cell to directly inhibit viral proliferation.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Effector Moiety (EM):&#160;A proprietary composition that contains the fragment crystallizable, or Fc, region of human IgG1 antibodies, which was selected to extend half-life engagement and engage the human immune system via Fc-gamma receptors.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">DFCs not only mediate pathogen clearance through a multimodal mechanism of action but also have potential for months of activity with a single dose.</span></div><div style="margin-top:6pt"><img src="cdtx-20231231_g12.jpg" alt="cdtx-2023-12-31_g13.jpg" style="height:260px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak DFC (drug-Fc conjugate) Program Overview</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are leveraging the Cloudbreak platform to address multiple diseases. Each DFC targets a serious disease, focused on solid tumor cancers and viral infections. Our DFC research and development programs include:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Influenza; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Cancer (solid tumors).</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">DFCs provide direct, sustained antiviral activity as well as immune system engagement, for effective prevention and treatment of disease. This is a potentially transformative approach, distinct from current approaches.&#160;DFCs are not vaccines, small-molecule drugs, or monoclonal antibodies. DFCs are novel, Fc-conjugates designed for the following features:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Multimodal mechanism of action:&#160;Potent, direct antiviral activity and tunable immune system engagement.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Strong target binding:&#160;High affinity to essential, conserved targets on the virus surface and/or surface of infected cells.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Long duration of action:&#160;Months of protection from disease with a single dose.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Rapid onset:&#160;Rapid distribution to site of infection for treatment of disease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak Influenza Program and Our DFC Development Candidate CD388</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Influenza is a respiratory infection caused by influenza viruses. The influenza virus can cause mild to severe illness, and at times can lead to death. Young children, adults older than 65 years, pregnant women and immunocompromised patients are more prone to infection, but even healthy people are at risk of infection with seasonal influenza. The primary preventive measure to protect against influenza is the seasonal vaccine, which remains the best mode to prevent influenza related illness, despite its limitations. However, the efficacy of the vaccine varies, with recent studies estimating that the influenza vaccine reduces the risk of influenza illness by between 38% and 62%, depending on the virus strain and age and health of the recipient, among other factors. While today&#8217;s influenza vaccines are credited with significant public health benefits and offer our current best defense, only 52% of Americans get an annual influenza vaccine. As a result, a large proportion of Americans are still at risk of getting influenza yearly. For example, during the 2018-19 influenza season, 71% did not respond to vaccination and 34,200 people died of influenza-related illness in the U.S. The estimated average annual total economic burden of influenza to the U.S. healthcare system and society is more than $11.2 billion. In years when the seasonal vaccine results in sub-optimal protection such as the 2018-2019 influenza season when the CDC estimated vaccine effectiveness to be 29% in the U.S., more patients are at higher risk for serious complications resulting from influenza. Vulnerable patient populations must then rely upon therapeutic options.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Older antiviral medications, such as amantadine and rimantadine, are no longer recommended for use because of high levels of resistance. Currently, four antiviral drugs are recommended by the CDC for treating influenza:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">oseltamivir phosphate (Tamiflu</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">);</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">zanamivir (Relenza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">);</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">peramivir (Rapivab</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">); and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">baloxavir marboxil (Xofluza&#8482;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The above list includes neuraminidase inhibitors and the recently approved cap-dependent endonuclease inhibitor, baloxavir. These molecules have one or more of the following limitations: short half-life; high susceptibility to resistance; multi-dose regimens; and dosing route limitations. The current therapies should be administered within 48 hours of symptom onset to be effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential Advantages of Cloudbreak DFCs for Influenza</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:14.68pt">Broad-Spectrum, Universal Coverage:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Cloudbreak DFCs have demonstrated activity against pandemic and seasonal influenza A and B viruses, including resistant strains (e.g. oseltamivir-resistant H1N1, zanamivir-resistant influenza B) and strains with high pandemic potential (e.g. H5N1, H7N9).</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:14.68pt">Superior Resistance Profile:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;DFCs may be less prone to viral resistance, by virtue of the targeting mechanism and multivalent target engagement.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:14.68pt">Protection for High-Risk Populations:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;Unlike vaccines, the potent intrinsic antiviral activity of the DFCs has demonstrated antiviral protection independent of immune system status in animal efficacy models.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:14.68pt">Seasonal and Pandemic Readiness:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;DFCs are well-suited for immediate and robust response to influenza challenges by providing rapid onset of protection and coverage of strains that are frequently missed by the seasonal vaccine. Moreover, DFCs are not subject to the lengthy and unpredictable process of vaccine manufacturing.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;padding-left:14.68pt">Long Duration of Action:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;A single DFC dose may protect from influenza for an entire influenza season.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">DFC Development Candidate for Influenza: CD388</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Pre-Clinical Studies of CD388 for Influenza</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have developed a novel DFC that provides a direct and sustained antiviral effect and retains potent activity in immune compromised hosts. The results of multiple preclinical studies with CD388 indicate that it is effective in both the treatment and prevention of influenza infections. CD388 has been engineered to extend half-life and has the potential to extend the duration of protection in prophylactic applications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">In Vitro Studies Measuring CD388 Potency Against Multiple Influenza Strains</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We evaluated CD388 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> for its ability to inhibit viral replication in cell-based assays versus a large panel of seasonal and pandemic Influenza A strains, including 2009 H1N1 pandemic strain, H3N2 and H5N1, H7N9, oseltamivir (Tamiflu)-resistant H1N1, and influenza B strains, including zanamivir (Relenza)-resistant influenza B. CD388 showed potent activity against all the strains tested, including influenza B, which is less sensitive to oseltamivir phosphate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">In Vivo Studies Measuring CD388 Potency Against Multiple Influenza Strains in Lethal Infection Models</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We evaluated CD388 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">in vivo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">in lethal mouse models against multiple H1N1, H3N2 and influenza B strains. CD388 provided full protection against all strains tested H1N1 with single, low doses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In all studies, we measured the average body weights of the mice over time to support the survival data with CD388. The CD388 dosed mice maintained stable body weights over the 21-day course of the experiments demonstrating the potency of CD388 at low doses and the potency and tolerability of CD388 at high doses. In a quantitative lung burden model versus H1N1 influenza, single, low doses of CD388 demonstrated superior reduction in lung viral burden compared to oseltamivir (Tamiflu) administered daily at 10x its human equivalent dose. Unlike oseltamivir, which only minimally impacted viral burden in lung at all tested doses, viral burden in CD388 treated animals increased with dose.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">In Vivo Study Evaluating CD388 as a Long-Acting Prophylactic Agent Against Influenza</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We tested mean plasma concentrations of CD388 in mice and based on the long half-life we observed, we evaluated CD388 in vivo in a lethal mouse model of H1N1 by administering CD388 to the mice 7 days before lethal influenza challenge. CD388 provided 100% protection from mortality across a broad range of dose levels, demonstrating its potential suitability as a long-acting prophylactic agent for influenza prevention.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak Oncology Program and Our DFC Development Candidate CBO421</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cloudbreak DFCs stably couple highly potent small molecules or peptides to a proprietary variant of a human antibody fragment. As a result, DFCs are long-acting, and are designed to directly inhibit specific disease targets. DFCs can be tuned to engage the immune system or to be immune silent, expanding the breadth of indications that can be targeted. Immune active DFCs can attract an immune response against cancer cells to maximize disease eradicating activity, while immune silent DFCs allow for expansion into cancer indications where immune system engagement would result in host toxicity.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">With our Cloudbreak oncology program we seek to develop a new generation of immunotherapies, and our CBO421 DFC is a first-in-class CD73 inhibitor that combines the strengths of small molecules and monoclonal antibodies targeting CD73. We are advancing CBO421 through IND-enabling studies.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CBO421 targets CD73 in the adenosine pathway, which contributes to immune evasion in solid cancers by flooding the microenvironment surrounding tumors with adenosine, a potent immune cell suppressor. CD73 is highly expressed on a variety of tumor and stromal cells as well as immunosuppressive cell populations such as regulatory T cells and myeloid-derived suppressor cells. CBO421 is designed to address the potency, efficacy, pharmacokinetic and safety limitations of small molecule and monoclonal antibody candidates targeting CD73 in clinical development. CBO421 has several attributes that potentially differentiate it from the most advanced small molecule and mAb inhibitors in clinical development:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Some solid tumors evade immune mediated clearance by expressing cell-anchored and soluble forms of CD73 to elevate adenosine levels in the tumor microenvironment, or TME. CBO421 fully inhibited both forms of the enzyme with high potency, whereas representative CD73 inhibitor mAbs in clinical development we evaluated (mupadolimab and oleclumab), only inhibited cell anchored CD73.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">In functional assays the ability of CBO421 to restore activation of human peripheral blood mononuclear cells, or PBMCs, suppressed with adenosine monophosphate, or AMP, were measured and compared to mAb and small molecule CD73 inhibitors in clinical development. CBO421 demonstrated superior activity to the mAb comparators (mupadolimab and oleclumab), and similar or improved activity compared to the small molecule inhibitor panel.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">CD73 internalization is an additional mechanism to potentially reduce adenosine levels in the TME that is only achievable via receptor cross-linking, which is not possible with small molecule inhibitors. The multivalent presentation of CD73 inhibitors on CBO421 induced receptor internalization and significant reduction of CD73 receptors expressed on a human breast cancer cell line.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">These attributes, coupled with the long half-life mediated by the DFC Fc domain, led to significant tumor reduction in a mouse syngeneic tumor model after a single dose of CBO421.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we believe the reduced size of CBO421 compared with conventional monoclonal antibodies is expected to translate to improved anticancer activity via enhanced tissue distribution and tumor penetration. CBO421 demonstrated improved tumor penetration into triple negative breast cancer tumor spheroids compared with the most advanced monoclonal antibody CD73 inhibitor in clinical development, oleclumab.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CBO421 exhibits superior tumor spheroid penetration versus full length CD73-targeting antibodies (oleclumab biosimilar):</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g13.jpg" alt="cdtx-2023-12-31_g11.jpg" style="height:344px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">REZAFUNGIN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We acquired rezafungin, a novel echinocandin antifungal agent, in 2014. We believe rezafungin has the potential to be differentiated from other echinocandins and other classes of antifungal agents based on its once-weekly dosing, high front -loaded exposure, high tissue penetration, safety and tolerability profile, lack of drug-drug interactions and broad spectrum.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin is being developed for both the treatment and prevention of serious, invasive fungal infections.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Overview of Systemic Fungal Infections and the Antifungal Market</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Fungal infections pose significant medical challenges in both the hospital and outpatient settings. We estimate that the annual worldwide sales of prescription systemic antifungals in 2017 were approximately $4.2&#160;billion. This includes therapies used as prophylaxis (preventive) in the inpatient and outpatient setting, particularly in patients or those undergoing blood and marrow transplantation and therapies used for the treatment of patients who are being discharged from the hospital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The majority of invasive fungal infections are caused by two fungi, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Candida</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Aspergillus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Despite advances achieved in the diagnosis and treatment of candidemia, these infections continue to cause high mortality rates. The current treatment alternatives for systemic fungal infections, including polyenes, azoles and older echinocandins, have limitations that we believe may be addressed. While these drugs have proven to be efficacious in many patients, mortality rates remain high, and the polyenes and azoles may cause severe side effects warranting discontinuation and are known to cause significant changes in a drug&#8217;s effect on the body when taken together with a second drug, or drug-drug interactions.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Rezafungin for the Treatment and Prevention of Serious Fungal Infections</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Due to its novel chemical structure, rezafungin has a prolonged half-life, a high maximum plasma concentration and a high area under the plasma concentration-time curve.&#160;In addition, rezafungin was tested </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> against 27 echinocandin-non-susceptible</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Candida</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> isolates and demonstrated equivalent or greater potency against these strains compared to caspofungin, with up to eight-fold greater potency for several isolates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin was designed to overcome the limitations of the echinocandin class and other antifungals by offering the following key benefits:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential to treat resistant pathogens.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Single-agent treatment.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Shorter and less costly hospital stays, and lower outpatient costs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Improved compliance.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Enabling or improving prophylaxis regimens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S., the FDA has granted rezafungin designations as a Qualified Infectious Disease Product, or QIDP, Fast Track, and Orphan Drug. QIDP and Orphan Drug designations together provide a total of 12 years of marketing exclusivity in the U.S. from the time of FDA approval. In March 2023, the FDA approved REZZAYO for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the EU, the European Commission has granted rezafungin Orphan Drug Designation for the treatment of invasive candidiasis. The Orphan Drug Designation provides 10 years of market exclusivity protection from similar medicines with similar indications upon approval of the marketing authorization, and two additional years of market exclusivity when the results from pediatric studies compliant with an approved Pediatric Investigational Plan, or PIP, are included in the Summary of Product Characteristics, or SmPC. In December 2023, the EMA granted approval for REZZAYO in the EU for the treatment of invasive candidiasis in adults.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LICENSE AND COLLABORATION AGREEMENTS</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we entered into the Mundipharma Collaboration Agreement with Mundipharma for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Under the Mundipharma Collaboration Agreement, we are responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes our ongoing ReSTORE Trial of the Mundipharma Licensed Product, and our ongoing ReSPECT Trial of the Mundipharma Licensed Product, as well as specified GLP-compliant non&#8209;clinical studies and CMC development activities for the Mundipharma Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Pursuant to the Mundipharma Collaboration Agreement, we granted Mundipharma an exclusive, royalty&#8209;bearing license to develop, register and commercialize the Mundipharma Licensed Product in the Mundipharma Territory, subject to our retained right as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar rights retained by us to conduct mutually agreed global development activities for such products. In addition, we granted Mundipharma a co&#8209;exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#8217;s territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Our Retained Rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;We retain the exclusive right to develop, register and commercialize the Mundipharma Licensed Product, Subcutaneous Product and Other Products in Japan, or the Company Territory, and Mundipharma has granted us certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Mundipharma Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;As of the execution of the Mundipharma Collaboration Agreement, we and Mundipharma agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#8217;s Global Development Cost share of $31.2&#160;million. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. We are also eligible to receive double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSTORE Trial and the ReSPECT Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. We may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of our patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we entered into the Janssen Collaboration Agreement with Janssen to develop and commercialize one or more DFCs based on our Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. We will collaborate with Janssen in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or Phase 2 Study. Unless otherwise agreed by the parties, we will be responsible for performing, or having performed, all IND-enabling studies and clinical trials under the Research Plan, and we will be the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the Research Plan. Janssen will be solely responsible, and reimburse Cidara, for internal full-time equivalent and out-of-pocket costs we incur in performing Research Plan activities in accordance with a mutually-agreed budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As part of a recent prioritization of its R&amp;D business, in July 2023 Janssen disclosed its intention to discontinue internal development of multiple product candidates in its infectious disease pipeline, including CD388. However, in September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen will assume the future development, manufacturing and commercialization activities of CD388 but intends to transfer its rights and obligations under the Janssen Collaboration Agreement to another transferee. We continue to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following Janssen&#8217;s Election to Proceed Notice, Janssen, or any third-party transferee, is obligated at its sole expense to diligently continue development and commercialization either itself or through the transferee to whom it sublicenses or assigns the rights. If Janssen sublicenses or assigns the rights to a transferee, then all terms under the current Janssen Collaboration Agreement will survive without modification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, we granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to our retained right to conduct Research Plan activities as described above. In addition, we granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. We will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and our delivery to Janssen of all Research Plan deliverables, Cidara and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that we have the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing our DFC technology more broadly. Our non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid Cidara an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, we were entitled to reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting Research Plan activities. We were also eligible to receive up to $695.0&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> In addition to our right to terminate the Janssen Collaboration Agreement for Janssen&#8217;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to the completion of all Research Plan activities and our delivery to Janssen of all Research Plan deliverables, upon 90 days&#8217; written notice to Cidara, provided that if any clinical trial under the Research Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after completion of the Phase 2 Study and before expiration of the Election Period, immediately upon written notice to Cidara; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after delivery of the Election to Proceed Notice, upon 90 days&#8217; written notice to Cidara, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, we entered into the Melinta License Agreement with Melinta under which we granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Pursuant to the Melinta License Agreement, we granted Melinta an exclusive, royalty&#8209;bearing license (including the right to sublicense through multiple tiers), to develop, register and commercialize the Melinta Licensed Product for all uses in humans and non-human animals in the Melinta Territory, subject to our retained right, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Until the fifth anniversary of the first commercial sale of the first Melinta Licensed Product in the Melinta Territory, neither Cidara nor Melinta, nor any of their respective majority-owned subsidiaries may, directly or indirectly, itself or in collaboration with any third party, develop, manufacture for development or commercialization, or commercialize any product in the echinocandin class of drugs in the Melinta Territory without the other party&#8217;s prior written consent, subject to certain provisions in connection with a change of control of a party.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Commercialization.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Melinta is solely responsible for the commercialization of rezafungin in the Melinta Territory, at its sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Our Retained Rights.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> We retain the non-exclusive right to practice the intellectual property rights licensed to Melinta in the Melinta Territory solely for the purpose of performing our obligations under the Melinta License Agreement and Mundipharma Collaboration Agreement. We also retain the right to grant licenses under the intellectual property rights licensed to Melinta to third parties to which we have granted licenses or rights to market, promote and sell Melinta Licensed Product outside the Melinta Territory, to make and have made Melinta Licensed Product anywhere in the world solely to develop, register, use, sell, have sold, offer for sale, commercialize and import Melinta Licensed Product outside the Melinta Territory, subject to the terms of the Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Continued Development and Regulatory Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> We will be responsible, at our sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that includes, among other activities, (a) completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the FDA of a sNDA for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain CMC activities for the Melinta Licensed Product, and (f) all other development activities that are required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We will remain the holder of the rezafungin IND and NDA. Both regulatory applications will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated sNDA for the Prophylaxis Indication, after which Melinta will be responsible for performing all activities that may be necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta&#8217;s sole expense, subject to Melinta&#8217;s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket expenses incurred by Melinta.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Supply and Transfer of CMC activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Until Melinta assumes responsibility for the manufacture and supply of the Melinta Licensed Product for development and commercialization in the Melinta Territory, which it may do by direct purchase from the Company&#8217;s contract manufacturing organizations for the Melinta Licensed Product or by having a manufacturing technology transfer to Melinta or its designee performed at Melinta&#8217;s sole expense, which, in either case, will be no later than December 31, 2026, we will be responsible for the manufacture and supply of the Melinta Licensed Product for development and commercialization by Melinta in the Melinta Territory, and during such period, shall supply Melinta Licensed Product to Melinta pursuant to the terms of a supply agreement negotiated by the parties.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Upon execution of the Melinta License Agreement, the total potential transaction value is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestone payments. In addition, we are eligible to receive tiered royalties on U.S. sales in the low double digits to mid-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Either party may terminate the Melinta License Agreement for uncured material breach by the other party. After July 26, 2023, Melinta may terminate the Melinta License Agreement at will. We may terminate the Melinta License Agreement if Melinta or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the patent rights licensed to Melinta by us.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">MANUFACTURING</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to rely, on third parties to manufacture supplies of rezafungin, any Cloudbreak development candidates, and any future product candidates. Our third-party contract manufacturers are currently producing, and will produce in the future, our product and development candidates for use in our preclinical studies and clinical trials utilizing reliable and reproducible processes and common manufacturing techniques.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For rezafungin, we have entered into commercial supply arrangements with all of the key contract manufacturers to support commercialization, including suppliers of starting materials, bulk drug substance and drug product. We are in the process of identifying and qualifying additional manufacturers to reduce manufacturing costs and ensure continuity of supply. We have entered into commercial supply agreements with all current licensees that govern the terms under which rezafungin will be supplied for commercial use in the Melinta and Mundipharma territories.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The proprietary nature of, and protection for, rezafungin, CD388, CBO421, our other DFCs, our Cloudbreak platform, our processes and our know-how are important to our business. We seek to protect our proprietary position through patent protection in the U.S. and internationally where available and when appropriate. Our policy is to pursue, obtain, maintain and defend patent rights, developed internally and/or potentially licensed from third parties, and to protect the technology, inventions and improvements that are commercially important to the development of our business. We also rely on trade secrets that may be important to the development of our business. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our inventions, improvements and technology. For this and more comprehensive risks related to our intellectual property, please see &#8220;Risk Factors-Risks Related to Our Intellectual Property.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our success will depend significantly on our ability to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain and maintain patent and other proprietary protection for the technology, inventions and improvements we consider important to our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">defend and enforce our current and potential future patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">preserve the confidentiality of our trade secrets; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">operate our business without infringing the patents and proprietary rights of third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have established, and will continue to build, proprietary positions for rezafungin, CD388, CBO421, and other product candidates and technology in the U.S. and abroad. As of April&#160;22, 2024, our patent portfolio included 10 families of patents and patent applications related to various aspects of rezafungin, 7 families of patents and patent applications related to various aspects of CD388, and one patent family of patent applications related to various aspects of CBO421.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For our issued patents related to rezafungin, we expect the last to expire in 2038, excluding any additional term for patent term adjustments or applicable patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">With respect to CD388, the latest of any patents that result from our currently pending applications would be expected to expire in 2042, should they be issued, excluding any additional term for patent term adjustments or applicable patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">With respect to CBO421, the latest of any patents that result from our currently pending applications would be expected to expire in 2043, should they be issued, excluding any additional term for patent term adjustments or applicable patent term extensions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Market exclusivity is the exclusive marketing right granted by the FDA and certain foreign equivalents upon the approval of a drug if certain statutory requirements are met. When granted, the applicable regulatory authority will not approve another application to market the same drug for the same indication during the period of market exclusivity.&#160;The length of market exclusivity depends on the type of exclusivity granted. We intend to seek market exclusivity on our product candidates where appropriate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA has granted rezafungin designations as an Orphan Drug, QIDP and Fast Track for the treatment of candidemia and invasive candidiasis which together provide 12 years of marketing exclusivity in the U.S. to be granted at the time of FDA approval. In March 2023, the FDA approved REZZAYO for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. The FDA has also granted rezafungin designations for QIDP and Fast Track for prophylactic use in patients undergoing allogeneic blood and marrow transplant which provides a five-year extension to any marketing exclusivity period for which the drug qualifies on approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The European Commission has granted rezafungin Orphan Drug Designation for the treatment of invasive candidiasis which provides 10 years of market exclusivity protection from similar medicines with similar indications upon approval of the marketing authorization, and the potential for two additional years of market exclusivity when the results from pediatric studies compliant with an approved PIP are included in the SmPC. In December 2023, the EMA approved REZZAYO in the EU for the treatment of invasive candidiasis in adults.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, we seek trademark protection in the U.S. and internationally where available and when appropriate. We have filed for trademark protection in several countries for the Cidara trademark, which we use in connection with our pharmaceutical research and development services and our pharmaceutical compounds. We currently have registered trademarks for the Cidara mark in the U.S., the EU, Australia and Canada.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. We believe that rezafungin and any Cloudbreak development candidates we pursue in the future, paralleled with our scientific and development expertise in the field of anti-infectives, provide us with competitive advantages over our peers. However, we face potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as from generic drug manufacturers, academic institutions, governmental agencies and public and private research institutions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin will primarily compete with antifungal classes for the treatment of candidemia and invasive candidiasis, which include polyenes, azoles and echinocandins. The approved branded therapies for this indication include Cancidas (caspofungin, marketed by Merck &amp; Co.), Eraxis (anidulafungin, marketed by Pfizer, Inc.) and Mycamine (micafungin, marketed by Astellas Pharma US, Inc.). There are generic versions of one or more of the current echinocandins available now, which will create added competition at the time of rezafungin regulatory approval. In addition, there are other generic products approved for candidemia, marketed by companies such as Baxter Healthcare Corporation, Mylan Inc. and Glenmark Generics Inc., among others. In addition to approved therapies, we expect that rezafungin will compete with product candidates that we are aware of in clinical development by third parties, such as fosmanogepix (PF-07842805), which is being developed by Pfizer, Inc. and ibrexafungerp, which is approved for other indications and is being developed for invasive candidiasis by Scynexis, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that CD388 will compete against approved vaccines for influenza and approved agents for the treatment of viral influenza infections, including neuraminidase inhibitors such as Tamiflu, Relenza, and Peramivir, and endonuclease inhibitors such as Xofluza. We intend to develop other product candidates through our Cloudbreak platform for the prevention and treatment of other viral infections. We are aware of a number of approved and investigational vaccines and/or therapies in these areas. We expect that CBO421 will compete against approved anticancer therapeutics as well as investigational CD73-targeting small molecule drugs, including Oric-533 being developed by Oric Pharmaceutical, Inc. and quemliclustat being developed by Arcus Biosciences, Inc. as well as monoclonal antibodies, including oleclumab being developed by AstraZeneca PLC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. These same competitors may invent technology that competes with our Cloudbreak platform.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical study sites and subject enrollment for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect any products that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that our products, if approved, will be priced at a significant premium over competitive generic products and our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Government authorities in the U.S., at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, including any manufacturing changes, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, import and export of pharmaceutical products, such as those we are developing.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">U.S. Drug Approval Process</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">manufacturing of clinical supplies in compliance with good manufacturing practice, or GMP, regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice, or GLP, regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety and efficacy of the proposed drug for each indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">submission to the FDA of an NDA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality, purity, and potency; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">FDA review and approval of the NDA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies and IND</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> and animal studies to assess the potential for adverse events, and in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. Some long-term preclinical testing, including animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises safety concerns or questions related to safety to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and/or the effectiveness criteria to be evaluated. A protocol for each clinical trial conducted in the U.S. and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:underline">www.clinicaltrials.gov</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Phase 3: The drug is administered to an expanded patient population in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and, more frequently, if SAEs occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Marketing Approval</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. Under federal law, the submission of most NDAs and clinical NDA supplements are additionally subject to a substantial application fee, and the sponsor of an approved NDA is also subject to annual program fees, which are typically increased annually.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission before accepting them for filing to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review of NDAs. Under these goals, the FDA has committed to review most such applications for non-priority products within 10 months, and most applications for priority review products, that is, drugs that the FDA determines represent a significant improvement over existing therapy, within six months from filing. The review process may be extended by the FDA to consider certain information or clarification regarding information already provided in the submission. The FDA may also refer applications for novel drugs or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">recommendation as to whether the application should be approved. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The testing and approval process requires substantial time, effort and financial resources, and each may take many years to complete. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs in our efforts to develop our product candidates and secure necessary governmental approvals, which could delay or preclude us from marketing our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">After the FDA&#8217;s evaluation of the NDA and inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction via additional information submitted to the FDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval and refuse to approve the NDA. Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including Risk Evaluation and Mitigation Strategies, or REMs, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Fast Track Designation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA aims to facilitate the development and expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track program, the sponsor of a new product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the submission of the IND for the product candidate. The FDA must determine if the product candidate qualifies for Fast Track designation within 60 days after receipt of the sponsor&#8217;s request.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to other benefits, such as the ability of the sponsor to use surrogate endpoints in the evaluation of the pivotal clinical trials and have more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track product&#8217;s NDA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the NDA is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Priority Review</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under FDA policies, a product candidate may be eligible for priority review, or review generally within a six-month time frame from the time a complete application is accepted for review. Products regulated by the FDA&#8217;s Center for Drug Evaluation and Research, or CDER, are eligible for priority review if they provide a significant improvement compared to marketed products in the treatment, diagnosis or prevention of a disease. A Fast Track designated product candidate would ordinarily meet the FDA&#8217;s criteria for priority review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy Designation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. Even if a product candidate qualifies for one or more of these programs, the FDA may later decide that the product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the U.S. for that product and for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same orphan indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Qualified Infectious Disease Product Designation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In response to the growing unmet medical need in the area of serious bacterial and fungal infections, the Generating Antibiotic Incentives Now Act, or the GAIN Act, is intended to provide incentives, including, for example, access to expedited FDA review for approval and five years of potential market exclusivity extension, for the development of new, qualified infectious disease products, or QIDP, including antibacterial or antifungal drugs intended to treat serious or life-threatening infections that are resistant to treatment, or that treat qualifying resistant pathogens identified by the FDA. A sponsor must request QIDP designation for a new drug before an NDA is submitted. If designated as a QIDP and approved, the drug is eligible for an additional five years of exclusivity beyond any period of exclusivity to which it would have otherwise been entitled. In addition, a QIDP receives NDA priority review and Fast Track designation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Exclusivity and Pediatric Use</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act, certain drugs may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, or a Written Request, relating to the use of the active moiety of the drug in children. The FDA may issue a Written Request for studies on unapproved or approved indications, but it may not issue a Written Request where it determines that information relating to the use of a drug in a pediatric population, or part of the pediatric population, may not produce health benefits in that population.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for most drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, biologics license applications and supplements thereto, must contain a pediatric assessment unless the sponsor has received a deferral or waiver. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which an orphan drug designation has been granted. The required assessment must assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any drug manufactured or distributed by us pursuant to FDA approvals is subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements, including REMS, as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">upon us and third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain cGMP compliance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product seizure or detention, or refusal to permit the import or export of products; or&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">consent decrees, injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Additional Health Care Laws</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws restrict our business activities, including certain marketing practices. These laws include, without limitation, anti-kickback laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, but the exceptions and safe harbors are drawn narrowly and practices that involve remuneration that are alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal healthcare program anti-kickback statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal healthcare program anti-kickback statute has been violated. Additionally, the intent standard under the federal healthcare program anti-kickback statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal healthcare program anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Federal false claims laws, including the federal civil False Claims Act, and civil monetary penalties laws, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate false claims laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal civil and criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal healthcare program anti-kickback statute, the Affordable Care Act amended the intent standard for certain healthcare fraud under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, imposes certain requirements on covered entities, which include certain healthcare providers, health plans and healthcare clearinghouses, and their business associates and covered subcontractors that receive or obtain protected health information in connection with providing a service on behalf of a covered entity relating to the privacy, security and transmission of individually identifiable health information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, the federal Physician Payments Sunshine Act, created under the Affordable Care Act, and its implementing regulations, require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The majority of states also have statutes or regulations similar to the aforementioned federal fraud and abuse laws, some of which are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments or other transfers of value provided to physicians and other health care providers and entities, marketing expenditures, or drug pricing. Certain state and local laws also require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to potentially significant criminal, civil and administrative penalties, damages, fines, disgorgement, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, exclusion from participation in government healthcare programs, as well as contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Sales of pharmaceutical products depend in significant part on the availability of coverage and adequate reimbursement by third-party payors. Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients and providers are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of therapies in which our products are used.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the U.S., for example, principal decisions about reimbursement for new products are typically made by CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. In the U.S., no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Decisions regarding the extent of coverage and amount of reimbursement to be provided for each of our product candidates will be made on a plan-by-plan basis. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other services. Even if coverage is obtained for a given product, the resulting reimbursement payment rates may change. Additionally, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Outside the U.S., the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has, and will continue to, put pressure on the pricing and usage of therapeutics such as our product candidates.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current and future legislative proposals to further reform healthcare or reduce healthcare costs may result in lower reimbursement for our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce our revenues from the sale of our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For example, implementation of the Affordable Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers, and significantly impacted the pharmaceutical industry. There have been executive judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, President Trump signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the Affordable Care Act have been enacted. Legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact Affordable Care Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, which, among other things includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional Congressional action is taken. On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024. Additionally, in January 2013, the President signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. At the federal level there have been several presidential executive orders and U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In order to market any product outside of the U.S., we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">New Legislation and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations changed or what the effect of such changes, if any, may be.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EMPLOYEES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of April&#160;12, 2024, we had 69 total employees, 21 of whom hold Ph.D. or M.D. degrees, 51 of whom were engaged in research and development activities and 18 of whom were engaged in business development, finance, information systems, facilities, human resources, legal or administrative support. None of our employees are subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CORPORATE INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We were incorporated in Delaware as K2 Therapeutics, Inc. in December 2012. In July 2014, we changed our name to Cidara Therapeutics, Inc. Our principal executive offices are located at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, and our telephone number is (858)&#160;752-6170.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing our product candidates in Europe.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We make available free of charge on or through our internet website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission. We also regularly post copies of our press releases as well as copies of presentations and other updates about our business on our website. Our website address is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:underline">www.cidara.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The information contained in or that can be accessed through our website is not part of this Annual Report on Form 10-K. Information is also available through the Securities and Exchange Commission&#8217;s website at&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, as well as the other information in this Annual Report on Form 10-K, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. When evaluating our business, you should consider all of the factors described as well as the other information in our Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div id="ib00951007fb342d8a49dba10256b8485_31"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We need substantial additional funding to complete the development of rezafungin and to advance CD388, CBO421 and our other Cloudbreak programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the preparation of our financial statements for the period ended December&#160;31, 2023, we performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months, which raises substantial doubt about our ability to continue as a going concern. Our ability to continue to fund the development of rezafungin through completion of our planned Phase 3 trials depends on our ability to obtain additional funding. Our ability to advance CD388, CBO421 and other product candidates from our other Cloudbreak programs is also dependent on our ability to obtain additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma, pursuant to which we granted Mundipharma exclusive commercialization rights to rezafungin outside the United States, or U.S., and Japan in exchange for a $30.0&#160;million upfront payment, near-term funding to support the global Phase 3 ReSTORE and ReSPECT trials, and the potential to receive development, regulatory and commercial milestone payments and double-digit royalties in the teens on tiers of annual net sales. The Mundipharma Collaboration Agreement requires, among other things, that we complete the rezafungin development program. On March 31, 2021, we entered into an exclusive, worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize our Cloudbreak drug-Fc conjugates, or DFCs, for the prevention and treatment of seasonal and pandemic influenza. Under the collaboration, we will be responsible for the development and manufacturing of the first influenza DFC, CD388, into the clinic and through Phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. We received an upfront payment of $27.0&#160;million. Janssen will fund all future research, development, manufacturing and commercialization for CD388, of which Janssen has funded $44.5&#160;million as of December&#160;31, 2023. On July 26, 2022, we entered into a License Agreement, or the Melinta License Agreement, with Melinta Therapeutics, LLC, or Melinta, pursuant to which we granted Melinta an exclusive license to develop, register and commercialize rezafungin in the U.S. in exchange for a $30.0&#160;million upfront payment and the potential to receive regulatory and commercial milestone payments and tiered royalties on U.S. sales in the low double digits to mid-teens. The Melinta License Agreement requires, among other things, that we complete the rezafungin development program. Our ability to meet our development obligations under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement depends on our ability to obtain additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There can be no assurance that additional funds will be available from any source or, if available, will be available on terms that are acceptable to us. There can also be no assurance that additional funds will be available to us without first obtaining the approval of our stockholders, which can be a difficult and lengthy process with an uncertain outcome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Even if we raise additional capital, our expenses may increase in connection with our ongoing activities beyond what is currently expected. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing to complete our Phase 3 ReSPECT trial, the remaining Chinese portion of the ReSTORE trial and the CD388 Phase 1 and Phase 2a trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs, timing and outcome of any regulatory review of rezafungin, CD388, CBO421 or future development candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to establish and maintain collaborations, when and if necessary, on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing of commercialization activities, including manufacturing, marketing, sales and distribution, for rezafungin or any future product candidates that receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the scope, progress, results and costs of drug discovery, preclinical development, manufacturing development, laboratory testing and clinical trials for our product candidates, for the Cloudbreak platform; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Identifying potential development candidates and conducting preclinical studies, manufacturing development and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for any of our current or future product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accordingly, we need substantial additional funding in connection with our continuing operations and to achieve our goals. As of December&#160;31, 2023, we had cash and cash equivalents of $35.8 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate, it may make any additional debt or equity financing more difficult, more costly and more dilutive. In addition, we may not be able to access a portion of our existing cash and cash equivalents due to market conditions such as recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures, which could have a material adverse effect on our business and financial condition. In addition, if the financial market disruptions and economic slowdown deepen or persist, we may not be able to access additional capital on favorable terms, or at all, which could negatively affect our financial condition and our ability to pursue our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional capital on attractive terms or at all, we may be forced to delay, reduce or eliminate our development programs, including CD388, CBO421 or one or more of our other Cloudbreak DFC programs, be unable to continue the development of rezafungin, complete the ReSPECT Phase 3 clinical trial and meet our development obligations under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, or our other current and future license or collaboration agreements, and/or be forced to make reductions in spending, extend payment terms with suppliers, and/or liquidate or grant rights to assets where possible. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity, debt or other financing structures, receipt of payments under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, as well as potentially entering into other collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts. In November 2018, we entered into a new controlled equity offering sales agreement with Cantor Fitzgerald &amp; Co., or the Sales Agreement, which currently has an aggregate offering price of up to $50.0&#160;million, and, other than the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, it is our only current external source of potential financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, we issued $9.0&#160;million of our common stock to Mundipharma in connection with entering into the Mundipharma Collaboration Agreement. In February 2020, we issued $30.0&#160;million of our common stock and Series X Convertible Preferred Stock upon the closing of a rights offering. In October 2021, we issued $38.5&#160;million of our common stock and Series X Convertible Preferred Stock upon the closing of concurrent but separate public offerings. In March 2023, we issued shares of our common stock and Series X Convertible Preferred Stock upon the closing of concurrent but separate public offerings, for gross proceeds of $19.5&#160;million. As of December&#160;31, 2023, we have issued 20,769,854 shares of common stock pursuant to the Sales Agreement with an aggregate offering price of approximately $41.1&#160;million. To the extent that we raise additional capital through the sale of equity or convertible debt securities, like the sale of our common stock to Mundipharma, the sale of our common stock and Series X Convertible Preferred Stock issued in our rights offering, the sale of our common stock and Series X Convertible Preferred Stock in our concurrent underwritten public offerings or the sale of common stock under the Sales Agreement, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds by entering into collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. On September 3, 2019, we licensed all rights to rezafungin outside of the U.S. and Japan to Mundipharma in exchange for certain payments and double-digit royalties in the teens on tiers of annual net sales. In March 2021, we granted exclusive worldwide rights to CD388 and other influenza DFCs to Janssen in exchange for certain payments and royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits. In July 2022, we licensed all rights to rezafungin inside of the U.S. to Melinta in exchange for certain payments and tiered royalties on U.S. sales in the low double digits to mid-teens. We may need to enter into similar agreements with other third parties for the development and commercialization of rezafungin outside of the Mundipharma and Melinta territories, or for the development of DFCs identified from our Cloudbreak program outside the scope of the Janssen Collaboration Agreement, which may require we relinquish valuable rights to these products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds through government grants and contracts, we may be subject to restrictions on our operations or certain unfavorable terms. U.S. government grants and contracts, if available, typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. If we receive a U.S. government grant or contract, we would be required to comply with numerous laws and regulations relating to the formation, administration and performance of the grant or contract, which can make it more difficult for us to retain our rights under such grant or contract and result in increased costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity, debt or other financing structures, or through collaborations, strategic alliances or licensing arrangements with third parties, or through receiving government and/or charitable grants or contracts, we may be required to delay, reduce or terminate our rezafungin development program, including our ReSPECT Phase 3 clinical trial, be unable to meet our development obligations under the Mundipharma Collaboration Agreement and the Melinta License Agreement, and be unable to continue advancing the Cloudbreak program for non-influenza DFCs, or be forced to grant rights in the Cloudbreak program for non-influenza DFCs that we would otherwise prefer to retain for ourselves.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since our inception, and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We had net loss of $22.9 million and $33.6 million for the years ended December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023, we had an accumulated deficit of $441.4 million. To date, we have financed our operations primarily through sale of our stock in public offerings and private placements, through borrowings under loan facilities, and through payments received in connection with the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement. We are currently conducting the ReSPECT and ReSTORE China Phase 3 clinical trials of rezafungin, Phase 1 and Phase 2a studies of CD388, and preclinical studies of our other DFCs, including CBO421. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">submit investigational new drug applications, or INDs, to the U.S. Food and Drug Administration, or FDA, and equivalent filings to other regulatory authorities, and seek approval of our clinical protocols by institutional review boards at clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">continue to advance rezafungin and CD388 through clinical development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">continue the preclinical development of our other DFCs from our Cloudbreak platform or otherwise, and advance one or more of such product candidates into clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">seek marketing approvals for rezafungin, CD388, CBO421 and other product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establish or contract for a sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">maintain, expand and enforce our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">hire additional manufacturing, clinical, regulatory, quality assurance and scientific personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">add operational, financial and management systems and personnel, including personnel to support product development; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acquire or in-license other product candidates and technologies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenue that is significant or large enough to achieve profitability.&#160;Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the recent global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, rising inflation, bank failures, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate, it may make access to our liquidity within the U.S. banking system and any additional debt or equity financing more difficult, more costly and more dilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Israel-Hamas war and the conflict between Russia and Ukraine could lead to disruption, instability and volatility in global markets and industries that could negatively impact our operations. For example, in connection with the conflict between Russia and Ukraine, the U.S. government and other governments in jurisdictions in which we operate have imposed severe sanctions and export controls against Russia and Russian interests and threatened additional sanctions and controls. The impact of these measures, as well as potential responses to them by Russia, is currently unknown and they could adversely affect our business, supply chain, partners or customers.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have no history of commercializing pharmaceutical products, which may make it difficult for you to evaluate the prospect for our future viability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have not yet demonstrated an ability to conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop one new product from the time it is discovered to when it is commercially available. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had product candidates in advanced clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. We will need to continue to transition from a company with a research focus to a company capable of supporting late-stage development activities and, if a product candidate is approved, a company with commercial activities. We may not be successful in any step of such a transition.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to continue to satisfy the applicable continued listing requirements of Nasdaq, our common stock could be delisted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;CDTX.&#8221; In order to maintain this listing, we must continue to satisfy minimum financial and other continued listing requirements and standards. We cannot assure you that we will be able to continue to comply with the applicable listing standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are not able to comply with applicable listing standards, our shares of common stock will be subject to delisting. For example, one of the continued listing requirements for The Nasdaq Capital Market is a minimum bid price of at least $1.00 per share, or the Minimum Bid Price Requirement. We were first notified by the Listing Qualification Staff of the Nasdaq Stock Market LLC, or Nasdaq, on February 28, 2022, that our common stock had failed to maintain the Minimum Bid Price Requirement for 30 consecutive business days. Following extension periods to regain compliance, on February 9, 2023, the Nasdaq Hearings Panel notified us that we had regained compliance with the Minimum Bid Price Requirement subject to a discretionary Panel Monitor until November 9, 2023. On November 9, 2023, we were notified by Nasdaq that our common stock had once again failed to maintain the Minimum Bid Price Requirement for the 30 consecutive business days preceding November 6, 2023. On November 17, 2023, Nasdaq granted us a hearing date with the Nasdaq Hearings </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Panel on February 1, 2024. The hearing was conducted on February 1, 2024, and on February 8, 2024, the Nasdaq Hearings Panel granted our request for continued listing on The Nasdaq Capital Market, pursuant to an extension, through May 7, 2024, to regain compliance with the Minimum Bid Price Requirement. The extension is subject to certain specified conditions and our submission of certain interim updates to the Nasdaq Hearings Panel. If it were to occur, the delisting of our common stock from trading on Nasdaq could have a material adverse effect on the market for, and liquidity and price of, our common stock and impair our ability to raise capital. Delisting from Nasdaq could also have other negative results, including, without limitation, the potential loss of confidence by customers and employees, the loss of institutional investor interest and fewer business development opportunities. In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</span></div><div id="ib00951007fb342d8a49dba10256b8485_28"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Drug Discovery, Development and Commercialization</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of rezafungin and CD388, which is currently in Phase 1 and Phase 2a clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are currently conducting two Phase 3 clinical trials of rezafungin. We have completed the ReSTORE trial and conducted the primary analyses required for approval in U.S. and Europe but are continuing to conduct the ReSTORE China trial to support Chinese regulatory filings. We also continue to enroll patients in the ReSPECT trial, which is designed to assess the safety and efficacy of rezafungin for the prevention of serious fungal infections in patients undergoing blood and marrow transplants. The FDA approved our new drug application, or NDA, for rezafungin for the treatment of candidemia and invasive candidiasis in adults with limited or no treatment options, in March 2023. Even though rezafungin has been approved for the treatment indication, we may not be successful in obtaining approval for a supplemental NDA, or sNDA, for the expanded prophylaxis indication. In addition, the European Medicines Agency, or EMA, may not approve rezafungin for any indication. The ReSPECT trial is currently enrolling globally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We received IND clearance for CD388, our DFC for prevention and treatment of influenza, from the FDA in March 2022 and subsequently initiated a Phase 1 clinical trial. In September 2022, we initiated a Phase 2a trial of CD388 to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus and a separate Phase 1 Japanese bridging study has been initiated. We are also conducting in vitro and in vivo preclinical studies of other product candidates from our Cloudbreak program for viral infections and oncology indications. Our assumptions about why rezafungin and CD388 are worthy of continued development, as well as our assumptions about the markets for rezafungin, CD388, CBO421 or any other potential products from our Cloudbreak program, are based on data primarily collected by other companies. The timing and costs of our preclinical and clinical development programs, the likelihood of European marketing approval for rezafungin and any marketing approval for CD388, and the regulatory paths for marketing approval for additional products from our Cloudbreak program remain uncertain. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of rezafungin, CD388, CBO421 and any other product candidates we may develop will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to secure adequate additional funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">agreement with regulatory authorities on study designs and other requirements for study initiation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful completion of preclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful enrollment and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">demonstration of safety and efficacy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">negotiation of favorable indications and other key elements of the product labeling;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">launching commercial sales of the product candidates if and when approved;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">effectively competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a continued acceptable safety profile of the products following approval; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enforcing and defending intellectual property rights and claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we do not timely enroll the ReSPECT Phase 3 clinical trial, or if we are unable to secure significant additional funding, we will not be able to complete the clinical development plans for the prophylaxis indication for rezafungin. If we do not accomplish one or more of any of the other goals in a timely manner, or at all, we could experience significant delays or an inability to successfully complete the development of and commercialize our product candidates, which would harm our business.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in enrolling patients in our clinical trials our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may not be able to complete the ReSPECT clinical trial if we are unable to identify and enroll a sufficient number of eligible patients, as required by the FDA or similar regulatory authorities outside the U.S., or if we do not believe that the number of patients required by such regulatory authorities can be enrolled in a reasonable timeframe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our rezafungin Phase 3 clinical development program is a global program and, as such, our ability to timely enroll the clinical trials may be affected by many different factors specific to those global localities, such as, delays in our receipt of approval to commence trials in a particular country from applicable regulatory authorities and ethics committees, timely completion of clinical trial site initiation within each country, delays in local importation and receipt of necessary clinical trial supplies, and our ongoing compliance with local regulations, which may change during the course of the clinical trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the rezafungin clinical trials are heavily reliant on third-party contractors, including contractors that import clinical trial materials, and contract research organizations, or CROs, that conduct and monitor our clinical trials, and interact with regional or local regulators and ethics committees on our behalf. If we experience significant difficulties with any of our key contractors such that we determine it is in the best interests of the clinical trials to replace a key contractor, this could result in a significant delay in enrollment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The COVID-19 global pandemic significantly impacted our ability to activate sites and enroll patients in the ReSPECT trial, resulting in substantial delays and increases in the cost of completing the trial. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, some of our competitors may have ongoing or new clinical trials for product candidates that would treat the same indications as rezafungin, or be used in the same patients and, therefore, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment may also be affected by other factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">eligibility criteria, including regional or local practices that place additional limitations on patient eligibility;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">availability, safety and efficacy of approved medications or other investigational medications being studied clinically for the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">perceived risks and benefits of rezafungin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reluctance of physicians to encourage patient participation in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">delays or failures in maintaining an adequate supply of quality drug product for use in clinical trials; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changing treatment patterns that may reduce the burden of disease which rezafungin addresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our inability to enroll and retain a sufficient number of patients in a reasonable timeframe may require us to abandon the entire rezafungin Phase 3 clinical development program or terminate the ReSPECT trial. Enrollment delays have and will continue to result in increased development costs, which could cause the value of our company to decline and could limit our ability to obtain necessary additional financing. For example, in the ReSPECT trial, a blinded interim analysis is planned in the first quarter of 2024 which will inform the current fungal free survival rates, or FFS. The FFS will determine if the 462 patients planned to be enrolled will be sufficient to power the trial to maintain non-inferiority. If the number of patients planned to be enrolled are not sufficient, the trial may need to enroll more patients which may potentially impact the overall timing to top-line data and increase trial costs. The study is currently enrolling in the EU, Canada and the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for rezafungin, CD388, CBO421 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A delay in starting or completing our clinical trials would materially impact our timelines and our ability to complete development of our product candidates in a timely manner or at all. For example, our entire rezafungin clinical development program was severely impacted by the effects of COVID-19. Additionally, our ability to complete our rezafungin Phase 3 development program is dependent on our ability to secure adequate additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A failure of one or more clinical trials could occur at any stage of testing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a particular clinical trial do not necessarily predict final results of that trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, preclinical and clinical data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. For example, the historically observed high rate of correlation for clinical efficacy for anti-infectives based on preclinical data may not apply for our current or future product candidates, and any of the potential benefits that we anticipate for human clinical use may not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not know whether either the ReSPECT trial or the Phase 1 or Phase 2a trials of CD388 will be completed on schedule. We may experience numerous unforeseen events that could delay or prevent our ability to commence or complete our clinical trials, which could then delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial on our expected timeline, or at all, or conduct a clinical trial at a prospective trial site or in a given country;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may disagree with our interpretation of preclinical data, which may impact our ability to commence our trials on our expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may require that trials or studies be conducted, or sized or otherwise designed in ways, that were unforeseen in order to begin planned studies or to obtain marketing authorization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, modify planned clinical trial designs or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enrollment in these clinical trials may be slower than we anticipate, clinical sites may drop out of our clinical trials or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators, institutional review boards or the data safety monitoring board assembled by us to oversee our rezafungin clinical trials may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks due to serious and unexpected side effects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the FDA or comparable foreign regulatory authorities could require that we perform more studies than, or evaluate clinical endpoints other than, those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the supply of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be delayed or insufficient, or the quality of such materials may be inadequate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may be required to delay or terminate studies due to financial constraints.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside the U.S. do not agree with the design and implementation of our planned or ongoing clinical trials, including the safety database to support an NDA submission, or if we are unable to secure additional funding, we may not be able to complete the overall Phase 3 clinical development program for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">rezafungin as currently envisioned. If we are required to conduct additional clinical trials, or other tests of our product candidates beyond those that we currently contemplate, if we are unable to complete clinical trials of our product candidates or other tests successfully or in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">not obtain marketing approval at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to additional post-marketing testing requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to significant restrictions on reimbursement from public and/or private payors; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Product development costs will also increase if we experience delays in testing or in receiving marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, could allow our competitors to bring products to market before we do, could increase competition from generics of the same class, and could impair our ability to successfully commercialize our product candidates, any of which may harm our business and results of operations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because it is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval, the risk of each of our programs is high. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. For example, the pharmacokinetic properties, such as a longer half-life or less frequent dosing regimen, that differentiate rezafungin from other echinocandins could have side effects that we have not anticipated and the consequences of such side effects could be more severe than have been seen with other echinocandins that have shorter half-lives or more frequent dosing regimens, or are dosed at lower concentrations than we expect for rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, the treatment advantages that we are predicting for rezafungin, such as lower healthcare costs resulting from an ability to administer rezafungin once-weekly, which could allow earlier hospital discharge, or the predicted ability of rezafungin to be effective against resistant strains of fungal pathogens, may not be realized. For our DFCs, the bispecific mechanism of action, including the use of the immune system, may lead to side effects that are not anticipated based on the preclinical work we have conducted to date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the biotechnology industry, many agents that initially show promise in early stage testing may later be found to cause side effects that prevent further development of the agents. In addition, infections can occur in patients with co-morbidities and weakened immune systems, and there may be adverse events and deaths in our clinical trials that are attributable to factors other than investigational use of our product candidates.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited financial resources. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential than opportunities we pursue. For example, we believe that an sNDA filing for rezafungin adding the prophylaxis indication can be supported by one Phase 3 trial in prophylaxis, however, financial constraints may require us to delay our prophylaxis program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In support of the global effort to identify effective therapeutics to treat and prevent the COVID-19 coronavirus we have expended financial resources to identify DFCs which may be effective in this area. In addition, we have recently expended financial resources on identification of DFCs targeting multiple potentially synergistic oncology targets. We have limited experience in identification and nonclinical and clinical testing of oncology therapeutics. Our resource allocation decisions may not result in us identifying valuable products or may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">commercial potential or target markets for a particular product candidate or opportunity, we may relinquish valuable rights to that product candidate or opportunity through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or opportunity.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Any of our product candidates that receive marketing approval may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any of our product candidates that receive marketing approval may nonetheless fail to gain sufficient market acceptance by hospitals and hospital pharmacies, physicians, patients, third-party payors and others in the medical community for us to achieve commercial success. If our product candidates do not achieve an adequate level of acceptance, we may not generate sufficient product revenue to become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and potential advantages compared to alternative therapies;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size of the markets in the countries in which approvals are obtained;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terms, limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to offer any approved products for sale at competitive prices;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of the target patient population to try new therapies or dosing regimens;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of physicians to prescribe these therapies and, in the case of rezafungin, transition to a once-weekly dosing regimen from traditional once-daily dosing;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the strength of marketing and distribution support;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the success of competing products and the marketing efforts of our competitors;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sufficient third-party payor coverage and adequate reimbursement; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the prevalence and severity of any side effects.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved. In addition, if we enter into agreements with third parties to sell and market our product candidates, such third parties may not be successful in commercializing our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure. To achieve commercial success for any approved product, we must license the rights to third parties with such capabilities, develop a sales and marketing organization or outsource these functions to third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot reposition our sales and marketing personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability of sales personnel to obtain access to physicians or to achieve adequate numbers of prescriptions for any future products; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenues to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties and any of them may fail to market and sell our products effectively, including by failing to devote the necessary resources and attention. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we do establish relationships with third parties to sell and market our product candidates, such third parties may not be successful in commercializing those products. For example, in the U.S. we are entirely dependent on Melinta to commercialize rezafungin. While Melinta has significant experience in commercialization of anti-infective drugs, they have limited experience with commercialization of antifungal drugs and may be unable to hire individuals with the requisite expertise or develop and execute an appropriate commercialization plan.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Regulatory incentives to develop drugs for treatment of infectious diseases have increased interest and activity in this area and will lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the indications on which we are focusing our product development efforts. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that rezafungin will primarily compete with certain antifungal classes of drugs, which include polyenes, azoles and echinocandins. Approved branded echinocandin antifungal therapies include Cancidas (caspofungin, marketed by Merck&#160;&amp; Co.), Eraxis (anidulafungin, marketed by Pfizer, Inc.), and Mycamine (micafungin, marketed by Astellas Pharma US, Inc.). We expect that there will be generics of all of the current echinocandins available at the time of rezafungin market approval, which will create added competition.&#160;In addition, there are other generic products approved for candidemia, marketed by companies such as Baxter Healthcare Corporation, Mylan Inc. and Glenmark Generics Inc., among others. In addition to approved therapies, we expect that rezafungin will compete with product candidates that we are aware of in clinical development by third parties, such as fosmanogepix (PF-07842805), which is being developed by Pfizer, Inc. and ibrexafungerp, which is approved for other indications and is being developed for invasive candidiasis by Scynexis, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that CD388 will compete against approved and investigational agents for the treatment or prevention of viral influenza infections, including influenza vaccines, neuraminidase inhibitors such as Tamiflu, Relenza and Peramivir, and endonuclease inhibitors such as Xofluza. We may develop other product candidates through our Cloudbreak platform for the treatment or prevention of other serious diseases, such as solid tumor cancers and viral infections.&#160;We are aware of a large number of approved and investigational therapies in these areas also. We expect that CBO421 will compete against approved anticancer therapeutics as well as investigational CD-73 targeting small molecule drugs, including Oric-533 being developed by Oric Pharmaceutical, Inc. and quemliclustat being developed by Arcus Biosciences, Inc. as well as monoclonal antibodies, including oleclumab being developed by AstraZeneca PLC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater name recognition, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These same competitors may invent technology that competes with our rezafungin program, CD388, CBO421, or our Cloudbreak platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we publicly disclose interim, preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analysis of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:15pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, these products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-top:6pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the U.S., new and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product-licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial marketing approval is granted. As a result, we might obtain marketing approval for a drug in a particular country but then be subject to price regulations that delay its commercial launch, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to commercialize and generate revenue from one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside the U.S. Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and the medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">circumstances under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our overall financial condition. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and we face an even greater risk for our products that receive marketing approval. If we cannot successfully defend ourselves against claims that our product candidates and products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">decreased demand for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant costs and distraction of management to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the initiation of investigations by regulatory bodies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability to commercialize any products we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we have product liability insurance for our clinical trials, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue or expand our clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees in our workplace, including those resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, chemical, hazardous or radioactive materials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify, discover, and develop potential product candidates through our Cloudbreak platform or otherwise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Through our Cloudbreak platform, we are developing DFCs for the treatment and prevention of serious diseases, including influenza and various cancers. We have nominated the DFC CD388 as our lead development candidate for influenza, and we have nominated CBO421 as our lead oncology DFC candidate.&#160;In applying our Cloudbreak platform, we may not be successful in identifying additional DFCs that could be developed as drug therapies. In addition, our Cloudbreak platform may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons. In particular, our research methodology used may not be successful in identifying compounds with sufficient potency, bioavailability or efficacy to be potential product candidates. In addition, our potential product candidates may, on further study, be shown to have harmful side effects or other negative characteristics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical expertise and human resources. For example, we have limited experience with the use of the Cloudbreak platform applied to viral pathogens and oncology targets. A failure to optimize our expertise using the Cloudbreak platform for the development of our Cloudbreak program may limit our ability to successfully advance this program and identify future product candidates. Research programs to identify new product candidates also require substantial financial resources. We may choose to expend our financial resources on potential product candidates that ultimately prove to be unsuccessful. For example, we have expended financial resources to identify therapeutics to treat or prevent the COVID-19 coronavirus, and we may be unsuccessful in identifying such a DFC. If we are unable to identify successful product candidates from our Cloudbreak platform for preclinical and clinical development, we will have spent financial resources on programs that did not yield viable products and therefore generate product revenue, which would harm our financial position and adversely impact our stock price.</span></div><div id="ib00951007fb342d8a49dba10256b8485_34"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our collaboration partners to provide funding to continue the development of rezafungin and CD388; for the commercialization of rezafungin outside Japan; and for the late-stage development, manufacturing, registration and commercialization of CD388. If the collaborations are not successful, we may not be able to complete the development of rezafungin and CD388, or capitalize on the full market potential for rezafungin and CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we licensed the rights to rezafungin outside of the U.S. and Japan to Mundipharma, a large international pharmaceutical company, and on July 26, 2022, we licensed the rights to rezafungin inside the U.S. to Melinta. Our ability to complete the development of rezafungin is dependent, in part, on funds provided by Mundipharma and Melinta. Additionally, our ability to receive payments from these arrangements will depend on Mundipharma&#8217;s and Melinta&#8217;s ability to successfully commercialize rezafungin in their respective territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Mundipharma Collaboration Agreement and the Melinta License Agreement pose many risks to us, including that our collaborator, Mundipharma, and our licensee, Melinta:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">have significant discretion in determining the efforts and resources they will apply to commercializing rezafungin in their respective territories, and may not commit sufficient resources to the marketing and distribution of rezafungin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may be unable to successfully commercialize rezafungin in one or more territories because, following regulatory approval, they may be unable to obtain formulary pricing approval, reimbursement approval, and/or formulary placement;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">have limited experience commercializing antifungal therapeutics and therefore may be unsuccessful in developing and implementing commercial launch plans for rezafungin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may terminate the Mundipharma Collaboration Agreement and the Melinta License Agreement at will;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may be subject to changes in key personnel or strategic focus, have limited available funding or be subject to other external factors diverting resources or creates competing priorities, all of which could negatively impact the commercialization of rezafungin in their respective territories;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may independently develop, or develop with third parties, products that compete directly or indirectly with rezafungin if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may use our intellectual property or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may not agree with certain development decisions resulting in the delay or termination of the programs, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be involved in a business combination and the continued pursuit and emphasis on rezafungin could be delayed, diminished or terminated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be financially impacted by inflation or bank failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our ability to generate revenue under the Mundipharma Collaboration Agreement and the Melinta License Agreement is adversely impacted by these or any other risks, our right to receive additional payments from the Mundipharma Collaboration Agreement and the Melinta License Agreement, including our share of the revenues generated by net sales of rezafungin, if approved, could be insufficient to allow us to complete our rezafungin development program including the ReSPECT Phase 3 clinical trial, to achieve or maintain profitability or may result in rezafungin being less valuable to us than if we had not entered into the Mundipharma Collaboration Agreement and the Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we licensed the exclusive worldwide rights to CD388 and other influenza DFCs to Janssen. Our ability to complete the development of CD388 is dependent, on funds provided by Janssen. As part of a recent prioritization of its R&amp;D business, in July 2023 Janssen disclosed its intention to discontinue internal development of multiple product candidates in its infectious disease pipeline, including CD388. However, in September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen will assume the future development, manufacturing and commercialization activities of CD388 but intends to transfer its rights and obligations under the Janssen Collaboration Agreement to another transferee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following Janssen&#8217;s Election to Proceed Notice, Janssen, or any third-party transferee, is obligated at its sole expense to diligently continue development and commercialization either itself or through the transferee to whom it sublicenses or assigns the rights. If Janssen sublicenses or assigns the rights to a transferee, then all terms under the current Janssen Collaboration Agreement will survive without modification. However, there is no guarantee that Janssen will execute an agreement with a transferee and may ultimately decide to terminate the Janssen Collaboration Agreement. Additionally, our ability to receive payments from this arrangement will depend in part on Janssen&#8217;s, or any third-party transferee&#8217;s, ability to successfully commercialize CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Janssen Collaboration Agreement poses many risks to us, including that our collaborator, Janssen:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">has significant discretion in determining the efforts and resources it will apply to developing, manufacturing, registering and commercializing CD388;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may terminate the collaboration agreement at will, subject to certain limitations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may be subject to changes in key personnel or strategic focus, have limited available funding or be subject to other external factors diverting resources or creates competing priorities, all of which could negatively impact the development, manufacturing, registration and commercialization of CD388;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may independently develop, or develop with third parties, products that compete directly or indirectly with CD388 if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may use our intellectual property or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may not agree with certain development decisions resulting in the delay or termination of the program, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be involved in a business combination and the continued pursuit and emphasis on CD388 could be delayed, diminished or terminated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be financially impacted by inflation or bank failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our ability to generate revenue under the Janssen Collaboration Agreement is adversely impacted by these or any other risks, our right to receive additional payments under the Janssen Collaboration Agreement, including milestone payments and royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits, could be insufficient to allow us to achieve or maintain profitability or may result in CD388 being less valuable to us than if we had not entered into the Janssen Collaboration Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may seek to selectively establish other collaborations and, if we are unable to establish them on commercially reasonable terms or at all, we may have to alter our research, clinical development and commercialization plans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may seek to collaborate with other pharmaceutical and biotechnology companies to advance the Cloudbreak program for DFCs outside the scope of the Janssen Collaboration Agreement, or for the completion of development and commercialization of rezafungin in Japan. We may also seek funding from government grants or contracts to advance the Cloudbreak program for DFCs outside of the Janssen Collaboration Agreement. We cannot be certain that we will be successful in completing any such collaboration or obtaining any such government grants or contracts, or completing any of them on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate pharmaceutical or biotech collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, on the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Those factors may include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the design or results of preclinical studies, chemistry, manufacturing and controls, or CMC, development activities or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the likelihood of approval by the FDA or similar regulatory authorities outside the U.S.;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential market for the product candidate in the territories that are the subject of the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and complexities of manufacturing and delivering such product candidate to patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential of competing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">industry and market conditions generally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also face significant competition for government grants and contracts for the Cloudbreak program, and there can be no assurances that such funding would be available to us if and when needed, or at all. For instance, government funding may be available only at certain phases of research and development, such as only after Phase 1 clinical trials have been completed. In order to advance the Cloudbreak program for DFCs outside of the Janssen Collaboration Agreement, we will need to obtain significant funding to complete IND-enabling studies, manufacturing development and Phase 1 clinical trials. Government grants and contracts may not be available to fund our activities at this earlier phase of the research and development process.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We intend to continue to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and preclinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely and expect to continue to rely on third parties, such as CROs, contract manufacturers of clinical supplies, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and to conduct some aspects of our research and preclinical testing. Many of these third parties may terminate their engagements with us at any time. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other international regulatory authorities require us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, available at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:underline">www.clinicaltrials.gov</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical studies and clinical trials and for commercial supply of any of these product candidates should we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have established agreements with third-party manufacturers for production of our products for clinical and commercial use, and our reliance on these- manufacturers entails additional risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible breach of the manufacturing agreement by the third party, including the inability to supply sufficient quantities or to meet quality standards or timelines; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with current U.S. Good Manufacturing Practice requirements, or cGMPs, or similar regulatory requirements outside the U.S. Our failure, or the failure of our third-party manufacturers, to comply with cGMPs or other applicable regulations, even if such failures do not relate specifically to our product candidates or approved products, could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product that we develop may compete with other product candidates and products for access to these manufacturing facilities. There are a limited number of manufacturers that operate under cGMPs and that might be capable of manufacturing for us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers, including a failure that may not relate specifically to our product candidate or approved product, could delay clinical development or marketing approval or adversely impact our ability to generate commercial sales. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Some of our manufacturers and suppliers are located in China. Trade tensions and conflict between the United States and China have been escalating in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules, regulations, and policies of the governments of the United States or China, or due to geopolitical unrest and unstable economic conditions. Certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. Government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting their supply of material to us. Such disruption could have adverse effects on the development of our product candidates and our business operations. In addition, the recently proposed BIOSECURE Act introduced in House of Representatives, as well as a substantially similar bill in the Senate, targets certain Chinese biotechnology companies. If these bills become law, or similar laws are passed, they would have the potential to severely restrict the ability of companies to contract with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties to release, label, store and distribute drug supplies for our clinical trials. Any performance failure on the part of these third parties, including a failure that may not relate specifically to our product candidate or approved product, could delay or otherwise adversely impact clinical development or marketing approval of our product candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, our manufacturers and suppliers may experience difficulties related to their overall businesses and financial stability, which could result in delays or interruptions of supply of our product candidates or approved products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have alternate manufacturing plans in place at this time. If we need to change to other manufacturers, the FDA and comparable foreign regulators may have to approve these manufacturers&#8217; facilities and processes prior to our use, which would require new testing and compliance inspections. In addition, the new manufacturers would have to be educated in or independently develop the processes necessary for production. This would result in delays and costs, and in the case of approved products, the potential loss of revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, release, safety, efficacy, regulatory filings, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the U.S. and by comparable authorities in other countries. For example, in order to commence clinical trials of our product candidates in the U.S., we must file an IND and obtain FDA agreement to proceed. The FDA may place our development program on clinical hold and require further preclinical testing prior to allowing our clinical trials to proceed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must obtain marketing approval in each jurisdiction in which we market our products. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. As a company we may not be able to prepare our contract manufacturers and clinical sites for inspection associated with NDA review, or appearing before an FDA advisory committee. We may receive a Complete Response Letter rather than approval. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process, testing and release and inspection of manufacturing facilities and personnel by the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the U.S. and elsewhere, is expensive, may take many years and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot assure you that we will ever obtain any marketing approvals in any jurisdiction. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical or other studies, changes in the manufacturing process or facilities or clinical trials. Moreover, approval by the FDA or an equivalent foreign authority does not ensure approval by regulatory authorities in any other countries or jurisdictions, but a failure to obtain marketing approval in one jurisdiction may adversely impact the likelihood of approval in other jurisdictions. In addition, varying interpretations of the data obtained from preclinical testing, manufacturing and product testing and clinical trials could delay, limit or prevent marketing approval of a product candidate. Additionally, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of promotional materials and safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements for product facilities, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and related recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not comply with these restrictions, we may be subject to enforcement actions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes and facilities or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on such products, manufacturers or manufacturing processes or facilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on the labeling, marketing, distribution or use of a product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">requirements to conduct post-approval clinical trials, other studies or other post-approval commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of the products from the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product seizure; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Healthcare professionals and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal healthcare anti-kickback statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false claims laws, which impose criminal and civil penalties, including civil whistleblower or qui tam actions under the federal civil False Claims Act, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal anti-kickback statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, also imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates and their covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which require, among other things, certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and information regarding physician ownership and investment interests; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business activities, including sales or marketing arrangements and claims involving healthcare items or services including, in some states, those reimbursed by non-governmental third-party payors, including private insurers, some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments or other transfers of value provided to physicians and other health care providers and entities, marketing expenditures, or drug pricing, state and local laws that require the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.&#160;Interpretations of standards of compliance under these laws and regulations are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems, or those of third parties upon which we rely, or our data are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and the third parties upon which we rely, may collect, store, use, transmit, receive, generate, transfer, disclose, make accessible, protect, secure, dispose of, process, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data (collectively, sensitive data). As a result, we and the third parties upon which we rely face a variety of evolving threats that could cause security incidents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, online and offline fraud, and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyberattacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to, social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, earthquakes, fires, floods, attacks enhanced or facilitated by artificial intelligence, or AI, and other similar threats.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network, including working at home, while in transit and in public locations. Additionally, future or past business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks, and other threats to our business operations. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, CROs, contract manufacturers of clinical and commercial supplies, clinical data management organizations, medical institutions, clinical investigators, cloud-based infrastructure, data center facilities, encryption and authentication technology, employee email, and other functions. We also rely on third-party service providers to provide other products, services, parts, or otherwise to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a security incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to manufacture or deliver our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate and remediate vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon which we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely basis. Further, we may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may negatively impact our ability to grow and operate our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive data of the Company could be leaked, disclosed, or revealed as a result of or in connection with our employee&#8217;s, personnel&#8217;s, or vendor&#8217;s use of generative artificial intelligence, or AI, technologies.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of business, we process sensitive data, and as a result, our data processing activities subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S., federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, and their respective implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the past few years, at least ten U.S. states have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020, or CPRA, collectively CCPA, applies to personal data of consumers, business representatives, and employees who are California residents, and requires businesses to provide specific disclosures in privacy notices and honor requests of such individuals to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. While these states, like the CCPA, may also exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Outside the U.S., an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the EU&#8217;s General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR, and Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018) impose strict requirements for processing personal data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For example, under GDPR, companies may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR, 17.5 million pounds sterling under the UK GDPR or, in each case, 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also conduct clinical trials in China and may be subject to new and emerging data privacy regimes in China, including China&#8217;s Personal Information Protection Law, or PIPL, Cybersecurity Law, Data Security Law, Measures for Cybersecurity Review, Measures on the Security Assessment of Cross-border Data Transfer, and Measures for the Standard Contract on the Cross-border Transfer of Personal Information. In Canada, the Personal Information Protection and Electronic Documents Act, or PIPEDA, and various related provincial laws, as well as Canada&#8217;s Anti-Spam Legislation, or CASL, may apply to our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may be unable to transfer personal data from Europe, China, and other jurisdictions to the U.S. or other countries due to data localization requirements or limitations on cross-border data flows. Europe, China and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area, or EEA, and the United Kingdom, or UK, have significantly restricted the transfer of personal data to the U.S. and other countries whose privacy laws it generally believes are inadequate. China also requires entities to rely on a transfer mechanism to lawfully transfer personal data overseas and ensure that the overseas </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">data recipients can meet the same data protection standards as required under the PIPL. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, the UK&#8217;s International Data Transfer Agreement/Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the U.S., or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activities groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR&#8217;s cross-border data transfer limitations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our employees and personnel may use generative AI technologies to perform their work, and the disclosure and use of personal information in generative AI technologies is subject to various privacy laws and other privacy obligations. Governments have passed and are likely to pass additional laws regulating generative AI. Any use of this technology could result in additional compliance costs, regulatory investigations and actions, and consumer lawsuits. If we are unable to use generative AI, it could make our business less efficient and result in competitive disadvantages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We use AI and machine learning, or ML, to assist us in making certain decisions, which is regulated by certain privacy laws. Due to inaccuracies or flaws in the inputs, outputs, or logic of the AI/ML, the model could be biased and could lead us to make decisions that could bias certain individuals (or classes of individuals), and adversely impact their rights, employment, and ability to obtain certain pricing, products, services, or benefits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions (including in relation to clinical trials); limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations.&#160;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&#160;We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.&#160;Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&#160;We may engage third parties for clinical trials outside of the U.S., to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&#160;We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations.&#160;We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Currently, we conduct the ReSTORE trial in China and have exclusively licensed the rights to commercialize rezafungin, our investigational drug studied in the ReSTORE trial, in China to our third-party collaborator, Mundipharma. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. For example, in order to conduct a clinical trial in China, sponsors must not only obtain the approval of the National Medical Product Administration of China, but also a separate approval from or filing with the Ministry of Science and Technology under the Administrative Regulations on Human Genetic Resources of the People&#8217;s Republic of China, or HGR Regulation, for clinical trials involving HGR Materials or Information. Any failure to comply with these requirements could cause our ReSTORE trial to be suspended by governing authorities, may result in fines and also may constitute a breach under our agreements with third parties assisting us in the conduct of the trial in China, such as our CRO. In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Certain changes or amendments to policy or law may result in increased compliance costs on our business, or cause delays in the timely completion of the ReSTORE trial in China, or prevent the approval of rezafungin in China. Chinese authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by us to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our clinical activities in China.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system, including cost-containment measures, that could reduce or limit coverage and reimbursement for newly approved drugs, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For example, in March 2010, President Obama signed into law the Affordable Care Act, a sweeping law intended to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable Care Act and subsequent regulations revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. However, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024. Further, the Affordable Care Act imposed a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance were also enacted under the Affordable Care Act, which may affect our business practices with healthcare practitioners. There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any additional healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments will remain in effect until 2032 unless additional Congressional action is taken. Additionally, in January 2013, the President signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively starting in fiscal year 2023. Under the new Drug Price Negotiation Program, the number of drugs subject to price negotiation will be 10 Part D drugs for 2026, another 15 Part D drugs for 2027, another 15 Part D and Part B drugs for 2028, and another 20 Part D and Part B drugs for 2029 and later years. These drugs will be selected from among the 50 drugs with the highest total Medicare Part D spending and the 50 drugs with the highest total Medicare Part B spending. The number of drugs with negotiated prices available will accumulate over time. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA permits HHS to implement many of the statutory provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&#8217;s Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result in lower drug prices for products covered by those programs. We cannot be sure whether additional legislative changes will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">be enacted, or whether the FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted within and outside the U.S. in the future, any of which could add difficulty to the regulatory approval processes for our product candidates or limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. The continuing efforts of third-party payors to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability and the level of taxes that we are required to pay.</span></div><div id="ib00951007fb342d8a49dba10256b8485_40"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to rezafungin, CD388, CBO421, our other Cloudbreak compounds or our other product candidates or compounds are not adequate, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to rezafungin and our other product candidates and compounds. Any involuntary disclosure to or misappropriation by third parties of our proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain and our commercial success will depend on our ability to obtain patents and maintain adequate protection for rezafungin, our DFCs and other compounds and product candidates in the U.S. and other countries. We currently hold issued U.S. utility and foreign patents and multiple pending U.S. utility patent applications, pending U.S. provisional patent applications and pending international, foreign national and regional counterpart patent applications covering various aspects of rezafungin and our DFCs. The patent applications may fail to result in issued patents in the U.S. or in foreign countries or jurisdictions. Even if the applications do successfully issue, third parties may challenge the patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, the existing and/or future patents, if any, may be too narrow to prevent third parties from developing or designing around these patents. If the sufficiency of the breadth or strength of protection provided by the patent and patent applications we own with respect to rezafungin or our DFCs or the patents we pursue related to any of our other product candidates or compounds is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize the product candidates or compounds. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced, although a patent term extension or supplementary protection certificate having varied scope may be available in certain jurisdictions to compensate for some of the lost patent term. In addition, we do not know whether:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to make the inventions covered by each of our pending patent applications or our issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">others will independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our pending patent applications will result in issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our patents, once issued, will be valid or enforceable or will issue with claims sufficient to protect our products, or will be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any patents issued to us will provide us with any competitive advantages;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we will develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the patents of others will have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office, or USPTO, developed new regulations and procedures to govern administration of the Leahy-Smith Act and many of the substantive changes to patent law associated with the Leahy-Smith </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Act and, in particular, the first to file provisions, only became effective in March 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable in one or more jurisdictions, inventions for which patents are difficult to enforce and any other elements of our drug discovery program that involve proprietary know-how, information and technology that is not covered by patents. Although we require all of our employees, consultants, advisers and third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or used in an unauthorized manner or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There also may be challenges or other disputes concerning the inventorship, ownership or right to use our intellectual property. For example, our consultants and advisors may have obligations to assign certain inventions and/or know-how that they develop to third-party entities in certain instances, and these third parties may challenge our ownership or other rights to our intellectual property, which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An inability to obtain, enforce and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S. We may encounter significant problems in protecting, enforcing and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of the intellectual property related to our technologies to third parties or are otherwise unable to protect, enforce or defend our intellectual property, we will not be able to establish or, if established, maintain a competitive advantage in our markets, which could materially adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various foreign or jurisdictional governmental patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm to pay these fees due to foreign patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such noncompliance events are outside of our direct control for (1)&#160;non-U.S. patents and patent applications owned by us and, (2)&#160;if applicable in the future, patents and patent applications licensed to us by another entity. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents with claims to materials, methods of manufacture or methods of treatment related to the use or manufacture of rezafungin, our DFCs and/or our other product candidates or compounds. If any third-party patents were held by a court of competent jurisdiction to cover the rezafungin or DFC manufacturing process, any molecules formed during these processes or the final products or any use thereof, the holders of any such patents may be able to block our ability to commercialize the product unless we obtained a license under the applicable patent or patents or until such patents expire. These same issues and risks arise in connection with any other product candidates we develop as well. We cannot predict whether we would be able to obtain a license on commercially reasonable terms, or at all. Any inability to obtain such a license under the applicable patents on commercially reasonable terms, or at all, would have a material adverse effect on our ability to commercialize the affected product until such patents expire.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, third parties may obtain patents in the future and claim that our product candidates and/or the use of our technologies infringes upon these patents. Furthermore, parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case of willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products, which may be impossible and/or require substantial time and monetary expenditure. In addition, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of one or more of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would not be able to further develop and commercialize such product candidates, which could harm our business significantly.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be required to file lawsuits or take other actions to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Competitors may infringe our current or future patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our asserted patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Pursuit of these claims would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Interference proceedings or derivative proceedings provoked by third parties or brought by the USPTO may be necessary to determine the entitlement to patent protection with respect to our patents or patent applications. An unfavorable outcome could result in a loss of our patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or patent office proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws or legal process may not protect those rights as fully as in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates and technologies could be found invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technologies, the defendant could counterclaim that the patent covering our product candidate or our technology, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates or our technologies. The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art or that prior art that was cited during prosecution, but not relied on by the patent examiner, will not be revisited. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection directed to our product candidates or technologies. Such a loss of patent rights could have a material adverse impact on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and are therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has implemented wide-ranging patent reform legislation, including patent office administrative proceedings that offer broad opportunities to third parties to challenge issued patents. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO and foreign governmental bodies and tribunals, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> the U.S. Supreme Court held in 2013 that certain claims to DNA molecules are not patentable and lower courts have since been applying this case in the context of other types of biological subject matter. We cannot predict how future decisions by the courts, the U.S. Congress, the USPTO or foreign governmental bodies or tribunals may impact the value of our patent rights.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws and legal processes of some foreign countries do not protect intellectual property to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any of our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of any of our current or future patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if any of our patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors, and academic or research institutions. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div id="ib00951007fb342d8a49dba10256b8485_43"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to U.S. Government Contracts and Grants</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be forced to suspend or terminate one or more of our preclinical Cloudbreak programs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In order to continue our Cloudbreak programs for DFCs outside the scope of the Janssen Collaboration Agreement, we will need to seek funding from partnerships, the government or other sources of funding. There can be no assurances that we will be able to obtain funding from partnerships, or enter into new contracts with the U.S. government or obtain other sources of funding to support such programs. The process of completing a partnership or obtaining government contracts is lengthy and uncertain and we will have to compete with other companies and institutions in each instance. Further, with respect to government contracting, changes in government budgets and agendas may result in a decreased and de-prioritized emphasis on supporting the discovery and development of anti-infective products. If we cannot obtain or maintain government or other funding for our Cloudbreak programs for DFCs outside the scope of the Janssen Collaboration Agreement, we may be forced to discontinue those programs.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our use of government funding adds uncertainty to our research and commercialization efforts and may impose requirements that increase our costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Contracts funded by the U.S. government and its agencies include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terminate agreements, in whole or in part, for any reason or no reason;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">claim rights, including intellectual property rights, in products and data developed under such agreements;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">audit contract-related costs and fees, including allocated indirect costs;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend or debar the contractor from doing future business with the government;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">control and potentially prohibit the export of products; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">pursue criminal or civil remedies under the Federal Civil Monetary Penalties Act and the federal civil False Claims Act and similar remedy provisions specific to government agreements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, government contracts contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">specialized accounting systems unique to government contracts;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory socioeconomic compliance requirements, including labor standards, anti-human-trafficking, non-discrimination, and affirmative action programs and environmental compliance requirements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we fail to maintain compliance with these requirements, we may be subject to potential liability and to termination of our contracts.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the&#160;FDA, the Securities and Exchange Commission, or SEC,&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018 and ending on January 25, 2019, the U.S. government has shut down several times and certain regulatory authorities, such as the&#160;FDA and the SEC, have had to furlough critical&#160;FDA, SEC and other government&#160;employees and stop critical activities. If repeated or prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to audit by the U.S. government and a negative audit could adversely affect our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. government agencies routinely audit and investigate government contractors and recipients of Federal grants. These agencies review a contractor&#8217;s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Government agencies also review the adequacy of, and a contractor&#8217;s compliance with, its internal control systems and policies, including the contractor&#8217;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">termination of contracts;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">forfeiture of profits;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension of payments;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or prohibition from conducting business with the U.S. government.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our government grant contracts. These laws and regulations affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Federal Acquisition Regulations, or FAR, and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other requirements such as the federal Anti-Kickback Statute and Foreign Corrupt Practices Act;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">export and import control laws and regulations; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any changes in applicable laws and regulations could restrict our ability to obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our senior management team and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management team, as well as the other principal members of our research and development teams. All of our executive officers are employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory, quality assurance and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisers, including scientific, regulatory, quality assurance and clinical advisers, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisers may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our operations, and may encounter difficulties in managing our growth, which could disrupt our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect to expand the scope of our operations, particularly in the areas of drug development, manufacturing, clinical, regulatory affairs, quality assurance and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the future, we may enter into transactions to acquire other businesses, products or technologies and our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may fail to strengthen our competitive position and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</span></div><div id="ib00951007fb342d8a49dba10256b8485_49"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the commencement, timing, enrollment or results of the current and planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter, &#8220;complete response&#8221; letter, or a request for additional information;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse results, suspensions, terminations or delays in pre-clinical or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial or development program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in laws or regulations applicable to our products, including but not limited to requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the structure of healthcare payment systems or limitations on the ability of hospitals and outpatient treatment centers to receive adequate reimbursement for the purchase and use of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse developments concerning our contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices or acceptable quality;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to establish collaborations, if needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to commercialize our product candidates successfully, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">announcements of significant acquisitions, strategic partnerships, joint ventures, government grants or contracts or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size and growth of our fungal infection, bacterial infection or other target markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to successfully enter new markets or develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our cash position and our ability to raise additional capital and the manner and terms on which we raise it, and the expectation of future fundraising activities by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">publication of research reports or other media coverage about us or our industry or our therapeutic approaches in particular or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sales of our common stock by us or our stockholders in the future or the expectation of such sales;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">disputes or other developments relating to proprietary rights, including patent rights, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">general political and economic conditions including the military conflict in Ukraine and Russia, the Israel-Hamas war and bank failures; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Capital Market, pharmaceutical companies and companies in the anti-infective sector in particular, have experienced extreme price and volume fluctuations that may or may not have been related or proportionate to the operating performance of these companies or their product potential. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The restatement of our consolidated financial statements has subjected us to a number of additional risks and uncertainties, including increased possibility of legal proceedings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed elsewhere in this Annual Report on Form 10-K, on April 11 and April 15, 2024, the Audit Committee determined, based on management&#8217;s recommendation, that our Prior Financial Statements filed with the SEC should no longer be relied upon and should be restated. We have restated the Prior Financial Statements in this Annual Report on Form 10-K. The restatement of the Prior Financial Statements has caused us to incur additional expenses for legal, accounting, and other professional services and has diverted our management&#8217;s attention from our business and could continue to do so. In addition, as a result of the restatement, investors may lose confidence in our financial reporting, the price of our common stock could decline, and we may be subject to litigation or regulatory enforcement actions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired and our public reporting may be unreliable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Based on our evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2023, we determined that we had a material weakness as of December 31, 2023 and in prior periods because our control over the evaluation of applicable indirect taxes in local jurisdictions and assessment of indirect tax accrued liabilities was not appropriately designed, and as a result a material misstatement in the Prior Financial Statements was not detected. A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are in the process of implementing a remediation plan, which includes additional training of existing staff, enhanced use of indirect tax consultants and experts, and designing controls over the completeness and accuracy of the supporting evidence related to indirect tax liabilities. The remediation actions are being monitored by the Audit Committee. However, we cannot assure you that these efforts will remediate this material weakness in a timely manner, or at all, or that we will be able to maintain effective controls and procedures even if we remediate this material weakness. If we are unable to successfully remediate this material weakness, design or operate effective controls and procedures, or identify any future material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and we may experience a loss of public confidence, which could have an adverse effect on our business, financial condition and the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal control procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are a &#8220;non-accelerated filer,&#8221; our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Any additional undetected material weaknesses in our internal controls could lead to further financial statement restatements and require us to incur additional expenses of remediation. In addition, if we are unable to remediate this material weakness, or if we are otherwise unable to conclude that our internal control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our securities could decline, and we could be subject to sanctions or investigations by The Nasdaq Capital Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders&#160;and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Securities Exchange Act of 1934, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Capital Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the political environment and the level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to continue to result in substantial legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. These costs could decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations could make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. We had 90,601,999 shares of common stock outstanding as of December&#160;31, 2023.&#160;We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate and may make it more difficult for you to sell shares of our common stock. In addition, shares of common stock that are either issuable upon the exercise of outstanding options or warrants or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act.&#160;If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the twelve months following the filing of this report. Significant additional capital will be needed to continue our operations as currently planned, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, new investors could gain rights, preferences and privileges senior to our existing stockholders and our existing stockholders may be materially diluted by such subsequent sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to our 2015 Equity Incentive Plan, or the 2015 EIP, our management is authorized to grant stock options to our employees, directors and consultants.&#160;The number of shares of our common stock reserved for issuance under the 2015 EIP will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by 4% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Additionally, the number of shares of our common stock reserved for issuance under our 2015 Employee Stock Purchase Plan, or the ESPP, will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by the lesser of 1% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or 490,336 shares. Unless our board of directors elects not to increase the number of shares available for future grant each year under the 2015 EIP and the ESPP, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of working capital and may not use it effectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our working capital. Because of the number and variability of factors that determine our use of our working capital, its ultimate use may vary substantially from its currently intended use. Our management might not apply our working capital in ways that ultimately increase the value of your investment. We expect to use our working capital to fund research and development activities and general operating expenses. The failure by our management to apply this working capital effectively could harm our business. Pending its use, we may invest our working capital in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our working capital in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer or by a majority of the total number of authorized directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While the Delaware courts have determined that exclusive choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under current law, unused U.S. federal net operating losses generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of capital raising and other transactions that have occurred since our inception in 2012, we have identified several ownership changes that will impact our ability to utilize our net operating losses and credit carryforwards. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December&#160;31, 2023, we had U.S. federal net operating loss carryforwards of approximately $153.8&#160;million, portions of which will begin to expire in 2035, and which could be limited if we experience an &#8220;ownership change.&#8221; In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. The issuance of additional guidance related to existing or future tax laws, or changes to tax laws or regulations proposed or implemented by the current or a future U.S. presidential administration, Congress, or taxing authorities in other jurisdictions, including jurisdictions outside of the U.S., could materially affect our tax obligations and effective tax rate. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes may adversely impact our business, financial condition, results of operations, and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The amount of taxes we pay in different jurisdictions depends on the application of the tax laws of various jurisdictions, including the U.S., to our international business activities, tax rates, new or revised tax laws, or interpretations of tax laws and policies, and our ability to operate our business in a manner consistent with our corporate structure and intercompany arrangements. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for pricing intercompany transactions pursuant to our intercompany arrangements or disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a challenge or disagreement were to occur, and our position was not sustained, we could be required to pay additional taxes, interest, and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations. Our financial statements could fail to reflect adequate reserves to cover such a contingency. Similarly, a taxing authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Effective January 1, 2022, the Tax Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the U.S. and over 15 years for research activities conducted outside the U.S. Although there have been legislative proposals to repeal or defer the capitalization requirement to later years, there can be no assurance that the provision will be repealed or otherwise modified. Future guidance from the Internal Revenue Service and other tax authorities with respect to such legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and we may incur substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and/or the further development of our product candidates could be delayed.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity, public health crisis, pandemic diseases and other events beyond our control, the occurrence of which could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Businesses located in California have, in the past, been subject to electrical blackouts as a result of a shortage of available electrical power and any future blackouts could disrupt our operations. We are also vulnerable to a major earthquake, wildfire, inclement weather and other natural and man-made disasters and public health crisis and pandemic diseases, such as coronavirus, and we have not undertaken a systematic analysis of the potential consequences to our business as a result of any such natural disaster, public health crisis or pandemic diseases and do not have an applicable recovery plan in place. In addition, if any of our third-party contract manufacturers are affected by natural disasters, such as earthquakes, power shortages or outages, floods, wildfire, public health crises, such as pandemics and epidemics, terrorism or other events outside of our control, our business and operating results could suffer. For example, as a result of the COVID-19 pandemic, we experienced significant disruptions in the conduct of our clinical trials and our general business operations as the result of various federal, state and local stay-at-home, shelter-in-place and quarantine measures. We carry only limited business interruption insurance that would compensate us for actual losses from interruption of our business that may occur and any losses or damages incurred by us in excess of insured amounts could cause our business to materially suffer.</span></div><div id="ib00951007fb342d8a49dba10256b8485_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_1568"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Risk management and strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We recognize the importance of maintaining the trust and confidence of its customers, clients, business partners and employees. Cybersecurity represents an important component of our overall approach to risk management. We have implemented and maintain various information security processes designed to identify, assess, and manage material risks from cybersecurity threats to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials, employees and contractors, or Information Systems and Data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Incident Response Team, or the IRT, is a functional and collaborative team consisting of the Chief Legal and Operating Officer, Chief Financial and Business Officer, Senior Vice President, People and Culture, and Director, Information Technology, or IT. The IRT, together with the wider IT, Legal, and Finance teams, as well as external cybersecurity consultants, help identify, assess, and manage our cybersecurity threats and risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Director, IT plays a pivotal role in our cybersecurity framework, actively identifying and assessing risks from cybersecurity threats. This is achieved through a variety of methods, including but not limited to, extensive audits, detailed assessments, and the engagement of outside cybersecurity consultants. In addition to these existing strategies, we have implemented several processes to increase our ability to identify, monitor, and assess material cybersecurity threats. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We subscribe to specialized reports and services that identify emerging cybersecurity threats, thereby keeping our defenses informed and up-to-date. The IT department systematically analyzes such reports of threats and actors, providing us with a deeper understanding of potential risks. We also conduct regular scans of the threat environment, providing real-time insights into the security landscape. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evaluating our own and our industry&#8217;s risk profile is an ongoing process, allowing us to continually tailor our cybersecurity measures to specific needs and vulnerabilities. We also coordinate with law enforcement agencies concerning threats, so that our approach benefits from broader insights and intelligence. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Conducting detailed threat assessments for both internal and external threats form a crucial part of our security strategy. Additionally, we leverage external intelligence feeds, integrating diverse sources of information to strengthen our overall cybersecurity posture. These concerted efforts are designed to achieve a comprehensive, dynamic, and proactive approach to managing and mitigating cybersecurity risks. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our approach to cybersecurity is tailored to suit the specific environment in which we operate. We implement and maintain an array of technical, physical, and organizational measures, processes, standards, and policies, designed to manage and mitigate material risks arising from cybersecurity threats to our Information Systems and Data. This includes a comprehensive strategy featuring a dedicated cybersecurity staff and a regularly tested IT Security Incident Response Plan. Regular risk assessments, tabletop exercises, threat modeling, and vulnerability testing form the backbone of our technical measures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our assessment and management of material risks from cybersecurity threats are integrated into our overall risk management processes. This is exemplified in the way our IT Security Incident Response Plan forms an integral part of the broader risk management framework, so that cybersecurity risks are visible and treated as strategic business risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Detailing the integration of cyber risk into our risk management, cybersecurity risk is addressed as a crucial component of our enterprise risk management program. The IT department works in close collaboration with executive management to prioritize risk management processes, with a particular focus on mitigating cybersecurity threats that could have a significant impact on our business. Furthermore, team members from the IT department or a relevant executive committee evaluate material risks from cybersecurity threats in alignment with our overall business objectives. These evaluations are then communicated to the audit committee of the board of directors. The audit committee assesses these risks as part of our overall enterprise risk, ensuring that cybersecurity is given due consideration in line with our strategic goals and governance framework. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We use third-party service providers to assist us from time to time to identify, assess, and manage material risks from cybersecurity threats, including for example assessors, cybersecurity consultants, auditors, and outside legal counsel. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We use third-party service providers to perform a variety of functions throughout our business, such as application providers and supply chain resources. We have a vendor management program to manage cybersecurity risks associated with our use of these providers. The program includes a risk assessment for each vendor, vulnerability scans related to the vendor, and imposition of information contractual obligations on the vendor. Depending on the nature of the services provided, the sensitivity of the Information Systems and Data at issue, and the identity of the provider, our vendor management process may involve different levels of assessment designed to help identify cybersecurity risks associated with a provider and impose contractual obligations related to cybersecurity on the provider.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For a description of the risks from cybersecurity threats that may materially affect us and how they may do so, see our risk factors under Part 1. Item 1A. Risk Factors in this Annual Report on Form 10-K.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Governance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our board of directors addresses our cybersecurity risk management as part of its general oversight function. The board of directors&#8217; and the IRT are responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our cybersecurity risk assessment and management processes are implemented and maintained by certain members of management, including the Director, IT, Chief Legal and Operating Officer, and Chief Financial and Business Officer. The Chief Legal and Operating Officer and Chief Financial and Business Officer are responsible for providing information on materiality to the Director, IT and producing documentation of known and unknown facts about a cybersecurity incident and factors considered in the materiality assessment. Our Chief Legal and Operating Officer and Chief Financial and Business Officer hold degrees relevant to their areas of expertise and both have over 20 years of experience in their respective fields. The Director, IT is primarily responsible for assessing and managing material risks from cybersecurity threats; they have 23 years of experience in core infrastructure, data infrastructure and analytics, business platforms, and integrations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Director, IT is responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into our overall risk management strategy, and communicating key priorities to relevant personnel. The Director, IT is also responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our IT Security Incident Response Plan is designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including the IRT. The IRT works with the IT department and external cybersecurity experts to help us mitigate and remediate cybersecurity incidents. In addition, our IT Security Incident Response Plan includes reporting to the board of directors for certain cybersecurity incidents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The audit committee receives quarterly updates from the IRT concerning our cybersecurity threats and risk and the processes we have implemented to address them. On an annual basis the board of directors receives a report from the IRT highlighting any significant cybersecurity threats.</span></div><div id="ib00951007fb342d8a49dba10256b8485_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 2. Properties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We lease a 29,638 square foot facility in San Diego, California for administrative, research and development activities.&#160;Our lease currently expires in December 2026, subject to our option to renew for up to two additional two-year terms. We believe that our facility is sufficient to meet our needs and that suitable additional space will be available as and when needed.</span></div><div id="ib00951007fb342d8a49dba10256b8485_58"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div id="ib00951007fb342d8a49dba10256b8485_61"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART II</span></div><div id="ib00951007fb342d8a49dba10256b8485_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our common stock is traded on The Nasdaq Capital Market under the symbol &#8220;CDTX.&#8221;&#160;</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of April&#160;12, 2024, there were 12 holders of record for our common stock.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions, business prospects and other factors our board of directors may deem relevant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to Part III, Item 12 of this Annual Report on Form 10-K.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Purchase of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="ib00951007fb342d8a49dba10256b8485_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div id="ib00951007fb342d8a49dba10256b8485_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains forward-looking statements that involve risks and uncertainties. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our first commercially approved product in the United States, or U.S., is REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. On July 31, 2023, Melinta Therapeutics, LLC, or Melinta, our commercial partner in the U.S., initiated the commercial launch of REZZAYO in the U.S. On October 2, 2023, Melinta announced receipt from the Centers for Medicare &amp; Medicaid Services, or CMS, of both a product-specific J-Code and a new technology add-on payment, or NTAP, for REZZAYO. Outside the U.S. and Japan, our development and commercial partner for REZZAYO is Mundipharma Medical Company, or Mundipharma. In December 2023, the European Medicines Agency, or EMA, granted approval for REZZAYO in the European Union, or EU, for the treatment of invasive candidiasis in adults. In January 2024, the United Kingdom, or UK, Medicines and Healthcare products Regulatory Agency, or MHRA, granted approval for REZZAYO for the treatment of invasive candidiasis in adults.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we have shifted our primary research focus to our proprietary Cloudbreak</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> platform, we continue to execute on the ongoing ReSPECT Phase 3 pivotal clinical trial for the prevention of invasive fungal infections in adult allogeneic blood and marrow transplant recipients. A significant portion of our future royalties and milestones to be received under both Melinta and Mundipharma licensing agreements are tied to the successful completion of the ReSPECT Phase 3 trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our proprietary Cloudbreak platform enables development of novel drug-Fc conjugates, or DFCs, that inhibit specific disease targets while simultaneously engaging the immune system. Our most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting multiple oncology and autoimmune indications.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe our Cloudbreak platform has the potential to offer a fundamentally new approach to treat and prevent serious diseases such as solid tumor cancers and viral infections, by developing product candidates designed to provide potent disease targeting activity and immune system engagement in a single long-acting molecule. Because serious disease often results when a pathogen or cancer cell evades or overcomes the host immune system, our Cloudbreak DFC candidates are designed to counter diseases in two ways: prevention of disease proliferation and immune evasion by directly targeting and, where applicable, by focusing the immune system on a pathogen or infected cell. We believe this is a potentially transformative approach, distinct from current therapies, including antibody drug conjugates, or ADCs, monoclonal or multispecific antibodies and vaccines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, DFCs are designed to have several advantages, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Multivalent binding which has the potential to increase potency;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Ability to engage different targets to serve as a &#8220;drug cocktail&#8221; in a single molecule, which may improve response to treatment and prevention; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential advantages over vaccines irrespective of the immune status of patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">DFCs are fundamentally different from ADCs: DFCs are biologically stable drug-Fc conjugates designed to engage extracellular targets, while ADCs are designed to enter target cells to deliver and release cytotoxic small molecule drugs. In contrast to ADCs and monoclonal antibodies, DFCs are smaller, providing the potential for better tissue penetration and are designed to target multiple sites. Unlike small molecules, we believe DFC optimization can be focused primarily on potency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lead Cloudbreak candidate for the prevention of influenza is CD388, a DFC in Phase 1 and Phase 2a clinical trials. Our lead oncology DFC is CBO421, a development candidate targeting CD73 for the treatment of solid tumors, which is in investigational new drug application, or IND, -enabling studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Cloudbreak Influenza Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2020, we nominated CD388, our influenza DFC, as a development candidate. We submitted an IND for CD388 in December 2021 and initiated a Phase 1 trial (NCT05285137) in March 2022. The Phase 1 trial is a randomized, double-blind, dose-escalation study to determine the safety, tolerability and pharmacokinetics of intramuscular and subcutaneous administration of CD388 in healthy subjects. Enrollment of all six planned cohorts has been completed. In addition, a separate Phase 1 Japanese bridging study (NCT05619536) has been initiated and enrollment has been completed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2022, we initiated a Phase 2a trial (NCT05523089) to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus. The Phase 2a trial, which dosed its first healthy volunteer in September 2022, is a single-center, randomized, double-blind, placebo-controlled, proof-of-concept study to assess the prophylactic antiviral activity, safety, tolerability and pharmacokinetics of CD388 against influenza via a human viral challenge (influenza) model. Multiple dose levels of CD388 will be evaluated in volunteers who will receive a single administration of CD388 or placebo prior to influenza viral challenge. Enrollment has now been completed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022, we received the first U.S. patent for CD388. The patent includes claims directed to the composition of matter of CD388. The patent is projected to expire in 2039 plus any available patent term extension.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In June 2023, the U.S. Food and Drug Administration, or FDA, granted Fast Track designation to CD388 for the prevention of influenza A and B infection in adults who are at high risk of influenza complications due to underlying immunodeficiency and may not mount an adequate response to influenza vaccine or are at high risk of severe influenza despite influenza vaccination, including those for whom vaccines are contraindicated. Fast Track designation aims to facilitate the development and expedite the review of drugs to treat serious conditions with unmet medical needs. The purpose is to get important new drugs to patients earlier. Companies that are granted this designation are given the opportunity for more frequent interactions with the FDA, and, if relevant criteria are met, eligibility for Priority Review.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Final CD388 Phase 2a Results</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In our recent R&amp;D Day, on September 21, 2023, we announced efficacy and safety data from our Phase 1 and Phase 2a trials evaluating the pre-exposure prophylactic activity of CD388 against an H3N2 influenza A virus strain.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 was well-tolerated up to 900 milligrams, or mg:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:45.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.660%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of participants that received one dose of CD388 in Phase 1 and Phase 2a trials</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">First in Human Study (Phase 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Japanese Bridging Study (Phase 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Human Challenge Study (Phase 2a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">50 mg</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">27</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">150 mg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">53</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">450 mg</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">900 mg</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">All Doses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:700;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">114</span></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Safety Summary:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No treatment-emergent serious adverse events, or SAEs, and no discontinuation of study drug or withdrawals due to safety findings.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No consistent adverse event, or AE, patterns. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No hypersensitivity reactions.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Most treatment-emergent adverse events, or TEAEs, were Grade 1 (90%), few Grade 2, all resolved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Incidence of TEAE not dose-dependent.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">Few injection site events (pain, intramuscular, or IM, route mainly), Grade 1, all resolved spontaneously.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:15.2pt">No clinically relevant electrocardiogram, or ECG, vital signs or physical exam abnormalities.</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 pharmacokinetics, or PK, profile is that of a long-acting compound, potentially enabling seasonal pre-exposure prophylaxis, or PrEP:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g1.jpg" alt="cdtx-2023-12-31_g01.jpg" style="height:243px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD388 demonstrates prophylactic reduction of viral replication in the upper respiratory tract, or URT, and the incidence of PCR-confirmed influenza infection:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Phase 2a prophylactic efficacy results are based on 56 subjects enrolled in the trial, with 28 subjects receiving a single dose of CD388 (150 mg) and 28 subjects receiving a placebo.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.368%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Placebo (n=28)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">CD388 150 mg (n=28)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">P-value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:700;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">2</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Quantitative reverse transcriptase polymerase chain reaction, or qRT-PCR, confirmed influenza infection </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(&#8220;attack rate&#8221; see Placebo data)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14 (50%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6 (21%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.0248</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">qRT-PCR confirmed symptomatic influenza infection</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9 (32%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4 (14%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.1023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">qRT-PCR confirmed moderately to severe symptomatic influenza infection</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7 (25%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3 (11%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.1477</span></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Statistical significance was pre-determined using a Wilcoxon rank-sum test with a one-sided type-1 error rate of 0.025.</span></div></td></tr></table></div><div style="margin-top:9pt"><img src="cdtx-20231231_g2.jpg" alt="cdtx-2023-12-31_g02.jpg" style="height:399px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As shown above, despite the small sample size in this analysis, a decrease in viral replication in the URT and influenza infection was observed in participants receiving a single dose of CD388 when compared to placebo. No treatment emergent adverse events leading to study discontinuation or SAEs were reported in the analysis. All participants included in the analysis received either CD388 or placebo and were then challenged with influenza five days later.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Viral culture data confirmed efficacy seen in early analyses:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g3.jpg" alt="cdtx-2023-12-31_g03.jpg" style="height:336px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/><img src="cdtx-20231231_g4.jpg" alt="cdtx-2023-12-31_g04.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we entered into an exclusive, worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize one or more DFCs based on our Cloudbreak platform for the prevention and treatment of influenza.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the Janssen Collaboration Agreement, we are collaborating in the research, preclinical and early clinical development of CD388, under a mutually-agreed research plan with the objective of advancing development through Phase 1 clinical trials and the first Phase 2a clinical trial. We are responsible for performing all IND-enabling nonclinical studies and early-stage clinical trials under the research plan. Both parties are responsible for conducting certain specified chemistry, manufacturing and controls, or CMC, development activities under the research plan. Janssen is solely responsible, and reimburses us for internal personnel and out-of-pocket costs incurred in performing the research plan activities in accordance with an agreed budget. As part of a recent prioritization of its R&amp;D business, in July 2023 Janssen disclosed its intention to discontinue internal development of multiple product candidates in its infectious disease pipeline, including CD388. However, in September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen will assume the future development, manufacturing and commercialization activities of CD388 but intends to transfer its rights and obligations under the Janssen Collaboration Agreement to another transferee. We continue to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following Janssen&#8217;s Election to Proceed Notice, Janssen, or any third-party transferee, is obligated at its sole expense to diligently continue development and commercialization either itself or through the transferee to whom it sublicenses or assigns the rights. If Janssen sublicenses or assigns the rights to a transferee, then all terms under the current Janssen Collaboration Agreement will survive without modification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid us an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, we were eligible for reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting research plan activities. As of December&#160;31, 2023, we have received the $27.0&#160;million up-front payment, $44.5&#160;million in research and development reimbursements, and $10.0&#160;million in milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to an additional $230.0&#160;million in development and regulatory milestone payments from Janssen for successful completion of certain activities over the next several years, including but not limited to Janssen&#8217;s decision whether to proceed with clinical development and initiation of Phase 2b and Phase 3 trials. In addition, we may be eligible to receive approximately $455.0&#160;million in commercial milestones as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Cloudbreak Oncology Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have expanded the Cloudbreak platform beyond infectious diseases, to discover and develop highly potent DFCs that can target multiple immune checkpoint pathways within a single DFC for oncologic diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Immune checkpoint antagonists have generated durable responses in cancers with improved side effect profiles compared to conventional chemotherapy. However, to date, improved outcomes from existing therapies have been limited to a relatively small subset of patients. To broaden the response rate to more patients, targeting additional mechanisms of tumor immune evasion will be critical.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cloudbreak Oncology seeks to develop a new generation of immunotherapies targeting the tumor microenvironment. Our lead oncology DFC candidate, CBO421, is a potential best-in-class CD73 inhibitor that combines the strengths of small molecules and monoclonal antibodies targeting CD73. CBO421 targets CD73 in the adenosine pathway, which contributes to immune evasion in solid cancers by flooding the tumor microenvironment with adenosine, a potent immune cell suppressor. The CD73 pathway is clinically validated in early/mid-stage clinical studies to reduce tumor growth in combination with PD-1/ PD-L1 inhibitors in disease areas that do not historically respond to checkpoint inhibition alone, such as advanced colorectal cancer, or CRC, and non-small cell lung cancer, or NSCLC. As a monotherapy and in combination with PD-1 inhibitors, CBO421 has demonstrated formation of immunologic memory in multiple murine tumor models, along with potential best-in-class activity in T-cell reactivation assays and tumor penetration compared with the most advanced CD73 antibody therapeutics in clinical development. We are currently advancing CBO421 through IND-enabling studies and expect to file an IND in mid-2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In February 2023, we expanded our existing collaboration with WuXi XDC, a leading global contract manufacturing organization dedicated to end-to-end bioconjugates services, under which WuXi XDC will provide IND-enabling CMC development services for our Cloudbreak Oncology program.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CBO421 demonstrates outstanding preclinical performance:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g5.jpg" alt="cdtx-2023-12-31_g05.jpg" style="height:304px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CBO421 enhances anti-tumor activity of PD-1 inhibitors:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CBO421 and Anti-PD-1 combination improves response rates versus monotherapies.</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g6.jpg" alt="cdtx-2023-12-31_g06.jpg" style="height:348px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CBO421 exhibits a second mechanism of action that differentiates it from small molecule CD73 inhibitors:</span></div><div style="margin-top:18pt"><img src="cdtx-20231231_g7.jpg" alt="cdtx-2023-12-31_g12.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD73/PD-1 DFC potently inhibits both PD-1 and CD73 receptors:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g8.jpg" alt="cdtx-2023-12-31_g07.jpg" style="height:296px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Enhancement of activity in preclinical models observed when CBO421 was combined with PD-1 inhibition inspired the development of a first in class multispecific CD73/PD-1 targeting DFC that potently inhibits both targets simultaneously. Emerging preclinical data is promising. The multispecific DFC retains the full activity of the monotherapy components in functional binding and activity assays. In a murine colorectal carcinoma efficacy model, the multispecific DFC exhibited superior activity compared with CBO421 and the marketed PD-1 inhibitor, pembrolizumab, validating the concept. Optimization and preclinical development of our CD73/PD-1 targeting DFCs is ongoing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CD73/PD-1 DFC outperforms monotherapies in humanized tumor models:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g9.jpg" alt="cdtx-2023-12-31_g08.jpg" style="height:363px;margin-bottom:5pt;vertical-align:text-bottom;width:336px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CCRs are a historically difficult-to-drug receptor family:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The DFC platform is also being expanded to include a validated, but difficult class of targets to drug, the chemokine receptors, or CCRs. CCR5 is a validated oncology target that can be a major driver in cancers that rely on the CCL5/CCR5 signaling pathway (e.g., breast, pancreatic and renal cell carcinomas). In several cancers, tumors secrete chemokine CCR5 agonists that promote tumor growth, metastasis and chemoresistance, while simultaneously recruiting immuno-suppressive macrophages and myeloid derived suppressor cells, or MDSCs, to the tumor microenvironment. We have rapidly been able to advance highly potent lead DFC CCR5-antagonist drug candidates that demonstrate robust activity as monotherapies in murine colorectal carcinoma models. Further optimization and preclinical characterization of our CCR5-DFC lead candidates including combination therapy studies, is ongoing.</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g10.jpg" alt="cdtx-2023-12-31_g09.jpg" style="height:335px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CCR5-DFC shows strong tumor control in preclinical model:</span></div><div style="margin-top:9pt"><img src="cdtx-20231231_g11.jpg" alt="cdtx-2023-12-31_g10.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:681px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Rezafungin</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin is a novel molecule in the echinocandin class of antifungals. We are developing rezafungin for the treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">FDA Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2023, the FDA approved REZZAYO for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over 15 years, and is the only available once-weekly echinocandin.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">EMA and UK MHRA Approval of Rezafungin for the Treatment of Invasive Candidiasis in Adults</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the EMA granted approval for REZZAYO in the EU for the treatment of invasive candidiasis in adults. In January 2024, the UK MHRA granted approval for REZZAYO for the treatment of invasive candidiasis in adults.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">REZZAYO Commercialization in the U.S. by Melinta</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 31, 2023, Melinta initiated the commercial launch of REZZAYO in the U.S.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSTORE Phase 3 clinical trial in China</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, enrollment in the ReSTORE Phase 3 trial in China, evaluating the efficacy and safety of rezafungin as a treatment for candidemia and invasive candidiasis, was completed. The portion of the trial conducted in China included 52 patients diagnosed with candidemia and/or invasive candidiasis. ReSTORE (NCT03667690) is a global, randomized, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin, the current standard of care, to treat patients with candidemia and/or invasive candidiasis. Data from this study are expected in the second quarter of 2024.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSPECT Phase 3 clinical trial</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are currently conducting the ReSPECT, single, global, randomized, double-blind, controlled Phase 3 pivotal clinical trial (NCT04368559) in patients undergoing allogeneic blood and marrow transplant to assess rezafungin in a 90-day prophylaxis regimen to prevent infections due to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Candida, Aspergillus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Pneumocystis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Rezafungin, dosed at 400 mg for the first week followed by 200 mg once weekly out to 90 days, is being compared to a regimen containing two drugs (an azole and Bactrim) dosed once daily for 90 days. The primary efficacy outcome for this trial for the FDA and EMA is fungal-free survival at Day 90. We expect this trial to enroll approximately 462 patients. A blinded interim analysis is planned in the second quarter of 2024 which will inform the current fungal free survival rates, or FFS. The FFS will determine if the 462 patients planned to be enrolled will be sufficient to power the trial to detect non-inferiority. The study is currently enrolling in the EU, Canada and the U.S.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, we entered into a License Agreement with Melinta, or the Melinta License Agreement, under which we granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin in the U.S.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Melinta is solely responsible for the commercialization of rezafungin in the U.S., at its sole expense. We are responsible for conducting an agreed upon development plan that includes, among other activities, completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prevention of invasive fungal infections in adult allogeneic blood and marrow transplant recipients. We will initially remain the holder of the rezafungin IND and new drug application, or NDA. Both regulatory applications will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated supplemental NDA, or sNDA, for the prophylaxis indication. Following the transfer date, we will remain financially responsible for post-marketing commitments and other remaining development obligations and the costs for those will be deducted from royalties owed to us by Melinta.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The total potential transaction value of the Melinta License Agreement is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestones. In addition, we are eligible to receive tiered royalties on U.S. sales in the low double digits to mid-teens. As of December&#160;31, 2023, we have received the $30.0&#160;million up-front payment and a $20.0&#160;million milestone payment.</span></div><div style="margin-top:11pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we announced a strategic partnership with Mundipharma to develop and commercialize rezafungin in an intravenous formulation for the treatment and prevention of invasive fungal infections. Under the terms of the Collaboration and License Agreement with Mundipharma, or the Mundipharma Collaboration Agreement, we granted Mundipharma an exclusive, royalty-bearing license to develop, register and commercialize rezafungin outside the U.S. and Japan. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">global development funding, and certain development, regulatory, and commercial milestones. We are also eligible to receive double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we have received $9.0&#160;million from the sale of our equity to Mundipharma, a $30.0&#160;million up-front payment, $31.2&#160;million in global development funding, and $25.1&#160;million in milestone payments (including an $11.1&#160;million milestone payment creditable against future royalties payable to us). In December 2023, we achieved a milestone of $11.1&#160;million under the Mundipharma Collaboration Agreement for which we have received payment in February 2024. In January 2024, we achieved a milestone of $2.8&#160;million under the Mundipharma Collaboration Agreement for which we have received payment in April 2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Compliance with Nasdaq Listing Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our common stock is listed on The Nasdaq Capital Market, which has as one of its continued listing requirements a minimum bid price of at least $1.00 per share, or the Minimum Bid Price Requirement. On November 9, 2023, we received a notification letter, or the Notice, from the Listing Qualification Staff, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, advising us that for 30 consecutive trading days preceding November 6, 2023, the bid price of our common stock had closed below the Minimum Bid Price Requirement. As a result of the Nasdaq Hearings Panel, or the Panel, imposing the previously disclosed Panel Monitor on the Company until November 9, 2023 pursuant to the February 9, 2023 Hearings Decision of the Panel, the Company was not eligible for a compliance period and the Staff notified us that this matter served as a basis for delisting the Company&#8217;s securities from The Nasdaq Capital Market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 16, 2023, we requested a hearing before the Panel, which stayed any delisting action in connection with the Notice and allowed the continued listing of our common stock on The Nasdaq Capital Market until the Panel renders a decision subsequent to the hearing. On January 12, 2024, we submitted a pre-hearing submission in which we presented a plan to regain compliance with the Minimum Bid Price Requirement and request that the Panel allow us additional time within which to regain compliance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The hearing was conducted on February 1, 2024, and on February 8, 2024, the Panel granted our request for continued listing on The Nasdaq Capital Market, pursuant to an extension, through May 7, 2024, to regain compliance with the Minimum Bid Price Requirement. The extension is subject to certain specified conditions and our submission of certain interim updates to the Panel.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Impact of Macroeconomic Conditions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our business is subject to various trends, events or uncertainties that are reasonably likely to cause our reported financial information not to be necessarily indicative of future operating results or of future financial condition. We may be impacted by broader macroeconomic conditions, including global pandemics, high inflation, bank failures, labor shortages, supply chain disruptions, recession risks and potential disruptions from the ongoing Russia-Ukraine conflict and related sanctions and the Israel-Hamas war. For example, the closures of Silicon Valley Bank, Signature Bank and First Republic Bank resulted in broader financial institution liquidity risk and concerns in the past. While we did not have deposits with these banks, if other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash and cash equivalents may be threatened, which could have a material adverse effect on our business and financial condition. The stock market, and in particular the market for pharmaceutical and biotechnology company stocks, has recently experienced significant decreases in value. This volatility and valuation decline have affected the market prices of securities issued by many companies, often for reasons unrelated to their operating performance.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our financial resources and efforts to research and development and have incurred significant operating losses. As of December&#160;31, 2023, we had an accumulated deficit of $441.4&#160;million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. In connection with the preparation of our financial statements for the year ended December&#160;31, 2023, we performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for twelve months from the issuance of these consolidated financial statements, which raises substantial doubt about our ability to continue as a going concern. Our ability to execute our current business plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. We may not be able to raise additional funding on terms acceptable to us, or at all, and any failure to raise funds as and when needed will compromise our ability to execute on our business plan.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, we have generated all of our revenues from our strategic partnerships with Mundipharma and Janssen, and our license and commercial supply agreements with Melinta. In the future, we may generate revenue from a combination of license fees and other upfront payments, other funded research and development agreements, milestone payments, product sales, government and other third-party funding and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of nonclinical, clinical, regulatory and commercialization milestones, the timing and amount of payments relating to such milestones and the extent to which our products are approved and successfully commercialized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to fund our development costs or we are unable to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues and our results of operations and financial position would be adversely affected.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to nonclinical development of our rezafungin acetate and our Cloudbreak platform, as well as clinical development of rezafungin acetate. Research and development expenses consist of wages, benefits and stock-based compensation for research and development employees, as well as the cost of scientific consultants, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;We accrue clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies or other activities within studies and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of the study or project and the invoices received from our external service providers. We adjust our accruals as actual costs become known.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may receive potential research and development funding through a partnership from the National Institute of Allergy and Infectious Diseases. We have evaluated the terms of the grants to assess our obligations and the classification of funding received. Amounts received for funded research and development are recognized in the consolidated statements of operations and comprehensive loss as a reduction to research and development expense over the grant period as the related costs are incurred to meet our obligations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of development, primarily due to the increased size and duration of later-stage clinical trials. However, it is difficult to determine with certainty the duration, costs and timing to complete our current or future nonclinical programs and clinical trials of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact of the COVID-19 pandemic and other similar health crises;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">potential additional safety monitoring or other studies requested by regulatory authorities;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the duration of patient follow-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the phase of development of the product candidate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and safety profile of the product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses by major program or category were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rezafungin</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cloudbreak platform</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68,532&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77,405&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We typically deploy our employees, consultants and infrastructure resources across our programs. Thus, some of our research and development expenses are not attributable to an individual program but are included in other research and development expenses as shown above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Selling, general and administrative, or SG&amp;A, expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning, and support functions. Other SG&amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or research and development expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other income and expense consist primarily of interest income and expense, and various income or expense items of a non-recurring nature. We earn interest income from interest-bearing accounts and money market accounts for cash and cash equivalents. Interest expense represents interest paid related to term loans, the amortization of debt issuance costs, and interest on finance lease liabilities.</span></div><div id="ib00951007fb342d8a49dba10256b8485_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based upon financial statements that we have prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities as of the date of the financial statements, and the revenues and expenses incurred during the reporting periods. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. Historically, revisions to our estimates have not resulted in a material change to our financial statements. While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, the significant accounting estimates that we believe are important to aid in fully understanding and evaluating our reported financial results include the following:</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We recognize revenue in accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Codification</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC, 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or service we transfer to a customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and identify those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, we recognize revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. We evaluate the measure of progress at each reporting period and, if necessary, adjust the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of milestones that are within our or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to our estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, we entered into the Mundipharma Collaboration Agreement with Mundipharma. We concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, we entered into the Janssen Collaboration Agreement with Janssen. We concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, we entered into the Melinta License Agreement with Melinta. We concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, are best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. We periodically review and update the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to our estimates have no impact on our reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment and milestones achieved to date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 9 to the financial statements for additional information.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on the facts and circumstances known at that time. Our accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</span></div><div id="ib00951007fb342d8a49dba10256b8485_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the years ended December&#160;31, 2023 and 2022 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended December&#160;31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(8,873)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,213)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Collaboration revenue was&#160;$59.6 million and $64.4 million&#160;for the years ended December&#160;31, 2023 and 2022, respectively. Revenue for the year ended December&#160;31, 2023 related to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma, Janssen and Melinta of $16.4 million, $23.3 million and $19.7 million, respectively, as well as $0.2 million in royalty revenue recognized following initiation of the commercial launch of REZZAYO in the U.S. on July 31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenue for the year ended December&#160;31, 2022 included $25.9 million of revenue recognized upon transfer of an intellectual property license to Melinta in August 2022. The remaining revenue for the year ended December&#160;31, 2022 related to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma, Janssen and Melinta of $14.3 million, $23.5 million and $0.8 million, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Product revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Product revenue was $4.3 million for the year ended December&#160;31, 2023 and related to shipments of REZZAYO naked vials to Melinta and Mundipharma. REZZAYO received approval by the FDA and was launched commercially in the U.S. by Melinta on July 31, 2023. REZZAYO also received approval by the EMA in December 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Cost of product revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of product revenue was $1.5 million for the year ended December&#160;31, 2023 and primarily consisted of direct material costs, third-party manufacturing costs and indirect overhead costs associated with the manufacture, quality assessment and delivery of REZZAYO naked vials shipped to Melinta and Mundipharma. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses were $68.5 million for the year ended December&#160;31, 2023 compared to $77.4&#160;million for the year ended December&#160;31, 2022.&#160;The decrease in research and development expenses is primarily due to lower clinical expenses associated with the rezafungin clinical trials and lower consulting and personnel costs, offset by higher clinical expenses associated with our Cloudbreak platform.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SG&amp;A expenses were $18.3 million for the year ended December&#160;31, 2023 compared to $20.5 million for the year ended December&#160;31, 2022. The decrease in SG&amp;A expenses is primarily due to lower consulting, personnel and legal costs, and lower amortization of contract costs related to obtaining the Melinta License Agreement, offset by higher selling expenses related to REZZAYO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other income, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other income, net during the&#160;year ended&#160;December&#160;31, 2023 related primarily to interest income generated from cash held in interest-bearing accounts, offset by interest expense on finance lease liabilities. Other income, net during the year ended December&#160;31, 2022 related primarily to interest income generated from cash held in interest-bearing accounts, offset by interest expense in connection with our loan from Pacific Western Bank.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income tax expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Income tax expense for the years ended December&#160;31, 2023 and 2022 is primarily the result of capitalized Internal Revenue Code, or IRC, Section 174 research and development expenditures, effective January 1, 2022, creating taxable income which can be offset with net operating losses and credits that are limited in use by IRC Sections 382 and 383.</span></div><div id="ib00951007fb342d8a49dba10256b8485_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, as well as the cash flows generated from our partnerships with Mundipharma and Janssen, our license to Melinta, and equity financings. We have devoted our resources to funding research and development programs, including research, preclinical and clinical development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to fund future operating needs will depend on a combination of equity, debt or other financing structures, receipt of payments under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, as well as potentially entering into other collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts. Our ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide from geopolitical and macroeconomic events, including global pandemics, the ongoing Russia-Ukraine conflict and related sanctions, the Israel-Hamas war, and bank failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to $470.3&#160;million in development, regulatory and commercial milestone payments from Mundipharma for successful completion of certain activities over the next several years, as well as double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to $230.0&#160;million in development and regulatory milestone payments from Janssen for successful completion of certain activities over the next several years, including but not limited to Janssen&#8217;s decision to proceed with clinical development and initiation of a pivotal trial. In addition, we may be eligible to receive approximately $455.0&#160;million in commercial milestones as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to $410.0&#160;million in regulatory and commercial milestone payments from Melinta for successful completion of certain activities over the next several years, as well as tiered royalties on U.S. sales in the low double digits to mid-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 8, 2018, we entered into the controlled equity offering sales agreement with Cantor Fitzgerald &amp; Co., or the Sales Agreement, pursuant to which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0&#160;million. As of December&#160;31, 2023, the remaining capacity under the Sales Agreement was $37.1&#160;million. We have not sold shares of our common stock under the Sales Agreement since July 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2023, we issued shares of our common stock and Series X Convertible Preferred Stock upon the closing of concurrent but separate public offerings, for gross proceeds of approximately $19.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we have no outstanding loan balances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lease with Nancy Ridge Technology Center, L.P. expires on December 31, 2026 with options for two individual two-year extensions, which have not been exercised, and remain in effect and available to the Company. As of December&#160;31, 2023, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. Total undiscounted operating lease payments are $5.0&#160;million as of December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed further below, we believe that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months, or beyond. There are many factors that could impact our operating cash flow, most notably achievement of milestones under our Mundipharma Collaboration Agreement, Janssen Collaboration Agreement and Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. We operate and conduct clinical trials in countries that face economic volatility and weakness. Sustained weakness or further deterioration of the local economies and currencies and adverse effects of the impact of pandemics, sanctions, or other macroeconomic events may pose operational challenges in those countries. We will continue to monitor these conditions and will attempt to adjust our business plans, as appropriate, to mitigate macroeconomic risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services that generally provide for termination either on notice or after a notice period. Our material cash requirements include costs to complete agreed-upon activities under our Mundipharma Collaboration Agreement, Janssen Collaboration Agreement and Melinta License Agreement, as well as personnel and SG&amp;A support costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $35.8 million in cash and cash equivalents. The following table shows a summary of our cash flows for the years ended December&#160;31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(22,432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(28,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(505)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(951)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,542)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in operating activities was $22.4 million for the year ended December&#160;31, 2023, compared to $28.5 million for the year ended December&#160;31, 2022. Cash used in operating activities for the year ended December&#160;31, 2023 was primarily attributable to a net loss of $22.9 million, and included $20.0 million for a milestone achieved in March 2023 under the Melinta License Agreement, which was received in April 2023, and $7.0&#160;million for a milestone achieved in September 2023 under the Janssen Collaboration Agreement, which was received in September 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash used in operating activities for the year ended December&#160;31, 2022 was primarily attributable to a net loss of $33.6&#160;million, and included $2.8&#160;million for a milestone achieved in December 2021 under the Mundipharma Collaboration Agreement, which was received in January 2022, $3.0&#160;million for a milestone achieved in March 2022 under the Janssen Collaboration Agreement, which was received in May 2022, $11.1&#160;million for a milestone achieved in August 2022 under the Mundipharma Collaboration Agreement, which was received in September 2022, and the $30.0&#160;million upfront payment received in August 2022 pursuant to the Melinta License Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For all periods presented, the primary use of cash was to fund research and development activities for our product candidates, which activities and uses of cash we expect to continue to increase for the foreseeable future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our investing activities during the years ended December&#160;31, 2023 and 2022 consist of purchases of property and equipment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the year ended December&#160;31, 2023 consisted primarily of (i) net proceeds of $17.3&#160;million from the sale of 11,086,000 shares of common stock and 286,000 shares of Series X Convertible Preferred Stock pursuant to concurrent but separate underwritten public offerings and (ii) net proceeds of $8.7&#160;million from the sale of 6,231,741 shares of common stock under the Sales Agreement, after deducting placement agent fees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in financing activities during the year ended December&#160;31, 2022 consisted primarily of net proceeds of $2.4&#160;million, after deducting placement agent fees, from the sale of 3,402,926 shares of common stock under our Sales Agreement, offset by principal payments of $2.6&#160;million made in connection with our loan from Pacific Western Bank and $0.7&#160;million related to issuance costs for our 2021 underwritten public offering.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months, which raises substantial doubt about our ability to continue as a going concern. Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. We plan to continue to fund our losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div id="ib00951007fb342d8a49dba10256b8485_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide information typically disclosed under this item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 8. Consolidated Financial Statements and Supplementary Data.</span></div><div id="ib00951007fb342d8a49dba10256b8485_97"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-top:12pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Cidara Therapeutics, Inc.</span></div><div style="margin-top:15pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Cidara Therapeutics, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:15pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Restatement of 2022 Financial Statements</span></div><div style="margin-top:6pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed in Note 1 to the consolidated financial statements, the 2022 consolidated financial statements have been restated to correct misstatements.</span></div><div style="margin-top:15pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">The Company&#8217;s Ability to Continue as a Going Concern</span></div><div style="margin-top:6pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered net losses and negative cash flows from operating activities since its inception and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-top:15pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:15pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;padding-right:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.259%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Estimated total costs expected to be incurred under the Mundipharma and Melinta Collaboration and License Agreements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As more fully described in Note 9 to the consolidated financial statements, the Company entered into collaboration and license agreements with Mundipharma Medical Company (&#8220;Mundipharma&#8221;) and Melinta Therapeutics, LLC (&#8220;Melinta&#8221;) for strategic collaborations to develop and commercialize rezafungin. For the collaboration and license agreements, the Company determined the license and intellectual property, research and development services, and clinical supply services represent the distinct performance obligations. Revenue related to research and development services and clinical supply services are recognized over the estimated period of time to conduct the research and development services and clinical supply services based on actual costs incurred compared to the estimated total costs expected to be incurred. Collaboration revenue was significant to our audit because the revenue recognition assessment process involved inherent uncertainty, uses subjective assumptions, and the amounts involved are material to the financial statements taken as a whole. The subjective assumption relates to the estimated total costs expected to be incurred under the collaboration and license agreements.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To test revenue recognized we performed audit procedures that included, among others, testing the assumption and underlying data used by the Company in its computation of the total estimated research and development services and clinical supply services budget expenses and testing the accuracy of the computations. We inspected evidence supporting the amount of actual costs incurred and assessed whether they were appropriate costs according to the terms of the contract by category. We performed corroborative inquiries of individuals outside of the finance department and inspected updated budget and change in estimated costs as approved by management. We assessed the reasonableness of the estimated costs to be incurred as of the reporting date based on current factors.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Accrued indirect tax liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed in Notes 1 and 2 to the consolidated financial statements, the Company&#8217;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to accrued indirect tax liabilities in various jurisdictions outside of the United States. The Company evaluated the indirect taxation consequences upon the first commercial sale of REZZAYO in 2023 and determined that it has a liability for indirect taxation in various tax jurisdictions outside of the United States based on its supply chain activities in 2023 and prior years. As of December 31, 2023, the Company recorded $18.0 million of accrued indirect tax liabilities.<br/></span><span style="font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s accrued indirect tax liabilities was challenging because the indirect tax liabilities was dependent upon an accumulation of a high volume of historical information related to the Company&#8217;s supply chain and clinical supply activities and the application of various international indirect tax laws and regulations, which varied between countries.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To test the accrued indirect tax liabilities, we performed audit procedures to test the completeness of the Company&#8217;s accrued indirect tax liabilities that included, among other procedures, inspecting evidence of supply chain activities for clinical and commercial drug supplies. With the assistance of our indirect tax specialists, we also performed testing of management&#8217;s determination of transactions subject to indirect taxes and the indirect tax rates applied to those transactions. In addition, we performed testing of the mathematical accuracy of the underlying computation of accrued indirect tax liabilities.</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-37">Ernst &amp; Young LLP</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2014.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-38">San Diego, California</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">April&#160;22, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">35,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-40">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">16,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">5,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-43">6,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">6,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">60,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">45,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-49">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-50">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finance lease right-of-use asset, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-51">782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="f-52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-53">3,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-54">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-57">67,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-58">47,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">3,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">14,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">7,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">18,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">11,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">5,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">4,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">25,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">14,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of finance lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-69">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">67,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">41,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">20,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term finance lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-77">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">3,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-81">75,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-82">61,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-83"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-84"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-85"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-86">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-88">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2023 and December&#160;31, 2022:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-89"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-90"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-91"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-92">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-94">4,947,759</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2023 and 2022; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95">2,156,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96">2,104,472</ix:nonFraction> shares outstanding at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97">1,870,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98">1,818,472</ix:nonFraction> shares outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-101"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-102">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-104">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2023 and 2022; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-106">90,601,999</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-108">72,470,440</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-109">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-110">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-111">433,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-112">404,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-113">441,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-114">418,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-115">8,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-116">14,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">67,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-118">47,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-119">59,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-120">64,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-121">4,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-123">63,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-124">64,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-125">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">68,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">77,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">18,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">20,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-131">88,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-132">97,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-133">24,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">33,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-135">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-136">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-137">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-138">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-139">22,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-140">33,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-141">443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-142">272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-143"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-144">22,931</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-145"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-146">33,584</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-147"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-148">0.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-149"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-150">0.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-151"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-152">87,427,439</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-153"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-154">69,857,698</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.809%"><tr><td style="width:1.0%"/><td style="width:21.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.524%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.524%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.531%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Additional Paid-In<br/>Capital<br/>(As Restated)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit<br/>(As Restated)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2021</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-155">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-157">67,863,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-158">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-159">398,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-160">384,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-161">13,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-162">3,414,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-163">2,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-164">2,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-165">828,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-166">363,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-167">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-168">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-169">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-170">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering (As Restated)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss (As Restated)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-173">33,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">33,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2022</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-175">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-177">72,470,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-178">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-179">404,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">418,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-181">14,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-182">286,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-183">11,086,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-184">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-185">17,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-186">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-187">6,219,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-188">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-189">8,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-190">8,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock for exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-191">25,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-192">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-193">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-194">490,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-195">309,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-196">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-197">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-198">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-199">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-200">22,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-201">22,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-202">2,104,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-204">90,601,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-205">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">433,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-207">441,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-208">8,210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.590%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;(As Restated)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">22,931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">33,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-211">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-212">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" format="ixt:num-dot-decimal" scale="3" id="f-213">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-214">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-215">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-216">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-217">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of finance lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="f-219">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" format="ixt:fixed-zero" scale="3" id="f-220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-221">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-222">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-223">10,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-224">477</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-225">6,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-227">3,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-228">2,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-229">8,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-230">2,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-231">6,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-232">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-233">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-234">203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-235">5,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-236">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-237">973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-238">1,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-239">22,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-240">28,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-241">505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-242">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-243">505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-244">118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-245">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-247">8,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-248">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-249">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-252">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-254">2,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-255">25,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-256">951</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-257">3,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-258">29,542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-259">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-260">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-261">35,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-262">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-264">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-265">797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of property and equipment, included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-267">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-268">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finance lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="f-269">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-271">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-273">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-274">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" scale="3" id="f-276">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div><span><br/></span></div><div id="ib00951007fb342d8a49dba10256b8485_115"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-277" continuedAt="f-277-1" escape="true">THE COMPANY AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="f-277-1" continuedAt="f-277-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company&#8217;s first commercially approved product in the United States, or U.S., is REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Melinta Therapeutics, LLC, or Melinta, is commercializing REZZAYO in the U.S. The Company&#8217;s proprietary Cloudbreak</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> platform enables development of novel drug-Fc conjugates, or DFCs, that inhibit specific disease targets while simultaneously engaging the immune system. The Company&#8217;s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting multiple oncology and autoimmune indications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-278" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December&#160;31, 2023, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-279">441.4</ix:nonFraction> million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-280">35.8</ix:nonFraction> million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-281" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-282" continuedAt="f-282-1" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s consolidated financial statements relate to estimated collaboration expenses related to the Company&#8217;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#8217;s </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-277-2" continuedAt="f-277-3"><ix:continuation id="f-282-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">collaboration and license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-283" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-284">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restatement of Consolidated Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the indirect taxation consequences upon the first commercial sale of REZZAYO in 2023 and determined that it had a liability for indirect taxation in various tax jurisdictions outside of the U.S. based on its supply chain activities in 2023 and prior years. As a result, it was concluded that in prior years the Company did not appropriately account for indirect taxes which led to understatements of accrued liabilities and operating expenses during the impacted periods. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-285">11.5</ix:nonFraction>&#160;million, an increase in operating expenses of $<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-286">3.9</ix:nonFraction>&#160;million, and an increase in beginning accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-287">7.6</ix:nonFraction>&#160;million, for 2022. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-288">7.6</ix:nonFraction>&#160;million, an increase in operating expenses of $<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-289">3.7</ix:nonFraction>&#160;million, and an increase in beginning accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-290">3.9</ix:nonFraction>&#160;million, for 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consolidated financial statements (as restated) also include adjustments to correct certain other previously identified misstatements relating to fiscal year 2022 and the quarters within 2023 that the Company had determined to be immaterial, both individually and in the aggregate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Impact of Restatement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See below for reconciliation from the previously reported amounts to the restated amounts in the consolidated balance sheet, consolidated statement of operations and comprehensive loss, consolidated statement of convertible preferred stock and stockholders&#8217; equity (deficit), and consolidated statement of cash flows as of and for the year ended December 31, 2022. The previously reported amounts were derived from the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. These amounts are labeled as "As Previously Reported" in the tables below. The amounts labeled "Restatement Adjustment" represent the effects of this restatement described above.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="f-291" continuedAt="f-291-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-292">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-293">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-294">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-295">47,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:Assets" scale="3" id="f-296">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-297">47,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-299">11,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-300">11,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-301">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-302">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-303">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-304">29,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-305">11,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-306">41,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-307">50,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-308">11,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-309">61,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-310">406,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-311">11,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-312">418,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-313">2,904</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-314">11,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-315">14,438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-316">47,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-317">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-318">47,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-277-3"><ix:continuation id="f-291-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Operations and Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-319">64,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-320">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-321">64,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-322">64,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-323">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-324">64,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-325">75,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-326">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-327">77,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-328">18,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-329">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-330">20,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-331">94,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-332">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-333">97,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-334">29,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-335">3,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-336">33,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-337">29,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-338">3,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-339">33,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-340"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-341">29,799</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-342"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-343">3,785</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-344"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-345">33,584</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-346"><ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-347">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-348"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-349">0.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-350"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-351">69,857,698</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-352"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-353">69,857,698</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:50.437%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-354">398,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-355">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-356">398,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-357">720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-358">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-360">404,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-362">404,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-363">377,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-364">7,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-365">384,916</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-366">29,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-367">3,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-368">33,584</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-369">406,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-370">11,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-371">418,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-372">21,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-373">8,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-374">13,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-375">720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-376">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-378">29,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-379">3,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-380">33,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-381">2,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-382">11,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-383">14,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:50.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.442%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Cash Flows</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-384">29,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-385">3,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-386">33,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" format="ixt:num-dot-decimal" scale="3" id="f-387">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-388">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-389">981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-391">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-392">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-393">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-394">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-395">2,646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-396">1,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-397">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-398">1,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The remainder of the notes to the Company&#8217;s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts from the restatement discussed above.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-399" continuedAt="f-399-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-399-1" continuedAt="f-399-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-400" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-401" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, and product sales. The Company records accounts receivables net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#8217;s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of December&#160;31, 2023 or 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-402" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to materials, third-party contract manufacturing, freight-in and overhead. Inventory is stated at the lower of cost or net realizable value with cost based on the first-in-first-out method. The Company performs an assessment of recoverability of capitalized inventory during each reporting period based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life, and writes down any excess, obsolete or unsaleable inventory to its estimated realizable value in the period which the required reserve is first identified. Such write downs, should they occur, are charged to cost of product revenue in the consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the Company did not identify any excess, obsolete or unsaleable inventory.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-403" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:f-404">three</span> to <ix:nonNumeric contextRef="c-65" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-405">seven years</ix:nonNumeric>).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-406" continuedAt="f-406-1" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Codification</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC, 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#8217;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#8217;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-399-2" continuedAt="f-399-3"><ix:continuation id="f-406-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-407" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cdtx:PatentCostsPolicyPolicyTextBlock" id="f-408" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in selling, general and administrative, or SG&amp;A, expenses in the accompanying statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-409" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company reports deferred income taxes in accordance with ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cdtx:TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" id="f-410" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indirect Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in research and development, or R&amp;D, expenses, and the related interest and penalties are included in SG&amp;A expenses. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#8217;s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed in future periods. Indirect tax amounts on commercial sales (product revenue) that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included within inventory.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-411" continuedAt="f-411-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-411-1" continuedAt="f-411-2"><ix:continuation id="f-399-3" continuedAt="f-399-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were <ix:nonFraction unitRef="obligation" contextRef="c-66" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-412">three</ix:nonFraction> performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, <ix:nonFraction unitRef="obligation" contextRef="c-67" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-413">one</ix:nonFraction> of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were <ix:nonFraction unitRef="obligation" contextRef="c-68" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-414">three</ix:nonFraction> performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a License Agreement with Melinta, or the Melinta License Agreement. The Company concluded that there were <ix:nonFraction unitRef="obligation" contextRef="c-69" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-415">three</ix:nonFraction> performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment and milestones achieved to date.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-399-4" continuedAt="f-399-5"><ix:continuation id="f-411-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 9 for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta are required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represents a distinct performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price to be recognized as revenue for each performance obligation under the Commercial Supply Agreements consists of variable consideration which is determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue are adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration is included in the transaction price only to the extent that it is considered probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections are recorded as indirect taxes liabilities. The transaction price will be fully allocated to the single performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that the performance obligation is satisfied and product revenue is recognized when the customer obtains control of the product, which occurs at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#8217;s product to the customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shipping and handling activities that are performed after a customer obtains control of the product are treated as activities to fulfill the promise to a customer and any amounts billed to a customer represent revenues for the product provided. Costs related to such shipping and handling billings are classified as cost of product revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-416" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-417" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-418" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or research and development expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" id="f-419" continuedAt="f-419-1" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-399-5" continuedAt="f-399-6"><ix:continuation id="f-419-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-420" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#8217;s stock, (c) the expected term of the award, and (d) the expected dividend yield.&#160;The Company computed the expected volatility data using the daily close prices for the Company&#8217;s common stock during the equivalent period of the calculated expected term of the Company&#8217;s stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-421">zero</ix:nonFraction> reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-422" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#8217;s losses. For all periods presented, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-423" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-424">17,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-425">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-426">21,044,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-73" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-427">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-74" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-428">12,764,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-75" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-429">9,323,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-430">33,826,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-431">40,025,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-399-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-432" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-433" escape="true"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the FASB issued </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Update</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025 and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures, or do not apply to the Company.</span></div></ix:nonNumeric></ix:continuation><div id="ib00951007fb342d8a49dba10256b8485_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-434" continuedAt="f-434-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-434-1" continuedAt="f-434-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-435" escape="true"><ix:continuation id="f-434-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-436">35,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-437">35,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-440">35,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-441">35,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-444">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-445">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-448">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-449">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ib00951007fb342d8a49dba10256b8485_1577"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-452" continuedAt="f-452-1" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="f-452-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-453" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-454">2,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-456">3,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:fixed-zero" scale="3" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-460">6,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s capitalized inventory consists of costs incurred subsequent to FDA approval of REZZAYO in March 2023. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred. There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:InventoryWriteDown" format="ixt:fixed-zero" scale="0" id="f-462">no</ix:nonFraction> inventory write downs during the year ended&#160;December&#160;31, 2023.</span></div></ix:continuation><div id="ib00951007fb342d8a49dba10256b8485_124"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-463" continuedAt="f-463-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-463-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-464" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-465">2,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-466">2,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-467">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-468">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-469">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-470">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-471">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-472">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-473">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-474">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-475">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-476">3,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-477">3,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-478">3,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-479">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-480">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Depreciation and amortization of property and equipment of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-481">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-482">0.1</ix:nonFraction> million were recorded for the years ended December&#160;31, 2023, and 2022, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-483" continuedAt="f-483-1" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="f-483-1"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-484">10.0</ix:nonFraction>&#160;million&#160;from the Lender, or the Term A Loan. The Term A Loan bore interest at a variable annual rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="c-92" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-485">4.50</ix:nonFraction>%&#160;or (ii)&#160;the Lender&#8217;s prime interest rate plus <ix:nonFraction unitRef="number" contextRef="c-93" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-486">0.75</ix:nonFraction>%, and matured on July 3, 2022. The Term A Loan had an interest-only period through April 3, 2020, which was followed by equal monthly principal payments and was paid in full on July 5, 2022.</span></div></ix:continuation><div id="ib00951007fb342d8a49dba10256b8485_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-487" continuedAt="f-487-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-487-1" continuedAt="f-487-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald &amp; Co, or Cantor. During the years ended December&#160;31, 2023 and 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="c-94" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-488">6,219,741</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-95" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-489">3,414,926</ix:nonFraction> shares of common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-490">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-491">2.4</ix:nonFraction> million, respectively, after deducting placement agent fees. As of December&#160;31, 2023, the remaining capacity under the Sales Agreement is $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="cdtx:SaleOfStockConsiderationRemainingOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-492">37.1</ix:nonFraction> million.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2023 Underwritten Public Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 7, 2023, the Company completed concurrent but separate underwritten public offerings with Cantor, the underwriter, to issue and sell <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-493">11,086,000</ix:nonFraction> shares of its common stock, including the exercise in full by Cantor of their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-494">1,446,000</ix:nonFraction> shares of common stock, and <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-495">286,000</ix:nonFraction> shares of the Company&#8217;s Series X Convertible Preferred Stock. Cantor agreed to purchase the shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="3" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-496">1.267</ix:nonFraction> per share and the shares of Series X Convertible Preferred Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-497">12.67</ix:nonFraction> per share. The total gross proceeds from the offerings, including the full exercise by Cantor of its option to purchase additional shares of common stock, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="f-498">19.5</ix:nonFraction>&#160;million, before deducting underwriting discounts and commissions and offering expenses. The Company received total net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-499">17.3</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-500">10,000,000</ix:nonFraction> shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-501">10,000,000</ix:nonFraction> shares of preferred stock authorized at December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-502">5,000,000</ix:nonFraction> shares of preferred stock as Series X Convertible Preferred Stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-103" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-503">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On August 12, 2020, at the request of certain holders, <ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-504">52,241</ix:nonFraction> shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-505">522,410</ix:nonFraction> shares of the Company&#8217;s common stock. As of December&#160;31, 2023 and 2022 shares of preferred stock designated as Series X Convertible Preferred Stock totaled <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-506"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-507">4,947,759</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into <ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="f-508">10</ix:nonFraction> shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="c-106" decimals="INF" name="cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" scale="-2" id="f-509">9.99</ix:nonFraction>% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#8217;s common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the Company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-487-2"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC 480, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-510">200,000,000</ix:nonFraction> shares of common stock authorized as of December&#160;31, 2023. Holders of outstanding shares of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-1" decimals="INF" name="cdtx:NumberOfVotesEntitlementForEachShareHeld" format="ixt-sec:numwordsen" scale="0" id="f-511">one</ix:nonFraction> vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="cdtx:CommonStockDividendsInArrearsOrDefault" format="ixt:fixed-zero" scale="0" id="f-512">no</ix:nonFraction> dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-513">17,331</ix:nonFraction> shares of the Company&#8217;s common stock were outstanding with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-108" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-514">11.54</ix:nonFraction> per share. During the year ended December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="cdtx:ClassOfWarrantOrRightExpired" format="ixt:num-dot-decimal" scale="0" id="f-515">12,499,997</ix:nonFraction> common stock warrants expired unexercised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-516">12,517,328</ix:nonFraction> shares of the Company&#8217;s common stock were outstanding with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-517">6.82</ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had <ix:nonFraction unitRef="usd" contextRef="c-107" decimals="INF" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="0" id="f-518"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="INF" name="us-gaap:WarrantsAndRightsOutstanding" format="ixt:fixed-zero" scale="0" id="f-519">no</ix:nonFraction></ix:nonFraction> intrinsic value at December&#160;31, 2023 and 2022. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-520" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-112" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-521">17,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-113" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-522">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-523">21,044,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-524">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-525">12,764,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-526">9,323,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-527">3,411,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-528">4,469,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-529">987,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-530">806,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-531">38,225,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-532">45,302,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ib00951007fb342d8a49dba10256b8485_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-533" continuedAt="f-533-1" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span></div><ix:continuation id="f-533-1" continuedAt="f-533-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company&#8217;s board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-533-2" continuedAt="f-533-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by <ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" scale="-2" id="f-534">4</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:f-535">three</span>- or <ix:nonNumeric contextRef="c-124" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-536">four-year</ix:nonNumeric> period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to <ix:nonNumeric contextRef="c-122" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-537">10</ix:nonNumeric> years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than <ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-538">100</ix:nonFraction>% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than <ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" scale="-2" id="f-539">10</ix:nonFraction>% of the voting power of all classes of stock of the Company, the exercise price shall be no less than <ix:nonFraction unitRef="number" contextRef="c-125" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-540">110</ix:nonFraction>% of the value on the date of grant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-126" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" scale="-2" id="f-541">1</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii) <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-542">490,336</ix:nonFraction> shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to <ix:nonFraction unitRef="number" contextRef="c-126" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-543">85</ix:nonFraction>% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to <ix:nonFraction unitRef="number" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="f-544">15</ix:nonFraction>% of the employee&#8217;s eligible compensation.&#160;During the years ended December&#160;31, 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-545">309,548</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-546">363,596</ix:nonFraction> shares, respectively, were issued pursuant to the ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, total unrecognized compensation expense related to the ESPP was immaterial and is expected to be recognized over approximately <ix:nonNumeric contextRef="c-129" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-547">0.4</ix:nonNumeric> years.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-548" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the year ended December&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-549">1,223,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-550">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-551">1,515,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-552">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-553">490,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-554">1.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-555">151,115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-556">1.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-557">2,098,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-558">1.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs and PRSUs granted by the Company during the year ended December&#160;31, 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-559">0.83</ix:nonFraction> per share. The total fair value of RSUs and PRSUs vested during the years ended December&#160;31, 2023 and 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-560">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-561">1.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At December&#160;31, 2023, estimated unrecognized compensation expense related to RSUs and PRSUs granted was approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-562">1.7</ix:nonFraction> million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-132" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-563">2</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-533-3"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-564" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the year ended December&#160;31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate<br/>Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-565">8,099,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-566">2.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-567">6.65</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-568">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-569">3,233,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-570">1.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-571">25,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-572">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-573">641,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-574">3.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-575">10,666,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-576">2.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-577">6.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-578">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-579">10,666,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-580">2.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-581">6.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-582">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-583">7,236,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-584">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-585">5.71</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-586">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-587">0.72</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-588">0.51</ix:nonFraction>, respectively, per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, total unrecognized share-based compensation expense related to unvested stock options was approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-589">2.4</ix:nonFraction> million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-135" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-590">1.9</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-591" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes the Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted to employees under the 2015 EIP and 2020 IIP and the shares purchasable under the 2015 ESPP during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2015 EIP and 2020 IIP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-592">3.58</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-136" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-593">4.61</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-594">1.39</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-137" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-595">4.02</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-596">0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-597">0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-598">82</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-599">83</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-600">70</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-601">75</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-138" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-602">5.50</ix:nonNumeric> - <ix:nonNumeric contextRef="c-139" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-603">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-604">5.50</ix:nonNumeric> - <ix:nonNumeric contextRef="c-141" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-605">6.08</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2015 ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-606">4.29</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-142" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-607">5.43</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-608">1.57</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-143" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-609">2.65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-610">0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-611">0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-612">64</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-142" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-613">147</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-614">75</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-143" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-615">98</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-144" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-616">0.50</ix:nonNumeric> - <ix:nonNumeric contextRef="c-145" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-617">2.00</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-146" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-618">0.50</ix:nonNumeric> - <ix:nonNumeric contextRef="c-147" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-619">2.00</ix:nonNumeric></span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-620" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-621">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-622">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-623">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-624">1,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-625">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-626">3,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-627" continuedAt="f-627-1" escape="true">SIGNIFICANT AGREEMENTS AND CONTRACTS</ix:nonNumeric></span></div><ix:continuation id="f-627-1" continuedAt="f-627-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Mundipharma Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#8209;bearing license to develop, register and commercialize the Mundipharma Licensed Product in the Mundipharma Territory, subject to the Company&#8217;s retained right as described below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#8209;exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#8217;s territory.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s Retained Rights.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As of December&#160;31, 2023, the Company retained the exclusive right to develop, register and commercialize the Mundipharma Licensed Product, Subcutaneous Product and Other Products in Japan, or the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Mundipharma Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;As of the execution of the Mundipharma Collaboration Agreement, the parties have agreed to share equally (<ix:nonFraction unitRef="number" contextRef="c-152" decimals="INF" name="cdtx:CollaborativeArrangementCostSharingPercentage" scale="-2" id="f-628">50</ix:nonFraction>/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#8217;s Global Development Cost share of $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="f-629">31.2</ix:nonFraction>&#160;million. The total potential transaction value is $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="f-630">568.4</ix:nonFraction>&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible to receive double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSTORE Trial and the ReSPECT Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company&#8217;s patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-631">30.0</ix:nonFraction> million, plus the research and development funding of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="f-632">31.2</ix:nonFraction> million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-633">25.1</ix:nonFraction> million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-627-2" continuedAt="f-627-3"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the revenue related to this performance obligation in the amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-634">17.9</ix:nonFraction> million&#160;in September 2019 as collaboration revenue in its consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In November 2020, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" format="ixt:num-dot-decimal" scale="6" id="f-635">11.1</ix:nonFraction> million milestone under the Mundipharma Collaboration Agreement, which is recorded as current contract liabilities as of December&#160;31, 2023 because the rights to consideration is expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. As of December&#160;31, 2023, the Company estimated the uncredited portion to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" format="ixt:num-dot-decimal" scale="6" id="f-636">10.1</ix:nonFraction>&#160;million in December 2024. In December 2021, August 2022, and December 2023, the Company achieved milestones of $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-637">2.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-638">11.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-639">11.1</ix:nonFraction>&#160;million, respectively, under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones achieved as of December&#160;31, 2023 in January 2022, September 2022, and February 2024, respectively. The Company determined that as of&#160;December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#8217;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.</span></div><div style="margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In January 2024, the Company achieved a milestone of $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-640">2.8</ix:nonFraction>&#160;million under the Mundipharma Collaboration Agreement for which the Company received payment in April 2024.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur.&#160;<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="6" id="f-641"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="6" id="f-642">No</ix:nonFraction></ix:nonFraction>&#160;royalty revenue was recognized during the years ended&#160;December&#160;31, 2023 and 2022.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs based on the Company&#8217;s Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-627-3" continuedAt="f-627-4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or Phase 2 Study. Unless otherwise agreed by the parties, the Company is responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company is the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified CMC development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen will assume the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continues to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following Janssen&#8217;s Election to Proceed Notice, Janssen, is obligated at its sole expense to diligently continue development and commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#8217;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#8217;s DFC technology more broadly. The Company&#8217;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-643">27.0</ix:nonFraction>&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company was eligible for reimbursement by Janssen of up to $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="f-644">58.2</ix:nonFraction>&#160;million in research and development costs incurred in conducting Research Plan activities. The Company was also be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="f-645">695.0</ix:nonFraction>&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In addition to the Company&#8217;s right to terminate the Janssen Collaboration Agreement for Janssen&#8217;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, upon <ix:nonNumeric contextRef="c-167" name="cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" format="ixt-sec:durday" id="f-646">90</ix:nonNumeric> days&#8217; written notice to the Company, provided that if any clinical trial under the Research Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after completion of the Phase 2 Study and before expiration of the Election Period, immediately upon written notice to the Company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after delivery of the Election to Proceed Notice, upon <ix:nonNumeric contextRef="c-167" name="cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" format="ixt-sec:durday" id="f-647">90</ix:nonNumeric> days&#8217; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-627-4" continuedAt="f-627-5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-648">27.0</ix:nonFraction>&#160;million, plus the research and development funding of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="f-649">49.8</ix:nonFraction>&#160;million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-650">10.0</ix:nonFraction>&#160;million. The transaction price includes the total estimated costs related to research and development and clinical supply services, which can increase or decrease as costs to continue the research and development efforts become known. No revenue was reversed due to the change in transaction price as revenue is recognized based on actual amounts billed. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-651">26.8</ix:nonFraction>&#160;million, as restated, in May 2021 as collaboration revenue in its consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The research and development services to be performed represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company&#8217;s initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> In March 2022 and September 2023, the Company achieved milestones of $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-652">3.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-653">7.0</ix:nonFraction>&#160;million, respectively, under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in May 2022 and September 2023, respectively. The Company determined that as of December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#8217;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur. <ix:nonFraction unitRef="usd" contextRef="c-173" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="6" id="f-654"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="6" id="f-655">No</ix:nonFraction></ix:nonFraction> royalty revenue was recognized during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Pursuant to the Melinta License Agreement, the Company granted Melinta an exclusive, royalty&#8209;bearing license (including the right to sublicense through multiple tiers), to develop, register and commercialize the Melinta Licensed Product for all uses in humans and non-human animals in the Melinta Territory, subject to the Company&#8217;s retained right, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Until the fifth anniversary of the first commercial sale of the first Melinta Licensed Product in the Melinta Territory, neither the Company nor Melinta, nor any of their respective majority-owned subsidiaries may, directly or indirectly, itself or in collaboration with any third party, develop, manufacture for development or commercialization, or commercialize any product in the echinocandin class of drugs in the Melinta Territory without the other party&#8217;s prior written consent, subject to certain provisions in connection with a change of control of a party.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-627-5" continuedAt="f-627-6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Commercialization.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Melinta is solely responsible for the commercialization of rezafungin in the Melinta Territory, at its sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s Retained Rights.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company retains the non-exclusive right to practice the intellectual property rights licensed to Melinta in the Melinta Territory solely for the purpose of performing its obligations under the Melinta License Agreement and Mundipharma Collaboration Agreement. The Company also retains the right to grant licenses under the intellectual property rights licensed to Melinta to third parties to which the Company has granted licenses or rights to market, promote and sell Melinta Licensed Product outside the Melinta Territory, to make and have made Melinta Licensed Product anywhere in the world solely to develop, register, use, sell, have sold, offer for sale, commercialize and import Melinta Licensed Product outside the Melinta Territory, subject to the terms of the Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Continued Development and Regulatory Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company is responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that includes, among other activities, (a) completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the FDA of a supplemental new drug application, or sNDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the Company&#8217;s ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain CMC activities for the Melinta Licensed Product, and (f) all other development activities that are required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company will remain the holder of the rezafungin IND and new drug application, or NDA. Both regulatory applications will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated sNDA for the Prophylaxis Indication, after which Melinta will be responsible for performing all activities that may be necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta&#8217;s sole expense, subject to Melinta&#8217;s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket expenses incurred by Melinta.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Supply and Transfer of CMC activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Until Melinta assumes responsibility for the manufacture and supply of the Melinta Licensed Product for development and commercialization in the Melinta Territory, which it may do by direct purchase from the Company&#8217;s contract manufacturing organizations for the Melinta Licensed Product or by having a manufacturing technology transfer to Melinta or its designee performed at Melinta&#8217;s sole expense, which, in either case, will be no later than December 31, 2026, the Company will be responsible for the manufacture and supply of the Melinta Licensed Product for development and commercialization by Melinta in the Melinta Territory, and during such period, shall supply Melinta Licensed Product to Melinta pursuant to the terms of a supply agreement negotiated by the parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Upon execution of the Melinta License Agreement, the total potential transaction value is $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="f-656">460.0</ix:nonFraction>&#160;million, including a $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-657">30.0</ix:nonFraction>&#160;million upfront payment and up to $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="f-658">430.0</ix:nonFraction>&#160;million in regulatory and commercial milestone payments. In addition, the Company is eligible to receive tiered royalties on U.S. sales in the low double digits to mid-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Either party may terminate the Melinta License Agreement for uncured material breach by the other party. After July 26, 2023, Melinta may terminate the Melinta License Agreement at will. The Company may terminate the Melinta License Agreement if Melinta or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the patent rights licensed to Melinta by the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="f-659">30.0</ix:nonFraction>&#160;million, plus a milestone achieved of $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-660">20.0</ix:nonFraction>&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022, therefore the Company recognized the revenue related to this performance obligation in the amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-661">25.9</ix:nonFraction>&#160;million&#160;in August 2022 as collaboration revenue in its consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-627-6" continuedAt="f-627-7"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company is required to provide research and development services, at its sole expense, as described under the Melinta Development Plan, which represents a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services. Revenue related to the clinical supply services performance obligation recognized during the year ended December&#160;31, 2023 was immaterial.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In March 2023, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-662">20.0</ix:nonFraction>&#160;million milestone under the Melinta License Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in April 2023. The Company determined that as of&#160;December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#8217;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="f-663">0.2</ix:nonFraction>&#160;million in royalty revenue during the year ended December&#160;31, 2023 following the commercial launch of REZZAYO by Melinta in the U.S. on July 31, 2023. <ix:nonFraction unitRef="usd" contextRef="c-183" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-664">No</ix:nonFraction> royalty revenue was recognized during the year ended December&#160;31, 2022.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="6" id="f-665">2.0</ix:nonFraction>&#160;million upon execution of the Melinta License Agreement, and capitalized an additional $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="6" id="f-666">0.5</ix:nonFraction>&#160;million upon achievement of a milestone, in accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company incurred these costs in connection with all the performance obligations identified in the Melinta License Agreement and allocated the capitalized contract costs to performance obligations on a relative basis (i.e., in proportion to the transaction price allocated to each performance obligation) to determine the period of amortization. The Company recognized expense during the years ended December&#160;31, 2023 and 2022 of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="f-667">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="f-668">1.8</ix:nonFraction>&#160;million, respectively, and is included within SG&amp;A expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the remaining balance of the asset recognized from costs to obtain the Melinta License Agreement was $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="f-669">0.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="f-670" continuedAt="f-670-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company&#8217;s contract liabilities pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the year ended&#160;December&#160;31, 2023&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:86.676%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2022 (As Restated)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-671">35,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" format="ixt:num-dot-decimal" scale="3" id="f-672">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" format="ixt:num-dot-decimal" scale="3" id="f-673">1,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-674">9,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-675">29,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-676">25,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-677">4,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total contract liabilities, December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-678">29,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-627-7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the aggregate transaction price allocated to performance obligations that are unsatisfied is $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-679">11.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-680">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="f-681">3.7</ix:nonFraction>&#160;million under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. These amounts are expected to be recognized over <ix:nonNumeric contextRef="c-191" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-682">2</ix:nonNumeric> years, <ix:nonNumeric contextRef="c-192" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-683">0.5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="c-193" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-684">2</ix:nonNumeric> years which represent the remaining research periods under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-685">13.9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-686">1.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-687">0.4</ix:nonFraction>&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. As of December&#160;31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-688">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-689">5.6</ix:nonFraction>&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.</span></div><ix:continuation id="f-670-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our collaboration revenue disaggregated by collaborator and timing of revenue recognition (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestones achieved</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-690">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-691">2,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-692">17,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-693">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-698">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-699">12,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-700">19,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-701">2,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-702">840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-703">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-705">16,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-706">23,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-707">19,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon transfer of license</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-710">25,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestones achieved</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-711">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-712">976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-714">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-717">9,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-718">18,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-719">811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-720">925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-721">3,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-723">14,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-724">23,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-725">26,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-726" continuedAt="f-726-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-726-1" continuedAt="f-726-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-727" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The tax provision for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current tax provision:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-728">393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-729">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-730">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-731">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-732">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-733">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax provision:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-740">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-741">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for income taxes under ASC 740. Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-742" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation between income taxes computed at the federal statutory rate and the provision for income taxes (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal income taxes at <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-743"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-744"><ix:nonFraction unitRef="number" contextRef="c-235" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-745">21</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for 2023 and 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-746">4,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-747">7,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-748">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-749">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nondeductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-750">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="f-751">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-752">2,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-753">1,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-754">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-755">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-756">6,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-757">19,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="3" id="f-758">519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="3" id="f-759">10,423</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">162m deferred tax asset limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" scale="3" id="f-760">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" scale="3" id="f-761">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">382 NOL and tax credit limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" format="ixt:fixed-zero" scale="3" id="f-762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" format="ixt:num-dot-decimal" scale="3" id="f-763">37,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expired stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="cdtx:EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" scale="3" id="f-764">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="cdtx:EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" format="ixt:num-dot-decimal" scale="3" id="f-765">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-766">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-767">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-768">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-769">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current year tax expense is primarily the result of capitalized Internal Revenue Code, or IRC, Section 174 research and development expenditures, effective January 1, 2022, creating taxable income which can be offset with net operating losses and credits that are limited in use by IRC Sections 382 and 383.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-726-2" continuedAt="f-726-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-770" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-771">35,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-772">42,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-773">9,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-774">9,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-775">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-776">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-777">25,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-778">14,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-779">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-780">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cdtx:DeferredTaxAssetsLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-781">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cdtx:DeferredTaxAssetsLeasingArrangements" scale="3" id="f-782">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-783">5,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-784">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="cdtx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-785">4,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="cdtx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-786">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-787">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-788">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-789">84,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-790">77,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-791">83,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-792">76,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-793">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="f-794">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="f-795">214</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="3" id="f-796">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized inventory costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" scale="3" id="f-797">244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" format="ixt:fixed-zero" scale="3" id="f-798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-799">1,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-800">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-801">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="f-802">438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had federal and state tax net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="cdtx:NetOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-805">153.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="cdtx:NetOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-806">131.2</ix:nonFraction> million, respectively. The federal and state net operating loss carryforwards begin to expire in 2035 and 2029, respectively, unless previously utilized. The Company also has federal research and development credit and orphan drug credit carryforwards totaling $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-807">9.5</ix:nonFraction> million and state research and development credit carryforwards totaling $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-808">5.3</ix:nonFraction> million. The federal research and development credit and orphan drug credit carryforwards begin to expire in 2035, unless previously utilized. The state research and development credit carryforwards begin to expire in 2029, with the exception of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-809">5.3</ix:nonFraction>&#160;million which have no expiration date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all evidence, including a history of operating losses, management has determined that it is more likely than not that the net deferred tax assets will not be realized. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-810">6.4</ix:nonFraction> million in 2023 and decreased by $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-811">19.7</ix:nonFraction> million in 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Future utilization of the Company&#8217;s net operating loss and tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to IRC Sections 382 and 383, as a result of ownership changes that may have occurred or that could occur in the future. An ownership change occurs when a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards through 2023 and has adjusted the attributes for their estimated limitation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized.&#160;At December&#160;31, 2023 and 2022, the unrecognized tax benefits recorded were approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-812">11.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-813">11.0</ix:nonFraction> million, respectively.&#160;Approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-814">9.7</ix:nonFraction> million of the unrecognized tax benefits would reduce the Company&#8217;s annual effective tax rates, if recognized, subject to the valuation allowance.&#160;The Company adjusted the uncertain tax position in the current year on certain attributes related to the IRC Section 382/383 analysis performed in the current year. The Company does not anticipate a significant change in the unrecognized tax benefits within the next 12 months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-726-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-815" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2023 and 2022 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-816">11,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-817">23,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-818">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-819">497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Decreases related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-820">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-821">13,472</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-822">11,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-823">11,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by the U.S. and state jurisdictions where applicable. There are currently no pending income tax examinations. The Company&#8217;s tax years from inception in 2013 are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#8217;s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties since inception.</span></div></ix:continuation><div id="ib00951007fb342d8a49dba10256b8485_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-824" continuedAt="f-824-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-824-1" continuedAt="f-824-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are <ix:nonFraction unitRef="claim" contextRef="c-4" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:fixed-zero" scale="0" id="f-825">no</ix:nonFraction> claims or actions pending against the Company at December&#160;31, 2023 which will have, individually or in the aggregate, a material adverse</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">effect on its business, liquidity, financial position or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#8217;s business.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease Obligations</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a finance lease for lab equipment which was entered into in November 2023. The finance lease has a term of <ix:nonNumeric contextRef="c-238" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durmonth" id="f-826">36</ix:nonNumeric> months, monthly lease payments of $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="0" name="cdtx:LesseeFinanceLeaseMonthlyRate" format="ixt:num-dot-decimal" scale="0" id="f-827">25,009</ix:nonFraction>, and an option to purchase the lab equipment for $<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="0" name="cdtx:LesseeFinanceLeaseOptionPurchaseEquipment" scale="0" id="f-828">1</ix:nonFraction> at the end of the finance lease term. As of December&#160;31, 2023, the Company was reasonably certain that it would exercise the option to purchase the lab equipment at the end of the finance lease term. The useful life of the lab equipment is estimated to be <ix:nonNumeric contextRef="c-82" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-829">10</ix:nonNumeric> years. The rate implicit to the finance lease used in measuring the Company&#8217;s finance lease liability was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="f-830">8.0</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-831" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s finance lease as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-832">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-833">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-834">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-835">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted finance lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-836">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-837">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of finance lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-838">793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cdtx:AssetsAndLiabilitiesFinanceLesseeTableTextBlock" id="f-839" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s finance lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" scale="3" id="f-840">788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="f-841">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net finance lease right-of-use asset</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="f-842">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of finance lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-843">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term finance lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-844">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-845">793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-824-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the weighted average remaining finance lease term was <ix:nonNumeric contextRef="c-4" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-846">3.1</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of finance lease liabilities was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:fixed-zero" scale="0" id="f-847">zero</ix:nonFraction> for the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Finance lease costs were immaterial for the year ended December&#160;31, 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has an operating lease for laboratory and office space in San Diego, California which was entered into in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015.&#160;On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional <ix:nonNumeric contextRef="c-240" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-848">36</ix:nonNumeric> months and increases the base rent to $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="INF" name="cdtx:LesseeOperatingLeaseMonthlyRate" format="ixt:num-dot-decimal" scale="0" id="f-849">133,371</ix:nonFraction> per month effective January 1, 2024, subject to <ix:nonFraction unitRef="number" contextRef="c-241" decimals="2" name="cdtx:LesseeOperatingLeaseAnnualRateIncrease" scale="-2" id="f-850">4</ix:nonFraction>% increases every January. The operating lease expires on December 31, 2026 with options for <ix:nonFraction unitRef="option" contextRef="c-241" decimals="INF" name="cdtx:NumberOfOperatingLeaseOptionsForExtension" format="ixt-sec:numwordsen" scale="0" id="f-851">two</ix:nonFraction> individual <ix:nonNumeric contextRef="c-241" name="cdtx:LesseeOperatingLeaseOptionRenewalTerm" format="ixt-sec:durwordsen" id="f-852">two-year</ix:nonNumeric> extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of December&#160;31, 2023, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes. The incremental borrowing rate used in measuring the Company&#8217;s operating lease liability was <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-853">12.0</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-854" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s operating lease as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-855">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-856">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-857">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-858">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-859">912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-860">4,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="cdtx:AssetsAndLiabilitiesOperatingLesseeTableTextBlock" id="f-861" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-862">3,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-863">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-864">3,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-865">4,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the weighted average remaining operating lease term was <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-866">3</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-867">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-868">1.2</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-869">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="f-870">1.3</ix:nonFraction> million for the years ended December&#160;31, 2023 and 2022, respectively. These costs are primarily related to the Company&#8217;s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than <ix:nonNumeric contextRef="c-1" name="cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" format="ixt-sec:durday" id="f-871">30</ix:nonNumeric> days.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><div><span><br/></span></div><div id="ib00951007fb342d8a49dba10256b8485_1604"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="f-872" continuedAt="f-872-1" escape="true">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ix:nonNumeric></span></div><ix:continuation id="f-872-1" continuedAt="f-872-2"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restatement of Interim Financial Information (Unaudited)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Due to the misstatements described in Note 1 above, <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="f-873" continuedAt="f-873-1" escape="true">the Company has restated its unaudited condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit), and condensed consolidated statements of cash flows for the quarterly periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023.</ix:nonNumeric></span></div><ix:continuation id="f-873-1" continuedAt="f-873-2"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-874">47,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-876">47,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-877">36,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-879">36,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-883">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-885">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-886">25,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-887">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-888">26,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-889">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-891">8,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-892">5,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-893">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-894">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-895">5,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-897">5,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-898">79,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="f-899">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-900">79,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-901">52,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-903">52,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-904">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-906">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-907">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-908">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-909">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-910">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-911">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-912">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-913">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-914">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-915">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-916">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-918">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-919">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-921">1,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-922">81,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:Assets" scale="3" id="f-923">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-924">81,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-925">55,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:Assets" scale="3" id="f-926">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-927">55,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-928">3,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-929">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-930">4,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-931">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-932">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-933">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-934">9,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-935">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-936">9,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-937">9,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-938">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-939">9,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-941">11,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-942">11,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-944">7,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-945">7,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-946">5,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-948">5,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-949">3,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-950">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-951">3,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-952">15,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" scale="3" id="f-953">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-954">15,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-955">14,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-957">14,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-958">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-959">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-960">920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-961">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-962">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-963">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-967">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-969">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-970">35,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-971">11,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-972">47,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-973">32,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-974">8,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-975">40,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-976">19,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" scale="3" id="f-977">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-978">19,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-979">17,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-981">17,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-982">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-985">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-986">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-987">920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-988">54,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-989">11,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-990">66,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-991">50,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-992">8,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-993">58,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-242" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-994"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-243" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-995"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-244" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-996"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-245" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-997"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-246" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-998"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-247" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-999"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-242" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1000"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-243" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1001"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-244" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1002"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-245" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1003"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-246" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1004"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-247" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1005"/></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1006">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1012">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-1013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1014">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1015">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-1016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1017">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1018">430,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:fixed-zero" scale="3" id="f-1019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1020">430,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1021">400,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="f-1022">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1023">399,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1024">403,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1025">11,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1026">415,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1027">395,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1028">7,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1029">403,390</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1030">26,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1031">11,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1032">15,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1033">4,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1034">8,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1035">3,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1036">81,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-1037">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1038">81,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1039">55,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" sign="-" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-1040">184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1041">55,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1042"><ix:nonFraction unitRef="usdPerShare" contextRef="c-247" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1043">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1044"><ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1045">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March 31, 2023 and March 31, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Series X Convertible Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-250" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1046"><ix:nonFraction unitRef="usdPerShare" contextRef="c-253" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1047">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1048"><ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1049">4,947,759</ix:nonFraction></ix:nonFraction> shares authorized at March 31, 2023 and March 31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1050">2,156,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-250" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1051">2,104,472</ix:nonFraction> shares outstanding at March 31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1052">1,870,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1053">1,818,472</ix:nonFraction> shares outstanding at March 31, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3) Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-244" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1054"><ix:nonFraction unitRef="usdPerShare" contextRef="c-247" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1055">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1056"><ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1057">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March 31, 2023 and March 31, 2022; <ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1058"><ix:nonFraction unitRef="shares" contextRef="c-244" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1059">90,024,562</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1060"><ix:nonFraction unitRef="shares" contextRef="c-247" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1061">69,049,247</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2022</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-2" continuedAt="f-873-3"><ix:continuation id="f-872-2" continuedAt="f-872-3"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1062">50,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-1063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1064">50,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1065">24,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-1066">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1067">24,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-1068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-1069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-1070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-1071">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="f-1072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RestrictedCash" scale="3" id="f-1073">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1074">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1075">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1076">5,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1077">4,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1078">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1079">4,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-1080">1,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:InventoryNet" scale="3" id="f-1081">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-1082">2,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-1083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-1084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-1085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1086">4,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-1087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1088">4,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1089">6,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-1090">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1091">6,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1092">62,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="f-1093">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1094">62,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1095">36,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-1096">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1097">36,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1098">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-1099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1100">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1101">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-1102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1103">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1104">4,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-1105">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1106">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1107">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-1108">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1109">1,602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1110">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1112">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1113">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1114">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1115">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1116">67,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:Assets" scale="3" id="f-1117">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1118">68,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1119">39,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="us-gaap:Assets" scale="3" id="f-1120">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1121">39,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1122">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1124">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1125">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1127">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1128">10,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1130">10,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1131">8,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1133">8,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-1134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1135">13,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1136">13,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1138">10,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1139">10,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1140">3,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1142">3,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1143">3,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1145">3,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1146">14,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1148">14,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1149">14,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-1150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1151">14,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1152">942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1153">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1154">861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1155">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1156">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1157">1,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:LoansPayableCurrent" scale="3" id="f-1161">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:LoansPayableCurrent" scale="3" id="f-1163">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1164">31,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1165">13,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1166">44,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1167">31,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1168">10,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1169">41,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1170">17,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1172">17,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1173">15,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1175">15,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1176">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1178">3,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-1179">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-1180">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-1181">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1182">52,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1183">13,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1184">65,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1185">47,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1186">10,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1187">57,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-254" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1188"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-255" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1189"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-2" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1190"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-256" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1191"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-257" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1192"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-258" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1193"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-254" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1194"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-255" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1195"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-2" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1196"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-256" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1197"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-257" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1198"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-258" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1199"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1206">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-1207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1208">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1209">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-1210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1211">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1212">431,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:fixed-zero" scale="3" id="f-1213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1214">431,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1215">400,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:fixed-zero" scale="3" id="f-1216">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1217">400,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1218">416,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1219">12,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1220">429,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1221">408,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1222">10,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1223">419,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1224">15,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1225">12,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1226">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1227">7,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1228">10,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1229">18,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1230">67,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-1231">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1232">68,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1233">39,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" sign="-" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-1234">162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1235">39,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4) Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1236"><ix:nonFraction unitRef="usdPerShare" contextRef="c-258" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1237">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1238"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1239">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2023 and June 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5) Series X Convertible Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-261" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1240"><ix:nonFraction unitRef="usdPerShare" contextRef="c-264" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1241">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1242"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1243">4,947,759</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2023 and June 30, 2022; <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1244">2,156,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-261" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1245">2,104,472</ix:nonFraction> shares outstanding at June 30, 2023; <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1246">1,870,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1247">1,818,472</ix:nonFraction> shares outstanding at June 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6) Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-258" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1248"><ix:nonFraction unitRef="usdPerShare" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1249">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1250"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1251">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June 30, 2023 and June 30, 2022; <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1252"><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1253">90,251,746</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1254"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1255">69,238,508</ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2022</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-3" continuedAt="f-873-4"><ix:continuation id="f-872-3" continuedAt="f-872-4"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1256">48,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-1257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1258">48,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1259">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="3" id="f-1260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1261">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1262">2,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="f-1263">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1264">3,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1265">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1267">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-1268">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:InventoryNet" scale="3" id="f-1269">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-1270">2,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-1271">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-1272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:InventoryNet" format="ixt:fixed-zero" scale="3" id="f-1273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1274">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-1275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1276">3,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1277">5,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-1278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1279">5,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1280">57,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AssetsCurrent" scale="3" id="f-1281">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1282">58,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1283">63,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-1284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1285">63,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1286">580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-1287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1288">580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1289">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-1290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-1291">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1292">4,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-1293">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1294">4,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1295">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-1296">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1297">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1298">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1300">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1301">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1303">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1304">63,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:Assets" scale="3" id="f-1305">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1306">64,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1307">66,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:Assets" scale="3" id="f-1308">137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1309">66,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1310">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1312">3,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1313">4,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1315">4,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1316">11,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1318">11,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1319">8,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1321">8,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-1322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1323">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1324">14,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="f-1325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1326">11,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1327">11,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1328">4,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1330">4,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1331">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-1332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1333">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1334">14,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-1335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1336">14,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1337">15,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-1338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1339">15,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1340">1,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1341">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1342">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1343">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1344">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1345">1,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1346">35,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1347">14,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1348">50,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1349">33,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1350">11,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1351">44,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1352">16,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1354">16,504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1355">24,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1357">24,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1358">3,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1360">3,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-1361">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-1362">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-1363">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1364">55,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1365">14,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1366">70,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1367">57,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1368">11,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1369">68,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-265" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1370"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-266" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1371"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-267" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1372"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-268" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1373"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-269" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1374"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-270" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-1375"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-265" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1376"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-266" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1377"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-267" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1378"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-268" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1379"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-269" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1380"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-270" xsi:nil="true" name="us-gaap:PreferredStockValue" id="f-1381"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-1387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1388">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-1389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1390">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1391">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:fixed-zero" scale="3" id="f-1392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-1393">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1394">432,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:fixed-zero" scale="3" id="f-1395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1396">432,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1397">402,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:fixed-zero" scale="3" id="f-1398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-1399">402,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1400">424,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1401">13,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1402">438,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1403">393,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1404">11,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-1405">404,903</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1406">8,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1407">13,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1408">5,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1409">9,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1410">11,314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1411">2,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1412">63,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-1413">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1414">64,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1415">66,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" sign="-" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="f-1416">137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1417">66,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7) Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-270" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1418"><ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1419">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1420"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1421">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September 30, 2023 and September 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8) Series X Convertible Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-276" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1422"><ix:nonFraction unitRef="usdPerShare" contextRef="c-273" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1423">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1424"><ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1425">4,947,759</ix:nonFraction></ix:nonFraction> shares authorized at September 30, 2023 and September 30, 2022; <ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1426">2,156,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-273" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1427">2,104,472</ix:nonFraction> shares outstanding at September 30, 2023; <ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1428">1,870,713</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1429">1,818,472</ix:nonFraction> shares outstanding at September 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9) Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-270" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1430"><ix:nonFraction unitRef="usdPerShare" contextRef="c-267" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1431">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1432"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1433">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September 30, 2023 and September 30, 2022; <ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1434"><ix:nonFraction unitRef="shares" contextRef="c-267" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1435">90,415,944</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1436"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1437">71,181,197</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September 30, 2022</span></div></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-4" continuedAt="f-873-5"><ix:continuation id="f-872-4" continuedAt="f-872-5"><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1438">25,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-1439">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1440">26,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1441">7,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-1442">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1443">7,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1444">25,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-1445">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1446">26,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1447">7,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-1448">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1449">7,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1450">18,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1451">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1452">18,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1453">20,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1454">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1455">20,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1456">4,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-1457">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1458">4,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1459">5,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-1460">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1461">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1462">23,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-1463">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1464">23,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1465">25,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-1466">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1467">25,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1468">2,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1469">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1470">2,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1471">18,261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1472">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1473">18,454</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1474">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1476">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1477">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1479">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1480">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1482">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1483">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1485">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1486"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1487">3,209</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="f-1488"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1489">196</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1490"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1491">3,013</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1492"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1493">18,281</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="f-1494"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1495">193</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1496"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1497">18,474</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="f-1498"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="f-1499">677</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="f-1500"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="f-1501">41</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="f-1502"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="f-1503">636</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1504"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1505">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1506"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1507">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1508"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1509">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1510">2,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="f-1511">155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1512">2,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1513">18,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="f-1514">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1515">18,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share (10)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1516">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1517">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-280" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1518">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-282" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1519">0.27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share (10)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-277" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1520">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-279" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1521">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-280" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1522">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-282" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1523">0.27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1524">78,640,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1525">78,640,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1526">68,138,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1527">68,138,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute diluted net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-277" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1528">101,189,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-279" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1529">101,189,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-280" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1530">68,138,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-282" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1531">68,138,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)  As the Company was in an income position for the three-months ended March 31, 2023, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1532">7,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-1533">117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1534">7,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1535">6,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-1536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1537">6,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1538">7,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:Revenues" scale="3" id="f-1539">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1540">7,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1541">6,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-1542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1543">6,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1544">17,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1545">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1546">17,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1547">15,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1548">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1549">16,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1550">3,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-1551">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1552">4,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1553">4,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1554">1,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1555">5,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1556">20,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1557">1,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1558">21,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1559">19,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1560">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1561">21,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1562">12,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1563">1,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1564">14,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1565">13,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1566">2,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1567">15,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1568">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1570">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1571">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1573">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1574">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1576">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1577">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1578">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1579">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1580">12,208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1581">1,267</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1582">13,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1583">13,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1584">2,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1585">15,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1586">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1588">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1589">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1592"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1593">12,357</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1594"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1595">1,267</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1596"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1597">13,624</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1598"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1599">13,119</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1600"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1601">2,640</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1602"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1603">15,759</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1604"><ix:nonFraction unitRef="usdPerShare" contextRef="c-283" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1605">0.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1606"><ix:nonFraction unitRef="usdPerShare" contextRef="c-285" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1607">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-286" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1608"><ix:nonFraction unitRef="usdPerShare" contextRef="c-286" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1609">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1610"><ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1611">0.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1612"><ix:nonFraction unitRef="shares" contextRef="c-283" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1613">90,115,859</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1614"><ix:nonFraction unitRef="shares" contextRef="c-285" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1615">90,115,859</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-286" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1616"><ix:nonFraction unitRef="shares" contextRef="c-286" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1617">69,133,700</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1618"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1619">69,133,700</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-5" continuedAt="f-873-6"><ix:continuation id="f-872-5" continuedAt="f-872-6"><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1620">33,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-1621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1622">33,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1623">13,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-1624">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1625">13,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1626">33,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-1627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1628">33,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1629">13,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-1630">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1631">13,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1632">35,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1633">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1634">36,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1635">35,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1636">1,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1637">37,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1638">7,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-1639">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1640">8,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1641">9,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1642">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1643">10,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1644">43,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1645">1,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1646">44,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1647">44,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1648">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1649">47,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1650">9,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1651">1,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1652">11,317</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1653">31,374</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1654">2,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1655">34,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1656">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1658">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1659">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1661">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1662">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1664">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1665">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1667">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1668">8,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1669">1,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1670">10,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1671">31,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1672">2,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1673">34,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1674">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1676">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1680"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1681">9,148</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1682"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1683">1,463</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1684"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1685">10,611</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1686"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1687">31,400</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1688"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1689">2,833</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1690"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1691">34,233</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-289" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1692"><ix:nonFraction unitRef="usdPerShare" contextRef="c-289" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1693">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-291" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1694"><ix:nonFraction unitRef="usdPerShare" contextRef="c-291" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1695">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-292" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1696"><ix:nonFraction unitRef="usdPerShare" contextRef="c-292" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1697">0.46</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1698"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1699">0.50</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1700"><ix:nonFraction unitRef="shares" contextRef="c-289" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1701">84,409,667</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1702"><ix:nonFraction unitRef="shares" contextRef="c-291" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1703">84,409,667</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1704"><ix:nonFraction unitRef="shares" contextRef="c-292" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1705">68,638,651</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1706"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1707">68,638,651</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1708">11,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-1709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1710">11,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1711">40,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-1712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1713">40,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1714">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1716">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1717">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1720">12,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-1721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1722">12,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1723">40,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-1724">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1725">40,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="f-1726">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="f-1728">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1732">17,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1733">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1734">17,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1735">20,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1736">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1737">20,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1738">3,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-1739">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1740">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1741">5,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="f-1742">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1743">6,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1744">21,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-1745">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1746">22,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1747">25,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="f-1748">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1749">26,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1750">8,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1751">935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1752">9,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1753">14,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="f-1754">732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1755">14,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1756">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1758">613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1759">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1760">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1761">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1762">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1763">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1764">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1765">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1767">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1768">7,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="f-1769">935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1770">8,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1771">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="f-1772">732</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1773">14,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1774">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1776">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1780"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1781">8,172</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1782"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="f-1783">935</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1784"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1785">9,107</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1786"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1787">14,978</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1788"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="f-1789">732</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1790"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1791">14,246</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1792"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1793">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1794"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1795">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1796"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1797">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:num-dot-decimal" scale="3" id="f-1798"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1799">3,081</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="3" id="f-1800"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" scale="3" id="f-1801">150</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1802"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:num-dot-decimal" scale="3" id="f-1803">2,931</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1804">8,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="f-1805">935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1806">9,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1807">11,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="f-1808">582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1809">11,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share (11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-295" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1810">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-297" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1811">0.10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-298" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1812">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-300" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1813">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share (11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-295" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1814">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-297" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1815">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-298" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1816">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-300" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1817">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1818">90,287,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1819">90,287,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1820">70,217,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-300" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1821">70,217,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute diluted net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1822">90,287,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1823">90,287,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1824">88,592,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-300" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1825">88,592,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)  As the Company was in an income position for the three-months ended September 30, 2022, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-6" continuedAt="f-873-7"><ix:continuation id="f-872-6" continuedAt="f-872-7"><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1826">44,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="f-1827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1828">44,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1829">54,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="f-1830">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="f-1831">54,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1832">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1834">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1835">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1838">46,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="3" id="f-1839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1840">46,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1841">54,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:Revenues" scale="3" id="f-1842">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="f-1843">54,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="f-1844">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" scale="3" id="f-1846">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:fixed-zero" scale="3" id="f-1849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1850">53,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-1851">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1852">53,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1853">55,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1854">1,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1855">57,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1856">11,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1857">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1858">12,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1859">15,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1860">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1861">16,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1862">64,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1863">2,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1864">67,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1865">70,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1866">3,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1867">74,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1868">18,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1869">2,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1870">20,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1871">16,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1872">3,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1873">20,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1874">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1876">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1877">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:fixed-zero" scale="3" id="f-1878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-1879">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1880">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1882">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1883">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-1884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1885">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1886">16,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1887">2,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1888">19,339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1889">16,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1890">3,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1891">19,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1892">379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1894">379</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1898"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1899">17,320</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1900"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1901">2,398</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1902"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1903">19,718</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1904"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1905">16,422</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1906"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1907">3,565</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1908"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1909">19,987</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-301" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1910"><ix:nonFraction unitRef="usdPerShare" contextRef="c-301" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1911">0.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-303" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1912"><ix:nonFraction unitRef="usdPerShare" contextRef="c-303" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1913">0.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1914"><ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1915">0.24</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-306" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1916"><ix:nonFraction unitRef="usdPerShare" contextRef="c-306" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1917">0.29</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-301" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1918"><ix:nonFraction unitRef="shares" contextRef="c-301" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1919">86,390,446</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1920"><ix:nonFraction unitRef="shares" contextRef="c-303" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1921">86,390,446</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-304" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1922"><ix:nonFraction unitRef="shares" contextRef="c-304" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1923">69,170,865</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-306" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1924"><ix:nonFraction unitRef="shares" contextRef="c-306" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1925">69,170,865</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-7" continuedAt="f-873-8"><ix:continuation id="f-872-7" continuedAt="f-872-8"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1926">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1927">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1928">3,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1929">18,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="f-1930">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1931">18,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-1932">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-1933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-1934">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1935">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-1936">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1937">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-1938">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" sign="-" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-1939">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-1940">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-1941">258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" sign="-" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-1942">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-1943">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-1944">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-1946">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-1947">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-1948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-1949">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-1950">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-1951">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-1952">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-1953">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-1954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-1955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-1956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-1957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-1958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-1959">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-1960">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-1961">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-1962">19,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-1963">295</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-1964">20,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-1965">3,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-1966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-1967">3,427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-1968">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-1969">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-1970">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1971">1,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-1972">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1973">1,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1974">3,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-1975">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1976">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-1977">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="f-1978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-1979">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-1980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" scale="3" id="f-1981">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" scale="3" id="f-1982">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-1983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" scale="3" id="f-1984">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" scale="3" id="f-1985">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-1986">921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:fixed-zero" scale="3" id="f-1987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-1988">921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1989">1,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:fixed-zero" scale="3" id="f-1990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1991">1,953</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-1992">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-1993">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-1994">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-1995">844</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-1996">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-1997">1,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-1998">316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-1999">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2000">290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2001">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2002">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2003">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2004">10,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-2005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2006">10,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2007">23,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-2008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2009">23,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2010">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-2011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2012">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2013">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-2014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2015">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2016">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2018">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2019">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2021">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-2022">17,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2023">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-2024">17,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2028">8,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:fixed-zero" scale="3" id="f-2029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2030">8,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" scale="3" id="f-2031">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:fixed-zero" scale="3" id="f-2032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" scale="3" id="f-2033">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-2034">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2035">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-2036">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2039">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2042">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-2043">1,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2044">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-2045">1,111</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2046">26,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2048">26,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-2049">611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-2051">611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2052">15,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:fixed-zero" scale="3" id="f-2053">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2054">15,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2055">24,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:fixed-zero" scale="3" id="f-2056">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2057">24,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2058">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2060">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2061">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2063">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2064">47,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2066">47,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2067">37,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2068">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2069">37,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2071">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-2073">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2074">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-2075">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-2076">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-2077">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-2078">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-2079">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-2080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-2081">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" scale="3" id="f-2082">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" format="ixt:fixed-zero" scale="3" id="f-2083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" scale="3" id="f-2084">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" format="ixt:fixed-zero" scale="3" id="f-2085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" scale="3" id="f-2086">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" scale="3" id="f-2087">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-8" continuedAt="f-873-9"><ix:continuation id="f-872-8" continuedAt="f-872-9"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2088">9,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2089">1,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2090">10,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2091">31,400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2092">2,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2093">34,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2094">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-2095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2096">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2097">2,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-2098">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2099">2,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2100">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" sign="-" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2101">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2102">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2103">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2104">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2105">476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2106">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-2107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2108">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2109">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-2110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2111">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-2112">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-2113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-2114">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-2115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-2116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-2117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-2121">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-2123">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-2124">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-2125">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-2126">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-2127">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-2128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-2129">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-2130">1,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-2131">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-2132">2,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-2133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-2134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-2135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2136">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2138">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2139">2,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2141">2,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2142">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2144">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-2145">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="f-2147">483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-2148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2149">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2150">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-2151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2152">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2153">2,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2154">1,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2156">1,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2157">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2159">1,324</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2160">2,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-2161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2162">2,613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2163">2,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-2164">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2165">2,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2166">620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2167">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2168">595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2169">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2170">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2171">512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2172">8,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-2173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2174">8,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2175">35,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-2176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2177">35,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2178">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-2179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2180">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2181">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-2182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2183">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2184">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2186">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2187">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2189">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-2190">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-2192">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2194">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2196">8,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:fixed-zero" scale="3" id="f-2197">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2198">8,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" scale="3" id="f-2199">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:fixed-zero" scale="3" id="f-2200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" scale="3" id="f-2201">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-2202">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-2204">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2207">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-2211">2,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-2213">2,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2214">25,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2216">25,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2217">1,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2218">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2219">1,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2220">17,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:fixed-zero" scale="3" id="f-2221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2222">17,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2223">37,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:fixed-zero" scale="3" id="f-2224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2225">37,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2226">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2228">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2229">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2231">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2232">50,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2234">50,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2235">25,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2237">25,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-2241">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-2243">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-2244">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-2246">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-2250">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-2252">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2256">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-2257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2258">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2259">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-2260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2261">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" format="ixt:fixed-zero" scale="3" id="f-2262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" format="ixt:fixed-zero" scale="3" id="f-2263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" format="ixt:fixed-zero" scale="3" id="f-2264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" scale="3" id="f-2265">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" format="ixt:fixed-zero" scale="3" id="f-2266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" scale="3" id="f-2267">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-9" continuedAt="f-873-10"><ix:continuation id="f-872-9" continuedAt="f-872-10"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2268">17,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2269">2,398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2270">19,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2271">16,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2272">3,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2273">19,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2274">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-2275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2276">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2277">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-2278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-2279">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2280">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" sign="-" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2281">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2282">895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2283">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2284">72</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="f-2285">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2286">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-2287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2288">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2289">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:fixed-zero" scale="3" id="f-2290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="f-2291">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-2292">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-2293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" scale="3" id="f-2294">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2295">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="f-2296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="f-2297">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-2301">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:PaidInKindInterest" format="ixt:fixed-zero" scale="3" id="f-2302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="f-2303">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-2304">2,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-2305">323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-2306">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-2307">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-2308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-2309">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-2310">2,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-2311">434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-2312">2,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-2313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-2314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-2315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2316">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2318">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2319">1,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-2321">1,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2322">6,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2324">6,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2325">1,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2327">1,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-2328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2329">3,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2330">3,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-2331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2332">3,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="cdtx:AccruedIndirectTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-2333">3,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-2334">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-2336">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-2337">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:fixed-zero" scale="3" id="f-2338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="f-2339">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2340">3,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-2341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2342">3,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2343">7,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-2344">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-2345">7,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2346">807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2347">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2348">781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2349">850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2350">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-2351">778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2352">9,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-2353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2354">9,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2355">7,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:fixed-zero" scale="3" id="f-2356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2357">7,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2358">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-2359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2360">327</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2361">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-2362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-2363">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2364">327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2366">327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2367">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-2368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-2369">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-2370">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-2372">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-2375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2376">8,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:fixed-zero" scale="3" id="f-2377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2378">8,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2379">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:fixed-zero" scale="3" id="f-2380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" format="ixt:num-dot-decimal" scale="3" id="f-2381">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-2382">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-2384">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-2387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-2388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-2389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-2390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-2391">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-2392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-2393">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-2397">2,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-2398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-2399">2,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2400">25,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2402">25,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2403">1,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-2404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-2405">1,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2406">15,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:fixed-zero" scale="3" id="f-2407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2408">15,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2409">9,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:fixed-zero" scale="3" id="f-2410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-2411">9,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2412">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2414">32,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2415">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2417">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2418">48,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2420">48,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2421">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-2422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-2423">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><ix:continuation id="f-873-10"><ix:continuation id="f-872-10"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2426">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-2427">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="f-2428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-2429">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-2430">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-2432">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-2435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-2436">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-2437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-2438">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-2439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-2440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-2441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-2442">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-2444">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-2447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2448">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-2449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2450">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2451">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:fixed-zero" scale="3" id="f-2452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2453">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" scale="3" id="f-2457">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" format="ixt:fixed-zero" scale="3" id="f-2458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" scale="3" id="f-2459">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_2199023257167"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"/><td style="width:32.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.892%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit<br/>(As Restated)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)<br/>(As Restated)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022 (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2460">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2462">72,470,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2463">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2464">404,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2465">418,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2466">14,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Underwritten public offering, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2467">286,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-308" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2468">11,086,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-2469">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-2470">17,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-2471">17,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2472">6,158,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-2473">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-2474">8,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-2475">8,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for exercise of options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-314" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-2476">16,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-2477">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-2478">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-314" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-2479">293,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2480">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2481">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2482">3,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2483">3,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023 (As Restated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-317" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2484">2,104,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-318" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2486">90,024,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2487">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2488">430,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2489">415,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2490">15,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-321" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2491">60,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-2492">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-2493">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-2494">4,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-324" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-2495">161,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2496">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2497">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2498">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2499">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2500">13,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2501">13,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023 (As Restated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2502">2,104,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2504">90,251,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2505">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2506">431,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2507">429,111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2508">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-2509">164,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2510">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2511">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2512">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2513">9,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2023 (As Restated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2514">2,104,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2516">90,415,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2517">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2518">432,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2519">438,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2520">5,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.783%"><tr><td style="width:1.0%"/><td style="width:32.088%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.906%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital<br/>(As Restated)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit<br/>(As Restated)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)<br/>(As Restated)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021 (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2521">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2522">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2523">67,863,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2524">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2525">398,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2526">384,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2527">13,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-338" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2528">644,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-2529">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-2530">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-341" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-2531">541,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-2532">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="f-2533">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2534">18,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2535">18,474</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022 (As Restated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2536">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-345" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2538">69,049,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2539">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2540">399,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2541">403,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2542">3,705</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-348" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-2543">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-348" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-2544">184,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2545">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-2546">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2547">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2548">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering (As Restated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2549">15,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2550">15,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2022 (As Restated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-351" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2551">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-352" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2553">69,238,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2554">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2555">400,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2556">419,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2557">18,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-355" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-2558">1,664,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-2559">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-2560">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-358" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-2561">278,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2562">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="f-2563">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (As Restated)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2564">14,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2565">14,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022 (As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-361" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2566">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-2567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-362" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2568">71,181,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-2569">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2570">402,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2571">404,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-2572">2,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements &#8212; Continued</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-2573" continuedAt="f-2573-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="f-2573-1"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the Company&#8217;s special meeting of stockholders held on April 4, 2024, the Company&#8217;s stockholders approved a proposal to (i) amend the Company&#8217;s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company&#8217;s outstanding common stock at a ratio in the range of 1-for-10 to 1-for-30, inclusive; and (ii) if and only if the reverse stock split is approved and implemented, a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the reverse stock split ratio, with such ratio to be determined in the discretion of the Company&#8217;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s board of directors in its sole discretion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 12, 2024, the Company&#8217;s board of directors approved a reverse stock split of all outstanding shares of the Company&#8217;s common stock at a ratio of 1-for-20, or the Reverse Stock Split. The Company&#8217;s board of directors also approved a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the Reverse Stock Split ratio. On April 22, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Amended and Restated Certificate of Incorporation to effect the Reverse Stock Split. As of the date of this filing, the Reverse Stock Split was not effective as trading on the Nasdaq Capital Market did not reflect the Reverse Stock Split.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All shares and per share information presented in these consolidated financial statements does not reflect the upcoming Reverse Stock Split. As of December 31, 2023, adjusting for the Reverse Stock Split will decrease the total number of the Company&#8217;s authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="c-365" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2574">200,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-366" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2575">20,000,000</ix:nonFraction>; will decrease the number of issued and outstanding shares of common stock from <ix:nonFraction unitRef="shares" contextRef="c-365" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2576"><ix:nonFraction unitRef="shares" contextRef="c-365" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2577">90,601,999</ix:nonFraction></ix:nonFraction> to approximately <ix:nonFraction unitRef="shares" contextRef="c-366" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2578"><ix:nonFraction unitRef="shares" contextRef="c-366" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2579">4,530,099</ix:nonFraction></ix:nonFraction>; and will decrease the number of outstanding warrants from <ix:nonFraction unitRef="shares" contextRef="c-365" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2580">17,331</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-366" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-2581">866</ix:nonFraction> and will change the exercise price on these warrants from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-365" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-2582">11.54</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-366" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-2583">230.95</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-2584" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information presents the Company&#8217;s basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2585"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-2586">22,931</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-2587"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-2588">33,584</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-367" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-2589"><ix:nonFraction unitRef="usdPerShare" contextRef="c-367" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-2590">5.25</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-368" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-2591"><ix:nonFraction unitRef="usdPerShare" contextRef="c-368" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-2592">9.61</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-367" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-2593"><ix:nonFraction unitRef="shares" contextRef="c-367" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2594">4,371,371</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-368" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" format="ixt:num-dot-decimal" scale="0" id="f-2595"><ix:nonFraction unitRef="shares" contextRef="c-368" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-2596">3,492,884</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="ib00951007fb342d8a49dba10256b8485_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of December&#160;31, 2023, due to a material weakness in internal control over financial reporting described below.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations, or COSO, of the Treadway Commission in its 2013 Internal Control&#160;&#8212; Integrated Framework. Based on this assessment, our management has concluded that, as of December&#160;31, 2023, our internal control over financial reporting was not effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm due to the Company&#8217;s status as a non-accelerated filer.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Except as discussed below, there were no changes in our internal control over financial reporting that occurred during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our plans for remediating the material weakness, described below, will result in changes in our internal control over financial reporting in future periods when such remediation plans are effectively implemented.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Material Weakness in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We determined that our control over the evaluation of applicable indirect taxes in local jurisdictions and assessment of indirect tax accrued liabilities was not appropriately designed. Specifically, we did not design a control to properly evaluate the indirect tax impact of our supply chain activities, and to review the completeness and accuracy of the underlying indirect tax obligation. As a result, a material misstatement in the Prior Financial Statements was not detected and we concluded that the control deficiency noted above represents a material weakness as of December&#160;31, 2023 and in prior periods. This material weakness resulted in the restatement of our financial statements for the years ended December 31, 2021 and 2022, and the quarters ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30 2023, and September 30, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Remediation Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have identified and begun to implement steps designed to remediate the foregoing material weakness. However, the material weakness cannot be considered remediated until the applicable remedial controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To remediate this material weakness, we are in the process of implementing a remediation plan, which includes additional training to existing staff, enhanced use of indirect tax consultants and experts, and controls over documentation of our indirect tax positions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While the foregoing measures are intended to effectively remediate the material weakness described in this Item 9A, it is possible that additional remediation steps will be necessary. As such, as we continue to evaluate and implement our plan to remediate the material weakness, our management may decide to take additional measures to address the material weakness or modify the remediation steps described above. Until this material weakness is remediated, we plan to continue to perform additional analyses and other procedures to help ensure that our consolidated financial statements are prepared in accordance with GAAP.</span></div><div id="ib00951007fb342d8a49dba10256b8485_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 17, 2024 we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) advising us that our failure to timely file our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, or the 2023 Form 10-K, with the SEC, in contravention of Nasdaq Listing Rule 5250(c)(1) (the Filing Requirement), could serve as an additional basis for the delisting of our securities from Nasdaq.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We were provided with the opportunity and plans to timely submit our plan to evidence compliance with the Filing Requirement for consideration by the Nasdaq Hearings Panel (the Panel) indicating that we filed the 2023 Form 10-K with the SEC on April 22, 2024, and as announced on April 22, 2024, will implement a reverse stock split of our common stock at a ratio of 1-for-20 shares effective for marketplace purposes with the open of business on Wednesday, April 24, 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As previously disclosed, by letter dated February 8, 2024, the Panel granted our request for continued listing on Nasdaq, subject to us regaining compliance with Nasdaq&#8217;s $1.00 bid price requirement by May 7, 2024.</span></div><div id="ib00951007fb342d8a49dba10256b8485_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART III</span></div><div id="ib00951007fb342d8a49dba10256b8485_166"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s Board of Directors, or the Board, is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#8217;s successor is duly elected and qualified.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board presently has eight members. The names of the members of the Board, their respective ages, their positions with the Company and other biographical information as of April&#160;12, 2024 are set forth below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Directors Continuing in Office Until the 2024 Annual Meeting of Stockholders</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Carin Canale-Theakston, 50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has served as a member of our Board since January 2021. Ms. Canale-Theakston currently serves as an executive biotech advisor for Inizio, a global healthcare commercialization firm that acquired Ms. Canale-Theakston&#8217;s previous company, Canale Communications Inc., a life sciences communications company that she founded in May 2010. Prior to founding Canale Communications, Ms. Canale-Theakston served as President of the life sciences division of Porter Novelli, an international public relations firm, from May 2005 until May 2010. Prior to Porter Novelli, Ms. Canale-Theakston was a Partner and Managing Director of Atkins + Associates, a life sciences communication firm, from February 2000 until it was acquired by Porter Novelli in May 2005. Since January 2007, Ms. Canale-Theakston has served as a member and vice chair of the board of directors of Biocom and is currently chair of the nominating-governance committee. Ms. Canale-Theakston also currently serves on the board of directors of Peel Therapeutics, a private biotechnology company, on the board of managers for Life Science Cares San Diego, and on the advisory board for Abintus Bio, Inc., a private biotechnology company. Ms. Canale-Theakston holds a B.A. in communications and marketing from the University of Tulsa.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes that Ms. Canale-Theakston&#8217;s experience with business and communication strategies for life science companies provide her with the qualifications and skills to serve on our Board.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Timothy R. Franson, M.D.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">, 72</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">has served as a member of our Board since March 2015. Currently, Dr. Franson is a Principal in Faegre Drinker Consulting, in the Health and FDA Practice sectors. From April 2014 to July 2019, Dr. Franson served as the Chief Medical Officer for YourEncore, Inc., a consultancy that helps global life sciences and consumer health companies accelerate new product pipelines and bring safer, more effective products to consumers. Dr. Franson was Vice President of Global Regulatory Affairs at Lilly Research Laboratories, a part of Eli Lilly and Company, or Eli Lilly, a publicly-traded pharmaceutical manufacturing company. He joined Eli Lilly and Company in 1986 and retired in 2008. Dr. Franson served as the President of the US Pharmacopeial Convention, which establishes drug quality standards enforced by regulators such as the FDA, from 2010 to 2015, and continued to serve on the organization&#8217;s Board of Trustees, as immediate Past President until 2020. Dr. Franson previously served on the board of directors of Paratek Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, or Paratek, from 2015 to 2023, and as past Chair of the Board of the Critical Path Institute from 2016 to 2021, which collaborates with FDA and industry in innovation advances. Dr. Franson has authored more than 50 articles in the fields of infectious disease, epidemiology, pharmacoeconomics and antibiotic utilization, as well as four book chapters relating to innovation policy topics. Dr. Franson currently serves as Adjunct Professor of Medicine in the Division of Clinical Pharmacology of the Indiana University School of Medicine. He also served as a director of Myrexis, Inc. (formerly Myriad Pharmaceuticals, Inc.), from 2010 to 2012. Dr. Franson holds a B.S. in pharmacy from Drake University and an M.D. from the University of Illinois, College of Medicine. He is Board Certified in Internal Medicine and Infectious Diseases.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes that Dr.&#160;Franson&#8217;s extensive expertise in the areas of pharmaceutical development and regulatory affairs provide him with the qualifications and skills to serve on our Board.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Chrysa Mineo, 59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">has served as a member of our Board since March 2018. From 2009 to 2015, Ms. Mineo led corporate development at Receptos, Inc., or Receptos, a biotechnology company acquired in 2015 by Celgene Corporation, now a Bristol-Myers Squibb company. Prior to Receptos, from 1997 to 2009 Ms. Mineo held roles of increasing business development responsibility at Neurocrine Biosciences, Inc., or Neurocrine, a publicly-traded biotechnology company. Prior to Neurocrine, Ms. Mineo served in various capacities in research, marketing and business development for such companies as Amgen Inc., a publicly-traded biotechnology company, DNAX Research Institute, Schering-Plough Corporation, now a subsidiary of Merck &amp; Co., Inc., a publicly-traded global health care company, and Baxter Biotech. Ms. Mineo holds a B.S. in Zoology from the University of California, Davis and an M.B.A. from Duke University&#8217;s Fuqua School of Business. In addition, Ms. Mineo is a co-founder of Alume Biosciences, Inc., a private biotechnology company, a member of the Director&#8217;s Council at the Scripps Institution of Oceanography, and a member of the Board of Directors at the San Diego Natural History Museum.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes that Ms.&#160;Mineo&#8217;s expertise and experience as an executive in the pharmaceutical industry, particularly with respect to evaluation and execution of strategic transactions, provide her with the qualifications and skills to serve on our Board.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Directors Continuing in Office Until the 2025 Annual Meeting of Stockholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Jeffrey Stein, Ph.D., 68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has served as a member of our Board and as President and Chief Executive Officer since January 2014. In addition to serving on the board of Cidara, Dr. Stein is currently a director of Ideaya Biosciences (IDYA), a public precision medicine oncology company, and previously served as a director of Paratek from 2014 to 2023. Prior to co-founding Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September of 2013. Dr. Stein was also the founding Chairman and President of the Antibiotics Working Group. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm&#8217;s San Diego office in 2005. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at UCSD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes that Dr.&#160;Stein&#8217;s expertise and experience as our President and Chief Executive Officer, his perspective and experience as a founder and executive at public and private pharmaceutical companies and his expertise in life sciences and venture capital industries provide him with the qualifications and skills to serve on our Board.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Bonnie Bassler, Ph.D., 61</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has served as a member of our Board since January 2021. Dr. Bassler also currently serves in several roles at Princeton University, including, Chair of the Department of Molecular Biology since 2013, associated faculty member of the Department of Chemistry since 2010, Investigator at the Howard Hughes Medical Institute since 2005, Professor in the Department of Molecular Biology since 1994, and associate faculty member of the Princeton Environmental Institute since 1996. Previously, Dr. Bassler served as the Director of the Council on Science and Technology at Princeton University from July 2008 to June 2013. Dr. Bassler currently serves as a board member of Royalty Pharma plc, a publicly-traded biopharmaceutical company, since June 2020, as a board member of Regeneron Pharmaceuticals, Inc. since 2016, a publicly-traded biotechnology company, and as a Trustee of the Alfred P. Sloan Foundation, since 2014. Dr. Bassler previously served as a board member of Kaleido Biosciences, Inc, a publicly-traded health care company, from 2018 to 2022, as a board member of Sanofi, a publicly-traded global health care company, from November 2014 to September 2016, and as a board member of the American Association for the Advancement of Science, from January 2012 to December 2016. She was a member of the National Science Board from January 2010 until May 2016. Dr. Bassler has been elected to the National Academy of Sciences, the National Academy of Medicine, and the Royal Society, among other honorific organizations. She received a B.S. in biochemistry from the University of California-Davis and a Ph.D. in biochemistry from the John Hopkins University.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes that Dr. Bassler&#8217;s expertise in molecular biology and experience serving on boards across academia and the biotech industry provide her with the qualifications and skills to serve on our Board.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">David Gollaher, Ph.D., 74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has served as a member of our Board since September 2018. Dr. Gollaher was Senior Vice President of Policy and Government Affairs at Vir Biotechnology, Inc., a publicly-traded infectious disease company, between 2019 and 2021. From February 2014 to June 2018, he served as the head of global government affairs and policy for Gilead Sciences, Inc., a publicly-traded biopharmaceutical company, or Gilead. Before joining Gilead, Dr. Gollaher was cofounder and Chief Executive Officer of the California Healthcare Institute from 1993 to 2013. In 2018, Dr. Gollaher was appointed a Senior Fellow at the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. He currently serves on the Board of Overseers for The Scripps Research Institute and on the board of Vision Robotics Corporation. Earlier in his career, Dr. Gollaher was a member of the History and Literature faculty at Harvard University and, subsequently, vice president at Scripps Clinic and Research Foundation, responsible for managed care, corporate strategy and public affairs. He earned his B.A. from the University of California Santa Barbara and his master&#8217;s and Ph.D. degrees, concentrating in the history of science and medicine, from Harvard University.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes that Dr.&#160;Gollaher&#8217;s expertise and experience as an executive in the pharmaceutical industry, as a founder of a pharmaceutical company and his educational background provide him with the qualifications and skills to serve on our Board.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Directors Continuing in Office Until the 2026 Annual Meeting of Stockholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Daniel Burgess</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">, 62</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">has served as a member of our Board since April 2014. Mr. Burgess is currently Chairman and Chief Executive Officer of Pulmocide Ltd., a private biopharmaceutical company, a position he has held since May 2021. Mr. Burgess is currently President and Chief Executive Officer of Tripex Pharmaceuticals LLC, a private biopharmaceutical company, since December 2014. He is also a venture partner at SV Health Investors, a position he has held since June 2014. Mr. Burgess served as President and Chief Executive Officer of Therini Bio, Inc., a private biotechnology company, on a part-time basis from May 2019 to December 2021, and now serves as a board member. From June 2011 until its acquisition in December 2013 by The Medicines Company, now a subsidiary of Novartis AG, he was the co-founder, President and Chief Executive Officer of Rempex Pharmaceuticals, Inc., or Rempex, a private biopharmaceutical company. Prior to that, Mr. Burgess was President and Chief Executive Officer of Mpex Pharmaceuticals, Inc., or Mpex, a private biopharmaceutical company, from May 2007 until its acquisition by Aptalis Pharma Inc., now a subsidiary of Abbvie, Inc., a publicly-traded pharmaceutical company, in April 2011. Mr. Burgess currently serves as a director of Arbutus Biopharma Corporation, a publicly-traded biopharmaceutical company, since March 2017, Chairman of the board of Nabriva Therapeutics plc, or Nabriva, a formerly publicly-traded biopharmaceutical company, since June 2017, as well as a director of several private biotechnology companies. He is also Chairman of the Joint Oversight Board of CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, on the board of advisors for Life Science Cares San Diego, and a board member of Biocom, the California life sciences trade association. Mr. Burgess holds a B.A. in economics from Stanford University and an M.B.A. from Harvard Business School.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes Mr.&#160;Burgess&#8217;s expertise and experience as an executive in the pharmaceutical industry and his educational background provide him with the qualifications and skills to serve on our Board.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Theodore R. Schroeder</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">, 68</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">has served as a member of our Board since April 2014. From June 2015, Mr. Schroeder served as President, Chief Executive Officer and a member of the board of directors of Zavante Therapeutics, Inc., a private biopharmaceutical company that he founded, until its acquisition by Nabriva in July 2018, where he served as Chief Executive Officer until January 2023 and continues to serve as a member of the board of directors. Mr. Schroeder co-founded Cadence Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, in May 2004 and served as its President and Chief Executive Officer, and a member of the board of directors, until its acquisition in March 2014 by Mallinckrodt plc, a publicly-traded global biopharmaceutical company. From August 2002 to February 2004, Mr. Schroeder served as Senior Vice President, North American Sales and Marketing, of Elan Pharmaceuticals, Inc., or Elan, a neuroscience-based pharmaceutical company. From October 2000 to August 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan. From May 1999 to October 2000, Mr. Schroeder held the position of Senior Director of Marketing Hospital Products at Dura Pharmaceuticals, Inc., or Dura, a specialty respiratory pharmaceutical and pulmonary drug delivery company, until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held several sales and marketing positions with Bristol-Myers Squibb Company, a global pharmaceutical company. Mr. Schroeder is the former chairman of Biocom, the California life sciences trade association. Mr. Schroeder served as a director of Otonomy, Inc., a public biopharmaceutical company, from August 2015 until January 2023, subsequent to Otonomy ceasing operations. He was the chairman of the board of the Antimicrobials Working Group, a not-for-profit 501(c)(6) organization, from May 2021 until the end of his term in December 2022. Mr. Schroeder previously served as a director of Collegium Pharmaceutical, a publicly-traded pharmaceutical company. He also served on the board of directors of Hyperion Therapeutics, Inc., Incline Therapeutics, Inc. and Trius Therapeutics, Inc. until their respective acquisitions. Mr. Schroeder received a B.S. in management from Rutgers University.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board believes that Mr.&#160;Schroeder&#8217;s expertise and experience as an executive in the pharmaceutical industry, as a founder of a pharmaceutical company and his educational background provide him with the qualifications and skills to serve on our Board.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Independence of the Board of Directors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As required under the Nasdaq Stock Market, or Nasdaq, listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. Our Board consults with the Company&#8217;s counsel to ensure that the Board&#8217;s determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company, its senior management, and its independent auditors, the Board has affirmatively determined that all of our directors, except Dr. Stein who is not considered independent because he is an executive officer of the Company, are independent directors as defined by Rule&#160;5605(a)(2) of the Nasdaq Listing Rules. In making this determination, the Board found that none of these directors had a material or other disqualifying relationship with the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Board Leadership Structure</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Daniel Burgess currently serves as the Chairman of our Board, and has authority, among other things, to call and preside over Board meetings, to set meeting agendas and to determine materials to be distributed to the Board. Accordingly, the Chairman has substantial ability to shape the work of the Board. We believe that separation of the positions of Chairman and Chief Executive Officer reinforces the independence of the Board in its oversight of our business and affairs. In addition, we have a separate chair for each committee of the Board. The chair of each committee is expected to report to the Board from time to time, or whenever so requested by the Board, on the activities of his or her committee in fulfilling its responsibilities as detailed in its respective charter or specify any shortcomings should that be the case. In addition, we believe that having a separate Chairman creates an environment that is more conducive to objective evaluation and oversight of management&#8217;s performance, increasing management accountability and improving the ability of the Board to monitor whether management&#8217;s actions are in the best interests of Cidara and our stockholders. As a result, we believe that having a separate Chairman can enhance the effectiveness of the Board as a whole.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Role of the Board in Risk Oversight</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">One of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board, as a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, and our Audit Committee has the responsibility to consider and discuss our major financial and other significant risk exposures, such as cybersecurity risk, and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee reviews cybersecurity risk, as part of its review of our cybersecurity framework, measures, tools, and compliance, on at least an annual basis. The Audit Committee also monitors compliance with legal and regulatory requirements. Our Nominating and Governance Committee monitors the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation and Human Capital Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Board Diversity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board Diversity Matrix below presents the Board&#8217;s diversity statistics in the format prescribed by Nasdaq rules.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.587%"/><td style="width:0.1%"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Board Diversity Matrix (As of April&#160;12, 2024)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Number of Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Did Not Disclose Gender</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part I: Gender Identity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part II: Demographic Background</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">African American or Black</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alaskan Native or Native American</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asian</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hispanic or Latinx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Native Hawaiian or Pacific Islander</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">White</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two or More Races or Ethnicities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Did not Disclose Demographic Background</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Commitment to Corporate Responsibility</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a company focused on improving the standard of care for patients facing serious diseases, we strive to identify ways to enhance and deliver on our commitment to patients, the medical community, our employees, our investors and our other stakeholders. Accordingly, we recognize the intersection between environmental, social and governance practices and these objectives. Given this, in 2023 we focused on the following areas:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Environmental Impact.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> We are cognizant of the impact we have on our broader environment and have supported several green measures in an effort to reduce our carbon footprint, including providing reusable dishes and cutlery to employees, and making available electric car chargers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Social Impact.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Our future performance depends significantly upon the continued service of our key scientific, technical and senior management personnel and our continued ability to attract and retain highly skilled employees. We provide our employees with competitive compensation, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives. In addition to salaries, these programs include potential annual discretionary bonuses, stock option and restricted stock unit awards, a 401(k) plan, healthcare and insurance benefits, flexible spending accounts, paid time off, family leave and flexible work schedules, among other benefits. We are committed to patients and to the communities in which we operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Diversity and Inclusion.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> We strive to invest in and create ongoing opportunities for employee development in a diverse and inclusive environment in which each team member plays a unique and vital role. We currently have three female directors (38%). We believe that a diverse workforce not only positively impacts our performance and strengthens our culture, but also cultivates an essential pipeline of experienced leaders for management. Hiring for diversity of skills, background and perspective, and diversity of personal characteristics such as age, gender, race and ethnicity continues to be an area of focus as we grow. As of April&#160;12, 2024, women make up approximately 55% of our workforce. We are also committed to building a racially and ethnically diverse workforce. As of April&#160;12, 2024, racially diverse employees (those self-identifying as Black or African American, Hispanic or Latino, Asian, or being two or more races) make up approximately 39% of our workforce.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Ethics and Corporate Governance.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> We aspire to maintain the highest standards of business conduct and ethics. All of our employees are required to adhere to our Code of Business Conduct and Ethics, which provides, among other things, that all of our employees, officers and directors must be honest and ethical both internally and in our business dealings, understanding that unyielding personal integrity is the foundation of corporate integrity.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Meetings of the Board of Directors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board met five times and acted by unanimous written consent seven times during 2023. All directors attended at least 75% of the aggregate number of meetings of the Board and of the committees on which they served during 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In 2023, the Company&#8217;s independent directors met four times in an executive session at which only independent directors were present.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board has an Audit Committee, a Compensation and Human Capital Committee and a Nominating and Governance Committee. The Board previously had a Science and Technology Committee which was decommissioned in December 2023. The Board has adopted a written charter for each committee all of which are available to stockholders on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:underline">www.cidara.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The information on our website is not incorporated by reference into this proxy statement or our Annual Report. The following table provides current membership information and fiscal year 2023 meeting and consent information for each of these committees of the Board:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"/><td style="width:252.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:79.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:79.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:79.75pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Audit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensation and Human Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nominating and</span></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate</span></div><div style="margin-bottom:2pt;margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Governance</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bonnie Bassler, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daniel Burgess</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;X*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carin Canale-Theakston</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Timothy R. Franson, M.D.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;X*</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David Gollaher, Ph.D.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chrysa Mineo</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Theodore R. Schroeder</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;X*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total meetings and consents in 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td></tr></table></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Committee Chairperson</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Below is a description of each committee of the Board. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that each member of each committee meets the applicable rules and regulations regarding &#8220;independence&#8221; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Audit Committee of the Board was established by the Board in accordance with Section&#160;3(a)(58)(A) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, to oversee the Company&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions, including, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">evaluating the performance, independence and qualifications of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and approving the engagement of our independent auditors to perform audit services and any permissible non-audit services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">monitoring the rotation of partners of our independent auditors on our engagement team as required by law;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee the independence of our independent auditor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing our annual and quarterly financial statements and reports, including the disclosures contained under the caption &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and discussing the statements and reports with our independent auditors and management;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing, with our independent auditors and management, significant issues that arise regarding accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our financial controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing with management and our independent auditors any earnings announcements and other public announcements regarding material developments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establishing procedures for the receipt, retention and treatment of complaints received by us regarding financial controls, accounting or auditing matters and other matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">preparing the report that the SEC requires in our annual proxy statement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and providing oversight of any related-party transactions in accordance with our related-party transaction policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business conduct and ethics;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and discussing with management and our auditors, as appropriate, our guidelines and policies with respect to risk assessment and risk management, including our major financial risk exposures, and the steps taken by management to identify, monitor and control exposures to strategic, financial, operational, regulatory and other risks inherit in our business, such as cybersecurity risks and vulnerabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing, on a periodic basis, our investment policy; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and evaluating, on an annual basis, the performance of the Audit Committee and the Audit Committee charter.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Audit Committee is currently composed of three directors: Messrs.&#160;Burgess (Chair) and Schroeder and Ms. Mineo.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of the Company&#8217;s Audit Committee are independent (as independence is currently defined in the applicable Nasdaq listing standards and Rule&#160;10A-3 of the Exchange Act).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Board has also determined that Mr.&#160;Burgess qualifies as an &#8220;audit committee financial expert,&#8221; as defined in applicable SEC rules. The Board made a qualitative assessment of Mr.&#160;Burgess&#8217; level of knowledge and experience based on a number of factors, including his formal education and previous and current experience in financial roles.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Human Capital Committee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Compensation and Human Capital Committee of the Board was comprised of four directors for 2023: Mr. Schroeder (Chair), Dr. Franson and Mses. Canale-Theakston and Mineo. Our Board has determined that each of the members of our Compensation and Human Capital Committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act and satisfies the Nasdaq independence requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Compensation and Human Capital Committee acts on behalf of the Board to review, adopt or recommend to the Board for adoption, and oversee the Company&#8217;s compensation strategy, policies, plans and programs. For this purpose, the Compensation and Human Capital Committee performs several functions, including, among other things:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full Board regarding) our overall compensation strategy and policies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">making recommendations to the full Board regarding the compensation and other terms of employment of our Chief Executive Officer;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing, modifying and approving (or if it deems appropriate, making recommendations to the full Board regarding) the compensation and other terms of employment of our other executive officers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and making recommendations to the full Board regarding performance goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals and objectives;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and approving (or if it deems it appropriate, making recommendations to the full Board regarding) the equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating existing plans and programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation policies and practices for our employees are reasonably likely to have a material adverse effect on us;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and making recommendations to the full Board regarding the type and amount of compensation to be paid or awarded to our non-employee board members;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establishing policies with respect to votes by our stockholders to approve executive compensation to the extent required by Section&#160;14A of the Exchange Act and, if applicable, determining our recommendations regarding the frequency of advisory votes on executive compensation;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and assessing the independence of compensation consultants, legal counsel and other advisers as required by Section&#160;10C of the Exchange Act;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">administering our equity incentive plans;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establishing policies with respect to equity compensation arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation policy and strategy in achieving expected benefits to Cidara;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">review and discuss matters relating to human capital management, including the Company&#8217;s policies and strategies regarding recruiting, retention, career development and progression, culture, diversity and inclusion, and other employment practices, including their implementation and effectiveness;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">overseeing our compensation clawback policy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing with management and approving our disclosures under the caption &#8220;Compensation Discussion and Analysis&#8221; in our periodic reports or proxy statements to be filed with the SEC, to the extent such caption is included in any such report or proxy statement; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and evaluating, on an annual basis, the performance of the Compensation and Human Capital Committee and the Compensation and Human Capital Committee charter.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Human Capital Committee Processes and Procedures</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Typically, the Compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">and Human Capital </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Committee meets approximately three to four times per year, with greater frequency if necessary</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The agenda for each meeting is usually developed by the Chair of the Compensation and Human Capital Committee, in consultation with management. The Compensation and Human Capital Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation and Human Capital Committee to make presentations, to provide financial or other background information or advice or to otherwise participate in Compensation and Human Capital Committee meetings. The Chief Executive Officer does not participate in, and is not present during, any deliberations or determinations of the Compensation and Human Capital Committee regarding his compensation. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">charter of the Compensation and Human Capital Committee grants the Compensation and Human Capital Committee full access to all books, records, facilities and personnel of the Company. In addition, under its charter, the Compensation and Human Capital Committee has the authority to obtain, at the expense of the Company, advice and assistance from internal and external legal, accounting or other advisers and other external resources that the Compensation and Human Capital Committee considers necessary or appropriate in the performance of its duties. The Compensation and Human Capital Committee has direct responsibility for the oversight of the work of any advisers engaged for the purpose of advising the Compensation and Human Capital Committee. In particular, the Compensation and Human Capital Committee has the sole authority to retain compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. Under its charter, to the extent required by SEC and Nasdaq rules, the Compensation and Human Capital Committee may select, or receive advice from, a compensation consultant, legal counsel or other adviser to the Compensation and Human Capital Committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and Nasdaq, that bear upon the adviser&#8217;s independence; however, there is no requirement that any adviser be independent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In 2023, the Company engaged Aon Consulting, Inc., or Aon, as its compensation consultant. Aon was retained to provide an assessment of the Company&#8217;s executive and director compensation programs in comparison to executive and director compensation programs at selected publicly-traded peer companies. As part of its engagement, Aon was requested by the Compensation and Human Capital Committee to develop the peer group of comparative companies and to perform analyses of compensation levels for that group. Aon developed peer group and related recommendations that were presented to the Compensation and Human Capital Committee for its consideration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Compensation and Human Capital Committee holds one or more meetings during the first quarter of the year</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> to discuss and make recommendations to the Board for annual compensation adjustments, annual bonuses, annual equity awards, and new corporate performance objectives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. However, the Compensation and Human Capital Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the effectiveness of the Company&#8217;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at periodic meetings throughout the year on an as-needed basis. Generally, the Compensation and Human Capital Committee&#8217;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation and Human Capital Committee solicits and considers evaluations and recommendations submitted to the Compensation and Human Capital Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation of his performance is conducted by the Compensation and Human Capital Committee, which determines recommendations to the Board regarding any adjustments to his compensation as well as awards to be granted. For all executives and directors as part of its deliberations, the Compensation and Human Capital Committee may review and consider, as appropriate, materials such as </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">analyses of historical executive compensation levels and current Company-wide compensation levels, compensation data from comparative companies, compensation surveys, and recommendations of any compensation consultant, if applicable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Nominating and Governance Committee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Nominating and Governance Committee of the Board is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors, selecting or recommending to the Board for selection candidates for election to the Board, making recommendations to the Board regarding the membership of the committees of the Board, assessing the performance of the Board, and developing a set of corporate governance principles for the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Nominating and Governance Committee was comprised of four directors for 2023: Drs. Franson (Chair), Bassler and Gollaher and Mr. Burgess. All members of the Nominating and Governance Committee are independent (as independence is currently defined </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">under applicable Nasdaq listing standards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">). The functions of this committee include, among other things:</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">identifying, reviewing and evaluating candidates to serve on our Board;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">determining the minimum qualifications for service on our Board;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">evaluating director performance on the Board and applicable committees of the Board and determining whether continued service on our Board is appropriate;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">nominating and recommending individuals for membership on our Board;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">evaluating nominations by stockholders of candidates for election to our Board;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">considering and assessing the independence of members of our Board;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">developing, if and when it deems appropriate, a set of corporate governance policies and principles and recommending to our Board any changes to such policies and principles;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">considering questions of possible conflicts of interest of directors as such questions arise; and</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and evaluating on an annual basis the performance of the Nominating and Governance Committee and the Nominating and Governance Committee charter.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Nominating and Governance Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic financial statements and possessing the highest personal integrity and ethics. The Nominating and Governance Committee also considers such factors as possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of the Company&#8217;s stockholders. However, the Nominating and Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Nominating and Governance Committee typically considers diversity of skills, background and perspective (such as age, gender, race and specialized experience) and such other factors as it deems appropriate, given the current needs of the Board and the Company, to maintain a balance of knowledge, experience and capability. In the case of incumbent directors whose terms of office are set to expire, the Nominating and Governance Committee reviews these directors&#8217; overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Governance Committee then compiles a list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating and Governance Committee meets to discuss and consider the candidates&#8217; qualifications </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">and selects candidates for recommendation to the Board by majority vote</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Nominating and Governance Committee will consider director candidates recommended by stockholders. The Nominating and Governance Committee does not intend to alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to recommend individuals for consideration by the Nominating and Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the Nominating and Governance Committee at the following address: Cidara Therapeutics, Inc., 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121, Attn: Corporate Secretary, no later than the close of business on the 90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> day nor earlier than the close of business on the 120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> day prior to the first anniversary of the preceding year&#8217;s annual meeting. Submissions must include the name and address of the Company stockholder on whose behalf the submission is made; the number of Company shares that are owned beneficially by such stockholder as of the date of the submission; the full name of the proposed candidate; a description of the proposed candidate&#8217;s business experience for at least the previous five years; complete biographical information for the proposed candidate; and a description of the proposed candidate&#8217;s qualifications as a director. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Science and Technology Committee</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, our Board formed the Science and Technology Committee, which was comprised of four directors for 2023: Drs. Bassler (Chair), Franson, Gollaher and Stein. The Science and Technology Committee acted on behalf of our Board to, among other things, review and evaluate the Company&#8217;s scientific research programs on behalf of our Board and make recommendations to our Board regarding strategic and tactical scientific issues and decisions regarding advancement of our technology. The functions of this committee included, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">developing and participating in a process for periodic review of our scientific research programs and technology;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">evaluating the long-term strategic value of the Company&#8217;s scientific research programs and technology, making recommendations to the Board regarding acquisition, disposition and/or development of our scientific and technology assets and advising the Board on scientific aspects of business development matters;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reviewing and evaluating on an annual basis the performance of the Science and Technology Committee and the Science and Technology Committee charter; and</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">upon request, assisting in setting annual scientific research performance goals and assessing achievement of such goals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023 the Science and Technology Committee was decommissioned.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CODE OF ETHICS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have adopted a code of ethics for directors, officers (including our principal executive officer, principal financial officer and principal accounting officer) and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:underline">www.cidara.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> under the Corporate Governance section of our Investor Relations page. We will promptly disclose on our website (i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, principal accounting officer, or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals that is required to be disclosed pursuant to SEC rules and regulations, the name of such person who is granted the waiver and the date of the waiver.&#160;The information contained on, or that can be accessed through, our website is not part of this Annual Report on Form 10-K, and the inclusion of our website address in this Annual Report on Form 10-K is an inactive textual reference only.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Jeffrey Stein, Ph.D. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">has served as our President, Chief Executive Officer and a member of our Board of Directors since January 2014. For additional information regarding Dr. Stein&#8217;s industry experience and education, see above under &#8220;Directors Continuing in Office Until the 2025 Annual Meeting of Stockholders.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Taylor Sandison, M.D., 52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has been with Cidara since October 2015 and became our Chief Medical Officer in January 2017. Prior to joining the Company, he served as senior medical director at Merck and prior to that held the same position at Cubist Pharmaceuticals, Inc. Dr. Sandison has also held positions at Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, and Novartis Diagnostics, and served as a member of the faculty in the Department of Medicine at both Stanford University and the University of Washington. He received B.S. and B.A. degrees from Dartmouth College, M.D. and M.P.H. degrees from the University of Washington, and a Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine. He completed internal medicine residency training at the University of Colorado and infectious diseases fellowship training at the University of Washington. Dr. Sandison currently holds board certifications in Infectious Diseases and Internal Medicine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Preetam Shah, Ph.D., MBA, 51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has served as our Chief Financial Officer and Chief Business Officer since September 2021. Prior to joining the Company, Dr. Shah served as Executive Vice President, Chief Financial Officer and Treasurer at Brainstorm Cell Therapeutics, Inc., or Brainstorm, a publicly-traded biotechnology company, since September 2019. Prior to Brainstorm, Dr. Shah spent over six years as an investment banker advising healthcare companies on equity, debt and M&amp;A transactions; holding senior roles at banks, including Barclays Capital PLC., from June 2016 to September 2019, and Canaccord Genuity Inc., from July 2013 to May 2016. From 2010 to 2013, Dr. Shah founded Saisarva LLC, a healthcare consulting firm. During this period, he also acted as a consultant for healthcare-focused private equity firms and hedge funds. From 2006 to 2009, Dr. Shah served as Vice President, U.S. Operations and Investments at Reliance Capital USA Ventures LLC, an affiliate of Reliance ADA Group Companies, where he was responsible for making early-stage venture investments in healthcare companies. Dr. Shah completed his post-doctoral fellowship in Infectious Diseases from Stanford University School of Medicine. He holds a Ph.D. in Microbiology from the University of Mississippi Medical Center, an M.B.A. in Finance from the Wharton School, University of Pennsylvania, and a B.A. in Mathematics and in Biology from McDaniel College.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Leslie Tari, Ph.D., 57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has served as our Chief Scientific Officer since July 2021. Previously, he served as our Senior Vice President, Research from March 2019 to July 2021, and as our Vice President, Discovery, from July 2014 to March 2019. Prior to joining Cidara, Dr. Tari held various leadership positions at Trius Therapeutics, Inc., a publicly-traded biopharmaceutical company, from March 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Prior to Trius Therapeutics, Dr. Tari co-founded and served as a Director of Structural Biology at ActiveSight, Inc. from 2003 to 2007. From 2001 until 2003, Dr. Tari served as Associate Director of Structural Biology at Syrrx Inc. Dr. Tari also served as a Professor and Alberta Heritage Foundation Scholar for Medical Research at the University of Calgary from 1998 to 2001, where he conducted research focused on antibiotic discovery. Dr. Tari serves on the board of advisors of Life Science Cares San Diego. Dr. Tari received a B.S. degree in Chemistry and a Ph.D. in Chemistry and Structural Biology from the University of Manitoba.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Shane Ward, 49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, has served as our Chief Operating Officer, Chief Legal Officer and Corporate Secretary since September 2022. Previously Mr. Ward served as our Chief Legal Officer and Corporate Secretary since August 2021. From December 2020 to August 2021, Mr. Ward was an independent biotechnology consultant. From May 2018 to December 2021, he served as the Chief Legal and Strategy Officer for Bellicum Pharmaceuticals, Inc. a publicly-traded biopharmaceutical company developing controllable cell therapies. Earlier in his career, Mr. Ward was a senior in-house attorney with commercial pharmaceutical companies Gilead Sciences, Abbott Laboratories and Human Genome Sciences. He began his legal career as an associate for the international law firm Sidley Austin LLP. Mr. Ward earned his B.A from the University of Virginia, and his J.D. from Georgetown University Law Center.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">DELINQUENT SECTION&#160;16(A) REPORTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Section&#160;16(a) of the Exchange Act requires the Company&#8217;s directors and executive officers, and persons who own more than ten percent of a registered class of the Company&#8217;s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all Section&#160;16(a) forms they file.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To the Company&#8217;s knowledge, based solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were required, during the fiscal year ended December&#160;31, 2023, all Section&#160;16(a)&#160;filing requirements applicable to its officers, directors and greater than ten percent beneficial owners were complied with, except for one Form 4 for Dr. Tari, an officer of the Company, relating to shares sold on January 12, 2023. The Form 4 was filed on January 27, 2023.</span></div><div id="ib00951007fb342d8a49dba10256b8485_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our named executive officers for the year ended December&#160;31, 2023, which consist of our principal executive officer and our two other most highly compensated executive officers, are:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Jeffrey Stein, Ph.D., our President and Chief Executive Officer;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Taylor Sandison, M.D., M.P.H., our Chief Medical Officer; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Shane Ward, Chief Operating Officer, Chief Legal Officer and Corporate Secretary.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:19.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.811%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.164%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.760%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NAME AND PRINCIPAL POSITION</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">YEAR</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SALARY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">STOCK AWARDS </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">OPTION AWARDS </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NON-EQUITY INCENTIVE PLAN COMPENSATION </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ALL OTHER COMPENSATION </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TOTAL</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.<br/>   President and<br/>   Chief Executive Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">593,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">274,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388,276&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,266,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,256,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taylor Sandison, M.D., M.P.H.<br/>   Chief Medical Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">716,492&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,710&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">726,395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:36pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shane Ward<br/>   Chief Operating Officer<br/>   Chief Legal Officer and<br/>   Corporate Secretary (5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127,934&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">773,455&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The amount reported in this column for 2023 represents the aggregate grant date fair value of restricted stock unit awards granted during 2023 under our 2015 Plan, computed in accordance with ASC Topic 718. The assumptions used in calculating the grant date fair value of these equity awards reported in this column are set forth in Note 8 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. This amount does not reflect the actual economic value that may be realized by Drs. Stein and Sandison and Mr. Ward.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards granted during 2023 computed in accordance with ASC 718. Assumptions used in the calculation of these amounts are included in Note 8 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. This amount does not reflect the actual economic value that may be realized by Drs. Stein and Sandison and Mr. Ward.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Reflects amounts earned pursuant to our annual performance-based cash bonus program, amounts for fiscal year 2023 have not yet been determined. We expect to be able to determine the annual performance-based cash bonuses for each named executive officer by mid-2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Represents Company 401(k) plan matching contributions to each named executive officer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Mr. Ward was not a named executive officer in 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">COMPENSATION PROGRAM OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our compensation program for executive officers is designed to encourage our management team to achieve our short-term and long-term corporate objectives while effectively managing business risks and challenges. We provide what we believe is a competitive total compensation package to our management team through a combination of base salary, an annual performance-based bonus and long-term equity-based incentives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The compensation of our named executive officers other than our Chief Executive Officer is generally determined and approved by the Compensation and Human Capital Committee of our Board, and the compensation of our Chief Executive Officer is approved by our Board based upon the recommendations of the Compensation and Human Capital Committee.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Annual Base Salary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Base salaries established for our named executive officers are paid to attract and retain talent and are set at a level that is commensurate with each executive&#8217;s duties and authority, contributions, prior experience and sustained performance. The 2023 base salaries for our named executive officers were as follows:</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.975%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NAME</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 BASE</span></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SALARY</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">593,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taylor Sandison, M.D., M.P.H.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shane Ward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr></table></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Drs. Stein and Sandison and Mr. Ward received base salary increases in March 2023 which were applied retroactively to January 1, 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Annual Bonus Opportunity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash bonuses, which are designed to provide appropriate incentives to our named executive officers to achieve defined annual corporate and individual goals and to reward them for achievement towards these goals. The annual performance-based bonus that each named executive officer is eligible to receive is generally based on the extent to which we achieve the corporate goals the Board establishes each year, the extent to which the executive achieves any related individual goals and each executive&#8217;s target bonus opportunity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The target bonus percentages that Drs. Stein and Sandison and Mr. Ward will be eligible for under the bonus plan for 2023 are 60%, 40% and 40% of their base salaries, respectively. Dr. Stein&#8217;s bonus award will be weighted 100% for our achievement of corporate goals established by the Board. The bonus awards for Dr. Sandison and Mr. Ward will be weighted 80% for our achievement of corporate goals and 20% for achievement of individual goals approved by our Chief Executive Officer. Our corporate goals for 2023, established by our Board upon recommendation of the Compensation and Human Capital Committee, were a mix of clinical, research and development and financial goals. For our executive officers, including our named executive officers, the actual bonus award for any year, if any, may be more or less than the applicable target, depending primarily on the Board&#8217;s determination of the extent to which we achieved the corporate goal component, and, other than for Dr. Stein, the executive&#8217;s individual performance with respect to such corporate goals. There is no minimum bonus percentage or amount established for the named executive officers and, as a result, the bonus amounts vary from year to year based on corporate and/or individual performance. Payments under the bonus plan may be made in cash, through the issuance of stock, stock options or another form of equity award, or by a combination thereof. The Compensation and Human Capital Committee has the right to terminate or change the bonus plan at any time and for any reason.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Annual performance-based cash bonuses have not yet been determined for 2023. We expect to be able to determine the annual performance-based cash bonuses by mid-2024.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Incentive Awards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our equity-based incentive awards are designed to align the interests of our employees, including our named executive officers, with our stockholders&#8217; interests. The Compensation and Human Capital Committee is responsible for approving equity grants, other than those for our Chief Executive Officer and directors which are approved by our Board based upon the recommendation of the Compensation and Human Capital Committee. Our executives generally are awarded an initial new hire equity grant upon commencement of employment. Additional annual grants may also be made at the discretion of the Compensation and Human Capital Committee or Board in order to specifically incentivize executives with respect to achieving certain corporate goals, reward executives for exceptional performance, or to ensure executives&#8217; equity holdings are consistent with our compensation philosophy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Prior to our initial public offering, we granted all equity awards pursuant to our 2013 Stock Option and Grant Plan, or the 2013 Plan. Upon and following our initial public offering, all equity awards are granted under our 2015 Equity Incentive Plan, or the 2015 Plan, and, starting in December 2020, new hire equity awards to individuals who were not previously employees or directors of the Company, may be granted under our 2020 Inducement Incentive Plan, or the 2020 Plan. The terms of our 2013 Plan, 2015 Plan and 2020 Plan are described below under &#8220;Equity Benefit Plans.&#8221; All options are granted with a per share exercise price equal to the fair market value of a share of our common stock on the date of the grant of such award, as determined by the Compensation and Human Capital Committee or the Board. Generally, our new hire equity awards vest over a four-year period and our annual equity awards vest over a three-year period, in each case subject to the holder&#8217;s continuous service to Cidara.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We granted annual equity awards to each of our named executive officers in March 2023. Our annual equity awards for Drs. Stein and Sandison and Mr. Ward consisted of stock options and RSUs. All stock options were granted and approved on the same date with an exercise price equal to the fair value of the Company&#8217;s common stock on the date of grant. All stock options are time-based awards, which vest monthly, on a pro-rata basis, over three years, and have a term of ten years. The RSUs vest in three annual installments on March 10, 2024, 2025, and 2026, contingent on each officer&#8217;s continued employment with the Company through the applicable vesting date.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Clawbacks</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a public company, if we are required to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws as a result of misconduct, the Chief Executive Officer and Chief Financial Officer may be legally required to reimburse our Company for any bonus or other incentive-based or equity-based compensation they receive in accordance with the provisions of section 304 of the Sarbanes-Oxley Act of 2002, as amended. Additionally, we have implemented a Dodd-Frank Act-compliant clawback policy, as required by SEC rules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed elsewhere in this Annual Report on Form 10-K, on April 11 and April 15, 2024, the Audit Committee determined, based on management&#8217;s recommendation, that our Prior Financial Statements filed with the SEC should no longer be relied upon and should be restated. We have restated the Prior Financial Statements in this Annual Report on Form 10-K. In accordance with our Incentive Compensation Recoupment Policy that was adopted on December 1, 2023, as required by the listing standards adopted pursuant to 17 CFR 240.10D&#8211;1, management concluded that recovery of erroneously awarded compensation was not required. This conclusion was reached because during the period relevant to the restatement, no compensation paid to our executives was granted, earned, or vested based wholly or in part upon the attainment of any measure that is determined and presented in accordance with the accounting principles used in preparing our financial statements.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Agreements with our Named Executive Officers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2016 we entered into an amended and restated employment agreement with Dr. Stein. In March 2017 we entered into an employment agreement with Dr. Sandison. In August 2021 we entered into an employment agreement with Mr. Ward. The agreements govern the terms of their at-will employment with us and provide for certain severance and change of control benefits, the terms of which are described below under &#8220;&#8212;Potential Payments Upon Termination or Change of Control.&#8221;</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Potential Payments Upon Termination or Change of Control</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Regardless of the manner in which a named executive officer&#8217;s service terminates, the named executive officer is entitled to receive amounts earned during his term of service, including salary and unused vacation pay. In addition, each of our named executive officers is eligible to receive certain benefits pursuant to his agreement with us. The benefits described below are contingent on the officer&#8217;s execution and non-revocation of a general release of claims against us and certain related parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Dr. Stein</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event that we terminate the employment of Dr.&#160;Stein other than for cause or if Dr.&#160;Stein resigns with good reason, in each case as defined in Dr. Stein&#8217;s amended and restated employment agreement, and provided such event occurs outside of the period beginning three months before and ending 12 months after a change of control transaction involving us, Dr.&#160;Stein will receive 12 months of salary, payable in a lump sum, and&#160;12 months of health care benefits continuation at our expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event that we terminate the employment of Dr.&#160;Stein other than for cause or if Dr.&#160;Stein resigns with good reason, in each case as defined in Dr. Stein&#8217;s amended and restated employment agreement, and provided such event occurs during the period beginning three months before and ending 12 months after a change of control transaction involving us, Dr.&#160;Stein will receive 18 months of salary, payable in a lump sum, 1.5 times the amount of Dr.&#160;Stein&#8217;s target bonus level for the year in which the termination occurs, and&#160;18 months of health care benefits continuation at our expense. In addition, all of Dr.&#160;Stein&#8217;s unvested stock awards will immediately become vested on the date of termination.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, in the event we undertake a change of control transaction in which Dr. Stein is subject to excise taxes under Section 280G of the Internal Revenue Code of 1986, as amended, or the Code, Dr.&#160;Stein will receive a gross-up payment, payable in a lump sum, to fully compensate Dr.&#160;Stein for any such taxes imposed by Section&#160;280G of the Code.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Dr. Sandison and Mr. Ward</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event that we terminate the employment of either Dr. Sandison or Mr. Ward other than for cause or if such executive resigns with good reason, in each case as defined in his employment agreement, and provided such event occurs outside of the period beginning three months before and ending 12 months after a change of control transaction involving us, such executive will receive nine months of salary, payable in a lump sum, and&#160;nine months of health care benefits continuation at our expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event we terminate the employment of either Dr. Sandison or Mr. Ward other than for cause or if such executive resigns with good reason, in each case as defined in his employment agreement, and provided such event occurs during the period beginning three months before and ending 12 months after a change of control transaction involving us, such executive will receive 12 months of salary, payable in a lump sum, an amount equal to his target bonus level for the year in which the termination occurs, and&#160;12 months of health care benefits continuation at our expense. In addition, all of such executive&#8217;s unvested stock awards will immediately become vested on the date of termination.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, in the event we undertake a change of control transaction in which either Dr. Sandison or Mr. Ward is subject to excise taxes under Section 280G of the Code, Dr. Sandison and Mr. Ward, as applicable, will receive a gross-up payment, payable in a lump sum, to compensate such executive officer for any taxes imposed by Section&#160;280G of the Code, provided that each such gross-up payment will be capped at $1.0&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding equity awards granted to our named executive officers that remain outstanding as of December&#160;31, 2023:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">OPTION AWARDS </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">STOCK AWARDS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">NAME</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">GRANT DATE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">VESTING COMMENCE-<br/>MENT DATE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">NUMBER OF SECURITIES UNDERLYING UNEXER-CISED OPTIONS<br/>(#) EXER-CISABLE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">NUMBER OF SECURITIES UNDERLYING UNEXER-CISED OPTIONS<br/>(#)<br/>UNVESTED AND UNEXER-CISABLE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">OPTION EXER-<br/>CISE PRICE<br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">OPTION EXPIR-<br/>ATION DATE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">NUMBER OF SHARES OR UNITS OF STOCK THAT HAVE NOT VESTED<br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">MARKET VALUE OF SHARES OR UNITS OF STOCK THAT HAVE NOT VESTED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">($) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">EQUITY INCENTIVE PLAN AWARDS: NUMBER OF UNEARNED SHARES, UNITS, OR OTHER RIGHTS THAT HAVE NOT VESTED<br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:700;line-height:100%">EQUITY INCENTIVE PLAN AWARDS: MARKET OR PAYOUT VALUE OF UNEARNED SHARES, UNITS OR OTHER RIGHTS THAT HAVE NOT VESTED ($) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:700;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(2)</span></div></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9/9/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5/30/2014</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">153,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9/8/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2/19/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2/19/2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">205,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2/18/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/16/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/16/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">159,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/15/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">7.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/30/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">235,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/28/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/21/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/21/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">265,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/20/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/19/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/19/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">330,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/18/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/17/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/17/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">481,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">43,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/16/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">192,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">137,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/30/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">108,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">86,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">135,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">407,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/26/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">271,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">214,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Taylor Sandison, M.D., M.P.H.</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9/18/2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9,875&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/29/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">70,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/28/2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/21/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/21/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/20/2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12/18/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12/18/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">61,925&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12/17/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12/18/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12/18/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4,075&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12/17/2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/19/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/19/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/18/2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/17/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/17/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">132,917&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">12,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/16/2031</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">50,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">39,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">58,333&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">41,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/30/2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">45,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">135,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/26/2033</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">90,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">71,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Shane Ward</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8/25/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(3) (11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8/25/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">145,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">104,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8/24/2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">40,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/30/2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">63,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">190,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/26/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:3.9pt;font-weight:400;line-height:100%;position:relative;top:-2.1pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">126,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">100,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Options granted prior to April 2015 were granted under the 2013 Plan, and options granted after April 2015 were granted under the 2015 Plan. Options granted under the 2013 Plan are immediately exercisable subject to a repurchase right held by us, which lapses as the shares vest. Options granted under the 2015 Plan become exercisable as they vest. The terms of the 2013 Plan and 2015 Plan are described below under &#8220;Equity Benefit Plans.&#8221; All equity award vesting is subject to continued service of the executive.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The amount shown is determined by multiplying the number of unvested restricted stock units</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">RSUs, and performance restricted stock units</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">PRSUs, by $0.79, the closing price of the Company's common stock on December 29, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2023, the last trading day of the Company&#8217;s fiscal year</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Stock options have a four-year vesting schedule, with 25% vesting on the one-year anniversary of the vesting commencement date, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">monthly thereafter in equal increments over the remaining&#160;36 months.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Stock options have a three-year vesting schedule, vesting in equal monthly</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> increments.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Awards include PRSUs that are subject to performance-based vesting conditions and are scheduled to vest on the achievement of various clinical and corporate milestones, subject to the officer&#8217;s continued service with the Company through the satisfaction of such performance conditions. As of December 31, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, none of the performance criteria underlying these PRSUs have been achieved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Represents stock options granted in our 2019 Option Exchange described in our proxy statement for our 2020 Annual Meeting of Stockholders, which vested in full on the first anniversary of the grant date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Represents stock options granted in our 2019 Option Exchange, which vest over three years, with 1/3 vesting on the one-year anniversary of the vesting commencement date, and monthly thereafter in equal increments over the remaining 24 months.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Represents RSUs that are subject to time-based vesting conditions and are scheduled to vest in three equal installments on September 10, 2022, 2023 and 2024, contingent on the officer&#8217;s continued service with the Company through the applicable vesting date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Represents RSUs that are subject to time-based vesting conditions and are scheduled to vest in three equal installments on March 10, 2023, 2024 and 2025, contingent on the officer&#8217;s continued service with the Company through the applicable vesting date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Represents RSUs that are subject to time-based vesting conditions and are scheduled to vest in three equal installments on March 10, 2024, 2025 and 2026, contingent on the officer&#8217;s continued service with the Company through the applicable vesting date.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Options were granted under the 2020 Plan and become exercisable as they vest. The terms of the 2020 Plan are described below under &#8220;Equity Benefit Plans.&#8221; All equity award vesting is subject to continued service of the executive.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Option Repricings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We did not engage in any repricings, modifications or cancellations of any of our named executive officers&#8217; outstanding equity awards during the year ended December&#160;31, 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Perquisites: Health, Welfare and Retirement Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All of our named executive officers are eligible to participate in our employee benefit plans, including our medical, dental, vision, group life, disability and accidental death and dismemberment insurance plans, in each case on the same basis as our other employees. We also provide a 401(k) plan to our employees, including our named executive officers, as discussed in the section below entitled &#8220;401(k) Plan.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not provide any other perquisites or personal benefits to our named executive officers. We do, however, pay the premiums for term life insurance and disability insurance for all of our employees, including our current named executive officers.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">401(k) Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We maintain a defined contribution employee retirement plan, or the 401(k) Plan, for our employees. Our named executive officers are eligible to participate in the 401(k) Plan on the same basis as our other employees. The 401(k) Plan is intended to qualify as a tax-qualified plan under Section&#160;401(k) of the Code. The 401(k) plan provides that each participant may contribute a portion of his or her eligible compensation, up to the statutory annual limit, which was $22,500 for employees under age 50 and was $30,000 for employees age 50 and over in 2023. All contributions made by participants are either pre-tax contributions or after-tax &#8220;Roth 401(k) contributions,&#8221; as elected by the participant. The plan permits us to make discretionary contributions, including matching contributions and discretionary profit-sharing contributions. In 2024 we made an employer matching contribution for 2023 employee pre-tax and Roth 401(k) contributions of fifty cents for every employee dollar electively deferred under the 401(k) Plan, limited to six percent of the participant&#8217;s compensation and further subject to any limitations set forth by the Internal Revenue Service. The 401(k) Plan currently does not offer the ability to invest in Cidara&#8217;s securities.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Nonqualified Deferred Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of our named executive officers participate in or have account balances in nonqualified defined contribution plans or other nonqualified deferred compensation plans maintained by us. The Board may elect to provide our officers and other employees with nonqualified defined contribution or other nonqualified deferred compensation benefits in the future if it determines that doing so is in our best interests.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Tax Deductibility of Executive Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under Section 162(m) of the Code, or Section 162(m), compensation paid to each of our &#8220;covered employees&#8221; that exceeds $1.0&#160;million per taxable year is generally non-deductible unless the compensation qualifies for certain grandfathered exceptions (including the &#8220;performance-based compensation&#8221; exception) for certain compensation paid pursuant to a written binding contract in effect on November 2, 2017 and not materially modified on or after such date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although the Compensation and Human Capital Committee will continue to consider tax implications as one factor in determining executive compensation, the Compensation and Human Capital Committee also looks at other factors in making its decisions and retains the flexibility to provide compensation for the Company&#8217;s named executive officers in a manner consistent with the goals of the Company&#8217;s executive compensation program and the best interests of the Company and its stockholders, which may include providing for compensation that is not deductible by the Company due to the deduction limit under Section 162(m). The Compensation and Human Capital Committee also retains the flexibility to modify compensation that was initially intended to be exempt from the deduction limit under Section 162(m) if it determines that such modifications are consistent with the Company&#8217;s business needs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EQUITY BENEFIT PLANS</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board adopted the 2020 Plan in December 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Eligible Award Recipients. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Grantees under the 2020 Plan must be individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Stock Awards. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The 2020 Plan provides for the grant of nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards to eligible employees as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Administration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Our Board administers the 2020 Plan. Awards may be granted under the 2020 Plan by either a majority of the Board&#8217;s independent members or the independent members of the Compensation and Human Capital Committee. Subject to the terms of the 2020 Plan, our Board or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability and the vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The plan administrator has the authority to modify outstanding awards under our 2020 Plan. Subject to the terms of our 2020 Plan, the plan administrator may not reduce the exercise, purchase or strike price of any outstanding stock award, but may cancel any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Nonstatutory stock options, or NSOs, are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2020 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2020 Plan vest at the rate specified by the plan administrator.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The plan administrator determines the term of stock options granted under the 2020 Plan, up to a maximum of ten years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1)&#160;cash, check, bank draft or money order, (2)&#160;a broker-assisted cashless exercise, (3)&#160;the tender of shares of our common stock previously owned by the optionholder, (4)&#160;a net exercise of the option, and (5)&#160;other legal consideration approved by the plan administrator.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unless the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&#8217;s death.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. RSU awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator. RSU awards may be granted in consideration for any form of legal consideration. An RSU award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by an RSU award. Except as otherwise provided in the applicable award agreement, RSUs that have not vested will be forfeited upon the participant&#8217;s cessation of continuous service for any reason.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Corporate Transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In the event of certain specified significant corporate transactions, the plan administrator has the discretion to take any of the following actions with respect to stock awards:</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity or parent company;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring entity or parent company;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">accelerate the vesting of the stock award and provide for its termination at or prior to the effective time of the corporate transaction;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">arrange for the lapse of any reacquisition or repurchase right held by us;</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as the Board may deem appropriate; or</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">make a payment equal to the excess of (1)&#160;the value of the property the participant would have received upon exercise of the stock award over (2)&#160;the exercise price otherwise payable in connection with the stock award.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our plan administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the 2020 Plan, a corporate transaction is generally the consummation of (1) a sale or other disposition of all or substantially all of our consolidated assets, (2) a sale or other disposition of at least 90% of our outstanding securities, (3) a merger, consolidation or similar transaction following which we are not the surviving corporation, or (4) a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Change of Control</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The plan administrator may provide, in an individual award agreement or in any other written agreement between a participant and us, that the stock award will be subject to additional acceleration of vesting and exercisability in the event of a change of control. For example, certain of our employees may receive an award agreement that provides for vesting acceleration upon the individual&#8217;s termination without cause or resignation for good reason (including a material reduction in the individual&#8217;s base salary, duties, responsibilities or authority, or a material relocation of the individual&#8217;s principal place of employment with us) in connection with a change of control. Under the 2020 Plan, a change of control is generally (1) the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction; (2) a consummated merger, consolidation or similar transaction immediately after which our stockholders cease to own more than 50% of the combined voting power of the surviving entity; or (3) a consummated sale, lease or exclusive license or other disposition of all or substantially of our consolidated assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Amendment and Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Our Board has the authority to amend, suspend, or terminate our 2020 Plan, subject to stockholder approval.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board adopted the 2015 Plan in March 2015 and our stockholders approved the 2015 Plan in April 2015. The 2015 Plan became effective upon the execution and delivery of the underwriting agreement related to our initial public offering. Once the 2015 Plan became effective, no further grants were made under the 2013 Plan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Stock Awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The 2015 Plan provides for the grant of incentive stock options, or ISOs, NSOs, stock appreciation rights, restricted stock awards, RSUs, performance-based stock awards, and other forms of equity compensation, or collectively, stock awards, all of which may be granted to employees, including officers, non-employee directors and consultants of us and our affiliates. Additionally, the 2015 Plan provides for the grant of performance cash awards. ISOs may be granted only to employees. All other awards may be granted to employees, including officers, and to non-employee directors and consultants.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Administration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Our Board, or a duly authorized committee thereof, has the authority to administer the 2015 Plan. Our Board may also delegate to one or more of our officers the authority to (1)&#160;designate employees (other than other officers) to be recipients of certain stock awards, and (2)&#160;determine the number of shares of common stock to be subject to such stock awards. Subject to the terms of the 2015 Plan, our Board or the authorized committee, referred to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability and the vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards granted and the types of consideration to be paid for the award.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The plan administrator has the authority to modify outstanding awards under our 2015 Plan. Subject to the terms of our 2015 Plan, the plan administrator has the authority to reduce the exercise, purchase or strike price of any outstanding stock award, cancel any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. ISOs and NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option, within the terms and conditions of the 2015 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2015 Plan vest at the rate specified by the plan administrator.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The plan administrator determines the term of stock options granted under the 2015 Plan, up to a maximum of ten years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. The option term may be extended in the event that exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options generally terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1)&#160;cash, check, bank draft or money order, (2)&#160;a broker-assisted cashless exercise, (3)&#160;the tender of shares of our common stock previously owned by the optionholder, (4)&#160;a net exercise of the option if it is an NSO, and (5)&#160;other legal consideration approved by the plan administrator.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Unless the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&#8217;s death.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Unit Awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. RSU awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator. RSU awards may be granted in consideration for any form of legal consideration. An RSU award may be settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in respect of shares covered by an RSU award. Except as otherwise provided in the applicable award agreement, RSUs that have not vested will be forfeited upon the participant&#8217;s cessation of continuous service for any reason.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Corporate Transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In the event of certain specified significant corporate transactions, the plan administrator has the discretion to take any of the following actions with respect to stock awards:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity or parent company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring entity or parent company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">accelerate the vesting of the stock award and provide for its termination at or prior to the effective time of the corporate transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">arrange for the lapse of any reacquisition or repurchase right held by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as the Board may deem appropriate; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">make a payment equal to the excess of (1)&#160;the value of the property the participant would have received upon exercise of the stock award over (2)&#160;the exercise price otherwise payable in connection with the stock award.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our plan administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the 2015 Plan, a corporate transaction is generally the consummation of (1) a sale or other disposition of all or substantially all of our consolidated assets, (2) a sale or other disposition of at least 90% of our outstanding securities, (3) a merger, consolidation or similar transaction following which we are not the surviving corporation, or (4) a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Change of Control</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The plan administrator may provide, in an individual award agreement or in any other written agreement between a participant and us, that the stock award will be subject to additional acceleration of vesting and exercisability in the event of a change of control. For example, certain of our employees may receive an award agreement that provides for vesting acceleration upon the individual&#8217;s termination without cause or resignation for good reason (including a material reduction in the individual&#8217;s base salary, duties, responsibilities or authority, or a material relocation of the individual&#8217;s principal place of employment with us) in connection with a change of control. Under the 2015 Plan, a change of control is generally (1) the acquisition by a person or entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction; (2) a consummated merger, consolidation or similar transaction immediately after which our stockholders cease to own more than 50% of the combined voting power of the surviving entity; or (3) a consummated sale, lease or exclusive license or other disposition of all or substantially of our consolidated assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Amendment and Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Our board of directors has the authority to amend, suspend, or terminate our 2015 Plan, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. No ISOs may be granted after the tenth anniversary of the date our Board adopted our 2015 Plan.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2013 Stock Option Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board initially adopted and our stockholders approved the 2013 Plan in February 2013. The 2013 Plan provides for the grant of stock options (ISOs and NSOs), restricted stock awards, unrestricted stock awards and RSU awards to our employees, directors, and consultants. Only stock options were awarded under the 2013 Plan. Our Board, or a duly authorized committee thereof, has the authority to administer the 2013 Plan. Subject to the terms of the 2013 Plan, our Board determined recipients, dates of grant, the number of and types of awards granted and the terms and conditions of awards made, including any applicable vesting schedule. Awards under the 2013 Plan were granted pursuant to award agreements adopted by the plan administrator. No additional awards may be granted under the 2013 Plan. However, any outstanding awards already granted under the 2013 Plan will remain outstanding, subject to the terms of such plan and the applicable award agreements, until such outstanding awards are exercised or until they terminate or expire by their terms.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our Board adopted the 2015 Employee Stock Purchase Plan, or the ESPP, in&#160;March 2015 and our stockholders approved the ESPP in April&#160;2015. The ESPP became effective immediately upon the execution and delivery of the underwriting agreement related to our initial public offering. The purpose of the ESPP is to retain the services of new employees and secure the services of new and existing employees while providing incentives for such individuals to exert maximum efforts toward our success and that of our affiliates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Administration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Our Board has delegated its authority to administer the ESPP to our Compensation and Human Capital Committee. The ESPP is implemented through a series of offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with durations of not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering may be terminated under certain circumstances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Payroll Deductions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Generally, all regular employees, including executive officers, employed by us or by any of our designated affiliates, may participate in the ESPP and may contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of our common stock under the ESPP. Unless otherwise determined by our Board, common stock will be purchased for accounts of employees participating in the ESPP at a price per share equal to the lower of (1)&#160;85% of the fair market value of a share of our common stock on the first date of an offering or (2)&#160;85% of the fair market value of a share of our common stock on the date of purchase.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Corporate Transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;In the event of certain significant corporate transactions, including the consummation of: (1)&#160;a sale of all our assets, (2)&#160;the sale or disposition of 90% of our outstanding securities, (3)&#160;a merger or consolidation where we do not survive the transaction and (4)&#160;a merger or consolidation where we do survive the transaction but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction, any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or substitute for such purchase rights, then the participants&#8217; accumulated payroll contributions will be used to purchase shares of our common stock within ten business days prior to such corporate transaction, and such purchase rights will terminate immediately.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Plan Amendments, Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Our Board has the authority to amend or terminate our ESPP, provided that except in certain circumstances any such amendment or termination may not materially impair any outstanding purchase rights without the holder&#8217;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by applicable law or listing requirements.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides certain information with respect to all of the Company&#8217;s equity compensation plans in effect as of December&#160;31, 2023.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.590%"/><td style="width:0.1%"/></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity Compensation Plan Information</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)<br/>Number of securities to be issued upon exercise of outstanding options, warrants and rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average exercise price of outstanding options, warrants and rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of securities remaining available for issuance under equity compensation plans, excluding securities reflected in column (a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,785,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,072,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders:</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">978,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,764,068&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,399,219&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Includes 9,814,165 shares subject to outstanding stock options and 1,971,053 shares subject to outstanding RSUs under our 2015 Plan and 2013 Plan.</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Includes 851,850 shares subject to outstanding stock options and 127,000 shares subject to outstanding RSUs under our 2020 Plan.</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The weighted-average exercise price is calculated based solely on the exercise prices of the outstanding stock options and does not reflect the shares that will be issued upon the vesting of outstanding awards of RSUs or PRSUs, which have no exercise price.</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Includes our 2013 Plan, 2015 Plan, 2020 Plan, and our ESPP. 987,756 shares in &#8220;Equity compensation plans approved by security holders&#8221; under column (c) were subject to purchase under our ESPP.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PAY VERSUS PERFORMANCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are providing the following information about the relationship between executive compensation actually paid and certain financial performance of our company as required by Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K. The disclosure included in this section is prescribed by SEC rules and does not necessarily align with how the Company or the Compensation and Human Capital Committee view the link between the Company&#8217;s performance and named executive officer, or NEO, pay. This disclosure is intended to comply with the requirements of Item 402(v) of Regulation S-K applicable to &#8220;smaller reporting companies.&#8221; For additional information about our compensation philosophy and how we seek to align executive compensation with the Company&#8217;s performance, refer to &#8220;Executive and Director Compensation&#8221; section above.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Required Tabular Disclosure of Pay Versus Performance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The amounts set forth below under the headings &#8220;Compensation Actually Paid to PEO&#8221; and &#8220;Average Compensation Actually Paid to Non-PEO NEOs&#8221; have been calculated in a manner consistent with Item 402(v) of Regulation S-K. Use of the term &#8220;compensation actually paid&#8221; is required by the SEC&#8217;s rules and as a result of the calculation methodology required by the SEC, such amounts differ from compensation actually received by the individuals and the compensation decisions described in the &#8220;Executive and Director Compensation&#8221; section above. Our Chief Executive Officer is our principal executive officer and is referred to as PEO in the headers in the following tables.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.588%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Summary Compensation Table Total for PEO </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensation Actually Paid to PEO </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Summary Compensation Table Total for Non-PEO NEOs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Compensation Actually Paid to Non-PEO NEOs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value of Initial Fixed $100 Investment Based on Total Stockholder Return (&#8220;TSR&#8221;) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Loss (thousands) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(e)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(f)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(g)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,266,444&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,309,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745,897&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,931)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,630,620&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,140,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,090,413&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,943&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,288)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dollar amounts reported in column (b) are the amounts of total compensation reported for Dr. Stein for each corresponding year in the &#8220;Total&#8221; column of the Summary Compensation Table. Refer to &#8220;Executive and Director Compensation&#8212;Summary Compensation Table&#8221;.</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The dollar amounts reported in column (c) represent the amount of &#8220;compensation actually paid&#8221; to Dr. Stein, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Stein during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to Dr. Stein&#8217;s total compensation for each year to determine the compensation actually paid:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reported Summary Compensation Table Total for PEO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Subtract: Reported Value of Equity Awards </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Equity Award Adjustments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensation Actually Paid to PEO</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,266,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">662,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,309,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256,948&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383,698&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,040,138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,630,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">794,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,140,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The grant date fair value of equity awards represents the sum of the totals of the amounts reported in the &#8220;Stock Awards&#8221; and &#8220;Option Awards&#8221; columns in the Summary Compensation Table for the applicable year.</span></div><div style="margin-top:4pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The equity award adjustments for each applicable year include the addition (or subtraction, as applicable) of the following: (i) the year-end fair value of any equity awards granted in the applicable year that are outstanding and unvested as of the end of the year; (ii) the amount of change as of the end of the applicable year (from the end of the prior fiscal year) in fair value of any awards granted in prior years that are outstanding and unvested as of the end of the applicable year; (iii) for awards that are granted and vest in same applicable year, the fair value as of the vesting date; (iv) for awards granted in prior years that vest in the applicable year, the amount equal to the change as of the vesting date (from the end of the prior fiscal year) in fair value; (v) for awards granted in prior years that are determined to fail to meet the applicable vesting conditions during the applicable year, a deduction for the amount equal to the fair value at the end of the prior fiscal year; and (vi) the dollar value of any dividends or other earnings paid on stock or option awards in the applicable year prior to the vesting date that are not otherwise reflected in the fair value of such award or included in any other component of total compensation for the applicable year. The amounts deducted or added in calculating the equity award adjustments are as follows:</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Subtract: Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Equity Award Adjustments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161,511&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76,495)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102,990)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;The dollar amounts reported in column (d) represent the average of the amounts reported for our company&#8217;s named executive officers as a group (excluding our PEO) in the &#8220;Total&#8221; column of the Summary Compensation Table in each applicable year. The names of each of the named executive officers (excluding our PEO) included for purposes of calculating the average amounts in each applicable year are as follows: for 2023, Dr. Sandison and Mr. Ward, for 2022, Drs. Sandison and Shah, and for 2021, Drs. Sandison and Tari.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">156</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The dollar amounts reported in column (e) represent the average amount of &#8220;compensation actually paid&#8221; to the named executive officers as a group (excluding our PEO), as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the named executive officers as a group (excluding our PEO) during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the following adjustments were made to average total compensation for the named executive officers as a group (excluding our PEO) for each year to determine the compensation actually paid, using the same methodology described above in Note (2):</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:6.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.220%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Reported Summary Compensation Table Total for Non-PEO NEOs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Subtract: Average Reported Value of Equity Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Average Equity Award Adjustments </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Compensation Actually Paid to Non-PEO NEOs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,055&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594,360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,090,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The amounts deducted or added in calculating the total average equity award adjustments are as follows:</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:6.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Average Year End Fair Value of Outstanding and Unvested Equity Awards Granted in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Average Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Subtract: Average Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Add: Average Value of Dividends or other Earnings Paid on Stock or Option Awards not Otherwise Reflected in Fair Value or Total Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Average Equity Award Adjustments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,368&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,837&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67,038)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,815&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,204)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,590)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,113)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;TSR is determined based on the value of an initial fixed investment of $100 on December 31, 2020. Cumulative TSR reported in column (f) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our company&#8217;s share price at the end and the beginning of the measurement period by our company&#8217;s share price at the beginning of the measurement period. No dividends were paid on stock or option awards in 2023, 2022 or 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;The dollar amounts reported in column (g) represent the amount of net loss reflected in our consolidated audited financial statements for the applicable years, as restated for 2022 and 2021.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Required Disclosure of the Relationship Between Compensation Actually Paid and Financial Performance Measures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We generally seek to incentivize long-term performance, and therefore do not specifically align our performance measures with &#8220;compensation actually paid&#8221; (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. In accordance with Item 402(v) of Regulation S-K, we are providing the following descriptions of the relationships between information presented in the Pay Versus Performance table.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">157</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Compensation Actually Paid and Net Loss</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We had revenue in 2023, 2022 or 2021 associated with the Company&#8217;s collaboration agreements with Mundipharma Medical Company, or Mundipharma, and Janssen Pharmaceuticals, Inc., and license agreement with Melinta Therapeutics, LLC, or Melinta, as well as revenue in 2023 associated with commercial supply of REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> shipped to Mundipharma, our licensee outside the U.S. and Japan, and Melinta, our licensee in the U.S. Consequently, we do not use net loss as a performance measure in our executive compensation program. Moreover, with only limited license, partnership and commercial supply revenue, we do not believe there is any meaningful relationship between our net loss and compensation actually paid to our NEOs during the periods presented. Our net loss was $22.9 million in 2023, $33.6&#160;million in 2022, as restated, and $46.3 million in 2021, as restated.</span></div><div style="margin-top:6pt"><img src="cdtx-20231231_g14.jpg" alt="cdtx_2023-12-31_pvp_nl01.jpg" style="height:514px;margin-bottom:5pt;vertical-align:text-bottom;width:708px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Compensation Actually Paid and Cumulative TSR</span></div><div style="margin-top:6pt"><img src="cdtx-20231231_g15.jpg" alt="cdtx_2023-12-31_pvp_tsr01.jpg" style="height:516px;margin-bottom:5pt;vertical-align:text-bottom;width:710px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">All information provided above under the &#8220;Item 402(v) Pay Versus Performance&#8221; heading will not be deemed to be incorporated by reference in any filing of our company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except to the extent the Company specifically incorporates such information by reference.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">NON-EMPLOYEE DIRECTOR COMPENSATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We maintain a non-employee director compensation policy approved by our Board based on the recommendation of the Compensation and Human Capital Committee. The policy originally became effective in 2015 and was amended by the Board, upon the recommendation of the Compensation and Human Capital Committee, in December 2016, in December 2019, in December 2020, in March 2021 (added Science and Technology Committee compensation), in December 2021, in December 2022, and in December 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The policy, as amended in December 2023, provides that each non-employee director will receive the following compensation for service on the Board:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an annual cash retainer of $40,000, or $70,000 for the Chairman of the Board;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an additional annual cash retainer of $9,000, $7,500 and $4,000 for service as a member of the Audit Committee, Compensation and Human Capital Committee, and Nominating and Governance Committee, respectively;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an additional annual cash retainer of $18,000, $15,000 and $8,000 for service as Chairman of the Audit Committee, Compensation and Human Capital Committee, and Nominating and Governance Committee, respectively (in lieu of the committee member retainer above);</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an initial option grant to purchase 85,000 shares of our common stock on the date of each non-employee director&#8217;s initial appointment to the Board, with 1/3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments over the next two years, subject to acceleration of vesting in full upon a change of control; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an annual option grant to purchase 42,500 shares of our common stock on the date of each of our annual stockholder meetings, which vests in one installment on the earlier of the first anniversary of the date of grant and the day prior to the date of our first annual stockholder meeting held after the date of grant, subject to acceleration of vesting in full upon a change of control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The policy in place during 2023 until amendment in December 2023 provided that each non-employee director would receive the following compensation for service on the Board:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an annual cash retainer of $40,000, or $70,000 for the Chairman of the Board;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an additional annual cash retainer of $9,000, $7,500, $4,000 and $4,000 for service as a member of the Audit Committee, Compensation and Human Capital Committee, Nominating and Governance Committee, and Science and Technology Committee, respectively;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an additional annual cash retainer of $18,000, $15,000, $8,000 and $8,000 for service as Chairman of the Audit Committee, Compensation and Human Capital Committee, Nominating and Governance Committee, and Science and Technology Committee, respectively (in lieu of the committee member retainer above);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an initial option grant to purchase 85,000 shares of our common stock on the date of each non-employee director&#8217;s initial appointment to the Board, with 1/3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments over the next two years, subject to acceleration of vesting in full upon a change of control; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">an annual option grant to purchase 42,500 shares of our common stock on the date of each of our annual stockholder meetings, which vests in one installment on the earlier of the first anniversary of the date of grant and the day prior to the date of our first annual stockholder meeting held after the date of grant, subject to acceleration of vesting in full upon a change of control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We provide reimbursement to all of our non-employee directors for their travel, lodging and other reasonable expenses incurred in attending meetings of the Board and committees of the Board.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth in summary form information concerning the compensation that was earned by each of our non-employee directors during the year ended December&#160;31, 2023:</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.107%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NAME</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">FEES EARNED OR PAID IN CASH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">OPTION AWARDS ($)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bonnie Bassler, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,837&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daniel Burgess</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carin Canale-Theakston</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Timothy R. Franson, M.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David Gollaher, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chrysa Mineo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Theodore R. Schroeder</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The amounts reported reflect the aggregate grant date fair value of each equity award granted to our non-employee directors during the fiscal year ended December&#160;31, 2023, as computed in accordance with FASB ASC 718. Assumptions used in the calculation of these amounts are included in Note&#160;8 to our consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. As of December 31, 2023, the aggregate number of options held by our non-employee directors was as follows: Dr. Bassler, 123,000; Mr. Burgess, 187,011; Ms Canale-Theakston, 123,000; Dr. Franson, 176,185; Dr. Gollaher, 136,500; Ms. Mineo, 147,500; Mr. Schroeder, 187,011. As of December 31, 2023, none of our non-employee directors held other unvested stock awards.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">160</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding the ownership of the Company&#8217;s common stock as of April&#160;12, 2024 by: (i)&#160;each director; (ii)&#160;each of our named executive officers; (iii)&#160;all executive officers and directors of the Company as a group; and (iv)&#160;all those known by the Company to be beneficial owners of more than 5% of its common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table is based upon information supplied by officers, directors and principal stockholders and Schedules 13G or 13D filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, the Company believes that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 91,235,020 shares outstanding on April&#160;12, 2024, adjusted as required by rules promulgated by the SEC. Unless otherwise indicated, the address for the following stockholders is: c/o Cidara Therapeutics, Inc., 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"/><td style="width:301.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beneficial Ownership</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beneficial Owner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares<br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of Total<br/>(%)</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 5% stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biotechnology Value Fund, L.P. and its affiliates (1)<br/>   44 Montgomery Street, 40th Floor<br/>   San Francisco, CA 94104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,364,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mundipharma AG (2)<br/>   St. Alban-Rheinweg 74<br/>   Basel 4020, Switzerland</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,781,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Named Executive Officers and Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D. (3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,892,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taylor Sandison, M.D., M.P.H. (4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shane Ward (5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daniel Burgess (6)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Timothy R. Franson, M.D. (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,685&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Theodore R. Schroeder (8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chrysa Mineo (9)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">David Gollaher, Ph.D. (10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bonnie Bassler, Ph.D. (11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carin Canale-Theakston (12)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;* </span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All current executive officers and directors as a group (12 persons) (13)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,198,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:144%">*&#160;&#160;&#160;&#160;Less than one percent.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Based upon a Schedule 13G/A filed with the SEC on February 14, 2024 by Biotechnology Value Fund, L.P., on behalf of itself, BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert. Represents 6,861,127 shares of common stock held by Biotechnology Value Fund, L.P. and its affiliates and 2,503,330 shares of common stock issuable upon conversion of 250,333 shares of Series X Preferred Stock. Excludes 18,541,390 shares of common stock issuable upon conversion of 1,854,139 shares of Series X Preferred Stock, as applicable, due to a 9.99% beneficial ownership limit as outlined in the Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock filed as Exhibit 3.1 to our Form 8-K filed with the SEC on May 21, 2018. Biotechnology Value Fund, L.P., BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings, LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert have shared voting and investment power over the shares.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based upon a Schedule 13G filed with the SEC on September 13, 2019 by Mundipharma AG. Represents 4,781,408 shares of common stock held by Mundipharma AG.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Includes 2,600,426 shares of common stock that Dr. Stein has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options and vesting of RSUs, as applicable; also includes 331,602 shares of common stock held by the Jeff Stein and Catherine Naughton Revocable Trust, 918,077 shares of common stock held by Dr. Stein and 42,009 shares of common stock held by Dr. Stein&#8217;s son.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">161</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Includes 220,395 shares of common stock held by Dr. Sandison and 646,305 shares of common stock that Dr. Sandison has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options and vesting of RSUs, as applicable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Includes 102,776 shares of common stock held by Mr. Ward and 334,838 shares of common stock that Mr. Ward has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options and vesting of RSUs, as applicable.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(6)&#160;&#160;&#160;&#160;Includes 3,000 shares of common stock held by Mr. Burgess&#8217; spouse and 144,511 shares of common stock that Mr. Burgess has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(7)&#160;&#160;&#160;&#160;Includes 11,000 shares of common stock held by Dr. Franson and 133,685 shares of common stock that Dr. Franson has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(8)&#160;&#160;&#160;&#160;Represents 144,511 shares of common stock that Mr. Schroeder has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(9)&#160;&#160;&#160;&#160;Represents 105,000 shares of common stock that Ms. Mineo has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(10)&#160;&#160;&#160;&#160;Represents 94,000 shares of common stock that Dr. Gollaher has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(11)&#160;&#160;&#160;&#160;Includes 312 shares of common stock held by Dr. Bassler and 80,500 shares of common stock that Dr. Bassler has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(12)&#160;&#160;&#160;&#160;Represents 80,500 shares of common stock that Ms. Canale-Theakston has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(13)&#160;&#160;&#160;&#160;Includes the shares reflected in footnotes (3) &#8211; (12) above and (a) 132,023 shares of common stock held by Dr. Tari, 1,484 shares of common stock held by Dr. Tari&#8217;s spouse and 551,195 shares of common stock that Dr. Tari has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options and vesting of RSUs, as applicable, and (b) 150,298 shares of common stock held by Dr. Shah and 370,508 shares of common stock that Dr. Shah has the right to acquire from us within 60 days of April&#160;12, 2024 pursuant to the exercise of stock options and vesting of RSUs, as applicable.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EQUITY COMPENSATION PLANS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For information regarding the equity compensation plans of the Company, please see the section above headed &#8220;Executive Compensation&#8212;Equity Benefit Plans,&#8221; which is incorporated into this section headed &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; by reference.</span></div><div id="ib00951007fb342d8a49dba10256b8485_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">RELATED-PERSON TRANSACTIONS POLICY AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of &#8220;related-person transactions.&#8221; For purposes of our policy only, a &#8220;related-person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any &#8220;related person&#8221; are participants involving an amount that exceeds $120,000.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related person is any executive officer, director or a holder of more than 5% of our common stock, including any of their immediate family members and any entity owned or controlled by such persons.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-party transaction to our Audit Committee (or, where review by our Audit Committee would be inappropriate, to another independent body of our Board) for review. The presentation must include a description of, among other things, all of the parties, the direct and indirect interests of the related parties, the purpose of the transaction, the material facts, the benefits of the transaction to us and whether any alternative transactions are available, an assessment of whether the terms are comparable to the terms available from unrelated third parties and management&#8217;s recommendation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">162</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To identify related-party transactions in advance, we rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related-party transactions, our Audit Committee or another independent body of our Board takes into account the relevant available facts and circumstances including, but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the risks, costs and benefits to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact on a director&#8217;s independence in the event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the terms of the transaction;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the availability of other sources for comparable services or products; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the terms available to or from, as the case may be, unrelated third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CERTAIN RELATED-PERSON TRANSACTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following includes a summary of transactions since January&#160;1, 2022 to which we have been a party, in which the amount involved in the transaction exceeded the lesser of $120,000 or one percent of the average of the Company&#8217;s total assets at year-end for the last two completed fiscal years. Since January&#160;1, 2022, the Company has engaged in the following transactions with related persons:</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indemnification Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our amended and restated bylaws. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at our request. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#8217;s investment may decline in value to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For information regarding our director and committee member independence, please see the sections above headed &#8220;Information Regarding the Board of Directors and Corporate Governance&#8212;Independence of the Board of Directors&#8221; and &#8220;Information Regarding Committees of the Board of Directors,&#8221; which are incorporated into this section headed &#8220;Certain Relationships and Related Party Transactions, and Director Independence&#8221; by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">163</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table represents aggregate fees billed to the Company by Ernst &amp; Young LLP, or Ernst &amp; Young, for the fiscal years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt;text-align:center;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:75.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.045%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended<br/>December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Audit Fees </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">669,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Audit Related Fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Fees </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fees</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">705,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">611,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Audit fees consist of fees billed for professional services by Ernst&#160;&amp; Young for audit and quarterly review of our financial statements and review of our registration statements and other documents in connection with our at the market offerings and related issuances of consents, and related services that are normally provided in connection with statutory and regulatory filings or engagements.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Tax fees consist of services related to tax compliance, tax planning and tax advice.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All fees described above were pre-approved by the Audit Committee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the audit of the 2023 financial statements, the Company entered into an engagement agreement with Ernst&#160;&amp; Young that sets forth the terms by which Ernst&#160;&amp; Young will perform audit services for the Company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PRE-APPROVAL POLICIES AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by the Company&#8217;s independent registered public accounting firm, Ernst&#160;&amp; Young. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to specified amounts. Pre-approval may also be given as part of the Audit Committee&#8217;s approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the Audit Committee&#8217;s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Audit Committee has determined that the rendering of services other than audit services by Ernst&#160;&amp; Young is compatible with maintaining the principal accountant&#8217;s independence.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">164</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ib00951007fb342d8a49dba10256b8485_184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 15. Exhibit and Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%;padding-left:46.09pt">Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;We have filed the following documents in Item 8 of this Annual Report on Form 10-K:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:91.286%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.514%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_97">Report of Independent Registered Public Accounting Firm (PCAOB ID:</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-2598">42</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_97">)</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_97">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_100">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_100">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_103">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_103">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_106">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_106">93</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_109">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_109">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_112">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_112">95</a></span></div></td></tr></table></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%;padding-left:46.09pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;All other schedules are omitted because they are not required or the required information is included in the financial statements or notes thereto.</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%;padding-left:46.09pt">Exhibits</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8212;For a list of exhibits filed with this Annual Report on Form 10-K, refer to the exhibit index below. The exhibits listed in the Exhibit Index are filed or incorporated by reference as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="ib00951007fb342d8a49dba10256b8485_187"></div><div style="-sec-extract:summary;margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312518322534/d631214dex12.htm">Controlled Equity Offering</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.32pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.32pt;vertical-align:baseline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312518322534/d631214dex12.htm">SM</a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312518322534/d631214dex12.htm"> Sales Agreement, dated as of November 8, 2018, by and between the Registrant and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 to the Registrant&#8217;s Registration Statement on Form S-3, filed on November 8, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322023-12.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Cidara Therapeutics, Inc.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex32.htm">Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex312018-05x21.htm">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May 21, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex41.htm">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312516729294/d161044dex102.htm">Form of Warrant to Purchase Common Stock issued to Pacific Western Bank (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on October 3, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex412018-05x21.htm">Form of Common Stock Purchase Warrant for First Private Placement (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on May 21, 2018)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061820000050/exhibit44.htm">Description of the Registrant&#8217;s Securities (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 13, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex101.htm">Form of Indemnity Agreement by and between the Registrant and its directors and officers (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515131339/d909250dex992.htm">2015 Equity Incentive Plan and Form of Grant Notice, Stock Option Agreement and Notice of Exercise thereunder (incorporated by reference to Exhibit 99.2 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-203434), filed on April 15, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex103.htm">2015 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex104.htm">2013 Stock Option and Grant Plan and Form of Stock Option Agreement, Notice of Exercise and Stock Option Grant Notice thereunder, as amended (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1052023-12.htm">Non-Employee Director Compensation Policy, as amended.</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">165</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000066/exhibit1022021-06.htm">Form of Amended and Restated Employment Agreement by and between the Registrant and its executive officers (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 12, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000074/exhibit9912021-08x31.htm">Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (incorporated by reference to Exhibit 99.1 to the Registrant&#8217;s Registration Statement on Form S-8, filed on August 31, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061820000064/ex102cdtx-2020induceme.htm">Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, filed on December 7, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061820000064/ex103cdtx-2020induceme.htm">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K, filed on December 7, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex1012.htm">Asset Purchase Agreement by and between Registrant and Seachaid Pharmaceuticals, Inc., dated May&#160;30, 2014 (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex1013.htm">Addendum to Asset Purchase Agreement by and between Registrant and Seachaid Pharmaceuticals, Inc., dated September 23, 2014 and deemed effective as of May 30, 2014 (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex1014.htm">Standard Industrial/Commercial Multi-Tenant Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated June 9, 2014 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex1015.htm">First Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated June 9, 2014 (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Registration Statement on Form&#160;S&#8209;1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000119312515091277/d843130dex1016.htm">Second Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated February 15, 2015 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed on March 13, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000156459015010802/cdtx-ex101_378.htm">Third Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated July 1, 2015 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 16, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.16+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061817000035/cidara-restrictedstockunit.htm">Form of Restricted Stock Unit Award Grant Notice (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May 10, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061818000073/item101.htm">Fourth Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated June 29, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, filed on July 3, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.18*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061819000078/exhibit101.htm">Collaboration and License Agreement, dated September 3, 2019, by and between the Registrant and Mundipharma Medical Company (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 8, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061819000078/exhibit102.htm">Stock Purchase Agreement, dated September 3, 2019, by and between the Registrant and Mundipharma Medical Company (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 8, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.20*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000044/exhibit1022021-03.htm">Exclusive License and Collaboration Agreement by and between the Registrant and Janssen Pharmaceuticals, Inc., dated March 31, 2021 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May 13, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061822000007/exhibit10262021-12.htm">Fifth Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated January 13, 2020 (incorporated by reference to Exhibit 10.26 to the Registrant&#8217;s Annual Report on Form 10-K, filed on March 7, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000066/exhibit1032021-06.htm">Sixth Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated July 14, 2021 (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 12, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.23*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061822000068/exhibit1022022-06.htm">Letter Agreement by and between the Registrant and Mundipharma Medical Company, dated April 20, 2022 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on August 9, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.24*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061822000085/exhibit1012022-09.htm">License Agreement by and between the Registrant and Melinta Therapeutics, LLC, dated July 26, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 3, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061822000085/exhibit1022022-09.htm">Employment offer letter between the Registrant and Taylor Sandison, dated March 22, 2017 (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 3, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.26+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061822000085/exhibit1032022-09.htm">Employment offer letter between the Registrant and Shane M. Ward, dated August 17, 2021 (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 3, 2022).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.27+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061822000085/exhibit1042022-09.htm">Employment offer letter between the Registrant and Preetam Shah, dated August 19, 2021 (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 3, 2022).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">166</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.370%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061823000056/exhibit1012023-03.htm">Seventh Amendment to Lease by and between the Registrant and Nancy Ridge Technology Center, L.P., dated April 20, 2023 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on May 11, 2023).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1610618/000161061821000008/exhibit2112020-12.htm">List of subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Annual Report on Form 10-K, filed on February 25, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit2312023-12.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib00951007fb342d8a49dba10256b8485_193">Power of Attorney. Reference is made to the signature page hereto.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3112023-12.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3122023-12.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3212023-12.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3222023-12.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit9712023-12.htm">Cidara Therapeutics, Inc. Incentive Compensation Recoupment Policy.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the Securities and Exchange Commission.</span></td></tr></table></div><div id="ib00951007fb342d8a49dba10256b8485_190"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">167</span></div></div></div><div id="ib00951007fb342d8a49dba10256b8485_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.827%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cidara Therapeutics, Inc.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: April 22, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeffrey Stein, Ph.D. and Preetam Shah, Ph.D., MBA, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:30.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Jeffrey Stein, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President, Chief Executive Officer and<br/>Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Jeffrey Stein, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Preetam Shah, Ph.D., MBA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Preetam Shah, Ph.D., MBA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and<br/>Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Daniel D. Burgess</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Daniel D. Burgess</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Bonnie Bassler, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Bonnie Bassler, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Carin Canale-Theakston</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Carin Canale-Theakston</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Timothy R. Franson, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Timothy R. Franson, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ David Gollaher, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">David Gollaher, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Chrysa Mineo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Chrysa Mineo</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Theodore R. Schroeder</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">April 22, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Theodore R. Schroeder</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">168</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>exhibit322023-12.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id1daa4b44f8a47eaab4a9ce5e011d4fc_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:11pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 3.2</font></div></div><div style="margin-bottom:11pt;margin-top:12pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTIFICATE OF AMENDMENT TO</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CIDARA THERAPEUTICS, INC.</font></div><div style="margin-top:6pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cidara Therapeutics, Inc. </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DGCL</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), hereby certifies that&#58;</font></div><div style="margin-top:6pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First&#58; The name of the Company is Cidara Therapeutics, Inc. The Company&#8217;s Certificate of Incorporation was originally filed with the Secretary of State of the State of Delaware on December 6, 2012, under the name of K2 Therapeutics, Inc.</font></div><div style="margin-top:6pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Second&#58; The Amended and Restated Certificate of Incorporation of the Company (the &#8220;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Charter</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) was filed with the Secretary of State of the State of Delaware on April 20, 2015.</font></div><div style="margin-top:6pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third&#58; The Board of Directors of the Company (the &#8220;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), acting in accordance with the provisions of Sections 141 and 242 of the DGCL, duly adopted resolutions to amend the Charter as follows&#58;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Article IV, Section A shall be amended and restated to read in its entirety as follows&#58;</font></div><div style="margin-top:6pt;padding-left:45pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The Company is authorized to issue two classes of stock to be designated, respectively, &#8220;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; The total number of shares which the Company is authorized to issue is 30,000,000 shares. 20,000,000 shares shall be Common Stock, each having a par value of $0.0001. 10,000,000 shares shall be Preferred Stock, each having a par value of $0.0001.&#8221;</font></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><font style="color:#231f20;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.42pt">Effective as of 5&#58;00 p.m., Eastern time, on April 23, 2024 (the </font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Effective Time&#8221;</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), each 20 shares of Common Stock, par value $0.0001 per share, issued and outstanding shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one share of Common Stock, par value $0.0001 per share&#59; provided, however, that the Company shall issue no fractional shares as a result of the actions set forth herein but shall instead pay to the holder of such fractional share a sum in cash equal to such fraction multiplied by the closing sales price of the Common Stock as reported on the Nasdaq Capital Market at the Effective Time.</font></div><div style="margin-top:6pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fourth&#58; Thereafter pursuant to a resolution of the Board, this Certificate of Amendment was submitted to the stockholders of the Company for their approval, and was duly adopted at a special meeting of the stockholders of the Company, in accordance with the provisions of Section 242 of the DGCL.</font></div><div style="margin-top:6pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fifth&#58; All other provisions of the Charter as currently on file with the Secretary of State of the State of Delaware shall remain in full force and effect.</font></div><div style="margin-top:6pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company on has caused this Certificate of Amendment to be signed by its Chief Executive Officer this 22</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</font><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> day of April, 2024.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.188%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">Cidara Therapeutics, Inc.</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">By&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Name&#58; Jeffrey Stein, Ph.D.</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Title&#58; President and Chief Executive Officer</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>exhibit1052023-12.htm
<DESCRIPTION>AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id00efb7428484c47bc5f9b07b25cd302_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.5</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cidara Therapeutics, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amended and Restated Non-Employee Director Compensation Policy<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approved by Board of Directors&#58; December 4, 2023</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each member of the Cidara Therapeutics, Inc. Board of Directors (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Board&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) who is not also serving as an employee of Cidara Therapeutics, Inc. (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Cidara&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) or any of its subsidiaries (each such member, an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Eligible Director&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her Board service on and following the date that this amended policy is first adopted by the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board (and as may be recommended by the Compensation Committee of the Board).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Annual Cash Compensation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If (i) the Effective Date is a date other than the first day of a fiscal quarter or (ii) an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, the first quarterly installment of each applicable annual retainer set forth below will be pro-rated based on days served in the first fiscal quarter in which this policy is effective or in which the Eligible Director provides the service, as applicable, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Board Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;All Eligible Directors&#58; $40,000</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Chairman of the Board Service Retainer (in addition to Eligible Director Service Retainer)&#58; $30,000</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Committee Member Service Retainer (non-Chairman)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Member of the Audit Committee&#58; $9,000</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Member of the Compensation Committee&#58; $7,500</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Member of the Nominating and Governance Committee&#58; $4,000</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Committee Chairman Service Retainer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Chairman of the Audit Committee&#58; $18,000</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Chairman of the Compensation Committee&#58; $15,000</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Chairman of the Nominating and Governance Committee&#58; $8,000</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity Compensation</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The equity compensation set forth below will be granted under the Cidara Therapeutics, Inc. 2015 Equity Incentive Plan, as may be amended from time to time (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">). All stock options granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock of Cidara (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than for death, disability or cause, the post-termination exercise period will be 12 months from the date of termination).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; On the date of the Eligible Director&#8217;s initial election to the Board, for each Eligible Director who is first elected to the Board following the Effective Date (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 85,000 shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Initial Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The shares subject to each Initial Grant will vest as follows&#58; (i) 1&#47;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the shares will vest on the first anniversary of the date of grant and (ii) the remaining 2&#47;3rds of the shares will vest in equal monthly installments over a two year period such that each Initial Grant is fully vested on the third anniversary of the date of grant, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58; On the date of each Cidara annual stockholder meeting held after the Effective Date, for each Eligible Director who continues to serve as a non-employee member of the Board (or who is first elected to the Board at such annual stockholder meeting), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 42,500 shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Annual Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The shares subject to the Annual Grant will vest in one installment on the earlier of (i) the first anniversary of the date of grant and (ii) the day prior to the date of Cidara&#8217;s first annual stockholder meeting held after the date of grant, such that each Annual Grant is fully vested on the earlier of (i) the first anniversary of the date of grant and (ii) the day prior to the date of Cidara&#8217;s first annual stockholder meeting held after the date of grant, subject to the Eligible Director&#8217;s Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As of the Effective Date, this Amended Non-Employee Director Compensation Policy shall replace and supersede any compensation agreements between the Company and any Eligible Director serving on the Board on the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit2312023-12.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i34200c80d6264df5844a23e7c6e8d5c8_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statement (Form S-3 No. 333-260970) of Cidara Therapeutics, Inc., and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.78pt">Registration Statements (Form S-8 Nos. 333-203434, 333-210263, 333-216722, 333-228282, 333-231326, 333-236874, 333-253545, 333-259219, 333-263350 and 333-270781) pertaining to the Cidara Therapeutics, Inc. 2013 Stock Option and Grant Plan, Cidara Therapeutics, Inc. 2015 Equity Incentive Plan, Cidara Therapeutics, Inc. 2015 Employee Stock Purchase Plan and Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan&#59;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our report dated April&#160;22, 2024, with respect to the consolidated financial statements of Cidara Therapeutics, Inc. included in this Annual Report (Form 10-K) of Cidara Therapeutics, Inc. for the year ended December&#160;31, 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">April&#160;22, 2024</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit3112023-12.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic8a51f6db2644b1aa99771501d4961e3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey Stein, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Annual Report on Form 10-K of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey Stein, Ph.D.<br>President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit3122023-12.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ieb3239e179424c12a03cb33207749d9a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Preetam Shah, Ph.D., MBA, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Annual Report on Form 10-K of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.09pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.93pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.4pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.09pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.4pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.4pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.164%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preetam Shah, Ph.D., MBA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Chief Business Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer and<br>Principal Accounting Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit3212023-12.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iec6d3909997b4593b95909fb568f8992_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ending December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof and to which this certification is attached as an exhibit (the &#8220;Report&#8221;), I, Jeffrey Stein, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:48.311%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jeffrey Stein, Ph.D.<br>President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is being furnished solely pursuant to 18 U.S.C. &#167; 1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cidara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exhibit3222023-12.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4ea86c76171d47e7b5a8b066cd21f7a8_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ending December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof and to which this certification is attached as an exhibit (the &#8220;Report&#8221;), I, Preetam Shah, Ph.D., MBA, Chief Financial Officer and Chief Business Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), that, to the best of my knowledge&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; April 22, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center;text-indent:31.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Preetam Shah, Ph.D., MBA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Chief Business Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer and<br>Principal Accounting Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Form 10-K to which it relates, is being furnished solely pursuant to 18 U.S.C. &#167; 1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Cidara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>exhibit9712023-12.htm
<DESCRIPTION>INCENTIVE COMPENSATION RECOUPMENT POLICY
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i48f599c24dfc4cbf89cdaedc75423719_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:11pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 97.1</font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cidara Therapeutics, Inc.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">adopted December 1, 2023</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Introduction</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Cidara Therapeutics, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) providing for the Company&#8217;s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Rule 10D-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Nasdaq Listing Rule 5608 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Listing Standards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Effective Date</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Incentive Compensation is deemed &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; in the Company&#8217;s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Definitions</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accounting Restatement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Compensation and Human Capital Committee or, in the absence of such committee, the Board.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Compensation and Human Capital Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Compensation and Human Capital Committee of the Board.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Covered Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each current and former Executive Officer.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Nasdaq Stock Market.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities Exchange Act of 1934, as amended.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company&#8217;s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total shareholder return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). A measure need not be presented in the Company&#8217;s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.  Examples of &#8220;Incentive Compensation&#8221; include, but are not limited to&#58; non-equity incentive plan awards that are earned based wholly or in part on satisfying a Financial Reporting Measure performance goal&#59; bonuses paid from a &#8220;bonus pool,&#8221; the size of which is determined based wholly or in part on satisfying a Financial Reporting Measure performance goal&#59; other cash awards based on satisfaction of a Financial Reporting Measure performance goal&#59; restricted stock, restricted stock units, performance share units, stock options, and SARs that are granted or become vested based wholly or in part on satisfying a Financial Reporting Measure goal&#59; and proceeds received upon the sale of shares acquired through an incentive plan that were granted or vested based wholly or in part on satisfying a Financial Reporting Measure goal. &#8220;Incentive Compensation&#8221; excludes, for example, time-based awards such as stock options or restricted stock units that are granted or vest&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">solely</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;upon completion of a service period&#59; awards based on non-financial strategic or operating metrics such as the consummation of a merger or achievement of non-financial business goals&#59; service-based retention bonuses&#59; discretionary compensation&#59; and salary.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Lookback Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Recoverable Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Recoupment</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">Applicability of Policy. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv)&#160;during the Lookback Period. </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Recoupment Generally.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation and Human Capital Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable (as explained below). Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company&#8217;s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.  </font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">Impracticability of Recovery.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Recoupment may be determined to be impracticable if, and only if&#58;</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation&#59; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards&#59; or</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.57pt">Sources of Recoupment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date&#58; (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer&#59; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid)&#59; (iii) cancelling or offsetting against any planned future cash or equity-based awards&#59; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A&#59; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.8pt">No Indemnification of Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company&#8217;s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:25.02pt">Indemnification of Administrator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:23.18pt">No &#8220;Good Reason&#8221; for Covered Officers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) &#8220;good reason&#8221; for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Administration</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy.  Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Severability</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">No Impairment of Other Remedies</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer&#8217;s obligations to the Company, including, without limitation, termination of employment and&#47;or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">SOX 304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that are applicable to the Company&#8217;s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and&#47;or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time&#59; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and&#47;or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt">Amendment&#59; Termination</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#171717;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> &#160;&#160;&#160;&#160;Covered Person Acknowledgement and Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#171717;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All Covered Officers subject to this Policy must acknowledge their understanding of, and agreement to comply with, the Policy by executing the Form attached hereto as </font><font style="color:#171717;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#171717;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#171717;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Notwithstanding the foregoing, this Policy will apply to Covered Officers whether or not they execute such certification.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Successors</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and&#47;or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Required Filings</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><div id="i48f599c24dfc4cbf89cdaedc75423719_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cidara Therapeutics, Inc.</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Incentive Compensation Recoupment Policy</font></div><div style="margin-bottom:11pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Form of Executive Acknowledgment</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Cidara Therapeutics, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Cidara Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and&#47;or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agreed and Acknowledged&#58;</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="margin-bottom:11pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cdtx-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fa590d2e-4039-4000-bdf7-5fb59710602c,g:d0764763-c16c-45c9-82e5-80b88e590043-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdtx="http://cidara.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cidara.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://cidara.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://cidara.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://cidara.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>0000006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://cidara.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATION" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION">
        <link:definition>0000008 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000010 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORY" roleURI="http://cidara.com/role/INVENTORY">
        <link:definition>0000011 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>0000012 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://cidara.com/role/DEBT">
        <link:definition>0000013 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000014 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANS" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS">
        <link:definition>0000015 - Disclosure - EQUITY INCENTIVE PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTS" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS">
        <link:definition>0000016 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://cidara.com/role/INCOMETAXES">
        <link:definition>0000017 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED">
        <link:definition>0000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://cidara.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000020 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONTables" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables">
        <link:definition>9954472 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954473 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYTables" roleURI="http://cidara.com/role/INVENTORYTables">
        <link:definition>9954475 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9954476 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9954477 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSTables" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables">
        <link:definition>9954478 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSTables" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables">
        <link:definition>9954479 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://cidara.com/role/INCOMETAXESTables">
        <link:definition>9954480 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>9954481 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables">
        <link:definition>9954482 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSTables" roleURI="http://cidara.com/role/SUBSEQUENTEVENTSTables">
        <link:definition>9954483 - Disclosure - SUBSEQUENT EVENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails">
        <link:definition>9954484 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails">
        <link:definition>9954485 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails">
        <link:definition>9954486 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Operations and Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails">
        <link:definition>9954487 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails">
        <link:definition>9954488 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails">
        <link:definition>9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954491 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYScheduleofInventoryDetails" roleURI="http://cidara.com/role/INVENTORYScheduleofInventoryDetails">
        <link:definition>9954492 - Disclosure - INVENTORY - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORYNarrativeDetails" roleURI="http://cidara.com/role/INVENTORYNarrativeDetails">
        <link:definition>9954493 - Disclosure - INVENTORY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails" roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails">
        <link:definition>9954494 - Disclosure - PROPERTY AND EQUIPMENT - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTAdditionalInformationDetails" roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTAdditionalInformationDetails">
        <link:definition>9954495 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTDetails" roleURI="http://cidara.com/role/DEBTDetails">
        <link:definition>9954496 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYAdditionalInformationDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails">
        <link:definition>9954497 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>9954498 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Summary of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSAdditionalInformationDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails">
        <link:definition>9954499 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails">
        <link:definition>9954500 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails">
        <link:definition>9954501 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails">
        <link:definition>9954502 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Black-Scholes Option Pricing Model Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails">
        <link:definition>9954503 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails">
        <link:definition>9954504 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails_1" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails_1">
        <link:definition>9954504 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails">
        <link:definition>9954505 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
        <link:definition>9954506 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Revenues Disaggregated by Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails" roleURI="http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails">
        <link:definition>9954507 - Disclosure - INCOME TAXES - Summary of Components of Benefit For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails" roleURI="http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails">
        <link:definition>9954508 - Disclosure - INCOME TAXES - Summary of Reconciliation Between Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails" roleURI="http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails">
        <link:definition>9954509 - Disclosure - INCOME TAXES - Summary of Significant Components of Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESAdditionalInformationDetails" roleURI="http://cidara.com/role/INCOMETAXESAdditionalInformationDetails">
        <link:definition>9954510 - Disclosure - INCOME TAXES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" roleURI="http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>9954511 - Disclosure - INCOME TAXES - Summary of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails">
        <link:definition>9954512 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails">
        <link:definition>9954513 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1">
        <link:definition>9954513 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails">
        <link:definition>9954514 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails">
        <link:definition>9954515 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1">
        <link:definition>9954515 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails">
        <link:definition>9954516 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails" roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails">
        <link:definition>9954517 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails" roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails">
        <link:definition>9954518 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails" roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails">
        <link:definition>9954519 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails" roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails">
        <link:definition>9954520 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Cash Flows (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails" roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails">
        <link:definition>9954521 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>9954522 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails" roleURI="http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails">
        <link:definition>9954523 - Disclosure - SUBSEQUENT EVENTS - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" abstract="false" name="LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_CommonStockDividendsInArrearsOrDefault" abstract="false" name="CommonStockDividendsInArrearsOrDefault" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" abstract="false" name="LesseeFinanceLeaseOptionPurchaseEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_OperatingLeaseRightOfUseAmortization" abstract="false" name="OperatingLeaseRightOfUseAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_AuthorizedSharesForFutureStockAwardsMember" abstract="true" name="AuthorizedSharesForFutureStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" abstract="false" name="IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" abstract="false" name="CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ClinicalDrugSupplyMember" abstract="true" name="ClinicalDrugSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" abstract="false" name="ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_ClassOfWarrantOrRightExpired" abstract="false" name="ClassOfWarrantOrRightExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesFinanceLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" abstract="false" name="ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_NumberOfVotesEntitlementForEachShareHeld" abstract="false" name="NumberOfVotesEntitlementForEachShareHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_LicenseOfIntellectualPropertyMember" abstract="true" name="LicenseOfIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" abstract="true" name="TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_SaleOfStockConsiderationRemainingOnTransaction" abstract="false" name="SaleOfStockConsiderationRemainingOnTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_MelintaTherapeuticsIncMember" abstract="true" name="MelintaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" abstract="false" name="TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_LesseeFinanceLeaseMonthlyRate" abstract="false" name="LesseeFinanceLeaseMonthlyRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CommonStockWarrantMember" abstract="true" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementCostSharingPercentage" abstract="false" name="CollaborativeArrangementCostSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_ResearchAndDevelopmentServicesMember" abstract="true" name="ResearchAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_JanssenPharmaceuticalsIncMember" abstract="true" name="JanssenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" abstract="false" name="DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_MundipharmaMedicalCompanyMember" abstract="true" name="MundipharmaMedicalCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_PaymentsRelatedToCollaborativeAgreements" abstract="false" name="PaymentsRelatedToCollaborativeAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" abstract="true" name="DevelopmentRegulatoryAndCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" abstract="true" name="ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" abstract="false" name="ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesOperatingLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cdtx_SeriesXConvertiblePreferredStockMember" abstract="true" name="SeriesXConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ClinicalSupplyServicesMember" abstract="true" name="ClinicalSupplyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_A2023UnderwrittenPublicOfferingMember" abstract="true" name="A2023UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTransactionPotentialValue" abstract="false" name="CollaborativeArrangementTransactionPotentialValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" abstract="true" name="LicenseOfIntellectualPropertyUponMilestonesAchievedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_NetOperatingLossCarryforwards" abstract="false" name="NetOperatingLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" abstract="false" name="CollaborativeArrangementMaximumThirdPartyShareOfCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" abstract="true" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseOptionRenewalTerm" abstract="false" name="LesseeOperatingLeaseOptionRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" abstract="true" name="MoreThanTenPercentVotingRightsClassesOfStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_RDFundingMember" abstract="true" name="RDFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_NumberOfOperatingLeaseOptionsForExtension" abstract="false" name="NumberOfOperatingLeaseOptionsForExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_CollaborationAgreementNumberOfPerformanceObligations" abstract="false" name="CollaborationAgreementNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_UpfrontPaymentMember" abstract="true" name="UpfrontPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" abstract="false" name="PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="cdtx_PatentCostsPolicyPolicyTextBlock" abstract="false" name="PatentCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" abstract="true" name="TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_JanssenCollaborationAgreementMember" abstract="true" name="JanssenCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseAnnualRateIncrease" abstract="false" name="LesseeOperatingLeaseAnnualRateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="cdtx_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_AccruedIndirectTaxLiabilities" abstract="false" name="AccruedIndirectTaxLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember" abstract="true" name="LicenseOfIntellectualPropertyUponTransferOfLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseMonthlyRate" abstract="false" name="LesseeOperatingLeaseMonthlyRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandFifteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="cdtx_DeferredTaxAssetsLeasingArrangements" abstract="false" name="DeferredTaxAssetsLeasingArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cdtx-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fa590d2e-4039-4000-bdf7-5fb59710602c,g:d0764763-c16c-45c9-82e5-80b88e590043-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://cidara.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dd1645b0-d5c2-44d2-997b-325fdec85a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4fc5e2f3-401c-44c1-a3c7-4b83e576e6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd1645b0-d5c2-44d2-997b-325fdec85a0b" xlink:to="loc_us-gaap_PreferredStockValue_4fc5e2f3-401c-44c1-a3c7-4b83e576e6f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9ebaa332-615e-4be4-94ce-a12578b19bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd1645b0-d5c2-44d2-997b-325fdec85a0b" xlink:to="loc_us-gaap_CommonStockValue_9ebaa332-615e-4be4-94ce-a12578b19bc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4936a985-3959-4551-9f0a-441759fdc82f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd1645b0-d5c2-44d2-997b-325fdec85a0b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4936a985-3959-4551-9f0a-441759fdc82f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5bec25a-58d1-48c8-af41-7236b7b7500f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_dd1645b0-d5c2-44d2-997b-325fdec85a0b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5bec25a-58d1-48c8-af41-7236b7b7500f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7c3df165-97f1-489a-b0c0-61e99b334639" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bef26d61-4909-4fa8-b90e-fcbfb0a3ec35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c3df165-97f1-489a-b0c0-61e99b334639" xlink:to="loc_us-gaap_LiabilitiesCurrent_bef26d61-4909-4fa8-b90e-fcbfb0a3ec35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_8e57df99-cbbc-4fae-a110-5cfde75d5a24" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c3df165-97f1-489a-b0c0-61e99b334639" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_8e57df99-cbbc-4fae-a110-5cfde75d5a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc176f73-8d98-4be3-8a5d-6e8c1ff02ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c3df165-97f1-489a-b0c0-61e99b334639" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc176f73-8d98-4be3-8a5d-6e8c1ff02ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_be3761c3-22df-4f86-9da2-ff071ea4de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7c3df165-97f1-489a-b0c0-61e99b334639" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_be3761c3-22df-4f86-9da2-ff071ea4de1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_130ccffe-02f4-4d55-b1e5-adb3365a80cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b0024c5-cf6d-423d-9381-d5d2f9741b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_130ccffe-02f4-4d55-b1e5-adb3365a80cf" xlink:to="loc_us-gaap_StockholdersEquity_4b0024c5-cf6d-423d-9381-d5d2f9741b31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8ef8fa12-6ca8-40b5-9a62-bffd136ea59d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_130ccffe-02f4-4d55-b1e5-adb3365a80cf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8ef8fa12-6ca8-40b5-9a62-bffd136ea59d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7102237c-958c-495e-9f4d-6e8fd0a2f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_130ccffe-02f4-4d55-b1e5-adb3365a80cf" xlink:to="loc_us-gaap_Liabilities_7102237c-958c-495e-9f4d-6e8fd0a2f62f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4953720f-77cf-470a-91ca-cdb91a23b2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc2a9ab4-131f-4747-8029-ae369e8381bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4953720f-77cf-470a-91ca-cdb91a23b2d6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_bc2a9ab4-131f-4747-8029-ae369e8381bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3378216b-f42b-4c40-904a-382e1d8ee424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4953720f-77cf-470a-91ca-cdb91a23b2d6" xlink:to="loc_us-gaap_InventoryNet_3378216b-f42b-4c40-904a-382e1d8ee424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_325a6927-65d1-47d5-b6bc-fc888c1f392d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4953720f-77cf-470a-91ca-cdb91a23b2d6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_325a6927-65d1-47d5-b6bc-fc888c1f392d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_384a06c3-649a-47e6-ac12-7ba9c904892e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4953720f-77cf-470a-91ca-cdb91a23b2d6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_384a06c3-649a-47e6-ac12-7ba9c904892e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_9d38f510-66fa-4d72-83a3-d19d06e67e38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4953720f-77cf-470a-91ca-cdb91a23b2d6" xlink:to="loc_us-gaap_RestrictedCash_9d38f510-66fa-4d72-83a3-d19d06e67e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b4fa9371-7608-4985-adee-161328b58352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3f6f343e-e550-4e44-9f02-a83fdfcaf09c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4fa9371-7608-4985-adee-161328b58352" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3f6f343e-e550-4e44-9f02-a83fdfcaf09c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ab0198e6-9c58-4ee7-a57d-fbe4a7119c19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4fa9371-7608-4985-adee-161328b58352" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ab0198e6-9c58-4ee7-a57d-fbe4a7119c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9276454d-85ef-4a5b-9d9f-b585734b871d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4fa9371-7608-4985-adee-161328b58352" xlink:to="loc_us-gaap_AssetsCurrent_9276454d-85ef-4a5b-9d9f-b585734b871d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_f15a8edd-038c-4ad8-90d2-d3c85509705b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4fa9371-7608-4985-adee-161328b58352" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_f15a8edd-038c-4ad8-90d2-d3c85509705b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06b2c5ee-467f-4bab-9bd4-052ded6c870e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b4fa9371-7608-4985-adee-161328b58352" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06b2c5ee-467f-4bab-9bd4-052ded6c870e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3b93bd30-4f23-4c8e-8b05-9e12047a0110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_3b93bd30-4f23-4c8e-8b05-9e12047a0110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2c0ad69d-ff22-43e2-81ed-e44b8a1fc271" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2c0ad69d-ff22-43e2-81ed-e44b8a1fc271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a47bc2f3-ce01-4ada-9c93-e92e315fafd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:to="loc_us-gaap_AccountsPayableCurrent_a47bc2f3-ce01-4ada-9c93-e92e315fafd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_df50a914-09e4-49a1-8963-2c17e295fdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_df50a914-09e4-49a1-8963-2c17e295fdbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0f17dbe5-a09f-48cb-bc11-1c5802887f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0f17dbe5-a09f-48cb-bc11-1c5802887f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_2a5ee257-a7f8-4d0b-bd02-0222df216adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_2a5ee257-a7f8-4d0b-bd02-0222df216adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_a1efe53d-c84b-4822-8203-acb2ed6fa749" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_63ba2429-a500-41c1-ada6-aee9905c918c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_a1efe53d-c84b-4822-8203-acb2ed6fa749" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_52604af3-bf4e-422a-9c34-5d13d9cffc88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2f6e45ff-a74d-4b7e-b298-65005460b278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_52604af3-bf4e-422a-9c34-5d13d9cffc88" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_2f6e45ff-a74d-4b7e-b298-65005460b278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7f4e997c-143d-48d5-ab36-97707a421555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_52604af3-bf4e-422a-9c34-5d13d9cffc88" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7f4e997c-143d-48d5-ab36-97707a421555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bda5b6-859a-45cc-9850-30aef71c0ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dc203134-897f-4bb9-ba3a-4168e9bc236b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bda5b6-859a-45cc-9850-30aef71c0ed5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dc203134-897f-4bb9-ba3a-4168e9bc236b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f7d2e59-c3eb-4b37-9fdf-364473443bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d3bda5b6-859a-45cc-9850-30aef71c0ed5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f7d2e59-c3eb-4b37-9fdf-364473443bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a6db4349-b9d0-4d0f-8d35-faf4f5e562a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9037b227-01bd-4166-b981-49f7fc8d4cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a6db4349-b9d0-4d0f-8d35-faf4f5e562a3" xlink:to="loc_us-gaap_OperatingExpenses_9037b227-01bd-4166-b981-49f7fc8d4cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e63f1840-03e1-4be1-8d99-c3a2284faaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a6db4349-b9d0-4d0f-8d35-faf4f5e562a3" xlink:to="loc_us-gaap_Revenues_e63f1840-03e1-4be1-8d99-c3a2284faaa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4594bac4-da00-4eb7-afdc-018648d628b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1cff8915-a468-4472-bd26-c73d6b6086c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_4594bac4-da00-4eb7-afdc-018648d628b2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1cff8915-a468-4472-bd26-c73d6b6086c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0ce9a856-d1e1-4530-b982-11f1911e20da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_155059ba-7579-4f22-831a-30f6b5b60384" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0ce9a856-d1e1-4530-b982-11f1911e20da" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_155059ba-7579-4f22-831a-30f6b5b60384" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_eb0b0e58-1b73-449a-8032-c057ac57ef11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0ce9a856-d1e1-4530-b982-11f1911e20da" xlink:to="loc_us-gaap_OperatingIncomeLoss_eb0b0e58-1b73-449a-8032-c057ac57ef11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e056b936-45c3-4908-b651-edcb9b7540ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_bcacf7e1-b0ca-4007-b0fd-c91f3781fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e056b936-45c3-4908-b651-edcb9b7540ad" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_bcacf7e1-b0ca-4007-b0fd-c91f3781fb6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1c2ebc4f-b107-4abf-bdd6-419d994283b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e056b936-45c3-4908-b651-edcb9b7540ad" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_1c2ebc4f-b107-4abf-bdd6-419d994283b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_50e88a38-39d7-422d-8280-34eaa8c6cca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e056b936-45c3-4908-b651-edcb9b7540ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_50e88a38-39d7-422d-8280-34eaa8c6cca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_28ad5748-1930-4276-a842-f799ae6628ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b92abfa8-3f69-492a-94e7-b3a7e3a2de55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_28ad5748-1930-4276-a842-f799ae6628ea" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b92abfa8-3f69-492a-94e7-b3a7e3a2de55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c19eaafe-2206-4506-b559-9c99aae3d61c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_28ad5748-1930-4276-a842-f799ae6628ea" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c19eaafe-2206-4506-b559-9c99aae3d61c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://cidara.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8fa44184-97c5-4948-82f9-5eea68558a06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fca35ee0-e81b-4271-a871-f77360301614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8fa44184-97c5-4948-82f9-5eea68558a06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fca35ee0-e81b-4271-a871-f77360301614" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a411f001-ce78-4830-9224-66afcaaacaff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8fa44184-97c5-4948-82f9-5eea68558a06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a411f001-ce78-4830-9224-66afcaaacaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42d75cd9-a407-4852-82a8-5ddd2ecd0394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8fa44184-97c5-4948-82f9-5eea68558a06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_42d75cd9-a407-4852-82a8-5ddd2ecd0394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fc8de13-ab64-4ec7-b782-8687dcd2ad4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a9c22f8c-c4e1-43c1-a027-260273fbcc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fc8de13-ab64-4ec7-b782-8687dcd2ad4c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a9c22f8c-c4e1-43c1-a027-260273fbcc8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e1c90cc7-1bd7-45bf-a337-965ee663348a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fc8de13-ab64-4ec7-b782-8687dcd2ad4c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e1c90cc7-1bd7-45bf-a337-965ee663348a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2e94f056-234d-49c2-814b-b27d3464ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fc8de13-ab64-4ec7-b782-8687dcd2ad4c" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2e94f056-234d-49c2-814b-b27d3464ca74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_f4755a25-ebf7-4b94-8ca2-3aee6509bd80" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fc8de13-ab64-4ec7-b782-8687dcd2ad4c" xlink:to="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_f4755a25-ebf7-4b94-8ca2-3aee6509bd80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f75175c3-b959-41ba-9b6e-a8e049ed4cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4fc8de13-ab64-4ec7-b782-8687dcd2ad4c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f75175c3-b959-41ba-9b6e-a8e049ed4cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ffdadf4d-69fe-4951-ab18-e47af1b11bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c5853c7-99d6-46d2-96df-64162d5165f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ffdadf4d-69fe-4951-ab18-e47af1b11bd2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1c5853c7-99d6-46d2-96df-64162d5165f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_347a7d31-cab0-41e0-bf76-5f1b084f4194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_347a7d31-cab0-41e0-bf76-5f1b084f4194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_f0e59929-123e-4cf5-86f7-ec3260802650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_DepreciationAndAmortization_f0e59929-123e-4cf5-86f7-ec3260802650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_af58ef33-0b42-4a57-8025-8e406c5a4602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_NetIncomeLoss_af58ef33-0b42-4a57-8025-8e406c5a4602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8a294d44-3c10-42aa-8edd-c483f65bf7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_ShareBasedCompensation_8a294d44-3c10-42aa-8edd-c483f65bf7ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_fb9447be-7e62-4def-a377-4b843623f2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_fb9447be-7e62-4def-a377-4b843623f2fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ec8cacfc-c6c8-4c7e-9cbb-6fb2ecab3218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ec8cacfc-c6c8-4c7e-9cbb-6fb2ecab3218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b877e907-13e6-4423-b542-1b6153759622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b877e907-13e6-4423-b542-1b6153759622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_7671e11b-5cb8-4d48-a428-744ba9cc74dd" xlink:href="cdtx-20231231.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_7671e11b-5cb8-4d48-a428-744ba9cc74dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_374730f5-a491-4532-8e62-2c47f60cb131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_374730f5-a491-4532-8e62-2c47f60cb131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_22beb23d-ebf4-4273-b591-962bfd9aa701" xlink:href="cdtx-20231231.xsd#cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_22beb23d-ebf4-4273-b591-962bfd9aa701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_65cb453f-169b-4d5d-9872-38ada21bced0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_65cb453f-169b-4d5d-9872-38ada21bced0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fb0beeb6-7fc4-4d8c-8de1-7bb548945048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fb0beeb6-7fc4-4d8c-8de1-7bb548945048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d34d0ff9-3a4e-4ec0-9cec-c8691bf51c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d34d0ff9-3a4e-4ec0-9cec-c8691bf51c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_103b41e4-12c7-4ed0-99c8-c2cfcc760bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_103b41e4-12c7-4ed0-99c8-c2cfcc760bf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_1259aa35-69ce-4d48-8d07-84d2b15eddd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_69cbfcb7-cb52-4d74-8388-3c19973dc441" xlink:to="loc_us-gaap_PaidInKindInterest_1259aa35-69ce-4d48-8d07-84d2b15eddd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1bc16edd-d199-4720-af02-f1b37a74fb31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_db09079f-c598-4db6-83be-e9b98b050cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1bc16edd-d199-4720-af02-f1b37a74fb31" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_db09079f-c598-4db6-83be-e9b98b050cfc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INVENTORYScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9239237a-acf2-4a87-bffe-2cc2a94bc3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_ee52a400-310b-4872-917f-9b6e247cc3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9239237a-acf2-4a87-bffe-2cc2a94bc3f0" xlink:to="loc_us-gaap_InventoryWorkInProcess_ee52a400-310b-4872-917f-9b6e247cc3d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_466abf50-fd36-4925-ae2a-d5c50256c6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9239237a-acf2-4a87-bffe-2cc2a94bc3f0" xlink:to="loc_us-gaap_InventoryRawMaterials_466abf50-fd36-4925-ae2a-d5c50256c6e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_fa3d4d8c-cc3b-43b2-92f2-ca14548944ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_9239237a-acf2-4a87-bffe-2cc2a94bc3f0" xlink:to="loc_us-gaap_InventoryFinishedGoods_fa3d4d8c-cc3b-43b2-92f2-ca14548944ee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_33b3a838-f266-48d9-a367-9614a793c4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5fff3079-0fa9-4f18-ae43-62db4cf595b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_33b3a838-f266-48d9-a367-9614a793c4fb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5fff3079-0fa9-4f18-ae43-62db4cf595b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1d26bb9d-541b-41bf-b051-150fe1c90d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_33b3a838-f266-48d9-a367-9614a793c4fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1d26bb9d-541b-41bf-b051-150fe1c90d6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_e89f074e-0870-44c0-902a-f39963663db9" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_74391b89-6f35-4f80-9650-7e0f4ece68e8" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_e89f074e-0870-44c0-902a-f39963663db9" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_74391b89-6f35-4f80-9650-7e0f4ece68e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_04bf834b-0aae-4749-928e-4ed80c2a1b8a" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_e89f074e-0870-44c0-902a-f39963663db9" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_04bf834b-0aae-4749-928e-4ed80c2a1b8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f39e8879-1c61-434b-bbb5-54a15f2266e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e90c7a75-83c3-480e-9693-4534e68ad4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f39e8879-1c61-434b-bbb5-54a15f2266e0" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e90c7a75-83c3-480e-9693-4534e68ad4bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7280ae70-ad8c-4f30-8e01-11f20cba6295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f39e8879-1c61-434b-bbb5-54a15f2266e0" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7280ae70-ad8c-4f30-8e01-11f20cba6295" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_54a5f4eb-8513-474b-946f-73d9717bd312" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6fe7eab2-18e8-48db-9235-b517e4c4fac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_54a5f4eb-8513-474b-946f-73d9717bd312" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6fe7eab2-18e8-48db-9235-b517e4c4fac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_24019faf-db7d-4109-a02f-ac892c34195c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_54a5f4eb-8513-474b-946f-73d9717bd312" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_24019faf-db7d-4109-a02f-ac892c34195c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fe9252ba-18f4-4f4f-b77c-de715ba62fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a0952081-28c7-4932-99a9-ff3a7d0d176f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fe9252ba-18f4-4f4f-b77c-de715ba62fcd" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a0952081-28c7-4932-99a9-ff3a7d0d176f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_528921a0-8136-437a-b8c0-f4d2ce79e7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_fe9252ba-18f4-4f4f-b77c-de715ba62fcd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_528921a0-8136-437a-b8c0-f4d2ce79e7f1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_de0d9285-3e0b-4d5f-ac72-ff31d615a359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_de0d9285-3e0b-4d5f-ac72-ff31d615a359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_40f7d2f7-e20f-48ee-9761-2e1592db66ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_40f7d2f7-e20f-48ee-9761-2e1592db66ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5f9504c3-7453-4cc5-852a-1c77844a5a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_5f9504c3-7453-4cc5-852a-1c77844a5a52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_d1c8c979-a4eb-4cd4-9eb3-57572baba5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_d1c8c979-a4eb-4cd4-9eb3-57572baba5d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9d994fb7-18cb-42ee-9d1c-1dd0046dade9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_9d994fb7-18cb-42ee-9d1c-1dd0046dade9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6282972d-339b-4879-8bcb-88f29b85dc90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6282972d-339b-4879-8bcb-88f29b85dc90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1c6de4c6-87b5-446a-aff4-8d67cfa3afbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_1c6de4c6-87b5-446a-aff4-8d67cfa3afbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_49f65491-3675-4745-9437-329b6d7658ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_49f65491-3675-4745-9437-329b6d7658ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount_b9176a5a-9aa7-4bab-aab4-429f4d8cff31" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount_b9176a5a-9aa7-4bab-aab4-429f4d8cff31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount_102d5927-93bd-48c9-87a8-bd2e7ae6383a" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount_102d5927-93bd-48c9-87a8-bd2e7ae6383a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount_999a183e-0528-4459-9fe4-8838bdbf9879" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a97c44fd-d812-4f46-bd99-1b4e96a6c470" xlink:to="loc_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount_999a183e-0528-4459-9fe4-8838bdbf9879" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_32bad98c-5088-4484-85cc-3179793463db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9bd2f009-f774-4c17-ac98-365dd29e1a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_32bad98c-5088-4484-85cc-3179793463db" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_9bd2f009-f774-4c17-ac98-365dd29e1a24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4a97ff3f-34d3-4faa-8f72-8a036142013b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_32bad98c-5088-4484-85cc-3179793463db" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_4a97ff3f-34d3-4faa-8f72-8a036142013b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts_54f8c3bd-733d-4968-9150-5349d6f195d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_32bad98c-5088-4484-85cc-3179793463db" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts_54f8c3bd-733d-4968-9150-5349d6f195d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e1d9da8a-3f46-4ef6-aba0-0cf921d162dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ebd989c0-32cb-4e9f-bc4f-07a194cdf6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e1d9da8a-3f46-4ef6-aba0-0cf921d162dd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ebd989c0-32cb-4e9f-bc4f-07a194cdf6b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f0f79fca-d482-4eb3-a242-fa185ee3b1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e1d9da8a-3f46-4ef6-aba0-0cf921d162dd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f0f79fca-d482-4eb3-a242-fa185ee3b1cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_90f9d13b-a0ce-47ff-9d7c-2fddd11b18c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7a6114a2-f2a2-4700-b8a5-9160ab4ea512" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_90f9d13b-a0ce-47ff-9d7c-2fddd11b18c6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7a6114a2-f2a2-4700-b8a5-9160ab4ea512" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e2cdba4f-ac31-441d-85ff-3352f2b4d0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_90f9d13b-a0ce-47ff-9d7c-2fddd11b18c6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e2cdba4f-ac31-441d-85ff-3352f2b4d0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e3761232-12f3-4fc8-9d4e-c587c2da8177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e3761232-12f3-4fc8-9d4e-c587c2da8177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DeferredTaxAssetsLeasingArrangements_fc592aef-3a54-47b9-8ade-3a8b72344444" xlink:href="cdtx-20231231.xsd#cdtx_DeferredTaxAssetsLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_cdtx_DeferredTaxAssetsLeasingArrangements_fc592aef-3a54-47b9-8ade-3a8b72344444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_04791bdf-d42c-4dc4-9970-d287f8eceb80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_04791bdf-d42c-4dc4-9970-d287f8eceb80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes_0a18fe93-d8d5-4946-86ca-4caea5292838" xlink:href="cdtx-20231231.xsd#cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes_0a18fe93-d8d5-4946-86ca-4caea5292838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6ddad641-d90b-40e5-894c-d1003fdb39a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_6ddad641-d90b-40e5-894c-d1003fdb39a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7501938d-fd2d-4628-bcec-25e0f4e73385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7501938d-fd2d-4628-bcec-25e0f4e73385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3493a3f2-609b-43e7-91dd-97e38bb05ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3493a3f2-609b-43e7-91dd-97e38bb05ed5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_297813b1-8d0f-4157-93d9-923545859c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_297813b1-8d0f-4157-93d9-923545859c0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0ad3f821-2929-415b-9ea2-8c443c27b92f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fa2f870c-46ad-4556-9630-a6e64d4313a8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0ad3f821-2929-415b-9ea2-8c443c27b92f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b9ebe5d9-6e3d-4742-b3df-9474a17303c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_2d24e753-1d35-4f74-9708-0d88252769cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b9ebe5d9-6e3d-4742-b3df-9474a17303c3" xlink:to="loc_us-gaap_FinanceLeaseLiability_2d24e753-1d35-4f74-9708-0d88252769cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_99e1936a-9867-4d08-9024-6ae5756941d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_b9ebe5d9-6e3d-4742-b3df-9474a17303c3" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_99e1936a-9867-4d08-9024-6ae5756941d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2d312e4c-2af7-4680-b673-444bf5930795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d39592ce-b97a-4e64-8405-fa4a43cb1122" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2d312e4c-2af7-4680-b673-444bf5930795" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d39592ce-b97a-4e64-8405-fa4a43cb1122" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_98658225-fdf1-49ce-9a46-ea8d351e1beb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2d312e4c-2af7-4680-b673-444bf5930795" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_98658225-fdf1-49ce-9a46-ea8d351e1beb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_6a88a6d5-8943-456f-a5bc-0a94aa7c9267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2d312e4c-2af7-4680-b673-444bf5930795" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_6a88a6d5-8943-456f-a5bc-0a94aa7c9267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f8b215e3-bd70-4309-bb69-cca0af88d571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_2d312e4c-2af7-4680-b673-444bf5930795" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f8b215e3-bd70-4309-bb69-cca0af88d571" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_c485ce1d-81f4-45c9-8166-85c0800e2ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d901ebe5-6ea3-40e9-93b7-3a714dbd1d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_c485ce1d-81f4-45c9-8166-85c0800e2ba1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d901ebe5-6ea3-40e9-93b7-3a714dbd1d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a0350b2d-1ead-4668-9592-ec96583f8cae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_c485ce1d-81f4-45c9-8166-85c0800e2ba1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a0350b2d-1ead-4668-9592-ec96583f8cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_424cf848-cd84-40bb-80a4-0dc14a7b2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_c60260ed-1b86-4e54-93c6-51065b4374fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_424cf848-cd84-40bb-80a4-0dc14a7b2d04" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_c60260ed-1b86-4e54-93c6-51065b4374fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_2b60f230-6078-4779-bf06-b5c914572cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset_424cf848-cd84-40bb-80a4-0dc14a7b2d04" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_2b60f230-6078-4779-bf06-b5c914572cce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47017aa1-633f-4669-b7be-2393b4da022c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3c288fcb-c99e-473f-89d6-838396ff2a41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47017aa1-633f-4669-b7be-2393b4da022c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3c288fcb-c99e-473f-89d6-838396ff2a41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9cd42f3c-8512-4bfb-9f05-acc92c868792" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47017aa1-633f-4669-b7be-2393b4da022c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9cd42f3c-8512-4bfb-9f05-acc92c868792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_59da79b6-daa3-460b-9d8a-954dcaefa8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_47017aa1-633f-4669-b7be-2393b4da022c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_59da79b6-daa3-460b-9d8a-954dcaefa8fc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cdea0f60-7312-464b-8a8b-d8089ae8d25d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3afc3b66-9203-4037-8007-11411bee1560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cdea0f60-7312-464b-8a8b-d8089ae8d25d" xlink:to="loc_us-gaap_OperatingLeaseLiability_3afc3b66-9203-4037-8007-11411bee1560" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7182a63a-38e8-43b7-a799-b2c6f8f1a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cdea0f60-7312-464b-8a8b-d8089ae8d25d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7182a63a-38e8-43b7-a799-b2c6f8f1a9ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ca5d055e-eb94-42bb-a5ce-06c7940b1b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f375ff7-7ae5-4cde-a4c3-e435ebffc1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ca5d055e-eb94-42bb-a5ce-06c7940b1b61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f375ff7-7ae5-4cde-a4c3-e435ebffc1db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d52ff1a-59ac-4ac8-acf0-7daad9b7c227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_ca5d055e-eb94-42bb-a5ce-06c7940b1b61" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d52ff1a-59ac-4ac8-acf0-7daad9b7c227" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cdtx-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fa590d2e-4039-4000-bdf7-5fb59710602c,g:d0764763-c16c-45c9-82e5-80b88e590043-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://cidara.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d814a2ee-10eb-4752-b3e4-01c8d5f84518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:to="loc_us-gaap_StatementTable_d814a2ee-10eb-4752-b3e4-01c8d5f84518" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d814a2ee-10eb-4752-b3e4-01c8d5f84518" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7" xlink:to="loc_us-gaap_ClassOfStockDomain_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_22d0d170-58ce-424f-9767-4b340f1b2d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7" xlink:to="loc_us-gaap_ClassOfStockDomain_22d0d170-58ce-424f-9767-4b340f1b2d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_0f44338c-fe10-464e-ac5f-5f8fafba953b" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_22d0d170-58ce-424f-9767-4b340f1b2d68" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_0f44338c-fe10-464e-ac5f-5f8fafba953b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:to="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8486a8f5-6700-406b-8c0a-8cb0517a4dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8486a8f5-6700-406b-8c0a-8cb0517a4dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_70b466f9-b6ac-4b6f-b9ee-a54c294d2a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_70b466f9-b6ac-4b6f-b9ee-a54c294d2a4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7a556ebf-cfde-4713-8c70-89a091ebf337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_InventoryNet_7a556ebf-cfde-4713-8c70-89a091ebf337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33281d4f-9158-435e-ac57-3d62dd239fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33281d4f-9158-435e-ac57-3d62dd239fae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9de79e60-3126-486b-ac3d-b9f1c63bab5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_AssetsCurrent_9de79e60-3126-486b-ac3d-b9f1c63bab5a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7dc904a7-58b4-41c7-8bc1-728283ca1012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7dc904a7-58b4-41c7-8bc1-728283ca1012" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ccec6c92-99ff-4779-8361-cc1139a04a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ccec6c92-99ff-4779-8361-cc1139a04a48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6bf55e87-8a62-4217-aaf8-b9c312120c93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6bf55e87-8a62-4217-aaf8-b9c312120c93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_86cafbd1-18f3-4602-832f-2cc1207ecdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_86cafbd1-18f3-4602-832f-2cc1207ecdfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9f7b747d-3de1-4871-8cff-28e1bbb7bf76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_Assets_9f7b747d-3de1-4871-8cff-28e1bbb7bf76" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_32d5be0b-d5e3-4d0b-b2d6-e9b6e13b36c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_AccountsPayableCurrent_32d5be0b-d5e3-4d0b-b2d6-e9b6e13b36c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0edf0970-11e6-416f-87dc-8962a4877ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0edf0970-11e6-416f-87dc-8962a4877ef4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_3185a432-2202-401c-81bb-488345cad6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_3185a432-2202-401c-81bb-488345cad6b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ef73f467-7f45-4b9e-8ff3-e08aae7b90fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ef73f467-7f45-4b9e-8ff3-e08aae7b90fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0ec508fe-5900-4b11-9d6e-b047b407ff1d" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0ec508fe-5900-4b11-9d6e-b047b407ff1d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_22793ba7-212c-42cb-b195-606d856d2da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_22793ba7-212c-42cb-b195-606d856d2da0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_112e5afd-6614-4867-b0df-b41a01c580c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_112e5afd-6614-4867-b0df-b41a01c580c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c83cdf89-2b57-48f9-9d3c-226412084c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_LiabilitiesCurrent_c83cdf89-2b57-48f9-9d3c-226412084c49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_ca418f2c-6a4b-4457-bdcc-2dac08985b03" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_ca418f2c-6a4b-4457-bdcc-2dac08985b03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_63cadd15-3c07-46bd-b1cc-94812eddb0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_63cadd15-3c07-46bd-b1cc-94812eddb0ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b4cc49e-0926-4f5a-820f-855ba9043fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b4cc49e-0926-4f5a-820f-855ba9043fc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_efdb5842-556f-4ee3-8aae-2420b8d00f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_Liabilities_efdb5842-556f-4ee3-8aae-2420b8d00f88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bd85edc9-c28e-462a-aaa7-8c3698e8208e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bd85edc9-c28e-462a-aaa7-8c3698e8208e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cc6600ae-71ea-4b18-859d-883c81fc40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_PreferredStockValue_cc6600ae-71ea-4b18-859d-883c81fc40a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_27bb0ef9-75d9-4419-90d7-7c7c2fb2736d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_CommonStockValue_27bb0ef9-75d9-4419-90d7-7c7c2fb2736d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5c1bc257-e485-40ce-9d53-1989351765fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5c1bc257-e485-40ce-9d53-1989351765fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7027ac8a-c5fe-49f6-96e6-1802479fb5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7027ac8a-c5fe-49f6-96e6-1802479fb5db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0b64d3d3-5d3c-489b-a502-bc4cd2dc21e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_StockholdersEquity_0b64d3d3-5d3c-489b-a502-bc4cd2dc21e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_382bfa72-5b81-4e69-beab-7504e1a39226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_382bfa72-5b81-4e69-beab-7504e1a39226" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_38306061-aec7-414d-b5a5-1a64048b9283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_StatementTable_38306061-aec7-414d-b5a5-1a64048b9283" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2f1ff181-c0aa-4a0b-8604-8bb812743c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_38306061-aec7-414d-b5a5-1a64048b9283" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2f1ff181-c0aa-4a0b-8604-8bb812743c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2f1ff181-c0aa-4a0b-8604-8bb812743c23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2f1ff181-c0aa-4a0b-8604-8bb812743c23" xlink:to="loc_us-gaap_ClassOfStockDomain_2f1ff181-c0aa-4a0b-8604-8bb812743c23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a1420bc-720a-4b2c-9adf-cf21ea01a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2f1ff181-c0aa-4a0b-8604-8bb812743c23" xlink:to="loc_us-gaap_ClassOfStockDomain_3a1420bc-720a-4b2c-9adf-cf21ea01a5db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_1d26bdc9-db20-4509-8f96-6cf8ad56e78e" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3a1420bc-720a-4b2c-9adf-cf21ea01a5db" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_1d26bdc9-db20-4509-8f96-6cf8ad56e78e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad0a7042-ae32-4be4-8966-7a7471b1509a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad0a7042-ae32-4be4-8966-7a7471b1509a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_53878b53-d812-4fc3-9420-c77ab1c551c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_53878b53-d812-4fc3-9420-c77ab1c551c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7299a4f6-ffdb-4283-8eb9-34fb202c9371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7299a4f6-ffdb-4283-8eb9-34fb202c9371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1e936a44-957d-4bae-9a17-b4b521065308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1e936a44-957d-4bae-9a17-b4b521065308" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_097d11ea-3131-416e-8908-738037daeda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_097d11ea-3131-416e-8908-738037daeda1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6ce2b21d-2869-434b-abfb-360e8f7d9360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6ce2b21d-2869-434b-abfb-360e8f7d9360" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b2874ee3-f39c-4da5-9460-61098bcbea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockSharesIssued_b2874ee3-f39c-4da5-9460-61098bcbea0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_621448e5-47d4-4d26-a3b6-d5fc83296856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_621448e5-47d4-4d26-a3b6-d5fc83296856" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49f62776-d0ac-4607-95c6-c8535acc1d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_49f62776-d0ac-4607-95c6-c8535acc1d39" xlink:to="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1" xlink:to="loc_us-gaap_EquityComponentDomain_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1" xlink:to="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9e7b3fee-886e-40f7-ae37-e2081006ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_PreferredStockMember_9e7b3fee-886e-40f7-ae37-e2081006ea83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_74c4a2d8-8a40-4fb2-9023-6a4c8a2e0aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_CommonStockMember_74c4a2d8-8a40-4fb2-9023-6a4c8a2e0aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e5ab9892-2afa-4c8c-b776-b5f659fdf307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e5ab9892-2afa-4c8c-b776-b5f659fdf307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e76930db-b778-4f55-b356-ff283ce0ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_RetainedEarningsMember_e76930db-b778-4f55-b356-ff283ce0ba74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8071d599-576c-4cb1-b4f2-adb52ae64b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8071d599-576c-4cb1-b4f2-adb52ae64b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8071d599-576c-4cb1-b4f2-adb52ae64b01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8071d599-576c-4cb1-b4f2-adb52ae64b01" xlink:to="loc_us-gaap_ClassOfStockDomain_8071d599-576c-4cb1-b4f2-adb52ae64b01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_71bb72e6-c204-421e-90d0-2449bfd4f11e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8071d599-576c-4cb1-b4f2-adb52ae64b01" xlink:to="loc_us-gaap_ClassOfStockDomain_71bb72e6-c204-421e-90d0-2449bfd4f11e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_17135479-7f20-4fd7-a90c-8cefc6b99406" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_71bb72e6-c204-421e-90d0-2449bfd4f11e" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_17135479-7f20-4fd7-a90c-8cefc6b99406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_853d01d0-cab9-41f1-8cbe-e360dd2b73a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_853d01d0-cab9-41f1-8cbe-e360dd2b73a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_853d01d0-cab9-41f1-8cbe-e360dd2b73a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_853d01d0-cab9-41f1-8cbe-e360dd2b73a8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_853d01d0-cab9-41f1-8cbe-e360dd2b73a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_853d01d0-cab9-41f1-8cbe-e360dd2b73a8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnderwrittenPublicOfferingMember_af38636c-206a-4b3f-91a3-21d6d0855495" xlink:href="cdtx-20231231.xsd#cdtx_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:to="loc_cdtx_UnderwrittenPublicOfferingMember_af38636c-206a-4b3f-91a3-21d6d0855495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicOfferingMember_59a51be8-e797-4bdc-9867-d174109e8ca2" xlink:href="cdtx-20231231.xsd#cdtx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:to="loc_cdtx_PublicOfferingMember_59a51be8-e797-4bdc-9867-d174109e8ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49f62776-d0ac-4607-95c6-c8535acc1d39" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_48e4351c-c800-4ddc-8aac-acc19bc63c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_48e4351c-c800-4ddc-8aac-acc19bc63c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0472b993-9192-4d3b-a5f4-affb5875a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockholdersEquity_0472b993-9192-4d3b-a5f4-affb5875a7b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7a48c3f4-1030-4ed8-bc85-a2b3ffc01bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7a48c3f4-1030-4ed8-bc85-a2b3ffc01bc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4213b3ad-ce71-456f-b285-414339b20e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4213b3ad-ce71-456f-b285-414339b20e92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02c85083-6226-416b-898c-d5c0e97d962e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02c85083-6226-416b-898c-d5c0e97d962e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28e08984-ae00-4f29-b2ce-608e0ef847ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28e08984-ae00-4f29-b2ce-608e0ef847ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7b486fe-867e-43f5-b1a5-22920f621f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7b486fe-867e-43f5-b1a5-22920f621f51" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_52a850ad-4f37-4dd3-a731-43d216b64bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_52a850ad-4f37-4dd3-a731-43d216b64bf2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9205aef9-a6c1-4dac-90bb-5910972f6d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9205aef9-a6c1-4dac-90bb-5910972f6d8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d5477f36-fbc4-4f0c-a6c6-7e703b68dd36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d5477f36-fbc4-4f0c-a6c6-7e703b68dd36" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3387da88-e9f4-4971-8320-bd929f86e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3387da88-e9f4-4971-8320-bd929f86e1de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2e40ed15-34ad-401f-b215-88fda6ef3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2e40ed15-34ad-401f-b215-88fda6ef3d5d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3828cef3-4a44-422a-bd51-ad4522c74e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_NetIncomeLoss_3828cef3-4a44-422a-bd51-ad4522c74e8d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_326fd7da-1f75-4e0b-b483-b76f7035eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a881b3da-9989-41ff-9a78-662b60e7cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d904b2f4-7aa3-45b4-bd68-81515c9be5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_752aed4b-a6fb-4176-8101-52660279e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_752aed4b-a6fb-4176-8101-52660279e4b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6453f860-adde-4ed8-980b-e143beea8292" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_752aed4b-a6fb-4176-8101-52660279e4b9" xlink:to="loc_srt_RestatementAxis_6453f860-adde-4ed8-980b-e143beea8292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6453f860-adde-4ed8-980b-e143beea8292_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_6453f860-adde-4ed8-980b-e143beea8292" xlink:to="loc_srt_RestatementDomain_6453f860-adde-4ed8-980b-e143beea8292_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_82cc8f1b-4fed-4a71-a95f-ae230e6e20b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_6453f860-adde-4ed8-980b-e143beea8292" xlink:to="loc_srt_RestatementDomain_82cc8f1b-4fed-4a71-a95f-ae230e6e20b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_af95783f-a35c-45c8-9c61-db9eaac8b788" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_82cc8f1b-4fed-4a71-a95f-ae230e6e20b3" xlink:to="loc_srt_RestatementAdjustmentMember_af95783f-a35c-45c8-9c61-db9eaac8b788" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b7ba96ad-a13b-466c-941d-78451cec6b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b7ba96ad-a13b-466c-941d-78451cec6b14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeb64cf3-c66c-40c3-9c07-d817ad427726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeb64cf3-c66c-40c3-9c07-d817ad427726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_64296a16-8670-41c7-85d8-2c0dbbbf6066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_64296a16-8670-41c7-85d8-2c0dbbbf6066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_ebe287a0-3a9d-48a6-8947-4059736224f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_ebe287a0-3a9d-48a6-8947-4059736224f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_df090eed-bc89-4c9a-9941-86d28abfbe91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_OperatingExpenses_df090eed-bc89-4c9a-9941-86d28abfbe91" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_391c82fa-a924-490a-8464-a224f2fec092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_391c82fa-a924-490a-8464-a224f2fec092" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_d9481e75-f51d-4ec9-b157-4cf62db121a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_391c82fa-a924-490a-8464-a224f2fec092" xlink:to="loc_srt_RestatementAxis_d9481e75-f51d-4ec9-b157-4cf62db121a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d9481e75-f51d-4ec9-b157-4cf62db121a1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_d9481e75-f51d-4ec9-b157-4cf62db121a1" xlink:to="loc_srt_RestatementDomain_d9481e75-f51d-4ec9-b157-4cf62db121a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_d9481e75-f51d-4ec9-b157-4cf62db121a1" xlink:to="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_37818992-aecf-44a8-b9ef-f560abd8a127" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_37818992-aecf-44a8-b9ef-f560abd8a127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_5d5de890-f2d6-423d-8eec-76ed09c3aa30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_5d5de890-f2d6-423d-8eec-76ed09c3aa30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b0a7a06-7526-4fe0-92e5-1259d51db356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b0a7a06-7526-4fe0-92e5-1259d51db356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d71eb252-7424-497e-8e8d-c2d4a3ce9bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_Assets_d71eb252-7424-497e-8e8d-c2d4a3ce9bce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_50f7d874-416d-4381-bf98-c2e58c7c4a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_50f7d874-416d-4381-bf98-c2e58c7c4a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_792f9e78-919d-4871-a255-f5bfe42e8a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_792f9e78-919d-4871-a255-f5bfe42e8a02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_accade74-edf6-4301-bc39-c0640c765b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_LiabilitiesCurrent_accade74-edf6-4301-bc39-c0640c765b0f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ecdc9b65-68e5-45b9-9ab2-bbc16132d0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_Liabilities_ecdc9b65-68e5-45b9-9ab2-bbc16132d0c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab12b685-fd91-49ad-aae3-88c9c50ea911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab12b685-fd91-49ad-aae3-88c9c50ea911" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd0f7ac0-a661-4858-bc40-b59219ecd8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_StockholdersEquity_fd0f7ac0-a661-4858-bc40-b59219ecd8b3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce401a32-17ba-4be1-8557-3dd70f2f79ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce401a32-17ba-4be1-8557-3dd70f2f79ea" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81fd801e-e770-40b1-ae59-19862367a80a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81fd801e-e770-40b1-ae59-19862367a80a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81fd801e-e770-40b1-ae59-19862367a80a" xlink:to="loc_srt_RestatementAxis_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf" xlink:to="loc_srt_RestatementDomain_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf" xlink:to="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_c3311bbf-123a-4bb7-898a-87b8f6e4c3a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_c3311bbf-123a-4bb7-898a-87b8f6e4c3a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_77964f85-befe-467b-bc2a-6094128a6125" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_77964f85-befe-467b-bc2a-6094128a6125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_911b26c7-a9b1-48ce-ae9c-938ad41e79df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_911b26c7-a9b1-48ce-ae9c-938ad41e79df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e6bedfd3-62d2-4668-ae4d-f9c9e6cbed2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_Revenues_e6bedfd3-62d2-4668-ae4d-f9c9e6cbed2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5758b5cf-a754-4c6e-8971-7c32c0e81887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5758b5cf-a754-4c6e-8971-7c32c0e81887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cd9d7983-057d-44f9-84cd-8ec29b22292b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cd9d7983-057d-44f9-84cd-8ec29b22292b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_48ac4a1c-9556-40b2-80dc-2550c5ba12a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_OperatingExpenses_48ac4a1c-9556-40b2-80dc-2550c5ba12a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0290076c-06a7-42a8-a9f2-81a948c08546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_OperatingIncomeLoss_0290076c-06a7-42a8-a9f2-81a948c08546" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba5c2a99-76e9-455e-a111-95ed1315d01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba5c2a99-76e9-455e-a111-95ed1315d01a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_40b25aa8-2cd7-43f0-86cf-f56685619aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_NetIncomeLoss_40b25aa8-2cd7-43f0-86cf-f56685619aa4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_77909d1d-8ef3-494e-a560-026c5533154e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_77909d1d-8ef3-494e-a560-026c5533154e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_85d591a0-85e9-4ead-b539-5af8027b4b88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_EarningsPerShareBasic_85d591a0-85e9-4ead-b539-5af8027b4b88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ff53cce9-d416-4749-8d6a-ef93cc17e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ff53cce9-d416-4749-8d6a-ef93cc17e6fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cdd3bdc2-ea50-4fd6-a1b0-14916be8df10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cdd3bdc2-ea50-4fd6-a1b0-14916be8df10" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4fee733-d0e3-428e-9ad7-d76500da2d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4fee733-d0e3-428e-9ad7-d76500da2d38" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_a08e28c8-9cfc-4567-acbd-bf9b4afb108d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:to="loc_srt_RestatementAxis_a08e28c8-9cfc-4567-acbd-bf9b4afb108d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_a08e28c8-9cfc-4567-acbd-bf9b4afb108d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_a08e28c8-9cfc-4567-acbd-bf9b4afb108d" xlink:to="loc_srt_RestatementDomain_a08e28c8-9cfc-4567-acbd-bf9b4afb108d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_a08e28c8-9cfc-4567-acbd-bf9b4afb108d" xlink:to="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_b5c86d9d-f1ee-457c-a6cc-03d1e6d44301" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_b5c86d9d-f1ee-457c-a6cc-03d1e6d44301" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f4c3f0f9-6e16-4282-8074-e49c96afdee5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f4c3f0f9-6e16-4282-8074-e49c96afdee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb816905-716d-409b-9b10-ef779a54b56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb816905-716d-409b-9b10-ef779a54b56f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_eb816905-716d-409b-9b10-ef779a54b56f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb816905-716d-409b-9b10-ef779a54b56f" xlink:to="loc_us-gaap_EquityComponentDomain_eb816905-716d-409b-9b10-ef779a54b56f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb816905-716d-409b-9b10-ef779a54b56f" xlink:to="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12a4b255-def5-427c-807e-05852bec8997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12a4b255-def5-427c-807e-05852bec8997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2fd1b663-cf61-4ad7-ad45-3400ec67aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:to="loc_us-gaap_RetainedEarningsMember_2fd1b663-cf61-4ad7-ad45-3400ec67aa47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ed01d105-4787-408a-9a79-3af04a8b19da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ed01d105-4787-408a-9a79-3af04a8b19da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ed01d105-4787-408a-9a79-3af04a8b19da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ed01d105-4787-408a-9a79-3af04a8b19da" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ed01d105-4787-408a-9a79-3af04a8b19da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60b566c2-359e-4a46-864b-43df06b81032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ed01d105-4787-408a-9a79-3af04a8b19da" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60b566c2-359e-4a46-864b-43df06b81032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnderwrittenPublicOfferingMember_c896850c-6106-4654-9bdd-57331644595a" xlink:href="cdtx-20231231.xsd#cdtx_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60b566c2-359e-4a46-864b-43df06b81032" xlink:to="loc_cdtx_UnderwrittenPublicOfferingMember_c896850c-6106-4654-9bdd-57331644595a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0bdce15c-d8f8-4419-bdf4-16647242d0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_StockholdersEquity_0bdce15c-d8f8-4419-bdf4-16647242d0ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90f06f38-8b11-4966-912c-37a0511c5302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90f06f38-8b11-4966-912c-37a0511c5302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8736426e-e07a-478e-bf24-b0cae2dd6893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_NetIncomeLoss_8736426e-e07a-478e-bf24-b0cae2dd6893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd425ff9-c380-4f0a-8c3c-dbbc94d93072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f46d4cf0-7c84-4bc6-a454-c8752276bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20b4259d-9473-4b45-866e-1194fe148916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f46d4cf0-7c84-4bc6-a454-c8752276bfbb" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20b4259d-9473-4b45-866e-1194fe148916" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f2591d74-a476-4a59-9934-0118cba097df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20b4259d-9473-4b45-866e-1194fe148916" xlink:to="loc_srt_RestatementAxis_f2591d74-a476-4a59-9934-0118cba097df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_f2591d74-a476-4a59-9934-0118cba097df_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_f2591d74-a476-4a59-9934-0118cba097df" xlink:to="loc_srt_RestatementDomain_f2591d74-a476-4a59-9934-0118cba097df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_f2591d74-a476-4a59-9934-0118cba097df" xlink:to="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_17751109-3e93-4e8d-b3e7-055d7e60c672" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_17751109-3e93-4e8d-b3e7-055d7e60c672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_356c0fdf-d82f-462f-9f81-beb41b739997" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_356c0fdf-d82f-462f-9f81-beb41b739997" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f46d4cf0-7c84-4bc6-a454-c8752276bfbb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f82d168-eb75-459b-bef0-4bcc8c11261b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:to="loc_us-gaap_NetIncomeLoss_8f82d168-eb75-459b-bef0-4bcc8c11261b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_959c81f0-ec6a-4dda-9c27-7a0f82ebcd78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_959c81f0-ec6a-4dda-9c27-7a0f82ebcd78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_a66fc904-54c9-4ccb-abd8-cc76a5a67edc" xlink:href="cdtx-20231231.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_959c81f0-ec6a-4dda-9c27-7a0f82ebcd78" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_a66fc904-54c9-4ccb-abd8-cc76a5a67edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccruedIndirectTaxLiabilities_e1a53d1b-1340-4a73-ac55-4ea10507dfa8" xlink:href="cdtx-20231231.xsd#cdtx_AccruedIndirectTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:to="loc_cdtx_AccruedIndirectTaxLiabilities_e1a53d1b-1340-4a73-ac55-4ea10507dfa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88baaa5b-fb5a-4925-b2eb-9138fe1c119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88baaa5b-fb5a-4925-b2eb-9138fe1c119e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_70c8bfa0-9801-4723-b567-c990fcbe3706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_70c8bfa0-9801-4723-b567-c990fcbe3706" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:to="loc_srt_RangeAxis_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c" xlink:to="loc_srt_RangeMember_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c" xlink:to="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e2b5a30-b7d7-4255-9a50-9efaaff5cca2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:to="loc_srt_MinimumMember_5e2b5a30-b7d7-4255-9a50-9efaaff5cca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a93c4f2-1381-4ba1-8be2-56ae5b7e923a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:to="loc_srt_MaximumMember_4a93c4f2-1381-4ba1-8be2-56ae5b7e923a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a5c363db-8c03-4503-9ee7-51efad1137e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:to="loc_srt_CounterpartyNameAxis_a5c363db-8c03-4503-9ee7-51efad1137e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5c363db-8c03-4503-9ee7-51efad1137e9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a5c363db-8c03-4503-9ee7-51efad1137e9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5c363db-8c03-4503-9ee7-51efad1137e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a5c363db-8c03-4503-9ee7-51efad1137e9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_5628a74d-5e82-451b-a894-8fb8f885b1d8" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_5628a74d-5e82-451b-a894-8fb8f885b1d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_74557660-d2f6-47ec-9a82-3a48b42a4e60" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_74557660-d2f6-47ec-9a82-3a48b42a4e60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_adc5b3fd-f4fd-41bf-bfbf-3d4cce1b1554" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_adc5b3fd-f4fd-41bf-bfbf-3d4cce1b1554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4c81d394-4eee-48d9-8562-251a76888dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4c81d394-4eee-48d9-8562-251a76888dff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c81d394-4eee-48d9-8562-251a76888dff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4c81d394-4eee-48d9-8562-251a76888dff" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4c81d394-4eee-48d9-8562-251a76888dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d665c54-f2c2-4d24-b1e6-482c3a139bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4c81d394-4eee-48d9-8562-251a76888dff" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d665c54-f2c2-4d24-b1e6-482c3a139bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenCollaborationAgreementMember_bbc25e55-b865-4adf-8574-a2f055f51182" xlink:href="cdtx-20231231.xsd#cdtx_JanssenCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d665c54-f2c2-4d24-b1e6-482c3a139bd9" xlink:to="loc_cdtx_JanssenCollaborationAgreementMember_bbc25e55-b865-4adf-8574-a2f055f51182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f2ce9aed-f8e7-4987-88cb-3b7e6582af03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f2ce9aed-f8e7-4987-88cb-3b7e6582af03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_7ed5148d-ed6d-46e8-b786-f926559818a0" xlink:href="cdtx-20231231.xsd#cdtx_CollaborationAgreementNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:to="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_7ed5148d-ed6d-46e8-b786-f926559818a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54626668-fd5f-4763-b04a-13edc08cae1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54626668-fd5f-4763-b04a-13edc08cae1c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e4e0896-1076-494a-a1aa-c6f37f3ebacc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7a2c511-ff9b-4169-9729-6c278d63598e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e4e0896-1076-494a-a1aa-c6f37f3ebacc" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7a2c511-ff9b-4169-9729-6c278d63598e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a298a17-6995-4778-afef-b3f4a356428a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7a2c511-ff9b-4169-9729-6c278d63598e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a298a17-6995-4778-afef-b3f4a356428a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a298a17-6995-4778-afef-b3f4a356428a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a298a17-6995-4778-afef-b3f4a356428a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0a298a17-6995-4778-afef-b3f4a356428a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a298a17-6995-4778-afef-b3f4a356428a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2d7ad869-9410-422d-acda-8f29b9fe1403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:to="loc_us-gaap_WarrantMember_2d7ad869-9410-422d-acda-8f29b9fe1403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1eb3e757-9cce-457e-8487-e0c92ca7f856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1eb3e757-9cce-457e-8487-e0c92ca7f856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_046696b8-0aab-4548-bddb-0ebe69097c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:to="loc_us-gaap_StockCompensationPlanMember_046696b8-0aab-4548-bddb-0ebe69097c33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3eb3866e-8191-4a3b-ba03-37ab2d62c089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e4e0896-1076-494a-a1aa-c6f37f3ebacc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3eb3866e-8191-4a3b-ba03-37ab2d62c089" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c751417-4109-4343-a7cb-4e2ade3b1700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddce1dc2-b4a2-496f-b676-d3f7cb5c393a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c751417-4109-4343-a7cb-4e2ade3b1700" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddce1dc2-b4a2-496f-b676-d3f7cb5c393a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddce1dc2-b4a2-496f-b676-d3f7cb5c393a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_26659bb2-b131-48a9-a6d1-79f406fe3a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_26659bb2-b131-48a9-a6d1-79f406fe3a3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4cc5c707-8953-4443-bc18-57018050ec40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4cc5c707-8953-4443-bc18-57018050ec40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_561518f4-10f7-4a5b-a8dd-706cd6a97592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_561518f4-10f7-4a5b-a8dd-706cd6a97592" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c751417-4109-4343-a7cb-4e2ade3b1700" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70d1db4f-3a60-408b-b991-1936d1ad762f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70d1db4f-3a60-408b-b991-1936d1ad762f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8922f298-3fae-4426-a7a2-69d5d2c3d043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8922f298-3fae-4426-a7a2-69d5d2c3d043" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ac74f98-a125-4e71-8de2-cc869f6561c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ac74f98-a125-4e71-8de2-cc869f6561c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ac74f98-a125-4e71-8de2-cc869f6561c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f9444f82-03a5-4713-8033-cd192ecb4eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_EquipmentMember_f9444f82-03a5-4713-8033-cd192ecb4eb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_06bb822b-e2f1-476f-9ff5-81c39b33203b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_06bb822b-e2f1-476f-9ff5-81c39b33203b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d15879d9-e1d2-4437-b4d5-5fdff6005f74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_ComputerEquipmentMember_d15879d9-e1d2-4437-b4d5-5fdff6005f74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_09da3485-4e61-432b-b26a-547c3538abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_OfficeEquipmentMember_09da3485-4e61-432b-b26a-547c3538abc8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_87af744f-ecd9-463b-ab3b-366ce2142799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_87af744f-ecd9-463b-ab3b-366ce2142799" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4dd73578-4e6a-4f27-9d1c-6a81e02114a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4dd73578-4e6a-4f27-9d1c-6a81e02114a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_550d948a-04a4-475f-87da-b5ed43d05a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_550d948a-04a4-475f-87da-b5ed43d05a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b437988-cefd-4ff2-ad75-21b4c9a43dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b437988-cefd-4ff2-ad75-21b4c9a43dc7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#DEBTDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/DEBTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:to="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d9b9d025-7c1d-4b8b-a438-60eb417ab995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d9b9d025-7c1d-4b8b-a438-60eb417ab995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d9b9d025-7c1d-4b8b-a438-60eb417ab995_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d9b9d025-7c1d-4b8b-a438-60eb417ab995" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d9b9d025-7c1d-4b8b-a438-60eb417ab995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_56adbcd1-50c1-4473-8f0a-6f36814a7984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d9b9d025-7c1d-4b8b-a438-60eb417ab995" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_56adbcd1-50c1-4473-8f0a-6f36814a7984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_fbfb982c-4851-42c9-b8aa-fa574038743e" xlink:href="cdtx-20231231.xsd#cdtx_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_56adbcd1-50c1-4473-8f0a-6f36814a7984" xlink:to="loc_cdtx_TermLoanMember_fbfb982c-4851-42c9-b8aa-fa574038743e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_223a9086-0135-4176-900e-7f9d90f32ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:to="loc_us-gaap_DebtInstrumentAxis_223a9086-0135-4176-900e-7f9d90f32ced" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_223a9086-0135-4176-900e-7f9d90f32ced_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_223a9086-0135-4176-900e-7f9d90f32ced" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_223a9086-0135-4176-900e-7f9d90f32ced_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_38fae803-4f38-4a4d-a74f-1536aaa81944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_223a9086-0135-4176-900e-7f9d90f32ced" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_38fae803-4f38-4a4d-a74f-1536aaa81944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_05700614-044e-46e2-8409-59c1a3d5d9d3" xlink:href="cdtx-20231231.xsd#cdtx_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_38fae803-4f38-4a4d-a74f-1536aaa81944" xlink:to="loc_cdtx_TermLoanAMember_05700614-044e-46e2-8409-59c1a3d5d9d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f9a23ea5-a99b-4843-8551-69e6c96b8028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:to="loc_us-gaap_VariableRateAxis_f9a23ea5-a99b-4843-8551-69e6c96b8028" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_f9a23ea5-a99b-4843-8551-69e6c96b8028_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_f9a23ea5-a99b-4843-8551-69e6c96b8028" xlink:to="loc_us-gaap_VariableRateDomain_f9a23ea5-a99b-4843-8551-69e6c96b8028_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_449f36c7-8093-448b-8497-eda879c31a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_f9a23ea5-a99b-4843-8551-69e6c96b8028" xlink:to="loc_us-gaap_VariableRateDomain_449f36c7-8093-448b-8497-eda879c31a7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_7d0d40c6-2a83-40f5-acf0-d23e059c0049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_449f36c7-8093-448b-8497-eda879c31a7b" xlink:to="loc_us-gaap_PrimeRateMember_7d0d40c6-2a83-40f5-acf0-d23e059c0049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5ced85b9-afb6-4e4d-aa36-5950a83e1620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5ced85b9-afb6-4e4d-aa36-5950a83e1620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a5a26cd9-2efd-4c51-91b7-0e3824959fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a5a26cd9-2efd-4c51-91b7-0e3824959fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ab3729cc-d261-4070-b3c2-e967d624d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ab3729cc-d261-4070-b3c2-e967d624d6b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_97433320-22fe-4f12-b032-b62a5c40ffee" xlink:href="cdtx-20231231.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_97433320-22fe-4f12-b032-b62a5c40ffee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_A2023UnderwrittenPublicOfferingMember_93a5c413-f59b-46a4-906d-ac1109b94bb8" xlink:href="cdtx-20231231.xsd#cdtx_A2023UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:to="loc_cdtx_A2023UnderwrittenPublicOfferingMember_93a5c413-f59b-46a4-906d-ac1109b94bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_bafd5aad-719a-4447-854f-1c34b076f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:to="loc_us-gaap_OverAllotmentOptionMember_bafd5aad-719a-4447-854f-1c34b076f2e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c57c6b43-194b-476e-97a0-403a5d522889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c57c6b43-194b-476e-97a0-403a5d522889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c57c6b43-194b-476e-97a0-403a5d522889_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c57c6b43-194b-476e-97a0-403a5d522889" xlink:to="loc_us-gaap_EquityComponentDomain_c57c6b43-194b-476e-97a0-403a5d522889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6967499f-a084-47ff-b345-1fd697829eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c57c6b43-194b-476e-97a0-403a5d522889" xlink:to="loc_us-gaap_EquityComponentDomain_6967499f-a084-47ff-b345-1fd697829eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e99b6f08-b001-404c-b42b-e89955523aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6967499f-a084-47ff-b345-1fd697829eb5" xlink:to="loc_us-gaap_CommonStockMember_e99b6f08-b001-404c-b42b-e89955523aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19" xlink:to="loc_us-gaap_ClassOfStockDomain_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19" xlink:to="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_4369d981-e68e-4bbe-a35a-7d1884385bdc" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_4369d981-e68e-4bbe-a35a-7d1884385bdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1339ee5-44f5-42a1-bdc4-69b0988bafeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:to="loc_us-gaap_CommonStockMember_e1339ee5-44f5-42a1-bdc4-69b0988bafeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d16e21df-45d4-4b82-8250-52cc29e5b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d16e21df-45d4-4b82-8250-52cc29e5b9f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d16e21df-45d4-4b82-8250-52cc29e5b9f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d16e21df-45d4-4b82-8250-52cc29e5b9f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d16e21df-45d4-4b82-8250-52cc29e5b9f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2b3ca187-6f7e-471f-b51d-d1335c91fda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d16e21df-45d4-4b82-8250-52cc29e5b9f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2b3ca187-6f7e-471f-b51d-d1335c91fda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_d12e99ef-cfab-419c-ac6d-160a20947cdc" xlink:href="cdtx-20231231.xsd#cdtx_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2b3ca187-6f7e-471f-b51d-d1335c91fda7" xlink:to="loc_cdtx_CommonStockWarrantMember_d12e99ef-cfab-419c-ac6d-160a20947cdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba25f96d-59be-42a3-867f-0a83c26107e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_srt_RangeAxis_ba25f96d-59be-42a3-867f-0a83c26107e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba25f96d-59be-42a3-867f-0a83c26107e2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba25f96d-59be-42a3-867f-0a83c26107e2" xlink:to="loc_srt_RangeMember_ba25f96d-59be-42a3-867f-0a83c26107e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2108cba1-1f34-4083-9942-d02d9a657078" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba25f96d-59be-42a3-867f-0a83c26107e2" xlink:to="loc_srt_RangeMember_2108cba1-1f34-4083-9942-d02d9a657078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_40e7eb62-cf4a-429b-8d73-3cf525152ae5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2108cba1-1f34-4083-9942-d02d9a657078" xlink:to="loc_srt_WeightedAverageMember_40e7eb62-cf4a-429b-8d73-3cf525152ae5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_457d190f-8cfc-49d6-a197-418f755b2bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_457d190f-8cfc-49d6-a197-418f755b2bc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a7133d2f-555f-4d20-8928-58cb4e9f4223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a7133d2f-555f-4d20-8928-58cb4e9f4223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_89e439f9-37f9-440c-9434-a5c125735d94" xlink:href="cdtx-20231231.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_89e439f9-37f9-440c-9434-a5c125735d94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d0aa3bb2-1e5b-47f7-91e0-68d35d3e2bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d0aa3bb2-1e5b-47f7-91e0-68d35d3e2bf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a8ae2cc5-5dba-44f7-bdf5-792947859ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a8ae2cc5-5dba-44f7-bdf5-792947859ec6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eba39dc6-b724-445c-990d-ba265676e3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eba39dc6-b724-445c-990d-ba265676e3d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ed18c965-e899-4a9f-885c-ed577528736d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ed18c965-e899-4a9f-885c-ed577528736d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c3fd07e2-ce35-4de5-8c70-f68502175ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c3fd07e2-ce35-4de5-8c70-f68502175ca2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_136aa778-9b01-4185-899d-52bf5ce83625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_136aa778-9b01-4185-899d-52bf5ce83625" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_cd14c541-7cdc-4370-9798-e7665869875c" xlink:href="cdtx-20231231.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_cd14c541-7cdc-4370-9798-e7665869875c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_477a8f0e-68b2-41d6-8407-f3937362f2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_477a8f0e-68b2-41d6-8407-f3937362f2c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_a490043b-a0bb-4c3b-9238-b195183ccafe" xlink:href="cdtx-20231231.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_a490043b-a0bb-4c3b-9238-b195183ccafe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9f4ed0c7-40bd-42f9-a148-8364d5b2fa09" xlink:href="cdtx-20231231.xsd#cdtx_CommonStockDividendsInArrearsOrDefault"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9f4ed0c7-40bd-42f9-a148-8364d5b2fa09" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_230cd1c9-9328-4a9d-89de-2d029b03cedf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_230cd1c9-9328-4a9d-89de-2d029b03cedf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_982322f9-bd9b-482c-83c8-f4e45546e7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_982322f9-bd9b-482c-83c8-f4e45546e7dd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExpired_5258e91b-cef8-44ad-9248-edf3d7801445" xlink:href="cdtx-20231231.xsd#cdtx_ClassOfWarrantOrRightExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_ClassOfWarrantOrRightExpired_5258e91b-cef8-44ad-9248-edf3d7801445" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_03c2a56c-91ec-4335-9a78-ee7a775644ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_03c2a56c-91ec-4335-9a78-ee7a775644ee" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b8004e19-8a66-4539-be3b-cab3d2a04bac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fbc6fadb-b962-4bf8-9b25-ec4a3dd93eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b8004e19-8a66-4539-be3b-cab3d2a04bac" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fbc6fadb-b962-4bf8-9b25-ec4a3dd93eed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fbc6fadb-b962-4bf8-9b25-ec4a3dd93eed" xlink:to="loc_us-gaap_AwardTypeAxis_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_32e7ef4a-a7ca-4867-9460-39896d067166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_us-gaap_WarrantMember_32e7ef4a-a7ca-4867-9460-39896d067166" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_2c50ae50-9dd2-437b-9137-842d1cfe9552" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_2c50ae50-9dd2-437b-9137-842d1cfe9552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_4763a607-430f-4550-b0ce-a30a7b2bd101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_us-gaap_StockCompensationPlanMember_4763a607-430f-4550-b0ce-a30a7b2bd101" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_12ce90e1-f983-4ae3-af40-9bf7ae9dc630" xlink:href="cdtx-20231231.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_12ce90e1-f983-4ae3-af40-9bf7ae9dc630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8a35b831-81fa-455c-9105-8d67d3abdd11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_us-gaap_EmployeeStockMember_8a35b831-81fa-455c-9105-8d67d3abdd11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11b4a6c8-e336-4402-80bf-efabcfdcfc63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b8004e19-8a66-4539-be3b-cab3d2a04bac" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11b4a6c8-e336-4402-80bf-efabcfdcfc63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_254aa51b-43fc-4c54-baea-c0f851b8158b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_us-gaap_PlanNameAxis_254aa51b-43fc-4c54-baea-c0f851b8158b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_254aa51b-43fc-4c54-baea-c0f851b8158b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_254aa51b-43fc-4c54-baea-c0f851b8158b" xlink:to="loc_us-gaap_PlanNameDomain_254aa51b-43fc-4c54-baea-c0f851b8158b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_254aa51b-43fc-4c54-baea-c0f851b8158b" xlink:to="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_0b6047b9-1ab5-4811-ad50-e8de3414ca34" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:to="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_0b6047b9-1ab5-4811-ad50-e8de3414ca34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1f14b65d-4602-4d8d-a4f3-d9a8f7ca9119" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1f14b65d-4602-4d8d-a4f3-d9a8f7ca9119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46b0801c-0980-448b-9cd3-401078396dfb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_srt_RangeAxis_46b0801c-0980-448b-9cd3-401078396dfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46b0801c-0980-448b-9cd3-401078396dfb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46b0801c-0980-448b-9cd3-401078396dfb" xlink:to="loc_srt_RangeMember_46b0801c-0980-448b-9cd3-401078396dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46b0801c-0980-448b-9cd3-401078396dfb" xlink:to="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d19d0ab8-f377-48ef-9e9e-4f6979b94beb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:to="loc_srt_MinimumMember_d19d0ab8-f377-48ef-9e9e-4f6979b94beb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f0f99b6-1d5d-4166-b330-efe3fb44cbe7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:to="loc_srt_MaximumMember_1f0f99b6-1d5d-4166-b330-efe3fb44cbe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2e886e4a-eff1-4636-a794-b56f73267825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2e886e4a-eff1-4636-a794-b56f73267825" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_2e886e4a-eff1-4636-a794-b56f73267825_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2e886e4a-eff1-4636-a794-b56f73267825" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_2e886e4a-eff1-4636-a794-b56f73267825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_61e98c08-0e4d-441d-8ab2-717a9b14decd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2e886e4a-eff1-4636-a794-b56f73267825" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_61e98c08-0e4d-441d-8ab2-717a9b14decd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_2d9bda6e-26ca-40ee-9e9c-213a6f336c2d" xlink:href="cdtx-20231231.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_61e98c08-0e4d-441d-8ab2-717a9b14decd" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_2d9bda6e-26ca-40ee-9e9c-213a6f336c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b502c7c-48eb-4e6e-9d4c-f2b597637788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_us-gaap_AwardTypeAxis_0b502c7c-48eb-4e6e-9d4c-f2b597637788" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b502c7c-48eb-4e6e-9d4c-f2b597637788_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0b502c7c-48eb-4e6e-9d4c-f2b597637788" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b502c7c-48eb-4e6e-9d4c-f2b597637788_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0b502c7c-48eb-4e6e-9d4c-f2b597637788" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bd7af3a6-505a-44f3-a162-87da182a6cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:to="loc_us-gaap_EmployeeStockMember_bd7af3a6-505a-44f3-a162-87da182a6cf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_a33e8d52-1736-4ebe-8a84-d8b85e0d6fb5" xlink:href="cdtx-20231231.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_a33e8d52-1736-4ebe-8a84-d8b85e0d6fb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a0ba4c4a-8f3a-4f38-a352-0ff42b478e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a0ba4c4a-8f3a-4f38-a352-0ff42b478e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_72fac9c1-80d0-4c50-a0aa-a1faf037122d" xlink:href="cdtx-20231231.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_72fac9c1-80d0-4c50-a0aa-a1faf037122d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_135f3cdf-d16f-4443-a3bc-f8f0f925e650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_135f3cdf-d16f-4443-a3bc-f8f0f925e650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e2d369d5-5239-4e34-80ad-5685be7c66b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e2d369d5-5239-4e34-80ad-5685be7c66b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_70abce16-92f2-482f-ba42-9c8c850ad9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_70abce16-92f2-482f-ba42-9c8c850ad9a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_bae1c7ff-f568-4371-b10d-19b82761dea2" xlink:href="cdtx-20231231.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_bae1c7ff-f568-4371-b10d-19b82761dea2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43abe4aa-321a-4134-abcb-b7c7e0a6e459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43abe4aa-321a-4134-abcb-b7c7e0a6e459" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1337708e-c456-4c75-89c8-ab2bbd973a40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1337708e-c456-4c75-89c8-ab2bbd973a40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9063460c-89ce-4233-9c86-0b36c48ed632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9063460c-89ce-4233-9c86-0b36c48ed632" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ecdfd77-007e-4398-a664-c86c733f9b19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ecdfd77-007e-4398-a664-c86c733f9b19" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bced4cf7-54c3-44b1-b138-1cc56271b93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bced4cf7-54c3-44b1-b138-1cc56271b93e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_69c716df-59f9-465a-abb0-14e6fa529f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_69c716df-59f9-465a-abb0-14e6fa529f42" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e73b12e9-6c93-45a4-836c-f179eb5c632b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e73b12e9-6c93-45a4-836c-f179eb5c632b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_284a6c94-809b-41b9-a689-ddf2b1af8357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_284a6c94-809b-41b9-a689-ddf2b1af8357" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4817629d-8e28-4195-9a26-9fe14bfb8824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4817629d-8e28-4195-9a26-9fe14bfb8824" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80da6893-9c8b-4613-a8d4-90720366d26b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80da6893-9c8b-4613-a8d4-90720366d26b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_03e9f70e-9f7d-4164-8442-535ef7ff1b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80da6893-9c8b-4613-a8d4-90720366d26b" xlink:to="loc_us-gaap_AwardTypeAxis_03e9f70e-9f7d-4164-8442-535ef7ff1b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03e9f70e-9f7d-4164-8442-535ef7ff1b21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_03e9f70e-9f7d-4164-8442-535ef7ff1b21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_03e9f70e-9f7d-4164-8442-535ef7ff1b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dbc25bd-0da5-48a2-9689-588166652837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_03e9f70e-9f7d-4164-8442-535ef7ff1b21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dbc25bd-0da5-48a2-9689-588166652837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_15fbc8e0-fc3c-4b45-9b5d-e174e2ab95de" xlink:href="cdtx-20231231.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dbc25bd-0da5-48a2-9689-588166652837" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_15fbc8e0-fc3c-4b45-9b5d-e174e2ab95de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c26e7f37-b7c9-4bea-8187-558024584f26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c26e7f37-b7c9-4bea-8187-558024584f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24fd675a-251d-48c4-a387-3b3f0954dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24fd675a-251d-48c4-a387-3b3f0954dc67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9e8bee25-be8b-46f7-8087-bbe211aabc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9e8bee25-be8b-46f7-8087-bbe211aabc1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9386b18c-e6e2-4220-be1a-c5c3072df7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9386b18c-e6e2-4220-be1a-c5c3072df7ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2561dda5-92ae-4192-a566-c6413bb9859f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ec49755-5501-4c41-899a-7f26eafe15cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ec49755-5501-4c41-899a-7f26eafe15cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25b3b8bf-8dfe-4537-8d58-00a417395f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25b3b8bf-8dfe-4537-8d58-00a417395f48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e44e9fa7-cb48-49d8-8389-114893416846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e44e9fa7-cb48-49d8-8389-114893416846" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46bbc75f-7667-452c-a1e4-8ab89a2d1380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46bbc75f-7667-452c-a1e4-8ab89a2d1380" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c53556d9-8087-47d7-97a1-199089d51395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0d228e75-50d6-40f7-84ed-dac5ed1d7d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:to="loc_us-gaap_PlanNameAxis_0d228e75-50d6-40f7-84ed-dac5ed1d7d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0d228e75-50d6-40f7-84ed-dac5ed1d7d12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0d228e75-50d6-40f7-84ed-dac5ed1d7d12" xlink:to="loc_us-gaap_PlanNameDomain_0d228e75-50d6-40f7-84ed-dac5ed1d7d12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0d228e75-50d6-40f7-84ed-dac5ed1d7d12" xlink:to="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b5b0f2f4-bf39-4ce2-ae11-208155de28ff" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:to="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b5b0f2f4-bf39-4ce2-ae11-208155de28ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1fcbd425-73c3-4eea-b1c8-d0cd29c9e0e9" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1fcbd425-73c3-4eea-b1c8-d0cd29c9e0e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5fd3a030-ece0-485d-9775-a20d85a8c36c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:to="loc_srt_RangeAxis_5fd3a030-ece0-485d-9775-a20d85a8c36c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fd3a030-ece0-485d-9775-a20d85a8c36c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5fd3a030-ece0-485d-9775-a20d85a8c36c" xlink:to="loc_srt_RangeMember_5fd3a030-ece0-485d-9775-a20d85a8c36c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5fd3a030-ece0-485d-9775-a20d85a8c36c" xlink:to="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a2703f5-9a60-403a-b807-7d941e088e33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:to="loc_srt_MinimumMember_6a2703f5-9a60-403a-b807-7d941e088e33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_35aec709-f0ed-44c3-a78b-d3b58d3be94a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:to="loc_srt_MaximumMember_35aec709-f0ed-44c3-a78b-d3b58d3be94a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b131fdaa-6c45-4885-93ce-48bf53545c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b131fdaa-6c45-4885-93ce-48bf53545c8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8988dc39-f934-4c1e-bd9d-29c3ee632dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8988dc39-f934-4c1e-bd9d-29c3ee632dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4610ae4e-8c99-4ab6-a5e8-11574f677548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4610ae4e-8c99-4ab6-a5e8-11574f677548" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_748c6619-563a-43e6-83e5-5c4eb774223a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_748c6619-563a-43e6-83e5-5c4eb774223a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9c549011-d6d6-48c0-ba5e-b727909232a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9c549011-d6d6-48c0-ba5e-b727909232a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c9c4eae-5066-49c5-b78e-2a729f6371aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c9c4eae-5066-49c5-b78e-2a729f6371aa" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8346357a-84ab-472e-bb38-8a3b66e05584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f20b9950-93d3-46b2-901c-3bfe9ee51070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8346357a-84ab-472e-bb38-8a3b66e05584" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f20b9950-93d3-46b2-901c-3bfe9ee51070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51b64c7e-eeca-4295-aaae-5a8006bf7786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f20b9950-93d3-46b2-901c-3bfe9ee51070" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51b64c7e-eeca-4295-aaae-5a8006bf7786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51b64c7e-eeca-4295-aaae-5a8006bf7786_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51b64c7e-eeca-4295-aaae-5a8006bf7786" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51b64c7e-eeca-4295-aaae-5a8006bf7786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51b64c7e-eeca-4295-aaae-5a8006bf7786" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cde133f1-aaf0-4461-9b90-5ed579adf1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cde133f1-aaf0-4461-9b90-5ed579adf1ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0168f14f-f969-4077-9cb8-6a7160691be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0168f14f-f969-4077-9cb8-6a7160691be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2f7b3b3-6786-45da-a51a-694fec760994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8346357a-84ab-472e-bb38-8a3b66e05584" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2f7b3b3-6786-45da-a51a-694fec760994" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d84fb28a-4ccb-4dcb-941b-9b5d7e459551_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d84fb28a-4ccb-4dcb-941b-9b5d7e459551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_3e4abfb6-0ba4-444a-ae47-a1f8a11097e2" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_3e4abfb6-0ba4-444a-ae47-a1f8a11097e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_15cfb0bd-23e6-4050-937a-bc854bb5e838" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_15cfb0bd-23e6-4050-937a-bc854bb5e838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_77f46566-d783-4dc4-acac-5723f0d7dc49" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_77f46566-d783-4dc4-acac-5723f0d7dc49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_418ad4b1-0f88-4635-a4a5-9c6358c94f93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:to="loc_us-gaap_RelatedPartyDomain_418ad4b1-0f88-4635-a4a5-9c6358c94f93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:to="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_28abfe6c-8b07-4b3f-b0c3-4cdb0861271f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:to="loc_us-gaap_RelatedPartyMember_28abfe6c-8b07-4b3f-b0c3-4cdb0861271f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d612ed0c-2ee0-49a1-8865-683996638342_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:to="loc_srt_ProductsAndServicesDomain_d612ed0c-2ee0-49a1-8865-683996638342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:to="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_704df7c3-6f98-4134-8af0-43f3e1355036" xlink:href="cdtx-20231231.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_cdtx_MilestoneAchievementMember_704df7c3-6f98-4134-8af0-43f3e1355036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyMember_d2e31b1e-2f7e-4d2b-acba-d48ae428b7c9" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyMember_d2e31b1e-2f7e-4d2b-acba-d48ae428b7c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_61eca6eb-bac9-4252-9452-b5be4f80bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_us-gaap_RoyaltyMember_61eca6eb-bac9-4252-9452-b5be4f80bb7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_53f07a89-cd3f-45f6-a4ad-cef15b6e0198" xlink:href="cdtx-20231231.xsd#cdtx_UpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_UpfrontPaymentMember_53f07a89-cd3f-45f6-a4ad-cef15b6e0198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_aa3f06c7-7e2f-4613-b5e0-63cda6c248ed" xlink:href="cdtx-20231231.xsd#cdtx_RDFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_RDFundingMember_aa3f06c7-7e2f-4613-b5e0-63cda6c248ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_22c5331a-d8c4-4b29-8080-e4a06199de06" xlink:href="cdtx-20231231.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_22c5331a-d8c4-4b29-8080-e4a06199de06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a97523b4-b701-4fcf-8c57-4d6adfc3464c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a97523b4-b701-4fcf-8c57-4d6adfc3464c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef0073e0-0bce-4fd9-a234-c8e7862b966a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:to="loc_us-gaap_SubsequentEventMember_ef0073e0-0bce-4fd9-a234-c8e7862b966a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyMember_4db6d9ad-f0e0-4961-89a1-79f997955103" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyMember_4db6d9ad-f0e0-4961-89a1-79f997955103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_a1d10a15-9209-4cdb-8a84-015748e67060" xlink:href="cdtx-20231231.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:to="loc_cdtx_MilestoneAchievementMember_a1d10a15-9209-4cdb-8a84-015748e67060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0433009f-1d0a-42c2-bebc-8d27d796cd17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0433009f-1d0a-42c2-bebc-8d27d796cd17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_f0a5fd3d-fe3e-4483-9610-4945d403f4c3" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_f0a5fd3d-fe3e-4483-9610-4945d403f4c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_c152277e-efee-4c8a-be95-e811b9aa6e5b" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_c152277e-efee-4c8a-be95-e811b9aa6e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_f7f3bfc0-bfdf-4ddb-a207-7b1e00d71fa0" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_f7f3bfc0-bfdf-4ddb-a207-7b1e00d71fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_a8438a65-b2e1-4e94-b9a6-f64499bdee8b" xlink:href="cdtx-20231231.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_a8438a65-b2e1-4e94-b9a6-f64499bdee8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_405eaa48-3623-4d93-80b4-60c9bd95f653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_405eaa48-3623-4d93-80b4-60c9bd95f653" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_e4dfd309-7755-4025-a313-de6d91ea472e" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_e4dfd309-7755-4025-a313-de6d91ea472e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_5f83724d-04b0-4f55-8724-8b56ace5bbed" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_5f83724d-04b0-4f55-8724-8b56ace5bbed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_0a2926b0-2651-452a-877b-db0a0abe71f4" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_0a2926b0-2651-452a-877b-db0a0abe71f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_474f7b73-82a2-4925-9b81-7eef647e80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostGross_474f7b73-82a2-4925-9b81-7eef647e80e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_bb6bb727-1a55-4a24-9988-183222bdf5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_bb6bb727-1a55-4a24-9988-183222bdf5fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_9f7cd0f4-1141-4903-b577-870ab42e4c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostNet_9f7cd0f4-1141-4903-b577-870ab42e4c67" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_15d83c4b-c7c0-487b-b0ff-0c39c9d1ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_15d83c4b-c7c0-487b-b0ff-0c39c9d1ab22" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5214385b-1367-46ce-971b-ed88a9a28e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5214385b-1367-46ce-971b-ed88a9a28e45" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a5243bac-ad1c-46cf-879a-967f15311e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a5243bac-ad1c-46cf-879a-967f15311e42" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails_1" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails_1"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d84fb28a-4ccb-4dcb-941b-9b5d7e459551_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d84fb28a-4ccb-4dcb-941b-9b5d7e459551_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_3e4abfb6-0ba4-444a-ae47-a1f8a11097e2" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_3e4abfb6-0ba4-444a-ae47-a1f8a11097e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_15cfb0bd-23e6-4050-937a-bc854bb5e838" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_15cfb0bd-23e6-4050-937a-bc854bb5e838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_77f46566-d783-4dc4-acac-5723f0d7dc49" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_77f46566-d783-4dc4-acac-5723f0d7dc49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_418ad4b1-0f88-4635-a4a5-9c6358c94f93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:to="loc_us-gaap_RelatedPartyDomain_418ad4b1-0f88-4635-a4a5-9c6358c94f93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:to="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_28abfe6c-8b07-4b3f-b0c3-4cdb0861271f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:to="loc_us-gaap_RelatedPartyMember_28abfe6c-8b07-4b3f-b0c3-4cdb0861271f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d612ed0c-2ee0-49a1-8865-683996638342_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:to="loc_srt_ProductsAndServicesDomain_d612ed0c-2ee0-49a1-8865-683996638342_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:to="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_704df7c3-6f98-4134-8af0-43f3e1355036" xlink:href="cdtx-20231231.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_cdtx_MilestoneAchievementMember_704df7c3-6f98-4134-8af0-43f3e1355036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyMember_d2e31b1e-2f7e-4d2b-acba-d48ae428b7c9" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyMember_d2e31b1e-2f7e-4d2b-acba-d48ae428b7c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_61eca6eb-bac9-4252-9452-b5be4f80bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_us-gaap_RoyaltyMember_61eca6eb-bac9-4252-9452-b5be4f80bb7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_53f07a89-cd3f-45f6-a4ad-cef15b6e0198" xlink:href="cdtx-20231231.xsd#cdtx_UpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_UpfrontPaymentMember_53f07a89-cd3f-45f6-a4ad-cef15b6e0198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_aa3f06c7-7e2f-4613-b5e0-63cda6c248ed" xlink:href="cdtx-20231231.xsd#cdtx_RDFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_RDFundingMember_aa3f06c7-7e2f-4613-b5e0-63cda6c248ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_22c5331a-d8c4-4b29-8080-e4a06199de06" xlink:href="cdtx-20231231.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_22c5331a-d8c4-4b29-8080-e4a06199de06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a97523b4-b701-4fcf-8c57-4d6adfc3464c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a97523b4-b701-4fcf-8c57-4d6adfc3464c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef0073e0-0bce-4fd9-a234-c8e7862b966a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:to="loc_us-gaap_SubsequentEventMember_ef0073e0-0bce-4fd9-a234-c8e7862b966a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyMember_4db6d9ad-f0e0-4961-89a1-79f997955103" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyMember_4db6d9ad-f0e0-4961-89a1-79f997955103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_a1d10a15-9209-4cdb-8a84-015748e67060" xlink:href="cdtx-20231231.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:to="loc_cdtx_MilestoneAchievementMember_a1d10a15-9209-4cdb-8a84-015748e67060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_f0a5fd3d-fe3e-4483-9610-4945d403f4c3" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_f0a5fd3d-fe3e-4483-9610-4945d403f4c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_c152277e-efee-4c8a-be95-e811b9aa6e5b" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_c152277e-efee-4c8a-be95-e811b9aa6e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_f7f3bfc0-bfdf-4ddb-a207-7b1e00d71fa0" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_f7f3bfc0-bfdf-4ddb-a207-7b1e00d71fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_a8438a65-b2e1-4e94-b9a6-f64499bdee8b" xlink:href="cdtx-20231231.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_a8438a65-b2e1-4e94-b9a6-f64499bdee8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_405eaa48-3623-4d93-80b4-60c9bd95f653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_405eaa48-3623-4d93-80b4-60c9bd95f653" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_e4dfd309-7755-4025-a313-de6d91ea472e" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_e4dfd309-7755-4025-a313-de6d91ea472e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_5f83724d-04b0-4f55-8724-8b56ace5bbed" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_5f83724d-04b0-4f55-8724-8b56ace5bbed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_0a2926b0-2651-452a-877b-db0a0abe71f4" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_0a2926b0-2651-452a-877b-db0a0abe71f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_474f7b73-82a2-4925-9b81-7eef647e80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostGross_474f7b73-82a2-4925-9b81-7eef647e80e6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_bb6bb727-1a55-4a24-9988-183222bdf5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_bb6bb727-1a55-4a24-9988-183222bdf5fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_9f7cd0f4-1141-4903-b577-870ab42e4c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostNet_9f7cd0f4-1141-4903-b577-870ab42e4c67" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_15d83c4b-c7c0-487b-b0ff-0c39c9d1ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_15d83c4b-c7c0-487b-b0ff-0c39c9d1ab22" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5214385b-1367-46ce-971b-ed88a9a28e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5214385b-1367-46ce-971b-ed88a9a28e45" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a5243bac-ad1c-46cf-879a-967f15311e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a5243bac-ad1c-46cf-879a-967f15311e42" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_117c60d2-9ead-4a78-9e02-3e703ac83c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_117c60d2-9ead-4a78-9e02-3e703ac83c89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_117c60d2-9ead-4a78-9e02-3e703ac83c89" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7" xlink:to="loc_us-gaap_RelatedPartyDomain_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_de680f3d-86d6-4045-b032-c0fc47c2918a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7" xlink:to="loc_us-gaap_RelatedPartyDomain_de680f3d-86d6-4045-b032-c0fc47c2918a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_42c7f9b6-00b3-4151-84c8-adccbffb3ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_de680f3d-86d6-4045-b032-c0fc47c2918a" xlink:to="loc_us-gaap_RelatedPartyMember_42c7f9b6-00b3-4151-84c8-adccbffb3ac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_2cee8b83-b72e-45b9-98b5-e39fd6a4c331" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_2cee8b83-b72e-45b9-98b5-e39fd6a4c331" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_b96f331a-b048-4a06-9746-f6a89dfb3ea5" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_b96f331a-b048-4a06-9746-f6a89dfb3ea5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_2d2bbddc-a3fb-4e68-acf2-d4c576d35925" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_2d2bbddc-a3fb-4e68-acf2-d4c576d35925" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_bfec06f0-534c-472b-a7e2-4bb45bf3fa47" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_bfec06f0-534c-472b-a7e2-4bb45bf3fa47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_674acdc0-f05d-421a-b6c1-a39ee5d4f1ef" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3ebdc2cc-d968-4290-a775-6854296cad2c" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3ebdc2cc-d968-4290-a775-6854296cad2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_964e1a3f-3968-4459-ac72-026081b2b75c" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_964e1a3f-3968-4459-ac72-026081b2b75c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_5df455bd-4c2f-426e-9abb-9d47a899f008" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aadda3af-acb3-48df-bac2-a36115e348b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aadda3af-acb3-48df-bac2-a36115e348b5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701e0f68-9078-4875-9645-3f871e2b74a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701e0f68-9078-4875-9645-3f871e2b74a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_701e0f68-9078-4875-9645-3f871e2b74a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701e0f68-9078-4875-9645-3f871e2b74a8" xlink:to="loc_us-gaap_RelatedPartyDomain_701e0f68-9078-4875-9645-3f871e2b74a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d557a1e5-4576-48d5-bede-ec8eadbc6b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701e0f68-9078-4875-9645-3f871e2b74a8" xlink:to="loc_us-gaap_RelatedPartyDomain_d557a1e5-4576-48d5-bede-ec8eadbc6b03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_198d0759-697a-4586-9523-93a42f102f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d557a1e5-4576-48d5-bede-ec8eadbc6b03" xlink:to="loc_us-gaap_RelatedPartyMember_198d0759-697a-4586-9523-93a42f102f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5db1b61e-37f9-40d6-97eb-1cf011739c1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_srt_CounterpartyNameAxis_5db1b61e-37f9-40d6-97eb-1cf011739c1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5db1b61e-37f9-40d6-97eb-1cf011739c1c_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5db1b61e-37f9-40d6-97eb-1cf011739c1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5db1b61e-37f9-40d6-97eb-1cf011739c1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5db1b61e-37f9-40d6-97eb-1cf011739c1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_00f4a40d-c47d-4902-875b-8e5df30dfc13" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_00f4a40d-c47d-4902-875b-8e5df30dfc13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_e462e118-085b-4d07-aa80-5644246f6854" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_e462e118-085b-4d07-aa80-5644246f6854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_f997fa9c-70a8-464b-8bde-cc0a8cf53721" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_f997fa9c-70a8-464b-8bde-cc0a8cf53721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c403690e-ab0f-4150-aea1-c8b7c4505a12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_srt_ProductOrServiceAxis_c403690e-ab0f-4150-aea1-c8b7c4505a12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c403690e-ab0f-4150-aea1-c8b7c4505a12_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c403690e-ab0f-4150-aea1-c8b7c4505a12" xlink:to="loc_srt_ProductsAndServicesDomain_c403690e-ab0f-4150-aea1-c8b7c4505a12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c403690e-ab0f-4150-aea1-c8b7c4505a12" xlink:to="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember_01f5ff1d-43e3-4621-b605-cd0375fbd947" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember_01f5ff1d-43e3-4621-b605-cd0375fbd947" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_8d450413-6b3d-48fd-a3fe-0643a6ef180b" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_8d450413-6b3d-48fd-a3fe-0643a6ef180b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalDrugSupplyMember_5917b976-42cc-4ff2-aff4-f6943b23bde0" xlink:href="cdtx-20231231.xsd#cdtx_ClinicalDrugSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_ClinicalDrugSupplyMember_5917b976-42cc-4ff2-aff4-f6943b23bde0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_3843f246-c8e0-44ec-be7d-fd0ca577720a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_us-gaap_RoyaltyMember_3843f246-c8e0-44ec-be7d-fd0ca577720a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_4dae4fdd-5435-4a6c-937c-e989bd72bddb" xlink:href="cdtx-20231231.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_4dae4fdd-5435-4a6c-937c-e989bd72bddb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_8690e6a2-c3d5-4232-8854-e35c57b50718" xlink:href="cdtx-20231231.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_8690e6a2-c3d5-4232-8854-e35c57b50718" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_2d67862f-1b52-46f8-a667-a78b9bce6c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_2d67862f-1b52-46f8-a667-a78b9bce6c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_253799a8-1bbb-4a22-b6c7-b2261eece64c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:to="loc_us-gaap_TransferredOverTimeMember_253799a8-1bbb-4a22-b6c7-b2261eece64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_256b43df-55ee-4758-ba27-321a7bc7a9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_256b43df-55ee-4758-ba27-321a7bc7a9e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_256b43df-55ee-4758-ba27-321a7bc7a9e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_256b43df-55ee-4758-ba27-321a7bc7a9e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_256b43df-55ee-4758-ba27-321a7bc7a9e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0848e8a4-b048-4268-af96-632387edef7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_256b43df-55ee-4758-ba27-321a7bc7a9e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0848e8a4-b048-4268-af96-632387edef7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e7fb5d50-0dca-4ecc-9e77-4ea7af50079f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0848e8a4-b048-4268-af96-632387edef7c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e7fb5d50-0dca-4ecc-9e77-4ea7af50079f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f0234667-9d17-49dc-bbad-65a5cc480eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aadda3af-acb3-48df-bac2-a36115e348b5" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f0234667-9d17-49dc-bbad-65a5cc480eeb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_c4cc8b5b-752b-42ca-ac6f-964525819dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_c4cc8b5b-752b-42ca-ac6f-964525819dc5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7235eadc-aad4-4f9d-aec3-064fa5e27d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_c4cc8b5b-752b-42ca-ac6f-964525819dc5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7235eadc-aad4-4f9d-aec3-064fa5e27d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_7235eadc-aad4-4f9d-aec3-064fa5e27d1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7235eadc-aad4-4f9d-aec3-064fa5e27d1f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_7235eadc-aad4-4f9d-aec3-064fa5e27d1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7235eadc-aad4-4f9d-aec3-064fa5e27d1f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_cdb84e74-d699-4e00-93af-316f39bf00d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:to="loc_us-gaap_DomesticCountryMember_cdb84e74-d699-4e00-93af-316f39bf00d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_790f141a-2e7c-43f7-b90a-11bcb0f7865d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_790f141a-2e7c-43f7-b90a-11bcb0f7865d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NetOperatingLossCarryforwards_d3007e04-3e8f-4ea2-bdc7-ca0685e46310" xlink:href="cdtx-20231231.xsd#cdtx_NetOperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_cdtx_NetOperatingLossCarryforwards_d3007e04-3e8f-4ea2-bdc7-ca0685e46310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a06d38fe-1046-46d6-933f-c5013f53ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a06d38fe-1046-46d6-933f-c5013f53ba9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_79cf4f50-2f37-4080-818e-38afa0d438c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_79cf4f50-2f37-4080-818e-38afa0d438c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e0c56077-81a1-4106-94a5-45399f0b1b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e0c56077-81a1-4106-94a5-45399f0b1b56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_adc8f91f-d914-48b6-8830-23fb25a2e582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_adc8f91f-d914-48b6-8830-23fb25a2e582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d92dc85d-14ac-47be-91bd-ac021fa89141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d92dc85d-14ac-47be-91bd-ac021fa89141" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dce8afed-92cc-4d9e-8f65-5b5b3c8e2fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dce8afed-92cc-4d9e-8f65-5b5b3c8e2fa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ebd4e8d-d15c-4723-8a85-c24d21334f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dce8afed-92cc-4d9e-8f65-5b5b3c8e2fa1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ebd4e8d-d15c-4723-8a85-c24d21334f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ebd4e8d-d15c-4723-8a85-c24d21334f34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ebd4e8d-d15c-4723-8a85-c24d21334f34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ebd4e8d-d15c-4723-8a85-c24d21334f34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f8d0db5-abfa-4ec7-9f92-1ffb9ab3686d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ebd4e8d-d15c-4723-8a85-c24d21334f34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f8d0db5-abfa-4ec7-9f92-1ffb9ab3686d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_60e76b73-82fd-47f5-ba7b-468432c7d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f8d0db5-abfa-4ec7-9f92-1ffb9ab3686d" xlink:to="loc_us-gaap_EquipmentMember_60e76b73-82fd-47f5-ba7b-468432c7d24d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_85025aaf-8760-4284-9996-0fbec14debba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_85025aaf-8760-4284-9996-0fbec14debba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseMonthlyRate_c6e5dd90-53df-4c2b-9554-0ddbd3c82f9e" xlink:href="cdtx-20231231.xsd#cdtx_LesseeFinanceLeaseMonthlyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_cdtx_LesseeFinanceLeaseMonthlyRate_c6e5dd90-53df-4c2b-9554-0ddbd3c82f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_454e4fd7-a290-4a0c-8e3d-f2c770313139" xlink:href="cdtx-20231231.xsd#cdtx_LesseeFinanceLeaseOptionPurchaseEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_454e4fd7-a290-4a0c-8e3d-f2c770313139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ccc3e10f-b3d7-48d6-94f9-f31288b899f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ccc3e10f-b3d7-48d6-94f9-f31288b899f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate_ce76f69a-f6fc-49d8-b943-39f60356215c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_LesseeFinanceLeaseDiscountRate_ce76f69a-f6fc-49d8-b943-39f60356215c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_3ceaed02-29fa-42d9-b4a0-0d6d8ee9fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_3ceaed02-29fa-42d9-b4a0-0d6d8ee9fb97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e8db056a-cd5e-49ec-a53e-f0679e4eb7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e8db056a-cd5e-49ec-a53e-f0679e4eb7c8" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_174b6e0f-4c37-4667-ac85-174a8bf4abb5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:to="loc_srt_RestatementAxis_174b6e0f-4c37-4667-ac85-174a8bf4abb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_174b6e0f-4c37-4667-ac85-174a8bf4abb5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_174b6e0f-4c37-4667-ac85-174a8bf4abb5" xlink:to="loc_srt_RestatementDomain_174b6e0f-4c37-4667-ac85-174a8bf4abb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_174b6e0f-4c37-4667-ac85-174a8bf4abb5" xlink:to="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1e7e5c91-b5b3-47a9-a36e-b159045f107b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1e7e5c91-b5b3-47a9-a36e-b159045f107b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_a54cfd45-0051-4eaa-8016-5e2130021474" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_a54cfd45-0051-4eaa-8016-5e2130021474" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e8cad943-1c6d-4646-962e-6f2f1aa78a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e8cad943-1c6d-4646-962e-6f2f1aa78a34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e8cad943-1c6d-4646-962e-6f2f1aa78a34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e8cad943-1c6d-4646-962e-6f2f1aa78a34" xlink:to="loc_us-gaap_ClassOfStockDomain_e8cad943-1c6d-4646-962e-6f2f1aa78a34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_60804fd4-a0ac-4905-9f17-f49a2396e5df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e8cad943-1c6d-4646-962e-6f2f1aa78a34" xlink:to="loc_us-gaap_ClassOfStockDomain_60804fd4-a0ac-4905-9f17-f49a2396e5df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_09ffbb2a-5597-4416-be74-de015097c50f" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_60804fd4-a0ac-4905-9f17-f49a2396e5df" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_09ffbb2a-5597-4416-be74-de015097c50f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:to="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1b870470-5cc1-4088-8369-9ef285d71203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1b870470-5cc1-4088-8369-9ef285d71203" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_adf1ca8a-ce43-4f9d-8326-0d7efae5313e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_RestrictedCash_adf1ca8a-ce43-4f9d-8326-0d7efae5313e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_afe640b0-a88b-45d9-bf9a-0f15da8021a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_afe640b0-a88b-45d9-bf9a-0f15da8021a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0cb639f5-77bf-4698-b84b-936770f70c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_InventoryNet_0cb639f5-77bf-4698-b84b-936770f70c1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_803d5296-bb1a-4df1-9b9f-b8bfe388f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_803d5296-bb1a-4df1-9b9f-b8bfe388f1f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_255a8db7-c71a-4cd1-abdb-8491ed01c40a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_AssetsCurrent_255a8db7-c71a-4cd1-abdb-8491ed01c40a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cd602c2f-6884-4be0-8781-2f0d562fd6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cd602c2f-6884-4be0-8781-2f0d562fd6c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f5feb09-7512-40fc-b745-09538d24de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f5feb09-7512-40fc-b745-09538d24de1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e92d9aef-9c2f-42ea-8a7b-a3be68a21b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e92d9aef-9c2f-42ea-8a7b-a3be68a21b40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e600ab90-d64b-4e2e-84b3-57d6d4a17ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_Assets_e600ab90-d64b-4e2e-84b3-57d6d4a17ca9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_87b70d6b-2fc0-4128-9ebe-c702baac2725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_AccountsPayableCurrent_87b70d6b-2fc0-4128-9ebe-c702baac2725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bfe3d792-ba8d-4945-b39d-d16061a7aef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bfe3d792-ba8d-4945-b39d-d16061a7aef4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f7b4a31d-42a4-4ef2-9408-d729b3975748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f7b4a31d-42a4-4ef2-9408-d729b3975748" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de680c02-2c92-45f9-b714-e36d1b4da588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de680c02-2c92-45f9-b714-e36d1b4da588" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3efada27-838e-44e4-8c43-31b169c3d2f1" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3efada27-838e-44e4-8c43-31b169c3d2f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57cf93d9-8f8c-4398-a01c-4de132dd4205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57cf93d9-8f8c-4398-a01c-4de132dd4205" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_d7b1f078-684a-4a14-93a5-65d7a5ba258d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_LoansPayableCurrent_d7b1f078-684a-4a14-93a5-65d7a5ba258d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0e3ff0b8-efde-4da0-8276-08230a0df3df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_LiabilitiesCurrent_0e3ff0b8-efde-4da0-8276-08230a0df3df" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_01b5a3e0-dd88-4428-9791-b7dea8e4935d" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_01b5a3e0-dd88-4428-9791-b7dea8e4935d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ebd0cb8-4d42-4769-95ca-5fc3cb868710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ebd0cb8-4d42-4769-95ca-5fc3cb868710" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_06a5abf4-c8ee-4248-a864-bdd844968766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_Liabilities_06a5abf4-c8ee-4248-a864-bdd844968766" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c23bcf28-2e43-40e8-9c6c-f2b65b45c6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c23bcf28-2e43-40e8-9c6c-f2b65b45c6bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_803c5db7-3e4b-403a-9dab-ff065c620025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_PreferredStockValue_803c5db7-3e4b-403a-9dab-ff065c620025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b9822c92-8f34-43d7-8ffa-2a97a382f5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_CommonStockValue_b9822c92-8f34-43d7-8ffa-2a97a382f5a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9e91813a-7095-44f8-929f-2ee6740d1651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9e91813a-7095-44f8-929f-2ee6740d1651" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf8b687b-6297-4daa-8bdf-c7a7861db971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf8b687b-6297-4daa-8bdf-c7a7861db971" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f2a2d803-1159-4c47-9d8e-b642847da917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_StockholdersEquity_f2a2d803-1159-4c47-9d8e-b642847da917" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6815df94-fc21-4bfc-92eb-626ca04907a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6815df94-fc21-4bfc-92eb-626ca04907a8" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1a5149f1-59fc-401e-8709-01a82a3fbcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1a5149f1-59fc-401e-8709-01a82a3fbcbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1a5149f1-59fc-401e-8709-01a82a3fbcbc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4" xlink:to="loc_us-gaap_ClassOfStockDomain_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac9dc439-d1e7-4601-b26c-1e8aa104fc61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4" xlink:to="loc_us-gaap_ClassOfStockDomain_ac9dc439-d1e7-4601-b26c-1e8aa104fc61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_8caf1f7b-75ab-4274-9b65-f38ebf5184d7" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ac9dc439-d1e7-4601-b26c-1e8aa104fc61" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_8caf1f7b-75ab-4274-9b65-f38ebf5184d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11b59dab-79b0-4d85-9254-33652641963b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11b59dab-79b0-4d85-9254-33652641963b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_80da3957-11ec-47ca-b163-a4488b7df71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_80da3957-11ec-47ca-b163-a4488b7df71b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_aca5690f-c8c9-42ae-bbb3-8adbd216c4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockSharesIssued_aca5690f-c8c9-42ae-bbb3-8adbd216c4e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_87d45a20-c23f-4825-ab4b-6b7332a015ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_87d45a20-c23f-4825-ab4b-6b7332a015ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6de8f08a-172e-47e6-a5e1-46d71d3f46eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6de8f08a-172e-47e6-a5e1-46d71d3f46eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c0916c99-90fa-48ee-aa0b-b372d8713dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c0916c99-90fa-48ee-aa0b-b372d8713dbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_edb05cd1-36c8-4a89-9866-7b557fe99e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockSharesIssued_edb05cd1-36c8-4a89-9866-7b557fe99e13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3f98be8b-c3c2-4abb-8d43-1da0c3305f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3f98be8b-c3c2-4abb-8d43-1da0c3305f0c" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_66816351-0731-4062-b1f4-a21c641ef34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_66816351-0731-4062-b1f4-a21c641ef34f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_66816351-0731-4062-b1f4-a21c641ef34f" xlink:to="loc_srt_RestatementAxis_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2" xlink:to="loc_srt_RestatementDomain_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2" xlink:to="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_fb308ef2-d6d4-4a68-96fd-c7c592a5cca0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_fb308ef2-d6d4-4a68-96fd-c7c592a5cca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_e261fb27-8db7-46c2-9391-89916d50081a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_e261fb27-8db7-46c2-9391-89916d50081a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f3a4de6c-d5d7-4f4b-b264-5c627dfdb68d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f3a4de6c-d5d7-4f4b-b264-5c627dfdb68d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46b1ab77-d72a-4277-8976-3c36e92f52f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46b1ab77-d72a-4277-8976-3c36e92f52f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_32dc6d23-4a5c-416b-a965-93be965bffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:to="loc_us-gaap_Revenues_32dc6d23-4a5c-416b-a965-93be965bffa7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_fe5894bc-5acb-4970-ae43-025bf384190a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_fe5894bc-5acb-4970-ae43-025bf384190a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3616ea71-3837-44e9-8061-d1900eae0f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3616ea71-3837-44e9-8061-d1900eae0f8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6f6ad8d7-59c5-4ab2-92c0-882fbaefe760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6f6ad8d7-59c5-4ab2-92c0-882fbaefe760" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0129e0ac-d063-4b10-ab85-83438d495615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_OperatingExpenses_0129e0ac-d063-4b10-ab85-83438d495615" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_92009d39-45af-43af-8e1a-f0d4746b00b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_OperatingIncomeLoss_92009d39-45af-43af-8e1a-f0d4746b00b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dc3132e5-8216-4f10-916a-26ad1dbb9606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dc3132e5-8216-4f10-916a-26ad1dbb9606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3c201ecb-4b82-4cf6-9ccf-7df8e1953496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3c201ecb-4b82-4cf6-9ccf-7df8e1953496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9e8752d-677c-4276-b741-d3b043f91b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9e8752d-677c-4276-b741-d3b043f91b57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5c00524f-2fe9-4892-a62a-d43af575ba68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5c00524f-2fe9-4892-a62a-d43af575ba68" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34559034-a99c-442a-9b76-7d55ff74409a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_NetIncomeLoss_34559034-a99c-442a-9b76-7d55ff74409a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_45ee7c10-dc43-48b5-bb3a-b1a6150a380e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_45ee7c10-dc43-48b5-bb3a-b1a6150a380e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_78e076da-6ac9-4c3e-86c4-575b9d0fc0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_78e076da-6ac9-4c3e-86c4-575b9d0fc0eb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_b01fd97c-debd-40bd-9558-ca1187148f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_b01fd97c-debd-40bd-9558-ca1187148f77" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_898d0a3a-07fb-4b73-ae79-5fb99f10b5de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_898d0a3a-07fb-4b73-ae79-5fb99f10b5de" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9a1ff723-9c38-4790-b058-57ab2701c670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_EarningsPerShareBasic_9a1ff723-9c38-4790-b058-57ab2701c670" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8140ff79-116f-497e-9860-722dacb3f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8140ff79-116f-497e-9860-722dacb3f9c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8357fb16-9623-48e6-84d1-eea50638414d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8357fb16-9623-48e6-84d1-eea50638414d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea036d13-47bf-479d-a76b-3339549c3eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea036d13-47bf-479d-a76b-3339549c3eb0" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bfbf1a07-3599-4b32-89c5-16e1c4ab514b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bfbf1a07-3599-4b32-89c5-16e1c4ab514b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_c3447256-a500-499c-9efd-b5209205ed44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bfbf1a07-3599-4b32-89c5-16e1c4ab514b" xlink:to="loc_srt_RestatementAxis_c3447256-a500-499c-9efd-b5209205ed44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_c3447256-a500-499c-9efd-b5209205ed44_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_c3447256-a500-499c-9efd-b5209205ed44" xlink:to="loc_srt_RestatementDomain_c3447256-a500-499c-9efd-b5209205ed44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_c3447256-a500-499c-9efd-b5209205ed44" xlink:to="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_0be00561-06fc-42a0-9a8c-9fd33369884d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_0be00561-06fc-42a0-9a8c-9fd33369884d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aef984ad-fa96-4987-a425-c16b208aab5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aef984ad-fa96-4987-a425-c16b208aab5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d415e6d-dc6d-4665-a1b2-0b11958b6b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:to="loc_us-gaap_NetIncomeLoss_9d415e6d-dc6d-4665-a1b2-0b11958b6b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_32326aea-695a-4bbd-99ac-411afcc457a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_ShareBasedCompensation_32326aea-695a-4bbd-99ac-411afcc457a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_db75f8b2-ad02-42cd-bb17-f5b8569afaf9" xlink:href="cdtx-20231231.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_db75f8b2-ad02-42cd-bb17-f5b8569afaf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a2557244-52e8-4f5a-b43c-cbed195586b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_DepreciationAndAmortization_a2557244-52e8-4f5a-b43c-cbed195586b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_4fb5b176-a678-4668-a8c5-931b7f98a4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_4fb5b176-a678-4668-a8c5-931b7f98a4cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_d104de3a-adfa-4753-826f-98fc284540ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_PaidInKindInterest_d104de3a-adfa-4753-826f-98fc284540ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27814557-9aec-46b5-b56d-f43593d0b9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27814557-9aec-46b5-b56d-f43593d0b9d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_249d0a5c-0a06-4496-a2ff-8aaab6f13d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_249d0a5c-0a06-4496-a2ff-8aaab6f13d5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4abb4db6-4099-4015-86b8-39ee9ff3d742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4abb4db6-4099-4015-86b8-39ee9ff3d742" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f976ffac-5b87-422b-8fbb-73d7982d41b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f976ffac-5b87-422b-8fbb-73d7982d41b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccruedIndirectTaxLiabilities_92743ca0-4806-458c-adc9-f1132806199e" xlink:href="cdtx-20231231.xsd#cdtx_AccruedIndirectTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_cdtx_AccruedIndirectTaxLiabilities_92743ca0-4806-458c-adc9-f1132806199e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8c6b9508-8a24-465c-aa1c-e99b13ec5386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8c6b9508-8a24-465c-aa1c-e99b13ec5386" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_91ff35e3-52c0-4ef5-902c-068c4cff1d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_91ff35e3-52c0-4ef5-902c-068c4cff1d8c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e0bf32c-eaad-4b73-a447-5da04604b819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e0bf32c-eaad-4b73-a447-5da04604b819" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30fdb008-13b6-46f9-8374-4260a259a5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30fdb008-13b6-46f9-8374-4260a259a5eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_909681ae-8de6-4d98-8c26-270af8ac6cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_909681ae-8de6-4d98-8c26-270af8ac6cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aad6708a-40f8-432a-b165-ede66c686553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aad6708a-40f8-432a-b165-ede66c686553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b44b8801-b870-470d-9bd7-d1f9db1c2cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b44b8801-b870-470d-9bd7-d1f9db1c2cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_dafc9980-cb07-456c-9027-015d1cb12411" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_dafc9980-cb07-456c-9027-015d1cb12411" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ea3739b6-130d-494a-a081-22cc9e373a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ea3739b6-130d-494a-a081-22cc9e373a4c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7cd9fa8-0658-45cd-b65a-30f57fc9bd13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7cd9fa8-0658-45cd-b65a-30f57fc9bd13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d6d1a470-5b3f-402e-9828-8a4312691785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d6d1a470-5b3f-402e-9828-8a4312691785" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bbc6c86f-efb2-4b5c-b9fd-e0998fcbc723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bbc6c86f-efb2-4b5c-b9fd-e0998fcbc723" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2354ca4-e9d7-46fd-a36f-cb7c54520add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2354ca4-e9d7-46fd-a36f-cb7c54520add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b56e7de9-e25f-42aa-b782-5250903791f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b56e7de9-e25f-42aa-b782-5250903791f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45c4e1a0-ea16-4073-883b-14e1f59c464b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2ae08e22-bfa4-48ea-b420-4d7cec0a3b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:to="loc_us-gaap_InterestPaidNet_2ae08e22-bfa4-48ea-b420-4d7cec0a3b64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_80a1d3f4-98a8-4602-a579-b3bced3a1837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_80a1d3f4-98a8-4602-a579-b3bced3a1837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8aec5938-de90-4504-92d7-6c727c3f63ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8aec5938-de90-4504-92d7-6c727c3f63ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8635525b-1dff-41f4-9ed1-19f996adb48a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8635525b-1dff-41f4-9ed1-19f996adb48a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a604458-0082-4d60-802b-ab4d5842e55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a604458-0082-4d60-802b-ab4d5842e55e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet_c91a31da-0f87-440b-94f5-d009f6796179" xlink:href="cdtx-20231231.xsd#cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:to="loc_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet_c91a31da-0f87-440b-94f5-d009f6796179" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_0da02af8-6636-4d98-8707-fb06f934fb2b" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:to="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_0da02af8-6636-4d98-8707-fb06f934fb2b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d42046f3-7b35-4d6a-8556-9aa58770af52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d42046f3-7b35-4d6a-8556-9aa58770af52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d42046f3-7b35-4d6a-8556-9aa58770af52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d42046f3-7b35-4d6a-8556-9aa58770af52" xlink:to="loc_us-gaap_EquityComponentDomain_d42046f3-7b35-4d6a-8556-9aa58770af52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d42046f3-7b35-4d6a-8556-9aa58770af52" xlink:to="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_696b1475-45fb-42c6-af53-64efd7dfc95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_696b1475-45fb-42c6-af53-64efd7dfc95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a6bf6e77-cae6-4163-b695-1bc9f5befba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_RetainedEarningsMember_a6bf6e77-cae6-4163-b695-1bc9f5befba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d7a275d0-4a6c-466f-a3dd-c6ba6026b2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_PreferredStockMember_d7a275d0-4a6c-466f-a3dd-c6ba6026b2f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_88b6a3ef-4380-4994-9a11-d626b8b38204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_CommonStockMember_88b6a3ef-4380-4994-9a11-d626b8b38204" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c30ca84d-8749-432e-b02d-c4790fdb16c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c30ca84d-8749-432e-b02d-c4790fdb16c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c30ca84d-8749-432e-b02d-c4790fdb16c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c30ca84d-8749-432e-b02d-c4790fdb16c4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c30ca84d-8749-432e-b02d-c4790fdb16c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c30ca84d-8749-432e-b02d-c4790fdb16c4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnderwrittenPublicOfferingMember_6ecbd6ac-6a20-4c5d-8186-1fa2e5a6c869" xlink:href="cdtx-20231231.xsd#cdtx_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:to="loc_cdtx_UnderwrittenPublicOfferingMember_6ecbd6ac-6a20-4c5d-8186-1fa2e5a6c869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicOfferingMember_c4307d8a-2081-448b-9df1-8ac7c3553e1f" xlink:href="cdtx-20231231.xsd#cdtx_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:to="loc_cdtx_PublicOfferingMember_c4307d8a-2081-448b-9df1-8ac7c3553e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f7875f18-6b2d-4435-92e0-1f480498a66b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f7875f18-6b2d-4435-92e0-1f480498a66b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f7875f18-6b2d-4435-92e0-1f480498a66b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f7875f18-6b2d-4435-92e0-1f480498a66b" xlink:to="loc_us-gaap_ClassOfStockDomain_f7875f18-6b2d-4435-92e0-1f480498a66b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e5ff1204-1422-4bfd-9fca-e9fa94a02b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f7875f18-6b2d-4435-92e0-1f480498a66b" xlink:to="loc_us-gaap_ClassOfStockDomain_e5ff1204-1422-4bfd-9fca-e9fa94a02b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_f46dd436-25da-4140-b9ae-858456ff1555" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e5ff1204-1422-4bfd-9fca-e9fa94a02b0a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_f46dd436-25da-4140-b9ae-858456ff1555" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4c9b0c31-1463-480f-97f2-eed61fb20aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4c9b0c31-1463-480f-97f2-eed61fb20aa5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e87a9b2-1edd-48d8-9a8d-bd55bf117e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockholdersEquity_0e87a9b2-1edd-48d8-9a8d-bd55bf117e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bbb5e2ec-9140-4f1c-b0f4-1975f54a4661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bbb5e2ec-9140-4f1c-b0f4-1975f54a4661" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_623a61a5-a9bf-46f0-8929-ffaf29e82854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_623a61a5-a9bf-46f0-8929-ffaf29e82854" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c2e13153-8114-45b9-a0cb-c7ca16888dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c2e13153-8114-45b9-a0cb-c7ca16888dec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa396717-3471-4328-89d6-997a6c3b7115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa396717-3471-4328-89d6-997a6c3b7115" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_45a5b185-4ba1-4d40-9eee-727e2bf66897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_45a5b185-4ba1-4d40-9eee-727e2bf66897" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69cb4c1d-8c78-483c-82c9-9b2aea86861a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69cb4c1d-8c78-483c-82c9-9b2aea86861a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4ac085da-3959-42be-ad96-641f106a753d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4ac085da-3959-42be-ad96-641f106a753d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1c175e6d-eb11-4ec0-8cfa-4faabd565460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1c175e6d-eb11-4ec0-8cfa-4faabd565460" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50b49a7c-530e-4fab-a13e-881f4669f537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50b49a7c-530e-4fab-a13e-881f4669f537" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f14d1b20-caff-49da-9d6d-8c2c187e3939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_NetIncomeLoss_f14d1b20-caff-49da-9d6d-8c2c187e3939" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_46f831df-7e2e-47c0-9377-08c99ba78f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07e2cfbf-a11b-4a8e-b855-2f1f6360bb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2e51af87-50b4-47bf-bf8d-43bcf7b5aa62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7a1c4aa4-e008-4554-9fc9-11a02f0297cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7a1c4aa4-e008-4554-9fc9-11a02f0297cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7a1c4aa4-e008-4554-9fc9-11a02f0297cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7a1c4aa4-e008-4554-9fc9-11a02f0297cc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7a1c4aa4-e008-4554-9fc9-11a02f0297cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93080dd9-3ba4-472d-8871-08fdf5689efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7a1c4aa4-e008-4554-9fc9-11a02f0297cc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93080dd9-3ba4-472d-8871-08fdf5689efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8b4bc0f7-7b49-465d-affd-a4552d89660c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93080dd9-3ba4-472d-8871-08fdf5689efb" xlink:to="loc_us-gaap_SubsequentEventMember_8b4bc0f7-7b49-465d-affd-a4552d89660c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c36afa26-8970-42b4-ad1e-db84e594ce03" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:to="loc_srt_StatementScenarioAxis_c36afa26-8970-42b4-ad1e-db84e594ce03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c36afa26-8970-42b4-ad1e-db84e594ce03_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c36afa26-8970-42b4-ad1e-db84e594ce03" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c36afa26-8970-42b4-ad1e-db84e594ce03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f253ce01-e540-424e-82c3-f645f1b7d73a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c36afa26-8970-42b4-ad1e-db84e594ce03" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f253ce01-e540-424e-82c3-f645f1b7d73a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_eb3f804f-45d1-43d5-82a9-8e1278ac4046" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f253ce01-e540-424e-82c3-f645f1b7d73a" xlink:to="loc_srt_ProFormaMember_eb3f804f-45d1-43d5-82a9-8e1278ac4046" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce0b96a-0c00-47cb-9823-9bad57bd70dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce0b96a-0c00-47cb-9823-9bad57bd70dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6f8bddbc-6f66-459b-a8fb-d017522393f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6f8bddbc-6f66-459b-a8fb-d017522393f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cb09a73b-7eea-4aec-b598-fe0a113e335f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_CommonStockSharesIssued_cb09a73b-7eea-4aec-b598-fe0a113e335f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bc5195d0-38d9-4ed6-a2e4-8b5917280b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bc5195d0-38d9-4ed6-a2e4-8b5917280b09" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8c62e1d7-3a3b-4dc1-a8d2-f8360c48a548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8c62e1d7-3a3b-4dc1-a8d2-f8360c48a548" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c0d49c-0a5b-4ba8-a6e5-64aaffea40e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c0d49c-0a5b-4ba8-a6e5-64aaffea40e6" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_109fe2c1-af35-4ac0-9736-4d3766a0dde9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_SubsequentEventTable_109fe2c1-af35-4ac0-9736-4d3766a0dde9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fe61a786-28aa-4d40-b968-beb25469a99e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_109fe2c1-af35-4ac0-9736-4d3766a0dde9" xlink:to="loc_srt_StatementScenarioAxis_fe61a786-28aa-4d40-b968-beb25469a99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fe61a786-28aa-4d40-b968-beb25469a99e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_fe61a786-28aa-4d40-b968-beb25469a99e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fe61a786-28aa-4d40-b968-beb25469a99e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c5171ebc-26dd-40bc-a1e0-2de7adf78c88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_fe61a786-28aa-4d40-b968-beb25469a99e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c5171ebc-26dd-40bc-a1e0-2de7adf78c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_d5ba0645-416b-4be4-9ec2-6851dfb3587f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c5171ebc-26dd-40bc-a1e0-2de7adf78c88" xlink:to="loc_srt_ProFormaMember_d5ba0645-416b-4be4-9ec2-6851dfb3587f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41b54c70-1192-4072-af02-87da0927d04d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_NetIncomeLoss_41b54c70-1192-4072-af02-87da0927d04d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e3ef0ffc-d3f0-4275-b5d9-f01e91290d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e3ef0ffc-d3f0-4275-b5d9-f01e91290d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f085162c-f78d-48ce-8115-6dc0a33c7828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f085162c-f78d-48ce-8115-6dc0a33c7828" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_888e0d42-a4fa-4e78-877f-c5bf9f1c9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_EarningsPerShareBasic_888e0d42-a4fa-4e78-877f-c5bf9f1c9fe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_72d1c6c6-073a-4627-8166-be3b632e6bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_72d1c6c6-073a-4627-8166-be3b632e6bdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0cff69ec-0612-4ea2-a1da-0a96d71eed1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0cff69ec-0612-4ea2-a1da-0a96d71eed1e" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cdtx-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fa590d2e-4039-4000-bdf7-5fb59710602c,g:d0764763-c16c-45c9-82e5-80b88e590043-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cdtx_CommonStockWarrantMember_88ab0ce2-9e66-4e73-8d0c-229e9317943e_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrant</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_label_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_documentation_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember" xlink:href="cdtx-20231231.xsd#cdtx_CommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockWarrantMember" xlink:to="lab_cdtx_CommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_f9b092e0-95c7-4e73-94c7-eee47f72ca77_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_1b1e1cdc-d7c8-4c4d-b1c2-22d1342ce654_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_78dacd2c-3a15-49de-a4f6-f3e0dd988c3a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_63edc0f1-ce8c-4a76-80e6-705e57039440_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_17897fff-4ef0-4be0-91d1-b6b2ac055bd9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_89363510-270b-440d-b66c-08f4fd2a9487_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_28290ed6-a7cc-4d4c-8def-35753f8defff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_800701a2-474d-4540-b799-22982015af6f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term for stock options to be granted (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_3c8b1c61-257f-4044-8139-842ec46d9b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for each preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9f70e6a-7960-4f25-8564-0abaa263718f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_c1955e39-8c0a-45cb-ac9b-826b5fc86e5a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_78844890-4743-4a9a-a43f-561e443355a7_terseLabel_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development, Regulatory, and Commercial Milestones</link:label>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_label_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development, Regulatory, And Commercial Milestones [Member]</link:label>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_documentation_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development, Regulatory, And Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:href="cdtx-20231231.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_29cce865-9011-4a5f-9c64-efa9c06952ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_678e8f9a-48af-4dfc-bbfa-256f215505c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_98997828-d947-442f-baa5-45d4f94a3401_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e759b8b5-a470-47b3-b4e9-27e62513ee2c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8d24917c-b56a-4ad9-b992-a0c93f39927c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_c16f3ce9-69d5-4b1c-9b67-fec5f76cea4b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_05a80898-d4aa-452c-9867-200dd4cd3841_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_06555c9c-a507-4b18-be8d-53ff1634596c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_71479f05-2c8f-49df-82d3-35249ae5bb5c_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_d79917d6-645e-4977-a65f-f4c7a8c31d6c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claims and actions pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_afa19329-f3f6-4b16-aa9d-dfb9b41fd774_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal statutory income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_06397296-b4eb-4082-b705-d20ce986f70f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_857293c7-26d9-4962-9753-20a25f8683f8_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">As Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e795ead7-8258-4903-85eb-d4ff815c8a70_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_db876074-a797-4522-bd1c-7d6d5564044d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_f4783761-8218-424e-a89f-fff778bcdba7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4bf6033d-a247-48fe-92a2-efca0dde4a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from underwritten public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClassOfWarrantOrRightExpired_40b4c7a6-8c8c-43d6-9f6d-c6d33544042a_verboseLabel_en-US" xlink:label="lab_cdtx_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants expired (in shares)</link:label>
    <link:label id="lab_cdtx_ClassOfWarrantOrRightExpired_label_en-US" xlink:label="lab_cdtx_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Expired</link:label>
    <link:label id="lab_cdtx_ClassOfWarrantOrRightExpired_documentation_en-US" xlink:label="lab_cdtx_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExpired" xlink:href="cdtx-20231231.xsd#cdtx_ClassOfWarrantOrRightExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClassOfWarrantOrRightExpired" xlink:to="lab_cdtx_ClassOfWarrantOrRightExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_afae716b-e5a5-40ad-b1a0-cda97906ed26_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_45696fb3-a4f5-46e5-8bc8-f9669f5c76ad_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of term loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_6cfa87ee-20ae-421f-b074-ba45b3ed5281_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangement, excluding revenue from contract with customer, uncredited portion</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer, Uncredited Portion</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer, Uncredited Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_25b51d8a-be53-47bd-926b-3f4fe7ae2b58_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_d16c8158-25c5-4c24-85a3-5828abc66254_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_1c52c2fc-4150-456b-932f-334c391b0b0f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7b3f7573-1ee2-41f8-b5d9-29b7a1fbe573_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">THE COMPANY AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_00c1d50b-6725-42c1-95a2-c3d227f1f2dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_9cdc2212-47c6-437d-8f36-f921ff4797d3_terseLabel_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand fifteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:to="lab_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7fdac803-10cc-4459-948b-4666de76413e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_5ac9e55e-33b4-49d2-a966-b3ecd4e3a442_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for restricted share units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_50be82c0-b8fb-49bb-a4ae-0aead2993fbd_terseLabel_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than 10% of voting power</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_label_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">More Than Ten Percent Voting Rights Classes Of Stock [Member]</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_documentation_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">More than ten percent voting rights classes of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:href="cdtx-20231231.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:to="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a93608d3-7b7d-404b-a101-d278b9552ce1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease and Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_76994070-a713-49f3-9695-1c434495d4b9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_9eab5814-efdb-452a-928e-77d288953496_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_eb2f53f4-84df-43a9-b48b-0952a0c62c6d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, finance lease, discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeFinanceLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_9fc887ab-b8f0-4b97-8e80-ebfbf4705587_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_913bc84c-dbb4-4d40-9615-ff80f1ab900d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8f88704b-480f-4474-b1b9-da596dc70580_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_5a21aa86-dfff-43a8-9b17-0b505714221d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate change</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_853186ae-a724-44d1-be52-a61a75a18030_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_aa395128-ac3c-4b0e-9a3d-b61873144fa5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_70940c89-ca0c-46de-a029-6bdd539d18f8_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Automatic annual increase in shares authorized for issuance in equity incentive plan (as a percent)</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Number Of Shares Authorized For Issuance Percentage</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:href="cdtx-20231231.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8028258e-75fb-4ef4-aa5a-4c576409b260_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts_a694fbd4-83ca-46f2-a742-33cccfc3e7dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized inventory costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Other Capitalized Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f850bb5d-21da-41f1-aabf-53d17cb989b1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss per common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c4fb2b34-5374-4103-a3ce-6412ffc7d180_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1d4c42a0-5fc9-4f10-91fb-e7e1d60f5771_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5877496c-0a45-4cbe-8cef-35e984595cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_bff1575c-acdb-477d-b273-5d27c8674f90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8c58de71-50ac-449f-9813-55a42e36cf7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a0796bae-aace-4a50-8a97-5bddcf52b6b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a1819fea-8bb4-41f2-98e4-5098e54250fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb11362c-4119-4b46-8967-fc6addaee732_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_303bd5e5-2188-4ecc-b605-ca37c7489b4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d12c9d6e-dd70-4f6c-8428-1c2f8916afbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60eb8e27-e5c7-4e37-976b-ef2d6b97e4e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value of employee stock options granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0d729d6a-617f-4249-b0e3-f3fdd816b7ed_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3403471e-1e11-48ea-aa2e-f38bfaaf71b5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_43a8282c-6a1d-4467-8ceb-0cf5d739cbb6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_42616400-e082-4903-8ca2-01537d370c2f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_53a0d0cf-b14b-426f-bc7b-8e32e3528ef5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_a4191061-9acb-4593-8ef0-d7cfe8f177b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_5e7741c5-6cd8-476b-939e-a36f1cc176a5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_444e0360-32e4-41ed-9b1b-70b27d4686d2_terseLabel_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, finance lease, option, purchase equipment</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_label_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Option, Purchase Equipment</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_documentation_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Option, Purchase Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:href="cdtx-20231231.xsd#cdtx_LesseeFinanceLeaseOptionPurchaseEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:to="lab_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_050529e0-bef2-4ef1-97ab-ad9acbf5c3d7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_aa97b8f0-4cb6-4cd3-aec9-b69c6f32ca9f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards available under the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_26ae387e-f26c-4d95-aee9-eaf2bfb27490_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_53b97d91-cbb7-4653-8c3f-00bbd79e3882_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1756e1ac-4c4f-46ef-a6a0-3a584ed7b7b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28e522c2-25c6-4903-9977-3378a49a1cde_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b781b964-f04c-402c-9c03-602ad8704d7c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0e421714-cb07-4bc5-af52-49b8936930d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_6dedd4fb-0a1e-4a3f-9895-b562100e7169_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9522908d-baff-43af-b0cd-8583fdb98449_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_89502c11-a570-4790-89d7-a6b8a85cdacd_terseLabel_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_label_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use, Amortization</link:label>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_documentation_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization" xlink:href="cdtx-20231231.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_OperatingLeaseRightOfUseAmortization" xlink:to="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_47ffe8e6-837f-4d5a-96ba-d15cfba9fdbb_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term contract liabilities</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_5df881d5-89ff-4004-8d8f-e5289fae7d01_verboseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of contract liabilities</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4782e43d-03c9-4c7a-b283-7788b7f90085_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_085d62bc-71e3-4dc3-b1e3-a1a609ead726_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8124657c-3022-4ee8-8e79-0ba0ef00d76e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_45810443-3216-4139-838f-f05658808a8d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_b0e92a7c-8853-4b19-a1f5-303277c487a5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_15067d7f-65aa-4e8b-8827-9a7ae5562040_terseLabel_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical and Clinical Trial Accruals</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:href="cdtx-20231231.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:to="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_27dada2b-6eb3-42ee-aba2-349c698207e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_688a5728-4c6a-41ae-9443-51220ccfd66e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeFinanceLeaseMonthlyRate_768f9d30-3096-4dde-847c-93223f2baf66_terseLabel_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, finance lease, monthly rate</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseMonthlyRate_label_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Monthly Rate</link:label>
    <link:label id="lab_cdtx_LesseeFinanceLeaseMonthlyRate_documentation_en-US" xlink:label="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Monthly Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:href="cdtx-20231231.xsd#cdtx_LesseeFinanceLeaseMonthlyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:to="lab_cdtx_LesseeFinanceLeaseMonthlyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f004d351-a928-44ef-8763-299114261b55_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants weighted average exercise price (USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock_3f424a23-dd5b-47bd-aa91-24347029c8a7_terseLabel_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information For Finance Leases</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock_label_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Finance Lessee [Table Text Block]</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Finance Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock" xlink:href="cdtx-20231231.xsd#cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock" xlink:to="lab_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2c2a2c0c-5664-4184-bb2c-00d089511e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_624d3a1d-8851-4a77-bc4b-02779a210ec1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_215687d5-1186-494d-81d5-83bd11597276_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_acfd375f-9a17-4b90-a960-0125f8723814_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_3bf73c8c-14c3-4e19-b85f-0fde2a367117_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage increase in base rent annual (as a percent)</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:href="cdtx-20231231.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:to="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_JanssenCollaborationAgreementMember_32a19aab-9e81-4ee5-886f-68e73316d3fd_terseLabel_en-US" xlink:label="lab_cdtx_JanssenCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Collaboration Agreement</link:label>
    <link:label id="lab_cdtx_JanssenCollaborationAgreementMember_label_en-US" xlink:label="lab_cdtx_JanssenCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Collaboration Agreement [Member]</link:label>
    <link:label id="lab_cdtx_JanssenCollaborationAgreementMember_documentation_en-US" xlink:label="lab_cdtx_JanssenCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenCollaborationAgreementMember" xlink:href="cdtx-20231231.xsd#cdtx_JanssenCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_JanssenCollaborationAgreementMember" xlink:to="lab_cdtx_JanssenCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_388d6bda-5f6f-471e-8b38-1d7f5563248f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_49134386-58b2-4d4b-9c90-1d81a09d6a4a_terseLabel_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized for future stock awards</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_label_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Authorized Shares For Future Stock Awards [Member]</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_documentation_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Authorized Shares For Future Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:href="cdtx-20231231.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:to="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_261b91c3-7f75-46e9-ac30-4a77accadfc1_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_ef7bbddf-c5e6-48ea-93c3-041a0ad9f0f4_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_967f468b-872e-4a13-b85d-0bff439301d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_616971e2-a4af-433f-a65e-071e1754a28c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received per transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_369a0ba9-a5b0-42fd-981e-281c0e2bc1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6fcec980-f9fa-4422-8eac-d021d9e9ea01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs for underwritten public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_322870c6-808e-47b5-ba9a-90e9cdcd8f9d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_14f64bdd-530b-474d-8097-80252232ef1a_terseLabel_en-US" xlink:label="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</link:label>
    <link:label id="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_label_en-US" xlink:label="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses, Other Current Assets And Other Assets</link:label>
    <link:label id="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_documentation_en-US" xlink:label="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses, Other Current Assets And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" xlink:to="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8a6ba0e3-436c-4021-8810-c66a015b45a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e2533a5-d2b1-4f5b-a665-d22f37120091_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_c3c76be6-a00a-47b0-a41f-73ef6be4ae4c_terseLabel_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units And Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:href="cdtx-20231231.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_840078a5-cda3-4393-b9ef-7c1b8bf05896_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Adjustment</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_22db7b06-92df-49a5-8b2a-03e8380161dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_75e0d5f0-bf4f-42a6-911e-02f3313980bf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_88232274-0c84-4e13-afdc-a73fdbc748f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs for underwritten public offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_46331eb2-5e23-4aa7-b9f3-d9f2631b470a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_b196d8ab-a42e-40ae-ae5d-d26609c95da1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Product Revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_68902081-754e-409b-a2ce-4c92f365d496_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_7d25fc55-a54c-43e6-917b-68c523a784e5_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_e31f25ab-9281-40c8-91bc-15f69beb3224_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount_64320572-b4f2-421d-88c1-6e221954d58f_terseLabel_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired stock awards</link:label>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount_label_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Stock Awards, Amount</link:label>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount_documentation_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Stock Awards, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" xlink:to="lab_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5aa984da-1457-4175-a125-50493f7cd159_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2b8738f7-7db8-4a56-9c1c-2cdca7877129_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ba03f0dc-d8b2-4487-bb56-9852d8dc7c51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a7dc1d0f-3047-49c3-b848-8c7bd72cb472_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_19297546-f3eb-40d2-9351-48f0f36e6562_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_99427128-a6f9-4ada-b7b9-b0acd5c70d3a_terseLabel_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License of Intellectual Property - upon milestones achieved</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_label_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property Upon Milestones Achieved [Member]</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_documentation_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property Upon Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:to="lab_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1b31abc1-c35d-47c1-8009-cf22c2ac63a1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8173e965-11b3-46bb-b342-ebc5dc4711c2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities excluded in the calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bac9a4e9-49eb-4c88-bf97-03c60187c09c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a8642139-1249-4871-9bd1-5a90315853c1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_8ca5b3b2-dfc5-4dc4-932e-55357345df32_terseLabel_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_label_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:to="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_fff6655f-1418-4941-abf1-a76a55ca38fb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing activity:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7e9e4210-3c88-4b43-948d-ac989842c96f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_773e3c8c-15a3-47ef-9e0d-8458ef194462_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_be025bcd-2116-4b78-81d1-27494395847b_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_40b949cf-3429-4880-a921-c9bc3d3a8236_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated unrecognized share-based compensation expense (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6f62c273-93f2-436b-af5d-0bfdfad3f101_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment, included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6df7b2e2-ab69-4ad3-bc7f-2cd17d366d8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_391d3269-ffac-4ed7-ad54-c4715c5100da_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AuditInformationAbstract_label_en-US" xlink:label="lab_cdtx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_cdtx_AuditInformationAbstract_documentation_en-US" xlink:label="lab_cdtx_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuditInformationAbstract" xlink:href="cdtx-20231231.xsd#cdtx_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AuditInformationAbstract" xlink:to="lab_cdtx_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_890b4637-096f-43e8-ac76-a548a100442b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_4bddc3ba-95df-4c99-be73-e186f6cceb0d_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e646337e-7c6d-404d-907d-c377733049dd_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_de6d6189-5e0c-466e-add1-ba3d114e1137_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5e09eba7-66b2-466d-8823-99a15cf00504_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_5a78f1c9-bfcc-419c-8672-e5aad3c0548c_periodStartLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Opening balance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_4dbf8534-1927-4463-88fe-7fe6260bbeb1_periodEndLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Closing balance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_116c5f14-caef-4686-9813-b63ede0bd317_totalLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fa755d3a-fa94-483d-9334-312bf5610253_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1d4fa9f3-de06-4db3-b321-08cb3ac28e91_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f7a19e31-5488-40d2-9e7e-10578a89f66d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_dcb9c96f-641b-422f-b307-746b8abf90dc_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0cc4b750-d2c9-41d8-946b-2e50dbd7f1a0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_975e1e9b-2a72-489e-be50-26424c0e59b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d5b425ac-d905-443e-8349-c3463501485f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_79e9a1e1-f273-42eb-b40c-967ce696396a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount_b7ce8aa2-29d4-430a-b460-31e14ffef82e_terseLabel_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">162m deferred tax asset limitation</link:label>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount_label_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 162M Deferred Tax Asset Limitation, Amount</link:label>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount_documentation_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 162M Deferred Tax Asset Limitation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" xlink:to="lab_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations_1db61c37-10f1-4f9e-a02a-e491105b220b_terseLabel_en-US" xlink:label="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations_label_en-US" xlink:label="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number of Performance Obligations</link:label>
    <link:label id="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:href="cdtx-20231231.xsd#cdtx_CollaborationAgreementNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:to="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5b972578-218d-46b0-b9ca-281dbbe4ae31_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_ca29ad3d-c100-431a-a3d8-59da4db1695b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_37cbacd1-8e44-4d48-a8c9-063fd7a08358_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a25acb2b-c541-417b-8b78-f8a12a9e2d7b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_61fec9e2-09a5-4953-af0f-441db765d6eb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAdjustmentMember_fae47b76-a360-4602-9563-47d38679b4c6_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_628d09bc-8e08-413e-beab-dee9560afcdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_df8a76c3-596b-4929-82e1-da8bb067b04b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f087519d-6c65-4ab8-a9f9-0f835abbbb46_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued and Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3cc0cdda-cd4d-407d-92e9-541b785ea26a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_17d3e88c-ab7f-4c9c-9c6a-2f022989251e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_fca87d3c-0df9-4e3d-b900-420dce621bea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2f2c6187-ab1a-4822-812b-d620799eebbf_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cb134e28-67c4-4cc3-a5b7-f9a6fa4575b7_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d6cb8058-0f44-4a37-a851-c9a9b977330b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_77e669f7-bd3b-4ce0-9e6f-66ef31287e29_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Allocation of earnings to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9cc007b6-ee97-4bd8-becc-3beb4eb54d4f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price (USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NetOperatingLossCarryforwards_98a452b5-d478-49a8-808e-9221a8f53fc4_terseLabel_en-US" xlink:label="lab_cdtx_NetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_cdtx_NetOperatingLossCarryforwards_label_en-US" xlink:label="lab_cdtx_NetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_cdtx_NetOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_cdtx_NetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NetOperatingLossCarryforwards" xlink:href="cdtx-20231231.xsd#cdtx_NetOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NetOperatingLossCarryforwards" xlink:to="lab_cdtx_NetOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_11e8e90f-703a-445f-9032-640f8cc2020c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7db65df4-f446-4fd0-b90e-5d525d3daa26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_a69681b9-678a-4d62-954e-f1080481eabe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_60b8ed46-46ce-4a6b-8d08-329e23775242_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Black-Scholes Option Pricing Model Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_fa0ef351-748e-4984-a4af-79744ddd852c_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, maximum cost share</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:to="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ea11e2b9-8bf3-49aa-92bd-bccc1d25c94d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_654ec883-26e5-48cc-a802-300fc177b1fb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b23ba48b-0a3e-4e20-8f4f-d334746ee15b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8de3abb0-bf72-439d-9040-d77c917e6472_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ae8c1db5-0343-49b5-9d70-2823a64c37e2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_56182047-93a4-4daf-8787-f901c34e760e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SIGNIFICANT AGREEMENTS AND CONTRACTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_75de39aa-c536-484a-8b1b-a3133804254a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4455d641-dec4-46b2-952b-1c7b5292f26a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize unrecognized compensation cost (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_6ce311d7-a975-422b-9802-dbe1b4b47259_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Of Stock By Unique Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6d29c6fc-ca3b-460b-b849-1508cb8547e7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_dbe1b890-7f89-4ce9-ad91-06972cb468e6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ffda403a-de2c-4a37-accd-dc2ef45c4fcc_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_63c1a3f8-3e97-49a5-8f12-fdf5cf1bfbd6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_8e129c59-4d32-435a-80eb-d9f396447f0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve for uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_317e28db-0fde-4692-90cd-07854da360be_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d8699c94-6238-473f-a2bc-66592da8fcd1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9dd40713-8ec6-4bbf-a8f4-1c5f3a6a66b7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_a0cf7f48-40ae-432d-9be8-365651697662_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_bf4ab603-6970-4860-a3e0-db1ca8e41734_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_940502be-4aa9-4cfb-8be9-bac14b97c9c1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_47a2c79f-e5f7-486e-a128-578260f1785f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_16c751a5-e24a-4df1-9bf8-594afcfa5491_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EQUITY INCENTIVE PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_fb5fca6e-c4fc-4b2d-9c5b-62c972ee9690_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contract liabilities</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_58070e10-ed07-4be0-9c74-9c77f1aa2a8f_verboseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_fd46ccc0-5e26-453d-9d4c-088d36a41cf9_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_0db7ee73-30f2-4c02-be74-904e5e8bfe5f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized contract cost, net</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6370bafa-e41d-4ede-b952-d23099bc8bba_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d766e739-a822-4b4b-ba11-66904ea0c4e0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a45abbe5-3c1e-4747-bd64-19806a3031f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes_7c6e5bdf-a070-4028-98c6-4763d15cef77_terseLabel_en-US" xlink:label="lab_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued indirect tax liabilities</link:label>
    <link:label id="lab_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes_label_en-US" xlink:label="lab_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals,Taxes Other than Income Taxes</link:label>
    <link:label id="lab_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes_documentation_en-US" xlink:label="lab_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals,Taxes Other than Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" xlink:href="cdtx-20231231.xsd#cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" xlink:to="lab_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_de7653f8-1787-446d-a9ba-776f63222d12_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_41e897c6-bf3f-4ea0-9432-0e69a99c5d79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee payroll deduction under the stock plan (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_30224e4d-f558-48c1-b674-c60cc31109a4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_be1b9d68-9636-4c43-b71e-6aa899baeb6b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_d1a11eaa-7a13-4764-b1a4-291ad9060b9f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f97da1b6-4afa-4d81-b7b5-863e9fc725dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1ad14f47-342b-4d53-956c-b31166e91fdb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_672d3bd1-209e-4299-ac3e-184c6c1a0c48_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_01c9a45e-6e0d-40a5-bf57-85f5b0457c34_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_19286aee-4209-41c7-836a-e15859b3a1ae_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f38bbd6-0a2a-4a79-b78a-044c3e8d17be_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and money market accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_768a1617-08ae-4576-9c14-d1ddb8e8a13d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AccruedIndirectTaxLiabilities_0a3aa01d-c5d3-4879-831c-6dc16eacfc47_terseLabel_en-US" xlink:label="lab_cdtx_AccruedIndirectTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued indirect tax liabilities</link:label>
    <link:label id="lab_cdtx_AccruedIndirectTaxLiabilities_label_en-US" xlink:label="lab_cdtx_AccruedIndirectTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Indirect Tax Liabilities</link:label>
    <link:label id="lab_cdtx_AccruedIndirectTaxLiabilities_documentation_en-US" xlink:label="lab_cdtx_AccruedIndirectTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Indirect Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccruedIndirectTaxLiabilities" xlink:href="cdtx-20231231.xsd#cdtx_AccruedIndirectTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AccruedIndirectTaxLiabilities" xlink:to="lab_cdtx_AccruedIndirectTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_b39a731b-11ee-4d03-8042-a58e6d596151_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, finance lease, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_98ff030a-9cb1-4b96-9204-c2a61f36bfbe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b6a9dd6-3e0f-4ecb-b0ec-9179a91eec2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3946748b-da87-4b64-8b7e-36d23c9afe37_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_da87d737-3d3e-4397-9c27-73f0053d8cc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_79b758d9-c618-41b6-b03b-aef0dd226331_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal income taxes at 21% for 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15ddc3d6-d409-44d8-8596-f192a5dda498_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_788ca37f-9f62-4b02-a274-6af09ce81949_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_5e59991a-ea62-44d1-8416-442369da4c5a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_38417619-6b65-4d3a-a5fe-52269f239c21_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_dc30eefb-6e7f-42ee-810d-2231da0fa231_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of costs to obtain a contract with a customer</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_052bd5f2-e9b5-4c36-a8fd-cd4edc5235a8_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Capitalized contract cost, expense</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_12feb3d2-274b-4eed-8026-16173bff6378_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to extend</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_label_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_documentation_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of operating lease options for extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:href="cdtx-20231231.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:to="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_86edf5b7-7831-4270-bf39-6dc3c7a03f78_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a44010e9-c455-4b12-a87e-1a397083efee_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4dcbe00b-a2c9-4d5a-9553-1e30451aa3b3_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProFormaMember_038d788b-4e74-4f33-8918-151e47c74089_terseLabel_en-US" xlink:label="lab_srt_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pro Forma</link:label>
    <link:label id="lab_srt_ProFormaMember_label_en-US" xlink:label="lab_srt_ProFormaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pro Forma [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProFormaMember" xlink:to="lab_srt_ProFormaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_e9af6870-e903-47f4-8a41-710949865ff0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c7f48f33-cd56-41c6-8dfa-52dbf093210f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6ba77353-08a4-4a01-85df-ccd5edb181d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_f81484f6-7442-4694-9d81-a5d4e7c8f54e_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends in arrears or default</link:label>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_label_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Dividends In Arrears Or Default</link:label>
    <link:label id="lab_cdtx_CommonStockDividendsInArrearsOrDefault_documentation_en-US" xlink:label="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock dividends in arrears or default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:href="cdtx-20231231.xsd#cdtx_CommonStockDividendsInArrearsOrDefault"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:to="lab_cdtx_CommonStockDividendsInArrearsOrDefault" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_b729a497-aba2-45c6-a224-ca29bf47b17f_terseLabel_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration remaining on transaction</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_label_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Remaining on Transaction</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_documentation_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Remaining on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:href="cdtx-20231231.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:to="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b17870f3-466d-4a09-9d8c-32889597cc9a_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1d485f3d-6cb4-4915-99a4-13fe555b0bad_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_eb3a97b5-53c5-46f2-828f-d98d6805faad_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_379bff49-03ea-4255-9599-360ae130ceea_terseLabel_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments related to collaborative agreement</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_label_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_documentation_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:href="cdtx-20231231.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:to="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1556029f-2e08-4527-ac81-25fb39ac983c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b5683dab-712d-40bb-a08a-32e609688799_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowed from the lender</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9722f447-fe09-40fa-9b3d-9fa45dc55c8e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_88c576b9-1ede-44d8-bff9-7afabe319ca0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_06772d87-bf5d-4c47-a039-df6897d8e829_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Net Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_23367fb7-a52a-4dc8-9060-8243ecf74441_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e43edd53-3cda-4e40-87d4-aac93bdfd03e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_ba1cee74-f36a-42d8-94fd-a3d3798bead3_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3d150b36-010f-4f74-b50b-dfff676692e0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_29d264fe-975c-4fe8-8ff5-44facafc9887_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_805f2105-16ee-494c-bfdd-018813d98997_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e9e7a2f5-b6f7-4f92-9ca0-4161b262c07f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ddac37e0-d7ab-4f6e-a9db-9f67bb3eddaa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0ac41fdd-dfa3-4013-a6b2-71afcae3ff24_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b6b7d166-f443-447d-890f-282c381eae2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_f09b359e-5b44-4011-bff3-3f967e5c26f6_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes for each share held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_label_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Votes Entitlement For Each Share Held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_documentation_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of votes entitlement for each share held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:href="cdtx-20231231.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:to="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_df36ef12-f924-481b-b737-fc3ab7feccb5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized contract cost, gross</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_b8aa02a9-8a62-4892-8397-3a7c539aba9a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_01eb6cdc-9b74-42de-a851-5868f66d1278_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UnderwrittenPublicOfferingMember_bd21f10a-4d2a-49b1-b7e6-47fcd47cee37_terseLabel_en-US" xlink:label="lab_cdtx_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_cdtx_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_cdtx_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_cdtx_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_cdtx_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnderwrittenPublicOfferingMember" xlink:href="cdtx-20231231.xsd#cdtx_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UnderwrittenPublicOfferingMember" xlink:to="lab_cdtx_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_665bdc18-8451-49a4-a6a9-d3b1dac9abe7_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion Of Stock Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5b76ba2c-e7b6-40f1-b5a3-e96bb89040fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dc9749a0-4607-43c2-a482-50b8ff1edcd9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e08fdb72-b4a6-41c9-bf47-b62c3071647d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_6cee9aca-6c4c-4dd8-a5c3-cb6964f0613e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease Obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6267f49f-4064-44d9-b7ff-e668bb29b6ed_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2ea7663f-8b23-4a99-9250-88868f52b1c4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3437248f-9882-422f-a455-e339fb2dc7cb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b9c0a55b-123c-4859-9bda-cc72bd3af9eb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_677a0df4-68cb-4d74-8701-e6b1c9a99900_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_bc458a96-b84c-4b72-a886-69f51c82bcb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_53d36118-b791-4c50-9874-731fb73a05f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_3b5f0cbb-1ee3-4b02-a1c1-fc77e9c144d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_e3b6d747-84d7-4e32-be57-888345324258_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_eb099313-2be4-458c-9559-8c2111ed6794_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_753ea8ac-1557-4148-a98b-ddac1c12956f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_678bb8f4-e7af-4929-8a82-bd1be3ad81ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8c59fa44-c96b-40fd-a645-ecfd3ef5d2ca_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_539794ef-d80d-4508-95d5-b2f30039bb60_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_339f50cc-2446-49c3-8545-5ac882d8b500_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current tax provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_46971f93-c94b-4b47-9d32-a7a2acb39b0e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_412856ac-ae99-492e-8438-b1432f1b0a4a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, other current assets, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_207f8638-a9de-4067-bcb5-6cc79607fbad_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1958c5a8-3660-4d83-9f1e-373e7ac37b3e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fd3d6d72-bcbf-40dc-968a-b806ee8d0706_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_5a308dfb-242a-40f9-966b-b58102d6417e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a4f596e4-6eb5-488e-a922-f581df2bbf24_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_96b54a49-d48d-494e-b3fc-f78495a125ce_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_ad424c99-cfb6-4c51-9468-2cc14aa870d5_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, potential transaction value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction, Potential Value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction, Potential Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:to="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_67af9932-4bd3-487b-a14e-30c5e2133ef8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_6b4e963c-809a-4f44-839d-d42380a16058_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_def66122-e8ef-4217-9e22-e756e3c27fcc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_f045f665-76db-4f98-9e7c-9253ec262cd7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_631a2aee-91d8-490f-9549-b038cbe10aaa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized at December&#160;31, 2023 and 2022; 90,601,999 shares issued and outstanding at December&#160;31, 2023; 72,470,440 shares issued and outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_602c27b2-7178-4b72-90b1-3117b2df810f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_ee649c49-ec02-4183-9fa1-6fc3612713d8_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments received in advance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3cddb90-c4ee-4d77-a63c-9e59fe7e7c3c_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_699c1a53-8973-486f-81de-3fee8142213c_terseLabel_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics Inc</link:label>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_label_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics Inc [Member]</link:label>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Melinta Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MelintaTherapeuticsIncMember" xlink:to="lab_cdtx_MelintaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cda48e4a-1ae7-49a5-bda0-23e3ec7d2ee1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8200efd7-0be8-4727-8c5b-ab7c93ee3535_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2517cac6-97f9-457f-b57c-c0813df4a644_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_08661aef-05ea-4562-8aa5-2af5c4d5a926_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_3d21f9ce-e375-4f5f-a57a-2fabf10082af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1d8d9ec3-e883-45b9-9bca-d0138f9907ad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax provision:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_2bb3977c-eda8-423b-8130-599ecbd6d98b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Finance Lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_0c3b4d99-c4d0-40b8-9022-521061672a53_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_88660e9f-4942-41ce-9b3d-bc32d5da93b6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b0cbf38d-5bd1-472f-8daf-384e85d998af_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ecd56a22-a746-43fb-bcf4-009751e79d15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_360ef4fd-5991-454c-81f7-c98778e6f406_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0ea2286d-7242-41ae-9406-e67d588d798d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_374d268c-759b-4405-aa51-8de6bd1fc2f3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7ddd2f2d-f8b0-4e24-96e9-b780690a667d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3a91bd4a-adae-4a30-9677-8561b89ffe5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation Between Federal Statutory and Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fd248a0b-4de8-4dfa-97bd-89d0e6b27bca_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d43273e0-fe56-4f62-b994-01a00d1e005f_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance as of the beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_194a53f2-d589-45ff-8393-0a7028542473_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f4c2a68b-91d7-46a8-8705-93195e7a145b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet_96870fb8-a375-4563-ac23-a0fb61a9c5b7_terseLabel_en-US" xlink:label="lab_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet_label_en-US" xlink:label="lab_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction, Net</link:label>
    <link:label id="lab_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet_documentation_en-US" xlink:label="lab_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" xlink:href="cdtx-20231231.xsd#cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" xlink:to="lab_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70672606-355b-4bd4-a4fb-6d210118b564_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PublicOfferingMember_b8bf9b5a-cc55-4160-9d42-8541c77eaa57_terseLabel_en-US" xlink:label="lab_cdtx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_cdtx_PublicOfferingMember_label_en-US" xlink:label="lab_cdtx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_cdtx_PublicOfferingMember_documentation_en-US" xlink:label="lab_cdtx_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicOfferingMember" xlink:href="cdtx-20231231.xsd#cdtx_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PublicOfferingMember" xlink:to="lab_cdtx_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_fea4fd1d-0ad0-40e2-9677-10555d8338d4_terseLabel_en-US" xlink:label="lab_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 EIP and 2020 IIP</link:label>
    <link:label id="lab_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_02e21f3f-3492-4c58-8ddc-19d42d3b4576_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6467e7cb-4eda-4a97-9f80-25c0a88acc0e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding warrants to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2492e07c-71e2-457b-8119-6d053f3afa45_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_718756f4-8050-4e7c-bb62-b0b167997725_negatedTerseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue from performance obligations satisfied during reporting period</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_91c8052c-ada2-4dcb-bea6-31e096589c49_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3a4232cd-34ae-45f6-aec6-294cccbea105_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs and PRSUs granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_18650b0c-b274-495b-ab80-6e9ae239c4d3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_26116006-fc81-428d-a3e3-331820809771_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ccb322f1-1331-4c79-b09c-930ad97942e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_893d5a85-e46f-4a43-b091-785a76ec2dac_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f74c142a-994a-4f40-803a-497c1f3737d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_44c6c617-5630-48f5-b650-18db370b1997_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_b131d62d-a614-4b57-994d-854d4a69d038_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9200d006-711d-4226-8bc8-f41717e5826b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3d2b2c71-fd16-4d02-8d02-99225a7686d1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4df585be-8f37-4904-8548-afbefe9ac0a0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5a947d53-acab-4236-8252-8462abfb4f84_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_aa03769d-7452-40b8-9c54-4ff47c2cc969_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_b961c511-0b15-478e-af5a-d82f3febc318_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_7d84b28b-fb1b-43e5-a0ad-b996292b5bef_terseLabel_en-US" xlink:label="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indirect Taxes</link:label>
    <link:label id="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Other than Income Taxes, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Taxes Other than Income Taxes, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:href="cdtx-20231231.xsd#cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:to="lab_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_86a93ebe-a499-4426-9f5f-1628a8c97e65_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, option renewal term (in years)</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option Renewal Term</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:href="cdtx-20231231.xsd#cdtx_LesseeOperatingLeaseOptionRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:to="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_5e431575-1202-4fda-8b4b-338b1c909d36_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_91be7176-126a-489d-9a8f-a83ec5470552_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable annual rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_1025a2fd-eedd-4076-8910-ce5cc5851ad7_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ae5d0f0f-a44a-4d6d-be2f-ad5218151c6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ef560a2e-77d6-4e45-ad99-4411c8aef8ac_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_517c9ad5-bb78-43de-b7f0-47ddd45369f9_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, monthly rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:href="cdtx-20231231.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:to="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_a73e17fa-1bdc-41d3-9ea2-820c3321db52_terseLabel_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Supply Services</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_label_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_documentation_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember" xlink:href="cdtx-20231231.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClinicalSupplyServicesMember" xlink:to="lab_cdtx_ClinicalSupplyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_cd3fcafc-93ed-44e3-937b-562e7c248c6e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0d3c0ff0-735a-4041-9083-9abf4f6f2459_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_edecc7ee-4a7e-4196-b207-7697f8006149_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_27d30e4f-9436-47ad-9d8a-b56b99f3a356_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d77f3899-517c-46db-93aa-149b4958a2c8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact on effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7bda3143-d4d5-4b8c-843a-71ee732403c4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7d45984-c2a0-4a1f-8773-87d5cd04163c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_fea4cf96-fefd-4d3e-a887-a5a4ca2b7438_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b20d4931-bc3a-4897-b500-d16e56afe478_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_63848661-a5e7-48bd-9a20-5f4494c7a8d9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_26cd0441-9dc0-484a-8eaa-ed317f37f01c_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_43e5c150-27a6-46f1-bfd2-9909d2324693_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_da383a5a-7ddc-4aeb-9598-318ad174a4c5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4b3c07c2-caf9-48b7-b30c-d2bf54d1a132_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_3a5da425-34d6-41a9-9f14-434387b0c802_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7fe56c8a-c973-4762-8df4-63d3b2788bef_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_227246d2-dce8-4fa5-9637-7cb1ed9e433c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_ad174ec7-d9a5-48c9-83e1-cb7d51180c2c_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization of property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2c3f1b5b-6ce7-48ac-a61d-6442462bd5a4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_593cab6c-6b47-4c00-b9a9-307fd7ced58b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of series X convertible preferred stock in exchange for common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f7afb9d7-1477-4c5a-a54c-8c182938f4fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEVEL 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_d0dd2890-33f7-4948-9d01-553cde9c4afe_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_47cf43ec-a822-42a0-9119-fe62bf00dfca_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_1853566b-d391-4f5c-ae8a-936cec00a6ff_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_90454c52-4f4c-4cc7-ac6c-55c62682327c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_b676e7c2-a327-4911-8875-ccc997e75a6b_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyMember_9c9bc35f-c91d-455d-8599-7166012f2498_terseLabel_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyMember_label_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property [Member]</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyMember_documentation_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyMember" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LicenseOfIntellectualPropertyMember" xlink:to="lab_cdtx_LicenseOfIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_69387051-425f-4cff-890f-3c3ded58ccfd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_66e948fc-1702-4ad2-b4e4-1741bf892fc8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3d559c71-e8b8-440a-a0bb-e50b764545e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_12d2b877-9202-4258-9d62-bd4c77b7041f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_b27a97d4-ab5d-48c0-a26b-84ddd44f554f_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options, RSUs and PRSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_f724187f-e7a4-4ab0-8c16-e9d2d97efbad_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock options, RSUs and PRSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_bc6c3d38-7820-45f2-907d-1c08fd0e4141_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9e53c220-f257-435b-9ab3-8f681ff2ba0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06024346-d3fc-4416-b6d9-1be4b697df02_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6b0f3310-36d3-4fee-b596-0f98f17e4817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_f0c282f0-b62f-455d-8f8d-c6a62554560f_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_47ca7258-f081-48c0-bb0d-6502440c3e3e_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7965862d-f1a9-40e4-8cde-d3dd451889e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_289c4800-c260-43e6-9bb7-6550b1bc15d8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, before Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b73929b7-02fd-41be-b82d-f092e740312f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0300622d-f276-4dae-ae12-485ee74311b1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0389a2b0-f02c-4eb1-a2cc-5845d2a88a14_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_ccbb07a4-4c60-4247-8d6b-77ed36f458be_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b77d1294-af7f-48fb-96cf-9e4eeb65f86c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a5bde277-cedc-442b-bb0c-91dfba4b0808_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_2290c98c-a6bf-488b-ac55-e6ef6e241d59_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Restatement Recovery Analysis</link:label>
    <link:label id="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Restatement Recovery Analysis [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:to="lab_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_91cc543d-051a-4021-ad45-d5ce5fb9ad86_terseLabel_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Services</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_label_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:href="cdtx-20231231.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:to="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_50ad5cc1-7014-4535-b624-503fdba82faf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClinicalDrugSupplyMember_70261bf0-21f5-427b-aefe-fa02c81a47a6_terseLabel_en-US" xlink:label="lab_cdtx_ClinicalDrugSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Drug Supply</link:label>
    <link:label id="lab_cdtx_ClinicalDrugSupplyMember_label_en-US" xlink:label="lab_cdtx_ClinicalDrugSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Drug Supply [Member]</link:label>
    <link:label id="lab_cdtx_ClinicalDrugSupplyMember_documentation_en-US" xlink:label="lab_cdtx_ClinicalDrugSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Drug Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalDrugSupplyMember" xlink:href="cdtx-20231231.xsd#cdtx_ClinicalDrugSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClinicalDrugSupplyMember" xlink:to="lab_cdtx_ClinicalDrugSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cdca459e-33e6-4137-9ffa-95fc9591e727_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_83979915-9ba2-482f-8104-4a633d79d0e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a03c3542-d149-4d96-8a88-d66b405869ff_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_07a14470-9af1-4dc4-bb1c-e8034b54f286_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3f5500eb-4603-40ad-8767-84d91507248b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_0df72820-8d52-48e2-b67a-c8d64fbde6ac_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued indirect tax liabilities</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrual for Taxes Other than Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_25f810af-53e6-4b25-a457-6646e46d78f4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_c6e8e13a-174f-4603-bace-c22c6f1efabe_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, cost sharing percentage (as a percent)</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Cost Sharing Percentage</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Cost Sharing Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:to="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_433cf4fc-2ed2-480e-9ade-25f47732edfa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_1163d783-10cf-433b-98bf-9b4333e6c554_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_17da2f01-322a-4cd3-95c4-e631e711b586_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voting power threshold (as a percent)</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:href="cdtx-20231231.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_4d1001cc-cd3d-4cd2-8ca0-c9131ab1cfd8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DeferredTaxAssetsLeasingArrangements_ace39b73-1d2d-4d7f-a07e-f907baab4ce8_terseLabel_en-US" xlink:label="lab_cdtx_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_cdtx_DeferredTaxAssetsLeasingArrangements_label_en-US" xlink:label="lab_cdtx_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:label id="lab_cdtx_DeferredTaxAssetsLeasingArrangements_documentation_en-US" xlink:label="lab_cdtx_DeferredTaxAssetsLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DeferredTaxAssetsLeasingArrangements" xlink:href="cdtx-20231231.xsd#cdtx_DeferredTaxAssetsLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DeferredTaxAssetsLeasingArrangements" xlink:to="lab_cdtx_DeferredTaxAssetsLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_2f56a7c5-d80e-49d4-96f4-97f44932293b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0cd9eb0e-7d4d-456f-8eb1-45cd73a9701f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_17ccb726-25b6-4c15-9d46-b1ffc99af443_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_41f72512-a7e1-49ee-a4cc-ab02a615de22_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_00559bd4-7544-42b6-9271-9c362fbc4c32_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Allocation of earnings to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9002cbfb-3623-49ef-b5cd-af6bcf2b6f01_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_A2023UnderwrittenPublicOfferingMember_63eaa30f-f4cd-402d-bf9a-ee03ebe8fb6a_terseLabel_en-US" xlink:label="lab_cdtx_A2023UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Underwritten Public Offering</link:label>
    <link:label id="lab_cdtx_A2023UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_cdtx_A2023UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_cdtx_A2023UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_cdtx_A2023UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_A2023UnderwrittenPublicOfferingMember" xlink:href="cdtx-20231231.xsd#cdtx_A2023UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_A2023UnderwrittenPublicOfferingMember" xlink:to="lab_cdtx_A2023UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_57153370-1e10-45f2-9563-9bc98ab61178_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9816be21-4da1-45e6-96c4-c44ef87ce17d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_e5e17125-dced-4684-ac49-f431548c1264_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4b231175-a1c9-4bd2-8e64-18ccfc6be20f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ea9c8e23-3e1b-4e60-b138-c769a8074fc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ffd3e891-9025-4c14-81f0-ed8bcbc39516_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss per common share (USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0ca99070-ef0d-47cb-b7b7-940aa2b84dba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7e66f2b5-537f-4b72-9c8f-43cb872e3b5c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized share-based compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_c4b7fdc1-ba95-4e83-a458-b9d0235715e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_365535b6-366c-454c-a9fb-61310a32a393_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_410d226d-f0e9-47fc-adde-466047dfbcaf_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchase of shares pursuant to Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7d9f8060-e2a0-4fe9-9c82-ee1f5165b7ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f89cbc1c-d2b9-47e6-b739-0b8efd5a0dfc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_d2acb163-5f17-49f7-aad6-ab839e05b73c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_a7b7be81-dc66-4d43-9a0d-74c5d88eeab9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_1b47f197-bedd-45d5-8722-310d32f6c214_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RDFundingMember_464248fc-28fe-4300-a7ce-23c0555450b3_terseLabel_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D Funding</link:label>
    <link:label id="lab_cdtx_RDFundingMember_label_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">R&amp;D Funding [Member]</link:label>
    <link:label id="lab_cdtx_RDFundingMember_documentation_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">R&amp;D Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember" xlink:href="cdtx-20231231.xsd#cdtx_RDFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RDFundingMember" xlink:to="lab_cdtx_RDFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7d44f395-7fab-41f8-82de-ff1b24233c81_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_7db1785d-cc93-471a-bc96-3222e1b5e9bc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5b38d9ca-6bcf-4c06-bd97-caa826bb86ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_fd578c87-9177-48c7-9dfd-a09fed41fbc3_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_b93b26f1-5509-4ac4-8130-0374efb5e432_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit carryforwards, no subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_8f6d9cca-829c-4e53-a365-af99d4a77a32_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_21781672-4fa2-4d23-a617-d8038ac19fcc_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_b0723dda-743b-4f32-9f23-5aef7bb372c7_terseLabel_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum ownership following conversion (as a percent)</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_label_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_documentation_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:href="cdtx-20231231.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:to="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c9b9f0d4-60de-4e35-ab95-a7e3d63df06e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_2e067017-43a1-4384-bfbd-e55953b26179_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_5922c116-2e4b-4653-b39d-be7374f7cb92_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_31902fe6-0929-468c-9dcd-16aeacfe8ade_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_e60a9438-6da9-42bf-85e5-a424ae67a774_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_c0b38fcf-6d52-44f1-b146-75429abcd6aa_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_cf071e96-01ee-4924-ad17-f31635e4bf33_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_fcbad532-4341-4d7c-bd87-6ce747196b17_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7014e594-5a06-4e59-827b-db022ca79109_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_28821c27-537a-479a-a46d-dabcfe7b97c8_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UpfrontPaymentMember_f7a75112-49cd-4e54-adf7-8b383c315f53_terseLabel_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_label_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_documentation_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember" xlink:href="cdtx-20231231.xsd#cdtx_UpfrontPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UpfrontPaymentMember" xlink:to="lab_cdtx_UpfrontPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_6556f6aa-97f6-4e94-9541-850fdc2af7f0_terseLabel_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued indirect tax liabilities</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_label_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrual for Taxes Other than Income Taxes</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_documentation_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrual for Taxes Other than Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:href="cdtx-20231231.xsd#cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:to="lab_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0150f5a4-7e9e-452b-871f-d338364f73b7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_58ad4a20-2e22-41a8-8aec-03bfc7485e7c_terseLabel_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_label_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_documentation_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:href="cdtx-20231231.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:to="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_2fcc79ef-c69f-4340-804f-40472f50fa4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TermLoanMember_6f0c5182-6c53-455f-936f-f9cf9d774133_terseLabel_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_cdtx_TermLoanMember_label_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanMember_documentation_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember" xlink:href="cdtx-20231231.xsd#cdtx_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanMember" xlink:to="lab_cdtx_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bb41eefe-6253-4bc5-9265-f49412b283a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a400ea2e-a97f-4f4f-b04a-a63a5091a667_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6cc8818e-de46-4c83-bd25-a80966c5744c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_700586d9-f68b-4158-bc27-ca31c0dff361_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_f1dead27-84c6-4cf7-b3d7-c438815c7385_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_fcc18885-e0d7-4418-bc7d-bcea1bdf8ddf_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_b6b13541-287f-445f-b08c-3e6bc7c31d39_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8db753fd-4f50-4d20-ae06-cbe8e995f9e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d351af8b-736b-4cc3-a586-20a1545773c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options canceled (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_56c22fc7-3f46-4b6a-ab3b-8f17004b103e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07a89525-52c3-43e5-a1dd-1c5c16fe909f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_f1f2ff84-d6fc-4ed0-af0e-f1a5cf9a1a8c_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_57a3a563-3487-45ca-9180-94e2f19fd53d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_6108b9b4-ecb7-4923-b36f-b18094b4d99d_terseLabel_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost, variable lease and short-term lease term (in days)</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_label_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_documentation_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:href="cdtx-20231231.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:to="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_28e28006-b6b2-446d-83f4-a581b2de72d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6f13c7ca-b819-4ec6-b654-f33b1b77f66b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b743b7ca-1d88-4728-835c-6e148aca10e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ca6686aa-d534-4bb8-af15-b7ce10f32938_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_40b43123-e5c8-40ba-bf70-b99a9ec69275_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_8823b3d2-4515-4aa3-8f91-edd849359736_terseLabel_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:to="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_92a0d928-cb83-4e0b-9ad6-ea0984ab9e66_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative arrangement, excluding revenue from contract with customer, noncurrent liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a2a50bf6-6016-4283-a273-0c73bcf30768_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2abb4cc7-3e18-46c1-963a-e75b413876b4_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18c9e556-2b61-4cb0-ac1f-e58ba1a970f3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_58670082-126e-4a1a-958e-bb94ba6b786e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_99aa5811-342f-4f5e-9fb2-5ee2cd2c72f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_f1e6d7eb-c0f3-481d-902e-ca8fc45bd9d0_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal repayments of Term Loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_5b14fdd8-d2cb-4feb-bf94-25a55e6bf626_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_368ed269-e922-4b07-ab60-98f8dd636795_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1eb546c3-49be-4dd9-adea-5b1a79684cbd_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f6088754-8fe7-4975-9cbd-700deb4ce8bf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ec7061dd-369f-4c8f-a22d-e335107eba6e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_33d744ab-888d-4ad0-acd7-5597910678b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7bb01570-94ae-427b-858a-96c5093c281d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_0853c011-b88a-4a60-9fdf-35853216fed3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_4dc6d053-9b05-4075-96ac-d323318ac0c4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use asset, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_dd7eacf1-1cb3-443f-9dd0-b2db4a048712_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6f25140f-0de4-47b9-9282-086ddc334af0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_c2a1d611-146e-40a6-828c-93a7497237d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_81f62d3a-d523-4690-b158-8bd0026fec6e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock_2d6b798a-c715-45be-8f81-b592c4df7a57_terseLabel_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information For Operating Leases</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock_label_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Operating Lessee [Table Text Block]</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Operating Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock" xlink:href="cdtx-20231231.xsd#cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock" xlink:to="lab_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_03a213e8-e757-480b-a4a9-b414bfea28c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of product revenue</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4eaa7cac-6331-4e35-be2a-275f80ddbafc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_aecb9a82-8eee-45ea-a5b9-6df5106cb902_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_50df38ed-580d-49ae-b2c2-8cb4ffbfbda3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_69831533-2e05-4d54-92ea-61810c9d1270_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5ec688a8-bdc0-47ba-a584-4a0661d3e9cc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_7154d7c6-75f8-41cd-8ae9-dc14ec4d6dd2_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, termination provisions, required period of written notice (in days)</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:to="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_62d451a7-6174-4068-a54b-14f1463eba8f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b3aff69b-e217-4900-b653-c65d65ee57cc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_c4658872-34ad-4d9e-83df-60a7f61f9784_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MilestoneAchievementMember_e3aca50e-b69d-4895-9f38-d96e0c4ba0d9_terseLabel_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_label_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember" xlink:href="cdtx-20231231.xsd#cdtx_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MilestoneAchievementMember" xlink:to="lab_cdtx_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_c336e86d-e71a-4725-9743-092b44331602_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_5beee228-0eb8-4a9d-a293-0df14b4c76d5_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards, research and development</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5fbd440-338f-4e33-83e4-2e9cb11fcec8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_5cdf0f24-9199-4dae-af89-9e27fd3a4fa9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_bf15354a-f79d-4fed-bdc6-c71e1158fa98_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember_66e97b42-389c-469e-990d-e3545e424759_terseLabel_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License of Intellectual Property - upon transfer of license</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember_label_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property Upon Transfer of License [Member]</link:label>
    <link:label id="lab_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember_documentation_en-US" xlink:label="lab_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Of Intellectual Property Upon Transfer of License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember" xlink:to="lab_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_5e0c49ac-b767-4848-a65d-fd594584252d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_5d1242c3-4216-4877-8799-c0bd7c55ccce_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_b64923ad-bb83-423c-93a3-afeb67151b76_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6ad7852f-a182-4bb8-9bd9-a033433ea98e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_f86117f2-680a-4418-a987-aaa988ea12a9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_082cc141-0680-4607-a554-76cc1f5888cb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PatentCostsPolicyPolicyTextBlock_f70576fa-94b5-4037-af14-e34a17dafe1c_terseLabel_en-US" xlink:label="lab_cdtx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Costs</link:label>
    <link:label id="lab_cdtx_PatentCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Costs, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_PatentCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_PatentCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patent Costs, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PatentCostsPolicyPolicyTextBlock" xlink:href="cdtx-20231231.xsd#cdtx_PatentCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PatentCostsPolicyPolicyTextBlock" xlink:to="lab_cdtx_PatentCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_89cf9d3d-22a2-4ac0-93aa-b47253bb4f2f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_77487a63-ca42-4e0d-9988-f808377d306f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_0abbb7b8-07db-4c62-9e31-ab2d1567cb15_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_5307a2e3-808a-4022-a395-84f125bbdd92_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e21d8048-cb45-4ab0-bb8a-4ffbc24f348d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_c32fccff-20c3-4d01-b9a2-dde1d14b1951_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_220d6edd-b3dc-49ed-ab4b-c8ff730c2e7d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute basic net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_ce7a3fa6-5eca-4e1c-81f3-719436228bba_terseLabel_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_label_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_documentation_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:href="cdtx-20231231.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:to="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ed87471-4593-45ac-adb3-b82cf6adad4d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7c75753a-7cbd-49ba-b9e5-8efe9cd98538_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_70f300e3-0caa-4bb4-8df0-8e52b30237ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_2ced4e06-33ee-4aef-94d2-cd0e6bf9dd88_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b8e7821d-9bac-4a40-9d92-26fef76c1b8f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_692d9add-6024-4ca8-ac85-942cb27e3a7a_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_c1084b47-63b8-42f9-a9b5-60fad92496ff_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_ddb2983c-952a-49bc-ad42-ac39dbd0e1d6_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6aeadb70-67ad-4775-9659-607f29ff3d43_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_04f45d02-3a36-4ca5-9822-0aac782eef92_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c571f952-055b-4641-98ae-113085fd25e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_27adf329-c7ea-42f7-9397-d5342e642f7e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_4a91694a-f7e6-4f78-951d-673e1e204db9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_e739faf2-ddae-487c-8b48-b19e47aa6dae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_9113c230-7136-41e6-ab08-98e4b240ae0a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2a84c6b8-b6fa-4684-a26e-3c4602fa0d58_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_ba3ae970-c6e1-4229-a9ac-7a43c24a4fa2_netLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_5989ec42-62dc-4466-8173-de7da776e55c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_7e6f709e-2cc0-4b43-bcb5-9d2a002298c7_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_a577defb-255f-4f1a-8477-c447fd5e1686_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f951062f-5d04-4fdf-a095-e8170e90c9d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_21676761-ccab-4686-8a07-93342e56f544_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4767220d-9592-49b1-aba9-a9c06486e8a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2ba7744-1908-49f1-a006-7e75ca62ab58_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3bdab35b-6a53-4028-b4b9-42d85089ce54_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, renewal term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_50b3bfde-67fa-4086-863c-0bb57f6fb710_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_9f7b92a1-1887-4865-b838-b961b7379532_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_ad2b92fc-df09-40c0-b812-66eeee3fef15_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_a0af8587-c4e0-4ba0-a498-9e0f99aef362_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_bd895c04-d0c7-4bfa-99f2-56810ffc2f5a_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_e68bf51b-3b1f-4d51-9859-09a0fc1d769c_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments receivable</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_447cb1af-1008-481d-ac88-7470439ae290_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_8023f29b-e8c7-4f7e-8410-b23f2cc8ee2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1ba98d2c-2824-4722-9220-4e1fda7fe722_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f0783c66-b20b-4fd2-8e75-80f4412435eb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute basic net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cbb7c6b8-8f2f-4b8a-9666-f6503d37300c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_47501913-9005-468f-9482-4f28e2140039_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_c59c58e1-ecb1-4254-9781-18d11d90a0bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_de4f3423-53e3-4555-a2c7-d968bb97fbeb_terseLabel_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mundipharma Medical Company</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_label_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_documentation_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:to="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_386a5f3e-6725-44b8-8ef5-1066b83bc2a7_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_60a5f63b-475e-4bf9-9a71-a1060617cda5_terseLabel_en-US" xlink:label="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_label_en-US" xlink:label="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock In Underwritten Public Offering</link:label>
    <link:label id="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_documentation_en-US" xlink:label="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock In Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:to="lab_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_41ad1c55-e0a6-4e94-bdb2-67f3c4e45ada_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_7433c27d-090c-4341-b326-919bcbeb9970_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TermLoanAMember_52cbc18f-a7a0-470d-9109-60b2d6ab99f1_terseLabel_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term A Loan</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_label_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_documentation_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember" xlink:href="cdtx-20231231.xsd#cdtx_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanAMember" xlink:to="lab_cdtx_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_408a8999-ff19-439e-99ba-09ba1715a6f7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_0fed6c93-5052-40b8-a20f-095e905ebf2a_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_21209807-bb0e-4ef4-a475-95513c3ff93a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fe6a4c99-8436-4958-acf0-8febdf17c010_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1a789dcf-b534-47ae-b45c-3ed2fc83000d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_91a8cc52-1a5c-4fcf-872d-95fb1474a5e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount_7cf1290c-1855-48dc-a714-35941cd4d3df_terseLabel_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">382 NOL and tax credit limitation</link:label>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount_label_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 382 NOL and Tax Asset Limitation, Amount</link:label>
    <link:label id="lab_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount_documentation_en-US" xlink:label="lab_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, 382 NOL and Tax Asset Limitation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" xlink:to="lab_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_0b60aeca-20b4-4a9b-9cdf-930d30889751_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_2150b150-2855-4dff-b1ca-bfd9ddf38ec4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cdtx-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:fa590d2e-4039-4000-bdf7-5fb59710602c,g:d0764763-c16c-45c9-82e5-80b88e590043-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/Cover" xlink:type="simple" xlink:href="cdtx-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://cidara.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0711082c-ee04-4530-be34-7cec54107d05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentType_0711082c-ee04-4530-be34-7cec54107d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_85c671ba-a9d5-4651-a0c4-34f5007094c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentAnnualReport_85c671ba-a9d5-4651-a0c4-34f5007094c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b74bf7ba-3f7e-45f2-8393-4ca277580f2f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentPeriodEndDate_b74bf7ba-3f7e-45f2-8393-4ca277580f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ce043060-9bae-4b35-a79b-99846bfb34a7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_CurrentFiscalYearEndDate_ce043060-9bae-4b35-a79b-99846bfb34a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_baecf103-9250-4e16-a236-2a5b707e3b41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentTransitionReport_baecf103-9250-4e16-a236-2a5b707e3b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c5893b52-36bf-40e5-a12b-405deaa41370" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityFileNumber_c5893b52-36bf-40e5-a12b-405deaa41370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c486c0fd-f38d-489a-b8b0-3c5dd00c91e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityRegistrantName_c486c0fd-f38d-489a-b8b0-3c5dd00c91e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5a8e02d4-3cfa-4bc3-b691-57cbbd233632" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5a8e02d4-3cfa-4bc3-b691-57cbbd233632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_02807d31-9a27-45a5-9350-3b89ce9c3afa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityTaxIdentificationNumber_02807d31-9a27-45a5-9350-3b89ce9c3afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_56aab7c7-ee2b-4ec2-8a13-d968027b3e08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityAddressAddressLine1_56aab7c7-ee2b-4ec2-8a13-d968027b3e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a20b4f62-3be7-4519-8d23-e7e130b04bf3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityAddressAddressLine2_a20b4f62-3be7-4519-8d23-e7e130b04bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2e2bf7df-b390-4921-9593-42d53527ffee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityAddressCityOrTown_2e2bf7df-b390-4921-9593-42d53527ffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5730751f-a77a-4bfd-b551-30871490a35c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityAddressStateOrProvince_5730751f-a77a-4bfd-b551-30871490a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7726d2a9-820f-46b2-9531-99dff9e2e3d8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityAddressPostalZipCode_7726d2a9-820f-46b2-9531-99dff9e2e3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a326f9c3-fa8b-4254-978e-5589b79722e3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_CityAreaCode_a326f9c3-fa8b-4254-978e-5589b79722e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ca49c094-7b2e-4787-a2cc-bc694f486abc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_LocalPhoneNumber_ca49c094-7b2e-4787-a2cc-bc694f486abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_af5cc0bd-6fc6-4929-8a2c-51f33ad0500f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_Security12bTitle_af5cc0bd-6fc6-4929-8a2c-51f33ad0500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4b949e38-712c-4395-b9ae-e6fabf638ac2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_TradingSymbol_4b949e38-712c-4395-b9ae-e6fabf638ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_027073be-cd46-4875-98b6-a72ea5fcb772" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_SecurityExchangeName_027073be-cd46-4875-98b6-a72ea5fcb772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_34749687-e6a2-4a94-86e9-afe59ec8c5bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_34749687-e6a2-4a94-86e9-afe59ec8c5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_3fbb1ae4-a1b1-4418-8893-e5292e289d0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityVoluntaryFilers_3fbb1ae4-a1b1-4418-8893-e5292e289d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_f3d908dc-7fa3-4fb7-a75f-1a5de9eccc78" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityCurrentReportingStatus_f3d908dc-7fa3-4fb7-a75f-1a5de9eccc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_076e1f63-da20-4c8e-ab66-d2a8c0377159" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityInteractiveDataCurrent_076e1f63-da20-4c8e-ab66-d2a8c0377159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0f397510-a329-435d-85b8-ba4085765e75" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityFilerCategory_0f397510-a329-435d-85b8-ba4085765e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_10c27003-ab75-402f-94bf-5dc66c0b7a68" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntitySmallBusiness_10c27003-ab75-402f-94bf-5dc66c0b7a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ca51bbd5-54e6-4d60-a55b-ffea49fd56fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityEmergingGrowthCompany_ca51bbd5-54e6-4d60-a55b-ffea49fd56fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9709f3e1-3c06-48ce-8bc6-8a1e7dd8ce11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9709f3e1-3c06-48ce-8bc6-8a1e7dd8ce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_78a3efdc-e613-4416-96c9-d643f95570ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_78a3efdc-e613-4416-96c9-d643f95570ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_3312e733-c2f3-4296-bade-ed33dcefe586" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtRestatementRecoveryAnalysisFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag_3312e733-c2f3-4296-bade-ed33dcefe586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b2808281-dd34-405f-9330-6579c884da55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityShellCompany_b2808281-dd34-405f-9330-6579c884da55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_7688d590-7e0b-4cd7-b509-95235bc7d4c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityPublicFloat_7688d590-7e0b-4cd7-b509-95235bc7d4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0df0bada-72f0-4515-995d-3d25475edc22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0df0bada-72f0-4515-995d-3d25475edc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_53a89557-dc91-4160-a25c-7ff3b549652b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_AmendmentFlag_53a89557-dc91-4160-a25c-7ff3b549652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_30d633ef-3f51-4323-a9dc-8f70ca50db47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentFiscalYearFocus_30d633ef-3f51-4323-a9dc-8f70ca50db47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_524e22c5-1627-4390-b38e-52e48360afbd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_524e22c5-1627-4390-b38e-52e48360afbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_21daa431-ff34-4c10-bd7a-2508163ec179" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_00d217f2-5edd-431b-a164-6c7a02ef65cf" xlink:to="loc_dei_EntityCentralIndexKey_21daa431-ff34-4c10-bd7a-2508163ec179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/AuditInformation" xlink:type="simple" xlink:href="cdtx-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://cidara.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuditInformationAbstract_40259aaa-90f0-453f-8580-8e4075927ffb" xlink:href="cdtx-20231231.xsd#cdtx_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_47dea510-1a5f-4ca5-b025-d5eb028b2565" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_AuditInformationAbstract_40259aaa-90f0-453f-8580-8e4075927ffb" xlink:to="loc_dei_AuditorName_47dea510-1a5f-4ca5-b025-d5eb028b2565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_012a0f18-ed81-4d40-b997-740f4a982154" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_AuditInformationAbstract_40259aaa-90f0-453f-8580-8e4075927ffb" xlink:to="loc_dei_AuditorLocation_012a0f18-ed81-4d40-b997-740f4a982154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_1a3272da-1784-43d0-b858-2fc6316e713c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_AuditInformationAbstract_40259aaa-90f0-453f-8580-8e4075927ffb" xlink:to="loc_dei_AuditorFirmId_1a3272da-1784-43d0-b858-2fc6316e713c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://cidara.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_70e0310f-53aa-432c-8a5d-09324fa16e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d814a2ee-10eb-4752-b3e4-01c8d5f84518" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_70e0310f-53aa-432c-8a5d-09324fa16e91" xlink:to="loc_us-gaap_StatementTable_d814a2ee-10eb-4752-b3e4-01c8d5f84518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d814a2ee-10eb-4752-b3e4-01c8d5f84518" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_22d0d170-58ce-424f-9767-4b340f1b2d68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a91cd943-a44e-477d-8d5d-5e5f6c3b0af7" xlink:to="loc_us-gaap_ClassOfStockDomain_22d0d170-58ce-424f-9767-4b340f1b2d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_0f44338c-fe10-464e-ac5f-5f8fafba953b" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_22d0d170-58ce-424f-9767-4b340f1b2d68" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_0f44338c-fe10-464e-ac5f-5f8fafba953b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d814a2ee-10eb-4752-b3e4-01c8d5f84518" xlink:to="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:to="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8486a8f5-6700-406b-8c0a-8cb0517a4dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8486a8f5-6700-406b-8c0a-8cb0517a4dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_70b466f9-b6ac-4b6f-b9ee-a54c294d2a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_70b466f9-b6ac-4b6f-b9ee-a54c294d2a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7a556ebf-cfde-4713-8c70-89a091ebf337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_InventoryNet_7a556ebf-cfde-4713-8c70-89a091ebf337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33281d4f-9158-435e-ac57-3d62dd239fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_33281d4f-9158-435e-ac57-3d62dd239fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9de79e60-3126-486b-ac3d-b9f1c63bab5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_38dba245-4398-4c60-851a-387a617a5143" xlink:to="loc_us-gaap_AssetsCurrent_9de79e60-3126-486b-ac3d-b9f1c63bab5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7dc904a7-58b4-41c7-8bc1-728283ca1012" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7dc904a7-58b4-41c7-8bc1-728283ca1012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_ccec6c92-99ff-4779-8361-cc1139a04a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_ccec6c92-99ff-4779-8361-cc1139a04a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6bf55e87-8a62-4217-aaf8-b9c312120c93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6bf55e87-8a62-4217-aaf8-b9c312120c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_86cafbd1-18f3-4602-832f-2cc1207ecdfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_86cafbd1-18f3-4602-832f-2cc1207ecdfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9f7b747d-3de1-4871-8cff-28e1bbb7bf76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_424d3ca5-30dc-4151-9ed5-6ea400f3923b" xlink:to="loc_us-gaap_Assets_9f7b747d-3de1-4871-8cff-28e1bbb7bf76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0c6b280f-97dd-4b14-b9c6-719c120a2f80" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_32d5be0b-d5e3-4d0b-b2d6-e9b6e13b36c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_AccountsPayableCurrent_32d5be0b-d5e3-4d0b-b2d6-e9b6e13b36c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0edf0970-11e6-416f-87dc-8962a4877ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0edf0970-11e6-416f-87dc-8962a4877ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_3185a432-2202-401c-81bb-488345cad6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_3185a432-2202-401c-81bb-488345cad6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ef73f467-7f45-4b9e-8ff3-e08aae7b90fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ef73f467-7f45-4b9e-8ff3-e08aae7b90fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0ec508fe-5900-4b11-9d6e-b047b407ff1d" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0ec508fe-5900-4b11-9d6e-b047b407ff1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_22793ba7-212c-42cb-b195-606d856d2da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_22793ba7-212c-42cb-b195-606d856d2da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_112e5afd-6614-4867-b0df-b41a01c580c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_112e5afd-6614-4867-b0df-b41a01c580c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c83cdf89-2b57-48f9-9d3c-226412084c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76de4ac6-c810-4e63-ab5f-b1e445ea2514" xlink:to="loc_us-gaap_LiabilitiesCurrent_c83cdf89-2b57-48f9-9d3c-226412084c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_ca418f2c-6a4b-4457-bdcc-2dac08985b03" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_ca418f2c-6a4b-4457-bdcc-2dac08985b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_63cadd15-3c07-46bd-b1cc-94812eddb0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_63cadd15-3c07-46bd-b1cc-94812eddb0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b4cc49e-0926-4f5a-820f-855ba9043fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2b4cc49e-0926-4f5a-820f-855ba9043fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_efdb5842-556f-4ee3-8aae-2420b8d00f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_Liabilities_efdb5842-556f-4ee3-8aae-2420b8d00f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_bd85edc9-c28e-462a-aaa7-8c3698e8208e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_bd85edc9-c28e-462a-aaa7-8c3698e8208e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_cc6600ae-71ea-4b18-859d-883c81fc40a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_PreferredStockValue_cc6600ae-71ea-4b18-859d-883c81fc40a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_27bb0ef9-75d9-4419-90d7-7c7c2fb2736d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_CommonStockValue_27bb0ef9-75d9-4419-90d7-7c7c2fb2736d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5c1bc257-e485-40ce-9d53-1989351765fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5c1bc257-e485-40ce-9d53-1989351765fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7027ac8a-c5fe-49f6-96e6-1802479fb5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7027ac8a-c5fe-49f6-96e6-1802479fb5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0b64d3d3-5d3c-489b-a502-bc4cd2dc21e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_6bf795e0-054d-4602-84eb-8c86bc5620de" xlink:to="loc_us-gaap_StockholdersEquity_0b64d3d3-5d3c-489b-a502-bc4cd2dc21e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_382bfa72-5b81-4e69-beab-7504e1a39226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ef48f531-471f-4d16-93f3-1c105c56524d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_382bfa72-5b81-4e69-beab-7504e1a39226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f5a939b1-13f1-4556-b35c-ffdc66292b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_38306061-aec7-414d-b5a5-1a64048b9283" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f5a939b1-13f1-4556-b35c-ffdc66292b2d" xlink:to="loc_us-gaap_StatementTable_38306061-aec7-414d-b5a5-1a64048b9283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2f1ff181-c0aa-4a0b-8604-8bb812743c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38306061-aec7-414d-b5a5-1a64048b9283" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2f1ff181-c0aa-4a0b-8604-8bb812743c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a1420bc-720a-4b2c-9adf-cf21ea01a5db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2f1ff181-c0aa-4a0b-8604-8bb812743c23" xlink:to="loc_us-gaap_ClassOfStockDomain_3a1420bc-720a-4b2c-9adf-cf21ea01a5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_1d26bdc9-db20-4509-8f96-6cf8ad56e78e" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3a1420bc-720a-4b2c-9adf-cf21ea01a5db" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_1d26bdc9-db20-4509-8f96-6cf8ad56e78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_38306061-aec7-414d-b5a5-1a64048b9283" xlink:to="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad0a7042-ae32-4be4-8966-7a7471b1509a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad0a7042-ae32-4be4-8966-7a7471b1509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_53878b53-d812-4fc3-9420-c77ab1c551c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_53878b53-d812-4fc3-9420-c77ab1c551c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7299a4f6-ffdb-4283-8eb9-34fb202c9371" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7299a4f6-ffdb-4283-8eb9-34fb202c9371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1e936a44-957d-4bae-9a17-b4b521065308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1e936a44-957d-4bae-9a17-b4b521065308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_097d11ea-3131-416e-8908-738037daeda1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_097d11ea-3131-416e-8908-738037daeda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6ce2b21d-2869-434b-abfb-360e8f7d9360" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6ce2b21d-2869-434b-abfb-360e8f7d9360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b2874ee3-f39c-4da5-9460-61098bcbea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockSharesIssued_b2874ee3-f39c-4da5-9460-61098bcbea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_621448e5-47d4-4d26-a3b6-d5fc83296856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_94edfd39-a079-48cf-9735-8be60e9a7067" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_621448e5-47d4-4d26-a3b6-d5fc83296856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_f1698367-610f-47f4-954f-3ee4668d770a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_RevenuesAbstract_f1698367-610f-47f4-954f-3ee4668d770a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_72f3f4b9-aaef-425d-a98a-48281d6f40d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f1698367-610f-47f4-954f-3ee4668d770a" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_72f3f4b9-aaef-425d-a98a-48281d6f40d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2275bc23-6228-4388-b858-3970c213dadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f1698367-610f-47f4-954f-3ee4668d770a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2275bc23-6228-4388-b858-3970c213dadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_16ebf8c7-6518-4464-83f5-1a9e2b25a3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_f1698367-610f-47f4-954f-3ee4668d770a" xlink:to="loc_us-gaap_Revenues_16ebf8c7-6518-4464-83f5-1a9e2b25a3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ee53d5ea-2967-4973-9018-0b7cd5be239c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ee53d5ea-2967-4973-9018-0b7cd5be239c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_93e678db-9fe9-4446-abc5-286b26824185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ee53d5ea-2967-4973-9018-0b7cd5be239c" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_93e678db-9fe9-4446-abc5-286b26824185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_730a1fdb-bc46-46f3-a506-17da06eac0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ee53d5ea-2967-4973-9018-0b7cd5be239c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_730a1fdb-bc46-46f3-a506-17da06eac0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_87b675a1-9748-4360-8a60-aad86f571a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ee53d5ea-2967-4973-9018-0b7cd5be239c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_87b675a1-9748-4360-8a60-aad86f571a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a25d11c6-5c04-40a8-b9d2-c3b3dbf1fca0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ee53d5ea-2967-4973-9018-0b7cd5be239c" xlink:to="loc_us-gaap_OperatingExpenses_a25d11c6-5c04-40a8-b9d2-c3b3dbf1fca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4ecce70d-a647-433e-8faf-be4dc60c6da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_OperatingIncomeLoss_4ecce70d-a647-433e-8faf-be4dc60c6da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43073bad-6f04-4b23-a2c5-c9e8deb740b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43073bad-6f04-4b23-a2c5-c9e8deb740b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d1335645-aa9c-4daa-a0db-f30c8faffe93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43073bad-6f04-4b23-a2c5-c9e8deb740b1" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_d1335645-aa9c-4daa-a0db-f30c8faffe93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0806dc5a-e2ed-4f3b-9e7a-014351b3eb93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_43073bad-6f04-4b23-a2c5-c9e8deb740b1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0806dc5a-e2ed-4f3b-9e7a-014351b3eb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b4d4070-dabc-43f1-9f1a-9e58ef236018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5b4d4070-dabc-43f1-9f1a-9e58ef236018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22b63da2-289b-4500-8be9-d3b84da362fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22b63da2-289b-4500-8be9-d3b84da362fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ae2a0a00-271f-44e5-8bcb-167380c003b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_NetIncomeLoss_ae2a0a00-271f-44e5-8bcb-167380c003b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_faec153f-b094-493b-aaa1-0cb09a810a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_faec153f-b094-493b-aaa1-0cb09a810a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_12f2e4ef-f112-433c-96a0-88adce4c5777" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_EarningsPerShareBasic_12f2e4ef-f112-433c-96a0-88adce4c5777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0c49a086-9a1f-4c2d-8867-a57c2d2e566a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0c49a086-9a1f-4c2d-8867-a57c2d2e566a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4a9f7303-2f83-4d15-91f9-f320d0c9c1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4a9f7303-2f83-4d15-91f9-f320d0c9c1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8567b4ab-eba7-4575-b04d-f51e137ff48f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32603dc9-b984-4db4-a49d-e09f271b4fa3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8567b4ab-eba7-4575-b04d-f51e137ff48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a92f5e86-166f-4d06-b345-ec3aff4231b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a92f5e86-166f-4d06-b345-ec3aff4231b3" xlink:to="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f4c2e327-a6e9-45e0-a491-135d8ac2f1d1" xlink:to="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_9e7b3fee-886e-40f7-ae37-e2081006ea83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_PreferredStockMember_9e7b3fee-886e-40f7-ae37-e2081006ea83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_74c4a2d8-8a40-4fb2-9023-6a4c8a2e0aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_CommonStockMember_74c4a2d8-8a40-4fb2-9023-6a4c8a2e0aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e5ab9892-2afa-4c8c-b776-b5f659fdf307" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e5ab9892-2afa-4c8c-b776-b5f659fdf307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e76930db-b778-4f55-b356-ff283ce0ba74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_992b56e9-676f-44ea-a4f6-738d3497f86d" xlink:to="loc_us-gaap_RetainedEarningsMember_e76930db-b778-4f55-b356-ff283ce0ba74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8071d599-576c-4cb1-b4f2-adb52ae64b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8071d599-576c-4cb1-b4f2-adb52ae64b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_71bb72e6-c204-421e-90d0-2449bfd4f11e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8071d599-576c-4cb1-b4f2-adb52ae64b01" xlink:to="loc_us-gaap_ClassOfStockDomain_71bb72e6-c204-421e-90d0-2449bfd4f11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_17135479-7f20-4fd7-a90c-8cefc6b99406" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_71bb72e6-c204-421e-90d0-2449bfd4f11e" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_17135479-7f20-4fd7-a90c-8cefc6b99406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_853d01d0-cab9-41f1-8cbe-e360dd2b73a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_853d01d0-cab9-41f1-8cbe-e360dd2b73a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_853d01d0-cab9-41f1-8cbe-e360dd2b73a8" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnderwrittenPublicOfferingMember_af38636c-206a-4b3f-91a3-21d6d0855495" xlink:href="cdtx-20231231.xsd#cdtx_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:to="loc_cdtx_UnderwrittenPublicOfferingMember_af38636c-206a-4b3f-91a3-21d6d0855495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicOfferingMember_59a51be8-e797-4bdc-9867-d174109e8ca2" xlink:href="cdtx-20231231.xsd#cdtx_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4dd8da6a-b8ff-440c-a45d-a75ba950ce7b" xlink:to="loc_cdtx_PublicOfferingMember_59a51be8-e797-4bdc-9867-d174109e8ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49f62776-d0ac-4607-95c6-c8535acc1d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_197bef94-4012-429d-988a-62307f44f361" xlink:to="loc_us-gaap_StatementLineItems_49f62776-d0ac-4607-95c6-c8535acc1d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49f62776-d0ac-4607-95c6-c8535acc1d39" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_48e4351c-c800-4ddc-8aac-acc19bc63c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_48e4351c-c800-4ddc-8aac-acc19bc63c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0472b993-9192-4d3b-a5f4-affb5875a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockholdersEquity_0472b993-9192-4d3b-a5f4-affb5875a7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7a48c3f4-1030-4ed8-bc85-a2b3ffc01bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7a48c3f4-1030-4ed8-bc85-a2b3ffc01bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4213b3ad-ce71-456f-b285-414339b20e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4213b3ad-ce71-456f-b285-414339b20e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02c85083-6226-416b-898c-d5c0e97d962e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_02c85083-6226-416b-898c-d5c0e97d962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28e08984-ae00-4f29-b2ce-608e0ef847ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28e08984-ae00-4f29-b2ce-608e0ef847ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7b486fe-867e-43f5-b1a5-22920f621f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b7b486fe-867e-43f5-b1a5-22920f621f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_52a850ad-4f37-4dd3-a731-43d216b64bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_52a850ad-4f37-4dd3-a731-43d216b64bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9205aef9-a6c1-4dac-90bb-5910972f6d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9205aef9-a6c1-4dac-90bb-5910972f6d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d5477f36-fbc4-4f0c-a6c6-7e703b68dd36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d5477f36-fbc4-4f0c-a6c6-7e703b68dd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3387da88-e9f4-4971-8320-bd929f86e1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_3387da88-e9f4-4971-8320-bd929f86e1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2e40ed15-34ad-401f-b215-88fda6ef3d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2e40ed15-34ad-401f-b215-88fda6ef3d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3828cef3-4a44-422a-bd51-ad4522c74e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_NetIncomeLoss_3828cef3-4a44-422a-bd51-ad4522c74e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_326fd7da-1f75-4e0b-b483-b76f7035eb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_326fd7da-1f75-4e0b-b483-b76f7035eb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a881b3da-9989-41ff-9a78-662b60e7cdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_StockholdersEquity_a881b3da-9989-41ff-9a78-662b60e7cdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d904b2f4-7aa3-45b4-bd68-81515c9be5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88b5a1c2-16cd-4c20-8f36-7dcc198eb42f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d904b2f4-7aa3-45b4-bd68-81515c9be5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cdtx-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://cidara.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eef455-84ee-4882-95cd-5ec7f9d08378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eef455-84ee-4882-95cd-5ec7f9d08378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4351803a-16f7-4095-83f3-6f8d1f9a6f73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eef455-84ee-4882-95cd-5ec7f9d08378" xlink:to="loc_us-gaap_NetIncomeLoss_4351803a-16f7-4095-83f3-6f8d1f9a6f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eef455-84ee-4882-95cd-5ec7f9d08378" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f9d70b56-5161-43d0-8256-34e06daf352f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:to="loc_us-gaap_ShareBasedCompensation_f9d70b56-5161-43d0-8256-34e06daf352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_bd115a43-ce55-4ac2-8537-083a5d974e06" xlink:href="cdtx-20231231.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_bd115a43-ce55-4ac2-8537-083a5d974e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_eba38ab2-ca58-4a61-9cac-3f605d60ecda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:to="loc_us-gaap_DepreciationAndAmortization_eba38ab2-ca58-4a61-9cac-3f605d60ecda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_7a212e8c-3164-4e11-8483-8b8e1e17e525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_7a212e8c-3164-4e11-8483-8b8e1e17e525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_43933479-8466-40fa-bd28-c36edd60a330" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_43933479-8466-40fa-bd28-c36edd60a330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_7ddcbe03-8a1d-41d8-9048-68785a0d9448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:to="loc_us-gaap_PaidInKindInterest_7ddcbe03-8a1d-41d8-9048-68785a0d9448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3696842d-d9bd-4c10-9499-a476fae0bc35" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c64f57a-5d17-4d32-86d9-2270bcf0451f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c64f57a-5d17-4d32-86d9-2270bcf0451f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2c116c49-c44a-4179-bf5b-99a3671b433b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2c116c49-c44a-4179-bf5b-99a3671b433b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b6fdf93a-f8b8-4a4f-b565-427a55321a94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b6fdf93a-f8b8-4a4f-b565-427a55321a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bcf2eab2-2902-4ba7-93f1-6f9543e5fc88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bcf2eab2-2902-4ba7-93f1-6f9543e5fc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_486b2b6d-6a58-447f-89fa-7d5cef73301b" xlink:href="cdtx-20231231.xsd#cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes_486b2b6d-6a58-447f-89fa-7d5cef73301b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_82fcf7c2-0116-4520-b5c8-94b41219d560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_82fcf7c2-0116-4520-b5c8-94b41219d560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_91438e02-cb05-4f46-be87-eadffc2fb175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_91438e02-cb05-4f46-be87-eadffc2fb175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ece65149-4bb8-4155-b5b1-b089eb4880eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_96de5fcb-31c4-42dc-a078-cc8ab06d504d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ece65149-4bb8-4155-b5b1-b089eb4880eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1a60b98-3e0d-4d7b-bb94-90ed22c8faba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_84eef455-84ee-4882-95cd-5ec7f9d08378" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f1a60b98-3e0d-4d7b-bb94-90ed22c8faba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869867ff-df17-4815-857e-dcf898a446cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869867ff-df17-4815-857e-dcf898a446cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da25e23b-6d25-415f-9c62-978aada40bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869867ff-df17-4815-857e-dcf898a446cf" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_da25e23b-6d25-415f-9c62-978aada40bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_140da3fe-4eff-40a4-90f6-c0ae695ca899" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_869867ff-df17-4815-857e-dcf898a446cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_140da3fe-4eff-40a4-90f6-c0ae695ca899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c026907c-b612-4b38-a84c-31cafbdf3448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c026907c-b612-4b38-a84c-31cafbdf3448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_86f39425-eed2-48d4-a4d5-1b547e3741a3" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:to="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_86f39425-eed2-48d4-a4d5-1b547e3741a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_cedcb58b-a95d-46fd-8131-026253f051fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_cedcb58b-a95d-46fd-8131-026253f051fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3d0550d5-0183-4d90-b80c-b4a9fdd8e255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3d0550d5-0183-4d90-b80c-b4a9fdd8e255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_17d99b30-dbaf-42a2-99b8-2318c2b98123" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_17d99b30-dbaf-42a2-99b8-2318c2b98123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2feca2ce-9215-40d4-b295-bd96fcfb37c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_826a7c6d-c91f-4b14-9d45-0894c599e889" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2feca2ce-9215-40d4-b295-bd96fcfb37c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92e75ded-80b1-4a46-85a4-4e7cbebbe9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_92e75ded-80b1-4a46-85a4-4e7cbebbe9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_974905b0-772d-4f73-99ae-f423989fa0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_974905b0-772d-4f73-99ae-f423989fa0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c93b6ba-8323-4222-b52b-1a17e4242605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c93b6ba-8323-4222-b52b-1a17e4242605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d576c774-d8c6-495c-a34f-b0da3997b31f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d576c774-d8c6-495c-a34f-b0da3997b31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_362d5faf-a7a7-4f52-82ee-65cabbdc2ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d576c774-d8c6-495c-a34f-b0da3997b31f" xlink:to="loc_us-gaap_InterestPaidNet_362d5faf-a7a7-4f52-82ee-65cabbdc2ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_26bdbc3a-7fcc-4f35-ba27-4fc8296504bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d576c774-d8c6-495c-a34f-b0da3997b31f" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_26bdbc3a-7fcc-4f35-ba27-4fc8296504bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ad315e6c-5084-4a03-ab8e-8a270b0d40b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ad315e6c-5084-4a03-ab8e-8a270b0d40b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1818bc87-dd00-4cce-8ba7-6cc35df335bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ad315e6c-5084-4a03-ab8e-8a270b0d40b4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1818bc87-dd00-4cce-8ba7-6cc35df335bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_42f66cb5-32e2-4a5c-b6ff-8d338aa329e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ad315e6c-5084-4a03-ab8e-8a270b0d40b4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_42f66cb5-32e2-4a5c-b6ff-8d338aa329e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7f8a184e-3205-4da4-a1d3-f23185e3e83c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ad315e6c-5084-4a03-ab8e-8a270b0d40b4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7f8a184e-3205-4da4-a1d3-f23185e3e83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_75addca0-05cc-46e3-b86f-815a6d163bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_641b0534-561f-4cee-894d-df8e6d695954" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_75addca0-05cc-46e3-b86f-815a6d163bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_19784f68-0410-45ad-99d7-629dd55f9ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_75addca0-05cc-46e3-b86f-815a6d163bec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_19784f68-0410-45ad-99d7-629dd55f9ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_bba066da-f844-43ba-9248-191ab6dbfc28" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_75addca0-05cc-46e3-b86f-815a6d163bec" xlink:to="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_bba066da-f844-43ba-9248-191ab6dbfc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2adfd7a4-e6b3-4438-b2a5-826bb78e756e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_84f6946d-b798-4976-bbdf-17cc42e2b7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2adfd7a4-e6b3-4438-b2a5-826bb78e756e" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_84f6946d-b798-4976-bbdf-17cc42e2b7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c3e15c0-afba-4fc8-b259-668071d74ace" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_02fd003c-3e88-4638-8f63-a882ab9237be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c3e15c0-afba-4fc8-b259-668071d74ace" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_02fd003c-3e88-4638-8f63-a882ab9237be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cdtx-20231231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fb09e8ba-855f-4971-b6d6-932c70bd3943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_201b634d-1208-4619-9d66-0173a782330a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fb09e8ba-855f-4971-b6d6-932c70bd3943" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_201b634d-1208-4619-9d66-0173a782330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INVENTORY" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INVENTORY"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INVENTORY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d89fde76-4806-46a6-816d-ac3917bac806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_13aef099-c7ed-473e-b84f-10e7172fb8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d89fde76-4806-46a6-816d-ac3917bac806" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_13aef099-c7ed-473e-b84f-10e7172fb8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cdtx-20231231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://cidara.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6fcf704d-20f0-47bd-81d0-9c9049ceba4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4eec8855-4ce9-42c5-8225-25bc9f3ae8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6fcf704d-20f0-47bd-81d0-9c9049ceba4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_4eec8855-4ce9-42c5-8225-25bc9f3ae8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBT" xlink:type="simple" xlink:href="cdtx-20231231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ae665ed8-a8ff-46bf-9e4b-5a9aa37f2cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_83b6518a-7589-43f0-a52d-79b64d8d4b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ae665ed8-a8ff-46bf-9e4b-5a9aa37f2cc0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_83b6518a-7589-43f0-a52d-79b64d8d4b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cdtx-20231231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ed3fddef-9d48-4cd1-9a17-231772c05d07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a90bb46a-1d30-4c92-83a1-00e36d0aea67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ed3fddef-9d48-4cd1-9a17-231772c05d07" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a90bb46a-1d30-4c92-83a1-00e36d0aea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc92a985-d2f7-4449-acc6-75abaebecba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81da0aea-4af1-4ff1-84c9-1674e0e06ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc92a985-d2f7-4449-acc6-75abaebecba6" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81da0aea-4af1-4ff1-84c9-1674e0e06ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37e71ff6-388f-422a-9c44-4c079d6f820c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ff8ccd66-7376-4a70-bb74-dbb2bd06a697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_37e71ff6-388f-422a-9c44-4c079d6f820c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ff8ccd66-7376-4a70-bb74-dbb2bd06a697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXES" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0fdb5e60-4284-4725-a540-569a3d878b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_94135858-aeb2-4991-89cc-88debf5e561e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0fdb5e60-4284-4725-a540-569a3d878b17" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_94135858-aeb2-4991-89cc-88debf5e561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6cf3f17-b756-41f0-8be7-3c8d1997b366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e9422650-d7ff-40a1-9b71-c5253d098863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f6cf3f17-b756-41f0-8be7-3c8d1997b366" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e9422650-d7ff-40a1-9b71-c5253d098863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITED"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ca2fde7f-dab4-451c-ba18-c3c81ba1bc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_8bb2b160-c875-42ec-8bfb-7b10b453e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ca2fde7f-dab4-451c-ba18-c3c81ba1bc7c" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_8bb2b160-c875-42ec-8bfb-7b10b453e9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ed0aa77f-a59d-4e32-b767-efb8e87c7d26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5d8f76fb-7ee0-443f-a05c-f1344370aed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ed0aa77f-a59d-4e32-b767-efb8e87c7d26" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5d8f76fb-7ee0-443f-a05c-f1344370aed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3f8069be-cde6-40c3-a31b-e877ccb75ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3f8069be-cde6-40c3-a31b-e877ccb75ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_cc9dc0b7-807f-4ffb-909a-836d4e552412" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_cc9dc0b7-807f-4ffb-909a-836d4e552412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_09aaa0ea-0430-4d10-96b2-b8cc2379af32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_UseOfEstimates_09aaa0ea-0430-4d10-96b2-b8cc2379af32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c95eca77-873f-40dc-8c75-de98b12c18cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_c95eca77-873f-40dc-8c75-de98b12c18cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ff97bf9f-0f02-4ed6-aca2-0015b08a7603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ff97bf9f-0f02-4ed6-aca2-0015b08a7603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6a0d26a2-fb2e-4edf-96d4-9c079e5cb953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_6a0d26a2-fb2e-4edf-96d4-9c079e5cb953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_959bc952-be51-40e2-9d08-be646501bd09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_959bc952-be51-40e2-9d08-be646501bd09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3b3e8d59-3cc4-4d7e-a7f4-d2c5ad435488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3b3e8d59-3cc4-4d7e-a7f4-d2c5ad435488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_f91f17d2-a5fe-4ecf-8e23-748549e7b346" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_f91f17d2-a5fe-4ecf-8e23-748549e7b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c09e3a04-bd48-46dc-a812-8e046ee1b050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c09e3a04-bd48-46dc-a812-8e046ee1b050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PatentCostsPolicyPolicyTextBlock_c65e88f4-aede-456f-a972-d19d2f8c152b" xlink:href="cdtx-20231231.xsd#cdtx_PatentCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_cdtx_PatentCostsPolicyPolicyTextBlock_c65e88f4-aede-456f-a972-d19d2f8c152b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9c52b0fe-b084-44c8-a213-7fecb47f4d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9c52b0fe-b084-44c8-a213-7fecb47f4d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_7b6c9893-b968-4994-bceb-1e50c389d6e5" xlink:href="cdtx-20231231.xsd#cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock_7b6c9893-b968-4994-bceb-1e50c389d6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7c1b2c08-1cb0-4a70-9cca-3b87c843bff2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7c1b2c08-1cb0-4a70-9cca-3b87c843bff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_73256fae-a4b4-4418-933c-3d384140af00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_73256fae-a4b4-4418-933c-3d384140af00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_75302d35-a347-498c-b6dd-19e00f7c6f04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_75302d35-a347-498c-b6dd-19e00f7c6f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_31dc00fc-f0d2-4b6e-8018-9279ed35b351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_31dc00fc-f0d2-4b6e-8018-9279ed35b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_26d387cf-c62c-479a-95f8-2e06080ccd93" xlink:href="cdtx-20231231.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_26d387cf-c62c-479a-95f8-2e06080ccd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a7f36030-e690-47f5-b4d9-c6ddcc4b4060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a7f36030-e690-47f5-b4d9-c6ddcc4b4060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2ab4699e-cc32-432d-a15e-45644e36b875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2ab4699e-cc32-432d-a15e-45644e36b875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_693f03ae-59ec-4651-aef7-792b3327fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_693f03ae-59ec-4651-aef7-792b3327fba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e491c2e8-9c61-4ec0-bf18-a96fefff5cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_34c56a2e-3058-4148-888b-5eb8d14cbbcb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e491c2e8-9c61-4ec0-bf18-a96fefff5cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21ce30e9-3cce-4099-a8b0-be0a20eff08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_3a5f811d-f99e-4cb1-8257-8a581c1a0fff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_21ce30e9-3cce-4099-a8b0-be0a20eff08d" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_3a5f811d-f99e-4cb1-8257-8a581c1a0fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_578b2d7a-743b-4704-8648-e6f7cf6fd166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_cedf1d5e-5691-484a-abcd-9baddba8ef29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_578b2d7a-743b-4704-8648-e6f7cf6fd166" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_cedf1d5e-5691-484a-abcd-9baddba8ef29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_15eefba0-80cc-48e3-8c92-ad0c203efdc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4f533a42-64c6-4a3b-8b05-8c30d586e99d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_15eefba0-80cc-48e3-8c92-ad0c203efdc7" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4f533a42-64c6-4a3b-8b05-8c30d586e99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INVENTORYTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INVENTORYTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INVENTORYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d9bd68f6-d09a-407a-a479-4bb52900ef4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_327f8edb-ffa0-42a1-a30a-b8b1c21143e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d9bd68f6-d09a-407a-a479-4bb52900ef4e" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_327f8edb-ffa0-42a1-a30a-b8b1c21143e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3ee48d9-46cf-456c-bbc3-099254f550d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b038f51-559e-4fe2-9fba-86bfd7f25aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3ee48d9-46cf-456c-bbc3-099254f550d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_0b038f51-559e-4fe2-9fba-86bfd7f25aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_93fa74db-ed70-4571-98b4-67ebc4ba1304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_eca292c4-2e0f-4d4f-a8a8-0296611baf8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_93fa74db-ed70-4571-98b4-67ebc4ba1304" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_eca292c4-2e0f-4d4f-a8a8-0296611baf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1684499b-1264-49ab-84e0-872375675383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c73bee5a-d381-4998-83e6-6d618112f15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1684499b-1264-49ab-84e0-872375675383" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c73bee5a-d381-4998-83e6-6d618112f15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6187af77-ec3c-4f48-80c0-069f66366e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1684499b-1264-49ab-84e0-872375675383" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6187af77-ec3c-4f48-80c0-069f66366e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_41de6671-65f5-441c-8087-2338eee608ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1684499b-1264-49ab-84e0-872375675383" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_41de6671-65f5-441c-8087-2338eee608ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_739dad7c-8b09-4fb2-98d4-f562b5fa0636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1684499b-1264-49ab-84e0-872375675383" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_739dad7c-8b09-4fb2-98d4-f562b5fa0636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a089c34-0214-4ee7-95d2-25079be76cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_310b8730-6853-4bc6-bb92-95cc1313c6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a089c34-0214-4ee7-95d2-25079be76cf5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_310b8730-6853-4bc6-bb92-95cc1313c6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_592ffa66-e85f-41e9-b524-b9b1eb30f2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d07d43b6-e30d-4440-a2e6-40d74a0d5582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_592ffa66-e85f-41e9-b524-b9b1eb30f2a2" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d07d43b6-e30d-4440-a2e6-40d74a0d5582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8f3c2d27-58b3-4afe-9efa-a9b67274e4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_592ffa66-e85f-41e9-b524-b9b1eb30f2a2" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_8f3c2d27-58b3-4afe-9efa-a9b67274e4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1dff75b0-b2d5-437a-bd19-7d4c1bd60d09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_592ffa66-e85f-41e9-b524-b9b1eb30f2a2" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1dff75b0-b2d5-437a-bd19-7d4c1bd60d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8c305451-ba2e-4076-bcd5-75701fbc5f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_592ffa66-e85f-41e9-b524-b9b1eb30f2a2" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8c305451-ba2e-4076-bcd5-75701fbc5f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2edc7d2b-1a96-4994-833e-900d03ee7867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_23f37c17-7df5-4fa8-bba1-4a335def95ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2edc7d2b-1a96-4994-833e-900d03ee7867" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_23f37c17-7df5-4fa8-bba1-4a335def95ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock_0623c07c-0746-4d11-9f45-46b28af6cf15" xlink:href="cdtx-20231231.xsd#cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2edc7d2b-1a96-4994-833e-900d03ee7867" xlink:to="loc_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock_0623c07c-0746-4d11-9f45-46b28af6cf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31f146fc-eea4-460a-b2e2-0e9d08ed692e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2edc7d2b-1a96-4994-833e-900d03ee7867" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31f146fc-eea4-460a-b2e2-0e9d08ed692e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock_0e4f4ac5-2dab-470c-85e4-cea61bafd809" xlink:href="cdtx-20231231.xsd#cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2edc7d2b-1a96-4994-833e-900d03ee7867" xlink:to="loc_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock_0e4f4ac5-2dab-470c-85e4-cea61bafd809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c7f4d150-216a-4f9e-bfa7-7a63432a02ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_f41e9202-1e5a-4b5d-8fcb-2049ae2da5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c7f4d150-216a-4f9e-bfa7-7a63432a02ad" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_f41e9202-1e5a-4b5d-8fcb-2049ae2da5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSTables" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUBSEQUENTEVENTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_15f63b37-2445-41c6-b8ba-79a7e04885c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ba692150-9300-4903-97a5-754a7d8921af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_15f63b37-2445-41c6-b8ba-79a7e04885c9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ba692150-9300-4903-97a5-754a7d8921af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ec1e91f-3606-4c5d-a494-bc73e585e169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_752aed4b-a6fb-4176-8101-52660279e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5ec1e91f-3606-4c5d-a494-bc73e585e169" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_752aed4b-a6fb-4176-8101-52660279e4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6453f860-adde-4ed8-980b-e143beea8292" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_752aed4b-a6fb-4176-8101-52660279e4b9" xlink:to="loc_srt_RestatementAxis_6453f860-adde-4ed8-980b-e143beea8292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_82cc8f1b-4fed-4a71-a95f-ae230e6e20b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_6453f860-adde-4ed8-980b-e143beea8292" xlink:to="loc_srt_RestatementDomain_82cc8f1b-4fed-4a71-a95f-ae230e6e20b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAdjustmentMember_af95783f-a35c-45c8-9c61-db9eaac8b788" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_82cc8f1b-4fed-4a71-a95f-ae230e6e20b3" xlink:to="loc_srt_RestatementAdjustmentMember_af95783f-a35c-45c8-9c61-db9eaac8b788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_752aed4b-a6fb-4176-8101-52660279e4b9" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b7ba96ad-a13b-466c-941d-78451cec6b14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b7ba96ad-a13b-466c-941d-78451cec6b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeb64cf3-c66c-40c3-9c07-d817ad427726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_aeb64cf3-c66c-40c3-9c07-d817ad427726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_64296a16-8670-41c7-85d8-2c0dbbbf6066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_64296a16-8670-41c7-85d8-2c0dbbbf6066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_ebe287a0-3a9d-48a6-8947-4059736224f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_ebe287a0-3a9d-48a6-8947-4059736224f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_df090eed-bc89-4c9a-9941-86d28abfbe91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_bad21bf7-9dbd-4da7-b161-96c51beb613c" xlink:to="loc_us-gaap_OperatingExpenses_df090eed-bc89-4c9a-9941-86d28abfbe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f847c78b-d3bd-4ad4-8942-e56dddb6d696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_391c82fa-a924-490a-8464-a224f2fec092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f847c78b-d3bd-4ad4-8942-e56dddb6d696" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_391c82fa-a924-490a-8464-a224f2fec092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_d9481e75-f51d-4ec9-b157-4cf62db121a1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_391c82fa-a924-490a-8464-a224f2fec092" xlink:to="loc_srt_RestatementAxis_d9481e75-f51d-4ec9-b157-4cf62db121a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_d9481e75-f51d-4ec9-b157-4cf62db121a1" xlink:to="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_37818992-aecf-44a8-b9ef-f560abd8a127" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_37818992-aecf-44a8-b9ef-f560abd8a127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_5d5de890-f2d6-423d-8eec-76ed09c3aa30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_7439eacc-f503-4f2b-8bdc-86680c7181ac" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_5d5de890-f2d6-423d-8eec-76ed09c3aa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_391c82fa-a924-490a-8464-a224f2fec092" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b0a7a06-7526-4fe0-92e5-1259d51db356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b0a7a06-7526-4fe0-92e5-1259d51db356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d71eb252-7424-497e-8e8d-c2d4a3ce9bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_Assets_d71eb252-7424-497e-8e8d-c2d4a3ce9bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_50f7d874-416d-4381-bf98-c2e58c7c4a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_50f7d874-416d-4381-bf98-c2e58c7c4a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_792f9e78-919d-4871-a255-f5bfe42e8a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_792f9e78-919d-4871-a255-f5bfe42e8a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_accade74-edf6-4301-bc39-c0640c765b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_LiabilitiesCurrent_accade74-edf6-4301-bc39-c0640c765b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ecdc9b65-68e5-45b9-9ab2-bbc16132d0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_Liabilities_ecdc9b65-68e5-45b9-9ab2-bbc16132d0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab12b685-fd91-49ad-aae3-88c9c50ea911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab12b685-fd91-49ad-aae3-88c9c50ea911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd0f7ac0-a661-4858-bc40-b59219ecd8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_StockholdersEquity_fd0f7ac0-a661-4858-bc40-b59219ecd8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce401a32-17ba-4be1-8557-3dd70f2f79ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c72394b4-c6ed-4969-a044-4b4eb19643a8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ce401a32-17ba-4be1-8557-3dd70f2f79ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06ba35dc-b67e-4259-b06d-d98ee87aff0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81fd801e-e770-40b1-ae59-19862367a80a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06ba35dc-b67e-4259-b06d-d98ee87aff0f" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81fd801e-e770-40b1-ae59-19862367a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81fd801e-e770-40b1-ae59-19862367a80a" xlink:to="loc_srt_RestatementAxis_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_49ad07b2-82db-4949-a9e1-2d48bd8bf9cf" xlink:to="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_c3311bbf-123a-4bb7-898a-87b8f6e4c3a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_c3311bbf-123a-4bb7-898a-87b8f6e4c3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_77964f85-befe-467b-bc2a-6094128a6125" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_b0f0f1bc-64dc-410d-bb13-782a7fe9727f" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_77964f85-befe-467b-bc2a-6094128a6125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_81fd801e-e770-40b1-ae59-19862367a80a" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_911b26c7-a9b1-48ce-ae9c-938ad41e79df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_911b26c7-a9b1-48ce-ae9c-938ad41e79df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e6bedfd3-62d2-4668-ae4d-f9c9e6cbed2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_Revenues_e6bedfd3-62d2-4668-ae4d-f9c9e6cbed2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5758b5cf-a754-4c6e-8971-7c32c0e81887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5758b5cf-a754-4c6e-8971-7c32c0e81887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cd9d7983-057d-44f9-84cd-8ec29b22292b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cd9d7983-057d-44f9-84cd-8ec29b22292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_48ac4a1c-9556-40b2-80dc-2550c5ba12a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_OperatingExpenses_48ac4a1c-9556-40b2-80dc-2550c5ba12a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0290076c-06a7-42a8-a9f2-81a948c08546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_OperatingIncomeLoss_0290076c-06a7-42a8-a9f2-81a948c08546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba5c2a99-76e9-455e-a111-95ed1315d01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba5c2a99-76e9-455e-a111-95ed1315d01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_40b25aa8-2cd7-43f0-86cf-f56685619aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_NetIncomeLoss_40b25aa8-2cd7-43f0-86cf-f56685619aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_77909d1d-8ef3-494e-a560-026c5533154e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_77909d1d-8ef3-494e-a560-026c5533154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_85d591a0-85e9-4ead-b539-5af8027b4b88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_EarningsPerShareBasic_85d591a0-85e9-4ead-b539-5af8027b4b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ff53cce9-d416-4749-8d6a-ef93cc17e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ff53cce9-d416-4749-8d6a-ef93cc17e6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cdd3bdc2-ea50-4fd6-a1b0-14916be8df10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cdd3bdc2-ea50-4fd6-a1b0-14916be8df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4fee733-d0e3-428e-9ad7-d76500da2d38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f4e22bd9-da22-4653-b635-4f75e9ee4cbe" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d4fee733-d0e3-428e-9ad7-d76500da2d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca292f0a-bddb-4d50-a9a3-2e03310388fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca292f0a-bddb-4d50-a9a3-2e03310388fd" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_a08e28c8-9cfc-4567-acbd-bf9b4afb108d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:to="loc_srt_RestatementAxis_a08e28c8-9cfc-4567-acbd-bf9b4afb108d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_a08e28c8-9cfc-4567-acbd-bf9b4afb108d" xlink:to="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_b5c86d9d-f1ee-457c-a6cc-03d1e6d44301" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_b5c86d9d-f1ee-457c-a6cc-03d1e6d44301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f4c3f0f9-6e16-4282-8074-e49c96afdee5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d46c56ac-8fec-476b-b5be-15a98796d451" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_f4c3f0f9-6e16-4282-8074-e49c96afdee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_eb816905-716d-409b-9b10-ef779a54b56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_eb816905-716d-409b-9b10-ef779a54b56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_eb816905-716d-409b-9b10-ef779a54b56f" xlink:to="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12a4b255-def5-427c-807e-05852bec8997" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12a4b255-def5-427c-807e-05852bec8997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2fd1b663-cf61-4ad7-ad45-3400ec67aa47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_cc978bb5-90a1-4f31-92b4-babe878eb8df" xlink:to="loc_us-gaap_RetainedEarningsMember_2fd1b663-cf61-4ad7-ad45-3400ec67aa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ed01d105-4787-408a-9a79-3af04a8b19da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ed01d105-4787-408a-9a79-3af04a8b19da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60b566c2-359e-4a46-864b-43df06b81032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ed01d105-4787-408a-9a79-3af04a8b19da" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60b566c2-359e-4a46-864b-43df06b81032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnderwrittenPublicOfferingMember_c896850c-6106-4654-9bdd-57331644595a" xlink:href="cdtx-20231231.xsd#cdtx_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_60b566c2-359e-4a46-864b-43df06b81032" xlink:to="loc_cdtx_UnderwrittenPublicOfferingMember_c896850c-6106-4654-9bdd-57331644595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_642f518d-d54a-41dd-b02c-7aed785783d5" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0bdce15c-d8f8-4419-bdf4-16647242d0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_StockholdersEquity_0bdce15c-d8f8-4419-bdf4-16647242d0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90f06f38-8b11-4966-912c-37a0511c5302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_90f06f38-8b11-4966-912c-37a0511c5302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8736426e-e07a-478e-bf24-b0cae2dd6893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_NetIncomeLoss_8736426e-e07a-478e-bf24-b0cae2dd6893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bd425ff9-c380-4f0a-8c3c-dbbc94d93072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e1b1d365-39d2-4cd2-b152-466baad8a4ad" xlink:to="loc_us-gaap_StockholdersEquity_bd425ff9-c380-4f0a-8c3c-dbbc94d93072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c98f12e9-13ee-478a-b8bc-348670f7cae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20b4259d-9473-4b45-866e-1194fe148916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c98f12e9-13ee-478a-b8bc-348670f7cae8" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20b4259d-9473-4b45-866e-1194fe148916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_f2591d74-a476-4a59-9934-0118cba097df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20b4259d-9473-4b45-866e-1194fe148916" xlink:to="loc_srt_RestatementAxis_f2591d74-a476-4a59-9934-0118cba097df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_f2591d74-a476-4a59-9934-0118cba097df" xlink:to="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_17751109-3e93-4e8d-b3e7-055d7e60c672" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_17751109-3e93-4e8d-b3e7-055d7e60c672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_356c0fdf-d82f-462f-9f81-beb41b739997" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_d5665431-85c0-4380-adda-8b81d275725c" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_356c0fdf-d82f-462f-9f81-beb41b739997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f46d4cf0-7c84-4bc6-a454-c8752276bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_20b4259d-9473-4b45-866e-1194fe148916" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f46d4cf0-7c84-4bc6-a454-c8752276bfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_f46d4cf0-7c84-4bc6-a454-c8752276bfbb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f82d168-eb75-459b-bef0-4bcc8c11261b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:to="loc_us-gaap_NetIncomeLoss_8f82d168-eb75-459b-bef0-4bcc8c11261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_959c81f0-ec6a-4dda-9c27-7a0f82ebcd78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_959c81f0-ec6a-4dda-9c27-7a0f82ebcd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_a66fc904-54c9-4ccb-abd8-cc76a5a67edc" xlink:href="cdtx-20231231.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_959c81f0-ec6a-4dda-9c27-7a0f82ebcd78" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_a66fc904-54c9-4ccb-abd8-cc76a5a67edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cb508d9d-c3fc-4e00-957f-9483a6c3f41d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccruedIndirectTaxLiabilities_e1a53d1b-1340-4a73-ac55-4ea10507dfa8" xlink:href="cdtx-20231231.xsd#cdtx_AccruedIndirectTaxLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:to="loc_cdtx_AccruedIndirectTaxLiabilities_e1a53d1b-1340-4a73-ac55-4ea10507dfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88baaa5b-fb5a-4925-b2eb-9138fe1c119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88baaa5b-fb5a-4925-b2eb-9138fe1c119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_70c8bfa0-9801-4723-b567-c990fcbe3706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6edeb8bf-dbf2-46f8-8798-0ad8433421f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_70c8bfa0-9801-4723-b567-c990fcbe3706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f8469310-46bc-4dd2-8bb1-e5d05415a0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f8469310-46bc-4dd2-8bb1-e5d05415a0fb" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:to="loc_srt_RangeAxis_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eaf52e22-36d9-4cbc-870e-a5e8938b9b0c" xlink:to="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e2b5a30-b7d7-4255-9a50-9efaaff5cca2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:to="loc_srt_MinimumMember_5e2b5a30-b7d7-4255-9a50-9efaaff5cca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4a93c4f2-1381-4ba1-8be2-56ae5b7e923a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ac9733bb-9d6a-45a2-8fe5-9fec8072100a" xlink:to="loc_srt_MaximumMember_4a93c4f2-1381-4ba1-8be2-56ae5b7e923a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a5c363db-8c03-4503-9ee7-51efad1137e9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:to="loc_srt_CounterpartyNameAxis_a5c363db-8c03-4503-9ee7-51efad1137e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a5c363db-8c03-4503-9ee7-51efad1137e9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_5628a74d-5e82-451b-a894-8fb8f885b1d8" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_5628a74d-5e82-451b-a894-8fb8f885b1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_74557660-d2f6-47ec-9a82-3a48b42a4e60" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_74557660-d2f6-47ec-9a82-3a48b42a4e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_adc5b3fd-f4fd-41bf-bfbf-3d4cce1b1554" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5db923d-081a-4ebb-8205-f38e71846b9b" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_adc5b3fd-f4fd-41bf-bfbf-3d4cce1b1554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4c81d394-4eee-48d9-8562-251a76888dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4c81d394-4eee-48d9-8562-251a76888dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d665c54-f2c2-4d24-b1e6-482c3a139bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4c81d394-4eee-48d9-8562-251a76888dff" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d665c54-f2c2-4d24-b1e6-482c3a139bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenCollaborationAgreementMember_bbc25e55-b865-4adf-8574-a2f055f51182" xlink:href="cdtx-20231231.xsd#cdtx_JanssenCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d665c54-f2c2-4d24-b1e6-482c3a139bd9" xlink:to="loc_cdtx_JanssenCollaborationAgreementMember_bbc25e55-b865-4adf-8574-a2f055f51182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_71858457-4b16-4946-a3b0-37d9fa5a3d43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f2ce9aed-f8e7-4987-88cb-3b7e6582af03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f2ce9aed-f8e7-4987-88cb-3b7e6582af03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_7ed5148d-ed6d-46e8-b786-f926559818a0" xlink:href="cdtx-20231231.xsd#cdtx_CollaborationAgreementNumberOfPerformanceObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:to="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_7ed5148d-ed6d-46e8-b786-f926559818a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54626668-fd5f-4763-b04a-13edc08cae1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_082e6b49-69bd-4981-afb6-eab29902e875" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54626668-fd5f-4763-b04a-13edc08cae1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7bf269ec-9ccd-4124-8859-e988172dd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7a2c511-ff9b-4169-9729-6c278d63598e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bf269ec-9ccd-4124-8859-e988172dd26b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7a2c511-ff9b-4169-9729-6c278d63598e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a298a17-6995-4778-afef-b3f4a356428a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7a2c511-ff9b-4169-9729-6c278d63598e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a298a17-6995-4778-afef-b3f4a356428a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0a298a17-6995-4778-afef-b3f4a356428a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2d7ad869-9410-422d-acda-8f29b9fe1403" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:to="loc_us-gaap_WarrantMember_2d7ad869-9410-422d-acda-8f29b9fe1403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1eb3e757-9cce-457e-8487-e0c92ca7f856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1eb3e757-9cce-457e-8487-e0c92ca7f856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_046696b8-0aab-4548-bddb-0ebe69097c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f9a92d7-5cfa-4440-93e0-82c0d4482835" xlink:to="loc_us-gaap_StockCompensationPlanMember_046696b8-0aab-4548-bddb-0ebe69097c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e4e0896-1076-494a-a1aa-c6f37f3ebacc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b7a2c511-ff9b-4169-9729-6c278d63598e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e4e0896-1076-494a-a1aa-c6f37f3ebacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3eb3866e-8191-4a3b-ba03-37ab2d62c089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7e4e0896-1076-494a-a1aa-c6f37f3ebacc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3eb3866e-8191-4a3b-ba03-37ab2d62c089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_42ea8ca5-f7ac-4b70-aa24-07139e1eee8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddce1dc2-b4a2-496f-b676-d3f7cb5c393a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42ea8ca5-f7ac-4b70-aa24-07139e1eee8e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddce1dc2-b4a2-496f-b676-d3f7cb5c393a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddce1dc2-b4a2-496f-b676-d3f7cb5c393a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_33d2f662-7b00-4e5d-90ec-33e2bcb72cd2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_26659bb2-b131-48a9-a6d1-79f406fe3a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_26659bb2-b131-48a9-a6d1-79f406fe3a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4cc5c707-8953-4443-bc18-57018050ec40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4cc5c707-8953-4443-bc18-57018050ec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_561518f4-10f7-4a5b-a8dd-706cd6a97592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab243856-53ef-48ef-9968-cc26b85ef686" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_561518f4-10f7-4a5b-a8dd-706cd6a97592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c751417-4109-4343-a7cb-4e2ade3b1700" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ddce1dc2-b4a2-496f-b676-d3f7cb5c393a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c751417-4109-4343-a7cb-4e2ade3b1700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c751417-4109-4343-a7cb-4e2ade3b1700" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70d1db4f-3a60-408b-b991-1936d1ad762f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_70d1db4f-3a60-408b-b991-1936d1ad762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8922f298-3fae-4426-a7a2-69d5d2c3d043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_48299882-b5d1-48bf-9151-26419c1b9d06" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8922f298-3fae-4426-a7a2-69d5d2c3d043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INVENTORYScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ade9fc90-ab8d-441c-8865-9cf0aec7f066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d304d3ed-5800-44dc-bde8-fcae2a67414e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ade9fc90-ab8d-441c-8865-9cf0aec7f066" xlink:to="loc_us-gaap_InventoryRawMaterials_d304d3ed-5800-44dc-bde8-fcae2a67414e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_f922f651-7ef6-4166-a80e-75812a2e6175" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ade9fc90-ab8d-441c-8865-9cf0aec7f066" xlink:to="loc_us-gaap_InventoryWorkInProcess_f922f651-7ef6-4166-a80e-75812a2e6175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_4a545fc4-50eb-4274-abb6-b931bcaec9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ade9fc90-ab8d-441c-8865-9cf0aec7f066" xlink:to="loc_us-gaap_InventoryFinishedGoods_4a545fc4-50eb-4274-abb6-b931bcaec9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0701f41-77d2-4969-b424-9bb3e27f67a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ade9fc90-ab8d-441c-8865-9cf0aec7f066" xlink:to="loc_us-gaap_InventoryNet_e0701f41-77d2-4969-b424-9bb3e27f67a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INVENTORYNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INVENTORYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INVENTORYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0abdb823-ed46-4694-94db-b9e76c8a9674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_37fd7511-15a0-4ec3-ad9b-f0d3a364fa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0abdb823-ed46-4694-94db-b9e76c8a9674" xlink:to="loc_us-gaap_InventoryWriteDown_37fd7511-15a0-4ec3-ad9b-f0d3a364fa5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e83af7ec-245d-4777-b3b5-e9add0896baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ac74f98-a125-4e71-8de2-cc869f6561c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e83af7ec-245d-4777-b3b5-e9add0896baf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ac74f98-a125-4e71-8de2-cc869f6561c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ac74f98-a125-4e71-8de2-cc869f6561c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1be3cd11-0d18-4a48-a5ce-4c871ddb3fe5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f9444f82-03a5-4713-8033-cd192ecb4eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_EquipmentMember_f9444f82-03a5-4713-8033-cd192ecb4eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_06bb822b-e2f1-476f-9ff5-81c39b33203b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_06bb822b-e2f1-476f-9ff5-81c39b33203b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d15879d9-e1d2-4437-b4d5-5fdff6005f74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_ComputerEquipmentMember_d15879d9-e1d2-4437-b4d5-5fdff6005f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_09da3485-4e61-432b-b26a-547c3538abc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_OfficeEquipmentMember_09da3485-4e61-432b-b26a-547c3538abc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_87af744f-ecd9-463b-ab3b-366ce2142799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ecd7d5-0511-459b-8160-971ecc4c9bd1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_87af744f-ecd9-463b-ab3b-366ce2142799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ac74f98-a125-4e71-8de2-cc869f6561c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4dd73578-4e6a-4f27-9d1c-6a81e02114a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4dd73578-4e6a-4f27-9d1c-6a81e02114a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_550d948a-04a4-475f-87da-b5ed43d05a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_550d948a-04a4-475f-87da-b5ed43d05a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b437988-cefd-4ff2-ad75-21b4c9a43dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_85939382-e15f-43a0-bc81-17d990a071c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b437988-cefd-4ff2-ad75-21b4c9a43dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/PROPERTYANDEQUIPMENTAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#PROPERTYANDEQUIPMENTAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/PROPERTYANDEQUIPMENTAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fd46c694-4070-44bc-b9f6-b046cc107308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_cf70d906-e0c0-46bc-b58d-9af5d36090f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_fd46c694-4070-44bc-b9f6-b046cc107308" xlink:to="loc_us-gaap_DepreciationAndAmortization_cf70d906-e0c0-46bc-b58d-9af5d36090f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#DEBTDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_10c33b5e-909e-4e6d-afcf-b5ef563050e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_10c33b5e-909e-4e6d-afcf-b5ef563050e1" xlink:to="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d9b9d025-7c1d-4b8b-a438-60eb417ab995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d9b9d025-7c1d-4b8b-a438-60eb417ab995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_56adbcd1-50c1-4473-8f0a-6f36814a7984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d9b9d025-7c1d-4b8b-a438-60eb417ab995" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_56adbcd1-50c1-4473-8f0a-6f36814a7984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_fbfb982c-4851-42c9-b8aa-fa574038743e" xlink:href="cdtx-20231231.xsd#cdtx_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_56adbcd1-50c1-4473-8f0a-6f36814a7984" xlink:to="loc_cdtx_TermLoanMember_fbfb982c-4851-42c9-b8aa-fa574038743e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_223a9086-0135-4176-900e-7f9d90f32ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:to="loc_us-gaap_DebtInstrumentAxis_223a9086-0135-4176-900e-7f9d90f32ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_38fae803-4f38-4a4d-a74f-1536aaa81944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_223a9086-0135-4176-900e-7f9d90f32ced" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_38fae803-4f38-4a4d-a74f-1536aaa81944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_05700614-044e-46e2-8409-59c1a3d5d9d3" xlink:href="cdtx-20231231.xsd#cdtx_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_38fae803-4f38-4a4d-a74f-1536aaa81944" xlink:to="loc_cdtx_TermLoanAMember_05700614-044e-46e2-8409-59c1a3d5d9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_f9a23ea5-a99b-4843-8551-69e6c96b8028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:to="loc_us-gaap_VariableRateAxis_f9a23ea5-a99b-4843-8551-69e6c96b8028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_449f36c7-8093-448b-8497-eda879c31a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_f9a23ea5-a99b-4843-8551-69e6c96b8028" xlink:to="loc_us-gaap_VariableRateDomain_449f36c7-8093-448b-8497-eda879c31a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_7d0d40c6-2a83-40f5-acf0-d23e059c0049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_449f36c7-8093-448b-8497-eda879c31a7b" xlink:to="loc_us-gaap_PrimeRateMember_7d0d40c6-2a83-40f5-acf0-d23e059c0049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_04313201-a504-4aa3-ada8-39d5438cd399" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_5ced85b9-afb6-4e4d-aa36-5950a83e1620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_5ced85b9-afb6-4e4d-aa36-5950a83e1620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a5a26cd9-2efd-4c51-91b7-0e3824959fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_a5a26cd9-2efd-4c51-91b7-0e3824959fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ab3729cc-d261-4070-b3c2-e967d624d6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d685e9ef-a10c-4c3f-bf60-59d40eaf999c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ab3729cc-d261-4070-b3c2-e967d624d6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#STOCKHOLDERSEQUITYAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8c88aa97-8a5d-40e9-a8fa-6924c448b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c88aa97-8a5d-40e9-a8fa-6924c448b58a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98a700fa-b6eb-4b05-81a4-ed3e58e49f8c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_97433320-22fe-4f12-b032-b62a5c40ffee" xlink:href="cdtx-20231231.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_97433320-22fe-4f12-b032-b62a5c40ffee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_A2023UnderwrittenPublicOfferingMember_93a5c413-f59b-46a4-906d-ac1109b94bb8" xlink:href="cdtx-20231231.xsd#cdtx_A2023UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:to="loc_cdtx_A2023UnderwrittenPublicOfferingMember_93a5c413-f59b-46a4-906d-ac1109b94bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_bafd5aad-719a-4447-854f-1c34b076f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec8eea40-d6f1-4f2d-86da-8e20d57fbc1f" xlink:to="loc_us-gaap_OverAllotmentOptionMember_bafd5aad-719a-4447-854f-1c34b076f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c57c6b43-194b-476e-97a0-403a5d522889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c57c6b43-194b-476e-97a0-403a5d522889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6967499f-a084-47ff-b345-1fd697829eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c57c6b43-194b-476e-97a0-403a5d522889" xlink:to="loc_us-gaap_EquityComponentDomain_6967499f-a084-47ff-b345-1fd697829eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e99b6f08-b001-404c-b42b-e89955523aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6967499f-a084-47ff-b345-1fd697829eb5" xlink:to="loc_us-gaap_CommonStockMember_e99b6f08-b001-404c-b42b-e89955523aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3dacb9ba-5fe8-423e-8141-a92b0bdb4f19" xlink:to="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_4369d981-e68e-4bbe-a35a-7d1884385bdc" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_4369d981-e68e-4bbe-a35a-7d1884385bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1339ee5-44f5-42a1-bdc4-69b0988bafeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_002655b1-b7f6-4e80-b44a-a26c2b485bd7" xlink:to="loc_us-gaap_CommonStockMember_e1339ee5-44f5-42a1-bdc4-69b0988bafeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_d16e21df-45d4-4b82-8250-52cc29e5b9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_d16e21df-45d4-4b82-8250-52cc29e5b9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2b3ca187-6f7e-471f-b51d-d1335c91fda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_d16e21df-45d4-4b82-8250-52cc29e5b9f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2b3ca187-6f7e-471f-b51d-d1335c91fda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_d12e99ef-cfab-419c-ac6d-160a20947cdc" xlink:href="cdtx-20231231.xsd#cdtx_CommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2b3ca187-6f7e-471f-b51d-d1335c91fda7" xlink:to="loc_cdtx_CommonStockWarrantMember_d12e99ef-cfab-419c-ac6d-160a20947cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba25f96d-59be-42a3-867f-0a83c26107e2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_srt_RangeAxis_ba25f96d-59be-42a3-867f-0a83c26107e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2108cba1-1f34-4083-9942-d02d9a657078" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba25f96d-59be-42a3-867f-0a83c26107e2" xlink:to="loc_srt_RangeMember_2108cba1-1f34-4083-9942-d02d9a657078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_40e7eb62-cf4a-429b-8d73-3cf525152ae5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2108cba1-1f34-4083-9942-d02d9a657078" xlink:to="loc_srt_WeightedAverageMember_40e7eb62-cf4a-429b-8d73-3cf525152ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_b0613c1b-5dbd-4df3-adf1-1badeb005f85" xlink:to="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_457d190f-8cfc-49d6-a197-418f755b2bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_457d190f-8cfc-49d6-a197-418f755b2bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a7133d2f-555f-4d20-8928-58cb4e9f4223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a7133d2f-555f-4d20-8928-58cb4e9f4223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_89e439f9-37f9-440c-9434-a5c125735d94" xlink:href="cdtx-20231231.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_89e439f9-37f9-440c-9434-a5c125735d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d0aa3bb2-1e5b-47f7-91e0-68d35d3e2bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d0aa3bb2-1e5b-47f7-91e0-68d35d3e2bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a8ae2cc5-5dba-44f7-bdf5-792947859ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_a8ae2cc5-5dba-44f7-bdf5-792947859ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_eba39dc6-b724-445c-990d-ba265676e3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_eba39dc6-b724-445c-990d-ba265676e3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ed18c965-e899-4a9f-885c-ed577528736d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ed18c965-e899-4a9f-885c-ed577528736d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c3fd07e2-ce35-4de5-8c70-f68502175ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c3fd07e2-ce35-4de5-8c70-f68502175ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_136aa778-9b01-4185-899d-52bf5ce83625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_136aa778-9b01-4185-899d-52bf5ce83625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_cd14c541-7cdc-4370-9798-e7665869875c" xlink:href="cdtx-20231231.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_cd14c541-7cdc-4370-9798-e7665869875c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_477a8f0e-68b2-41d6-8407-f3937362f2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_477a8f0e-68b2-41d6-8407-f3937362f2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_a490043b-a0bb-4c3b-9238-b195183ccafe" xlink:href="cdtx-20231231.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_a490043b-a0bb-4c3b-9238-b195183ccafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9f4ed0c7-40bd-42f9-a148-8364d5b2fa09" xlink:href="cdtx-20231231.xsd#cdtx_CommonStockDividendsInArrearsOrDefault"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_CommonStockDividendsInArrearsOrDefault_9f4ed0c7-40bd-42f9-a148-8364d5b2fa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_230cd1c9-9328-4a9d-89de-2d029b03cedf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_230cd1c9-9328-4a9d-89de-2d029b03cedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_982322f9-bd9b-482c-83c8-f4e45546e7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_982322f9-bd9b-482c-83c8-f4e45546e7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClassOfWarrantOrRightExpired_5258e91b-cef8-44ad-9248-edf3d7801445" xlink:href="cdtx-20231231.xsd#cdtx_ClassOfWarrantOrRightExpired"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_cdtx_ClassOfWarrantOrRightExpired_5258e91b-cef8-44ad-9248-edf3d7801445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_03c2a56c-91ec-4335-9a78-ee7a775644ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_300b1afa-d5b3-4f6c-91a8-3268b7db19ff" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_03c2a56c-91ec-4335-9a78-ee7a775644ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_03a484df-8bb4-4413-86aa-da003820b60a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_fbc6fadb-b962-4bf8-9b25-ec4a3dd93eed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_03a484df-8bb4-4413-86aa-da003820b60a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_fbc6fadb-b962-4bf8-9b25-ec4a3dd93eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fbc6fadb-b962-4bf8-9b25-ec4a3dd93eed" xlink:to="loc_us-gaap_AwardTypeAxis_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_02c5fe87-6eb8-43ec-b6bb-40faf71fb7f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_32e7ef4a-a7ca-4867-9460-39896d067166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_us-gaap_WarrantMember_32e7ef4a-a7ca-4867-9460-39896d067166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_2c50ae50-9dd2-437b-9137-842d1cfe9552" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_2c50ae50-9dd2-437b-9137-842d1cfe9552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_4763a607-430f-4550-b0ce-a30a7b2bd101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_us-gaap_StockCompensationPlanMember_4763a607-430f-4550-b0ce-a30a7b2bd101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_12ce90e1-f983-4ae3-af40-9bf7ae9dc630" xlink:href="cdtx-20231231.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_12ce90e1-f983-4ae3-af40-9bf7ae9dc630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_8a35b831-81fa-455c-9105-8d67d3abdd11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_89ab4f27-8f8c-4c75-8574-4607dc8bc22a" xlink:to="loc_us-gaap_EmployeeStockMember_8a35b831-81fa-455c-9105-8d67d3abdd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b8004e19-8a66-4539-be3b-cab3d2a04bac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_fbc6fadb-b962-4bf8-9b25-ec4a3dd93eed" xlink:to="loc_us-gaap_ClassOfStockLineItems_b8004e19-8a66-4539-be3b-cab3d2a04bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11b4a6c8-e336-4402-80bf-efabcfdcfc63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b8004e19-8a66-4539-be3b-cab3d2a04bac" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_11b4a6c8-e336-4402-80bf-efabcfdcfc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b789e96a-8de7-41cf-b729-b75d35b856f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b789e96a-8de7-41cf-b729-b75d35b856f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_254aa51b-43fc-4c54-baea-c0f851b8158b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_us-gaap_PlanNameAxis_254aa51b-43fc-4c54-baea-c0f851b8158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_254aa51b-43fc-4c54-baea-c0f851b8158b" xlink:to="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_0b6047b9-1ab5-4811-ad50-e8de3414ca34" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:to="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_0b6047b9-1ab5-4811-ad50-e8de3414ca34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1f14b65d-4602-4d8d-a4f3-d9a8f7ca9119" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f43f66e2-040b-4da7-a1ef-402e5121e468" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1f14b65d-4602-4d8d-a4f3-d9a8f7ca9119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46b0801c-0980-448b-9cd3-401078396dfb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_srt_RangeAxis_46b0801c-0980-448b-9cd3-401078396dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46b0801c-0980-448b-9cd3-401078396dfb" xlink:to="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d19d0ab8-f377-48ef-9e9e-4f6979b94beb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:to="loc_srt_MinimumMember_d19d0ab8-f377-48ef-9e9e-4f6979b94beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1f0f99b6-1d5d-4166-b330-efe3fb44cbe7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ff68874-eb54-4655-bc4f-1cf9588763a4" xlink:to="loc_srt_MaximumMember_1f0f99b6-1d5d-4166-b330-efe3fb44cbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2e886e4a-eff1-4636-a794-b56f73267825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2e886e4a-eff1-4636-a794-b56f73267825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_61e98c08-0e4d-441d-8ab2-717a9b14decd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_2e886e4a-eff1-4636-a794-b56f73267825" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_61e98c08-0e4d-441d-8ab2-717a9b14decd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_2d9bda6e-26ca-40ee-9e9c-213a6f336c2d" xlink:href="cdtx-20231231.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_61e98c08-0e4d-441d-8ab2-717a9b14decd" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_2d9bda6e-26ca-40ee-9e9c-213a6f336c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b502c7c-48eb-4e6e-9d4c-f2b597637788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_us-gaap_AwardTypeAxis_0b502c7c-48eb-4e6e-9d4c-f2b597637788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0b502c7c-48eb-4e6e-9d4c-f2b597637788" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bd7af3a6-505a-44f3-a162-87da182a6cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:to="loc_us-gaap_EmployeeStockMember_bd7af3a6-505a-44f3-a162-87da182a6cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_a33e8d52-1736-4ebe-8a84-d8b85e0d6fb5" xlink:href="cdtx-20231231.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_a33e8d52-1736-4ebe-8a84-d8b85e0d6fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a0ba4c4a-8f3a-4f38-a352-0ff42b478e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04086830-9ac3-4b61-878b-24e5b2f5ba6d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a0ba4c4a-8f3a-4f38-a352-0ff42b478e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18b3e9a0-924b-4efa-b5b5-08fb2ace4db8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_72fac9c1-80d0-4c50-a0aa-a1faf037122d" xlink:href="cdtx-20231231.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_72fac9c1-80d0-4c50-a0aa-a1faf037122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_135f3cdf-d16f-4443-a3bc-f8f0f925e650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_135f3cdf-d16f-4443-a3bc-f8f0f925e650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e2d369d5-5239-4e34-80ad-5685be7c66b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_e2d369d5-5239-4e34-80ad-5685be7c66b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_70abce16-92f2-482f-ba42-9c8c850ad9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_70abce16-92f2-482f-ba42-9c8c850ad9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_bae1c7ff-f568-4371-b10d-19b82761dea2" xlink:href="cdtx-20231231.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_bae1c7ff-f568-4371-b10d-19b82761dea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43abe4aa-321a-4134-abcb-b7c7e0a6e459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_43abe4aa-321a-4134-abcb-b7c7e0a6e459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1337708e-c456-4c75-89c8-ab2bbd973a40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_1337708e-c456-4c75-89c8-ab2bbd973a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9063460c-89ce-4233-9c86-0b36c48ed632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_9063460c-89ce-4233-9c86-0b36c48ed632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ecdfd77-007e-4398-a664-c86c733f9b19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9ecdfd77-007e-4398-a664-c86c733f9b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bced4cf7-54c3-44b1-b138-1cc56271b93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bced4cf7-54c3-44b1-b138-1cc56271b93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_69c716df-59f9-465a-abb0-14e6fa529f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_69c716df-59f9-465a-abb0-14e6fa529f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e73b12e9-6c93-45a4-836c-f179eb5c632b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_e73b12e9-6c93-45a4-836c-f179eb5c632b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_284a6c94-809b-41b9-a689-ddf2b1af8357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_284a6c94-809b-41b9-a689-ddf2b1af8357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4817629d-8e28-4195-9a26-9fe14bfb8824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2922eb45-3312-42bf-8c70-7f5948e919ca" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4817629d-8e28-4195-9a26-9fe14bfb8824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f06f952-5bb9-4152-b1cd-a6a69efd334c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80da6893-9c8b-4613-a8d4-90720366d26b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5f06f952-5bb9-4152-b1cd-a6a69efd334c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80da6893-9c8b-4613-a8d4-90720366d26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_03e9f70e-9f7d-4164-8442-535ef7ff1b21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80da6893-9c8b-4613-a8d4-90720366d26b" xlink:to="loc_us-gaap_AwardTypeAxis_03e9f70e-9f7d-4164-8442-535ef7ff1b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dbc25bd-0da5-48a2-9689-588166652837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_03e9f70e-9f7d-4164-8442-535ef7ff1b21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dbc25bd-0da5-48a2-9689-588166652837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_15fbc8e0-fc3c-4b45-9b5d-e174e2ab95de" xlink:href="cdtx-20231231.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0dbc25bd-0da5-48a2-9689-588166652837" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_15fbc8e0-fc3c-4b45-9b5d-e174e2ab95de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_80da6893-9c8b-4613-a8d4-90720366d26b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c26e7f37-b7c9-4bea-8187-558024584f26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c26e7f37-b7c9-4bea-8187-558024584f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24fd675a-251d-48c4-a387-3b3f0954dc67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_24fd675a-251d-48c4-a387-3b3f0954dc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9e8bee25-be8b-46f7-8087-bbe211aabc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9e8bee25-be8b-46f7-8087-bbe211aabc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9386b18c-e6e2-4220-be1a-c5c3072df7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9386b18c-e6e2-4220-be1a-c5c3072df7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2561dda5-92ae-4192-a566-c6413bb9859f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3748c504-416b-4f9d-877f-eee5faf95ab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2561dda5-92ae-4192-a566-c6413bb9859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4e3e8002-01fb-4146-93b8-0ea78b0bb352" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ec49755-5501-4c41-899a-7f26eafe15cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ec49755-5501-4c41-899a-7f26eafe15cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25b3b8bf-8dfe-4537-8d58-00a417395f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_25b3b8bf-8dfe-4537-8d58-00a417395f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e44e9fa7-cb48-49d8-8389-114893416846" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e44e9fa7-cb48-49d8-8389-114893416846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46bbc75f-7667-452c-a1e4-8ab89a2d1380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_46bbc75f-7667-452c-a1e4-8ab89a2d1380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c53556d9-8087-47d7-97a1-199089d51395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f2345d02-5a6c-4cd6-983e-b7c83e44d7b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c53556d9-8087-47d7-97a1-199089d51395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c91065-0147-41b0-ba4e-d19e8c52f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c91065-0147-41b0-ba4e-d19e8c52f1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a353e7b-97a5-45af-8891-1283c14d4e87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c91065-0147-41b0-ba4e-d19e8c52f1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2a353e7b-97a5-45af-8891-1283c14d4e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7f13e95-5863-4745-b7ff-6bfb56c88a11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c91065-0147-41b0-ba4e-d19e8c52f1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a7f13e95-5863-4745-b7ff-6bfb56c88a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3cb67424-76ee-4098-9a68-51283e18e379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c91065-0147-41b0-ba4e-d19e8c52f1eb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3cb67424-76ee-4098-9a68-51283e18e379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1197a08b-83aa-4d27-83fc-07bc8afbb02f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c91065-0147-41b0-ba4e-d19e8c52f1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1197a08b-83aa-4d27-83fc-07bc8afbb02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9fa7cc9c-4716-40b1-b287-c5e0b04ae254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0c91065-0147-41b0-ba4e-d19e8c52f1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9fa7cc9c-4716-40b1-b287-c5e0b04ae254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_937f337f-fb87-4f85-a067-4a24d1109d78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_937f337f-fb87-4f85-a067-4a24d1109d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d4e51785-63cb-4568-a783-3be34c4cdb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d4e51785-63cb-4568-a783-3be34c4cdb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_710f699e-e448-4b58-aee2-fd7ba83a0981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_710f699e-e448-4b58-aee2-fd7ba83a0981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1b67b998-0886-4d2d-95e1-ed9a1cff7549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_710f699e-e448-4b58-aee2-fd7ba83a0981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1b67b998-0886-4d2d-95e1-ed9a1cff7549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6347206e-2e62-4611-8cc3-140e165f9f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_710f699e-e448-4b58-aee2-fd7ba83a0981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6347206e-2e62-4611-8cc3-140e165f9f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_94b8e456-b177-49ad-8e28-c8ea259f61b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_710f699e-e448-4b58-aee2-fd7ba83a0981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_94b8e456-b177-49ad-8e28-c8ea259f61b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ca6ef61-b51e-4fd5-afce-714bc86a46a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_710f699e-e448-4b58-aee2-fd7ba83a0981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8ca6ef61-b51e-4fd5-afce-714bc86a46a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66936150-42e0-4aad-9222-74e3d2ba0969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_710f699e-e448-4b58-aee2-fd7ba83a0981" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66936150-42e0-4aad-9222-74e3d2ba0969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_449cf855-fbc5-4cd5-8b91-c1cea402bf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_449cf855-fbc5-4cd5-8b91-c1cea402bf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e15d68a8-2dc0-495b-82ef-c4f05395ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e15d68a8-2dc0-495b-82ef-c4f05395ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5edb8cbb-dcb8-44c1-bac6-bb32a115b621" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5edb8cbb-dcb8-44c1-bac6-bb32a115b621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_233eb1b5-31ae-4bd7-8f92-93ffc64a306e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5edb8cbb-dcb8-44c1-bac6-bb32a115b621" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_233eb1b5-31ae-4bd7-8f92-93ffc64a306e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1ab7697f-73f1-45a6-a7b1-fefcc04422c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5edb8cbb-dcb8-44c1-bac6-bb32a115b621" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1ab7697f-73f1-45a6-a7b1-fefcc04422c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6115d745-7965-4667-9cbf-d29504bddaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5edb8cbb-dcb8-44c1-bac6-bb32a115b621" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6115d745-7965-4667-9cbf-d29504bddaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_a8d5c24f-5c4c-4830-bacf-c272636862c6" xlink:href="cdtx-20231231.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aefb96f5-71cc-476b-9b71-7538e0f205ac" xlink:to="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_a8d5c24f-5c4c-4830-bacf-c272636862c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04c90c50-740b-401d-93c5-383ce3fdb9af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_a8d5c24f-5c4c-4830-bacf-c272636862c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_04c90c50-740b-401d-93c5-383ce3fdb9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9d729da3-1979-4e22-a512-df0b45fd0d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_a8d5c24f-5c4c-4830-bacf-c272636862c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9d729da3-1979-4e22-a512-df0b45fd0d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d68c91e7-6ce2-41b2-b519-934dfef62169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_a8d5c24f-5c4c-4830-bacf-c272636862c6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d68c91e7-6ce2-41b2-b519-934dfef62169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a443d797-6693-4b2f-ac95-d1efb3bb394f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a443d797-6693-4b2f-ac95-d1efb3bb394f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0d228e75-50d6-40f7-84ed-dac5ed1d7d12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:to="loc_us-gaap_PlanNameAxis_0d228e75-50d6-40f7-84ed-dac5ed1d7d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0d228e75-50d6-40f7-84ed-dac5ed1d7d12" xlink:to="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b5b0f2f4-bf39-4ce2-ae11-208155de28ff" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:to="loc_cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember_b5b0f2f4-bf39-4ce2-ae11-208155de28ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1fcbd425-73c3-4eea-b1c8-d0cd29c9e0e9" xlink:href="cdtx-20231231.xsd#cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3eefaf99-8284-4719-8890-9ac5b88f465c" xlink:to="loc_cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember_1fcbd425-73c3-4eea-b1c8-d0cd29c9e0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5fd3a030-ece0-485d-9775-a20d85a8c36c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:to="loc_srt_RangeAxis_5fd3a030-ece0-485d-9775-a20d85a8c36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5fd3a030-ece0-485d-9775-a20d85a8c36c" xlink:to="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6a2703f5-9a60-403a-b807-7d941e088e33" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:to="loc_srt_MinimumMember_6a2703f5-9a60-403a-b807-7d941e088e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_35aec709-f0ed-44c3-a78b-d3b58d3be94a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8920c938-6281-4b53-b7f4-55338ecc8772" xlink:to="loc_srt_MaximumMember_35aec709-f0ed-44c3-a78b-d3b58d3be94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a13cd1d3-1759-4075-9ea6-4ee2bfe65748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b131fdaa-6c45-4885-93ce-48bf53545c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b131fdaa-6c45-4885-93ce-48bf53545c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8988dc39-f934-4c1e-bd9d-29c3ee632dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8988dc39-f934-4c1e-bd9d-29c3ee632dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4610ae4e-8c99-4ab6-a5e8-11574f677548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4610ae4e-8c99-4ab6-a5e8-11574f677548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_748c6619-563a-43e6-83e5-5c4eb774223a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_748c6619-563a-43e6-83e5-5c4eb774223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9c549011-d6d6-48c0-ba5e-b727909232a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9c549011-d6d6-48c0-ba5e-b727909232a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c9c4eae-5066-49c5-b78e-2a729f6371aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0148f7d4-4a21-4d7a-8ebf-2bb05a0aceb9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7c9c4eae-5066-49c5-b78e-2a729f6371aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0f1b6d5-7d1f-407a-bed2-c4c2ef7a9a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f20b9950-93d3-46b2-901c-3bfe9ee51070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c0f1b6d5-7d1f-407a-bed2-c4c2ef7a9a1d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f20b9950-93d3-46b2-901c-3bfe9ee51070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_51b64c7e-eeca-4295-aaae-5a8006bf7786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f20b9950-93d3-46b2-901c-3bfe9ee51070" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_51b64c7e-eeca-4295-aaae-5a8006bf7786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_51b64c7e-eeca-4295-aaae-5a8006bf7786" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cde133f1-aaf0-4461-9b90-5ed579adf1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cde133f1-aaf0-4461-9b90-5ed579adf1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0168f14f-f969-4077-9cb8-6a7160691be3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_cd587cda-b069-441b-a031-77ee93249571" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0168f14f-f969-4077-9cb8-6a7160691be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8346357a-84ab-472e-bb38-8a3b66e05584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f20b9950-93d3-46b2-901c-3bfe9ee51070" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8346357a-84ab-472e-bb38-8a3b66e05584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2f7b3b3-6786-45da-a51a-694fec760994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8346357a-84ab-472e-bb38-8a3b66e05584" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a2f7b3b3-6786-45da-a51a-694fec760994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e21f1e2c-d5ea-4530-8fc1-fbd880c8f1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e21f1e2c-d5ea-4530-8fc1-fbd880c8f1d0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d84fb28a-4ccb-4dcb-941b-9b5d7e459551" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_3e4abfb6-0ba4-444a-ae47-a1f8a11097e2" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_3e4abfb6-0ba4-444a-ae47-a1f8a11097e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_15cfb0bd-23e6-4050-937a-bc854bb5e838" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_15cfb0bd-23e6-4050-937a-bc854bb5e838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_77f46566-d783-4dc4-acac-5723f0d7dc49" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0f703dcf-3eba-4b91-ab9c-bd848742f5c7" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_77f46566-d783-4dc4-acac-5723f0d7dc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_418ad4b1-0f88-4635-a4a5-9c6358c94f93" xlink:to="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_28abfe6c-8b07-4b3f-b0c3-4cdb0861271f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f5527059-28ba-4be6-bc17-850190190258" xlink:to="loc_us-gaap_RelatedPartyMember_28abfe6c-8b07-4b3f-b0c3-4cdb0861271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d612ed0c-2ee0-49a1-8865-683996638342" xlink:to="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_704df7c3-6f98-4134-8af0-43f3e1355036" xlink:href="cdtx-20231231.xsd#cdtx_MilestoneAchievementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_cdtx_MilestoneAchievementMember_704df7c3-6f98-4134-8af0-43f3e1355036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyMember_d2e31b1e-2f7e-4d2b-acba-d48ae428b7c9" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyMember_d2e31b1e-2f7e-4d2b-acba-d48ae428b7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_61eca6eb-bac9-4252-9452-b5be4f80bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0684690-696a-4d38-88af-5a0adbec7738" xlink:to="loc_us-gaap_RoyaltyMember_61eca6eb-bac9-4252-9452-b5be4f80bb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_9d7b3e13-21b9-4097-91d1-f1c4c77e0cac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_53f07a89-cd3f-45f6-a4ad-cef15b6e0198" xlink:href="cdtx-20231231.xsd#cdtx_UpfrontPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_UpfrontPaymentMember_53f07a89-cd3f-45f6-a4ad-cef15b6e0198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_aa3f06c7-7e2f-4613-b5e0-63cda6c248ed" xlink:href="cdtx-20231231.xsd#cdtx_RDFundingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_RDFundingMember_aa3f06c7-7e2f-4613-b5e0-63cda6c248ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_22c5331a-d8c4-4b29-8080-e4a06199de06" xlink:href="cdtx-20231231.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_cf318583-3e44-4b70-bea2-7f8e195d72e2" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_22c5331a-d8c4-4b29-8080-e4a06199de06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a97523b4-b701-4fcf-8c57-4d6adfc3464c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ef0073e0-0bce-4fd9-a234-c8e7862b966a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b350fe46-57b7-4e70-8dd1-8b3b9bce52fa" xlink:to="loc_us-gaap_SubsequentEventMember_ef0073e0-0bce-4fd9-a234-c8e7862b966a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_706250bd-5dc4-4c1b-bbf9-fd04c37f70ff" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyMember_4db6d9ad-f0e0-4961-89a1-79f997955103" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyMember_4db6d9ad-f0e0-4961-89a1-79f997955103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_a1d10a15-9209-4cdb-8a84-015748e67060" xlink:href="cdtx-20231231.xsd#cdtx_MilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_a01ddcbe-ac1b-4386-85b5-ec3a4af7baae" xlink:to="loc_cdtx_MilestoneAchievementMember_a1d10a15-9209-4cdb-8a84-015748e67060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0433009f-1d0a-42c2-bebc-8d27d796cd17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0433009f-1d0a-42c2-bebc-8d27d796cd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_49ec3bb9-d24a-48af-ae60-4b1ff497e7cc" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_f0a5fd3d-fe3e-4483-9610-4945d403f4c3" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_f0a5fd3d-fe3e-4483-9610-4945d403f4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_c152277e-efee-4c8a-be95-e811b9aa6e5b" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_c152277e-efee-4c8a-be95-e811b9aa6e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_f7f3bfc0-bfdf-4ddb-a207-7b1e00d71fa0" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_f7f3bfc0-bfdf-4ddb-a207-7b1e00d71fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_a8438a65-b2e1-4e94-b9a6-f64499bdee8b" xlink:href="cdtx-20231231.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_a8438a65-b2e1-4e94-b9a6-f64499bdee8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_405eaa48-3623-4d93-80b4-60c9bd95f653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_405eaa48-3623-4d93-80b4-60c9bd95f653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_e4dfd309-7755-4025-a313-de6d91ea472e" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_e4dfd309-7755-4025-a313-de6d91ea472e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_5f83724d-04b0-4f55-8724-8b56ace5bbed" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion_5f83724d-04b0-4f55-8724-8b56ace5bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_0a2926b0-2651-452a-877b-db0a0abe71f4" xlink:href="cdtx-20231231.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_0a2926b0-2651-452a-877b-db0a0abe71f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_474f7b73-82a2-4925-9b81-7eef647e80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostGross_474f7b73-82a2-4925-9b81-7eef647e80e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_bb6bb727-1a55-4a24-9988-183222bdf5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_bb6bb727-1a55-4a24-9988-183222bdf5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_9f7cd0f4-1141-4903-b577-870ab42e4c67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_CapitalizedContractCostNet_9f7cd0f4-1141-4903-b577-870ab42e4c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_15d83c4b-c7c0-487b-b0ff-0c39c9d1ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_15d83c4b-c7c0-487b-b0ff-0c39c9d1ab22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5214385b-1367-46ce-971b-ed88a9a28e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_5214385b-1367-46ce-971b-ed88a9a28e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a5243bac-ad1c-46cf-879a-967f15311e42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fd6e71d-afb2-4fd0-8fa2-4aa48b69dce1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a5243bac-ad1c-46cf-879a-967f15311e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9fc73bc-24c5-4c1b-be90-610d7ef98060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_117c60d2-9ead-4a78-9e02-3e703ac83c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9fc73bc-24c5-4c1b-be90-610d7ef98060" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_117c60d2-9ead-4a78-9e02-3e703ac83c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_117c60d2-9ead-4a78-9e02-3e703ac83c89" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_de680f3d-86d6-4045-b032-c0fc47c2918a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d2ffe2c-59db-4fb3-8dd9-9cb04f5067b7" xlink:to="loc_us-gaap_RelatedPartyDomain_de680f3d-86d6-4045-b032-c0fc47c2918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_42c7f9b6-00b3-4151-84c8-adccbffb3ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_de680f3d-86d6-4045-b032-c0fc47c2918a" xlink:to="loc_us-gaap_RelatedPartyMember_42c7f9b6-00b3-4151-84c8-adccbffb3ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_117c60d2-9ead-4a78-9e02-3e703ac83c89" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_2cee8b83-b72e-45b9-98b5-e39fd6a4c331" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_2cee8b83-b72e-45b9-98b5-e39fd6a4c331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_b96f331a-b048-4a06-9746-f6a89dfb3ea5" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_b96f331a-b048-4a06-9746-f6a89dfb3ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_2d2bbddc-a3fb-4e68-acf2-d4c576d35925" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable_2d2bbddc-a3fb-4e68-acf2-d4c576d35925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_bfec06f0-534c-472b-a7e2-4bb45bf3fa47" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_bfec06f0-534c-472b-a7e2-4bb45bf3fa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_674acdc0-f05d-421a-b6c1-a39ee5d4f1ef" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_dfdbd98d-d2fa-43cf-9a38-c38fbad33755" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_674acdc0-f05d-421a-b6c1-a39ee5d4f1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3ebdc2cc-d968-4290-a775-6854296cad2c" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3ebdc2cc-d968-4290-a775-6854296cad2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_964e1a3f-3968-4459-ac72-026081b2b75c" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_964e1a3f-3968-4459-ac72-026081b2b75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_5df455bd-4c2f-426e-9abb-9d47a899f008" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e39ff4c0-4483-48b7-944d-c60eb4d4a994" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_5df455bd-4c2f-426e-9abb-9d47a899f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eef8fd86-366f-4379-b5f3-26d516f55c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_eef8fd86-366f-4379-b5f3-26d516f55c04" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701e0f68-9078-4875-9645-3f871e2b74a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701e0f68-9078-4875-9645-3f871e2b74a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d557a1e5-4576-48d5-bede-ec8eadbc6b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_701e0f68-9078-4875-9645-3f871e2b74a8" xlink:to="loc_us-gaap_RelatedPartyDomain_d557a1e5-4576-48d5-bede-ec8eadbc6b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_198d0759-697a-4586-9523-93a42f102f29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d557a1e5-4576-48d5-bede-ec8eadbc6b03" xlink:to="loc_us-gaap_RelatedPartyMember_198d0759-697a-4586-9523-93a42f102f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5db1b61e-37f9-40d6-97eb-1cf011739c1c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_srt_CounterpartyNameAxis_5db1b61e-37f9-40d6-97eb-1cf011739c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5db1b61e-37f9-40d6-97eb-1cf011739c1c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_00f4a40d-c47d-4902-875b-8e5df30dfc13" xlink:href="cdtx-20231231.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_00f4a40d-c47d-4902-875b-8e5df30dfc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_e462e118-085b-4d07-aa80-5644246f6854" xlink:href="cdtx-20231231.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_e462e118-085b-4d07-aa80-5644246f6854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_f997fa9c-70a8-464b-8bde-cc0a8cf53721" xlink:href="cdtx-20231231.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4e1c64a2-b2c9-42cf-89a9-b434e8ae232b" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_f997fa9c-70a8-464b-8bde-cc0a8cf53721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c403690e-ab0f-4150-aea1-c8b7c4505a12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_srt_ProductOrServiceAxis_c403690e-ab0f-4150-aea1-c8b7c4505a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c403690e-ab0f-4150-aea1-c8b7c4505a12" xlink:to="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember_01f5ff1d-43e3-4621-b605-cd0375fbd947" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember_01f5ff1d-43e3-4621-b605-cd0375fbd947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_8d450413-6b3d-48fd-a3fe-0643a6ef180b" xlink:href="cdtx-20231231.xsd#cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember_8d450413-6b3d-48fd-a3fe-0643a6ef180b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalDrugSupplyMember_5917b976-42cc-4ff2-aff4-f6943b23bde0" xlink:href="cdtx-20231231.xsd#cdtx_ClinicalDrugSupplyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_ClinicalDrugSupplyMember_5917b976-42cc-4ff2-aff4-f6943b23bde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_3843f246-c8e0-44ec-be7d-fd0ca577720a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_us-gaap_RoyaltyMember_3843f246-c8e0-44ec-be7d-fd0ca577720a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_4dae4fdd-5435-4a6c-937c-e989bd72bddb" xlink:href="cdtx-20231231.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_4dae4fdd-5435-4a6c-937c-e989bd72bddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_8690e6a2-c3d5-4232-8854-e35c57b50718" xlink:href="cdtx-20231231.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_caa31d74-e749-4291-9ea6-e428962e7a9d" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_8690e6a2-c3d5-4232-8854-e35c57b50718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_1ec228e3-4d8a-44c2-8705-63d1ee1c45c1" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_2d67862f-1b52-46f8-a667-a78b9bce6c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_2d67862f-1b52-46f8-a667-a78b9bce6c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_253799a8-1bbb-4a22-b6c7-b2261eece64c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_cf0571b2-e08f-4a3d-90fe-ebc5867138e8" xlink:to="loc_us-gaap_TransferredOverTimeMember_253799a8-1bbb-4a22-b6c7-b2261eece64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_256b43df-55ee-4758-ba27-321a7bc7a9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_256b43df-55ee-4758-ba27-321a7bc7a9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0848e8a4-b048-4268-af96-632387edef7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_256b43df-55ee-4758-ba27-321a7bc7a9e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0848e8a4-b048-4268-af96-632387edef7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e7fb5d50-0dca-4ecc-9e77-4ea7af50079f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0848e8a4-b048-4268-af96-632387edef7c" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_e7fb5d50-0dca-4ecc-9e77-4ea7af50079f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aadda3af-acb3-48df-bac2-a36115e348b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a9fa9230-4831-4d70-9e5c-a2ace36390c5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aadda3af-acb3-48df-bac2-a36115e348b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f0234667-9d17-49dc-bbad-65a5cc480eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_aadda3af-acb3-48df-bac2-a36115e348b5" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f0234667-9d17-49dc-bbad-65a5cc480eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f15f13ae-76cd-4d2c-a117-4c1eb1b90cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fd4f5363-fe08-4057-820f-270bbdefa437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f15f13ae-76cd-4d2c-a117-4c1eb1b90cd3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fd4f5363-fe08-4057-820f-270bbdefa437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7fafc18e-c2c9-42bb-a029-ce909dafd15d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fd4f5363-fe08-4057-820f-270bbdefa437" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_7fafc18e-c2c9-42bb-a029-ce909dafd15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4ed90ffa-360b-4ecd-b438-2ff0f58fa1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fd4f5363-fe08-4057-820f-270bbdefa437" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4ed90ffa-360b-4ecd-b438-2ff0f58fa1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1f9d1bfa-83ed-457f-95fb-a94bcf182c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_fd4f5363-fe08-4057-820f-270bbdefa437" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1f9d1bfa-83ed-457f-95fb-a94bcf182c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_281fecd7-fc56-47b2-9b4a-b26222f1f365" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f15f13ae-76cd-4d2c-a117-4c1eb1b90cd3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_281fecd7-fc56-47b2-9b4a-b26222f1f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d61ecce7-a70d-4821-8fd2-f0f196012e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_281fecd7-fc56-47b2-9b4a-b26222f1f365" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d61ecce7-a70d-4821-8fd2-f0f196012e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7f50662d-e248-408f-89b1-fd50f09828ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_281fecd7-fc56-47b2-9b4a-b26222f1f365" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7f50662d-e248-408f-89b1-fd50f09828ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4101180-91a1-40fb-8409-2bf6752823ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_281fecd7-fc56-47b2-9b4a-b26222f1f365" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c4101180-91a1-40fb-8409-2bf6752823ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a188a2ce-72a6-42ec-8f8f-79a18aecbc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f15f13ae-76cd-4d2c-a117-4c1eb1b90cd3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a188a2ce-72a6-42ec-8f8f-79a18aecbc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c0dfafea-2e4c-4eea-8f18-e8e679182ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c0dfafea-2e4c-4eea-8f18-e8e679182ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d82db1ac-cc0b-4e2d-a73b-38c266820604" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c0dfafea-2e4c-4eea-8f18-e8e679182ca4" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d82db1ac-cc0b-4e2d-a73b-38c266820604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fca0f29b-2247-4100-8570-842d8aeeb7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_fca0f29b-2247-4100-8570-842d8aeeb7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_203c27fb-6606-4b06-9385-2e3a510d58d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_203c27fb-6606-4b06-9385-2e3a510d58d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_1310884d-afc3-446e-87e4-32639093cd71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_1310884d-afc3-446e-87e4-32639093cd71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_72172901-90fc-467e-93bb-eb92f68b4721" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_72172901-90fc-467e-93bb-eb92f68b4721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a0734b6-821e-40af-a3ac-2471ed49bb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a0734b6-821e-40af-a3ac-2471ed49bb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_5a101bc3-bbdf-4d82-939d-77de74aa0550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_5a101bc3-bbdf-4d82-939d-77de74aa0550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount_0585fb58-1836-44e8-9f43-2d530fa7c092" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount_0585fb58-1836-44e8-9f43-2d530fa7c092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount_4390c83f-5685-405b-af25-b3354b9bea8c" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount_4390c83f-5685-405b-af25-b3354b9bea8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount_06cbe3e1-b1f7-4964-ae57-972c970d9fb7" xlink:href="cdtx-20231231.xsd#cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount_06cbe3e1-b1f7-4964-ae57-972c970d9fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_5f35f169-8cc3-4ebb-bcac-7151d7502b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_5f35f169-8cc3-4ebb-bcac-7151d7502b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b87eb713-d435-455e-aee2-d770b9558bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3e874219-6e0f-4c09-adbb-19b50fa2dfa5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b87eb713-d435-455e-aee2-d770b9558bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_175461e7-a34f-49b5-a571-a434c5bf3c42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_175461e7-a34f-49b5-a571-a434c5bf3c42" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bfcf0c1a-b72b-4f40-9bee-c0107106ecf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bfcf0c1a-b72b-4f40-9bee-c0107106ecf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f23a2602-0b33-4c0b-bf86-44d3ac8d64fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_f23a2602-0b33-4c0b-bf86-44d3ac8d64fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2d22ca68-35eb-4598-87ce-816882f22474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2d22ca68-35eb-4598-87ce-816882f22474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a3ac3e25-30c6-4387-89f5-ea1710f45f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a3ac3e25-30c6-4387-89f5-ea1710f45f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5f227ed8-598b-4808-87fc-d57c02fc8e45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5f227ed8-598b-4808-87fc-d57c02fc8e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DeferredTaxAssetsLeasingArrangements_e1b61a7e-4f5e-44b0-b393-54f6e8eaab81" xlink:href="cdtx-20231231.xsd#cdtx_DeferredTaxAssetsLeasingArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_cdtx_DeferredTaxAssetsLeasingArrangements_e1b61a7e-4f5e-44b0-b393-54f6e8eaab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b47c7c65-7e04-4d1a-992d-c24f8069dd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b47c7c65-7e04-4d1a-992d-c24f8069dd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes_e6537d97-62eb-4c3d-a580-e00f3633009b" xlink:href="cdtx-20231231.xsd#cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes_e6537d97-62eb-4c3d-a580-e00f3633009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e825d2e0-421d-4923-83eb-b91ed4deec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e825d2e0-421d-4923-83eb-b91ed4deec2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6a3547a0-2188-4f52-bf70-3486d903933a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6a3547a0-2188-4f52-bf70-3486d903933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_289db51c-5f5c-4253-9278-d7f5e7beb7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_289db51c-5f5c-4253-9278-d7f5e7beb7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dac5fd72-349a-49a6-9b6d-6d55ea544427" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_e02f699a-2ad8-4752-93ea-0c9aa6755aec" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_dac5fd72-349a-49a6-9b6d-6d55ea544427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_70fad1b6-41f5-43fc-a8b5-b67081c6cb24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_175461e7-a34f-49b5-a571-a434c5bf3c42" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_70fad1b6-41f5-43fc-a8b5-b67081c6cb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d32d6e0c-6855-4653-9dfc-7cb8affa5192" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_70fad1b6-41f5-43fc-a8b5-b67081c6cb24" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d32d6e0c-6855-4653-9dfc-7cb8affa5192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts_32019642-0502-4eab-9fe5-084a3a8bbde8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_70fad1b6-41f5-43fc-a8b5-b67081c6cb24" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts_32019642-0502-4eab-9fe5-084a3a8bbde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e0b68475-11be-4dad-8f3e-5a31bcc626b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_70fad1b6-41f5-43fc-a8b5-b67081c6cb24" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e0b68475-11be-4dad-8f3e-5a31bcc626b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1cc09b3c-14d4-4c1e-8ee7-b982b33f311b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_70fad1b6-41f5-43fc-a8b5-b67081c6cb24" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1cc09b3c-14d4-4c1e-8ee7-b982b33f311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1ce0b8e6-9717-44bd-b070-a334eae3a390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_175461e7-a34f-49b5-a571-a434c5bf3c42" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1ce0b8e6-9717-44bd-b070-a334eae3a390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b3c1fb08-83ed-4087-8cd9-b7b46bf875db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_c4cc8b5b-752b-42ca-ac6f-964525819dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3c1fb08-83ed-4087-8cd9-b7b46bf875db" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_c4cc8b5b-752b-42ca-ac6f-964525819dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_7235eadc-aad4-4f9d-aec3-064fa5e27d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_c4cc8b5b-752b-42ca-ac6f-964525819dc5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_7235eadc-aad4-4f9d-aec3-064fa5e27d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_7235eadc-aad4-4f9d-aec3-064fa5e27d1f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_cdb84e74-d699-4e00-93af-316f39bf00d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:to="loc_us-gaap_DomesticCountryMember_cdb84e74-d699-4e00-93af-316f39bf00d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_790f141a-2e7c-43f7-b90a-11bcb0f7865d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b407ea58-9210-4ca5-ad75-0c68c071c2d7" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_790f141a-2e7c-43f7-b90a-11bcb0f7865d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_c4cc8b5b-752b-42ca-ac6f-964525819dc5" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NetOperatingLossCarryforwards_d3007e04-3e8f-4ea2-bdc7-ca0685e46310" xlink:href="cdtx-20231231.xsd#cdtx_NetOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_cdtx_NetOperatingLossCarryforwards_d3007e04-3e8f-4ea2-bdc7-ca0685e46310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a06d38fe-1046-46d6-933f-c5013f53ba9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a06d38fe-1046-46d6-933f-c5013f53ba9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_79cf4f50-2f37-4080-818e-38afa0d438c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_79cf4f50-2f37-4080-818e-38afa0d438c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e0c56077-81a1-4106-94a5-45399f0b1b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e0c56077-81a1-4106-94a5-45399f0b1b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_adc8f91f-d914-48b6-8830-23fb25a2e582" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_adc8f91f-d914-48b6-8830-23fb25a2e582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d92dc85d-14ac-47be-91bd-ac021fa89141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_54bf2048-4ad7-41df-9492-cd11e210fbef" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d92dc85d-14ac-47be-91bd-ac021fa89141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f8f17873-2de1-4575-97f9-3e6f3e266af4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1e7050a6-2b6e-4dd4-b45f-5a2717fded5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f8f17873-2de1-4575-97f9-3e6f3e266af4" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1e7050a6-2b6e-4dd4-b45f-5a2717fded5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7ca97018-5c72-4363-9cc2-3932bd4fdab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1e7050a6-2b6e-4dd4-b45f-5a2717fded5a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7ca97018-5c72-4363-9cc2-3932bd4fdab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6be252dc-007e-402c-a63f-7721934299ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1e7050a6-2b6e-4dd4-b45f-5a2717fded5a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6be252dc-007e-402c-a63f-7721934299ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e8be8fa0-c5b0-474e-b0a1-978c63f9823b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1e7050a6-2b6e-4dd4-b45f-5a2717fded5a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_e8be8fa0-c5b0-474e-b0a1-978c63f9823b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_8b4b46ca-f5c8-4312-8b25-9e30aef0105e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1e7050a6-2b6e-4dd4-b45f-5a2717fded5a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_8b4b46ca-f5c8-4312-8b25-9e30aef0105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d59eb9ce-8f10-47bc-9bbc-bcbc3b2da9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_9c26849e-53d1-49da-b609-ecb8286ff9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d59eb9ce-8f10-47bc-9bbc-bcbc3b2da9e9" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_9c26849e-53d1-49da-b609-ecb8286ff9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_5c555ee2-f697-4d62-a34e-4ef75be8b429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d59eb9ce-8f10-47bc-9bbc-bcbc3b2da9e9" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_5c555ee2-f697-4d62-a34e-4ef75be8b429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dce8afed-92cc-4d9e-8f65-5b5b3c8e2fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_5c555ee2-f697-4d62-a34e-4ef75be8b429" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dce8afed-92cc-4d9e-8f65-5b5b3c8e2fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ebd4e8d-d15c-4723-8a85-c24d21334f34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dce8afed-92cc-4d9e-8f65-5b5b3c8e2fa1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ebd4e8d-d15c-4723-8a85-c24d21334f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f8d0db5-abfa-4ec7-9f92-1ffb9ab3686d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6ebd4e8d-d15c-4723-8a85-c24d21334f34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f8d0db5-abfa-4ec7-9f92-1ffb9ab3686d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_60e76b73-82fd-47f5-ba7b-468432c7d24d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4f8d0db5-abfa-4ec7-9f92-1ffb9ab3686d" xlink:to="loc_us-gaap_EquipmentMember_60e76b73-82fd-47f5-ba7b-468432c7d24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dce8afed-92cc-4d9e-8f65-5b5b3c8e2fa1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_85025aaf-8760-4284-9996-0fbec14debba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_85025aaf-8760-4284-9996-0fbec14debba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseMonthlyRate_c6e5dd90-53df-4c2b-9554-0ddbd3c82f9e" xlink:href="cdtx-20231231.xsd#cdtx_LesseeFinanceLeaseMonthlyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_cdtx_LesseeFinanceLeaseMonthlyRate_c6e5dd90-53df-4c2b-9554-0ddbd3c82f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_454e4fd7-a290-4a0c-8e3d-f2c770313139" xlink:href="cdtx-20231231.xsd#cdtx_LesseeFinanceLeaseOptionPurchaseEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment_454e4fd7-a290-4a0c-8e3d-f2c770313139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ccc3e10f-b3d7-48d6-94f9-f31288b899f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_ccc3e10f-b3d7-48d6-94f9-f31288b899f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDiscountRate_ce76f69a-f6fc-49d8-b943-39f60356215c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_LesseeFinanceLeaseDiscountRate_ce76f69a-f6fc-49d8-b943-39f60356215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_3ceaed02-29fa-42d9-b4a0-0d6d8ee9fb97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_3ceaed02-29fa-42d9-b4a0-0d6d8ee9fb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e8db056a-cd5e-49ec-a53e-f0679e4eb7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_552ab9e8-cc37-451c-8ef2-1c2dc1cf7232" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_e8db056a-cd5e-49ec-a53e-f0679e4eb7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d59eb9ce-8f10-47bc-9bbc-bcbc3b2da9e9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b4feba4f-6e8c-4566-98b9-49ddfa2aa138" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b4feba4f-6e8c-4566-98b9-49ddfa2aa138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate_08690f3c-cef1-4686-a0c4-a813b78c7942" xlink:href="cdtx-20231231.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_cdtx_LesseeOperatingLeaseMonthlyRate_08690f3c-cef1-4686-a0c4-a813b78c7942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_c0f223d7-170f-4626-83c8-87dc4164169b" xlink:href="cdtx-20231231.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_c0f223d7-170f-4626-83c8-87dc4164169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_c86da4e8-613d-422c-b320-7dc836fe0eee" xlink:href="cdtx-20231231.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_c86da4e8-613d-422c-b320-7dc836fe0eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_5228946e-830c-4e18-aae2-aa77a066a4f7" xlink:href="cdtx-20231231.xsd#cdtx_LesseeOperatingLeaseOptionRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_5228946e-830c-4e18-aae2-aa77a066a4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_d5872562-bb12-4e95-b8c8-cca0086d838b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_d5872562-bb12-4e95-b8c8-cca0086d838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_53938e54-cef0-4694-a300-2c23bf4502b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_53938e54-cef0-4694-a300-2c23bf4502b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_327f23af-22dc-456a-876a-69ce5d95028e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_us-gaap_OperatingLeasePayments_327f23af-22dc-456a-876a-69ce5d95028e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_cb784111-999b-4552-8de7-abaf2a8bc75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_us-gaap_OperatingLeaseExpense_cb784111-999b-4552-8de7-abaf2a8bc75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_f79f2207-97a0-436a-bb03-b21e5bfd6ad6" xlink:href="cdtx-20231231.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_bed2887a-3fc3-45c1-8ee0-81e36f8a1f0e" xlink:to="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_f79f2207-97a0-436a-bb03-b21e5bfd6ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_cd6ea59e-86a4-4fa6-936f-c645972eb6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_cd6ea59e-86a4-4fa6-936f-c645972eb6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_bbe8c23c-f8c4-4a8a-9a22-51a98e01702a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_bbe8c23c-f8c4-4a8a-9a22-51a98e01702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_dcb22fa0-6ec9-4b09-9acc-f3de85eeb28e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_dcb22fa0-6ec9-4b09-9acc-f3de85eeb28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8a546d72-909a-4e23-a683-71b3b6e11a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8a546d72-909a-4e23-a683-71b3b6e11a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c6b5ee5-d3c2-406e-b175-3e8dcc820747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0c6b5ee5-d3c2-406e-b175-3e8dcc820747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f6b94607-d4a6-4574-bc96-4c951a1efb77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f6b94607-d4a6-4574-bc96-4c951a1efb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_ccf11313-6f9d-48cd-8672-9a8b9392eeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b0017841-abd7-4f7b-a594-10c6a1dd97e0" xlink:to="loc_us-gaap_FinanceLeaseLiability_ccf11313-6f9d-48cd-8672-9a8b9392eeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cc466a4-8087-4c3b-8d9c-10bd838c5bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_484015f8-71d1-423e-8f29-75a35d928afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cc466a4-8087-4c3b-8d9c-10bd838c5bb7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization_484015f8-71d1-423e-8f29-75a35d928afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_fb443efc-04e1-46de-b688-7b8434367e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cc466a4-8087-4c3b-8d9c-10bd838c5bb7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_fb443efc-04e1-46de-b688-7b8434367e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_197050ea-90df-472e-b0f4-bcb22af6e803" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cc466a4-8087-4c3b-8d9c-10bd838c5bb7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_197050ea-90df-472e-b0f4-bcb22af6e803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5cdd245f-3f7d-4138-b737-68152187de8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cc466a4-8087-4c3b-8d9c-10bd838c5bb7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5cdd245f-3f7d-4138-b737-68152187de8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f05de90b-5926-41e0-bd2b-b9a5b3c0b1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cc466a4-8087-4c3b-8d9c-10bd838c5bb7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f05de90b-5926-41e0-bd2b-b9a5b3c0b1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_0528393e-7cbc-4536-ad7a-257841c15951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0cc466a4-8087-4c3b-8d9c-10bd838c5bb7" xlink:to="loc_us-gaap_FinanceLeaseLiability_0528393e-7cbc-4536-ad7a-257841c15951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b18ce7-948a-4521-a47f-0cffe41214d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6c2ec95d-ccb4-45ac-b486-5bc6bf939928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b18ce7-948a-4521-a47f-0cffe41214d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6c2ec95d-ccb4-45ac-b486-5bc6bf939928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_182143a1-4caa-463a-b9b4-38cffa2511e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b18ce7-948a-4521-a47f-0cffe41214d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_182143a1-4caa-463a-b9b4-38cffa2511e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aa47238c-fb8f-472f-b7f0-cb31b1ea5a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b18ce7-948a-4521-a47f-0cffe41214d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_aa47238c-fb8f-472f-b7f0-cb31b1ea5a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6665f4da-675a-4ff7-88cf-c60a90a1252d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b18ce7-948a-4521-a47f-0cffe41214d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6665f4da-675a-4ff7-88cf-c60a90a1252d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_588c9acb-60c6-40a3-9809-659cb97affc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b18ce7-948a-4521-a47f-0cffe41214d4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_588c9acb-60c6-40a3-9809-659cb97affc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e0b3395b-6939-4259-add6-323f21027eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f7b18ce7-948a-4521-a47f-0cffe41214d4" xlink:to="loc_us-gaap_OperatingLeaseLiability_e0b3395b-6939-4259-add6-323f21027eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3096a59f-8529-4988-bc75-1495a118fea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_64aeefc2-6a1a-4e29-9507-edc32370a730" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3096a59f-8529-4988-bc75-1495a118fea8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_64aeefc2-6a1a-4e29-9507-edc32370a730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c1fec58-a8d5-48bb-b992-fc1c909f2b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3096a59f-8529-4988-bc75-1495a118fea8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c1fec58-a8d5-48bb-b992-fc1c909f2b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_85d73424-1f11-4d57-a1a4-85ecf0afbde9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3096a59f-8529-4988-bc75-1495a118fea8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_85d73424-1f11-4d57-a1a4-85ecf0afbde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c104d48c-5b58-41c2-a12e-c6b21faef5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3096a59f-8529-4988-bc75-1495a118fea8" xlink:to="loc_us-gaap_OperatingLeaseLiability_c104d48c-5b58-41c2-a12e-c6b21faef5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4f08bbe4-f9e2-49d7-ac48-11819c3e802b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_4f08bbe4-f9e2-49d7-ac48-11819c3e802b" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_174b6e0f-4c37-4667-ac85-174a8bf4abb5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:to="loc_srt_RestatementAxis_174b6e0f-4c37-4667-ac85-174a8bf4abb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_174b6e0f-4c37-4667-ac85-174a8bf4abb5" xlink:to="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1e7e5c91-b5b3-47a9-a36e-b159045f107b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1e7e5c91-b5b3-47a9-a36e-b159045f107b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_a54cfd45-0051-4eaa-8016-5e2130021474" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_b96660b2-aef7-42c8-afe1-a1e4865c88a4" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_a54cfd45-0051-4eaa-8016-5e2130021474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e8cad943-1c6d-4646-962e-6f2f1aa78a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e8cad943-1c6d-4646-962e-6f2f1aa78a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_60804fd4-a0ac-4905-9f17-f49a2396e5df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e8cad943-1c6d-4646-962e-6f2f1aa78a34" xlink:to="loc_us-gaap_ClassOfStockDomain_60804fd4-a0ac-4905-9f17-f49a2396e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_09ffbb2a-5597-4416-be74-de015097c50f" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_60804fd4-a0ac-4905-9f17-f49a2396e5df" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_09ffbb2a-5597-4416-be74-de015097c50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_76bc0544-5fc5-412b-9a67-500870539b8b" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:to="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1b870470-5cc1-4088-8369-9ef285d71203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1b870470-5cc1-4088-8369-9ef285d71203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_adf1ca8a-ce43-4f9d-8326-0d7efae5313e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_RestrictedCash_adf1ca8a-ce43-4f9d-8326-0d7efae5313e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_afe640b0-a88b-45d9-bf9a-0f15da8021a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_afe640b0-a88b-45d9-bf9a-0f15da8021a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_0cb639f5-77bf-4698-b84b-936770f70c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_InventoryNet_0cb639f5-77bf-4698-b84b-936770f70c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_803d5296-bb1a-4df1-9b9f-b8bfe388f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_803d5296-bb1a-4df1-9b9f-b8bfe388f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_255a8db7-c71a-4cd1-abdb-8491ed01c40a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_fd5c5f97-35c2-4432-be51-b04e367af66d" xlink:to="loc_us-gaap_AssetsCurrent_255a8db7-c71a-4cd1-abdb-8491ed01c40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cd602c2f-6884-4be0-8781-2f0d562fd6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cd602c2f-6884-4be0-8781-2f0d562fd6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f5feb09-7512-40fc-b745-09538d24de1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f5feb09-7512-40fc-b745-09538d24de1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e92d9aef-9c2f-42ea-8a7b-a3be68a21b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e92d9aef-9c2f-42ea-8a7b-a3be68a21b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e600ab90-d64b-4e2e-84b3-57d6d4a17ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_583cbb56-bd50-4bd2-a1db-380161ac5586" xlink:to="loc_us-gaap_Assets_e600ab90-d64b-4e2e-84b3-57d6d4a17ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_cd92666c-2963-4a9e-8616-439593d63339" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_87b70d6b-2fc0-4128-9ebe-c702baac2725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_AccountsPayableCurrent_87b70d6b-2fc0-4128-9ebe-c702baac2725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bfe3d792-ba8d-4945-b39d-d16061a7aef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bfe3d792-ba8d-4945-b39d-d16061a7aef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f7b4a31d-42a4-4ef2-9408-d729b3975748" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_f7b4a31d-42a4-4ef2-9408-d729b3975748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de680c02-2c92-45f9-b714-e36d1b4da588" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de680c02-2c92-45f9-b714-e36d1b4da588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3efada27-838e-44e4-8c43-31b169c3d2f1" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_3efada27-838e-44e4-8c43-31b169c3d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57cf93d9-8f8c-4398-a01c-4de132dd4205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57cf93d9-8f8c-4398-a01c-4de132dd4205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_d7b1f078-684a-4a14-93a5-65d7a5ba258d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_LoansPayableCurrent_d7b1f078-684a-4a14-93a5-65d7a5ba258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0e3ff0b8-efde-4da0-8276-08230a0df3df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_27180f90-b2cb-465e-b7f7-51b5dacdceaf" xlink:to="loc_us-gaap_LiabilitiesCurrent_0e3ff0b8-efde-4da0-8276-08230a0df3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_01b5a3e0-dd88-4428-9791-b7dea8e4935d" xlink:href="cdtx-20231231.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_01b5a3e0-dd88-4428-9791-b7dea8e4935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ebd0cb8-4d42-4769-95ca-5fc3cb868710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8ebd0cb8-4d42-4769-95ca-5fc3cb868710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_06a5abf4-c8ee-4248-a864-bdd844968766" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_Liabilities_06a5abf4-c8ee-4248-a864-bdd844968766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c23bcf28-2e43-40e8-9c6c-f2b65b45c6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c23bcf28-2e43-40e8-9c6c-f2b65b45c6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_803c5db7-3e4b-403a-9dab-ff065c620025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_PreferredStockValue_803c5db7-3e4b-403a-9dab-ff065c620025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b9822c92-8f34-43d7-8ffa-2a97a382f5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_CommonStockValue_b9822c92-8f34-43d7-8ffa-2a97a382f5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9e91813a-7095-44f8-929f-2ee6740d1651" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9e91813a-7095-44f8-929f-2ee6740d1651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf8b687b-6297-4daa-8bdf-c7a7861db971" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bf8b687b-6297-4daa-8bdf-c7a7861db971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f2a2d803-1159-4c47-9d8e-b642847da917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e3bd5f2-01d1-478e-b53d-3175a7648630" xlink:to="loc_us-gaap_StockholdersEquity_f2a2d803-1159-4c47-9d8e-b642847da917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6815df94-fc21-4bfc-92eb-626ca04907a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31b73d20-49ff-414c-a2ac-98c4585ec126" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6815df94-fc21-4bfc-92eb-626ca04907a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_97a90fa6-b1e0-43e9-9cd5-0446c96e2a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1a5149f1-59fc-401e-8709-01a82a3fbcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_97a90fa6-b1e0-43e9-9cd5-0446c96e2a34" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1a5149f1-59fc-401e-8709-01a82a3fbcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1a5149f1-59fc-401e-8709-01a82a3fbcbc" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ac9dc439-d1e7-4601-b26c-1e8aa104fc61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d1a9cad0-4c4c-4640-91b0-c36f3b852eb4" xlink:to="loc_us-gaap_ClassOfStockDomain_ac9dc439-d1e7-4601-b26c-1e8aa104fc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_8caf1f7b-75ab-4274-9b65-f38ebf5184d7" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ac9dc439-d1e7-4601-b26c-1e8aa104fc61" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_8caf1f7b-75ab-4274-9b65-f38ebf5184d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1a5149f1-59fc-401e-8709-01a82a3fbcbc" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11b59dab-79b0-4d85-9254-33652641963b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_11b59dab-79b0-4d85-9254-33652641963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_80da3957-11ec-47ca-b163-a4488b7df71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_80da3957-11ec-47ca-b163-a4488b7df71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_aca5690f-c8c9-42ae-bbb3-8adbd216c4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockSharesIssued_aca5690f-c8c9-42ae-bbb3-8adbd216c4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_87d45a20-c23f-4825-ab4b-6b7332a015ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_87d45a20-c23f-4825-ab4b-6b7332a015ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6de8f08a-172e-47e6-a5e1-46d71d3f46eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6de8f08a-172e-47e6-a5e1-46d71d3f46eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c0916c99-90fa-48ee-aa0b-b372d8713dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c0916c99-90fa-48ee-aa0b-b372d8713dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_edb05cd1-36c8-4a89-9866-7b557fe99e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockSharesIssued_edb05cd1-36c8-4a89-9866-7b557fe99e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3f98be8b-c3c2-4abb-8d43-1da0c3305f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_329fc1f9-e096-4d66-8708-7093593bb047" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3f98be8b-c3c2-4abb-8d43-1da0c3305f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3b82b27d-73eb-42cb-9b96-b73667993566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_66816351-0731-4062-b1f4-a21c641ef34f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_3b82b27d-73eb-42cb-9b96-b73667993566" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_66816351-0731-4062-b1f4-a21c641ef34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_66816351-0731-4062-b1f4-a21c641ef34f" xlink:to="loc_srt_RestatementAxis_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_9aa31040-6ed9-4c1e-9d9e-0b486e89d3b2" xlink:to="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_fb308ef2-d6d4-4a68-96fd-c7c592a5cca0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_fb308ef2-d6d4-4a68-96fd-c7c592a5cca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_e261fb27-8db7-46c2-9391-89916d50081a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_6f8db4b6-8b92-415a-b465-2040012f9ed0" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_e261fb27-8db7-46c2-9391-89916d50081a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_66816351-0731-4062-b1f4-a21c641ef34f" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f3a4de6c-d5d7-4f4b-b264-5c627dfdb68d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_f3a4de6c-d5d7-4f4b-b264-5c627dfdb68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46b1ab77-d72a-4277-8976-3c36e92f52f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_46b1ab77-d72a-4277-8976-3c36e92f52f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_32dc6d23-4a5c-416b-a965-93be965bffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_29b93587-4d16-4ba2-a651-7db55c4e7bc9" xlink:to="loc_us-gaap_Revenues_32dc6d23-4a5c-416b-a965-93be965bffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_fe5894bc-5acb-4970-ae43-025bf384190a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_fe5894bc-5acb-4970-ae43-025bf384190a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3616ea71-3837-44e9-8061-d1900eae0f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3616ea71-3837-44e9-8061-d1900eae0f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6f6ad8d7-59c5-4ab2-92c0-882fbaefe760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6f6ad8d7-59c5-4ab2-92c0-882fbaefe760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0129e0ac-d063-4b10-ab85-83438d495615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0f198302-a8df-4784-91c9-c3dabd29bb8a" xlink:to="loc_us-gaap_OperatingExpenses_0129e0ac-d063-4b10-ab85-83438d495615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_92009d39-45af-43af-8e1a-f0d4746b00b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_OperatingIncomeLoss_92009d39-45af-43af-8e1a-f0d4746b00b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dc3132e5-8216-4f10-916a-26ad1dbb9606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_dc3132e5-8216-4f10-916a-26ad1dbb9606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3c201ecb-4b82-4cf6-9ccf-7df8e1953496" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_189930b0-b7f9-49b2-81b1-b28b9f8bf844" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3c201ecb-4b82-4cf6-9ccf-7df8e1953496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9e8752d-677c-4276-b741-d3b043f91b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d9e8752d-677c-4276-b741-d3b043f91b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5c00524f-2fe9-4892-a62a-d43af575ba68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5c00524f-2fe9-4892-a62a-d43af575ba68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34559034-a99c-442a-9b76-7d55ff74409a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_NetIncomeLoss_34559034-a99c-442a-9b76-7d55ff74409a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_45ee7c10-dc43-48b5-bb3a-b1a6150a380e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_45ee7c10-dc43-48b5-bb3a-b1a6150a380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_78e076da-6ac9-4c3e-86c4-575b9d0fc0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_78e076da-6ac9-4c3e-86c4-575b9d0fc0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_b01fd97c-debd-40bd-9558-ca1187148f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_b01fd97c-debd-40bd-9558-ca1187148f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_898d0a3a-07fb-4b73-ae79-5fb99f10b5de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_898d0a3a-07fb-4b73-ae79-5fb99f10b5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9a1ff723-9c38-4790-b058-57ab2701c670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_EarningsPerShareBasic_9a1ff723-9c38-4790-b058-57ab2701c670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8140ff79-116f-497e-9860-722dacb3f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8140ff79-116f-497e-9860-722dacb3f9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8357fb16-9623-48e6-84d1-eea50638414d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8357fb16-9623-48e6-84d1-eea50638414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea036d13-47bf-479d-a76b-3339549c3eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_473fddf0-ffa9-4d3c-9a13-a0c26bb970fc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ea036d13-47bf-479d-a76b-3339549c3eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_beee83fb-5e45-4af1-baf9-d3e92d78f714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bfbf1a07-3599-4b32-89c5-16e1c4ab514b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_beee83fb-5e45-4af1-baf9-d3e92d78f714" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bfbf1a07-3599-4b32-89c5-16e1c4ab514b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_c3447256-a500-499c-9efd-b5209205ed44" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bfbf1a07-3599-4b32-89c5-16e1c4ab514b" xlink:to="loc_srt_RestatementAxis_c3447256-a500-499c-9efd-b5209205ed44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_c3447256-a500-499c-9efd-b5209205ed44" xlink:to="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_0be00561-06fc-42a0-9a8c-9fd33369884d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_0be00561-06fc-42a0-9a8c-9fd33369884d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aef984ad-fa96-4987-a425-c16b208aab5c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_a4d56f21-6853-49f6-83dc-52ab951ce335" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_aef984ad-fa96-4987-a425-c16b208aab5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_bfbf1a07-3599-4b32-89c5-16e1c4ab514b" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d415e6d-dc6d-4665-a1b2-0b11958b6b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:to="loc_us-gaap_NetIncomeLoss_9d415e6d-dc6d-4665-a1b2-0b11958b6b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_32326aea-695a-4bbd-99ac-411afcc457a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_ShareBasedCompensation_32326aea-695a-4bbd-99ac-411afcc457a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_db75f8b2-ad02-42cd-bb17-f5b8569afaf9" xlink:href="cdtx-20231231.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_db75f8b2-ad02-42cd-bb17-f5b8569afaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a2557244-52e8-4f5a-b43c-cbed195586b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_DepreciationAndAmortization_a2557244-52e8-4f5a-b43c-cbed195586b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_4fb5b176-a678-4668-a8c5-931b7f98a4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_4fb5b176-a678-4668-a8c5-931b7f98a4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_d104de3a-adfa-4753-826f-98fc284540ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_PaidInKindInterest_d104de3a-adfa-4753-826f-98fc284540ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_02a75b95-5f0e-478e-8ce6-bd1b217364bd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27814557-9aec-46b5-b56d-f43593d0b9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27814557-9aec-46b5-b56d-f43593d0b9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_249d0a5c-0a06-4496-a2ff-8aaab6f13d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_249d0a5c-0a06-4496-a2ff-8aaab6f13d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4abb4db6-4099-4015-86b8-39ee9ff3d742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4abb4db6-4099-4015-86b8-39ee9ff3d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f976ffac-5b87-422b-8fbb-73d7982d41b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f976ffac-5b87-422b-8fbb-73d7982d41b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AccruedIndirectTaxLiabilities_92743ca0-4806-458c-adc9-f1132806199e" xlink:href="cdtx-20231231.xsd#cdtx_AccruedIndirectTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_cdtx_AccruedIndirectTaxLiabilities_92743ca0-4806-458c-adc9-f1132806199e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8c6b9508-8a24-465c-aa1c-e99b13ec5386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8c6b9508-8a24-465c-aa1c-e99b13ec5386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_91ff35e3-52c0-4ef5-902c-068c4cff1d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_91ff35e3-52c0-4ef5-902c-068c4cff1d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e0bf32c-eaad-4b73-a447-5da04604b819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fff9e6be-4664-4df0-be67-cd2f260a3d8e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_6e0bf32c-eaad-4b73-a447-5da04604b819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30fdb008-13b6-46f9-8374-4260a259a5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_df15bc4f-c903-4ca8-9acc-356cbf7cd277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30fdb008-13b6-46f9-8374-4260a259a5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_909681ae-8de6-4d98-8c26-270af8ac6cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_909681ae-8de6-4d98-8c26-270af8ac6cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aad6708a-40f8-432a-b165-ede66c686553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_29aac800-8275-49a8-ab04-6d732798989b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aad6708a-40f8-432a-b165-ede66c686553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b44b8801-b870-470d-9bd7-d1f9db1c2cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b44b8801-b870-470d-9bd7-d1f9db1c2cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_dafc9980-cb07-456c-9027-015d1cb12411" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering_dafc9980-cb07-456c-9027-015d1cb12411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ea3739b6-130d-494a-a081-22cc9e373a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ea3739b6-130d-494a-a081-22cc9e373a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7cd9fa8-0658-45cd-b65a-30f57fc9bd13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_c7cd9fa8-0658-45cd-b65a-30f57fc9bd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_d6d1a470-5b3f-402e-9828-8a4312691785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_d6d1a470-5b3f-402e-9828-8a4312691785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bbc6c86f-efb2-4b5c-b9fd-e0998fcbc723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cd0f1c09-018b-413b-b3f6-bfd6bcf9a7d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bbc6c86f-efb2-4b5c-b9fd-e0998fcbc723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2354ca4-e9d7-46fd-a36f-cb7c54520add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a2354ca4-e9d7-46fd-a36f-cb7c54520add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b56e7de9-e25f-42aa-b782-5250903791f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b56e7de9-e25f-42aa-b782-5250903791f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45c4e1a0-ea16-4073-883b-14e1f59c464b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_45c4e1a0-ea16-4073-883b-14e1f59c464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_2ae08e22-bfa4-48ea-b420-4d7cec0a3b64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:to="loc_us-gaap_InterestPaidNet_2ae08e22-bfa4-48ea-b420-4d7cec0a3b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_80a1d3f4-98a8-4602-a579-b3bced3a1837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_19023845-ed51-44ed-bf22-11d9ac32a5ba" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_80a1d3f4-98a8-4602-a579-b3bced3a1837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8aec5938-de90-4504-92d7-6c727c3f63ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8aec5938-de90-4504-92d7-6c727c3f63ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8635525b-1dff-41f4-9ed1-19f996adb48a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_ab388862-176e-4bd2-80d9-9ebb3f67544e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8635525b-1dff-41f4-9ed1-19f996adb48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_5c385551-970e-4318-a75a-628b39869e64" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a604458-0082-4d60-802b-ab4d5842e55e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a604458-0082-4d60-802b-ab4d5842e55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet_c91a31da-0f87-440b-94f5-d009f6796179" xlink:href="cdtx-20231231.xsd#cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:to="loc_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet_c91a31da-0f87-440b-94f5-d009f6796179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_0da02af8-6636-4d98-8707-fb06f934fb2b" xlink:href="cdtx-20231231.xsd#cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_cace71e4-73f7-4c37-a4fc-ddfa0f0184a6" xlink:to="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets_0da02af8-6636-4d98-8707-fb06f934fb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ba5ac3a2-b682-4e11-b1e3-6ee367aba8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_ba5ac3a2-b682-4e11-b1e3-6ee367aba8ab" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d42046f3-7b35-4d6a-8556-9aa58770af52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d42046f3-7b35-4d6a-8556-9aa58770af52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d42046f3-7b35-4d6a-8556-9aa58770af52" xlink:to="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_696b1475-45fb-42c6-af53-64efd7dfc95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_696b1475-45fb-42c6-af53-64efd7dfc95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a6bf6e77-cae6-4163-b695-1bc9f5befba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_RetainedEarningsMember_a6bf6e77-cae6-4163-b695-1bc9f5befba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d7a275d0-4a6c-466f-a3dd-c6ba6026b2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_PreferredStockMember_d7a275d0-4a6c-466f-a3dd-c6ba6026b2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_88b6a3ef-4380-4994-9a11-d626b8b38204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7b692262-ec72-4c47-b2c8-43fda901d8b8" xlink:to="loc_us-gaap_CommonStockMember_88b6a3ef-4380-4994-9a11-d626b8b38204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c30ca84d-8749-432e-b02d-c4790fdb16c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c30ca84d-8749-432e-b02d-c4790fdb16c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c30ca84d-8749-432e-b02d-c4790fdb16c4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnderwrittenPublicOfferingMember_6ecbd6ac-6a20-4c5d-8186-1fa2e5a6c869" xlink:href="cdtx-20231231.xsd#cdtx_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:to="loc_cdtx_UnderwrittenPublicOfferingMember_6ecbd6ac-6a20-4c5d-8186-1fa2e5a6c869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicOfferingMember_c4307d8a-2081-448b-9df1-8ac7c3553e1f" xlink:href="cdtx-20231231.xsd#cdtx_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a2668f82-5487-4ea5-b9a1-b572f46d5fc1" xlink:to="loc_cdtx_PublicOfferingMember_c4307d8a-2081-448b-9df1-8ac7c3553e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f7875f18-6b2d-4435-92e0-1f480498a66b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f7875f18-6b2d-4435-92e0-1f480498a66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e5ff1204-1422-4bfd-9fca-e9fa94a02b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f7875f18-6b2d-4435-92e0-1f480498a66b" xlink:to="loc_us-gaap_ClassOfStockDomain_e5ff1204-1422-4bfd-9fca-e9fa94a02b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_f46dd436-25da-4140-b9ae-858456ff1555" xlink:href="cdtx-20231231.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e5ff1204-1422-4bfd-9fca-e9fa94a02b0a" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_f46dd436-25da-4140-b9ae-858456ff1555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_1e505522-4507-49de-9668-cb92f66c5a97" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4c9b0c31-1463-480f-97f2-eed61fb20aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4c9b0c31-1463-480f-97f2-eed61fb20aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e87a9b2-1edd-48d8-9a8d-bd55bf117e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockholdersEquity_0e87a9b2-1edd-48d8-9a8d-bd55bf117e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bbb5e2ec-9140-4f1c-b0f4-1975f54a4661" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bbb5e2ec-9140-4f1c-b0f4-1975f54a4661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_623a61a5-a9bf-46f0-8929-ffaf29e82854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_623a61a5-a9bf-46f0-8929-ffaf29e82854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c2e13153-8114-45b9-a0cb-c7ca16888dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c2e13153-8114-45b9-a0cb-c7ca16888dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa396717-3471-4328-89d6-997a6c3b7115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fa396717-3471-4328-89d6-997a6c3b7115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_45a5b185-4ba1-4d40-9eee-727e2bf66897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_45a5b185-4ba1-4d40-9eee-727e2bf66897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69cb4c1d-8c78-483c-82c9-9b2aea86861a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_69cb4c1d-8c78-483c-82c9-9b2aea86861a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4ac085da-3959-42be-ad96-641f106a753d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4ac085da-3959-42be-ad96-641f106a753d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1c175e6d-eb11-4ec0-8cfa-4faabd565460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1c175e6d-eb11-4ec0-8cfa-4faabd565460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50b49a7c-530e-4fab-a13e-881f4669f537" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50b49a7c-530e-4fab-a13e-881f4669f537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f14d1b20-caff-49da-9d6d-8c2c187e3939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_NetIncomeLoss_f14d1b20-caff-49da-9d6d-8c2c187e3939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_46f831df-7e2e-47c0-9377-08c99ba78f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_46f831df-7e2e-47c0-9377-08c99ba78f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_07e2cfbf-a11b-4a8e-b855-2f1f6360bb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_StockholdersEquity_07e2cfbf-a11b-4a8e-b855-2f1f6360bb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2e51af87-50b4-47bf-bf8d-43bcf7b5aa62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_c1e757b2-edbd-4ef8-a02c-413281b2386e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2e51af87-50b4-47bf-bf8d-43bcf7b5aa62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d184bfc7-3819-4e62-b301-24c3e45f54bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d184bfc7-3819-4e62-b301-24c3e45f54bf" xlink:to="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7a1c4aa4-e008-4554-9fc9-11a02f0297cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7a1c4aa4-e008-4554-9fc9-11a02f0297cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_93080dd9-3ba4-472d-8871-08fdf5689efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7a1c4aa4-e008-4554-9fc9-11a02f0297cc" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_93080dd9-3ba4-472d-8871-08fdf5689efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8b4bc0f7-7b49-465d-affd-a4552d89660c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_93080dd9-3ba4-472d-8871-08fdf5689efb" xlink:to="loc_us-gaap_SubsequentEventMember_8b4bc0f7-7b49-465d-affd-a4552d89660c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c36afa26-8970-42b4-ad1e-db84e594ce03" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:to="loc_srt_StatementScenarioAxis_c36afa26-8970-42b4-ad1e-db84e594ce03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f253ce01-e540-424e-82c3-f645f1b7d73a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c36afa26-8970-42b4-ad1e-db84e594ce03" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f253ce01-e540-424e-82c3-f645f1b7d73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_eb3f804f-45d1-43d5-82a9-8e1278ac4046" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f253ce01-e540-424e-82c3-f645f1b7d73a" xlink:to="loc_srt_ProFormaMember_eb3f804f-45d1-43d5-82a9-8e1278ac4046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5cd8870b-9aa4-4b37-8d5b-ddb41b669f57" xlink:to="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce0b96a-0c00-47cb-9823-9bad57bd70dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_4ce0b96a-0c00-47cb-9823-9bad57bd70dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6f8bddbc-6f66-459b-a8fb-d017522393f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6f8bddbc-6f66-459b-a8fb-d017522393f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cb09a73b-7eea-4aec-b598-fe0a113e335f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_CommonStockSharesIssued_cb09a73b-7eea-4aec-b598-fe0a113e335f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bc5195d0-38d9-4ed6-a2e4-8b5917280b09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bc5195d0-38d9-4ed6-a2e4-8b5917280b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8c62e1d7-3a3b-4dc1-a8d2-f8360c48a548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8c62e1d7-3a3b-4dc1-a8d2-f8360c48a548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c0d49c-0a5b-4ba8-a6e5-64aaffea40e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1c6ba21c-3b67-4ab8-ab1a-c5726724bb43" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c0d49c-0a5b-4ba8-a6e5-64aaffea40e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="simple" xlink:href="cdtx-20231231.xsd#SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d58e132c-ed4d-4d16-8d0f-b80d991ee2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_109fe2c1-af35-4ac0-9736-4d3766a0dde9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d58e132c-ed4d-4d16-8d0f-b80d991ee2a0" xlink:to="loc_us-gaap_SubsequentEventTable_109fe2c1-af35-4ac0-9736-4d3766a0dde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_fe61a786-28aa-4d40-b968-beb25469a99e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_109fe2c1-af35-4ac0-9736-4d3766a0dde9" xlink:to="loc_srt_StatementScenarioAxis_fe61a786-28aa-4d40-b968-beb25469a99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c5171ebc-26dd-40bc-a1e0-2de7adf78c88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_fe61a786-28aa-4d40-b968-beb25469a99e" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c5171ebc-26dd-40bc-a1e0-2de7adf78c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProFormaMember_d5ba0645-416b-4be4-9ec2-6851dfb3587f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProFormaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_c5171ebc-26dd-40bc-a1e0-2de7adf78c88" xlink:to="loc_srt_ProFormaMember_d5ba0645-416b-4be4-9ec2-6851dfb3587f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_109fe2c1-af35-4ac0-9736-4d3766a0dde9" xlink:to="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41b54c70-1192-4072-af02-87da0927d04d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_NetIncomeLoss_41b54c70-1192-4072-af02-87da0927d04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e3ef0ffc-d3f0-4275-b5d9-f01e91290d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e3ef0ffc-d3f0-4275-b5d9-f01e91290d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f085162c-f78d-48ce-8115-6dc0a33c7828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f085162c-f78d-48ce-8115-6dc0a33c7828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_888e0d42-a4fa-4e78-877f-c5bf9f1c9fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_EarningsPerShareBasic_888e0d42-a4fa-4e78-877f-c5bf9f1c9fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_72d1c6c6-073a-4627-8166-be3b632e6bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_72d1c6c6-073a-4627-8166-be3b632e6bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0cff69ec-0612-4ea2-a1da-0a96d71eed1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1cc6e4a2-a64e-47ea-9f21-d6f9e673e2da" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0cff69ec-0612-4ea2-a1da-0a96d71eed1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cdtx-20231231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #Q 4T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM^$.J^*OV:]0^&,&MV>DZAJ7AXZ!/JDED]Y%$DD/DS,D0EB+'87"$L,$JQ#
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MU;P+\/[35-,UMO#\*ZC%%>7L-WIEM.(V1PBQOJ1%MDS>2&#'<4\S9\^VL?\
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M$&G;/DM?[-\5ZM:?8(>]M:>5=+]EMCB/-M!LA/DP90^3%L]5HH \*^(7P/\
MB#-X!\2Z-X,^*-Q>OJ&F7.FVNC_$#2[/6--BBDB9$C+K"EP[#Y%\VZDNP5+F
M6*=FR/%? /[*^D_#G5=6U3PM^SO<:'X3DAMTBL5\26]MXTL[U6F%Q<6%]%=.
M1!-'):QM&VI6^U8+G$3>:5F^WZ* /E7_ (6;\2_A=\JZ#XPET5>;#0_&N@2Z
MQ>3#[IA35M!>_:"*%?*8-?6LT\S;P9Y"S/#T'@G]O7X3>(M5ET7Q1J=Q\)O$
MT<)NGT'XB>3I5VD.Y55Y,RLD3,6RL,CK,R 2B/RF1V^BJ* .4\/_ !2\,>*/
M%6I>'=,U/[1JMAYF]#;RI%-Y4@CG^SS,HCN/)E98IO)9_)D94DV.0IZNOC_2
M?^"<NEZ3XV\6ZI9_%CX@>'M!O?.'AK0_"NJMI*>%TN;E+J]BMO+)C,4DL:@1
MB)45/O+)(J2IZKJ7P[^-7AK^U;CPE\7-/\2^99+]ET_XA>&H9MMTGF'Y;G36
ML_+BDW1*VZ&9E\O<N<E: /:Z*^7]2_:-^-OPON$C^('P#N-:TBUAACN-?^&^
MJ2:RVHW31J6%IIWV=9HUWER3<O&B+&X$LCF)9LK3_P!O+4=8U4:I9_!GQ0GP
MUL-3M=!U_P 17%]9/J6E:G<-"J6W]E6\DTTS*]W9K(B-YJ-)*AB\R(H0#ZUH
MKE/ OQ8\$?%#[=_PAOC+P_XM^P[/M?\ 86J07OV??NV>9Y3MMW;'QG&=K8Z&
MNKH **** "LGQ3X3T/QQH-UHGB31M/\ $&BW6WS].U2U2YMYMK!UWQN"K895
M89'!4'J*UJ* //\ _A0O@2W\5?\ "2:;H7_".:U)>_VA>7/AN[GTG^TY_,\S
M??+:R1K>_,6.+@2#]Y)QB1]Q_P (9X[TWQ5]OTWXB_;M%NKWS[S2/$FAP7/V
M>#S-WD6,MJ;5HOE++ON/M1^6,]5?S/0** //_"VL_$/2]>M=%\6:#I^N6D^[
M9XL\-.+:W3:I<_:K&XE,L&25C3R);O>0SOY (6CPM\7O[;UZUT/6/!7C#PAK
M5UN:&WU32OM-N8U4MYCWUD]Q9Q9VNH26=),J/DP\9?T"B@#G_!/Q"\*_$K2I
M=3\(^)='\5:;#,;:2\T2_BO(4E"JQC+QLP#!70[<YPP/<5T%<IXB^$_@CQAK
MRZWKW@WP_K>M+92::NHZCI<%Q<"UD61)+<2.A;RF6:563.TB5P1ACG*\/_!Z
MW\&_VE;^&/$OB#P_HMU926UOHD,\-S9Z;,V MQ9K<Q2M!Y:JJ1VRM]D15XM\
MDD@'H%%>/^(-)^,G@7P;XHF\->(-'^)>I6VF2MH.G>(M.6POKB\RK*;F\MY$
MMW4?O L:6L&[]TK3)AYCX5^PA\:OCWJ7PY\>ZY^T1H7B"&TTV]M5TFXD\*S1
M:I<;P5GC6QM8?-DB0F!@ZP?\M)<NPC(C /M6N4\=?"WPQ\2/L4FO:9YU_I^_
M[!JMG<2V>HV&_;YOV:\@9)X-X15?RW7>N5;*D@Y6B_M!?#3Q!Y:6?COP^+MK
MVWTQ["YU".WO(+V??Y-G-;R%98;EC%*H@D59-T4B[<HP'H% 'FEY9_$GP+;V
M#Z5?V_Q*TVVA*WMKK*PV&M7#>8\C30W,*):.PCV11VS00*QPSW28.=:Y^+WA
M[1=4T'2?$<EQX2U;6H;=K6VUN$Q0M<3-M2Q%XNZUDN]P8?9XIGD8*64,GS5V
MM5-6TFQU[2[S3-3L[?4=-O87MKJSNXEEAGB=2KQNC AE9205(P02#0!;HKS3
M4OASXA\*7"7OPYURWTNSAAAA'@W5H ^BM'%&J*EL8P);!BD448:,R6\8WO\
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MY"KEF51D\E@.IK6KRK]I;_DG6D?]CGX3_P#4ATZD4'_#6/P0_P"BR?#_ /\
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M^(VJQ:MXC\(:/JFNP0BWM=;DM$74K-59F0V]VH$T#([LZ/$ZLC'<I#<UVM%
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M,!BK!V#;B7;/'I6DQWT.E6<>IW%O>:DL*+=7%I;M!#+*%&]TC9W**6R0I=R
M0"S8R0#P;XC^!;;2;O7K_3]5\.:%)<ZZUW#/-KTVD-:7DNGQQK*S0C$DI96<
MPN")$DR3V.SHW@[4AXR\0V5KK>B&^MK34I4>TU!S?^9J#121R30A,P*K0LJD
M,^0JD8((IOC'X*:M<7^M7?AN'3;.>]U:35+:6+4[K37MIWL8X/M)-NA\U_,1
MRT3@JZO\S \'1T_X7^);+7-7G6YT^&)K?5OLFH0W,HN9I[UH7#2)LQ$(VB*@
MJ[G 0\$8K.VDE;H_R6G]=E\M5]CR:^6^K[]K:[MZ=<36/A7XK\,Z=JVH:;K6
MI7>U6<6@UF_FDFA$-GNB&2S*S2071WQAI%$Y9 S,5/+^(/!M[JWPCT.3QMJ^
MF>'H#JNK%QXIU>8J;>ZDN5MH!+<HLA_=.@".JLJC;M&W%=1K'PK\5^&=.U;4
M--UK4KO:K.+0:S?S230B&SW1#)9E9I(+H[XPTBB<L@9F*EN@^"?&FM?#?19G
MME778-6U.\@74M=O(YK:WFFN/L^V>6"1G B=%\FX@(VD953& =:FJ?71?\-Z
M_P#!,H+]W%;:_/;=^G7Y%_X3:'#X)^(VIVFM^*]#O_%&I:7:6\>GPWX:]>"U
M,RQ2>4P#;6B,;L0"!(\N.,$ZOQD_Y*+\"?\ L<[G_P!1[6:Y/0?@WXWT'1=$
M\.R1>&KS3(];L=9OM7MYGMKM7B:%W6&W6#RP T1A7YU'DL% 7;M;K/C)_P E
M%^!/_8YW/_J/:S5/;5Z_\!/\VU?K:_47VG_6VB]-$G;I>W0]5HHHJ!A1110
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MU/I*BBBD 5Y5^R=_R:S\&_\ L3-&_P#2&&O5:\J_9._Y-9^#?_8F:-_Z0PT
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MTRA=PBX]]^KT?X?\ ZKX0^$_%FG>,M=UWQ5"RW-YIECIR2&='!^RO<(2 K'
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M.'U*VABN9[-?A[X@,T44C2+'(R?8<JKM#*%8C!,;@?=. #V"BO*O^&EO"/\
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M618Y4#JLT31N 1GYD8!E/L0".])>WMOIMG/=W<\5K:P1M+-/,X1(T499F8\
M  DD]*SO!^@OX5\*Z1HTEY)J#V%K';&ZD7:TI10-V,G'3IDX]3UK7(##!&13
MEUY2(WLKGF-U\1_AI=>)- \53:FC:BNDS0Z;J?EW A^RW8AN'B#!?+,D@LX9
M%C;]Z5CRHPQSW^@Z]9>)M)@U+3I7EM9L@>9$\4BLI*LCQN R.K JRL RD$$
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MKI&M?#OER6A0P%_L;M<.;=I3%(93\XD,Q)4'<6]XK1VZ&>M]0HHHJ2@HHHH
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AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cdtx-20231231_g10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g10.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +U!@$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45D^)O$UAX3TN2^OY=D:\*H^\Y] *\UM?VBK"2
M\VSZ9-%;$\2*P8@>I%;0HSJ*\4:QI3FKQ1[!16=H?B"P\1V*W6GW"W$3>G4>
MQ':M&LFFG9F;36C"BBBD(**** "BBB@ HHHH **** "BBB@ KFOB-K7]@^#-
M3N@VV3R_+0_[3<5TM>'?'GQA#?-;Z%:3"01-YMP4.1N[+71AZ;J5$C:C#GFD
M>/*I;D\D\DU)Y-21Q\5.L5?3J)[I5B\RWD62)VCD7D,A((KMO#OQB\1:#M26
M8:C;CCR[@9/X-UKE/)]J0PU,Z49JTE<B48R5I(]BC_:(MOLY,FDRB;'"K(-O
MYUYIXU\=:GXXO ]TWE6J']U;1_=7W/J:QOL]'D^U94\-3IOFBC.-*G!WBBGY
M7%=A\(]>;0?&UGE]L%S^XD'8YZ?KBN9:.HE9[::.:,[9(V#J?0BKJ0YHN+ZF
MLES1:[GV916)X-\11>*?#MGJ$1^9T D7^ZXZC\ZVZ^5DG%V9\^TXNS"BBBD(
M**** "BBB@ HHHH CFF2WA>61@D:#+,>PKAK_P")$OV@BSMT,*G[TF<M2>/?
M$7G-_9UNV54YE8=SZ5QFWWKLI4E:\CJITU:\CTW0_&UKJK"*8?9IST#'@_C7
M25X?M*X(/-=;X7\;/:%+6_8O#T67NOU]J52CUB*=+K$]#HIL<BS1JZ,'1AD,
M.AIU<AS!1129H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_>%?/U\'*+<H:H\VKAFG>&Q[117C/QK_:.T_P"&=O:V^F1Q:OJMW'YJ+O\
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M@GK@FOD;XK?#F/\ 8(^(WPHU_P"&7B#6_P#A'?$&MP^'=3\(:IJ,EY!<1R'
MDB$A)5DR#QQP/>OI+XY?LLVWQT\ ^&M'U'QAKNE>(_#KI/8>)M-F$-SYRJ%+
MN@^5MV.?TQ7&_"?]AT^&_B)IGCGXD?$77_BSXAT<'^R/[<8"WL6/_+18P3E\
M=">E &_\;/VQK+X*^.Y/#$_PY\<>)72".<ZAH.CR7-L=XSM#J,$CN*\V^)%\
M-4_X*+_ J]6*2 7'A+4)A%,NUTW<X8=B,\BOM"OG;]HK]CFU^/WQ"\.^,X/'
MGB'P/KFB6DEG;W&@F-7*.V6RS D>E ')_P#!3;7=$7]F74_#%RT=UXH\07=M
M:>'].C^:YFO/-4JT:]1M&<MVS[UXI\5OAEXK^(G[?7A'P]I'CK4? ?B"'X>J
M]QK6EQJTK%&42)AN,,3G\*^C/@U^PCX)^%OC*#QEK6L:Y\1O&5MG[+K'BFZ\
M]K7/>*, *I_VL9KOIOV>]*F_:0MOC&=3O!K$&B/H@T_:OV<QLX8OG&[=QZXH
M ^0/VR/@#\0?AW^QSX^&M_$O7OBC&UY87<L>I1JC6UM%(?-V[.QW+G/3;7W5
M\*?%&@>,OAOX;UCPO<6]QH%U80O:-;$;%CV#"X'0CICMBNBU'3K76-/N+&^M
MX[NSN(VBF@F4,DB,,%6!Z@BOCC4_^"==]X3UR]N?A!\8?%7PNT>]F::70[*3
MSK2(M]X1 D%1UXYQ0!]GY'(SS2UY/^SK\"9O@/X8U*PO?&6M^.=4U.\^W7>J
M:Y*'D+[%7:@'W5 7I[FO6* "BBB@ HHHH **** "BBB@ KSS2?@KH]I\2?%'
MC74Y6U[4]:C@MTCOX8VCL;>($+%$-O ))8D\DFO0Z* /'?%'[+OA3Q5KGB^Y
MGDN+32?%6EPZ=J>CV:I#"\D3;HKE2HW+*O R#C@>E9'PU_9-L/ ]QXAU+6O&
M7B'QSXDU;2FT1=:UZ2-IK.R*D>3$J*%')W$D$D@9KWFB@#PR?]DGP[-\'/!O
M@:/6M8LKWP>@_L3Q/92K#J%G* 1YBE1M.0>5(VG'(I/"/[(GA73='\3Q>,-3
MU3XD:SXELAIVJ:UXCE#W$MJ"2L*! JQJIY&T#GGK7NE% 'SE9_L?WL?A/Q1X
M4U'XM^,M=\+:QI<FE0:7J;P2K81MC:T;^7N9E P"Y/'6O0_$WP-TWQ-8_#NV
MFU*\A7P7>P7MJT83-PT4+1!9,CH0V3MQS7I5% 'A<'[)NAP?!F+X=#7=3.GQ
MZ\-?%[MB\[S1>_:_+^[MV[OEZ9QWS6;X\_8WTKQ/XUU'Q#X>\8Z]X%&L2B?6
M;#1E@:'4), %SYL;&-BHP2A&>O6OH:B@"AH.BV_AW1;'2[0-]FLX5AC+G+$*
M,98]R>I/<DUXIXY_9+L-8\3:AXC\$>-/$GPLUK5)/-U.3PU,@@O6_OO!(K('
M]7 !/>O>J* /);O]FWP[XD^%]OX,\7:CK'C#R9_MBZWJ5X1J$=SVFCE3!C8=
MMN *R?AQ^S?K?@CQ9;:MJOQ@\;^,+"TS]ET?5KF(6Z<$#?L0-)@'^(GIFO<*
M* /!+;]D31=-\'>'-*TWQ%JFG:SX=UJXUG3/$,*1?:H&GF:2:$@KM:)PQ0J1
MR,'J,U-\1OV6CXQ\:W7B?0?B1XP\"7VI)'%JT.AWJ^1?(@P/DD5A$V,C<F#S
M7NM% '+_  U^&N@?"7P?9>&?#5F;/2[7<P#N7DD=CN>21SRSL226/)->>Z[^
MR]I?B;XS6/CW5?$^O:A;Z?/]NL?#D\ZM8VMYL*>>GR[Q\I/R;MN3G%>U44 ?
M)'Q8_9O\/_#7X(^%+&V_X3*_O/"NH375AXH\++&VL:5Y[L\DJQ  2Q_-M9 #
MD8."17'?!?X#7/QGU+XKZCJ&H^,!X5\5>&K7PRFO^*8O)U6^D1G::X6!U C0
M;@J@J!QTK[HHH \RN/@3I=UXH^'6M2:C=M)X*L)]/MH"J&.Z26%(F,O'7$8/
M&!R:\O\ $'[!OAW6O"_B#PG;^./%^E^"=423R?#5O?J;.RD=MY:,,I)4-DB-
MB5&>E?3M% 'B7BC]EC1?%%UXHGFUO48&U_PK#X4F$:QXBAC+$2KE?OG=WX]J
MO>%?V;=(\*^)?&VLP:Q?SS>*M&L]%N(I%CVP1VUN8%=,+G<0<G.1GI7K]% '
MQ]\>/@SHWPR\)_#N>QN_'^EWWABQ_LB/QGX*@2YO8;8 #R[BW"GS(W/.50[2
M.V:Z3]C#P1JNFZG\2?&=W9ZW8Z3XIU&WETP>)G)U*XAA@$9N)U/*&1@6"G!
M/05].T4 <%\1OA%8?$CQ-X*UJ[O[JSF\+7\M_;Q6X4K.SP/"5?()P Y/&.17
M%>'?V4=$\-_"+PCX AUW4I;#PWK,>M07DBQ^=+(EPTX1\+MVY8C@ X%>Y44
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MVGPE^'.@>#[&[GO[31[9;6*YN0HDD )Y;: ,\]A76T4 %%%% !1110 4444
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MFIY@/9V\8:,AP=0AS[$U8M?$>FWC;8;Z%V]-V#^M>(>4OI2^6O;@T<S ]_W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !11534M6M=(M_.NY1%']"2?H!3WV MT50T77+#Q
M#8K>:==1W=L6*[XST8=0?0CT-7Z0!1110 4444 %%%% !116)>^--$TW4H+"
MYU"*"YGD$4:N2 SG@+GID^E,5S;HHHI#"BBB@ HHHH **** "BBB@ K/O/$&
MEZ<\B7>I6=J\>T.LTZ(5W'"YR>,]O6M"OB_XN?!_3?B+\=/CC<>(?#TVM6</
M@FU;35N(W: 72I*0\0Z&52!@CD4 ?8L>K64NH/8I>6[WJ()'MEE4R*IZ,5SD
M ^M1W&O:9:330SZC:0S0IYLL<DZJR)_>8$\#W-?!_@'X<WOASQI^RSXHT[2M
M0M_%6M:5?Q^)-9F25I[AOL:F-;QCU ?& W3&!7G.M^$O#UK^S;X^T3Q=X!\6
M:C^T$RWTE]J<=E<2W=S*9&(FCO%RAM]A7Y W(XVF@#] M4^._A+2/BYHOPXN
M+TCQ#J^GR:C;,K)Y'EHP7:S;LAVR"JX.16KXV^(4/AOPKJ>I:1!#XFU2U@>:
M#2+6_AAENBAPRJ[L%7'.23@8YKY@A^$.CZI^U]\&];OO"%O<O'X&:>XU":QS
MLO(O*$3,Y'$BC(7/(YKEO#/PAM;?]COXOZ^_AN=_&]U_;]O#=30.U[Y+3OMC
MBR-P0X!"KP2<]Z /M[0O$D6JV.GFZ6/3=4N;1+N32Y+A'FA! R#M/S 'C<..
M*T+&_MM2MEN+.XAN[=LA98'#H<'!P1QU%?#7[1W@[Q3\2M*^&7AOX:V6H6'Q
M)TGPY]IO==1GMH[:P>VV/9O+MPTDS?*J]4(W<5]0_LWZMHFK?!?PO_8&C77A
MVQM;5;1M)O8W2:TEC^62-]P!)# _-_%G/>@#O&\0:6MU]F;4K,7/FB#R3.F_
MS",A,9SNQSCK2KX@TM]6;2UU*T;4U&XV8G7S@,9SLSG&/:OE7X1_">+6?CM^
MT'XCN]#\SQ!:ZY&WA[4-1A8I;R&Q51+ 6& =W!9?3%?)O@?X7Z\;G2-&U&_B
MT/XKQZPMQ<ZDW@K49M<2X\_+2-J"S>4\)'/7;L/W>U 'ZMW/B'2K.8Q7&IV<
M$JR+$4DG16#L,JN">I'0=ZF@U6RNKV>SAO+>6[MP#-;QRJTD>>FY0<C/O7PO
M\7O@[;>,M>_:>U?6- N=6U.ST_3YM#G:&0B.Y2T)\ZU Z2!@/F7GM4+?"W7?
M"_Q7^&U_X"L+K2?%7B/X;:D^J:O(LG^E:F8(FB>[<]9!(S$;N1VZ4 ?=$/B#
M2[G5)=-AU*SEU&(9DLTG0S)]4!R/RIU]K>GZ;<V]M=7]K;7-R=L$,TRH\I]%
M!.6_"OS=T3PKX:NOA_X'T#P/X%\2:%^TC:WUFVHZQ>6%Q'=0W"N#=SW=Z1LE
M@8;_ )=S9#+Q7H_B/0_!NG_M,?$.7XT>"]<\2ZGJ;P_\(=J":=/?6HM @ AM
M3&"+><29)8[>H.X4 ?2'[.WQ=OOBG\*7\5>(5LM-ECU&^M9#"2D*1P7#QJQ+
M'CY5!//6M_XF?$1?#/PC\3^+M GLM5DTW3YKJW99!+ [HI(!*GD9ZX-? FI^
M ?%][^R%\.;:VT[5-.\,V/BO4+GQ#INJ6,]]*+;SY#";J"-UDGC#8+[6.<Y^
M:N@^$?@>\C\ _'#4?#]]#-X:O_#;6Z:+H?A:]T?3Y+L*<2P13N3OQE6"J,Y'
M6@#['\!_%G4?$%QI\>K:$-.TR7P]9ZQ)X@:\A6V::507A$1;S%VD_>8;3G&<
MUZ#8ZWIVJ3SPV=_:W<UN0)HX)E=HR>@8 \?C7P-\8/"^M7O@SQU!#IFI,TWP
MBTJT00P2;C*)8]R+@?? SP.177V?P17X8_&CPW'\-=$D\/WFK?#F_BN+J!76
M.>_"IY$EPQX:7<<[FYH ^PF\5:*L]S VL6"S6Q GC-TFZ+)P-PS\N3QS6I7Y
M7:UH_P +M)_9MCL6^'OB32/B_IU_8C7=0O+&>.Y6Z-W&)99[QL)+ S9PH8]5
M^48K]&-!^+GA[5OB9JGP[MI;A_$NCZ;;ZC=IY)\E8I>$^?INXZ'% '57WB'2
MM+DD2\U.SM'C02.L\Z(54G 8Y/ )XS3UUJP>^6R2^MGO6C\Y;99E\PI_>"YS
MCWZ5\D?%#X1:;\3OVQ/%$?B;0)M:\/K\/@L<=Q&YM'N/.?'^R9%ZKW&<BO/O
M@_\ "UM T/\ 9>\51Z)J$7B^;5IK36-5FCE-V;3R9@L4[GGRAM0!6X&!B@#[
M5\"^/I_$G@]M=\0:1_PAQ2>:)[:^OH90B(Y59#)&Q0!@ <9R,X/-=!;>(=+O
M%#6^I6<X,/V@&.=&_=9(W\'[N0>>G%? .M>%;A?@O\-9_&/AK7-;^&^G^+=5
MG\3Z18P2M*R-/)]FEEA7#R0JQRRC.01P>E:O@>U\$O\ ';XC#X;>&]2T#0KK
MX92O!;2VLMK!.QDE :VMGPT:DC!&U<MDXYR0#[LM=:TZ_D9+:_M;AUC65EBF
M5B$/1C@]#V-1P^(])N/*\K5+.3S7:./9<(=[*,LHYY(')%?%MS\%]0T?]@_2
MG\&Z!>P^*-3T[3)/$8LMT>K:A9HZM<P"0X?=Y98!<C"Y4>E85GH/PZU3]HCX
M#W/PN\!ZYHFD6][>Q:M.=+N+*R&;*0!)DD WRY.#)@CG&XYH ^G+7]IK1?%/
MAWQE>^"M,N/%>I^&-4.E7&EK=V]L\SJZJTD;N^TQC=D,<9P0.:]2OO$6FZ/'
M;'4[^TTQ[C C2ZN$C+-_=&3R>>U? >G?!O3_  K\'_VAYM$\&+I6I3>,WMK5
MK.P:.62S6YA94CP,F,'<1CCK73_$;2? ^D_''Q[>?'CP9JWBJSU"WME\)WB:
M5/J-I';"$![>!8PWDW'F;B6(7.1\PH ^V;[7-.TME%[J%K:%D:11/,J95?O,
M,GH.Y[5/97UMJ5K'<VEQ%=6T@RDT+AT8>H(X-?GAX0^".K^,/&W[.>B?$70=
M5O\ 0(;?Q%,FFZP7F:WL2T;65O>MR&81[058G.,<XKV7X ^+_#_[./A'6="U
M>WOM*TK4/B)=Z'X?L4MW?:)?+,:QKU$0.[D9 % 'U5>7UMIML]Q=W$5K;I]Z
M69PB+VY)XJFWB?1UM[N=M6L1#:,%N)#<IMA)Z!SGY3]:\3_;RTN]UK]E7QQ9
M:?;W5U=S0PJD5FC-*?WR9VA><X]*\?;]FWPE_P -"7.DMX/\WPM?> Q>7UG)
M$[6=YJ"N%6693\KS@$G)^;//6@#[3O=9T_3=/^W7E];6MC@'[3-,J1X/0[B<
M<US/Q)^+7ASX5_#O4?&VL7@DT*RB$QDLV21I@2 !'E@&)STS7YX^*_!OBZ\^
M$OP"O/$4;GP-I>EWL-_;Z]HEUJ]K%>"=U@-U:1.LC#RP%4D,!@<=ZZ32?@^^
MJ?L>_&1)HU\3:%<W*WN@Z,GARYL8+.92H:2S@G=W5&R< !<8/ H _033?%VC
MZKX=M-=AU&V&E7,2RI<M,@3# $ MG&>?6K@UBP(G(O;<B!!)+^]7]VI&0S<\
M CG)KXJ^+7PW\/\ @_Q=\'/^$G\%WEY\$M.T65)=(T>QDFL[+4W"LLUU:Q L
MZE2P'RG#=JY[0_!.@ZKH_P"T?;:;HGBSPEX'OH]+DLU&GRR2M$JAF:"V;GR"
M1S%P=N1@=* /L'XC?';P?\+])T'4]7U..2RUO48=-LYK26-U:20D!R2P'EC'
MS,,XKM)M:T^VBMY9KZVBBN"!"[S*!*3T"DGG/M7YXM\--+^(/P'\$17OPZTJ
MYL;/XB6]O9S6>AS6L%W8.Q\V9;67+P1/@!E.%X[5W_C_ ,(>%/#?[3NLS?%C
MP9J6O>"6T:SL_!AMM.FOM-L@@(E@$,0/ES%MN&*].XH ^S9_$&EVMG/=S:E:
M0VD#F.6>2=52-@<%68G .>QK"N?&E]'\0M+T"#09+K1[S3Y+UM?2\A$43JV!
M%Y1;S&+ YW*-H[FO@^T\#Z=-^R]?QZU8>(?#VE6?C^^O+6QUS1YM73R\N(EO
M[=27DA.1RN2#M^M=_P"#M&U77KWX?G4?#NH>%[>3X:ZM:36VD02AK7<^$\I7
M.5D9?F1&.02!0!]I:;JUCK$+36%Y;WT2L4:2VE610PZ@D$\CTJW7PE^RW\2O
M#?[/?@/QSJVIZ3]C\%V5UI]K;Z]::%/IUQJ-Q+MB\M[60_-,A(WNF QW'FON
MFWF6YMXYDSLD4.NX8.",]* )**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#SCQY\4+_2_%-GX0\+:4NM>)[F'[1()I#';64.<>9*P&>3T Y-6=%3
MXEV^I6QU:7PW>V#L!,MI'-#)&O<J6+!C^5<=J6K0_"GX\:QK>O!H- \36=O#
M#JK F*VGB&WRG/\ "&!R">,UZBOCKPW<2001:_ITLURPCACBND9G8]  #UKM
MG'EC%0C=-;_UV/,IR]I.3J3LT]KVTZ>M]SAKCXE^)?&OB;5-'\!Z?8M9Z5*;
M>\US568P><.L<2)RY'<Y %:\&I^.O#^DZU=^(!H=W%:V,MQ!/IXEC)D5<A61
MB>.#R#7#?!/7]/\ A.VJ^ O$]TFE:E#J$]S9W5XVR/4()&W"17/!89P1G(KT
M/Q=XNT36/"OB.QL-6LKZ[72[B8PV\ZR,$"$;C@GC)%54CRSY(Q]WOW\[F=*?
M/3]I.?O:Z7V?:WD>8V/QJ\<Z#X!T3QWXAM-%OO#=^8?/M].62.ZMUD;:"-S$
M.0>W%=Y\:/B1?^!=)T*/1OL?]K:UJ,-C;MJ!(A0-RSO@@X ]Z\$^$7A:/0+C
MX>WOB^_O=<\*ZO:QG2H[ZZ9K;3K]22$,>=N&'W2>A%>[^--6^''B3QDGAGQ;
M!8SZE9V_VF!-8B"P%6X)C9_E9ACG'2MZL(1JJT;I7V7];=3EP]6K4H.\[-V2
MN];[MW\UMO\ H=%X)7Q8PFE\1ZAHM_ Z@V[:3#(@]R2S-D?2NJKPW]GL)9^+
MO'6G^'YYKKP);W,?]G.[EX4F*YE2%CU0'TXKW*N"O'EFU_P#UL+/VE)2]>M]
MGWZKL%%%<O\ $/QM%X'T$W902W,C>7!$?XF]3["LHQ<FHK<[8Q<G9'2RS)!&
M7D=8T'5F. *Y;6OBEX:T-6$NI)-(/^6=O\[?IQ^M?.?B#QEK/BJZ:6^OI'4G
MB)3M1?8 5E1PUZU/ +[;/0CA%]IGL&O_ +0<DJM'HUAY1/ FN3DCWVBO*KZ\
MNM8OI;R]F:XN93EI&ZFHTAJQ'%BO2I8>%/X4=D:<*?PH9''TJ98ZD2.I0F*Z
MU$JY#Y?M2>5[58HJN416\H>E)Y8]*M8%(4HL!2>*JTL/&,5I-'4+QYJ'$=SM
M_A[\8)?"=FFG:E"]W8(?W<B??C'I[BO7=)^)GAO6E4P:I$CM_P LYOD8?G7S
M')#5=X?2O-JX.%1\VS,)X>%1WV/0?CAHL-KXCBU2T=)(+Y<LT; C>.#T]17
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "N>\9Z+/JVFYMCF6,',?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^:OVK%"^!_$IP /*8G]*^E:^:_VKL?\
M""^)PW"F%L_^.UT4=WZ'/6V7J>M>#OB!X;A\(Z&CZW9*ZV, *F49!\M:U_\
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M_#KP1-XL\7>)=(&MG2+J_2RAL+4-L+SSE6QEPRJ ISCM7 ?'7]K+QG=?L_\
MQ D\->&IO"WQ&\)W=I::[8W%^F[35E=&CGAD"%9T<$ <+PQ/:NY@_8UN/#OA
M'P5'X0^(-]X4\<^%]-;2(O$UOI\<R7=JSES'/:NVU@"25^;Y3SS5RX_8YL[W
MX1^-_#%YXMOM1\5>-)8+C6_%MY;(\UQ)$Z% L(*JB*J;50'@'J: /)U^)/Q#
MT7]I.YUFU^'2ZWXSN?AS93W6CQ:NB6]N%NIV):Y*<DC& $R2<>]=GXP_X* ^
M'M!^'_P_U:STFW'B'QE:R7-MINN:M#IMK:+$Q2;S[J0%0 X*C"DMZ"O8M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ)#+X?CTZ=_^7C3G,+#WP/E_,5\E_M"? %O@>MG'H?B"^U"#5V=3IZQLK[%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,0PJ*!@ "O3QV,I5J:IT]=;GA95EM?#5G6K66EK(LU%=7"6=M+/(<1QH7;Z
M9J6H[B!+J"2&0;HY%*L/8C%>$?5>AXU-\9]=D:34;?3;?^R$?&QB=[+ZY[&O
M7-&U6'7-*M;^W.8;B,2+GW[5Y5-\"[Y;A[:WUI4T=WW&-D/F 9Z#M7J^E:;#
MH^FVUC;+M@MT$:#V%=-7V=ER''A_;7?M/Z9;HHHKF.T^??B]^T%X@T7QX_@_
MP7I=O>ZC:Q":[N+S.Q<C(50",\=ZZ[X!_&:3XM:/J":A8KIVMZ7,(+N&,Y1L
MC(9?8\_E7-_%_P#9OO?&7C#_ (2GPOKJZ#J\T0ANEF0M'* , \<@XKK?@?\
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M@.JL>JGL:]3_ &F/@)K?C;6]/\6^$VCDUBT3RY;21MOFJ.A4^O\ ]:O+=#^
M/Q+^*/B33QXOLCHFD6LBM+)+(K.R@]% )KW:/L/9*]K=;[GRF*^M>WER\U[^
M[;:WGT];GVQ9W4=_9P7,)W0S1K(C>JD9!_(U-4-G:QV-I!;0KMAA18T7T4#
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MB)J?@F\C\N5KG3R?WEI(V5([E?0U]-Z+K%MKVEV^H6;^9;SKN4^GL?<5<97
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M-&;_ (]O"7C.\_ZXZ(_X?>85/UNA_.C9</9MUPTEZJWYV/7Z*\:/[15[<?\
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MFXZ,KEN=Q156QO!>6Z2#C/45:KL3N8A1113 *YWQ%'_ID+>JUT5<SK%PMUJ
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MRG\6?&1SXH\?^5$WWXOM,LW_ (Z,*:PO'/[).A?#F/3_ +3K%YK$]P6+$1K
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M16LJ,X3<&M4<]/$TJE-55+1]]#JJ*\W^(WQU\.?#NWT":>]MKI-7N(TB*3J
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M]83KC9(6C;LR$Y!%92]:Y^HQ GMBE\OWJ11NIVWVJK 5VCY#=_[PX-=GX/\
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MO#/B)\2M27Q)=6-G<R6<-I*8L(=NXCJ3ZU[G7F7Q&^!EEX\U3^T8-6O-$NW
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MN.(5U"HN67GU]'U_/R.?$9/45-XG!S5:DMW'>/\ CC\4?76-]I,]$HHHKJ/
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M4 %?#G[77[9FM>$O%-YX0\&W T[["?+O=2"@RM)C)1,_= R.>I.:^XZ_,/\
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M760*&&,=*Y;P[<WO[/VO:QI6H:1>WW@O4;R2_LM5T^$SFT:0Y>*9%&X#/(8
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M:))4/574$?K4N-P/C&/=*P6-"['H%&37<^#?A#K7BB99;J-M-L,\RS##L/\
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MU2G+EBOB1XN93@^6*W1H4445\X>&%%%% !1110 4444 %%%% !1110 4444
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MSZ<H-K='_IO;GY7^HP?>N;EK4?A?,NSW^3Z_/[SVO;9=F7\>/L*G\T4W3?\
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M]S["O$_$GCK6_%DA^WWTAASD6\9VQC\!U_&I<D!]$ZM\4/#&C,5GU2.1UZI
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSP>S22P&[LL\75N"0/\ >':OJ6D90RE6 93P01D&I<4P/C!7I^ZOI3Q5\']
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M8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMQ_9$<JRWRF)KK:9I85ZX0]5!]JW/"<FC>$=%C\3:H%U/Q#*Q-EIDHREN?\
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M^V2<_P J]TKY_&5I<_LT]#SL34ES<BV$'' X%+117EG %%%% !1110 4444
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M1@CGIS7S=#\ =6O=8_:=OK_PBMQ<^)K&TM=(GFB1FNU33T1D0GL)5Q]13/\
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MG26V7MG:SAY(3G!R/KQQWI?''QA\%?#28Q>*?$NGZ%(+5KW;>2["858*SCU
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M:W8^#K-DE&EP>=%N&1\H=@C2,%X!8CFOM>&%((5CC18T X50 !^% '@'P_\
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M4V>S/J</BJ>)5X;]C0M^U7XNU9UMVK2A[5YATLLK4E,C[T^I$%%%%( HHHH
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MVR?"<WC;]F3X@Z59Z1_;>HRZ8YM+-8!*[3#&THI'WNN".:]HHH ^--;T.[^
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M .9\CF=.<:[F]F3T445[QY 4444 %%%% !1110 4444 %%%% !1110 4444
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MK_.O-L><1:7I<>FP[$^9S]Y^YJY115@%1-4C&HF-0!#)6[X%U0:?K'DN<1W
MVY]^U83]ZB#F.174X93D5C-<RL#5U8]OHJCHM\-2TNVN,Y+H-WU[U>KR7IH<
M&V@4444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7@?[1?B]9KFUT"!LB']]/@\;B/E'X#G\:]\KY[^*OPE\0ZGXJN]2L+?
M[=;W#;QL(W+[$$]J\7-O:O#<M)7N];=CU,M]FJ_-4=K;>IY'"^W%:$,G2MZW
M^#OBYS_R"9%_WBH_K6+K&AZAX9U V>HV[6UPH#;6[@]#7PDZ%6FN:<6EYH^M
MC5IS=HR3?J6H9O6KD<G2LB&7I5J.:N4T-59!WJ0/6<L]2K-2$7@_K3JJI-4J
MR4K"):*:&IU(#Y*_;#M98_&VAW+ ^3)9%%/;(;D5X='(,<U]R_&OX5P_%3PI
M]D1EAU6U8S64[= V.4/LU?&FH?#?Q;I.KMI<_A[4/MH.T+% SJWN&'&/QKOI
M24HV['JX>HN2W8PYK@*O7%?4_P"S'\('T&S_ .$MUB$IJ%VF+*!QS#$?XS[G
M^597P7_9DFLKV'7/&4:;XR'M]*R& ;J&D/\ 2OI;@8'0=!BLJM16Y8F6(K\W
MNQ#IT.*/J:0M3&;\!7*>>*S9XJ"1Q^%#28X'2J\DE4,CF;K6?-5F:3-59&W5
M2&4+A,FNR^&OQ4OO!-ZEO.[7&ELWSPD_=]U]#_.N0F]:IS>M=%&M.C-3INS1
M$Z<:L7":NC[<T_4(-5L8;NUD$L$RAT8=P:LUY1^SSKDFH>%[FQE8L;24%,_W
M6'3\P?SKU>OTS"UOK%&-7N?"XBE[&K*GV"BBL;Q9XPT;P-H\FJ:[J$.G6,9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2I0TDS9&_P#VSZNPSA>PY-+X@\3>+_VR/%G]A^'XY-%\"64H,]S)D!^?O/\
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M;L2>K77C[1;5BINQ*P[1J35!_BAI2M@).P_W*\P$8%+M'I4\S ]3M_B5H\S
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M=C<Q7EK(,I-"X=6'L17%6H5*#M-?Y'J8?%T<5'FI2OY=5ZHLT445SG6%%%%
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M?>$6MI7U.S0F-CF:-1]T_P!X>U3)=0.+I=N::K;A3E;M20"[/:FXQ4FZFM0
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MJC7C5TZF T_!YKJOA#X+?XB?$+2M( )@:3S+AL9VQKRV?Y?C7$[FD8*H)8\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ-.$@*% X[585LUGQR5;CDK4S)Z*0'-+6ER0I*6BF!4N]+M+['VBWBF(Z&1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!DGI0!UM%?,&A_M.>+]8UVWMVT>PM(KG5KC0[:&XM)%CN;Z#?YEJETL[?/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cdtx-20231231_g11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g11.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *F!@ # 2(  A$! Q$!_\0
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M/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHI#6YNT445_(9_?:V"BBBD,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,*BBBOZ^/X""BBB@ HHHH *
M*** "BBB@ HI-PH) ZT +1129YQW]* %HI P/0YHW '!(S0 M%%)N&<9&: %
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHVG&=K8]<'%% !11M.,[6QZXXHH **** "BBB@ HHHH **** "BBB@
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M:@8,F?NDGC..<5G_ +4'@E? OQFUJT2]FOTNBMZLMR^^0>8,E6/?!_2O7_V
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M0M1ETX#=]J2V<QX]<XK%K]&O%WQ"T7P;\5(;2[^(QTFRM(T1O"<>E!XWC*]
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M%OX]+SC[8UNPB_[ZQ7UU^R9<)%\5OBU,0)8U=V*]F D;BNA^ /Q:U7XZ:?\
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MMXQ,<>@6D[.]K"!#'-)C<P^7&V-1V%=X_P"TQ\%EUG_A'_\ A X6\/B3[/\
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MC?\ %1?!G@OPAX_L="T^?Q+J$21)=74>XP1E=[JOU/ /;-8'[2_AO3O'E_\
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M<G ]*H5\G-WDVC[>"<8)/L%%%%06%%%% !1110 4444 85%%%?U\?P$%%%%
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M<T?BW".+KT^3EE;DV\K[GM_Q8_:JUSXE>&?^$<L=)L_#.B.<SV]ERTW.<$X
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MO\C..*KPY.65N6]O*^Y[?\2/VI+_ ,:>#I?"VC^&]+\+Z/<'=<):(&:0]>.
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M2:/DM!%<,/W>3DJ<@@KGGVJ?QY^U)=^//AU?^%9] M;&.XD!BDM6VI#&&!5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$_\ @6?_ (FC_AAGXD_]0G_P+/\ \37Z%T4?VMB/+[@_U>P?G]__  #\]/\
MAAGXD_\ 4)_\"S_\31_PPS\2?^H3_P"!9_\ B:_0NBC^UL1Y?<'^KV#\_O\
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M_0NBC^UL1Y?<'^KV#\_O_P" ?GI_PPS\2?\ J$_^!9_^)H_X89^)/_4)_P#
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M (89^)/_ %"?_ L__$U^A=%']K8CR^X/]7L'Y_?_ , _/3_AAGXD_P#4)_\
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M -39_P"2G_V5?7-%']AX#_GW^+_S#_6+,_\ G[^"_P CY&_X8+_ZFS_R4_\
MLJ/^&"_^IL_\E/\ [*OKFBC^P\!_S[_%_P"8?ZQ9G_S]_!?Y'R-_PP7_ -39
M_P"2G_V5'_#!?_4V?^2G_P!E7US11_8> _Y]_B_\P_UBS/\ Y^_@O\CY&_X8
M+_ZFS_R4_P#LJ/\ A@O_ *FS_P E/_LJ^N:*/[#P'_/O\7_F'^L69_\ /W\%
M_D?(W_#!?_4V?^2G_P!E1_PP7_U-G_DI_P#95]<T4?V'@/\ GW^+_P P_P!8
MLS_Y^_@O\CY&_P"&"_\ J;/_ "4_^RH_X8+_ .IL_P#)3_[*OKFBC^P\!_S[
M_%_YA_K%F?\ S]_!?Y'R-_PP7_U-G_DI_P#94?\ #!?_ %-G_DI_]E7US11_
M8> _Y]_B_P#,/]8LS_Y^_@O\CY&_X8+_ .IL_P#)3_[*C_A@O_J;/_)3_P"R
MKZYHH_L/ ?\ /O\ %_YA_K%F?_/W\%_D?(W_  P7_P!39_Y*?_94?\,%_P#4
MV?\ DI_]E7US11_8> _Y]_B_\P_UBS/_ )^_@O\ (^1O^&"_^IL_\E/_ +*C
M_A@O_J;/_)3_ .RKZYHH_L/ ?\^_Q?\ F'^L69_\_?P7^1\C?\,%_P#4V?\
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MP7_U-G_DI_\ 95]<T4?V'@/^??XO_,/]8LS_ .?OX+_(^1O^&"_^IL_\E/\
M[*C_ (8+_P"IL_\ )3_[*OKFBC^P\!_S[_%_YA_K%F?_ #]_!?Y'R-_PP7_U
M-G_DI_\ 94?\,%_]39_Y*?\ V5?7-%']AX#_ )]_B_\ ,/\ 6+,_^?OX+_(^
M1O\ A@O_ *FS_P E/_LJ/^&"_P#J;/\ R4_^RKZYHH_L/ ?\^_Q?^8?ZQ9G_
M ,_?P7^1\C?\,%_]39_Y*?\ V5'_  P7_P!39_Y*?_95]<T4?V'@/^??XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 444F: %HK"\5>.-#\#V7VO7-2@TZW)P'F<"F^$O'F@^.K-
MKO0M3@U&!3@O"P.* -^BO/\ 7/CYX"\-ZD^GZCXDL[6\0[6B=^0:Z(^.-"70
M1K;:G NED;A<EL+BCI?H'6QO45S'A'XE>&?'1D&A:Q;:B8_O"%P2*A\6?%;P
MIX&NHK?7-;M=/FE^XDK@$T =;15/2]6M-:L8[RRN$N;:0922,Y!%6Z %HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKBZENH[6^:*+S6R54$\5]A4+8;T84444Q!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9)^M>%?#?]D?XK_M+>$;#XA_%'XU^*/#VJ:Y$+^ST+PX_P!GM[")_FB7&1R
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MM.FZM8ZS T^GWEO?0JYC:2WE610PZJ2#U'I5NOBK_@D[_P F^^+,?]#KJ?\
MZ##7MWCS]LCX,?#/Q*= \1?$'2+#5D8+-;B0R& G_GH5!"?\"(H ]E>18T9W
M8*BC)9C@ >M4M%U[3?$FGI?:3?VVIV3DJMQ:2K+&2#@@,I(X-8.J^)-*\8?#
M'5=7T34;;5M+N],GD@O+.4212*8FY##@U\Q_\$F@%_8_T[ Q_P 3G4/_ $;0
M!]DT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXEM;'XO:=KOAJYFEF/A468L6NK7>66U,RJ3]W"\D ]S7KG@'2_VF=2\!^/\
M5_%6I^&]'\9ZA$@\,Z):IYUGIS(6)\U_XR^0"<]L\=*X;4/C/^V$VCOX>3X&
M:"OB.6$Q#Q!'KR-8JV,>;Y9YZG.W=0!T'[$O[1'@?Q-^S'>RQ:!%X$L_ :2Z
M?K>C9\R.U,:EG8,>6#88\\YW9KY$\#? +XJ?'1O'WQ$_9RNKCX-?#KQ&LL5I
MI-YJ+@ZTVXB21$P1;AB" <\= 0,X^L/V??V&I?AO^S/X]\#>(M:6]\6>/DN)
MM:U" 'RHYI$955.Y"[B2>Y)]JX3X&W?[4'[+?PZT[X9O\'M-^(&GZ09(-*UK
M3];CME:(NS@2JP)&"QY//.,<4 ==_P $Y?B%X;M_"FN?"1?!S^ O'O@^0?V]
MILLGG-=R,<&Z\T\MN.,YZ9&.*][_ &G/&5]\/?V?/B#XBTQVCU#3]'N)H)%Z
MJ^W 8>XSG\*\:_9'_9O\=^$_BS\0?C)\49=/M/&/C#;$NAZ7)YL-A I!"F3H
MS851QZ'UKZ2^(7@JQ^)'@77O"VI9^PZO9RV<I7J%=2,CZ9S^% 'YL_L<?$32
M/ O[/NDV\G[,_C;QW>:[')>:IXBCTNVNXM5=W;++)(^YDXQ@]P:]2_81^&^M
M:;X=^,^B>)OA[J?AWX>76IG4?#V@>*[99!;JR.654;<O!V].X%.^#=K^TU^R
M+X3B^'$/PTT_XJ^&--ED31=:T_5TM)$@+$A)4<''))SVSWKZ9^#>I_%GQ9X5
M\0W/Q0\/:+X7O[IRNF:3I-V;IH83'@B:7H6+>@% 'RI_P2Q^''A+Q/\ !GQ=
M/K'A;1=6GC\47D:2WVG0S.J C"@LI( ]*K?L?_#GPGJW[:G[3^G7WA?1;RPL
MM1A6UM;C3X7BMQN?B-2N%'TQ7M7_  3Z^!7C#X!_"_Q+HWC2PAT_4+W7[F^@
MCAN4G#0OC:V5) SZ=:@_9I^ OC/X;_M3?'SQIKVGPVWA[Q9>Q3:3<1W*2-,H
M9B24!RO4=: ///#_ (;TCPM_P5@:RT72K'1[/_A F?[/86R01[C(F3M0 9]Z
MS_V;_"&C_M#_ +:OQV\;^.-.MO$$WA6_30]$L]0B66&SB7<-PC;*EB%ZD<$D
MUZ\OP.\8#_@H2WQ3-A#_ ,(5_P (B=*%[]I3S/M&]3M\O.[&!UQBO/O&WP;^
M,'[./[2OBOXI_!WPY9^.O"_C)%EUWPU<7HMYDN1G,L3-ZDD\ ]2#ZT ?1Z_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#O\ X*._%OQGKFG?9/!T]_I\\JH9(XB5Y//->Y_\%0]/L[?X$O)%90),9/\
M6+& WYUM_P#!,W3+*X_9ETB:2RMVF\UOWC1@M^=9];&FEKGU3X9U*YUCP_87
MMW;FUN9X5DDA/\!(Z5J4BC:  ,"EK0S"BBB@ HHHH *^=?VP+?XM2^$T/POD
MQ=@_.O<U]%4E 'XDZW^TA^TEX:\:6_A'4=3:+7ISMCM^>37W=^Q;'\>VNYI?
MB:Y6P8;HU8<U\L_M$X_X>"^'.!_KU_G7ZT6'_'C;_P#7-?Y5FKW-'+2Q,,\Y
MI:**T,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!R7PS_Y%^Y_["%W_P"CFKK:
MY+X9_P#(OW/_ &$+O_T<U=;0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,EG!
M-/%/)#&\T.?+D9 63(P<'MD>E?.W[:'[87AC]D/POI>KZCI/]O>)=2=X=,T^
M,JC%0 9':0@E4&5SCJ2!7T?7P!_P5ZL? $'PM\+:]K]]]F\;:9?^9X?M1%YH
MO "K312KVBP%);L<=<T >26W_!7KXMZA ES9_ Z.YM)1OBFC%VZNIZ$$)@\>
ME?HI^SK\2]5^,7P4\)^,M;T?^P-5U>U,]QIH#CR&#LNW#C=T4'GUKX"\/_\
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M/^"@WAO_ *[K_.OUHT__ (\;;_KFO\A7Y,?M$?\ *03PX?\ INO\Z_6?3_\
MCQMO^N:_RJ([LM[%BBBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^&?^1J\5_P#7Q#_Z)6NHKE_#/_(U>*_^OB'_ -$K744 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ')?
M#/\ Y%^Y_P"PA=_^CFKK:Y+X9_\ (OW/_80N_P#T<U=;0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-O9)_)['MU%?)_Q6_:8^*/PQU.]:Z\%V<>AQS+#!J$ZR!)25!X(;US^5>D?
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M10 4444 %%%% !1110 4444 %(:6B@#Y\_;(M?$U]\.7L_#&C0ZI<W)\MRZ
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M&"C5^27_  4,_9M\'? _Q!H">&;-;6.]F42H!V)K]DZ_+_\ X*UG_BI/"?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<3JGQ$O\
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MAW4?CU^U#J6FS:LL^IQ^$/"UFC -<10N(E1&["6<AL^E 'Z"5Q]G\5O#U_\
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MHV^FW4.@W,IO=(>X.(BY?Y9 #PV,5]?HXD164Y5AD&@!U%%% !1110 4444
M%%%% !1110 4444 %%%% '#_ !;^-G@KX%^'[;6O'&O6^@Z;<W*6D4T^3OD8
M\   G ZD]@,FN)^,G[.?PJ_;"T/P]?\ B0#Q'I=F&GT^ZTR_*QL) ,D,APP(
M KO?BI\(?!_QL\*S^'/&NA6NO:3+R(KA?FC;&-Z,.48>H(-?%%Y_P2Y\3_#G
M4I[GX+?'#Q%X*M)'+IIUV[2)'GL&0KG\5SZDT >B_P##I_\ 9W_Z%S4?_!I+
M_C7JG@/X@_!WX$ZIX1^!&B>)K*TU:*W:'3=&>Z,TRJ"7VN_.'.3A6.3V%?,
M_8'_ &D?%,9LO%?[3NJ2:6YP\=GYY<C\7':O=OV;?^"?_P ,/V<;Q=:M;:X\
M5>,2=[^(M<82SJQZF-<;4^HRWJ30!],4444 -*@]>10JA>@ 'L*=10 PQJ6S
MM&?7%.VYZ\TM% #5C5>@ ^@H:-7QN56^HS3J* $VCTKC_C!_R2_Q-_UXR?RK
ML:X[XP?\DO\ $W_7C)_*D]AK<^;?^":R[?AIXA_["3_S-?8=?'G_  37_P"2
M:^(?^PD_\S7V'2CL#W"BBBJ$%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %)2TC=* /GG]HG]M3P;^SEJEKIVNB1[J
M;G;&.E>0'_@K)\,EC+FWN<?2OI'XN?LZ>!/BXK7GB318;VZAC8K,PY'%?DQ\
M(_A!X9U[]M*X\(7MDLNB"X9!;D<8!J&VBE8_63]G_P#:(\._M$>&6UC0"RQH
M<,C]17JXKC?AK\(O"_PETLV'AG3(M/@;[PC&,UV=42%>,_M)?#GPSJWPS\3:
MG>:-:SWRVCE9VC&X''7->S5YE^T9JUEI_P (?$J75U%;L]HX42-C)QT% UN?
M!7_!+/P+X?\ %5[XU&K:5;WYAN#Y7G(&V_-VK].K&PM]-M8[:UA2"",;5C08
M %?FG_P2CUW3=)OO')O;Z"U+SDIYKA<C-?4'QX_;D\$?!Z8Z9;3'7-=D&(K:
MS^?YNV<5,;)%2NV?1=]J-KI=N9KNXCMHEZO(P %?)W[3'[=6B?#^T;0_!GE^
M)O$MSNA6WMSO )X[5\^ZEH/[0O[8GB!;KS9_"'A9_P#EERA*?_JKZJ^!'[$/
M@GX1VUG>7MJNM>((SO:^N?F;=^-.[>PO4_'/XM?#/Q[#JE]XL\4:!<Z9#J$K
M3%I$(49YQFNA_9T_9N^(?Q0\1:?JWA>RFABB?,-\5(0'ZU^E7_!4:*.+X"E4
MC1 'XVJ!BM__ ()DHH_9@T@[5W>:V6QS4VUL7?2YX_J'Q _::_9YCAM+O2O^
M$NBD 1&0%]@KK/"O_!1N;0[%++QWX1U"QUP-\Z11':%]>E?<LD,<OWT5_P#>
M -<WK/PU\+>(+EKC4="L[N=Q@R21#.*JS[D71P7A3]K/X:^*K>U,7B*UM[F=
M-QMY7 93C.#7YF?\%%?VCO#WQ>\>6.GZ/N?^R+@"23LVT]17WS\4?V'? NK>
M']9NO#VE)I^NR1L\$L9(VMCM7XL?$;P?K/@OQEJNG:S!(MS%.T?F2 _/@]JE
MMK<I),^^[?\ X*"^)-=\!Z+X+^%>B27^JV]HEO-)MRR<8R*]J_9W_86T_5H;
M;QU\3UDU;Q9=/]H,5P25BSSC!KYP_P""4OPGUM_B%?\ B::S\G3%3 ,R?>^F
M:_6X8Q@=*I:A)V>A!8V,&FV<-K;1+!!$H1$08  [5/2TE49GY(_M$?\ *0;P
MY_UW7^=?K/I__'C;?]<U_E7Y,?M$?\I!O#?_ %W7^=?K/I__ !XVW_7-?Y"H
M6Y<NA8HHHJR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6,'&0&'8X'!]*U?AY\-?#_PM\.1Z)X?LA:V2N9&+'>\CG +,QY)P!^5=310
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M&3^5=C7'?&#_ ))?XF_Z\9/Y4GL-;GS;_P $U_\ DFOB'_L)/_,U]AU\>?\
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M.BBBK,Q&&X8/3O7Y8?\ !5[P_I>E^*/#$UG8Q6TLTZ&5XUP7RPZU^J%?E_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.E'8'N%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:1#?8JZ7I-GHMG':V-M':V\8PL<2@ 5PW[06?^%.^*<<G[&_\J]"D;:C$#)
MS7YO?M=_M7?%RP\2:[X,T7P=-)HTT9B\\Q$D@\9!Q0W82U8G_!)//VSQV2.?
MM!_]"K])*_#K]GCXP?%_]G&YU&31/!]Q/_:4NZ421$CD]N*_8;X'^-M6^('P
MZTS6=;TZ32]1FC!E@D&"#4Q9<EU._HI*6K,SXP_X*D_\D&;_ *Z5N?\ !,G_
M )-?TG_KJU8?_!4G_D@S?]=*W/\ @F3_ ,FOZ3_UU:H^T:?9/K.DI:*LS.&^
M,'Q4L/@_X+N_$&H1O-% I/EQC)-?CK^V?^UOI_[26M:5+8Z;/:1Z?,K?,AY
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MLGUG1115F84E+10 4444 %)2T4 %)2T4 %%%% !1110 4444 %%%% !1110
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MB1@%F=LC"@9KGOA;^T_X)^+/BN[\+Z<=6TCQ);P?:O[)U_3)K"XE@SCS8UD
MWK[CIWQ0!ZW17@GC#]MSX7^"];UC3Y[O5]2AT2?[-J^IZ3I,]U9:<_<33HI5
M<=\$X[U[;H>N:?XFT>RU;2KN&_TV]A6>WNH&#)+&PRK*>X(H Q?#/_(U>*_^
MOB'_ -$K745R_AG_ )&KQ7_U\0_^B5KJ* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?%V_L@9;:TAD2UT"R9N+2V#J. 2 S]6(]*^QJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^$O^"JG@/XF?$KP;X,T;X>^"YO%1COGO)[FSM?
M,N+&1 IC='R-F><]<XK[MKY4_;H^(WQ_\ VOA5O@9X;D\0RW+S#4Q'IHN_+
M"[.XVYRWY4 ?)>E_'[_@H'ING6UJ_P .+R]:% AN+G1%,DF!C<Q#C)/?BOT8
M_9UUSQIXE^"?A/4_B)I[:7XUN;0OJEFT/DF*7>P V9.WY0IQ[U^:.L?\% ?V
MN_@5>Z?K'Q1^'T</AN298Y4OM&:T$G^RLRMA6],@_2OU'^$OQ*TOXQ?#7PYX
MUT7=_9FM6:7<2O\ >3/#*?=6!'X4 ==1110 E'UI:* $YHI:* $Y[T?2EHH
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MXGO/FO=<OCON)F/4 G[J_P"R*]%HHH Y/Q-_R.W@W_KM=?\ I.U=97)^)O\
MD=O!O_7:Z_\ 2=JZR@ HHHH **** "BBB@ HHHH *CGMXKI=LT22KG.V10P_
M6I** *\.GVMO)OBMH8G_ +R1@'^56*** "BBB@ HHHH *\\N/@[;77QYL_B=
M-J,CW-GH4FB0:=Y0V('F61I=^<Y.T+C'2O0Z* $ "]!BEHHH *3 &<#%+10
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M!GPKXYGTMM%EUJU-PU@S%C"0[+C) S]W/3O0!Z'1110 4444 %%%% !1110
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M3Z18W#Z?\.-+GVO/&<+/@\_6OO/X4_"[1/A#X-L?#VA6R06ML@4LHY<XY)K
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MB@ HHHH ***2@".XD6WA>5CA4!8Y]J_(K_@IG^T)X>^)WBS1?#VF'=/HL_\
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MBBB@"OJ$/VJQN83$DXDC9/*D^Z^01M/L:^#_ (*_#S]K7X :?JOA_P ,^%?
M5SX/EO)+G2]'U#693_9BNQ9HHY NYDR<@-TK[MU:^&EZ7>7I7>+>%YBOKM4G
M'Z5\"?!/]FRX_;8\&6WQC^)7Q"\4?:O$$LTVFZ+H>H-9VNF6RR,L<:A>K #D
MT ?3_P #]=^.VJ:]?Q_%7POX2T/2%M\VLWA_4);B5YMP^5@X "[<\^M>SU\G
M?LZKXI^"?[1&O_!+5O&%_P"./#(T"/Q#H=YK#B2]LH_.\E[>1^KKGE2>>M?6
M- !7S%^V!\-_C'X[\(>*(/"WC#1K#P9)IY-YH<MFT=Y=1*I::);L$^7O QG;
MQFOIVOG7Q%^QG::]>:O;Q_$[Q]IWA;5I)9+SPW:ZO_HK^8<R(K,I=4;)^4-W
MH \#L_'F@^/V_8HUKPWI!\.^$7U6ZMK?3';<+6=+5HUCW?Q<JV#WS7K'[4,,
MEY^U'^S[%I[$ZI =:N72/[WV<69#$_[.XJ/K7J/C3]ESP)XP^$6D?#J.RFT+
M1-$>&;2)M)E,-QI\T1RDL4G4,"22>^3FH?A7^S/I/PY\:7/C/5/$>N^.O&,M
MH+"/6?$5P)9+:VSDQ1*H"H">3@9- 'D'["MW8_\ #"TSW$B*L0UD:@S?P2"6
M;S-WO70_\$^]-U(_L:^ DMKPV+2)-+!+)"),PF9RF 2.",5:U?\ 82\*WFH>
M)(=+\5^*O#GA+Q+=->:SX3TJ_$=A=R.<R<;2R!_X@I&:^AO#OAW3?"6@Z?HN
MCV<6GZ5I\"6UK:P+A(HU&%4#T % '/\ @>&ZM]?\4I>72WDXN8<RK$(\CREP
M,"NQKE_#/_(U>*_^OB'_ -$K744 %%%% !1110 4444 %%%% !1110 4444
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M%4A7*J>.^!7;5=2'LY.-[F=.I[2*E:UPHHHK,U"BBB@ HHHH **** "BBB@
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MT:[TVYSY%Q&4;:<$9%954W!J.Y4;)IL_,C7/V7=>\&Z'XG^*>B^-8S<P7+7
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M_P""B7QGLM6MII]7-[$C@M;JN2X]*FY?+<_<C4-2M]*M9;J\FCMK:-2S22,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM\>^)?C5K.C^*-,T"%;K3=6T6V^R3WJE3F*2'[JONV*"IP=Q/:@#Z&HKXZ\
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M\8>+)O$FJ^!].N=6N)EN+F0!D2YD!R&EC4A7.?[P->NPPQV\*11(L44:A41
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M-;ZO=[Y4!((,9.!CU'TKHO@7^RCK'AOP@_\ ;WB?6M"U"YF\UK'1KWRXT7
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M8#Y6-\9(*D@@CD'O7>K_ ,$[?AG8ZA<#1]5\7^'?#UR[23^&](U^>WL'+9R
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M&#D)N<X5<\X4 5ZU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQBB4J$L/[-3U3;6F_P#D%..*CB_;.EI))/5:;_><%\5/@+/X5T_Q5\5/#7Q
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M[$KQ/X%_M06_QR\07^E0_#_QMX1:TM_M'VGQ-HTEE#)\P7:C-P6YSCTKVR@
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M&@#KO#/_ "-7BO\ Z^(?_1*UU%<MX6=9/%'BLJP8?:(>0<_\L5KJ: "BBB@
MHHHH **** "BBB@ HHKE_$?Q*T'PG=M;:G->02*%):/3KF:/YN!\Z1E<^V:
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MS: Z;7@M54I^E)W92WT/CSP/X'U/QIXHTRPLK*6<O<)&[1ID)D]37]"'P/\
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MVCOVBIKF3Q'K<_A739%&((R1E37W/\/_ (3^$O!OA^R@TG0K2U3RD;_5 MG
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MP/X;TOP]X9TZVTZQAM(4@0!8XP.U=!BFPQK#$L:#:BC %/JS,**** "BBB@
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M?+SZ BN^M_V1?!5Q<"XUZZUOQ1<]6DU34I6W?4*17!?'C]G_ .#OV*V@CO\
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MVK5T/\@*?U&MU<5_V]'_ #)_M*AT4GZ0G_D>XT5X=_PDGQ[O3^[\)>%[ ?\
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M"BBBLC8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O$_VNM>^*.D_!_4++X0^&+CQ#XRU,&TAFAN((5L$8?-.3*ZY('"@9YKVRB@
M#\T?@]^R7\3/''[)_B_X/^*_A]_PKO66FBUNU\3W>J0WCZMJ:R[\S>6S%1@
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M1K>,,L(QD8'I7Z$Q_=7Z"M(M.-_-HB:<9V\D_O'T444Q!1110 4444 %%%%
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MWG,:?=ZTJ/[Q1GTDF_N+J148SMO&R^\^^ESWI:04M:& 4444 %%%% !1124
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MYMK(F.S,SYC3[H.36E%^TM?JFPK15-2?:WXGWQ1116A@%%%% !1110 444E
M%+6]6@T+2KK4+EMEO;QF1V]@*^!O$?\ P4OU*P\<7,6G^&9+KPG;3^3+J2H2
M!SCK7WKXAT>#Q!HMWIUT,V]Q&8Y/]T]:^ ?VF+'PQI?A\?"+X::9'J.M:A<;
MKF2% WEY/.37-+G]HK?)'31C"7Q'T1\5_P!K"Q\%_ ^S\>:7&EX;M T4+>I'
M2O-/V9_VRO'GQJ\806&I^$&T_2I5W"[53BO.OCI\ =;?X-^"/A]#J]I8:B-G
MFQSR8.XXZ5F?!C3?&G[*'QRT/PIKFLC5]-U*%2B\'9GTK2E+FJ-2[M+S,YQ4
M:<6M[79^E5+3(G\R-''1@#3ZU,@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "JVI60U+3;NT8[5N(GB)]-RD?UJS10!\$_!
MOQQXO_9M^"WB/X.:M\.?%6J^,+*YO[?P_-I>F//8ZE#.[F"3[0HV(%W_ #;B
M,8KZ8_9-^$VH_!7]GOP=X0ULPOK-E:E[[R3N03NQ=P#W +8S[5Z]3)IDMX7E
ME=8XD4LSN<!0.22>PH RM*T(Z?K&LWCLCI?2QR*H'*[4"G/Y5J^4G]Q?RKQ3
M1OVS/A3XC\<6GA72==N]3OKNZ^QP7=II=U)8R3<_*+H1^4>AYW8]Z]NH 9Y2
M?W%_*CRD_N+^5/HH 9Y2?W%_*CRD_N+^5/HH 9Y2?W%_*CRD_N+^5/HH 9Y2
M?W%_*CRD_N+^5/HH 9Y2?W%_*L_7]'_M?36MHRD;%T?<PX^5PW]*TZ\K^+7[
M3?P_^"NK6ND^)-4NFUFYA-RFFZ7I\]]<B$''F-'"C%4SGYFP#B@#U'RD_N+^
M5'E)_<7\JY?X9_%+PO\ &#PG;^)/".K1:OI,S,@EC#(T;KPR.C ,CCNK $5U
M= #/*3^XOY4>4G]Q?RI]% #/*3^XOY4>4G]Q?RI]% #/*3^XOY4>4G]Q?RI]
M% #/*3^XOY4>4G]Q?RI]% #/*3^XOY5FZ;HILM5U6Z8HR7CHZJ!RNU O-<7X
MP_:,^'?@7X@>'_!&L>)K:'Q5KL_V:RTN%7FE+D9&\(#Y8/8O@&MSXH?%;PM\
M&_"<_B/Q=JL>DZ5$RQAV5I'D=N%2.-06=CV5030!U7E)_<7\J/*3^XOY5YG\
M'_VDOA_\=)[^U\)ZQ)-J5@JO=:9?VDMG=Q(WW7,4JJVT_P!X#%>GT ,\I/[B
M_E1Y2?W%_*GT4 ,\I/[B_E1Y2?W%_*GT4 ,\I/[B_E1Y2?W%_*GT4 ,\I/[B
M_E1Y2?W%_*GU0US7=.\,Z5<ZGJU];Z9IULA>:ZNI1''&H[EB<"@"'Q+HIUS0
M;VPB*123Q[ S#@&M)84"@;%_*N,^$OQF\'_'+P[=:[X)U==:TFVO9;![I(GC
M4S1XW!=ZC</F'S#@YX-><>(_VZO@MX5\7'P]J/BUH[A+D6<M]'87$EC#-NV[
M)+E4,:D'@Y; QS0![UY2?W%_*CRD_N+^5)#-'<PQS0NLL4BATD0Y5E(R"#W&
M*DH 9Y2?W%_*CRD_N+^5/HH 9Y2?W%_*CRD_N+^5/HH 9Y2?W%_*CRD_N+^5
M/HH 9Y2?W%_*CRD_N+^5/KS?XA?M%?#OX6^*-!\-^(_$UK9Z_KETEI8Z;&K3
M3O(QPNY$!**3_$V![T =I:Z.;?7+Z^)1H[B.- F.1M!K1\I/[B_E3Z\T^''[
M1WP]^+?CCQ3X1\)^($UC7/#+!=3AB@D"1$L5^60J$?Y@1\I/(H ](\I/[B_E
M1Y2?W%_*GT4 ,\I/[B_E1Y2?W%_*GT4 )TZ4M%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!2L]$T[3KZ^O;2QMK:\OF5KJXAB59)RHPI=@,L0.!GH
M*NT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %?-W[7O[-VH?&S3=/U'0+D6VO::XD@8G )
M'-?2-)4RCS%1ERL^'/@3^RO\0;[XJ67C3XEW4<D^FQB&WCC.>!T-?<2TM+5;
M*Q+O)W84444 %%%% !1110 4444 %?-/[7O[.>M?&.VTW5_#%\UGKVEL'A^8
M@-CGFOI:BHE'FMY%1ERNY\(?"G]D/X@^,/B1I_B[XI:@DDFF86WAC;(..E?=
M=O"L$,<:C"HH4?A4E%7LK+84FY2YF%%%% @HHHH **** "BDW#UHW#UH #TK
MY6\'_L^>)-'_ &JM5\=S^6-'N/N8/-?5.X>M'!J.5<RGU17-HUW/C+]H_P#9
MC\=7'Q0'C[X;7:1:I,NV:.0X'-=5^R/^S/K7PLU+5O%7BVX6X\2:J=TVTY"U
M]2440C[-66W3R] E)R5A%Z4M%%62%%%)F@!:*2B@!:*3-+0 QU&T@=P:^1/#
M?[-OB?3?VL+SQ[+Y?]C2C Y^:OKZBIY5SJ?5#N[-'QE^T1^S;\0_^%J'Q[\-
M+\17]PNR:"1R%Q6_^RK^RSK'PX\0:CXS\9W8O/$VH$LX4Y"YKZNI,9I4X^SV
M*E)R5F%+129JR!:*0-FEH **** "BBB@#P?]KSP;XY\??#IM%\#S+!=W!VRN
M3CY:^8OV?_@;^T'\%YK>QM(+!K*67==3MR[ GGFOT5HJ(QY9N?<T<VX*#V/B
M/XT?LT_$C3O'D'CGX<W44>L7<'EWL4AP,D<UZ+^R1^S?J?PGCU'7?%$JW'B3
M4Y#),5.0N:^EJ*=./L[\O44Y.:2?_#^HM%%%40%%%% !1110 4444 87CB'4
M;CPGJD6D$#49(&6 G^\1Q7YR>"/V9?V@_AWX\U7Q3IR6-YJ-Y*S^9.<E03VS
M7Z<45"BE/GZE<SY>4^.OC-^S'XV^-'@K1-;O+Y;'QUIH$@$3D(S#M6+\#_V5
M?B#J_P 2K/QC\4[^.:?3D$=M#&V1@=#7V_11"*@[Q*<W)<HU0%4 < # IU%%
M69A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7S;_P42\4:CX5_9%\<S:7)+#=7<<-B9(6VN$EE5' /;()'XU])5P7
MQU^$.F?'CX3^(_ NK32VMIJ]L8A=0XWP2 ADD&>N& .._2@#YRT3X^>.OV>?
M#OPZM?&GPGTKPU\.-0GL]#MKC1M56XGL))5"PF6,*%(8]2IXSWK[)ZU\B0_L
MR?&'XF#P1X?^+'C/PW=^"O"5_;:@L.@6<J7>K2VPQ 9VD.U .IVYR:^O* "B
MBB@ HHHH **** "BBB@ KXA^-GBWQ5\)?VN-4\0?"C0E^)_B;6/#\-MK_A9=
MR2:;'$6:WG$^"J!LX\H\MU'K7V]7S)XH^ WQ1\#_ !L\7_$/X2Z[X<9?&,=M
M_:^D^*H9F6.:",1I)#)$<X*@94_A0 ?L#_V/=?#/Q+JUMJ9O/$VL>(+K4?$E
MBUHUH=-U"0@R6OE-RH3  )^]U[U]-UXU^S=\$=9^$]OXMUKQ9K-KKOC;Q?J?
M]J:Q<Z= 8;17""...%#SM50.3R2:]EH **** "BBB@ HHHH **** /BK]K#X
M=^&O!/QF_9^OM$T:UT^^UCX@/>:A=1KF:YE:V;+.YRQ' P,X'8"NL_: 8:]^
MV9^SYX>U!4FT>&/5-72WD4%&NHX@L;$=RH8D>F:R?CY^S[^T!\7/B3X<US3_
M !1\/['2/">N-K&@07-E=F?[A0+<D$JW!/W<=J[+XL? /X@_$[PO\/O$:>(]
M#T?XR>#;IKVVU*UM93I<[.I26%T8^9Y;+COD$4 8WQ-M1IG_  4"^#M]I\:)
M=ZEX;U>UOR@ :6!-CJ7]=K8QGIFOJ:OGSX1_ _QY)\7)/BE\6==T;5/$]MIC
M:/I.F^'8)([.QMW</*V9#N>1RHSV  KZ#H **** "BBB@ HHHH *PO&'@;0/
MB!IL.G>(]*M]8L(;B.Z6UNEW1F1#E69>C8/8Y'M6[7(?%*W\<W7A.6/X=WFA
MV/B7S4,<WB&&66U$>?G!6,ALXZ4 >)?L'PQV_A?XK0Q1K%%'\1-:5(T4!542
M)@ #H*I_MV:QH\'P;N?A-H.C6^H^-/B 3IND:-:0J"K,P,MVX ^5(QN8OZXJ
M7]E[X(_&SX,>(M8A\3>(O!.I^%=:U:]UR_BTNTNDNQ=7&"1&SG:(PP'!!.,\
MUQ^@_LY?M(>$_BMXL\>6?B[X<:UKFM2-%!?Z[87DL]E9@YCM8=A41H."0.IY
M)- 'UC\.?"[^!_A[X8\.27#7<FCZ7:Z>UPQ),ABB5"Q^NW/XUT58?@B+Q%!X
M3TR/Q;<:==>)%BQ?3:3&Z6K29/,:N2P&,=:W* "BBB@ HHHH **** "OBS]M
MSX>>&O"NM?"G6-*T6TL]7U?XBV$]_?JF9[A\$?,YRV, 87.!V%?:=?)'[2W[
M/_QV^-GB[29-)\3> ].\,^'];AUK1X;RSNVNO,B'RK.RDJPR3D+CM0!VW[7O
MQB/@CPWH_@C1]6M])\8^.+@Z7875Q*L:V4!'^D7;,3@"-"<>K$8KPS]D/1_!
M7PY_;2^)_A?PKJ5C)I%MX6TBULWCN4=KJ16<R-N!^=RQ+-U/-?2,W[/^F_%S
MPKH?_"\?#GA?QCXJL%=3<6-M*MJFYLXC#G<!@#.>XKSSX2_L*^%/A3^TKXD^
M(NGZ+H5MH<UE;1:'IUK"XETZX7<)I1GY1O! X)- 'U-1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4=QN,
M,@7[VT[?K4E(PS0!^?7QITC]J#3?%OB#5-"U&./PW;AI8DSSL'-?/?P9_:#_
M &C/CUK.J:3X8U-?M6GNT<WF-QD'%?K'\2@?^%>^(1G_ )<9?_037YG_ /!)
MS/\ PMKXA8_Y_)?_ $(TAH]!\97G[0WA7PCI$>I^*+#2M69OWAN)-N_Z5]@_
M"GQL=!^$^BWWC;7+-;Z1/WMVT@".?8U\0_\ !8/4;VQD\$?9+N2VW.<^6Q&>
M:YW]IS4[V#]@WP+.ES*)RG,BL03Q2#<_0W4OVC/AMI,D:7/C#2XVD^Z/.!S5
MC4OC]\/=(L8+N[\6:;%;S?ZN0S##5^4G@/\ 93TCQ9^QSJ?Q*U74KJ;6(EW0
M?O#A<#ZUE?LD_LXQ?'KX9^,M3\1ZM=20:/$S6<?F'"D#ZT7*Y3]D/"/C_P /
M>/+1KG0-7MM5@7J]NX8"L?Q7\;/ W@>\-IKGB6PT^Y'_ "REE ;\J_,7_@F9
MXLU'PCJ7Q-M1>3365C',L43,3@@<$5X-X1U'3OB]\:O$>I?$.74]4M$N)DBA
MM68L.3MXI<P<I^Y7A+X@>'?'=FUUH.K6VJ0+]YK=PV*^"OVEOVQ?%UQ^TKI/
MPR\$3+%&LZ">5#RPSR*\,_8QUGQ=\+OV@-1TO2[34AX/NHI65;DDA5 ..M9W
M[.-N/'W_  4 FU.].XPWDFU3ST-.]Q6L?KK)XHTWP?X9LKGQ#J4%AB!3)+<.
M%!;'-?/_ .TY^U=X8T7X*^(=2\&>++"ZURW3]S'#*"V:^0?^"IWC[6M5^+F@
M^#;34)K2QWQH\<;$*P8CK5G]H+]@KP[\/?V78_%VDWUS_:\-JMQ<;W.V3<,^
MM CZ?_X)X?&[Q%\8/A3=:SXKNA+/&Q)E9N *]OU#]I3X9:7>R6ESXQTR*XC.
MUD,PX-?!O[$$VG']CGQ'%J>N'P_;2(P:\#[2..QKYSU"S^$FD>!_$4-HFK>)
M?$DA8IJ2EFC7WS1>P^6Y^TEO\2O"]WH?]LPZY9R:7C)NED&P?C5_0?%NC>)[
M$WNE:C;W]J!DRP.&4?C7Y:?L&^%]2^+WP!^)'A:>^FD40,;4,Y/EG':L/]D#
MX_7GP2\)?$_PKXAOG$UBDD5H)G.<\CC-+F#E/U;TGXB>&M>U*73]/UJSO+R(
MD/##(&9<=<US_B#]H/X=^%[^2RU/Q9IUK=1G#1/*,@U^?O\ P3B\!^(O$FC_
M !(\<"YFFN-0$OV%I&)PQSTKY/GTVZ\"_%;Q'-\7=&U.XMKBXDVR#<2 3P11
MS!8_='PG\0_#?CZU>7P]K-KJB@<FWD#8K\_/&O[6GQ ^"?[8L/A#7)_.\+WD
MP +] I/&*R?^"<B^!]/^(E]-HGBFZ0W3$PZ7<RGD=A@FN<_X*U: FA_$?PKX
MBMV*7<L\:Y''\0IWZ@?JOI]['J5C;W41S'-&LBGV(S5FN!^ ^IRZO\(?"US.
M<RM8QY/K\HKOJHD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\._:._:0O/@?KO@+P]
MHW@Z[\:^(O&-U<VUA8VMRD !@C61R6?CHW'T- 'N-%?,.E_MMCPWXLT7P]\5
M_AQXA^%DVLSBUL-4U$QW.G3SDX$?G1D["?\ : KZ=W C(/'7- "T444 %%(2
M!U.*6@ HHHH **3/..]+0 45S_C[QQI/PU\$ZWXLUR62+1M'M)+Z[DAC,C+$
MB[F(4<DX'059\(>*;#QQX5TCQ#I3R2:;JEK'>6S2H48QR*&4E3R#@CB@#7HK
MCOB%\6/#WPPN_#%MKLT\4OB358]&T\0P-)ON9 2JMC[HPIY-=C0 4444 %%%
M% !129YQWI: "BD#!N0<BEH ***3.>G- "T5\U^&_P!I'Q%JWCG]HK1YK.Q%
MK\/(XWTPJK;I=ULTI\WGGYE[=J[[]EGXJ:I\;/@#X-\;:U!;VVJ:Q:&>>*U!
M$88.R_*#_NT >K45P%GXT\73_&:_\,S>"Y(?!D.G)<P^*OM2E9K@GYH/*QD8
M'?-=]0 M%<5\8/%GB?P3X#O=6\'^%'\::]$\:PZ.EP(#*&8!CO(.-H)/X5UN
MGSS76GVTUS!]EN)(E>2 MN\MB 2N>^#Q^% %BBDSGD<BEH **XK6?B]X<T'X
MJ>'?AY=SSKXFUZSN+^QA6!C&T4&/,+/T4C/0]:K:QXT\767Q@T+PW9^#)+WP
MA>64UQ>^)_M(5;29?N1>7C+;O7- '?44A('4XI: "BDSV[TM !1110 4444
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M?%3]HCXL_!8^ I_A_>6MO!$(9IA$0TBJ,"OUGT&VGM-$L;:[(>XB@1)&[%@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB(\]<2@U[=^S[^SAXQ^&WQI^(/Q&\9>*[#Q)J7BZTM8Y8K*V:%+=XLC8@/\
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M5/A7I-OXJ^($,OQ/T771XBTCQ!96/EVMC,OW;=8LY:''!R=QKK/ 6B_M"?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@U8619%W*P8>H.: '44U)%D4,C!E/0J<BJ\FJ6<-TML]W ERW2%I%#G\,YH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMI) Y;:P)!Z<D=>*K^-_B9KFDP^-;NPFL+.+PZ\$26][&2TY=48OD,, [\#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>cdtx-20231231_g12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $% JP# 2(  A$! Q$!_\0
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M NY%4D$_>E%$8\J2WM;?6]FWKWO?WN]KZ,)3YFW:UV]O1+3M:WN]K]4?#?Q
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M<^A^-M%\2:]X@T73KW[3J6@3Q6VI0B)U$$DD2RHNXJ%8E'4_*3C.#@\5NU\
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M7:>'=&:9GC!(,:37,K*-RD'<8<JP'4 [M/3_  O=>'+Z^>Y\2:OXA:\*2_\
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M1N][>FGY'7'"T8JW+?UU?WN[(+*RM]-LX+2T@BM;2WC6*&"% B1HHPJJHX
M   Z8J>BBL#JV"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QM9
M_P"/I?\ <'\S6S67K,!.R4 D8VM[>E7#<PK*\&9=8^K>$=)UW6M(U:^M//U#
M27D>RF\QU\IG4*QP" V0!]X&MBBNE-Q=T>:XJ2LT<[XX\'Q^.-+L]/N)Q%:1
MW]M>3QF/?YRPRK*(^HQED7GGITKS"R_9G:S\)7>F/XF-[JT^@W6B?VM=6.6(
ME$2*6190"B16\,8C!4G#MNW.QKW&BH2M>W7_ "M^7W;K4OF>GE_P_P#P_?9Z
M'A?_  SKKEP)]0O/&=G>^(YKR._-X^B%;99!>6UPZB!;@-Y92SMHE!D+ 1 E
MG).:/B3]GC6?%/Q,U2\FU*QBT*]222[NKK3?M%Q<+<RQK/;0-YX^SE8+*SC,
MA1PP=L*#T^@J*<?=Y;=+V^=O\D)MR4D^IX3XF_9B/B3XDVWBR7Q DJO>2S:A
M87$5ZL=S;NT($ %O>PHP\NWAC83I/&_EJ?+'S!NL\<?!O_A,8_&\G]IPP7_B
M*QM=.BFN+!9X[:" LZQ.F]3-&TDDI9=R95RH(/S5Z512LE!4ULA\S<G+J>#Z
MM^SGXAUJ1+BX\;V27>H?:5U^2'0B%NXYI+8M';*UR1;*8[2*$[O.8KD@JWS4
MGQ'_ &;=7\>:]?:C%XOAL%DUE=6MH5MK^%H<V26DBM+9ZA;2.VR/Y2&50))
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M9':VJV"6:QQJ)X]LB!9620DJ/.=3&P.:]SHHE%2YK]=_/^O\P4G&UNE[?/\
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MWFBDXJ2Y7M_P6_S;\M1*33NOZV_R7GH>9+\+-<O/@E-X%U'7M(-[]C6Q@O\
M3M$>WM%B0*$1[5KF0NI5=KJ)5W*2!LKR[Q-\$_'5MXKT>VLKY]>CUEY!XEUE
M])M([1;>6\CFFABW7@E@W0Q+#@0W.Y4C!:,@R#Z>HJKMU%5>_P#6GSZ]Q+2'
ML^AX-J7[+HU?Q=XVU.\U]+G3?$P?-I-'>O) 9%CBFP&O3;?- CP!X[:.0(^"
M[#=OU/$7P'U:ZU2[OM$\0:39O>1:C#<P:MHLMW"R71M@ @ANX&0I%:1ID-D]
M1MZ5[+14J*22[*WR[%<\KW\[_,Q/!.@W/A7PCH^CWNJ3ZU=V-K'!+J%R7,D[
M*H!<EW=SGU=W;^\S'+';HHJVVW=F:5E9!1112&%%%6K?39KB/>-JCMNR,^_2
ME>VY2BY:(WJ***Y3U@HHHH **** "BBB@ HHHH **** /'_VIO#E[X@^&*RV
M,+W#:;?Q7LL,,;22-'M>-MJJ"3CS Q[!58]J^2[?4;6XM%>.YB=2,AE<$&OT
M*U+5+/1;&6]O[J&RM(@"\\[A$7) &2?4D#ZFOG+QYXA^$GQ*URY6'PSI.IZS
M(OG2ZU>Z1"#.J1,-OF2#S&*C'!&,+QTKU,)7E33BHW1Y^)I1D^9RLSX[^(%C
M<>,+J'PUH4+:OK^I-Y-GIUIAY96P2>.R@ LS'"JH+,0 37Z,_&CPM=Z]\&M<
MTBP5I[J.UCD2-49GE\ETD*JJ@DLPC(  Y) KS/\ 9=^(GPUT+X>>&=&T^TL?
M"VLW%A:)>G[#':B^N5MT#2O(@VLS$$!I"&).,9(S]$W5U#96TMQ<2I!;PH9)
M)96"HB@9+$G@ #G)K'$5I2FFXVL:T:<8P:3O<_/"SOK=H63SD$D9*.C'#*P.
M""#R""#P:X7XB7\$L L87^TWUTRP6UI;@R33RN=J1QHN69F) "@$DG K[0^(
M'BSX3_$+7O[/N- TOQ+K;1-%'JUUI4,JPJA+%/-D&[& V-@*G=UYK#_9^^(7
MPH\'Z7##;:1IWA;69E$%QJL>F10+> R-M)FC&2@&#NDPH!!S7H2Q51P^#4XH
MT(*?QZ'L?P/\.WWA'X-^!]%U.!K74K'1;2"ZMV96,4JPJ'0E20=K9&02..M=
MO3(I4FC22-UDC<!E=3D,#T(/I3Z\$]@**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** (FMH6))B0D\DE11]EA_Y
MXQ_]\BI:*=V+E78B^RP_\\8_^^11]EA_YXQ_]\BI:*+L.5=B+[+#_P \8_\
MOD4?98?^>,?_ 'R*EHHNPY5V(OLL/_/&/_OD4?98?^>,?_?(J6BB[#E78B^R
MP_\ /&/_ +Y%'V6'_GC'_P!\BI:*+L.5=B+[+#_SQC_[Y%'V6'_GC'_WR*EH
MHNPY5V(OLL/_ #QC_P"^11]EA_YXQ_\ ?(J6BB[#E78B^RP_\\8_^^11]EA_
MYXQ_]\BI:*+L.5=B+[+#_P \8_\ OD4?98?^>,?_ 'R*EHHNPY5V(OLL/_/&
M/_OD4?98?^>,?_?(J6BB[#E78B^RP_\ /&/_ +Y%'V6'_GC'_P!\BI:*+L.5
M=B+[+#_SQC_[Y%'V6'_GC'_WR*EHHNPY5V(OLL/_ #QC_P"^11]EA_YXQ_\
M?(J6BB[#E78B^RP_\\8_^^11]EA_YXQ_]\BI:*+L.5=B+[+#_P \8_\ OD4?
M98?^>,?_ 'R*EHHNPY5V(OLL/_/&/_OD4?98?^>,?_?(J6BB[#E78B^RP_\
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M(Z9I\UK<)=07.DQ?8)XY%SM82P%'X)SC.,@'J 1-J?5O[O\ @E.5;I%?>_\
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M?^/<?2O=P-O9NW<\_$N7/[ZU_K7^OQW/*?C$<:#>_P"X?Y5]_P#QW_Y-RO\
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MXB/*?C'_ ,@&]_W#_*OT&^/G_)O6J?\ 7"R_]'PU^>_QF<)X?OF8A56,DDG
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M%2E&;YEI)=?ZW7DS,\/^)=+\4V;W6E7L=Y''(89E4XD@E !:*5#AHY%R-R.
MRYP0#6G7#>*/A@FH:]_PDGA[4I?#'BEI(#/>PAI+>^CCW*(KJV#JLPV.RALA
MU^7:XV@4>%_B>FH:]_PC?B+39?#'BEI)U@LIB\EM?1Q[6,MK<E%68;'5BN Z
M_-N0;2:IP4ES4]?S7_ \_OL2JKB^6KIV?1_Y/R^ZYW-%%%8G2%4=88K:  \,
MP!_4_P!*O50UG_CU7_?'\C51W,ZGP,QJ***Z3RPHHHH **** "BBB@ HHHH
M**** "N1^+WBZ\\ ?"?QGXGT^.":_P!%T:\U&WCNE9HFDB@>10X4@E25&<$'
M'<5UU8?CCPC9_$#P7K_AC4))X;#6K"?3KB2U95E6.6-HV*%@0& 8XR",]C65
M52=.2AO9V]36DXJI%SVNK^A\S_"O]L;7/%[_  [TKQ!I^DZ-XENM8O=+\66B
MQS*EM''I\]Y;W%MN?(CEC2)PS[OE+CJ,UV=O^VEX0;2YM4O/#WB?2],ET*\\
M2:3>7=M;[-:L;4 RO;!9V93M*L%G$3%7!QUQKZE^R/X%U3XG>#?'<IU)-;\,
MZ4VCHD<Z""_M_(D@7[2NSYF5)I,,A0_/SD  9=G^QCX1BT.?1KWQ#XEU;38]
M NO#.DP7L]M_Q);&X 65+8I;J6;:J*'G,K80#/)SI4;;;AYV^YV^]\K\DY)[
M)A#DO'FVTO\ ?=_<FU?K9/N;'AG]K#P-JUUJT.OR3_#U;"UL]06?QA/:V4-S
M:W7F?9YHW$[ !_*;Y)-D@Z% >*N6?[0FD^+=<U_2/"VFZMK-GI@>WF\56,4,
MVE0W?V7[0L6_S/,8[&0[Q&8LNJE]Q K;\'_!71/!/C>?Q38W6H2ZA-H5CX?:
M.XD0Q"WM3(8V " [SYC;CG!P, 51TOX"Z7H?C;Q'K^F:_KVGVGB&X>^U'0()
MX?L$UV\ @:XYB,H8H!\OF>664,4R!45DY1DH=I6];^[?Y:Z?:MTN*FTFG+R_
M+7\=/\/G8\*\%_M[>&?!?PA^'T_Q!U&;5O%FH^&[?7-5F@ET^S,<;EAYOES3
M0>:S%'(BMDD?Y/N#<N[TO7_VQO!6@_$BR\%FTO\ 4=2OXO,LGT^ZT^9K@FT-
MTB_9A=?:H]Z#"M+"B%BOS88,7^&_V2M&\"?V!+X/\9^*_"=_I6AP^'GOK%[&
M:2_M(G+Q"=+BTECWHS/AHT0_.P.1C$T7[)OAN'XEQ>,E\0^(O,CU]O$XT?S;
M;[$=0:U^S23']QYOS1CE?,V@_="]*TE>4W;1-OY+FT_\EU]59IIW2CRQCKJT
MOQLO_;M/371K6LO[8W@FYT)=7L;34;RR_P"$=L_$DDSSV-G%!#<SF"*&6:YN
M8HHYMRR95W"_(0&+%5/&^,OVM)?$W@[X3>,/A[!JEQIVN>,SH=_I$,5G-=7:
M1QW*O CF1H/FDB0B5)@N,'S N:Z#2?V&? ?A_1_$%CIFK>([&75=?M?$4-XM
MU \NF7%M,TT$=LKPM&(49WPDB./G.<\8UK?]D?PW:^#]"T*#Q+XFAET;Q#<>
M*;35UN+;[8+^;SBTC?N/+90T[,$,>TD ,&7*F5=N[T5T_ES1=O/3F3OO9/JT
MJ]U)I=FO_)6D_P#P*S5MKM=$WQ$W[7UE?_$KPOJ8OK[P]X$AT'Q%=>(M+U.R
MC-S:W6GS01L)/+\P[DW2<1.5;<.O&/2/@;^U-X-^/VJZKI>@>;;ZGIUM#>26
MTMY8W>Z"0L%<26=Q/&#E2"CLKKD94 @G(L_V+_ $4$$5Y/K.K+_9^KV%ZUY=
M)NU'^TI$DNYIBD:D2%D&/+V*O9>F/1/AI\.K[X=:>+"X\<>(O%UG%!%;VT6O
M)8YMDC&T;7M[6%G)&,F0N3M'?))3O9*?;\;R;\[?#:_331DU.75P[_A:*7E?
M>_GJNQ\S>!?VJ-8TK4YM2\8^)-4OK#3AXQNY](L=&LRMS:Z=>JD7[[?&R21Q
M_*JA2)-Q+L" 3V_Q"_:J&J_"#XKW/ABPUKPCXL\.>%O^$@L'UJUMB9;>:.4V
MUU&BR2J5)B.4E"L. R#I6Q<?L5>"+B&^B;5?$ 6\M==M),7$&0FK2B6Y(_<]
M590(_0?>W]:V]:_98\*:];>*(+C4-91/$7A6W\(71CFB!2SA$@1X\Q'$I\UL
MDY7@?*.^/+-T%#[7+;YVEK?UY?O?E;;FIJMS].:_RO'2WIS?A\^6M?VV?!.G
M?#2U\57XU"XTZ2]BT:SU1FM+2UUJ]$9:<VTT\\40CC*2!I96BC+(0C.< ZWP
MP_;"\)?&+Q7IWA_PEHNO:M=W%H;VZN(%M&M=/C6XEMW,LRW!1\21?\L3)O#J
MR;U#%1?V._"-E#,ND:WXBT&1=;A\1V$EA/;YTS4$A\F6:!9('7]\N[S$D5T)
M9BJKFNV\(_!Z#PSXXD\87OB76_$WB&72$T66[U46B;X$N))U)2WMXE#@RE<@
M ;0.,Y)ZFU*HY/:__MO_ ,E?MI:W8Y[*-.RW_P"#_P#(_C?2UCT&BBBI$%%%
M% !1110 4444 %%%% !1110 5+:_\?4/^^O\ZBJ6U_X^H?\ ?7^=)[%1W1T=
M%%%<IZP4444 %%%% !1110 4444 %%%% !1110 4444 %<QH/@O^P_&OBKQ!
M]L\[^W/LO^C^5M\CR8RGWMQW;LYZ#'O73T52DTFEU$TG9OH%%%%2,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO%7@_2/&VFQ6.LVGV
MJ&&>.ZA9)'BE@FC.4DCD0AXW!_B4@X)'0D5LT4TW%W1,HJ2Y9*Z/+5\<:U\+
M;R6S\=/+J7AR2[2.R\8HD2)"LI;;%?QIM\HJP5!,B>6V]-WEG->I5!>V5OJ5
MG/:7<$5U:7$;1303('21&&&5E/!!!((/7->=S:/KGPKU+4-2T2&Z\0>"V@,T
MGAN%C)>:?(@  T]6(5HBHYMBRA-O[KKY9W]VKMH_P?\ D_P.;WJ&]Y1^]K_-
M?CWOT]+JAK/_ !ZK_OC^1J/PUXETOQAH-EK6BWL6H:7>1^9!<0GAAT(P>000
M05(!!!! ((J36?\ CU7_ 'Q_(UDDU*S-9R4J;:V/,O%7QD\&^"?'7A?P;K>N
M16'B7Q.9%TFQ:*1C<F,9;YE4JG7C>5R>!D\5M^$?&&D>.M%&K:'=_;M/,\]L
M)O*>,&2&5X9  X!(#QN,XP<9!((-?-7[2?P#\9?$GQYXB\::!IP;7O#.DZ3-
MX,D:YA43W\-[+<W*?,WR;D$467VJ0Y[ UYO>_LJ_$'4;+0] O_#(OKR+0]"@
MTGQ0UY;-!X7O%N3<ZO.(C*)!<22 ;9($?=\BEU4-6U-N22EH[V^3O9_A[VJM
M='%.,5=Q>ED_GI?\U;=Z2T/M;Q)XN_X1W6/#NGC1=8U4ZS=M:?:=-M/-@L0(
MGD,MR^0(X_DVAN2690!S6CK&O:9X=M8[G5=1M-,MI)H[=)KR=8D:61PD<8+$
M LS,%"]22 .37SM^U5\+?'GQ&\01W'A;2WO8M,\'ZU:V$JWL4&=4O1#;IPSK
M@K!Y[;R,#. <G%>6:Q^QQ>:?XHAM;+X<V6K^"(_%>@-/8R?8I)+JRL]/D6:]
M999 ':2XEV2ASYCJC':^ZE%MVTW:^[FY7Z6^+S3OLA.*2O?H_O2NOOO;U3ZG
MW717Q)<?LU^*+?2-&UC4/AS:^*K[4O%.KZEXA\/O<V0,MHQG_LRVD>1Q&;.-
MA;RO"K, ^'\MV!%3?!?]FWQ;X.USPY:^)_ EGKT>D^%;&/0M2U"YM+BST#52
M\]S?R%&=G\\W#0[988VRL:@NN*7-[MVNWXQ;T]&K=M=QN"5]?ZYK?\'TV/KW
MQAXNTCP#X7U3Q'K]ZNG:+I=N]U=W3JS".-1DG:H+'Z $GH :A\,^.M#\97>M
M6VCWWVV;1KL6-^HB=!#.8HYO+)90"=DL9.,XW8.""!\7^!?V5_$EM\.)H;GP
MKXFC\:Z]<Z-9>)[SQ%>Z,T5S;"]6YU"='LG#W1)5QON]\Q5U"]7%7M0^#WQ?
MTG4(?$>G>"4U#7KN+QA>"%-3M(DL[^^E1+)I6:7YE^RQ*H*;R"0K;!E@Y-QO
MI?1_>K-?)IVO_-IT*4(R:5[:K[GU^36NNUF?8MGXTT;4/%VI^%[:]$VNZ9:P
M7EY:+&_[F*8R")BV-N6,4GR@YPN2 ",[=?"=E^S/XZ\-VUK:W'@5/%?AF#5;
M6SN/#;7MF%U*QLM'2WL7N/,D"- +PRRO&<MG:PC;&*[K]F?]F/5/!_B/0;SQ
MMH,+6_AOPKIMII:74T-TD>J/-/=7TRJK-B2.21464C."^TX8YTM[S72ZU\FF
M]N^R:Z-[]#)VY>9;VV\[I-?KZ;7W/K*BOB;XJ?L^^)/%WQ;\>>)=>\!>(_'M
MT\^WPVD&HZ-!I!M/L:Q)!)-*ZZA;H));AI8X3Y;\DK)N(/GJ_![Q7\/!X$^'
MGBCPS>?$#Q+<^)7O[N>RO+=)=?T;3+%8[109956&&-YXT,4KKNVR'YC*=V*D
M[7:UT?WM7^:6K79/71FDJ:O9.^_Y-_<[6OW:T/T;HK\_H?V2_B0VCZ'X8U;P
M]#J=U;:1H]MH7B:.\MWL_",BWCW.HF.)Y%E$V!''')#&^Y4C4LBAJZ#XY? ?
MQ_XT^*/C#7M$\!7&K:3?R:8MRVNG2O[1D6VOK<R)I-RMQOCMI;>)V>&Y,0W'
M(YD=1I]I1?=K[NOH_P#AKD\JLW?HG]_^7Z:V/N&BOC[P#^SGXJ\4_&H>(_B-
MX6MET&XU'6]<NK":Z@N[9[F1[6VL(G0$F0+:VWFC<NT/M. P &S\ ?@)JFC_
M !HUSQOXWT;Q*/%WVS4Y(]<N+G27TVXAEN-L*120$7SH+=8@L-SF*/!VJ"J8
M(WDHMZ75_1]G\[_*SZZ*45'FL[V=O7?7TM_D?5%<7JWQB\*:+XX@\(W%]<R:
M](80\-IIUS<Q6YF)$(N)XXVB@+E3M$KJ6[9S7(>!?@IXE\._$JY\4:QXT_M>
MSD>>1--MYM;C16D)Q^[GU>>VVJ"?E%N #@KLP!7BGQV^$OQ0\:>./&>K_#WP
MIJ_A*^U;1=5TO6Y;K6[-]+\2QBW:"P,4(E9X[GE&$CI"$560LP.3FY223MT;
M:].E_/Y^C+C",I--Z='_ ,#_ (;S:/LZBO@7XH^!_%FE^$]?BU3PG>:7>^-M
M3\,>#M$T&UU"W>\ETRSC\^:/S8Y#'%(<72D[PJD [R,.5U/]E7Q=JUEHVGZW
MX2UT>!KV_P!<U5_"?AF?1)FTF:YGB6U6:+4&:V<K;^:?,@+/'(\FQOFR=-7)
MJ.VJOYV3U[73^3T?0E17*G)VO9V\M?R::\UJNQ]O^-/$P\&>$]5UTZ5JFN?V
M?;M<?V;HML;F\N=HSY<,>1O<] ,CZBM2SN#=VD$YADMS*BN8I@ Z9&=K $X(
MZ&OCOQ9^ROK?B8^,WE\-_:9=2\4:+I>F37E]%--9>'+5;5;B5)&D+*TJQS*X
MSYD@VA@0!7(ZE^SK\6+UO$.L67A/^S_'8L_$D-_XB>_LW?Q(]\_DV,4+^;O2
MV@@".$G6((8T5$)R:GF=KQ5[IVZ;)25^U[V\I)I7'&"=KNVMG\W;\+/Y--V1
M]\45\_\ Q6^!]MI/[-5U\/?!_AW5IY+J.*-O^$>73_/EN$"M]HNQ>RQ17*.\
M2"979FE5R#D$D>'>$/V?/%VF^-?#&L_$'P-H&A0:!KL&MW_BO3;JSMM+TS2[
M732T5E:1;_,BMUN]\DBE$7=A\ODLMZ>T<;Z*VOEI=KTW]%WT(4;TU/JT].NB
MT7SV]?+4^S-+^(FA:WXRU?PM87%Q=:QI*JU\([&?[/ S*KK&USL\GS-LB-Y8
M??M8';CFM:'7M,N-9N=(BU&TEU:UACN)[!)U,\43E@CM'G<JL4< D8.UL=#7
MYZ:;^S>_Q;:V\9P^"=2O/"'BS4M>U.ZB\*PZ*)Y&DO!'83S1ZFOE21?91*\<
MD>71IG9,>82=_P".7P3_ .$!L_C/XF;PA;6.KR3^'8? VM;H+BYOI+8VWEVJ
M.7:Y:XDFCVMO3YPB'<V,C.,GRQE-6;W75=U;OKHOM:V-)4USN,'?\M]_3?T\
MUJ??=%?+?BKX#^+5_9C\21V>F0ZM\5M:U>W\77-K%<QQ(VI)=PSK DSX79$D
M2PJ6/(3/&:Y*]_9P\8R:QX U*Z\,Q:]XKN->D\1^)Y]3AT^[\.*UTZB:$QRR
M_:1/;111)!-%&V-N"=LC[;C?G4):;)]KNW7JE[UWY)_:1G9.#FGW^Y7_ #TL
MO-]F?:-%?-OQ,^'?BO7/VEM#\8Z+X1?5+31]+FMI;GQ#'ITUD&$;202:8WG&
MYMKHS.(W9D2-U')^1"W@<W[#OB0^ [VQ?P;#>ZS-X$L].DEGO;=S=:Y<W;O=
MW,I,G[QK1&!C9S@#B,YQB8MRMI_7O6^^WRYE<TY(K>7;\6D_NO?S2?8_0ZN)
M\,_&CP9XQUJTTG1M;6_U"[6^D@BC@E&];.X%O<MN* ;5F8)DG#'[NX FOF;X
M2_ 7QSHOQ6T[Q=K_ ()_XJ#0[77[FX\237]I)-KU]-*J6*#;(7$"6N4C\S9L
MRR[4'+=7^SS\&_&WPYN)-2UG0XHK_2_ MEIEB([B!C<:E))<75^ 0Y"YG>)=
MS85MN02!FES>ZIVTLV^^TK6^<5?RDNXN5:J^MUZ;I/\ !WOY/Y?4E%?GC-^P
M[XD_X0.]L7\&PWNLS>!+/3I)I[VW<W6N7-V[W=S*3)^\:T1@8V<X XC.<8]!
MU[X#_$'4OC/<Z^?##7>L:9XEAU;3?&L][:N#H]M8[8M+MU,HFB>6=W$@*+&V
M^1V=OE%4WR[^>VNTK:=]/>7=;:Z!RIWY7^G1-?B^5]FM=-OK+PAXTT;QYI+Z
MIH-Z-0L$NKBS,ZQNBF6"5H95&X#(61'7<.#C()'-;=?"7A_]D[Q)J&N> +#Q
M[X?\1:EHFFZ'I85M!NM':UT_46N)+C47F-RWVB)VE\LF>Q(D9!@-E0*T;[X"
M^-]0^&GC!M1^&,>H?$34?$T=UJFO?;;%KS6=-&K1S>1:3/+N6%;6"%1%.\(!
M4 *>M5JI*,N[7W-*_H[W]%U$XQU<7V_%-_>K6?F^A]@Z]XTT;PSJV@Z7J5Z+
M:_UZZ:STZ#RW=KB58GF91M!V@1QNQ9L#C&<D [=?#>H_ 7XQ:OK'C#Q'#HB:
M)X@OX/$NJ64MOJD'F17UPMM9V,<4H;*.+.W<B0@!6DY*\@=OX/\ @%J_@#]G
M+XC:=\/M%\2^&/&NN6YBAAUN?2;:X9DB6,-#_9I%JCLN\"5L2,^#(V I$)OD
MYK:V3MY]5ZI_>M;%.$>=13ZV_P"#Z--?.^O;Z0A\;:+<>-KGPC'>[_$-M81Z
MG-9B)_DMY)'C1R^W9RT;C;NW?+G&.:W:^(+/]E_Q%)I/Q @T+X?+X T_Q5J_
MAW38],LKZUCEMM&MFCDNKAFAE*K,6:?<$8L6Y!?[[+XN^ ?C;3?$_C'3] \'
MZ9X:\'W'BK3M;BUA;RTM["WL+"Q$D"B$-N4"\BS)N0 !\C?EF52GRJ[7]77Y
M*7?5QEM82@I/1]/TV^]/;HX[W/MZI;7_ (^H?]]?YU^7_P /OAR/B]8^(CX<
M\)ZE?7EGX2L='O-7\+ZCH^I-J.M33M<W=U=RR77V2Z#-;0"6-I7D:*9594#[
M5_1/X-:#?^%_AYX3TK5-+T;1=4M;.!+O3_#T @L()L R+ @&%3=G K6WNMOI
M_F]5Y:7^:$THR27]:)Z_?;Y,]0HHHKC/4"BBB@ HHHH **** "BBB@"EK5Q)
M::/?3Q-LEC@D=&P#@A20>:^(?@G^T9\47\)6GCK4;[Q#XW\-VO@R_P!;U]-<
MT*+2K.&^B.Z"*QNDM(?-#JKAB//50,YS@5]SW%O'=V\L$J[XI5*.N2,@C!%<
MI8?"7PIIGPP/P\MM*\OP=]A?3/[-^T2G_1W!#)YA?S.0QYW9YZUI&22U1+3;
M/#=4_; \3Z=INM78^&]C(?#N@P>)M<@/B0K);V4^YH4A_P!$*S7'EH[LA*(I
M 42OG(T_B9^UMJ'@[5M=AT'P1'XAT_1/"]MXNO+JYUC[$YLI6D#)''Y$FZ50
M@(4LJM\V64@!O0O%'[-WP[\875M<:IH4TC164&G21V^IW=M%=VL+;HH+J.*5
M5NHU.<+.''+#N<\UXT_9-\*_$CXL:GXM\3RSZAI=YH=OHO\ 8-O/<6<>R*5Y
M#YKP3)YT;;E!A=2GR G/&&G"^J)M+N>;?%K]I?4/$,FIV&GZ!J>G^'-&\0^'
M;:37=+\2?V?>W#7LEM+$@B%M)F/$I$J,Z[E  8[SLZGQ=^USJFG_ !+U[PIX
M6^'.J>+%T._@TN]N;>+4"1<2HC[@8+&:!8D$J%VDGC< .1&V%W^HZI\!? >M
M-JIN] 5QJFH6.JW:I<S1J]S9A!;. K@*$$2?*N%.WD'FG7GP-\(77CBY\7Q6
MVJ:9KUT\,EW-I&N7UA#>-%Q&UQ!!,D4Q ^7,B-E>#D<4KQ[!:7<\"\!_M6>,
MM!_9]\.>)O%NG:/KGBC6-0O;:QM8KZ[,U]% TQ=A%9Z;*RL@CV\1E-H#O(A.
MVNQ\$_M4:[\3]0T.U\)^ (;S^T/"%MXMD;4-<^S^4LQE1;90MN^]]\:@-\JD
M%B=I4*W72_LH_#&328-,&AWT-E;7]QJ-M';Z[J$1M9IU99Q"R3AHHY [;HD*
MQMN.5KIO _P8\&_#>[M+GPYHW]FSVFDPZ% PN9I-EE$[/'%AW(.&=CN/S'/)
M--N'8:4NYQ'P)_::M?CUK2VNCZ)]GLH-"MM2U&Z:[W-97LLLD9L63RQED\F0
ME\C^'Y><UY)\/_VEK_0M"^)GC7QCXG\9:VOAG5-7@B\/P^'8H=(>&&Y\JW1+
MY;%09<E%P;DGDEE.#7O'P+^!=A\$T\926]S;WE[XGU^YURZEMK/[*B>:?DB5
M-[\(!USR2QP,XK;M?@SX,M/!FO\ A-="AE\.Z]/=7.I6%Q)),EQ)<,6F8EV)
M&YB3\I 4XVXP*+Q3>@K2T)/"_B_7&\'7VL^,_#]OX:N+.-[B2'3]1_M&%X5C
M$F])#%$Q."5*M&OS*<;AAC\NO^U=KD?CCP]\0O$.BW6@>"7\ ZIXAM=)T_6#
M=B_C$]KY#RQ;(UCN &QCYPHEXD/S ?5W@WX=Z%X#T&71]*M[E[&9BTO]I7UQ
MJ$LN5"8>6X>21@%55"EB H   XKA]"_9-^%/AV.:.T\*^;!+IT^CF"^U"[NX
MDLIBIDMD2:5E2+*@A% 5225 W'*3CU&TSSSQ)^V-K?@6WURS\2?#RW@\2Z?;
MZ1>P:?INO_:;>YM[^X%NI\][:,I(CYRAC*G P^#D+#^U_P")-/UV^L==^'-E
M8VVD^*[/PEJUU8>(S<F.XNE1H9;=&M(_-0"1-^\Q$9& _./3+7]F'X<6^D:A
MITFB75_#?S6D]S/J6L7MY=2&U</;+]HFF:41QLH*QAM@R?EY.=._^ O@34[C
M59KG0O,EU36K;Q%=M]KG'FW]N$$,W$G&T1I\HPIQR#DT[P["M+N>5^&_VN8?
M'/Q(UGP5%HBC3VTK5+W3_$&DWMV4G%I((I%#S64,>[+??MY+A%92"W0G@?!_
M[8^I^%?A/I3Z?X/O?$MKHO@:P\6:CJ'B#Q1OO6M9&D1U,@M3Y\XV Y(17RV2
MA #?0'A?]F/X;^#?$4NMZ1H$UK?O!=VJ[M4O)88(;E_,N(X87E,<*N_S$1JH
M!Y&*;;_LO_#*UT&]T6+PUMTR\T&/PQ/!]ONCOTV,L4@W>;D8+M\X.\YY:B\+
M[:!:7<],T^^CU/3[:\AW>3<1+,FX8.U@",_@:L5#9V<6GV<%K;IY<$$:Q1ID
MG:JC &3ST%35D:!1110 4444 %%%% !1110 4444 %%%% !1110!YUXE\#ZI
MX6EO?$'P^2*#5)[O[?J6@S/MM-9.W:XRV1;SD#(E3:&<#S0XY76T'QQI?Q \
M+Q:II;RJJSM!<VERGEW%G.F1)!-&>4D4\%3[$$@@GKZY+Q3X)TO4/$FD>)C'
M);ZUIX>W6YMWV&>!U;,$P'^LC#$2 '[KJ",98'HC-2TGOW_1_P!:'%4INFFZ
M>SW7ZKMYKKY.]X&UG3TU9-+:^MEU-XO/6R,R^<8P<;PF<[<\9QBN?^)'Q*TO
MX8Z+'?ZA#<7LT[M';6-GY8EG98VD?#2ND<:K&CNTDKHBA22PXKH&T;3WU9-4
M:QMFU-(O(6],*^<(R<[ ^,[<\XSBL'QYX!'C9=-EM]=U3PQJNG3-+:ZKH_V<
MSQ[D*.A6XBEB964\AD/(!&" :<_A]W<Y8_%[VQS'A/\ :.\&^*-/M+A[B;3)
M)].?5W20Q7D-M9J\R":6\LWGM45C!+M_?<[<?>^6G77[27@*RTFWU">^U:))
M99(3;-X>U$7<!CV;VGMOL_G01CS8OWDB*F)$Y^893_AGGPVW@K7_  U/=:A>
M6VMV4%E=W-TT,LI6($AMK1F-BTCR2LKHR.TC[E*G;63I_P"RWX>TW3_#]A:Z
MWK%EIVE1K#+8Z=#86%OJ"+="Z59HK:UC10),Y$ BWAB'WYJOMZ[?\/\ \!?.
M_2P:<MUO_P -^M_R\S9M?VB?"$^CZIJ4B:]:V]AJDND>7)X>OFGNYXRP?[-"
MD+27"KY<A8QJVT1L6V@$U9NOCYX-ATWQ)>V]Y?:E!X?T]=3OWL-+NID2)H4G
M0+(L>QG,4L;[%8MM;)  )'.>+_V6?#7CC0;72=7U2_OH+36+S6+=KZPTR]$3
M7,C22PB.YLY(BFYV(=D,HR0),$@[OC+X9WTW@W7-!\.FWE/B;4&?5[K5;ID,
M-M* DQB5(B'98D6-(SL&,$OQAH7,TTWK;3ULOU;\E;L[J_<4DUJKO[KO]-/5
MW\C,T']H[1H]!TJ3Q?:7/AOQ#>:='JDNBVEAJ%Z]M#+(Z0*Y^R1L)9#&46)H
MU=I 40.=I;<M_CUX(N[G1;>+4[HR:L%\G=I5VH@+2-&JW1,6+1FD1T5;@QEG
M1E )4@4_B3^S_P"'/BE8ZW;ZO-=9U66TE=VAM;I(?LP81HL%S#+"R_/(2LD;
MC=(6&"%*XT?[*?@Z/Q98:^K.MU::.NBB--,TQ,PBW:W#1RK:":V/EL?DMI(H
MO2/E@7)MW:77\+/];+\?(24>KZ?CI^&[_#S<L/[4G@R;4KU5.J/ID,%N]O=1
M:-?R3WTDIG(%M;+;F6>,1V[2>=$&0J=P. 35S7/VH/AOX?O!:W.M7L\QC61?
M[/T6^O%?=;K<A%:&!PS^0XF\L$L(PSXVJQ&1#^R[:6\<<J?$'QF-8!V/K'GV
M/VA[?R!!]G"_9?*CCV 8,<:.&W,'#,Q;?_X9[\+QZ;/8V[WMI;RP7\"B%XP8
MA=11PLR$H<-'%$L<9.<+D'=0[WDE\O\ @^7;TU[CCRW3E\_+T[_\&_D:WC#X
MP^'O!.F^&M0O%U*]L_$%S';64NEZ9/>??C:42.(T)1 BLQ8C@ GL<6? _P 5
MO#'Q$M[^XT.^GF@L@CRR7=C<6:M$X)2:,S1IYL+A6*RIN1MIPQQ3?'7PRL?'
MEGHUK/J&H:9!I<[2HNGM$OFJUO+;O&^^-L*8YG&4VN."K"J'@_X.V7A;P[J^
MEW>N:QXDFU6V6RN=3U5X$N?LZQ&..%?L\42(J*SD80'+LQ))S1*_O\J]/^#_
M %U?97B-O<YOG_P/Z_-VS#^TS\.UTEM2.K7_ -F^T);1#^Q+_P VZ9XI)8VM
MXO(WSQO'#*RR1*R,$;:QQ4FJ?M >'+;Q!::)8K>7EW=VEA?P7SV%VNG-#=W"
MPP_Z4D+H'?)VJ<!B,$KR5Y:X_9CNI+W2HU\>^(WAAAF6[UB1K(:E)B);>W@0
M+:"%(5A>[!*HLFZ;<&W$L.UN/@GHT_BJRUA;[4(;:S@L88]'4PFS_P!#:5[=
MCNB,N5,S' D R%.,C-4OB\KK[M;W_"WW;:A]GSL_ONK?A>_R?D9NH_M/?#G2
MM<GTBXUB^^VP3R6\GDZ)?RQ!HYO(E;S4@,92.4A)) VR-F4.5W+FZOQW\,6>
MI&PU:ZDL)F:_:.ZCL;R2Q\JTEE24R7;6ZPQNODMN0OP<8+AE9BW^!'AZVMX8
MEGOF$<=M'N9X\MY5Z;UB<)UEE/[S^\ ,;3S6!/\ LO:'=6^LV<_B+7+G2M4T
MPZ9+IMQ'82P1@R^<TJ[K4L6:4L[H[-$Y8[XV& ,_>Y5WU_X'Z?B:>Y=]M/\
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M2^4TTA@618(BQ&'F*8SAMI! S_'G[06G^!?B5:^%[G3;EK.*Q%_J>J-:WK+
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MU"ZU#68]0FU$ZIH%W>:&5:0*@B3[/<>8(1''"GEO*X;RE+9(&.O\;?#?0_B
MNG_VL-2BFL'9[:ZTG5[O3;A-P 9?.MI8W*-A<H6*G:I(.!@ X"^_:6BF\$ZA
MX@T'P+XFUJ6SU"UTLZ=*EO8RO=37 A\H&>91N7=&Q[8E09R'"9>B?ME>#/$L
M_B"'2-,U;59-(N8+$II\MA<M<74MP+<6ZK'=,T4@E)&+@1!@CNA=%+5WMO\
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MFI?;ETR-;G[5#>@AW"B6*$P1D+G: L9("@8SSC/-=%0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>cdtx-20231231_g13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g13.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" A-$&\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMKYAG.UWC5G7ZAB1^%>A92HJ2W3U^>WY,X;M5;/9K\GK^:.SHHHKG-PHHHH
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M)3WK@JMMJG'=_DM_\N^M^AVTDE>I+9?GT_S^1E?\/1OVG?\ HIG_ )0-+_\
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MSP?&O]KSXO7_ ,8_'5QI'Q8\;:=I,FN7K6=I8^(KR&"&'SW\M$19 JJ%P
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P $K?B-I/Q?T/Q?\6=/M?#.B>'[N._BTM;Z&ZN+Z>-@\0S"SHL88 L2V3C
M7G(,'[M1^T[N]^U_\NW7S'B]:?[OMI;O;_/OT\C]>J***!!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0^8N4FU%H7\E>>OEC,A]"(_6O-I:QGB'M9O_ +=6WW]/-I'?4?+R45W7WO\
MR_1L^+:_HX_8?_Y-#^$7_8N6G_H K^<>OZ./V'_^30_A%_V+EI_Z *]&/\&7
MJORD<,OXT?1_G$^8/^"UGBK^S?V?_!V@K)MDU3Q")V3/WHX8),_^/2)7Y >!
M],M-:\::!I^H74-C87>H6\%Q=7,@CBAC:159W<D!5 )))(  K]%?^"WGBS[7
M\1OAGX:5_P#CQTNZU!T]YY50'_R7-?FA7#A)\LW67\U_NT_0[<3%N$:=[>[^
M=W^I_2/<_M=? G0]-,C?&#P*;>W3 2V\0VDS[0.BHDA8].@%?D]_P4X_;:\,
M?M0:WX<\->!5FN_"WAZ26X;5[B%H3>W$@5?W:, RQJH/+ %BQX  )^&:LZ8U
MFFI6K:A'/+8"53<1VSA)6CR-P1F! ;&<$@@'L:N5/VLES/K^/G^9G&7LXOE7
M0^V?^"1_P2U/X@?M,6OC3[/(OA_P=!+<S717Y'N98VBBB!_O8=W]@GN*_<:O
MFO\ 8'\;?!;Q-\#;+3_@M$VG:5IS!=0TN] &HPW##F2ZY.]GQPX)4@87 7:/
MI2NRMI:FME^-];_Y>5CFI>]>;W?X>7]=0HHHKF-PKY)_;B_8-G_;.U;PG='Q
M_P#\(A;:!!<1+;?V/]M\YI60E\^?'MP(U&,'ZU];45,HJ33?0I2<;VZGQ)^Q
MG_P3/M?V2OBM=>-YO'W_  F,[Z;+I\%J=%^Q>0TCQL9-_P!HDR=J%<8'WCS7
MVW17R;_P4"_;:L/V4OA]_9VC2PW?Q'UN%ETNS.&%I'T-W*O]U3D*I^\PQT5L
M.K5<8J^MM$OQM_7Y"IT^:3MUU?\ G_7YGPW_ ,%G/C+I7C3XO>%? NES)=3>
M$[6:34)8R"$N+DQGRL^JI$A/_73'4&O%_P#@F)\/;GQ]^V5X)>*+?::%YVLW
M3XR$2*,A#_W]>(?C7S#K&L7_ (DUB\U34[N;4-3OIGN+FZN'+R32NQ9G8GDD
MDDY]Z_</_@ES^R7<?L^?".;Q3XELVMO&OBY(YYK>92LEC9C)A@8'D.<EV'8E
M5/*UK@X.C%U)=+O_ +>>UO3?T1GBI*K:E'9Z?+K]_P";/M2YMX[RWE@E7=%*
MA1UR1E2,$9'2OEK_ (=<_LQ?]$S_ /*_JG_R37U5165E>YI=VL4=#T6Q\-Z+
M8:3IENMIIUA;QVMM;IG;'$BA449YP  .?2OS%_X*]?M9>%-8\$VWP=\,:I!K
M6L/?QWFM2V<@DALTBW;(&8'!D+D,5_A"<X)%>(?\%7/CEXOE_:C\1>#M-\6Z
MU9>&M/TZSM9M'M=2FCLY'>$2NS0A@A8^: 21R /2OA?2[>WNM2M(;RZ^PVDD
MJ)-=>69/)0L S[1RV!DX')Q6&N*LWM?[[/1W_$ULL-HET^Y-=O1G=_L]_!S5
M?CY\8_"_@?2())9=4O$6XD09%O; [IIF] J!C[D =2*_I>LK.+3[."U@79!!
M&L4:CLJC 'Y"OF#]@G]F/X4?!+X86?B/X>ZM#XVO-?MU:X\8,H#W*@\Q1ISY
M"!@<QYW!AAR2HQ]2UZ-1\D5273?U_P"!_F<5/WI>T?R]/^#_ )!7RS_P4X\8
M'P=^Q;X_:-]D^I+;:9'[^;/&''_?L/7U-7YS_P#!;#QA_9OP/\#>&TEVR:KK
MS7;)G[T=O P/X;IT_2O,Q.M/E[M+Y-J_X'?A_P")?LF_N3:/QOK^E[]FGP;_
M ,*]_9[^'/APKLET_0+*&48_Y:>2I?\ \>+5_.9\)O"9\>?%+P?X;"EO[7UB
MTL"!Z2S(A_1J_IZAB6")(T&U$4*H'8#I7I_#0]7^2_\ MCS_ (JWHOS?_ 'T
M445S'0%%%?/O[57[;'@?]D&3PVGC+2O$&I'7A.;;^P[>"79Y/E[M_FS1XSYB
MXQGH>E)R2M?J4HN6Q]!45\ ?\/J_@A_T*WQ _P#!=8__ "91_P /J_@A_P!"
MM\0/_!=8_P#R93)/O^BO@#_A]7\$/^A6^('_ (+K'_Y,H_X?5_!#_H5OB!_X
M+K'_ .3* /O^BOC7X+_\%4?A/\=?BAH'@/0?#WC*TU?6IF@MYM2LK1+=6",Y
M+LET[ 80]%/.*^RJ?*[<W07,KVZA113)I5@A>1SM1%+,3V J6U%796^A_/'_
M ,%"_% \7?MF?%*\63S$@U,6"G.<?9XD@(_.,U]9_P#!,CXU> /V6_V:?'WC
M_P >:LNG+JNNBRLK.%?,O+\V]NC;(8\Y;!N,%CA5R-S"OSI^*'B9O&OQ*\6>
M(68LVK:M=WV3U_>S,_\ [-7TU^QK_P $Y?%O[7/AN[\37'B.+P9X0MY6M;6^
MGLVNY;J9<%Q%%OC&P9P7+CYN #@XG!J:PW*M^57\M5?_ "]65BN3ZQ>6RD[?
M<TE\OR1]6R?\%Q/#R^)/(C^$^IMX?\S'VYM9C6ZV?WOL_DE<_P"SYN/>OOSX
M'?'/PA^T1\/;+QEX*U WVE7!,;QRKLGM9@!NAE3)VNN1QD@@@@D$$_S_ '[6
MO[+^M?LE_%B3P9J^I0:U%+:1W]CJ=O$8A<0.64$QDG8P9'!7)Z=3FOK[_@B7
MX_U"S^+'CSP5YKMI6H:.NK>43\J30S1Q[@.Q*SX/KM'H*Z,.HUHM+>S=_3>_
MW/YF-;FI23?EIZ[?FOD?HC^U/^U]X+_9%T'0]5\8V.M:C%K%R]K;0:)!#+*"
MB;F9A++& HR!P2<D<5Y-\%_^"J'PJ^.WQ0T#P'X=\->-8=8UJ9H;>6_LK1($
M*HSLSLMTS !5)X4_2OES_@N!XH\_QA\+?#JM_P >MC>W[KG_ )ZR1HI_\@M7
MBW_!(KPJ/$7[8VF7S)N71-(OM0SCH2@@!_\ (]983]])N6WO?^2W_5,O$_NH
M+EW:7WO;\&C]UJ^0_C]_P4\^%7[.GQ2U7P#XBT7Q9J6LZ8L+7$VCV=K);@R1
M+(JAI+E&)"NN?EZU]>5_.;^W5XH_X3#]K[XKZ@.577)K-><\6^(!^D58RD_:
MQ@MFF_NM_F;1BO9RF_)???\ R/VU_95_;/\ !G[7T/B.;P=H_B'3(M":!+E]
M=MH(A(TH<J(_*FDS@1G.<=1U[5OVJOVX/ 7[(-YX<M?&.F^(-3GUV.>2V70K
M>"78L10,7\V:/&3(,8ST/2OGG_@BKX9_L_\ 9Y\7ZVT1234O$;1!R/OQPV\6
M/R:1_P!:^9O^"TGBPZM^TCX:T-6S%I/AV-RN>DDTTK-_XZL=;XK]U4IQCUM^
M,;_F8X?]Y"<I=+_A*Q]U_ 7_ (*<?"O]H;XA1^$=!T;Q5I-T;2XOI;_7+:T@
ML[>&%"[O(ZW+E1@==N.><=:\W^-O_!9#X9_#W6KC2O!/A^_^(T]O(8Y+Z.Y6
MPL&(R#Y<K([O@CJ(PIZAB*_*/]GWX2^.OCE\0HO _@!9?[3U>!H;QQ*T4$=H
M&5I&N'4'$0*H2,')"@ D@'ZT_:$_X)&^)/@?\%=7\>6?CVS\47.BV_VS4=*3
M2VM@D(_UC12F5M^T?-@HF0#WX,U?<BJCTC^>KU]/^#J%/WI."U?Y:?G<^U?V
M4?\ @J1X$_:2\96G@[5-"N_ GBF^W"QAN;M+JTNF SY:3!4(D(SA60 XP"20
M#]"?M ?M*> ?V9O"(U_QUK(L8Y2RV=A;KYMW>N!DI#%D;L9&6)"KD;B,U_-M
MH.MWOAG7-/U?3;A[34=/N([JVGC.&CE1@R,/<$ U]]?#G]E7XN?\%0/$VK?%
MSQOXGA\'>')Y&M=-FDM'NAL0X\JU@WH/*0[@7+C+[N&.XC247.*]FK-;^FEO
MF_Z[$QDH2?M'H]O7_+K_ %<]DO/^"XF@)XA\FU^$VI3:%YF/MLVMQQW.S^]Y
M A9<^WF_C7WA^SW^T1X-_::^'L'B_P %WDDUDTA@N;2Z0)<V<P )BE0$@-@@
MY!(((()K\&/VPOV3=;_9"^)EOX7U358=?L;ZS6^T_5H(# )X]Q1@T99MCJRG
M(#,,%3GG ^IO^")_C:[T_P"-7CCPGYK?8-3T,:@8RW'FP3HBD#UVSO\ E3P_
M+6BTNSU]-[_<_F*MS4FGZ:>O_#KY'[!:MJUEH.F7>I:E=P6&GVD33W%U<R".
M*&-1EG9B<*H ))-? 7QD_P""S'PT\#ZQ<:;X(\,ZE\07MWV/?FX73K*3U,;L
MCR, >,F, ]02.:\(_P""N_[6]_XA\:/\%?#EX]OH.D^7-KS0MC[9=$!TA8CJ
MD8*L1T+GG[@KX;^!7[/WCC]H[QJGA?P+H[:G?A/.N)I'$=O:Q9 ,DLAX5<GW
M)Z $\5S4G*L[QVZ>?GZ?IJ=%3EHJTM_ROT]?^&/U6^$7_!9_X:^,-4AL/'/A
M75/ /G/M6^BG&I6D?O(RHDB_\!C;WQ7O_P"T7^WI\,OV:]!\'ZSK U3Q1IGB
MN.:;3+KPLEO=1O'&(R7+/-&-I\Q<%2>AZ5^57Q>_X)3_ !R^$/@VZ\2O#H?B
MRRLT,UU;^&[N6:X@C RSF.6&,N!W";CWQ@$U\D76O:E?:38:7<W]S/IM@TKV
MEG)*S16[2%3(44G"[BJDXZX%:.2E[L=&M_3^NIG&+C[TM4_S_P"!V/W@_9__
M ."FWPR_:0^*6E^ O"_ASQE:ZOJ"32)<:G96D=O&L<;2,79+EV'"X&%/)'UK
MOOVJOVT? W[(-OX<D\96&N:DVO-.MK%H=O#*ZB()O9_-FC '[Q0,$]Z_-#_@
MB_X5;5OVF/$&M,FZ+2?#LV&Q]V26:)%_\=$E;G_!;+Q8-0^-W@3PZK9&F:"]
MVP]&GG9?Y0+3Q'[M4>7[6_\ Y-_D*A^\=7FVC_P/\S[&^#7_  52^$/QL^(%
MEX3TS2?%6BSW$,]Q)J6NV]G;V5K%#"\LDDTBW3%%"H><'DCIUKSKXS_\%FOA
MYX&\02Z7X%\*WWQ#2!RDNI->#3;1R/\ GDS1R.X[9**#C@D<U^5/P#^!?BG]
MHWXF:;X(\(P1OJ5X&DDN+ABL%K"O+S2L 2%7CH"22  20*^GOVMO^"7.N?LO
M_".3Q];>.;;Q?86<T46HVW]F-9/ )&"*Z'S9!(-[*#G:><^M%3W(QF]%^;O^
M73[]>Q3]Z3@M7^7_  ?ZL?HQ^R+_ ,%%? '[5VIMX>AL[KPCXT6)IET;4)5E
M2Y1>6,$P \PJ.2I56QD@$ D?5U?S!?"?Q[J'PN^)GA?Q;I<TD-]HVHP7D;1M
M@L$<%D/LRY4CN"17]/4,GG0I(!@,H;'U%;SBO9QJ+2]U]UO\S&,FIN#]5_7E
M^H^BBBL#8^7OVOOV]/ _[)^H6WAO7].U[4->U;3);RR.D00211<M&AE,DR,N
M74_=#< _2OY^I)&FD:1SN=B69CW)K])/^"NWP+^)OB'XK:E\4?\ A'#_ ,*X
MT32;+3AK#:A:@;FD.<0^;YO^MGV_<[9Z<U^;]G9S:A>06MO&9;B>18HXQU9F
M. /Q)KGH)U)-_:O;\7;3S3^9O6:A%)?#H_G97^[\#]G_ /@F;^V-X!\3>"_
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MZ+_A;\5O"GQH\%V/BOP9K5OKNA7@_=W$!(*L.J.I 9''=6 (]*\^_;;\6?\
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M ,$\/VI/ _[)OQ,\1^*O&>F:YJ7VW2?[.M%T.WAE="TR2.7\V6/ Q&O0FOW
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M 2 ZC(!QG!Q4_8V_:$U']FSX^^&_%-O<O'I$LZ6.LVX/RSV4C 2 CN5X=?\
M:0>]504:S]GU>E_/S_KS\G%;GIKG^=O+R_KR/Z*?$6O6OA?P_J>LWS,MEIUK
M+=SLH!(CC0NV,GK@&OA'_A]7\$/^A6^('_@NL?\ Y,KZ*_;B\6IX2_9!^*NJ
M+*$$F@SVD<F?XK@"!?S,HK^<RN12;JRAT27WZ_\  .EQ7LHS75O]/\S]O/B5
M_P %@?@[X/\ #.E7F@6&L>+-;U&S2[_LF$10BRW $17,VYT63!Y6/S-I!#8/
M%=A^Q+_P4&M_VQ_$>OZ(O@"\\*7.DVBWCW U%;VV92X0*7\N-E<DD@;2"%;D
M8Y_+S]GO_@FM\9?VC/!\/BK1[;2/#GA^Y&ZSO?$=U) +Q<D%HTCCD?;D?>90
M#V)K]-/^";G['/B+]DOPSXY3QD=.E\0:OJ,2I<:;.9H7M(HLH5+*K#+RRY#*
M#\H]J[(Q47-U.ST_+[KW^1RRDY1C[/NM?S_I=3ZX\3>)](\%Z#?:WKVIVNCZ
M/8QF:YOKV58H84'=F8X%? OQ6_X+0_#+PG?SV?@GPMK'CMH6V_;9I5TVTE&.
MJ,ZO(?\ @42U\7_\%(?VT-2_:)^*%_X4T+4'C^''AZZ:WM8('PFHSH2KW3X^
M\,Y"=@O/5C7._L>?\$]?''[7%G<ZY;ZA;>$O!MM,;=M:O86F>>4#++!""OF;
M>-Q+*!G )((')2YZRYUHM_EW?KT7ZZ+IJ\M%\DM_U[+T_K34^T? W_!;SPAJ
MFI+#XN^&>K^'K-B +G2M2CU$KD]61XX.![$GV-???PF^,7@WXY>#[?Q/X'UZ
MU\0:-,=AFMR0\3@ F.1& :-P"/E8 X(/0BOR3^/W_!'CQ?\ "?X>ZIXJ\*^-
MK;QW_9<#W5WIK:6UC<&%!EVA'FRB1@ 3M)4D XR< ^$_L"_M,ZG^S;\?M#NC
M>2+X3URXBTW7+,N?*:%VVK,1G&Z)FW!NN-XZ,:ZJ/)6G[+[7^>WW]SGJ\U*/
MM>G^6Y_0K7B?[2G[87PU_96T>&X\::M(^J72%[/0M-037UR <;E0D!5Z_.[*
MO! )/%=+^T1\:M,_9[^#/B?Q]JBB>'2;;?!;;L?:9V(2&('MN=E&>P)/:OYR
M/BE\3O$7QD\>ZQXQ\5:@^I:YJDQFGE;[JCHJ(/X44855'0 5QN3E/DCTW?Z>
MO]=3JC%*'/+Y'Z>3?\%QM(76O*A^$-\^D>9C[4^OHL^S/7R1;E<X[>9^-?8'
M[-/[<WPK_:EC>U\+ZK-IWB**,RS>'M818+P*.K( S+*HQDE&. 1N"YK\E_@K
M_P $L_C=\;?!-IXJM8=#\+:7?1K-9+XCNY89KJ(C*R+'%%(54]M^TD8(&""?
M&_C%\#?B;^R'\1[.Q\26MSX<UN$_:M,U;3;@^7.%./-@F3'0]1PPR,@9KIE:
MF_9SW_7^NASZU%SPV_K^KGZKZA_P6>^".G:A<VA\->/)S!*T1EAT^R*/M)&5
M)O <''&0*^L/@I\>/#WQR^#^G?$K2X+[0_#E]'/,O]O+%!+''%(Z/))MD=57
M,;'.[ISQ7\SS,68DG)/))K]2OVQO$^L?!?\ X)E_ _P/IDDFGCQ+9VB:F8SM
M+1?9_M,D1]FDD7/J%(Z&HE^[PSJ/5WBO_ KHM6GB%!:1M)^=ET/6/C1_P65^
M&G@/6KG2_!/AO4?B%);2&-[\7*V%C)C@F*1DD=QGOY8!Z@D<U/\  W_@L9\,
M_B-KMMH_C;0+WX<7%U((XKZ:Z6^L%). )90B-'DG[QCVCDLP'-?F/^Q_^ROJ
MG[77Q4D\'Z=K=KX=AM;)]1O-0N8S,T<*LB?NX@R^8Q:1>-R@#))Z _0WCC_@
MCS\5/#OQ3\/>']#U2R\2^%-4EV3>*$B^SC3T R[3P%V(.,[0K,&.!E2:TC%P
M<>?7F_KY?,B4E+FY=+?U\_D?M;;W$5U!'/!(DT,BATDC8,K*1D$$=017Y _\
M%+/V^O!?QT^']Y\+/"FGZ_:ZEI7B3_B87>H6\"6LZ6_G1GRF29V8&0JPW*O
M[=*_47X8_#&U^!_P=TCP7X;>]U2'0M.^S6C7UQYDT[JI(RSG"Y;HO"J"
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MI%XDO)89YXF *R".*&0J"#QOVGOC!!JN5M770GF2DD_Z_K]3]3/V)/VUK?\
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M:;R%UU*TB'J[(J2X_P!V)J^\O!?C;0/B-X9L/$7AC5[/7=#OD+VU_8RB2*0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXO\ &WB'7ICNEU34;B^<^K22LY_]"K7%:XV5NG-^+5OR9EA-,%'_ +=_)_\
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M_*_JG_R361H5?^"7VM>*/%7[)FC^(?%OB/6/$^J:MJ5[.M[K=]+=S"))?)5
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MFM][1N4?Y)41N&4C)':NJ<N?X5:*_K7S?]:61S0CRZR>K_JR_KS.PHK\EO\
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MYH+>-%CB4GINVJ"V.-Q.*PLXU%&.R6O;R_K_ (!LFI4W*6_3]?E^MO,^T_\
M@BS\9-6L?B9XI^&5Q<RS:#J&G-K%K;LQ*V]S$\:.5';>C\^OEK7Z_P!?CI_P
M17^%NHZI\8/%OQ >%TT;2-*;2TF((62YG='V@]]J1DD=MZ^M?L77HUMH7WM^
MKM^%OE8X*6\[;7_17_&_SN%?CK_P6T\8C4/C)X \,*^5TO1)+YESP&N)BO\
M*W'YU^Q5?@+_ ,%1/&!\7?MI>.%#[X-)6UTR+V\N!"X_[^/)7FU-:E.*[M_*
MS7YM'H4](3;[6_%?HF9W_!-7P;_PFG[:'P[A>+S8-/GFU27T7R8'=#_W\"5_
M077XS?\ !%3P=_:GQ\\8^(W7,>D:!]G4^DD\R8_\=B?\Z_9FO2JZ4Z<5V;^=
MVOR2//IZU)R]%^%_U84445S'0%?FC_P6.^$OCCXGW'PL/@WP9X@\6BS74?M)
MT/2Y[WR-QM]N_P I&VYVMC/7!]*_2ZBHE'F:?9FD)\E_-6/YK/\ AD[XW_\
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MYO@SP_)XL\8:%HD7^MU*_@LEQZR2*@_]"K^HFQLX]/L;>UA4)#!&L2*.@50
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MK\5<>-BW35-=$OFF^9K[G8_I,KX&_P""SFAZ=??LOZ)J=S&G]HV/B.W2TF.
MP$D,PD0>H(4$C_8![5]#>&?VXO@)XJ\+V^NV_P 6/"ME;2Q^9]EU/5(K2[3U
M5K>1ED##TV\]LU^5W_!3+]N+2?VF_$&D>$? \LL_@7096N3?R1M'_:-V5V^8
MJ, RHBEE7(!)=CC&*QQ$6[4UO=?@T_T-J$DKSZ6?XIH^9OV8WFC_ &D/A8T!
M83#Q3IFS9US]JCZ5^D?_  7 \6"W\%_"_P ,JW-WJ%YJ+K_URC2-3_Y':ODS
M_@ES\%KSXL?M7>'M4^SL^B>$<ZU?38.U77(MTS_>,I4@=PC>E>F_\%J/%9U3
M]HGPIH2OF+2O#J2E?22:>4G_ ,=C2NC%?PJ--]9-_*VGXQ,,/_$JS[12^;T_
M*5SQO_@F3X3;Q9^VI\/E,>^'3GN=2EXSM$5O(5/_ 'V4K]&_^"QGBR[\/_LF
MV^FVSE(]<U^UL[G!^]$B2SX_[[B3\J^2?^"*_A-M4_:'\6:^4S#I/AYH=V.D
MDT\87_QV.2OM/_@K-\,[SXA?LBZE?6$3SW'AG4;?6GCC!),*AXI3CT59BY]
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MX9>&U?\ X\=+NM09/^NTJH#_ .2YKIS#^-[/^];_ ,!U_*-CGP'\+VG]UO\
M\"_X,CY)_8,\)_\ ":?MA?"K3BF](]9COF'M;JUP?_15?T6U^'/_  1Y\+#7
MOVN#J+1[DT70;R[#8X5G,< _'$K5^XU=53W:5./>[^]V_P#;3GAK5G+T7Z_J
M?ST?\%$/A%_PIO\ :U\<:=#!Y&F:K<#6['T,=SEV ]EE\U?^ U]3?LG_ +=U
MM\%?^">?BJUENXY/&'AO4'TK0+61MS.;L-+"Y!ZK&PN&/;$8'<5VO_!;'X1_
M;O"O@3XE6D.9=/N)-$OG5>?+E!DA)/HK)*/K(*_).O,H-^PGA_\ MWTLTU\^
M72_2_P COK).K"O\_G9I_*_Y&WHNCZY\2O&EGIEC'/K'B+7+Y88E)+2W-Q*^
M!DGJ2S<D^N:_HU_9A^ ^E_LT_ _P]X'T_P N2:R@\[4+Q1C[5>.-TTI]BW S
MT55':OSJ_P"".G[+8UC7+_XUZ_:9M-.9]/\ #Z2+P\Y&)[@9'(13Y:GU9^ZU
M^MC+N4@]#Q7H5$Z5'V4-&U?_ "7Z_=V.&+=6HZDME^?5_I]_<_E^^)WBJZ\=
M?$CQ5XCOG:2[U;5+F]E9CD[I)68C]:N>"?C1\0OAG83V/A#QWXF\*65Q+YTU
MMHFL7%G'))@#>RQ.H+8 &3S@"M#]H3X:WGP?^-WC;P??0O#)I6JSPQ[\Y>$N
M6A?GLT;(P]FK]#O^"/?[4WAGPSX=UKX1^*-7MM&OIM0.I:)-?2K%%<F1422W
M5F(&_<BLJ]6WMCI7-A(J=%<CM[JLN^VGW:_(Z\9+EKR=M.9_+?7^NY\"?\-8
M_&__ *+)\0/_  J+[_X[7FNK:O?^(-4N]3U2]N-2U*\E:>YO+N5I9IY&.6=W
M8DLQ))))R2:_IP^)'Q8\'_!_PS/X@\9>(]/\/:3"I;S[V<*9,#.V-?O2,<<*
MH)/85\O?!?\ X*N?!3XL>)KK0M3N[KP)<_:&BL;K7PJ6EY'D[&\X';$Q !*R
M;0,@!F-.-I2Y5O\ U_5B)7C'F>QUW_!,_P 03>(OV)_AO+.YDEMH;JRYSPL5
MU,B#\%5:^H*9#,EQ$DL3K)&ZAE=#D,#R"#W%/K:K/VE24[6N94XJ$%%;(*^,
MO^"MWBK_ (1W]C/6[(2;'UK5+&P4?WL2^>1^4!K[-K\S_P#@MYXK^R_#GX9^
M&U<@WVJW.H,H](8E09_\"#7#B/A275Q_-?H=F'^._9/\F?EE\)?!B_$;XI^#
MO"CRF"/7-8L]-:5>J":9(R1[@-7]-7AGPWIG@WP[IF@Z-9Q:?I.FVT=I:6L*
M[4BB10JJ![ "OY@/"/BB^\$^*]&\1:8XCU+2;V&_MG89 EB<.A(],J*_?CX'
M?\%#O@I\8/ ]EK%]XYT/P7K'E*+_ $?Q%J$5E);S8^94:5E$JYZ,A.1C.#D#
MTKIT++=-W^Y6_7TOYG!M5N^VGZ_I]WD7O^"AWAW3_$O[&GQ/BU%4*6NF_;H6
M;'RS12(\9'N6 '_ L=Z_GCK]//\ @IM_P4(\+_$KP;-\)_AEJ2ZWI]U,CZYK
MMOD6\BQL&6WA8X\P%U5F<?+A0 6R<?$'[)WP3O?V@OC_ .$/!MM TMI<7B3Z
MC(HR(;.,AYW)[?*"HSU9E'>N+#4W5KM[)V7W;R_KHK['77FJ5%7U:N_^!Z_Y
M]S]4/^"G7BJX\/?\$_\ 0].N7*7NM3:38RJ>I98_/?I[PU^1'P1\!?\ "TOC
M%X)\($,8];UFTL)2AP1')*JN1]%+'\*_2_\ X+>^*A:>%OA7X4BPJ3W=YJ+H
M.WE)'$G_ *.?\J^1/^"8'A4^*?VU? 1*;X=-^UZC)QT\NVDVG_OMDK?"R57%
M3JM:.5_DDK_DSGQ$71PL*:>JC;YMNWWZ'[YZ3I=IH>EV>FV%O':6-G"EO;V\
M2[4CC10JJ!V   _"O/?VG/%EWX%_9U^)?B"P<Q7VG>';ZXMY!U200/M8>X.#
M^%>FUP_QR\!R?%#X,^.?"$+;)]<T6[T^)CT$DD+*A/MN(KEQ5Y4:E]6T_P C
MJP]HU(=$FC^8^O0/"_[0OQ4\#Z';:+X<^)?C#0-'MMWD:?I>O75M;Q;F+-MC
M20*N6))P.22:X?4-/N=)U"YL;V"2UO+:5H9H)5*O&ZDAE8'H0001[5^W'_!+
M/]JGPQ\1O@/H/P[U#5[6R\;>%XC8C3[F58Y+RU#$PRP@GYPJ$(P'(*Y( 89Z
MX1YX-Q?;YKO\OU.:<N2:4E_P&?DC-^U7\:[B%XI?C#X^EBD4JZ/XGO2K C!!
M'F\BO+02I!'!%?TI_'[]ISX??LU^$[K6O&>O6UK.L3/:Z1%(K7UZPZ)%%G<<
MD@;CA5SEB!S7EO[-/_!1WX1_M'R6NE1:DW@_Q=,0BZ#KKK&TSG Q!-]R7).
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M0C()+M.H\H*H4DX<M@=#7<?M$?#^?XJ_ GQ]X0M3B\UG1+JTM\]/.:)O+_\
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ME*M-K:[_ #./#W5&%^R"O&OVRO%7_"&?LJ?%751)Y4B>'KN"-LXQ)+&8D_\
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M+;_#6]U#PO\ #KQY;1/)9Z;<7.E7C*"1'YP1XF/H,Q2#/JRCO7YO_LU?%X_
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M8<_,4[J:^&?V>?V"_BI\4OC%X:\/>)OA]XL\*>&I[D2:GJVK:-<V<,-LGS2
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MCR*WK^+N%<_\0O$ESX/\"^(-<LM+O-;O=.L)[J#3=/@>:>ZD1"R11H@+,S$
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MUAI,VTMKNM1/9V"(?XQ(XS(/:(.WM7[3_L=?L6^$?V1/!\EMIK#6O%FH(O\
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MFYR3&B?>GC'\)7+@$ J<;S\#:YX:U?POJ<FFZSI5[I.HQMM>TOK=X95/H48
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MO5KN+7O"-]J6C0EC'X@T:%[JQD0?QEU&8O\ =D"G@\8YK^BZBL>2TG*/7?\
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MDWN?F3_P4#_X)@ZC\1/$FH_$KX0VT,NM7SF?5_#+.L0N93]Z>W9B%#L>61B
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MU;\_\[G\[?P=_9 ^+VI_%OP5::Q\)O&VGZ1-K5E'>75[X=O(8(8#.@D>1VC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIHKHC-PUCN8RBI;[!1116984444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3:I?+8Z;9WQ;R>%+R2N%96*JHQ@$<NO-1.:@KO\ J^A<8N;LCZ4HK\D/@?\
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M6Q]&S[U]D?LF_P#!7VT^('B33_"?Q>TBQ\.7M]*L%MXCTLLED9&.%6>)V8Q
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MS@.9,C&0IX&;FN;E6K+46US=#]<:*_!&W_X*C?M/VEQ'?R^.$GL]X(AF\/V
MA?G[NY8 V.#T;/O7U;^S#_P6,F\6>*]*\,?%GPU9:>=1N$M8O$&@[UBB=V"I
MYT#LQVY/+J_']RMX0<WRQW,9S4%S/8_4&BBBH+"BBB@ HHHH BNKJ&RMY;BX
ME2"WA0R22RL%5% R6)/  '>N.\'_ !P^'/Q#U9]*\*^/_"_B;4XT,CV6CZS;
M7<RJ#@L4C<L /7%9'[3W_)MGQ6_[%35?_226OQK_ ."2W_)ZGAO_ +!VH?\
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M4I\D82_F5_Q:_0YHRYG)=G^B?ZA1116)H%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_DR3X9?]>]U_P"E<U>P?'O_ )(9\1/^Q=U#_P!)I*\?_P"":?\ R9)\,O\
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M!?6%UXXM(+BUN8Q)%-&U\H9'5@0RD$@@\$&OW[_X9I^$/_1*O!/_ (3MG_\
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MT&E1VVE&2,Y#210KY@^JNSK_ ,!KEG>-:'+UO?T[_)V7S.F'O4I<VRM;UO\
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MM]!:]CUOP9=7RQ[_ .S8]0N!(QQG8':W";NW+!?]JO,=6_:9^,/P9^%?C_\
M9X^)=E?W-E=6JV<%IK3G[5I+K(CJ8I#GS(&5,!<E<%60@9#37BJE*=-/WK:>
M9="3A5A4M[J:OY:GJO\ P19_Y.C\2?\ 8I7/_I7:5^U=?BI_P19_Y.C\2?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMK'A[581<:9JMG+8W,1_BCD0HP_(FOYVO!NKZS^QK^UO9W%T)!?>"O$+6]V
MN#/;JYCEP/22%FQ[.#7V?_P_$U__ *)+IO\ X.Y/_C-?#_[4WQZA_:6^,%_X
M_7PQ!X5N]0@ACN[2WNC<+++&NSS=Q5<$HJ C'\.>]*#E2Q$:T?G\M5\MU\QR
MY:E&5*7R_)_I]Q_2%IFI6VLZ;::A93+<6=U"D\$T9RKQLH96!]""#2WVI6FE
MPB6\NH;2(G:))Y BY],D]:^2?^"6?QJ_X6Y^RGHNGW4_FZQX2D;0[D,?F,2
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MZ]45G*%WS+1EQFTN5ZH_FX^'OQF^,G[(/C*ZM-$U77/ VJPR WNAZA"R12'
M_P!=:RC:21T8KG!X(K]2OV-_^"K'AWXWZMIW@WXCV5MX/\97;"&TO[=C_9M_
M(> @W$M#(QX"L64G@,"0M?7'QJ_9]^'_ .T)X;?1?'?ANSUN#:1!=.FVZM2?
MXH9A\\9R!T.#C!!'%?@K^V?^R[>_LE?&BY\*&]DU/1;F%=0T?4)%"R2VS,P
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MPS\WVZ#&/?K7Y^_\$68W;]J#Q,X5BB^$[@%L< F[M<?R/Y5S8)?O:L>C3_\
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M 9K\\/\ @N/_ ,?/P@_W-4_G:U>-DI5^:.SD_P!2<"G&E:6_+^AI_P#!&_\
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M(T"Y\5_#OQ1HEG)Y5WJ6EW5G#)G&UY(F13GZD5^._P#P19_Y.C\2?]BE<_\
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M'D '/'0UPU/CI^OZ,[Z+7)47E_[=$^R?^":?_)DGPR_Z][K_ -*YJ]@^/?\
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M*P:*P#?Q7<O[N 8[_.ZD^P->KVEI!86L-M;0QV]M"BQQ0Q*%1% P%4#@  8
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M-5R.S,]/#3YH_6)*S2LO)W?Y-MW\EY!B(<K]A':3N_2R_-)*WF_,^IJ_+/\
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M -&"OM.ODS_@E_\ #_Q+\-?V3=(TCQ7H.H>'-6;4KRX^P:I;M;SK&TGREHV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX)'O7T+7H8AJ55M''134=>[_ #"BBBN<V"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#*'IO_ ,CT?\/)OVC?^BB_^4/3?_D>OF:B@#Z9_P"'DW[1O_11?_*'IO\
M\CT?\/)OVC?^BB_^4/3?_D>OF:B@#Z9_X>3?M&_]%%_\H>F__(]'_#R;]HW_
M **+_P"4/3?_ )'KYFHH ^F?^'DW[1O_ $47_P H>F__ "/1_P /)OVC?^BB
M_P#E#TW_ .1Z^9J* /IG_AY-^T;_ -%%_P#*'IO_ ,CT?\/)OVC?^BB_^4/3
M?_D>OF:B@#Z9_P"'DW[1O_11?_*'IO\ \CT?\/)OVC?^BB_^4/3?_D>OF:B@
M#Z9_X>3?M&_]%%_\H>F__(]'_#R;]HW_ **+_P"4/3?_ )'KYFHH ^F?^'DW
M[1O_ $47_P H>F__ "/1_P /)OVC?^BB_P#E#TW_ .1Z^9J* /IG_AY-^T;_
M -%%_P#*'IO_ ,CT?\/)OVC?^BB_^4/3?_D>OF:B@#Z9_P"'DW[1O_11?_*'
MIO\ \CT?\/)OVC?^BB_^4/3?_D>OF:B@#Z9_X>3?M&_]%%_\H>F__(]'_#R;
M]HW_ **+_P"4/3?_ )'KYFHH ^F?^'DW[1O_ $47_P H>F__ "/1_P /)OVC
M?^BB_P#E#TW_ .1Z^9J* /IG_AY-^T;_ -%%_P#*'IO_ ,CT?\/)OVC?^BB_
M^4/3?_D>OF:B@#Z9_P"'DW[1O_11?_*'IO\ \CT?\/)OVC?^BB_^4/3?_D>O
MF:B@#Z9_X>3?M&_]%%_\H>F__(]'_#R;]HW_ **+_P"4/3?_ )'KYFHH ^F?
M^'DW[1O_ $47_P H>F__ "/1_P /)OVC?^BB_P#E#TW_ .1Z^9J* /IG_AY-
M^T;_ -%%_P#*'IO_ ,CT?\/)OVC?^BB_^4/3?_D>OF:B@#Z9_P"'DW[1O_11
M?_*'IO\ \CT?\/)OVC?^BB_^4/3?_D>OF:B@#Z9_X>3?M&_]%%_\H>F__(]'
M_#R;]HW_ **+_P"4/3?_ )'KYFHH ^F?^'DW[1O_ $47_P H>F__ "/1_P /
M)OVC?^BB_P#E#TW_ .1Z^9J* /IG_AY-^T;_ -%%_P#*'IO_ ,CT?\/)OVC?
M^BB_^4/3?_D>OF:B@#Z9_P"'DW[1O_11?_*'IO\ \CT?\/)OVC?^BB_^4/3?
M_D>OF:B@#Z9_X>3?M&_]%%_\H>F__(]'_#R;]HW_ **+_P"4/3?_ )'KYFHH
M ^F?^'DW[1O_ $47_P H>F__ "/1_P /)OVC?^BB_P#E#TW_ .1Z^9J* /IG
M_AY-^T;_ -%%_P#*'IO_ ,CT?\/)OVC?^BB_^4/3?_D>OF:B@#Z9_P"'DW[1
MO_11?_*'IO\ \CUV_P "_P#@H%\?/&7QM^'V@:QX\^V:3JOB'3[&\M_['L$\
MV&6YC21-RP!ERK$9!!&>"*^+Z]*_9E_Y.1^%'_8V:3_Z614 ?T,T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'YF_P#!9_\ YH]_W&/_ &QK\SJ_3'_@L_\
M\T>_[C'_ +8U^9U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z5^S+
M_P G(_"C_L;-)_\ 2R*O-:]*_9E_Y.1^%'_8V:3_ .ED5 ']#-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH^GW5_?7$5G96L33SW$[A(XHU!9G9CP  "23TQ0!9J.:XBMU#2R)$I8*&=@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7I7[,O_)R/PH_[&S2?_2R*O-:]*_9E_Y.1^%'_8V:3_Z614 ?T,T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD&&'^TW%G=2,K>Z*4C_[9BL?_@BC_P G*>,/^Q3F_P#2RUH _:"OYF/VB/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z
M5^S+_P G(_"C_L;-)_\ 2R*O-:]*_9E_Y.1^%'_8V:3_ .ED5 ']#-%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXAZEKTGB[QE=:UXDN[B>75+]KS4KN%%>9S)(7E=5) +'<Q ) )[BOV \/?\
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MY1&TP09VAB#C/K@T =M17Y@?\/QM#_Z))J'_ (/(_P#XQ1_P_&T/_HDFH?\
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M^E4=?TT+]T4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!^9O_!9_P#YH]_W&/\ VQK\SJ_3'_@L_P#\T>_[C'_MC7YG4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7I7[,O\ R<C\*/\ L;-)_P#2R*O-
M:]*_9E_Y.1^%'_8V:3_Z614 ?T,T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_7\^O_!,[5K'0_VW/AO?:E>6^GV47]I>9<W4JQ1IG3;H#+,0!DD#ZD5^[_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7I7[,O_)R/PH_[&S2?_2R*O-:]*_9E_Y.1^%'
M_8V:3_Z614 ?T,T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIOE?:[+^R+^?R_,B25/GB@9#E)$/#'&<'D$5] 5^ /\ P5&_Y/L^)G_<,_\
M37:4 ?JI_P /1OV8O^BF?^4#5/\ Y&H_X>C?LQ?]%,_\H&J?_(U?@#10!^_W
M_#T;]F+_ **9_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-7X T4 ?O]_P]&_9
MB_Z*9_Y0-4_^1J/^'HW[,7_13/\ R@:I_P#(U?@#10!^_P!_P]&_9B_Z*9_Y
M0-4_^1J/^'HW[,7_ $4S_P H&J?_ "-7X T4 ?O]_P /1OV8O^BF?^4#5/\
MY&H_X>C?LQ?]%,_\H&J?_(U?@#10!^_W_#T;]F+_ **9_P"4#5/_ )&H_P"'
MHW[,7_13/_*!JG_R-7X T4 ?O]_P]&_9B_Z*9_Y0-4_^1J/^'HW[,7_13/\
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M_(U?@#10!^_W_#T;]F+_ **9_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-7X
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M0-4_^1J/^'HW[,7_ $4S_P H&J?_ "-7X T4 ?O]_P /1OV8O^BF?^4#5/\
MY&H_X>C?LQ?]%,_\H&J?_(U?@#10!^_W_#T;]F+_ **9_P"4#5/_ )&H_P"'
MHW[,7_13/_*!JG_R-7X T4 ?O]_P]&_9B_Z*9_Y0-4_^1J/^'HW[,7_13/\
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M_(U?@#10!^_W_#T;]F+_ **9_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-7X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS+_R<C\*/^QLTG_TLBH _H9HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH S]>OGTW2;JYC^]'&6'X5_.W^
MW%XON/'?[5/C[6KK_7S7%O$>,<1VL,0_1!7]#WBK_D6]1_ZXM_*OYPOVIO\
MDX+QK_U^C_T6E $/[//A"V\:>-+VQNO"_P#PED<>GO,++S9H]A$D8\S,3JW&
MXC!./FZ=*^A?^%!:1_T17_R>U'_X_74_\$5XTD_:F\4AU5Q_PAET<,,_\OUC
M7[2_9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ
M_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\
MO@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\ C]'_  H+2/\ HBO_ )/:
MC_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /PQ_P"%!:1_T17_ ,GM1_\
MC]'_  H+2/\ HBO_ )/:C_\ 'Z_<[[)!_P \8_\ O@4?9(/^>,?_ 'P* /YE
MOC7X=A\*_$;4M-M]#_X1R*)82--\R5_+S$K9S(S-SG/)[UV/[%_BRX\#_M/>
M =:M?]?;W<BKQG[\$D9_1S7I?_!51%C_ &X/'2JH5?L^F\ 8_P"7&"O%OV:/
M^2\>#/\ K^'_ * U '])/AO4)-4T6TNI/ORQACQ6G6+X+_Y%;3/^N*_RK:H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /S-_P""S_\ S1[_ +C'_MC7YG5^F/\
MP6?_ .:/?]QC_P!L:_,Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M]*_9E_Y.1^%'_8V:3_Z615YK7I7[,O\ R<C\*/\ L;-)_P#2R*@#^AFBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#)\5?\BWJ/_7%OY5_.%^U-_R<%XU_Z_1_Z+2OZ/?%7_(MZC_UQ;^5
M?SA?M3?\G!>-?^OT?^BTH ^JO^"*G_)TWBG_ +$RZ_\ 2ZQK]J:_%;_@BI_R
M=-XI_P"Q,NO_ $NL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R?%7_(M
MZC_UQ;^5?SA?M3?\G!>-?^OT?^BTK^CWQ5_R+>H_]<6_E7\X7[4W_)P7C7_K
M]'_HM* /JK_@BI_R=-XI_P"Q,NO_ $NL:_:FOQ6_X(J?\G3>*?\ L3+K_P!+
MK&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\#O^"JW_)\/CK_ *]]-_\
M2&"O%/V:/^2\>#/^OX?^@-7M?_!5;_D^'QU_U[Z;_P"D,%>*?LT?\EX\&?\
M7\/_ $!J /Z0O!?_ "*VF?\ 7%?Y5M5B^"_^16TS_KBO\JVJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S@_;;_
M .2_:G_UYVO_ *+%>O?LM_LZ_#WXC?"&QUOQ%X?_ +0U.2YGC>?[;<1957(4
M;4D5>![5[/\ $3]F#P/\4?%$VOZ[!?2:A+&D;-!=&-<*,#C'I7:?#OX>:/\
M"[PO#H&A)-'I\4CR*L\AD;+')Y^M 'G_ /PQW\(?^A1_\J5Y_P#'J/\ ACOX
M0_\ 0H_^5*\_^/5[-5:;4[.VD,<UW!%(.JO(H/Y$T >1?\,=_"'_ *%'_P J
M5Y_\>H_X8[^$/_0H_P#E2O/_ (]7K/\ ;6G_ //_ &O_ '^7_&C^VM/_ .?^
MU_[_ "_XT >3?\,=_"'_ *%'_P J5Y_\>KE/BQ^RO\+O#/PP\6:MIOAC[-J%
MCI=S<V\W]H73[)$C9E;#2D'! X((KZ$&M:>>!?6Q/_79?\:B\2>'[3Q9X>U+
M1;\.UCJ%O):SB-MK%'4JV#V.#0!^67P)_P"2T^!?^PW9_P#HY:_5^O$?#?['
MOPZ\)^(=-UJPMM06^T^XCNH#)>%E#HP9<C'(R*]NH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\S?^"S_ /S1[_N,?^V-
M?F=7Z8_\%G_^:/?]QC_VQK\SJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "GQ_>XIE2P'Y^O%)[$RV+5O:F5L@9:KLFG$8P/FQ5C
M3XP-C+QGK6Q)"RX*KG\*\RI6<96/(JXAQE9',+8L/O# HN+<)"<_A77I8K?*
M%2,E_0"JNL>%KY8T98&*MZ"LXXJ+DE)V,HXV+FHS=CA\?+3:V+CP[?V^6>UD
M [<5E21M"Q5U*M[UZD)QG\+N>S"I"?PNXRBBBM#4**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **SM5\1:5H2J=2U.ST\-T-U<)%G_ +Z(J+2_%FAZ
MY,8M-UG3]0E'\%K=1RM^2DUE[:GS<G,K]KZFWL:CCSJ+MWMH:U%%%:F(4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#\S?\ @L__ ,T>_P"XQ_[8U^9U?IC_ ,%G_P#FCW_<8_\ ;&OS.H ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7I7[,O_ "<C\*/^QLTG_P!+(J\UKTK]F7_DY'X4?]C9I/\ Z614 ?T,T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 9/BK_D6]1_ZXM_*OYPOVIO^3@O&O_7Z/_1:5_1[XJ_Y%O4?^N+?
MRK^<+]J;_DX+QK_U^C_T6E 'U5_P14_Y.F\4_P#8F77_ *76-?M37XK?\$5/
M^3IO%/\ V)EU_P"EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M45/_ *]_K(^QPO\ R3F(_P :_P#;3WVBBBOL3XH**** "BBB@ HHHH ****
M"BBB@ HHHH **** /P._X*K?\GP^.O\ KWTW_P!(8*\4_9H_Y+QX,_Z_A_Z
MU>U_\%5O^3X?'7_7OIO_ *0P5XI^S1_R7CP9_P!?P_\ 0&H _I"\%_\ (K:9
M_P!<5_E6U6+X+_Y%;3/^N*_RK:H **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ,@'7?\ KY7_ - %>WZWHMEXBTJXTW48?M%E<+MEBW,NX9!ZJ01R.QK.\(^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^P986>@7>H^!]2OY;^WC,HTN_*2B?')2-U52K8Z @Y/&1G- 'QWHG_(:L/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6O)?/X/\<PQK"-;M;<31W48QM2XBW+OP,A7#*PSSN "C.+E2JJK%7NK->7_
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M>@76/DN+:ZDF&>VY96;(]ACZUE_M<?>T?E_7^9\W&?%U:/MU&E'^X[W].O\
MZ4OD>R>'?%&D>+M-34-%U*VU2R?I-:R!USZ''0^QYK4K\[M0LO&O[(?Q(B:&
MY\^SFPZLI(MM0A!Y#+V89^JGID'G[R\!^,K'X@>$M,U_3CFUO8A(%)R4;HR'
MW!R#]*Z*%:->+:5FMT>ODF?2S&I4P6+I^RQ%/XH]&NZ\MOO5FT87CCXY^"/A
MOK$6E^(];_LZ_DB$RP_9)Y<H20#E$8=0>]=Q#,EQ"DL9W1NH96QC(/2OA/\
M;B_Y+!IO_8,B_P#1DE?<>B_\@>Q_ZX)_Z"*G#U95E-RZ2:^ZY>79M7Q>:XO
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M/!G_ %_#_P! :@#^D+P7_P BMIG_ %Q7^5;58O@O_D5M,_ZXK_*MJ@ HHHH
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M)[PQ@1K_ ./"3]*^DJS_  _H-CX7T.QTC3+=;73[*%8((5Z*JC ^I]3W-:%
M!1110 4444 ?+_CC_E(I\,?^Q&U;_P!*(J^H*^7_ !Q_RD4^&/\ V(VK?^E$
M5?4% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?F;_ ,%G_P#FCW_<8_\ ;&OS.K],?^"S_P#S1[_N,?\ MC7YG4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!14L$!G; XK:L=-BZ29(]JRG44-S&I5C36I@45U%QX=CF0RP'D=C6;'I+2,5
MP0U9QQ$)*YE'%4Y*Z9EA<]J0K77V'@R[O("\418#TJ6/X?W[V[.D#-CVK%XV
MC%V<CG>88>+LYHXJM*RTE[J/(4Y[5IKX3O0_[R!E5>^*Z.UMHM-A4$9;%16Q
M<4OW;NS.OCHQBO9N[,9-%:TC5V7FO1OA)KTVDWTAMWV3-C;@XKC-5U$2)A,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-9O]>T[4KW4[L+%!+8P1.(XQDL,O(I!)QT_NBO?/^&\/ /\ T"/$G_@-;_\
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M5=VFONYD=];+\=E>48_#5ZG/147[-MWDE;5/3TM\]$CJOV/?^2$Z+_UUN/\
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M/[VKA1113/HC\#O^"JW_ "?#XZ_Z]]-_](8*\4_9H_Y+QX,_Z_A_Z U>U_\
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ML-S!;M=VS"5T<,JX5<G)&..:^I:_*#X$_P#):? O_8;L_P#T<M?J_0 4444
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M_P"Q&U;_ -*(J^H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDD5CEN41C*5:KHV<^49#&$I8BLK2;+_B!?M<VY.2?2LNUT5Y,DCC-:6G1O,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 9/BK_ )%O4?\ KBW\J_G"_:F_Y."\:_\
M7Z/_ $6E?T>^*O\ D6]1_P"N+?RK^<+]J;_DX+QK_P!?H_\ 1:4 ?57_  14
M_P"3IO%/_8F77_I=8U^U-?BM_P $5/\ DZ;Q3_V)EU_Z76-?M30 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQK\SJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY.F\4_\ 8F77_I=8U^U-?BM_P14_Y.F\4_\ 8F77_I=8U^U- !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW^U-\(OBQJ?]F^$_B+X>UK4R0%L8;Y%N),_W(VPS_P# 0: /4Z*** "BBB@
MHHKF_'7Q*\)?"_25U/QAXFTGPOI[-L2YU>]CMD=L9VJ7(W-CL,F@#I**^?V_
M;\_9Y6_>S/Q8\/\ FKU82N8^I'$FW:>1V/3!Z&O9?"/CCP[\0-'35?#&O:;X
MBTQSA;S2KN.YA)ZXWH2,^U &W1110 45A^,/'/ASX>Z,^K^*=?TSPWI2,%:^
MU:\CM80QZ#>Y R>PSS7CEU^WU^SS:7IM7^+'A]I0"VZ*9Y(^,?QJI7//3/KZ
M&@#W^BN;\#?$KPG\3M+_ +2\(>)M)\3V QNN-)O8[E4)Z!BA.T\'@X/!KI*
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M_P T>_[C'_MC7YG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+(J /Z&:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^C_T6E?T>^*O^1;U'_KBW\J_G"_:F_Y."\:_]?H_]%I0!]5?\$5/^3IO%/\
MV)EU_P"EUC7[4U^*W_!%3_DZ;Q3_ -B9=?\ I=8U^U- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?@=_P56_Y/A\=?]>^F_\ I#!7BG[-'_)>/!G_ %_#_P!
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M8)%$I/0L[*,X.!DXXKXM_P""+/Q3F\2?!7Q=X&NI?,?PSJ:75L&/W+>Z5FV
M>@EBF;_MI7%_\%MOBM/;:;\/?AQ:SLD5TTVN7\:MC<$_=6^1W&3.>>X'I0!\
M=:;8?&;_ (*7?M 7*BY:^O92UPYN)733-#M,@ *.=B#@ *"[GD[CN-?8TO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8K\3?IIO_ISM:^J*^5_^"H?_ "8K\3?IIO\ Z<[6@#X<_P"")/\ R6KX@?\
M8 3_ -*$K]BZ_'3_ ((D_P#):OB!_P!@!/\ TH2OV+H **** "BBB@ HHHH
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MF6<-I9V\5I:PH(XH($")&HX"JHX 'H*GJ"^O$T^QN+J17>."-I66-2S$*"2
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;=,A4'Z@+@_C7F7B3]I#P!\#/B)=>"I?#?\ 8UK D)>\TBVB6)2Z!P&C4*0
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M3P_XXMI?M$:=!LF;$RC ^7)9!@84BOU*_8M_;;T#]LK0M?FTWP_?^&]8\/\
MV8:C9W4B30_O_-\LQ2K@N/W+YW(I''7->Q_$KX1>"_C%H3:/XV\,:9XFT_G;
M'J%NLC1$]6C?[T;?[2D'WKSC]FW]CGP+^RGKWC6]\"2:E!8>*/LAETV^N!/'
M:&W,^T1.1OVGSSPY8_+UYH ]VHHHH \(_;L\&-X^_9!^*NDI$9I%T62_2-1D
MLULRW*@#US",5^8/_!&KQQ#X=_:DU/0KB78OB#0+B"!/[\\4D<P_*-)C7[87
M5K%>VTMO<1+-!,ACDCD&5=2,$$=P17\]/Q>\$^*OV!_VO"^F;HYM U-=4T.Z
MD!$=[9,Q* GN&0M$X!Z[Q0!_0W17SE\!_P!OKX.?'/PC:ZG'XPTKPMJXB4WV
MAZ]>QVD]M)QN"F0J)4ST=,@@C(4\#R/]N3_@I%X(^%/P[U;P[\.?$]CXG^(.
MI0M:P7&CSK<0:6&&&G>524+J"=J D[L%@ .0#\NOVD+R3X[_ +:GC2+17-VV
MO>+7TRP=>?-!G%O$1[$!<>QK^B;3[&+3=/MK.!=L%O$L4:^BJ  /R%?BQ_P2
M._9ON?B=\;I/B5K%D\OAKP@2]O-*/DGU-@/+4>IC5C(?1O*]:_:^@ HKX@_:
M0_X*F>%OV</C-XA^'>I>!]8UB]T?[/YE[:W421R>=;Q3C ;D8$H'U!KZF^"'
MQ4M?C=\)_#/CJQL9M,M-<M!=QVEPX:2($D8)'!/':@#\BO\ @LYX/?1/VG=$
MUQ(R+?6_#T#&3& TT4LL;#/?""+\Q7Z9?L%^+HO&G['?PHOXI/-$&B0Z:Q]&
MM2;9A^!A->0?\%6_V;+_ ..'P'M_$F@V_P!J\0^"9)M06W1<R3V;J/M*)CJP
M$<<F.XC8#DBOCS_@F7^WYH?P!L[KX;?$2>:T\)7MT;O3M8 ,B:=,X >.10"1
M$Y&[<N=K%B1AB5 /V>KX7_X+%>+(=!_9-ATHR8N-;UZTMDC'5EC629B?8&-?
MQ(KZ3U3]JSX,Z/X?DUNZ^*?A$::D7G>9#K-O*S*1D;41BS$_W5!/M7XS_P#!
M03]L)OVQOBEH^F^$[.[_ .$0T1GM='@:,_:+^>5E#S&,<@L5147J .Q8@ 'T
M9_P0_P#!LDFL?%/Q7(I6**"RTR%L<,S-))(/P"1?]]5QO_!:[P2VE?'/P5XI
M2)DM]8T(VC28^5Y;>9RW/KLGB_2OT,_8._9R'[,_[.N@^'KR!8O$NH?\376V
MX)%U*J_N\_\ 3- D?'!*$]ZYG_@I)^S/>?M(_L\W,6A0"?Q7X;F.KZ;"%R]R
M%1A-;J?5T.0.[1H.,YH A_X):>+(?%'[%/@B))/,N-)EO=.N!_=9;J1T'_?N
M2/\ .OK.OPW_ .";/[<UA^RSK^K^$/' N5\#:Y<+.UU$C.VEW078TIC RR.H
M0/C+#RU(!Y%?KJO[57P:?0/[:'Q4\'_V;Y7G>=_;=N#M_P!W?NSVVXSGC&:
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M[>GBN+P;^QY\5[^:3REFT273U/JUR5MP/Q,M=/I?[5OP9UGP_%K=M\4_"/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?#'_ +$;5O\ THBKZ@KY?\<?\I%/AC_V(VK?^E$5?4% !1110 4444 %%%%
M!1110 4444 %%%% !1110!YU^T-\(?\ A?7P7\5^ /[6_L+^W;46W]H?9OM'
MD8=7W>7O3=]W&-PZU\M?LA_\$P?^&5?C);>/?^%E_P#"4>39SVG]G_V#]DSY
MB@;O,^TR=,=-O/M7W510 4444 %%%% !1110 4444 %%%% !1110 4444 %>
M1?M)?LM^ OVIO!Z:%XUT]WEMBSV&JV;".[L9&&"T;X((/&48%3@9&0"/7:*
M/Q[\;?\ !$?Q]::E*/"'Q!\-ZKI^[,;:W%<64H'/!$23 D<<Y&?0=*Z+X2_\
M$2M4_M2"X^)GCZQ2PC<&73_"\4DCS+G[HGF1-GU\MJ_6*B@#E_AK\,_#/P?\
M%Z9X3\(:3#HN@Z?'Y<%K!D^Y9F/+.QR2S$DDY)KJ*** /@#]J3_@E+_PTK\=
MO$OQ'_X6C_PCG]L_9?\ B6?\(_\ :O)\FUB@_P!;]J3=GRMWW1C=CG&3]??
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MZX_X(H?&);T+!XQ\#R6F1F62ZO$DQW.P6Q&?^!?E7[044 ?#'[)?_!*OP7\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\S?^"S_P#S1[_N,?\
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MF+UXK.N"N"N>:T6PB%<UEW156Z9-8T]S"CN5#Z4E*?7-)78=X4^,C.#TIE%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7=>+)?*A$B<AO2O.I9#)(6/6OJ\!&ZYS[;+(\T?:#****]<]T**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_4T ?K>_PW\(R2F5_"VBM*3DNVGPDY]<[:W+.QM]/MU@M;>*V@7[L<*!%'T
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MK>:A$$/RYKZ^T^[L;#PG#'*%9E3'([U\%^%?&,OAZY7;@@&OHKPOXT'BS28
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M*** "OEK_@IG\0KSX=_L;^.)]/E:"\U40Z.LB]0D\@64>V8O,'XU]2U\L_\
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M_P""*G_)TWBG_L3+K_TNL:_:FOQ6_P""*G_)TWBG_L3+K_TNL:_:F@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"K?2;(6^E<G+(S2-DYYKI-9DV6YKF/XB:\
M;&R]Y(]C!Q]UL6BBBO-/0"BBB@ HHHH *3IS2TC=* .HT5MUJOTK1K#T2;:J
MKFMROH\/+FIH^?KQY:C"BBBN@YPHHHH **** "BBB@ HHHH _ [_ (*K?\GP
M^.O^O?3?_2&"O%/V:/\ DO'@S_K^'_H#5[7_ ,%5O^3X?'7_ %[Z;_Z0P5XI
M^S1_R7CP9_U_#_T!J /Z0O!?_(K:9_UQ7^5;58O@O_D5M,_ZXK_*MJ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_L1M6_]*(J^H*^7_''_ "D4^&/_ &(VK?\ I1%7U!0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\_?MY?&CQ%\ OV7?%_C#PH\,&OP
M?9[6UN9XQ(+<S3)$90IX+*KDKG(W 9##(/T#7R%_P5=_Y,D\8_\ 7WIW_I9%
M0!^?GPET7]NGXY^![/QAX*\6>+=8\/7CR1PW9\600;FC<HXV2SJPPRD<CM78
M_P#"B/\ @HK_ -!GQ9_X6EG_ /)-?:'_  2?_P"3)?!__7YJ/_I9+7U_0!^.
M'_"B/^"BO_09\6?^%I9__)-'_"B/^"BO_09\6?\ A:6?_P DU^Q]% 'XX?\
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M_DJ'Q/\ ^P5:_P#HYZ_7J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ#[4OG;,\TFTMQI-[$]%
M%%,0444E &/X@;_1\"N?6M?6I-P(K(%?/XI\U1GO89<M-(6BBBN0Z@HHHH *
M*** "DI:* +NCR%;I1[UU5<=8MMN ?>NN@;=&#7LX*7NM'D8R/O)DE%%%>D>
M<%%%% !1110 4444 %%%% 'X'?\ !5;_ )/A\=?]>^F_^D,%>*?LT?\ )>/!
MG_7\/_0&KVO_ (*K?\GP^.O^O?3?_2&"O%/V:/\ DO'@S_K^'_H#4 ?TA>"_
M^16TS_KBO\JVJQ?!?_(K:9_UQ7^5;5 !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!^;'[0/QV\;Z]XM\:>$-
M0U>*[\.V^L75O#9R6%L?+2.=UCVOY>\$  ;MV>O/)KQ;3]2N])NX[JQNIK*Z
MC.4FMY#&Z_1@<BOO_P 5_L-^$_%WBC6-<N=>UF&XU.\FO9(XC%L5I'+D+E,X
M!;O65_P[Y\&_]#'KOYP__&Z /CY/C/\ $&-%1/'7B5548"KJ]P !Z??IW_"Z
MOB'_ -#YXF_\'%Q_\77U_P#\.^?!O_0QZ[^</_QNC_AWSX-_Z&/7?SA_^-T
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M_MC7YG5^F/\ P6?_ .:/?]QC_P!L:_,Z@ HHHH **** "BBB@ HHHH ****
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M#GVZ5X[XBT.;2=1N()AM=2?E_&MSP#XX>SF1)"V=P&:Z'XCZ++J4IU.--Z2
M?=KS:'M,#BG3J/W9?F>/AO:Y;C71JOW);>IX]=*&0@]1TJ@T9]*VKR 0LQ=>
M?2JUC9R7DV$7/MBOKX5$HW/O(5%&-^AT/@&$+?1,R_*""<U[7-Y-_9[8XUW
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M*)9;#+S4+1C&/RJ9L[1BH9&*KQ4Q\B(D$@*G!XIE/V[N1S367%;(Z%V 48-
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MK]"PL81HQC3V/U3!QIPP\(TMD@HHHKJ.T**** "BBB@ HHHH **** "BBB@
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M.>BL<D8^7KG%?J;115RFY**?33\6_P!2(Q46VNO^5OT"BBBH+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,GQ5_R+>H_]<6_E7\X7[4W_
M "<%XU_Z_1_Z+2OZ/?%7_(MZC_UQ;^5?SA?M3?\ )P7C7_K]'_HM* /JK_@B
MI_R=-XI_[$RZ_P#2ZQK]J:_%;_@BI_R=-XI_[$RZ_P#2ZQK]J: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI
M,T +1137;:I- $-U=+ AR>:P;6Z-QJ0?MFDU>\,DI ^E5+%MEP#[UXU:NY5%
M%;)GL4:/+3;>[.Q!S2U' VZ,&I*]A:H\AZ,*0]#2TUVVJ:8'*ZI)NF853J:^
M^:Z;ZU#7S%1WFSZ.FK104445F:!1110 4444 %%%% #H?ED!KK[,Y@6N-R5;
M-=?IIS:K7IX%^\T>;C%[J9:HHHKV#R0HHHH **** "BBB@ HHHH _ [_ (*K
M?\GP^.O^O?3?_2&"O%/V:/\ DO'@S_K^'_H#5[7_ ,%5O^3X?'7_ %[Z;_Z0
MP5XI^S1_R7CP9_U_#_T!J /Z0O!?_(K:9_UQ7^5;58O@O_D5M,_ZXK_*MJ@
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M? GX1WOQ>\7)8:?JVFZ=<6I6Y:*^D=9)(PV6,:A3N(XR,CKZ9K]3Z "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y"_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 44UI%7J<4Z@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFC_DO'@S_K^'_H#4 ?TA>"_^16TS_KBO\JVJQ?!?_(K:9_UQ7^5;5 !1110
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MB@#Y?\<?\I%/AC_V(VK?^E$5?4%?+_CC_E(I\,?^Q&U;_P!*(J^H* "BBB@
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MFM2U\53,J@G(7BO/E2K15Z;T/)E1Q$$G2EH=':^#?)M5D=EV]JYSQ'9K"LB
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MCDLP#$D9)QG XP*^I/VCM>\9>%?@;XTUKX?QVTOB_3=.DO+&.[A,R.8\.ZA
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%)FC- "T45'-((HR30 RXO([7'F
M-BG0W"7"Y0Y%<1KE\UY<,N20O%)IFK26;*NXA?K7-[;WK')[=<UNAT.J:T;.
M1E!Y!JW;:O%) &9ANQ7&ZK<?:[IG!R":K+(R]*CVS3,O;M29O:MKC-=*$;@>
ME;,>L(MHK%ANQ7#=3D]:=YC8QVJ%5:;9"K23;.SL]>6>0*S"MA6#+D=*\R5C
M&VY>M=)9Z]LC1&8]0*UA5_F-Z=:^DCJJ*BMYA-&"#4M=1V!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M445T'4%%%% !1110 4444 %%%% !1110 4444 %%%% !7I7[,O\ R<C\*/\
ML;-)_P#2R*O-:]*_9E_Y.1^%'_8V:3_Z614 ?T,T444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E7&[FDHH
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M-FR0SS9^4>6I:29LX(#LV",@"OU?M?\ @E'^S7;S!Y/!=[=*/^6<NN7H4_\
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M7PI\4+)[GPSK5OJ8C ,L*Y26+/3?&P##ZD8.* .LHHHH **** "BBB@#Y?\
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M_MC7YG5^F/\ P6?_ .:/?]QC_P!L:_,Z@ HHHH **** "BBB@ HHHH ****
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M/DDNB/F &>YKKI-#DO=(\U1D@<UPVER>7(JD97->PZ7?0_\ ".O%&F#LY:O
MS"<J+BX+J?,9I4GAW%TUU/%KRW,=P\9[=Z;'!Q\Q&*TM>VPW3$<Y/%92W!W#
M"]Z]J$G*"9]#3DYP3.CT*U+W",GZUZ/I-B9$<EL'BN'\.7D32(BIM/<UZ+))
M'I^D//C*@5\QF$Y<ZCW/CLTJ3YU&VK*6L:E-#;M$APG<FN19GN9&=V)J]<7\
MFHR\MMB/:K>E:%)?8\M24/>HIJ.'A>6A%)1PM.\M&)X92=[P>5&2!T '->CZ
M5X=2>-Y[\;% /RGK4.CZAHW@RQ62XB62Z]2>:YSQ9\6H[Q72WPF1@8->/4^L
M8VK:C"R[G@5GBLQK<N'IM1_F.#\;-";Z58CA W'YUR2.%R*M:I?-?2.[=2<U
MG*IXR,U]WAZ?LZ:BV?I6%H^RHJ#-NVF7RP/XL5GW\>Q22<YH^T", C@@8K.N
M+AIVYZ5I3IOFN:TZ3YKHAHHHKM/1"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O2OV9?^3D?A1_V-FD_^ED5>:UZ5^S+_ ,G(_"C_ +&S
M2?\ TLBH _H9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OG_\ ;\D:/]C;XL%6*G^QG&0<<%T!'Y5YM_P4P_:F\<_LM_#W
MPAJ7@5K*"^U;5)+:XN+VV$ZK&D18*%)P"2>O^S7YD_$__@I=\;OB]X!UOP=X
MBU+1Y=$UB#[-=I;Z6D;E,@X# \=!7)6_?TZM*&]FOFU_P3HI_NIPG+;?\?\
M@'V3_P $/6/_  @OQ57)VC4K$@=O]5+_ (5^FU?SD?LZ?ME?$K]EK3M:L? =
MYI]M;ZQ+'-="]LEN"6C#!<$].&->P?\ #W;]HC_H+:#_ .">/_&O1K34Y)KL
ME]R2."C!TXM/NW][;/W7J"^LX-1L;BTNHUEMIXVBEC;HR,""#^!-?A?_ ,/=
MOVB/^@MH/_@GC_QKC?B)_P %*OVAOB3H][I-[X[;2M,O$\N:#1;*"T8J0 0)
MD3S5!YSAQG)'3BN::YHM6O<Z8Z-.]CK?^"?>N-\,_P#@H5I>B:%>/+HMYJ.I
M:(Q1\K<6P28QDX."-T4;?A7[N5^-W_!)']E/Q/K7Q<L_B_KFDW.F>%-%MYO[
M+N+J,Q_VA=2QF/,0/+1JCN2_3=M R0<?LC73*+IT:=.3O)+^K_B_F8<RG6J3
MBK)O^OT7R"BBBL34**** "BBB@#@OCYX&F^)OP1\>^$[;_CZUG0[RQ@R<#S'
MA94S[;B*_,#_ ((K_$6W\,_%+X@_#_43]FOM9LX;RVCEPK&6U9UDC ZEMLV[
M'I&U?KY7Y$?MS?L%_$;X4_&:X^,WP0L]2O[.ZOCJLEKH",U_I%XS9=HXD^:2
M)F);Y =H+!@% )B$_8UG*7PR7*_+M^+O\DNI4X^UH\D?BB[K]?R_%GZ[U^/?
M_!:;X@P>)_C!X!\!Z>?M=YHNGR74\<.699KIT"1X!^]MA5L8SB1?6N*?_@K9
M^T@VD_\ "*#3?#Z>(MGV?^T1HDO]I^9C[WE&3RM_?'DX_P!FO2?V$/V#?B!\
M3/C''\9_CC8ZA:6UM=_VI!9Z\K+?:K>YW)++&WS)$C8;Y@-Q"@ KFJ5+VM6#
MD_<B[M_+9?UV^2]K[.G*R]]JR7]?=_6OZ;_ KP/+\,_@MX$\)W'_ !\Z+HEG
M83X.?WD<*J_/^\#7<T5^9OB#_@IG\4-*_;4/P@AT'PBWAK_A,8?#WVI[.Z-Y
M]G>Y6(MO%SL\S:Q.=F,]NU:N;Q&(4/M3;?XK_,SC#V-#FZ1LOP_X!^@7QA\<
MWGPQ^%?BSQ=8:0=?N]#TR?44TP3&$W/E(7*;PK8R ?X37RI^P-_P4(O_ -KK
MQMXP\.^(-$TOPW>6%M%?:5:V,KN\T.XI-O9S\Q4M#]U5X8\5]K7-M%>6\MO<
M1)/!*ACDCD4,KJ1@@@]017XN?M+?L'_%G]D?XO+\1_@E;ZMJ?AR"ZDO-.NM"
MB:XO='R&W0S1 ,SQ!2R[R&5DR'QGG",N6K^\^%K[GK_P/N:TN;2CSTO<^)._
MJOZ_._0_:BOR1_X+?>)]'O/%WPNT""6.37;&SO;NZ13EHX)GA6+=Z9:&4CZ?
M2O.?^'O'[1>IZ>OARTT?PRNNLOV=;RVT6=[\R=-PC,QCW^WE8]JZ#]E?_@GK
M\4/VD?BNOQ+^/$&JZ=H$ER+^[CUW*:CK,@(*Q>4V&BAP "2%^0!8QSN1^Q=6
MI&[M%:M_>OZ^[KHO:JC&6GO-62_K^NO0_2S]B[2;_1/V3OA/9ZF7^V+X=LW9
M9%(95:,,BD>RLH_"O:*9'&D,:1QHL<: *JJ,  = !Z4^MZL_:5)375MF-*/L
MX1@^B04445D:&3XJ_P"1;U'_ *XM_*OYPOVIO^3@O&O_ %^C_P!%I7]'OBK_
M )%O4?\ KBW\J_G"_:F_Y."\:_\ 7Z/_ $6E 'U5_P $5/\ DZ;Q3_V)EU_Z
M76-?M37XK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1139&V1LWH,T 9FM:D+.$C/)Z5QMS>27+<L2*
MO:]??;)0H_A-95<%2?,SS*LW)V"BBBL3G"BBB@ HHHH **** "BBB@ HHHH
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MKGA?1?$\<2:SI%AJR0DF-;ZV28(3U(W XS@=*R/^%3^!_P#H3?#_ /X*X/\
MXBNKHH Y3_A4_@?_ *$WP_\ ^"N#_P"(H_X5/X'_ .A-\/\ _@K@_P#B*ZNB
M@#E/^%3^!_\ H3?#_P#X*X/_ (BOE;_@I[\/O"V@_L5^.KW3/#6CZ=>1S:<$
MN+2PBBD7-] #AE4$9!(_&OM2ODO_ (*I?\F.^/O^NVF_^E]O0!SW_!,'X?>%
MM>_8K\#7NI^&M'U&\DFU$/<7=A%+(V+Z<#+,I)P !^%?57_"I_ __0F^'_\
MP5P?_$5\Z?\ !*O_ ),=\!?]=]2_]+[BOK:@#E/^%3^!_P#H3?#_ /X*X/\
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M@ HHHH **** "BBB@#\S?^"S_P#S1[_N,?\ MC7YG5^F/_!9_P#YH]_W&/\
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M@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5UQG?OV_K7V;XA_;&^'/ACQ!J>C7USJ*WNG74MI.$LRRB2-RC8.>1D'FL_\
MX;B^%_\ S]:G_P" +?XT 1?LQ?LNK\&VEU[79X;[Q/<1&%%@R8K.,_>52?O,
M<#+8&!P.Y/,_M[>$+_Q)H?@N?3+"XU&\CO9[5(;6)I9&\Q%; 502?]575_\
M#<7PO_Y^M3_\ 6_QH_X;B^%__/UJ?_@"W^- '-_LF_LNS_#Z1/%_BVW$?B%E
M*V5@2&^QHPP7<CCS""1C^$$]S\OU)7@=O^VW\,;JXBACNM3+R,$7-BW4G [U
M[Y0 4444 %%%% !1110!X9^VG_R;YKG_ %\6O_H]*\2_X)X_\C-XR_Z\[?\
M]#>O;?VT_P#DWS7/^OBU_P#1Z5XE_P $\?\ D9O&7_7G;_\ H;T ?<%?*?\
MP4(NF3X?^&+;^&35&D/U6)@/_0S7U97S#^W]I#WGPIT:_3D6>K(''HKQ2#/Y
MA1^- $7_  3[A5?A?XAE'WVUEE/T$$1'_H1KZCKY1_X)[:C')X%\4V ;,L.I
M).RYZ!X@H/X^6?RKZNH Y?XI6Z7GPQ\702G$<NCWB,?0&%P:_/K]C61T_:)\
M,A1E62[#<]OLLI_F!7WO\;=431?@_P"-+MR%V:1=*N>FYHF51_WT17Q)^PKH
M3ZI\;A>A3Y>FZ=/.S8X!;;$!]3YA_(T 7/V^+II_C/I\1X6'185'XRS-G]?T
MKZ[_ &;85@^!/@E5Z'3D;\223^IKY2_X*!:0]M\4-!U+_EE=:2L0_P!Z.60G
M])%KZ;_9/U>+6/@#X3>)]S6\,EM(.ZLDKK@_A@_B* /7*\ _;AC23X"WC,<%
M+^V9?<[B/Y$U[_7SA^WEJB67P5MK4D>9>:M#&%[X5)')_P#'1^= 'G7_  3M
MD<:AX[0#Y&BLF)]P9\?S-?:E?'__  3PTEH]'\:ZH5.R>>VME;ME%D9A_P"1
M%K[ H \7\7_MF_!+P#XFU'P]XA^)&BZ3K6GRF&ZLKB1A)"X .TX7KR*Q_P#A
MOS]GG_HK'A__ +^O_P#$U[=<>&](NYGFGTNRFE<Y:22W1F8^I)'-1_\ ")Z'
M_P! ;3__  %C_P * /%?^&_/V>?^BL>'_P#OZ_\ \31_PWY^SS_T5CP__P!_
M7_\ B:]J_P"$3T/_ * VG_\ @+'_ (4?\(GH?_0&T_\ \!8_\* /CG1_CMX
M^-'_  4(^'5WX(\4V'B2VMO!NJVTTEDQ(24RQN%.0.=JD_A7VY7RKXJTNRTW
M_@HE\,EL[.WM5;P/JS$0Q*@)^T1#/ KZJH **** "BBB@ HHHH **** "BBN
M&^(WQR^'OPAFLH?&WC31/"TUZK/;1:K?1P/,JD!BH8Y(!(Y]Z .YHKQ3_AM;
MX"?]%>\'_P#@VB_QH_X;6^ G_17O!_\ X-HO\: /:Z*\4_X;6^ G_17O!_\
MX-HO\:/^&UO@)_T5[P?_ .#:+_&@#VNBO%/^&UO@)_T5[P?_ .#:+_&C_AM;
MX"?]%>\'_P#@VB_QH ]KHKQ3_AM;X"?]%>\'_P#@VB_QH_X;6^ G_17O!_\
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M9.J)9Z;H*7.1+)MR%;FN:&+]LJ=5P:;Z')3QWUB-*M*#3ET9X5KVD7&\L%9
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MA?\ @B-_R5#XG_\ 8*M?_1SU^O5 !1110 4444 %%%% !1110 4444 %%%%
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M=KGNOA'X:R"P:^MCY]J.&9.<&N!^)&J6EB9(0VYU./EKO_AQ\1CH'@NXTWS
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MI-5R22BT]_\ -D1;;=U_5@HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#)\5?\BWJ/_7%OY5_.%^U-_R<%XU_Z_1_Z+2OZ/?%7_(M
MZC_UQ;^5?SA?M3?\G!>-?^OT?^BTH ^JO^"*G_)TWBG_ +$RZ_\ 2ZQK]J:_
M%;_@BI_R=-XI_P"Q,NO_ $NL:_:F@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N5\37PDC,:GG-=+<3"",L:\_P!0F,UTYS\N:YZTK*QRUY6C8K4445Q'
MG!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX-5DMUV@9'UI#JDK9X_6JE+6OM)VM<S]G"]["R2&5MQI***S- HHHI %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)I/_ +NF_P#I&E<.._W2K_AE^3/4RO\ W_#_ ../_I2.ZHHHK^=3^OPHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;DC)0-EY#]3A!^?K7F?[;?\ R7[4_P#KSM?_ $6*]R_X)[_\B#XH_P"PFO\
MZ*6@#ZMHHHH *\H_:F\.V_B3X#^+(YT5FM+;[=$QZH\1#Y'U 8?1C7J]>?\
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M@JU_]'/7Z]4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^9O\ P6?_ .:/?]QC
M_P!L:_,ZOTQ_X+/_ /-'O^XQ_P"V-?F=0 4444 %%%% !1110 4444 %%%%
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M<ADMTAB.,#M66\RA7=^.*[J--QW1Z5"BXK5>@EUJ!CC95/XYKEKZZ:24L?O
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MW_)P7C7_ *_1_P"BTK^CWQ5_R+>H_P#7%OY5_.%^U-_R<%XU_P"OT?\ HM*
M/JK_ ((J?\G3>*?^Q,NO_2ZQK]J:_%;_ ((J?\G3>*?^Q,NO_2ZQK]J: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% "-TK9T'O6,W2MG0>IKIP_P#$1S8C^&S?I:2EKZ(\ **** "BBB@
MHHHH _ [_@JM_P GP^.O^O?3?_2&"O%/V:/^2\>#/^OX?^@-7M?_  56_P"3
MX?'7_7OIO_I#!7BG[-'_ "7CP9_U_#_T!J /Z0O!?_(K:9_UQ7^5;58O@O\
MY%;3/^N*_P JVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /S@_;;_Y+]J?_ %YVO_HL5P/P]^./C;X5Z?=67A;6
M_P"R[6ZE$TT?V2";<X&,YD1B.!VKZS_:"_9'\1_%[XE7?B33=9TNRM9H(8A#
M=&3>"B!23M4C]:\W_P"'?/C+_H8]#_.;_P"(H \__P"&Q/B]_P!#=_Y3;/\
M^,T?\-B?%[_H;O\ RFV?_P 9KT#_ (=\^,O^ACT/\YO_ (BC_AWSXR_Z&/0_
MSF_^(H \_P#^&Q/B]_T-W_E-L_\ XS6?X@_:F^*'BG0[[1]4\3_:M.OH6@N(
M?[/M4WHPP1N6($<=P0:]0_X=\^,O^ACT/\YO_B*/^'?/C+_H8]#_ #F_^(H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O2OV9?\
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M^">C:3\)==^)UQ9Q3^(M6U"73;:Z=<O!:1!-RH?X=\A;=CKL7TKZ._X*,?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^TE\3IM4LXY/&>ILCS(K*77D%AD=*_4&@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y?\<?\I%/AC_V(VK?^E$5?
M4%?+_CC_ )2*?#'_ +$;5O\ THBKZ@H **** "BBB@ HHHH **** "OQ/_;P
M_P"4FD_^[IO_ *1I7[85^)_[>'_*32?_ '=-_P#2-*X<=_NE7_#+\F>IE?\
MO^'_ ,<?_2D=U1117\ZG]?A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'EO[.G_*4/P?\ ]?H_]-;5^Y%?AO\ LZ?\I0_!_P#U^C_TUM7[
MD5_0N5_[A0_P1_\ 24?R/GG_ "-<5_U\G_Z4PHHHKTSQ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#\S?^"S_ /S1[_N,?^V-?F=7Z8_\%G_^:/?]QC_VQK\SJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "IH)_*SD9%0T4FKB:OHR^VH!8]JK@U2DD:1LDYIM%*,5'8
MF,%'8****HL**** "BBB@ HHHH **** "BBB@ HHHH **** %H-%)2$%%%%,
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
MCK2L?;%(HYYZ4Z8Y:EU)ZC****904444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Z5^S+_R<C\*/^QLTG_TLBKS6O2O
MV9?^3D?A1_V-FD_^ED5 ']#-%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\T_\ !1KX87OQ7_9!\=:9ID#76IV,46K6\*+N
M9_L\BR.% Y),8D  ZGBOI:D90ZE6 92,$$9!K*K#VD'%;]/5:K\32G+DFI/^
MNY^4?_!'W]J[PYX8T?5/@]XHU&#2;NZU ZAH5S=2!([AY%5)+;<> ^45E!^]
MN8#D '[,_P""C'_)E?Q2_P"O"+_THBKX?_;>_P""4>OV?B/4_&_P5L4U71[Q
MVN;KPG&P2XM')RQM02!)&3DB/(9> H88"_%'BGXV?'#PEX8U3X:>*O$_BVQT
M>XA6VNO#GB)YCLC5@RH(YP6C *CA<=**\_K5)Q>DK6^[3^NX48_5JJFM8WO^
M-V?I=_P1)_Y(;X__ .QC7_TFBK[,_:(_:"\*?LV?#34_%WBF_B@6&-A96'F
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M*K/>3_K]7\PHHHK$U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU,@HHHH 1NE;.@]36,W2MG0>IKIP_P#$1S8C^&S?I:2EKZ(\ **** "BBB@
MHHHH _ [_@JM_P GP^.O^O?3?_2&"O%/V:/^2\>#/^OX?^@-7M?_  56_P"3
MX?'7_7OIO_I#!7BG[-'_ "7CP9_U_#_T!J /Z0O!?_(K:9_UQ7^5;58O@O\
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MB_\ W17V910!\<V/_!//['>6]Q_PG^_RI%DV_P!C8S@YQ_Q\5]C444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M+_CC_E(I\,?^Q&U;_P!*(J^H*^7_ !Q_RD4^&/\ V(VK?^E$5?4% !1110 4
M444 %%%% !1110 5^)_[>'_*32?_ '=-_P#2-*_;"OQ/_;P_Y2:3_P"[IO\
MZ1I7#CO]TJ_X9?DSU,K_ -_P_P#CC_Z4CNJ***_G4_K\**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \M_9T_Y2A^#_ /K]'_IK:OW(K\-_
MV=/^4H?@_P#Z_1_Z:VK]R*_H7*_]PH?X(_\ I*/Y'SS_ )&N*_Z^3_\ 2F%%
M%%>F>(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?F;_P6?_YH]_W&/_;&OS.K],?^"S__
M #1[_N,?^V-?F=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 **2EI* "BBE^M !2444 %%%% !1110
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MW_)P7C7_ *_1_P"BTK^CWQ5_R+>H_P#7%OY5_.%^U-_R<%XU_P"OT?\ HM*
M/JK_ ((J?\G3>*?^Q,NO_2ZQK]J:_%;_ ((J?\G3>*?^Q,NO_2ZQK]J: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *SM4UB/3E&X9)]ZOR-M1CZ"N)\0W7VF4#/0UE4ERK0QJ
MSY(W0:IKKWGRIPE9/7D]:,45P.3EJSS)2<G=A1112)"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&[G$,9]:F/ S6#JMP9)L X%
M85JGLXW-Z-/VDK%.:0S2%CUIE%%>-OJSV=@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ 4E3E>#6WHNLLL@CDYSP*Q*? WESHWH::=C2G-PDFCOU;<H-+5
M/3)_M%OG.<5<KI/=B^97"BBB@H**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***5>O/2F!D^+-073M#GDSAE4U\L65M-XZ\3>6"0[R8S^->N_&[Q8=
M-9[.-P591_*L'X)^%PUW;Z@5[ALU^89U+^U<TIX&/PQ^(_3,EC_9>65,;+XI
M?"=/X8^"5I:RJU]F0>U<?\<O#,'AM;=K12!O_I7T4[DOQTKS+XV:.-2TEI2N
M[R^:]G-LFPU'+*D,/"S77J>-E.<8FMF5.>(G=/IT*'P*UKS-+*2'+5ZVN%R2
M<#%?,OPJUTV.J+:AL MC%>^>.M970]!DN%?#A,_I6O#^/C++.:3_ (>YGQ!@
M91S+E@OXFQ\]?%;Q"^I:K/9]5#8X/O7&V=]>V,;00AE64;3G-;^AV)\8>*@S
M#=N?)Q]:]R'PAT^86DPCV[#EAZ\5^>T<MQF=U:F*HRMK^!]]6S+"9+2IX6JN
MGXGG?PN^%@UUFO+X,8AC*XKW72/#MCH,0CM$VCWQ4^FZ=!I-N(;:,1KCG%6:
M_5<JRFAEM%144Y]6?EV:9M7S*JY2DU#HA^[?E2 <^U?.?[0&G&TUL/&,9 /3
MVKZ*7[PKR?XV:.+Y7G*Y*KU_"N7B6@\1ETDMT=?#==8?,8M[,TO@KJ@F\+V\
M3'Y]@%>BGBO!/@GK1%U!:;N,@8KWV0;6K7A_$_6<O@_Y=#'/\/\ 5\?-?S:C
M:***^B/G@HHHH 1NE;.@]36,W2MG0>IKIP_\1'-B/X;-^EI*6OHCP HHHH *
M*** "BBB@#\#O^"JW_)\/CK_ *]]-_\ 2&"O%/V:/^2\>#/^OX?^@-7M?_!5
M;_D^'QU_U[Z;_P"D,%>*?LT?\EX\&?\ 7\/_ $!J /Z0O!?_ "*VF?\ 7%?Y
M5M5B^"_^16TS_KBO\JVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\\/VI/CM'\0->USPMJ/A:Q6XT/4[B
MTLM7BF<7"+'*R'/&"&"\KTSR.17FWPT^//C;X2Q26_AW6&@L9&WO97$:S0EN
M,L%8?*>!RN,U[S\0OV'_ !UXL\?>)=<L]6\.QVFIZG<WL*3W,XD5))6=0P$)
M .&&<$_6N?\ ^'?_ ,0_^@SX9_\  JX_^,4 8O\ PW%\4?\ G[TS_P  5_QH
M_P"&XOBC_P _>F?^ *_XUM?\._\ XA_]!GPS_P"!5Q_\8H_X=_\ Q#_Z#/AG
M_P "KC_XQ0!G:;^VU\3KK4K6&2ZTW9)*B-BQ7H2 >]?HA7P1IW[ _P 0;/4+
M6=]8\-%(I5<A;JXS@$'C]Q7WO0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!\O^./^4BGPQ_[$;5O_2B*OJ"OE_QQ
M_P I%/AC_P!B-JW_ *415]04 %%%% !1110 4444 %%%% !7XG_MX?\ *32?
M_=TW_P!(TK]L*_$_]O#_ )2:3_[NF_\ I&E<.._W2K_AE^3/4RO_ '_#_P".
M/_I2.ZHHHK^=3^OPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#RW]G3_E*'X/_ .OT?^FMJ_<BOPW_ &=/^4H?@_\ Z_1_Z:VK]R*_H7*_
M]PH?X(_^DH_D?//^1KBO^OD__2F%%%%>F>(%%%% !1110 4444 %%%% !111
M0 4444 <_P".OB!X;^&/ANY\0>+-<L?#VBV^!+?:A.L48)X"Y/5B> HY/85X
M_P#\-^?L\_\ 16/#_P#W]?\ ^)KM?V@OV>_"'[3/P^;P=XTANI-+^U1WL4EE
M-Y4T,R!@KJV",[7=>01AC7S!_P .;?@)_P _GC#_ ,&D7_QB@#VK_AOS]GG_
M **QX?\ ^_K_ /Q-'_#?G[//_16/#_\ W]?_ .)KQ7_AS;\!/^?SQA_X-(O_
M (Q1_P .;?@)_P _GC#_ ,&D7_QB@#VK_AOS]GG_ **QX?\ ^_K_ /Q-'_#?
MG[//_16/#_\ W]?_ .)KQ7_AS;\!/^?SQA_X-(O_ (Q1_P .;?@)_P _GC#_
M ,&D7_QB@#VK_AOS]GG_ **QX?\ ^_K_ /Q-'_#?G[//_16/#_\ W]?_ .)K
M\J/^";/[(?@;]K#Q!X\LO&TNK10Z);VDMK_95RD))D>4-NW(V>$7'3O7W;_P
MYM^ G_/YXP_\&D7_ ,8H ]J_X;\_9Y_Z*QX?_P"_K_\ Q-'_  WY^SS_ -%8
M\/\ _?U__B:\5_X<V_ 3_G\\8?\ @TB_^,4?\.;?@)_S^>,/_!I%_P#&* /:
MO^&_/V>?^BL>'_\ OZ__ ,36YX+_ &Q_@E\0_$EGH'A[XEZ!J6LWC>7;6:W.
MQYG[(FX#<Q[*.3V%?//_  YM^ G_ #^>,/\ P:1?_&*Z'X>?\$H_@=\-_'&A
M>*K'_A)+Z_T:\BO[6&_U%'A\Z-@\;,JQ*2 P!QG!QSD<4 ?9-%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?F;_ ,%G_P#FCW_<8_\ ;&OS.K],?^"S_P#S1[_N,?\ MC7YG4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFC_DO'@S_K^'_H#5[7_P56_Y/A\=?]>^F_\ I#!7BG[-'_)>/!G_ %_#_P!
M:@#^D+P7_P BMIG_ %Q7^5;58O@O_D5M,_ZXK_*MJ@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\3^)'[7
MGP]^'5W+8_;9M?U*,E7M])59%C8=FD)" YZ@$D8Y%>5_MJ?M"7NAW+> /#ET
MUK.\2R:K>0OAU5AE8%(Y&5PS'N&4=S7Q;8V-SJ5W%:V=O+=W4K;8X8$+NY]
MHY)H ^TI/^"B&GBXPG@BY:#GYVU%0W7CY?+/;W_.O0_ /[:OP]\:74=G?377
MAF[D.!_:BJ("?3S5) ^K;17Q''\ /B3)9FY'@;71&/X6L9%?_O@C=^E<?K6@
M:IX;OFL]7TV[TN\49-O>P-#(!Z[6 - '[#1R)-&DD;K)&X#*RG((/0@^E/KX
M0_8U_:%O/#_B&S\":]=M/HM^WE:=+.Y)M)C]V,$_P.> .S$8ZFON^@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /S-_P""S_\ S1[_ +C'_MC7YG5^F/\ P6?_ .:/
M?]QC_P!L:_,Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J157RR3UJ.BD(****8PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO2OV9?\ DY'X4?\ 8V:3_P"ED5>:UZ5^S+_R<C\*/^QLTG_TLBH _H9HHHH
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M?2OHNAIJS?4::>BZ!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,GQ5_R+>H_]<6_E7\X7[4W_)P7C7_K]'_HM*_H]\5?\BWJ/_7%
MOY5_.%^U-_R<%XU_Z_1_Z+2@#ZJ_X(J?\G3>*?\ L3+K_P!+K&OVIK\5O^"*
MG_)TWBG_ +$RZ_\ 2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ4WDVK-G%<'?2>==,^<UU
M/B6\"6YC[DUQZUQ5I:V//Q$KNP4445SG(%%%% !1110 4444 %%%% !1110
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M_P!T2':1[$8(]C7Z(_LL_%33/B)\*=%M(KE!K.D6L=A>6C./-'EJ%63'4JP
M.>F21VH ]DK@?C7\)M,^,'@6^T>]@C^W+&TEA>;07MY@,J0?0D ,.X/T([ZN
M(^,?Q0TWX2> ]1UV_F43K&R6=ON >XG(PB*._/)/8 F@#\I+>XGTZ\CFB9H;
MB"0.K="C*<@_4$5^P/AW5!KGA_3-2  %Y:Q7&%Z?.@;C\Z_'N-)+J=44-+-(
MV !RS,3^I)K]@O"^FMHOAG2=/8!6M+2& @=BJ!?Z4 :=%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+_CC_E(I\,?^
MQ&U;_P!*(J^H*^7_ !Q_RD4^&/\ V(VK?^E$5?4% !1110 4444 %%%% !11
M10 5^)_[>'_*32?_ '=-_P#2-*_;"OQ/_;P_Y2:3_P"[IO\ Z1I7#CO]TJ_X
M9?DSU,K_ -_P_P#CC_Z4CNJ***_G4_K\**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \M_9T_Y2A^#_ /K]'_IK:OW(K\-_V=/^4H?@_P#Z
M_1_Z:VK]R*_H7*_]PH?X(_\ I*/Y'SS_ )&N*_Z^3_\ 2F%%%%>F>(%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?DK_P0_P#^1R^+G_7G
MI_\ Z,N*_6JOR5_X(?\ _(Y?%S_KST__ -&7%?K50 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'YF_\%G_ /FCW_<8_P#;&OS.K],?^"S_ /S1[_N,?^V-?F=0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>E?LR_P#)R/PH_P"QLTG_
M -+(J\UKTK]F7_DY'X4?]C9I/_I9%0!_0S1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>1?M8_'!?V=/V?_ !=X\2)+B^T^
MV$=C#(,J]U*XCA##NH=PQ]E->NU\A_\ !5;POJ'B?]C#Q4VGQO,=-N[/4)XX
MQDF%)@'/T4/N/LI-<^(DXTW;R^2;LW\EJ;T4G45_^'[+YO0_'SX8_"/XK_MP
M?%[4ETKSO$GB2\;[;JNM:I.5@ME)QYDTF#M7LJ*"<+A5PN!]L:#_ ,$.=8N-
M/A?6OB]8Z?>E<R0V&@/=1JWHKM<1%A[E1]*[_P#X(BW>C-\*?B-;0M#_ ,)
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MKTSS!&Z5LZ#U-8S=*V=!ZFNG#_Q$<V(_ALWZ6DI:^B/ "BBB@ HHHH ****
M/P._X*K?\GP^.O\ KWTW_P!(8*\4_9H_Y+QX,_Z_A_Z U>U_\%5O^3X?'7_7
MOIO_ *0P5XI^S1_R7CP9_P!?P_\ 0&H _I"\%_\ (K:9_P!<5_E6U6+X+_Y%
M;3/^N*_RK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_AR?\7O^AT\$_\ ?^\_^1ZVBVH*FW>VW?T_K_.^<DG-S2M??MZ_U_E;[_\
M^'F'[-/_ $5"U_\ !7??_&*/^'F'[-/_ $5"U_\ !7??_&*^ /\ AR?\7O\
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MC_V(VK?^E$5?4%?+_CC_ )2*?#'_ +$;5O\ THBKZ@H **** "BBB@ HHHH
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MZ\]/_P#1EQ7ZU5^2O_!#_P#Y'+XN?]>>G_\ HRXK]:J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _,W_@L_\ \T>_[C'_ +8U^9U?IC_P6?\ ^:/?]QC_ -L:
M_,Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]*_9E_P"3D?A1_P!C
M9I/_ *615YK7I7[,O_)R/PH_[&S2?_2R*@#^AFBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S?$OB/3?!_A[4]=UB[CL-
M)TVVDN[NZE.$BB12SL?8 &IE)13D]D-)R=D:5>=^)?VC?A1X-OY+'7OB;X/T
M:_CX>TO]=M89E^J-(&_2OQ=_:;_;:^*_[:7Q"F\)^#$UJT\)W4K6^F>$M#5V
MGOD&?GN1'\TK$#<4.40#@<%CQWCC_@GE\<OAG\,=9\>>+/"UOH.AZ5$D]PMQ
MJ=O)/L9E4$1QNW.6'!P?:IYGR^TDK1\RW%<WLXN\O(_?SP?XV\._$'0XM9\+
MZ]IOB/2)&9$O])NX[F!F!PRAT)&0>HSQ6W7YS_\ !$J1V^!7CU"S%%\2 A<\
M FUBS_(?E7V?^TC\/=3^*GP)\;>%M$U.ZTC6=0TV1;&[LYVAD6=</&-ZD$*S
M*%;'568=ZUQ'[E.2ULD_PN94/WS2>EW;\;'I-%?D]_P1\_:,\37GQ&\4_"SQ
M5K6H:I!<6;:CIJ:E<O,UM/"X6:)"Y) 97W%1QF,GN:_6&KE'E46G=-7)C*[E
M%JS3L%%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &
M3XJ_Y%O4?^N+?RK^<+]J;_DX+QK_ -?H_P#1:5_1[XJ_Y%O4?^N+?RK^<+]J
M;_DX+QK_ -?H_P#1:4 ?57_!%3_DZ;Q3_P!B9=?^EUC7[4U^*W_!%3_DZ;Q3
M_P!B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1129 H 6FLX4$DTRXN%MXRS=JX[4]?FDG;RB N:SE-0W,I
MU%#<7Q!?"X8H.QK&I9':1BS<FDK@E+F=SS)2YG<****D@**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HI:222*!=TDBI_O&@!>M.\OW'YUQ7C3X
MJZ7X1TV:5RLK!3C:_>O F_:>NUU)CMS;@],]JX*V.HT&HR>IYN(S'#X:2C.6
MI]8%2*<L9:O$?#O[3VC369:Y@)<?[?\ ]:LW5/VKM)CF=88"!R!\]'U_#)<W
M.)YGA%%2YT>OZS\0]#\.MMOIV0YQ\H%<QXN^.'AW1].9XYV9V'R]/\:^1_$'
MBO6?B'KDIA?]SNW*H!/?-)_P@FO>))H[>:1ASQ\I_P :\6IFM65U2CH>#+.J
M]236'A?L?2_@[XN:7XJF>(R$3=0.*QOB[\6+7P[8BVLV+W3 Y&<5\[ZCH>N?
M#/48_*+22L."%-6]'\,ZY\2-3$ERQ5N <J>GYUYCQ564>2WO&\L\QE2D\(H6
MJ[#?#'A74/B9K5Q=#.'?YLU[;X?_ &<]-M6AGGF/F@ D;*[;X<> +3P7I,2H
MO^D,,NQ ZUV)8FNJCA(Q5ZBNSW,MR&C3IJIBH\TWJRIIFEP:-:K;P*-JC .*
MLT45Z*TT1]:DHJRV"BBBF,**** '*HD^1ONGK7S;^T7X)/VJ+4HAM1"<X%?2
M%<9\8-%35?!<ZJ/WN[C\C7+B*:J4VCQLWPL<7@YP:U6IYY^SGXP^V6[:43GR
MSGDU[S(NV0BOCGX1ZB_@[QA.DA^\1UX[FOK[3[G[?I\-SVD&:QP<^:G9[H\_
MAW$NMA/9S^*)+1117H'U(4444 %%%% !1110 4444 %))(MO&9)#A1UHDD6&
M,R,< 5Y=XZ\>OYTEO:<+T/.:\G,LRHY;1]I5>O1'M95E5?-J_L:*TZOL=#KW
MQ$M-/;9"2S5S,GQ:N YQ'D?6L'PYX3N_$USY\K$)WXKNX?AC:+& X):OB*>(
MSO-/WU#W(]#]$J87A[)[4,2N>:W.*UCXC7VL8B$97/ YK+C\+ZS=J94R0WS=
M37K%G\.=+A8,\;%A720Z?;VT8C1?E P*UAPYB\;)U,PJW]#&IQ9@<OBJ>5T+
M+K='CFG?#G4+F$/+PU:&G_"^:21Q<'"X.*]:3$:[5 Q3MY]!7KT^%L!"W-=V
M/"K<99E4YN6RO^!X;=_#O5([H)$H\HG&>:GE^&NIJ@*<GZFO:N.I S]*=YA]
M!^59_P"J>!UU>IL^-LQT]V.GXGE>A_"L7"YOFVGZ9KLM%\#V.A9,3;R>>170
M%L^U)7LX3)<%@[.$+M=7N>!C>(,QQ]U4J-1?1;"CY5P!@4E%%>X?.C+B".Z3
M:Z@BLAO!]FTQD[GMBMJBN>IAZ59WJ13.FEB:U!-4IM7([>WCM(PD:@ "I***
MV2459&#;D[O<****HD**** "BBB@ HHHH **** %!Q6-KGA6UUR!ED^4D=A6
MQ1TK&K1IUX.G5C=,WHUZN&FJM&7+)'AGBGPK-X7N4GA)(#?2NP\ ^-%N(U@G
MXDZ#FNN\3Z+%K&F3!Q^\Q\IKQ&XM[CPOJH<\@-FOS/&4:O#V-5;#_P *7X'Z
M]@:]+BK+Y8?$_P :.S[GT(RXHQ7G]I\5[-+$>;'F7']ZHXOBS:AB6C./]ZOL
MO[>RZR?M5J? ?ZM9K=KV+T/0II!;PO*Q^51DUXS\0O$$FJ:@EO;\KSGFM37O
MB@M[9R0VR8W#'6N>\&Z1-K6MB:<?N_I7RN<YK',I0P."=U+=GVN09++*(SS'
M,(V<5HF=3X"\"));B[N#\S'TKT:WL8+-0BQJ0/:EL[5+&W6&,86I*^UR_+Z.
M HQA".O5GY]FF:5\SKRJU)/EZ+R,W6O#]MK4;"0!,C' K+T/X?V6BS+*C[V7
MG!6NFHK>>!PU2JJTX)R74YJ>88NC1>'A4:@^@U;>%6R(US]*AOM/@U"%D9%&
M1CI5BBNN4(RBXM:,X8SG&2G%ZH\2\8>#Y]#OGGMAE,[JV_!_Q$2UMXX;DD #
M!.:](U+2X-4MV25<DBO(?$7PYN+>[<V[D1YZ8K\XQN7XK)\0\5ERO%[H_6<N
MS3!9]AE@LT=I1V9M:U\9;Q2T%K'O0\ [JY6\\3:M-(MPX(P<]376>$_AJJLD
MM[ETZX%=7JW@JPFTV6.%"LF/E-9?V;F^8TW7KU+/HCHEG62994CA*%/F6S9F
M> /B U_:M:7!VR'&.:[7&Y<ALBO ]2T?4/"EYYL1R<\<5U7A/XE/'^[OAN(]
M\5W95GSHVP>8>[)=6>7G?#?UF^/RQ\T'T7Z'JL-P;/,A/ Y->;?%#XDR7LS6
MEKRF-IYI_BSXC0_9@MJ-NX<\YKB?#>@S^)-0^T29\MGR>/>EG>;2Q;6 P#NY
M;M&W#>4?V?&68YBN6,=DST#X0_#[[5Y.HS<[OFP17O4<$-O&L:Q*0!Z5P_AN
M8:%!';1C$2C%=G:W2W48=:^SRG+Z>78=4HKWNI\YF&;RS:NZC>G1>1'J>DVV
MK6[1/&JY&.E?-'Q/\&OX0UIY+4[E8[O3KS7U$IVG-<-\4O"Z:QIDUT1EU7T]
MJ\_B'+88["N<5[\=4SV.'\RE@<4H2?N2T:*7P?\ %*ZAH-O!*<S%0.M>BL-I
MQ7RO\,?%3^'?$$2W'^I5P-O3O7U%9ZC#JENL\+##<A<YJ.&\R6.P:A)^]'0O
MB/+W@L6YQ7NRU)J***^L/E HHHH * ,T5#?7J:9:/<2?= H;45>6PTG)I+<P
M/&GC*W\+6:R,?G/:L[P3\2+3Q,SJ6(8''6O%?BAXGG\1:\]O$<P < 5SFD7]
M]X2N(Y(FVJQR<U^78CBBI3Q[Y%>E'1GZ;A^&:4\ N=VJRU1]::M>+;PD \D9
M%9FBZL9&6)JX_0?%O_"3Z?$Y."J@'FM2UF-M,''K7Z+2Q$<1"-6F[Q9^0XEU
M,/B'2J*SB[,[ZBJ]C-YUNK=ZL5V'>G=7"BBC!]*8PHI)&6&-G<X"^M</X@^,
M&EZ!<".2/><X.&KEQ&*H82/-7FHHZL/A:^+ERT(.3.YHKDO#_P 4-+\1R!(5
M\L_[35UJM'(H99%(^M.AB*.)CST9J2)K8>MAI<E:+BPHI?D/212:2NDYPHHH
MI %%'!Z'-&/7BF ^-=QKY[^-'BH:H[::IPV\+^M>Y>(-431=,DN"X^52>M?*
M]TLOBGQBK(<@S ^O>O@^*\7*%&&$I/WIO7T/N>%<*IUIXNI\,-O4]=^!?AEM
M,ADFE'WDXKUHUG>'=-CTW28 @PVW!K1KZC+<(L#A(4%T/F<RQ;QN+G6?4***
M*],\P**** "BBB@ HHHH **** "BBB@ HHHH *53@TE%,#DOB-H/]LZ;(X4?
M*N>E>"> =8;2?%#6F<*)B/UKZCU",3:;.A[K7RIKEC_8/C.21>,R[OUK\VXG
MI?5L31QD.^I^C<,U5B,/6PD^VA]8[UDC1EY&!25C^$-0.I:+%*3D[!6Q7Z)3
MJ*K"-1=3\]J4W2FZ;Z"-TK9T'J:QFZ5LZ#U-=N'_ (B.+$?PV;]+24M?1'@!
M1110 4444 %%%% 'X'?\%5O^3X?'7_7OIO\ Z0P5XI^S1_R7CP9_U_#_ - :
MO:_^"JW_ "?#XZ_Z]]-_](8*\4_9H_Y+QX,_Z_A_Z U '](7@O\ Y%;3/^N*
M_P JVJQ?!?\ R*VF?]<5_E6U0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 45XO\ M1>,O'7PY\&P>)?!\UN;6TDV
M:C!/;"4A&("RCT ;@_[P/8U\G?\ #<7Q1_Y^],_\ 5_QH ]%\?\ [<OBOPCX
M\\2:';:!HTUOIFI7-E')*)=[+'*R MA\9(7M7UE\.?$L_C+P#X<UZZBC@N=3
MT^"[DCASL5G0,0,G.,GO7Y,^(=<NO$^OZGK-\5:]U"ZENYRB[5,DCEVP.PR3
MQ7KOAO\ ;"^(OA3P]INBV%SIZV.GV\=K LEFK,$10JY.>3@4 ?I74-YY_P!C
MG^RB,W.QO*\W.S?CY<X[9Q7YV?\ #<7Q1_Y^],_\ 5_QJIJG[:GQ4U*S>!-7
MM+'>,&6ULHPX'L6!Q]1S0!T%]^WC\1I+Y1]AT2RBCD^>&&UD+$ \J2\C<XXR
M!7WYI]]%J>GVUY 28;B)9HRPP=K $?H:_''YYI/XI)'/U))_K7Z^>"=/GTGP
M;H-C= K=6MA;P2@]G6-5;]0: -JBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /E_P <?\I%/AC_ -B-JW_I1%7U!7R_
MXX_Y2*?#'_L1M6_]*(J^H* "BBB@ HHHH **** "BBB@ K\3_P!O#_E)I/\
M[NF_^D:5^V%?B?\ MX?\I-)_]W3?_2-*X<=_NE7_  R_)GJ97_O^'_QQ_P#2
MD=U1117\ZG]?A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'EO[.G_*4/P?_P!?H_\ 36U?N17X;_LZ?\I0_!__ %^C_P!-;5^Y%?T+E?\
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M_._ZHG_Y=?\ ]Q4?\/SO^J)_^77_ /<5<)_9MG_SZ0?]^U_PH_LVS_Y](/\
MOVO^%']I+^3\?^ '^ND?^@?_ ,F_^U.[_P"'YW_5$_\ RZ__ +BH_P"'YW_5
M$_\ RZ__ +BKA/[-L_\ GT@_[]K_ (4?V;9_\^D'_?M?\*/[27\GX_\  #_7
M2/\ T#_^3?\ VIW?_#\[_JB?_EU__<5'_#\[_JB?_EU__<5<)_9MG_SZ0?\
M?M?\*/[-L_\ GT@_[]K_ (4?VDOY/Q_X ?ZZ1_Z!_P#R;_[4]-\-_P#!<32K
M[7]/M]<^$=QI.D2S*EU?6OB$74L$9/+K$;5-Y'7;O&?6OTYTW4+?5M/M;ZTD
M\VUN8EFBDP1N1@"IP>1P1UK^?+]KVUAM[3POY4,<67N<[% SQ%Z5^^?PW_Y)
MYX8_[!=M_P"BEKTZ-7VT%.UKGW&6X[^T<+#$J/+S7TWV;7Z'1T445N>F%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^9O\
MP6?_ .:/?]QC_P!L:_,ZOTQ_X+/_ /-'O^XQ_P"V-?F=0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>E?LR_\ )R/PH_[&S2?_ $LBKS6O2OV9?^3D
M?A1_V-FD_P#I9%0!_0S1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?(G_!5;Q5=>&/V+_%B6DCQ/JEU9Z<[)P?+>=6<'V*H
M5/UKZ[KYM_X*)?"N^^+O[(OCK2=+@:ZU2SACU6VAC7<[M;R+(ZJ.[&,. .Y-
M<N)_A-]%:_HFK_A<Z,/_ !$EOT];:?B?//\ P1C^#>CZ-\&]=^)$MI%+XAUK
M49=.ANV4%X;2$)E%/\.Z0L6QUVIZ"OH?_@HQ_P F5_%+_KPB_P#2B*OB?_@D
M/^UUX9\$:;JGP@\7ZE!HKWU^=0T.^NY!'#++(JI);%CPK$HK)D_,68==H/VQ
M_P %&/\ DRKXI?\ 7A%_Z415TYEK1;6W*OR5_P ;F&7Z5XI[\WZZ?A;\CYV_
MX(D_\D-\?_\ 8QK_ .DT5?HU7YR_\$2?^2&^/_\ L8U_])HJ^P_VDOVD/"7[
M,OPVU'Q3XGU"&.X6)QIVE^8!<:A<8^6*->IYQENBC)-;8J:IOF?:/Y(QPT7-
M<J[O\V?DK^S;,/"?_!6::UT\A;8^+];L]L?"^6PNACIT'''M7[@U^'?_  2]
M\+ZO\9OVX&\=7R-*-)6^U_4;A5^3S[@/&JY[$O.S >B'TK]Q*F,73PU&$MTO
MPVM]Z?WESDJF)JSCM?\ X/Y-!1114%!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% &3XJ_Y%O4?^N+?RK^<+]J;_DX+QK_U^C_T6E?T>^*O
M^1;U'_KBW\J_G"_:F_Y."\:_]?H_]%I0!]5?\$5/^3IO%/\ V)EU_P"EUC7[
M4U^*W_!%3_DZ;Q3_ -B9=?\ I=8U^U- !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 C' )KFM7UYK>?:O:MV_N/L\)/K7 7T
MGG7<C$Y&:YZLN561RUYN*LB]J&O27F #M&,<5ET45QN3EN<$I.3NPHHHI$A1
M110 4444 %%%% !1110 4444 %%%% !1110 4H!:E5"QP*Y[QSXPMO!NCR7#
MR*D_0!OI4RDH)REL3.2IQ<I;(T[S7-/T]@L]RL;_ -TFK5K/#?1B2!Q(I[BO
M@?XD?$35?&'B9YK:\F1$[1N0.OM79_#;]HK4_"^GO9SS%VBX!D )_6O"AF].
M51QDK+N?-4\]HRJN$U:/<^N-?\06OANQDN)Y%#H,[&-?)'Q0_:!U3Q!=7%II
M4GV<L2JF.N8\>?&#7/B)J#K'+(H8X"Q\#T[5VWPE^"<<ZV^H:E$QE.&(<FN'
M$XZIBY>SH:+N<]3%8C-JOU?!Z1ZL\SM=*\5>*GBBOYYY8W8 [A_]:O6_#G[.
M,$FER>>[&21>">U>Z6NDV%C"L26< V]&\L9JSNV\+\H]!44\'&+O-W/H<+PW
MAZ6M=\[/DWQ!\";S1;[R;>:5D8^W^%='IO[)YU325NWO94<C.W(_PKZ,:&&3
MF2)';U9<U*)F1-B':OHO JXX.@F^97$N&<'SN3U78\K^&_P1L_!5X)KG-T,$
M8D^E>CKH>F0R!XK1$8="*M%B>II*Z84XTX\L5H?18?!8?"P4*4$D9U_X6T75
MI ]Y81SNO0MFGV/AW2=*.ZSLHX&]5S5ZBJY5>]CI]G3OS<JOZ"Y_*DHHJC0*
M*** "BBB@ HHHH *AU"Q75+-[=QE2,U-2JVVEN)I25F?&GQ4TNX\,>.6EA5H
MX>#N_$U]!_![XC6WB#0+>UG=(WA&W.>M7?BC\.[3QAI@S"OG+D[E&#7RYJVC
M:W\/]4E$9FAA5LI@D UXTN?"5'):IGYS5]OD.,E7BN:G(^W@4DYC;<OK25Y%
M\#?B+/XBTA4O7S*N5&[KP<5Z^5YKU:=15(J2/N\)BH8RC&M3V8VBH+C4K6T.
M)7"GW-0KKU@_24'\:3K4HNSDKGI1H5I+FC!M>A=HJN-4M#_RT'YUG:IXJLK!
M&Q*N\=LU%3$T:<>:4U8TIX6O6DH0@[^AM;:165N%;)K@]8^(ZV]HS0.I<BN.
MA^*-_:W!;=D>XKY[$\28'#34'*_H?4X/A/,L93<XQM;N>W;2*-O<]*\>7XQ7
MSS*"!C_=%:%U\6)Q9@J5WGCH*4>)\MDFU)Z>14N#\W@XIP6OF;?Q%\3G281'
M"WS,O-<%X3\-R>([S[5,696;)';K6=--?>+-0#D-(I/->S>#]"CT738U"#<5
MR:^:P\)\19@ZTU^YCL?6XJ<.%<K5"FU[>>]C2TK28-)MPD2!>*N;CZTA-%?I
ML(1IQ4(*R1^05)RJR<ZCNV%%%%60%%%% !1110 4444 %%%% !1110 4444
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M8_\ 8C:M_P"E$5?4%?+_ (X_Y2*?#'_L1M6_]*(J^H* "BBB@ HHHH ****
M"BBB@ K\3_V\/^4FD_\ NZ;_ .D:5^V%?B?^WA_RDTG_ -W3?_2-*X<=_NE7
M_#+\F>IE?^_X?_''_P!*1W5%%%?SJ?U^%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >6_LZ?\ *4/P?_U^C_TUM7[D5^&_[.G_ "E#\'_]
M?H_]-;5^Y%?T+E?^X4/\$?\ TE'\CYY_R-<5_P!?)_\ I3"BBBO3/$"BBB@
MHHHH **** "OS"_X+B?\BG\)?^OW4?\ T7;U^GM?F%_P7$_Y%/X2_P#7[J/_
M *+MZ /(_"__ "+6D_\ 7I%_Z *TZS/"_P#R+6D_]>D7_H K3KXN6[/YIJ_Q
M)>K"BBBD9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.G[8?\
MQY^%O]^Y_E%7[W?#?_DGGAC_ +!=M_Z*6OP1_;#_ .//PM_OW/\ **OWN^&_
M_)//#'_8+MO_ $4M?3X+^!'Y_F?N?#/_ "*J7_;W_I3.CHHHKN/J HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S-_X+/\
M_-'O^XQ_[8U^9U?IC_P6?_YH]_W&/_;&OS.H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O2OV9?^3D?A1_V-FD_P#I9%7FM>E?LR_\G(_"C_L;-)_]
M+(J /Z&:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+>H_]<6_E7\X7[4W_)P7C7_K]'_HM*_6O7?^"FGAB^T>\@7PW>*9(RH/F?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT_Y2A^#_ /K]'_IK:OW(K\-_V=/^4H?@_P#Z_1_Z:VK]R*_H7*_]PH?X(_\
MI*/Y'SS_ )&N*_Z^3_\ 2F%%%%>F>(%%%% !1110 4444 %?F%_P7$_Y%/X2
M_P#7[J/_ *+MZ_3VOS"_X+B?\BG\)?\ K]U'_P!%V] 'D?A?_D6M)_Z](O\
MT 5IUF>%_P#D6M)_Z](O_0!6G7Q<MV?S35_B2]6%%%%(R"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ^=/VP_\ CS\+?[]S_**OWN^&_P#R3SPQ
M_P!@NV_]%+7X(_MA_P#'GX6_W[G^45?O=\-_^2>>&/\ L%VW_HI:^GP7\"/S
M_,_<^&?^152_[>_]*9T=%%%=Q]0%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!^9O_!9_P#YH]_W&/\ VQK\SJ_3'_@L_P#\
MT>_[C'_MC7YG4 ;'@_PAK/C[Q1IGAWP]I\VJZUJ4ZVUI9P ;I'8\#)P !U+$
M@  DD $U^LW[,?\ P2Y\%?#FQM=9^)L=OXX\4[A(+ ECI=IC!"^6<&X/#9,@
MV$-CR^-QYS_@DY^SG9Z#X#NOB[J]I'-K.M/+9Z,[_,;:SC<I*ZC/#22*RG(R
M%B&#AV!Y#_@HY^W9X@T;Q=>_"GX<ZK-HB:<4&N:]I\^VYDF(#?989%.8U3(W
ML"'+93Y0K"36I)4;0BKR>_E_PVEW:Z>GKG&G*JW*7P+_ #_'R7:[=^GVCXJ_
M:(^!O[.^EMHE_P"+?#'A:#2W$!T'2=CS6I.#M^QVRLZ#Y@?N <YJ'PK^TU\"
M?V@;%] LO&/AOQ%#J3"U.AZPHA>\))P@MKE5:7)7H%/;U%?@1166COS:EM=(
M:?U\C]D/VD/^"8/P[^*&FWFI^ +:#P!XMP\L:6VX:9=.0-J20C(A7Y<!H0 N
MYB4<X%?D=X^\!Z]\+_&.J^%O$^G2Z3KNES>3=6DV,J< @@CAE92K*P)#*P()
M!!K[W_X)Q?MRZ[!XOTGX3>/M4FU;2=2/V70M4O9=\UI/_P L[9W8Y>-_N)G)
M5BBCY2-GM7_!5#]G>#XA?"-/B-I5DK>)/"8'VIXH\R7&G,V'4X7)\IF$@R0%
M4S'O656/U=*<?@?X?\-I=;):^M49.NW"2M)?CO\ ??IUOH? ?[ /AC1O&7[7
M'@+1_$&DV.N:1<F^\_3]2MDN()=MA<,NZ-P5;#*K#(X(![5]?_\ !53X/^ _
MAW\$O"U]X5\$^'?#-]-XA2"6YT?2;>TD>/[-.VQFC0$KE0<'C('I7RG_ ,$W
M?^3TOAU]=0_]-US7VU_P6$_Y(%X0_P"QFC_]);BN3'MQHQ:_GA_Z7$JG\;]'
M^3/R.HHKT'X4_L^_$;XWW:P^!_!VJ:_'YC0M>0Q>79Q2*F\I)<N5BC;;@@,X
M)RH&20#Z*3>QG=+<\^HKZ8;_ ()M_M&*I8_#HX SQK>G$_E]HKP'Q=X)\0_#
M_67TCQ/H6H^'M451(;/5+5[>7:<X;:X!VG!P>AJ>97M<KE=KVT,6BBBF(**]
MT\!_L-_'7XE:*-6T/X<ZG]@8@))J4L&G&4%0P=%N9(V="&&'4%3Z\&M#Q-_P
M3]_:"\):+/JE]\-;^>VA*AH],N[6_G.Y@HVPV\KR-R>=JG R3@ FB7NZ2T$F
MI*Z/GNOU,_X)7_!WP#\0OV?_ !%J/BKP/X;\3:A%XGGMX[O6-)M[N5(Q:6C!
M \B$A068XSC+$]Z_+>YMIK.XEM[B)X)XG,<D4BE61@<%2#R"#VK]>/\ @C__
M ,FV^)_^QMN/_2.SH3NKH'NC\_OV[?#>D>$/VL/'^D:#I5EHFDVL]L(+#3K=
M+>"(&TA8A8T 5<L2>!U)->"5]&?\%#_^3ROB1_U\6G_I%!7FNF?L[?%;6M+M
M-2T[X8^,K_3KN%;BWO+70+N2&:)E#+(CK&0RD$$$'!!S7G9=*^!HRD_L1_)&
MM3XY>IY[112JI=@J@LQ. !U->DDY.RW,Q**[_6OV?/BEX:TFZU35_AKXOTK3
M+5#+<7M[H-U##"@ZL[M&%4>Y-<EX=\-ZOXPUJVTC0=*O=;U:Y)$%AIUN]Q/*
M0I8A8T!9L*">!T!-3?6P/17>QFT5U/C/X5>-?AS%:R^+/!^O>%X[IF6W?6M,
MGM!,5P6"&15W$9&<=,BO4?!'["/QX^(GAZ#6]%^'5\=-N.8I-0NK:P>1< AU
MCN)4<J000V,'L35)-IM= ?NV3Z[>9X+17I_Q>_9D^*'P&CMYO'7@Z^T2TN-H
MCO@T=S:EFW8C,\+/&'.QCL+!L#.,<UQ?@WP3X@^(6OV^A^&-%OM?U>?/EV6G
MV[32$#JV%!PHZECP!R2*(IR=HZA+W%>6AB45],_\.V?VC?\ HG7_ )7--_\
MDBO!/&W@+Q'\-?$,^A>*M$OO#^KP<O9ZA T3[<D!ER/F4X.&&0>H)J.9)I-Z
ML=FU<P:**V_"'@?Q'\0-6.E^%] U3Q)J2QF8V>DV<EU*(P0"Y2-20H+ $].1
M5I-NR)O;<Q**^EX_^";O[1DL:NOPZ8!@"-VM:<IY]0;C(_&N?\<_L+_'CX=Z
M.-4UGX;ZHUEO*LVERP:BR84L6=+:21D0!3EV 4<#.2*EM15V->]L>$5]??\
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MZ"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2AILC[:E32M""T,W4K@RS$9XJE2EBQR>M)7BRDY/F9[L8J*L@HHHJ2@HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 6]-OFLY2<Y'I6G+XF)QA16#28IJ36B-8U915DS:NO$+S)M4;:R'
MFDDSN<FF8I:&VQ2J2GNPHHHI&84444 %'0@^E%% %J/5)8H]JMBNGT6\-Q;
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M44 %%%% !1110!Y;^SI_RE#\'_\ 7Z/_ $UM7[D5^&_[.G_*4/P?_P!?H_\
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M4%?L)^S+_P FO_"O_L4-+_\ 2.*OQ[_X*'_\GE?$C_KXM/\ TB@K]A/V9?\
MDU_X5_\ 8H:7_P"D<5>1A?\ D4P_Z]K_ -)-)_QGZO\ ,_GOJQI__(0MO^NJ
M_P Q5>K&G_\ (0MO^NJ_S%?5Y;_OU#_''\T83^%G[X?MJ?\ )J/Q1_[ <_\
M(5^2G_!.W_D\KX;_ /7>[_\ 2*XK]:_VU/\ DU'XH_\ 8#G_ )"OR4_X)V_\
MGE?#?_KO=_\ I%<5XE'_ 'V7I#\YFN,_Y%[_ .W_ /TF)^RWQ,^&_@GQ%K/A
M_P ;>-8;66#P2EUJ%K)J+J+2T=E0M=2!N,QK$2I;A22V-RJR_'OCK_@L)X(T
M7Q-'9>%_!&K>)M'29H[C5+JZ2Q+*'QYD$11V=2OS#S#$W(!"\X[O_@JWXNN_
M#/[*CV%LVV/7M<M--N"!SY866YQ[?-;+^H[U^,=:1YN=OI^>G_#+IL:5'>,+
MN^GW*[T^]M_,_H3\"^-O /[7'P5&I6MJNN>$->A>VN].U*$+(C X>*503M=&
M .5)P0K*Q^5J\0M&^"W_  2]^%:17<MYJ&L:U.S&2&%)-4U9E;@8)5%CB5QU
M95&21EWPW(?\$?9G;]GOQ7$6S&GBB8JOH3:6N?Y"OC__ (*B^++SQ#^UUK^G
M7#YM]"L+&PMEZ (T"W![]=]PW/';TS5UDXS7LM+VOZ6O^?YF%%JM3_>.ZBW9
M>=[;=[+YVZ'U[\(?^"M7@GQYX\AT'Q1X5NO!.GWDX@L]9DOTNH0S$A3<C8GD
MJ?E^8%P"W)"@M7I__!17X%Z;\8/V<?$&JM##'X@\)6TNM6%ZRC<L<2[KB(M@
MG:\2M\HP"Z1D_=K\/J_H-^+URVK?LL>-;BX"N]SX,O9) 1D$M8N3U[<]Z=6F
MIT&^JZ^>Z?RMZ>0Z-3_:X4/YT_31I/\ ]*7Z'X(^ ?!.I?$CQOH/A71XQ)JF
MLWL5C;AL[0\CA0S'LHSDGL 37[P>#/!_PV_8G^!<B"6'0O#&CQ+/J6K3H6FN
MYV*H9I-H+/([%5"@'&510  *_!/PSXGU;P9KUCK>A:C<Z1J]C();:]LY3'+$
MWJ&'L2/<$BO=]:^,G[1O[8F@IX.FFUOX@Z99W<%R]KIFB0X@E(=(GFE@A4JN
M&?F1MO!)^[D:R?-2Y*:]Z^_EI;[M?Z1BH_ON>I\*6GKKT\]%?IK9;W^P?%?_
M  64\/6>J&/PU\,M3U?3MH(N-6U6.QFW8Y'EQQSC'OO_  %?1?[-/[=OPY_:
M<UB;0=%74="\30V_VC^R]7B13.BXWF&1&97"DC@[6(R=N 2/S2\._P#!,?\
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M4 %%%% !7I7[,O\ R<C\*/\ L;-)_P#2R*O-:]*_9E_Y.1^%'_8V:3_Z614
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M8HV&<G!QBOZ(M-T/3='T6VT>PT^UL=)MH%M8+"VA6."*%5VK&L8 54"C 4#
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MZ?\ *4/P?_U^C_TUM7[D5^&_[.G_ "E#\'_]?H_]-;5^Y%?T+E?^X4/\$?\
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M)_:,_P""3WBS3/$FI:O\(I;/6?#L[>;!X?O;OR;VU+$YB227]W)&O9GD5\$
MAB"[0_LZ_P#!*'QEJ_B33=6^++V7A_P];R>9<:%;70N+VZVN,1,\1,<<;C.7
M61G & JD[E*?O[Z?U_6QG.\(WM?T_K\['S;J'[$?QPTWP+;>,)/A[J$^@W%K
M'>QRV<\%S-Y+H'5S!'(TJC:03E 5[XK]"_\ @C__ ,FV^)_^QMN/_2.SKT;_
M (*$?M :=\#?V>]8TR*6+_A)/%-M+H^EV>.1&ZA)YL C"QQN<'D;VC&,$UYS
M_P $?_\ DVWQ/_V-MQ_Z1V=9J:E.:C\*_K_+H:2@HTJ;?Q.]^UNGXW/@_P#X
M*'_\GE?$C_KXM/\ TB@K]A/V906_9@^%0 R?^$0TO_TCBK\>_P#@H?\ \GE?
M$C_KXM/_ $B@K]2?^">_Q)L_B/\ LH^"3#/%)?:';G1+V",\P/ =L8;W:'RG
M_P"!_6N#+Z/MLKIJ_P!B*^^._P#7=&=6;CB+6T=_O[?-7?R/PJK7\'Z'=^)O
M%VB:/8()+[4+Z"T@0]&DDD5%'YD5]O\ [1W_  2Q^(FE^-M2U7X8V]GXJ\.Z
MA>230:;]KCM;NP5V9MC>>ZHZ+PH8.6/=1UKU7]D+_@FU>_!KQI9?$KXL:SI*
M?V"AO[/2K67?#!*JD^?=3.H5?*Y8!,C<JMOPI5O9P=9TZD*[TY6GKY:V\_R\
M[:BQ$'>5*B[MWY7;[K]O3<^K?VU/^34?BC_V Y_Y"OR4_P""=O\ R>5\-_\
MKO=_^D5Q7ZS?ME745]^R/\2[FW<2P3:!+)&Z]&4@$'\C7Y,_\$[?^3ROAO\
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M^/\ KI I'H&-?N-6TN6<(58;25_Z_!_,QCS0G*E/>+_K]5\@HHHK(T"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,GQ5_R+>H_]<6_E7\X
M7[4W_)P7C7_K]'_HM*_H]\5?\BWJ/_7%OY5_.%^U-_R<%XU_Z_1_Z+2@#ZJ_
MX(J?\G3>*?\ L3+K_P!+K&OVIK\5O^"*G_)TWBG_ +$RZ_\ 2ZQK]J: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,?4HXG^R\3\4=O0^AXIP%*MAUF>&^&6_J>O4M%%?L9^0!1110 4444 %%%%
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MV?R('X4 >N$!@01D'J*^!_VX?@]I_@CQ)I?B?1+..RL-8WQW4$"[8TN5P=P
MX&]2>!W1CWK[YKYV_;LTU+[X'BX*@M9ZG;S*W<9#H?\ T.@#I_V3?B!+\0O@
MKI$]W,9]0TUFTVYD9LLQCQL)/4DQM'D]SFO8J^//^"=^K/)IGC?3&/[N&:UN
M4'NZRJW_ *+6OL.@ HHHH **** /E_QQ_P I%/AC_P!B-JW_ *415]05\O\
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MY4'5CSFMSX _M*>._P!FKQ--K'@K4T@6Z5$OM-O(_-L[U%.5$L>0<C)PZE7
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MOE0QPKM5W=A\L:DY8\D].E<-11OJR8Q459!7V'KG_!4;XJ^(/A[J'@VX\/\
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M/A)_T /%/_@-#_\ ':/^'O'PD_Z 'BG_ ,!H?_CM 'Y]?\,*?'O_ *)CK/\
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MQUG_ ,A?_%U^@O\ P]X^$G_0 \4_^ T/_P =H_X>\?"3_H >*?\ P&A_^.T
M?GU_PPI\>_\ HF.L_P#D+_XNC_AA3X]_]$QUG_R%_P#%U^@O_#WCX2?] #Q3
M_P" T/\ \=H_X>\?"3_H >*?_ :'_P".T ?GU_PPI\>_^B8ZS_Y"_P#BZ/\
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MM]%9U(>TBXEPER24C\)?V'?V_-5_8O;7?!OB;PS=:UX9NKUIY[-)/(O=.NE
MCD*JXPV0BAHVVX*YR.04_;L_X**:C^UII]CX5T'1I_#'@BTG%U)!<S![F_F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPD"X XJ<G-%%?=1BH+EBK(_.)2E-\TG=A1115$A1110 4444 %%%% !1110
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M]S(%DE"DI!'GYI'/95&3[]!R17ZSZ3IL.C:79Z?;@BWM84@CW')VJH49_ 4
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MJQV2>W)F/]*^U*^7?V ?#,FF_#76]:E4K_:>H;(\C[T<2 ;O^^G<?\!KZBH
M^=?'_P#PUK_PF6K?\(1_PI?_ (1/SC_9W_"0?VM]N\K QYWE?)NSG[O%<_\
M\9O?]6__ /E<KZJHH ^5?^,WO^K?_P#RN4?\9O?]6_\ _E<KZJHH ^#_  ;_
M ,+H_P"'@GP]_P"%N?\ "!_;_P#A#]4^S?\ "%_;?*^S^9'NW_:>=^_;C'&W
M/>OO"OE_QQ_RD4^&/_8C:M_Z415]04 %%%% !1110 4444 %%%% !7XG_MX?
M\I-)_P#=TW_TC2OVPK\3_P!O#_E)I/\ [NF_^D:5PX[_ '2K_AE^3/4RO_?\
M/_CC_P"E([JBBBOYU/Z_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /+?V=/\ E*'X/_Z_1_Z:VK]R*_#?]G3_ )2A^#_^OT?^FMJ_<BOZ
M%RO_ '"A_@C_ .DH_D?//^1KBO\ KY/_ -*84445Z9X@4444 %%%% !1110
M5^87_!<3_D4_A+_U^ZC_ .B[>OT]K\PO^"XG_(I_"7_K]U'_ -%V] 'D?A?_
M )%K2?\ KTB_] %:=9GA?_D6M)_Z](O_ $ 5IU\7+=G\TU?XDO5A1112,@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G3]L/\ X\_"W^_<_P H
MJ_>[X;_\D\\,?]@NV_\ 12U^"/[8?_'GX6_W[G^45?O=\-_^2>>&/^P7;?\
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MCD4 ?JA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM4BCYVCKBM.O8R7*(Y;1]_6;W9X/$&>3S;$?NW:FMD+GL.E)117TI\F%%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC FO)!PI95)PHR<+DY)R>0 /H+]C'X&WGPW\,7?B/7;5K77=9552VE7$EM;
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M3?(V6;J>"<#)QB@"WX#\&6'P]\'Z3X<TP$6>GP")&;[SGJSGW9BS'W-;]%%
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M6M)_Z](O_0!6G7Q<MV?S35_B2]6%%%%(R"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^=/VP_\ CS\+?[]S_**OWN^&_P#R3SPQ_P!@NV_]%+7X
M(_MA_P#'GX6_W[G^45?O=\-_^2>>&/\ L%VW_HI:^GP7\"/S_,_<^&?^152_
M[>_]*9T=%%%=Q]0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&H _I"\%_P#(K:9_UQ7^5;58O@O_ )%;3/\ KBO\JVJ "BBB@ HHHH ****
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MD>5F''K@BOU;\#6\EGX)\/P3%C-%I]NC[NNX1*#G\: -RBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E_QQ_RD4^&/
M_8C:M_Z415]05\O^./\ E(I\,?\ L1M6_P#2B*OJ"@ HHHH **** "BBB@ H
MHHH *_$_]O#_ )2:3_[NF_\ I&E?MA7XG_MX?\I-)_\ =TW_ -(TKAQW^Z5?
M\,OR9ZF5_P"_X?\ QQ_]*1W5%%%?SJ?U^%%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_E(I\,?^Q&U;_P!*(J^H*^7_ !Q_RD4^&/\ V(VK?^E$5?4% !1110 4444
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MMV?S35_B2]6%%%%(R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^=/VP_\ CS\+?[]S_**OWN^&_P#R3SPQ_P!@NV_]%+7X(_MA_P#'GX6_W[G^
M45?O=\-_^2>>&/\ L%VW_HI:^GP7\"/S_,_<^&?^152_[>_]*9T=%%%=Q]0%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA_Z U '](7@O_D5M,_ZXK_*MJL7P7_R*VF?]<5_E6U0 4444 %%%% !1110
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M@S_P"N__ )*H_P"'JWQ9_P"A>\&?^ 5W_P#)5?&=% 'V9_P]6^+/_0O>#/\
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M@S_P"N__ )*H_P"'JWQ9_P"A>\&?^ 5W_P#)5?&=% 'V9_P]6^+/_0O>#/\
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M@S_P"N__ )*H_P"'JWQ9_P"A>\&?^ 5W_P#)5?&=% 'V9_P]6^+/_0O>#/\
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M@S_P"N__ )*H_P"'JWQ9_P"A>\&?^ 5W_P#)5?&=% 'V9_P]6^+/_0O>#/\
MP"N__DJC_AZM\6?^A>\&?^ 5W_\ )5?&=% 'V9_P]6^+/_0O>#/_  "N_P#Y
M*H_X>K?%G_H7O!G_ (!7?_R57QG10!]F?\/5OBS_ -"]X,_\ KO_ .2J/^'J
MWQ9_Z%[P9_X!7?\ \E5\9T4 ?9G_  ]6^+/_ $+W@S_P"N__ )*H_P"'JWQ9
M_P"A>\&?^ 5W_P#)5?&=% 'V9_P]6^+/_0O>#/\ P"N__DJC_AZM\6?^A>\&
M?^ 5W_\ )5?&=% 'V9_P]6^+/_0O>#/_  "N_P#Y*H_X>K?%G_H7O!G_ (!7
M?_R57QG10!]F?\/5OBS_ -"]X,_\ KO_ .2J/^'JWQ9_Z%[P9_X!7?\ \E5\
M9T4 ?9G_  ]6^+/_ $+W@S_P"N__ )*H_P"'JWQ9_P"A>\&?^ 5W_P#)5?&=
M% 'V9_P]6^+/_0O>#/\ P"N__DJC_AZM\6?^A>\&?^ 5W_\ )5?&=% 'V9_P
M]6^+/_0O>#/_  "N_P#Y*H_X>K?%G_H7O!G_ (!7?_R57QG10!]F?\/5OBS_
M -"]X,_\ KO_ .2J/^'JWQ9_Z%[P9_X!7?\ \E5\9T4 ?9G_  ]6^+/_ $+W
M@S_P"N__ )*H_P"'JWQ9_P"A>\&?^ 5W_P#)5?&=% ']#R-N12>XS3J9%_JT
M^@I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M44R65((WDD=8XT!9G8X"@=23Z4KVU8#ZK7VI6FEQ"6\NH;2/IOGD"#\R:_'_
M /;8_P""JWBCQ1XDU/P?\&]3;P]X7M9&MYO$EK_Q^:B1D,T+D?N8L_=9<.<
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MUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFS=EO2O,?$GB^Z\17#PQ*0K''6L^&&Z\3ZD-Y.&/:O3]#^&UM8NCS@L1@U\
MZ^8\0RE&C[M*Y^G1P^5<+1C.O[U:QF>!_ /EM'<W)XZ]*])55AC"(, 4D<:V
M\8C0844M?H.7Y?1R^BJ=)>I^7YGF=?-*[K5GZ+L%%%%>F>0%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%*JEC@4
M *B&1L"K_P#9+E015K3=/55#OR36GZ5Z%+#IJ\SSZN(:=HF(VDE;?=_'BLU@
M5;!ZUUC8;@]*SIM+5BS#K15P^W(%+$;\YAT5)-"86(-1UY^VC/03OJ@HHHH
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M445R'4%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)GJ97_O^'_QQ_P#2D=U1117\ZG]?A1110 4444 %%%% !1110 4444 %%%%
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M'_8+MO\ T4M?3X+^!'Y_F?N?#/\ R*J7_;W_ *4SHZ***[CZ@**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSO\ ^"N7_-*/^XM_
M[9U^B%?G?_P5R_YI1_W%O_;.@#\[Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _H=B_P!6GT%/ID7^K3Z"GT %%%% !1110 4444 %%%%
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MX+_Y%;3/^N*_RK:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,;)\ !AD]*_4VD!R,CD4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P!B9=?^EUC7[4U^*W_!%3_DZ;Q3_P!B9=?^EUC7[4T %%%% !1110 4444
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MT\-'YPZBIE'2Z,*U"*C>*.9HH]CUHK$\P**** "BBB@ HHHH **** "BBBD
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MS58HZ:U;VD>5'I%+24M?4' %%%% !1110 4444 ?@=_P56_Y/A\=?]>^F_\
MI#!7BG[-'_)>/!G_ %_#_P! :O:_^"JW_)\/CK_KWTW_ -(8*\4_9H_Y+QX,
M_P"OX?\ H#4 ?TA>"_\ D5M,_P"N*_RK:K%\%_\ (K:9_P!<5_E6U0 4444
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M.OT0K\[_ /@KE_S2C_N+?^V= 'YWT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 !2W0
M9HZ=:GM;C[.V[ )]ZCFD\V1GQ@L<TM;DW=[6&4444R@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _H=B_P!6
MGT%/ID7^K3Z"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6#X[\<:)\,_!VL>*O$EZ--T+2;9KN\NC&TGEQJ,D[5!9C[ $GM6
M]7GW[0/PI/QP^"WC#P&NH?V2^NV#VB7IB\P0L2"K%<C(R!D9'%9U')0DX*[M
MIZEP47)*6QX=_P /4/V9O^B@S?\ @BU#_P",4?\ #U#]F;_HH,W_ ((M0_\
MC%?(O_#CO7_^BM:;_P""23_X]1_PX[U__HK6F_\ @DD_^/5H0?77_#U#]F;_
M **#-_X(M0_^,4?\/4/V9O\ HH,W_@BU#_XQ7R+_ ,..]?\ ^BM:;_X))/\
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MN+9C([,><G-7-8N&FO) 22 :I5Y]27,SRJL^:04445D8A1110 4444 %%%%
M!2[?7BDDD2WB:20X &:\?\;?'.UT6XGMH+A/,CXQQ7/6KPH1YILSJ5J='6H[
M(Z;XJ?$2'PGH\\2.HGVY![]*^,[>;6?BCX@\J:>0QROCCW-6?'WCC4?B)KS
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M 4444 %%%% !1110 4444 %%%% !1110!_0[%_JT^@I],B_U:?04^@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S/$OB72_!
MOA_4-<UR_@TO2-/@:YN[VY<)'#&HRS,>P I-I*[&DV[(TZ*^?/\ AX!^SO\
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MC"BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^ ?]::ZL+_&0,](I:2EKZLR"BBB@ HHHH **** /P._X*K?\GP^.O^O?3?\
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M%% !1110 4444 >6_LZ?\I0_!_\ U^C_ --;5^Y%?AO^SI_RE#\'_P#7Z/\
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M **** "BBB@ HHHH _H=B_U:?04^F1?ZM/H*?0 4444 %%%% !1110 4444
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MU^U-?BM_P14_Y.F\4_\ 8F77_I=8U^U- !1110 4444 %%%% !1110 4444
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MIE>>>8%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4?9IWU04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\I0_!__ %^C_P!-;5^Y%?AO^SI_RE#\'_\ 7Z/_ $UM7[D5_0N5_P"X4/\
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M^Y\,_P#(JI?]O?\ I3.CHHHKN/J HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!_0[%_JT^@I],B_U:?04^@
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M\0RK^BVYFNU..,U0^]P.374Z#9[(4<\&G%79=&//,V%7:N*=1172>X%%%%(
MHHHH **** "BBB@ HI/;O5NVTZ68].*J,7)V2)E)15V51EFP.:UM/T8R*';B
MK=KH:)AB>:U44(H [5ZE#":WJ'FUL5I:!'#;+"HP.:FHHKU$DM$>8VWJPHHH
MIB"BBB@ HHHH *3KP:6B@#%UC1A<JSH #7'SP/;R%'&,5Z36)K.ABX5G3[_I
M7-4IWU1R5J7-K$XVBIKBSEM?OC J&N/8X-@HHHH$%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** /E_QQ_RD4^&/_8C:M_Z415]05\O^./\
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M^"_@1^?YG[GPS_R*J7_;W_I3.CHHHKN/J HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_.__ (*Y?\TH_P"XM_[9U^B%?G?_ ,%<
MO^:4?]Q;_P!LZ /@O1=7^SQF%V^5OX:JW49\UGZ=Q6<K%6!%79KQ9X0O1A7,
MZ?+/FCU.1TN6?-%;E61C(W3FK$4?D1,[#Z5"FV/#'FDFG,I]NU:ZO1&UF]%L
M1-R31116AJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?T.Q?ZM/H*?3(O]6GT
M%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P
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M2@HHHH R?%7_ "+>H_\ 7%OY5_.%^U-_R<%XU_Z_1_Z+2OZ/?%7_ "+>H_\
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MDV?A^P6WM(A#&!T%8EY*9+A\G/-=D:$<'05..[/J,HP,<)#E6_4@HHHKF/I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[>OT]K\PO^"XG_(I_"7_ *_=1_\ 1=O0!Y'X7_Y%K2?^O2+_ - %:=9GA?\
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MT;P/X\^%6A>']+M-%T:Q\/S16UC8PK%%$HN#PJ@8'K[DDU^MOPF_Y)7X-_[
MME_Z(2ORG_X+=?\ )7/AQ_V YO\ TH-?JQ\)O^25^#?^P+9?^B$HPK;PM1O^
M=_G,G$)+$P2_E_2!U=%%%,85\D?M@?'3XG_"WQ]I.G>"-.:\TV?3$N)G6 28
ME,LJD9Q_=5?SKZWJ.2&.0Y>-7/JR@T ?F1K'[77Q_N-+NHYM$D$31D,?L@Z?
ME7Y@_%S6-0\0?$C7M0U6/RM1N)PTR$8PVT#I] *_I>\56L'_  C>H_N8_P#4
MM_"/2OYQOVIE"_M ^-0!@?;1T_ZYI0!]5_\ !%3_ ).F\4_]B9=?^EUC7[4U
M^*W_  14_P"3IO%/_8F77_I=8U^U- !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]2NA:P$DXS5RN
M6\47P8"('D5$Y<JN9U)<L;G/W4GG74CYSDU%0**\T\D****!!112JNXT "KN
M-><_&[XA?\(7X:G:WD"R.FS\^*Z[Q1XNL/".GRW-Y*D:HI)W-BOB'XC^.KGX
MA>(EM(Y6FM9)@J@'(ZUY&88M8>GRQ?O,\/-,<L+2Y(OWF0^#/#]_\3O&$;3-
M)<6[/N?<20!7VUX#\%67@C1Q;6T2@N 2<<UQGP&^'2>#=+\]X!&TT?4KCTKU
M9F Y/2IR[">QA[2?Q,G*L#]7I^UGK-E#5K@QPC!YK 9BQR:NZI<>9-M!XJC3
MKSYYGVU"'+ ****YSH"BBB@ HHHH ***5>30 =!D]*Y7QAXMATJU*12#S2#D
M4SQWXK31[,PQR;9VZ8/->5:?IMYXNU)GPTC=^]?$YUG4J,_J6$7-4?X'Z#P_
MP_'$0_M#'/EI1[]1NGV\GB;7E8DN"^2/QKW72-)MM/LX]L*!\==O-8OA'P;#
MH>V5H@LN.3BNI-=.0Y7+!4Y5:^LY'+Q-G4<PJQH89VIPT]1****^M/B HHHH
M ***=&OF2HHYYH&:6A6/G3!R/N\UURC:H%5--M5MX00,$BKE=$5RH]JC3]G$
M****HZ HHHH **** "BBB@ HHHH ***3VH DMX3/,H SS75V=HD,8^49JCH]
MCY>'Q^E;%>WA:/+'F>YXV*K<SY5L)2T45Z!P!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4%Q:QW*%64&IZ* ,#4M#CCM&*+\V:Y*2,PR
M%#P:]*90ZX-<OK.@R33%XDR?85RU:?5'%6I=8G-T5:FTNXM1^\4C\*JUR6:W
M.)IK<****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %+244 *</PZAQZ'FL?7O!^E>(;5X9;&W&X8+", _G6O
M14RBI*TD3**DK25S@O#WP3T/P[??:H[>-VSGYAFN^14@0)"BQ*.,*,44E3"G
M"FK05B*=*G15J:L+N)ZFDHHK0U%J.2RL9SNFLX)7[,\8)I]%(!JVMFG"6L*#
M_90"G\+PHVCT%)10 Y79>A-<A\3O!-MXR\/SVTD2M(Z$;L<UUM*K;:F<54BX
MRV9%2$:L7"6S/A?Q-\%=6\.B5[5)TCCR=RDUM_ +XEW?ACQ$NG75R[B4[")&
MS_.OLK4K>/4M/GMY%5O,0KC'J*^*/C9\.Y_ >M1ZG;PM$QER&5<>M?+8G"/
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M\/\ T!J /Z0O!?\ R*VF?]<5_E6U6+X+_P"16TS_ *XK_*MJ@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M+W]IKXE7'Q+^+FM7!G:33-/F:QL(LG:L<9VE@/\ ;8%L^X]!7F%G87.H2B*U
MMYKF7^Y"A<_D*T_&VCW'A_QEKFF7:NES:7TT,@DZY5R,U^J/PK\$Z1X!\"Z-
MI>CVT$,*6L1DFA0 W#[!ND8_Q%CDY/K0!^5O_"%^(?\ H ZG_P" <G_Q-'_"
M%^(?^@#J?_@')_\ $U^O]% 'Y&:+X,\0+K%BS:%J0 GC))LY/[P]J_7.BB@
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M^&_[.G_*4/P?_P!?H_\ 36U?N17]"Y7_ +A0_P $?_24?R/GG_(UQ7_7R?\
MZ4PHHHKTSQ HHHH **** "BBB@ K\PO^"XG_ "*?PE_Z_=1_]%V]?I[7YA?\
M%Q/^13^$O_7[J/\ Z+MZ /(_"_\ R+6D_P#7I%_Z *TZS/"__(M:3_UZ1?\
MH K3KXN6[/YIJ_Q)>K"BBBD9!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?.G[8?_'GX6_W[G^45?O=\-_^2>>&/^P7;?\ HI:_!']L/_CS\+?[
M]S_**OWN^&__ "3SPQ_V"[;_ -%+7T^"_@1^?YG[GPS_ ,BJE_V]_P"E,Z.B
MBBNX^H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK\[_ /@KE_S2C_N+?^V=?HA7YW_\%<O^:4?]Q;_VSH _.^BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5\I_\$[?VL/$O[6GPGUO6_%FG:=8ZSI&JG3VDTM'CAG0Q)(K;'9BK?,0><'
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M_2OHZ...WC$4*^7&.BCM7EX' RF_K%?5O8\?+<NE4?UK$ZM["HBPQ)$@PJ\
M5G:I=>7'L'6K\C;$+>E<]J$WG39]*]O$5.2-D?;8>'-+T*I8L<GDTE%%>0>L
M%%%% !1110 44H!-#,D8RYVB@  )K+\2:Q'I.FRL6 ;'%9WB#QQ;Z-"Y3;(U
M>5Z]XHO/%5PL,9*H6Y"U\IFV>4,)!TJ3O4?1'VF2<.8G'U(UJRY:2U;96NII
MO%6M",$MS7L7@[P_'H^FKE0)>YKG_A]X+2S3[5,I,G;->@' X' KCX?RN5*^
M-Q*]^1W\49S"LUE^$?[N ,Q:DHHK[<_/ HHHH **** "M#0[?[1= 8Z<UG@%
MFP!S75:'IWV?$AZU45=G10@YS1KHNU0*=1170>V%%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVF?]<5_E6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-JW_ *415]05\O\ CC_E(I\,?^Q&U;_THBKZ@H **** "BBB@ HHHH ****
M"OQ/_;P_Y2:3_P"[IO\ Z1I7[85^)_[>'_*32?\ W=-_](TKAQW^Z5?\,OR9
MZF5_[_A_\<?_ $I'=4445_.I_7X4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Y;^SI_P I0_!__7Z/_36U?N17X;_LZ?\ *4/P?_U^C_TU
MM7[D5_0N5_[A0_P1_P#24?R/GG_(UQ7_ %\G_P"E,****],\0**** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\[_P#@KE_S2C_N+?\
MMG7Z(5^=_P#P5R_YI1_W%O\ VSH _.^BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ13
ME8J#[T -HHHH **** "BBB@ HHHH **** "BBB@ HHH49H .M2_9VV9Q4UOY
M<8R>:DAO LFYU&WIBLG)]$8RD^B*31LO44VM._N$F1=J@#VK/_E3C)M78X2<
ME=H:1BDI[+^5,-6:(****8PIP ]:;1FD(****8PHHHH **** "BBB@ HHHH
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M?>O7_P#@HQ_R97\4O^O"+_THBK?'_NJ+C#2T5^*3,<"W5K1E/6\ORE8^=O\
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M8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 R2)9!AE!^HJNFFPI(6V+^56Z*5D*R&"&->B*/PJ.XLX[A"&1?
MRJ>B@+&%/X9A9#@5S-[ILEFY^7Y:]#JO=V<=Y&5<9K&5)2V.>=&,EH><YHKH
M]3\.%1F%/R%8<MA-!PP(KDE!QW.&5.4=R"BGM"ZKDBH]U00+12;J7- @HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!=Q'>EWM_>--HH =N/K4<B[D-.I?X30,Y:ZXN
M''O456+Y=MT]5Z\"6DFCW8_"A<@\,-P]#7-^+O .F>+K%X);>-"1]Y5 -='1
M42BI*S)J4X5HN%173/E/Q]\%7\,[YM/$B@<Y5C5GX)_$2XT.Z&ESW#/\Y4^8
M<]_>OIW4[*/4K"6%U#%ACI7QU\3O"LW@;Q5)<11M$6?>"!CKS7CUJ7U:2J4]
MC\]S+ O)JT<9A=(]4?9@9)8U=#D$9I*\W^#?CJ/7M!MXIY@]RR@8)YKTEEVG
M%>M3FJD5)'WN&Q$,52C5ALQK?=-=GX!_UIKC&^Z:[/P#_K37=A?XR.D](I:2
MEKZLR"BBB@ HHHH **** /P._P""JW_)\/CK_KWTW_TA@KQ3]FC_ )+QX,_Z
M_A_Z U>U_P#!5;_D^'QU_P!>^F_^D,%>*?LT?\EX\&?]?P_] :@#^D+P7_R*
MVF?]<5_E6U6+X+_Y%;3/^N*_RK:H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,B;PCH5U-)--HNG2RR,7>1
M[2,LS$Y))(Y)-,_X0GP]_P! '3/_  #C_P#B:\#_ &I/VJ)_A/?1^&?#$=O/
MXA:,2W-U.-Z6BM]U0O=R.>> ".#GCY4U']JGXJZG,9)?&-W$<\+;Q10J/P1!
MZ4 ?I/\ \(3X>_Z .F?^ <?_ ,31_P (3X>_Z .F?^ <?_Q-?F;_ ,-+_%#_
M *'74_\ OM?\*/\ AI?XH?\ 0ZZG_P!]K_A0!^ET_A7PS8PM<3:/I-O%'\S2
MR6L2JON21Q6]7Y+:A\1O%/CG7-//B#Q!J.KJ+F,K'=7+/&IW#HF=H_ 5^M-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'R_XX_Y2*?#'_L1M6_\ 2B*OJ"OE_P <?\I%/AC_ -B-JW_I1%7U!0 4
M444 %%%% !1110 4444 %?B?^WA_RDTG_P!W3?\ TC2OVPK\3_V\/^4FD_\
MNZ;_ .D:5PX[_=*O^&7Y,]3*_P#?\/\ XX_^E([JBBBOYU/Z_"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /+?V=/^4H?@_P#Z_1_Z:VK]
MR*_#?]G3_E*'X/\ ^OT?^FMJ_<BOZ%RO_<*'^"/_ *2C^1\\_P"1KBO^OD__
M $IA1117IGB!1110 4444 %%%% !7YA?\%Q/^13^$O\ U^ZC_P"B[>OT]K\P
MO^"XG_(I_"7_ *_=1_\ 1=O0!Y'X7_Y%K2?^O2+_ - %:=9GA?\ Y%K2?^O2
M+_T 5IU\7+=G\TU?XDO5A1112,@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /G3]L/_ (\_"W^_<_RBK][OAO\ \D\\,?\ 8+MO_12U^"/[8?\
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M:0QI'&BQQH JJHP !T 'I3ZNI/G:MLM%_7XD0ARW;W84445D:!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &3XJ_Y%O4?^N+?RK^<+]J;_
M )."\:_]?H_]%I7]'OBK_D6]1_ZXM_*OYPOVIO\ DX+QK_U^C_T6E 'U5_P1
M4_Y.F\4_]B9=?^EUC7[4U^*W_!%3_DZ;Q3_V)EU_Z76-?M30 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56O[I;6
M!G)QQ5FN9\27PVO#GGI43ERJYG4ERQN<[>3&XN&;.14- Z45YIY.X4444""E
MI*=YB0KOD.U!U- %#7/$-GX9L'NKF5% '0FOB+XR>,G\<>-/+LMT\&0-J GN
M:[+]HCXH23ZU=:3:.S1[RH9>G6IOV>?@[-JDQUB]4-$Y&"WY_P!:^6QE:>-J
M_5J6RW/C,=B)YC6^IT=D]3V;X"^"SX7\+6MRT?EO.NXCO7IK'+$TRUMTL;2.
MVCX2,8&*=7TE*FJ5-070^MH4E0IQIQZ!4=Q((XFSZ5)6=K%QMAP#S3J2Y8MG
M53CS22,61MTC&FT45X7F>X%%%%, JMJ>H1:5:-/*P4#CFIYIEMH3*YPH[UY+
M\0O%QO9A:6Q+@GG%>-FF90RZ@ZC?O=$>_DN4U,VQ*I17N]68?BO6)?$6L%(2
MTD?0 5WO@?P+':V:3W<:G?R,UC?#CP?(TAO)U^5NF:]45!$@1?NBOE\CRMXB
M;S'&*\I;)GV/$><QPM..58!VC'=H9!;Q6JA8EVBI"Q-)17Z DHJR/S!MR=V[
ML****8@HHHH **** "E53(V%!)]J3D\#K70:%I1_UKCK32N[&E.#J2LBC;Z'
M-)L?'!KJK.V%K"J@8XJ4(J@ #I3JWC%1/7IT53V"BBBJ.@**** "BBB@ HHH
MH **** "I[&W-Q.%QD$U"J-(V%&:Z+2M/,*JS#!KIH4G4EY'/6J*G'S)X]+B
M51E>:M1PK$/E&*DHKWXPC'9'A2G*6["BBBK("BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH 3K4,EG%)]Y<U/10+<J-ID#+C8*SF\/KYQ.T;<UN45+BF2X1?0S%T.
M#RR"@S5&X\-[@=@%=#12<(L3IQ?0\\U#3Y+*3#*<54KO]4TU;Z/'0UQ5]I\E
MG,P*_+V-<=2GR['!5IN#NMBK1116)SA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'8T44
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M4+PCJCZYX3T7493F2\LH+ACC'+QJQ_G0!KT444 %%%% !1110 4444 %%%%
M!1110 4444 %9^N^(M+\+Z>]_K&I6NE62'#7%Y,L48)Z#<Q S[5F_$+QM8_#
MGP7J_B34CFUT^ RF,'!D;HD8/JS%5'UK\Z88?'_[77Q+FV2>?,<R$2R,MGIT
M.0 !UVCH. 68\\\F@#[OC_:0^&,EV;8>-M)$@XW--M3O_&1M[>O\Z]!L-0M=
M4LXKNRN8;RUE&Z.>WD#HX]0PX(KXNNO^"=^HKIV^W\;VLM_M_P!1+IS)%G'3
MS!(3CISMKRKPGXS\<_LD_$J72[]9%MED4WNF%]UO>0D\21D\9(SM<8((P>ZT
M ?I=16;X;\16/BSP_I^M:9-Y^GW\"7$$F,$JPR,CL?4=C6E0 4444 %%%% '
MR_XX_P"4BGPQ_P"Q&U;_ -*(J^H*^7_''_*13X8_]B-JW_I1%7U!0 4444 %
M%%% !1110 4444 %?B?^WA_RDTG_ -W3?_2-*_;"OQ/_ &\/^4FD_P#NZ;_Z
M1I7#CO\ =*O^&7Y,]3*_]_P_^./_ *4CNJ***_G4_K\**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \M_9T_P"4H?@__K]'_IK:OW(K\-_V
M=/\ E*'X/_Z_1_Z:VK]R*_H7*_\ <*'^"/\ Z2C^1\\_Y&N*_P"OD_\ TIA1
M117IGB!1110 4444 %%%% !7YA?\%Q/^13^$O_7[J/\ Z+MZ_3VOS"_X+B?\
MBG\)?^OW4?\ T7;T >1^%_\ D6M)_P"O2+_T 5IUF>%_^1:TG_KTB_\ 0!6G
M7Q<MV?S35_B2]6%%%%(R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^=/VP_P#CS\+?[]S_ "BK][OAO_R3SPQ_V"[;_P!%+7X(_MA_\>?A;_?N
M?Y15^]WPW_Y)YX8_[!=M_P"BEKZ?!?P(_/\ ,_<^&?\ D54O^WO_ $IG1T44
M5W'U 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
MG?\ \%<O^:4?]Q;_ -LZ_1"OSO\ ^"N7_-*/^XM_[9T ?G?1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4N!MSGFDHH **4]O6DH **** "BBB@ H
MHHH 7=^=.09/M3*7&*0A\R@/A3FE4 ?>II7CFE4#;S4D="21>AQBD_AYI1\K
M"F2*-V1TI"&<<\YIM._G3:M&B"BBBF,**** "BBB@ HHHZT %%+M-)0 4444
M %/A7=,@/=@/UIE*K;6!]#F@3V/I'P?X M[OP/+= *>.:\VUO1HK-V48!6MS
MX;_%%M/TV339#E6&.:H^,!%>*9XWP>N :^%P\,31Q=2-9Z-Z'YOA:>,P^.JP
MQ#]UO0\]U2958*HYJ6POHPI5CDUFW2NTK$@GFHU<+QTK['V:<$C[[V2E!1.F
MA:W^SO(Y XXKF;EQ),Q'3/%2->,8MG:J].E3Y&VQT:/LVVWN%%%%=!U!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
MN/2BBB@ HHHH **** /Z'8O]6GT%/ID7^K3Z"GT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7CG[8FC^(O$'[+_P 2M/\ "<-[
M<^(9]&F6TATW<;F1N"5C"_,6*A@ .3G'>O8Z*SJ0]I"4+VNK%TY<DU+L?SX?
M"_\ ;R_:$_9SU5M)'BG4KR&SDV3^'_%\3W21D<>61+B6(#^ZCI7W/\%_^"U'
M@_7OL]C\3O"-[X6NFVH^JZ*WVVTSCYG:(XEC7V7S37WE\3/@GX!^,VF_8?''
MA#2/$\"J5C;4+17EAR,$QR8WQGW0@U\2?&+_ ((P?#;Q49KOX>^)-4\#7;'*
MV5X/[1L@,?=7<RRKD_Q&1_I6GM)?:5_Z^_\ ,CDC]EV/M/X4_'SX=_'#3OMG
M@3QCI/B5 @DDAL[@?:(5/3S(6Q)']'45WU?@E\3?^":_[1/P'U!=8TC1)?$T
M-DPFAU?P7<O-/$P/!6(!+@,.N50@>M7?A/\ \%/_ -H#X'WPT?Q!J(\8V=F_
MDS:9XNMV:[BP?F7SQMF#]OWA?']VFG"6B=OZ_KH)J<=6K_U_74_>"BOD?]C7
M_@HMX3_:XUZ?PNGAW4/"OBZVLFOY+2:5+BUEC5U5O*F&UB1O4D,B\'@G!KZX
MIRBXVOU%&2E>W0****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH R?%7_(MZC_UQ;^5?SA?M3?\ )P7C7_K]'_HM*_H]\5?\BWJ/_7%O
MY5_.%^U-_P G!>-?^OT?^BTH ^JO^"*G_)TWBG_L3+K_ -+K&OVIK\5O^"*G
M_)TWBG_L3+K_ -+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHI.E #9I!&A8UP6M3_ &B\9@>,UO:]K/DEHEZU
MRC,7.6ZUQUI7T1P5YW]U"4445S'&%%%% "@;CBN.^*/C"W\-^';E6;%QM.!^
M%=A)(+>!YF^ZO)KXZ_:0^(,VN>))+2P;$8PA&<]L5Y^.Q"P]%OJSR\RQ2PE!
MRZLX;P;I5S\2O&(,X^_)GUK[E\#^'T\*^&X=/51\IW9Q["O'_P!G3X9PV>BV
MNJRJ1.4#'(]J]\D;<1],5R99AG2I^UG\3.+)\&Z-+VT_BD-I***]L^A$=Q&N
MX]*YN\N#-(?2M;5+C;"RCK6#UZUYN*GKR(]+#0TYF%%%%<)W!2J,FDJOJ5\E
MA:2.QP<9%1*2A%RELBXQE4DH1W9RGQ \4)I<,EJ#\S#M]*\^\&Z)+KVL^;(/
MW77)JKKFH2^*-<=#_?VC'UKUCP+X=71]/)<9<X(K\PIQGQ!F?/+^%!G[#5=/
MAC)_9Q_C5%K\SH+&SCTVU6",<#O4U*3FDK]0C%12C%:(_'92E-N4G=L****H
MD**** "BBB@ H-%3V5N;JX5>U TKNR+FCZ:UU*'/W1760PB",(.E0V%HMI#A
M>]6JZ(QY4>U1I*G'S"BBBJ.@**** "BBB@ HHHH ***%!9L#K3 2A<L< 5=M
M])EGYS@?2M>ST:.-07Y:NFGAZE1['-4Q$(=2#2=,^4/)UK; Q2)&(U '2G5[
ME.FJ<;(\6I4=25V%%%%:F04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 51U#3([Y>>#CTJ]12:3T8FDU9G#ZAH$UNY,8RM93*5;!ZU
MZ5)&LB[6'%<EKVC_ &=GE3[O6N2I2MJCAJT>76)@T4@S_=(I:YCC"BCGL#3X
MH7F;:%(H&,R**V(_#$\B[MWZ5!/H,]OR3G\*ODEV+]G+L9U%226\D74'\JCJ
M" HHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(/V>?"/P66:71+>:YU.==DNI7SAYRO7:N  JY[ #.!DG KTR@ HHHH ****
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M:'_T&=/_ / J/_&C_A+-#_Z#.G_^!4?^- &M163_ ,)9H?\ T&=/_P# J/\
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MRS15;^U++_G[@_[^K_C39-8L(U+/>VZ*.K-*H'\Z?++L'M(=T6Z*K?VI9?\
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M*Y?\TH_[BW_MG7Z(5^=__!7+_FE'_<6_]LZ /SOHHHH **** "BBB@ HHHH
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M>*Z&W@6!,*,5W8;#MRYIG'B,0DN6(Y(UC&%&*?117LGCA1110 4444 %%%%
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M#4 ?TA>"_P#D5M,_ZXK_ "K:K%\%_P#(K:9_UQ7^5;5 !1110 4444 %%%%
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M_P#P-N__ (]7TK10!\U?\.W?V;?^B6Z?_P"!MW_\>H_X=N_LV_\ 1+=/_P#
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M/^';O[-O_1+=/_\  V[_ /CU?2M% 'S5_P .W?V;?^B6Z?\ ^!MW_P#'J/\
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M7TK10!\U?\.W?V;?^B6Z?_X&W?\ \>H_X=N_LV_]$MT__P #;O\ ^/5]*T4
M?-7_  [=_9M_Z);I_P#X&W?_ ,>H_P"';O[-O_1+=/\ _ V[_P#CU?2M% 'Y
MW?L-_L0_ _XI_LYZ-XB\5> +/6-:GU#4X9+N2ZN49DBOIXXQA9 .$11T[5[Y
M_P .W?V;?^B6Z?\ ^!MW_P#'JJ_\$V_^32_#_P#V%=8_].5S7T_0!\U?\.W?
MV;?^B6Z?_P"!MW_\>H_X=N_LV_\ 1+=/_P# V[_^/5]*T4 ?-7_#MW]FW_HE
MNG_^!MW_ /'J/^';O[-O_1+=/_\  V[_ /CU?2M% 'S5_P .W?V;?^B6Z?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9_UQ7^5;58O@O_D5M,_ZXK_*MJ@ HHHH **** "BBB@ HHHH **** "BBB@
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M?BA_UPLO_2^VH ^GE^Z*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 -TKH?#'WJYYNE=#X8^]6E/XC:E\:.LI:2
MEKT3U0HHHH **** "BBB@#\#O^"JW_)\/CK_ *]]-_\ 2&"O%/V:/^2\>#/^
MOX?^@-7M?_!5;_D^'QU_U[Z;_P"D,%>*?LT?\EX\&?\ 7\/_ $!J /Z0O!?_
M "*VF?\ 7%?Y5M5B^"_^16TS_KBO\JVJ "BBB@ HHHH **** "BBB@ HHHH
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M@TG0M.@TO3H?N6]NN!GN2>I)[DY)[UK5\*:?^W[XPO+^V@;P[H:K+*J$@39
M) _OU]UT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7FG[2'P5A_:(^"OB7X>7&JR:'#K20HU_% )FB\N>.;(0LN<^7CJ.M
M>ET4 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >:?L[?!6']GWX5V'@JWU636HK2ZN[
MD7DD A9O/N9)R-H9L;3)MZ\XS7I=%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^=
M_P#P5R_YI1_W%O\ VSK]$*_._P#X*Y?\TH_[BW_MG0!^=]%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN[-)MJRJ;@1BHY(SUZU7,5S$-'K2X]Z!G!XJBQ****8PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G1J9)%4=2:;0#@Y%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"F2Q+,A5AD&GT4 <EKVAB%3)$F!G)P*YX=Z](NH?M$+)ZBN(UC3GLYCA3BN*
MK"VJ//K4^7WD9U%%%<YR!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 #=*Z'PQ]ZN>;I70^&/O5I3^(VI?&CK*6D
MI:]$]4**** "BBB@ HHHH _ [_@JM_R?#XZ_Z]]-_P#2&"O%/V:/^2\>#/\
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MG(@AN&\D_6,DJ?Q% 'N'_#O_ .(?_09\,_\ @5<?_&*/^'?_ ,0_^@SX9_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW:DY]JYZWPG+B/A*-%%%<1YP4444 %%%% !1110 4444 %%%% !113E0M[4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW&T![B4CYI'/<D_D, <"@#KJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\[_\
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MB_$OPQ::]H-V+JQN!R.CQ./O1NO\+#N/Q&00:_.[]HO]G34O@GKGVBW\R_\
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M-$EB?++@^E;4-Q*K8Z&IA-*TASR*Y_;5$SF^L58N^AR+Z=(I9BISGTJ&17C
MW9KTJSABN+<K(H#'IFF7O@!I+<W$14IZ4EF$(NU30F.:0C+EJZ'G#$\'M4R_
M/@]"*NWNBW-C(P>)@N>#CBL\[MVUNE>E&49J\6>O&<:BO%EB)6ZGUJVMPD:\
M\D\&LYFVKM4XI4^7EN3ZU$H\VYG*'-N2, TC-G ITC[5"J.HJM))N;TIP<,N
M0>E5R[%\NUQ^X_Q' I3\V!VJ&-CR*D# +@'D4[ T+O(RHX%36T@Z-ZU&.5)/
M4=*FMUV\XZUG*UC.5K%G[*)"OR_(>]._LO9)G&1VK9T]8Y+/9C+ 9J[I\D3+
MY<@R17G2KRC>W0\J>)E&]EL<9*KJS*5VC/I3=K;LMSVKJ]<LXY%W1CC'2N9:
M,*N#P,]ZZJ595(W.RC656%]BM-;G=G'RU&D?S@%?EK16/Y<YR.XJ18XV7*CF
MMO:6T.CVME8RV4'H.*7&5R>M6GQNY&*DC5&7&,"GSZ%.I9&='PV0,T_YNX&*
MG:WW/QP*22W:,=/EJ^9,KG396>'IM/O3HUW-4@8%>F:85*YP.:=RKMDRK\P^
M7BDF7/S#D4V!BW!-69$)CR#6?PLR?NLS;@G;QSGBJ>-N0:O7'RYQ5-E/;O73
M'8[(/0;S3XV.X#L.]"J,8_BIY7   YJRVRQ(R;>#UI(FQQ42H% SU-2;OD*Y
MK*QC;0CD=BV!TJO)UI^W<WI3),?C6L3:.@VBBBK- HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** !>2!6NT+6VG_*WWCTK('45;::6>/:3E164TW8
MPJ1<K=B".(R-[4V10K$"D;@TE:&NH4Z.5XCE&*GVIM/2,LI-#\QNUM1TES))
M@DG([U%RQ]33MQP5I_DF-=Q/%+1$Z1/Z&(O]6GT%/ID7^K3Z"GU184444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444V21(E+.RHHZLQP*
M'57U#3[;5M/N;&\A2YM+F)H9H9!E9$8$,I'<$$BC^T+7_GYA_P"_@_QH_M"U
M_P"?F'_OX/\ &DTI*SV&FT[H^(?@!_P2^M/V=/VB[?XD^&OB5?#1;=[@)X<;
M2P&>WE1E$$ESYQWJI*G/E@G8O0\U]S57_M"U_P"?F'_OX/\ &C^T+7_GYA_[
M^#_&JN^50Z+8FRYG+JS\\/VW_P#@E6?C5XROO'WPNU'3]$\1:BYFU31=1W1V
MMW*?O3QR*K>7(W\2E=K$[LJ<Y^.=!_X)(_M%ZOK"V=WH.CZ);$D'4+[68'A&
M#UQ"9).?]ROW5_M"U_Y^8?\ OX/\:/[0M?\ GYA_[^#_ !K.$53T6W8N4G/5
M[GS;^Q'^P_X?_8^\*WI6]'B#QGJP4:EK1B\M0@Y6"%225C!Y))RQY.,*J_35
M1174,[$1S1R$<D*P-2UM*3F[LRC%15D%%%%06%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 9/BK_D6]1_ZXM_*OYPOVIO^3@O&O_7Z/_1:
M5_1[XJ_Y%O4?^N+?RK^<+]J;_DX+QK_U^C_T6E 'U5_P14_Y.F\4_P#8F77_
M *76-?M37XK?\$5/^3IO%/\ V)EU_P"EUC7[4T %%%% !1110 4444 5K_\
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M1_R7CP9_U_#_ - :O:_^"JW_ "?#XZ_Z]]-_](8*\4_9H_Y+QX,_Z_A_Z U
M'](7@O\ Y%;3/^N*_P JVJQ?!?\ R*VF?]<5_E6U0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9?BCQ%9>$?#FIZWJ
M,GEV.GV[W,S=]JJ20/4G& .Y(K4KR']K6&ZG_9[\7+:9\P10L^!D^6+B,O\
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M^E?JW115RFY**?33\6_U(C%1;??_ "M^@4445!84444 %%%% !1110 4444
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M^2\>#/\ K^'_ * U '](7@O_ )%;3/\ KBO\JVJQ?!?_ "*VF?\ 7%?Y5M4
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M]2W3J#7W_P##'X?V?PN\#Z9X:L;BXNX+)"/.N7+,[$EF('11DG"C@?K74T4
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M87%E>0K/!* 0'1@"IP>1P>]7*15"J%48 X %+0 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH ***D6$M&S=A2O85[$=%%%,84>E% ZB@"7G;M
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M((7.&.>E?H57X@_L?D?";_@J9/X>TY?L^G?\)!K6B^2O \C%QL7CL"D9_P"
MU^WU',JE&G6BK<RU]?\ AK#<72K5*3>S_#_ATPHHHK,L**** "BBB@ HHHH
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M5C?>J2UUZ%YQGSK+ZK@_=IK33J-5(XQB.-8QZ*,4M%%?;'Q(4444 %%%'H*
M$IT<9F8*O-6K?2Y9B#M)%;=AI:0?,5^:NJEAYU'Y'-4Q$::\PTFS$,08C#5I
M4E+7O0BH1Y4>'.3F^9A1115D!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% %.\TV*\C(*C)]JY'4M%>UW,@)%=U3)(EE4JPR#64Z:D8
MSIJ9YIWP>#173:QX?_C@3GO@5@2V$T*DL#CZ5Q2@XL\^5.478@HI-V.M/\ML
M9QQ4&0VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 5\%?M_^%O[-^(VAZZB;8M4L#"QQ]Z2%^3_WS)&/PK[UKYK_ &\O"O\
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M2C_N+?\ MG7Z(5^=_P#P5R_YI1_W%O\ VSH _.^BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\,^-7[6WA7X274VE6R-XB\0QG;)8VT@2.
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MN+U&1_ZL<<BFK_K!DT^'Y^AI'AVMGK6IT=;$BPENI!IZA8QQWIL<FU<=Z3S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)(YP,<$Y'T-\7OV'?#.L:"]QX$A;0]:MTREK)<226]U@?=)D9BC'LV<>HYR
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M4FC22-UDC<!E93D$'H0?2GU)04444 9/BK_D6]1_ZXM_*OYPOVIO^3@O&O\
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MHA582T4D:M%-5U?D'-.K,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HI*-P]: %HI-PHS0 M%%% !1110
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M-'_)>/!G_7\/_0&H _I"\%_\BMIG_7%?Y5M5B^"_^16TS_KBO\JVJ "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\[_P#@KE_S2C_N+?\
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M32+/3;GQ#;7EQ?);7T4C6A>99%<%5D5]H$C8^?/ Y-?MK_PZX_9B_P"B9_\
ME?U3_P"2:/\ AUQ^S%_T3/\ \K^J?_)-:KW9JHMU^IF]8N#V9\ ?\/J_C?\
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MO_VU!7?+A?\ %)+Y72_'F_ _8ZTM(-/M8;6UACMK:%%CBAA0*D: 8"J!P
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M*/VM-5VX-H?^^C_A2K^UCJF>;4_]]'_"OIZ3]COPESM@D'XC_"F?\,=>%/\
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M_/A_X^?\*3_ANKQ+_P ^'_CY_P *^EO^&/?!?_/M)^8_PH'['G@KO;2_F/\
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MQ_O#_"JS_LB_#^0Y-G+_ -]#_"C^T\I?Q4!_V5G"^&N?('_#=_C _P#,-_\
M(A_PJ[;_ +=GBEA^\T_'_ S_ (5]7M^R#\/^UG+_ -]#_"J=Q^Q]X&/W+64?
MB/\ "C^T<G?_ "Y%_9N=K_E^?,$_[=7B<#Y+#)_WS_A5"3]N[Q@&XTWC_?/^
M%?5=O^Q[X('W[64_B/\ "KT?[(/@#;\UG+_WT/\ "C^T,GC_ ,N1_P!FYU+_
M )?GQ[+^V[XOO>/[/Q_P,_X5%_PUWXPD^86)_P"^S_A7V6G[(OP_0Y%G+_WT
M/\*G7]E+P(HP+.7_ +Z'^%/^U,I7PT1?V3G#^*N?&4/[:7C'31C^S\_\#/\
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M^/G_  H_X;B\8X_Y!W_CY_PKZ_7]D/X?KTLY?^^A_A3O^&1_ '_/G+_WT/\
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M_P"^A_A1_:63?\^ _LS.O^?Y\@?\-Q>,6^;^SO\ Q\_X4O\ PW=XQ7C^S?\
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M+_WT/\*!^Q_X&[VLOYC_  H_M#)_^?(_[/SK_G\?+?\ PW7XJ_Z!_P#X^?\
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MS_A7UQ_PR#X _P"?.;_OH?X4[_AD+X?_ //G-_WT/\*7]I9/_P ^ _LS.O\
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M%7R_OK20Y]"/\*?]M8*6E2E="_L+'1UIU=3XO7]N7QC;+C^SL_\ ;0_X4O\
MPWAXP[:;_P"/G_"OK]OV1O #];.7_OH?X4W_ (9!^'W_ #Y2_P#?0_PJ?[2R
M?_GP/^R\ZZ5SY"_X;O\ &/\ T#/_ "(?\*/^&[_&/_0,_P#(A_PKZ]_X9!^'
MW_/E+_WT/\*/^&0?A]_SY2_]]#_"G_:63_\ /@/[,SO_ *"#Y"_X;O\ &/\
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M +Z'^%'_  R#\/O^?*7_ +Z'^%']I9/_ ,^ _LS._P#H(/D+_AN[QC_T#?\
MQ\_X4?\ #=WC'_H&_P#CY_PKZ]_X9!^'W_/E+_WT/\*/^&0?A]_SY2_]]#_"
MC^TLG_Y\!_9F=_\ 00?(7_#=WC'_ *!O_CY_PH_X;N\8_P#0-_\ 'S_A7U[_
M ,,@_#[_ )\I?^^A_A1_PR#\/O\ GRE_[Z'^%']I9/\ \^ _LS._^@@^0O\
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M\I?^^A_A2_M+)O\ GP']EYW_ ,_SY"_X;P\8?] W_P ?/^%'_#>'C#_H&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OSO_P""N7_-*/\ N+?^V=?HA7YW
M_P#!7+_FE'_<6_\ ;.@#\[Z*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH !1110 JG;S2$Y.:** '*V*57VN"*912L*R/IKX$_M!6FAZ7#H>
MM@K;(3Y=PN25SV(]*[?Q1_PBWB*X&H6,Z"-Q\XR!S["OC/=LP4)4_6K46LWL
M"[4N9 O^\:^*Q'#-&>)>*P\W"4M^S/SS%\'T*F+EC,+4=.4MUT9[SXFO/#WA
MN5I(3YDAZ8P17D/BCQ,VK3;D4*N> *P)M0GN&/FR,['U.:K[CD^M>W@\MCAK
M.4N:7=GT.7Y3'!VE.7-+NR]#.2P!/.,U=A<NH K&W;>_-68;MHQG/)KTIT[[
M'KSIWV.DLV^38:]"\%6L$<D4DS*$!!//->2PZF4QCKZU?CUZY3&R1@/K7CXK
M"3K1<4[7/!QF!J8B#@G:YZ[\8/$FG7D%M;62@[<9/X5YQ8:DMOD2 'TP*QI;
MR6X.7<M]::K%3N)^]6.%P,<-05&]S#!Y;#!X=8=.]CIFU:W:1",[LUZ#X3\>
M)I,8: 9EZ'/2O%7FS( HVCUK5TO4#;3  \=ZSQ6 A6I\LC+&993Q%+EEJCU+
MQ9>OXD:2XP-Q&<URVAWDFG7!(SD'\*T-&U978*YW0'^&NIL_!J^(#_H$!^;[
MS+S7B<\,)!TJBM$^==2G@:;HU5:!E:UHC:S8?:(^7VY->>2:?-!<;?+;@]Q7
MM=KH6H:*WV0HSIW4BK>JZ3IMK;I/-:+YN>4[UA1S+V'N+WD]K'+A\W^K/V:]
MZ+VL>86.DRRVOF,,>V*=8:']LN-F,'//%=9=:A!(YC@A$4?I19R1VR23>7B1
M?NGUK9XJI9NUFSH>,J\K=K-[&6WA]=)=5DP<\\5ZC\,9A)(848+&5QS7FUW/
M<W#9E^<&NG\!WIM;A(VSC/(KRL?"=;#OF=V>+F<)U\)+F=V=WJ'A2YU*:Y\@
M+L4]<5XOXR\.W6GWL@()<'\*^D]%UF"W#+D8;MGFN3\<6ECJTS"*%0[#)-?/
MY=F%6A6Y)Q]T^6RG-*V&Q')./NGSY#(PC(D'S5'(=\95ON_K75:IX=:1F,$9
MB;-9\?AF16#W#?)[\5]U'$4VN:Y^E0Q5*2YKV,BUC**,#"U?CNI[B$^6 -M+
MJ%W;P9@"C"\ U#H^H+%=;2F]&XJG>4>>Q<N:<7/E&VMZMQ-B?UQ70+I4=];F
M-"I)Z5SOB'318WPEC!\J3D'TJQH=_)'-D/P#WK.I'F@JE-F56'/356D[%+5O
M#<T$A7%5X_#,[1@[<@<]*^B_"/@O1_%&DI<WKAY0<;5(!K2U[0_#&C:3)'##
M%YJCA@V37A/B#DG[!1;DG8^:?%/LY_5U!N2=GH?+=W9O;H=R_-VK/DG;: 1@
M8YKKO%0C-Y(T9 4GH*Y6ZQMQCFOK\/4]I%2:/NL+4]K!2:W,:5A(WXU=M^-J
M$<#I564!&!";1FK O5;Y0N/>O1E=JR/6E=I)(LS1E@2WW1TJM<2!5&W('ZUH
MI(CP@,PS69<PRF0X_"L8:NS,*;N[,JB\82,,?+C\:C1CYA.WK4JP$R].?6M2
MQLO,D4,G_ JZ)2C!7.J4XTU<-'T=KA2S\+G-:DT,5J/E7)]ZW[2T5;=4 QQ6
M;JD"QKP>:\?ZPZD[,\%XIUJEGL2Z/J&W:A^4'IBO4-)U4V^E.Q?<% XS7C=M
M(8W5LUTVDZM*<Q^9E6_AKS<;A55U1Y&8X-5E='3:Q,-3'F*<'I@=*XO5]':'
M<Q4X[<5Z'X=T4W#!ISB#KD]*Z?7/#NB)I;.UQ',67 0'D&O(CCHX6:IK4\*&
M90P-14HIOT/G)M/<3 XR#6A8LUE(#@XKHM7L8=-5GC("]A4%O!'-&&F(&[H*
M^D>(]I"[6A]<\6JL+M:&+J7FW!\U?N]*QI+=FD5CUKL]0CATV'8TBNAY K+6
M2UF 8;01VK6C6M'1:&M#$6C>*T*7V!1;[ACD<UASZ>?,;'W?:O2+[0(+?2$N
MA(#O7)6N.9AYC!>E7A\1SW<37"XKVEW$YE5DMY 0"3GFEOY&D484C/7BNPT_
M3X9$\PQ[BW&*N7_AN(6N\KCC\JZWC(1FDT=KQ].,TI(\JD1NX-,W"-0,5VU]
MX; M7DB^?V%<A<0&.7 '?%>M1KQK+0]S#XF%=:$94JORD$GUIT<9VY./>F-E
M&R./6I(%+*6+?C6[V.A[#&5<?-T]J:[850*64[1@&JLDS*1SFJBKFD8W-"WD
M\L%FZ]L5,U\&PWIQ62LA/.>.])')][TS2=--W9+HIN[-.ZO?W>X]3Q6-+(7;
M)J223/ ZU >M:TX*)O2IJ&P4445L;A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!_0[%_JT^@I],B_P!6GT%/H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#,\4::VL^&=7T]?O75I- ,''+(5_K7XZ?\$8]630?VF_
M%VAWA$%W>>'IHT1^"9(KF$LH]\;CC'\)K]GJ_$7]K+PKXK_8)_;HC^)_AO3M
MVA:GJ$FM:6[J1;7"R@_:[-B.A!>08'(5T85-*:HXE2EM)./SL[?FW\AU8NKA
MW%:N+3_%7_)'[=5^?W_!:+Q)#IO[-/AS1RR?:=3\1PLJMG=LB@F9B/H60<^M
M=GX3_P""MG[/6N>$X=4U;7]2\-ZL8]TNAW6DW,\RN!RJR11M$P)Z$L/<+7Y\
M?M*?'3Q/_P %,OVCO"7A+P-HEQ9:+;N]GH]K= >:BR%6N+RYVDJ@"HI(!(58
MP,DGF*E.564:,5JVOP=]]NEOQZ,NE4C"+JR=E9^NJMMN?I!_P2OT.;1?V)_!
M#3*R->S7UVH8_P +74H4_B%!_&OK6N:^&G@2P^%_P\\->$-+&-/T/3H-/A.,
M%EC0)N/N<9/N37 ?&W]L#X1?LYZ]8:-\0_%O_"/:E?6WVNWA_LV\N=\6XKNW
M0PN!\RD8)!XKKQ%2,JKL]-EZ+;\$<U"$E35UKN_GO^+/9*_$W]DF1?AW_P %
M7=2TS4"(&D\0Z[IZF0_Q.+CR^>.6PH'KN'K7[.>$?%6E^.O"VD>(]#NOMVC:
MM:17UE<^6\?FPR('1]K@,N5(.& (SR*_(O\ X*F?!WQ)\#/VE-#^._A2"2'3
M]2GM;HWT49*6FJ6^,"3L!(L:,,_>(D':N=2]ABH2J:+6+\N:W^5O6R-I1]MA
MYQAJ])+Y?\/?T3/V*KY3_P""H/B2'P[^Q3X]61D$FH&TL85?/S,]S&2!COM5
MS^%</\(?^"NWP2\7>#+6[\<:E=>!?$J1JMWI\FG7-W"\F/F:&2"-\H3TW[2.
MG/6OBK]N_P#;5N?VX/%7ACX:?#+1-0G\.0ZBK6L<T6+O5KY@T4;",$[(P';:
M"<G>2VW&!G7IRG:C%7;:^Z^OX%T*D8_OI:*.NO?I^/X'U?\ \$5=#FL?V=?%
MVIR*RQWWB618R3PPCMH02/Q8C\*_0JO)?V4O@BG[.OP \(> RT4M]IUKOOYH
M?NRW4C&29@>XWN0">RBO6J[L1).H^7I9?<DK_.QR44U"[ZW?WNX4445SFYD^
M*O\ D6]1_P"N+?RK^<+]J;_DX+QK_P!?H_\ 1:5_1[XJ_P"1;U'_ *XM_*OY
MPOVIO^3@O&O_ %^C_P!%I0!]5?\ !%3_ ).F\4_]B9=?^EUC7[4U^*W_  14
M_P"3IO%/_8F77_I=8U^U- !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP[K5CJEA*T%[93I<0R+U5U8,#^8K]A+*X^V6<$^W9YL:OM/;(SB@#\SOV?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P._X*K?\GP^.O\
MKWTW_P!(8*\4_9H_Y+QX,_Z_A_Z U>U_\%5O^3X?'7_7OIO_ *0P5XI^S1_R
M7CP9_P!?P_\ 0&H _I"\%_\ (K:9_P!<5_E6U6+X+_Y%;3/^N*_RK:H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9;J[GCM;:)2\DTSA$11U))X JGXD\1:?X2T&^UG5;E;33K*(S3S/T51_,GH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?@=_P56_Y/A\=?]>^F_\ I#!7BG[-'_)>/!G_ %_#_P! :O:_^"JW
M_)\/CK_KWTW_ -(8*\4_9H_Y+QX,_P"OX?\ H#4 ?TA>"_\ D5M,_P"N*_RK
M:K%\%_\ (K:9_P!<5_E6U0 4444 %%%% !1110 4444 %%%% !1110 4444
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M+C3-/M7U&>V;I.$9%5#[;I%)'< CO7O/_!0?PC-=:!X6\20QLT5G/+97##G
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MFAWU\3DW-SIT,DA/KN*DUOV=G;Z?;1V]K!';6\8PD4*!$4>@ X%344 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^=__!7+_FE'
M_<6_]LZ_1"OSO_X*Y?\ -*/^XM_[9T ?G?1110 4444 %%%% !1110 4444
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M_P :_G2HH _HM_X;P^ 7_15/#?\ X')_C1_PWA\ O^BJ>&__  .3_&OYTJ*
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MT?\ #>'P"_Z*IX;_ / Y/\:_G2HH _HM_P"&\/@%_P!%4\-_^!R?XT?\-X?
M+_HJGAO_ ,#D_P :_G2HH _HM_X;P^ 7_15/#?\ X')_C1_PWA\ O^BJ>&__
M  .3_&OYTJ* /Z+?^&\/@%_T53PW_P"!R?XT?\-X? +_ **IX;_\#D_QK^=*
MB@#^BW_AO#X!?]%4\-_^!R?XT?\ #>'P"_Z*IX;_ / Y/\:_G2HH _HM_P"&
M\/@%_P!%4\-_^!R?XT?\-X? +_HJGAO_ ,#D_P :_G2HH _HM_X;P^ 7_15/
M#?\ X')_C1_PWA\ O^BJ>&__  .3_&OYTJ* /Z+?^&\/@%_T53PW_P"!R?XT
M?\-X? +_ **IX;_\#D_QK^=*B@#^BW_AO#X!?]%4\-_^!R?XT?\ #>'P"_Z*
MIX;_ / Y/\:_G2HH _HM_P"&\/@%_P!%4\-_^!R?XT?\-X? +_HJGAO_ ,#D
M_P :_G2HH _HM_X;P^ 7_15/#?\ X')_C1_PWA\ O^BJ>&__  .3_&OYTJ*
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MT?\ #>'P"_Z*IX;_ / Y/\:_G2HH _HM_P"&\/@%_P!%4\-_^!R?XT?\-X?
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M_P :_G2HH _HM_X;P^ 7_15/#?\ X')_C1_PWA\ O^BJ>&__  .3_&OYTJ*
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MT?\ #>'P"_Z*IX;_ / Y/\:_G2HH _HM_P"&\/@%_P!%4\-_^!R?XT?\-X?
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M_P :_G2HH _HM_X;P^ 7_15/#?\ X')_C1_PWA\ O^BJ>&__  .3_&OYTJ*
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MT?\ #>'P"_Z*IX;_ / Y/\:_G2HH _HM_P"&\/@%_P!%4\-_^!R?XT?\-X?
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M_P :_G2HH _HM_X;P^ 7_15/#?\ X')_C1_PWA\ O^BJ>&__  .3_&OYTJ*
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MT?\ #>'P"_Z*IX;_ / Y/\:_G2HH _HM_P"&\/@%_P!%4\-_^!R?XT?\-X?
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M_P :_G2HH _HM_X;P^ 7_15/#?\ X')_C1_PWA\ O^BJ>&__  .3_&OYTJ*
M/I;_ (*,?$#P[\4/VN/&'B/PKJUKKFAW4-@L-]9R!XI"EG"C $>C*1^%>:_L
MT_\ )=_!G_7\/_0&KS.O?_V"?"<'CC]KKX=:+<MLAN+JX9FQG[EK-(/U44 ?
MT'>"V#>%=-P<_N5_E6W5/2=.32=/AM4.Y(U"@U<H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^?\ XI?L%? GXT^.]3\9>,O W]L>)-2\
MK[7>_P!KW\'F>7$D2?)%.J#"1H.%&<9/))KZ HH ^5?^'7'[,7_1,_\ ROZI
M_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#K
MC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
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M4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\
MY)KZJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^
M5?\ AUQ^S%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7
M_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\
M*_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_
M ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/
MV8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5
M_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_
M .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ*
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M "OZI_\ )->MZ1^SOX4T7XA77C.W:^_MBY14</*ACP"2,#9GN>]>GT ?*O\
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M_5/_ ))H_P"'7'[,7_1,_P#ROZI_\DU]544 ?*O_  ZX_9B_Z)G_ .5_5/\
MY)H_X=<?LQ?]$S_\K^J?_)-?55% 'RK_ ,.N/V8O^B9_^5_5/_DFC_AUQ^S%
M_P!$S_\ *_JG_P DU]544 ?*O_#KC]F+_HF?_E?U3_Y)H_X=<?LQ?]$S_P#*
M_JG_ ,DU]544 ?*O_#KC]F+_ *)G_P"5_5/_ ))H_P"'7'[,7_1,_P#ROZI_
M\DU]544 ?*O_  ZX_9B_Z)G_ .5_5/\ Y)H_X=<?LQ?]$S_\K^J?_)-?55%
M'RK_ ,.N/V8O^B9_^5_5/_DFC_AUQ^S%_P!$S_\ *_JG_P DU]544 ?*O_#K
MC]F+_HF?_E?U3_Y)H_X=<?LQ?]$S_P#*_JG_ ,DU]544 ?*O_#KC]F+_ *)G
M_P"5_5/_ ))H_P"'7'[,7_1,_P#ROZI_\DU]544 ?*O_  ZX_9B_Z)G_ .5_
M5/\ Y)H_X=<?LQ?]$S_\K^J?_)-?55% 'RK_ ,.N/V8O^B9_^5_5/_DFC_AU
MQ^S%_P!$S_\ *_JG_P DU]544 ?*O_#KC]F+_HF?_E?U3_Y)H_X=<?LQ?]$S
M_P#*_JG_ ,DU]544 ?*O_#KC]F+_ *)G_P"5_5/_ ))H_P"'7'[,7_1,_P#R
MOZI_\DU]544 ?*O_  ZX_9B_Z)G_ .5_5/\ Y)KY^_;0_8(^!OPI^$]_K'A'
MP(=,U2*)F28:M?S8(_V9)V'Z5^E=<=\3_A7HOQ;\.S:+KAN!9RJ5;[,ZJV#[
ME3_*@#XS_9N_X)U_L^^//A?IFK>(/A]]MU&:)6DF_MG4(\DCGY4N /TKU/\
MX=<?LQ?]$S_\K^J?_)-?17@GP3IW@#08-(TLS&TA4*OG,&; ]P!704 ?*O\
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M\J_\.N/V8O\ HF?_ )7]4_\ DFC_ (=<?LQ?]$S_ /*_JG_R37U510!\J_\
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M_5/_ ))H_P"'7'[,7_1,_P#ROZI_\DU]544 ?*O_  ZX_9B_Z)G_ .5_5/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OSO_X*Y?\ -*/^XM_[9U^B%?G?_P %<O\ FE'_ '%O_;.@#\[Z***
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MWKG1;.ZT9+B(_OAR5K#C9[-<#E3UKS/;^VBU'1H\?ZS]8BU#1K0U1;VL+ $
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M)R.*UB^AM%]"K12MC-)6YTA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?T.Q?ZM/H*?3(O]6GT%/H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K\[_^"N7_ #2C_N+?^V=?HA7YW_\
M!7+_ )I1_P!Q;_VSH _.^BBB@ HHHH **** "BBB@ HHHH **** "G1.8W#
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M3Z9%_JT^@I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P (9U=1VS)VZ;4^6HY07Q)7]5_2?W>E\ZG-32GO%Z>C_K^M[?J-7S-\>O\
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MO*_Q)^*'A3X/^$[KQ-XSUZS\.Z';</=WCX!;!(1%&6=R <(H+'' -?'>M?\
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MJ<_9SZJZ?='54445!84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P $^?&T\L?B;PG-)N@BV:C;*?X<G9+^'^K_ %]:^R: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K\[_\ @KE_S2C_ +BW_MG7Z(5^=_\
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M,"NPM=2-QA7RA/'X5]SBJ5IMTMF?HV-HVFY47[K.YM[RTO+585<)MX&VN?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUM=_F<-!-4H)]E^04445@;A1110 4444 %%%% !1110 4444 %%%% !1110
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MOMY).+3N[GY+PWPYFV5Y@L1-)Q::;OW.!F8QMAN<=*AD;C.,FH))C(Y)-/\
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M*:BT=UM&=MM<A4+GZ2)"/^!FOJ+]E3]E/PA^R7\//^$<\-"2^O[IEGU76[I
M+B_F QD@?<C7D)&"0H)Y9BS-ZEXM\)Z1X[\,:IX=U^PBU/1=4MWM+NSF'R2Q
M.,,IQR.#U'(ZCFLZ\(JC"C1VAMYO_@I6]-;="Z,W[:5:IO+?TU_S;/E#_@E[
M^T5HWQ?_ &;M \+OJ,/_  EOA"V73+S3V8"7[.AVV\RK_$ACVJ2.C*0>V?I#
MXR_%_P -? GX<ZQXS\5W\=AI>GQ%@'8!YY<'9#&/XG<\ #Z] 37Y9?%W_@DO
M\6_A7XWF\1_ OQ'_ &I91R-)81QZF=-UBTSGY!*2D; # WB1"<_='6N8T_\
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M'D'%3A?=PTXO1\_ZS#$>]B(26W+^D3S/]M+Q'X^\&?LU^,O$?PUU)M*\5:/
ME_'.EK%<GR(W5IQLE1U/[K>>G\-?-/\ P3(_;NU?X])K_@[XH^*;>_\ ',=P
M+G2I9K>WLS>6Q3#1(L2(K/&REB,;B'SR%./T!N+>*\MY8)XDF@E4I)'(H974
MC!!!Z@CM7Y6?M/?\$?\ 6G\6W?BKX(:M9P6LTS70\-ZA,UM):29W 6LX!4KG
MHK[-H ^9NQ3E[.I+F5XR7S3\OZ[]RI1]I!*+M)/[U_5_P['ZI75U#96\MQ<2
MI!;Q*7DEE8*J*!DL2>  .]?AQ^WQ\6(?VTOVOM \*_#U_P"V-/M/)\.Z==0'
M?'=S/*3+.I'_ "S!?&[H5CW=#6U<?L/?MP?$J%/#GBK4=??09"%8>(?&Z7=D
MH'0F)+B5L?1#7W)^PW_P3BT+]E6Z;Q7XAU"'Q5\0I8C"EU%&5M-.C8?,MN&&
MYG;D&5@#M^4*H+;KA3C*I&I4?NQUMU;_ *_S[(F52482IP^)]>B_K3^M3U7]
MH;X"#QQ^QYXB^&&FAYYX/#\=MIXZN\ULJ/"/JS1*/QKX'_X(W?M"Z3X-USQ3
M\)_$-_%ID^L7*ZAHXN3L$MR%\N:')_C*I&57OL;OQ7ZXU^:G[9W_  2>N/B1
MXSO_ !Y\(-1L-'U2_E:ZO_#^H.T,#SG+-+;RJ#L9FP=C +DDAE&%J/:2A6G4
M:NIK7UO>_P#79= ]FI4(THNSB[K\K?UY];'Z2WEY!I]I-=74\=M:P(TLLTSA
M$C0#)9F/   R2:_#SX\>)8/V\/\ @HEI.D^&9FU+PR]]:Z1;7,:DJ;&#Y[F8
M _PG]^XX&05]:T[S]A7]MOXA6\?A7Q->ZY-X;W*FW7?&T=UIZ*I 4^2MQ(V!
MU&(\C'3/%??O["?[ .C_ +(VGWFM:K?P^(_B!J47D7&H0QE;>TAR"88 WS$$
M@%G."VU>%QSK3BHUHUI/2.J7=_U^%^MB9R?LG2CO+1OLOZ_JUSZVAB6"%(T&
M%10H'L*?114#2LK(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4
MR65(8WDD=8XT!9G8X"@=23Z4^O'/VO\ 1/'7BC]G'QMH?PWT]M3\7ZK:"QMH
M$N8K<^7(ZK,1)*Z*"(C)_$/:LZDG&#<5=ETXJ4DI.R/S*_;0_:[\:_MJ?%B'
MX*_!M+F[\*-=FV1;!RCZW*N=TLK' 6W3!(4_+@;V_A"?;_[$O_!/7PG^ROIM
MOKNK"W\3?$F:(^?K#1_NK+<,-%:J?NC!*F0_,W/W0=H_-GP9_P $^?VQOAQJ
MTFJ>$O"^K^%]3DB,#WNB^+;"TF:,D$H7CNU)4E5.,XR!Z5VW_#-/_!0S_H+_
M ! _\./#_P#)U:T[4H6C\3W??^O^!L9U+U)W?PK9?U_77?;]J:;)&LL;(PW*
MPP0>XK\6/^&:?^"AG_07^('_ (<>'_Y.K];?@/I7B70_@KX&T[QF]S)XMM=&
MM(=6>\NA=3&Z6)1*7E#,)&W Y;<<]<FGR*4&V_*WK?\ KYBYFI)6/QT^#/B2
M#]@O_@HMJVF^(Y6L/#2WMQI-U=2J<+8W!$D$Q_V1^Y8GTS7[?V%_;:I907EG
M<17=I.@DBGA<.DBD9#*PX(([BOD[]NC_ ()_:)^UO8V^N:5?0^&_B#I\/DP:
MC,A:WO(ADK#<!>0 3Q(H)4$C:PP!\"0?L*_MM_#VWD\*^&;_ %M?#08IMT'Q
MLEKI[ACAB(6N(VP>IS'GVK.G.7LHTIK6.B?=?U\_S-*D;U75B]):M=G_ %^G
M6YZ3_P %E/V@M)\5ZMX6^$_A^_34KO2;E[_68[9BXBN"H2&$XX+A6D)'4;U'
M7(K] OV._A+)\&?V8_ 7A"]BV7MOIJRWT;#[L\Q,LJ_@\C#\*^//V*_^"4-W
M\,_&VF^/OBY?V&J:II\BW6G^'[!S-%%..5EN)6 #LAY"J"-P!W'&*_2RM(P5
M.C*FW=R=W^27W?DNMS.4G4J*2TC%67^?]=WTL?AQ\&_$D'[!?_!1;5M-\12M
M8>&EO;C2;JZE4X6QN")()C_LC]RQ([9K]O["_MM4LH+RRN(KNTN$$D4\+ATD
M4C(96'!!'<5\G?MT?\$_M$_:WL;?7-*OH?#?Q!T^'R8-1F0M;WD0R5AN O(
M)XD4$J"1M88 ^!(/V%?VV_A[;R>%?#-_K:^&PQ3;H/C9+73W#'#$0M<1M@]3
MF//M65.<O91I36L=$^Z_KY_F:5(WJNK%Z2W79_U^G6YZ3_P64_:"TGQ7JWA;
MX3^'[]-2N])N7O\ 6([9BXBN"H2&$XX+A6D)'4;U'7(K]!/V-_A3-\%?V9_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOSO_ ."N7_-*/^XM_P"V=?HA7YW_ /!7+_FE'_<6_P#;.@#\[Z*** "BBB@
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M)I<UTA\M2!ZBG7=NT%KY2??QRWO7LGB6PT;P_H'DQ ?:G7'3I7F8TW[8J@G
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M1IJHZJ7O,*D:X=DVY^7TJ.BM3:R84444QA1110 4444 %%%% !1110 4444
M%%%% ']#L7^K3Z"GTR+_ %:?04^@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K/\0>(-.\*Z+=ZMJUW'8:=:1F2:XF.%11_,
M]@!R20!5NZNH;&UFN;F6.WMX4,DDLK!510,EB3P !WKXV_;Y\>R7FE^#]%TV
MZ6;1[Z-]2>:"3='< 86(@C@@ L?0Y'I0!F^.O^"@.LR:P\?A#0K&'3(W(6;5
ME>26=1T)5&4(#Z9)]Z\(\??$U?B]\3+/Q'XAL8+".9K:*^CLRVQHT(5F&22,
MJ.F3TZUK_#O]E_Q]\3O#;Z[I&G0QZ<<^0][.(3<XX/E@CD9XR<#/?@UYSXD\
M-ZIX0UNZTC6;*73M2M6V36\PPRGK]"".01P0<B@#]?=,AM+?3;6*P2*.Q2)5
M@6W $8C &T+CC&,8Q7S!^U5^RJOC*.Z\8>#[4)KZ@R7NG1# O0.KH/\ GKZC
M^+_>^]YM^RK^U4W@V2U\'^,+HOH#$1V6HRG)LB>B.?\ GEZ'^'_=^[]WQR+-
M&KHP=&&593D$'N* /QN5I[&Z5E,EO<0OD,I*NC ]?4$$5][?LK_M41_$"&W\
M)^++A8O$T:[+6\D("WZ@=#Z2@?\ ?74<U4_:J_957QE'=>,/!]J$U]09+W3H
MA@7H'5T'_/7U'\7^]][YK_9]^ .N_&'Q6OEM/I.C:=,IO=3 *M&P.?+C_P"F
MG_H/4]@0#[Z\3?L^_#KQAJ4FH:MX2T^XO9"6DFC#0M(QZEMA7<?<\UU'A3P9
MH7@;2QIWA_2K72+('<8K6,+N;^\QZL?<Y-:EI;BTM88 \DHB14#RL6=L#&6)
MZGWJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *_.__@KE_P TH_[BW_MG7Z(5^=__  5R_P":4?\ <6_]LZ /SOHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH <,G':C!W>M)DG HS[<TB15&?SIS8W9'2D3G.:-V5Q2%U%^\013]ZJ
M,8YIB\8Q0&W2<C=2%8DC?;DMS2CUS@"HF; QC%.X.WG%*PK#>6D..!1]TX(X
MIVT;NO'>EX;@FF,=D[5&>]2QDL2N:K*Y#=<U)O*Y/0BI:(:-"XA6")=KJ<C)
MYID=\?),?\.<U4,@;&>?:I8$#;B1CCBLN73WC'DM'WM219%=AL!!]:EW,W /
M-55W8P!@5)"YWA0:3B*420'G/>IH9%B7U:JSYZA:7@\D5+5R7&Z)?.ZG&<T]
M)]JXQQZ5&J[A\HPO>I)%5<#OZU+ML9NVQ9C8;<DU9CA61 Y8$KS69&S&0CJ/
M6I_,:/H>#6$HOH82@^C+<,ZJQ!Y)-:4US;+&-BX?')K!W%7!QBIMP;@G!K*5
M--IF,Z2;3++7QVOM;%5FO&9,9^;L:KW"D'(/U%(H)QZ>M:J"M<UC3BE<U=/^
M;[QKTCX?0C3V:X+@*%RN:\OM6=&'&:] \(F6YC"8+#'W:\;,8WI-7T/ S6#E
M1DKZ,V?&FO27:KA\^9Q6%9B1(55@>G!K5N-,\R\99(R0I^7VH>V)^4'&.,5Y
M--PITU")X=*5.E25.!CZI!)-:9;D9KG3:(G/2NZO[-A:^6OUKD)K?8S!VW*O
M:O1PU2ZLCU<'6YHM)CK5Q 5)8&JVI:X8%*!^2<\54N[E8XF*C8W:L*;<S9D;
M=GFO1IT%-\TCUJ.&C.7-(L75T\S;BQK3T*8M,D9_B[GH*PE8L_\ LCI6I8EO
MO@[1Z5U58KDY3LK07L^4[*32&"C('/.ZGK86\4>20S>U,TW7Q=6ZPLN67Y:O
M&SB?[OR#J:^=E*<7:>A\K*52#Y:FAB74\,(;'![5S<LAFF8YR<UK^(C''<".
M,Y6L!5,<C!3U->OAXKEYNY[N%@N3F[EF.%U;!(Q4=P"WR'MT-3JK1Q[W.X^E
M5)W,F><?UKHCJSJCJ[E&1/G /6EW;6&WJ/2G%3)WP1VIC Q\CIWKK6NAV[Z%
MJ&[=9.O;I77Z#XLS'':7(_=C@9%<(&;=O[]*M0R,V&+?=YS7+7P\*L;21QXC
M"PK1M)'L-UIT:V:SP -&PR<=JYN2T:9FD*$]L@5?\ Z\MRZZ=<L##-QN/:NM
MUKPV-/&(#YD3#/ KY.51X6JZ4]^GH?#RK2P=9T*F[V?D<CH^E(L$KY4,5.#[
MU!<6;!0"P)K9T7P[J>H7T=K!;2,LC[0 /6NOU;X4W>DV_P!IO288EZL>E14Q
ME*C4Y9S5WL16S"C0K<M2HKRV1YDJPZ?:RSS'E<XKRG5+PW5Y(^<@FNR\=:LD
M,LMM#('4''%>?GDU]AEU%J+JRZGWN58=J+K2WD+FDHHKVCZ **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#^AV+_ %:?04^F1?ZM/H*?0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YQKO[27PC\+
MZO=:5K/Q3\%:1JEHYCN+&^\0VD,\+CJKHT@93[$4K]!^9Z/17E7_  UC\$/^
MBR?#_P#\*BQ_^.T?\-8_!#_HLGP__P#"HL?_ ([3$>JT5R'@?XQ> ?B=<W5O
MX.\;^'/%EQ:H)+B'0]6M[UX5)P&<1.Q4$\9-=?3$%%%%(845PGQW^(=S\)?@
MOXW\:65I%?7F@:/=:C#;3L1'*\<;,JL1S@D<XKX?_8-_X*4?$+]I[XZ#P-XM
M\.^&;*QFTZXNXKG18;B&6-X]I ;S)I P()' 'K[40]^;@MTK_G_DQ3_=P4WL
MW;\O\S]&Z***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?G
MA^TG^T9XG\3?$;5=,T75[_0]#TJ=[&."RN'A,[1N0TKE2"<L. >  O&<DXOP
MK_:N\<?#>]@2ZU"?Q)HRX5]/U&<L=H! $<K!FCQD=,C@<5[4<JK2IJ::OV/E
MY<08:-9TFG9:7_X'8_2FBO,OA#^T)X2^,ELJZ7=&RU8 F32;TJMP-H!9E )W
MKSU'X@=*]-KR9TY4Y<LU9GT=*M3K04Z;NF%%%%9FH4444 %%%% !1110 444
M4 %%%% !16#XR\>>&OAWH[:MXJ\0:7X;TM3M-YJUY';1;CT&YR!D^G6O -8_
MX*7?LTZ'?R6=S\4+626,[2UGIE]<Q_A)% RD>X-*ZO8=G:Y].T5Y5\,OVJOA
M#\9+B"U\'?$30=9U"?)BT];L17;X&3B"3;)_X[7JM4TUN3=/8****0PHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G?_P %<O\
MFE'_ '%O_;.OT0K\[_\ @KE_S2C_ +BW_MG0!^=]%%% !1110 4444 %%%%
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M55:7'4BL^XMRTA4*<>N*YO6F:-C&>E51PU.HTBZ&#HU))6)M:\;WNJKY:*L
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M/<FHJ7<1D4E>NCW5H%%%%,84444 %%%% !1110 4444 %%%% !1110 4444
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M3I7:WN1*'(*H^60CRSP6;.1S7UI6DX.#L_ZOJ1&2FKH****@L**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **A
MO+R#3K2:ZNIH[:VA0R2S2L%1% R6)/  '>O&_AQ^UAX.^)/CZ_\ #%F\EG(K
M[=.N[DA4U# ^;:.JG.<*>6'/!XH U_VD/A?K'Q:^&MUHVB:K)I]ZKB<6^X+%
M>[<XBD/4#.".<9 SZC\QM6TJ^\/:K<Z?J%M+8ZA:R&.6"52KQN#R"/6OV,KP
MC]IC]F>R^,FEMJVDK%9>+[6/$4QPJ7B@<12'U_NMVZ'CH <%^RG^U8/$2VG@
MSQG=XU88BT_5)F_X^NPBD)_Y:>C?Q=#\WWOH?XG?#'0_BUX5N-"UVW\R%_FA
MN$P);>3'$B'L1^1&0>*_*#5M*OO#VJW.GZA;2V.H6LACE@E4J\;@\@CUK[8_
M92_:L'B-;3P9XSN\:L,1:?JDS?\ 'UV$4A/_ "T]&_BZ'YOO 'RK\8/@_KGP
M9\52:1J\?F0/E[.^C4B*ZCS]Y?0CC*]0?;!/3?L[_M$:I\$=>\J7S+_PQ=N#
M>Z>#RIZ>;%GHX';HP&#V(_0OXG?#'0_BUX5N-"UVW\R%_FAN$P);>3'$B'L1
M^1&0>*^)?#/[$GBN\^*5QH6KDVWAJS(FDUN(?+<0DG:L0/\ RT.""#]SJ<_+
MN /O/PSXGTOQEH-GK.C7D=_IMVGF0SQ'@CN#Z$'((/(((-:E9/A7PKI7@GP_
M9Z+HMG'8:;:)LBAC'YDGJ23R2>222:UJ "BBB@ HHHH **** "BBB@ HHHH
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MG:C8()!K]G[?]D'X'VN@KHZ?"3P8;$1^7A]$MVD(QC)E*%RW^T6W=\U\J?\
M!%;P[#8?LZ>+-8"K]JU#Q))$SCJ8XK>':#]#(Y_&OT)KNK14%&FEI9/UNK_K
M8XZ4G-NHWK=_@[?I?_AC\8O^"A7_  3=_P"%#V5S\1_A='=3>!P2-3T<NTLV
MDAN-Z.<L\!SM.XEESR64DKQ7_!(/_D\BP_[ E]_Z"M?K7^VA_P FE?%__L5]
M0_\ 1#5^2G_!(/\ Y/(L/^P)??\ H*US85N-:5/HHM_>I?Y&N+M*E&?5R2^Z
M4?\ ,_="218HV=R%51DD]A7\\VIS:M^W-^VY]GNKZ1!XL\0?9HILY-IIZ,0H
M0'C*0)P.Y'O7]"]Q"MQ;R1-]V12I^A&*_GE^%>KR_L<?MP:9/XJ@D@B\)^(I
M;74/D);[,V^)IE'5@8I/,7'48QUJ:*B\934]OPW5[_A][-:EUA*CAO\ \!_U
M]Q^\7PN^!?@/X,^$[;P[X0\+Z;H^G0QB-_*MU,MP0 "\TA&Z1SCEF))K\_O^
M"M?[(7@O1OABGQ;\):'9>'=9L;Z*WU>/3H5AAO(9FVK*R+A?,60K\P&6#G=G
M Q^EN@>(--\5:+9:QHU_;ZII5]$L]M>6D@DBFC895E8<$$5\!_\ !8KX\:!X
M?^!\/POAOH+GQ1X@O+>YGL8V#26UI"_F>8X'W=SJBKG[PW$?=-98IRT;^*Z]
M=]?PO?R*P]K-1^&S]-M/QV\SS7_@DSX+^%OQT^&_B71O&'PX\+ZWXC\*WL,D
M6J7>F1/--;S[V02,1\S*\<@R>Q4=J_3CQUXQTWX<^"-=\4:M)Y&E:+8S7]RP
M[1Q(78#WP.!7YV_\$2?AW>Z5X ^(GC6YA>*TUB^MM/LV88$@MUD:1E]1NG5<
M^JD=C7T/_P %/M?N?#_[$OQ!>U8H]T+.S9AUV27<*N/Q4D?C75CI.$?<W:C]
M[2U_*YA@XQG/WMKO[D]?NUL?DIX+T?Q=_P %%/VP8H]7O98I_$%V]S>3J2ZZ
M9IT>6*1@\ (F$4'@LPSU)K]R_@[^SI\.O@/X;M]&\%^%=/TJ*.,))=^0KW=R
M0/OS3$;G8^YP.@ &!7X1?L7?M8)^R#\1-7\6CPBGBVYOM,;38X7O_LGD!I$=
MF#>5)G/E@8P/K7V5_P /R[O_ *(S#_X4Q_\ D2J]RG2C3I_/[_\ +7YLE\U2
MK*I/Y?UZZ?(^M?VS/V%O O[1GP[UNYT_P]8:1\0K>W>?3-:L8%AEFF5<K#.5
M \Q&QM^;)7.1CO\ F]_P2?\ CMJ/PI_:6M_!%W/(F@>, UA/:R'"QWB*S028
M[-D-'[^8,]!7MG_#\JZ_Z(S#_P"%,?\ Y$KX7^!/B*77OVO_  'KEA:-9/?>
M-K.[BM(V,AB$EZC>7D ;@ V,X&<=*C"1:Q48KX9Z/\OQO]Z16(DI8=M_%'5?
MG^#7XL_I$HHHJ2@HHHH \G_:HUK4/#OP%\3ZAI5_=:9?P_9?+NK.9HI4S=0J
M=K*01D$C@]":_/G_ (71\0?^A[\3?^#BX_\ BZ_0;]JC1=0\1? 7Q/I^E6%U
MJ=_-]E\NULX6EE?%U"QVJH). ">!T!K\^?\ A2_Q!_Z$3Q-_X)[C_P"(KZG*
M_9>Q?/:]^OHCX+/_ &_UJ/LKVY5M?NP_X71\0?\ H>_$W_@XN/\ XNC_ (71
M\0?^A[\3?^#BX_\ BZ/^%+_$'_H1/$W_ ()[C_XBC_A2_P 0?^A$\3?^">X_
M^(KV/W'E^!\U_M?][\0_X71\0?\ H>_$W_@XN/\ XNC_ (71\0?^A[\3?^#B
MX_\ BZ/^%+_$'_H1/$W_ ()[C_XBC_A2_P 0?^A$\3?^">X_^(H_<>7X!_M?
M][\0_P"%T?$'_H>_$W_@XN/_ (NC_A='Q!_Z'OQ-_P"#BX_^+H_X4O\ $'_H
M1/$W_@GN/_B*/^%+_$'_ *$3Q-_X)[C_ .(H_<>7X!_M?][\0_X71\0?^A[\
M3?\ @XN/_BZ/^%T?$'_H>_$W_@XN/_BZ/^%+_$'_ *$3Q-_X)[C_ .(H_P"%
M+_$'_H1/$W_@GN/_ (BC]QY?@'^U_P![\0_X71\0?^A[\3?^#BX_^+H_X71\
M0?\ H>_$W_@XN/\ XNC_ (4O\0?^A$\3?^">X_\ B*/^%+_$'_H1/$W_ ()[
MC_XBC]QY?@'^U_WOQ#_A='Q!_P"A[\3?^#BX_P#BZ/\ A='Q!_Z'OQ-_X.+C
M_P"+H_X4O\0?^A$\3?\ @GN/_B*/^%+_ !!_Z$3Q-_X)[C_XBC]QY?@'^U_W
MOQ#_ (71\0?^A[\3?^#BX_\ BZ/^%T?$'_H>_$W_ (.+C_XNC_A2_P 0?^A$
M\3?^">X_^(H_X4O\0?\ H1/$W_@GN/\ XBC]QY?@'^U_WOQ#_A='Q!_Z'OQ-
M_P"#BX_^+H_X71\0?^A[\3?^#BX_^+H_X4O\0?\ H1/$W_@GN/\ XBC_ (4O
M\0?^A$\3?^">X_\ B*/W'E^ ?[7_ 'OQ#_A='Q!_Z'OQ-_X.+C_XNC_A='Q!
M_P"A[\3?^#BX_P#BZ/\ A2_Q!_Z$3Q-_X)[C_P"(H_X4O\0?^A$\3?\ @GN/
M_B*/W'E^ ?[7_>_$/^%T?$'_ *'OQ-_X.+C_ .+H_P"%T?$'_H>_$W_@XN/_
M (NC_A2_Q!_Z$3Q-_P"">X_^(H_X4O\ $'_H1/$W_@GN/_B*/W'E^ ?[7_>_
M$/\ A='Q!_Z'OQ-_X.+C_P"+H_X71\0?^A[\3?\ @XN/_BZ/^%+_ !!_Z$3Q
M-_X)[C_XBC_A2_Q!_P"A$\3?^">X_P#B*/W'E^ ?[7_>_$/^%T?$'_H>_$W_
M (.+C_XNC_A='Q!_Z'OQ-_X.+C_XNC_A2_Q!_P"A$\3?^">X_P#B*/\ A2_Q
M!_Z$3Q-_X)[C_P"(H_<>7X!_M?\ >_$/^%T?$'_H>_$W_@XN/_BZ/^%T?$'_
M *'OQ-_X.+C_ .+H_P"%+_$'_H1/$W_@GN/_ (BC_A2_Q!_Z$3Q-_P"">X_^
M(H_<>7X!_M?][\0_X71\0?\ H>_$W_@XN/\ XNC_ (71\0?^A[\3?^#BX_\
MBZ/^%+_$'_H1/$W_ ()[C_XBC_A2_P 0?^A$\3?^">X_^(H_<>7X!_M?][\0
M_P"%T?$'_H>_$W_@XN/_ (NC_A='Q!_Z'OQ-_P"#BX_^+H_X4O\ $'_H1/$W
M_@GN/_B*/^%+_$'_ *$3Q-_X)[C_ .(H_<>7X!_M?][\0_X71\0?^A[\3?\
M@XN/_BZ/^%T?$'_H>_$W_@XN/_BZ/^%+_$'_ *$3Q-_X)[C_ .(H_P"%+_$'
M_H1/$W_@GN/_ (BC]QY?@'^U_P![\0_X71\0?^A[\3?^#BX_^+H_X71\0?\
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M_A2_Q!_Z$3Q-_P"">X_^(H_X4O\ $'_H1/$W_@GN/_B*/W'E^ ?[7_>_$/\
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M (BC]QY?@'^U_P![\0_X71\0?^A[\3?^#BX_^+H_X71\0?\ H>_$W_@XN/\
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M?^A[\3?^#BX_^+H_X4O\0?\ H1/$W_@GN/\ XBC_ (4O\0?^A$\3?^">X_\
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M='Q!_P"A[\3?^#BX_P#BZ/\ A='Q!_Z'OQ-_X.+C_P"+H_X4O\0?^A$\3?\
M@GN/_B*/^%+_ !!_Z$3Q-_X)[C_XBC]QY?@'^U_WOQ#_ (71\0?^A[\3?^#B
MX_\ BZ/^%T?$'_H>_$W_ (.+C_XNC_A2_P 0?^A$\3?^">X_^(H_X4O\0?\
MH1/$W_@GN/\ XBC]QY?@'^U_WOQ#_A='Q!_Z'OQ-_P"#BX_^+H_X71\0?^A[
M\3?^#BX_^+H_X4O\0?\ H1/$W_@GN/\ XBC_ (4O\0?^A$\3?^">X_\ B*/W
M'E^ ?[7_ 'OQ#_A='Q!_Z'OQ-_X.+C_XNC_A='Q!_P"A[\3?^#BX_P#BZ/\
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M_B*/^%+_ !!_Z$3Q-_X)[C_XBC]QY?@'^U_WOQ#_ (71\0?^A[\3?^#BX_\
MBZ/^%T?$'_H>_$W_ (.+C_XNC_A2_P 0?^A$\3?^">X_^(H_X4O\0?\ H1/$
MW_@GN/\ XBC]QY?@'^U_WOQ#_A='Q!_Z'OQ-_P"#BX_^+H_X71\0?^A[\3?^
M#BX_^+H_X4O\0?\ H1/$W_@GN/\ XBC_ (4O\0?^A$\3?^">X_\ B*/W'E^
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M_H1/$W_@GN/_ (BC_A2_Q!_Z$3Q-_P"">X_^(H_<>7X!_M?][\0_X71\0?\
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M_MK?"V68A4>_F@!)_BDMI47]6%&$_P!]OU]W\Y6_$,5_N;OM[WY(_H7HHHH
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M'A32O"T%]I]W)<QZ7;+"LS+)&%+!1R0"?SK]I*_(S_@N%_R/GPK_ .P;??\
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MZ A-J%BL:@,?E0*.2<<UZ#117/=O<VM;8****0PHHHH **** "BBB@ HHHH
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M:-B1CBL>34-S<<&I7F\RV&#70Z3T;.IT7HV5+BX^\ :I,V6Z<T^9<Y).:BW
MN#7H1BDM#U(Q26@L<F,YY-1-SUZU955=3R!4$RA2 .?>K5KFD=R/=2&@T59H
M%%%%,84444 ')X%!4KP1BGQEHG5\8Q1-*9G+&EK<6MQE%%%,84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?T
M.Q?ZM/H*?3(O]6GT%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :_W6^E?S=?"7_D[SP?\
M]CQ:?^EZU_2*_P!UOI7\T/AGQ79^!/VC-+\2ZBLSZ?H_BJ/4+A;=0TACBNP[
M!02 6PIP"1SWJ:$E''4Y2V7^:-*B<L'42[K\I'],%%?!O_#YSX$_] CQM_X+
M+;_Y)H_X?.? G_H$>-O_  66W_R35&9]Y5^8G_!<+P[+/X-^%>O*H\FUO[ZQ
M=L<[I8XG49^D+U]1?LV?\%"/A=^U+XXNO"7A*#7K'6(+-[X)K%G'$DL:LJMM
M9)7Y&]3@XXK0_;X_9]N?VC_V:O$7AS2X1-XBL2NK:2F.9+B$$^6/=T:1![N*
MPQ$91@I]K/Y7U_"YOAY+VCC?NOFUI^:/G7_@BCXJ@U#X"^-?#_FAKO3?$/VI
MH^,K%/;QA3]"T,GY5^B=?SR?L5_M6:I^QK\99]4O=-N;S0;U/[.U[2 -D^Q7
MX= V )8VS@-C.64E<Y'ZU?\ #TS]FO\ L/\ M'_A/9?-\O=_9_\ 8U[]HW8S
MLQY.W/;.[;[]Z[JTE44:B?1+[E;]+_@<5.+@W!KJ_P =?Z^\]%_;:NH+/]D;
MXNO<31P(WAJ]C#2,%!9HF55R>Y8@ =R0*_)G_@D'_P GD6'_ &!+[_T%:T?V
MG/VL/B)_P44\<0> ?AUH-[9>"K+??)IA8"6=8P2UW>N#M14'1<E5)'+,5K._
MX)!_\GD6'_8$OO\ T%:PPJ;K2F]+Q=O1*6OSU^[OHKQ32I1@M;27YQT_K_@O
M]P/$NOVGA7P[JFMW[%+'3;66\G8#)$<:%V/Y U^#7@WP?XN_X*>_M;>([BXU
M6V\.SWMM/J+7$D'FI96<(6."$(I7>06A0G(/+-R>#^[?CCPG:^//!6O^&KYF
M2RUG3[C3IV3J(Y8VC8CWPQK^?C4&^)W_  3J_:2O;;2]7L(/$VE Q&:VDCNK
M:]M)"&"RQY)4.%5BC;77Y2,?*U8PY?K'[W:SMZZ_EI\KVZG3+F]@_9[WU]-/
M^#\[>1[:?^">?[8_P<N)])\"WU]-IDI+O-X3\7+8V\A/&6266!B<>J_C77?!
MO_@CO\2O''B6/6/B_P"([7P_ITTGGWEO9W?V_5+EB<L#)@QJ6Y^?<YS_  FL
M.U_X+6?&>,$7'A+P+-P,&.SO4/X_Z4?Z5UFB?\%O_%]O+&=8^%^B7T84!UL=
M2FMBS=R"RR8'7C!^M=$7RN[U?F82U5EHO(_5;X>_#_0/A7X+TCPGX7TZ/2M!
MTJ 6]K:QDG:HY))/+,222QY)))Y-?/G_  4X\.7'B3]B?XAQ6R-)):):WQ5?
M[D5U$[GZ!0Q_"I_V3?\ @H'\.?VL)VT?31=>&O&,41E?0=4*EI5 !9H)5^65
M1GGA6X)V@<U]"^,_">G>//".M^&M7B\_2]7LIK"ZC_O1R(4;'O@FLL5"I*#;
M^)ZKS>_YEX><(S79:/T_X8_%+_@D?X7\$>.OV@/$/AWQKX7T/Q3#=:!)-9V^
MNZ?#>1I+'-$24656 ;8S<@9P#7ZX_P##)WP0_P"B-_#_ /\ "7L?_C5?A7XB
MT#X@?\$^OVI(75##K?AR\^T6%U+&PM]3LVW*&']Z.2,LK '*G<,@K7ZU_!G_
M (*E? GXH:)9OK'B1? >O.@^T:7KJ.B1O_%MN OE,N>A)5B.2HZ5T\T:U*$H
M=%;SW;_6WE;4PY)4:LXRZZ_@E^E_.Y[3_P ,G?!#_HC?P_\ _"7L?_C5:OAC
M]GGX5^"=:M]8\._#3P?H&KV^?)U#2]!M;:XBR"#MD2,,,@D<'O7E_C#_ (**
M_L[>"K7S;KXG:7J#E<I#HZ2WSL?3]RC!3_O$"O.?V=_^"FFA?M,?M%6_P[\+
M>"]1L]#FLKBY76]2N%6<M$N[!MT#!5/(R9"<D<#I64;RE:.^OX*YI.T8WEMI
M^+L?:U%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5XI\8/VKO!WPMAGM+:Y7Q#X@7*KI]BX9(
MVP?];)T09Z@9;V[CY^_:B_:B\0ZAXKUKP=X;NI-'T?3YY+*ZN(,K/=.N%D!;
MJJA@Z@+]X<D\X'RW7T>$ROF2J5GIV_S/B\PS[V<G2PJU6EW^AZ'\6?COXL^,
ME\KZW>"*PC.8=-M,I;Q^^W)W-_M,2?3%>>4^&&2YFCAAC:661@B1HI+,Q.
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M'V]?MQ7H5O@I^G_MTCDI_%/U_1!1117*;A1110 4444 %%%% !1110 4444
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M/]EXE !^JM7V_P"!_%FD_&3X>VVK#39AI6JP,DEEJ4&-RG*LI!X93S@C((H
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M:?\ ;I&95WELFN*6'?-<\^6&ES<R-:6X"YP,"LNX;]YSR#5B1CY>&'2H1$N
M68^U7!*.I=-*.I5C4,I)Z>M2V_[S@<K23E8VR>%]JC6XV+E171K)'7K):$<R
M[)B,Y4&H6CYW8IIF)D)/0U94"5>*UUB;:Q6HP$!>G-,8';]VI/+."#3&VK'D
MGYC0@*U%!!HK8W"BBB@ HHHH 5F+* :2BB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Z'8O]6GT%
M/ID7^K3Z"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML!R"SD ]5:BIM:UQ0WWL?$:V=W^SS^V ^G^%;^>XN/"?C%K.QNE($DRPW1C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /SS_:9_9S\3>%O'VKZYH^DW6K^'=2G>\6>RB:8V[NQ9XY%&
M67!SAC\I##G.0,+X8?LG>//B/,LLVGMX<TO=A[S58VC;@\[(C\S'\ />OTIH
MKVHYK6C34$E?N?,2X?PTZSJMNSUM_P 'L>:?"7]GOP?\'H4ETFQ^TZQY>R75
M;OYYWR.=O9 ?10/?->ET45Y,ZDJDN:;NSZ*E2IT8J%.-D%%%%9FH4444 %%%
M% !1110 4444 %)UX/(I:* /D;X[?\$O?@C\;M4N-833+SP3KEPYDFN_#,B0
MQSN>[P.K1\GDE%4D\DFOFR\_X(:VCWC-:_&::&UW?+'-X9$C@9Z%A=J"<=]M
M?J914QBH[%.3EN? _P +_P#@C;\'?!]Q;W?BS5==\=7$8^>VGF6RLW/KLB_>
M?AYN/7-?;_@_P9H/P_\ #MIH/AG1['0=%M%VP6&GP+##'DY.%4 9)))/4DDG
MFMFBM.9M6,^57N%?*G[1'_!-?X-?M#ZQ/KMWIUWX2\2W#&2?5/#CI!]I<Y.Z
M:)D:-R222P4.>[&OJNBLW%2U9HI-;'Y9W?\ P0TM7O':U^,TT-KN^6.;PR)'
M"^A87:@GWVCZ5Z=\-_\ @C+\'_"\]O<^*]<\0^-9HQ^\M6F2QM)?JL0\T?A+
M7W]15IVV(:N8/@;P'X=^&?A>Q\.>%=&L] T.R4K;V-C$(XTR<DX'4DDDL>22
M2236;\7OA7HGQM^&NO>!_$?VD:-K4'V>X:SD$<R@,&#(Q! (90>01QR#7845
M,U[1-3UN5%^S:<=+'S5^RY^P'\.?V2?%&K>(/".H^(M3U/4K/[#(^N7<,JI%
MO5R$6*&,9)5>3GIQBOI6BBK<G))/H0HI7:ZF/XQ\*V'CKPCK?AO55D?3-8LI
MM/NEB?8YBEC9' ;L=K'FOFK]G/\ X)M?"S]F7XE1^./#.I^)]3UF&"6W@76;
MV"2&)9!M8A8H(R3M)'S$CGIGFOJVBIC[LG*.[T^7]-E2]Z*A+9._ST_R05R_
MQ,^&?AKXP>"=4\(^+M*BUG0-2C\NXM9<CH<JRL""K*0"&!!! (KJ**4HJ2LQ
MIN+NC\Q_&'_!#[PW?ZQ)-X8^*NI:+IC'*VFJ:/'?RK[>8DT((_X#7TK^QS^P
M%X0_8_OM5UC3=<U+Q+XCU2U6SN+Z]1(8DB#!RL42@E=S!2=SM]T8QSGZCHJX
MR</A)DE/X@KY@_:,_P""=/P=_:2U2;6]5TNZ\->)YCNFUKP[(EO+<'GF9&5H
MY#ZL5WG &[%?3]%9N*EJRU)K8_+34/\ @AK9R7CM8_&6>WM"?DBN/#2RN!Z%
MQ=*#_P!\BO1OAS_P1?\ A)X;GM[GQ9XC\1>,98SE[972PM9?8J@,H_"45^@M
M%6G;8AZG-?#OX;>%_A+X3L_#/@_0[/P]H5H/W5G91[5R>K,>K,>[,2Q[DTGQ
M,^'ND_%CX?Z_X.UT3'1];LY+*Z^S2>7((W&"5;!P1VX/TKIJ*F?[Q-3UN./N
M6<=+'S!^S'_P3R^&G[*7CF\\6>%-3\2ZGJUS9/89UN\@ECCB9T9MJQ0Q\DHO
M)S7T_115N3:2?0225VNH4445(PHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /SF_;$^,EW\0/B+=^'[:=E\/Z#.UO'"I
M^66X7*R2GUP<J/0#C[QJ?X _LAZE\7M$7Q#JVI'0M"E9EMO+BWSW.#@L <!4
MSD9.22#QWKQ'QE')#XOUR.;/FK?3J^[KN$C9K]&_V1_%EEXH^!?A^.U*K/IB
MMI]S$.J2(<@G_>4JW_ J /,/!_[ VFZ'XZAOM8UT:YX<@_>+8M 8I)9 >$D(
M)!3UQ@GI@5]80PQ6L$<,,:PPQJ$2- %55 P  .@ J2OF7]N3Q]XJ\'^"]-L-
M&'V/1]7=[:]U")\2YQD0C^Z&7<21R0I' Z@'N&@^,/"OQ4L-;LM.N[77;&UF
M?3KZ+ >-CM&Y<'AE(.,C@X."<5\)_M/?LPW7PDOY-=T*.2[\(7$GNSV#$\1N
M>Z$\*Q^AYP6T/V#_ !5/I'Q=NM&#,;75["16CSQYD7SJWX+Y@_X%7W[J.G6N
MKV%Q97UO'=V=Q&T4T$RADD4C!4@]010!\!_L1^"?&.I?$#^W]'NY-+\.VG[K
M49G7='=CKY 7^)N^[^#KW /Z"UE^&?#.E^#=#M-'T6RCT_3+5-D-O%G"CJ>3
MR23DDDDDG)K4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_._\ X*Y?\TH_[BW_
M +9U^B%?G?\ \%<O^:4?]Q;_ -LZ /SOHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "I[>[EM\^6Q7\:@HI-)Z,32:LQ\DC,Q+-DFD5^F:;118+(=NYIN"**5F+=
M: $SWIV\G--HI@ HI=P]*2@!ZS-'T-*LQ)^8Y%1T4K(7*BRS#R\]Z@Y[4F[F
MEW8J;6%:P<]<T^&3;G/-1_2G#Y>@P:8,>S;<8XS3_,81G#<5"[94>GI3><4K
M"Y1_F-ZTO+MR>:CYQ[4!L4[%6)^%4J3DCI3.5P<\5&?6E5CTI6%8G384):HM
MPW?RIOWJ3-%@425I-V,]J16VL>X-1GUZ4N[Y<=Z+!87)Z9I3QA0:9FBG8=A>
M3QGFM/1[?SKA0QR<\5E9K4T>Z2WN(Y'Y*FLJM^1V,:R?(^4WKRSD6<*5^M9E
MY!)OVK]T=ZW+C5XKB0."/GZ^U-O+BV:'9"NYCUQ7E0G.-KH\2G4G&UXG/0VQ
MDP@0LV:74+,V<9!^48Z5T%L(-/C\YV"MC@&N;US5/MTQQTKJISE4GHM#LI5)
MU:EDM#*J:&8QC-0T5Z+5SUFKEF2Z+1X'7-5V8MUI**2BD)12V%V^M.V<=:1F
MW <<TW)IZAJ.>/;WS3:4L2,=J2@:OU"BBBF,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _H=B
M_P!6GT%/ID7^K3Z"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR9\R[O&4![F8CESZ#L!V '7DGN* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K\[_\ @KE_S2C_ +BW_MG7Z(5^=_\ P5R_YI1_W%O_ &SH _.^BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4TE%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQB=S^)7-;,%O%:PI##&D,2#"QQJ%51Z #I4E% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?G?_P5R_YI1_W%O_;.OT0K\[_^"N7_ #2C_N+?^V=
M'YWT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5)'<21KM4X%1T4K7W$TGN#,6.31113&%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% ']#L7^K3Z"GTR+_5I]!3Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA2]O< =-RY'(YPP((R>>37L7C#]O;QAKNB-9:1I-CH%S*A22^C=II%R.L8.
MI^H;^M>M^//V"?"GB+4)+OP[K%UX8,C;FM6A%U OLBEE9?Q8CTQ65X?_ .">
MNAVETKZUXNOM2@!R8K.T2U)]BS-)_GTH ^3_ (8_#;6_C%XVM]%TQ7DGN'\R
MZO) 66"/.7E<_P"<D@=Z_4_PEX7L/!7AG3="TN+R;#3X%@B7O@#J3W).23W)
M-4/ /PW\-_#'1_[,\-Z7#IML2#(R9:29@,;G<_,Q^IX[8KIJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "OSO_X*Y?\ -*/^XM_[9U^B%?G?
M_P %<O\ FE'_ '%O_;.@#\[Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _H=B_U:?04^F1?ZM/H*?0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7G/Q\^+<'P;^'-]K9"2ZE(?L
MVGV[]))V!P2/[J@%C[+CJ17HU?#O_!0K6KF3Q7X3T@R$6D-E)=B/L7>3:2?7
MB,?3)]: /EV\O-6\;>)'GG>?5=:U.YY/+R3RNV  /4D@ #V%?9OPN_8*TBUT
MZ&[\=7\]]J#J&;3M/D\N&+_99\;G/NNT=>O6O)/V&?"EOXA^-)OKE ZZ/82W
MD0/_ #U++&I_ 2,?J!7Z)4 ?.GB3]A3X=:M9LFEMJ6A76WY)8;DS)GU99,Y'
ML"/K7R'\:_V>/$_P2OE;4474-%F?9;ZM;*?*<]0KCJCX['@X."<&OU'K.\0>
M'].\5:+>:3JUI'?:==QF*:WF&593_(]P1R" 10!^4?PQ^)>M?"?Q9:Z]HDYC
MFB.V:!B?+N(R?FC<=P?T.".17Z>_#KQ]HGQE\!VVM6,:SV%]&T-S9W #&-\8
MDBD'0]?H00>AK\YOVA?@O<_!/QY+I@9[C1[I3<:==/U>+."K?[2G@^O!XS7I
M'["_Q*F\-_$B;PM<3D:9KL3&.-C\JW2+N5AZ;E#+[G;Z"@"']J3]EN;X9W4_
MB;PS!)<>%)GS- N6;3V)Z'N8R>C=NA[$^+_#;XE:[\*?%%OKN@W/D7,?RR1/
MDQ3QGK'(O=3^8.",$ U^M5U:PWUK-;7,,=Q;S(8Y(I5#*ZD8*D'@@CM7R1X@
M_8+L[[XH176G:B+'P3,3/<6H)-Q"P(_<QD\%6SPQY4 ]<#(!] _!GXMZ9\9O
M!<&O:=%);.&\BZM90<P3  LH;&&'((([$9P<@=W6;X=\.:;X1T2TTC1[.*PT
MVT3RX;>$851_4D\DGDDDFM*@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *_._\ X*Y?\TH_[BW_ +9U^B%?G?\ \%<O^:4?]Q;_ -LZ
M /SOHHHH ***^R/V>?\ @FWXM^)EE;:YXYNY? ^B2.K)8M;[M1N8P5W?(Q @
M!&X!GW,",F,@@FXQ<M>A+DD[=3XWHK]A?#G_  3C^!FAZ5':7OAR^\07"DDW
M^I:K<),^3D B!XDXZ<(/?-3:Q_P3K^!&IZ7<VMMX3N=(GE0JE]9ZM=M-"?[R
MB61T)_WE8>U0]"EJ?CI17V1^TY_P3IUWX1Z/?>*?!6H3>*_#-KF2XLYHL:A9
MQ=W.P;9D7JS*%(!SLVAF'QO4QES%RBXJ_0**^K/V&?V4O"7[34?C1O%&HZU8
M'139BW_LB>&/=YWG[M_F1/G'E+C&.IZ]OJC_ (=4_";_ *&'QG_X&VG_ ,BU
MK*+B[/\ J^I!^5=%?JI_PZI^$W_0P^,__ VT_P#D6LWQ!_P2C^'MSI,T>A^+
M_$VG:F<>5<:@;>[A7GG=$D41;C/1QCWZ5F-'Y>T5[7^TE^R;XQ_9IU*V;6?)
MU7P_?2-'9ZY8JWDNPR1'(I&8I2HW;3D$9VLVUL>*4HR4E= U9V8445]D_LY_
M\$W?%/Q.LK;7O'5W-X+T"4AHK'RLZC<IQSM;B $$X+AFROW,$$Z*+DK]")24
M=.I\;45^Q&@_\$Y_@5I&EPVEWX8O-;GC&&OK_5KI9I/=A#)&GY**=K?_  3I
M^!.JZ7<6EKX5NM&GE7:E]8ZM=--"<]5$LCH3_O(1STJ7H4C\=:*^V_V@/^"9
M?B3P+8W>M_#O49O&&F0AY7TBXB"ZC%& "-FWY;@X#9"A&^Z%1B:^)65HV*L"
MK*<$$8(-1&2EIU*<6A****LD**LZ7I=YKFI6FG:=:S7U_=RK!;VMO&7DFD8A
M515')8D@ #J37VYXB_X)>W_A/X6ZKXJU3X@Q1ZEIFCS:G<Z5#I'F()(X6D:%
M9O/&1E2N_9[X[4VFH\[V"/O35-;L^&J**LZ7I=YK>I6NGZ?:S7U_=RK!;VMM
M&9)9I&(5411RS$D  <DFA)R=D!6HK[^^#?\ P2MOM4L;74?B7XDDT=I 6?0]
M$5))T4J"N^Y;<BN&)!54<8 P_/'JW_#JGX3?]##XS_\  VT_^1:&K:$IW/RK
MHK[:^/W_  3+\2^!=/O-<^'NIR>,-,@$DKZ3/$$U&., $;-ORW#8W9"A&. %
M1B<#XEK.,E+3J6U8***?!#)=31PPQM+-(P1(XU+,S$X  '4DUHDV[(F]M6,H
MK]#? ?\ P3+T%?@R-?\ 'FJZ[8^+_L,U]+I^FSP)!;80M'$^^%F9P -V& R2
M!TW'\\JER2J.GU5OQO\ Y,J*<J:JK9_I;_,****8@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^AV+_5I
M]!3Z9%_JT^@I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQE\5H-=FA)TGP^/M+R'[K3D$1(/<'+_\ ]Z /T5HHHH **** "BBB@ HHHH
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M9 (W+#&%C5L'!8+D]S2K>_.,XZ=_U_S*HMPC*$G=/;]/U5][>9]K_P#!(_\
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M3DC.9$=FPY=UVJ<CD9[\5F_M'?MM>._VAEGTN5U\->$&92-"L)"PEVDD&>7
M:4Y(XPJ953LW#-;2G[-1]E\36K[:O]/GYJYA"+J2E[5>ZGIYZ)W^^Z^74_7G
MQE=P7_P\URYMIH[BVFTJ>2*:%@R2*86(92."""""*_ *OW9T3_DW2P_[%2/_
M -(Q7X35S5*:I8VK371)?<Y'5"?M,'2F^K;_  B%%%%:&04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_0
M[%_JT^@I],B_U:?04^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK1\%^ ] ^'>BQZ5X=TR#3+).2L*_,Y_O.QY9O<DFM^@ HHHH **** "BBB@
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MXVM=?L+B\6R-O-8O:3^8RLRA 'D5_E1R22F-O&<XI2?(DY=?\[#C[[:CNO\
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M^7(0.E%&I[1:A0K>T6NY'11170=04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?T.Q?ZM/H*?3(O]6GT%/H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$K\L*,#\RJ6)QC?M+*?CJLY-UFI2V6WZ?UW+@HTH-1U;_K[^G9+1:/3]$_\
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MKW^Z/^04444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 6],;%THQFMUKA;%MY7DCO7,1R&-@RG!K4L[H7UU!%,<*6 R?K
M7)6I\SYNAQ5Z?,^9[%QIKC5)-EM&Q<_W:SM6TF[TUE-U"T9;IN%?;GPC^'OA
MW3?"MEJ)MK>>9DW--(!A?SKQ+]J[Q!H>I:OIUGI!@DFMP?/>W VY/;CK7R&7
M\0+&9A]2H4GRJ]WZ'P65\4+'YI_9^'H/E5[R[6/ ****^Z/TH**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Z'8O]6GT%/ID7
M^K3Z"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?G?_P %<O\ FE'_ '%O_;.OT0K\
M[_\ @KE_S2C_ +BW_MG0!^=]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4J
ML58$'!'(I** .AB\?^(+>P%G%JEQ';CC8K\5A7%S+=2&29VD<]6;K4=%90HT
MZ;;A%*_D84Z%*DVZ<4F^R"BBBM3<**** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\[_ /@KE_S2C_N+
M?^V=?HA7YW_\%<O^:4?]Q;_VSH _.^BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^!4-?F;10!^F7_#V3PE_T(FM?^!4-'_#V3PE_P!")K7_ (%0U^9M% 'Z9?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ?E7_P .J?BS_P!##X,_\#;O_P"1:/\ AU3\6?\ H8?!G_@;=_\ R+7ZJ44
M?E7_ ,.J?BS_ -##X,_\#;O_ .1:/^'5/Q9_Z&'P9_X&W?\ \BU^JE% 'Y5_
M\.J?BS_T,/@S_P #;O\ ^1:/^'5/Q9_Z&'P9_P"!MW_\BU^JE% 'Y5_\.J?B
MS_T,/@S_ ,#;O_Y%H_X=4_%G_H8?!G_@;=__ "+7ZJ44 ?E7_P .J?BS_P!#
M#X,_\#;O_P"1:/\ AU3\6?\ H8?!G_@;=_\ R+7ZJ44 ?E7_ ,.J?BS_ -##
MX,_\#;O_ .1:/^'5/Q9_Z&'P9_X&W?\ \BU^JE% 'Y5_\.J?BS_T,/@S_P #
M;O\ ^1:/^'5/Q9_Z&'P9_P"!MW_\BU^JE% 'Y5_\.J?BS_T,/@S_ ,#;O_Y%
MH_X=4_%G_H8?!G_@;=__ "+7ZJ44 ?E7_P .J?BS_P!##X,_\#;O_P"1:/\
MAU3\6?\ H8?!G_@;=_\ R+7ZJ44 ?E7_ ,.J?BS_ -##X,_\#;O_ .1:/^'5
M/Q9_Z&'P9_X&W?\ \BU^JE% 'Y5_\.J?BS_T,/@S_P #;O\ ^1:/^'5/Q9_Z
M&'P9_P"!MW_\BU^JE% 'Y5_\.J?BS_T,/@S_ ,#;O_Y%H_X=4_%G_H8?!G_@
M;=__ "+7ZJ44 ?E7_P .J?BS_P!##X,_\#;O_P"1:/\ AU3\6?\ H8?!G_@;
M=_\ R+7ZJ44 ?E7_ ,.J?BS_ -##X,_\#;O_ .1:/^'5/Q9_Z&'P9_X&W?\
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M#;O_ .1:/^'5/Q9_Z&'P9_X&W?\ \BU^JE% 'Y5_\.J?BS_T,/@S_P #;O\
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M "+7ZJ44 ?E7_P .J?BS_P!##X,_\#;O_P"1:/\ AU3\6?\ H8?!G_@;=_\
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M_H8?!G_@;=__ "+7ZJ44 ?E7_P .J?BS_P!##X,_\#;O_P"1:/\ AU3\6?\
MH8?!G_@;=_\ R+7ZJ44 ?E7_ ,.J?BS_ -##X,_\#;O_ .1:/^'5/Q9_Z&'P
M9_X&W?\ \BU^JE% 'Y5_\.J?BS_T,/@S_P #;O\ ^1:/^'5/Q9_Z&'P9_P"!
MMW_\BU^JE% #47:B@]ABG444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117Y^_P#!0']O#QE\
M,/B)I/P9^#MI'/X_U(0"XU PK/);/.0(8(8W!0R,"K%G! 5AQDY67*S44KMZ
M)%*-TY-V2U9^@5%?EI'^Q7^W+K4*Z[=?'XZ?JTH$S:6?%6H(D;'G84BB,((Y
M&%!7WQ7TA^PMKG[25OKGC7PE\?K&6=-)CMI-)UR2"';=!S('19X0$E "*W(W
MKN^;J!6D8W;3>O\ 74S;LN9+3^NA]=T5\]_MU?M$>(/V7_@#>^./#%AINHZO
M'?VUI'#JT<CP!9&(8E8W1B<#CYAUKIOV2OC)JG[0'[//@[Q]K=E9Z?JNL02/
M<6^GAQ K)-)'E [,P!V9P6.,]34P]]3E'[+2?JU?\BI>XXI_:5U\M#UZBBB@
M HHHH **** .6\9?%3P5\.KBQM_%?C#0?#$]^2MI%K.IP6C7!! (C$C O@D=
M,]174 Y&1R*_)'_@MQ_R43X3?]@^\_\ 1T5?K19?\><'_7-?Y4Z?OT55_O27
MW!4]RHH=U?\ +_,GHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% %#
M7O$&E^%='N]6UK4K32-*M$\RXOK^=8((4_O.[$*H]R:J>$?&OA[Q_HJ:OX7U
M[3/$FDR,R)?Z1>1W4#,IPP$D;%21W&>*\(_X*,?\F5_%+_KPB_\ 2B*O+O\
M@CM_R:"?^QBO?_08:5+]Y*I'^5)_>["J?NXTY?S2:^Y7/N*BBBF,**** "BB
MB@ HJ&\G-K9SS ;C'&S@'O@9KXI_X)X_MR^-/VN/$WCW3/%FBZ#I<>A16\UH
M^BQ31EA(\BE9/,E?<1L'(V]^*(^_-P6Z5_Z^X<O=ASO:Z7WGVY1110(****
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M?"_@W7M9AC2:;3K"XNTCDSM9HXV< X[$BL:DU3@YRV6II&+G)16[-JBOC?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  25\>_!_4)/&?P$\8ZAJ<UB3-#ISW!L]7@&.?(N(RJRG&>/W9QP-Q//K/\
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MB:34+>W^(&C^%_M,U];PQR1+?+$OF2*C+L(W[B 5Q[5YC_P3#^/_ (Z_:*^
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M,M7OM \;Z59Q-=7NCVUG92M#&!EMR0Q0RN /^>3L>,].:^JOV)_VQM%_:_\
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MNGVWEJWW&N[UDE;V)58_^^17ZXZ9IMKHVFVNGV,$=K96L2P001*%2.-0%55
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MC_A5/[*>D:I=0>5JWB^9M;GW#YA"P"6Z_3RU#_\ ;0UA0]Z=2H]HJW_;TO\
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M5RJRU<N9_@[?A;YGW5\%_$U]XP^#G@?Q!JTRS:EJ>AV5]=S*@0-+) CNV!P
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M[_AS@_VNOVK/#O[)/PP;Q/K%N^J:G=R&UTG1X7"/>3[2>6YV1J.6;!QP "2
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M%K_@H5\3?B]\8+_X5_LN^%[;Q!>6/F1W?B>[19(\J=KR1!V6*.)6X$DI8.2
MJ]-WUA^UAKW_  JC]D[XE:AX?@CTMM/\/W,=FEG&(E@9U,:LBK@#!?/'I7Y2
M?\$^_P!NCX>_L?\ @SQ/::]X2UK6/$.M7Z2M?:8L&T6T<8$<9+NIR':5L=/F
M%1S0J5YK:*5[=[MI*_E;YEJ,J=&+WDW:_HM7;SO\CZ'\<?$3]OO]FC1I?&OB
MVX\/_$'PO91^=J$%O9VKI:QY&6<01P38 ZLNY5')X%?:O[)G[47A_P#:Q^%-
MOXMT:!M-OH9/LFJ:3(^][*Y !*[L#<A!#*V!D'D @@?).H_\%I?A/JVGW5E=
M?#[Q9/:W,30RQ2"U*NC AE(\WH037G/_  1+U"Y_X3OXMVMFDZZ#+:VDRK(I
M(5Q+*(P3TW;&;ZX]JUI7G*5.2TM=/S6Z?RV\S.I:$5-/6Z37>_5>CW/HG]M_
M]NSQ-\&_B+H'PC^$_AVW\2_$O6EB;==*9(K;S6*Q1K&&7=(V"V68*JX)R#QY
MO)#_ ,%&_!MK#XAEU#PWXP1?WLOAM8=/WJ,9*MLCA+8Z8CE)/;-8/_!0SX-_
M$_X2_M0>'_VE?AYHTGB6SL(X'O88H&G^QRPH8V\V-/F\EXN"X^Z=V2ORD^S?
M /\ X*S?![XLM9Z;XJDN/AMX@FVH4U=A)8,Y[+=*,*/>58QSU-84$YTV[^_=
MZ>733S_$VK/EFM/<LM?/KKY'U9\'O%&O>-OA9X5U[Q1HC^&_$>HZ=#<ZAI,D
M;QM:3LH+QE7^9<'LW(Z&NPID,T=Q#'+$ZRQ2*&21""K*1D$$=13ZUD[R;M8R
MBK12O<****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<@<M_JQZ>];1GS8M5GHN6:]+I67Z&$H6PSI+5WB_75W9]7U^1?B3_E-I9?\
M83M__32*_72ODK4/V!8-0_;9@_:#/C>1#',EQ_PCHTL'++:?9Q_I'G=. W^K
M]L]ZRI^[B:=1[+?\#>>N'JP6[6AQ'_!8GX<W_C+]EVRURPA><^&=9AOKI4!)
M6WD1X6; ]&>,GT&37<_\$T?CWH'Q>_9C\*:):ZA"?$OA2RCTG4M-+@31K%\D
M,NWJ4>,+AAQD,.H-?4NN:'I_B;1K[2=6LX=1TR^A>VN;2Y0/'-&X*LC*>"""
M1BOSK^(G_!%7PAK'B:74? WQ%U3P58R.S_V?=:>-1$.3]R*031,%'0;RYQU)
MJ:;=-SBU=2:?HTK?D.HE-0DG9QNO5-W_ *_X<Z[_ (*G_M5>!O"'P1\1_"N'
M4(]8\;>((XX&TZRE5CI\8D20RW!&=F0N%0_,VX'&,FM+_@CM_P F@G_L8KW_
M -!AK1^&W_!++X9?#/X9>+M#M+VZU7Q?XBTBYTIO%FJ0I+)9":(QLUO "%0<
MDGYBY!(WX.*]B_8^_9G3]D[X/)X%3Q$WBAOM\]^^H-9?9,F3:-HC\Q\ !!SN
M.>>E:45&FZMW=R2U_P"WEHO1*]WU9C6YJBI65E&3=O\ MVU_F]++HC\[_P#@
MI?>/\*?^"@GPO^(&IPR-HD$6E:CYB*3N6UO&,JCU( 4X_P!H5^K]K\0?#-[X
M*C\80Z_IK>%GM?MHUDW2"U\C&?,,A.T+CN3Q7GW[37[*_@?]JWP3%X?\8V\\
M<MI(9K#5;!E2[LI",,49@058 !E8$' /4 CXL\._\$1?#UIK@.N?%C5M3\/"
M3>=-L=)CM)CZ?OFED7..,^7^59T^:-/V+Z.33_Q>6_\ 7GIM4Y7-55V2:].S
M_K\-?F_]JS]H?PM^TA^WY\/=;\'/-<Z'I6HZ3I$=](NU;MH[XNTJ*>0A,F!G
MD[<X&:_3[_@H#\,[_P"+'[(OQ#T/2H7N=2CLTU&W@C4LTK6TJ3E% ZDK&P ]
M2*\U^(W_  3'\&^(O&'PIU'P=J\?@/0_ DL<O]DV^F_:FU!EN$F+O.TRL'8I
M@NP<]/3%?9_7@U+@I8;V2=G>3_%6?WJ]OD.,VL1[5K2T?POI]VA^<?\ P1U_
M:&\/:G\([KX4:CJ5O9>)])OYKK3[.>0(]Y:RG>?*!/SLC^9N Y *GUQ]M?&O
MX_>!/V>_"<WB'QUX@MM'M%4F&W9@US=L/X(8A\TC?08'4D $U\I_M!_\$BOA
MK\7O$UYXB\)ZW>?#G5;V0S7%O:6J75@SDDLZ0%D9"2>BN%]%%8'PJ_X(R^ /
M#.N0ZIX^\9ZM\03#('6R2W&G6TH'190)))&'^[(O3TXK>4W6LW[KLD^NVFG_
M  ?^ 91C&BVE[RNWVWUU_K_,^]--UJV\8>#;75]-+26>JV"75L77:S)+&&3(
M/0X8<5^4/_!%W7++0_C1\4?#U_<)::Q>V$+6]I,=KR>1-()0 >I7S%)'ID]J
M_7&QLK?3;*WL[2%+:UMXUBBAB4*L:*,*H Z   8KX*_:&_X)$>#OB]\0M1\8
M>%/&5Y\/[[4[AKR]M%T];VV,S'+/$OF1-'N;+$;F&2< #BH3]GB'4@O=::]-
M[?GJ59SP_LYOWKQ?W;_\ ^V/'&@V?Q!\$^*?#!GB==1L+C3;A0P;R_-A*X8=
MN'!P>QK\J?\ @E!\6M/_ &?_ (P?$3X1>/[B+PUJVI7,45N;]Q$GVVW:2-[<
MLW&YPX*^NS R2,_H!^QW^R7I7[(7P]U'PYI^OWGB6ZU.^.H7NH7<2PAI-BIA
M(P3M7"CJS')//:N5_:E_X)V_"_\ :DU5O$&HK>>&/%Y0(^M:,4!N0!A1<1L"
MLF!@;AM?  W8 %"_<U7./O*2L_S5O1_?^#'^]I<DM&G=?E^*_P O,^HRP"[B
M0%QG/:N6\*_%;P;XZU_6=$\.>)]*UW5=&V?VC:Z==I.UH7+!1)M)"ME&X/(Q
MS7Y\6/\ P1CN_*BTW4OCWK5YX;4@'2H-',0VYS@%KIT'?G8?I7U]^RY^QQ\/
M_P!DG2=4M?!BZC=7VJF/[?J>K7(EGG$>[8N%5455WMC:H//).!5Q2U;9+;V2
M/@+_ (*]>'=5^'/[2'PN^+-I;M+9K;01))@[!=6=RTX0GH-RR#'KM;TK]/\
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M%'.?UU\=6]_JGP?\0P2P[M3N-"N$:%.\S6[ J/\ @1Q7RQ^S?_P2L^'7P/\
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MA9C%D?ZZ/81Y77YNO3BJ<4ITFG>SN_QV^5BJ,[.;EHFG;[NOSO\ *Q[+\1/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\2_\
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MG_5M2XR<'='BG['O[.L/[+OP'T/P.9K>\U6-I+O5+VU!\NXNI&RS+D E0 J
MD X0<5[7116TYN<N9F,8J"Y4%%%%06%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
*1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>cdtx-20231231_g14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g14.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" U-$E0# 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_
M *$:*-:_Y#-__P!?$G_H1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&
M_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#R;6O^0S?_ /7Q)_Z$:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @:;_K
MX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q
M)_Z$:* .S^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W__
M %\2?^A&BC6O^0S?_P#7Q)_Z$:* .S^'_P#R!IO^OAO_ $%:Z:N9^'__ "!I
MO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#R;6O\ D,W_ /U\2?\ H1HHUK_D,W__ %\2?^A&B@#L_A__ ,@:
M;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?"'_ +&:Q_\ 1JT ?T?4444 %%%% !1110 4444 %%%% !7P+^U5_P %5/\
MAF7XY:_\.O\ A6'_  DG]E);/_:7_"0?9?-\VWCFQY?V5]N/,V_>.<9XSBOO
MJOP+_P""JG_)\?C[_KCIO_I!;T ?4'_#\[_JB?\ Y=?_ -Q4?\/SO^J)_P#E
MU_\ W%7Y86EI/J%U#:VL,ES<S.L<4,*%GD<G 50.222  *]*NOV6OC180-/<
M_"+QY;PKC=)+X:O549.!DF*@#]";?_@N9$TR"?X+/'%GYFC\4AV ]@;,9_,5
MU/A[_@MUX$NKA%USX;^(=-A+8:2PNX+L@<<X;RL]^,]J_+74/@;\2-*MS<7O
MP^\4V< X,MQHMRBC\2F.U<0RE6((P1P0: /Z3/@%^U9\,OVF-,EN? ?B2'4+
MNW0/=:5<*8+VV' R\3<[<D#>N5SQFO7*_EX^'_Q \0_"WQAIGBCPKJMQHNNZ
M;*)K>\MGVLI'52.C*1P5.0P)!!!K^AK]CS]I*R_:F^!NC^-(8H[35E9K'6+&
M/.VWO8P-X7.?E8,KKR?E< \@T >VT444 %%%% !1110 5\"_M5?\%5/^&9?C
MEK_PZ_X5A_PDG]E);/\ VE_PD'V7S?-MXYL>7]E?;CS-OWCG&>,XK[ZK\&_^
M"I'A_5;_ /;<\>3VVFWEQ"T.F[9(H'93BP@!P0* /L7X*?\ !8;_ (7#\7/"
M'@?_ (5)_9'_  D&IP:=]N_X27S_ "/,<+O\O[(N[&<XW#/K7Z/U_.G^Q?X9
MUBU_:R^$DLVE7T42>);%FD>V=54>:O))'%?T64 %%%% !1110!\:_MM?\%$O
M^&.?'VA>&?\ A7__  EW]J:9_:/VK^VOL7E?O7CV;?L\F?N9SD=>E?/5I_P7
M'^U74,/_  I7;YCJF[_A*\XR<9_X\J\Z_P""VG_)?? O_8LC_P!*IZ_/72?^
M0K9?]=D_]"% ']3U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7/_ !"\6?\ "!^ ?$OB;[+]N_L73+G4?LOF>7YWDQ-)LW8.W.W&
M<'&>AKH*\_\ VA/^2!?$O_L6=3_])9* /SK_ .'YW_5$_P#RZ_\ [BKZO_8:
M_;@_X;0M?&4W_"%_\(=_PCKVB;?[5^W?://$QS_J8MNWR??.[MCG^?ROU>_X
M(:_\@KXR?]=M)_\ 0;R@#]2J*** "BBB@#\X/C7_ ,%AO^%/?%SQ?X'_ .%2
M?VO_ ,(_J<^G?;O^$E\CS_+<KO\ +^R-MSC.-QQZUB>"O^"W6D:YXNT?3M?^
M%;^'M%N[J."[U:/Q#]J-G&S &7ROLJ;PN<D!@< XR>*_/O\ ;6_Y.X^+W_8S
M7W_HUJ\5H _JCMKF&\MXKBWE2>"5!)'+&P974C(8$<$$=ZEK\\O^"1_[67_"
MROAY+\)O$=[O\2^%X ^E23-\]WIV<!!ZM"2%_P!QDQ]UC7Z&T %?G!\:_P#@
ML-_PI[XN>+_ _P#PJ3^U_P#A']3GT[[=_P )+Y'G^6Y7?Y?V1MN<9QN./6OT
M?K^<']M;_D[CXO?]C-??^C6H _53]D/_ (*??\-5?&2V\!?\*U_X1?SK*>\_
MM#^WOM>/*4';Y?V:/KGKNX]Z^ZJ_"O\ X)#_ /)Y.F_]@:__ /0%K]U* "BB
MB@ HHHH **** "HKJZAL;:6XN)8[>WA0R232L%1% R6)/  '.37'?&SXG0_!
MCX2^*_'-Q82:I#H.GRWS64<@C:;8,[ Q!VY/?!QZ&OP9_:?_ &\OBC^U)<S6
MFM:G_87A+?NA\-:2S1VV ?E,S?>G8<<OP",JJT ?N]\*_CKX(^-LGB#_ (0C
M78/$5MH=V+&\O+,$V_G% ^V.3&)  1\RY7G@FN^K\X/^"(__ "1?XA_]C!'_
M .DR5^C] !1110 5P_QN^*EK\$?A/XG\=7UC-J5IH5H;N2TMW"R2@$# )X!Y
M[UW%?/\ ^WY_R9M\6/\ L#/_ .AI0!\J_P##[SP1_P!$T\0?^!L'^%?37[&_
M[;&B?MD6WBR;1O#>H>'1X?>U247TZ2>;YXE(V[>F/)/7U%?SSU^KW_!#7_D%
M?&3_ *[:3_Z#>4 ?J51110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >3:U_P AF_\ ^OB3_P!"-%&M?\AF_P#^OB3_ -"-% '9
M_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7Y3QB@#[<_X+:?\ )?? O_8LC_TJGK\]=)_Y"ME_UV3_ -"%>@_&K]H3Q?\
MM 1^$Y?&EXNJ:IX>TS^R8]28'S[J$2.Z-,?XG&\J6ZL "<G)/GVD_P#(5LO^
MNR?^A"@#^IZBBB@ HHHH *\V^+_[1_PR^ EM'+X^\9Z7X<>5#)%:SR&2ZE0=
M62",-(XSQE5/->:_MZ?M71_LG_!.;5[#R9_&&L2&PT.VFPRB7;EYV7ND2X..
MA9D4_>K\ O%_C#6_'WB74/$/B/5+K6=;U"4S75]>2%Y)7/<D]NP X   P!0!
M^UFN_P#!8KX Z3+*EJGBO6U0?*]CI2*'Y[>=+&?S INC_P#!8WX!:HT0N8?%
MND!^K7FE1L$Y[^5,_P!>,U^//@'X!_$OXIV9O?!_@'Q)XEL0Q0WFF:7-/ &'
M53(JE0?;.:H^/?A!XZ^%DD2>,O!NO>%3,Q6)M8TV:U64C/W&=0&Z'IGI0!_1
M-\%_VI/A7^T)'*/ /C33]>NHD\R6P^>"[C7."Q@E59-N3C=MQSUKU2OY:O#/
MB;5_!NO66MZ#J=WHVL64@FMKZQF:*:%Q_$K*00:_H&_8%_:8N_VIOV?;'Q)J
MZ1Q^)=-NGTC5O) 5)9XT1A,%[!TD1B!P&+ <"@#Z/KYJ_P"'D/[-O_14M/\
M_ *[_P#C-?2M?RKT ?TQ?!S]HCX=_M 6VJ7'P^\3V_B6'2WCCO&@AEC\IG#%
M ?,1<Y"MTSTKF/CC^V=\'OV=YI+/QGXRM+?64 /]C6*M=WO(!&Z*,$QY!R"^
MT$=Z_$CX _MA^(OV;_@W\0?"W@U9+'Q)XLN;7&N*P#6%O&DJN8AU\UC( &_A
M )'S8(\X\'_!_P")OQJN+O4O#7@_Q/XSDDF8W6H6.GSW:F4_,QDE"D;CG/S'
M)S[T ?L%'_P60^ CWYMS:^+XX@0/M3:7%Y9R2,X$V[C&?N]QUY%?2WP3_:@^
M%_[1%K+)X!\7V.N7$*"2>P^:"[A7IEH) KA<\;L;<]#7\X?BSP7XA\ ZP^D^
M)]!U/PYJJ*':QU:SDM9U4]"4D4, ?I2>#_&&M_#_ ,3Z;XB\.:G<:/K>FS+<
M6E]:OMDB<="/4=B#P02""#B@#^I"BO%/V.?V@5_:9_9]\,^-Y8XX-6E1K/5;
M>+[L=Y$=LF!V#?+(!V6117M= #)94AC>21UCC0%F=C@*!U)/I7RM\4O^"G7[
M/WPMU*;3I/%LOB?4(7*2P^&[5KM4(.#^^RL3=_NN>GTK\^/^"DW[>^K?&;QE
MJWPV\$ZH]I\.=+F-M=S6K%6UFX0X=G8=8%;A5'#;=YSE0OP50!^Z7A'_ (*\
M?L^^)]1CM;R]\0>&5D?8+C5]+S$.2 28'E(!P#DC@$9QSCWSXI^-M ^(?[,'
MC_7_  QK-EKVBW?A?4V@OM/G6:)_]%E! 93U!X(Z@C!K^?[2?V7_ (PZ_H(U
MK3?A9XQOM*90Z7=OH5RZ2*?XD(3YA[KD"K/PB_: \>?L[S>*-(TBYFMM.URP
MN=)UG0;Y6$,JR1M$6:,XV2INRK#!!&#E25(!Y37ZO?\ !#7_ )!7QD_Z[:3_
M .@WE?E#7ZO?\$-?^05\9/\ KMI/_H-Y0!^I5%%% !1110!_.#^VM_R=Q\7O
M^QFOO_1K5XK7M7[:W_)W'Q>_[&:^_P#1K5C_ +.?P)U#]HSQ]=^#M&G$.MOI
M-Y?6"-@+-/!&9%B8GH'VE<]BP)X!H Y[X/\ Q5UWX(_$SP]XX\-S^1J^C72W
M$8).V5>5>)_5'0LC#T8U_2!\%/B[H7QW^%WA[QUX<E\S3-8MA,(V8%X)!\LD
M+X_B1PRGW7TK^9.\LY]/NY[6ZADM[F!VBEAE4J\;J<,K \@@@@@U]^?\$E_V
MLC\*?B8_PM\17OE^%?%DX-A),V$L]2("K]%F 6,_[2Q=/F- '[3U_.#^VM_R
M=Q\7O^QFOO\ T:U?T?5_.#^VM_R=Q\7O^QFOO_1K4 >U?\$A_P#D\G3?^P-?
M_P#H"U^ZE?A7_P $A_\ D\G3?^P-?_\ H"U^ZE !7F/QF_:8^&'[/MK%+X^\
M8Z?H$LR%X;-RTUU*H_B2",-(1GC(7'O7@O\ P46_;E'[*W@ZUT#PL]O<_$?7
M8F:U64!UTZVY4W3IW8L"L:G@E6)R$*M^&7B;Q1J_C37KW6]>U.ZUC5[V0RW-
M]>RM++*YZEF)R: /VNU#_@L=\ [.^$$-OXNOXMV/M-OI48C'&<X>96QGC[O7
MVYKT3X8_\%+OV??BC>Q6-OXV7P]J$I54M_$5N]D"3CCS6S%G)QC?7X:^"_@)
M\2_B1IK:CX4^'WB?Q)IZ@DW>E:1<7$1QP0'1""<@\ YXKDM<T'4_#.J3Z;K&
MG7>E:C <2V=] T,T9(SAD8 C@CJ* /ZEXI4FC22-UDC<!E=3D,#T(/I3Z_"S
M]@#_ (*":_\ L[>*M,\(>+M2FU3X7WTZP2)=2-(VC%CCSH3R1&#R\8XQDJ V
M=W[GV]Q%>6\4\$J3P2J'CDC8,KJ1D$$<$$=Z /B/]MC]M#X+:M\"?BU\/[3Q
MW9S>,#87>D_V6+:X#_:D8HT6XQ[<AE(SG''6OPWKTK]IK_DY+XK_ /8VZM_Z
M62UYK0!^F?\ P2G_ &I_A7\ _A=XTTOQ_P",+;PW?WVLI<VT,\$\ADC$"J6!
MC1AU!'-?I5\&OVD/AM^T'_;'_"O?%-OXE_LCR?MWD0S1^3YN_P O/F(N=WE2
M=,_=K^:*OU4_X(8_\UL_[@G_ +?T ?JI1110 5\__M^?\F;?%C_L#/\ ^AI7
MT!7S_P#M^?\ )FWQ8_[ S_\ H:4 ?SKU^KW_  0U_P"05\9/^NVD_P#H-Y7Y
M0U^KW_!#7_D%?&3_ *[:3_Z#>4 ?J51110 4444 %(S!5))P!R2:CNKJ&QM9
MKFYFCM[:%&DEFE8*B*!DLQ/   R2:_$+]O3_ (*/>(_CQKFL>"/ M_)HOPS@
ME:W,UJ62?6E7@O*W!$).=L8QD8+Y. H!^F7Q6_X*'_ /X0WDUAJOCVUU35(F
M*/8Z#&]^ZL.H9XP8U(Z89P?UKR&/_@LM\!I+PPMIWC*./ /VAM+@V')Z8%P6
MX^E?B+6[)X!\3PZ2=4D\.:LFF"/S3>-8RB'9_>W[<8]\T ?T$?"']OCX%_&R
M^MM.\/\ CRSM]8N&\N/3-81[&=W/1$\T!78]@C-7T'7\J]?H-_P3_P#^"E6M
M_"G7-+\ ?%#59=7\!W4BV]KK%](7N-&)X7+G)>WS@$'E!RIP-I /VBHID,R7
M$22Q.LD3J&5T.0P/((/<5\P?\%"?VLI?V4_@J+W1?*?QIK\K6&C"90ZPD+F6
MY*GAA&I& >-[ID$9% 'J?QB_:<^%GP"A5O'OC;2_#\[*'2R=VFNW4\;EMX@T
MI7W"XKYIUK_@L9\ M*EG2UB\6:PL?W9++2HU$G^[YLR'_OH"OQ.\2>)M6\9:
M]?:WKNI76L:Q?2F:ZOKV9I9IG/5F9B237KO@;]B/X[?$?28-3T'X8:]<:?.N
M^&YN85M$E7CYD,S)N!SP1P>W2@#]6=#_ ."PW[/^K31I=-XHT967<9+[2594
M/]T^5)(<_0$<=:^F/A%^T=\,_CQ;/+X"\::7XC>-!)):V\I2YB4]&>!PLB#W
M917\^'Q4_9>^+'P3L1?>-O 6M:!IQ;9]OF@\RV#$@!3,A9 23P">>U<)X3\6
M:SX%\1Z?K_A[4[K1M:T^43VM]9R&.6)QW!'Y$=""0>* /ZDJ*^;?V!_VJ&_:
ML^!MOK>IB&+Q=I,W]FZW#"-JM,%!2=5[+(I#8' 8.!PM?0>O:Y8^&=#U'6-3
MN%M--T^VDN[JX?[L44:EW8^P4$_A0!!XI\7:'X'T.YUGQ%K%CH.D6PS-?:E<
MI;PQC_:=R /SKY3\;?\ !5_]G;P?=M;6WB34O$\J,4<Z)I<K(I!QP\OEJP]U
M)!K\E_VQ/VO/%/[6'Q(O-3U"[N+3PE:3LNB:"'(AM802%D90<-,PY9^O.!A0
M /./AE\#_'_QFNY[?P/X/UCQ.\'^N?3K1I(X>,@/)C:I/;)&>U '[ 6__!9K
MX$333(^D^-;=8SA9)-,MRLG7E=MR3CZ@=:]?^%__  44_9_^+%]%8:9X_M-+
MU*5@B6FNQ26#,QZ!7E C8D\8#$Y^HK\;-=_X)^_M#^'-.DOKSX4ZX\$:EV%G
MY5U)@#)PD3LQ^@%> W=I/I]U-:W4,EM<PNT<L,R%7C<'!5@>00000: /ZHE8
M.H92&4C((Z&EK\A/^"3_ .VIK>D^-]/^"OB_4I+_ ,/:FC)X?N+IRSV-PJEA
M;!C_ ,LG4,%4GY6"A?O&OU[H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*@#^<ROU\_X(JZ+I^I_!OX@/>6%M=NNOQA6GA5R!]G3@9%?D'7[$_P#!$?\
MY(O\0_\ L8(__29* /T4L=)L=+W_ &*RM[3S,;_(B5-V,XS@<]3^=?"O_!9[
M_DU#1/\ L;;/_P!);NOO6O@K_@L]_P FH:)_V-MG_P"DMW0!^)E?T)_\$WO^
M3)?A;_UY7'_I7/7\]E?T)_\ !-[_ ),E^%O_ %Y7'_I7/0!7_P""C?QUN_@)
M^ROXCU/2KDVFOZTZ:%ILZG#123AC(ZD<AEA29E(Z,%-?SZ9SR>37ZY_\%PM2
MGB\!_"NP5R+:?4[Z=T[%TBB53^ D?\Z_(R@#]./^"4_[#7A[XB:))\8/B#I4
M.M:<MT]MH&D7D8>VE:,[9;F1#Q( ^453P"CD@_+C];884MXDBB18XD4*J(,!
M0.  .PKQ#]AO1[?0_P!D'X1VUJJ)$_AVUNB$Z;YD\US]2SL3[DU[E0!\*_\
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M3;?!O_8VP_\ I'=5^A5?GK_P6P_Y-M\&_P#8VP_^D=U0!^,-?T9_L*_\F?\
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M#]/Z_EAU;_D*WO\ UV?_ -"-?U/5_+#JW_(5O?\ KL__ *$: /T*_P"")?\
MR7WQU_V+)_\ 2J"OV4K\:_\ @B7_ ,E]\=?]BR?_ $J@K]E* /P+_P""JG_)
M\?C[_KCIO_I!;UYK^Q3_ ,G<?"'_ +&:Q_\ 1JUZ5_P54_Y/C\??]<=-_P#2
M"WKS7]BG_D[CX0_]C-8_^C5H _H^K\=O^"T/P1_X1OXI>&/B=8V^VR\1VO\
M9VH.J\"\MP-C,?5X2JC_ *X&OV)KYY_;Z^"/_"^_V6O&6A6\'GZSI\']LZ4
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M&@&2S$\   DDU^<?[1G_  62\,>"M6N]$^%/A^/QI<0$HVO:C*\-AO'7RXU
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MP1;O)-I$$B7>ES3<L]I*H>,$]RF3&3W,9/>O'])_Y"ME_P!=D_\ 0A7Z ?\
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M$?\ Y(O\0_\ L8(__29*_1^@ HHHH *^?_V_/^3-OBQ_V!G_ /0TKZ KY_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_ /7Q)_Z$
M:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_
M $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#P5_\ %7PM\*VGAGXB^'Y/'EG9((K76(;OR;]8P,!9=RLLV. &)5L=2QH
M_9JOQ\_X+5_%NP\1?$SP1\/["X6>?PY9SWVH"-@1'-<^7Y<;>C".(/CTF7UK
MIOB[_P %LIK_ ,/W5E\-O 4NF:K,I6/5]?N4D%MVW+;H"';TW/@$#*L.*_,?
MQ/XFU;QIXAU'7==U"XU76-1G:YN[VZ<O)-(QRS,: ,Z&&2XE2*)&DE=@JH@R
M6)X  [FOZ;O@9X&E^&/P6\!^$9RIN=#T*RTZ9EZ-)% B.?Q8$_C7X]?\$L_V
M/[[XS?%6Q^).O66SP+X4NUGB,R?+J%^GS1Q)ZK&VV1STX5>=QQ^WM 'X%_\
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M<J2>H+*?T?@_X+<_#QM $TWP[\31ZWLR;..>W:VW8/'GE@V,XY\K\* /7?\
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M/)> /&VI_#?QQH/BK1IFM]4T:]AOK=U8K\\;A@"1V.,$=P2*]K_;B_:ZG_;
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M[#5))M'DD8X >XB:.'\YC$/QK^@FOY68Y'AD62-F1U(964X((Z$&OTN^ /\
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MZZ_8-_;W?]CE?$NEZAX7;Q/H.N217#+;W0MY[::-67<I*D.K @%3C&T$'J"
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M&'!FDVRW##T*H(5^DS5^877@<FOZ-OV)_@K_ ,*"_9F\$>%)[?[/JWV,7^J
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MSS@DUZW\9-/T3P'^SM\1%L;"ST72+/PWJ4I@LH$ABC5;60DA% '05\Z> ?\
M@KI\ _$WA6"_\1:IJ7@_6?+'GZ1=:;/=$/W$<L*,C+GH6*DCJ >*^//V[?\
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M\2_VJOC!XA\,^-(-"BTZPT*34HCI=F\,GFK<01C):1LKMD;C'7% 'FG_  7
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MI<EMJJ-+;Z_X6=K$RX8JSXCPCMN# ET)R#7X!W%O+:SR03QO#-&Q1XY%*LK
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R
M&;__ *^)/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIOQ;X#OOA_HMMJMMI-C<P7;3W\-L4=Y$90!(PSPIZ5^AE% 'X+?\.G_VDO\
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MUK]3OV/?^"?_ ($_9+MVU."1O%/CBXC\N?Q!?0JAA4C#1VT?/E*>YR6/=L8
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M>&MX,_VB5)M0E0'D10H2%)Z9D*XZ[6Z']OJ* /S;_;B_X)WZYXB^%OPE\#_
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MW:?_ !ROWIHH _*__@GC^P;\9/V??VD++Q=XV\/VFG:%'IMW;-/#J=O.P=U
M4;4<GMZ5^J%%% '*_%#X8>&OC)X%U7PAXNTR/5M"U*+RY[>3@@]5=&'*NIP5
M8<@@5^2W[0'_  1M\?\ A?5KN^^%.IVOC+06^>'3=1N$M=1B_P!C<VV&3'][
M<A/]WN?V3HH _G&UC]B'X^Z'(4N/A%XLD(Q_QYZ;)<CDXZQ!AU_3GI71>"?^
M"<_[0_CJ^C@M_AKJ6DQ,X5[K6WCL8XP?XB)&#$#_ &58^U?T+T4 ?"'[%?\
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M'3_[27_0H:?_ .#NT_\ CE?O310!^"W_  Z?_:2_Z%#3_P#P=VG_ ,<KZ_\
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M7+B((L*'EHK>/)V(2!DDEFQU ^4?4U%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >3:U_P AF_\ ^OB3_P!"-%&M?\AF_P#^
MOB3_ -"-% '9_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YU?\
M!;3_ )(%X%_[&8?^DL]?C97]5%% 'A7["O\ R9_\)/\ L7[?^5>ZT44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!Y-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\
MT(T4 =G\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O_P#K
MXD_]"-%&M?\ (9O_ /KXD_\ 0C10!V?P_P#^0--_U\-_Z"M=-7,_#_\ Y TW
M_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!Y-K7_(9O_\ KXD_]"-%&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\
M7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!Y-K7_(9O\ _KXD_P#0C11K7_(9O_\
MKXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\ (9O_
M /KXD_\ 0C11K7_(9O\ _KXD_P#0C10!V?P__P"0--_U\-_Z"M=-7,_#_P#Y
M TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMK4$5O=6UW.\+A8V9@8W7(4_,>JMVK]>OV2?^"AWP[_:LG71($E\)^-]K/\
M\(]J$HD,ZJ"S-;S  2@*"2,*P )VX&: /J>BBB@ HHK\Z_VOO^"K<_P#^-6I
M^ _!_A;3?$\>CQI%J-]>W+H%NR-SQ($ZA%* D\[MPQ\O(!^BE%?*_P"P+^V%
MK'[87A'Q5K&L>'K'P]+H]]%:1QV,SR"0-'OR=W0U]44 %%%% !1110 445^>
M'[8'_!5Q?@+\7KOP-X)\.:;XM;24\K5;Z[NG1([K/S0)LZE!@,3T8E>JF@#]
M#Z*^,_V /V[->_;&UCQG9ZSX7T[P\N@P6LT36,\DAE,K2@AMW3'ECIZU]F4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%<;\6OB]X2^!O@>^\6^--8AT71+08,
MLF2\KG[L<:#YG=L'"J">">@) !UEY>6^G6DUU=SQVMK"ADEFF<(B*!DLS'@
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M,W__ %\2?^A&B@#L_A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH
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M)'&H&2S,>  .YJQ7YS?\%L[ZXM_@?X$MXIY8X+C7V$T2.0LF+=R-PZ'!Y&:
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M_!#G_D:OBW_UY:;_ .C+BOUJK\E?^"'/_(U?%O\ Z\M-_P#1EQ7ZU4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#R;6O^0S?_ /7Q)_Z$:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @:;_KX;_T
M%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /D;_@H9^Q&G[6?@6SU'P^\%E\0M 1_[.EG.V.]A;EK61OX
M<GYD8\*V0<!R1^&GQ"^&WBGX4>)KGP]XPT&^\.ZS;G#VE_"8V(SC<IZ.IQPR
MDJ>H)K^H2O)?VJ?!7A_QE\ /'ZZ]H>G:T+/P_J%S;?VA:I/Y$J6SLLB;@=K!
ME!##!! H _GH^$_QN\=_ S7)-8\!^*=0\,WTRA)FLY/W<Z@DA9(V!20 DX#
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M_O\ +_C1_;6G_P#/_:_]_E_QJE_PA^D?\^G_ )%?_&C_ (0_2/\ GT_\BO\
MXT 7?[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QJE_PA^D?\^G_D5_\
M&C_A#](_Y]/_ "*_^- %W^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &J7_
M  A^D?\ /I_Y%?\ QH_X0_2/^?3_ ,BO_C0!=_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\:I?\(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"- %W^VM/_ .?^U_[_
M "_XT?VUI_\ S_VO_?Y?\:I?\(?I'_/I_P"17_QH_P"$/TC_ )]/_(K_ .-
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MY]/_ "*_^- %W^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &J7_  A^D?\
M/I_Y%?\ QH_X0_2/^?3_ ,BO_C0!=_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y
M?\:I?\(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"- %W^VM/_ .?^U_[_ "_XT?VU
MI_\ S_VO_?Y?\:I?\(?I'_/I_P"17_QH_P"$/TC_ )]/_(K_ .- %W^VM/\
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M +7_ +_+_C1_;6G_ //_ &O_ '^7_&J7_"'Z1_SZ?^17_P :/^$/TC_GT_\
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M^- %W^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &J7_  A^D?\ /I_Y%?\
MQH_X0_2/^?3_ ,BO_C0!=_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:I?\(?
MI'_/I_Y%?_&C_A#](_Y]/_(K_P"- %W^VM/_ .?^U_[_ "_XT?VUI_\ S_VO
M_?Y?\:I?\(?I'_/I_P"17_QH_P"$/TC_ )]/_(K_ .- %W^VM/\ ^?\ M?\
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M?^_R_P"-']M:?_S_ -K_ -_E_P :I?\ "'Z1_P ^G_D5_P#&C_A#](_Y]/\
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M_P"17_QH_P"$/TC_ )]/_(K_ .- %W^VM/\ ^?\ M?\ O\O^-']M:?\ \_\
M:_\ ?Y?\:I?\(?I'_/I_Y%?_ !H_X0_2/^?3_P BO_C0!=_MK3_^?^U_[_+_
M (T?VUI__/\ VO\ W^7_ !JE_P (?I'_ #Z?^17_ ,:/^$/TC_GT_P#(K_XT
M 7?[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&J7_"'Z1_SZ?^17_QH_X0_2/^
M?3_R*_\ C0!=_MK3_P#G_M?^_P O^-']M:?_ ,_]K_W^7_&J7_"'Z1_SZ?\
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M )_[7_O\O^-']M:?_P _]K_W^7_&J7_"'Z1_SZ?^17_QH_X0_2/^?3_R*_\
MC0!=_MK3_P#G_M?^_P O^-']M:?_ ,_]K_W^7_&J7_"'Z1_SZ?\ D5_\:/\
MA#](_P"?3_R*_P#C0!=_MK3_ /G_ +7_ +_+_C1_;6G_ //_ &O_ '^7_&J7
M_"'Z1_SZ?^17_P :/^$/TC_GT_\ (K_XT 7?[:T__G_M?^_R_P"-']M:?_S_
M -K_ -_E_P :I?\ "'Z1_P ^G_D5_P#&C_A#](_Y]/\ R*_^- %W^VM/_P"?
M^U_[_+_C1_;6G_\ /_:_]_E_QJE_PA^D?\^G_D5_\:/^$/TC_GT_\BO_ (T
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M_/I_Y%?_ !H_X0_2/^?3_P BO_C0!=_MK3_^?^U_[_+_ (T?VUI__/\ VO\
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M1_;6G_\ /_:_]_E_QJE_PA^D?\^G_D5_\:/^$/TC_GT_\BO_ (T 7?[:T_\
MY_[7_O\ +_C1_;6G_P#/_:_]_E_QJE_PA^D?\^G_ )%?_&C_ (0_2/\ GT_\
MBO\ XT 7?[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QJE_PA^D?\^G_D
M5_\ &C_A#](_Y]/_ "*_^- %W^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\
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M/^$/TC_GT_\ (K_XT 7?[:T__G_M?^_R_P"-']M:?_S_ -K_ -_E_P :I?\
M"'Z1_P ^G_D5_P#&C_A#](_Y]/\ R*_^- %W^VM/_P"?^U_[_+_C1_;6G_\
M/_:_]_E_QJE_PA^D?\^G_D5_\:/^$/TC_GT_\BO_ (T 7?[:T_\ Y_[7_O\
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M?\(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"- %W^VM/_ .?^U_[_ "_XT?VUI_\
MS_VO_?Y?\:I?\(?I'_/I_P"17_QH_P"$/TC_ )]/_(K_ .- %W^VM/\ ^?\
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M'_/I_P"17_QH_P"$/TC_ )]/_(K_ .- %W^VM/\ ^?\ M?\ O\O^-']M:?\
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M_P!_E_QJE_PA^D?\^G_D5_\ &C_A#](_Y]/_ "*_^- %W^VM/_Y_[7_O\O\
MC1_;6G_\_P#:_P#?Y?\ &J7_  A^D?\ /I_Y%?\ QH_X0_2/^?3_ ,BO_C0!
M=_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:I?\(?I'_/I_Y%?_&C_A#](_Y]
M/_(K_P"- %W^VM/_ .?^U_[_ "_XT?VUI_\ S_VO_?Y?\:I?\(?I'_/I_P"1
M7_QH_P"$/TC_ )]/_(K_ .- %W^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\
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M_P#:_P#?Y?\ &J7_  A^D?\ /I_Y%?\ QH_X0_2/^?3_ ,BO_C0!=_MK3_\
MG_M?^_R_XT?VUI__ #_VO_?Y?\:I?\(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"-
M %W^VM/_ .?^U_[_ "_XT?VUI_\ S_VO_?Y?\:I?\(?I'_/I_P"17_QH_P"$
M/TC_ )]/_(K_ .- %W^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\:I?\
M(?I'_/I_Y%?_ !H_X0_2/^?3_P BO_C0!=_MK3_^?^U_[_+_ (T?VUI__/\
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MT_\ Y_[7_O\ +_C1_;6G_P#/_:_]_E_QJE_PA^D?\^G_ )%?_&C_ (0_2/\
MGT_\BO\ XT 7?[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QJE_PA^D?\
M^G_D5_\ &C_A#](_Y]/_ "*_^- %W^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?
MY?\ &J7_  A^D?\ /I_Y%?\ QH_X0_2/^?3_ ,BO_C0!=_MK3_\ G_M?^_R_
MXT?VUI__ #_VO_?Y?\:I?\(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"- %W^VM/_
M .?^U_[_ "_XT?VUI_\ S_VO_?Y?\:I?\(?I'_/I_P"17_QH_P"$/TC_ )]/
M_(K_ .- %W^VM/\ ^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\:I?\(?I'_/I_
MY%?_ !H_X0_2/^?3_P BO_C0!=_MK3_^?^U_[_+_ (T?VUI__/\ VO\ W^7_
M !JE_P (?I'_ #Z?^17_ ,:/^$/TC_GT_P#(K_XT 7?[:T__ )_[7_O\O^-'
M]M:?_P _]K_W^7_&J7_"'Z1_SZ?^17_QH_X0_2/^?3_R*_\ C0!=_MK3_P#G
M_M?^_P O^-']M:?_ ,_]K_W^7_&J7_"'Z1_SZ?\ D5_\:/\ A#](_P"?3_R*
M_P#C0!=_MK3_ /G_ +7_ +_+_C1_;6G_ //_ &O_ '^7_&J7_"'Z1_SZ?^17
M_P :/^$/TC_GT_\ (K_XT 7?[:T__G_M?^_R_P"-']M:?_S_ -K_ -_E_P :
MI?\ "'Z1_P ^G_D5_P#&C_A#](_Y]/\ R*_^- %W^VM/_P"?^U_[_+_C1_;6
MG_\ /_:_]_E_QJE_PA^D?\^G_D5_\:/^$/TC_GT_\BO_ (T 7?[:T_\ Y_[7
M_O\ +_C1_;6G_P#/_:_]_E_QJE_PA^D?\^G_ )%?_&C_ (0_2/\ GT_\BO\
MXT 7?[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QJE_PA^D?\^G_D5_\
M&C_A#](_Y]/_ "*_^- %W^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &J7_
M  A^D?\ /I_Y%?\ QH_X0_2/^?3_ ,BO_C0!=_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\:I?\(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"- %W^VM/_ .?^U_[_
M "_XT?VUI_\ S_VO_?Y?\:I?\(?I'_/I_P"17_QH_P"$/TC_ )]/_(K_ .-
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MY]/_ "*_^- %W^VM/_Y_[7_O\O\ C1_;6G_\_P#:_P#?Y?\ &J7_  A^D?\
M/I_Y%?\ QH_X0_2/^?3_ ,BO_C0!=_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y
M?\:I?\(?I'_/I_Y%?_&C_A#](_Y]/_(K_P"- %W^VM/_ .?^U_[_ "_XT?VU
MI_\ S_VO_?Y?\:I?\(?I'_/I_P"17_QH_P"$/TC_ )]/_(K_ .- %W^VM/\
M^?\ M?\ O\O^-']M:?\ \_\ :_\ ?Y?\:I?\(?I'_/I_Y%?_ !H_X0_2/^?3
M_P BO_C0!=_MK3_^?^U_[_+_ (T?VUI__/\ VO\ W^7_ !JE_P (?I'_ #Z?
M^17_ ,:/^$/TC_GT_P#(K_XT 7?[:T__ )_[7_O\O^-']M:?_P _]K_W^7_&
MJ7_"'Z1_SZ?^17_QH_X0_2/^?3_R*_\ C0!?CU:RFD5([RWD=N JRJ2?PS5N
MLJU\+Z99W"30VVR5#E6\QCC\S6K0 4444 %%%% !1110 5\7?\%&OV%)/VJ/
M#5CXF\)>1!\1="@:&".=@D>IVN2WV=G/"LK%F1CQEF#8#;E^T:* /Y=/&W@7
MQ%\-_$=UH'BG1+[P_K-J<2V.H0-#(O/!PPY4XX8<$<@FN@^$/QZ^(/P%UB?4
M_ 'BO4/#-U<!!<+:N&BN A)02Q."DFW<V-RG&X^IK]\?VXO!?A_Q5^RU\3[K
M6M#T[5KK3/#>H7=C/>VJ2R6LR6[LDD3,"48$ @K@U^0/["_[%-A^V1I?Q(MV
M\1W'AS6_#\-E)ITRPK+;2--]HW+,G#8_=)AE88R3AN!0!]:?LH?\%A1KVL6'
MACXU6%IIIN'6&'Q9IJ&.!6/ -U#D[03UD3@9&4 RP_4&*5)HTDC=9(W 974Y
M# ]"#Z5_,%\4/AOKGP?^(6O>#/$MNMKK>BW36ERB$LA(Y#H<#*,I5E.!D,#7
M[E_\$M_B=??$S]CWPS_:4K7%YX?N)]",SG):.$JT(_X#%)&G_ * /R:_X*+7
M+77[:WQ4=NHU"*/\%MH5'Z"OKK_@AJH_M?XQM@;A!I(![_>N_P#"OE;_ (*9
M:3)H_P"V]\3$=-JSS6=RA P&#V4#9_,G\0:^H?\ @AS?)'XF^+MF2/,EL]-E
M'KA'N0?_ $,4 ?K17\U?[5ZA/VI/C&J@*H\9:R !T'^G35_2I7\T7[3E_'JO
M[2GQ9O8B&BN?%NK3(5.00UY*1C\Z /T]_P""(]TS_!GXAVQ!V1Z_'(..,M;H
M#_Z *_2"OSP_X(GZ3+;_ +//C347CVQW7B=XD8_Q>7:P$\>F7Z_7TK]#Z "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?M^?\GD_%C_L-/\ ^@+7]%-?SK?M^?\ )Y/Q8_[#3_\ H"T ??\ _P $0_\
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MCO-MG<"9/+?=M^8=_E/%?TQU^&W_  6%_P"3P'_[%^Q_G+0!X'^SC^R?X_\
MVJ+W7;7P';V%Q-HT<,MW]NNQ;@+(7";<CGE&K]I/^"=?[/OB[]FOX W'A+QK
M#:0:P^M7-\%L[@3IY3QQ*IW =<HW%?&W_!#G_D:OBW_UY:;_ .C+BOUJH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *_GB_:;^*7QJ\ _&KQQX(U_P")_C2Y72-4
MGM8X;C7KHQO!G,3A-^T!XBC=.0U?T.U\#_\ !2;_ ()^WO[121?$+X?PPGQ]
M8VXM[S37=8QJT"_<VL2%$R#(&X@,N 2-JY /&?V;/VP-,^)G_!/_ .*WPP\3
M:SCQYH/A/6!:?;IB9=3LS;RNK*S'YWCW%2O7:JMS\V*7_!$W6+#P_P#\+OU/
M5+VWT[3;.TTN>XN[J58XH8U-X6=V8@*H R2:_-OQ;X-U_P  Z]<Z+XDT:_T#
M5[<[9;+4;=X)4Y(Y5@#C@\]#6?;ZA>1VD]C!<SI:W3(TMM&[!)67.PLHX8C<
MV,],G'6@#V7]M;XO:5\=_P!J'Q]XUT++:-?7<<-G(5VF:*"".W67'7YQ%OYY
M 8 U^NO_  2?\ WG@?\ 8YT*YO8F@E\0ZA=:RD;KM81NRQ1D^S)"K@^CBOSU
M_8R_X)G^./CMXCT[7?'>DWW@_P"'44@EG>^C:WO-148/EP1L P5N/WI &"2N
MX\5^X>CZ39>'])LM+TVVCLM.LH$MK:VA7:D42*%1%'8!0 ![4 ?CC_P6D^&,
M_A_X[>%O&T:'[!XBTC[*[8X%S;.0W/O'+#CZ-7G7_!*GXZ:9\&/VG(K/7KV+
M3]$\56+Z.]S<-MBAN"ZR0,Q[99#'D\#S<G@9K]>OVLOV:=$_:K^#VH>"]5F^
MP7F];O2]46,.UE=(#M?'=2"R,.ZL<8."/P&^.G[.?Q _9S\53:'XY\/W.F.'
M*V]^JE[.\7L\,P&UP1SC[PZ, <B@#^B;XV?%S0O@7\+_ !!XV\17<-M8:7:O
M*J2OM-Q-@^7 GJ[MA0!ZU_,SJVJ7&MZK>:C=OYEU>3/<3/\ WG=BS'\R:L:E
MXFUC6K2UM=0U6^O[6U&VWAN;AY$A&,816)"\ =/2OLW]@;_@GAXF^.WC#2?%
M_C?1[C1?AG92I='[=$4?6MK9$,2G!,1(^:3IC(7))*@'Z8?\$X?A7<?"7]D#
MP+8WT?E:CJT+ZW<+C!'VEO,C!'J(C$#GN#7TS38XTAC6.-51% 5548  Z "G
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Y-K7_(9O_\ KXD_]"-%&M?\AF__ .OB3_T(
MT4 =G\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>:?M(>#['QE\#O'=I=:);ZY=
M+H.H&R@FM%N'$_V9]AC4@G?NQC;SG&*]+HH _*3_ ((Y_"+Q#X3^(/Q"O?%W
M@K4]&9;"T^Q7&M:5) 0XEDW>4TB#G&,[?:OU;HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q?\ ;%\$
MVOC3]FCXFVYT"'7M57PWJ!T^(V8N9Q/Y#F/R1M+;]P7&WG.,5\/_ /!&GX3Z
M]X/U[XHWGBWP;J6B7'DZ8+&XUK2Y+=\YNO,\II$!_N9V_P"SGM7ZD44 %%%%
M !574]+LM:LI+/4+.WO[23A[>ZB62-N_*L"#5JB@#B]*^"?P[T*_COM-\!>&
M-/O8SN2YM='MXI%.<Y#*@(KM*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:
M_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05KIJYG
MX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \FUK_D,W_P#U\2?^A&BC6O\ D,W_ /U\2?\ H1HH
M [/X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-__ -?$G_H1
MHHUK_D,W_P#U\2?^A&B@#L_A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]
M!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /)M:_Y#-__P!?$G_H1HHUK_D,W_\ U\2?^A&B@#L_A_\ \@:;_KX;_P!!
M6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-__P!?$G_H
M1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_ /7Q
M)_Z$:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @:;_KX;_T%:Z:N9^'_P#R!IO^
MOAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_ /R!IO\
MKX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W__ %\2?^A&BC6O^0S?_P#7
MQ)_Z$:* .S^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHI,T +14;/CO4;7"KWH GHS57[4OK2?;%]: +>:,U4^V+
MZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +
M>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+Z
MT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>
M:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT
M?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:
M,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:,U4^V+ZT?;%]: +>:6JGVM?6G"
MZ4]Z +-%1+(#WIX:@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF__P"OB3_T(T4:U_R&
M;_\ Z^)/_0C10!V?P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@;H'_@//_P#'J^>Z*/J.&_D0?VKC?^?K/H3_ (;@\>_] W0/_ >?_P"/4?\
M#<'CW_H&Z!_X#S__ !ZOGNBCZCAOY$']JXW_ )^L^A/^&X/'O_0-T#_P'G_^
M/4?\-P>/?^@;H'_@//\ _'J^>Z*/J.&_D0?VKC?^?K/H3_AN#Q[_ - W0/\
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M\-P>/?\ H&Z!_P" \_\ \>KY[HH^HX;^1!_:N-_Y^L^A/^&X/'O_ $#= _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__
M .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C
M5FZDW[LUI-67J?\ JS0!Y%\0+DQPR<U^<-?HI\1C^YE^AK\ZZ^ER;_EY\OU/
MA^)O^7/_ &]^@4445],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!]0_LF3F/PW>J#_P Q!C_Y#CK[%\.R;H4KXS_92_Y
M-Y_U_M_Z+CK[(\-?ZA*^"QW^\S]3];RK_<J7H=5'T%25'%]T5)7">J%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >3:U_R&;__ *^)/_0C11K7_(9O_P#KXD_]"-% '9_#_P#Y TW_ %\-
M_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^A&B@#L_A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U9>I
M_P"K-:C5EZG_ *LT >+_ !&_U,OT-?G97Z)_$;_4R_0U^=E?2Y-_R\^7ZGP_
M$W_+G_M[] HHHKZ8^'"BBB@ HHHH **** "BBB@ HHJYI>BZCK<QBTZPNK^4
M8REK"TC#)P.%!I7MJQI-NR/L;X!_MIV']EVF@_$"5[:Y@410ZV%+I*HX F &
M0W3YAD'J<=3]7:'X@TOQ/IZ7^CZC:ZI9.<+<6<RRH3Z94D9YZ5^4>J?#7Q;H
M6COJNI^&-7TW34*JUW>6,D4>6.%^9E Y-?:W[ G_ "1W6/\ L/3?^D]O7R^8
M8.C"#KTGUVZ'WN3YEB:E586NNF[W_P"">Y^-/AUX:^(FGFS\1Z+::K%C"M-'
M^\C]T<893[J17P=^TU^S+)\&YH=9T6::^\+W4GE_ON9;20Y(1R!RI'1O;!YP
M3ZS^S-^TYX@\1_$9O!'BB<:G'=/,MA?,BK+&T89MCD8#*55L$_-G')SQ[M^T
M1HL&O? _QK;W"JRQ:9-=+N'1XE\U3^:"N>C*M@*\:<GH_NLSKQ%/"YOA)5Z:
M]Y7UZW71GY:4$D\GDT45]B?FQ]!_L-?\ER7_ +!EQ_-*^[OB!_R(7B3_ +!E
MS_Z*:OA']AK_ )+DO_8,N/YI7W=\0/\ D0O$G_8,N?\ T4U?(9E_O:^1^C9'
M_P B^7J_R/R.HHHKZ\_.0HHHH *N:+;0WFL6%O<RK!;RW$<<LLAPJ*6 +$]@
M!5-5+, !DG@ 5;O-'O\ 3H8IKNQN;6&;(CDFA9%?'7!(YZCIZTGV*CWL?IOI
M_P"TM\+]0U./3;;QA8"X8A$WAXXR2< "1E"?K4WQN^#@^-'AM=+/B+4=%1/F
M$=JP-O,W;S4X+@=AN&.M?EO7Z/\ [&WBJ^\4_ _3Q?RO/)IMQ)I\<DG4QH%*
M#/<!6"_\!KY3%8+ZDE6I2V?4_0,OS/\ M24L-B(*S72Y\$_$KX;:W\*?%5QH
M&NP+'=1@21R1G='/&20LB'N#@]>000<$5RV2.G%?<G_!0#PW;S>"?#>O>4@O
M+;4#9>;T8QR1N^/< Q?AD^IKX;KW\'7>(HJH]SY#,L*L'B94HO3H%?<__!/S
M_D0O$_\ V$U_]%+7PQ7W/_P3\_Y$+Q/_ -A-?_12US9I_NTOE^9VY#_OT?1_
MD=-^W+_R0UO^PG;_ ,GK\\J_0W]N7_DAK?\ 83M_Y/7YY5&4_P"[_-FW$'^^
M?)?J%%%%>R?,A1110 4444 %%%% !1110 4444 ?3/[*7_(!O/\ K_;_ -%Q
MU]D^&O\ 4)7QM^RE_P @&\_Z_P!O_1<=?9/AK_4)7P6._P!YGZGZWE7^Y4O0
MZJ+[HJ2HXONBI*X3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#R;6O\ D,W_ /U\2?\ H1HHUK_D,W__
M %\2?^A&B@#L_A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O_P#KXD_]"-%&M?\ (9O_
M /KXD_\ 0C10!V?P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]
M#7YV5]+DW_+SY?J?#\3?\N?^WOT"BBBOICX<**** "BBB@ HHHH **** "BB
MB@ KZS_9+_:"\%?"GX<ZCI'B349K.^FU:2Z1([624&,PPJ#E01U1N/:ODRBN
M;$4(XB'LY[';A,74P57VM.U_,LZG,ESJ5W-&<QR2NZG'8L2*K445T''OJ%%%
M%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'TS^RE_R ;S_K_;_P!%QU]D^&O]0E?&W[*7_(!O/^O]
MO_1<=?9/AK_4)7P6._WF?J?K>5?[E2]#JHONBI*CB^Z*DKA/5"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__ "!IO^OAO_05
MKIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&K+U/_5FM1JR
M]3_U9H \7^(W^IE^AK\[*_1/XC?ZF7Z&OSLKZ7)O^7GR_4^'XF_Y<_\ ;WZ!
M1117TQ\.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'TS^RE_R ;S_K_;_P!%QU]D^&O]0E?&W[*7_(!O/^O]O_1<=?9/AK_4
M)7P6._WF?J?K>5?[E2]#JHONBI*CB^Z*DKA/5"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-_\
M]?$G_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__ "!IO^OAO_05KIJYGX?_ /(&
MF_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!&K+U/_5FM1JR]3_U9H \7^(W
M^IE^AK\[*_1/XC?ZF7Z&OSLKZ7)O^7GR_4^'XF_Y<_\ ;WZ!1117TQ\.%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TS^RE_
MR ;S_K_;_P!%QU]D^&O]0E?&W[*7_(!O/^O]O_1<=?9/AK_4)7P6._WF?J?K
M>5?[E2]#JHONBI*CB^Z*DKA/5"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_
M )#-_P#]?$G_ *$:* .S^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KI
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!&K+U/_5FM1JR]3_U9H \7^(W^IE^AK\[*_1/
MXC?ZF7Z&OSLKZ7)O^7GR_4^'XF_Y<_\ ;WZ!1117TQ\.%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TS^RE_R ;S_K_;_P!%
MQU]D^&O]0E?&W[*7_(!O/^O]O_1<=?9/AK_4)7P6._WF?J?K>5?[E2]#JHON
MBI*CB^Z*DKA/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_
M *$:* .S^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__
M "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFC? ;X6^)_$=YJ>CPZQ8:5<WNG:7J=\ENU]-'&S)$@)#,68!<*"<GCFOEO\
MX*:?MX:C^SGI]GX \"3+!X[UBU^U7&I,@?\ LRT8LJL@/'G.5;&0=H4G&2IK
M\:[N;Q3\3-<U35;EM6\4ZOY,E_?WDGF7<XB0;I)I7.2%4<EFX ZT ?M=^PG_
M ,%$&_:JUSQ1I7BRQ\/^#;W3TM6TZWCU'$M^9#*) BR$%MFQ/NYQO&>HK[:K
M^5^/3;N;3[B^CM9I+*WD2*:Y6,F.-W#%%9L8!8(^ >NQL=#7VA^P;_P4/\4?
M /Q?H_A7QKK5UK'PNN9!;21WA,TFD;C@30L?F$:D@M'R,;BHW=0#]T**;'(L
ML:NC!T895E.01ZBG4 %8FM>./#GANZ6UU?Q!I>E7+()%AO;V.%RI) 8*S XR
M",^QKG?C=\;O"7[/?P\U'QEXRU%;#2K0;4C7#374Q!V0PID;Y&P<#H "20H)
M'\\'[2'QTUC]I#XR>(O'NL*T#ZC-BTL]^Y;.U3Y880<#.U0,G W,6;&30!_2
M5H?B32/$UO)/H^J66JP1ML>2QN$F56QG!*DX."./>M*OSJ_X(E_\D"\=?]C,
M?_26"OT5H *1F"J23@#DDURGQ6^)NA?!KX<Z_P"-?$ES]ET71;5KJ=AC<^.%
MC0'J[L511W9@*_ K]J+]N3XE_M/^(;UM3UBZT3PD786?AC3YV2VCB/ $NW'G
MOCJSYY)VA0<4 ?T#0>./#EUJ!L(?$&ERWP )M8[V-I><8^4-GN/S%;=?RL>6
MPC#E2$)(#8X)&,C]1^=?7G['?_!1CQ]^SIXFL-.\1ZKJ'B[X=RR".[TJ]F,T
MUHAX\RU=SE2O7R\[&Y& 2& !^]=>??$/]H+X:_"75K?2_&GCC0_"^HW$ N8;
M;5+U('DB+%0ZACR,JPSZ@UV>A:Y8>)M$T_6-*NX[_2]0MX[NUNH3E)HG4,CJ
M>X*D$?6OA7_@L'\!U^(7P!L_']A;[]9\%W.^9D7+/8SLJ2@]SM?RG] HD/>@
M#[=\&>-O#_Q$\.6NO^%]9LM?T2ZW>1J&GSK-#)M8JV&4X.&4@^X-;=?C)_P2
M+_:N?X<_$>3X2:_='_A'/%4^_2GD/RVNI8P%'HLR@+_OK'C&YC7[-T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_
M /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y
MTW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"+M-FTS5M,N$\R&9)(VC\P#/RR*'.&!]CD<4 ?</\ P1Y\ Z+\4O#?Q_\
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MH&K)?P!CR(+J/&T#T$D$A^LE 'Z.T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!Y-K7_(9O_P#KXD_]"-%&M?\ (9O_ /KXD_\
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MH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*NFHH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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MH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*NFHH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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MH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*NFHH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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M_P"^O_LJ/[6\1?\ 0*C_ .^O_LJZ:B@#F?[6\1?] J/_ +Z_^RH_M;Q%_P!
MJ/\ [Z_^RKIJ* .9_M;Q%_T"H_\ OK_[*C^UO$7_ $"H_P#OK_[*NFHH YG^
MUO$7_0*C_P"^O_LJ/[6\1?\ 0*C_ .^O_LJZ:B@#F?[6\1?] J/_ +Z_^RH_
MM;Q%_P! J/\ [Z_^RKIJ* .9_M;Q%_T"H_\ OK_[*C^UO$7_ $"H_P#OK_[*
MNFHH YG^UO$7_0*C_P"^O_LJ/[6\1?\ 0*C_ .^O_LJZ:B@#F?[6\1?] J/_
M +Z_^RH_M;Q%_P! J/\ [Z_^RKIJ* .9_M;Q%_T"H_\ OK_[*C^UO$7_ $"H
M_P#OK_[*NFHH YG^UO$7_0*C_P"^O_LJ/[6\1?\ 0*C_ .^O_LJZ:B@#F?[6
M\1?] J/_ +Z_^RH_M;Q%_P! J/\ [Z_^RKIJ* .9_M;Q%_T"H_\ OK_[*C^U
MO$7_ $"H_P#OK_[*NFHH YG^UO$7_0*C_P"^O_LJ/[6\1?\ 0*C_ .^O_LJZ
M:B@#F?[6\1?] J/_ +Z_^RH_M;Q%_P! J/\ [Z_^RKIJ* .9_M;Q%_T"H_\
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MO_LJ/[6\1?\ 0*C_ .^O_LJZ:B@#F?[6\1?] J/_ +Z_^RH_M;Q%_P! J/\
M[Z_^RKIJ* .9_M;Q%_T"H_\ OK_[*C^UO$7_ $"H_P#OK_[*NFHH YG^UO$7
M_0*C_P"^O_LJ/[6\1?\ 0*C_ .^O_LJZ:B@#F?[6\1?] J/_ +Z_^RH_M;Q%
M_P! J/\ [Z_^RKIJ* .9_M;Q%_T"H_\ OK_[*C^UO$7_ $"H_P#OK_[*NFHH
M YG^UO$7_0*C_P"^O_LJ/[6\1?\ 0*C_ .^O_LJZ:B@# L=2UR:[B2XTZ.*!
MCAW!Z#\ZWZ** "BBB@ HHHH **** "OYX?\ @HAK4FO?MI?%6YE;<T>II:@Y
MS\L,$4('Y1BOZ'J_G<_X*#:6VC_MG?%>!@07U;[1SZ2Q1RC_ -#H _1#_@B9
MIHB_9_\ '-_MP9_$[0;L==EI V,_]M/UK]$Z_/K_ ((HW2M^S)XNM_XH_%]Q
M(>>S65F!Q_P$U^@M '/>/OA_X<^*7A+4/#'BS1[77=!U!/+N+&[7*. <@@CE
M6! (8$$$ @@BORD_:W_X)&P_#3PGXJ\??#SQ<I\/:-8SZI<:'KJL9XXHD:1U
MBG0'>< A5=5Z#+GK7O?C+_@LW\*?#>H7FG6?@SQG?7UI*\$JW,%K;('4X(SY
M[-P<@Y4=*]7\<?'32/VD/^">'Q$\?Z);O96FI^$M85[*:0/);21Q31M&Y'?*
MY]PP/>@#\$]/\,ZQJVDZCJECI5[>:9IOE_;;RWMW>&UW[MGFN!A-VQL;B,[3
MCI73?!OXU>,/@+XYL?%G@O6)M)U2U<%E5B8;F/.3%,F<21GNI^HP0"/T,_X(
M?VL-]>?&FWN(8[BWFMM*CDAE4,CJ3> J0>"".,&OC?\ ;P^&N@?"/]K7XB>%
M_"\,=KH=M=PW%O:PC"6_GV\4[1*!P%1I64 =  .U '[S?L[_ !HT[]H3X+^%
M?'^F1?9HM8M?,FM=^[[/.K%)HL]]LBN >,@ X&:]&KX9_P"".4EU)^R),MP6
M,2>)+U;?))Q'Y<!./3YR_2ON:@ K^<']M;_D[CXO?]C-??\ HUJ_H^K^<']M
M;_D[CXO?]C-??^C6H _2G_@B7_R0+QU_V,Q_])8*_16OSJ_X(E_\D"\=?]C,
M?_26"OT5H _#O_@L7;M#^UY&[=)O#EDZ_3?,O\U-7_\ @C"P'[6&M G&?"=X
M!_X$VE=3_P %MO";6/QJ\ >)0C"+4M >PW8.TM;W#N?QQ<K^E>7_ /!)'Q1!
MX>_;,T6UGE6+^V-+OM/CW8PS^6)@N>Q/DG\>.] '[N5^ '_!48Y_;L^)N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_P"0
MS?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05KIJYGX?\
M_(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5^OW[+?_  3]^%W[+-PFKZ1:W'B+Q?L*'Q!K!5Y8@1AA B@+$#SR 6P2"Q%
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MY<:%B%'=CC '<D5_-7\9/BKK?QN^)WB+QOXAG>?4]8NWN&5FW"%,XCA7_81
MJ#V45_1)^TU\&;K]H3X(^)?A[:>(O^$5;6TABDU3[']K,<:S)(RB/S(\[@A7
M[W 8]:_/S_AQC_U6S_RU/_NV@#\X_@Q\8-;^!/Q L?&7ARWTV?7+!7%I)J=J
M+A(&88\Q4)QO ) /;)(YP1].?\/>/VAO^@EX?_\ !.G^-?0'_#C'_JMG_EJ?
M_=M'_#C'_JMG_EJ?_=M 'S__ ,/>/VAO^@EX?_\ !.G^-?M1\)/$E[XQ^%/@
MS7]19&U#5=%LKZY:-=JF66!'<@=AECQ7YK_\.,?^JV?^6I_]VU^FGP]\*?\
M"!^ ?#7AG[5]N_L73+;3OM7E^7YWDQ+'OVY.W.W.,G&>IH Z"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05K
MIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "L7QMX7M_''@W7O#=W+);VNL:?<:?++#C>B2QM&S+D$9 8D
M9%;5% 'S1^R3^PCX2_8_UKQ%J7AKQ!K6M2ZU;Q6\R:J8=J+&S,"OEHO)W'K7
MTO110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDWP#<>&?"KW5Z;RZ:\O=3U H;FY<\*&*J %50  !CJ>K&O9: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-_\ ]?$G
M_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^
M&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-
M_P#]?$G_ *$:* .S^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!&K+U/_5FM1JR]3_U9H \7^(W^IE^AK\[*_1/XC?Z
MF7Z&OSLKZ7)O^7GR_4^'XF_Y<_\ ;WZ!1117TQ\.%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'TS^RE_R ;S_K_;_P!%QU]D
M^&O]0E?&W[*7_(!O/^O]O_1<=?9/AK_4)7P6._WF?J?K>5?[E2]#JHONBI*C
MB^Z*DKA/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:
M* .S^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!&K+U/_5FM1JR]3_U9H \7^(W^IE^AK\[*_1/XC?ZF7Z&OSLKZ7)O
M^7GR_4^'XF_Y<_\ ;WZ!1117TQ\.%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'TS^RE_R ;S_K_;_P!%QU]D^&O]0E?&W[*7
M_(!O/^O]O_1<=?9/AK_4)7P6._WF?J?K>5?[E2]#JHONBI*CB^Z*DKA/5"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__ "!I
MO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHI* %HII;\*;YH]: )**A\X4><* )J*A\X4
M><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )
MJ*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X
M4><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4><*
M)J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4><* )J*A\X4[S1ZT 244
MT-2YH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!&K+U/_5FM1JR]3_U9H \7^(W^IE^AK\[*_1/XC?Z
MF7Z&OSLKZ7)O^7GR_4^'XF_Y<_\ ;WZ!1117TQ\.%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'TS^RE_R ;S_K_;_P!%QU]D
M^&O]0E?&W[*7_(!O/^O]O_1<=?9/AK_4)7P6._WF?J?K>5?[E2]#JHONBI*C
MB^Z*DKA/5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /)M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:
M* .S^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!*CDDVT]JS[^?RT)H Y_X@?$'
M3?AWX6U#7]5:06-DJM((5W.2S!5 &1R68#D@<UX1)^W?X);II/B'_P !X/\
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M%']E8;L_O#^W\;W7W'W%_P -V>#/^@3X@_\  >#_ ./4?\-V>#/^@3X@_P#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 8]8>M2;8FQZ5N2=#7/:]_J7^E 'S%^U#>%OAWK$>>
M"8?_ $<E?&%?8/[3C?\ %"ZK_O1?^C4KX^KZ_)_X$O7]$?G/$?\ O<?\*_-A
M1117N'RH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?9_[+UX5^'>CQYX#3?^CGKZBT63=$N?2OD_]F-O^*%TK_>E_P#1KU]5
MZ#_J4^E?GN*_CU/5_F?L6!_W2E_AC^2.A2GTR/H*?7,=P4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_J
MS6HU9>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?^
MWOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /IG]E+_ ) -Y_U_M_Z+CK[)\-?ZA*^-OV4O^0#>?]?[?^BXZ^R?
M#7^H2O@L=_O,_4_6\J_W*EZ'51?=%25'%]T5)7">J%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&
M;_\ Z^)/_0C11K7_ "&;_P#Z^)/_ $(T4 =G\/\ _D#3?]?#?^@K735S/P__
M .0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ,DZ&N>U[_4O]*Z&3H:Y[7O]2_TH ^4_P!IS_D1=5_WHO\ T:E?']?8
M'[3G_(BZK_O1?^C4KX_KZ_)_X$O7]$?G/$?^]Q_PK\V%%%%>X?*A1110 444
M4 %%%% !1110 444#)X')H **^C/A?\ L1^+?&VGPZEKMY%X4LIE#QQ31&:Z
M92,@F/*A0?\ :8'VK[!U'X/PW_P3'PZ&IR1PKIT=@-0\D%ODV_/LSWV],_C7
MDU\RHT9*,7?77R/H<+DF)Q$'.2Y=-+]7VW5O4_+*BO?OBI^QKXQ^'>FRZIIT
MT7BC3(06E:RC9)XE'\31'.1_NEL=^.:\!KT*5:G6CS4W='CU\-6PLN2M&S"B
MBBMCF"BO6_V?OV>;_P".^H:FJ:C_ &+IFGQJ9+YK;S\R,?EC"[ESP&).>,#U
M%==\;_V1/^%-^!)?$G_"6?VQY=Q'!]E_LWR,[R1G=YK=/I7)+%48U/8N7O?,
M]".7XF=!XB,/<76ZZ?.Y\[4445UGGA1110 4444 %%?4WP]_84O_ !AX,TK6
M]2\4_P!AW-_"+C[!_9OG&-&Y3+>:O)7!(QQG':O%_C?\*O\ A3?CN7PW_:G]
ML>7!'/\ :OL_D9W@G&W<W3ZUR4\51JS=.$KM>IZ%;+\3AZ2K586B_-=?*]S@
M:***ZSSPHHKOO@K\']3^-7C*/1+&7[%;1H9KN_:/>MO&.,[<C<2< +D9SZ F
MHG.-.+G)V2-*=.=::ITU=LX&BOK7Q/\ L$_\(YX;U;5O^$Z^T?8+2:Z\G^R-
MN_8A;;GSSC.,9P:^2JQHXBEB$W2=['3B<'7P;2KQM?S3_(****Z3B"BBB@ H
MHHH **** "BBB@ HHHH ^P/V8_\ D1=*_P!Z7_T:]?5F@_ZE/I7RG^S'_P B
M+I7^]+_Z->OJS0?]2GTK\]Q7\>IZO\S]BP/^Z4O\,?R1T,?04^F1]!3ZYCN"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** $:LO4_P#5FM1JR]3_ -6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^E
MR;_EY\OU/A^)O^7/_;WZ!1117TQ\.%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'TS^RE_P @&\_Z_P!O_1<=?9/AK_4)7QM^
MRE_R ;S_ *_V_P#1<=?9/AK_ %"5\%CO]YGZGZWE7^Y4O0ZJ+[HJ2HXONBI*
MX3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#R;6O^0S?_P#7Q)_Z$:*-:_Y#-_\ ]?$G_H1HH [/X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\1O\ 4R_0
MU^=E?HG\1O\ 4R_0U^=E?2Y-_P O/E^I\/Q-_P N?^WOT"BBBOICX<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /IG]E+_D
MWG_7^W_HN.OLGPU_J$KXV_92_P"0#>?]?[?^BXZ^R?#7^H2O@L=_O,_4_6\J
M_P!RI>AU47W14E1Q?=%25PGJA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?
M\AF__P"OB3_T(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_4O]
M*Z&3H:Y[7O\ 4O\ 2@#Y3_:<_P"1%U7_ 'HO_1J5\?U]@?M.?\B+JO\ O1?^
MC4KX_KZ_)_X$O7]$?G/$?^]Q_P *_-A1117N'RH4444 %%%% !1110 4444
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M4:OXOU.34=;U.ZU6]?K/=RF1L>@ST'L.!6717TG*K\UM3XKGER\E].Q]P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1JR]3_U9K4:L
MO4_]6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_EY\OU/A^)O^7/\ V]^@
M4445],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!],_LI?\@&\_P"O]O\ T7'7V3X:_P!0E?&W[*7_ " ;S_K_ &_]%QU]
MD^&O]0E?!8[_ 'F?J?K>5?[E2]#JHONBI*CB^Z*DKA/5"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:
M_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05KIJYG
MX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>OJS0?\ 4I]*_/<5_'J>K_,_8L#_ +I2_P ,?R1T,?04^F1]!3ZYCN"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* $:LO4_]6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_.ROI<F_Y>?+]
M3X?B;_ES_P!O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?3/[*7_(!O/^O]O_ $7'7V3X:_U"5\;?LI?\@&\_
MZ_V_]%QU]D^&O]0E?!8[_>9^I^MY5_N5+T.JB^Z*DJ.+[HJ2N$]4**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \FUK_D,W_P#U\2?^A&BC6O\ D,W_ /U\2?\ H1HH [/X?_\ (&F_Z^&_
M]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4 %%%% !1110!]@?LQ_\B+I7^]+_ .C7KZLT'_4I]*^4_P!F/_D1=*_WI?\
MT:]?5F@_ZE/I7Y[BOX]3U?YG[%@?]TI?X8_DCH8^@I],CZ"GUS'<%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M(U9>I_ZLUJ-67J?^K- 'B_Q&_P!3+]#7YV5^B?Q&_P!3+]#7YV5]+DW_ "\^
M7ZGP_$W_ "Y_[>_0****^F/APHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^F?V4O^0#>?]?[?^BXZ^R?#7^H2OC;]E+_ ) -
MY_U_M_Z+CK[)\-?ZA*^"QW^\S]3];RK_ '*EZ'51?=%25'%]T5)7">J%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0--_U\
M-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:
MU_R&;_\ Z^)/_0C11K7_ "&;_P#Z^)/_ $(T4 =G\/\ _D#3?]?#?^@K735S
M/P__ .0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ,DZ&N>U[_4O]*Z&3H:Y[7O]2_TH ^4_P!IS_D1=5_WHO\ T:E?
M']?8'[3G_(BZK_O1?^C4KX_KZ_)_X$O7]$?G/$?^]Q_PK\V%%%%>X?*A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]@?LQ_\
MB+I7^]+_ .C7KZLT'_4I]*^4_P!F/_D1=*_WI?\ T:]?5F@_ZE/I7Y[BOX]3
MU?YG[%@?]TI?X8_DCH8^@I],CZ"GUS'<%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ-67J?^K- '
MB_Q&_P!3+]#7YV5^B?Q&_P!3+]#7YV5]+DW_ "\^7ZGP_$W_ "Y_[>_0****
M^F/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ^F?V4O^0#>?]?[?^BXZ^R?#7^H2OC;]E+_ ) -Y_U_M_Z+CK[)\-?ZA*^"
MQW^\S]3];RK_ '*EZ'51?=%25'%]T5)7">J%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_ /Z^
M)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7
MPW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R
M3H:Y[7O]2_TKH9.AKGM>_P!2_P!* /E/]IS_ )$75?\ >B_]&I7Q_7V!^TY_
MR(NJ_P"]%_Z-2OC^OK\G_@2]?T1^<\1_[W'_  K\V%%%%>X?*A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]@?LQ_P#(BZ5_
MO2_^C7KZLT'_ %*?2OE/]F/_ )$72O\ >E_]&O7U9H/^I3Z5^>XK^/4]7^9^
MQ8'_ '2E_AC^2.ACZ"GTR/H*?7,=P4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$
M;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?^WOT"BBBOICX<****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /IG]E+_
M ) -Y_U_M_Z+CK[)\-?ZA*^-OV4O^0#>?]?[?^BXZ^R?#7^H2O@L=_O,_4_6
M\J_W*EZ'51?=%25'%]T5)7">J%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_\ Z^)/_0C11K7_
M "&;_P#Z^)/_ $(T4 =G\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_4
MO]*Z&3H:Y[7O]2_TH ^4_P!IS_D1=5_WHO\ T:E?']?8'[3G_(BZK_O1?^C4
MKX_KZ_)_X$O7]$?G/$?^]Q_PK\V%%%%>X?*A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!]@?LQ_\B+I7^]+_ .C7KZLT'_4I
M]*^4_P!F/_D1=*_WI?\ T:]?5F@_ZE/I7Y[BOX]3U?YG[%@?]TI?X8_DCH8^
M@I],CZ"GUS'<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 (U9>I_ZLUJ-67J?^K- 'B_Q&_P!3+]#7YV5^B?Q&
M_P!3+]#7YV5]+DW_ "\^7ZGP_$W_ "Y_[>_0****^F/APHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^F?V4O^0#>?]?[?^BX
MZ^R?#7^H2OC;]E+_ ) -Y_U_M_Z+CK[)\-?ZA*^"QW^\S]3];RK_ '*EZ'51
M?=%25'%]T5)7">J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)
M/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>
M_P!2_P!* /E/]IS_ )$75?\ >B_]&I7Q_7V!^TY_R(NJ_P"]%_Z-2OC^OK\G
M_@2]?T1^<\1_[W'_  K\V%%%%>X?*A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH 1JR]3_U9K4:LO4_]6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_EY\
MOU/A^)O^7/\ V]^@4445],?#A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\
MR!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH 9)T-<]KW^I?Z5T,G0USVO?ZE_I0!\I_M
M.?\ (BZK_O1?^C4KX_K[ _:<_P"1%U7_ 'HO_1J5\?U]?D_\"7K^B/SGB/\
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M_AN#Q[_T#= _\!Y__CU?/=%'U'#?R(/[5QO_ #]9]"?\-P>/?^@;H'_@//\
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MPW\B#^U<;_S]9]"?\-P>/?\ H&Z!_P" \_\ \>H_X;@\>_\ 0-T#_P !Y_\
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MN@?^ \__ ,>H_P"&X/'O_0-T#_P'G_\ CU?/=%'U'#?R(/[5QO\ S]9]"?\
M#<'CW_H&Z!_X#S__ !ZE_P"&X/'O_0-T#_P'G_\ CU?/5%'U'#?R(/[5QO\
MS]9]$+^W+X^7_F&>'S_V[3__ !ZOK;X(_$NY^)7PYT;Q!?016EW>+()88"=@
M9)7CR,\X.S.,G&:_,&ONO]E75#'\)=!@S]TW'ZW$AKR,SPU&C14J<;._Z,^B
MR+&XC$8F4*LVURW_ !1].PR;A4XK*TV;S(U-:BU\R?<CJ*** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]
M?$G_ *$:*-:_Y#-__P!?$G_H1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_
M *^&_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!DG0USVO?ZE_I70R=#7/:]_J7^E 'RG^TY_P B+JO^]%_Z-2OC^OL#]IS_
M )$75?\ >B_]&I7Q_7U^3_P)>OZ(_.>(_P#>X_X5^;"BBBO</E0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\1O\ 4R_0
MU^=E?HG\1O\ 4R_0U^=E?2Y-_P O/E^I\/Q-_P N?^WOT"BBBOICX<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /IG]E+_D
MWG_7^W_HN.OLGPU_J$KXV_92_P"0#>?]?[?^BXZ^R?#7^H2O@L=_O,_4_6\J
M_P!RI>AU47W14E1Q?=%25PGJA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?
M\AF__P"OB3_T(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114=Q<16=O+//*
MD$$2EY))&"JB@9))/  '>@"2BL?0_&&@^)Y)8]&UO3=6>$!I%L;N.8H#T)"D
MX_&MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[W+_  O\T?5F@_ZE/I70Q]!7/:#_ *E/I70Q]!7R!^C#Z*** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***AO+RWTZTFNKN>.UM84,DLTSA$10,EF8\  =S0!-163H?B[0O%#3#1M
M:T_5S#@RBQNHYO+SG&[:3C.#U]#6M0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7R9^Q-^P!XB_;$35]7&N1>$_".ESK:2ZI):FYDGN"H<Q11[E!*J4+,6&/,7
M;D"G^VQ^PCXA_8YU#1[F76H_%/A76&>*UU:.V-NZ3*-QAECW-M.WD$,0P#=,
M$4 ?N_\ #/XG^%_C%X+T_P 6>#M8M]=T"^4M#=V^1R#AE96 9&!X*L 0>HKJ
M:_#+_@E/^TM??!_]H"Q\$7UT3X3\;3+820R.0D%\01;S*/[S-B(],AU)SL K
M]S: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 9)T-<]KW^I?Z5T,G0USVO?ZE_I0!\I_M.?\B+JO\
MO1?^C4KX_K[ _:<_Y$75?]Z+_P!&I7Q_7U^3_P "7K^B/SGB/_>X_P"%?FPH
MHHKW#Y4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /L#]F/\ Y$72O]Z7_P!&O7U9H/\ J4^E?*?[,?\ R(NE?[TO_HUZ^K-!
M_P!2GTK\]Q7\>IZO\S]BP/\ NE+_  Q_)'0Q]!3Z9'T%/KF.X**** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRY%R%SYK9RK=!T[_ *]_LD?\% /AY^UBHTJQ$OACQM'&TLOAS4'#LZ+U>"4
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MP00<T 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-__P!?$G_H1HH [/X?_P#(&F_Z^&_]
M!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH ****
M "LCQAX5TSQYX2UOPUK4!NM'UFQGTZ]@61HS)!-&T<BAE(*Y5B,@@C/%:]%
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M/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\
M&@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1
M_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U15
M7^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6
M?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_
M )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?
MQ?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^
M+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@
M"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-
M']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^
MU+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _
M<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[
M@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\
M7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B
M_P"-']J6?_/W!_W\7_&@"U36JO\ VI9_\_<'_?Q?\:1M4L_^?N#_ +^+_C0!
MG:Q_J6^E?.GQX_Y$_7O^O*?_ -%M7T%K&IV?DM_I<'3_ )Z+_C7SM\=KZVD\
M(ZZJW$3$V4P #@Y^1JUI?Q(^J,*_\*?H_P CX=HHHK]&/Q8**** "BBB@ HH
MHH **** "BBB@">QOKC3+VWO+29[>ZMY%EBFC.&1U.58'L00#7W7\$?VT]"\
M36-MI?C>9-#UM0(_[088M;D_WB1_JF/?/R^A&<#X<TO0-4UQBNFZ;=Z@P."+
M6!I3GT^4&K^N> ?$WA?3X;_6?#VJ:393/Y<4]]9R0H[$$X4L!G@$\>E<.)P]
M'$I1J;].YZN!QF)P+=2DM.O8_6G3M2M-8LXKRPNH;VTE&Z.XMY!)&X]0P.#7
M+_$#X0^$?B?9M!XBT2VO9-NU+M5V7$?^[(/F'TSCCD&O+/V;;N:P_9'AN;>1
MH;B&SU*2.13@JPEF((]P16)^R+^T?K/Q.OKWPOXHD2[U2VMS=6VH*BHTT:LJ
MLC@ #<-RD$#D9SR,GY+ZO4INI.F_@=O,_0_KE&LJ5*O'^*K]UML?-7[1'P!O
M/@=XB@6.=]0\/W^YK*\< .".L<F.-PR.1P0<C'('D8)'(X-?H]^VAH=OJWP#
MUFYE4&;3;BVNH">S&58C_P".RM7YPU]3E^(EB*/-/=:'P6;X.&#Q3A3^%JZ"
MOK7_ ()[_P#(R^,?^O2W_P#0VKY*KZU_X)[_ /(R^,?^O2W_ /0VIYA_NL_Z
MZDY/_O\ 3^?Y,^D/VE/^2$^-/^O!O_0EK\NJ_47]I3_DA/C3_KP;_P!"6ORZ
MKAR?^%+U_0]7B3_>(?X?U84445[Y\B%?IA^R,JK^SQX1"]-MR>/7[5-G]:_,
M^OT=_8MU);[X :- IR;*YNH&]B9FD_E(*\/-U^X7K^C/J>'6EBY+^Z_S1YY_
MP4(_Y%KP=_U]W'_H"5\2U]R?\%!+-G\#^%KK'RQZB\1/^]$3_P"R'\J^&ZWR
MS_=8_/\ ,Y<]_P!^G\OR/U1^ ))^"?@C//\ Q*+?_P! %?,G_!0A4_X2+P:P
M/[PVMP"/;>F/ZU]4_!JS.G_"/P5;L,/'HMF&'^UY*$_KFOD/_@H!JB3_ !&\
M.V"\O;Z7YS<\#?*X ^O[O]17AX'7&W7F?4YK[N5I/M']#@_V7?@>_P 8/'"R
MW\3?\(UI96:^<CB8Y^2 'U;'/HH/<BON_P"+WQ-TSX,_#^[UNY2,M$H@L;(?
M+YTQ'R1@#H.,G'15-9G[-?AG3O"_P3\*)IUN(?MMC%?W#=6DFE16=B>_8#T
M [5!\8/V=]"^-FH6-SKVL:W;Q6492"TL)XDA4DY9\-$QW' !.>BBIQ&(CB,3
M^]=H1_K\33!8.I@\#_LZ3J25[^O^7YGP_P# WQ!?^+/VE/#6L:I<-=:A>ZKY
M\TK=V(;IZ = .P %?II7@O@?]C/P5X!\6:9XAT_5->FO=/F$T4=S<0-&S $8
M8+"#CGL17O59YAB*>(G%TMDK&V3X2M@Z4XU]V[]S\=;S_C\G_P"NC?SJ&OM'
MXM?L9^"O!?P]\2>(['5->EOK&UDN8H[BX@,98<X8"$''T(KXNKZW#XBGB(N5
M/H?GF,P57!34*V[U"BBBNHX HHHH **** "BBB@ HHHH *^P/V8_^1%TK_>E
M_P#1KU\?U]=?LSWD$/@?2U>:-&#2Y#. ?]:]>'G'\"/K^C/JN'/][E_A?YH^
MLM!_U*?2NACZ"N5T'4K/R4_TJ#I_ST'^-=#'JEG@?Z7!_P!_%_QKY _1BY15
M7^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6
M?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_
M )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?
MQ?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^
M+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@
M"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-
M']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^
MU+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _
M<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[
M@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\
M7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B
M_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U
M157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG
M_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+
M/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W
M!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X
M/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\
M&@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1
M_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U15
M7^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6
M?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_
M )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?
MQ?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^
M+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@
M"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-
M']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &@"U157^
MU+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"U157^U+/_G[@_[^+_C1_:EG_P _
M<'_?Q?\ &@"U157^U+/_ )^X/^_B_P"-']J6?_/W!_W\7_&@"RU9>I_ZLU:;
M5+/_ )^X/^_B_P"-9FIZG9^6?]+@_P"_B_XT >0?$;_4R_0U^=E?H9\1=0M6
MAEQ<PG@_\M!7YYU]+DW_ "\^7ZGP_$W_ "Y_[>_0****^F/APHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^F?V4O^0#>?]?[
M?^BXZ^R?#7^H2OC+]E>ZAAT.\$DL<9^W,<,P'_+..OL3PWJ5IY"?Z5#_ -_!
M_C7P6._WF?J?K>5?[E2]#LXONBI*HQ:I9[1_I<'_ '\7_&I/[4L_^?N#_OXO
M^-<)ZI:HJK_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^- %JBJO]J6?_ #]P?]_%
M_P :/[4L_P#G[@_[^+_C0!:HJK_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^- %J
MBJO]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C0!:HJK_:EG_S]P?]_%_QH_M2
MS_Y^X/\ OXO^- %JBJO]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C0!:HJK_:
MEG_S]P?]_%_QH_M2S_Y^X/\ OXO^- %JBJO]J6?_ #]P?]_%_P :/[4L_P#G
M[@_[^+_C0!:HJK_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^- %JBJO]J6?_ #]P
M?]_%_P :/[4L_P#G[@_[^+_C0!:HJK_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^
M- %JBJO]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C0!:HJK_:EG_S]P?]_%_Q
MH_M2S_Y^X/\ OXO^- %JBJO]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C0!:H
MJK_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^- %JBJO]J6?_ #]P?]_%_P :/[4L
M_P#G[@_[^+_C0!:HJK_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^- %JBJO]J6?_
M #]P?]_%_P :/[4L_P#G[@_[^+_C0!:HJK_:EG_S]P?]_%_QH_M2S_Y^X/\
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MQTG_ -"O*_5'2]#T[0X6BTW3[73XF.2EK"L2DY)R0H'J?SK^9_X2_'3Q_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-FE_:2\97ZJ3;P>$IH';' :2\M&4?E&WY5^S] !1110 4444 %%%% !1110
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M10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\
MOXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_
M +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D
M_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7
MI/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M%
M &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_
MC?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\
MOXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_
M ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D
M_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4
M87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-
M_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_
MC?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\
MSP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_
M ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A
M?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\ OXW^
M-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-
M_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D_P#/
M!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\
MSP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C36\%Z3_P \&_[^-_C6_36H XK5
M_!NE+$W[ANG_ #T;_&OGKXX>&K"U\*:W)'$P=+.9A\Y/(0U]0:Q_J6^E?.GQ
MX_Y$_7O^O*?_ -%M6M+^)'U1A7_A3]'^1\+4445^C'XL%%%% !1110 4444
M%%%% !1110!]9_L!^.X-/\0>(/"ES($;48TO+0,<;I(\B11ZDJP/T0U]1?&K
MX66OQB^']]X>GE%M.Q6>TN6&1#.N=K$>A!*GV8U^7&A:Y?\ AG6+/5=+N9+/
M4+.59H)XSAD8'@__ %NA'%?>/PD_;6\*>*]/@M/%LB^&M; "O*RL;28_WE<9
MV>N'X']XU\UF&%JQJ_6:*O\ YGV^48^A/#O!8EVWM?9I]+G3_"7P'K?@C]FN
MZ\,ZI9LFL06NI1?9X3YA<L\Q39MZ[@RD=^1QGBO/OV-?V?=<\ W]_P"+O$UJ
MVFWEQ;&TL["7'FJA96>1Q_"?D4 =<%L@<5],Z;XDTG6-%&L6&IV=YI)1G%]!
M.KP[5SN.\'&!@YYXP<UXU\1/VR/A_P"#+.5=+O?^$HU, ^7;:?GRL]MTQ&T#
M_=W'VKS(5,15]I3A'6;U_KH>Y5HX/#^QK59V5-6CKOY^?R,;]NCQM;Z'\)XO
M#XD'VW6[J,>5GGR8F$C-_P!]",?C7Y_UU7Q,^)6M?%?Q7<Z]KDXDN)/DBACX
MCMXP25C0=@,GW)))Y-<K7U6#P_U:BH/?=GP.9XSZ]B'56VR] KZU_P"">_\
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M7U;7Y4_ OQ!I_A7XN>%M6U6Y6STZTO!)/.P)"+@\X )K[^_X:J^%/_0XVO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)1I4/:1V#(A'W=KMP0M 'F'_  4@_P""DC^$Y=5^$_PHU$#60&MM<\2VK_\
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M.OA+_@CQ\*Y_!/[,5WXGO(S'<>+M5ENX<C!^S0CR8\_5UF8>S"ONV@#\</\
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M1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF__P"OB3_T(T4:U_R&;_\
MZ^)/_0C10!V?P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[ _9C_Y$72O]
MZ7_T:]?5F@_ZE/I7RG^S'_R(NE?[TO\ Z->OJS0?]2GTK\]Q7\>IZO\ ,_8L
M#_NE+_#'\D=#'T%/ID?04^N8[@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *:U.IK4 8NL?ZEOI7SI\>/^1/U[_KRG_]%M7T7K'^I;Z5
M\Z?'C_D3]>_Z\I__ $6U:TOXD?5&%?\ A3]'^1\+4445^C'XL%%%% !1110
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M45],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!],_LI?\ (!O/^O\ ;_T7'7V3X:_U"5\;?LI?\@&\_P"O]O\ T7'7V3X:
M_P!0E?!8[_>9^I^MY5_N5+T.JB^Z*DJ.+[HJ2N$]4**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MR._X+;?#%[/QK\/?B#!;DP7]C+HEW,H^59(7,L08^K+-+CVB/I7ZXUX%^W3\
M"C^T+^S+XO\ #-K;?:=<MX?[4TA57+_;( 71%]Y%WQ?]M30!^=/_  15^)7]
M@_&[QEX*FD"0>(M(2\B!_BGM9#M4?6.>8_\  *_9.OYN?V0?BHOP0_::^'WB
MZZF^RV-CJJ0W\C<".UF!@G8_2.1S^%?TBYSR.10!\&?\%)/^"?MW^T=%#X_\
M Q0CX@6%L+>ZT^1UB75H%R4 8X43+D@%B RX4D;5K\9?&'@GQ!\/M>N-%\3:
M)?Z!J]N<2V6I6[P2KSC.U@#CC@]#7]1U>,_MB>#H/&?[,OQ-M?[#CUW4U\.:
M@=/@^R"XF%Q]G?88EP3OW8QMYSC% '\XUK<WK0R6%M+.8KITWVL3-MF=<A,J
M/O$;CC_>..M?;'[&O_!,;QU\;/$FG:[\0=)OO!GP_@D6:9;^-H+W4E!!\J*)
ML,BL.LK #!^7<>GT%_P1E^%?B'P7KWQ3O/%7A#4]!N&@TU;*XUC3)+=SS=>8
M(FD4'^YNV_[.>U?J+0!4TC2;/0=)LM,TZUBLM/LH$MK:VA4+'%$BA410.@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U
M[_4O]*Z&3H:Y[7O]2_TH ^4_VG/^1%U7_>B_]&I7Q_7V!^TY_P B+JO^]%_Z
M-2OC^OK\G_@2]?T1^<\1_P"]Q_PK\V%%%%>X?*A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!]@?LQ_\ (BZ5_O2_^C7KZLT'
M_4I]*^4_V8_^1%TK_>E_]&O7U9H/^I3Z5^>XK^/4]7^9^Q8'_=*7^&/Y(Z&/
MH*?3(^@I]<QW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4UJ=36H Q=8_U+?2OG3X\?\B?KW_7E/_Z+:OHO6/\ 4M]*^=/CQ_R)^O?]
M>4__ *+:M:7\2/JC"O\ PI^C_(^%J***_1C\6"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K[ _9C_Y$72O]Z7_T:]?']?8'
M[,?_ "(NE?[TO_HUZ\/./X$?7]&?5<.?[W+_  O\T?5F@_ZE/I70Q]!7/:#_
M *E/I70Q]!7R!^C#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHJ2N$]4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK2@AMW3'ECIZU]F4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $:LO4_]6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK]
M$_B-_J9?H:_.ROI<F_Y>?+]3X?B;_ES_ -O?H%%%%?3'PX4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O\ D,W_ /U\2?\ H1HHUK_D
M,W__ %\2?^A&B@#L_A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH
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M** "BBB@ HHHH ^P/V8_^1%TK_>E_P#1KU]6:#_J4^E?*?[,?_(BZ5_O2_\
MHUZ^K-!_U*?2OSW%?QZGJ_S/V+ _[I2_PQ_)'0Q]!3Z9'T%/KF.X**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z
M?'C_ )$_7O\ KRG_ /1;5]%ZQ_J6^E?.GQX_Y$_7O^O*?_T6U:TOXD?5&%?^
M%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %?8'[,?_(BZ5_O2_\ HUZ^/Z^P/V8_^1%TK_>E_P#1KUX>
M<?P(^OZ,^JX<_P![E_A?YH^K-!_U*?2NACZ"N>T'_4I]*Z&/H*^0/T8?1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ
M-67J?^K- 'B_Q&_U,OT-?G97Z)_$;_4R_0U^=E?2Y-_R\^7ZGP_$W_+G_M[]
M HHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#Z9_92_P"0#>?]?[?^BXZ^R?#7^H2OC;]E+_D WG_7^W_HN.OLGPU_
MJ$KX+'?[S/U/UO*O]RI>AU47W14E1Q?=%25PGJA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF__
M .OB3_T(T4:U_P AF_\ ^OB3_P!"-% '9_#_ /Y TW_7PW_H*UTU<S\/_P#D
M#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,P522<
M<DFEKYS_ ."AGQ*NOA9^Q]\1=6L)6AU"ZLTTJWDC;:RFYE2!F![$)([ CN!0
M!^:W_!0[_@H=K?QJ\4:KX \ :K-IGPWL9&MKBZM'*2:W(I(9V8'/D9^ZG\6-
MS9RJK\&5WOP%^#^I?'SXP>%O &DSQVM[KEWY'VF12RP1JK22R$#KMC1VQWQC
M(ZU^_P!\$_V-/A%\!-!M[#PWX,TV:\0*9=8U.W2ZOIW'\32N"5YYVIM4=@*
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M"OD#]&'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "-67J?^K-:C5EZG_JS0!XO\1O\ 4R_0U^=E?HG\1O\ 4R_0U^=E?2Y-_P O
M/E^I\/Q-_P N?^WOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /IG]E+_D WG_7^W_HN.OLGPU_J$KXV_92_P"0
M#>?]?[?^BXZ^R?#7^H2O@L=_O,_4_6\J_P!RI>AU47W14E1Q?=%25PGJA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 R3H:Y[7O\ 4O\ 2NADZ&N>U[_4O]* /E/]IS_D
M1=5_WHO_ $:E?']?8'[3G_(BZK_O1?\ HU*^/Z^OR?\ @2]?T1^<\1_[W'_"
MOS84445[A\J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'V!^S'_R(NE?[TO_ *->OJS0?]2GTKY3_9C_ .1%TK_>E_\ 1KU]
M6:#_ *E/I7Y[BOX]3U?YG[%@?]TI?X8_DCH8^@I],CZ"GUS'<%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FU
MK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_ /R!IO\ KX;_ -!6NFKF
M?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M_-7_ (?>>"/^B:>(/_ V#_"OK_6/VH-+T?\ 93C^.3Z)>2:4^C0:S_9*RH)]
MDI0!-WW<C>.?:@#J?C=\ _ W[1'@Z3PUX[T*'6+#)>"4_)<6DF,>9#*/F1OI
MP1P01D5^=_Q(_P""(:2:E-/X!^)7D6+<QV/B*RWR(?0SQ$!AT_Y9#\:ZC_A]
MYX(_Z)IX@_\  V#_  H_X?>>"/\ HFGB#_P-@_PH \O\/?\ !$'QE<3)_;OQ
M-T.PAW?,=/L)KIL9'0.8^<9_(>O'VK^S'_P3G^%'[,FIPZ]86UUXI\71IA-:
MULHYMV_B-O$JA8B?[WS.!D;L$Y^>O^'WG@C_ *)IX@_\#8/\*/\ A]YX(_Z)
MIX@_\#8/\* /TJHKYA_8Y_;LT+]L;4O%%GHWA?4?#S:##;S2-?3QR"42M( %
MV],>6>OK7T]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% #).AKGM>_U+_2NADZ&N>U[_4O]* /E/\ :<_Y$75?]Z+_ -&I7Q_7V!^T
MY_R(NJ_[T7_HU*^/Z^OR?^!+U_1'YSQ'_O<?\*_-A1117N'RH4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?8'[,?_(BZ5_O2
M_P#HUZ^K-!_U*?2OE/\ 9C_Y$72O]Z7_ -&O7U9H/^I3Z5^>XK^/4]7^9^Q8
M'_=*7^&/Y(Z&/H*?3(^@I]<QW!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4UJ=36H Q=8_U+?2OG3X\?\B?KW_7E/\ ^BVKZ+UC_4M]
M*^=/CQ_R)^O?]>4__HMJUI?Q(^J,*_\ "GZ/\CX6HHHK]&/Q8**** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 1JR]3_U9K4:LO4_]6: /%_B-_J9?H:_.ROT3^(W
M^IE^AK\[*^ER;_EY\OU/A^)O^7/_ &]^@4445],?#A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!],_LI?\@&\_Z_V_\ 1<=?
M9/AK_4)7QM^RE_R ;S_K_;_T7'7V3X:_U"5\%CO]YGZGZWE7^Y4O0ZJ+[HJ2
MHXONBI*X3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZFM0!BZQ_
MJ6^E?.GQX_Y$_7O^O*?_ -%M7T7K'^I;Z5\Z?'C_ )$_7O\ KRG_ /1;5K2_
MB1]485_X4_1_D?"U%%%?HQ^+!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5]@?LQ_P#(BZ5_O2_^C7KX_K[ _9C_ .1%TK_>
ME_\ 1KUX><?P(^OZ,^JX<_WN7^%_FCZLT'_4I]*Z&/H*Y[0?]2GTKH8^@KY
M_1A]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-__P!?$G_H1HH [/X?_P#(
M&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#^8'_A;'C?_H<O$'_@TG_^+H_X6QXW_P"AR\0?^#2?_P"+
MK]J?^'0W[//_ $#O$'_@X?\ PH_X=#?L\_\ 0.\0?^#A_P#"@#\5O^%L>-_^
MAR\0?^#2?_XNC_A;'C?_ *'+Q!_X-)__ (NOVI_X=#?L\_\ 0.\0?^#A_P#"
MC_AT-^SS_P! [Q!_X.'_ ,* /Q6_X6QXW_Z'+Q!_X-)__BZ/^%L>-_\ H<O$
M'_@TG_\ BZ_:G_AT-^SS_P! [Q!_X.'_ ,*/^'0W[//_ $#O$'_@X?\ PH \
M!_X(K>+]=\3^)_BLNLZUJ.K+#9Z<8UOKN28(2\^2NXG&<#IZ5^J=>'?LX_L;
M_#C]E>]UVZ\!VVHV\VLQPQ7?VZ]:X!6,N4VY''+M7N- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_ %+_ $KH9.AKGM>_
MU+_2@#Y3_:<_Y$75?]Z+_P!&I7Q_7V!^TY_R(NJ_[T7_ *-2OC^OK\G_ ($O
M7]$?G/$?^]Q_PK\V%%%%>X?*A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!]@?LQ_\B+I7^]+_P"C7KZLT'_4I]*^4_V8_P#D
M1=*_WI?_ $:]?5F@_P"I3Z5^>XK^/4]7^9^Q8'_=*7^&/Y(Z&/H*?3(^@I]<
MQW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=36H
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M1110 4444 %%%% 'DVM?\AF__P"OB3_T(T4:U_R&;_\ Z^)/_0C10!V?P_\
M^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2=#7/:]_J7^E=#)T-<
M]KW^I?Z4 ?*?[3G_ "(NJ_[T7_HU*^/Z^P/VG/\ D1=5_P!Z+_T:E?']?7Y/
M_ EZ_HC\YXC_ -[C_A7YL****]P^5"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5]@?LQ_\ (BZ5_O2_^C7KX_K[ _9C_P"1
M%TK_ 'I?_1KUX><?P(^OZ,^JX<_WN7^%_FCZLT'_ %*?2NACZ"N>T'_4I]*Z
M&/H*^0/T8?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ<<#\:\GO]6U;7"?M=Y-*I_Y9YVI_P!\CBH[?1V;J*^RP?!2T>+JW\H_YO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_ )$_7O\ KRG_ /1;
M5]%ZQ_J6^E?.GQX_Y$_7O^O*?_T6U:TOXD?5&%?^%/T?Y'PM1117Z,?BP444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?8'[,
M?_(BZ5_O2_\ HUZ^/Z^P/V8_^1%TK_>E_P#1KUX><?P(^OZ,^JX<_P![E_A?
MYH^K-!_U*?2NACZ"N>T'_4I]*Z&/H*^0/T8?1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ-67J?^K- 'B_Q&_U,OT-
M?G97Z)_$;_4R_0U^=E?2Y-_R\^7ZGP_$W_+G_M[] HHHKZ8^'"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !36IU-:@#%UC_4M]*^=/CQ_R)^O?]>4_P#Z+:OHO6/]2WTK
MYT^/'_(GZ]_UY3_^BVK6E_$CZHPK_P *?H_R/A:BBBOT8_%@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^P/V8_^1%TK_>E
M_P#1KU\?U]@?LQ_\B+I7^]+_ .C7KP\X_@1]?T9]5PY_O<O\+_-'U9H/^I3Z
M5T,?05SV@_ZE/I70Q]!7R!^C#Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(
M9O\ _KXD_P#0C11K7_(9O_\ KXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\
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M1110 4444 %%%% !1110 4444 ?8'[,?_(BZ5_O2_P#HUZ^K-!_U*?2OE/\
M9C_Y$72O]Z7_ -&O7U9H/^I3Z5^>XK^/4]7^9^Q8'_=*7^&/Y(Z&/H*?3(^@
MI]<QW!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=3
M6H Q=8_U+?2OG3X\?\B?KW_7E/\ ^BVKZ+UC_4M]*^=/CQ_R)^O?]>4__HMJ
MUI?Q(^J,*_\ "GZ/\CX6HHHK]&/Q8**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OL#]F/_D1=*_WI?\ T:]?']?8'[,?_(BZ
M5_O2_P#HUZ\/./X$?7]&?5<.?[W+_"_S1]6:#_J4^E=#'T%<]H/^I3Z5T,?0
M5\@?HP^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>!6Y;Z=;V_*1+N_O-R:LU\%C>/'K'!4?G+_)?YGZCEOA>E:68XCY07_MS_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "FM3J:U &+K'^I;Z5\Z?'C_D3]>_Z\I_\ T6U?1>L?ZEOI7SI\>/\ D3]>
M_P"O*?\ ]%M6M+^)'U1A7_A3]'^1\+4445^C'XL%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7V!^S'_ ,B+I7^]+_Z->OC^
MOL#]F/\ Y$72O]Z7_P!&O7AYQ_ CZ_HSZKAS_>Y?X7^:/JS0?]2GTKH8^@KG
MM!_U*?2NACZ"OD#]&'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *:U.IK4 8NL?ZEOI7SI\>/\ D3]>_P"O*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#1KU]6:#_J4^E?GN*_CU/5_F?L6!_W2E_AC^2.ACZ"GTR/H*?7,=P4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ ,76/]2WT
MKYT^/'_(GZ]_UY3_ /HMJ^B]8_U+?2OG3X\?\B?KW_7E/_Z+:M:7\2/JC"O_
M  I^C_(^%J***_1C\6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K[ _9C_Y$72O]Z7_ -&O7Q_7V!^S'_R(NE?[TO\ Z->O
M#SC^!'U_1GU7#G^]R_PO\T?5F@_ZE/I70Q]!7/:#_J4^E=#'T%?('Z,/HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'Y9KY*53-,ZGJY5/OLOT1]Y"EDG#L/=4*/W7?_MS_$ZNFR2I#&7D=8T7JS'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K[ _9C_P"1%TK_ 'I?_1KU\?U]@?LQ_P#(BZ5_O2_^C7KP\X_@1]?T
M9]5PY_O<O\+_ #1]6:#_ *E/I70Q]!7/:#_J4^E=#'T%?('Z,/HHHH ****
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MRH=+5>U7([(+VJ\L0%/VBME%(YG4;*Z6X7M4JQ 5)15&=V-"@4ZBBF(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#Z9_92_Y -Y_P!?[?\ HN.OLGPU_J$KXV_9
M2_Y -Y_U_M_Z+CK[)\-?ZA*^"QW^\S]3];RK_<J7H=5%]T5)4<7W14E<)ZH4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\/_\
MD#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_U+_2@#Y3_:
M<_Y$75?]Z+_T:E?']?8'[3G_ "(NJ_[T7_HU*^/Z^OR?^!+U_1'YSQ'_ +W'
M_"OS84445[A\J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'V!^S'_P B+I7^]+_Z->OJS0?]2GTKY3_9C_Y$72O]Z7_T:]?5
MF@_ZE/I7Y[BOX]3U?YG[%@?]TI?X8_DCH8^@I],CZ"GUS'<%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !36IU-:@#%UC_4M]*^=/CQ_R
M)^O?]>4__HMJ^B]8_P!2WTKYT^/'_(GZ]_UY3_\ HMJUI?Q(^J,*_P#"GZ/\
MCX6HHHK]&/Q8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OL#]F/_D1=*_WI?_1KU\?U]@?LQ_\ (BZ5_O2_^C7KP\X_@1]?
MT9]5PY_O<O\ "_S1]6:#_J4^E=#'T%<]H/\ J4^E=#'T%?('Z,/HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^P/V8_^1%TK_>E_]&O7U9H/
M^I3Z5\I_LQ_\B+I7^]+_ .C7KZLT'_4I]*_/<5_'J>K_ #/V+ _[I2_PQ_)'
M0Q]!3Z9'T%/KF.X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "FM3J:U &+K'^I;Z5\Z?'C_D3]>_Z\I__1;5]%ZQ_J6^E?.GQX_Y$_7O
M^O*?_P!%M6M+^)'U1A7_ (4_1_D?"U%%%?HQ^+!1110 4444 %%%% !1110
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M3?%H6FVVDQ'@33GSY?J.BCZ$&O&?$WC[Q%XRD+ZUK-WJ SD1RR'RP?9!A1^
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MZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117P!_P5:_:D^)_[-?_  J[_A7'B;_A'/[:_M3[?_H%K=>=Y/V/RO\ 7Q/M
MQYLGW<9W<YP, 'W_ $5^ /\ P]&_:=_Z*9_Y0-+_ /D:C_AZ-^T[_P!%,_\
M*!I?_P C4 ?O]17X _\ #T;]IW_HIG_E TO_ .1J/^'HW[3O_13/_*!I?_R-
M0!^_U%?@#_P]&_:=_P"BF?\ E TO_P"1J/\ AZ-^T[_T4S_R@:7_ /(U '[_
M %%9_AVZEOO#^F7,[;YIK6*1VP!EB@).![FM"@ HHHH **** "BBB@ HHHH
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M]FU^0?\ P1'^(5]:_$[X@^!C*6TR^T=-:$39(26">.$LOIN6Y&?78OI7Z^4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[7O]
M2_TKH9.AKGM>_P!2_P!* /E/]IS_ )$75?\ >B_]&I7Q_7V!^TY_R(NJ_P"]
M%_Z-2OC^OK\G_@2]?T1^<\1_[W'_  K\V%%%%>X?*A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!]@?LQ_P#(BZ5_O2_^C7KZ
MLT'_ %*?2OE/]F/_ )$72O\ >E_]&O7U9H/^I3Z5^>XK^/4]7^9^Q8'_ '2E
M_AC^2.ACZ"GTR/H*?7,=P4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %-:G4UJ ,76/\ 4M]*^=/CQ_R)^O?]>4__ *+:OHO6/]2WTKYT
M^/'_ ")^O?\ 7E/_ .BVK6E_$CZHPK_PI^C_ "/A:BBBOT8_%@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^P/V8_\ D1=*
M_P!Z7_T:]?']?8'[,?\ R(NE?[TO_HUZ\/./X$?7]&?5<.?[W+_"_P T?5F@
M_P"I3Z5T,?05SV@_ZE/I70Q]!7R!^C#Z*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M45],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!],_LI?\ (!O/^O\ ;_T7'7V3X:_U"5\;?LI?\@&\_P"O]O\ T7'7V3X:
M_P!0E?!8[_>9^I^MY5_N5+T.JB^Z*DJ.+[HJ2N$]4**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS%X0\&Z[\0/$5EH/AK2+S7=:O'V6]C80M++(?95'0#DGH "3Q0!CU[1^S?\
MLA_$K]J37/LG@W16&E12!+S7K[,5A:],AI,'<V"#L0,W?&.:^]_V3?\ @CW!
M9_8O$OQPN!<S_++'X0TZ?]VOM=3J?F/^Q$<<??.2*_3?P[X;TGP?H=GHVAZ;
M::/I-G&(K:QL85AAA0?PJB@ #Z4 3:-8MI>CV-FS!VMX(X2R]"54#/Z5<HHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /L#]F/_D1=*_WI?_1KU]6:#_J4^E?*?[,?
M_(BZ5_O2_P#HUZ^K-!_U*?2OSW%?QZGJ_P S]BP/^Z4O\,?R1T,?04^F1]!3
MZYCN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZFM
M0!BZQ_J6^E?.GQX_Y$_7O^O*?_T6U?1>L?ZEOI7SI\>/^1/U[_KRG_\ 1;5K
M2_B1]485_P"%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%% !1110
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M:'C>F^!)),93]*Z_2OA[TS'^E>O:?X.CCQ^[_2N@M/#L<>/D'Y5W'FGF.E^
M%3&8_P!*ZK3_  ;''CY/TKN8-*2/M5R.T5>U '-V?AN./'RBM:#24CQ\M:BQ
M =J>%H JQV:KVJ=80.U24M #0M+BEHH **** "BBB@ HHHH **** $:LO4_]
M6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_.ROI<F_Y>?+]3X?B;_ES_
M -O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?3/[*7_(!O/\ K_;_ -%QU]D^&O\ 4)7QM^RE_P @&\_Z_P!O
M_1<=?9/AK_4)7P6._P!YGZGZWE7^Y4O0ZJ+[HJ2HXONBI*X3U0HHHH ****
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M'WACQ!>"TTOQ'I.I71&1!:7T4KD>NU6)H WJ*** "BBFR2+%&SNP1%&69C@
M>IH =17-P_$KPC<WBV</BG19;MFV"!-1A,A;TVALY]JZ2@ HHKS[XA_M!?#7
MX2ZM;Z7XT\<:'X7U&X@%S#;:I>I \D18J'4,>1E6&?4&@#T&BL/P7XX\/_$;
MP[;:_P"%]:L?$&BW180W^G3K-#(58JP#*<9# @^XK<H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K,\2>)M(\&Z%>ZUKVIVFC:191F6YOKZ98
M884'\3.Q  K3K\L_^"Y6I7<.G_!JPCNIDL;B36)IK99"(I'0601F7."5$C@$
M\C>V.IH B_:T_P""P:Q_;?#/P.@WMS%)XPU"#@>]K XY_P!^4>OR=&K\O/%'
MBK6?&VOWNN>(-4O-:UB]D\VYOKZ9III6]69B2?\ ZU9=:_A+Q9J7@?Q#9ZWH
M\D$.I6;^9!+<6D5RJ..C!)59<CJ#C(.".: /K#]DW_@F3\1_VBOL>NZZDG@/
MP-)AQJ-_"?M5XG_3O <$@_\ /1]JX.1OQBOV'_9]_9:^''[,GAW^S/ V@QVE
MQ*@6[U>YQ+?7F.\LV,D9&=BX0'HHK\1?^'D/[27_ $5+4/\ P"M/_C-'_#R'
M]I+_ **EJ'_@%:?_ !F@#^A2BOYZ_P#AY#^TE_T5+4/_  "M/_C-'_#R']I+
M_HJ6H?\ @%:?_&: /Z%**SO#MS+>>']+N)G\R:6UBD=CW8H"3^=:- !1110
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MU*M^5>B5^2O_  0Y_P"1J^+?_7EIO_HRXK]:J "BBB@ HHHH **** "BBB@
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M ,V, UM?"3P"?A7\,?#'@[^U;C6TT+3X=.CO[M5666.-0J;@O&0H4?A7Y?\
M_!;;XJSW7B_X?_#>!V6UL[*37[I0?E>25WAAS[JL4WX2T ?%/[1'[6OQ)_::
M\17%_P"+]?N#I9D)M=!M':.PM$SE56('#$<?.^6..3TKR&2UN+>*&=X9(HY<
MF*1E(#X."5/?!]*^GO\ @FS\"M+^/G[4VB:9K]G'J/A_1;6;7+^SE7<DZQ%5
MC1QT*F:6+<#PR@@]:_<OXM?!GPM\9OACJO@7Q#IEO-HE[:FWC01+_HC!<1RQ
M?W&0X*D8QC'2@#\;?V&_^"CWC#X'>+]*\,^.]:N_$?PWNY5MY?[0E,T^D[B
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MI7Q_7U^3_P "7K^B/SGB/_>X_P"%?FPHHHKW#Y4**** "BBB@ HHHH ****
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M_H(+_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-'K7G?_"V-"_Z""_]\/\
MX4?\+8T+_H(+_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-'K7G?_"V-"_Z
M""_]\/\ X4?\+8T+_H(+_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-'K7G
M?_"V-"_Z""_]\/\ X4?\+8T+_H(+_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH
M]:/-'K7G?_"V-"_Z""_]\/\ X4?\+8T+_H(+_P!\/_A1[&I_*_N#Z]A?^?L?
MO7^9Z)YH]:/-'K7G?_"V-"_Z""_]\/\ X4?\+8T+_H(+_P!\/_A1[&I_*_N#
MZ]A?^?L?O7^9Z)YH]:/-'K7G?_"V-"_Z""_]\/\ X4?\+8T+_H(+_P!\/_A1
M[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-'K7G?_"V-"_Z""_]\/\ X4?\+8T+_H(+
M_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-'K7G?_"V-"_Z""_]\/\ X4?\
M+8T+_H(+_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-'K7G?_"V-"_Z""_]
M\/\ X4?\+8T+_H(+_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-'K7G?_"V
M-"_Z""_]\/\ X4?\+8T+_H(+_P!\/_A1[&I_*_N#Z]A?^?L?O7^9Z)YH]:/-
M'K7G?_"V-"_Z""_]\/\ X4H^+&@_]!!?^^'_ ,*/8U/Y7]P?7L+_ ,_8_>O\
MST3S!ZTNZO/X_BQX?[ZD@_X _P#A74:1KUKK%I'=6DRSP2<JZ]#S@_K42ISC
MK)6-:>(HUGRTYIOR:9LTM1H^ZI*@Z HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_D3]>_Z\I__1;5]%ZQ_J6^
ME?.GQX_Y$_7O^O*?_P!%M6M+^)'U1A7_ (4_1_D?"U%%%?HQ^+!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]@?LQ_\B+I7
M^]+_ .C7KX_K[ _9C_Y$72O]Z7_T:]>'G'\"/K^C/JN'/][E_A?YH^K-!_U*
M?2NACZ"N>T'_ %*?2NACZ"OD#]&'T444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-__P!?$G_H1HH
M[/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#E/^%3^!_^A-\/_P#@K@_^(K;D\/Z7+HXTA]-L
MWTGRQ%]A:!#!L'1?+QMP,#C':M"D9@BEF(50,DGH* .5_P"%3^!_^A-\/_\
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M '345S/]K>(O^@5'_P!]?_94?VMXB_Z!4?\ WU_]E0!TU%<S_:WB+_H%1_\
M?7_V5']K>(O^@5'_ -]?_94 =')T-<]KW^I?Z5%)JWB+!_XE4?\ WU_]E6!K
MNJ^(/)?.EQCC^]_]E0!\[_M.?\B+JO\ O1?^C4KX_KZI_:,O=4F\':DMU9)#
M$6BW,#T_>K[^M?*U?7Y/_ EZ_HC\YXC_ -[C_A7YL****]P^5"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M7PE_R-6C?]?L/_HQ:
MRJU?"7_(U:-_U^P_^C%J9;,#ZPHHHKR3G"BBB@ HHHH **** "BBB@ HHHH
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MJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJ .FHKF?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
MOK_[*@#IJ*YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RH Z:BN9_M;Q%_T
M"H_^^O\ [*C^UO$7_0*C_P"^O_LJ .FIK5S?]K>(O^@5'_WU_P#94UM6\1?]
M J/_ +Z_^RH N:Q_J6^E?.GQX_Y$_7O^O*?_ -%M7L^KZMXA\ILZ7'T_O?\
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M '345S/]K>(O^@5'_P!]?_94?VMXB_Z!4?\ WU_]E0!TU%<S_:WB+_H%1_\
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M 'U_]E1_:WB+_H%1_P#?7_V5 '345S/]K>(O^@5'_P!]?_94?VMXB_Z!4?\
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MVMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\
M94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^
M@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB
M_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =
M-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_
M -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@
M5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,
M_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?
M_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_W
MU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K
M>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?
MVMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\
M94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^
M@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB
M_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =
M-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_
M -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@
M5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,
M_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?
M_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_W
MU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K
M>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?
MVMXB_P"@5'_WU_\ 94 =-17,_P!K>(O^@5'_ -]?_94?VMXB_P"@5'_WU_\
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MY/\ [4J[_P $2=8\GXY>/M*W8^U>'!=;<]?*NHESC_MM^M '['T444 %%%%
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M]?D_\"7K^B/SGB/_ 'N/^%?FPHHHKW#Y4**** "BBB@ HHHH **** "BBB@
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M+_-'OF@G]RM=%'T%<[H'^I6NBCZ"OGS],'T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !36IU-:@#%UC_4M]*^=/CQ_R)^O?]>4__HMJ^B]8
M_P!2WTKYT^/'_(GZ]_UY3_\ HMJUI?Q(^J,*_P#"GZ/\CX6HHHK]&/Q8****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OL#]F/
M_D1=*_WI?_1KU\?U]@?LQ_\ (BZ5_O2_^C7KP\X_@1]?T9]5PY_O<O\ "_S1
M]6:#_J4^E=#'T%<]H/\ J4^E=#'T%?('Z,/HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVS_UTNX&_P#:->=?\%</&@\5_ME:O8*X=/#VDV.E CIRAN2/P-R1]0:^I_\
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M[+O@;PGJL!MM:2U:]U&)OO1W$\C3-&WN@<(?]RO=Z** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4UJ=36H Q=8_U+?2OG3X\?\B?KW_7E/\
M^BVKZ+UC_4M]*^=/CQ_R)^O?]>4__HMJUI?Q(^J,*_\ "GZ/\CX6HHHK]&/Q
M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
ML#]F/_D1=*_WI?\ T:]?']?8'[,?_(BZ5_O2_P#HUZ\/./X$?7]&?5<.?[W+
M_"_S1]6:#_J4^E=#'T%<]H/^I3Z5T,?05\@?HP^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3=0
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,A$(_",(/PK]Z?V%?@R_P)_9;\#>&[NW-OK$UI_:>I(PPXN;@^:R-[H&6/\
M[9U^/7_!.+]FQ_VBOVC-*&H6AG\)>&2FKZPS+F-PC?N;<]OWD@ ([HLGI7]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'DVM?\ (9O_ /KXD_\ 0C11K7_(9O\ _KXD_P#0
MC10!V?P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110
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M/V=_C]X2\8VERT-E#>);:I$#\L]C(P6=".A^4EAGHRJ>U '])-%%% !1110
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M2O'=NWC#Q':I=6TP:T\,S(4.H$#(S(V%89_Y9KEFP<\9S^J*J%4 # '  K?
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M,S#^$O7_ #/K.&O]\E_A?YH]\T#_ %*UT4?05SN@?ZE:Z*/H*^?/TP?1110
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MZ2.T5>U3+$!VH R[?24CQ\M78[-5[5:"TM $:P@=J>%IU% "8I:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!&K+U/_5FM1JR]3_U9H \7^(W
M^IE^AK\[*_1/XC?ZF7Z&OSLKZ7)O^7GR_4^'XF_Y<_\ ;WZ!1117TQ\.%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TS^RE_
MR ;S_K_;_P!%QU]D^&O]0E?&W[*7_(!O/^O]O_1<=?9/AK_4)7P6._WF?J?K
M>5?[E2]#JHONBI*CB^Z*DKA/5"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !1110 4444 %%%% 'DVM?\ (9O_ /KXD_\ 0C11K7_(9O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,L/Q^^'C-T.NV:_B95 _4U^RU?AWX+\1-X0\9:#KJ(7?2[^WO@HZDQR*^/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K[ _9C_Y$72O]Z7_ -&O7Q_7V!^S'_R(NE?[TO\ Z->O
M#SC^!'U_1GU7#G^]R_PO\T?5F@_ZE/I70Q]!7/:#_J4^E=#'T%?('Z,/HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BDI-U #J2F-*!WJ&2Z5>]
M %C=36D [UFS:HB9^:N$\8?&[PIX+WKJNN6L$R];=&\R;_OA<M^8K.I4A27-
M-I+S-:=*I6ER4XMOR5ST>2Z5>]5)M21/XJ^4?%_[:ELF^+P[HLUTW07%^XC0
M'UV+DD?BM>*>+/V@/'/C#>EQK4EE;-Q]GT_]PN/3(^8CZDUX&(S[!T=(-R?E
M_F_^"?3X7AG'XC6:4%Y[_<OUL?<_B[XN^&O!J,=8UJULG'/DM)NE/T1<L?P%
M>'^,/VTM+MM\7A_2KC4GZ">Z;R8OJ!RQ'UVU\BR2-*[.[%W8Y+,<DGUIM?-8
MCB+$U-*245][_P OP/K<+PKA*.M=N;^Y?AK^)Z?XL_:0\=^+-Z'5?[*MF_Y8
MZ:OE?^/Y+_\ CU>:7%Q+=S/-/*\TSG+22,69CZDGK3K:SGO&VP0O*?\ 94G%
M;MCX&OKK!F9;=?3[S?D./UKR8TL=F,KI2G^7XZ'N2K9=E4>5N,/);_<M6<Y4
MD%M+=/LAB>5O1%)KT?2_AW;(07C>X;_IH>/R']:[+2_!;;56.$1I_=5<"O<P
M_#=:6M>:CY+5_P"7YGS>*XLH0TPT'+S>B_S_ "/(K'P3J%U@R!;=?]HY/Y"N
MFTSX=6ZX,JR7+?[7"_D/\:]BTSP \F,Q_I78:5\/ ,9C_2OI</DN"P^O+S/S
MU_#;\#Y'%<09ABM.?E7:.GX[_B>/Z5X*,:A(H%C7T5<5UFF> 7?&4_2O8],\
M!HF,Q_I746'A&./'R?I7N1BHJR5D?/2DY/FD[L\CTOX>?=S'^E=AIG@-$Q^[
M_2O2;7P_''CY16G#IJ)_#3).+T_P?''CY/TK?M?#\<>/E%= EJJ]JE6,#M0!
MFPZ6B8XJY':JO:K.VB@!BQ =J=MIU% "4M%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$;_
M %,OT-?G97Z)_$;_ %,OT-?G97TN3?\ +SY?J?#\3?\ +G_M[] HHHKZ8^'"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z9_
M92_Y -Y_U_M_Z+CK[)\-?ZA*^-OV4O\ D WG_7^W_HN.OLGPU_J$KX+'?[S/
MU/UO*O\ <J7H=5%]T5)4<7W14E<)ZH4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** &2=#7/:]_J7^E=#)T-<]KW^I?Z4
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M!O$'P'\97&E:I;R3:7([-IVJ*A\JZBSQST#@8W)U!]002>$?VEOB=X#\+_\
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M<-?[Y+_"_P T>^:!_J5KHH^@KG= _P!2M=%'T%?/GZ8/HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_D3]>_Z\
MI_\ T6U?1>L?ZEOI7SI\>/\ D3]>_P"O*?\ ]%M6M+^)'U1A7_A3]'^1\+44
M45^C'XL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1JR]3_U9K4:L
MO4_]6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_EY\OU/A^)O^7/\ V]^@
M4445],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!],_LI?\@&\_P"O]O\ T7'7V3X:_P!0E?&W[*7_ " ;S_K_ &_]%QU]
MD^&O]0E?!8[_ 'F?J?K>5?[E2]#JHONBI*CB^Z*DKA/5"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\*_:?_;)\!?LD_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\/_\
MD#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_U+_2@#Y3_:
M<_Y$75?]Z+_T:E?']?8'[3G_ "(NJ_[T7_HU*^/Z^OR?^!+U_1'YSQ'_ +W'
M_"OS84445[A\J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*^?/TP?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ
M ,76/]2WTKYT^/'_ ")^O?\ 7E/_ .BVKZ+UC_4M]*^=/CQ_R)^O?]>4_P#Z
M+:M:7\2/JC"O_"GZ/\CX6HHHK]&/Q8**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OL#]F/\ Y$72O]Z7_P!&O7Q_7V!^S'_R
M(NE?[TO_ *->O#SC^!'U_1GU7#G^]R_PO\T?5F@_ZE/I70Q]!7/:#_J4^E=#
M'T%?('Z,/HHHH **** "BDS32] #Z3-1-,!WJO)?*O>@"X6J-I@.]8>I>(K7
M3K=Y[BXCMX4&6DE<*J_4FO(O&'[57@GPWOCAU%M8N5_Y9::OF#_OLD)CZ$US
MUL11PZO5DH^IU4,+7Q4N6A!R?DCW*2\5>]9]YKD-K$\DDJQQJ,LS$  >I-?%
MOB[]LCQ%JF^+0M.MM(B/ FG/GR_4=%'T(->,^)O'OB+QE*7UK6;O4 3GRY9#
MY8/L@^4?@*^<Q'$6&IZ44Y/[E_G^!]7A>%<75UKR4%][_#3\3[A\9?M/>"?"
MOF1MJRZE<KQY&FCSCGTW [!^+5X?XN_;.UB_WQ>'](AL(SP+B\8RR?4*, 'Z
M[J^<**^:Q&?8RMI!\J\O\_\ ACZW"\-8##ZS3F_/;[E^MSI_%7Q,\4^-F;^V
M=;N[R)CDP;]D/_?M<+^E<Q6A9Z!?W^#%;.%_O/\ */UKHM/^'DDF#<S'_=A'
M]3_A7'2P&.QTN=1;OU?^;.^MF679='D<TK=(_P"2V.-J[9Z+>ZACR;=V4_Q$
M87\S7J6D^ ;>$@QVBEO[SC<?U_I78:=X)EF(RGZ5]%A^&GOB*GR7^;_R/EL5
MQ<ML+3^<O\E_F>/:?\/IYL&YFVCNL0R?S/\ A76:3\/[:'!2U\QO[TGS&O8=
M*^'I;&8_TKL=+^'RKC,?Z5]+A\KP>&UA!7[O7\SY'%9SCL7I4J-+LM%^'ZGC
MNG>"I9,?)Q]*ZS2_A\S8S'^E>Q:;X)CCQ^[_ $KI++PO''CY!7JGBGE6E?#U
M5QF/]*ZW3? Z1X_=_I7H-OHJ1X^6K\=BJ]J .4L?"L<>/D%;5OHJ1X^6ME8
MO:I!'B@"E#8*F.*LK;JO:IMM+0 P1@=J=MI:* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH 1JR]3_U9K4:LO4_]6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[
M*^ER;_EY\OU/A^)O^7/_ &]^@4445],?#A1110 4444 %%%% !1110 4444
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M^WKZT 7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH^WKZT
M7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH^WKZT 7\BC(J
MA]O7UH^WKZT 7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH
M^WKZT 7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH^WKZT 7\BC(JA]O7UH^WKZT
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M3?"]CXPM!A6U32B+&]'JS)@Q2'V41CWK[Y^"O_!0KX&?'+R+?2O&5OH6L2X
MTCQ'BQN-QZ*K,?+D;VC=C0!](44BL&4$'(/((I: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** &2=#7/:]_J7^E=#)T-<]KW^I
M?Z4 ?*?[3G_(BZK_ +T7_HU*^/Z^P/VG/^1%U7_>B_\ 1J5\?U]?D_\  EZ_
MHC\YXC_WN/\ A7YL****]P^5"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "M7PE_R-6C?]?L/_ *,6LJM7PE_R-6C?]?L/_HQ:F6S
M^L****\DYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *ZKP'_P ?A^M<K75> _\ C\/UKS,P_A+U_P SZSAK_?)?X7^:/?-
M_P!2M=%'T%<[H'^I6NBCZ"OGS],'T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !36IU-:@#%UC_4M]*^=/CQ_P B?KW_ %Y3_P#HMJ^B]8_U
M+?2OG3X\?\B?KW_7E/\ ^BVK6E_$CZHPK_PI^C_(^%J***_1C\6"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[ _9C_ .1%
MTK_>E_\ 1KU\?U]@?LQ_\B+I7^]+_P"C7KP\X_@1]?T9]5PY_O<O\+_-'U9H
M/^I3Z5T,?05SN@M^Y3Z5OK( .M?('Z,34FZH&N%7O5:;4%7O0!>,@J-IPO>N
M9U[QMIGAZU-SJ6H6VGVX_P"6ES*L:_3)->+>,/VP/".B[X]--SKMP,C_ $9/
M+BS[N^/S4&N2OBZ&&5ZTTOZ[';A\%B<6[4*;E\M/OV/H>6^5.]8^L>*['1[5
M[F]O(+.W7[TMQ($0?4DXKXB\7?M;>,M?WQZ8MMH,#< PKYLOXNPQ^2BO(=:\
M1:IXDNC<ZKJ-UJ,__/2ZF:0CV&3P/85\YB.(Z$-*$7)_<O\ ,^LPO">)J:XB
M:@NRU?\ E^+/MCQA^UMX,T#?'9W,VMW R-EBGR9]W; Q[KFO$/%W[8/BO6M\
M>C6MKH<+<"3_ %\P_%@%_P#':\%I54LP"@DGH!7S6(SS&XC12Y5Y?Y[GUV&X
M=R_#:RCSO^]K^&QK>(/%VM^++CSM8U6[U*3.1]HE+!?]T=!^ K(K6LO"VHWV
M"(#$I_BE^7].OZ5TFF_#D-@W$KRG^Z@VC\ZQHY7CL8^;D>O5Z?GJ;U\XR[ K
MDYUITCK^6B.%K3LO#>HWV"ENR*?XI/E%>KZ1X&CM\>1:K&?[V,M^?6NMTWP+
M)(1E#^5?18?AJ*UQ$[^2_P W_D?*8KBV3TPM.WG+_)?YGCVG?#LR8-S,SG^[
M$,#\S_A77:1X#AM]ODVJJW]XC+?F:]ATOX>'Y<Q_I78:7\/U7&8_TKZ7#Y=A
M<+_"IJ_?=_>SY+%9KC<9I6J.W9:+[D>.Z;X'DDQE#76Z5\/"<9C_ $KV'3_!
M<<>/D_2NAL_#4<>/DKTCR3RW2_A^JX_=_I76Z=X)CCQ\GZ5W=OI"1X^6KT=F
MJ]J .8L_#,<>/D%;%OHZ1X^45K+"!VJ0)B@"G'9*O:K"PA>U2XI: &A,4N*6
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:LO4_]
M6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_.ROI<F_Y>?+]3X?B;_ES_
M -O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?5_@SP[:>"]/6'3 \8<^8[.Q8LQ4 GGZ"NUMO'.LV:@1704?]
M<U/]*YV'_4Q_[H_E3Z\*5*G-\THILVACL53BH0JR27FSJ5^)GB!>EXO_ 'Z7
M_"E_X6=XA_Y_5_[]+_A7*T5/L*7\J^XO^T<9_P _I?>SJO\ A9WB'_G]7_OT
MO^%'_"SO$/\ S^K_ -^E_P *Y6BCV%+^5?<']HXS_G]+[V=5_P +.\0_\_J_
M]^E_PH_X6=XA_P"?U?\ OTO^%<K11["E_*ON#^T<9_S^E][.J_X6=XA_Y_5_
M[]+_ (4?\+.\0_\ /ZO_ 'Z7_"N5HH]A2_E7W!_:.,_Y_2^]G5?\+.\0_P#/
MZO\ WZ7_  H_X6=XA_Y_5_[]+_A7*T4>PI?RK[@_M'&?\_I?>SJO^%G>(?\
MG]7_ +]+_A1_PL[Q#_S^K_WZ7_"N5HH]A2_E7W!_:.,_Y_2^]G5?\+.\0_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_4Q_P"Z/Y4^F0_ZF/\
MW1_*GUXYSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5K^&93'J:8[UD5I:!_P A2*N+&?P)?UU/=R/_ )&%+Y_^DL^@?"LF
MZ%/I790_=%<3X3_U*?2NV@^Z*^9/ULFHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y-K7_(9O\ _KXD_P#0C11K7_(9O_\ KXD_]"-%
M '9_#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $:LO4_]6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK
M]$_B-_J9?H:_.ROI<F_Y>?+]3X?B;_ES_P!O?H%%%%?3'PX4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?84/^IC_ -T?RI],
MA_U,?^Z/Y4^O'.<**** "BBB@ HHHH **** "BBB@ HILDBQ1L[L$11EF8X
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M3=.HK-!17S7^UC^U];? <1>']"MH=4\87,7FE9\F"RC.=KR <LQQPF1QR3C
M;X(\1?M2?%GQ1>-<W?C_ %RW=CG9IUTUF@]@L.T=_2N.MC*=)\N[/=P61XG&
M056ZC%[7ZG[%T5^2OP\_;1^*W@'4(9'\2W'B.Q5AYMCKC&Y$@Z8\QOWBGW#=
M>H-?I'\!_CEH?Q\\$QZ]I :VN8F$-]I\C9DM9L9VD_Q*>JL.H]""!='%0K.R
MT9AC\HQ& 7//6/=?J>CT445V'B!117PM^W5\?_B!\*OBYI&D^%/$D^CZ=-H<
M-U)!%#$X:4W%PI;+H3]U%'X5C6JJC'GD=^"P<\=6]C3:3\S[IHK\BO\ ALOX
MS?\ 0]7?_@-;_P#QNC_ALOXS?]#U=_\ @-;_ /QNN'^T*?9GT'^K.*_GC^/^
M1^NM%?D5_P -E_&;_H>KO_P&M_\ XW7T!^Q'^T+\0_BA\99M'\4>)KC5]-72
MI[@6\D,2#S%>,!LJ@/ 8]^]73QM.I)12>ISXCA_$8:E*M*4;15^O^1]ZT45^
M<_[5W[5GQ#\)?';Q'H7A3Q1/I>CZ;Y-NL$4,3CS/*1I#ED)SN9AU[5TUJT:$
M>:1Y6!P-3,*CI4VDTKZGZ,45^17_  V7\9O^AZN__ :W_P#C='_#9?QF_P"A
MZN__  &M_P#XW7'_ &A3[,]W_5G%?SQ_'_(_76BOA;]A7X__ ! ^*OQ<U?2?
M%?B2?6-.AT.:ZC@EAB0+*+BW4-E$!^Z[#\:^Z:[:-55H\\3Y_&X.>!K>QJ--
M^04445N< 4444 %%%% !1110 4444 %:.@_\A2*LZM'0?^0I%7%C/X$OZZGN
MY'_R,*7S_P#26>_>$_\ 4I]*[:#[HKB?"?\ J4^E=M!]T5\R?K9-1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7XY_\%MX;I?C
M;\/YG/\ H;>'F2,8_P"6@N9"_P"C1_E7[&5\._\ !63]F^_^-7P(L_%6@VDE
M[XA\$RR7@M84W//92!1<A0.25V1R?2-^"2* /'O^"'VO:1_PCOQ3T53''KWV
MNRO'5G >6VV2(N%ZD(^[)[>:OJ*_4.OYBOA#\8/%OP)\=V'C#P5JTFCZY9[E
M655#I)&PP\<B,"KHPZ@CL",$ C]$_!?_  7!U&WTV"'Q7\*K>^OEC EO-(UA
MK>.1_40O$Y4'G_EH: /UBK\ O^"H6O:/X@_;6\>RZ.8Y%MQ9VEU-"P99+B.U
MB63IW4@1D>L9KVGXT?\ !9[Q[XTT&?2_ 7A.S\ RS91M5FO/[1NE0\9C!B1$
M;W*OCMSS7P/X9\-Z]\2_&5AHND6MSK?B+6;M88(5S)+<32-U)/<DDEC[DF@#
M]N?^"1,%S#^QII3SL3%+K%^\ /9/,"D#_@:O^=?:=><_LZ_"&#X"?!#P=X!@
MG6Z.B6"PS7"+M6:=B9)I .P:1W8#WKT:@ HHHH **** "BBB@ HHHH ****
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MY8(6R!U*M^5>B5^2O_!#G_D:OBW_ ->6F_\ HRXK]:J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 9)T-<]KW^I?Z5T,G0USVO?ZE_
MI0!\I_M.?\B+JO\ O1?^C4KX_K[ _:<_Y$75?]Z+_P!&I7Q_7U^3_P "7K^B
M/SGB/_>X_P"%?FPHHHKW#Y4**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *U?"7_(U:-_U^P_\ HQ:RJU?"7_(U:-_U^P_^C%J9;,#Z
MPHHHKR3G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1JR
M]3_U9K4:LO4_]6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_EY\OU/A^)O
M^7/_ &]^@4445],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+'W52+>Q^B<-M2PM6$':5_TT_4^H/V_O >@?#?Q1X(T3PWI=OI.G0:.P$4"
M%R)6&]VZNQQRS9)KOOV@OV,=0\<:7X*\1?#;0;?[=>Z?&-8MTGCMXR_E(4GP
M[ 9)W!MO4X..2:^;OCY\?K_X_P!QX:U#5M/BLM5TNP-G<2P-^[N6WEO,"X^3
M.>5Y'IZ#]1/@M\2?"OCCP3HD.@>(-/U6XMM/@2>WMKA6FB(C4$/'G<O/J*JE
M&EB*DUT=K&6,JXS+</AY[RCS7ZK7O^9\[_L=_LN?$GX&_$"ZUK7)M'BT:]LG
MM;JTANWDF+;@T;*!'M)!7'+#ASUZ5]?:UJUMX?T>_P!4O7\JSLH)+F=\?=C1
M2S'\@:N5Y-^UAK4F@_LY^/KJ(X9]-:UZXXF983^DAKTXPCAZ;4=D?)U*]3,L
M5%U;7DTM#\F_B!XTO_B)XVUKQ+J4C27FIW3W#[CG8"?E0>RKA1Z!17W;^QK^
MR9X.U+X5V'B[QAHD.NZIK.^:WAO<M%;V^XJF$S@LV-VXYP& &,'/YY5^UOP;
MTU='^$?@FQ1=JV^B646/<0(#^M>/@8*I4<IZGV_$%>>%PT*5%\MWT[);'Y\_
MMT_LY:-\'-<T;7O"MFUCH&L>9#+9JS,EO<)@_*6)(5U)(7L4;H, 8O[!OQ*E
M\"_'?3]+DG9-+\1(=/GCS\IEP6@;'KO&T>TAKZJ_X*.:>MW\ ;2<J"UKK=O*
M#W&8YD_]FK\Z?ASK$GAWXA>&-5B.V2QU2UN5/NDJM_2IKI4,2G'39FN7REF&
M5N%5W>J_R_0_;RBBBOHC\P"O#_CA^R'X.^/WBRT\0^(=2URSO;:R2P2/3)X4
MC,:R2."0\3G=F5N^, <5[A142A&HK25T;T:]3#S]I2E9GR9_P[3^&/\ T'?%
MO_@9:_\ R-535_\ @G3\)=!TJ\U+4?$WBFSL+.%I[BXEO;4)'&H)9B?LW0 &
MOKZOA3_@HI\>)[9K;X8:1/Y:R1I>:S)&W)!.8H#Z#@2'URGO7%6IT*,'-Q/?
MP.+S''5XT8U7Y^2/B'Q1_8W_  D>HCPZMX-#$[+9?V@ZO<-$#A2Y55&XCG '
M&<<XS7Z1?L0_LQ_\*G\.KXP\00LGBW5[?:ENY(^PVS88(1_ST;"EL],!>,-G
MYD_8/^!<?Q1^);^(=5@6;0/#31SM'(,K<71R8D([A=I<_P"ZH/#5^H5<V!H7
M_?2^1ZO$&8./^Q4G_B_R_5A7XD_%'Q-_PF?Q*\4Z]NWKJ6J7-TA_V7E8J/H
M0/PK]@_C1XG_ .$,^$?C'6P^R6RTFYEB/_33RV"#\6*BOQ5I9C+X8E<+TM*M
M5^2_5_H?;_P)_8'\,_$SX3>'?%.M:]K-CJ&J0M.]O:>4(U7S&"8W(3R@4]>I
M-=Y_P[-\"_\ 0T^(OS@_^-UX!:_M]^.?#GA70O#OAC2M(T;3=)L(+&-IHVN9
MG\M%7>6)"\[<XV]SR:ZOP#_P4H\6Z;J$,?B_0=.UG3BP$DNG*UO<J.Y&6*-Z
MXPN?4=IA/"62:-:]#.W*52$]+NRNKV_KS/IWX"_L@>&_V?\ QA>>(='UK5=1
MNKFP>P:*^,6P(TD;EAM0'.8A^9KWFN7^&_Q*\/\ Q8\)VOB+PU?+?:=/\I[2
M0R #='(O\+C(R/<$9!!/45Z].,(QM#8^'Q-6M5JMXAMR6FH4445J<H4444 %
M%%% !1110 4444 %:.@_\A2*LZM'0?\ D*15Q8S^!+^NI[N1_P#(PI?/_P!)
M9[]X3_U*?2NV@^Z*XGPG_J4^E=M!]T5\R?K9-1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBB@#R;6O^0S?_\ 7Q)_Z$:*-:_Y#-__ -?$G_H1HH [/X?_ /(&F_Z^&_\
M05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .4_X5/X'_P"A-\/_ /@K@_\ B*/^%3^!_P#H3?#_ /X*X/\ XBOQ6_X>
M\?M#?]!+P_\ ^"=/\:/^'O'[0W_02\/_ /@G3_&@#]J?^%3^!_\ H3?#_P#X
M*X/_ (BC_A4_@?\ Z$WP_P#^"N#_ .(K\5O^'O'[0W_02\/_ /@G3_&C_A[Q
M^T-_T$O#_P#X)T_QH _:G_A4_@?_ *$WP_\ ^"N#_P"(H_X5/X'_ .A-\/\
M_@K@_P#B*_%;_A[Q^T-_T$O#_P#X)T_QH_X>\?M#?]!+P_\ ^"=/\: /V]T/
MPAH/A=IFT;1-.TEI@!*UC:1PEP,X#;0,XR>OK6O7P-_P3'_;(^(_[5&N>/[7
MQY<Z=<1:-;6<MI]ALEMR&D:4/NP>>$6OOF@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJO
M?_'X?K7*UU7@/_C\/UKS,P_A+U_S/K.&O]\E_A?YH]\T#_4K711]!7.Z!_J5
MKHH^@KY\_3!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4U
MJ=36H Q=8_U+?2OG3X\?\B?KW_7E/_Z+:OHO6/\ 4M]*^=/CQ_R)^O?]>4__
M *+:M:7\2/JC"O\ PI^C_(^%J***_1C\6"BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_ *LUJ-67J?\ JS0!
MXO\ $;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?^WOT"BBBOICX
M<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L
M*'_4Q_[H_E3Z9#_J8_\ ='\J?7CG.%%%% !1110 4444 %%%% !1110 5\E_
MM*_L)Z?\4M4O/$_@V[@T+Q'<,9;JSN 1:7;GJ^5!,;GN0"">2 22?I#QS\2/
M#'PTT^"^\4:W:Z):SR>5%)=/@.V,[1ZG'-<3X3_:L^%OCKQ=8>&-!\4IJ6LW
MQ98(4M+A%8JA<C>T87HI[]>.M<]54JGN5&CT\'+&8=_6,-%V6[M=6\^A^5?Q
M-^$OBOX/:Y'I/BS2FTN[E0RP_O4D25,D;E9"01D?7UKF=-U2\T6^AO=/NY[&
M]A;?%<6TC1R1MZJRD$'Z5]@?\%-?^2D^$/\ L$O_ .CFKT7]J+]G7PIK/[.M
MOXWTW3+?2?$NDZ9:W4EQ:1B,7:%8PZR@<,V"2&ZY&,X->%+#/FFH/X3]$I9K
M'V-"5>.M733:^P[]BC]KS5/B)JR^ _&UR+S6FB9],U1@%>Y"+EHI !@N%!8-
MW"G//)];_;<5V_9=\;B,X;9:$Y]/MD&?TS7YF? O4KC2/C5X$N[8L)DURS "
M_P 0,R K^()'XU^J/[5&BOK_ .SOX_M4SN32Y+KC_ICB4_I'7?AZDJN'G&6Z
MO^1\YF6%I8/,J-2FK*33MZ,_':OV_P# /_(B>'/^P;;?^BEK\0*_:KX*ZDFL
M?!WP->QL&6?0[)SCL3 F1^!R/PK'+OBD=O%"_=TGYO\ 0\<_X*$_\FY7G_82
MM?\ T(U^86EJS:I9A,[S,@7'7.X8K])_^"D&J)9_ G3K0G][>:W @7_96*9B
M?S _.OSU^%NAOXF^)?A/2(QEK[5K6WZ9^],JD_K66-UKV7D=G#_N9>Y/:[9^
MVU%%%?0GYD%%%% &/XR\5V'@7PIJWB'5)/*T_3;:2ZF;OM52<#U)Z =R17XL
M>//&6H?$3QIK/B74VW7VJ73W,B@Y";CPB^RC"CV K]#_ /@HUX^?PW\'=/\
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M<_C&]N/^ T ?%/@OP9KGQ$\5:9X;\-Z9<:QKNI3""TL;9<O*Y[#L  "23@
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MY#\<?]%+\/\ _@%/1_PY#\<?]%+\/_\ @%/7Z_T4 ?D!_P .0_''_12_#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#T6U:TOXD?5&%?^%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%%
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MCBM..U"]JL+$!7;&FD>;*LY%.*S"]JM)"!4H4"EK6QSN38T*!3J**9(4444
M%?8'[,?_ "(NE?[TO_HUZ^/Z^P/V8_\ D1=*_P!Z7_T:]>'G'\"/K^C/JN'/
M][E_A?YH^K-!_P!2GTKH8^@KGM!_U*?2NACZ"OD#]&'T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\
M1O\ 4R_0U^=E?HG\1O\ 4R_0U^=E?2Y-_P O/E^I\/Q-_P N?^WOT"BBBOIC
MX<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
ML*'_ %,?^Z/Y4^F0_P"IC_W1_*GUXYSA1110 4444 %%%% !1110 4444 >$
M_MI?"V?XI? G5H+"$SZKI$BZM:QJ,LYC#"11W),;28'<A:_*GPWXBU#PEX@T
M[6M*N&M=2T^X2YMYE_A=6!!]QD=.]?N97QM^T-_P3]M/'&LWGB+P#>VNB:C=
M,9;C2;L%;620Y+-&R@F,D_PX*Y/&T5Y6,P\JC52GN?8Y'FE+#P>&Q.D7L^GF
MF?+/[4'[0%I^T)?^%-8CT^33-1LM--K?VY.8_.\PMNC;.2A![\CISU/JW[2'
M[8FB^+_@[IGP]\'>?<K-:6T6J:E-$8DVQJI,4:L-Q)=1EB ,+@9W9'SA\5/@
MWXL^"^M6VE^+=.73[JYB\^#R[B.99(]Q7<"C''(/!P?:O<OA?_P3U\>>-%L;
M_7KW3_#6CW$:3[O-%S<,C $;43Y<X/=QCT->?&5><I12U>Y]-5IY=1IT:DY+
MDA=QUO\ \/8Y+]BGX7W7Q&^.VAW0@9M+T"5=5O)BI*J8SF%<],M(%X]%8]J_
M5G5--MM:TN\T^\C$UI=PO!-&W1D92K#\037(_!_X-^&O@CX3CT'PW:M'%N\R
MXNIB&GNI,8WR, ,GT   '05W%>UAJ'L8<KW9\'FN8?7\1[2&D5HO\S\2?B=X
M!U'X7^/=;\+ZI&R76G7#1!F'$D?5)![,I5A]:^O_ -D']M#PKX#^'=OX-\=W
M5SIW]F,_V'45@>>-X68L(V" L&4D@<$;<#C'/T-^TI^RKH'[0FGQ71F&B^*+
M1"EMJD<>X.O)$4J\;DR>#G*Y..I!^%_$W[!OQB\/WDD5MH%MKMNO2ZTV_AV-
M]%D9'_\ ':\MT:V%J.5-71];'&X'-\,J6*ERR7G;7NF]"U^V9^TO8?'OQ'I5
MCX>2X3PUHZR&*6X78UU,^-TFSLH"@+GGECQG%:/_  3]^%L_C3XSQ^))[<MI
M'AN-KAI&'RFY=2L2?499_;8/44[X?_\ !//XF^)-2B'B*.R\):=N'FRSW,=S
M,5_V$B9@3[,RU^A/PE^$WA_X+^"[7PWX=MS%:QGS)IY,&6YE( :60]V.![
M 8 %:4:%2K5]K55CGQ^883!X/ZG@Y7;5M-;)[N_=G9U\&?%+_@H/XR\"?$GQ
M1X<M/#FA7%KI.IW%E%+,)M[K'(R@MB0#) ["OO.OSR^+7[!OQ*\;?%'Q;X@T
MZ?0EL-4U6YO(!->.KB.21F7<!&<'!'>NW%.JHKV1\_D\<'*I/ZY:UM+GT]^R
M7\>-7_:"\!ZKKNLZ?9:=<6FIM9)'8[]A411OD[F)SES^0KV^O!/V./@CXB^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)X_\/[S]FU30MKR.O.!);D^8C8ZX#+GHQK3_ &=_^"6/Q@^*?BS3V\9:%<>
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M;R2^\0>#?)2VNIVS)<:?(&$0)ZLT11D)_NM'U.37WK0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% #).AKGM>_U+_2NADZ&N>U[_4O]
M* /E/]IS_D1=5_WHO_1J5\?U]@?M.?\ (BZK_O1?^C4KX_KZ_)_X$O7]$?G/
M$?\ O<?\*_-A1117N'RH4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5J^$O^1JT;_K]A_]&+656KX2_P"1JT;_ *_8?_1BU,MF!]84
M445Y)SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ K1T'_D*15G5HZ#_R%(JXL9_ E_74]W(_^1A2^?\
MZ2SW[PG_ *E/I7;0?=%<3X3_ -2GTKMH/NBOF3];)J*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\/_\
MD#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110
M4444 %%%% !1110 5\N_\%,/ ]UX[_8N^(,%C&TUWIL5OJRHO_/."=))B?81
M"1OPKZBJ"^L;?5+&XL[R".YM+B-H9H95#)(C AE8'J""01[T ?SD_L=_M'2?
MLL_';1O'+6$FJZ;''+9:C90L%DEMI1AMA/&Y6". < E,$@'(_8;]JK4-$_:X
M_P"">OB_Q)X46ZN-.OM(.N:?]HMVCG!M)A*Z[#_%B"1.,@YR"00:^&_VO/\
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M1110 4UJ=36H Q=8_P!2WTKYT^/'_(GZ]_UY3_\ HMJ^B]8_U+?2OG3X\?\
M(GZ]_P!>4_\ Z+:M:7\2/JC"O_"GZ/\ (^%J***_1C\6"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1JR]3_U9K4:L
MO4_]6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_EY\OU/A^)O^7/\ V]^@
M4445],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MET59(& ((Y0,IZ9=LD8%?&O[2'Q>?X]?'3QIX^:&6WAUO4'FMH)R#)%;J!'
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M$KP3)IBE9(V*L/W\?0B@#Z&HK^6S_A+-<_Z#.H?^!4G^-'_"6:Y_T&=0_P#
MJ3_&@#^I.BOY;/\ A+-<_P"@SJ'_ (%2?XT?\)9KG_09U#_P*D_QH _J3HK\
MH?\ @B1K%_JGBCXLB\O;B["6>G%1/*S[<O<9QD\5^KU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_ %+_ $KH9.AKGM>_
MU+_2@#Y3_:<_Y$75?]Z+_P!&I7Q_7V!^TY_R(NJ_[T7_ *-2OC^OK\G_ ($O
M7]$?G/$?^]Q_PK\V%%%%>X?*A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6KX2_Y&K1O^OV'_ -&+656KX2_Y&K1O^OV'_P!&+4RV
M8'UA1117DG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !75> _\ C\/UKE:ZKP'_ ,?A^M>9F'\)>O\ F?6<-?[Y+_"_S1[Y
MH'^I6NBCZ"N=T#_4K711]!7SY^F#Z*** "BBB@ HHHH **** "BBB@ HHHH
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M><?P(^OZ,^JX<_WN7^%_FCZLT'_4I]*Z&/H*Y[0?]2GTKH8^@KY _1A]%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_ *LU
MJ-67J?\ JS0!XO\ $;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?
M^WOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /L*'_4Q_[H_E3Z9#_J8_\ ='\J?7CG.%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6CH/_ "%(JSJT=!_Y"D5<
M6,_@2_KJ>[D?_(PI?/\ ])9[]X3_ -2GTKMH/NBN)\)_ZE/I7;0?=%?,GZV3
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^
MT]^SSH7[3_P?U?P-KC_93/MN+#4%3>]C=H#Y<RC(SC+*1D95F&1G->KT4 ?S
M@?'#]CGXM? 'Q!=:?XE\':E+91N1#K6FV[W-A<+SADF48&1SM;##N!6G^SO^
MQ+\4_P!HGQ9I]AI?AC4M)T&25?MGB+4K1X;2VA_B8,P'F-CHB9))'09(_HLH
MH Y3P3\,]!\ _#/2? FE6BIX>TW3ETR.!L$O$$V$MZLW)8]RQ/>ORM_9G_X)
M >)]4\>)J_Q;:#2O!MC=N4T>"X#WNIHCD)O*?+#&X )^;?@D80G</U]HH @L
M;&WTNQM[.S@CMK2WC6&&&)0J1HH 55 Z    >U3T44 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R
M&;__ *^)/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !11
M10 4444 %%%% !1110 4444 %%%% !1110 5S'Q,^&^A?%[P)K'@_P 3VKWF
M@ZM$(+N".5HF= P; =2".5'0UT]% 'Q__P .G_V;?^A0U#_P=W?_ ,<H_P"'
M3_[-O_0H:A_X.[O_ ..5]@44 ?%.K?\ !(7]GG41,+?3_$&E[\;3::P[>7C'
MW?,5^N.^>IK\\/VW_P!AJ_\ V*O%&@^)-&O/^$K\"7]T$M9M6MT=H9UR_P!F
MN5&%D#(I(8!=P#C:NW)_>6OSI_X+.?%;PQ9_!+1/A^;Z"Y\67VL0:BMA&X:2
MWMXXY097 .5#%U5<_>RV/NF@#UW_ ()P^(/A'\0OA+/XQ^'7@K2O _B*<II_
MB33=-W?N[B/++C<23&P<NA_VB"25-?7-?CG_ ,$2?%5]:_&[Q]X:223^S;[P
M\-1EC_@\V"YBC0_7;<R?K7[&4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_U+_2@#Y3_ &G/^1%U7_>B
M_P#1J5\?U]@?M.?\B+JO^]%_Z-2OC^OK\G_@2]?T1^<\1_[W'_"OS84445[A
M\J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:OA+_
M )&K1O\ K]A_]&+656KX2_Y&K1O^OV'_ -&+4RV8'UA1117DG.%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !75> _P#C\/UK
ME:ZKP'_Q^'ZUYF8?PEZ_YGUG#7^^2_PO\T>^:!_J5KHH^@KG= _U*UT4?05\
M^?I@^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.IK4 8
MNL?ZEOI7SI\>/^1/U[_KRG_]%M7T7K'^I;Z5\Z?'C_D3]>_Z\I__ $6U:TOX
MD?5&%?\ A3]'^1\+4445^C'XL%%%% !1110 44F:8T@% #Z0N!5>2X"]Z=#:
MW-YS&FU/[[\"N3$XNAA(>TKS48]V['?@\#B<?45'"TW.79*XKS =ZCC:6Y;;
M"C2'VZ5JV^@Q)AIF,S>G05HI&L:A44*HZ!1@5^<9CQSAZ5X8&'.^[T7W;O\
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MS_>Y?X7^:/JS0?\ 4I]*Z&/H*Y[0?]2GTKH8^@KY _1A]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+
M_$;_ %,OT-?G97Z)_$;_ %,OT-?G97TN3?\ +SY?J?#\3?\ +G_M[] HHHKZ
M8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#["A_P!3'_NC^5/ID/\ J8_]T?RI]>.<X4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %:.@_\A2*LZM'0?^0I%7%C/X$OZZGN
MY'_R,*7S_P#26>_>$_\ 4I]*[:#[HKB?"?\ J4^E=M!]T5\R?K9-1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!Y-K7_(9O_\ KXD_]"-%&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\ 7PW_ *"M
M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !111
M0 5X%^WKK>H^'/V0?B;J6DW]UI>HV^G*T-Y93-#-$WG1C*NI!!P3T/>O?:X_
MXN_"W1OC5\-]=\$>(&NDT;68!;W+64@CF"AE;Y6((!RH[&@#^<;_ (:$^*?_
M $4OQA_X/KK_ ..4?\-"?%/_ **7XP_\'UU_\<K]?_\ AS;\!/\ G\\8?^#2
M+_XQ1_PYM^ G_/YXP_\ !I%_\8H _'2^^-?Q#U.17O/'GB:[=1A6GUBX<@>@
MR]<A=74U[<23W$LD\\AW/)*Q9F/J2>M?MU_PYM^ G_/WXP/_ '%(O_C%>A_#
MO_@F3^SS\.=4348?!/\ ;U[&X>)M>O);R./'./*)$;<C^)30!\]_\$:?V=]6
M\'>%?$OQ5UVRDLAXCACL-%24;7DM$<O+-M_NNXC"D]1&3T8$_I73(HDAC2.-
M%CC0!511@*!T 'I3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\1O\ 4R_0
MU^=E?HG\1O\ 4R_0U^=E?2Y-_P O/E^I\/Q-_P N?^WOT"BBBOICX<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_ %,?
M^Z/Y4^F0_P"IC_W1_*GUXYSA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5HZ#_R%(JSJT=!_Y"D5<6,_@2_KJ>[D?_(PI?/_
M -)9[]X3_P!2GTKMH/NBN)\)_P"I3Z5VT'W17S)^MDU%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 445X/\ M@?M;:%^R#\.K7Q)J^D7
MNO7FH7)LM.T^T98UDF"%_P!Y(<[$P#R%8]/E/8 ]V=UC5F9@JJ,EF. !ZU\P
M_&S_ (*1? KX'S2V5WXI_P"$JUB,D/IOA=%O74CJ&DW+"I!X*F0,/2OQ[_:2
M_;H^*_[3M]-#K^MOI/AIF(A\-Z.S0V87MY@SNF;'>0GO@*#BLCX8_L4?''XO
MQ1S^&?AMK4UE)@I?7\2V-NX]5DG**P_W2: /MGXB?\%O=2D>2+P'\-+6V0?<
MO/$5\TQ;ZPPA,?\ ?PUY#K'_  60^/>I%OL]KX0TK)&/L>ERMC'_ %UG?K6G
MX1_X(P_&G6HXIM:U[PGX=C;[T+W<US.G3^&.+8>,]'[?C7H]C_P0XU>0K]M^
M+]E;C;EO(T!Y<-CH,W"Y&>_Z4 >6Z)_P68^.NFR1?;=,\':O&HPXN--GC9N1
MDYCG7!QQTQST->W_  U_X+>6,TD%OX_^&L]JN1YNH>'+X2_E;S!<?]_37(ZE
M_P $/_%L2 Z?\4=%NGP<BYTR:$9[#*N_'\O>O)?&O_!(7]H'POYK:99:!XMC
M7E?[)U58V8?2X6+GVS],T ?K-\"OVROA#^T7L@\&>+[6?5R,MHM^#:WP[G$3
MX+@#JT>X#UKVNOYDOB'\%_B+\$=2A'C#PEKGA*X60&"XO;22%&<<@Q2XVL01
MU5CTKZL_95_X*M?$/X+S6NB^/WN?B+X04A-]U+G5+1?6.9O]:!_<E// #J*
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MB!]W [''ZST %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 R3H:Y[7O]2_TKH9.AKGM>_P!2_P!* /E/]IS_ )$75?\ >B_]&I7Q_7V!
M^TY_R(NJ_P"]%_Z-2OC^OK\G_@2]?T1^<\1_[W'_  K\V%%%%>X?*A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6KX2_Y&K1O^OV'
M_P!&+656KX2_Y&K1O^OV'_T8M3+9@?6%%%%>2<X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %=5X#_X_#]:Y6NJ\!_\ 'X?K
M7F9A_"7K_F?6<-?[Y+_"_P T>^:!_J5KHH^@KG= _P!2M=%'T%?/GZ8/HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_+G_M[] HHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#["A_U,?\ NC^5/ID/^IC_ -T?RI]>.<X4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:.@_P#(4BK.K1T'
M_D*15Q8S^!+^NI[N1_\ (PI?/_TEGOWA/_4I]*[:#[HKB?"?^I3Z5VT'W17S
M)^MDU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\[?M
MD_LA6W[8&A^$="U'Q%-X=TO1]3:_NGM;<2SSJ8BGEH6(5#\V=Q#8Q]TU]$T4
M >&? G]BCX/?L[QV\OA/PA:OK,0&==U0"[OV8?Q"1Q^[/3B,(..E>YT5\:_\
M%$OVVO%7['/_  K_ /X1G0M'UK_A(_[0^T?VL)?W7V?[-MV>6Z]?/;.<]!0!
M]E45^-?_  ^T^*?_ $(O@_\ [YNO_CU'_#[3XI_]"+X/_P"^;K_X]0!^RE%?
MC7_P^T^*?_0B^#_^^;K_ ./4?\/M/BG_ -"+X/\ ^^;K_P"/4 ?L5JFEV6N:
M?/8:C9V]_8SKLEMKJ)9(Y%]&5@01]:^.?CO_ ,$H_@M\7%N;WP]93?#?7I,L
M+C0E!LRW;?:,=@'M&8_K7N_[*?Q@U+X^?L^^#O'VL65KI^I:U;RRS6UCN\E"
ML\D8"[B3T0'D]Z]9H XKX)^ )OA3\'_!7@RXO(]0G\/Z/::7)=Q(469H8EC+
MA3R =N<>]=K110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'DVM?\ (9O_ /KXD_\ 0C11K7_(9O\ _KXD_P#0C10!V?P__P"0--_U\-_Z
M"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444
M %%%% ',_$CX;^&OB[X*U/PCXOTF+6_#NI(([JRF9D#@,&4AD(92&52&4@@@
M$&OBW]IC_@F/\'=+^!/C"Z^&7PPF?QY%: Z2MOJ]_/(9?,3.$EN"C?+N^\"*
M^^** /PD_9G_ .">GQ+U3X[>#[7XF_"G6D\!RW9&K-<,T$8B\M\9>*0.OS;?
MND&OTQ_X=<?LQ?\ 1,__ "OZI_\ )-</^V-_P5%\)_LZZU>^#_".G)XV\<6I
M,=V&E,=AI\G]R5QS)(.\:8QR"RD8KVW]B;X\:E^TE^SCX:\<ZVEI%KMW)=07
M\-C&R0QR1W$B*%4DD#RQ&>2>O6@#BO\ AUQ^S%_T3/\ \K^J?_)-7M%_X)I?
MLU:#?)=VWPNM)95Z+>ZG?74?XI+.RG\17JW[1WQ#N/A/\ _B#XPLY5@U#1]#
MN[JSD=0P%R(F\G(((/[PIP0:_-[]G'_@LUJT.K6ND?&70[6ZTV5PA\1:%$8Y
MK?/&Z6WR5D&>28]I Z*QXH _5?P_X>TOPGHUII&B:;::1I5HGEV]C8P+##"O
M]U$4 */H*T*SO#WB'3/%FAV&LZ+?V^J:3?PK<6MY:R"2*:-AE65AP016C0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #).AKGM>_U+
M_2NADZ&N>U[_ %+_ $H ^4_VG/\ D1=5_P!Z+_T:E?']?8'[3G_(BZK_ +T7
M_HU*^/Z^OR?^!+U_1'YSQ'_O<?\ "OS84445[A\J%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1JR]3_U9K4:LO4_]6:
M/%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_EY\OU/A^)O^7/_ &]^@4445],?
M#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]
MA0_ZF/\ W1_*GTR'_4Q_[H_E3Z\<YPHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *T=!_Y"D59U:.@_\ (4BKBQG\"7]=3W<C
M_P"1A2^?_I+/?O"?^I3Z5VT'W17$^$_]2GTKMH/NBOF3];)J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^
M0S?_ /7Q)_Z$:* .S^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\B_:V^,,_P$_9Q\=^.K1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)K&Q?C[%8YBC(]&.=S?B2/:O.ZFMK2:\D\N")I7]%&:Z;2O -Q<E6NG\L?\
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M&C22/QF==LH0:>%[5=CM@O:K"Q@4ZME%(Y7-L8L0%/V@4M%69A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?8'[,?_ "(NE?[TO_HUZ^/Z
M^P/V8_\ D1=*_P!Z7_T:]>'G'\"/K^C/JN'/][E_A?YH^K-!_P!2GTKH8^@K
MGM!_U*?2NACZ"OD#]&'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\1O\ 4R_0U^=E?HG\1O\ 4R_0
MU^=E?2Y-_P O/E^I\/Q-_P N?^WOT"BBBOICX<**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_ %,?^Z/Y4^F0_P"IC_W1
M_*GUXYSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5HZ#_R%(JSJT=!_Y"D5<6,_@2_KJ>[D?_(PI?/_ -)9[]X3_P!2GTKM
MH/NBN)\)_P"I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %? '_!5K]J3XG_ +-?_"KO^%<>)O\ A'/[:_M3
M[?\ Z!:W7G>3]C\K_7Q/MQYLGW<9W<YP,??]?*O[<_[#'_#:7_"$_P#%;?\
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M 4444 %%%% !1110 4444 >3:U_R&;__ *^)/_0C11K7_(9O_P#KXD_]"-%
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M!7SY^F#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BDW4QI .] #\TUGQ5:6\5!UK%UCQ19Z3:R7-Y=0VEO&
M,O--($11ZDG@4F[*[&DV[(W9+@+WJC<ZHD>?FKYU^('[8'AW0_-M]#CDU^[&
M1OC/EP _[Y&3_P !!!]:^</'7QZ\8^/O,BN]2:RL7X^Q6.8HR/1CG<WXDCVK
MY_%9YA,-I%\\O+_/_ASZ?!<.XW%VE-<D>[W^[?[['V#\0?VC_"7@?S(9]1%]
M?KQ]CL,2R ^C'.U?Q(-?-GCS]K+Q3XF\R#1DC\/V;9&Z,^9.P_WR,#\!D>M>
M'4JJ68 #)/0"OCL5GF+Q/NQ?(O+?[]_R/O,'P[@L)[TUSR[O;[MOON37U_<Z
MI=27-Y<2W=S(<O-.Y=V/J2>34%;NF^#[_4""Z?9HSWD'S?E_CBNUT/X>V\)5
MC$;B3^](,C\!TJ<+DV+Q;YFN5=W_ );FF,S_  ."7)&7-)=(_P">QYYI^AWN
MJ$>1"Q3_ )Z-POY_X5UVC_#M6*M<LT[?W%X7_$_I7JFD>"9)MN4_2N[T3X??
M=S'^E?887(<+A_>J>^_/;[O\[GP>-XDQF*O&D^2/EO\ ?_E8\PT7P2554BA$
M:?W57 KNM%^'Y;:3'^E>I:/X%2,+^[_2NPT[PO'$!\GZ5]&DHJR6A\K*3D^:
M3NSSO1? *IMS'^E=IIWA&.%1\E=A:Z2D>/EJ\MJJ+TIDG'7>BI#"?E[5X5\<
MK58_!^N\?\N4_P#Z+:OI/5HP(6X[5\[?'@?\4?KW_7E/_P"BVK6E_$CZHPK_
M ,*?H_R/A4*!3J**_1C\6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K[ _9C_Y$72O]Z7_T:]?']?8'[,?_ "(NE?[TO_HU
MZ\/./X$?7]&?5<.?[W+_  O\T?5F@_ZE/I70Q]!7/:#_ *E/I70Q]!7R!^C#
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&K+U/
M_5FM1JR]3_U9H \7^(W^IE^AK\[*_1/XC?ZF7Z&OSLKZ7)O^7GR_4^'XF_Y<
M_P#;WZ!1117TQ\.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'V%#_J8_]T?RI],A_P!3'_NC^5/KQSG"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K1T'_D*15G5HZ#_ ,A2
M*N+&?P)?UU/=R/\ Y&%+Y_\ I+/?O"?^I3Z5VT'W17$^$_\ 4I]*[:#[HKYD
M_6R:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBOS+_X+1_$+Q5X#_P"%._\ ",^)=8\._:O[9^T?V3?RVOG;?L.W?Y;#=C<V
M,]-Q]: /TTHK^9;_ (:$^*?_ $4OQA_X/KK_ ..4?\-"?%/_ **7XP_\'UU_
M\<H _IIK\)/^"M7B;PSXF_:^U!O#D]M=36.DVMCJ\UJRL&OHVDW*Q'5DC,*'
MN"F#TP/FC4/CE\2-7M'M;[X@>*;VVD&'AN-:N9$;ZJ7P:Y"QL;K5K^WLK.WE
MO+VYE6&&WA0O)+(Q 554<EB2  .I- '[S?\ !*SQM?\ C/\ 8S\+)J,C32:/
M=76E12-U,,<FZ,?15<(/917UW7@W[#OP/O?V>_V8_!OA'5H_*UU87OM2CR#Y
M=Q.YD:/(X)0,J9&0=F<U[S0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKYM_93_;U^&W[6 ?3M%EN-!\70QF6;P]JFT3,@ZO"X^651GG&&'4J!S7TE0
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M[T7_ *-2OC^OK\G_ ($O7]$?G/$?^]Q_PK\V%%%%>X?*A1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?^Z[XY%?<U?B%_P6/\8R>(/VK[71Q*QM]!T"UMO*S\HDD:2=FQZE9(Q_P$4
M?(OP?^%.O_'#XEZ!X&\,0QS:UK-QY$/G-MCC 4N\CG!PJ(K.< G"G )XK[Q^
M+W_!&7Q!X#^%>H>(O#7CV/Q5X@TRT>[N-%;2C;+<*J[G6"3S6)8 ' 9?G/=>
ME<[_ ,$7?"D.K_M+>)-:GC#_ -C^&YC"2/N2RSPH&'_ !*/^!5^U% '\N/@G
MQGK'P[\7:/XG\/WTFFZWI-U'=VEU$>4D0Y'U!Z$'@@D'@U_25^SU\7K3X]?!
M3P?X^LXT@76[!9YH(VW+#.I*31@]PLJ.O_ :_G?_ &C/"MOX&_:!^)7AZSB6
M"RTOQ)J-I;1J,!8DN9%C 'IM K]8O^"+OC)]:_9M\2>'YI"\FB>(93$I/"0S
M0Q. /^VBS'\: /T"HHHH *_%;_@K-^UAJ/Q(^+-U\*=$O);?PCX5E$5_'&^%
MO]0 !<N!U6+.P ]&#GTQ^R_B;7K;PMX<U76KP[;33;26\F/HD:%V_0&OY>O$
MFOWGBOQ%JFMZC*T^H:E=2WES*QR7ED<N['ZEB: />/V._P!B?Q?^V#XDOH=)
MNHM \,:7M&H^(+J(RI$[ E(HXPRF60XS@$!1R2,J&]W_ &L/^"3FK_ /X67_
M ([\+>,#XPL=(C$VJ6-Q8"VGCA& TT9$C!E7.2IP0H)R<5]@_P#!/SQ'X%_9
MC_81\(^(_&WB+3/"MOX@NKS59IKZ8(UQ(TK1H(U^](WDPQ?*H)P.E=Z__!0S
M]EGXF6=YX7O?B+IUW8:K;R6=U;:MI=[;6TT,B['1WF@5 I#$'+#@F@#\1?V?
M_C=K_P"SQ\6-!\<>';B2*YT^8?:+=6PEW;$CS8''=77CV.UA@J"/Z5M"UJT\
M2:'I^K6$GG6-_;QW5O(/XXW4,I_$$5YGX&_9[^!T.EV6J^$_AWX$EL;A!+;:
MEIND6<JS(22&694.\<\')]J]5M;6&QMHK>WACM[>%!''#$H5$4# 4 <  <8%
M $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_U+_2@#Y3_ &G/^1%U7_>B
M_P#1J5\?U]@?M.?\B+JO^]%_Z-2OC^OK\G_@2]?T1^<\1_[W'_"OS84445[A
M\J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:OA+_
M )&K1O\ K]A_]&+656KX2_Y&K1O^OV'_ -&+4RV8'UA1117DG.%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !75> _P#C\/UK
ME:ZKP'_Q^'ZUYF8?PEZ_YGUG#7^^2_PO\T>^:!_J5KHH^@KG= _U*UT4?05\
M^?I@^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2D+8H =2;JB
M>8+WJI/J"1YR: +K2 =ZK2WBH.M<1XT^*WA_P/:F;6=5M[$$96-VS(_^Z@RS
M?@*^;_'W[9DT_F6_A73=HZ"^U#K]5C!_(D_A7G8K,,-@_P"+/7MN_N/5P>5X
MO'/]S#3N]%]_^1]7:QXHLM(M)+F\NH;2WC&7FFD"(OU)X%>!?$#]L#P]HOF6
M^A12:]=C(\Q?W=NI_P!XC+?@,'UKY+\5>.->\;7?VC6]4N-0?.561OD3_=0?
M*OX"L.OCL5Q'5G[N&CRKN]7_ )?F?>8+A2C3M+%RYGV6B^_=_@>@^.OCOXQ\
M?>9%>:FUG8OQ]BL<Q1D>C<[F_P"!$BO/JFM;.>]DV01-*WHHS73Z5X N+DJU
MT_EC_GG'R?SZ#]:\.GA\;F4^9)R\WM][/HZN*R_**?(VH+LM_N6OS.352S *
M"2> !6YIO@Z_U @NOV:,]Y!\WY?XXKTS0? L5MCR+<*?[Q&6/XUW>C> WDVY
M3]*^JPO#D(VEB97\EM]^_P"1\7C>+*DKQPD.5=WJ_NV_,\MT/X>V\)5C$;B3
M^](,_ITKO])\$R3;<I^E>H:)\/PNW,?Z5W6D^"TB"_)^E?64</2P\>2E%)>1
M\1B,56Q4N>O-R?F>8Z)\/ONYC_2N\T?P,D87]W^E=[8^'4A ^45M6^G)'C K
MH.8YG3O"\<0'R#\JW[724CQ\M::0!>U2A<4 5X[55[5.L8':G4M "8I:** "
MBBB@ IK4ZFM0!BZQ_J6^E?.GQX_Y$_7O^O*?_P!%M7T7K'^I;Z5\Z?'C_D3]
M>_Z\I_\ T6U:TOXD?5&%?^%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?8'[,?_ "(NE?[TO_HUZ^/Z
M^P/V8_\ D1=*_P!Z7_T:]>'G'\"/K^C/JN'/][E_A?YH^K-!_P!2GTKH8^@K
MGM!_U*?2NACZ"OD#]&'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\1O\ 4R_0U^=E?HG\1O\ 4R_0
MU^=E?2Y-_P O/E^I\/Q-_P N?^WOT"BBBOICX<**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_ %,?^Z/Y4^F0_P"IC_W1
M_*GUXYSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5HZ#_R%(JSJT=!_Y"D5<6,_@2_KJ>[D?_(PI?/_ -)9[]X3_P!2GTKM
MH/NBN)\)_P"I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YK^TA\:+#]GWX)>+/'
ME^48Z59LUK [8^T73?)!%_P*1E!QT&3VKTJORN_X+:?&"6*/P#\+[2=D242>
M(-1C!P' +0VP/J,BY.#W"F@#\Z/ /AC7_P!HSXY:-HLUY->^(?%^MHEU?R_.
MYDGES-.WK@%W/L#7]*GA?PWI_@WPSI&@:3 +72M*M(;&T@7I'#$@1%_!5 K\
M8/\ @C;\-8O%G[36I^*+F(/#X6T:6:!B,[;F<B%?_(;3U^V= 'X;?\%;OC=J
M/Q$_:;O/!JW,@\/>#8([2"V!(1KF2-)9Y2/[WSK'GTBXZDGB_P!G/]B=OBU^
MSG\5/C%KVHW.G:'X7TN^?2K6U"A[Z\@MS*2[,#B)24! &6)(!7;S0_X*4^$;
MSPC^VC\1DNT81ZC<0ZE;2$8$D4L"-D>H#;U^J&O6?V4?VPO"GAS]B?XP?!7Q
M3=KI&L7&C:M-H%S(I\F\::V8&V+#[LF\$KG ;?M'( 8 \:_93_8_NOVJ? ?Q
M6O-%U*2U\3^$;6TO=/LC'OBO]XN2\!QRKGR4",.,D@CG*^+?#7Q!XH\(>.]&
MU[P:UY%XETNY2ZLI+&-I)%D5ACY0#N!SM*D8(8@Y!Q7Z1?\ !#7_ )"OQD_Z
MXZ3_ .A7E?JIINDV.CPF&PLK>QA)W&.VB6-<^N !0!C?#;Q?_P + ^'OAGQ,
M;26P;6--M[]K2=&22!I(U<QLK<@J20<^E=)110!SOQ"\?:'\+?!&M^+?$EZN
MGZ'H]J]W=7#=E4=%'=F.%51R20!R:_G3_:C_ &B-<_:>^,6L^-M8+PP3-]GT
MW3RV5LK-2?+B'OR68]V9CWQ7UK_P5C_;'_X6=XT/PC\)WV_PKX=N-VL7$#?+
M?:@N1Y>1U2'D>ADW<'8IKY6B_9KUBS_98O/C5JOFV6EW&N6^C:/ RX^V K*9
MY^?X%:,(,=6W_P!WD @_8[_Y.O\ @]_V-NE_^E4=?TDU_-M^QW_R=?\ ![_L
M;=+_ /2J.OZ2: /D[_@I=^T=??L\?LWWCZ%<&U\3^)I_[%L)XV*R6RNC--.O
MH512H(Y#2(>U?A'X)\':Q\1O&6C>&-"M6O\ 6]8O([*T@SC?+(P5<D\ 9/)/
M &2:_0C_ (+<>,GOOB]\/?"HD8Q:;HDNHF/)P&N)VCS]<6H_.O)/^"2_A6#Q
M)^V;H-U/&LHT73;[445N0'\KR5./8S9'N >U 'M?B;_@B7XCTOX<W&H:3\1;
M35_&4%N9AHYTTPVL\@&?)2<RD@GH&9 "<9"CD?FY9WFI^$]>ANK6:XTK6--N
M1)'+&3'-;S1MD$'JK*P^H(K^IBOYU?V^?"EOX+_;&^*NFVL2P0-J[7HC7H#<
M1I<''H,RGB@#]P/V-_CT?VDOV=_"?C:X$::O/"UIJD47"I>0L4E('\(; D [
M+(M1?MI?!-?C_P#LT^-O"<<'G:J;,WVEX&6%Y!^\B ]-Y4QGVD-?&_\ P1 \
M9/=^!_BAX4>0[+#4;/4XHR>/W\;QN0/^W9,_45^F] '\V/[*OQWU#]F_X[>%
M_&UI+*EG:W*P:I;Q_P#+Q8NP$\9'<[?F7/1E4]J_I%TW4+;5]/M;ZRG2ZL[J
M)9X)XSE9(V 96![@@@_C7\Y?[:GPUB^$?[5/Q+\,VT0@LX=7DNK6)1@1P7 6
MXB0>RI*J_A7Z^_\ !*SXM3?%']D70K2]N#<:CX5NI= D9C\WE1A7@_!898T'
M_7.@#[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS5_X+*?"?
MQQ\4/^%0?\(;X-\0>+?L/]L?:_["TN>]^S[_ +%L\SRD;;NV/C.,[6QT-?I5
M10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10
M!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!\
M4_"WX?\ BC3_ /@E/>^$KKPWJ]MXK;P;K%J-"FL94OC,YN=D?D%=^]MRX7&3
MN&.M?D%_PR=\;_\ HC?Q _\ "7OO_C5?TIT4 9GAB&2W\-Z3%*C1RI:0JR.,
M%2$ (([&M.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05K
MIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH CG@CNH9(9HUEAD4H\<BAE92,$$'J"*^5/CE_P3*^!GQJ-S>)X=/@K79L
MM_:7A@K;!FZY>#!B;)Y)"!CD_-7U?10!^(_QP_X(_P#Q<^'?GWO@FZL?B/I*
M981VN+._51SDP2-M;Z)(S'^[7Q)XH\)ZWX(UJXT?Q%H]_H6K6YQ+8ZE;/;S1
M_5' (_*OZDZY#XD_"'P5\8M%.D^-O"^E^)K#G9'J-LLC1$]6C?&Z-O\ :4@^
M] '\PU?I-\ _^"S/B#PAINFZ'\1_!EKKVFVD4=NFIZ"_V:Z6-0 "T3DQR-@=
MFC%>O_''_@B[X,\1_:+_ .%WB:Z\(79RR:3J^Z]LB>RK+GS8Q[L93[5^>_QR
M_85^-/[/WGW'B7P==7>BQ9)UO1?]-L]H_B9D&Z(?]=%0^U '[C_LY_M;?#;]
MJ73;ZY\!ZO/<W6GK&U_IU[:O!<6F_.W<"-K9VMRC,.#S7LE?DK_P0Y_Y&KXM
M_P#7EIO_ *,N*_6J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$+TG_G@W_?QO\: -/^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &LO_ (0S2?\
MG@W_ '\;_&F-X/TD?\L6_P"_C?XT :_]J67_ #]P?]_%_P ::VK60_Y>X/\
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MC?XT?\(SH_\ SR;_ +^-_C0!T7]J67_/W!_W\7_&C^U++_G[@_[^+_C7._\
M",Z/_P \F_[^-_C1_P (SH__ #R;_OXW^- '1?VI9?\ /W!_W\7_ !H_M2R_
MY^X/^_B_XUSO_",Z/_SR;_OXW^-'_",Z/_SR;_OXW^- '1?VI9?\_<'_ '\7
M_&C^U++_ )^X/^_B_P"-<[_PC.C_ //)O^_C?XT?\(SH_P#SR;_OXW^- '1?
MVI9?\_<'_?Q?\:/[4LO^?N#_ +^+_C7._P#",Z/_ ,\F_P"_C?XT?\(SH_\
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M_OXO^-']J6?_ #]P?]_%_P :S/\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\
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MX/\ OXO^-']J6?\ S]P?]_%_QK,_X0O2?^>#?]_&_P :/^$+TG_G@W_?QO\
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M[^+_ (T?VI9_\_<'_?Q?\:S/^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\: -/\
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M/PGIL<,N(6Z'^,U\!U]+DW_+SY?J?#\3?\N?^WOT"BBBOICX<**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_4Q_[H_E3Z
M9#_J8_\ ='\J?7CG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRVVD16>FVXS]Q5MHW=?^_LDOYU^^]?SH?MY-*W[8GQ:,PP_]NS ?[N!M_3%
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MJ'SU9FN&('KP@_,>M?K'0!^(7_!9+PO%H?[6EEJ,0P=:\-V=Y*>.9$EG@_\
M0(4KU?\ X(?^+KF/Q%\4?"[2;K.:TL]22,_PNCO&Q'U$B9_W17+?\%MH8U^.
M7@&4']ZWAPJW^Z+J4C]2U9W_  10DG'[2GC&-1_HS>$IF<_[8O+3;^A>@#]H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\U?^"RGQ8\<?"_\
MX5!_PAOC+Q!X2^W?VQ]K_L+5)[+[1L^Q;/,\IUW;=[XSG&YL=37Z55\__M7?
ML4^"/VPO^$6_X3+5?$&F?\([]J^R?V%<01;_ +1Y._S/-ADSCR$QC'5LYXP
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M9=4"L#Y$"'#;6Z&7&T#=@EABOW/M+2#3[6&UMH8[>VA18XH8E"HB@8"@#@
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MS*;?4+=HRV#@E">'7T920<@@UCM-JGB;4+>)GO-6OF"P0H2\TI X5%')^@%
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M_<7!#73^6/\ GG'R?SZ?SKO-!\"Q6V/(MPI[MC+'\:]/T7X?EMI,?Z5W^B^
ME3;F/]*^QPN6X7!ZTH:]WJ_Z]#X/&9MC,=I6GIV6B_X/SN>6:-X#>3;F/]*[
M[1?A^%VDQ_I7I6E^$8XE'R?I72V>AI&!\N*],\<XK2?!:1 ?)^E=58^'4B ^
M6M^&R5!TJRL0':@"C;Z<D>,"KB0!>U3;:6@!H7%+2T4 %%%% !1110 4444
M%%%% !1110 4444 %-:G4UJ ,76/]2WTKYT^/'_(GZ]_UY3_ /HMJ^B]8_U+
M?2OG3X\?\B?KW_7E/_Z+:M:7\2/JC"O_  I^C_(^%J***_1C\6"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (6=XA_Y_5_[]+_A7*T4>PI?RK[@_M'&?\_I?>SJO^%G>(?^?U?^_2_X4?\
M"SO$/_/ZO_?I?\*Y6BCV%+^5?<']HXS_ )_2^]G5?\+.\0_\_J_]^E_PH_X6
M=XA_Y_5_[]+_ (5RM%'L*7\J^X/[1QG_ #^E][.J_P"%G>(?^?U?^_2_X4?\
M+.\0_P#/ZO\ WZ7_  KE:*/84OY5]P?VCC/^?TOO9U7_  L[Q#_S^K_WZ7_"
MC_A9WB'_ )_5_P"_2_X5RM%'L*7\J^X/[1QG_/Z7WLZK_A9WB'_G]7_OTO\
MA1_PL[Q#_P _J_\ ?I?\*Y6BCV%+^5?<']HXS_G]+[V=5_PL[Q#_ ,_J_P#?
MI?\ "C_A9WB'_G]7_OTO^%<K11["E_*ON#^T<9_S^E][.J_X6=XA_P"?U?\
MOTO^%'_"SO$/_/ZO_?I?\*Y6BCV%+^5?<']HXS_G]+[V=5_PL[Q#_P _J_\
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M?^_2_P"%'_"SO$/_ #^K_P!^E_PKE:*/84OY5]P?VCC/^?TOO9U7_"SO$/\
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M],A_U,?^Z/Y4^O'.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@CO&]=LULB#];=J_1^OQJ_X(J_$@:#\</&/@R:39!XBT=;N)2?O3VLF54?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?^I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEB4!))[FM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[T7_ *-2OC^OK\G_ ($O7]$?G/$?^]Q_PK\V%%%%>X?*A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6KX2_Y&K1O^OV'_ -&+656K
MX2_Y&K1O^OV'_P!&+4RV8'UA1117DG.%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !75> _\ C\/UKE:ZKP'_ ,?A^M>9F'\)
M>O\ F?6<-?[Y+_"_S1[YH'^I6NBCZ"N<T%OW*UOK( .M?/GZ839IK/BJLMXJ
M \UB:UXJL=%LY+J^NX;.VC&7FGD"(OU)XI-I*[&DY.R-^2X5>]4+G5$CS\U?
M./Q _;"T#1_,M] ADUZZ' E&8K<'_>(RWX#!]:^<?'7QR\8?$ R1W^IM:V+_
M /+E99BBQZ'!RP_WB:^?Q6>83#Z0?._+;[_^'/J,%PYC<5:4UR1\]_NW^^Q]
M@_$']I7PCX)\R%]0_M*_7C[)I^)&!]&;.U?Q.?:OFSQY^U?XL\4-)!I.SP_9
M-QF$[YR/=R./^ @'WKQ*E56=@J@LQX  R:^.Q6=XO%>[%\J[+_/<^\P?#N!P
M?O37/+N]ONV^^Y+>7MQJ-U)<W<\MU<2'<\TSEW8^I)Y-0UO:9X-O[_!D7[-&
M>[CYOR_QKMM#^'MO"RMY)GD_O2#/Y#I4X7)<7BO>DN5=W_EN5C.(,#@ER1ES
MR72/^>QYWIV@WNJ$>3"=A_Y:/PO_ -?\*Z_1_ATFY6N2UPW]U>%_Q->IZ3X(
MDF*Y3]*[S1/A]]W,?Z5]CA<BPN'M*:YWY[?=_G<^#QO$F-Q5XTWR1\M_O_RL
M>8:+X)(54CA$:?W57 KNM%^'Y;:3'^E>I:/X'2/;^[_2NPT[PQ'"!\GZ5]$D
MHJR/E92<G=N[/.]%\!*FW,?Z5VVF>$8X@/D_2NLM=)2,#Y:T([55[4Q&/9Z(
MD>/EK4ALE0=*MK'BG8H C6(#M4FVEHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IK4ZFM0!BZQ_J6^E?.GQX_P"1/U[_
M *\I_P#T6U?1>L?ZEOI7SI\>/^1/U[_KRG_]%M6M+^)'U1A7_A3]'^1\+444
M5^C'XL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &KX2_Y&K1O^OV'_T8M?6%?)_A+_D:M&_Z_8?_ $8M?6%<.(W1G,****Y3
M,**** "BBB@ HHHH **** "BBJ6M:S8^'=(O=4U.YCLM/LX7N+BXE.%CC4$L
MQ]@!2&DV[(NUX'\6/VQ/#7PB^)</@K4M%U:\OY%@87%J(O*'FG"_><'COQ7Q
MU\>_VZ/&7Q&U:[L?"5]<>%/"ZL4A^R-Y=Y<+TWR2CE<_W4( S@ENM?-NH:M?
M:M?->7U[<7MXQ!:XN)6DD..F6)S7D5L<MJ7WGW& X=;]_%]5LM_F?NG17Y#_
M  N_:W^)?PMU*VD@\176MZ;'\KZ7K$SW$+)_=4L=R>Q4C\1D']//@G\8-(^.
M'P_L/$^D_NC*/*N[-GW/:S@#?&Q[XR"#@94@X&<5V4,5"OHM&>#F&4U\O2E+
M6+ZK]3O***^/?VMOVVI_AEK%SX-\#"";Q#"-M]JDR"2.R8@$)&IX>0 Y);*K
MTP3G;O4JQHQYI'!A,)5QM3V5%7?Y>I]A45^,NK?M$?%#6[QKJZ^('B3S&8/M
M@U.6&-6'0JB,%7\ *[OX6_MN?$[X<ZA";[6IO%NDAOWUCK4AF=AWVSG,BGTY
M(]0:\^.84V[-,^DGPSB8PO&:;['ZOT5R'PH^*.B?&+P/I_BC096:SN@5>&3
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M?^I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+H_X6QXW_P"AR\0?^#2?_P"+K]J?^'0W[//_ $#O$'_@X?\ PH_X=#?L\_\
M0.\0?^#A_P#"@#P'_@BMXOUWQ/XG^*RZSK6HZLL-GIQC6^NY)@A+SY*[B<9P
M.GI7ZIUX=^SC^QO\./V5[W7;KP';:C;S:S'#%=_;KUK@%8RY3;D<<NU>XT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[7O\
M4O\ 2NADZ&N>U[_4O]* /E/]IS_D1=5_WHO_ $:E?']?8'[3G_(BZK_O1?\
MHU*^/Z^OR?\ @2]?T1^<\1_[W'_"OS84445[A\J%%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^4/\
M@I+^TY??LU_L^S2Z!<"V\7>))SI.FS X>V4H6FN%]T4  ]GD0\XQ7U?7X^?\
M%NM>FN/BW\.-$9G^SV>AS7B*<[=TUP48CWQ N?PH _.WP_X?UCQIX@M-(T73
MKS6]:OY?+M[*RA:>>>0\X55!9CU-?9/@S_@C_P#'[Q7IL%Y>KX9\*M+'Y@MM
M:U-_-7.,!A!%* >>F>.^#7N?_!$KX7Z)>GXA>/[NV@NM=LI;?2;"1^7M(W1G
MF91VW_NUW=<(P'!.?U9H _ #XT?\$S?CK\$]!GUR\T"U\3:1;Y-Q<^&;AKLP
MJ.=[1%5DVX!)8(0 .<5X=\%?C%XC^ GQ,T3QOX6NOL^JZ9-O\MB?+N(SQ)#(
M!U1URI'OD8(!'].%?SV?\%&/A?HGPD_:\\;Z-X=MX+'1[@V^HPV5OPELT\*2
M2(!_"/,+L%& %90!C% '[T?"GXB:;\7/AKX9\::0?^)?KNGPW\2%LF/>@)C8
M_P!Y3E3[J:ZNOC7_ ())ZY-J_P"Q?H%M+NVZ;J=_:1ENZF8R\>V92/PK[*H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W
M_P#U\2?^A&BC6O\ D,W_ /U\2?\ H1HH [/X?_\ (&F_Z^&_]!6NFKF?A_\
M\@:;_KX;_P!!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN?^
M(/CC2_AGX%U_Q;K<K0Z1HEC-?W3*,MY<:%B%'=CC '<D"@#B/VB/VG? '[+_
M (177O'.JFV\\E++3;51+>7KCJL4>1G&1EF(49&2,C/YL?$;_@MMXUO-0=?
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M%-+4 .I-U1M(%ZFJ\MXJ]Z15BTTE027*KWK UGQ98Z0A:YN4C/9<Y8_0#FN
MUKXJ2S;DT^#8/^>LW)_!:\7'9S@LO7[^HK]EJ_N_S/J\HX8S7.FGA*+Y?YGI
M'[WO\KL]-OM9ALXFDFE6*->K,P %</KGQ4M+?<EDC7;_ -[[J?GU->::AJEW
MJDOF7=Q).W;<>!]!T%5:_.<?QCB*MXX./(N[U?\ DOQ/VW)_#+!X>U3,ZGM)
M?RK2/W_$_P#R7T-G6/%VIZUN$UP4B/\ RRB^5?Q]?QK&IKR+&,LP45-I<8U*
MXV*&VYZU\G'#X_-9^U:<_-[?>_R/TGZQE614_J\.6G;[,;7];+7YO[QBJ78*
MH+,>@ YK=TSP;?:@09%^S1GNXRWY?XUW7A7P<-JF.$*3U;')_&O3-#\!M)M)
M3]*^GPO#E./O8F5_);??O^1\GC>+*D[QPD.5=WJ_NV7XGE^A_#VWA93Y)GD_
MOR<_D.E=_I'@F28KE/TKU'1?A^%VYC_2NYTGP6D07Y/TKZRC0I8>/)2BDO(^
M)Q&)K8J7/7FY/S/,=$^'WW<Q_I7>:/X'2/;F/]*[RQ\/1Q ?+^E;-OIRQ@?+
M6YS'-:?X8CA ^3]*WK724CQ\M::0!>U2A: *\=JJ]JG6/%.I: $Q2T44 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %-:G4UJ ,76/]2WTKYT^/'_ ")^O?\ 7E/_ .BVKZ+U
MC_4M]*^=/CQ_R)^O?]>4_P#Z+:M:7\2/JC"O_"GZ/\CX6HHHK]&/Q8**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -7PE_R-6C
M?]?L/_HQ:^L*^3_"7_(U:-_U^P_^C%KZPKAQ&Z,YA1117*9A1110 4444 %%
M%% !1110 445Q?Q#^,W@KX4-:KXL\06^BO=*SP+,KLT@4@,5"J<X)&?K4N2B
MKMEPISJ2Y8*[\CY@_:(_X)]V_BG4;OQ#\.;BWTJ]G9I9]#NCLMG8\DPL!^[)
MY^4C;D\%1Q7PMX^^'WB#X8^))] \3:<VEZK"H9X&=7^4]&#*2"#Z@U^M/PY_
M:<^''Q9\5/X>\*Z^VIZDMNUSM:SFA5D4J&P9$7)&X<>F3VKX?_;<4-^UQ9 C
M(,6G @_6O%Q5&ER^TI]_D??Y/CL9[7ZKBEM&^JLSYDT'Q!J?A?5(-2T?4+G2
M]0@;=%=6DK12(?9@<U^E/[%O[55Y\:K.[\,>*&C;Q7IT/GI=HH07T (4L5'
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MZN+_ ($CX[)4WF%)>OY,^0_V?U=OCO\ #D)G/_"1:>>/3[3'G],U^S]?C_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !6CH/\ R%(JSJT=!_Y"D5<6
M,_@2_KJ>[D?_ ",*7S_])9[]X3_U*?2NV@^Z*XGPG_J4^E=M!]T5\R?K9-11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y;_\
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M=_"7]D'P%I6I6\MKJE[!)JUU#,NUT:XD:5%*]01&T8(/.0?I7TC2=.!P*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?
M_P#7Q)_Z$:*-:_Y#-_\ ]?$G_H1HH [/X?\ _(&F_P"OAO\ T%:Z:N9^'_\
MR!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY%_P""
MJVOW.A_L4^,8[9VC.H75C9R,G78;F-F&?0A-I^N.]?75> ?M[?"^\^,'[(_Q
M&\/:;'YNIK8KJ-K&!EG>VE2XV*/[SK$R#W>@#\6/V!?A7HWQE_:T\ >&?$-O
M#>:*]Q->75I.?EN%M[>2<1D?Q!FC4$=UW=J_HD15C5550JJ,!5& !Z5_,=\%
M?BQK'P,^*GAKQYH(C?5-#NQ<1Q3?<E4@K)&W?:Z,ZDCD!N.:_>3X(_\ !03X
M(_&[P_#>V_C73/"VJ8 GT7Q+=Q6-S$^,E5\Q@LHX/S1EACK@\4 ?1]?EO_P6
MR^%.B0Z#X$^(UM;06VO2WKZ)>3)Q)=1&)I8BP[["D@SUQ( >,8^^_&'[3OPC
M\ V$]WK_ ,2_"VGQPQF0QMJT+S. ,_)$K%W/LJDGTK\:?^"C7[;EG^UCXTTC
M2_"T$]OX$\.^8;26ZC\N:^N'P'G9<_*F%"HIYQN)P6VJ >G?\$2]=N;?X_>.
MM&5W%I>>&#>2(/NEX;N!$)]P)WQ]37[*U^4?_!$7X8W?]H?$;XAS)LL1%#H%
MJ^/]9(6$\PS_ +($'_??M7ZN4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_U+_2@#Y3_ &G/^1%U7_>B
M_P#1J5\?U]@?M.?\B+JO^]%_Z-2OC^OK\G_@2]?T1^<\1_[W'_"OS84445[A
M\J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:OA+_
M )&K1O\ K]A_]&+656KX2_Y&K1O^OV'_ -&+4RV8'UA1117DG.%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !12;J:TE [#LTA:J\ERJ]ZSK[6H;.)I)I5BC7JS, !4RD
MHJ[>AI"G*;48J[9J/,%[U4FOE7O7GNN?%2UM]R62-=O_ 'ONI^?4UP>L>+=3
MUHL)[@I$?^647RK_ /7_ !KX_'\4X#!WC3?M)>6WW[?=<_3,G\/LWS*TZ\?8
MP?66_P H[_?8]2USXB:;I>Y?.^T3#_EG#\WYGH*X#6?B-J>I;D@(LHC_ '#E
M_P#OK_"N4H)QR>!7YSCN)LPQUX0ER1?2._W[_=8_;LIX#R;*4JE2'M9KK/;Y
M1V^^[\QTDCS2%Y&9W;DLQR33:KR7J+P@\P^W2FK#<WG'*KZ+6."X>QV-?/*/
M)%]9?Y;G9F7&&596O9PE[22Z1V^_9?*[\B66ZCAX+9/H.34/G3W!Q&NP>O4U
MK:?X9>3&5KJ=,\(],I7Z!@>&,'A;2J+GEY[?=_G<_'LVX\S'&WA1?LH?W=__
M  +?[K'%V>@RW# L"Q]Z]&^'_@\RW7*=_2MG3?"ZIMRE>D_#O046\^[WKZ+%
M4U3I)):7/ELFQ#KXR7,[NS_-'9>#? JB)"4_2O4=(\)1Q*OR"K?AG2TCA3 K
ML+>U55'%>0?;F59Z(D0'RUJ0V2H.E6UCQ3L4 1K$!VJ3;2T4 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U?"7_ "-6C?\
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MI7SI\>/^1/U[_KRG_P#1;5K2_B1]485_X4_1_D?"U%%%?HQ^+!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!J^$O^1JT;_K]A
M_P#1BU]85\G^$O\ D:M&_P"OV'_T8M?6%<.(W1G,****Y3,**** "BBB@ HH
MHH **** "BBB@ KY3^/7[&^L_%_XT6_C:S\16.GVL:VJFUGA=G/E')Y''-?5
ME%95*<:JY9'7AL55PD_:479VL%%%%:G(%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;OA'_D*"
MO?O#/^I7Z5X#X1_Y"@KW[PS_ *E?I7RV*_C2/V'*/]QI>AUD7W14E1Q?=%25
MRGKA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ
M-67J?^K- 'B_Q&_U,OT-?G97Z)_$;_4R_0U^=E?2Y-_R\^7ZGP_$W_+G_M[]
M HHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#["A_U,?\ NC^5/ID/^IC_ -T?RI]>.<X4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %:.@_P#(4BK.K1T'_D*15Q8S
M^!+^NI[N1_\ (PI?/_TEGOWA/_4I]*[:#[HKB?"?^I3Z5VT'W17S)^MDU%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+_ .VQ
M^P[8_MG?\(9]M\77'A;_ (1O[;L\BQ6Y\_[1Y&<Y==NWR!ZYW>U?4%% 'Y@?
M\..=#_Z*WJ'_ ((X_P#X_5>]_P""&^FR0@6GQANH)<\M-X=61<>F!<KS^-?J
M/10!^0GCS_@B+XNTG29[CPE\2M+\27T:;DL]2TQ].\QA_"'$LP!QTS@9/) Y
MKXZ^%?PY\$>&?CE-X$_: M_$WA.TCN?[/N[K2;F""73)\@"299890\/(R5Q\
MI#@L.#_2!7X9_P#!8)M%;]L*;^RFA:]_L&Q&J^5C(NLR;0^/XO(^S]>VV@#]
MDO@;\)]$^!OPI\.^!O#=Y>:AH>D0LEK<ZA*DDTBO(TF69$53RYQA1QBNZKY4
M_P""8OQ(U#XD_L<^#Y=4E-Q>:,\^BF9B26C@?$.?<1-&O_ :^JZ "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_P"0S?\ _7Q)
M_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05KIJYGX?\ _(&F_P"O
MAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _G6_X;\_:&_Z
M*QX@_P"_J?\ Q-?K%XN^+7C"Q_X)?P?$&#Q!>1>-&\(65\=:5AY_GN8MTF<8
MR=Q[=Z\<_P"'(?@C_HI?B#_P!@_QKZ_UC]E_2]8_93C^!KZW>1Z4FC0:-_:R
MQ(9]D10A]OW<G8./>@#\0?\ AOS]H;_HK'B#_OZG_P 31_PWY^T-_P!%8\0?
M]_4_^)K[_P#^'(?@C_HI?B#_ , 8/\:/^'(?@C_HI?B#_P  8/\ &@#X _X;
M\_:&_P"BL>(/^_J?_$T?\-^?M#?]%8\0?]_4_P#B:^__ /AR'X(_Z*7X@_\
M &#_ !H_X<A^"/\ HI?B#_P!@_QH D_X)'_M#?$?XX>(OB5!X\\7ZCXGBTZU
ML7M$OG5A"SO,'*X ZA5_*OTFKYA_8Y_83T+]CG4O%%YHWBC4?$+:]#;PR+?0
M1QB(1-(05V]<^8>OI7T]0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #).AKGM>_P!2_P!*Z&3H:Y[7O]2_TH ^4_VG/^1%U7_>B_\
M1J5\?U]@?M.?\B+JO^]%_P"C4KX_KZ_)_P"!+U_1'YSQ'_O<?\*_-A1117N'
MRH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ-6
M7J?^K- 'B_Q&_P!3+]#7YV5^B?Q&_P!3+]#7YV5]+DW_ "\^7ZGP_$W_ "Y_
M[>_0****^F/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^PH?\ 4Q_[H_E3Z9#_ *F/_='\J?7CG.%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6CH/_(4BK.K1T'_D*15Q
M8S^!+^NI[N1_\C"E\_\ TEGOWA/_ %*?2NV@^Z*XGPG_ *E/I7;0?=%?,GZV
M34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\%
M?\%3/VL/B3^R_P#\*Q_X5[J]OI7]N?VI]N\^QAN?,\G[)Y>/,4[<>=)TZY]J
M^]:^2OV]OV';[]L[_A!OL7BZW\+?\(W]NW^?8M<^?]H^SXQAUV[?(/KG=[4
M?F7_ ,/8/VDO^AOT_P#\$EI_\;H_X>P?M)?]#?I__@DM/_C=>_\ _#CG7/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[7O\
M4O\ 2NADZ&N>U[_4O]* /E/]IS_D1=5_WHO_ $:E?']?8'[3G_(BZK_O1?\
MHU*^/Z^OR?\ @2]?T1^<\1_[W'_"OS84445[A\J%%%% !1110 4444 %%%%
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M?66_RCO]]CU+7/B)INE[D$WVB8?\LX?F_,]!7 :S\1M3U+<D!%E$?^>9R_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ;OA'_ )"@KW[PS_J5^E> ^$?^0H*]^\,_
MZE?I7RV*_C2/V'*/]QI>AUD7W14E1Q?=%25RGKA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 (U9>I_ZLUJ-67J?^K- 'B_Q&_U,OT-?G97Z
M)_$;_4R_0U^=E?2Y-_R\^7ZGP_$W_+G_ +>_0****^F/APHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^PH?]3'_NC^5/ID/^
MIC_W1_*GUXYSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5HZ#_R%(JSJT=!_P"0I%7%C/X$OZZGNY'_ ,C"E\__ $EGOWA/
M_4I]*[:#[HKB?"?^I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %,FF2WB>65UCB12S.YP% Y))["GU\"?\
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M $[5<M@$XP#C\ _!?@S7/B)XJTSPWX;TRXUC7=2F$%I8VRY>5SV'8  $DG
M!)( K:\;>!?&_P"S[\1O[(\0Z??>$O%^CRQ7*+O EA?AXY8Y$)![$,I(R.O%
M '].E%>/?LA_&B7]H+]G'P1XYN]O]IZA9F+4-B[1]JA=H9B%[!GC9@/1A7L-
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M7PE_R-6C?]?L/_HQ
M:RJU?"7_ "-6C?\ 7[#_ .C%J9;,#ZPHHHKR3G"BBB@ HHHH **** "BBB@
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M%@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH U
M?"7_ "-6C?\ 7[#_ .C%KZPKY/\ "7_(U:-_U^P_^C%KZPKAQ&Z,YA1117*9
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!N^
M$?\ D*"O?O#/^I7Z5X#X1_Y"@KW[PS_J5^E?+8K^-(_8<H_W&EZ'61?=%25'
M%]T5)7*>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C5EZ
MG_JS6HU9>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\
MN?\ M[] HHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#["A_U,?^Z/Y4^F0_ZF/_='\J?7CG.%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !6CH/_(4BK.K1T'_ )"D
M5<6,_@2_KJ>[D?\ R,*7S_\ 26>_>$_]2GTKMH/NBN)\)_ZE/I7;0?=%?,GZ
MV34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH
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M./Q"^#L'C7Q/XQT!M$TKQ)96!TII;B)Y+A%,KE]B,2JD2+C=C.>*_1^OS?\
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MGP^6O_/6;D_@.U>)CLZP67*U:I[W9:O[NGS/K,HX7S7.FGA:+Y?YGI'[WO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN8?],X$S(P]PN!W(H ]*HKGOA[XXTWXF>!?#_BW1Q,-)URPAU&T^T($D\J5
MZ;E!.#AAQFNAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#R;6O^0S?_\ 7Q)_Z$:*-:_Y#-__ -?$G_H1HH [/X?_ /(&F_Z^&_\ 05KI
MJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9)T-<]KW
M^I?Z5T,G0USVO?ZE_I0!\I_M.?\ (BZK_O1?^C4KX_K[ _:<_P"1%U7_ 'HO
M_1J5\?U]?D_\"7K^B/SGB/\ WN/^%?FPHHHKW#Y4**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_ /Z^)/\
MT(T4:U_R&;__ *^)/_0C10!V?P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7PW_H
M*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 445S?Q(\?:5\+/ /B
M'Q?KDC1:1H=C-?W)09<I&I8JH[L<8 [D@4 :VM:YIOAO3I=0U;4+72["+'F7
M5[,L,29.!EF( R2!^-7J_F^_:;_:N\<?M2?$"?Q#XCOYK73HI,Z7H=O,WV73
MHQ]T(O>3'WI"-S'T "C]Q/B=^TW;_#G]C4_&4B.>>X\.6FHV,+?=ENKJ*,0*
M1_=\R5<X_A#>E &K\;OVQO@_^SO>KI_CCQI::=J[*KC2K:.2ZNPIQAFBB5B@
M(.07P"!QFLWX/?MT_ _XZ:U#HOA3QW:2ZW,VR'3=0AELIYF_NQB95$A[X0D^
MU?SQ^)?$FJ>,?$&HZ[K=]-J>KZC.]U=WEPVZ2:5R2S$^I)JF/M&GSPR#S;:9
M=LL;\HP[JRG\B"* /ZHJ*^-O^"8?[5>I?M(?!6[TSQ/=F]\9^$Y8[.\NI&S)
M>6[J3;SO_MG9(C'G)CW$Y:OLF@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** &2=#7/:]_J7^E=#)T-<]KW^I?Z4 ?*?[3G_ "(NJ_[T
M7_HU*^/Z^P/VG/\ D1=5_P!Z+_T:E?']?7Y/_ EZ_HC\YXC_ -[C_A7YL***
M*]P^5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M7
MPE_R-6C?]?L/_HQ:RJU?"7_(U:-_U^P_^C%J9;,#ZPHHI,UY)SBT4TM43SA>
M] [$I:F-*%ZFJ,^H+&#DXKDM<^(VFZ9N19?M,P_Y9P\_F>E<>)Q=#"0]I7FH
MKS/3P.6XO,JGL<'2<Y>2O]_;U9V4MXJ]ZPM:\76.CJ3<W*HV,A,Y8_0#FO*]
M9^(FJ:H66%A91'M&<M_WU_ABN8>1I&+.Q=CR68Y)KX#'\94H7A@H<S[O1?=N
M_P #]DR?PPQ%6U3-*O(OY8ZOYO9?+F.[UKXJ3W&Y-/A\I?\ GK-RWX#H/UKB
M[[4KK4YO,NIY)W_VSP/H.U5JBENHXN"<M_=7DU\#7QV8YQ4Y)2<_);?<OS9^
MPX/*<EX9H^TIPC3M]J6[^;U^2^XEILDJ1C+,%JMYL]P<1KL'KWJY9^'Y;A@S
M DGN:^AP/"=>K:6*ERKLM7_DOQ/D<T\0L)A[PP$/:/N](_=N_P "FUXTAQ$F
M?]IJEATNXO&!<D_RKK=-\)DXRE=9IOA4+CY/TK]!P.383 _P8:]WJ_O_ ,C\
M;S;BC,,T;6)JOE_E6D?N6_SNSA=-\*LV,K76:9X3 QE/TKLK'0$CQ\OZ5LV^
MFK'CY:]Z-,^,J8ELYNP\-K&!\M;MKI*QX^6M6.V5>U3+&.PK912.*51R*L5F
M%[596,+T%2;:6J,KC0M.HHIDA1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !75> _\ C\/UKE:ZKP'_ ,?A^M>9F'\)
M>O\ F?6<-?[Y+_"_S1[YH'^I6NBCZ"N=T#_4K711]!7SY^F#Z*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZFM0!BZQ_J6^E?.GQX_P"1
M/U[_ *\I_P#T6U?1>L?ZEOI7SI\>/^1/U[_KRG_]%M6M+^)'U1A7_A3]'^1\
M+4445^C'XL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &KX2_Y&K1O^OV'_T8M?6%?)_A+_D:M&_Z_8?_ $8M?6%<.(W1G,**
M**Y3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* -WPC_R%!7OWAG_ %*_2O ?"/\ R%!7OWAG_4K]*^6Q7\:1^PY1_N-+T.LB
M^Z*DJ.+[HJ2N4]<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!&K+U/_ %9K4:LO4_\ 5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_.ROI<F_P"7
MGR_4^'XF_P"7/_;WZ!1117TQ\.%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'V%#_ *F/_='\J?3(?]3'_NC^5/KQSG"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K1T'_D*1
M5G5HZ#_R%(JXL9_ E_74]W(_^1A2^?\ Z2SW[PG_ *E/I7;0?=%<3X3_ -2G
MTKMH/NBOF3];)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M25'%]T5)7*>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C
M5EZG_JS6HU9>I_ZLT >+_$;_ %,OT-?G97Z)_$;_ %,OT-?G97TN3?\ +SY?
MJ?#\3?\ +G_M[] HHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#["A_P!3'_NC^5/ID/\ J8_]T?RI]>.<X4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:.@_\A2*L
MZM'0?^0I%7%C/X$OZZGNY'_R,*7S_P#26>_>$_\ 4I]*[:#[HKB?"?\ J4^E
M=M!]T5\R?K9-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!Y-K7_(9O_\ KXD_]"-%&M?\AF__ .OB3_T(T4 =
MG\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI::W2@"":3:*OZ%;
M;BEX6(D5\Q%3C:0>OUS6/>,0IIWA_P 1);3)8SAOWD@6)@,\DXP?QKY#B=8V
M67RC@;\UU>V_+UM^&W2Y]_P6\MAFL99G;DL[<WPJ6EK].^^E['7O(TC%G8LQ
MY+,<DTVDFW1<;"34 MKFZ;'*KZ+7XU@^',?BWS3CR+O+?[M_OL?T!F7&F4Y<
MN6E/VLNT=O\ P+;[K^@^2ZCCX)W-_=7FH?,GN#B-=@_6M?3_  PTF,K75:9X
M2Z92OT# \,X/"VE-<\O/;[MOON?D&;<=9ECKPI2]E#M'?YRW^ZQQ=GX?EN&W
M,"Q/<UTVF^$R<92NXT_PPJ8^7]*Z&ST5(\?+7U\*2BK):'YG6QDI-MN[.1TW
MPJ%QE/TKI;+0$CQ\OZ5O0V*KVQ5M(0O:NE0L>=*LY&=;Z:J 86KT=LJ]JL!*
M7%78YW(8L?M3]M+13)N%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ZKP'_ ,?A
M^M<K75> _P#C\/UKS,P_A+U_S/K.&O\ ?)?X7^:/?- _U*UT4?05SN@?ZE:Z
M*/H*^?/TP?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G
M4UJ ,76/]2WTKYT^/'_(GZ]_UY3_ /HMJ^B]8_U+?2OG3X\?\B?KW_7E/_Z+
M:M:7\2/JC"O_  I^C_(^%J***_1C\6"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#5\)?\C5HW_7[#_Z,6OK"OD_PE_R-6C?]
M?L/_ *,6OK"N'$;HSF%%%%<IF%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &[X1_Y"@KW[PS_ *E?I7@/A'_D*"O?O#/^I7Z5
M\MBOXTC]ARC_ '&EZ'61?=%25'%]T5)7*>N%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 C5EZG_ *LUJ-67J?\ JS0!XO\ $;_4R_0U^=E?
MHG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?^WOT"BBBOICX<**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_4Q_[H_E3Z9#_J
M8_\ ='\J?7CG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6CH/_ "%(JSJT=!_Y"D5<6,_@2_KJ>[D?_(PI?/\ ])9[]X3_
M -2GTKMH/NBN)\)_ZE/I7;0?=%?,GZV34444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-_91^%G[-MUJ]S\.?"W_  CLVK)''>M_:%U=>:L98H,3ROMP7;[N,YYKUN@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2=#7/:]_J
M7^E=#)T-<]KW^I?Z4 ?*?[3G_(BZK_O1?^C4KX_K[ _:<_Y$75?]Z+_T:E?'
M]?7Y/_ EZ_HC\YXC_P![C_A7YL****]P^5"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *1NE+10!1NH]RFJ&E:>9O$6F#'6ZB'_ (^*V9(]
MU6_#-H)/%&CC'6\A_P#0Q6-2-TS>%3E/37\*EY,[:TK'PF%(RGZ5Z NDIN^[
M^E6H=-5>U>,J93Q#.9L/#BQX^6MVUTE8\?+6I';*O:IUCK112.651R*L5FJ]
MJL+&%Z"I-M+5&5QH6G444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH U?"7_ "-6C?\ 7[#_
M .C%KZPKY/\ "7_(U:-_U^P_^C%KZPKAQ&Z,YA1117*9A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!N^$?\ D*"O?O#/^I7Z
M5X#X1_Y"@KW[PS_J5^E?+8K^-(_8<H_W&EZ'61?=%25'%]T5)7*>N%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >
M+_$;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?\ M[] HHHKZ8^'
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#["
MA_U,?^Z/Y4^F0_ZF/_='\J?7CG.%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !6CH/_(4BK.K1T'_ )"D5<6,_@2_KJ>[D?\
MR,*7S_\ 26>_>$_]2GTKMH/NBN)\)_ZE/I7;0?=%?,GZV34444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[7O\ 4O\ 2NADZ&N>
MU[_4O]* /E/]IS_D1=5_WHO_ $:E?']?8'[3G_(BZK_O1?\ HU*^/Z^OR?\
M@2]?T1^<\1_[W'_"OS84445[A\J%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %:GA-1_PE6C?]?L/_ *,6LNM7PE_R-6C?]?L/_HQ:
MF6S ^K?+]J7;3J*\DPN)BEHHH$%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %=5X#_ ./P_6N5KJO ?_'X?K7F9A_"7K_F?6<-?[Y+
M_"_S1[YH'^I6NBCZ"N=T#_4K711]!7SY^F#Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IK4ZFM0!BZQ_J6^E?.GQX_Y$_7O^O*?_T6U?1>
ML?ZEOI7SI\>/^1/U[_KRG_\ 1;5K2_B1]485_P"%/T?Y'PM1117Z,?BP4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :OA+_D:
MM&_Z_8?_ $8M?6%?)_A+_D:M&_Z_8?\ T8M?6%<.(W1G,****Y3,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -WPC_R%!7OW
MAG_4K]*\!\(_\A05[]X9_P!2OTKY;%?QI'[#E'^XTO0ZR+[HJ2HXONBI*Y3U
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:LO4_P#5FM1J
MR]3_ -6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_EY\OU/A^)O^7/_;WZ
M!1117TQ\.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'V%#_J8_\ ='\J?3(?]3'_ +H_E3Z\<YPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *T=!_P"0I%6=6CH/_(4BKBQG
M\"7]=3W<C_Y&%+Y_^DL]^\)_ZE/I7;0?=%<3X3_U*?2NV@^Z*^9/ULFHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!7SY^F#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZFM
M0!BZQ_J6^E?.GQX_Y$_7O^O*?_T6U?1>L?ZEOI7SI\>/^1/U[_KRG_\ 1;5K
M2_B1]485_P"%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 :OA+_D:M&_Z_8?_ $8M?6%?)_A+_D:M&_Z_
M8?\ T8M?6%<.(W1G,****Y3,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** -WPC_R%!7OWAG_4K]*\!\(_\A05[]X9_P!2OTKY
M;%?QI'[#E'^XTO0ZR+[HJ2HXONBI*Y3UPHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** $:LO4_P#5FM1JR]3_ -6: /%_B-_J9?H:_.ROT3^(
MW^IE^AK\[*^ER;_EY\OU/A^)O^7/_;WZ!1117TQ\.%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'V%#_J8_\ ='\J?3(?]3'_
M +H_E3Z\<YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *T=!_P"0I%6=6CH/_(4BKBQG\"7]=3W<C_Y&%+Y_^DL]^\)_ZE/I
M7;0?=%<3X3_U*?2NV@^Z*^9/ULFHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_P#U\2?^A&BC6O\
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ME?#_ .UW\+_B%\._CEXKO/B%X=N]"U#Q!JMYJL$DI62&Y66=G+12H2C@;QD
MY&0"!TK[@_X(:_\ (5^,G_7'2?\ T*\KV_\ X+*+HG_#*NGOJ$<3:M_PD-LF
MF.0/,5S'*9,=]IC5LX[[<]J ,;_@CY^T;J'Q*^%>M_#K7[V:^U3PBT;Z?/<,
M79M/ER%CR>OE.K 9Z*Z <+7Z$U^,7_!$^:Y7]H[QG"A_T-O"<KR#_IH+RU"?
MHTE?L[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)
M.AKGM>_U+_2NADZ&N>U[_4O]* /E/]IS_D1=5_WHO_1J5\?U]@?M.?\ (BZK
M_O1?^C4KX_KZ_)_X$O7]$?G/$?\ O<?\*_-A1117N'RH4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5J^$O^1JT;_K]A_]&+656KX2
M_P"1JT;_ *_8?_1BU,MF!]84445Y)SA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5U7@/_C\/UKE:ZKP'_Q^'ZUYF8?PEZ_Y
MGUG#7^^2_P +_-'OF@?ZE:Z*/H*YW0/]2M=%'T%?/GZ8/HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_D3]>_Z
M\I__ $6U?1>L?ZEOI7SI\>/^1/U[_KRG_P#1;5K2_B1]485_X4_1_D?"U%%%
M?HQ^+!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!J^$O^1JT;_K]A_P#1BU]85\G^$O\ D:M&_P"OV'_T8M?6%<.(W1G,****
MY3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-WPC_P A05[]X9_U*_2O ?"/_(4%>_>&?]2OTKY;%?QI'[#E'^XTO0ZR+[HJ
M2HXONBI*Y3UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:
MLO4_]6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_.ROI<F_Y>?+]3X?B
M;_ES_P!O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 9)T-<]KW^I?Z5T,G0USVO?ZE_I0!\I_M.?\B+JO\ O1?^
MC4KX_K[ _:<_Y$75?]Z+_P!&I7Q_7U^3_P "7K^B/SGB/_>X_P"%?FPHHHKW
M#Y4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U?"7
M_(U:-_U^P_\ HQ:RJU?"7_(U:-_U^P_^C%J9;,#ZPHHHKR3G"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJO ?_ !^'ZURM
M=5X#_P"/P_6O,S#^$O7_ #/K.&O]\E_A?YH]\T#_ %*UT4?05SN@?ZE:Z*/H
M*^?/TP?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ
M ,76/]2WTKYT^/'_ ")^O?\ 7E/_ .BVKZ+UC_4M]*^=/CQ_R)^O?]>4_P#Z
M+:M:7\2/JC"O_"GZ/\CX6HHHK]&/Q8**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** -7PE_R-6C?]?L/_HQ:^L*^3_"7_(U:-_U
M^P_^C%KZPKAQ&Z,YA1117*9A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!N^$?^0H*]^\,_ZE?I7@/A'_ )"@KW[PS_J5^E?+
M8K^-(_8<H_W&EZ'61?=%25'%]T5)7*>N%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$;_ %,OT-?G97Z)_$;_
M %,OT-?G97TN3?\ +SY?J?#\3?\ +G_M[] HHHKZ8^'"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#["A_P!3'_NC^5/ID/\
MJ8_]T?RI]>.<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %:.@_\A2*LZM'0?^0I%7%C/X$OZZGNY'_R,*7S_P#26>_>$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% #).AKGM>_U+_2NADZ&N>U[_4O]* /E/]IS_D1=5_WHO_1J
M5\?U]@?M.?\ (BZK_O1?^C4KX_KZ_)_X$O7]$?G/$?\ O<?\*_-A1117N'RH
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J^$O^1J
MT;_K]A_]&+656KX2_P"1JT;_ *_8?_1BU,MF!]84445Y)SA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5U7@/_C\/UKE:ZKP
M'_Q^'ZUYF8?PEZ_YGUG#7^^2_P +_-'OF@?ZE:Z*/H*YW0/]2M=%'T%?/GZ8
M/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^
MI;Z5\Z?'C_D3]>_Z\I__ $6U?1>L?ZEOI7SI\>/^1/U[_KRG_P#1;5K2_B1]
M485_X4_1_D?"U%%%?HQ^+!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!J^$O^1JT;_K]A_P#1BU]85\G^$O\ D:M&_P"OV'_T
M8M?6%<.(W1G,****Y3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** -WPC_P A05[]X9_U*_2O ?"/_(4%>_>&?]2OTKY;%?QI
M'[#E'^XTO0ZR+[HJ2HXONBI*Y3UPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** $:LO4_]6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_
M.ROI<F_Y>?+]3X?B;_ES_P!O?H%%%%?3'PX4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?84/^IC_ -T?RI],A_U,?^Z/Y4^O
M'.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"M'0?^0I%6=6CH/_ "%(JXL9_ E_74]W(_\ D84OG_Z2SW[PG_J4^E=M!]T5
MQ/A/_4I]*[:#[HKYD_6R:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]#
M7YV5]+DW_+SY?J?#\3?\N?\ M[] HHHKZ8^'"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#["A_U,?^Z/Y4^F0_ZF/_='\J?7
MCG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6CH/_(4BK.K1T'_ )"D5<6,_@2_KJ>[D?\ R,*7S_\ 26>_>$_]2GTKMH/N
MBN)\)_ZE/I7;0?=%?,GZV34444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !114%[>P:;9SW=U,EO:V\;2R
MS2,%5$499B3T  )H XKXJ_';X?\ P/M].F\>>+-.\+QZ@SI:?;Y"IF* %]H
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M<\CD5_+%#I-]<:;=:C%9W$MA:R1Q7%TD3&*)Y-QC5VQA2VQ\ ]=K8Z&OK_\
M8-_X* >)OV<?&&D>&O%.KW6J?"NZE\BXLK@F4Z6&.!/;D_,JJ3EHQ\I!8@;L
M&@#]WZ*9%*DT:21NLD;@,KJ<A@>A!]*Y#XS>-1\-_A#XV\5E]AT71;S4%/\
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M@ HHHH **** /)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\
MR!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *^=?^"AW_)EOQ5_[!B_^CXJ^BJI:UHFG>(]+N--U:PM=
M4TZX7;-9WL*S0RKG.&1@01D#J.U '\LE%?TT?\,]_"S_ *)IX/\ _!#:_P#Q
MNC_AGOX6?]$T\'_^"&U_^-T ?S+T5_31_P ,]_"S_HFG@_\ \$-K_P#&Z/\
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M7/B/J!7+P:'#;AO027 8C_R$/RK]@Z /Y;?%WAF[\%^+-:\/:@ +_2;V:PN
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M5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M7PE_R
M-6C?]?L/_HQ:RJU?"7_(U:-_U^P_^C%J9;,#ZPHHHKR3G"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KJO ?_'X?K7*UU7@/
M_C\/UKS,P_A+U_S/K.&O]\E_A?YH]\T#_4K711]!7.Z!_J5KHH^@KY\_3!]%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=36H Q=8_P!2
MWTKYT^/'_(GZ]_UY3_\ HMJ^B]8_U+?2OG3X\?\ (GZ]_P!>4_\ Z+:M:7\2
M/JC"O_"GZ/\ (^%J***_1C\6"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#5\)?\ (U:-_P!?L/\ Z,6OK"OD_P )?\C5HW_7
M[#_Z,6OK"N'$;HSF%%%%<IF%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &[X1_P"0H*]^\,_ZE?I7@/A'_D*"O?O#/^I7Z5\M
MBOXTC]ARC_<:7H=9%]T5)4<7W14E<IZX4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\1O]3+]#7YV5^B?Q&_U,
MOT-?G97TN3?\O/E^I\/Q-_RY_P"WOT"BBBOICX<**** "BBB@ HHHH ****
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M6/&=YK/BC3O$*Z]!:PQ+8P21F(Q-*26W=<^8.GI7V90 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!E^*/"^D>-O#VH:%KVFVVKZ-J$+07
M5C>1B2*9#U5E/^1UK\N_VKO^"06B^']#\2>-OAAXG.D:=IMG<:E/X>UL/,BI
M$C2,L%PN7 VJ0%=6.>KUZK\2?^"R'P]\!^)M:\/P> /%EYJFDWDUA<QWAMK9
M1-$[(XRLDAQN7'3IV[5[-X<_:.TC]J;]B'QWX[TBR;2C-H&LVEUIDDXFDM)H
M[>4;&8 9RA1QP.)!0!^!FB>#=?\ $NFZIJ&D:+J&J6.E1K+?W%E;/,EHC9"O
M*5!V*2I^9L"M#X:_$[Q/\'_&6G^*O"&L7.AZY8N'BN;9\9&02CKT=&QAD8$$
M<$5^A?\ P1 4/X]^*BL RG2[($'H?WLE?,W_  4@^&?AWX4_M>>,M&\+6T-A
MI4PMK_[!;J%CM9)H4D=%4 !5W,6"C@!P!P* /VP_9/\ C[;?M,? ?PUX\C@C
ML[V\C:#4+.,DK!=QL4E49YVDC<N>=KKGFOQC_P""IELT'[='Q&<])DTV1?I_
M9ULO\U-??/\ P16:Y/[+_B@2EC;CQ=<B'=_UYV>['MG]<^]?(/\ P6.\(MH/
M[65MJPC80ZYX?M+KS,<&2-Y8&'U"Q)_WT* /2/\ @A_(H^(GQ1C)^=M*LV ]
MA,^?YBOUWK\6_P#@BUXIM])_:1\3Z+/*L;ZMX;E, 8_ZR2*>%MH]3L,C?137
M[24 ?SD_MRR+-^U]\7&0[A_PD-TOXAL']17WM_P0YM77PO\ %RY);9)>:;&!
MGC*I<$\?\"'Z5^;?[1WBJ#QQ^T%\2_$%K()K/4_$FHW5NX.08GN9#'S_ +I6
MOUD_X(O^#6T7]FKQ#K\L9277/$,OEL1]^&&&)%/_ '\,P_"@#] **** ./\
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MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_
MZ!4?_?7_ -E7344 <M)JWB+!_P")5'_WU_\ 95@:[JOB#R7SI<8X_O?_ &5>
MBR=#7/:]_J7^E 'QY^T9>ZI-X.U);JR2&(M%N8'I^]7W]:^5J^P/VG/^1%U7
M_>B_]&I7Q_7U^3_P)>OZ(_.>(_\ >X_X5^;"BBBO</E0HHHH **** "BBB@
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M !*H_P#OK_[*I- _U*UT4?05\^?IASG]K>(O^@5'_P!]?_94?VMXB_Z!4?\
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M*^=/CQ_R)^O?]>4__HMJUI?Q(^J,*_\ "GZ/\CX6HHHK]&/Q8**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -7PE_R-6C?]?L/
M_HQ:^L*^3_"7_(U:-_U^P_\ HQ:^L*X<1NC.84445RF84444 %%%% !1110
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MH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^^O\
M[*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\ OK_[
M*NFHH YG^UO$7_0*C_[Z_P#LJ/[6\1?] J/_ +Z_^RKIJ* .9_M;Q%_T"H_^
M^O\ [*C^UO$7_0*C_P"^O_LJZ:B@#F?[6\1?] J/_OK_ .RH_M;Q%_T"H_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_4Q_[H_E3Z9#_J8_\
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M#SPYJ5]I]C\//%MS?6<KP2PZDUK:E9$)5E.R27&&&/\ .*]A\8?'C2?VE?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\.O^"KW[,^H?"?X]7WQ
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MO7X@_#+PG\5]#CT;QEX=T[Q-I4<ZW*6>J6ZS1+*JLJN%88W .PS_ +1KSO\
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MO"R3V"VWD^4TA!!$C9SYGMTKZJH **** "BBB@ HHHH **** "BBB@ HHHH
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MN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_JS6HU9
M>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?\ M[]
MHHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#["A_U,?^Z/Y4^F0_ZF/_='\J?7CG.%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.YP% Y))["@#\)_^"MWC0>+/VRM9L5?>GA[2K'2@1T&8S<D?@UR1]<U]4_\
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M&('4 B@#^>[]F_\ 9]\1?M.?%;3O OAJ6VM;RX1[B>\O"PBMH$ +R-M!)Z@
M#J6 XSD?I3I__!$'P?';PB^^)^N7$X \U[?3H8E;UV@LQ7\2:^,OV2_B)>_L
M)_MB1#XC:7=:3%:^?HFMQ&,M);Q2[2LZ@??0,L3Y7.Y,E<Y%?N[X+^('AGXC
M:/%JOA;Q!IOB+3I5#+<Z9=).F#ZE2<'V/- 'P5_PY+^%G_0]>,/^^K7_ .,T
M?\.2_A9_T/7C#_OJU_\ C-?HK10!\V?LC_L+^$_V/=1\2WGAK7]:UI]=B@BG
M753#B,1%RI7RT7KYASG/05])T44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %8_C+PO:^./"&N>'+Z2:*QUBQGT^>2W8+(L<L;1L4)!
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ZKP'_ ,?A^M<K75>
M_P#C\/UKS,P_A+U_S/K.&O\ ?)?X7^:/?- _U*UT4?05SN@?ZE:Z*/H*^?/T
MP?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ ,76/
M]2WTKYT^/'_(GZ]_UY3_ /HMJ^B]8_U+?2OG3X\?\B?KW_7E/_Z+:M:7\2/J
MC"O_  I^C_(^%J***_1C\6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#5\)?\C5HW_7[#_Z,6OK"OD_PE_R-6C?]?L/_ *,6
MOK"N'$;HSF%%%%<IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[PKXCNY;[Q-X+>&U-Y.VY[FRD#?9V8]69?+DC)]%0DDL:^X: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9)T-<]KW^I?Z5T,G0USV
MO?ZE_I0!\I_M.?\ (BZK_O1?^C4KX_K[ _:<_P"1%U7_ 'HO_1J5\?U]?D_\
M"7K^B/SGB/\ WN/^%?FPHHHKW#Y4**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *U?"7_(U:-_U^P_^C%K*K5\)?\C5HW_7[#_Z,6IE
MLP/K"BBBO).<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "NJ\!_\?A^M<K75> _^/P_6O,S#^$O7_,^LX:_WR7^%_FCWS0/]
M2M=%'T%<[H'^I6NBCZ"OGS],'T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !36IU-:@#%UC_ %+?2OG3X\?\B?KW_7E/_P"BVKZ+UC_4M]*^
M=/CQ_P B?KW_ %Y3_P#HMJUI?Q(^J,*_\*?H_P CX6HHHK]&/Q8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -7PE_P C5HW_
M %^P_P#HQ:^L*^3_  E_R-6C?]?L/_HQ:^L*X<1NC.84445RF84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;OA'_ )"@KW[P
MS_J5^E> ^$?^0H*]^\,_ZE?I7RV*_C2/V'*/]QI>AUD7W14E1Q?=%25RGKA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ-67J?
M^K- 'B_Q&_U,OT-?G97Z)_$;_4R_0U^=E?2Y-_R\^7ZGP_$W_+G_ +>_0***
M*^F/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ^PH?]3'_NC^5/ID/^IC_W1_*GUXYSA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5HZ#_R%(JSJT=!_P"0I%7%C/X$OZZG
MNY'_ ,C"E\__ $EGOWA/_4I]*[:#[HKB?"?^I3Z5VT'W17S)^MDU%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'DVM?\AF_P#^OB3_ -"-%&M?\AF__P"OB3_T(T4 =G\/_P#D#3?]?#?^@K73
M5S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444
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M &2=#7/:]_J7^E=#)T-<]KW^I?Z4 ?*?[3G_ "(NJ_[T7_HU*^/Z^P/VG/\
MD1=5_P!Z+_T:E?']?7Y/_ EZ_HC\YXC_ -[C_A7YL****]P^5"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M7PE_R-6C?]?L/_HQ:
MRJU?"7_(U:-_U^P_^C%J9;,#ZPHHHKR3G"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KJO ?_'X?K7*UU7@/_C\/UKS,P_A+
MU_S/K.&O]\E_A?YH]\T#_4K711]!7.Z!_J5KHH^@KY\_3!]%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4UJ=36H Q=8_P!2WTKYT^/'_(GZ
M]_UY3_\ HMJ^B]8_U+?2OG3X\?\ (GZ]_P!>4_\ Z+:M:7\2/JC"O_"GZ/\
M(^%J***_1C\6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#5\)?\ (U:-_P!?L/\ Z,6OK"OD_P )?\C5HW_7[#_Z,6OK"N'$
M;HSF%%%%<IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% &[X1_P"0H*]^\,_ZE?I7@/A'_D*"O?O#/^I7Z5\MBOXTC]ARC_<:
M7H=9%]T5)4<7W14E<IZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% "-67J?^K-:C5EZG_JS0!XO\1O]3+]#7YV5^B?Q&_U,OT-?G97TN3?\
MO/E^I\/Q-_RY_P"WOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /L*'_4Q_[H_E3Z9#_J8_]T?RI]>.<X4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:.@_\A2*
MLZM'0?\ D*15Q8S^!+^NI[N1_P#(PI?/_P!)9[]X3_U*?2NV@^Z*XGPG_J4^
ME=M!]T5\R?K9-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y-K7_(9O\ _KXD_P#0C11K7_(9O_\ KXD_]"-%
M '9_#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[7O\ 4O\ 2NAD
MZ&N>U[_4O]* /E/]IS_D1=5_WHO_ $:E?']?8'[3G_(BZK_O1?\ HU*^/Z^O
MR?\ @2]?T1^<\1_[W'_"OS84445[A\J%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %:OA+_D:M&_Z_8?\ T8M95:OA+_D:M&_Z_8?_
M $8M3+9@?6%%%%>2<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %=5X#_P"/P_6N5KJO ?\ Q^'ZUYF8?PEZ_P"9]9PU_ODO
M\+_-'OF@?ZE:Z*/H*YW0/]2M=%'T%?/GZ8/HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_ )$_7O\ KRG_ /1;
M5]%ZQ_J6^E?.GQX_Y$_7O^O*?_T6U:TOXD?5&%?^%/T?Y'PM1117Z,?BP444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :OA+_D
M:M&_Z_8?_1BU]85\G^$O^1JT;_K]A_\ 1BU]85PXC=&<PHHHKE,PHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH W?"/_(4%>_>
M&?\ 4K]*\!\(_P#(4%>_>&?]2OTKY;%?QI'[#E'^XTO0ZR+[HJ2HXONBI*Y3
MUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:LO4_\ 5FM1
MJR]3_P!6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_ )>?+]3X?B;_ )<_
M]O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?84/\ J8_]T?RI],A_U,?^Z/Y4^O'.<**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "M'0?^0I%6=6CH/_(4BKBQ
MG\"7]=3W<C_Y&%+Y_P#I+/?O"?\ J4^E=M!]T5Q/A/\ U*?2NV@^Z*^9/ULF
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_ /R!IO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%%>2<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %=5X#_X_#]:Y6NJ\!_\ 'X?K7F9A_"7K_F?6<-?[Y+_"_P T>^:!_J5K
MHH^@KG= _P!2M=%'T%?/GZ8/HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,?+([,)YAGU4)!_W\K]8: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ;OA'_D*"O?O#/^I7Z5X#X1_Y"@KW[PS_ *E?I7RV*_C2
M/V'*/]QI>AUD7W14E1Q?=%25RGKA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 (U9>I_ZLUJ-67J?^K- 'B_Q&_U,OT-?G97Z)_$;_4R_0U^
M=E?2Y-_R\^7ZGP_$W_+G_M[] HHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#["A_U,?\ NC^5/ID/^IC_ -T?RI]>
M.<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%:.@_P#(4BK.K1T'_D*15Q8S^!+^NI[N1_\ (PI?/_TEGOWA/_4I]*[:#[HK
MB?"?^I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'DVM?\ (9O_ /KXD_\ 0C11K7_(9O\
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M1110 4UJ=36H Q=8_P!2WTKYT^/'_(GZ]_UY3_\ HMJ^B]8_U+?2OG3X\?\
M(GZ]_P!>4_\ Z+:M:7\2/JC"O_"GZ/\ (^%J***_1C\6"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#5\)?\ (U:-_P!?L/\
MZ,6OK"OD_P )?\C5HW_7[#_Z,6OK"N'$;HSF%%%%<IF%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% &[X1_P"0H*]^\,_ZE?I7
M@/A'_D*"O?O#/^I7Z5\MBOXTC]ARC_<:7H=9%]T5)4<7W14E<IZX4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "-67J?^K-:C5EZG_JS0!XO
M\1O]3+]#7YV5^B?Q&_U,OT-?G97TN3?\O/E^I\/Q-_RY_P"WOT"BBBOICX<*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L*'
M_4Q_[H_E3Z9#_J8_]T?RI]>.<X4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %:.@_\A2*LZM'0?\ D*15Q8S^!+^NI[N1_P#(
MPI?/_P!)9[]X3_U*?2NV@^Z*XGPG_J4^E=M!]T5\R?K9-1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(
M9O\ _KXD_P#0C11K7_(9O_\ KXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\
M_D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #).AKGM>_U+_2NADZ&N>U[_ %+_ $H ^4_VG/\ D1=5_P!Z+_T:E?']
M?8'[3G_(BZK_ +T7_HU*^/Z^OR?^!+U_1'YSQ'_O<?\ "OS84445[A\J%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:OA+_D:M&_Z
M_8?_ $8M95:OA+_D:M&_Z_8?_1BU,MF!]84445Y)SA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5U7@/_C\/UKE:ZKP'_P ?
MA^M>9F'\)>O^9]9PU_ODO\+_ #1[YH'^I6NBCZ"N=T#_ %*UT4?05\^?I@^B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.IK4 8NL?ZEO
MI7SI\>/^1/U[_KRG_P#1;5]%ZQ_J6^E?.GQX_P"1/U[_ *\I_P#T6U:TOXD?
M5&%?^%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 :OA+_ )&K1O\ K]A_]&+7UA7R?X2_Y&K1O^OV'_T8
MM?6%<.(W1G,****Y3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** -WPC_ ,A05[]X9_U*_2O ?"/_ "%!7OWAG_4K]*^6Q7\:
M1^PY1_N-+T.LB^Z*DJ.+[HJ2N4]<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!&K+U/_5FM1JR]3_U9H \7^(W^IE^AK\[*_1/XC?ZF7Z&O
MSLKZ7)O^7GR_4^'XF_Y<_P#;WZ!1117TQ\.%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'V%#_J8_]T?RI],A_P!3'_NC^5/K
MQSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K1T'_D*15G5HZ#_ ,A2*N+&?P)?UU/=R/\ Y&%+Y_\ I+/?O"?^I3Z5VT'W
M17$^$_\ 4I]*[:#[HKYD_6R:BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_\ 7Q)_Z$:*-:_Y#-__
M -?$G_H1HH [/X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2=#7/:]_J7^E=#)
MT-<]KW^I?Z4 ?*?[3G_(BZK_ +T7_HU*^/Z^P/VG/^1%U7_>B_\ 1J5\?U]?
MD_\  EZ_HC\YXC_WN/\ A7YL****]P^5"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "M7PE_R-6C?]?L/_ *,6LJM7PE_R-6C?]?L/
M_HQ:F6S ^L****\DYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ-6
M7J?^K- 'B_Q&_P!3+]#7YV5^B?Q&_P!3+]#7YV5]+DW_ "\^7ZGP_$W_ "Y_
M[>_0****^F/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^PH?\ 4Q_[H_E3Z9#_ *F/_='\J?7CG.%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6CH/_(4BK.K1T'_D*15Q
M8S^!+^NI[N1_\C"E\_\ TEGOWA/_ %*?2NV@^Z*XGPG_ *E/I7;0?=%?,GZV
M34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 >3:U_R&;__ *^)/_0C11K7_(9O_P#KXD_]"-% '9_#_P#Y TW_
M %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ,DZ&N>U[_ %+_ $KH9.AKGM>_U+_2@#Y3_:<_
MY$75?]Z+_P!&I7Q_7V!^TY_R(NJ_[T7_ *-2OC^OK\G_ ($O7]$?G/$?^]Q_
MPK\V%%%%>X?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6KX2_Y&K1O^OV'_ -&+656KX2_Y&K1O^OV'_P!&+4RV8'UA1117DG.%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !75>
M _\ C\/UKE:ZKP'_ ,?A^M>9F'\)>O\ F?6<-?[Y+_"_S1[YH'^I6NBCZ"N=
MT#_4K711]!7SY^F#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ IK4ZFM0!BZQ_J6^E?.GQX_P"1/U[_ *\I_P#T6U?1>L?ZEOI7SI\>/^1/
MU[_KRG_]%M6M+^)'U1A7_A3]'^1\+4445^C'XL%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &KX2_Y&K1O^OV'_T8M?6%?)_A
M+_D:M&_Z_8?_ $8M?6%<.(W1G,****Y3,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** -WPC_R%!7OWAG_ %*_2O ?"/\ R%!7
MOWAG_4K]*^6Q7\:1^PY1_N-+T.LB^Z*DJ.+[HJ2N4]<**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!&K+U/_ %9K4:LO4_\ 5F@#Q?XC?ZF7
MZ&OSLK]$_B-_J9?H:_.ROI<F_P"7GR_4^'XF_P"7/_;WZ!1117TQ\.%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'V%#_ *F/
M_='\J?3(?]3'_NC^5/KQSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K1T'_D*15G5HZ#_R%(JXL9_ E_74]W(_^1A2^?\
MZ2SW[PG_ *E/I7;0?=%<3X3_ -2GTKMH/NBOF3];)J*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=36H Q=8_U+?2O
MG3X\?\B?KW_7E/\ ^BVKZ+UC_4M]*^=/CQ_R)^O?]>4__HMJUI?Q(^J,*_\
M"GZ/\CX6HHHK]&/Q8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** -7PE_R-6C?]?L/_HQ:^L*^3_"7_(U:-_U^P_\ HQ:^L*X<
M1NC.84445RF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ;OA'_D*"O?O#/\ J5^E> ^$?^0H*]^\,_ZE?I7RV*_C2/V'*/\
M<:7H=9%]T5)4<7W14E<IZX4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% "-67J?\ JS6HU9>I_P"K- 'B_P 1O]3+]#7YV5^B?Q&_U,OT-?G9
M7TN3?\O/E^I\/Q-_RY_[>_0****^F/APHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^PH?]3'_NC^5/ID/^IC_P!T?RI]>.<X
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:.
M@_\ (4BK.K1T'_D*15Q8S^!+^NI[N1_\C"E\_P#TEGOWA/\ U*?2NV@^Z*XG
MPG_J4^E=M!]T5\R?K9-1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y-K7_(9O_P#KXD_]"-%&M?\ (9O_ /KX
MD_\ 0C10!V?P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKG
MM>_U+_2@#Y3_ &G/^1%U7_>B_P#1J5\?U]@?M.?\B+JO^]%_Z-2OC^OK\G_@
M2]?T1^<\1_[W'_"OS84445[A\J%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %:OA+_ )&K1O\ K]A_]&+656KX2_Y&K1O^OV'_ -&+
M4RV8'UA1117DG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !75> _P#C\/UKE:ZKP'_Q^'ZUYF8?PEZ_YGUG#7^^2_PO\T>^
M:!_J5KHH^@KG= _U*UT4?05\^?I@^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *:U.IK4 8NL?ZEOI7SI\>/^1/U[_KRG_]%M7T7K'^I;Z5
M\Z?'C_D3]>_Z\I__ $6U:TOXD?5&%?\ A3]'^1\+4445^C'XL%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &KX2_Y&K1O^OV'
M_P!&+7UA7R?X2_Y&K1O^OV'_ -&+7UA7#B-T9S"BBBN4S"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M
M:_Y#-_\ ]?$G_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__ "!IO^OAO_05KIJY
MGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K5\)?\C5HW_7
M[#_Z,6LJM7PE_P C5HW_ %^P_P#HQ:F6S ^L****\DYPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ZKP'_Q^'ZURM=5X#_X
M_#]:\S,/X2]?\SZSAK_?)?X7^:/?- _U*UT4?05SN@?ZE:Z*/H*^?/TP?111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ ,76/]2WTK
MYT^/'_(GZ]_UY3_^BVKZ+UC_ %+?2OG3X\?\B?KW_7E/_P"BVK6E_$CZHPK_
M ,*?H_R/A:BBBOT8_%@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH U?"7_(U:-_U^P_\ HQ:^L*^3_"7_ "-6C?\ 7[#_ .C%
MKZPKAQ&Z,YA1117*9A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!N^$?^0H*]^\,_ZE?I7@/A'_D*"O?O#/\ J5^E?+8K^-(_
M8<H_W&EZ'61?=%25'%]T5)7*>N%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]#7YV
M5]+DW_+SY?J?#\3?\N?^WOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /L*'_4Q_P"Z/Y4^F0_ZF/\ W1_*GUXY
MSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MHZ#_ ,A2*LZM'0?^0I%7%C/X$OZZGNY'_P C"E\__26>_>$_]2GTKMH/NBN)
M\)_ZE/I7;0?=%?,GZV34444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >3:U_P AF_\ ^OB3_P!"-%&M?\AF_P#^
MOB3_ -"-% '9_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_4O]*Z&
M3H:Y[7O]2_TH ^4_VG/^1%U7_>B_]&I7Q_7V!^TY_P B+JO^]%_Z-2OC^OK\
MG_@2]?T1^<\1_P"]Q_PK\V%%%%>X?*A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6KX2_Y&K1O^OV'_T8M95:OA+_ )&K1O\ K]A_
M]&+4RV8'UA1117DG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !75> _^/P_6N5KJO ?_'X?K7F9A_"7K_F?6<-?[Y+_  O\
MT>^:!_J5KHH^@KG= _U*UT4?05\^?I@^BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *:U.IK4 8NL?ZEOI7SI\>/^1/U[_KRG_\ 1;5]%ZQ_
MJ6^E?.GQX_Y$_7O^O*?_ -%M6M+^)'U1A7_A3]'^1\+4445^C'XL%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &KX2_Y&K1O^
MOV'_ -&+7UA7R?X2_P"1JT;_ *_8?_1BU]85PXC=&<PHHHKE,PHHHH ****
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M10!]A0_ZF/\ W1_*GTR'_4Q_[H_E3Z\<YPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *T=!_Y"D59U:.@_\ (4BKBQG\"7]=
M3W<C_P"1A2^?_I+/?O"?^I3Z5VT'W17$^$_]2GTKMH/NBOF3];)J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05K
MIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 9)T-<]KW^I?Z5T,G0USVO?ZE_I0!\I_M.?\ (BZK_O1?
M^C4KX_K[ _:<_P"1%U7_ 'HO_1J5\?U]?D_\"7K^B/SGB/\ WN/^%?FPHHHK
MW#Y4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U?"
M7_(U:-_U^P_^C%K*K5\)?\C5HW_7[#_Z,6IELP/K"BBBO).<**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NJ\!_\?A^M<K75
M> _^/P_6O,S#^$O7_,^LX:_WR7^%_FCWS0/]2M=%'T%<[H'^I6NBCZ"OGS],
M'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36IU-:@#%UC_
M %+?2OG3X\?\B?KW_7E/_P"BVKZ+UC_4M]*^=/CQ_P B?KW_ %Y3_P#HMJUI
M?Q(^J,*_\*?H_P CX6HHHK]&/Q8**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** -7PE_P C5HW_ %^P_P#HQ:^L*^3_  E_R-6C
M?]?L/_HQ:^L*X<1NC.84445RF84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ;OA'_ )"@KW[PS_J5^E> ^$?^0H*]^\,_ZE?I
M7RV*_C2/V'*/]QI>AUD7W14E1Q?=%25RGKA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 (U9>I_ZLUJ-67J?^K- 'B_Q&_U,OT-?G97Z)_$;
M_4R_0U^=E?2Y-_R\^7ZGP_$W_+G_ +>_0****^F/APHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^PH?]3'_NC^5/ID/^IC_W
M1_*GUXYSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5HZ#_R%(JSJT=!_P"0I%7%C/X$OZZGNY'_ ,C"E\__ $EGOWA/_4I]
M*[:#[HKB?"?^I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?
M\AF__P"OB3_T(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_4O]
M*Z&3H:Y[7O\ 4O\ 2@#Y3_:<_P"1%U7_ 'HO_1J5\?U]@?M.?\B+JO\ O1?^
MC4KX_KZ_)_X$O7]$?G/$?^]Q_P *_-A1117N'RH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5J^$O^1JT;_K]A_\ 1BUE5J^$O^1J
MT;_K]A_]&+4RV8'UA1117DG.%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_ES_ -O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ?84/^IC_W1_*GTR'_ %,?^Z/Y4^O'.<**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M'0?^0I%6=6CH/\
MR%(JXL9_ E_74]W(_P#D84OG_P"DL]^\)_ZE/I7;0?=%<3X3_P!2GTKMH/NB
MOF3];)J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /)M:_Y#-__P!?$G_H1HHUK_D,W_\ U\2?^A&B@#L_A_\
M\@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKW[PS_J5^E?+8K^-(_8<H_W&EZ'61?=%25'%]T5)7*>N%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$;_ %,O
MT-?G97Z)_$;_ %,OT-?G97TN3?\ +SY?J?#\3?\ +G_M[] HHHKZ8^'"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#["A_P!3
M'_NC^5/ID/\ J8_]T?RI]>.<X4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %:.@_\A2*LZM'0?^0I%7%C/X$OZZGNY'_R,*7S
M_P#26>_>$_\ 4I]*[:#[HKB?"?\ J4^E=M!]T5\R?K9-1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9
MO_\ KXD_]"-%&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\ 7PW_ *"M=-7,_#__
M ) TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 R3H:Y[7O\ 4O\ 2NADZ&N>U[_4O]* /E/]IS_D1=5_WHO_ $:E?']?
M8'[3G_(BZK_O1?\ HU*^/Z^OR?\ @2]?T1^<\1_[W'_"OS84445[A\J%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:OA+_D:M&_Z_
M8?\ T8M95:OA+_D:M&_Z_8?_ $8M3+9@?6%%%%>2<X4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %=5X#_P"/P_6N5KJO ?\
MQ^'ZUYF8?PEZ_P"9]9PU_ODO\+_-'OF@?ZE:Z*/H*YW0/]2M=%'T%?/GZ8/H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^I;
MZ5\Z?'C_ )$_7O\ KRG_ /1;5]%ZQ_J6^E?.GQX_Y$_7O^O*?_T6U:TOXD?5
M&%?^%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 :OA+_D:M&_Z_8?_1BU]85\G^$O^1JT;_K]A_\ 1BU]
M85PXC=&<PHHHKE,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH W?"/_(4%>_>&?\ 4K]*\!\(_P#(4%>_>&?]2OTKY;%?QI'[
M#E'^XTO0ZR+[HJ2HXONBI*Y3UPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** $:LO4_\ 5FM1JR]3_P!6: /%_B-_J9?H:_.ROT3^(W^IE^AK
M\[*^ER;_ )>?+]3X?B;_ )<_]O?H%%%%?3'PX4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?84/\ J8_]T?RI],A_U,?^Z/Y4
M^O'.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "M'0?^0I%6=6CH/_(4BKBQG\"7]=3W<C_Y&%+Y_P#I+/?O"?\ J4^E=M!]
MT5Q/A/\ U*?2NV@^Z*^9/ULFHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_U+_2@#Y3_:<_Y$75?]Z+_T
M:E?']?8'[3G_ "(NJ_[T7_HU*^/Z^OR?^!+U_1'YSQ'_ +W'_"OS84445[A\
MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?5&%?^%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC/OL_ U\%_!OX3:_\<_B;X?\#>&84EUG6;CR8C*=L<2@%I)7/94168XR<*<
MG K[X^,7_!&35O _PJU#Q!X5\=MXH\1Z9:M=3Z1+IH@2Z"*6=86$C$-@':K
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M -&+656KX2_Y&K1O^OV'_P!&+4RV8'UA1117DG.%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !75> _\ C\/UKE:ZKP'_ ,?A
M^M>9F'\)>O\ F?6<-?[Y+_"_S1[YH'^I6NBCZ"N=T#_4K711]!7SY^F#Z***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZFM0!BZQ_J6^E?
M.GQX_P"1/U[_ *\I_P#T6U?1>L?ZEOI7SI\>/^1/U[_KRG_]%M6M+^)'U1A7
M_A3]'^1\+4445^C'XL%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% &KX2_Y&K1O^OV'_T8M?6%?)_A+_D:M&_Z_8?_ $8M?6%<
M.(W1G,****Y3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** -WPC_R%!7OWAG_ %*_2O ?"/\ R%!7OWAG_4K]*^6Q7\:1^PY1
M_N-+T.LB^Z*DJ.+[HJ2N4]<**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!&K+U/_ %9K4:LO4_\ 5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_.R
MOI<F_P"7GR_4^'XF_P"7/_;WZ!1117TQ\.%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'V%#_ *F/_='\J?3(?]3'_NC^5/KQ
MSG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M92SLP.(5)48 RQW#*[>0#F?V._VU/$G['.M>(+K0]!TOQ!9:\MNE];Z@9$D
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M'8/@2!>PD [4?MH?!5?C]^S5XV\)1P>?JK6;7NE@#+?;(/WD07TW%?+/LYH
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M3QWX-U[PU?RW$%CK-A/IUQ+:.$F2.6-HV*,0<, QP<'!KX#US_@B7\+KC/\
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M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y
M^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]
M_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_O
MXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H
MM455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI
M9_\ /W!_W\7_ !H GDZ&N>U[_4O]*V)-4L\'_2X/^_B_XUSVO:E9^2_^E0=/
M^>@_QH ^7/VG/^1%U7_>B_\ 1J5\?U]=?M,7D$W@?5%2:-V+18"N"?\ 6I7R
M+7U^3_P)>OZ(_.>(_P#>X_X5^;"BBBO</E0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K5\)?\C5HW_7[#_Z,6LJM7PE_R-6C?]?L
M/_HQ:F6S ^L****\DYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *ZKP'_Q^'ZURM=+X'O((;]EDFC1L]&< UYF8?PEZ_P"9
M]9PU_ODO\+_-'T#H'^I6NBCZ"N4T'4K3R5_TJ'_OX/\ &NBCU2SP/]+@_P"_
MB_XU\^?IA<HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\
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MXO\ C0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\
M?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_X
MT 6J:U5_[4L_^?N#_OXO^-(VJ6?_ #]P?]_%_P : ,[6/]2WTKYT^/'_ ")^
MO?\ 7E/_ .BVKZ"UC4[/R6_TN#I_ST7_ !KYV^.U];2>$==5;B)B;*8 !P<_
M(U:TOXD?5&%?^%/T?Y'P[1117Z,?BP4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T
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M^7/_ &]^@4445],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!]A0_ZF/\ W1_*GTR'_4Q_[H_E3Z\<YPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M')X% 'U77/>/_'V@?"WP;JOBKQ3J<.CZ#I<)GNKR<_*BC@  <LQ)"A1DDD
MDUT-?A9_P4Q_;*O?V@OBE=^"]!O67X>>&+MX($B;Y=1NT)22Y;!PR@[EC_V<
MM_&< '&?MP?MR^(_VMO%S6MLUQHOP\TZ8G2]$+X,I&0+FXP<-*03@<A <#)+
M,V5^QG^Q3XK_ &NO&1BM/,T;P7I\BC5O$#QY6/C/DP@\22D=NB@Y;L&\Y_9\
M\!^%/B-\5-(TGQSXMM/!7A$,9]3U6YDVL(5QF.+@YD?A1P0,EB"%P?V\^'/[
M6W[*WPE\%Z7X3\)_$3PSHV@Z;$(K>U@D? [EF)7+,QR68Y))))R: /=OA/\
M"GPS\$_ .D^#?"&FIIFAZ;'LBB!R[L3EI';JSL226/4FNOKY_P#^&_/V>?\
MHK'A_P#[^O\ _$U[IHVL67B#1['5=.N$N]/OH([FVN(_NRQ.H9''L00?QH N
M4444 %%%% !1110 5GZEH-GJ\B/<QL[(,##$?RK0HH PO^$+TG_G@W_?QO\
M&C_A"])_YX-_W\;_ !K=HH PO^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_ !K=
MHH PO^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_ !K=HH PO^$+TG_G@W_?QO\
M&C_A"])_YX-_W\;_ !K=HH PO^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_ !K=
MHH PO^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_ !K=HH PO^$+TG_G@W_?QO\
M&C_A"])_YX-_W\;_ !K=HH PO^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_ !K=
MHH PO^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_ !K=HH PO^$+TG_G@W_?QO\
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M_C6S%]T5)7*>N87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\
M"%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_
M  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6
M[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;
M_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \
M&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (
M7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\
M"%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M
M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^
M_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;
M_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>
MD_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (
M7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4
M 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^
M-_C1_P (7I/_ #P;_OXW^-;M% &"W@O2?^>#?]_&_P :S-2\&:4(S^X;_OXW
M^-=@U9>I_P"K- '@'Q#\)Z;'#+B%NA_C-? =?HG\1O\ 4R_0U^=E?2Y-_P O
M/E^I\/Q-_P N?^WOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /L*'_ %,?^Z/Y4^F0_P"IC_W1_*GUXYSA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5/I^EV^
MI:E;BX0L%SC!(ZXJ"M'0?^0I%7%C/X$OZZGNY'_R,*7S_P#26>R>%?!^EM"F
M86Z?\]&_QKLX?!>E;1^X;_OXW^-8WA/_ %*?2NV@^Z*^9/ULR/\ A"])_P">
M#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O
M2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK
M=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\
MG@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$
M+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\
M:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_
M )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(
M9O\ _KXD_P#0C11K7_(9O_\ KXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\
M_D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!\6?\ !13]@H_M4:+:>*O"+06GQ'T>W,$27#A(M3M@2PMW8\(ZLS%'/'S%
M6X(9?Q2^(GPM\7_"77Y-$\9>&]2\-:HA(^SZC;M%O ZLA(PZ]/F4D'(P:_J
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M. H%Y%DDXZ5_2710!X?^VU\1-1^%W[*_Q%U[1WGCUE=.-G9/:J6E2:X=8%=
M!G*^9NSVVY[5_.Y_PB>N?] ;4/\ P%D_PK^I.B@#^6S_ (1/7/\ H#:A_P"
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MZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-67J?\ JS6H
MU9>I_P"K- 'B_P 1O]3+]#7YV5^B?Q&_U,OT-?G97TN3?\O/E^I\/Q-_RY_[
M>_0****^F/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ^PH?]3'_NC^5/ID/^IC_P!T?RI]>.<X4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\4E^!_[3'P_\77<C6MGIVJI%?N>#';2@PSDCVCD<X]J_I(5@ZAE(92,@CH:
M/A?_ (*.?\$_9OVF+6#QQX%%O!\0]-M_L\UG,PCCU>!>50N>%E3)"LW!!VL0
M I'XQ>//ASXH^%^OS:)XN\/ZCX<U:(G=:ZE;-"Y .-R[A\RGLPR#V-?U#5Y'
M^UOX5E\9?LS?$_2[31WUS4YO#E^MC90VIN)I+@V[^6(D +%]V,;1G.,4 ?S=
MV:W=XPL;59IC.ZD6T(+>8XR%^4=2-S8^I]:^Z/V-/^"7/C?XN>(]-\1?$W2;
MOP=X!A<326=\#!J&I <B-(C\T2-W=L'!^4'.Y?H+_@CC\'?&OPSUCXJ3^-/
M^O>%&NH=-6SEU[29[,R[6NO,$9E1=V,IG'JN>U?IM0!6TW3;71].M;"QMX[2
MRM8E@@MX5"I%&H"JB@<    #VKB/CQ\$_#G[0WPMUKP+XIA=],U)!MGAP)K:
M93NCFC)'#*P!]",@Y!(KT"B@#^=?]IG]B'XG_LPZ[>)K>B7&K>&%=C:^)M-A
M:2SECSP9",^2^.J/CG."PY/@8NIA;&W$L@MRV\Q;CL+8QG'3..]?U1LH=2K
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MDGN2!DGN2: -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO
M^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH 9)T-<]KW^I?Z5T,G0USVO?ZE_I0!\I_M.?\
M(BZK_O1?^C4KX_K[ _:<_P"1%U7_ 'HO_1J5\?U]?D_\"7K^B/SGB/\ WN/^
M%?FPHHHKW#Y4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *U?"7_(U:-_U^P_^C%K*K5\)?\C5HW_7[#_Z,6IELP/K"BBBO).<****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** -7PE_P C5HW_ %^P_P#HQ:^L*^3_
M  E_R-6C?]?L/_HQ:^L*X<1NC.84445RF84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ;OA'_ )"@KW[PS_J5^E> ^$?^0H*]
M^\,_ZE?I7RV*_C2/V'*/]QI>AUD7W14E1Q?=%25RGKA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 (U9>I_ZLUJ-67J?^K- 'B_Q&_U,OT-?
MG97Z)_$;_4R_0U^=E?2Y-_R\^7ZGP_$W_+G_ +>_0****^F/APHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^PH?]3'_NC^5/
MID/^IC_W1_*GUXYSA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5HZ#_R%(JSJT=!_P"0I%7%C/X$OZZGNY'_ ,C"E\__ $EG
MOWA/_4I]*[:#[HKB?"?^I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?C!_P
M4D_8/\6Z#\=)_%OPS\%:UXF\/>*]]]<6OA_3);LV%YD><K+$K%$<D2*3QEG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >3:U_P AF_\ ^OB3_P!"-%&M?\AF_P#^OB3_ -"-% '9
M_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_4O]*Z&3H:Y[7O]2_TH
M ^4_VG/^1%U7_>B_]&I7Q_7V!^TY_P B+JO^]%_Z-2OC^OK\G_@2]?T1^<\1
M_P"]Q_PK\V%%%%>X?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6KX2_Y&K1O^OV'_T8M95:OA+_ )&K1O\ K]A_]&+4RV8'UA11
M17DG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !75> _^/P_6N5KJO ?_'X?K7F9A_"7K_F?6<-?[Y+_  O\T>^:!_J5KHH^
M@KG= _U*UT4?05\^?I@^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *:U.IK4 8NL?ZEOI7SI\>/^1/U[_KRG_\ 1;5]%ZQ_J6^E?.GQX_Y$
M_7O^O*?_ -%M6M+^)'U1A7_A3]'^1\+4445^C'XL%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]A0_ZF/\
MW1_*GTR'_4Q_[H_E3Z\<YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *T=!_Y"D59U:.@_\ (4BKBQG\"7]=3W<C_P"1A2^?
M_I+/?O"?^I3Z5VT'W17$^$_]2GTKMH/NBOF3];)J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_P"0S?\
M_7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05KIJYGX?\ _(&F
M_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ;OA'_ )"@KW[PS_J5^E> ^$?^0H*]^\,_ZE?I7RV*_C2/V'*/
M]QI>AUD7W14E1Q?=%25RGKA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 (U9>I_ZLUJ-67J?^K- 'B_Q&_U,OT-?G97Z)_$;_4R_0U^=E?2Y
M-_R\^7ZGP_$W_+G_ +>_0****^F/APHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^PH?]3'_NC^5/ID/^IC_W1_*GUXYSA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ#_R
M%(JSJT=!_P"0I%7%C/X$OZZGNY'_ ,C"E\__ $EGOWA/_4I]*[:#[HKB?"?^
MI3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'DVM?\AF_P#^OB3_ -"-%&M?\AF__P"OB3_T
M(T4 =G\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>U[_4O]*Z&3H:Y[7O\
M4O\ 2@#Y3_:<_P"1%U7_ 'HO_1J5\?U]@?M.?\B+JO\ O1?^C4KX_KZ_)_X$
MO7]$?G/$?^]Q_P *_-A1117N'RH4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5J^$O^1JT;_K]A_\ 1BUE5J^$O^1JT;_K]A_]&+4R
MV8'UA1117DG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !75> _^/P_6N5KJO ?_ !^'ZUYF8?PEZ_YGUG#7^^2_PO\ -'OF
M@?ZE:Z*/H*YW0/\ 4K711]!7SY^F#Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*^?/TP?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ
M ,76/]2WTKYT^/'_ ")^O?\ 7E/_ .BVKZ+UC_4M]*^=/CQ_R)^O?]>4_P#Z
M+:M:7\2/JC"O_"GZ/\CX6HHHK]&/Q8**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** -7PE_R-6C?]?L/_HQ:^L*^3_"7_(U:-_U
M^P_^C%KZPKAQ&Z,YA1117*9A1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!N^$?^0H*]^\,_ZE?I7@/A'_ )"@KW[PS_J5^E?+
M8K^-(_8<H_W&EZ'61?=%25'%]T5)7*>N%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 C5EZG_JS6HU9>I_ZLT >+_$;_ %,OT-?G97Z)_$;_
M %,OT-?G97TN3?\ +SY?J?#\3?\ +G_M[] HHHKZ8^'"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#["A_P!3'_NC^5/ID/\
MJ8_]T?RI]>.<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %:.@_\A2*LZM'0?^0I%7%C/X$OZZGNY'_R,*7S_P#26>_>$_\
M4I]*[:#[HKB?"?\ J4^E=M!]T5\R?K9-1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O_\ KXD_]"-%
M&M?\AF__ .OB3_T(T4 =G\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*
MUTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R3H:Y[
M7O\ 4O\ 2NADZ&N>U[_4O]* /E/]IS_D1=5_WHO_ $:E?']?8'[3G_(BZK_O
M1?\ HU*^/Z^OR?\ @2]?T1^<\1_[W'_"OS84445[A\J%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %:OA+_D:M&_Z_8?\ T8M95:OA
M+_D:M&_Z_8?_ $8M3+9@?6%%%%>2<X4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %=5X#_P"/P_6N5KJO ?\ Q^'ZUYF8?PEZ
M_P"9]9PU_ODO\+_-'OF@?ZE:Z*/H*YW0/]2M=%'T%?/GZ8/HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_ )$_
M7O\ KRG_ /1;5]%ZQ_J6^E?.GQX_Y$_7O^O*?_T6U:TOXD?5&%?^%/T?Y'PM
M1117Z,?BP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 :OA+_D:M&_Z_8?_1BU]85\G^$O^1JT;_K]A_\ 1BU]85PXC=&<PHHH
MKE,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M W?"/_(4%>_>&?\ 4K]*\!\(_P#(4%>_>&?]2OTKY;%?QI'[#E'^XTO0ZR+[
MHJ2HXONBI*Y3UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$:LO4_\ 5FM1JR]3_P!6: /%_B-_J9?H:_.ROT3^(W^IE^AK\[*^ER;_ )>?
M+]3X?B;_ )<_]O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?84/\ J8_]T?RI],A_U,?^Z/Y4^O'.<**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M'0?^0I%6
M=6CH/_(4BKBQG\"7]=3W<C_Y&%+Y_P#I+/?O"?\ J4^E=M!]T5Q/A/\ U*?2
MNV@^Z*^9/ULFHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_R,*7S_ /26>_>$_P#4I]*[:#[HKB?"?^I3Z5VT'W17S)^MDU%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'D
MVM?\AF__ .OB3_T(T4:U_P AF_\ ^OB3_P!"-% '9_#_ /Y TW_7PW_H*UTU
M<S\/_P#D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% #).AKGM>_U+_2NADZ&N>U[_4O]* /E/\ :<_Y$75?]Z+_ -&I
M7Q_7V!^TY_R(NJ_[T7_HU*^/Z^OR?^!+U_1'YSQ'_O<?\*_-A1117N'RH444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J^$O\ D:M&
M_P"OV'_T8M95:OA+_D:M&_Z_8?\ T8M3+9@?6%%%%>2<X4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5X#_ ./P_6N5KJO
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M[*^ER;_EY\OU/A^)O^7/_;WZ!1117TQ\.%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'V%#_J8_\ ='\J?3(?]3'_ +H_E3Z\
M<YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*T=!_P"0I%6=6CH/_(4BKBQG\"7]=3W<C_Y&%+Y_^DL]^\)_ZE/I7;0?=%<3
MX3_U*?2NV@^Z*^9/ULFHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_P#U\2?^A&BC6O\ D,W_ /U\
M2?\ H1HH [/X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^=/CQ_R)^O?]>4__ *+:M:7\2/JC"O\ PI^C_(^%J***_1C\6"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#5\)?\C5HW_7[#
M_P"C%KZPKY/\)?\ (U:-_P!?L/\ Z,6OK"N'$;HSF%%%%<IF%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &[X1_Y"@KW[PS_J
M5^E> ^$?^0H*]^\,_P"I7Z5\MBOXTC]ARC_<:7H=9%]T5)4<7W14E<IZX444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-67J?^K-:C5EZG_J
MS0!XO\1O]3+]#7YV5^B?Q&_U,OT-?G97TN3?\O/E^I\/Q-_RY_[>_0****^F
M/APHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^PH?]3'_ +H_E3Z9#_J8_P#='\J?7CG.%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6CH/\ R%(JSJT=!_Y"D5<6,_@2_KJ>
M[D?_ ",*7S_])9[]X3_U*?2NV@^Z*XGPG_J4^E=M!]T5\R?K9-1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y
M-K7_ "&;_P#Z^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\/_\ D#3?]?#?^@K7
M35S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_U+_2@#Y3_:<_Y$75?]Z+_T
M:E?']?8'[3G_ "(NJ_[T7_HU*^/Z^OR?^!+U_1'YSQ'_ +W'_"OS84445[A\
MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?5&%?^%/T?Y'PM1117Z,?BP4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-_
M_P!?$G_H1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DG0USVO?ZE_I7
M0R=#7/:]_J7^E 'RG^TY_P B+JO^]%_Z-2OC^OL#]IS_ )$75?\ >B_]&I7Q
M_7U^3_P)>OZ(_.>(_P#>X_X5^;"BBBO</E0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K5\)?\C5HW_7[#_Z,6LJM7PE_R-6C?]?L
M/_HQ:F6S ^L****\DYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!N^$?\
MD*"O?O#/^I7Z5X#X1_Y"@KW[PS_J5^E?+8K^-(_8<H_W&EZ'61?=%25'%]T5
M)7*>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C5EZG_JS
M6HU9>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?\
MM[] HHHKZ8^'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#["A_U,?^Z/Y4^F0_ZF/_='\J?7CG.%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !6CH/_(4BK.K1T'_ )"D5<6,
M_@2_KJ>[D?\ R,*7S_\ 26>_>$_]2GTKMH/NBN)\)_ZE/I7;0?=%?,GZV344
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >3:U_R&;_ /Z^)/\ T(T4:U_R&;__ *^)/_0C10!V?P__ .0--_U\
M-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 R3H:Y[7O]2_TKH9.AKGM>_P!2_P!* /E/]IS_ )$7
M5?\ >B_]&I7Q_7V!^TY_R(NJ_P"]%_Z-2OC^OK\G_@2]?T1^<\1_[W'_  K\
MV%%%%>X?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !6KX2_Y&K1O^OV'_P!&+656KX2_Y&K1O^OV'_T8M3+9@?6%%%%>2<X4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=5X#_X_
M#]:Y6NJ\!_\ 'X?K7F9A_"7K_F?6<-?[Y+_"_P T>^:!_J5KHH^@KG= _P!2
MM=%'T%?/GZ8/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F
MM3J:U &+K'^I;Z5\Z?'C_D3]>_Z\I_\ T6U?1>L?ZEOI7SI\>/\ D3]>_P"O
M*?\ ]%M6M+^)'U1A7_A3]'^1\+4445^C'XL%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!DG
M0USVO?ZE_I70R=#7/:]_J7^E 'RG^TY_R(NJ_P"]%_Z-2OC^OL#]IS_D1=5_
MWHO_ $:E?']?7Y/_  )>OZ(_.>(_][C_ (5^;"BBBO</E0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K5\)?\C5HW_7[#_P"C%K*K
M5\)?\C5HW_7[#_Z,6IELP/K"BBBO).<**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "NJ\!_\ 'X?K7*UU7@/_ (_#]:\S,/X2
M]?\ ,^LX:_WR7^%_FCWS0/\ 4K711]!7.Z!_J5KHH^@KY\_3!]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4UJ=36H Q=8_U+?2OG3X\?\
M(GZ]_P!>4_\ Z+:OHO6/]2WTKYT^/'_(GZ]_UY3_ /HMJUI?Q(^J,*_\*?H_
MR/A:BBBOT8_%@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH U?"7_(U:-_U^P_^C%KZPKY/\)?\C5HW_7[#_Z,6OK"N'$;HSF%
M%%%<IF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &[X1_Y"@KW[PS_J5^E> ^$?\ D*"O?O#/^I7Z5\MBOXTC]ARC_<:7H=9%
M]T5)4<7W14E<IZX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "-67J?^K-:C5EZG_JS0!XO\1O\ 4R_0U^=E?HG\1O\ 4R_0U^=E?2Y-_P O
M/E^I\/Q-_P N?^WOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /L*'_ %,?^Z/Y4^F0_P"IC_W1_*GUXYSA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ#_R%
M(JSJT=!_Y"D5<6,_@2_KJ>[D?_(PI?/_ -)9[]X3_P!2GTKMH/NBN)\)_P"I
M3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'DVM?\AF__P"OB3_T(T4:U_R&;_\ Z^)/_0C1
M0!V?P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% #).AKGM>_P!2_P!*Z&3H:Y[7
MO]2_TH ^4_VG/^1%U7_>B_\ 1J5\?U]@?M.?\B+JO^]%_P"C4KX_KZ_)_P"!
M+U_1'YSQ'_O<?\*_-A1117N'RH4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5J^$O^1JT;_K]A_P#1BUE5J^$O^1JT;_K]A_\ 1BU,
MMF!]84445Y)SA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5U7@/_ (_#]:Y6NJ\!_P#'X?K7F9A_"7K_ )GUG#7^^2_PO\T>
M^:!_J5KHH^@KG= _U*UT4?05\^?I@^BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1JR]3_P!6:U&K+U/_
M %9H \7^(W^IE^AK\[*_1/XC?ZF7Z&OSLKZ7)O\ EY\OU/A^)O\ ES_V]^@4
M445],?#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!]A0_P"IC_W1_*GTR'_4Q_[H_E3Z\<YPHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *T=!_Y"D59U:.@_\A2*N+&?P)?U
MU/=R/_D84OG_ .DL]^\)_P"I3Z5VT'W17$^$_P#4I]*[:#[HKYD_6R:BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#R;6O^0S?_P#7Q)_Z$:*-:_Y#-_\ ]?$G_H1HH [/X?\ _(&F_P"OAO\
MT%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!DG0USVO?ZE_I70R=#7/:]_J7^E 'RG^TY_R(NJ_[T7_
M *-2OC^OL#]IS_D1=5_WHO\ T:E?']?7Y/\ P)>OZ(_.>(_][C_A7YL****]
MP^5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M7PE
M_P C5HW_ %^P_P#HQ:RJU?"7_(U:-_U^P_\ HQ:F6S ^L****\DYPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *ZKP'_ ,?A
M^M<K75> _P#C\/UKS,P_A+U_S/K.&O\ ?)?X7^:/?- _U*UT4?05SN@?ZE:Z
M*/H*^?/TP?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G
M4UJ ,76/]2WTKYT^/'_(GZ]_UY3_ /HMJ^B]8_U+?2OG3X\?\B?KW_7E/_Z+
M:M:7\2/JC"O_  I^C_(^%J***_1C\6"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#5\)?\C5HW_7[#_Z,6OK"OD_PE_R-6C?]
M?L/_ *,6OK"N'$;HSF%%%%<IF%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% &[X1_Y"@KW[PS_ *E?I7@/A'_D*"O?O#/^I7Z5
M\MBOXTC]ARC_ '&EZ'61?=%25'%]T5)7*>N%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 C5EZG_ *LUJ-67J?\ JS0!XO\ $;_4R_0U^=E?
MHG\1O]3+]#7YV5]+DW_+SY?J?#\3?\N?^WOT"BBBOICX<**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_4Q_[H_E3Z9#_J
M8_\ ='\J?7CG.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6CH/_ "%(JSJT=!_Y"D5<6,_@2_KJ>[D?_(PI?/\ ])9[]X3_
M -2GTKMH/NBN)\)_ZE/I7;0?=%?,GZV34444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 >3:U_R&;_\ Z^)/_0C1
M1K7_ "&;_P#Z^)/_ $(T4 =G\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"
MM=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,DZ&N>
MU[_4O]*Z&3H:Y[7O]2_TH ^4_P!IS_D1=5_WHO\ T:E?']?8'[3G_(BZK_O1
M?^C4KX_KZ_)_X$O7]$?G/$?^]Q_PK\V%%%%>X?*A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6KX2_P"1JT;_ *_8?_1BUE5J^$O^
M1JT;_K]A_P#1BU,MF!]84445Y)SA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5U7@/\ X_#]:Y6NJ\!_\?A^M>9F'\)>O^9]
M9PU_ODO\+_-'OF@?ZE:Z*/H*YW0/]2M=%'T%?/GZ8/HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_D3]>_Z\I_
M_1;5]%ZQ_J6^E?.GQX_Y$_7O^O*?_P!%M6M+^)'U1A7_ (4_1_D?"U%%%?HQ
M^+!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MJ^$O^1JT;_K]A_\ 1BU]85\G^$O^1JT;_K]A_P#1BU]85PXC=&<PHHHKE,PH
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH W?"/
M_(4%>_>&?]2OTKP'PC_R%!7OWAG_ %*_2OEL5_&D?L.4?[C2]#K(ONBI*CB^
MZ*DKE/7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1JR]3_
M -6:U&K+U/\ U9H \7^(W^IE^AK\[*_1/XC?ZF7Z&OSLKZ7)O^7GR_4^'XF_
MY<_]O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?84/^IC_P!T?RI],A_U,?\ NC^5/KQSG"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K1T'_ )"D59U:.@_\
MA2*N+&?P)?UU/=R/_D84OG_Z2SW[PG_J4^E=M!]T5Q/A/_4I]*[:#[HKYD_6
MR:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#R;6O^0S?_ /7Q)_Z$:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @
M:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU-:@#%UC_4M]*^=/CQ_R)^O?]>4__HMJ^B]8_P!2WTKYT^/'_(GZ]_UY3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#["A_U,?\ NC^5/ID/
M^IC_ -T?RI]>.<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %:.@_P#(4BK.K1T'_D*15Q8S^!+^NI[N1_\ (PI?/_TEGOWA
M/_4I]*[:#[HKB?"?^I3Z5VT'W17S)^MDU%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DVM?\ (9O_ /KXD_\
M0C11K7_(9O\ _KXD_P#0C10!V?P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-
M_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)
M.AKGM>_U+_2NADZ&N>U[_4O]* /E/]IS_D1=5_WHO_1J5\?U]@?M.?\ (BZK
M_O1?^C4KX_KZ_)_X$O7]$?G/$?\ O<?\*_-A1117N'RH4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5J^$O^1JT;_K]A_]&+656KX2
M_P"1JT;_ *_8?_1BU,MF!]84445Y)SA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5U7@/_C\/UKE:ZKP'_Q^'ZUYF8?PEZ_Y
MGUG#7^^2_P +_-'OF@?ZE:Z*/H*YW0/]2M=%'T%?/GZ8/HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "FM3J:U &+K'^I;Z5\Z?'C_D3]>_Z
M\I__ $6U?1>L?ZEOI7SI\>/^1/U[_KRG_P#1;5K2_B1]485_X4_1_D?"U%%%
M?HQ^+!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!J^$O^1JT;_K]A_P#1BU]85\G^$O\ D:M&_P"OV'_T8M?6%<.(W1G,****
MY3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-WPC_P A05[]X9_U*_2O ?"/_(4%>_>&?]2OTKY;%?QI'[#E'^XTO0ZR+[HJ
M2HXONBI*Y3UPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $:
MLO4_]6:U&K+U/_5F@#Q?XC?ZF7Z&OSLK]$_B-_J9?H:_.ROI<F_Y>?+]3X?B
M;_ES_P!O?H%%%%?3'PX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#R;6O\ D,W_ /U\2?\ H1HHUK_D,W__ %\2?^A&B@#L_A__
M ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** &2=#7/:]_J7^E=#)T-<]KW^I?Z4 ?*?
M[3G_ "(NJ_[T7_HU*^/Z^P/VG/\ D1=5_P!Z+_T:E?']?7Y/_ EZ_HC\YXC_
M -[C_A7YL****]P^5"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "M7PE_R-6C?]?L/_HQ:RJU?"7_(U:-_U^P_^C%J9;,#ZPHHHKR3
MG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#5\)?\ (U:-_P!?L/\ Z,6O
MK"OD_P )?\C5HW_7[#_Z,6OK"N'$;HSF%%%%<IF%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &[X1_P"0H*]^\,_ZE?I7@/A'
M_D*"O?O#/^I7Z5\MBOXTC]ARC_<:7H=9%]T5)4<7W14E<IZX4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "-67J?^K-:C5EZG_JS0!XO\1O]
M3+]#7YV5^B?Q&_U,OT-?G97TN3?\O/E^I\/Q-_RY_P"WOT"BBBOICX<****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /L*'_4Q_
M[H_E3Z9#_J8_]T?RI]>.<X4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %:.@_\A2*LZM'0?\ D*15Q8S^!+^NI[N1_P#(PI?/
M_P!)9[]X3_U*?2NV@^Z*XGPG_J4^E=M!]T5\R?K9-1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_(9O\
M_KXD_P#0C11K7_(9O_\ KXD_]"-% '9_#_\ Y TW_7PW_H*UTU<S\/\ _D#3
M?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_>B_]&I7Q_7U^3_P)>OZ(_.>(_\ >X_X5^;"BBBO</E0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K5\)?\C5HW_7[#_Z,6LJM7PE
M_P C5HW_ %^P_P#HQ:F6S ^L****\DYPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *ZKP'_Q^'ZURM=5X#_X_#]:\S,/X2]?
M\SZSAK_?)?X7^:/?- _U*UT4?05SN@?ZE:Z*/H*^?/TP?1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %-:G4UJ ,76/]2WTKYT^/'_(GZ]_U
MY3_^BVKZ+UC_ %+?2OG3X\?\B?KW_7E/_P"BVK6E_$CZHPK_ ,*?H_R/A:BB
MBOT8_%@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH U?"7_(U:-_U^P_\ HQ:^L*^3_"7_ "-6C?\ 7[#_ .C%KZPKAQ&Z,YA1
M117*9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!N^$?^0H*]^\,_ZE?I7@/A'_D*"O?O#/\ J5^E?+8K^-(_8<H_W&EZ'61?
M=%25'%]T5)7*>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M C5EZG_JS6HU9>I_ZLT >+_$;_4R_0U^=E?HG\1O]3+]#7YV5]+DW_+SY?J?
M#\3?\N?^WOT"BBBOICX<**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /L*'_4Q_P"Z/Y4^F0_ZF/\ W1_*GUXYSA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5HZ#_ ,A2*LZM
M'0?^0I%7%C/X$OZZGNY'_P C"E\__26>_>$_]2GTKMH/NBN)\)_ZE/I7;0?=
M%?,GZV34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*2F+;GH'?UH Z;_@FC^WK?\ [1VGW?@+Q[/$_C[2;?[1;ZB L?\ :UL#AF*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH W?"/_ "%!7OWAG_4K]*\!\(_\A05[]X9_
MU*_2OEL5_&D?L.4?[C2]#K(ONBI*CB^Z*DKE/7"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 1JR]3_U9K4:LO4_]6: /%_B-_J9?H:_.ROT
M3^(W^IE^AK\[*^ER;_EY\OU/A^)O^7/_ &]^@4445],?#A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]A0_ZF/\ W1_*GTR'
M_4Q_[H_E3Z\<YPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA*@#\_/^"G_[=VK? .UM/AMX!NOL7C/5K3[5?:LF"^FVK%E01>DSE6^8_<4
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MS;^!_P '/$/[0/Q4T+P/X:A#ZGJT^UIF7]U;1#YI)GQT1%!8^N !R0*_HG^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_P#7Q)_Z$:*-:_Y#-_\
M]?$G_H1HH [/X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _'W_@LE^SEJ6B_$;3O
MC#IEH\^AZU;PZ?JTT:Y^SWD2[(F?T62)44'UB()^917PQ\*/CQXV^"L?B&#P
MIK,EC8^(-/ETS5;%U$EO=P.C(0Z'^)0[;7&&7)P<$@_TK>)O#.D^,] O]#U[
M3;76-'OHC!=6-[$)89D/564\$5^8/[5W_!(/P]HF@^)O&_PS\3R:'8Z;8W&I
M3>'=71IX@L4;2,L,X.]1A2 KJYR?O"@#YM_X)L_M=>#?V3_'7BJZ\:VNJ2Z?
MKUK;VL=UID"3?9V1V8M(I=3MPW\.3QTK]H?@]^T!\//C[HK:GX!\5Z?XB@C
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M?87_  JWX)^ND_\ @[D_^/4?\*M^"?KI/_@[D_\ CU']L4/Y7^'^8?ZN8O\
MFC][_P CX]HK["_X5;\$_72?_!W)_P#'J/\ A5OP3]=)_P#!W)_\>H_MBA_*
M_P /\P_U<Q?\T?O?^1\>T5]A?\*M^"?KI/\ X.Y/_CU'_"K?@GZZ3_X.Y/\
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M /%T?;? /_08TG_P9K_\71_:%+L_Z^8?ZLXS^:/WO_(Y&BNN^V^ ?^@QI/\
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M .#-?_BZ/[0I=G_7S#_5G&?S1^]_Y'(T5UWVWP#_ -!C2?\ P9K_ /%T?;?
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MI6NBCZ"O-K6]UN)0($GV_P"S #_2K8U;Q..B7/\ X"C_ .)KRSZ\]!HKS_\
MM;Q1_P \[K_P$'_Q-']K>*/^>=U_X"#_ .)H ] HKS_^UO%'_/.Z_P# 0?\
MQ-']K>*/^>=U_P" @_\ B: /0**\_P#[6\4?\\[K_P !!_\ $T?VMXH_YYW7
M_@(/_B: /0**\_\ [6\4?\\[K_P$'_Q-']K>*/\ GG=?^ @_^)H ] HKS_\
MM;Q1_P \[K_P$'_Q-']K>*/^>=U_X"#_ .)H ] HKS_^UO%'_/.Z_P# 0?\
MQ-']K>*/^>=U_P" @_\ B: /0**\_P#[6\4?\\[K_P !!_\ $T?VMXH_YYW7
M_@(/_B: /0**\_\ [6\4?\\[K_P$'_Q-']K>*/\ GG=?^ @_^)H ] HKS_\
MM;Q1_P \[K_P$'_Q-']K>*/^>=U_X"#_ .)H ] HKS_^UO%'_/.Z_P# 0?\
MQ-']K>*/^>=U_P" @_\ B: /0**\_P#[6\4?\\[K_P !!_\ $T?VMXH_YYW7
M_@(/_B: /0**\_\ [6\4?\\[K_P$'_Q-']K>*/\ GG=?^ @_^)H ] HKS_\
MM;Q1_P \[K_P$'_Q-']K>*/^>=U_X"#_ .)H ] HKS_^UO%'_/.Z_P# 0?\
MQ-']K>*/^>=U_P" @_\ B: /0**\_P#[6\4?\\[K_P !!_\ $T?VMXH_YYW7
M_@(/_B: /0**\_\ [6\4?\\[K_P$'_Q-']K>*/\ GG=?^ @_^)H ] HKS_\
MM;Q1_P \[K_P$'_Q-']K>*/^>=U_X"#_ .)H ] HKS_^UO%'_/.Z_P# 0?\
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MD_\ CU']L4/Y7^'^8?ZN8O\ FC][_P CX]HK["_X5;\$_72?_!W)_P#'J/\
MA5OP3]=)_P#!W)_\>H_MBA_*_P /\P_U<Q?\T?O?^1\>T5]A?\*M^"?KI/\
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M>_\ (^/:*^PO^%6_!/UTG_P=R?\ QZC_ (5;\$_72?\ P=R?_'J/[8H?RO\
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M^5_A_F'^KF+_ )H_>_\ (^/:*^PO^%6_!/UTG_P=R?\ QZC_ (5;\$_72?\
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M_P"1R-%==]M\ _\ 08TG_P &:_\ Q='VWP#_ -!C2?\ P9K_ /%T?VA2[/\
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MJD>I6ZL>?)N8RI4>P>W8_63WKP;_ (+8:<(?VBO!=\%P9_"L<);'79=W)_\
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M,/PK\</!/@W6/B)XNT?PQX?L9-1UO5KJ.TM+6(<O(YP/H!U)/  )/ K^DO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ+>SL'),=AKVG^:\?/ \^-EW#&?^68Z#UX=\-_\ @B+9VNJ0W/COXDR7UBC
MOI^@V'DM(,]//D9L C'2//)YXY_4FB@#E/A?\+/"OP9\%V'A3P9HUOH6@V0/
ME6L&3EC]YW8DL[D]68DGUKJZ** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@/_
M (+&?!%_'WP!TKQW8PF74?!=X6GVC)-E<E(Y3COMD6!O9=Y]:^_*Q?&GA'3/
MB!X/UOPSK4/VC2-8LIK"[B'!:*5"C 'L<,<'L: /PK_X)7?$C_A7O[8_ABWE
ME\JR\26USH<YSP3(GF1#\9H8A^-?O=7\V7Q8^'?BG]D+]HJ[T625H=<\*ZI%
M>Z;?[2%G1'66VN%'HP"$CL<CJ#7]#OP?^)FF?&;X7>%_&^CL#I^N6$5XB!LF
M)F'SQ$_WD<,A]U- %GXD?#/PO\7O!]_X6\8Z+;:]H-\N)K.Z4XR.C*PPR.#R
M&4@@]#7Y??M4?\$A_#WPZ\!^,?'W@CQS>VNF:'IUSJKZ%K%HMPS)%&TA1+A&
M4CA<#<C'U;U_6BN;^)7@/3_BE\/?$G@[59KFWTS7M.GTRZELV59DCEC*,4+*
MRA@&."5(SV- 'X1_L'_L1Q?MF:SXLBNO%S^%;+PZEK)+Y-@+F2Y\\R@*I,BA
M,>4>2&ZCBOV#_9G_ &(?A;^RO"UQX4TJ2^\12QF*?Q%JSK->NIZHI "QJ?[J
M*,X&[=BH/V4_V(_ W[']QXEF\&ZKXAU-M?6W2Z&N7,$H00F0IL\J&/&?-;.<
M]!T[_0E !1110!^;WC[_ ((S:3X^\=>(_$]Q\5K^WN-:U*YU*2%=%1@C32M(
M5R9N<%L9K[ _91_9TM/V6?@_9^ [/6I/$$=O=3W1OIK<0,YE;=C8&;&.!U[5
M[#10 4444 %?&'[4'_!+?X:?M"Z]>>)M(N[CP!XLO&:2ZN].A6:UNY3SYDMN
M2OS9ZE&3<22<DYK[/HH _(R/_@A[XH;4-DGQ4TA;'/\ KETF5I<8_N>8!_X]
M7V/^RC_P3F^&W[+6HQ^((7N/%WC1%*IKFJ(JBV!&&^SPC*QY&1N)9L$@, 2#
M]644 %1SSQVL,DTSK%%&I=Y'. J@9))[#%25\K_\%*OCHGP0_95\2_9K@0Z]
MXF7^P-.4-A_WRD3..XVPB0AAT8IZT ?A_P#M ?$4_%WXX>.O&*L7AUK6;J[M
M\CD0-(?*7\(P@_"OWR_8?^#+_ ?]E_P-X7NK?[-J[6?]H:FC##BZN#YLB-[I
MN$?TC%?CW_P3:_9G;]HK]HC3I=1MFE\(^%3'J^JN5RDK*V8+<GI^\=>1W2.2
MOWZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_ /R!IO\ KX;_ -!6
MNFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#YS_ &IOV#_AO^UQK&B:OXNGUK2M
M5TJ![5+W09X89)X6;<(Y?-BD#!6W%< 8WMUS7;_LV_LZZ'^R_P##G_A"?#>M
MZ[K.BI=R7<']O3PS26YDP6CC,448"%@7P03N=CGFO5:* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KYV_:H_8>\&?M>:GH-UXR\1^*M/AT6&2*TL=$
MN[>* -(P+R,)()"7(5!G.,(..N?HFB@#R3]FG]F+P9^RIX"E\*^#%O9K>XNG
MO+J_U21)+NYD; &]D1%PJ@*H"@ #U))];HHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_
M /7Q)_Z$:* .S^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "O._B#^T5\,/A1KD>C>,O'F@^&=5D@6Y2SU2^CAE:)F95<*QS
MM)1AG_9->B5^)?\ P6>_Y.OT3_L4K/\ ]*KN@#]2?^&UO@)_T5[P?_X-HO\
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M^[&JE@@/)#LQQD!?./\ @F]_R>U\+?\ K]N/_22>@#^A2BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .&^(_P <OA]\'YK&'QOXRT;PK+?*
M[VJ:K>) 9E0@,5W'G&Y<_45QO_#:WP$_Z*]X/_\ !M%_C7P!_P %QO\ D:OA
M)_UY:E_Z,MZ_,G3M-N]8O8K.PM9KV[F.V.WMXS)(YZX"@9/X4 ?T:_\ #:WP
M$_Z*]X/_ /!M%_C1_P -K? 3_HKW@_\ \&T7^-?SV?\ "I_&_P#T)OB#_P %
M<_\ \11_PJ?QO_T)OB#_ ,%<_P#\10!_0Q:_MF? J^NH;:W^+7A&:XF=8XXT
MU6(L[$X  SU)-=9\1OCI\/?A!<6,'C;QEH_A6:^1GM4U:[2 S*I 8IN(S@D9
MQTR/6OYV? /PK\:P^._#DDGA#7D1=2MF9FTR<  2KDD[:_=[]M_]EVS_ &JO
M@?J/AZ-(8O%.GYO]!O),#R[I5_U;-V20?(W895L$J* -A?VU/@*S!1\7O!^2
M<#_B;P__ !5>T(ZR*K*P96&0RG((]:_ECU;2;S0=5O-,U&UELM0LIGMKFUG4
MK)#*C%71@>A!!!'J*_;+_@E'^U;_ ,+G^$+?#_7[PR^+_!T*11/*V7O-.^[%
M)D]6C.(V]O+.26- 'W94<\\=K#)--(L4,:EWDD8*JJ!DDD] !4E? ?\ P5K_
M &JO^%4_"B/X9:!>>7XH\80LMZT;?/:Z9DK(?8S$&,?[(EZ'% 'TC_PVM\!/
M^BO>#_\ P;1?XUW'PX^,W@7XP1W\G@CQ9I/BJ.P*+=/I5TLZPE\[0Q4\$[6Q
M]#7\T'A+PIJWCKQ1I7AW0K*34=9U2YCL[2UB'S2RNP55]N3U/ ZFOZ+OV3/V
M<M)_9=^"FB^"[#RY]05?M6K7Z#'VR]<#S)/7:,!%!Z*B]\T >R4444 %9^N>
M(-+\+Z9+J.LZE9Z3I\/,EW?3I#$GU=B /Q->8_M6?M$Z5^R[\%=9\<ZE$MY<
MP[;73=/9]GVR\<'RXL]APS,>RHQ'2OY^_C=^T+X^_:(\52Z]XZ\0W.KSEB8+
M3<4M;13_  0Q#Y4 Z<<GJ23DT ?OW<?MH? >UF>)_B_X-+H<'9K,#K^!#$'\
M*](\'?$#PO\ $/3O[0\+>(])\26/&;G2;V*ZC&>F61B!7\V.D_ 3XFZ_X>37
MM,^'/BS4="=!(NJ6FAW4ML5/1A*L97'(YSWK'\!_$3Q1\*_$UMK_ (3UR^\.
MZU:L"EU8S&-^#G:PZ,IQRK @]"#0!_4+17RQ_P $_/VR$_:V^%MP^L1P6GCG
M0&2VU>WAPJ3A@?+N8U_A5]K KV96[%:^H;R\@TZSGN[J:.VM8(VEEFF8*D:*
M,LS$\   DDT .GGCM89)II%BAC4N\DC!550,DDGH *\DU;]L#X':'?2V=[\6
MO!L5S$=LD8UJ!RAZ$':QP1Z=:_&K]NS]NSQ-^TYXYU31M&U2YT[X864[0Z?I
M=NS1+?JC<7-P/XV8C<JMP@P,;LD_/'A/X0^._'NDW>J^&?!/B+Q%I=F2+F]T
MG2I[J& @9(=XT*K@<\GI0!_2WX-^('A?XC::=1\*>(])\2V (!NM(O8KJ,$]
MBT;$ ^U=!7\POPP^*WB_X)^,+7Q+X-UR\\/ZU:M_K;9RHD4$$QR)T=#CE&!!
M]*_H%_8T_:>T_P#:M^">G>+(DAL]=@8V6M:;"3BVNU )*@DG8ZE77D\-C)*F
M@#W6FR2+%&SNP1%&69C@ >IJEKVN6'A?0]1UG5;J.RTO3K:2[N[J4X2&&-2[
MN?8*"?PK\!_VR/V\O''[47BK4;.#4KK0_AW%,R:?X?MI#&LL8.%EN<?ZR1AS
M@Y5<X4=20#]K=>_:V^"GAF_>RU/XK^#[6[3[\)UJW9D/HP#G:?8UT'@+X[?#
MGXI2F'PAXZ\.^);@9S;Z9J<,\HQURBMN'Y5_-[X)^$?CKXEQSR>$/!?B+Q5'
M VV9M$TJ>\$9P#AC$C8.".OJ*R-0TW7/ OB VU]::AX>URQ=6,-Q');7-N_#
M*<$!E/0CIVH _J3HK\RO^"7_ /P4 USXCZY#\(OB5J3:KK#0,^@Z[=.#/<^6
MN6MIF/+OL!97/S$*P8DXK])M>URP\+Z'J.LZK=1V6EZ=;27=W=2G"0PQJ7=S
M[!03^% %V218HV=V"(HRS,< #U->3Z]^UM\%/#-^]EJ?Q7\'VMVGWX3K5NS(
M?1@'.T^QK\4OVR/V\O''[47BK4;.#4KK0_AW%,R:?X?MI#&LL8.%EN<?ZR1A
MS@Y5<X4=2?"O!/PC\=?$N.>3PAX+\1>*HX&VS-HFE3W@C. <,8D;!P1U]10!
M_2%X"^.WPY^*4IA\(>.O#OB6X&<V^F:G#/*,=<HK;A^5=U7\MFH:;KG@7Q ;
M:^M-0\/:Y8NK&&XCDMKFW?AE." RGH1T[5^KW_!+_P#X* :Y\1]<A^$7Q*U)
MM5UAH&?0==NG!GN?+7+6TS'EWV LKGYB%8,2<4 ?IK1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOS$_X(\_M6?VUHEW\$O$5[F^TY9+[P[),W,EOG=-; GJ4),BCKM9^R"OT[H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .S^'_
M /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ+_
M ."SW_)U^B?]BE9_^E5W7[:5^)?_  6>_P"3K]$_[%*S_P#2J[H RO\ @CU_
MR> G_8OWW\XJ_<FOYQOV/?VF/^&3_C /'7_"-_\ "4XT^>Q^P?;OL?\ K"IW
M^9Y<G3;TV\YZU]R_\/SO^J)_^77_ /<5 'ZJ45^5?_#\[_JB?_EU_P#W%7V5
M^Q+^UY_PV-X!UWQ-_P (G_PB/]EZG_9WV7^TOMOF_NDDW[O*CQ]_&,'IUH ^
MBJ_$/_@JM^R/_P *3^*@^(/ARR\KP7XNG>26.%<1V.HG+21^BK(,R*/7S
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M#\;?^":/[%?BRS_:6_MWXI?#S6]%TOP[IKW]@=;TV2*VFOBZ)$ 77:Y16ED
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M:PM?VI/C9&_A^:23P3X;A>PTEW!7[2S,#/<[3R!(50 '^&-"0"2*];_X(W_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R5_X+C?\C5\)/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG^_*P W.1SC  4 "O^UE^U=XK_:P^)$_B#796M-&MF>+1]#C<F&P@)Z?[4C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.H^,WV6GB3P2AOK6[V\RV[,JS6['T.0P]&0= S5]K5\__M^?\F;?%C_L#/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_.K_ (+:
M?\D"\"_]C,/_ $EGK]%:_.K_ (+:?\D"\"_]C,/_ $EGH _(;P3X7N/''C+0
M?#=I+';W6L:A;Z?%+-G8CRR+&K-@$X!8$X%??7_#DOXI_P#0]>#_ /OJZ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_$O_ (+/?\G7Z)_V*5G_ .E5W7[:5\M_M.?\$[?AQ^U=\0K7
MQCXMUOQ3IVIV^G1Z8D6BW=M%"8TDD<$B2WD;=F5N=V, <>H!^;7_  1Z_P"3
MP$_[%^^_G%7[DU\I_LV_\$X/AI^RY\2!XV\*ZYXKU#519RV7DZQ=VTL&R0KN
M.([>-L_*,?-CVKZLH **** "BBB@#XJ_X*\_\F;:C_V&K#_T-J_"ROZ6/VCO
MV>?#G[3WPSF\#^*;W5+#29KJ&[:;1Y8XY]\9)4 R1NN.>?EKY0_X<J?!#_H:
M?B!_X,;'_P"0Z /O^BBB@ HHHH *_'[_ (+.?'ZXU[XB:!\)=/G=-,T&%=4U
M-%.%ENYE_=*1_P!,XCD?]=SZ"OV!KXV^-7_!++X6?'KXHZ_X]\2>)O&T6M:U
M*LL\=C?6B0)MC6-50-:LP4*B@98].M 'X05[]X1_;T^//@/PSIGA[P_\0;G2
M=$TV!;:TLK:PM%2*-1@ ?N?S)Y)))R37Z5_\.5/@A_T-/Q _\&-C_P#(='_#
ME3X(?]#3\0/_  8V/_R'0!^=7_#R']I+_HJ6H?\ @%:?_&:^\?\ @E#^T]\4
M/C_XQ^(-G\0/%MSXDMM-L+66TCG@AC$3M(X8CRT7.0!U]*Z3_ARI\$/^AI^(
M'_@QL?\ Y#KW/]E?]A7P%^R'K&OZEX.U?Q'J4^M016]PNN7-O*JK&S,I3RH(
MR#ECG)- '8?M7? B#]I+X"^*O <DRVMY?0++873C(ANXF$D+'T4LH5L<[6:O
MYS/%WA'6_A[XJU+P]X@TZXT;7=+G:"ZL[A2DD,B_Y!!'!!!!((-?U'UX)^TI
M^Q'\*_VIHX[CQ=H\EIK\,?E0^(-(<07RH.B,Q5ED4=A(K8YQC)H _,SPG_P6
M2^+?AOX=VV@7>@Z#K>N6MM]FC\0WOF^:^!A9)8PP5W]2" 3R1US\.ZYK6M?$
M+Q;>ZKJ,USK7B'6;QIYY2"\US<2ODG '+,S= .^!7ZIWG_!#O07OB]K\6M1A
ML_FQ#-HD<DG;;\XF4<<Y^7G(Z8Y^E?V:?^"</PD_9JU>#Q!96MWXJ\60X,.L
M:ZR2&V;NT$2J$C/^T0SCLW)H N?\$\?V:;G]F;]G73M*UB+RO%6N3'6-7C(Y
M@ED152WS_P!,T50>V\OC@UPG_!6+X_7'P?\ V;F\.:7.]OKGC:9M+26,X:.T
M50UTP/\ M*4C^DQ]*^UZ^=OVJOV'?!'[7VI>'KOQEKGB;3O["BFBM(-$NK>*
M/]ZR%V82P2$L?+0<$<*.* /YX*]9^$/[5GQ5^ NB7>D> ?%LOAJPO)_M-Q';
MV=N[2R;0H+.\;,< <#.!SCJ:_5#_ (<J?!#_ *&GX@?^#&Q_^0Z/^'*GP0_Z
M&GX@?^#&Q_\ D.@#\ZO^'D/[27_14M0_\ K3_P",U[9^Q9^W-\=/B9^U)\//
M"_B?XA7NK:#J5^T5W926MLJRH(9&P2L0(Y Z'M7U3_PY4^"'_0T_$#_P8V/_
M ,AUV?P9_P""5?PG^!WQ.\/^.M"\0^,[O5]$G-Q;PZC>VCP.Q1EPZI:JQ&&/
M1A0!]F4444 ?F!_P7&_Y%7X2?]?NI?\ HNWKXJ_X)O?\GM?"W_K]N/\ TDGK
M]G/VJOV-_!?[7VG^';/QCJ>O:;%H4L\ML=#N((BYE"!M_FPR9 \L8QCJ>M>7
M_!/_ ()8_"CX#?%+0/'N@>(/&5YK&BRO+;P:E>VCV[%HWC.]4M48C#GHPYQ0
M!]D4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKJOA3_P4*_:&\0?%'P=I>H?$R_N;"]UFSMKB%K.U DC>=%921%GD$CBONO\
MX<J?!#_H:?B!_P"#&Q_^0ZU/"O\ P1U^#/A'Q/I&NV?B;QW)=Z7>0WL*3W]D
M8V>-PZA@+0$C*C."#CO0!]UT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-_\ ]?$G
M_H1HHUK_ )#-_P#]?$G_ *$:* .S^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^
M&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#R;6O^0S?_P#7Q)_Z$:*-:_Y#-_\ ]?$G_H1HH [/X?\ _(&F_P"O
MAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_\ 7Q)_Z$:*-:_Y#-__ -?$
MG_H1HH [/X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_P"0S?\
M_7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO^OAO_05KIJYGX?\ _(&F
M_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH \FUK_D,W_P#U\2?^A&BC6O\ D,W_ /U\2?\ H1HH [/X?_\
M(&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y#-__ -?$G_H1HHUK_D,W
M_P#U\2?^A&B@#L_A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_
MY#-__P!?$G_H1HHUK_D,W_\ U\2?^A&B@#L_A_\ \@:;_KX;_P!!6NFKF?A_
M_P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_Y#-__P!?$G_H1HH [/X?
M_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/L-V;<AI&E#[L#GA%K[X_P"'0W[//_0.\0?^#A_\* /(]-_X+@>$9?\ C_\
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M+PA_T%__ "6F_P#B*/\ A<7A#_H+_P#DM-_\11[&K_*_N#^T,'_S^C_X$O\
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MYD\</#E6QCS,]#TKTNOE_P#X*:?\F.?$_P#ZXV/_ *7VU &%^QG_ ,%#=/\
MVPO'6M^&K/P3=>&'TO3?[1-Q/J*W(D'FI'LVB-<??SG/:OKVOQK_ .")?_)?
M?'7_ &+)_P#2J"OV4H **** "BBB@ HHHH **** "BBB@ HHHH *^*?VMO\
M@IAIG[*7Q:/@:[\!7?B.46$-]]MAU-;=<2%AMVF)NFWKGO7VM7X;?\%A?^3P
M'_[%^Q_G+0!]%?\ #\;0_P#HDFH?^#R/_P",4?\ #\;0_P#HDFH?^#R/_P",
M5I?LI?\ !,WX)?%[]G7P%XR\0V.M2:UK&G+<W36^IM'&7+,/E4#@<"O6/^'0
MW[//_0.\0?\ @X?_  H \WT/_@MM\.+FYC35_A_XGT^!L;Y+26WN2I[\,Z9
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MV*_AI^RWK6KZKX%M=2M[O5;=+:Y-]>M."BMN& 1P<U[Q0 F<<G@5\>?M!?\
M!4KX-? [4KC1K"[N?'_B"'*R6WAXH]M"X_ADN6;9G/!";R",$"OEW_@J3^WM
MJ4GB#4O@Q\.]6DL;"SW6WB;5+1MLD\O1K-''*HO(DQRQ)3HK!O.OV*O^"6&L
M?';0]/\ ''Q&O[KPKX+O%6>QL+0+]OU*(\B3+ B&,\88AF8<@ %6(!W.K?\
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M_P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17[/_@_QVWDIJ&H6FS48;<$)%>1L8YU"DDJN]2R@DG:R\GK7@/\ P5J^"/\
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M='_9Q^*FA^*?!=JFD^%_%0FE33[7*I87D10R+&!]U&$B,JC[I#@8  'Z;?\
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M4?)Z)+A4;T(C/ #9^_\ _@E7_P F.> ?^NVI?^E]Q7YR?\%//V/C^SS\5?\
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M6AZ/"8+5+C3%DD"EBW+$\\L:ZO\ X>\?M#?]!+P__P""=/\ &@#]U**_"O\
MX>\?M#?]!+P__P""=/\ &O4/V7_^"G'QO^*W[0G@#PAK]_HLFC:SJT-G=K!I
M:QN8V/.U@>#[T ?L)7XX_P#!:3XP7>O?&#PQ\.;>X_XE.@:<NHW,*GAKRX+
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M%%% !7\ZW[?G_)Y/Q8_[#3_^@+7]%-?SK?M^?\GD_%C_ +#3_P#H"T ?0_\
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MK*W>O@7_ (+E?\@KX-_]=M6_]!LZ /8/^"-O_)H]Y_V,U[_Z*MZ]_P#VUO\
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MW]Q[G^K&8]E]Y]T45\+_ /#=/CW_ *!'AS_P&N/_ (_1_P -T^/?^@1X<_\
M :X_^/T?ZP8'N_N#_5C,>R^\^Z**^%_^&Z?'O_0(\.?^ UQ_\?H_X;I\>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y-K7_ "&;_P#Z
M^)/_ $(T4:U_R&;_ /Z^)/\ T(T4 =G\/_\ D#3?]?#?^@K735S/P_\ ^0--
M_P!?#?\ H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO6_VDOVPF\<?\$U_A+X5CO2_B#7)O[*UE=V6,.F%!\_^U(QLY,]_F]Z^D?\
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M>29ML.\^0,RQ_*57/IQ7ZR?\$D_^3+?#_P#V$]0_]'FOD#_@MA\1M-U_XM>
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M]HK]M3XE^#]7\+>);+Q=J>@ZM;M:WEFW@:&/S8VZC<EF&7ZJ01V-=[_P2?\
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M\)8] A8-#I6ABQ1@, K%;[ ?R6OP:_X)O?\ )[7PM_Z_;C_TDGH _H4HHHH
M_GA_89_Y/>^&?_8P?T>OVW_;'^*6N_!7]FGQSXV\,R01:[I%M#+:O<Q"6,,U
MQ$ARIZ_*YK\2/V&?^3WOAG_V,']'K^A#6]"TWQ-I=QIFL:?:ZKIMP LUG?0+
M-#( 00&1@0>0#R.U 'X<_P##WC]H;_H)>'__  3I_C1_P]X_:&_Z"7A__P $
MZ?XU^RG_  SW\+/^B:>#_P#P0VO_ ,;H_P"&>_A9_P!$T\'_ /@AM?\ XW0!
MQ7[#_P 7O$7QX_9=\%>.O%<EO-K^J_;?M+VL(BC/E7L\*84=/DC7\<U^5?\
MP6%_Y/ ?_L7['^<M?MSH/A[2O"NDP:7HFF6>CZ9;[O)LK"W2"&/<Q9MJ( HR
MS$G Y))[U^(W_!87_D\!_P#L7['^<M 'M/[-/_!)WX=_&SX#^"_'.J^+_$]C
MJ&N6"W<UM9FW\J-BS#"[HB<<=R:]+_X<E_"S_H>O&'_?5K_\9KZ5_8#_ .3-
MOA/_ -@9/_0WKZ H ^"O#/\ P1D^!VCSQ3:GK'C#7RN=\%Q?P0POSQQ% KCC
M_;KZU^#_ , OA]\ ]#;2O /A73_#EO(%$\MNA:XN-O0RS,3)(1DXW,<9.*]
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M+XJ?M)ZO\7O@7\,O NO^9=7_ (&FOH;747;)ELIEMQ#$W?='Y++G^YL'4$D
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M8<2SQV'EAXTN7FW=[_HCXU_X*V?\F6^(/^PGI_\ Z/%?+_\ P0Y_Y&KXM_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#^:3X"_'SQ9^S?X\'B_P9-:P:R+62SW7EN)D\M]N[Y3W^4<U]'_\/>/VAO\
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M .-T?\* \0_\_FF?]_9/_C=>_P!%=OUZL>#_ *O8'L_O/ /^% >(?^?S3/\
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M L,/(?N@*-L8QD8"J?WB\+^&M.\&>&M)T#1[9;/2=+M(K*TMTZ1PQH$11]%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / ?VTOV3
M],_:X^$;^&Y;I-+\06$IO=&U.12RPS[2"DF.3&XX;'(PK8)4 _D-8>#_ -JG
M]@/Q9J$NCZ;XA\/V\C?Z1=:=:_VAI%\JYVLQVO$QP3C< ZAC]W)K]]Z* /PQ
MN/\ @IM^U3XLMY=,TR[2*[YB>32_#L;W"G;SP48*<<\ $5<^!?\ P3E^-O[4
MGCP^*_BF=8\+:+>R"YU#6_$1)U.]Z#9%#(=X)  #2!548QNP%K]PJ* ,/P/X
M*T7X<^$-(\,>';"/3-#TFV2TM+6+HD:C YZDGJ6/))).2:W*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R;6O^0S?_\
M7Q)_Z$:*-:_Y#-__ -?$G_H1HH [/X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_
MZ^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /)M:_P"0S?\ _7Q)_P"A&BC6O^0S?_\ 7Q)_Z$:* .S^'_\ R!IO
M^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \FUK_D,W_P#U\2?^A&BC6O\ D,W_
M /U\2?\ H1HH [/X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)M:_Y
M#-__ -?$G_H1HHUK_D,W_P#U\2?^A&B@#L_A_P#\@:;_ *^&_P#05KIJYGX?
M_P#(&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /)M:_Y#-__P!?$G_H1HHUK_D,W_\ U\2?^A&B@#L_A_\
M\@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \FUK_ )#-_P#]?$G_ *$:*-:_
MY#-__P!?$G_H1HH [/X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R
M;6O^0S?_ /7Q)_Z$:*-:_P"0S?\ _7Q)_P"A&B@#L_A__P @:;_KX;_T%:Z:
MN9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \FUK_D,W_\ U\2?^A&BC6O^0S?_ /7Q)_Z$:* .
MS^'_ /R!IO\ KX;_ -!6NFKRVVUJ_P!%\ZVM;C9&)"3\BG)Z9Y!]!4W_  F&
MK_\ /W_Y"3_"@#TRBO,_^$PU?_G[_P#(2?X4?\)AJ_\ S]_^0D_PH ],HKS/
M_A,-7_Y^_P#R$G^%'_"8:O\ \_?_ )"3_"@#TRBO,_\ A,-7_P"?O_R$G^%'
M_"8:O_S]_P#D)/\ "@#TRBO,_P#A,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_
MPH ],HKS/_A,-7_Y^_\ R$G^%'_"8:O_ ,_?_D)/\* /3**\S_X3#5_^?O\
M\A)_A1_PF&K_ //W_P"0D_PH ],HKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\
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M_(2?X4?\)AJ__/W_ .0D_P * /3**\S_ .$PU?\ Y^__ "$G^%'_  F&K_\
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M5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  H ],HKS/\ X3#5_P#G[_\ (2?X4?\
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MF&K_ //W_P"0D_PH ],HKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  H
M],HKS/\ X3#5_P#G[_\ (2?X4?\ "8:O_P _?_D)/\* /3**\S_X3#5_^?O_
M ,A)_A1_PF&K_P#/W_Y"3_"@#TRBO,_^$PU?_G[_ /(2?X4?\)AJ_P#S]_\
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M\* /3**\S_X3#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PH ],HKS/_ (3#5_\
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M* /3**\S_P"$PU?_ )^__(2?X4?\)AJ__/W_ .0D_P * /3**\S_ .$PU?\
MY^__ "$G^%'_  F&K_\ /W_Y"3_"@#TRBO,_^$PU?_G[_P#(2?X4?\)AJ_\
MS]_^0D_PH ],HKS/_A,-7_Y^_P#R$G^%'_"8:O\ \_?_ )"3_"@#TRBO,_\
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M'_"8:O\ \_?_ )"3_"@#TRBO,_\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\
M"@#TRBO,_P#A,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_PH ],HKS/_A,-7_Y
M^_\ R$G^%'_"8:O_ ,_?_D)/\* /3**\S_X3#5_^?O\ \A)_A1_PF&K_ //W
M_P"0D_PH ],HKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  H ],HKS/\
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MRBO,_P#A,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_PH ],HKS/_A,-7_Y^_\
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M&K_\_?\ Y"3_  H ],HKS/\ X3#5_P#G[_\ (2?X4?\ "8:O_P _?_D)/\*
M/3**\S_X3#5_^?O_ ,A)_A1_PF&K_P#/W_Y"3_"@#TRBO,_^$PU?_G[_ /(2
M?X4?\)AJ_P#S]_\ D)/\* /3**\S_P"$PU?_ )^__(2?X4?\)AJ__/W_ .0D
M_P * /3**\S_ .$PU?\ Y^__ "$G^%'_  F&K_\ /W_Y"3_"@#TRBO,_^$PU
M?_G[_P#(2?X4?\)AJ_\ S]_^0D_PH ],HKS/_A,-7_Y^_P#R$G^%'_"8:O\
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MKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  H ],HKS/\ X3#5_P#G[_\
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MPH ],HKS/_A,-7_Y^_\ R$G^%'_"8:O_ ,_?_D)/\* /3**\S_X3#5_^?O\
M\A)_A1_PF&K_ //W_P"0D_PH ],HKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\
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M_(2?X4?\)AJ__/W_ .0D_P * /3**\S_ .$PU?\ Y^__ "$G^%'_  F&K_\
M/W_Y"3_"@#TRBO,_^$PU?_G[_P#(2?X4?\)AJ_\ S]_^0D_PH ],HKS/_A,-
M7_Y^_P#R$G^%'_"8:O\ \_?_ )"3_"@#TRBO,_\ A,-7_P"?O_R$G^%'_"8:
MO_S]_P#D)/\ "@#TRBO,_P#A,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_PH ]
M,HKS/_A,-7_Y^_\ R$G^%'_"8:O_ ,_?_D)/\* /3**\S_X3#5_^?O\ \A)_
MA1_PF&K_ //W_P"0D_PH ],HKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_
M  H ],HKS/\ X3#5_P#G[_\ (2?X4?\ "8:O_P _?_D)/\* /3**\S_X3#5_
M^?O_ ,A)_A1_PF&K_P#/W_Y"3_"@#TRBO,_^$PU?_G[_ /(2?X4?\)AJ_P#S
M]_\ D)/\* /3**\S_P"$PU?_ )^__(2?X4?\)AJ__/W_ .0D_P * /3**\S_
M .$PU?\ Y^__ "$G^%'_  F&K_\ /W_Y"3_"@#TRBO,_^$PU?_G[_P#(2?X4
M?\)AJ_\ S]_^0D_PH ],HKS/_A,-7_Y^_P#R$G^%'_"8:O\ \_?_ )"3_"@#
MTRBO,_\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "@#TRBO,_P#A,-7_ .?O
M_P A)_A1_P )AJ__ #]_^0D_PH ],HKS/_A,-7_Y^_\ R$G^%'_"8:O_ ,_?
M_D)/\* /3**\S_X3#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PH ],HKS/_ (3#
M5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  H ],HKS/\ X3#5_P#G[_\ (2?X4?\
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MF&K_ //W_P"0D_PH ],HKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  H
M],HKS/\ X3#5_P#G[_\ (2?X4?\ "8:O_P _?_D)/\* /3**\S_X3#5_^?O_
M ,A)_A1_PF&K_P#/W_Y"3_"@#TRBO,_^$PU?_G[_ /(2?X4?\)AJ_P#S]_\
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M\* /3**\S_X3#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PH ],HKS/_ (3#5_\
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M* /3**\S_P"$PU?_ )^__(2?X4?\)AJ__/W_ .0D_P * /3**\S_ .$PU?\
MY^__ "$G^%'_  F&K_\ /W_Y"3_"@#TRBO,_^$PU?_G[_P#(2?X4?\)AJ_\
MS]_^0D_PH ],HKS/_A,-7_Y^_P#R$G^%'_"8:O\ \_?_ )"3_"@#TRBO,_\
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M'_"8:O\ \_?_ )"3_"@#TRBO,_\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\
M"@#TRBO,_P#A,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_PH ],HKS/_A,-7_Y
M^_\ R$G^%'_"8:O_ ,_?_D)/\* /3**\S_X3#5_^?O\ \A)_A1_PF&K_ //W
M_P"0D_PH ],HKS/_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  H ],HKS/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>cdtx-20231231_g15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g15.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" U0$E,# 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO
M^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#QFBBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q
MFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?
M_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ"^OK;2[&XO+VXBM
M+.WC:6:XG<)'&BC+,S'@  $DGIBOS\_:*_X+$> OA[>3Z/\ #326^(6I1DH^
MJ2RM;:=&P_N':7F_ *IZAS0!^A5%?A#XN_X*V?M%>(KZ6?3?$&D^%H&.5MM+
MT:WD1!SP#<+*Q_$]NU<UIO\ P4\_:7TR4NOQ*DN%9][1W.D6$@/MS!D#Z$4
M?T!T5^0'P=_X+5>,-)OK:U^)G@_3=?TS(674- W6EXH[N8W9HY#_ +(,8]Z_
M3?X$_M#>!/VD/!R^(_ FM1ZG:*0ES;./+N;.3^Y-$>4/7!Z'&5)'- 'I%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/^RC\1/">B>"H-#EL]4TIKV<ZI9O,_F"9D^4K(N!@#M7R%_P^2^/?_/GX/\
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M3/%>B6.L:+J%MJNDWT2SVM]9RK+#-&PRK(ZD@@CN*T* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_\
M(&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *1F"*68A5 R2>@I:^4_^"F'QVE^
M!O[*^O-82M%KGB9QX?L70_-'YR.9I/;$*2 'LS+0!^>O_!2/]OK4?C=XLU+X
M=^!=6:#X;:;)Y%S<6K8_MJ=#\SLPZP*PPB]&V[SG*A?@VBOTN_X)&_L>:3X^
MN;WXQ>,=/BU'3]*N_L>@6-RFZ-KI K273*>&$>Y53.1NW'@HIH ^;_@__P $
MW/CS\9M)M]6T_P )+H.CW""2"^\17 LQ*IZ%8SF4@CD-LP1T)KIO&W_!)[]H
M;P?IL][!H.E^)8X8S(\>B:DDDI ZA8Y C.<=E!)[9/%?O)10!_+%JVCW_A_4
M[G3=4LKC3=1M9#%/:7<312Q..JNC %2/0BNY^ GQX\6?LY?$C3?&7A&]:WO;
M9@MQ:NQ\B]@)&^"90?F1A^(.",$ U^LO_!6;]E/1_B'\(;_XKZ1I_E>,_"\:
M/>36X -[I^X*XD'<Q!MX;J%5QSQC\JOAW^RK\7_BQY3^%?AQXBU6VEQLO/L+
MPVIS_P!-Y L?_CU ']#_ ,%_BSHGQS^%OASQUX><MI>M6HG2-B"\+@E9(FQ_
M$CJR'W4UVM?&W_!,GX!_%;]G/X6>(_#/Q)M+/3[2XU!-0TNTAOUNIH&=-LZO
MLRBKE(B K')9SQW^R: "BHKFYAL[>6XN)4@@B0R22R,%5% R6)/  '>OC3XR
M?\%9/@=\+;ZXT[2+S4/'^I0DHW_"/1*;16'8W$C*K#_:CWCF@#[0HK\LI/\
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MG^\C;E/NIH ZRBBB@ HK-\1^)=)\'Z'>:SKNIV>C:19IYEQ?7\ZPPPKZL[$
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MISD"@#Z,HHKG?'WQ#\-?"WPO=^(_%VMV7A_0[09EO;Z41H">BCNS'H%&23P
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M_P!(XJ /-?\ @I#_ ,F2_%+_ *\K?_TK@K^>ROZ$_P#@I#_R9+\4O^O*W_\
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M*]S_ &5_VZO 7[7FL:_IW@[2/$>FSZ+!%<7#:Y;6\2LLC,JA/*GD).5.<@4
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MO(GBG34*+U97N8T91]58C\:_I1H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0X%Q L$I!Z$12,KG\%]Z\;\5>$=<\#:Y<Z+XCT>_T'5[8XFL=2MGMYX_3*.
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M^.O#6I>']?TZWU;1=2@:VN[*Z0-'+&PP01_7J" 1S7\WW[4'P;;]G_X_>-?
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M"6DR,%N($_V 6C<#L)0O\- 'VG_P3)_X*!7OQE:/X6?$?4/M7C.WA+Z/K$N
M^J0HN7BE/>=%!;=_&H)/S*2WZ*5_+KX!\;ZM\-?&VA>*]"N#:ZQHUY%?6LHZ
M"2-@P!'=3C!'<$CO7]-O@3Q=9_$#P1X>\4:<=VGZUI]OJ-N<Y_=S1K(OZ,*
M/Q]_X+8?\G)>#?\ L4H?_2RZKX?^%?CZY^%7Q*\+>,[.UBOKO0-2M]3AMIR1
M'*\,@=58CG!*C..<5]P?\%L/^3DO!O\ V*4/_I9=5^>U 'LEAX9^,?[;GQ8U
M?5-.TK5/'GBN^D\Z\GC 6&V4Y"*TCD1P1@#:H9E  P*[#XD?\$Y_V@/A7X4N
M?$>L^ Y)M*M4,MU)I=[;WDEN@&2[1Q.S[0,DL 0 "20*_:_]D7X$:/\ L\_
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M[?#WQ5\2OV;?#>F>$?#.L>*M2A\6VUS)9Z)82WDR1"SO%,A2-6(4,Z#=C&6
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M $NFKW7_ ())_P#)Z7A__L&:A_Z(->%?M8_\G3?&3_L<]9_]+IJ]U_X))_\
M)Z7A_P#[!FH?^B#0!^[U9/BS_D5=9_Z\IO\ T6U:U9/BS_D5=9_Z\IO_ $6U
M '\MM?II_P $/O\ D?OBG_V#++_T;)7YEU^FG_!#[_D?OBG_ -@RR_\ 1LE
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MED; &2F\Q] /X.U '\^6G:==ZQJ%M86%M->WMU*L,%M;QEY)9&("HJCDL20
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M_P!B#X7/*VYA;7<8/^RM[<*H_("IO^"D/_)DOQ2_Z\K?_P!*X* /Y[*_;/\
MX(P_\FH:W_V-MY_Z2VE?B97[9_\ !&'_ )-0UO\ [&V\_P#26TH ^]&8(I9B
M%4#))Z"OP,_X*#?MHZK^T]\3KW2M(OYH?AKHMPT.EV*-M2[=<JUY(!]YFYV
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M_94$*/8"@!/AKX"U+XI?$'PYX0T=-^IZY?PV$'&0K2.%W'_94$L?0 U_3+X
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M_1[_ ,-K? 3_ **]X/\ _!M%_C4=Q^V]\ K6%Y7^+OA(JHR1'J<;M^"J23^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9TC(WR+&A;8N?XFQM'N17SQ\(_\ @IU\ ?BQY$#^*V\&ZG*0/L7BF+[( ?\
MKN"T.,^L@/M7SC_P5T_;!TF'PI)\$?"NH1WNK7DT<OB2:W?<MI%&P=+4D?\
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M (/KK_XY67XD^+?CGQCIC:=K_C/Q#KFGLP<VFI:K/<1%AT.QW(R/7%?TI?\
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MEY8@NIP5Z9/8UF_$K_@FA^SU\3))KB7P+'X;OI<G[5X;N'L0N?2%3Y(_[]T
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M^ ?2OYZ: /U4_P""&/\ S6S_ +@G_M_7ZJ5^5?\ P0Q_YK9_W!/_ &_K]5*
M"BBB@ K\ZOVRO^"LFG_"+Q)J7@GX6Z99^)?$5A(UO?:W?DM86THX:.)$8&9U
M.022J@KCY^<?4W[;/Q.U#X._LJ_$?Q7I4WV;5+73?L]K< D&&6XE2W21?]I6
MF##W K^<;.>3R: /??B-^WG\?/BC)*-8^)NM6MM)D&TT:4:=#M_NE8 FX?[Q
M)]<UY7X=\%>-OBUK,HT+0M>\8ZK(W[S[!:37LS,>[%0Q_.OT>_X),_L<^ /B
M1X#U;XH^-]&L_%-VFJ2:;INF:@BS6MNL:1NTKQ'Y7=FDP X( 7('S9'ZK:7I
M-EH=C#9:=9V]A90C;';VL2QQH/154  ?2@#^:#XL? 7Q]\"Y-'B\>>&[GPU/
MJ\#7-G!>/'YKQJVTDHK%DYXPP!]JXO2?^0K9?]=D_P#0A7Z&?\%L?$5E??'/
MP-H\$JR7FGZ TMPJL#Y?FSOL4^AQ'G![,#WK\\])_P"0K9?]=D_]"% ']3U?
MEK_P7*_Y!7P;_P"NVK?^@V=?J57Y:_\ !<K_ )!7P;_Z[:M_Z#9T ?E#7],/
M[-MHEA^SK\++6/\ U</A72HU^@M(@/Y5_,]7]-'[/?\ R0+X:?\ 8LZ9_P"D
ML= 'H%?BI_P6J55_:H\+D* 6\&VI) ZG[;?#)_ #\J_:NOQ6_P""U?\ R=-X
M6_[$RU_]+KZ@#X@^'O\ R/WAG_L)VW_HU:_J(K^7?X>_\C]X9_["=M_Z-6OZ
MB* /YW?^"A$LTW[9WQ6:?.\:J%&?[HAC"_\ CH%+_P $]HXY/VS_ (4B4 K_
M &J2,G'S"&0K^H%=M_P58\$2^#_VT/%5TRLMOKUI9ZK!N'53"L+X]?WD$E?/
MOP&^(P^$/QJ\#^-'1I(-#UBUOIXT&6>%)%,BCW*;A^- ']-M%4M%UJP\2:/8
MZMI=W%?Z;?0)<VMU VZ.:)U#(ZGN"""/K5V@#\</^"VUO$OQS\ S@#SW\.%&
M;OM6ZE*_JS?G7YS5]A?\%5/C)8?%O]K#4[;2;A;K3/"ME%H"S1ME))HWDDG(
M]UDE:,_]<J^/: /ZJ**** "BBB@#\D_^"W_@ZXA\7?##Q6J;K2YL;O2W<#[C
MQR)(H)]Q,V/]UJ_,.OW\_P""EWP%G^._[+>MQZ;"T^O>&9!K]A%&N6F\I'$T
M0[G,3R$ =65*_ .@#^BC]@7QK!X\_8[^%=]#*DAL]&BTJ0*>4:US;[3Z'$0/
MXBOH"OQM_P""3O[9ND?"/5=0^%?C?48],\.ZW="[TC4KEL16UZP5'BD8\*D@
M5"&. K*<_?R/V15@R@@Y!Y!% "US'Q.^(&G?"GX<^)O&6K!FT[0=.GU&=(R-
M\BQH6V+G^)L;1[D5T]?F'_P5T_;!TF'PI)\$?"NH1WNK7DT<OB2:W?<MI%&P
M=+4D?\M&=59A_"J '[_ !]'?"/\ X*=? 'XL>1 _BMO!NIRD#[%XIB^R '_K
MN"T.,^L@/M7U)I>JV6N:?!?Z=>6]_8SKOBN;659(Y%]59201]*_EAK]H_P#@
MC7\'[[P;\!]=\;:DL\3^++\"QAD8[?LEN&02*O8O(TH)QR(T/(Q0!]8?M8_\
MFL_&3_L3-9_](9J_FLK^ES]IZQ?5/V:OBS9Q_P"LN/".K0KQGEK.4#^=?S1T
M ?KG_P $/F'_  @/Q4&>?[3LCC_ME)7Z:U^5_P#P0XUJ#[/\7](9U6YW:7=1
MQ_Q.N+I6(]@=G_?0K]4* /CS_@K),L?[$_BM6.#)?Z<J_7[5&?Y U^#5?M;_
M ,%F/'FGZ%^S3H_AE[F,:MKVNPM#:Y&]H($=Y9,?W58PJ?>05^*5 '[O?\$D
M_P#DRWP__P!A/4/_ $>:[7_@I#_R9+\4O^O*W_\ 2N"N*_X))_\ )EOA_P#[
M">H?^CS7:_\ !2'_ ),E^*7_ %Y6_P#Z5P4 ?SV5^U7_  17M?)_99\33%0&
MF\871#=RHL[(#]<U^*M?MG_P1A_Y-0UO_L;;S_TEM* /O6OQ@_X+8?\ )R7@
MW_L4H?\ TLNJ_9^OQ@_X+8?\G)>#?^Q2A_\ 2RZH ^!O#MM'>>(-,MY1NBEN
MHHW'J"X!K^IBOY;/"?\ R-6C?]?L/_HQ:_J3H R?%G_(JZS_ ->4W_HMJ_EM
MK^I+Q9_R*NL_]>4W_HMJ_EMH _33_@A]_P C]\4_^P99?^C9*_72OR+_ ."'
MW_(_?%/_ +!EE_Z-DK]=* /YK/VL?^3IOC)_V.>L_P#I=-7NG_!)-@/VTO#P
M)QG3-0 _[\-7BG[8%B^G_M7?&&*3[S>+M4F''9[J1Q^C"O4/^"6^M0:+^V]\
M/_M#K%'=K?VH=^!N:RGV#ZE@JCZT ?OU6-XRF6W\'Z[*YPB6$[,?81L:V:\N
M_:C\>:?\-?V=?B-XAU*YCM8+70KM8VD(&^=XFCAC&?XGD=%'NPH _FHK]-/^
M"'W_ "/WQ3_[!EE_Z-DK\RZ_33_@A]_R/WQ3_P"P99?^C9* /UTK^<']M;_D
M[CXO?]C-??\ HUJ_H^K^<']M;_D[CXO?]C-??^C6H ]*_P""5?\ R?'X!_ZX
MZE_Z07%?OI7X%_\ !*O_ )/C\ _]<=2_](+BOWTH ^5OVU/V_/"?[(MG!I2V
M9\3>.[Z S6NBQ2A(X(\X6:Y?DHI(.% +-M/0?,/RJ^*7_!3C]H+XG7$X3QFW
MA'3Y"=MCX9A6T$8]IN9OSDKQ#X\?$_4/C/\ &/QAXUU.;S[G6-2EN%Y)"1;M
ML4:Y_A2-44>RBO>?^":?[,_AS]ICX^W%AXO5KGPYH.G-JMQIZ2%#>N)8XTB8
M@A@F7+,1_= XW4 ?.%_K'C#XK:[&+V^USQAK,I.P7$LU]</GKC)9C77>*OV6
MOBQX#^'LOC?Q-X#U?PYX9CFC@:[U>(6K[Y#A (9")#GU"X]Z_HT\%_#OPM\-
M]+73?"GAS2O#=@H ^SZ59QVZ''<A ,GW/-?''_!8SQ%9:5^R7#IT\JK>:IK]
MI%;Q;AN;8LDCMCK@!>3V++ZT ?A_7]!'_!,O_DQSX8?]<;[_ -+[FOY]Z_H(
M_P""9?\ R8Y\,/\ KC??^E]S0!VO[:W_ ":/\7O^Q9OO_135_.%7]'_[:BM)
M^R1\7@JEC_PC%^< 9X$+$G\J_G H _7[_@B'_P DL^)?_89M_P#T0:_2JOS4
M_P""(3K_ ,*O^)BY&X:S;$KGD P'!_0_E7Z5T ?"O_!9+_DT>S_[&:R_]%7%
M?B#7[??\%DO^31[/_L9K+_T5<5^(- ']!'_!,O\ Y,<^&'_7&^_]+[FOJ"OE
M_P#X)E_\F.?##_KC??\ I?<U]04 ?A%_P58^!)^$/[4&H:Y96WDZ%XTB.LP,
MHPJW).VZ3_>\S$A]IQ7BW[(/QH?X _M&^"/&33&'3K6^6WU+G@V<W[J?([X1
MRP]U%?KW_P %6/@3_P +>_9?U#7+*V\[7?!<IUF!E&6:V VW2?[OEXD/O *_
M"*@#]M?^"PGQJ/@']G.Q\&6-QLU'QK>B!]K8/V*#;+,1]7,"^X=J_$JO9OVD
M_P!I#5?VB6^'YU(RC_A%_#%IH;>8<^=/'N\VXZ_>?Y,_[@KH?V!/@7_PT!^U
M%X1T*ZM_M&AZ=+_;.K*5RIM;<AMC?[,DABB/_72@#]F_V!_@7_PS_P#LO^$=
M N;?R-<OXO[8U8$8;[5. Q1O>-!''_VSK@O^"LES+!^Q/XJ2,92:_P!.23_=
M^U1M_-5K[#KYR_X*(>!9OB%^QK\3=.MHFENK6P35(U09;_19H[A\?\ B<?C0
M!_/)74^&?BMXV\%Z<VG^'O&.OZ#8-(93:Z9JD]M$7( +;48#) '/L*Y:OUX_
MX(XWW@KQU\&?%7A/6-(T;5/$FC:PUXJ7ME%+-]CFBC"$%E)*B2.4'!XW#.,C
M(!^8W_#0GQ3_ .BE^,/_  ?77_QRLOQ)\6_'/C'3&T[7_&?B'7-/9@YM-2U6
M>XB+#H=CN1D>N*_I2_X5/X'_ .A-\/\ _@K@_P#B*\J^/'Q(^ '[-%OH=Q\0
M]+T#1(=9FDAM&305N6;8 78I%$S;5W+DXZL/6@#^=>OZ!/\ @F)J#:E^PW\,
MWD?>\<=_ ><X":A<JH_[Y"UH>#OCQ^REX\V#1_$GPW:63[D-[':V<K>PCF5&
M)_"OH+P[:Z1::+:IH,-C#I++YENNG*BP%6.[<FSY<$DG(ZYH TJ*** "BBB@
M K\M?^"Y7_(*^#?_ %VU;_T&SK]2J_+7_@N5_P @KX-_]=M6_P#0;.@#\H:_
MHS_85_Y,_P#A)_V+]O\ RK^<ROZ,_P!A7_DS_P"$G_8OV_\ *@#W6BBB@#S/
MQ5^TY\(?!%_<V&O?%#PAI6H6TC0SV5SK=LMQ$ZL596BW[@0P(.1P0<USO@O]
MM;X(_$7QQI?@_P -?$+3=9\1:FS+:6=K',PE*QM(1OV; =J,>6'0#J0#^-O_
M  4V^&=Q\-?VQO&K/#Y=CX@:/7;-_P#GHLR_O3_W^28?A7@'PK^(FH_"7XD^
M&?&>DX.H:%J$-_$C'"R>6X8HQ_NL 5/LQH _I_KSOXD?LZ_#'XO))_PF7@/0
M?$$T@P;JZL8_M(_W9@!(OX,*O?!GXP>&OCQ\.-&\:^$[Y+W2=2B#[<CS+>3
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MX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB = !ZGJ2:^EO^'2_P"T=]L\G_A&M*$>[;]H_MJWV8_O8W;L?AGVKVKX/_\
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MH).?1?!O_!'GX\>(+Z%-9/AWPM:%OWLUWJ/VAU7N52%7W'T!(^HK]%?V1/\
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M !VO4O@]_P $6O'>M:G!<?$GQ3I?AO2%D_>V>C.;N]D4=0&*B-,]FR^.Z]J
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MHX_KB,3M[$(?2O@2OWU_X)A?!3_A3O[)_AVXNK?R=:\5,=?O-P^8+* +=?7
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M.18P FQ6).48L6Y);)))-?(G_#DOXI_]#UX/_P"^KK_XS0!^RE%%% !1110
MG7@\BOQ7_P""DW_!/_4?@_XHU3XF> -)-Q\.]0<W%_9V:9.BSL?G^0#BW8G*
ML.$)*G: N?VIJ*ZM8;ZVEM[B&.XMYD,<D,JAD=2,%2#P01Q@T ?RN5] _"']
MO;XZ?!'1X='\-^.[I]%@4)#IVJPQWT,*CHL?FJS1J/[JD#GI7Z7_ +17_!(7
MX;?%*^FUCP!J#?#35I27EL[>V^TZ;*?]F'<IAY_N-M Z)7QEXJ_X(\?'O0KJ
M9-+_ .$;\26Z\QRV>IF$N/=9D3!]LXXZF@#@_B%_P4V_:'^(FDS:9-XW_L*R
MF0I*N@V<5G*P]IE7S5_X"XKY:FFDN)7EE=I)78LSN<EB>22>YK[(TO\ X))?
MM&7]TL,_A_1]-C/6XNM9@9!R!TC+-[].U?1_P7_X(GK;WD%[\5?'$=U#&P9M
M(\+HP63'.&N95! /0@1@XZ,* /B/]C?]D?Q'^UE\3K72+*&XL_"EE(DFN:VJ
M_):P]=BD\&5P"%7G^\1M4U_0KX3\+Z7X'\+Z3X>T2T2PT?2K6*RL[6/[L44:
MA47\ !S6;\-_ACX5^$'A.T\,^#="L_#VAVO,=I9IM!8@ NY/+N<#+L2QQR37
M44 9WB+0[?Q-X?U/1[P$VFH6LMI,!UV2(4;]":_F0^*'PYUKX0_$+7_!OB&V
M:UU?1KM[2=&4@-@_*Z^JLNUE/<,#WK^H"OE?]LG_ ()^>"OVMHH]7:Z;PKXZ
MMXA##KUM#YJS1CI'<197S%&3A@0R^I VT ?B9^SO^T-XM_9C^)5KXT\'SPB]
MCC:VN;.Z4O;WENQ!:*5002I*J<@@@J"#Q7WUJ'_!<?4)-$*6/P@MH-8*$>?<
M:^TMNK8&&\L6ZL1G/R[Q@ ?,<\>*^+/^"/\ \?M!OYHM+M_#_B6U5\1W%EJB
MP[EYP2LP0@],CGKP3UKKOA?_ ,$7_BCX@U*-O&_B30_".EC!<6;M?W9YZ! %
M0<=R_'H: /E;XJ?$[XH_MB>.M;\6Z^TVNW>EZ=+>S16B;+/2K&+EMBDXC0$@
M<DEF8<LS<^.U_0/'^PCX/^'_ .R_XY^%OPVM8-,U7Q-IC6=SKVK,9)[N7!"O
M.ZKG:,MA44*,G"Y))^#/^')?Q3_Z'KP?_P!]77_QF@#[*_X))_\ )EOA_P#[
M">H?^CS7:_\ !2'_ ),E^*7_ %Y6_P#Z5P5N_L3_ +/NL_LQ_ /3/ >O:C8Z
MKJ-K=W-PUSIV_P DK+(7 &]5.0#SQ6_^U9\(-2^/G[/OC'P#H][:Z=J6M6\4
M4-S?;O)0K/'(2VT$]$(X'>@#^;"OVS_X(P_\FH:W_P!C;>?^DMI7S!_PY+^*
M?_0]>#_^^KK_ .,U^@?[!/[,>O?LG?!?4/!OB+5=.UB^N-:GU-;C2S)Y01X8
M$"G>JG=F(]L<B@#Z1K\8/^"V'_)R7@W_ +%*'_TLNJ_9^O@G_@H!_P $]?&?
M[7'Q6T'Q5X<\1Z%HUGI^BIIDD.J&;S&=9YI"PV1L-N)0.N<@T ?C%X3_ .1J
MT;_K]A_]&+7]2=?CQHO_  19^*.F:S87DGCCPBZ6]Q'*RJ;K)"L"0/W/M7[#
MT 9/BS_D5=9_Z\IO_1;5_+;7]3>M6+ZGHU_9QLJ/<6\D2LW0%E(!/YU^/'_#
MDOXI_P#0]>#_ /OJZ_\ C- '0?\ !#[_ )'[XI_]@RR_]&R5^NE?$7_!/7]A
M'Q=^Q_XE\8ZEXE\0:+K46M6EO;PII1FW(T;NQ+;T7@[ATK[=H _!G_@JC\'=
M1^&?[6/B#6Y+5TT/Q<$U:PN=OR.^Q$N$S_>64$D=A(A[U\F^'?$&I>$]?TW6
M]'O)=/U;3;F.[M+N$X>&:-@R.I]0P!_"OZ1OVBOV;O!7[3W@&3PMXTL7FA1C
M-97]LVRYL9L8\R)L'G'52"I'4'BORK^)W_!&7XM>&]4E_P"$+US0_&6E<F)I
MI3877<X:-\IZ#(D/T% ';^"_^"WVOZ;X8@M?%'PNL]=UV*/:^HZ?K#644[#
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M8'\RO&G_  1Y^//AV_>/11X>\5VF[]W/9ZD+=MO."R3JF#[ MUZF@#Z?N?\
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MV_91\<:OXQ\7>)=(N9]2TA],.BZ4LDH0M-%*)&F8(-R^45VA2/G/S<<@%_\
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M$K);W&,@>9"X:-R,G!921DXQ7TE%_P %?/VA([$0->^'99<@_:FTA?,.!C&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7\T/[37_)R7Q7_ .QMU;_TLEK^EZOP _:"_9 ^-OB#X]_$
MK5-,^%?BJ^TV^\3:E<VUU!I<K1S1/=2,CJ0.5*D$'T- '5_\$A_^3R=-_P"P
M-?\ _H"U^ZE?CI_P3!_9K^*GPO\ VJK#7/%OP^\0^'-'32KR)K[4K"2&(.R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#QFBBB@#T#X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/
MA_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'__ "!IO^OA
MO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX
M?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_
M $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@
M#T#X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT7C;P3X>\0P8\C5M.M[^/;TVRQ+(/T:@#<HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A__P @:;_KX;_T
M%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@
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M'[0G_) OB7_V+.I_^DLE?S+T ?T>_L4_\FC_  A_[%FQ_P#12U[77BG[%/\
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MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
M?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345
MS/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#G
MM=?]]+_\31_PK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_P
MK_3_ /GM=?\ ?2__ !- '345S/\ PK_3_P#GM=?]]+_\31_PK_3_ /GM=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY"ME_P!=D_\ 0A7[T_\ !53_ ),<\??]=M-_]+[>OP6TG_D*V7_79/\ T(4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?#?\
MH*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'C-%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y
M TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?
M^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'C-%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%%
M 'H'P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P__P"0
M--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?#?\
MH*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'C-%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y
M TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !132U1M,%H FI,U6:Z
M7UIOVQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@
M"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB
M^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"
MWFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^
MM'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"W
MFC-5/MB^M'VQ?6@"WFC-5/MB^M'VQ?6@"W2U4%TOK3UG5J +%%,5\TZ@!:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFKF?A_
M_P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK&G5%(WRT 5KJY$:DYKYJ
M_:+_ &G-7^$OBC3](TG3;.]$]I]JDENRYQEV4* I']P_G7O.O7ODQL<U\%_M
M>7OV[XC:>V<[=-5?_(LE>EE]*%:NHS5UJ>)G%>IA\(ZE)V=T;[?MS>+V_P"8
M)H_Y2_\ Q=-_X;D\7_\ 0%TC\I?_ (NOG"BOJOJ&&_D/@?[6QW_/U_@?1_\
MPW)XO_Z ND?E+_\ %T?\-R>+_P#H"Z1^4O\ \77SA11]0PW\@?VMCO\ GZ_P
M/H__ (;D\7_] 72/RE_^+H_X;D\7_P#0%TC\I?\ XNOG"BCZAAOY _M;'?\
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M_P"@+I'Y2_\ Q='_  W)XO\ ^@+I'Y2__%U\X44?4,-_(']K8[_GZ_P/H_\
MX;D\7_\ 0%TC\I?_ (NC_AN3Q?\ ] 72/RE_^+KYPHH^H8;^0/[6QW_/U_@?
M1_\ PW)XO_Z ND?E+_\ %T?\-R>+_P#H"Z1^4O\ \77SA11]0PW\@?VMCO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_
M $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\UZG8M^[%>1_#X_N8_I7K>G_ .K6OS@_:B^O2EI%Z4M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'C-%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1?7I2TB]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_ /(&F_Z^&_\
M05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!XS1110!Z!\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*
MUTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFDHKZT_/#ZI_X)^?\C[XG_[!B_\ HU:^HOVBO^2&^-O^P9+_ "KY=_X)^?\
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M>(G1OM^6X5^AO[#7_)#5_P"PG<?R2OSRK]#?V&O^2&K_ -A.X_DE<&;?[O\
M-'K\/_[Y\G^AS/\ P4#_ .1"\,?]A-O_ $4U?#%?<_\ P4#_ .1"\,?]A-O_
M $4U?#%7E?\ NR^9CGW^_2]%^04445ZQ\^%%%% !1110 4444 %:OA/_ )&K
M1O\ K]A_]&+656KX3_Y&K1O^OV'_ -&+6=3X)>AM1_BQ]4?H?\/?]1']*]<T
M_P#U:UY'\/?]1']*]<T__5K7YP?M1?7I2TB]*6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#QFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M74C333S-N:1R<DD_6JM?48>BL/2C370^#QF)>+Q$ZS6_](*_0W]AK_DAJ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57N/N
MU8JO<?=H X+QE_J'^AKX*_:1_P"1\@_Z\U_]&/7WKXR_U#_0U\%?M(_\CY!_
MUYK_ .C'KU\K_P!Y7HSYW/O]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@
MK[$^!?Q^\!>#?V>CX9UC7?L>M^3>K]E^QW#\R,Y3YEC*\[AW[\U\=T5S8C#Q
MQ$5&?1W.[!XRI@INI32;:MJ%%%%=)PA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5J^$_P#D:M&_Z_8?_1BU
ME5J^$_\ D:M&_P"OV'_T8M9U/@EZ&U'^+'U1^A_P]_U$?TKUS3_]6M>1_#W_
M %$?TKUS3_\ 5K7YP?M1?7I2TB]*6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB
M@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "J]Q]VK%5[C[M '!>,O\ 4/\ 0U\%?M(_\CY!_P!>:_\ HQZ^]?&7
M^H?Z&O@K]I'_ )'R#_KS7_T8]>OE?^\KT9\[GW^XOU1Y31117VA^8A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5J^$_^1JT;_K]A_\ 1BUE5J^$
M_P#D:M&_Z_8?_1BUG4^"7H;4?XL?5'Z'_#W_ %$?TKUS3_\ 5K7D?P]_U$?T
MKUS3_P#5K7YP?M1?7I2TB]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X
M?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2+TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFK
MF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ5>X^[0!P7C+
M_4/]#7P5^TC_ ,CY!_UYK_Z,>OO7QE_J'^AKX*_:1_Y'R#_KS7_T8]>OE?\
MO*]&?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %:OA/\ Y&K1O^OV'_T8M95:OA/_ )&K1O\ K]A_]&+6=3X)>AM1_BQ]
M4?H?\/?]1']*]<T__5K7D?P]_P!1']*]<T__ %:U^<'[47UZ4M(O2EH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;0!_1[^Q3_R:/\(?^Q9L?_12U[77BG[%/_)H_P (?^Q9L?\ T4M>UT %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
M\31_PF%Q_P! >Z_7_P")KIJ* .9_X3"X_P"@/=?K_P#$T?\ "87'_0'NOU_^
M)KIJ* .9_P"$PN/^@/=?K_\ $T?\)A<?] >Z_7_XFNFHH YG_A,+C_H#W7Z_
M_$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\ \31_PF%Q_P! >Z_7_P")
MKIJ* .9_X3"X_P"@/=?K_P#$T?\ "87'_0'NOU_^)KIJ* .9_P"$PN/^@/=?
MK_\ $T?\)A<?] >Z_7_XFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)K
MIJ* .9_X3"X_Z ]U^O\ \31_PF%Q_P! >Z_7_P")KIJ* .9_X3"X_P"@/=?K
M_P#$T?\ "87'_0'NOU_^)KIJ* .9_P"$PN/^@/=?K_\ $T?\)A<?] >Z_7_X
MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
M\31_PF%Q_P! >Z_7_P")KIJ* .9_X3"X_P"@/=?K_P#$T?\ "87'_0'NOU_^
M)KIJ* .9_P"$PN/^@/=?K_\ $T?\)A<?] >Z_7_XFNFHH YG_A,+C_H#W7Z_
M_$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\ \31_PF%Q_P! >Z_7_P")
MKIJ* .9_X3"X_P"@/=?K_P#$T?\ "87'_0'NOU_^)KIJ* .9_P"$PN/^@/=?
MK_\ $T?\)A<?] >Z_7_XFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)K
MIJ* .9_X3"X_Z ]U^O\ \31_PF%Q_P! >Z_7_P")KIJ* .9_X3"X_P"@/=?K
M_P#$T?\ "87'_0'NOU_^)KIJ* .9_P"$PN/^@/=?K_\ $T?\)A<?] >Z_7_X
MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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MFNFHH YG_A,+C_H#W7Z__$T?\)A<?] >Z_7_ .)KIJ* .9_X3"X_Z ]U^O\
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M-=*O2EH YG_A,+C_ * ]U^O_ ,31_P )A<?] >Z_7_XFNFHH YG_ (3"X_Z
M]U^O_P 31_PF%Q_T![K]?_B:Z:B@#F?^$PN/^@/=?K_\31_PF%Q_T![K]?\
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M (FNFHH YG_A,+C_ * ]U^O_ ,31_P )A<?] >Z_7_XFNFHH YG_ (3"X_Z
M]U^O_P 31_PF%Q_T![K]?_B:Z:B@#F?^$PN/^@/=?K_\31_PF%Q_T![K]?\
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M (FNFHH YG_A,+C_ * ]U^O_ ,31_P )A<?] >Z_7_XFNFHH YG_ (3"X_Z
M]U^O_P 31_PF%Q_T![K]?_B:Z:B@#F?^$PN/^@/=?K_\31_PF%Q_T![K]?\
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MO@S]F/P;:>)_'-Q>6VE75ZNGQ-96CW#-,R.X4A>GRQN<DC[OK0!X_P#M@?\
M!.WP%^U=.VO_ &B3PCX[6(1#7+*(2)<JHPBW,)($F!P&!5P !D@ 5^.O[57[
M(WC+]D?Q5INC>++K2]0CU2*2>QO=+F9TEC1@&W*ZJR,-PX(QZ$]:_6[X7_\
M!5;X/_%SXK>&_ >AZ=XF@O=<NOLD&H:E:00VJR%6**2)F?+,%0?+U<5\K?\
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M  Y'VBX(Y2('/'5R"JXPS+)^W)^VAHW[(OP]6:)(-5\<ZLK1Z-H\C<<<-<3
M<B)#CC@N<*"/F9?P0\>^/?$7Q6\9ZEXG\3ZG<:WX@U2;S;BZG.YG8\!0!P%
MPJJ!@    "@"7XF?$SQ)\8/'&J^+O%NIRZOKVIR^;<7,OY*BJ.%10 JJ.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %5[C[M6*KW'W: ."\9?ZA_H:^"OVD?^1\
M@_Z\U_\ 1CU]Z^,O]0_T-?!7[2/_ "/D'_7FO_HQZ]?*_P#>5Z,^=S[_ '%^
MJ/*:***^T/S$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M7PG_R
M-6C?]?L/_HQ:RJU?"?\ R-6C?]?L/_HQ:SJ?!+T-J/\ %CZH_0_X>_ZB/Z5Z
MYI_^K6O(_A[_ *B/Z5ZYI_\ JUK\X/VHOKTI:1>E+0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^OV'_T8M9U/@EZ&U'^+'U1^A_P]_P!1']*]<T__ %:UY'\/?]1']*]<T_\
MU:U^<'[47UZ4M(O2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^4/VTOV![#]L
MC7O#&IWGC*Y\+MH=M-;+'!IZW(E\QE;))D7&-OOUKZOHH P? /A5/ G@7PYX
M:CN6O$T;3;;3EN&3891#$L8<KDXSMSC/>MZBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_ /R!IO\ KX;_ -!6NFKF?A__
M ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ5>X^[0!P7C+_ %#_
M $-?!7[2/_(^0?\ 7FO_ *,>OO7QE_J'^AKX*_:1_P"1\@_Z\U_]&/7KY7_O
M*]&?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %:OA/_D:M&_Z_8?_ $8M95:OA/\ Y&K1O^OV'_T8M9U/@EZ&U'^+'U1^
MA_P]_P!1']*]<T__ %:UY'\/?]1']*]<T_\ U:U^<'[47UZ4M(O2EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \9HHHH ] ^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^
M&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J]Q]VK%5[C[M '!>,O]0_T-?!7[2/
M_(^0?]>:_P#HQZ^]?&7^H?Z&O@K]I'_D?(/^O-?_ $8]>OE?^\KT9\[GW^XO
MU1Y31117VA^8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J^$_^
M1JT;_K]A_P#1BUE5J^$_^1JT;_K]A_\ 1BUG4^"7H;4?XL?5'Z'_  ]_U$?T
MKUS3_P#5K7D?P]_U$?TKUS3_ /5K7YP?M1?7I2TB]*6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#QFBBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J]Q]VK%5[C[M '!>,O]0_T-?!7[2/_ "/D'_7F
MO_HQZ^]?&7^H?Z&O@K]I'_D?(/\ KS7_ -&/7KY7_O*]&?.Y]_N+]4>4T445
M]H?F(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:OA/_ )&K1O\
MK]A_]&+656KX3_Y&K1O^OV'_ -&+6=3X)>AM1_BQ]4?H?\/?]1']*]<T_P#U
M:UY'\/?]1']*]<T__5K7YP?M1?7I2TB]*6@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MQFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***3- "T4TM2>8/6@!]%1^:/6CS1ZT 245'YH]:/-'K0!)14?FCUH
M\T>M $E%1^:/6CS1ZT 245'YH]:/-'K0!)14?FCUH\T>M $E%1^:/6CS1ZT
M245'YH]:/-'K0!)14?FCUH\T>M $E%1^:/6CS1ZT 245'YH]:/-'K0!)14?F
MCUH\T>M $E%1^:/6CS1ZT 245'YH]:/-'K0!)14?FCUH\T>M $E%1^:/6CS1
MZT 245'YH]:/-'K0!)14?FCUH\T>M $E%1^:/6CS1ZT 245'YH]:/-'K0!)1
M3/,IVZ@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_
M /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (I.AKE?$DQCA;GM74S?=KCO%1_</0!\6_M=71N+K0 3G
M:UQ_[3KYXKWK]JIMU]HO^]/_ .R5X+7V^6_[K'Y_FS\LSO\ W^I\OR04445Z
MAX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?I%\/;\RV=ODY^1
M?Y5^;M?HA\,W_P!#M_\ ='\J^:SG_EW\_P!#[?AG>M_V[^I[=I[;HQ6BM96E
M_P"K7Z5JK7S)]R+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !5>X^[5BJ]Q]V@#@O&7^H?Z&O@K]I'_D?(/^O-?_1CU]Z^,O\
M4/\ 0U\%?M(_\CY!_P!>:_\ HQZ]?*_]Y7HSYW/O]Q?JCRFBBBOM#\Q"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K5\)_\ (U:-_P!?L/\ Z,6L
MJM7PG_R-6C?]?L/_ *,6LZGP2]#:C_%CZH_0_P"'O^HC^E>N:?\ ZM:\C^'O
M^HC^E>N:?_JUK\X/VHOKTI:1>E+0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XS1110!
MZ!\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH *_0WX8_\>=O_ +H_E7YY5^AOPQ_X\[?_ '1_*OFLY_Y=_/\
M0^WX9WK?]N_J>VZ7_JU^E:JUE:7_ *M?I6JM?,GW(M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5[C[M6*KW'W: ."\9?ZA_H
M:^"OVD?^1\@_Z\U_]&/7WKXR_P!0_P!#7P5^TC_R/D'_ %YK_P"C'KU\K_WE
M>C/G<^_W%^J/*:***^T/S$**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "M7PG_P C5HW_ %^P_P#HQ:RJU?"?_(U:-_U^P_\ HQ:SJ?!+T-J/\6/J
MC]#_ (>_ZB/Z5ZYI_P#JUKR/X>_ZB/Z5ZYI_^K6OS@_:B^O2EI%Z4M !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'C-%%% 'H'P__ .0--_U\-_Z"M=-7,_#_ /Y TW_7
MPW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG@]B?%/V)O!.L_#[5OB+HNNV4EC?6\UF"K@[77]_AT/1E/8BOF3QSXZU_P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O(?C;^UI\)OV=U5/'7C.QTJ_<;DTN$-<WK C(
M/D1!G53V9@%]Z^2/^"DG_!12[^#-U<?##X97J)XS:,?VQK2J'_LM'4%8HL\>
M>RD$MSL!&/F.4_'34M2N]8U"YO[^ZFOKZYD::>YN9#)+*['+,S$DL2>23R:
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MM+N"_M8;JVFCN+:9%DBFB8,CJ1D,"."""#FIJ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;
M_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH ****
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M#7P5^TC_ ,CY!_UYK_Z,>O7RO_>5Z,^=S[_<7ZH\IHHHK[0_,0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *U?"?_(U:-_U^P_\ HQ:RJU?"?_(U
M:-_U^P_^C%K.I\$O0VH_Q8^J/T/^'O\ J(_I7KFG_P"K6O(_A[_J(_I7KFG_
M .K6OS@_:B^O2EI%Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(%SM#-U(&YL9Z9-9NC^%-!\)S:I>Z=IMGILU],]W?74:!7F<DLSR/U/)8\G
MR<8KS?K_ +]2IRZR5OP/<>4_NJ-'FTIMOUUN,\=ZU!X=\$Z_JERP2"SL)YW)
M]%0G'U-?D97UO^UY^TQ8>)]/E\$>$[M;RQ9P=2U&$YCEVD$11M_$N0"6'!P
M,C-?)%>UE>'E1I.4U9R/F,^QD,37C"F[J/7S85Z[^R5_R<-X0_ZZ7'_I-+7D
M5>N_LE?\G#>$/^NEQ_Z32UZ.)_@3]'^1XN!_WJE_BC^:/TSK\=;S_C\G_P"N
MC?SK]BJ_'6\_X_)_^NC?SKPLFWJ?+]3ZSB;:C_V]^A#74:7\+/&FN:?#?:=X
M0U[4+*8;HKFUTR>2.09QE652",^E<O7Z?_LP_P#)!/!O_7H?_1CUZN.Q4L+!
M3BKW9\_E>!CF%65.4K65S\UO$/A#7O",D,>NZ)J.BR3 M$FH6DD!<#J5#@9
M]JR:^M?^"A'_ ",O@[_KTN/_ $-:^2JWPU9UZ4:C5KG)CL.L)B)T8NZ7^05]
MY_L _P#)*==_[#3_ /HB&O@ROO/]@'_DE.N_]AI__1$-<6:?[L_5'J9!_OJ]
M&7?V]/\ DC&G_P#8:@_]$SU^?]?H!^WI_P D8T__ +#4'_HF>OS_ *65?[M\
MV5Q!_OK]$?:O['_QB\%^!?A/-INO^(K/2[XZE-,(+AB&V%(P&Z=.#^5>X?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9H _J.T'Q!I?BK2;?5=%U*SUC3+E=T%[83I/#*O3*NA*L/H:T*\P_9B^$Z?
M_P#9_P# G@@(L=QI.EQ)=[>ANGS)<,/8RO(?QKT^@#PS]HW]LWX7?LQZ;=_\
M)5XA@F\1)!YUOX;L6$M_<$CY!L'^K5O[\FU>#@GI7X'?M!?&W6_VB/B[XA\>
MZ]^ZNM4GS#:*Y9+2W4;8H%.!D(@ S@9.6/)-?<?_  6T^'(TOXH_#_QO#%M3
M6-+FTR=U''F6T@=2?<K<8^D?M7SK^QG^PEXT_:N\36MV;:;0_A[;3J-2\03+
ML$B@C=#;9'[R4C(S@JG5CT5@#]!O^",GPKN_"/P \1^,;ZW>W?Q9JH^R[O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG/\ R[^?Z'V_#.];_MW]3VW2_P#5K]*U5K*TO_5K]*U5KYD^Y%HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ5>X^[0!
MP7C+_4/]#7P5^TC_ ,CY!_UYK_Z,>OO7QE_J'^AKX*_:1_Y'R#_KS7_T8]>O
ME?\ O*]&?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %:OA/\ Y&K1O^OV'_T8M95:OA/_ )&K1O\ K]A_]&+6=3X)>AM1
M_BQ]4?H?\/?]1']*]<T__5K7D?P]_P!1']*]<T__ %:U^<'[47UZ4M(O2EH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG^;/RS._]_J?+\D%%%%>H>$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7Z&_#'_ (\[?_='\J_/*OT-^&/_ !YV_P#NC^5?-9S_ ,N_G^A]OPSO
M6_[=_4]MTO\ U:_2M5:RM+_U:_2M5:^9/N1:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!#-]VN-\5_ZAZ[*;[M<;XK_
M -0] 'P_^U1_R$-&^L__ +)7@]>\?M4?\A#1OK/_ .R5X/7V^6_[K'Y_FS\L
MSO\ W^I\OR04445ZAX04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%?H;\,?^/.W_ -T?RK\\J_0WX8_\>=O_ +H_E7S6<_\ +OY_H?;\,[UO^W?U
M/;=+_P!6OTK56LK2_P#5K]*U5KYD^Y%HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@"&;[M<;XK_U#UV4WW:XWQ7_ *AZ /A_]JC_ )"&
MC?6?_P!DKP>O>/VJ/^0AHWUG_P#9*\'K[?+?]UC\_P V?EF=_P"_U/E^2"BB
MBO4/""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K]#?AC_QYV_\
MNC^5?GE7Z&_#'_CSM_\ ='\J^:SG_EW\_P!#[?AG>M_V[^I[;I?^K7Z5JK65
MI?\ JU^E:JU\R?<BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_KS7_T8]?>OC+_
M %#_ $-?!7[2/_(^0?\ 7FO_ *,>O7RO_>5Z,^=S[_<7ZH\IHHHK[0_,0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U?"?_ "-6C?\ 7[#_ .C%
MK*K5\)_\C5HW_7[#_P"C%K.I\$O0VH_Q8^J/T/\ A[_J(_I7KFG_ .K6O(_A
M[_J(_I7KFG_ZM:_.#]J+Z]*6D7I2T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4-W=P:?:S75U-';6T*-)+-,P5(T R68G@  $
MDFIJ\J_:Q_Y-9^,G_8F:S_Z0S4 =5_PMGP/_ -#EX?\ _!I!_P#%T?\ "V?
M_P#T.7A__P &D'_Q=?S!44 ?T^_\+9\#_P#0Y>'_ /P:0?\ Q='_  MGP/\
M]#EX?_\ !I!_\77\P5% ']1VB>-O#OB:Y>WT?7]+U6X1/,:&QO(YG5<@;B%8
MD#) S[BMJOQ@_P"")_\ R<EXR_[%*;_TLM:_9^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'
M_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OT-^&/_'G;_P"Z/Y5^>5?H;\,?^/.W_P!T?RKY
MK.?^7?S_ $/M^&=ZW_;OZGMNE_ZM?I6JM96E_P"K7Z5JK7S)]R+1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>X^[5BJ]Q]V@
M#@O&7^H?Z&O@K]I'_D?(/^O-?_1CU]Z^,O\ 4/\ 0U\%?M(_\CY!_P!>:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 0S?=KC?%?^H>NRF^[7&^*_P#4/0!\/_M4?\A#1OK/_P"R5X/7O'[5'_(0
MT;ZS_P#LE>#U]OEO^ZQ^?YL_+,[_ -_J?+\D%%%%>H>$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Z&_#'_CSM_P#='\J_/*OT-^&/_'G;_P"Z
M/Y5\UG/_ "[^?Z'V_#.];_MW]3VW2_\ 5K]*U5K*TO\ U:_2M5:^9/N1:***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57N/NU8JO
M<?=H X+QE_J'^AKX*_:1_P"1\@_Z\U_]&/7WKXR_U#_0U\%?M(_\CY!_UYK_
M .C'KU\K_P!Y7HSYW/O]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K5\)_P#(U:-_U^P_^C%K*K5\)_\ (U:-_P!?L/\ Z,6L
MZGP2]#:C_%CZH_0_X>_ZB/Z5ZYI_^K6O(_A[_J(_I7KFG_ZM:_.#]J+Z]*6D
M7I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
ME7[6/_)K/QD_[$S6?_2&:O5:9-"EQ$\4J+)$ZE61QD,#P01W% '\K5%?U)?\
M(GH?_0&T_P#\!8_\*/\ A$]#_P"@-I__ ("Q_P"% '\MM"J68 #)/  K^GC5
M?@YX!UZ*>+4O _AO48IR3*EUI-O*),]=P9#G\:_-C_@J+^P7X'\ _#.;XM?#
MO1X/"[:==0Q:SI-D-EG)%-((DFCCZ1LLCQJ57"D/G (^8 ]:_P""6O[$>L?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 444AH 8[8YK/O+X0@Y.*LW4FU37#^)M8^
MS1MS0!\^:A^WI8Q7D\4'A2YEB1V5)&O54L >#C8<?3-4S^WI;_\ 0I7'_@>O
M_P 17R+<<W$I_P!H_P ZCK[99;A;?#^+/RYYYC[_ !_@O\CZ]_X;SM_^A2G_
M / Y?_B*/^&\[?\ Z%*?_P #E_\ B*^0J*?]F87^7\6+^W,?_/\ @O\ (^O?
M^&\[?_H4I_\ P.7_ .(H_P"&\[?_ *%*?_P.7_XBOD*BC^S,+_+^+#^W,?\
MS_@O\CZ]_P"&\[?_ *%*?_P.7_XBC_AO.W_Z%*?_ ,#E_P#B*^0J*/[,PO\
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M^&\[?_H4I_\ P.7_ .(H_P"&\[?_ *%*?_P.7_XBOD*BC^S,+_+^+#^W,?\
MS_@O\CZ]_P"&\[?_ *%*?_P.7_XBC_AO.W_Z%*?_ ,#E_P#B*^0J*/[,PO\
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M^&\[?_H4I_\ P.7_ .(H_P"&\[?_ *%*?_P.7_XBOD*BC^S,+_+^+#^W,?\
MS_@O\CZ]_P"&\[?_ *%*?_P.7_XBC_AO.W_Z%*?_ ,#E_P#B*^0J*/[,PO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(U+2-0!G:@W[LUY)X^NC'%)SVKU
MG4O]6U>-?$9L0RT ?G7-_KG_ -X_SIE.F_UK_P"\:;7Z4MC\0>X4444Q!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110![S^R?.8=9UP XW+!_-Z^XO
M"\I:%.>U?"O[+1QK6L?[L/\ -Z^Y/"?^H3Z5\/F7^]3^7Y(_4\C_ -PI_/\
M-G:PG*BIJA@^Z*FKS#W0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/NT <%XR_
MU#_0U\%?M(_\CY!_UYK_ .C'K[U\9?ZA_H:^"OVD?^1\@_Z\U_\ 1CUZ^5_[
MRO1GSN??[B_5'E-%%%?:'YB%%%% !1110 4444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_ /R!IO\
MKX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BO,?C=^TK\-OV=M)2^\?>*K/1&E0O;V))EN[D#C]W"@+
ML,\;L;0>I%?G3\;?^"UVISW<ME\)_!=O:VBY4:MXHS)*_NMO$X5/4%G;.>5%
M 'ZR45_.U\0/^"@'[07Q'N#)J'Q0US38\Y6#09AIB*/3_1PA8?[Q->4ZG\8/
M'FM2+)J/C;Q%?NI4JUUJT\A!!R""SGH>10!_3W17\S6A?M&?%;PQ)$^D_$OQ
M=IQC.5%MKETB]<D8#X()Z@\&O>/A_P#\%5/VB/ TD*W/BFS\66D9'^BZ]IT4
MFX=P9(A'*<^[T ?O;17YQ? __@L_X&\4206'Q-\-7G@N[;"G5--+7UD?5F0
M2QCV42?6OOWP-X_\-_$SPY;:_P"%-<L?$.C7 S'>Z?.LL9/=20>&'=3@CN*
M.@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9M2_P!6
MU>,_$;_4RT ?G7+_ *Q_J:;3I?\ 6/\ 4TVOTI;'X@]PHHHIB"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7@/[?'B"]\,_L<_%:]T]I%N6T9
M[7=&<,$F=(9#_P!\2-7OU<A\7OAS9?%[X6^*_!6H-Y=IKVFSV#2CK$70A7'N
MK88?2@#^;?X/_"G7?CA\3/#W@7PU%'+K6M7/V>'S21'& I=Y'(!(5$5G. 3A
M3P:_5'P__P $1O 4.EP+KGQ$\1WNI8'G2Z?;V]O"3@9VHZR$#.>K5\+?LR:Y
M-^QE^W%X=;XBVS:5_P ([J=QIFK9!984F@D@\\'&6C E64$#YD&1G-?T#V&H
M6VJ6-O>V5S#>6=Q&LL-Q;N'CD1AE65AP01R"* /@C_ARI\$/^AI^('_@QL?_
M )#H_P"'*GP0_P"AI^('_@QL?_D.OO\ HH ^8_V7?^"??P[_ &2_&VI^*?"&
ML^)]2U#4-.;3)8];NK>6(1M+'(2HC@C.[,2\DD8)XKZ<HHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:
M*** /0/A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OD'_ (*7?M2>,/V7_@_HU]X)%G!K.NZ@
MVG?VA=1>:UHHB9R\:'Y2_  W @>AKZ^KS[XN? 3P)\=H]#A\=Z!#XCL]&NC>
MVEG=2.(?.*E=SHI D&"?E;*\\@T ?SV^&?AS\8/VL/&EYJ&DZ/XB^(6OW4N;
MO4Y \RJW;S;AR$C&, !F  P!7V-\*/\ @BMX_P#$$4-UX_\ &.D^$(6 8V6F
MQ-J-ROJK'*1J?=6<5^OVAZ#IGAG2K;2]'TZTTG3;9/+@L[&!888E'1510 H]
M@*OT ?!7@S_@C/\ !+0=DFN:KXI\43#&Z.>]CMH#CT6*,.,_[YKT&Q_X)6_L
MSVBN)? $]Z6/!GUW4 5^FR=?UKZTHH ^0=4_X)0_LVZAYGD>#K_3-P 'V76[
MQMGN/,D?K[YZUY'XW_X(F_#?5/,?PKX[\2>'I&!PNHQ0:A$A]@HB;'3@L3[U
M^C5% 'XC_%3_ ((Z?&?P7#-=>%;[1/'MHF2L-I.;.\('?RYL)^ D)]J^<?!_
MCKXR?L7_ !&,UB=<\ >((R/M&G:A;O%%=Q@])89!ME0\X.#URI!P:_I&KE_B
M)\+O"/Q:\/R:)XS\.:;XETM\_P"CZC;K*$)&-R$C*-_M*01V- &-^SY\0[_X
MM? [P)XSU2"WM=2UW1[;4+F&U#")))(PS! Q)"Y)P"2?<UZ#6'X'\%Z1\.?!
M^C^%_#]J;+1-(M4L[*V,C2&*)!A5W,2QP!U))K<H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBHYYX[6&2:5UCBC4N[L<!5 R2: /+/VAOVGOA]^S
M!X536_'6KFU-P66RTVU3S;V]8#E8H\C.,C+,549&6&1G\B?VZ_\ @HW;?M>>
M!+#P7IG@>7PYI6GZS'JT6HW>HB:>;9!-$%:)8PJ9\\GAV^Z/7CY[_:A^/FL?
MM)?&KQ#XUU6>1[>XG:'3+5C\MI9*Q\F)1VPIR?5F8]37:_$K]C#7OA)^R?X5
M^,GB6_%K=>)]7MK.PT%8?FCM);:XF6>5R>&80J0@'"MDG)V@ ^AOV)/^"HV@
M?LY_";0/AMXI\$:A>:7IDMPPUO2KM'E(FG>4YMW51\ID(R).<=*_6#X1?&?P
M9\=O!]OXG\#:];:]I$IV,\)(D@DP"8Y8SAHW (^5@#@@]"#7\_\ XE_90\0:
M/^ROX1^.EE>1:AX;U:YGLK^U"%9M/F2YFAC8]0\;^4/FX(9@,8(->@_\$S_V
MAM2^"'[3'A[2C>^7X6\7W,6CZI:R'Y"[DK;2_P"RR2NOS?W7<=\@ _?6BBLG
MQ5XLT7P-X?O-<\1:K9Z)H]FGF7%]?S+##$OJ68@?XT 7-4U.TT73;O4+^XCM
M+&TA>>>XF;:D4:J69F/8  DGVK\Q-?\ ^"XEA8Z[J-MI7PADU32X;F2.UOI?
M$GD/<1!B$D,?V1MA9<';N.,XR>M>3?\ !07_ (*7-\;K.Z^'GPNN+JQ\#R9C
MU/6'0PS:L,_ZM%/S)!ZAL,_0@+D-^>M '].?P4^)'_"X?A'X0\<?V=_9'_"0
M:9!J/V'S_/\ (\Q VSS-J[L9QG:,^E=K7BG[%/\ R:/\(?\ L6;'_P!%+7M=
M !1110 5Y+^T)^U-\./V8O#\>I^.M=6SGN%)L]*M5\Z^O,=?*B!Z#NS$*,C+
M#(KNOB%XWTWX:^!?$/BS6'9-+T2PGU"Y*XW&.)"Y"YZL0, =R17\VWQX^-7B
M']H/XJ:[XX\27#R7NI3LT5OO+1V< )\NWCST1%X'J<D\DF@#],-8_P""X?AN
M#4G32OA1JE[8>9A9[S6([>4IC[QC6*0 Y_AWD>_:O:_V>_\ @JI\(/C?K%GH
M.JF\^'_B"Z81PPZVR&SFD)P$2Y4XR>WF*F3P,DBOS_\ @)_P2@^*'QP^&-EX
MTEUC1_"5KJD/VC3+/5!*TUQ$1E)7"*?+1^"IY)4YVXQGY2^+'PK\2?!3XA:S
MX+\66)T_7=*F\J>,'<C@@,DB-_$C*593W!% ']/=%?"?_!)W]J.^^-GP?OO!
M/B.[DO/$_@SRHDN[A]TEW8R;A"Q)Y+1E&C)_N^7G))K[LH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH AF^[7&^*_]0]=E-]VN-\5_P"H>@#X?_:H_P"0
MAHWUG_\ 9*\'KWC]JC_D(:-]9_\ V2O!Z^WRW_=8_/\ -GY9G?\ O]3Y?D@H
MHHKU#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_0WX8_\>=O_
M +H_E7YY5^AOPQ_X\[?_ '1_*OFLY_Y=_/\ 0^WX9WK?]N_J>VZ7_JU^E:JU
ME:7_ *M?I6JM?,GW(M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJJQ/]VOSO_9,_8O\<_M>:YJ5OX:DL])T;2PGV_6M2+"&)FSMC0*"7D(!.!@
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M% 'C-%%% 'H'P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%%
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M6IZ^6_\ @F;\0+GXA?L9^ YKV5IKS24GT9W;^Y!*R0@?2'RA^%?4E !1110
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M !1110 4444 %%%% !1110 4444 0S?=KC?%?^H>NRF^[7&^*_\ 4/0!\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK_Z,>O7RO_>5Z,^=S[_<7ZH\IHHHK[0_,0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *U?"?_(U:-_U^P_\ HQ:RJU?"?_(U:-_U^P_^C%K.I\$O
M0VH_Q8^J/T/^'O\ J(_I7KFG_P"K6O(_A[_J(_I7KFG_ .K6OS@_:B^O2EI%
MZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M63P_J5N+,:9X:VCSP)KJ*(R71/\ JSL=L1CYLD;BN"I^3])_Y"ME_P!=D_\
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M@Y&V6-7'Z,*_EPK^D_\ 9(NFO?V5_@],^=Y\(:2I).22+2(9_'&: /6:***
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M;_\ /[=?]]#_  KIJ* .9_X06W_Y_;K_ +Z'^%'_  @MO_S^W7_?0_PKIJ*
M.9_X06W_ .?VZ_[Z'^%'_""V_P#S^W7_ 'T/\*Z:B@#F?^$%M_\ G]NO^^A_
MA1_P@MO_ ,_MU_WT/\*Z:B@#F?\ A!;?_G]NO^^A_A1_P@MO_P _MU_WT/\
M"NFHH YG_A!;?_G]NO\ OH?X4?\ ""V__/[=?]]#_"NFHH YG_A!;?\ Y_;K
M_OH?X4?\(+;_ //[=?\ ?0_PKIJ* .9_X06W_P"?VZ_[Z'^%'_""V_\ S^W7
M_?0_PKIJ* .9_P"$%M_^?VZ_[Z'^%'_""V__ #^W7_?0_P *Z:B@#F?^$%M_
M^?VZ_P"^A_A1_P (+;_\_MU_WT/\*Z:B@#F?^$%M_P#G]NO^^A_A1_P@MO\
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MZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\
M""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X0
M6W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!
MS/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#
M_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'
M^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _
MMU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_
M;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""
MV_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A
M!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU%
M',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_
MPH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH
M?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[
M=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?V
MZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\
M""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X0
M6W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!
MS/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#
M_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'
M^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _
MMU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_
M;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""
MV_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A
M!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU%
M',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_
MPH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH
M?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[
M=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?V
MZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\
M""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X0
M6W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!
MS/\ P@MO_P _MU_WT/\ "D;P+;_\_MU_WT/\*Z>D:@#A]0\#VXC;_3+G_OH?
MX5X]\0O!\,<,O^E7!^I'^%?0VI?ZMJ\9^(W^IEH _.N3B1OJ:;3I?]8_U--K
M]*6Q^(/<****8@HHHH **** "BBB@#]4_@3XNM/&_P )_#>K6NP/):)'<J@
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M0_PKIJ* .9_X06W_ .?VZ_[Z'^%'_""V_P#S^W7_ 'T/\*Z:B@#F?^$%M_\
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M_A2_\(+;_P#/[=?]]#_"NE7I2T <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\
MOH?X5TU% ',_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__
M #^W7_?0_P */^$%M_\ G]NO^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?
M_G]NO^^A_A7344 <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_
M\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__ #^W7_?0_P *
M/^$%M_\ G]NO^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A73
M44 <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_\(+;_P#/[=?]
M]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__ #^W7_?0_P */^$%M_\ G]NO
M^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A7344 <S_P@MO\
M\_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_\(+;_P#/[=?]]#_"C_A!;?\
MY_;K_OH?X5TU% ',_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A7344 <S
M_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A7344 <S_P@MO\ \_MU_P!]#_"C
M_A!;?_G]NO\ OH?X5TU% ',_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X5TU
M% ',_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A7344 <S_P (+;_\_MU_
MWT/\*/\ A!;?_G]NO^^A_A7344 <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\
MOH?X5TU% ',_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__
M #^W7_?0_P */^$%M_\ G]NO^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?
M_G]NO^^A_A7344 <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_
M\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__ #^W7_?0_P *
M/^$%M_\ G]NO^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A73
M44 <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_\(+;_P#/[=?]
M]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__ #^W7_?0_P */^$%M_\ G]NO
M^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A7344 <S_P@MO\
M\_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_\(+;_P#/[=?]]#_"C_A!;?\
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M&;5/VA/V>?"'Q!UFQM--U/6H[AYK6QW>2GEW,L(V[B3R(P>3U)KU^@ HHHH
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M2Q^%_AS2?V4?!GB.7PGIEGXMGEU 7&K2:=&E\X%Y,BAI2N\@(% !/0"OM&@
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M5'_(0T;ZS_\ LE>#U]OEO^ZQ^?YL_+,[_P!_J?+\D%%%%>H>$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7Z&_#'_CSM_\ ='\J_/*OT-^&/_'G
M;_[H_E7S6<_\N_G^A]OPSO6_[=_4]MTO_5K]*U5K*TO_ %:_2M5:^9/N1:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "D:EI&H S-2_U;5XS\1O\ 4RU[-J7^K:O&?B-_J9:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "BBB@ HHHH **** "J]Q]VK%5[C[M '!>,O\ 4/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% 'C-%%% 'H'P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%%
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M*\'KWC]JC_D(:-]9_P#V2O!Z^WRW_=8_/\V?EF=_[_4^7Y(****]0\(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OT-^&/_ !YV_P#NC^5?GE7Z
M&_#'_CSM_P#='\J^:SG_ )=_/]#[?AG>M_V[^I[;I?\ JU^E:JUE:7_JU^E:
MJU\R?<BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9M2_U;5X
MS\1O]3+0!^=<O^L?ZFFTZ7_6/]33:_2EL?B#W"BBBF(**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /</V6_\ D-:Q_NP_S>ON3PG_ *E/I7PW^RW_
M ,AK6/\ =A_F]?<GA/\ U*?2OA\R_P!ZG\OR1^IY'_N%/Y_FSMH/NBIJA@^Z
M*FKS#W0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/NT <%XR_U#_0U\%?M(_\
M(^0?]>:_^C'K[U\9?ZA_H:^"OVD?^1\@_P"O-?\ T8]>OE?^\KT9\[GW^XOU
M1Y31117VA^8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J^$_\
MD:M&_P"OV'_T8M95:OA/_D:M&_Z_8?\ T8M9U/@EZ&U'^+'U1^A_P]_U$?TK
MUS3_ /5K7D?P]_U$?TKUS3_]6M?G!^U%]>E+2+TI: "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>>.UADFFD6*&-2[R2,%55
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MGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***X;XV?&+P]\ _AAKOCKQ1.T6DZ5#O,<0!EGD8A8XHQW=V*J.PSDX
M)H ZG7O$&E^%M)N=4UK4K/2-,MEWSWM_.D$,2^K.Q"J/J:^>/$/_  4E_9L\
M,:E)8WGQ2L9ID."VGV%Y>Q?A)!"Z'\#7XL?M/?M:^//VJO&4VK>*+][?1XI#
M_9WA^UD86=C'SC"_QR8^](W)]AA1XK0!_1G\.?VYO@-\5M0BL/#GQ-T6:^F8
M)%:Z@9-/EE8G 5%N4C+$GL 37NM?RKU]Z?\ !/O_ (*-:[\%_$FE^!/B)JTV
MK_#B\D6WAO+QS)-HK'A65R<F#.-R'[H^9<8*L ?MI134=9%5E8,K#(93D$>M
M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH AF^[7&^*_]0]=E-]VN-\5_P"H>@#X?_:H_P"0AHWUG_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O\
M5M7C/Q&_U,M 'YUR_P"L?ZFFTZ7_ %C_ %--K]*6Q^(/<****8@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ]P_9;_Y#6L?[L/\ -Z^Y/"?^I3Z5
M\-_LM_\ (:UC_=A_F]?<GA/_ %*?2OA\R_WJ?R_)'ZGD?^X4_G^;.V@^Z*FJ
M&#[HJ:O,/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\<6EB38R>3')N.]F.<N1P>PKZDH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "J]Q]VK%5[C[M '!>,O]0_T-?!7[2/\ R/D'_7FO_HQZ^]?&
M7^H?Z&O@K]I'_D?(/^O-?_1CUZ^5_P"\KT9\[GW^XOU1Y31117VA^8A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5J^$_P#D:M&_Z_8?_1BUE5J^
M$_\ D:M&_P"OV'_T8M9U/@EZ&U'^+'U1^A_P]_U$?TKUS3_]6M>1_#W_ %$?
MTKUS3_\ 5K7YP?M1?7I2TB]*6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*]&?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %:OA/_D:M&_Z_8?_ $8M95:OA/\ Y&K1O^OV'_T8M9U/@EZ&U'^+'U1^
MA_P]_P!1']*]<T__ %:UY'\/?]1']*]<T_\ U:U^<'[47UZ4M(O2EH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>#U]OEO^ZQ^?YL_+,[_W^I\OR04445ZAX04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?H;\,?\ CSM_]T?RK\\J_0WX8_\ 'G;_ .Z/Y5\UG/\
MR[^?Z'V_#.];_MW]3VW2_P#5K]*U5K*TO_5K]*U5KYD^Y%HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *1J6D:@#,U+_5M7C/Q&_U,M>S:E_JVKQGXC?ZF6@#\ZY?]8_U--IT
MO^L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >X?LM_P#(:UC_ '8?YO7W)X3_ -2GTKX;_9;_ .0UK'^[#_-Z^Y/"?^I3
MZ5\/F7^]3^7Y(_4\C_W"G\_S9VT'W14U0P?=%35YA[H4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 0S?=KC?%?^H>NRF^[7&^*_P#4/0!\/_M4?\A#1OK/_P"R
M5X/7O'[5'_(0T;ZS_P#LE>#U]OEO^ZQ^?YL_+,[_ -_J?+\D%%%%>H>$%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Z&_#'_CSM_P#='\J_/*OT
M-^&/_'G;_P"Z/Y5\UG/_ "[^?Z'V_#.];_MW]3VW2_\ 5K]*U5K*TO\ U:_2
MM5:^9/N1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "D:EI&H S-2_P!6U>,_$;_4RU[-J7^K
M:O&?B-_J9: /SKE_UC_4TVG2_P"L?ZFFU^E+8_$'N%%%%,04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >X?LM_\ (:UC_=A_F]?<GA/_ %*?2OAO
M]EO_ )#6L?[L/\WK[D\)_P"I3Z5\/F7^]3^7Y(_4\C_W"G\_S9VT'W14U0P?
M=%35YA[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#_"@#U7_ (=#?L\_] [Q!_X.'_PH_P"'0W[//_0.\0?^#A_\*\J_X?>>"/\
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MZM?I6JM96E_ZM?I6JM?,GW(M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2-2TC4 9FI?ZMJ\
M9^(W^IEKV;4O]6U>,_$;_4RT ?G7+_K'^IIM.E_UC_4TVOTI;'X@]PHHHIB"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W#]EO\ Y#6L?[L/\WK[
MD\)_ZE/I7PW^RW_R&M8_W8?YO7W)X3_U*?2OA\R_WJ?R_)'ZGD?^X4_G^;.V
M@^Z*FJ&#[HJ:O,/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ5>X^[0!P7C+_4/]
M#7P5^TC_ ,CY!_UYK_Z,>OO7QE_J'^AKX*_:1_Y'R#_KS7_T8]>OE?\ O*]&
M?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %:OA/\ Y&K1O^OV'_T8M95:OA/_ )&K1O\ K]A_]&+6=3X)>AM1_BQ]4?H?
M\/?]1']*]<T__5K7D?P]_P!1']*]<T__ %:U^<'[47UZ4M(O2EH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-?T"UT"_3P[K^GE+&5GAN1'IS$S*&&4!9V7:2V-F=W.  ?$O_!&'_DZ_6_\
ML4KS_P!*K2OMK_@KOX%T'Q%^R/J/B'4881K7AW4+2;2[AE_> S3QPRQ*?[K(
MY8CH?*4]0*_+O]A;]J#2OV2_B]JGC35]%O->AN-$GTR*SLI$C;S'F@<,S-T4
M")N@)R1Q6[^VA^W]XM_:\DL])?3HO"W@JPG-Q;Z-;SM*\TN-HEN), .P!;:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H S-2_P!6U>,_$;_4
MRU[-J7^K:O&?B-_J9: /SKE_UC_4TVG2_P"L?ZFFU^E+8_$'N%%%%,04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >X?LM_\ (:UC_=A_F]?<GA/_
M %*?2OAO]EO_ )#6L?[L/\WK[D\)_P"I3Z5\/F7^]3^7Y(_4\C_W"G\_S9VT
M'W14U0P?=%35YA[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10 4444 %%%% !1110 5\@_\%5M:U#P_^QWKUYI=_=:;=KJ5@JW%I,T4@!G
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MWB#_ ,'#_P"% 'XK?\+8\;_]#EX@_P#!I/\ _%T?\+8\;_\ 0Y>(/_!I/_\
M%U^U/_#H;]GG_H'>(/\ P</_ (4?\.AOV>?^@=X@_P#!P_\ A0!W_P#P3>U2
M]UK]BKX:WNHWEQ?WDL-Z9+BZE:21\7UP!EF))X 'X5]+5QOP?^$^@? WX<:-
MX'\+QW$6@Z2LBVR74QED >5Y6RQZ_-(U=E0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57N/NU
M8JO<?=H X+QE_J'^AKX*_:1_Y'R#_KS7_P!&/7WKXR_U#_0U\%?M(_\ (^0?
M]>:_^C'KU\K_ -Y7HSYW/O\ <7ZH\IHHHK[0_,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *U?"?_(U:-_U^P_^C%K*K5\)_P#(U:-_U^P_^C%K
M.I\$O0VH_P 6/JC]#_A[_J(_I7KFG_ZM:\C^'O\ J(_I7KFG_P"K6OS@_:B^
MO2EI%Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_P#^0--_U\-_Z"M=
M-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %5=4U2RT33;G4-1NX+"PM8VFGNKJ58XHD499W9B J@<DDX%6J_,7_@
MM-\<M6T'0?!WPOTJZFM+/6DDU75_*?;]HBC<)!$<=5WAW(/&43TH ];^(W_!
M7[X%>!]5N=.TI?$'C.6%BGVK1;*-;4D'!Q)-(A8=<,JD''!P<UQ/_#[3X6?]
M"+XP_P"^;7_X]7Y">$_!GB#QYJZ:5X9T+4O$6J.I9;'2;.2ZG8#J0D8+$<CM
MWKU%?V*?CTR@CX0^,.?72)A_[+0!^E7_  ^T^%G_ $(OC#_OFU_^/4?\/M/A
M9_T(OC#_ +YM?_CU?FM_PQ3\>_\ HD/C#_P4R_X4?\,4_'O_ *)#XP_\%,O^
M% '[^_ +XS:9^T)\(_#_ ,0=&L;O3=,UI)GAM;[;YR>7-)"=VTD<F,G@]"*]
M!KYX_P""??@W7?A]^Q_\//#_ (ETF[T/6[.*\%SI]]$8IHBU[.Z[E/(RK*?H
M17T/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!#-]VN-\5_ZAZ[*;[M<;XK_ -0] 'P_^U1_R$-&^L__
M +)7@]>\?M4?\A#1OK/_ .R5X/7V^6_[K'Y_FS\LSO\ W^I\OR04445ZAX04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?H;\,?^/.W_ -T?RK\\
MJ_0WX8_\>=O_ +H_E7S6<_\ +OY_H?;\,[UO^W?U/;=+_P!6OTK56LK2_P#5
MK]*U5KYD^Y%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@#,U+_ %;5XS\1O]3+7LVI
M?ZMJ\9^(W^IEH _.N7_6/]33:=+_ *Q_J:;7Z4MC\0>X4444Q!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110![A^RW_P AK6/]V'^;U]R>$_\ 4I]*
M^&_V6_\ D-:Q_NP_S>ON3PG_ *E/I7P^9?[U/Y?DC]3R/_<*?S_-G;0?=%35
M#!]T5-7F'NA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_:
M1_Y'R#_KS7_T8]?>OC+_ %#_ $-?!7[2/_(^0?\ 7FO_ *,>O7RO_>5Z,^=S
M[_<7ZH\IHHHK[0_,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U
M?"?_ "-6C?\ 7[#_ .C%K*K5\)_\C5HW_7[#_P"C%K.I\$O0VH_Q8^J/T/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $,WW:XWQ7_J'KLIONUQOBO_ %#T ?#_ .U1_P A#1OK/_[)
M7@]>\?M4?\A#1OK/_P"R5X/7V^6_[K'Y_FS\LSO_ '^I\OR04445ZAX04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %?H;\,?^/.W_P!T?RK\\J_0
MWX8_\>=O_NC^5?-9S_R[^?Z'V_#.];_MW]3VW2_]6OTK56LK2_\ 5K]*U5KY
MD^Y%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *1J6D:@#,U+_5M7C/Q&_P!3+7LVI?ZMJ\9^
M(W^IEH _.N7_ %C_ %--ITO^L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >X?LM_\AK6/]V'^;U]R>$_]2GTKX;_9;_Y#
M6L?[L/\ -Z^Y/"?^I3Z5\/F7^]3^7Y(_4\C_ -PI_/\ -G;0?=%35#!]T5-7
MF'NA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_
M *\U_P#1CU]Z^,O]0_T-?!7[2/\ R/D'_7FO_HQZ]?*_]Y7HSYW/O]Q?JCRF
MBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K5\)_\C5HW
M_7[#_P"C%K*K5\)_\C5HW_7[#_Z,6LZGP2]#:C_%CZH_0_X>_P"HC^E>N:?_
M *M:\C^'O^HC^E>N:?\ ZM:_.#]J+Z]*6D7I2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7G_ .T)XIU3P/\  +XE^)-$NOL6
MM:/X9U/4+&Y\M9/)GBM9)(WVN"K890<,"#CD$5Z!7'_&3P//\3?A#XX\'VMS
M'97/B'0K[28KF92R1//;O$'8#D@%P3CTH _#'_AZ-^T[_P!%,_\ *!I?_P C
M4?\ #T;]IW_HIG_E TO_ .1J]_\ ^'(?CC_HI?A__P  IZ/^'(?CC_HI?A__
M , IZ / /^'HW[3O_13/_*!I?_R-1_P]&_:=_P"BF?\ E TO_P"1J]__ .'(
M?CC_ **7X?\ _ *>C_AR'XX_Z*7X?_\  *>@#P#_ (>C?M._]%,_\H&E_P#R
M-7@_Q;^,/B_XZ>-+CQ;XXU?^V_$%Q%'#)>?9H;?<B+M0;(D11@>@K[W_ .'(
M?CC_ **7X?\ _ *>OB[]J#]GO4?V8/BY?> M4U:UUN[M;>"X:\LXV2-A*@<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ I&I:1J ,S4O]6U>,_$;_ %,M>S:E_JVKQGXC?ZF6@#\ZY?\
M6/\ 4TVG2_ZQ_J:;7Z4MC\0>X4444Q!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110![A^RW_R&M8_W8?YO7W)X3_U*?2OAO]EO_D-:Q_NP_P WK[D\
M)_ZE/I7P^9?[U/Y?DC]3R/\ W"G\_P V=M!]T5-4,'W14U>8>Z%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !5>X^[5BJ]Q]V@#@O&7^H?Z&O@K]I'_D?(/\ KS7_ -&/7WKX
MR_U#_0U\%?M(_P#(^0?]>:_^C'KU\K_WE>C/G<^_W%^J/*:***^T/S$****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "M7PG_R-6C?]?L/_ *,6LJM7
MPG_R-6C?]?L/_HQ:SJ?!+T-J/\6/JC]#_A[_ *B/Z5ZYI_\ JUKR/X>_ZB/Z
M5ZYI_P#JUK\X/VHOKTI:1>E+0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !114<T\=K"\LTBQ1(-S2.P55'J2>E $E%%%
M!7X0_P#!6S_D]+Q!_P!@S3__ $0*_=ZOA#]K;_@EU_PU+\:=0\?_ /"S/^$8
M^UVMO;?V=_8'VO;Y483=YGVF/.<9QMX]Z .9_P"")?\ R0+QU_V,Q_\ 26"O
MT5KYU_8E_9#_ .&.? .N^&?^$L_X2[^U-3_M'[5_9OV+ROW21[-OFR9^YG.1
MUZ5]%4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >,T444 >@?#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M
M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7PK_P5+_:L\0?
MLZ^&_!N@:9X9\+^*=&\9P:G;ZK9>)[2>XC:.$6P55$<T>,^>^2<G(4C!'/W5
M7R5^WM^P[??MG?\ "#?8O%UOX6_X1O[=O\^Q:Y\_[1]GQC#KMV^0?7.[VH _
M"_PG\0_$'P]\7)XE\(:I=>%-6AD9X)M)N)(FA5CS&&+%BF.,,6R.N:^D]-_X
M*J?M*:?9QP-XYMKS8,"6YT6R+D>Y$0S]3SZU]$?\..=<_P"BMZ?_ .".3_X_
M1_PXYUS_ **WI_\ X(Y/_C] '@'_  ]@_:2_Z&_3_P#P26G_ ,;H_P"'L'[2
M7_0WZ?\ ^"2T_P#C=>__ /#CG7/^BMZ?_P"".3_X_1_PXYUS_HK>G_\ @CD_
M^/T ?>_[$/Q2\1?&K]ESP-XT\67<=]X@U2*Z:ZN(H4A5REW-&N$0!1\J*.!V
MKW.O*OV6_@K/^SM\!_"OP\N-5CUR;14G1K^* PK+YEQ+-PA9L8\S'4]*]5H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH AF^[7&^*_P#4/793?=KC?%?^H>@#X?\ VJ/^0AHWUG_]DKP>
MO>/VJ/\ D(:-]9__ &2O!Z^WRW_=8_/\V?EF=_[_ %/E^2"BBBO4/""BBB@
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MBBB@ HHHH **** "J]Q]VK%5[C[M '!>,O\ 4/\ 0U\%?M(_\CY!_P!>:_\
MHQZ^]?&7^H?Z&O@K]I'_ )'R#_KS7_T8]>OE?^\KT9\[GW^XOU1Y31117VA^
M8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5J^$_^1JT;_K]A_\
M1BUE5J^$_P#D:M&_Z_8?_1BUG4^"7H;4?XL?5'Z'_#W_ %$?TKUS3_\ 5K7D
M?P]_U$?TKUS3_P#5K7YP?M1?7I2TB]*6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\*_\$@?C)=?$;]FN[\+ZG=275_X.U#[#"9#DBRD020#/^RPF0#LJ*.E?=5
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M^E?#YE_O4_E^2/U/(_\ <*?S_-G;0?=%35#!]T5-7F'NA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_KS7_P!&/7WKXR_U#_0U
M\%?M(_\ (^0?]>:_^C'KU\K_ -Y7HSYW/O\ <7ZH\IHHHK[0_,0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *U?"?_(U:-_U^P_^C%K*K5\)_P#(
MU:-_U^P_^C%K.I\$O0VH_P 6/JC]#_A[_J(_I7KFG_ZM:\C^'O\ J(_I7KFG
M_P"K6OS@_:B^O2EI%Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H S-2_U;5XS\
M1O\ 4RU[-J7^K:O&?B-_J9: /SKE_P!8_P!33:=+_K'^IIM?I2V/Q![A1113
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'N'[+?_(:UC_=A_F]?
M<GA/_4I]*^&_V6_^0UK'^[#_ #>ON3PG_J4^E?#YE_O4_E^2/U/(_P#<*?S_
M #9VT'W14U0P?=%35YA[H4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[C[M6*KW'W: ."\9
M?ZA_H:^"OVD?^1\@_P"O-?\ T8]?>OC+_4/]#7P5^TC_ ,CY!_UYK_Z,>O7R
MO_>5Z,^=S[_<7ZH\IHHHK[0_,0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *U?"?_(U:-_U^P_\ HQ:RJU?"?_(U:-_U^P_^C%K.I\$O0VH_Q8^J
M/T/^'O\ J(_I7KFG_P"K6O(_A[_J(_I7KFG_ .K6OS@_:B^O2EI%Z4M !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4G7@\BEHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(U
M+2-0!F:E_JVKQGXC?ZF6O9M2_P!6U>,_$;_4RT ?G7+_ *Q_J:;3I?\ 6/\
M4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J
M]Q]VK%5[C[M '!>,O]0_T-?!7[2/_(^0?]>:_P#HQZ^]?&7^H?Z&O@K]I'_D
M?(/^O-?_ $8]>OE?^\KT9\[GW^XOU1Y31117VA^8A1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5J^$_^1JT;_K]A_P#1BUE5J^$_^1JT;_K]A_\
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MP:[.N"^/_A/4O'OP'^)'AG1H5N-8UKPUJ6FV4+N$#SS6LD<:EB<*"S 9/ H
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M%OQV:WTK3T 6*/PGNFN9FXCAB7[;R['@=AR20 2 #Y\_X>0_M)?]%2U#_P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_-Z^Y/"?^I3Z5\/F7^]3^7Y(_4\C_P!PI_/\V=M!]T5-4,'W14U>8>Z%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5>X^[5BJ]Q]V@#@O&7^H?Z&O@K]I'_D?(/^O-?_ $8]
M?>OC+_4/]#7P5^TC_P CY!_UYK_Z,>O7RO\ WE>C/G<^_P!Q?JCRFBBBOM#\
MQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K5\)_\C5HW_7[#_Z,
M6LJM7PG_ ,C5HW_7[#_Z,6LZGP2]#:C_ !8^J/T/^'O^HC^E>N:?_JUKR/X>
M_P"HC^E>N:?_ *M:_.#]J+Z]*6D7I2T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 44C,$4LQ"J!DD]!7Y]_MB_P#!5[PM
M\)UOO"WPI:T\9>+US%+J^?,TRP;H<,#_ *1(/13L!ZL<%: .'_X+<?$/2E\(
M_#SP-'<1RZU)?RZQ-;JV7AA2(Q(S#L':1\>OEMZ5X+_P1DF6/]K+5E8X,GA2
M\5?K]HM3_(&OBWQYX]\0_$[Q9J/B?Q5JUSKFO:C)YMS?739=SC ''"J   H
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M  ;U#4M)\#?$ZQ@>>RTT2:+J;*,^2LC"2W<^BEO-4GIED'>@#KO^")EKI"_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4C4M(U &9J7^K:O&?B-_J9:]
MFU+_ %;5XS\1O]3+0!^=<O\ K'^IIM.E_P!8_P!33:_2EL?B#W"BBBF(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /</V6_^0UK'^[#_ #>ON3PG
M_J4^E?#?[+?_ "&M8_W8?YO7W)X3_P!2GTKX?,O]ZG\OR1^IY'_N%/Y_FSMH
M/NBIJA@^Z*FKS#W0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/NT <%XR_U#_0
MU\%?M(_\CY!_UYK_ .C'K[U\9?ZA_H:^"OVD?^1\@_Z\U_\ 1CUZ^5_[RO1G
MSN??[B_5'E-%%%?:'YB%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6KX3_Y&K1O^OV'_ -&+656KX3_Y&K1O^OV'_P!&+6=3X)>AM1_BQ]4?H?\
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M1110 4444 %%%% !1110 4444 >,T444 >@?#_\ Y TW_7PW_H*UTU<S\/\
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M_MW]3VW2_P#5K]*U5K*TO_5K]*U5KYD^Y%HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI%Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=\)Z'XH\C^V=&T_5_(W>5]NM8Y_+W8W;=P.,X&<=<"@#^6VBOZ??^%3^!_\
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M+B&0=&1U#*?Q!% %NBBB@"MJ6I6NCZ==7]]<1VEE:Q-//<3,%2*-069V)X
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MFE'_  .OV<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG6^8/6CS!ZUR7_"<:7_T$;7_ +_+_C1_PG&E_P#01M?^_P O^-'++L'MJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>YS_ +LS[(6_"2OGK7/^"X?ARWDD&C?"C5+]!]PWVL1VI;GN%BDQQSWYX]Z
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M Y;QS_P6V\?76K3?\(;X \-Z9I@D(B&N/<7DS)S@MY4D*@G@X&<=,GK7-?\
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M"5K^=;XU_ OQU^S/\1)_#WBW3+C2M0M)R]GJ$:L+>\56^6>WD( =3P>.5/#
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MOU_^)H_X3"X_Z ]U^O\ \30!TU%<S_PF%Q_T![K]?_B:/^$PN/\ H#W7Z_\
MQ- '345S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !- '345S/\ PF%Q_P!
M>Z_7_P")H_X3"X_Z ]U^O_Q- '345S/_  F%Q_T![K]?_B:/^$PN/^@/=?K_
M /$T =-17,_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,30!TU%<S_PF%Q_T![K
M]?\ XFC_ (3"X_Z ]U^O_P 30!TU%<S_ ,)A<?\ 0'NOU_\ B:/^$PN/^@/=
M?K_\30!TU%<S_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q- '345S/_"87'_0'
MNOU_^)H_X3"X_P"@/=?K_P#$T =-17,_\)A<?] >Z_7_ .)H_P"$PN/^@/=?
MK_\ $T =-17,_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$T =-17,_\ "87'
M_0'NOU_^)H_X3"X_Z ]U^O\ \30!T$WW:XWQ7_J'JY-XPN-O_('NOU_^)KD/
M%'BR=H7_ .)1<C\_\* /D+]JC_D(:-]9_P#V2O!Z]J_:4U)]1O\ 2=]K);;3
M-]_OG9[5XK7V^6_[K'Y_FS\LSO\ W^I\OR04445ZAX04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >C? ?_D<Y_\ KR?_ -#2O?Z\!^ __(YW'_7D
M_P#Z&E>_5YU?XS*6X4445@0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7T%X!U;=H.FQ[ONV\:_DHKY]KM_!'C*>W5(!I\\JQ_(&7.#CC/2O)S#
MX(GV?#'\>IZ?J?1-K+YBBK0KA=,\97#1K_Q*+D_G_P#$UIKXPN/^@/=?K_\
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MHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\
MQ-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H
MZ:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T
M?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:
M.FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-
M'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .
MFHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__
M !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .F
MHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\
MQ-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H
MZ:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T
M?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:
M.FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-
M'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .
MFHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__
M !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .F
MHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\
MQ-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H
MZ:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T
M?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:
M.FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-
M'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .
MFHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__
M !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .F
MHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\
MQ-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H
MZ:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T
M?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\
MB: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W
M7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B
M: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7
MZ_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_
M^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_
M /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?
M_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^
MO_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\
MB: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W
M7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B
M: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7
MZ_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_
M^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_
M /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?
M_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^
MO_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\
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M)Z$PQ\-,1V8[4Z$;Q7Y@_%KX_?$;X]:LM[X[\7:IXEF#EH;>XEQ;PL?^>4"
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MH **** "BBB@ HHHH **** "BBB@ HHHH AF^[7&^*_]0]=E-]VN-\5_ZAZ
M/A_]JC_D(:-]9_\ V2O!Z]X_:H_Y"&C?6?\ ]DKP>OM\M_W6/S_-GY9G?^_U
M/E^2"BBBO4/""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T?X#_\
MCG<?]>3_ /H:5[]7@/P'_P"1SN/^O)__ $-*]^KSJ_QF4MPHHHK @**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N]^';G*CWK@J[KX=??'^]7DYA
M\$3[/AC^/4]/U/==';,*UM+6)HO^I6MM:\(_11U%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U>,_$;_ %,M 'YUR_ZQ_J:;
M3I?]8_U--K]*6Q^(/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[*7_  V%\*]*\&_\)3_PB7V'6HM7^V_V?]MW[()XO+V>;'C/GYW;C]W&.<@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJV,C."<9'K7U1^P/^TI?:9XDMOAMXCOWN-)O@5T>6=MQMIQSY )_@<9P.S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M._99_9!\"?LF>$Y=-\+6\EYJ]X%_M+7KT W5X1D@''"1C)PB\#J<G)/N-%%
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M<<L1<_OT'!^Z%7CCI7UK7\L"M>:+J.09["_M9.VZ.6&13^!5@1]17U5\$_\
M@I]\=?@WY%K<>(5\<Z+'@?8/%"M<N%_V;@$3 XZ;G8# ^7M0!^^M%?)?[%G_
M  4*\/?M@:OJ'AR+POJ'ACQ3IU@=1N(9)DN+1XA(D9,<HVMG=(ORL@X/4XKZ
MTH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:
MZ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\F_:N^+\WP%_9U\=^.
MK55>^TK3S]CW_=%S*ZPP$CN!)(A([@8KUFOC[_@K#>&V_8E\71@D?:+W3HCC
MOB[C?!_[YH _!^^OKG5+ZXO+RXEN[RXD:::XF<O)([$EF9CR22223US7TS\*
M_P#@FS\>OBYX/M?$VE>%(=/TF\C$UHVL7L=K)<QD95UC8[@K @@L """,CFO
M.?V2_!&G_$C]ICX9^'-5@%SI=]KMJMU;L 1+$KAW0Y[,JD'V)K^DU5"*%4!5
M P .@H _F)^+'P?\8_ _QA<>%_'&@W/A_6X5$GV>XVLLD9SB2-U)5T."-RDC
M((Z@U]^_\$7?CMJ&F_$#Q)\)[ZY:71M3LWUC3HW)(@NHBBRJOH)(VW'WA'J<
M^Q_\%KO MAJ'P-\%^+C;I_:VEZ^-.6?'S?9YX)7=<]QO@C//3GUY^&_^"6^H
M-8?MR?#I0VV.X748'XZ@Z?<D#_OI5H _?NBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AF^[
M7&^*_P#4/793?=KC?%?^H>@#X?\ VJ/^0AHWUG_]DKP>O>/VJ/\ D(:-]9__
M &2O!Z^WRW_=8_/\V?EF=_[_ %/E^2"BBBO4/""BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#T?X#_P#(YW'_ %Y/_P"AI7OU> _ ?_D<[C_KR?\
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M)'J%M(1RN'"2#/H4=N.Y5?2ORUT'6KKPWKFGZM8R>3>V%Q'=02#^&1&#*?S
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ME_J'^AKX*_:1_P"1\@_Z\U_]&/7KY7_O*]&?.Y]_N+]4>4T445]H?F(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %:OA/_D:M&_Z_8?_ $8M95:O
MA/\ Y&K1O^OV'_T8M9U/@EZ&U'^+'U1^A_P]_P!1']*]<T__ %:UY'\/?]1'
M]*]<T_\ U:U^<'[47UZ4M(O2EH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\<^&]T,-P6@N["9PTMC<ICS(7QW&00>-RLK8&<5\G?M0?\%/KO\ 9D_:DOO
M=UX5M?$GA.RL;1KM[:9H;^">5/-8JQRCCRWBPA"\Y^89X /)/^"5O[/GQ&^
MW[4GC"R\>^$-3\.,_A6:.*XN8MUM,PO+7(CG4F.3I_"QK]7*XSX0_%_PI\=/
M .F^,?!NJ1ZKHM\ORNORR0R#[T4J=4D4GE3[$9!!/9T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%%
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M9W_O]3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_KS7_P!&/7WKXR_U#_0U\%?M
M(_\ (^0?]>:_^C'KU\K_ -Y7HSYW/O\ <7ZH\IHHHK[0_,0HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *U?"?_(U:-_U^P_^C%K*K5\)_P#(U:-_
MU^P_^C%K.I\$O0VH_P 6/JC]#_A[_J(_I7KFG_ZM:\C^'O\ J(_I7KFG_P"K
M6OS@_:B^O2EI%Z4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ]
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M;XK_ -0]=E-]VN-\5_ZAZ /A_P#:H_Y"&C?6?_V2O!Z]X_:H_P"0AHWUG_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[C[M6*KW'W: .
M"\9?ZA_H:^"OVD?^1\@_Z\U_]&/7WKXR_P!0_P!#7P5^TC_R/D'_ %YK_P"C
M'KU\K_WE>C/G<^_W%^J/*:***^T/S$**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "M7PG_P C5HW_ %^P_P#HQ:RJU/"G'BC1S_T^0_\ H8K.I\$O
M0VH_Q8^J/T0^'O\ J(_I7K>GG]VM>.?#^X"P1\]J]9T^\7RUYK\X/VHVE/%&
M:J+>+CK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]
ML7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS
M53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L
M7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS5
M3[8OK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7UH MYHS53[8OK1]L7
MUH MYHS53[8OK1]L7UH MTM5/M2^M/6X5N] %BBHUDSWI^: %HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'Q[
MXRL/ASX&\1>+-569M+T'3;G5+M;= TAA@B:5]@) +;4.!D<]ZWJ\R_:@T^ZU
M?]FCXMV-C;37M]=>$=7@@MK>,R22R-92JJ(H&68D@ #DDT ?,7_#Y+X"?\^?
MC#_P5Q?_ !^C_A\E\!/^?/QA_P""N+_X_7Y ?\,]_%/_ *)IXP_\$-U_\;H_
MX9[^*?\ T33QA_X(;K_XW0!^O_\ P^2^ G_/GXP_\%<7_P ?H_X?)? 3_GS\
M8?\ @KB_^/U^0'_#/?Q3_P"B:>,/_!#=?_&Z/^&>_BG_ -$T\8?^"&Z_^-T
M?K__ ,/DO@)_SY^,/_!7%_\ 'Z/^'R7P$_Y\_&'_ (*XO_C]?D!_PSW\4_\
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M#2O?J\!^ _\ R.=Q_P!>3_\ H:5[]7G5_C,I;A1116! 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %=U\.OOC_>KA:[KX=??'^]7DYA\$3[/AC^/
M4]/U/=-%_P!2M;:UB:+_ *E:VUKPC]%'4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %(U+2-0!F:E_JVKQGXC?ZF6O9M2_P!6U>,_$;_4RT ?G7+_ *Q_J:;3I?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "J]Q]VK%5[C[M '!>,O]0_T-?!7[2/_(^0?]>:_P#HQZ^]?&7^H?Z&O@K]
MI'_D?(/^O-?_ $8]>OE?^\KT9\[GW^XOU1Y31117VA^8A1110 4444 %%%%
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MM'^4/[8Q_P#S]?X'?_\ "Y=7_P"?:U_)O\:/^%RZO_S[6OY-_C7 44?5:/\
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MFXACY[5Z#9R;E%?+GZ\MB[12+2T#"BBB@ HHHH **** "BBB@ HHHH ****
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M^[7&^*_]0]=E-]VN-\5_ZAZ /A_]JC_D(:-]9_\ V2O!Z]X_:H_Y"&C?6?\
M]DKP>OM\M_W6/S_-GY9G?^_U/E^2"BBBO4/""BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#T?X#_\CG<?]>3_ /H:5[]7@/P'_P"1SN/^O)__ $-*
M]^KSJ_QF4MPHHHK @**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
MZ^'7WQ_O5PM=U\.OOC_>KR<P^")]GPQ_'J>GZGNFB_ZE:VUK$T7_ %*UMK7A
M'Z*.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@#,U+_5M7C/Q&_P!3+7LV
MI?ZMJ\9^(W^IEH _.N7_ %C_ %--ITO^L?ZFFU^E+8_$'N%%%%,04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >X?LM_\AK6/]V'^;U]R>$_]2GTK
MX;_9;_Y#6L?[L/\ -Z^Y/"?^I3Z5\/F7^]3^7Y(_4\C_ -PI_/\ -G;0?=%3
M5#!]T5-7F'NA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_
M:1_Y'R#_ *\U_P#1CU]Z^,O]0_T-?!7[2/\ R/D'_7FO_HQZ]?*_]Y7HSYW/
MO]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU
M_P#9Z_UVN_[L/\WKR"O7_P!GK_7:[_NP_P WK&M\#)EL>S4445YIB%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!ZM\/;DO#'SVKV'36_=K7
MBGPY;]U'7M.E_P"K7Z5\8?NZV-5:6D6EH&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7@/[?'B"]\,_L<_%:]T]I%N6
MT9[7=&<,$F=(9#_WQ(U>_5R'Q>^'-E\7OA;XK\%:@WEVFO:;/8-*.L1="%<>
MZMAA]* /YM_@_P#"G7?CA\3/#W@7PU%'+K6M7/V>'S21'& I=Y'(!(5$5G.
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MR/N^P_*@#\N_@C_P2+^,OQ,^SWOBPV7PWT>3!)U(_:+XJ>ZVT9X/M(Z'VK]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"&;[M<;XK_P!0]=E-]VN-\5_ZAZ /A_\ :H_Y"&C?
M6?\ ]DKP>O>/VJ/^0AHWUG_]DKP>OM\M_P!UC\_S9^69W_O]3Y?D@HHHKU#P
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]'^ __ ".=Q_UY/_Z&
ME>_5X#\!_P#D<[C_ *\G_P#0TKWZO.K_ !F4MPHHHK @**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "NZ^'7WQ_O5PM=U\.OOC_>KR<P^")]GPQ_'
MJ>GZGNFB_P"I6MM:Q-%_U*UMK7A'Z*.HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*1J6D:@#,U+_ %;5XS\1O]3+7LVI?ZMJ\9^(W^IEH _.N7_6/]33:=+_ *Q_
MJ:;7Z4MC\0>X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![
MA^RW_P AK6/]V'^;U]R>$_\ 4I]*^&_V6_\ D-:Q_NP_S>ON3PG_ *E/I7P^
M9?[U/Y?DC]3R/_<*?S_-G;0?=%35#!]T5-7F'NA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*[CY\**** "BBB@ HHHH **** /3/AQ_JHZ]ITO_ %:_2O%OAQ_JHZ]ITO\
MU:_2OC#]W6QJK2TBTM PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+M3\07&H:6VF-;WUO'&B*TL4F\%><YB _$U];4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_
M_P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7QK_P5L_Y,M\0?]A/3_\ T>*^RJI:OHNG^(+)K/5+
M"UU*T8AFM[R%98R1R"58$<4 ?RR45_3[_P *G\#_ /0F^'__  5P?_$4?\*G
M\#_]";X?_P#!7!_\10!_,%17]/O_  J?P/\ ]";X?_\ !7!_\11_PJ?P/_T)
MOA__ ,%<'_Q% '\P5%?T^_\ "I_ _P#T)OA__P %<'_Q%'_"I_ __0F^'_\
MP5P?_$4 >%?\$R_^3'/AA_UQOO\ TON:^H*JZ7I=EHEC%9:=9V]A9Q9$=O:Q
M+'&F22<*H '))_&K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $,WW:XWQ7_ *AZ[*;[M<;XK_U#T ?#
M_P"U1_R$-&^L_P#[)7@]>\?M4?\ (0T;ZS_^R5X/7V^6_P"ZQ^?YL_+,[_W^
MI\OR04445ZAX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >C_ ?_
M )'.X_Z\G_\ 0TKWZO ?@/\ \CG<?]>3_P#H:5[]7G5_C,I;A1116! 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %=U\.OOC_>KA:[KX=??'^]7D
MYA\$3[/AC^/4]/U/=-%_U*UMK6)HO^I6MM:\(_11U%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U>,_$;_4RT ?G7+_K'^II
MM.E_UC_4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#W#]EO_ )#6L?[L/\WK[D\)_P"I3Z5\-_LM_P#(:UC_ '8?YO7W)X3_
M -2GTKX?,O\ >I_+\D?J>1_[A3^?YL[:#[HJ:H8/NBIJ\P]T**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7SI^WU\</%'[//[-^K>-/!\MK#KEM>VD$;W< FCVR2A6RI]C7T77AO
M[9O[/>H_M/\ P)U+P%I>K6NB7=U=VUPMY>1L\:B*0.00O/.* /R=_P"'O'[0
MW_02\/\ _@G3_&C_ (>\?M#?]!+P_P#^"=/\:]5_X<A^./\ HI?A_P#\ IZ/
M^'(?CC_HI?A__P  IZ /*O\ A[Q^T-_T$O#_ /X)T_QH_P"'O'[0W_02\/\
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MZGNFB_ZE:VUK$T7_ %*UMK7A'Z*.HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J
M6D:@#,U+_5M7C/Q&_P!3+7LVI?ZMJ\9^(W^IEH _.N7_ %C_ %--ITO^L?ZF
MFU^E+8_$'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >X?
MLM_\AK6/]V'^;U]R>$_]2GTKX;_9;_Y#6L?[L/\ -Z^Y/"?^I3Z5\/F7^]3^
M7Y(_4\C_ -PI_/\ -G;0?=%35#!]T5-7F'NA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57N
M/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_ *\U_P#1CU]Z^,O]0_T-?!7[2/\
MR/D'_7FO_HQZ]?*_]Y7HSYW/O]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KU_P#9Z_UVN_[L/\WKR"O7_P!GK_7:[_NP_P W
MK&M\#)EL>S4445YIB%%%% !1110 4444 %%%9^L^(M*\.PK-JVIV>EPMG$EY
M<)"IQUP6(I#2<G9'Q%^TS^P+>:EJ]]XH^&B12?:G:>Y\/.PCVN>6:W8G;@GG
MRSC'\)QA1\2^*/".N>"=4?3=?TB]T:_49-O?0-$Y&<9 8#(]QQ7[,:/\8/ W
MB+7X=#TGQAH>JZO*&*65CJ$4\IV@EAA&/("DD>U?"?\ P4R_Y*QX6_[ @_\
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MB!&] &;<P'KE<^@K[?9@I4$@%C@9/4XS_2EKAA@:4=]3Z#$<08RM;D:AZ?\
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M"VT!0%W'J>: .I_X)%W-S!^V;HZ0;O*FTB_CN,,1^[\K<,^OSJE?NQ7Y/?\
M!%KX":@-;\4_%[4K5H=,%JVA:2\JD>?(SH]Q(F>RA$3<."7<=5-?K#0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXB%?R%?L?7Y)?\%OO!-S#XP^&?B]8V:SN;"YTF20?=22.02H#[L)GQ_N'TH
MV/\ @D'^R[X \??#;Q1\1/&'AC3?%.IKK)TFPAUBU2Y@M8XH8I6D2-P5WLTP
M&X@D>4-I&3GY<_X*;?!^P^"O[6VMPZ'80:5HNM6MMK=E9VT*QPQ;P4D"J!M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;:UB:+_J5K;6O"/T4=1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C4M(U &9J7^K
M:O&?B-_J9:]FU+_5M7C/Q&_U,M 'YUR_ZQ_J:;3I?]8_U--K]*6Q^(/<****
M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]P_9;_P"0UK'^[#_-
MZ^Y/"?\ J4^E?#?[+?\ R&M8_P!V'^;U]R>$_P#4I]*^'S+_ 'J?R_)'ZGD?
M^X4_G^;.V@^Z*FJ&#[HJ:O,/="BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNKH1-O\ -=N 1R,,*^PZ*RJTXU8\LMCLPF*J8*JJU+==S/\ #]G+IN@Z;:3
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M_GLH5IY"2TLI Z%Y&=R/5J[JBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&;[M<;XK_P!0]=E-]VN-
M\5_ZAZ /A_\ :H_Y"&C?6?\ ]DKP>O>/VJ/^0AHWUG_]DKP>OM\M_P!UC\_S
M9^69W_O]3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ]'^ __ ".=Q_UY/_Z&E>_5X#\!_P#D<[C_ *\G_P#0TKWZO.K_ !F4MPHH
MHK @**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NZ^'7WQ_O5PM=U
M\.OOC_>KR<P^")]GPQ_'J>GZGNFB_P"I6MM:Q-%_U*UMK7A'Z*.HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *1J6D:@#,U+_ %;5XS\1O]3+7LVI?ZMJ\9^(W^IE
MH _.N7_6/]33:=+_ *Q_J:;7Z4MC\0>X4444Q!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110![A^RW_P AK6/]V'^;U]R>$_\ 4I]*^&_V6_\ D-:Q
M_NP_S>ON3PG_ *E/I7P^9?[U/Y?DC]3R/_<*?S_-G;0?=%35#!]T5-7F'NA1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_KS7_T
M8]?>OC+_ %#_ $-?!7[2/_(^0?\ 7FO_ *,>O7RO_>5Z,^=S[_<7ZH\IHHHK
M[0_,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]?_9Z_P!=KO\
MNP_S>O(*]?\ V>O]=KO^[#_-ZQK? R9;'LU%%%>:8A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >F?#C_51U[3I?^K7Z5XM\./]5'7M.E_Z
MM?I7QA^[K8U5I:1:6@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,[_W^I\OR04445ZAX04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
MC_ ?_D<[C_KR?_T-*]^KP'X#_P#(YW'_ %Y/_P"AI7OU>=7^,REN%%%%8$!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5W7PZ^^/]ZN%KNOAU]\?
M[U>3F'P1/L^&/X]3T_4]TT7_ %*UMK6)HO\ J5K;6O"/T4=1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\$7?AG=Z]\>_$OC5X7&E^']':U$VWY3<W#J$7/\ USCF)_X#ZU^SE !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^0?]>:_^C'KU\K_WE>C/G<^_W%^J/*:***^T/S$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O7_ -GK_7:[_NP_S>O(*]?_ &>O]=KO^[#_ #>L
M:WP,F6Q[-1117FF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'IGPX_U4=>TZ7_ *M?I7BWPX_U4=>TZ7_JU^E?&'[NMC56EI%I:!A1110
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M%%% !1110 4444 %%%% !1110!XS1110!Z!\/_\ D#3?]?#?^@K735S/P_\
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M\1]2^)7['OA*ZU>[DO\ 4M-FNM+ENII"\DBQS,8RQ/)(C=!SZ9KZJH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH AF^[7&^*_]0]=E-]VN-\5_P"H>@#X?_:H_P"0AHWUG_\ 9*\'KWC]
MJC_D(:-]9_\ V2O!Z^WRW_=8_/\ -GY9G?\ O]3Y?D@HHHKU#P@HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>X^[5BJ]Q]V@#@O&7^
MH?Z&O@K]I'_D?(/^O-?_ $8]?>OC+_4/]#7P5^TC_P CY!_UYK_Z,>O7RO\
MWE>C/G<^_P!Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KU_\ 9Z_UVN_[L/\ -Z\@KU_]GK_7:[_NP_S>L:WP,F6Q[-1117FF
M(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'IGPX_P!5'7M.
ME_ZM?I7BWPX_U4=>TZ7_ *M?I7QA^[K8U5I:1:6@84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<?\9/'$_PR^$/CCQA
M:VT=[<^'M"OM6BMIF*I*\%N\H1B.0"4 ./6NPKA/CUX0U'XA? WXB^%M(6-]
M6USPYJ.F6:S/L0S36LD<89NPW,,GM0!^7?\ P^\\<?\ 1-/#_P#X&ST?\/O/
M''_1-/#_ /X&SUY5_P .A_VAO^@;X?\ _!PG^%'_  Z'_:&_Z!OA_P#\'"?X
M4 >J_P##[SQQ_P!$T\/_ /@;/7B'[77_  46\1_M=?#;3?!^K^$-+T"VL=6C
MU9;FQN))'9TAFB"$-Q@B<G_@(K:_X=#_ +0W_0-\/_\ @X3_  KR_P#:&_83
M^*G[,/@NR\4^.+32X-)O-033(FLK]9W\YXY) "H' VPOS]/6@#/_ &0_VKM6
M_9#^(&K>*M'T*S\07&H:8VF-;WTKQHBM+%)N!7G.8@/Q-?;7@G_@N!<?VE#'
MXO\ A=%]@9P)+G1=4/FQ+QDB*1,.>O&]?J*^!/V>?V;/&G[4'B[4/#?@:"SG
MU.QL6U"9;ZY$""$2)&2&(Y.Z1>/K4_[07[+'Q(_9AU;3K'Q_H:Z<NI*[V5Y;
MW"7%O<!,;PKH3@C<N5;!Y!Q@T ?T1?"OXI>&_C1X!T?QEX2U!=3T+5(O-@F
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MU?A+JWP?_9'\*:?KMM)8ZOJDD^L3VDR[7A69LQ*P[-Y2QD@X(+$'D5]1T44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 0S?=KC?%?^H>NRF^[7&^*_\ 4/0!\/\ [5'_ "$-&^L__LE>
M#U[Q^U1_R$-&^L__ +)7@]?;Y;_NL?G^;/RS._\ ?ZGR_)!1117J'A!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!Z/\  ?\ Y'.X_P"O)_\ T-*]
M^KP'X#_\CG<?]>3_ /H:5[]7G5_C,I;A1116! 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %=U\.OOC_ 'JX6NZ^'7WQ_O5Y.8?!$^SX8_CU/3]3
MW31?]2M;:UB:+_J5K;6O"/T4=1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/NT
M <%XR_U#_0U\%?M(_P#(^0?]>:_^C'K[U\9?ZA_H:^"OVD?^1\@_Z\U_]&/7
MKY7_ +RO1GSN??[B_5'E-%%%?:'YB%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6KV4EK.!;QR.S;)%#8/VH#IU7VK]&:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_P#\@:;_ *^&
M_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JEK6M6'AS2+W5=4O(=/TVRA>XN;NY<)'#&H)9V8\   DFKM
M?G#_ ,%GOCE?^$?ACX7^&NF.T(\5327FI2JV";:W9"D7T>1U8_\ 7''<T 8/
MQD_X+.:;9>.K+1OAGX<AU#P]%?1QWOB+6PZ^?!Y@$AMX%*LHVYVO(<\\H,<_
MIVK!E!!R#R"*_FW_ &:_V5_'W[5?BVXT/P196Y2R19+_ %34)3%:62MD(9&
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M !1110 4444 %%%% !1110!#-]VN-\5_ZAZ[*;[M<;XK_P!0] 'P_P#M4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *1J6D:@#,U+_5M7C/Q&_P!3+7LVI?ZMJ\9^(W^I
MEH _.N7_ %C_ %--ITO^L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >X?LM_\AK6/]V'^;U]R>$_]2GTKX;_9;_Y#6L?[
ML/\ -Z^Y/"?^I3Z5\/F7^]3^7Y(_4\C_ -PI_/\ -G;0?=%35#!]T5-7F'NA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_ *\U
M_P#1CU]Z^,O]0_T-?!7[2/\ R/D'_7FO_HQZ]?*_]Y7HSYW/O]Q?JCRFBBBO
MM#\Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU_P#9Z_UVN_[L
M/\WKR"O7_P!GK_7:[_NP_P WK&M\#)EL>S4445YIB%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Z9\./]5'7M.E_P"K7Z5XM\./]5'7M.E_
MZM?I7QA^[K8U5I:1:6@84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%5]0U"UTC3[F^OKF&RL;6)IY[FXD$<<4:@LSN
MQ.%4 $DG@ 4 6**\_P#^&A/A9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P
M?6O_ ,<H ] HKS__ (:$^%G_ $4OP?\ ^#ZU_P#CE'_#0GPL_P"BE^#_ /P?
M6O\ \<H ] HKF/"_Q1\&>.+Z6R\.>+M"\07D4?G26^EZE#<R(@(!<JC$A<D#
M/3)%5M>^,G@'PKJT^EZWXX\-Z/J=OM\ZRO\ 5K>":/<H9=R.X895@1D<@@]Z
M .PHK%\+>-O#OCBSEN_#>O:7X@M89/*DGTN\CN41\ [2R,0#@@X/J*VJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /&:*** /0/A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\<?^"VQNO^%Y>  Y_T+_A'
M&\I?23[3+O/Y>7^5?L=7P7_P5V_9SU#XM_!72_&V@6<E[K/@J6::XMX4W/)8
M2A?.8 <DQF.-\=E\PT <9_P1'UW1Y/A-\0]&C:)=?AUN.\G7</,:V>!$B..N
MT/'-SZM7Z3U_,C\&/C=XS_9_\<6_BSP-K,FCZO$AB=@H>*>(D%HI48$.AP.#
MT(!&" 1]OZ'_ ,%M/B7:V*1ZMX"\+:A=+P9[5[BW5O<J7?G\?PH _8^OP(_X
M*D>(-'\0_MJ>-GT=XIA:Q6=G=S0L&5[F.VC609'=>(R.QC([5VOQ2_X+!?&S
MQYI-UIFA6VA>!K>=2AN]*@DEO54Y!"RRNRJ<?Q*@8'D$5\8^'?#^M?$#Q58Z
M/I-I<ZUK^K72P6]O'F2:XFD; 'N23R3[DT ?MQ_P2#@FA_8YLGESLEUN^>+/
M]W<B_P#H0:OMBO+_ -F/X-1_L_? ;P9X!62.>?2+$+=S1#"2W+L9)V7V,COC
M/.,5ZA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I&I:1J ,S4O\ 5M7C/Q&_U,M>S:E_
MJVKQGXC?ZF6@#\ZY?]8_U--ITO\ K'^IIM?I2V/Q![A1113$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'N'[+?_ "&M8_W8?YO7W)X3_P!2GTKX
M;_9;_P"0UK'^[#_-Z^Y/"?\ J4^E?#YE_O4_E^2/U/(_]PI_/\V=M!]T5-4,
M'W14U>8>Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@#,U+_5M7C/Q&_P!3
M+7LVI?ZMJ\9^(W^IEH _.N7_ %C_ %--ITO^L?ZFFU^E+8_$'N%%%%,04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >X?LM_\AK6/]V'^;U]R>$_]
M2GTKX;_9;_Y#6L?[L/\ -Z^Y/"?^I3Z5\/F7^]3^7Y(_4\C_ -PI_/\ -G;0
M?=%35#!]T5-7F'NA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^A
MKX*_:1_Y'R#_ *\U_P#1CU]Z^,O]0_T-?!7[2/\ R/D'_7FO_HQZ]?*_]Y7H
MSYW/O]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KU_P#9Z_UVN_[L/\WKR"O7_P!GK_7:[_NP_P WK&M\#)EL>S4445YIB%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z9\./]5'7M.E_P"K
M7Z5XM\./]5'7M.E_ZM?I7QA^[K8U5I:1:6@84444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4+;5=*O8EGMKVSE66&:,C(964D$'U%:% !1110 4444 %%%% !1110 4444
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M>/\ FON?J:^G:Q>:3)OM+B2 YR0IX/U'0UVNB_%66+:FH0;A_P ]8>OXJ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H S-2_U;5XS\
M1O\ 4RU[-J7^K:O&?B-_J9: /SKE_P!8_P!33:=+_K'^IIM?I2V/Q![A1113
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDTR6\3RR.L<:*69F.
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M;XK_ -0]=E-]VN-\5_ZAZ /A_P#:H_Y"&C?6?_V2O!Z]X_:H_P"0AHWUG_\
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M56ES07VH^\OGU7S2.X#4M9T-\K8YJTLP;O7T1\18GHIH:ES3$+1110(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KNOAU]\?[U<+7=?#K[X_WJ
M\G,/@B?9\,?QZGI^I[IHO^I6MM:Q-%_U*UMK7A'Z*.HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *1J6D:@#,U+_5M7C/Q&_U,M>S:E_JVKQGXC?ZF6@#\ZY?]8_U
M--ITO^L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >X?LM_P#(:UC_ '8?YO7W)X3_ -2GTKX;_9;_ .0UK'^[#_-Z^Y/"
M?^I3Z5\/F7^]3^7Y(_4\C_W"G\_S9VT'W14U0P?=%35YA[H4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %5[C[M6*KW'W: ."\9?ZA_H:^"OVD?\ D?(/^O-?_1CU]Z^,O]0_
MT-?!7[2/_(^0?]>:_P#HQZ]?*_\ >5Z,^=S[_<7ZH\IHHHK[0_,0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *]?_9Z_UVN_[L/\WKR"O7_V>O\
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MO#6D>+]'N-)UW2K'6M+N!MFL=1MTN()!Z,C@J?Q% 'SC_P $R_\ DQSX8?\
M7&^_]+[FOJ"L'P-X$T#X9^%[+PWX7TJWT30K,R&VL+4$11;Y&D8*"> 7=CCH
M,\<5O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?C#_P
M4O\ V!]?^'WCK7/BIX&TJ;5?!.L327^J6UFA>32;ACNE=D'/D,Q+AAPA)!V@
M*3^>M?U3]>#R*_+W_@L!^SS\-_ OP?T3QYX<\'Z;H/BJ^\3PV-U?:;&8!/$]
MK=2.'C0B,L7B0[]N[@\\G(!\A?LR?\%'/BI^S'X?L/"^E_V7X@\&V<CO'HVI
MVH4QB20R2>7-'M<$LS'YBX&>G:OUC_9#_;\\ _M:0MIEBDOAGQK;Q&:X\/7T
M@=G0?>>WE  E4=^%8=UQR?R:T'_@G[XR\<?LEZ=\</">H0ZW"8[R;4/#WDF.
MY@AMYY8WDB;)$ORQ;RN%;J!N. ?GOX=^/=9^%OCK0O%OA^Z:SUG1[N.\MI5)
M'S*<[3CJK#*D=""0>#0!_3CXLO/[.\+:S=_\\+*:7IG[J$_TK^6ROZ@M%UNV
M^)'PVL-7LE;[)KVDQW<"Y&=D\(91D^SBOY?Y8WAD>.12DB$JRL,$$=0: /WM
M_P""4]ND/[#_ ('=1\TMSJ3M]?MTR_R45[#^UK&LW[*_QC5QN \&ZPWXBRE(
M_45XQ_P2@OEN_P!B3P?$",VMYJ,38]3=ROS^#BO9/VO+I+/]E/XQ2/T/A#5H
M^N.6M)5'ZD4 ?S95_1A^PC=M>_L>?"61LY708(^?1,J/T6OYSZ_HY_8ATU])
M_9#^$4#IL+>'+.XQ[21B0'\0X/XT >WT444 ?GI_P6POFC_9P\&V@)"S>*XI
M#Z';9W0_]GK\>?!_B:Y\%^+=$\0V4<,UYI-]!?P1W"EHVDBD5U# $$J2HR 1
MQWK]C?\ @M5I;W7[,_A2]2,N+7Q7 KL,_*KVET,GVR%'XBOQ<16D95499C@
M=Z /:-/^'OQR_;&\3:QXMM-$\1_$34C(1>:KY9>.-N6$0=L(@ /RQKC (  &
M*\^U_P -^,?@OXU%EJUCK'@SQ5IKI,B3+):7=NV,HZGAAQR&'X&OZ2_@O\+M
M(^"_PM\,^"M#M4M;#1[*.WPH&9) ,R2,>[.Y9B>Y8U\8?\%E_A7I?B+]GO2/
M'/V4#7?#NJQ6ZW:@;C:W&5>-CW'F"(CT.<?>- #O^"9?[?5_\?+>3X:_$&[6
M?QSI]N9]/U1AM;5;= -XD[><@P21]]<G&58G] J_FJ_97\=7GPV_:0^&OB*Q
MD:*6TUZT63:2-\,D@BF3/HT;NO\ P*OZ5: "BBB@ HHHH **** "BBL"^\(0
MWUW+<-=7"-(<E5(P/TH WZ*YG_A!;?\ Y_;K_OH?X4?\(+;_ //[=?\ ?0_P
MH Z:BN9_X06W_P"?VZ_[Z'^%'_""V_\ S^W7_?0_PH Z:BN9_P"$%M_^?VZ_
M[Z'^%'_""V__ #^W7_?0_P * .FHKF?^$%M_^?VZ_P"^A_A1_P (+;_\_MU_
MWT/\* .FHKF?^$%M_P#G]NO^^A_A1_P@MO\ \_MU_P!]#_"@#IJ*YG_A!;?_
M )_;K_OH?X4?\(+;_P#/[=?]]#_"@#IJ*YG_ (06W_Y_;K_OH?X4?\(+;_\
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MPH Z";[M<;XK_P!0]7)O MOM_P"/VZ_[Z'^%<AXH\$P+"_\ IER?^!#_  H
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M"V__ #^W7_?0_P */^$%M_\ G]NO^^A_A0!TU%<S_P (+;_\_MU_WT/\*/\
MA!;?_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X4 =-
M17,_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X4 =-17,_P#""V__ #^W7_?0
M_P */^$%M_\ G]NO^^A_A0!TU%<S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A
M_A0!TU%<S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X4 =-17,_\(+;_P#/
M[=?]]#_"C_A!;?\ Y_;K_OH?X4 =-17,_P#""V__ #^W7_?0_P */^$%M_\
MG]NO^^A_A0!TU%<S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@
MMO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!
M;?\ Y_;K_OH?X4 =-17,_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A0!T
MU%<S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]
M#_"C_A!;?_G]NO\ OH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?
MX4 =-17,_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A0!TU%<S_P (+;_\
M_MU_WT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]#_"C_A!;?_G]
MNO\ OH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X4 =-2-7-?\
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MPH ['-&:X[_A$;7_ )_KG_OH?X4?\(C:_P#/]<_]]#_"@#L<T9KCO^$1M?\
MG^N?^^A_A1_PB-K_ ,_US_WT/\* .QS1FN._X1&U_P"?ZY_[Z'^%'_"(VO\
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M\(C:_P#/]<_]]#_"@#L<T9KCO^$1M?\ G^N?^^A_A1_PB-K_ ,_US_WT/\*
M.QS1FN._X1&U_P"?ZY_[Z'^%'_"(VO\ S_7/_?0_PH ['-&:X[_A$;7_ )_K
MG_OH?X4?\(C:_P#/]<_]]#_"@#L<T9KCO^$1M?\ G^N?^^A_A1_PB-K_ ,_U
MS_WT/\* .QS2UQW_  B%K_S_ %S_ -]#_"E'@^U_Y_KG_OH?X4 =A17)KX+M
MC_R^W7_?0_PJ0>![?_G]NO\ OH?X4 =117,_\(+;_P#/[=?]]#_"C_A!;?\
MY_;K_OH?X4 =-17,_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A0!TU%<S
M_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]#_"C
M_A!;?_G]NO\ OH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X4 =
M-17,_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A0!TU%<S_P (+;_\_MU_
MWT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\
MOH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X4 =-17,_P#""V__
M #^W7_?0_P */^$%M_\ G]NO^^A_A0!TU%<S_P (+;_\_MU_WT/\*/\ A!;?
M_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X4 =-17,_
M\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X4 =-17,_P#""V__ #^W7_?0_P *
M/^$%M_\ G]NO^^A_A0!TU%<S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A0!
MTU%<S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X4 =-17,_\(+;_P#/[=?]
M]#_"C_A!;?\ Y_;K_OH?X4 =-17,_P#""V__ #^W7_?0_P */^$%M_\ G]NO
M^^A_A0!TU%<S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@MO\
M\_MU_P!]#_"C_A!;?_G]NO\ OH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!;?\
MY_;K_OH?X4 =-17,_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A0!TU%<S
M_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]#_"C
M_A!;?_G]NO\ OH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X4 =
M-17,_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A0!TU%<S_P (+;_\_MU_
MWT/\*/\ A!;?_G]NO^^A_A0!TU%<S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\
MOH?X4 =-17,_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X4 =-5>X^[6#_P (
M+;_\_MU_WT/\*KW'@6WV_P#'[=?]]#_"@#(\9?ZA_H:^"OVD?^1\@_Z\U_\
M1CU]I>,/!<"0O_I=P>#_ !#_  KXB^/^G+IOC2&))'D!M5;+]?OO7KY7_O*]
M&?.Y]_N+]4>:4445]H?F(4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>O_L]?Z[7?]V'^;UY!7K_ .SU_KM=_P!V'^;UC6^!DRV/9J***\TQ"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ],^''^JCKVG2_]6OT
MKYW^'OA"&2-#]JN!]"/\*]CTSP/;M&O^F7/3^\/\*^,/W=;'=+2US"^!;?\
MY_;K_OH?X4O_  @MO_S^W7_?0_PH&=-17,_\(+;_ //[=?\ ?0_PH_X06W_Y
M_;K_ +Z'^% '345S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^% '345S/\
MP@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X4 =-17,_\ ""V__/[=?]]#_"C_
M (06W_Y_;K_OH?X4 =-17,_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^% '
M345S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^% '345S/\ P@MO_P _MU_W
MT/\ "C_A!;?_ )_;K_OH?X4 =-17,_\ ""V__/[=?]]#_"C_ (06W_Y_;K_O
MH?X4 =-17,_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^% '345S/_""V_\
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M_P"$LUS_ *#.H?\ @5)_C1_PEFN?]!G4/_ J3_&OW3_X=/\ [-O_ $*&H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U>,_$;_4RT ?G7+_K'^II
MM.E_UC_4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#Z*^#_A*+PSI,&JQ7$DL^H012NC ;5X) '?^*O9-/\ B'J&G*%CBA8#
M^\#_ (UYUX'_ .1,T/\ Z\H?_0!6Y7A5:-.I-RFKLZZ698O#P5.E4:2.\7XQ
M:LHP+>V_)O\ &G_\+EU?_GVM?R;_ !K@**Q^JT?Y3;^V,?\ \_7^!W__  N7
M5_\ GVM?R;_&C_A<NK_\^UK^3?XUP%%'U6C_ "A_;&/_ .?K_ [_ /X7+J__
M #[6OY-_C1_PN75_^?:U_)O\:X"BCZK1_E#^V,?_ ,_7^!W_ /PN75_^?:U_
M)O\ &C_A<NK_ //M:_DW^-<!11]5H_RA_;&/_P"?K_ [_P#X7+J__/M:_DW^
M-'_"Y=7_ .?:U_)O\:X"BCZK1_E#^V,?_P _7^!W_P#PN75_^?:U_)O\:/\
MA<NK_P#/M:_DW^-<!11]5H_RA_;&/_Y^O\#O_P#A<NK_ //M:_DW^-'_  N7
M5_\ GVM?R;_&N HH^JT?Y0_MC'_\_7^!W_\ PN75_P#GVM?R;_&C_A<NK_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5[C[M6*KW'W: ."\9?ZA_H:^"OVD?\ D?(/^O-?_1CU
M]Z^,O]0_T-?!7[2/_(^0?]>:_P#HQZ]?*_\ >5Z,^=S[_<7ZH\IHHHK[0_,0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]?_9Z_UVN_[L/\WKR"
MO7_V>O\ 7:[_ +L/\WK&M\#)EL>S4445YIB%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!BO6M1//$0<@I)*693[@@U[!110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH AF^[7&^*_P#4/793?=KC?%?^H>@#X?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@
M#,U+_5M7C/Q&_P!3+7LVI?ZMJ\9^(W^IEH _.N7_ %C_ %--ITO^L?ZFFU^E
M+8_$'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?5/@?\
MY$S0_P#KRA_] %;E8?@?_D3-#_Z\H?\ T 5N5Y$MV8/<****0@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O7_V>O]=KO^[#_-Z\@KU_]GK_ %VN_P"[
M#_-ZQK? R9;'LU%%%>:8A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >F?#C_51U[3I?^K7Z5XM\./\ 51U[3I?^K7Z5\8?NZV-5:6D6EH&%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS?'[XB)X7BU3^QD%K+=RWOV;S_+5,#[F]<Y9E'7O7U#_ ,.N_P#JIG_E!_\
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /3/AQ_JHZ]ITO\
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MP]<Z=%=ZI;Z=-?:-+Y8,D%[$A>+RSC*[BH1L=5=AWH ^?/\ @D;^TEJ?Q?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KU_P#9Z_UVN_[L/\WKR"O7_P!GK_7:[_NP_P WK&M\#)EL>S4445YI
MB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z9\./]5'7M.E
M_P"K7Z5XM\./]5'7M.E_ZM?I7QA^[K8U5I:1:6@84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "ORR_X+<_#&]N+/X<_$&WCWV%LT^B7C!>8V?$T!)]#MF'U ]:_
M4VN*^,WPB\._';X:ZYX(\4VOVG2-5@,;,N!) XYCFC)Z.C ,#ZCG(R* /Q&_
MX)T?MH6O[)?Q#U6U\20S3^!O$B1)J+VT?F36DT6_RIT7/S*/,=64<D$$9*A3
M^TW@G]I+X5?$;3;>^\.?$3PUJD,T?F+''J<2S*,9P\3,'0C(RK*".XK\%/VH
MOV-_B'^RGXEDM/$NG-?>'YI"+#Q)8HS6=TN> 3_RSDQUC;!ZXW##'PJ@#^BW
MXT?MS?!;X':#<7^L>.=+U:^0$1:-H5U'>WLS?W?+1CL'!^:0JO!YSQ7X*?M
M_&C5OVA?C%XF^(&M0QVU[K-P'6UA.4MX418XH@>^V-$7/<@GO7GM?=7[ /\
MP3J\1_&[Q3HWCCQYI$FE?#.SF%P+>^4I+K17E8XT(SY)(&YS@$95<DDJ ?I5
M_P $Z/AG=_"O]CWX?Z;J*>5J%_;2:Q,A&"OVF1IHU([$1-&"/4&OI2F0PI;Q
M)%$BQQ(H5408"@<  =A3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6S/C_4O">H:?D^7Y\8_BCY/Y=:QB"I((P:^G]8\"/&6Q'^E<+KO@.*XW>=;
MM_?48;\Z^2Q7#<9>]AI6\G_G_P .?;8/BR<;1Q<+^:W^[_ACQJN_\#_'3QCX
M!\N.QU1[JR3 %E?9EB ]!DY4?[I%9FJ> ;BW):UD\P?W).#^?3^5<S=6<]E)
MLGB:)O\ :'6OEZF'QN6SYFG'S6WWH^RI8K+\VAR)J:[/?[GK\S[#\!?MC:%J
MGEP>(;:70[@\&9<S0$_4#<OX@@>M>_:#XPT[7[-+K3[Z"^MG^[-;R!U/X@U^
M7%:OA[Q5K'A.\%UH^I7.G3]VMY"H;V8=&'L:]O"\15J?NXB/,NZT?^7Y'SV,
MX5H5+RPLN1]GJO\ -?B?JA#>JXZU964'O7P_X#_;(U;33';^)]/74H1P;NSQ
M'*!ZE/NL?IMKZ.\!_'#PMX\5%TK5H9+DC)M)CY<P]?D/)^HR/>OK\+F>%QFE
M.>O9Z/\ KT/A<9E&,P-W5A[O=:K_ ('SL>J[J=67;ZDDF.:N1W ;O7J'C%BB
MF*^:=F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D:EI&H S-2_P!6U>,_$;_4RU[-J7^K:O&?B-_J9: /SKE_UC_4TVG2
M_P"L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
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M5*S2MVVV:?<U/V$_'OA[X;_%[5M9\3:O;:-IJZ%/'Y]RV SF: A% Y9B 3M
M)X/I7(_M3?&R+X\?%BZUZRAD@TBU@2PL%F&)#"A9M[#/!9G<X[ @=J\^\&>!
M?$'Q$UH:3X:TBZUK4=AE-O:1[F5 0"Q[!06 R>.17UO\"O\ @G?K5]JEKJOQ
M*DBTS3(F60Z);2B2>XQSMDD4[47UVDD\CY>M<U-5:T%2@M#UL3+!X+$2QE:?
MOVM;_)>9ZY_P3I^'MSX5^#]_X@O(FAE\17GFP*PQFWB&Q&Q[L93[C![UF?\
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M:1F_CD'8 ;5/.6."/L&NO!X>5.\Y[L\7/<TIXJV'H.\5JWW?D?FS^U#^T/\
M&3X=_&3Q-X:3Q?=6.EPW'G6$=O:P1XMI 'C =8]S8!VY))RISWKT']C7]L:R
M_LW5?#WQ.\4R+J!N#=6.KZO,2CQE0&A9SPNTKN&>#O([ 'V3]K#]E>U_:"T>
MWU#39XM-\7Z=&8[6XF'[JXCSGR92!D#.2K#."3P<U^=_BS]F?XI>"[R2WU'P
M-K4@0X^T6-HUU"?0B2(,O/N<USU?;X>KSJ[1Z>$_L_,L&J,K0GI>UD[KJN]S
M[1_:T_;&\(6?PYU?PKX-UB#Q#K>LP/927-@^^"TA<;9&,@X9BI95"DXSDD8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'IGPX_U4=>TZ7_ *M?I7BWPX_U4=>TZ7_JU^E?&'[NMC56EI%I
M:!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 55U32[+7-,N].U&T@U#3[R%[>YM+J)9(IXG4JZ.C AE8$@@C!!(JU7F_
M[2NMW_AK]G/XJ:OI5Y-I^J:?X4U6[M+RW<I)!-'9RLDB,.0RL 0>Q% 'H-C8
MVVEV<-I9V\5I:0H(XH($")&HZ*JC@ >@J>OYP?\ AM;X]_\ 17O&'_@VE_QH
M_P"&UOCW_P!%>\8?^#:7_&@#^CZBOYP?^&UOCW_T5[QA_P"#:7_&C_AM;X]_
M]%>\8?\ @VE_QH _H^HK^<'_ (;6^/?_ $5[QA_X-I?\:/\ AM;X]_\ 17O&
M'_@VE_QH _H^HKX6_P""1_Q7\9?%SX*^,=1\:>)M4\47]MX@-O#<:I<M.\<?
MV:%M@+'@98G'N:^Z: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFKF?A__P @
M:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^6_P#@
MI1\2_%'PE_95UKQ%X/UJZ\/ZY#J%E%'?69 D57F 8#(/4<4 ?4E%?A)^S!^V
MQ\<_&'[1WPPT+6OB9KFHZ1J7B33[2[M)I%*30O<(KHWR]""1^-?8W_!7CX_?
M$/X&_P#"I_\ A O%FH>%_P"U/[6^V_86"^?Y?V/R]V0?N^8^/]XT ?H;J&GV
MNK64]G>VT-Y:3H8Y;>XC#QR*>JLIX(]C7@7B7_@GW^SOXLOFN[[X5:)%,TGF
MG^SS+9)NR#]R!T7''3&.O')K\6_^&_/VAO\ HK'B#_OZG_Q-'_#?G[0W_16/
M$'_?U/\ XF@#]QO /['?P3^&.I0ZCX;^&?AZPU&''E7DEH+B:(CHR/+N96_V
M@<^]>QU_.M_PWY^T-_T5CQ!_W]3_ .)H_P"&_/VAO^BL>(/^_J?_ !- ']%-
M%?/O[ OCO7_B9^R/\/O$OBC5;C6]>OXKMKF_NB#)*5O9T7.!V55'X5]!4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 0S?=KC?%?^H>NRF^[7&^*_]0] 'P_^U1_R$-&^L_\ [)7@]>\?
MM4?\A#1OK/\ ^R5X/7V^6_[K'Y_FS\LSO_?ZGR_)!1117J'A!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!Z/\!_^1SN/^O)__0TKWZO ?@/_ ,CG
M<?\ 7D__ *&E>_5YU?XS*6X4445@0%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *1J6D:@#,U+_5M7C/Q&_P!3+7LVI?ZMJ\9^(W^IEH _.N7_ %C_ %--
MITO^L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 ?5/@?\ Y$S0_P#KRA_] %;E8?@?_D3-#_Z\H?\ T 5N5Y$MV8/<****
M0@HHHH **** "BBB@ HHHH ^+?V-_P!E7QY\$_BI>Z]XFM[&+3Y=*FLU:VNQ
M*WF-+$PX Z81N:^TJ**QI4HT8\L3MQF+J8VK[6K:_D%%%%;'$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &C
MH/\ R%(J]^\)_P"I3Z5X#H/_ "%(J]^\)_ZE/I7S.,_CR^7Y'ZSD/_(OI_/_
M -*9VT'W14U0P?=%35Q'OA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57N/NU8JO
M<?=H X+QE_J'^AKX*_:1_P"1\@_Z\U_]&/7WKXR_U#_0U\%?M(_\CY!_UYK_
M .C'KU\K_P!Y7HSYW/O]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_ /(&F_Z^&_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9O
MNUQOBO\ U#UV4WW:XWQ7_J'H ^'_ -JC_D(:-]9__9*\'KWC]JC_ )"&C?6?
M_P!DKP>OM\M_W6/S_-GY9G?^_P!3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 %%%% !1110 4444 %%%% !1110 4444 >F?#C_51U[3I?^K7Z5XM\./\
M51U[3I?^K7Z5\8?NZV-5:6D6EH&%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+Q!X2^W;/M?]A:I/9?:-F[9YGE.N[;O?&<XW-CJ:ZO\ X:Q^-_\ T63X@?\
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M_P#V2O!Z^WRW_=8_/\V?EF=_[_4^7Y(****]0\(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /1_@/_R.=Q_UY/\ ^AI7OU> _ ?_ )'.X_Z\G_\
M0TKWZO.K_&92W"BBBL" HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *[KX=??'^]7"UW7PZ^^/]ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L31?\ 4K6V
MM>$?HHZBBB@ HHHH *3%+10 QDS44ENK=JL44 9-QIJ2?PUBWWAR.4'Y/TKK
MBM,:$'M0!Y5JW@I)0?D_2N&UKX?AMV(_TKZ$FL5?/%9=YH:2@_+0!\IZQX">
M,MA/TKAM<\"QW&1/;!SV;&&'XU]A:GX1CE!^3]*XO6? *ONQ'^E1.G"I'EFK
MKS-*=2=*2G3DTUU6A\;:I\/I8"S6LF?^F<O^-<O>:?<Z>^VXA:(]BPX/T/>O
MK76OA^5W8C_2N&UCP2ZJRM$&7NK#(-?,XKA_#5O>HOD?WH^OP?%&+H6CB%SK
M[G]__ ^9\]U?T77M2\.WRWFEWUQI]TO26VD*-]#CJ/:NWUCX=PL6:$-;/_L\
MK^5<?J/A>_TW):+S8Q_'%S^G6OD<3E.,P;YN6Z75?U='W.$SO 8]<G-9OI+3
M_@,]K\"?M@>(-%\N#Q%:1ZU;C@W$.(IP/4@#:WY#ZU]'^ ?V@?"?CORXK#5$
MAO7X^Q7?[J;/H >&_P" DU^=]'3D5T87/L5A_=F^=>>_W_YW.7&<-X+%7E37
M)+RV^[_*Q^KMOJ:28PU7H[A6[U^;O@?]H/QGX%\N*'4CJ5BG'V34,RJ!Z*V=
MR_@<>U?17@']L#PYK?EV^MQRZ!=G@O)^\@)]G R/^! #WKZ_"YYA,3I)\K\_
M\]OR/A,9P[CL)>48\\>Z_P M_P SZ=5\T[-<SH_BBRUBUCN;.ZAN[>092:"0
M.C?0C@UM17BOCFO?335T?,M-.S+M%1+*#WJ3=3$+1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U>,_$;_ %,M 'YUR_ZQ_J:;3I?]8_U-
M-K]*6Q^(/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^J?
M _\ R)FA_P#7E#_Z *W*P_ __(F:'_UY0_\ H K<KR);LP>X4444A!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!HZ#_R%(J]^\)_ZE/I7@.@_P#(
M4BKW[PG_ *E/I7S.,_CR^7Y'ZSD/_(OI_/\ ]*9VT'W14U0P?=%35Q'OA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#
M_KS7_P!&/7WKXR_U#_0U\%?M(_\ (^0?]>:_^C'KU\K_ -Y7HSYW/O\ <7ZH
M\IHHHK[0_,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]?_ &>O
M]=KO^[#_ #>O(*]?_9Z_UVN_[L/\WK&M\#)EL>S4445YIB%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!Z9\./\ 51U[3I?^K7Z5XM\./]5'
M7M.E_P"K7Z5\8?NZV-5:6D6EH&%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !139)$AC:21E1%!9F8X  ZDFO#_VCOVEO
M#7PO^!/CGQ1HGBC1+W6].TJ9]/@AOX9&:Y9=D/RAB6 =E)&.@- 'R[^WA_P5
M&'P7\0:A\/?A9%9ZIXMLV,.IZY=*);;3I.ABC3.))E/WBWRH1M(8[@ORK^PM
M^U9\3_B3^W!\/G\<^/=<\066H3WEO)8W5XPM TEG.$*VZXB3Y]A^51TKXHL;
M/4_&7B2"UB9[_6-4NUC5IY1NFFD?&6=CC)9N68]\DU^PW[(7[!_P4^ MSH'C
M#Q;X_P!(\3?$2Q=+M'@UR."QL)@.D2*X:7&2-TA(;&=B]* /T/KX<_;:_P""
MG&@_LUZS<^"_!VG0>+?'L*C[5]H<BPTTD9"RE2&DDQ@^6I& >6!^6O;/VE/V
MJO"GP9^!?C'Q?I?B/1=4UC3[)AIUG!?13-+=2$1PC8K$LH=U9L?PAJ_G8U35
M+W7M4N]1U"YFOM0O)GN+BYG8O)-([%F=B>22223[T ?5^L?\%6/VE=2U)[JV
M\<6FDP,<BRL]#L6B7V!EA=_S8U[[^S=_P64\16>OV>D?&72K/4M%G<1MX@T>
MW,-S:Y/^LEA!*2(.X0(P&2 QP*/V??\ @E]\)]6^'MAJOQ8^*JV?B74(5G.D
MZ#K%E NGAAD1R-*DA>0 C. H4Y'S8W5\B?MA_LP0?LQ_$"VT[2/%>G^,_"^J
M1M/INJ6<T;R*%(#Q3JC$*Z[EY'#!@1CE5 /Z(-%UFQ\1:19:KI=Y#J&FWL*7
M%M=V[AXYHW 975AP0000?>KM?G3_ ,$?_P!H*TU3X$ZQX(\2Z]9VUQX;U-8]
M,6_NTC=K:X!=8D#$%MLBR],XW@>E?HM0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!XS1110!Z!\/_P#D#3?]?#?^
M@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !117P'_ ,%>/VD=6^$GPCT3P-X=NY+#5?&;SK=WD#E9(K&'9YB*
M1R#(TBKG^ZL@[T >[^.?^"@G[/7PYU:;3=:^*&E_;89#%+'IL-QJ 1QG*EK:
M.0 @@@\\'@\US7_#T;]F+_HIG_E U3_Y&K\ XHGFD2.-&DD<A511DL3T 'K2
MR6\L,[0R1O',K;6C92&#=,$>M '[]_\ #T;]F+_HIG_E U3_ .1JY/QK_P %
M>/V??#-G-)I&I:YXNN%!\N'3-*DA#MCC+7'E8&>IY/!X/?\ #F^T74-,C5[R
MPN;1&.%:>%D!/H,BM+P+X$U_XF>*]/\ #/A?2YM9UW4',=K8V^-\K!2Q R0.
M ">3T!H _H\_9I^-2_M$_!/PW\0TTDZ''K0N'2P:?SC$L=S+",OM7)(C#'CC
M..<9KTZO"/V&?AEXC^#G[*O@+P?XML!I?B+38+G[79B9)O*,EW-*HWHS*3M=
M>A/I7N] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% $,WW:XWQ7_J'KLIONUQOBO\ U#T ?#_[5'_(0T;Z
MS_\ LE>#U[Q^U1_R$-&^L_\ [)7@]?;Y;_NL?G^;/RS._P#?ZGR_)!1117J'
MA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 :.@_P#(4BKW[PG_ *E/I7@.@_\ (4BKW[PG_J4^
ME?,XS^/+Y?D?K.0_\B^G\_\ TIG;0?=%35#!]T5-7$>^%%%% !1110 4444
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M5;K5"6O]7NTSMGO9 OF%?]E0J1KTRL:D\DU[90 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH T=!_Y"D5>_>$_P#4I]*\!T'_ )"D5>_>$_\ 4I]*^9QG
M\>7R_(_6<A_Y%]/Y_P#I3.V@^Z*FJ&#[HJ:N(]\**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J]Q]VK%5[C[M '!>,O]0_T-?!7[2/\ R/D'_7FO_HQZ^]?&7^H?
MZ&O@K]I'_D?(/^O-?_1CUZ^5_P"\KT9\[GW^XOU1Y31117VA^8A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Z_^SU_KM=_W8?YO7D%>O_L]?Z[7
M?]V'^;UC6^!DRV/9J***\TQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ],^''^JCKVG2_]6OTKQ;X<?ZJ.O:=+_P!6OTKXP_=UL:JTM(M+
M0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#E?B7\*_"7QC\*W'AOQKH%EXCT68AVM;Q,A6&<.C##(XR<,I!&3S
M7Q9XH_X(O_!C6-4DNM)\0>+/#]L_/V*&ZAGC3GHIDB+X_P!YC]:^_:* /CSX
M+_\ !*SX&?"'6+;6+G3M0\<:I;,)(7\2SI+!&X/#""-$1L>D@?UZXK["50J@
M 8 X %+7F_[0OQKM?V>?A3JWCS4-#U+7]-TMHS=6VE!#,D;N$\S#L 54LN>>
M 2>@- '>ZMI5IKNE7FFW\"W-C>0O;W$+YQ)&ZE64X[$$C\:Y?X;_  9\"?![
M3S9>"?".C^&(&4+(=-LTBDE _P">C@;G/NQ)KY!^''_!8/X5?$+Q[H'AAO#7
MB30SK%[%8IJ&H+;_ &>!Y&"JTA64D+N(!..,Y/ K[QH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:***
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %=U\.OOC_>KA:[KX=??'^]7DYA\$3[/AC^/4]/U
M/=-%_P!2M;:UB:+_ *E:VUKPC]%'4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 )MJ-H@>U2T4 4IK-7[5EW>BI(#\M=!BFM'F@#@-
M2\)QS _)7&:QX#23=B/]*]LDMU;M5&XTM),_+0!\RZU\/B-V(_TKAM6\$O'O
M!CR.X(KZXO\ PW'-GY*Y/5O!*2[L)^E 'QMK7P[@D9F1&MG]8^GY?X8KC=2\
M(ZAI^2(_M$8_BCZ_EUK["UKX?@[L1_I7!ZQX#>,MA/TKPL5DN$Q6O+RONO\
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M[:#[HJ:H8/NBIJXCWPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/NT
M <%XR_U#_0U\%?M(_P#(^0?]>:_^C'K[U\9?ZA_H:^"OVD?^1\@_Z\U_]&/7
MKY7_ +RO1GSN??[B_5'E-%%%?:'YB%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]>4/_H K<KR);LP>X4444A!1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *]?_9Z_UVN_[L/\WKR"O7_V>O\ 7:[_ +L/\WK&
MM\#)EL>S4445YIB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!Z9\./]5'7M.E_ZM?I7BWPX_P!5'7M.E_ZM?I7QA^[K8U5I:1:6@84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<O\
M%/P.GQ.^&/B_P=+=MI\7B'1[S2&NTC\PP">!XBX7(W%=^<9&<=:ZBB@#\P/^
M''.A_P#16]0_\$<?_P ?H_X<<Z'_ -%;U#_P1Q__ !^OT_HH _,#_AQSH?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#-]VN-\5_ZAZ[*;[M<
M;XK_ -0] 'P_^U1_R$-&^L__ +)7@]>\?M4?\A#1OK/_ .R5X/7V^6_[K'Y_
MFS\LSO\ W^I\OR04445ZAX04444 %%%% !1110 4444 %%%% !1110 4444
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M/_4I]*^9QG\>7R_(_6<A_P"1?3^?_I3.V@^Z*FJ&#[HJ:N(]\**** "BBB@
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M[17@&RFO-1^&.I7EI%DF31YX-08@=Q'!([X^JUX9X9\3>(/AGXPLM;T2]N]
M\1Z1<^9!<PDQS6\JG!!!_$%2,$9!&"10!_4917A_[&?[0Z?M/?L_^'O&DL<<
M&L?-8ZM;Q?=CO(L"0@=E<%9 .PD [5[A0 4444 %%%% !1110 4444 %%%%
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MV=W$LL,\3J5='1@0RL"001@@XI=,TNRT73X+'3K2"PLH%V16UK$L<<:^BJH
M ]A7\NW_  EFN?\ 09U#_P "I/\ &C_A+-<_Z#.H?^!4G^- ']2=%?,G_!-6
MZGOOV(_AE/<327$S0WNZ25BS'_3[D<DU]-T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^J? __ ")FA_\
M7E#_ .@"MRL/P/\ \B9H?_7E#_Z *W*\B6[,'N%%%%(04444 %%%% !1110
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O7_V>O]=KO^[#_-Z\
M@KU_]GK_ %VN_P"[#_-ZQK? R9;'LU%%%>:8A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >F?#C_51U[3I?^K7Z5XM\./\ 51U[3I?^K7Z5
M\8?NZV-5:6D6EH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMMNU#5YHL%6O)<%P".H0!(PW<1@]Z]TH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_
M $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH ****
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M@#DOA3\+?#OP5^'^D^"_"=I)8^']+61;6WEF>9D#R/(V7<EC\SL>3WKK:**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#ZI\#_ /(F:'_UY0_^@"MRL/P/_P B9H?_
M %Y0_P#H K<KR);LP>X4444A!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!HZ#_R%(J]^\)_ZE/I7@.@_\A2*O?O"?^I3Z5\SC/X\OE^1^LY#_P B
M^G\__2F=M!]T5-4,'W14U<1[X4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[C[M
M6*KW'W: ."\9?ZA_H:^"OVD?^1\@_P"O-?\ T8]?>OC+_4/]#7P5^TC_ ,CY
M!_UYK_Z,>O7RO_>5Z,^=S[_<7ZH\IHHHK[0_,0HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *]?\ V>O]=KO^[#_-Z\@KU_\ 9Z_UVN_[L/\ -ZQK
M? R9;'LU%%%>:8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >F?#C_51U[3I?\ JU^E>+?#C_51U[3I?^K7Z5\8?NZV-5:6D6EH&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MPOQ?^!_@;X]>%W\/^._#EGXATXY:/SU*RV['^.*52'C;W4C(X.1Q7P7\2/\
M@B3X1U:\DN/ WQ#U3P["W/V+6+)-04'T61&B91]0QXZFOT7\6>+]#\!^'[S7
M/$>KV6AZ/9IOGOM0G6&&,>[,0/8#N>*^//B)_P %>?@)X)NY+72KC7O&LJ';
MYNBZ>$@W?[]P\61[J&'IF@#Y$U+_ ((F?%6(2_V?XY\'7)!_=_:6NX=PSWVP
MOCC/K5>Q_P"")_Q?D5OMGC/P1 V?E$%Q>2@CW)MEQ7L5]_P7$\/1S2BS^$^I
MSQ#_ %;3ZS'$S<=P(6QS[FJUG_P7(TJ2%3=_!^\@ES\RP^($D4#/8FW7/Y4
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M /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *[KX=??'^]7"UW7PZ^^/]ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L31?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *S_$.O6'A70-3UK5+A;33--M9;RZN'Z10QH7=C[!5)_"
MM"OG3_@HAJ5WI7[%OQ5FLRPF;3$@;8<'RY)XHY/PV.V?:@#\8?VQOVO?%'[6
M7Q(NM2O[B:S\)6<SIHFA*Q$5M#DA9'4'#3,.6?WP,* *\F\%_#'QC\2)I(?"
M7A+7/%$L?#QZ+ILUXR\9Y$:MCBNG_9C\'Z!\0/VA?AWX;\4RK%X?U36[6UO
MS[!(C2 >66[;SA,CD;J_I(\-^&-(\&Z)::/H.EV>C:3:((X+&P@6&&)1V5%
M H _G<T_]AKX_P"I9\GX1^*DP-W^D6#0_P#H>.?:I;W]A']H+3XA)+\)?$S*
M6VXAM/-/Y(2<<=:_HQHH _F2\9_ 3XF?#FUDNO%/P^\4>';.,X:ZU/1[B"'_
M +^,@4CW!IGP;^-7C#X"^.;'Q9X+UB;2=4M7!958F&YCSDQ3)G$D9[J?J,$
MC^FZ2-98V1U#HPPRL,@CT-?A#_P5:^&'@[X7?M4/;^#K6UTZ+5=(@U34=.LP
M%BM[MY)5;:@X3>B1R;?5R?XJ /V/_9F^.^F?M)?!7PYX]TR/[*=0A*7=GG)M
M;I"4FB]P&!P>ZE3WKU&OSH_X(EZC=S? GQW92%C96_B,20Y)(#/;1!P!V^XA
M_&OT7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \9HHHH ] ^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KI
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^._^"G7[5&H_
MLW_ ^WL/#5TUEXQ\6326-A=QG#VD"*#<3I_M@.B*>QE#=5Y -C]I;_@I)\)/
MV;M2N="GN[CQ?XM@!$FCZ%L<6[_W9YB0D9]5&YQW7D5\;>)O^"X'BNYF?_A'
MOA?HVG0\;/[3U*6[;W)V)%U_3WK\_OA?\)O&GQT\91^'?!FA7OB77;C,KQVX
MSL7(#2RR,0J)EAEW(&2.<FNP_:,_91\=_LLW?A^T\=Q:?;W>MP2W%O!8W7GE
M%C8*P<@;0<L.A- '[C?"7]IB\\7?L9Q?&WQ!IMG;7<>A7^LW.GV;LD)^SF;"
M*6+$;A$!SGD_A6/^RC^W[\-OVKF72=*DN/#OC-(#--X=U,C>RK]]H)!\LRCV
MPV.2@%>(?#OPIXL\=?\ !'S3_#W@?2Y-9\2ZGHLMM!912)&TD;:B_G8+L!GR
MO,.,Y)X&2:_(&POO%/PA\=Q75N^H^%?%N@W>5+*UO=6=PAY!4@%2#P01Z@B@
M#^H6BO+_ -F3XT6_[0GP'\'>/H(_)DU:RS=0XP([F-FBG4?[(EC?![C![UZA
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!#-]VN-\5_ZAZ[*;[M<;XK_ -0] 'P_^U1_R$-&^L__ +)7
M@]>\?M4?\A#1OK/_ .R5X/7V^6_[K'Y_FS\LSO\ W^I\OR04445ZAX04444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,_L>?!67]GW]F_P1X)NXT35;.S\_4MA##[7,S2S+N_B"LY0'T45[-0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!#-]VN-\5_ZAZ[*;[M<;XK_P!0] 'P_P#M4?\ (0T;ZS_^R5X/7O'[
M5'_(0T;ZS_\ LE>#U]OEO^ZQ^?YL_+,[_P!_J?+\D%%%%>H>$%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'H_P !_P#D<[C_ *\G_P#0TKWZO ?@
M/_R.=Q_UY/\ ^AI7OU>=7^,REN%%%%8$!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5W7PZ^^/\ >KA:[KX=??'^]7DYA\$3[/AC^/4]/U/=-%_U
M*UMK6)HO^I6MM:\(_11U%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 TK4;PANHJ:B@"A-8
MK)U%9-]H:2J?EKI-M1R1@CI0!Y5XB\)))&_R?I7SS\3O!JK'*0GKVK["U:U5
MHFXKP[XF::K0R\4 ?EG?:*1(^%[FLO[+<6,PE@DDAE7H\;%2/Q%>E7FGAI'X
M[FLJZT@-GY:^ZGAU)6:T/RFGBW&5T[-&=I/Q,U33=L=]&M_$.-Q^63\QP?Q'
MXUW&C>.M(UK:J7'V><_\L;CY#^!Z'\#7G]WHG7Y:Q[K1V7/%?$YAPI@<7>4(
M^SEWCM]VWW6/TC*N.,RP-H5)>UCVEO\ *6_WW/>**\2TOQ1K/A_"P7+20C_E
MC-\Z_AW'X8KM='^*EC=;8]0A:RDZ>8OSQ_XC]:_.<=POC\'>5->TCY;_ ';_
M '7/US+.-<KS"T*LO92[2V_\"V^^QU5SH]O<<A?*?^\G'Z5FS:5=6V2G[]/]
MGK^5;5I>07T(EMIHYXCT>-@P_2IJSP'$N9Y8^3GYHK[,M?\ @K[_ )&F:<'9
M+G,?:>SY)/[4-/P^%_=?S.66XVG#95AU!J=9@:W+BSANEQ+&K>_?\ZS+C067
MFWE_X"_^-?IF7<:X'$VAB4Z<OOC]_P#FOF?C6;>'&98.]3!-5H^6DON>C^3;
M\B$,#3JJ2>=:MB:-D]^Q_&GI.&[U]]2K4Z\%4I24D^J=T?E=?#UL--TJT'&2
MW35G]S+%%,60&G5N<PM%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!]4^!_\ D3-#_P"O*'_T 5N5A^!_
M^1,T/_KRA_\ 0!6Y7D2W9@]PHHHI""BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#1T'_D*15[]X3_ -2GTKP'0?\ D*15[]X3_P!2GTKYG&?QY?+\
MC]9R'_D7T_G_ .E,[:#[HJ:H8/NBIJXCWPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *KW'W:L57N/NT <%XR_U#_0U\%?M(_P#(^0?]>:_^C'K[U\9?ZA_H:^"O
MVD?^1\@_Z\U_]&/7KY7_ +RO1GSN??[B_5'E-%%%?:'YB%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $,WW:XWQ7_J'KLIONUQOBO_ %#T ?#_ .U1_P A#1OK/_[)
M7@]>\?M4?\A#1OK/_P"R5X/7V^6_[K'Y_FS\LSO_ '^I\OR04445ZAX04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >C_  '_ .1SN/\ KR?_ -#2
MO?J\!^ __(YW'_7D_P#Z&E>_5YU?XS*6X4445@0%%%% !1110 4444 %%%%
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M6M$PC2_;(!QY=QEB/HW6OS?'\&5(7E@YW\I?Y_\  7J?KV5^(=*I:&84[/\
MFCM\T]?N;]#V1E#J58!@>H(K/N-#@ER8B86_V>GY5@Z/\3-+U':EUNT^8_\
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M/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_ *\U_P#1CU]Z^,O]0_T-?!7[2/\
MR/D'_7FO_HQZ]?*_]Y7HSYW/O]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KU_P#9Z_UVN_[L/\WKR"O7_P!GK_7:[_NP_P W
MK&M\#)EL>S4445YIB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Z9\./]5'7M.E_P"K7Z5XM\./]5'7M.E_ZM?I7QA^[K8U5I:1:6@84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#>1?L9Z0UT&$$FKW[6NX'!B\P X]MXDZ=\U]HT %%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** "J]Q]VK%5[C[M '!>,O\ 4/\
M0U\%?M(_\CY!_P!>:_\ HQZ^]?&7^H?Z&O@K]I'_ )'R#_KS7_T8]>OE?^\K
MT9\[GW^XOU1Y31117VA^8A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5Z_\ L]?Z[7?]V'^;UY!7K_[/7^NUW_=A_F]8UO@9,MCV:BBBO-,0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /3/AQ_JHZ]ITO_ %:_
M2O%OAQ_JHZ]ITO\ U:_2OC#]W6QJK2TBTM PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y+XO>!Y/B=\)_&O@Z*[73Y
M?$.B7ND+=O'Y@@,\#Q!RN1N"[\XR,XZUUM9GB;Q)IO@WPWJVOZS=+8Z/I5I-
M?7MTZEA#!$A>1R "2 JD\ GB@#\J/^''.N?]%;T__P $<G_Q^C_AQSKG_16]
M/_\ !')_\?K[5_X>0_LV_P#14M/_ / *[_\ C-'_  \A_9M_Z*EI_P#X!7?_
M ,9H ^*O^''.N?\ 16]/_P#!')_\?H_X<<ZY_P!%;T__ ,$<G_Q^OM7_ (>0
M_LV_]%2T_P#\ KO_ .,T?\/(?V;?^BI:?_X!7?\ \9H \X_8:_X)UZC^Q_\
M$[6O%=YXXM?$\>H:.^EBU@TYK8H6FAEW[C(V1^ZQC'>N,_:N_P""5>J_M(_'
MWQ3\1K;XBV>A0ZU]EVZ?+I3S-%Y-K# <N)5SDQ;N@QG%?6GPA_:P^$WQZ\07
M>A^ ?&5KXCU6UM3>S6T%O/&4A#JA?,D:C&YU'7/->MT ?-G["_[(]W^Q[\/=
M?\-7GB6'Q.^J:I_:(N(+,VPC'DQQ[-I=L_<SG/>OI.BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X
M?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KY#_ ."E'[.>D?M#?!NTMUUG2]%\;:+)+>Z"
M=3O(K9;SY5$]MND8 !QY?/0,L>2 37UY7Y5_\%SO^:)_]QO_ -L* /G/]@7]
MM"7]BWQ[XA\/>,=,N[GPCJLHCU&WM$5KJQNHB5$J L RX)5USR I'*X;];/"
MO[<WP!\86D-Q9?%KPO:K(@D":KJ"6#J" <,L^P@\]#S7\Y=% '] 'Q;_ ."E
MWP$^%N@W-W;>,[7QEJBJ?L^E>'#]J>9L< RC]V@Z9+-ZX!(Q7XW>-/'6J_MH
M_M+7.O\ BO7=&\&C7KI5EOM3NEALM*LT4*JAF(W[(U& .7;)XW''B%% ']"/
MPG_:*_9J^#/PW\.^"?#WQ9\(Q:/HEHMK!OU>(N^.6D8Y^\[%F/NQKK/^&UO@
M)_T5[P?_ .#:+_&OYPJ* /ZI()X[J&.:)UDBD4.CJ<AE(R"*DK)\)_\ (JZ-
M_P!>4/\ Z+6M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O#
M_P!KO]J?2OV1?AMIOC#5]#O-?MK[5H])6VLI4C=7>&:4.2W& ("/^!"OC7_@
MHE_P4PUCX=^*M2^%OPFNX[/5K$F#6O$H59'MY<?-;VX(*AUZ-(<D'*J 5W5^
M5_B[Q[XG\?ZA)?\ B;Q#JOB&\=MS7&J7DERY)SSER?>@#^CO]FOX[6'[2GP;
MT3XA:;I=QHUGJCW")9W4BO(GE3O"<E>.3&3^->GU_,5\/?C1X]^$UVEQX-\8
MZWX:=6WE--OI(HW/^V@.UQ[,"*_8;_@G9_P40F_:7N)O GCY;.R\?VL'GV=W
M:KY46KQ*/WA"=%F4#<57AAN*A0I  /N^BBOG']MS]LK1?V0/AY!?O;)K'B[5
MR\.BZ0S;4=E WS2D<B)-RYQRQ95&,EE /HZBOYROBM^V]\;OC%JT]YK?Q"UF
MSMY&8IIFC73V-G$IXVB.(@, .,ON;'4G)K#\!_M7_&/X::E#>^'OB5XDLWAZ
M03:C)<6YYSAH92T;#.>JGJ: /Z4:*^+_ /@GS_P4"M_VK-/N/"WBJWM])^(V
MFV_VAUM@5M]2MP0IFB!)VNI(WIGON7C(3[0H **** "BBB@ HKQS]K#]I#1?
MV6_@UJWC/4_+N+\#[+I.FLV#>WC ^7'Z[1@LQ'15;O@'^??Q-\>OB+XN\1:G
MKFI>-=<>_P!1N9+J=HM0EC3>[%B%16 5>>% P!@"@#^FNBOE_P#X)FZM?:Y^
MQ%\-[[4KRXU"]E_M+S+BZE:61\:E= 99B2<  ?0"OJ"@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@"&;[M<;XK_U#UV4WW:XWQ7_J'H ^'_VJ/^0AHWUG
M_P#9*\'KWC]JC_D(:-]9_P#V2O!Z^WRW_=8_/\V?EF=_[_4^7Y(****]0\(*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /1_@/_R.=Q_UY/\ ^AI7
MOU> _ ?_ )'.X_Z\G_\ 0TKWZO.K_&92W"BBBL" HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY8S?(_T]#^&:VZ^>P^89GDE3DA*4/[KV^YZ?-'UF+RG)>)*7M*D(U+_:CO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/NT <%XR_U#_0U\%?M(_\CY!_
MUYK_ .C'K[U\9?ZA_H:^"OVD?^1\@_Z\U_\ 1CUZ^5_[RO1GSN??[B_5'E-%
M%%?:'YB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7K_ .SU_KM=
M_P!V'^;UY!7K_P"SU_KM=_W8?YO6-;X&3+8]FHHHKS3$**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#TSX<?ZJ.O:=+_ -6OTKQ;X<?ZJ.O:
M=+_U:_2OC#]W6QJK2TBTM PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=6&X(4<GEFB9D&X\E9%S]TD_H70 4444 %%%% !1110 4444 %%%% !1110
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M>&1>CHP#*?Q!%?RP5_25^R#K\OB?]EGX3:C.=T\GAC3TD8]69($1F_$J3^-
M'KU%%% !5?4-0M=)T^YOKVXCM+*UB::>XF8*D4:@LS,3P  "23Z58K\P?^"N
MG[8W]BZ:WP/\)7V+^]C2;Q-=0/S# <-'9Y'=QAW_ -C:O(=@ #XO_;Z_:VNO
MVK/C-/=V$TJ>!]#+V6A6K9 =,_/<LIZ/*0#ZA51>H)/S+7VI_P $Q?V/O^&A
M_BM_PEGB.R\WP#X5F2:=)4S'J%X,-%;<\,HX=QSQM4_?S7R!XLX\4ZR!P/ML
MW_H9H _>G_@EQ_R8G\,O^XG_ .G2[KZJKY5_X)<?\F)_#+_N)_\ ITNZ^JJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** (9ONUQOBO_4/793?=KC?%?\
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M\9^5Q_P$\U\!B,LS+)Y^U<7&WVHO3[UM\['ZEA,YR?/Z?L5*,K[PDE?[GO\
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M^_W%^J/*:***^T/S$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+7M7[)G[-^M_M8?&S3?"=K)-#8,QO=:U7&XVMHK#S'R>KL2%7/5G&>,D;O\
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M6&FV=QJ%]<-LAM;6)I99&]%5023["@#[(_X)$_:_^&S-*^S9\G^Q[_[3C/\
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M "BBB@ HHKG?B#\0?#_PK\&ZGXJ\4ZBNDZ!IJ+)=WC1/((E9U0$JBLQ^9@.
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M^$PN/^@/=?K_ /$UTU% ',_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,37344
M<G-XPN-O_('NOU_^)KD/%'BR=H7_ .)1<C\_\*]5F^[7&^*_]0] 'PC^TIJ3
MZC?Z3OM9+;:9OO\ ?.SVKQ6O>/VJ/^0AHWUG_P#9*\'K[?+?]UC\_P V?EF=
M_P"_U/E^2"BBBO4/""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTU% ',_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,37344 <S_PF%Q_T![K]?\
MXFC_ (3"X_Z ]U^O_P 37344 <S_ ,)A<?\ 0'NOU_\ B:/^$PN/^@/=?K_\
M37344 <S_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q-=-10!S/_"87'_0'NOU_
M^)H_X3"X_P"@/=?K_P#$UTU% ',_\)A<?] >Z_7_ .)H_P"$PN/^@/=?K_\
M$UTU% ',_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$UTU% ',_\ "87'_0'N
MOU_^)H_X3"X_Z ]U^O\ \37344 <S_PF%Q_T![K]?_B:/^$PN/\ H#W7Z_\
MQ-=-10!S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !-=-10!S/\ PF%Q_P!
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MV,[?[R\BB.X#=Z_0Z&)HXJ"J4)J4>Z=S\FQ6#Q&"J.EB:;A)=&FG^)9HIBR
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M#W7Z_P#Q-=-24 <U_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q-=+FC- '-?\
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M ]U^O_Q-'_"87'_0'NOU_P#B:Z#SQZTGV@>OZT 8'_"87'_0'NOU_P#B:/\
MA,+C_H#W7Z__ !-;OVA?6C[2OK0!A?\ "87'_0'NOU_^)H_X3"X_Z ]U^O\
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MZ_7_ .)K0_M9/[U-.KQ_WA0!0_X3*?\ Z ]U^O\ \35>X\93[?\ D#W/Z_\
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M"M^[2'_@59/C;*EMS/Y?\$Z(^&^=RWY%_P!O?\ S?.'K1YWO6F-#M1V<_P#
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M3>/A7/[6,7_@'_VQR_VH>M+]H/H?RKJ**Q?'\NF&_P#)_P#[4Z(^%<.N,_\
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M@/=?K_\ $UTU% ',_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$UTU% ',_\
M"87'_0'NOU_^)H_X3"X_Z ]U^O\ \37344 <S_PF%Q_T![K]?_B:/^$PN/\
MH#W7Z_\ Q-=-10!S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !-=-10!S/\
MPF%Q_P! >Z_7_P")H_X3"X_Z ]U^O_Q-=-10!S/_  F%Q_T![K]?_B:/^$PN
M/^@/=?K_ /$UTU% ',_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,37344 <S_P
MF%Q_T![K]?\ XFC_ (3"X_Z ]U^O_P 37344 <S_ ,)A<?\ 0'NOU_\ B:/^
M$PN/^@/=?K_\37344 <S_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q-=-10!S/
M_"87'_0'NOU_^)H_X3"X_P"@/=?K_P#$UTU% ',_\)A<?] >Z_7_ .)K:TJ_
M?4K03/;O;-DCRY.O'?I5RB@ HHHH **** "BBB@ HHK@/C/\>? G[/?AFW\0
M?$'7E\/:/<7(LXKEK6>??,59P@6)';)5&/3^$T ?-7[:7_!,_P +?M.:E<>+
MO#=_'X-\?N@$]SY.^SU' P#.B_,K]!YJY.!RK<8_(3]HK]EWQ_\ LM^);+1O
M'>GVUK)?QO-975E=I/#=1HP5F4@[EP2.'53STK]KOA[_ ,%)/@9\5/B9H?@;
MPQK^H:AJVL3&WM9WTR6"W+A78 M*%(W;,#Y>2RCUQ\6?\%P?^1^^%G_8,O?_
M $;'0!^9\$\MG<1S0R/!/$P=)(V*LC Y!!'0@U^J7_!,7_@H-XD\4>,M/^$'
MQ,U276VOD9- UZ\?=<+*B%OLT[GF0,JML=B6W *2VY=O?_M8_LN^"_B5^P'H
M7CS^R+/3_&_AOP;INHP:S;QK'+/'';0F2&8C'F H#MW9*MC'4@_E/\ =4N]%
M^.WPZO[!F6]MO$>G2PE2,[A<QD#G^M ']('Q4^)V@?!OX>Z[XS\3W8LM$T>V
M:XGDZLW98T'=V8JJCN6 K^=7X^?&GQ3^U5\;-2\6:G#-<:EJ]PMKINEP9D^S
M0[ML%K$ .<9'0?,S,V,L:_37_@MMJMY:_!OX?6$-U+%976N2O/ CD)*4@.PL
M.^-S8SZU^2G@7QQK?PU\6Z;XF\.7HT[7--E\ZTN_)CE,,F" P6167(SP2.#@
MCD T ?OG^P-^R9;?LI_!>WLKZ*-_&VM[+W7KI<-MDP=ELK#JD08CT+,[#A@!
M^1W_  4T_P"3X_B?_P!=K'_T@MJJ?\/(?VDO^BI:A_X!6G_QFO#OB)\1/$7Q
M8\9:CXK\6:G)K/B#42C75]*B(TI1%C7(0!1A44<#M0!^J/\ P0^_Y$'XI_\
M83LO_14E??GQTCEF^"7Q!CA.V9_#VH*A SAC;28X^M?SP?!W]I[XH? "QU*S
M^'_BVY\-VVI2)+=QP00R"5U!"D^8C8P">GK7[@?L2^+O$/[0'[$OAC5O&FKR
MZQKOB"TU2UO-0D1$=Q]LNH%.$ 4815' [4 ?SW5_0G_P3>_Y,E^%O_7E<?\
MI7/7\^=]93:;?7%G<(8[BWD:*1#U5E)!'YBOWO\ ^"66O1:U^Q#X"B1U:;3Y
M=0LY@I^ZPO9G4'WV.A_&@#O?VZO^3/\ XM_]B_<?RK^<ROZ%/^"CWB&/PW^Q
M5\4+B1@#<64-D@S@LTUS%%@?@Y/T!K^>M5+, !DG@ 4 ?TE_L@QO'^RG\'1)
M][_A$-*(YSP;2,C]"*]=KD_A'X3?P'\*?!?AF08DT71;+3F^L,"1G_T&NLH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JOJ&GVNKZ?<V-];0W
MMC=1-!/;7$8DCEC8%61U(PRD$@@\$&K%% 'G_P#PSW\+/^B:>#__  0VO_QN
MC_AGOX6?]$T\'_\ @AM?_C=>@5E^)?%6C>"]&N-7\0:M8Z'I5N-TU]J-PD$,
M8_VG<@#\Z .3_P"&>_A9_P!$T\'_ /@AM?\ XW73Z#X+\/>%F)T70M,T@L-I
M-A9QP9'I\JCBOBCXZ?\ !7[X2_#G[18>"+6\^(^L1Y426N;33U8<<SNNYO\
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M]GCX+V7[//P;\.?#W3M2N-7L]%29([RZ14DD\R>28Y"\#!D(_"O1J "BBB@
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MH55'T  K\*/^"IGP#O?@_P#M0:SK\5H8_#?C1VUBRG4?+]H./M<9/]X2DO\
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M97[0)Y*.[J-H'7,C<_2O,_\ AT-^SS_T#O$'_@X?_"OM6B@#XJ_X=#?L\_\
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MQ#1YO]DGL9A+!(\,B\AXV*D?B*Z/2?B5JNF[8[U%OX1QN;Y9!^(Z_B*TKG2
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MO")OVLOAW&A9==>4_P!U;*XS^J"JLW[7W@&-"RZA=2G^ZMI(#^H%9O,,&O\
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MD>I/^U)\1F4@:U$I(QN%G#D>_P!VJK?M+?$EE(/B5L$8XL[<?^TZ\Z&FWC'
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MD?TK6&2YA4?+&D[_ "_S.>KQ#E=&/-.NDOG_ )'445YZWQ>AR<:7(1VS,/\
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MTPO_ )/_ /:GNS:M8QKEKRW4>IE4?UJ-O$&EQKEM2M%'J9U']:\/&E/Z4O\
M9+^E:K@BGUK/[E_F82\2*O3#K_P)_P"1[6WBC1U7)U6R(]KA#_6HV\7Z*JDG
M5+;'M(#7C*Z0_I3AH[>E;+@G#]:LOP,)>(^*Z4(_>SU]O&^A*I)U*''MD_TJ
M-O'^@*I)U%<>T;G^E>3#1V]*7^QF]*U7!.#ZU)?A_D82\1L?TI0_\F_^2/4V
M^(WAX D7Y/L()/\ XFHV^)>@ $_:9#["%O\ "O,ET5O2G+HC?W:U7!> _FG]
MZ_\ D3!^(F9O:%-?*7_R1Z.?BAH8!.^<^WE5$?BKHW_/.[/_ &S'_P 57G_]
MBGTI?[#/I6JX-R];\WW_ / ,'XA9J]N3_P !_P""=W_PMK2.UK??]\)_\74?
M_"W-._Y\KK_QW_&N*&AG^[3AH9]*V7"&6_RO[V8/C[-W]N*_[=1U_P#PMRT_
MZ!T__?8J+_A;T7_0+D_[_#_XFN7_ +#/I3AH?M6JX2RS_GV__ I?YF#X[SE[
M5E_X#'_(Z+_A<!_Z _\ Y,__ &%1_P#"WI_^@4G_ '^/_P 36&-!]J=_8/M^
ME;+A7*U_RY_&7^9SOC?.GOB/_)8?_(FL?BU>]M.AQ_OFHS\6-3R<6-J!_P "
M_P :S_[#_P!FG#0O]FM5PSEB_P"7"^]_YF#XRSA_\Q+^Y?Y%H_%;6=QQ:V0'
M;Y'_ /BJC/Q0UPG(BM1["-O_ (JH_P"P1Z4[^PQZ5LN'<N7_ "XB82XMS:6^
M)E]X?\+(U]FSN@4>@B_^O7=?#+5K_P 47%Z+XK(L6PJJJ%QG=GI]*XA=#_V:
M]<^ ^@"2?5SM^Z(?_9ZMY'E\(W5"/W(XZO%&:RB_]JG_ .!,]2\,VIAC157:
MHZ 5Z!IX.U:R-,TD0XXQ706\.Q17ITX*"44K)'PU>JZLG*3NV64IU(M+6QR!
M1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ],^''^JCKVG2_\ 5K]*
M\6^''^JCKVG2_P#5K]*^,/W=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%X[B+0=)DMEMDNIC+( ]I#*V6/7YI&K^CNORY_; _P""7'Q5_:!_:.\9>/\
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MS;]IC1[_ ,1?LX?%;2M+LY]1U.^\)ZM:VMG:QF26>9[.54C11RS,Q  '))%
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MB'R+G59Y'N+R=,@E6E<DA2RJ2J[5R <<5[!110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *[KX=??'^]7"UW7PZ^^/]ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L31?\
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M\81Z4/\ R;_@'@_7@<FG^3)_SS;_ +Y->]#PC/\ W33U\'SG^$UHN&%UK?\
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M/7PC'_<% 'SHOP]?_GG^E-?X>OM_U?Z5](CPG'_<'Y5%-X5CV_<% 'R9XB\
MLD3'9^E?*7QH\-&U\51)MQ_HX/\ X^U?I7XM\-1K"^$[&OA_]H;25A\;0#'_
M "Z*?_'WKT\NCS8A(\/.9^SPCEYH^>!H?M2_V#[5V_V!?2E^P+Z5]9[%'Y]]
M99Q7]@_[/Z4[^P_]FNT^PKZ?I2_85]*/8HGZRSC!H7^S3O[!'I79?8U]*7[&
MOI3]BA?6&<=_88]*=_8?^S78?8QZ4OV,>E/V*%]89R']AC^[3O[#']VNM^RC
MTI?LJ^E/V2%]89R?]AC^[3O[#']VNK^RKZ4OV4>E/V2%]8D<J-#']VG?V(/[
MM=1]F'I2_9QZ4>R0O;LY?^Q1_=IW]BCTKI_LX]*/LX]*?LT+V\CFAHH]*<-&
M'I72?9QZ4>3[4_9H7MI'.?V./[M.&CCT_2NB\D>E'DBCV:%[:1SXT=?2G#2%
M_NUO^2*/)I^S0>V9@_V2/[OZ4HTD>E;WE"CR11R(GVK,,:2OI3AI:^E;7E"C
MRQ3Y$'M68W]ECTI1I:^E;/EBCRQ1R(7M&9 TQ?[M*--7^[6MY8H\L4<J#VC,
MO^S5]*!IR^E:NP4;13Y4+VC,P:>OI2_8%]*TMHHVBCE0<[,[[ OI2_85]/TK
M0VBEVBGRH7.S/^PKZ4OV-?2K^T4;11RH7.RC]C7TI?L8]*N[111RH.9E/[(/
M2O7_ -GVS5IM<X_AA_\ 9Z\LKV#]GL?OM=_W8?YO659>XR92=CUV.W"U,JT[
M%+7G'/<****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z9\./]
M5'7M.E_ZM?I7BWPX_P!5'7M.E_ZM?I7QA^[K8U5I:1:6@84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#V2O!Z^WRW_=8_/\V?EF=_[_4^7Y(****]0\(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /1_@/_R.=Q_UY/\ ^AI7OU> _ ?_ )'.X_Z\G_\
M0TKWZO.K_&92W"BBBL" HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *[KX=??'^]7"UW7PZ^^/]ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L31?\ 4K6V
MM>$?HHZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&I:1J ,S4O]6U>,_$;_ %,M
M>S:E_JVKQGXC?ZF6@#\ZY?\ 6/\ 4TVG2_ZQ_J:;7Z4MC\0>X4444Q!1110
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M%];9X\OA%O[GZ4\>$&_N_I7L(T!/[M.&A)_=%/V8OK;/'U\'G^Y^E2+X//\
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M_3_GG^E>O?V:G]VG#34]/TH \D7P G_//]*D7P"G_//]*]8_LY/[M+_9Z^E
M'E:^ D_YY_I4B^!(_P#GF/RKU'["O]VG?84]* /,%\"Q_P!S]*D7P/'_ ,\_
MTKTS[$OI1]C7TH \W7P1'_SS'Y4]?!,?]P?E7HWV1?2E^RKZ"@#SQ?!<?_//
M]*D7P;'_ '/TKT#[*OI1]F7TH X,>#H_[@_*GKX/C_N?I7=?9U]*7[./3]*
M.''A&/\ N"GCPG'_ '!^5=MY ]*/('I0!QJ^%8_[@IR^%H_[@KL/)%+Y(]*
M.1'A>/\ N#\J>/#,?]P5UGE#TH\H>E '++X;C_N?I3AX<C_N"NG\H>E+Y8H
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M[?(GPS^)'B+X-^/]'\7>&+V32]>T>X$T,HR.1PT;CNC*2K*>H)%?T_U_/_\
M\%.?!FB^"/VSO'%KH<<-M;7BVNHS6MNH589YK='EX]68F0^\E '[C_ [XK:?
M\<?A'X4\>:9&8+37;".Z\@MN,$GW9(B>Y1U=<_[-=S7Q=_P2+O[F\_8ST>*<
M-Y5KJ]_#!N)(V&7><>@WN_XYK[1H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "D:EI&H S-2_P!6U>,_$;_4RU[-J7^K:O&?B-_J
M9: /SKE_UC_4TVG2_P"L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444
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M:* $VT;:6B@!-HHVBEHH 3:*-HI:* $Q12T4 )12T4 )2T44 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5X#^WSH,OB3]C?XL6D(8O'HLEY\O7
M; RS-^D9KWZJ^H:?;:M87-E>0)<VES$T,T,@RLB,"&4CN""10!_._P#L&_&;
M0/@+^U+X-\7>*"8M!A:>TNKI4+FU6>%XA-@<X4N"V.=N[ /0_N'^TEX@TOQ5
M^R#\6]5T74;35M,NO!.LO!>6,RS0RK]AFY5U)!'T-?B+^VM^R#XA_9-^)US8
MS6\EUX,U*:2;0M74%DDAW$B%V[3(" P[\,.#7W[^R#X-/A?_ ()&_$J^9-C^
M(-!\3ZH0>O%K+; _B+8?AB@#YM_X(P_\G7ZW_P!BE>?^E5I7U1_P5V_:2\)Z
M)\#;[X3V>IVVI>+M>NK9KJQMI%D>PMX94GWS8.8V9DC"J<$@L>@Y_'/1?$6J
M^&YIIM(U.\TN:>(P2R65P\+21DABC%2,KE5.#QE1Z5>\'^#?$?Q.\56NA^'-
M*OO$6OZA(1%:6<;2S2L>2Q]NI+'@#))Q0!]C?\$=_"-SK_[6S:ND>;70M#N[
MJ60C@-)L@5?J?-8_137[B5\N?\$__P!CR+]DOX42PZJT-UXYUYDNM:N(<,L.
MT'R[5&[K'N;)[L['IMQ]1T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7=?#K[X_WJX6NZ^'7WQ_O5Y.8?!$^SX8_CU/3]3W31?]2M;:UB:+_J
M5K;6O"/T4=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4C4M(U &9J7^K:O&?B-_J
M9:]FU+_5M7C/Q&_U,M 'YUR_ZQ_J:;3I?]8_U--K]*6Q^(/<****8@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^J? __(F:'_UY0_\ H K<K#\#
M_P#(F:'_ ->4/_H K<KR);LP>X4444A!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!HZ#_P A2*O?O"?^I3Z5X#H/_(4BKW[PG_J4^E?,XS^/+Y?D
M?K.0_P#(OI_/_P!*9VT'W14U0P?=%35Q'OA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_KS7_T8]?>OC+_ %#_ $-?
M!7[2/_(^0?\ 7FO_ *,>O7RO_>5Z,^=S[_<7ZH\IHHHK[0_,0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *]?_9Z_P!=KO\ NP_S>O(*]?\ V>O]
M=KO^[#_-ZQK? R9;'LU%%%>:8A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 >F?#C_51U[3I?^K7Z5XM\./]5'7M.E_ZM?I7QA^[K8U5I:1:
M6@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &3XJ\):)XXT*ZT7Q%I%CKFD72[)['4+=9X9![HP(-<Q_P *6\(+
M\%]1^%VEV)TGP9>:7=:*;2PE.Z&"=724([;B&_>/@G.#^5?D_P#\%"/^"D'B
M3XA>,-8^'OPRUF?0O!.FS/9WFJZ=*8[C5Y5)63$JG*P9R %/SC)8D$*/LO\
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M5S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444
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M3+BTN(#LL]6QU" G]W-CG9DAL$J?X0 ?=M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,WW:XWQ7_
M *AZ[*;[M<;XK_U#T ?#_P"U1_R$-&^L_P#[)7@]>\?M4?\ (0T;ZS_^R5X/
M7V^6_P"ZQ^?YL_+,[_W^I\OR04445ZAX04444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >C_ ?_ )'.X_Z\G_\ 0TKWZO ?@/\ \CG<?]>3_P#H:5[]
M7G5_C,I;A1116! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=U\
M.OOC_>KA:[KX=??'^]7DYA\$3[/AC^/4]/U/=-%_U*UMK6)HO^I6MM:\(_11
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U
M>,_$;_4RT ?G7+_K'^IIM.E_UC_4TVOTI;'X@]PHHHIB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#ZI\#_\B9H?_7E#_P"@"MRL/P/_ ,B9H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X_\
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M** "BBB@ HHHH **** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\
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M5_030 5B>-O"&G_$#P=K?AC5A,=*UBRFL+M;>4Q2-#*A1PKCE258C(]:VZ*
M/R%_:T_X)!W/@/PWJ7BWX0ZM>:]96,3W-UX;U3:UX(U&6:WE4*)"!D^6RAL#
M@NQ /YNZ-K%]X>U>QU73+J6QU&QG2YMKJ!BLD,J,&1U/8@@$'VK^IROYP_VU
M_!FG_#_]J_XH:'I44,&G0:U++!! NV.)9<2^6H[!?,VX]J /WI_9=^,0^/W[
M/_@CQX55+K5K!3>*@PJW4;-%<!1V7S8WQ[8KU.OB3_@C_>SW7['=O%-N\NVU
MV^BAW'C8?+<X]MSM^M?;= !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% $,WW:XWQ7_ *AZ[*;[M<;XK_U#
MT ?#_P"U1_R$-&^L_P#[)7@]>\?M4?\ (0T;ZS_^R5X/7V^6_P"ZQ^?YL_+,
M[_W^I\OR04445ZAX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >C
M_ ?_ )'.X_Z\G_\ 0TKWZO ?@/\ \CG<?]>3_P#H:5[]7G5_C,I;A1116! 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %=U\.OOC_>KA:[KX=??'
M^]7DYA\$3[/AC^/4]/U/=-%_U*UMK6)HO^I6MM:\(_11U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U>,_$;_4RT ?G7+_K
M'^IIM.E_UC_4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH AF^[7&^*_P#4/793?=KC?%?^H>@#X?\ VJ/^0AHW
MUG_]DKP>O>/VJ/\ D(:-]9__ &2O!Z^WRW_=8_/\V?EF=_[_ %/E^2"BBBO4
M/""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#T?X#_P#(YW'_ %Y/
M_P"AI7OU> _ ?_D<[C_KR?\ ]#2O?J\ZO\9E+<****P("BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KNOAU]\?[U<+7=?#K[X_WJ\G,/@B?9\,?Q
MZGI^I[IHO^I6MM:Q-%_U*UMK7A'Z*.HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD5>_>$_]2GTKYG&?QY?+\C]9R'_D7T_G_P"E,[:#[HJ:H8/NBIJXCWPHHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK[X_WJ\G,/@B?9\,?QZGI^I[IHO^I6MM:Q-%_P!2M;:UX1^BCJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "D:EI&H S-2_U;5XS\1O\ 4RU[-J7^K:O&?B-_J9:
M/SKE_P!8_P!33:=+_K'^IIM?I2V/Q![A1113$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'U3X'_ .1,T/\ Z\H?_0!6Y6'X'_Y$S0_^O*'_ - %
M;E>1+=F#W"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'0?
M^0I%7OWA/_4I]*\!T'_D*15[]X3_ -2GTKYG&?QY?+\C]9R'_D7T_G_Z4SMH
M/NBIJA@^Z*FKB/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ5>X^[0!P
M7C+_ %#_ $-?!7[2/_(^0?\ 7FO_ *,>OO7QE_J'^AKX*_:1_P"1\@_Z\U_]
M&/7KY7_O*]&?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>O_ +/7^NUW_=A_F]>05Z_^SU_KM=_W8?YO6-;X&3+8]FHH
MHKS3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TSX<?ZJ.
MO:=+_P!6OTKQ;X<?ZJ.O:=+_ -6OTKXP_=UL:JTM(M+0,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+_VG_AK<?&#]
MGGX@^#[(%K_5='N(K11CYK@+OA7GL751^->H5Q_QD\<3_#+X0^./&%K;1WMS
MX>T*^U:*VF8JDKP6[RA&(Y )0 X]: /QY_94_P""??[0O@3X\?#_ ,9ZK\.D
MLM'T;6K6\NFO]4L@PA65?,98Q*S;E7+#Y>H&.:_;:OR _P"'WGCC_HFGA_\
M\#9Z/^'WGCC_ *)IX?\ _ V>@#]?Z^2/^"E'[-GC3]J#X-^'?#?@:"SGU.QU
M^/4)EOKD0((1;SQDAB.3ND7CZU\;_P##[SQQ_P!$T\/_ /@;/1_P^\\<?]$T
M\/\ _@;/0![%_P $U_V&?BE^R_\ &3Q%XD\<VFF0:9?:!)I\+6-\L[F8W$$@
M!4#@;8VY^E?H[7PM^P;_ ,%#_$7[7GQ2USPKK'A+2_#]OI^C/J:W%C<22.[+
M/#'M(;C&)2?P%?=- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!XS1110!Z!\/\ _D#3?]?#?^@K735S/P__
M .0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!#-]VN-\5_ZAZ[*;[M<;XK_U#T ?
M#_[5'_(0T;ZS_P#LE>#U[Q^U1_R$-&^L_P#[)7@]?;Y;_NL?G^;/RS._]_J?
M+\D%%%%>H>$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H_P'_Y'
M.X_Z\G_]#2O?J\!^ _\ R.=Q_P!>3_\ H:5[]7G5_C,I;A1116! 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %=U\.OOC_>KA:[KX=??'^]7DYA\
M$3[/AC^/4]/U/=-%_P!2M;:UB:+_ *E:VUKPC]%'4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9M2_P!6U>,_$;_4RT ?G7+_ *Q_
MJ:;3I?\ 6/\ 4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#ZI\#_ /(F:'_UY0_^@"MRL/P/_P B9H?_ %Y0_P#H K<KR);L
MP>X4444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!HZ#_R%(J]^
M\)_ZE/I7@.@_\A2*O?O"?^I3Z5\SC/X\OE^1^LY#_P B^G\__2F=M!]T5-4,
M'W14U<1[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5[C[M6*KW'W: ."\9?ZA_
MH:^"OVD?^1\@_P"O-?\ T8]?>OC+_4/]#7P5^TC_ ,CY!_UYK_Z,>O7RO_>5
MZ,^=S[_<7ZH\IHHHK[0_,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *]?\ V>O]=KO^[#_-Z\@KU_\ 9Z_UVN_[L/\ -ZQK? R9;'LU%%%>:8A1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >F?#C_51U[3I?\
MJU^E>+?#C_51U[3I?^K7Z5\8?NZV-5:6D6EH&%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7"?'KPAJ/Q"^!OQ%\+:0L
M;ZMKGAS4=,LUF?8AFFM9(XPS=AN89/:N[HH _"O_ (=#_M#?] WP_P#^#A/\
M*/\ AT/^T-_T#?#_ /X.$_PK]U** /P@U+_@DG^T98VK2P>']'U&0=(+;68
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M% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?#?\
MH*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 0S?=KC?%?^H>NRF^[
M7&^*_P#4/0!\/_M4?\A#1OK/_P"R5X/7O'[5'_(0T;ZS_P#LE>#U]OEO^ZQ^
M?YL_+,[_ -_J?+\D%%%%>H>$%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'H_P'_Y'.X_Z\G_ /0TKWZO ?@/_P CG<?]>3_^AI7OU>=7^,REN%%%
M%8$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5W7PZ^^/]ZN%KNO
MAU]\?[U>3F'P1/L^&/X]3T_4]TT7_4K6VM8FB_ZE:VUKPC]%'4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9M2_U;5XS\1O\ 4RT
M?G7+_K'^IIM.E_UC_4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#ZI\#_P#(F:'_ ->4/_H K<K#\#_\B9H?_7E#_P"@"MRO
M(ENS![A1112$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &CH/_(4
MBKW[PG_J4^E> Z#_ ,A2*O?O"?\ J4^E?,XS^/+Y?D?K.0_\B^G\_P#TIG;0
M?=%35#!]T5-7$>^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>X^[5BJ]Q]V@#@
MO&7^H?Z&O@K]I'_D?(/^O-?_ $8]?>OC+_4/]#7P5^TC_P CY!_UYK_Z,>O7
MRO\ WE>C/G<^_P!Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD\V[BOBB^8\TG'FEP 5DP 5  "[2B_4- !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XS1110!Z!\/\ _D#3
M?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#-]VN-\5_ZA
MZ[*;[M<;XK_U#T ?#_[5'_(0T;ZS_P#LE>#U[Q^U1_R$-&^L_P#[)7@]?;Y;
M_NL?G^;/RS._]_J?+\D%%%%>H>$%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'H_P'_Y'.X_Z\G_]#2O?J\!^ _\ R.=Q_P!>3_\ H:5[]7G5_C,I
M;A1116! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=U\.OOC_>K
MA:[KX=??'^]7DYA\$3[/AC^/4]/U/=-%_P!2M;:UB:+_ *E:VUKPC]%'4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9M2_P!6U>,_
M$;_4RT ?G7+_ *Q_J:;3I?\ 6/\ 4TVOTI;'X@]PHHHIB"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#ZI\#_ /(F:'_UY0_^@"MRL/P/_P B9H?_
M %Y0_P#H K<KR);LP>X4444A!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >,T444 >@?#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M
M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!#-]VN-\5_P"H>NRF^[7&^*_]0] 'P_\ M4?\A#1O
MK/\ ^R5X/7O'[5'_ "$-&^L__LE>#U]OEO\ NL?G^;/RS._]_J?+\D%%%%>H
M>$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H_P'_P"1SN/^O)__
M $-*]^KP'X#_ /(YW'_7D_\ Z&E>_5YU?XS*6X4445@0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7=?#K[X_WJX6NZ^'7WQ_O5Y.8?!$^SX8_C
MU/3]3W31?]2M;:UB:+_J5K;6O"/T4=1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKW[PG_J4^E?,XS^/+Y?D?K.0_P#(OI_/_P!*9VT'W14U0P?=%35Q'OA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 57N/NU8JO<?=H X+QE_J'^AKX*_:1_Y'R#_K
MS7_T8]?>OC+_ %#_ $-?!7[2/_(^0?\ 7FO_ *,>O7RO_>5Z,^=S[_<7ZH\I
MHHHK[0_,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]?_9Z_P!=
MKO\ NP_S>O(*]?\ V>O]=KO^[#_-ZQK? R9;'LU%%%>:8A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >F?#C_51U[3I?^K7Z5XM\./]5'7M
M.E_ZM?I7QA^[K8U5I:1:6@84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<Y\2/!-K\3/AWXI\(7T\UK8^(-*NM)GGM\>
M9''/"T3,F01N <D9!&171T4 ?G5_PY+^%G_0]>,/^^K7_P",T?\ #DOX6?\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\
M\@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MKW'W:L57N/NT <%XR_U#_0U\%?M(_P#(^0?]>:_^C'K[U\9?ZA_H:^"OVD?^
M1\@_Z\U_]&/7KY7_ +RO1GSN??[B_5'E-%%%?:'YB%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7K_[/7^NUW_=A_F]>05Z_^SU_KM=_W8?YO6-;
MX&3+8]FHHHKS3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#TSX<?ZJ.O:=+_U:_2O%OAQ_JHZ]ITO_ %:_2OC#]W6QJK2TBTM PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWXB>
M-K#X:^ ?$?BW5#C3M#TZXU&<9P62*-G*CW.W ]R*Z*OG7_@H<UPO[%WQ5^S+
MND_LM<C_ &//CWG\%W4 ?@G\5_B=XB^.?Q-UOQAX@F>^US6[MIF1,L$!.(X8
MQU"(NU%'H!7T59_\$O?C+;_!OQ#\1_$D>D^$--T;1[K69-*U2>3^T9(H(7E*
M^4B,J,P0C#NI!(R!S6)_P3-\.Z+XF_;4^'EMKB0S6\$EU>007"@K)<16LLD/
M7NKJ''N@K]LOVL?^36?C)_V)FL_^D,U 'X%?LP_LR^)/VKOB!>^#O"NHZ5IF
MJ6VFR:GYNL22QP,B211E=T<;L#^]!'RXX-0_M"_LN_$3]F#Q%;Z3X\T7[$EV
M&:RU&UD$UI>!<;C'(.XW#*L PR,C!&?IS_@C#_R=?K?_ &*5Y_Z56E?<O_!7
M"QT2Y_8SUN?5%C_M"WU2P?26<#=]I,P5PI/.?(,_3L* /%?^"-O[3.H^)M+U
MSX.Z_>/=G1[;^U-"DG?+):[U2:W&?X49T91V#N.B@#].:_"7_@D;'<2?MG:*
MT/\ JTTF_:?C^#RL#_QXI7[M4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P__ .0--_U\-_Z"
MM=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,WW:XWQ7_J'KLIONUQ
MOBO_ %#T ?#_ .U1_P A#1OK/_[)7@]>\?M4?\A#1OK/_P"R5X/7V^6_[K'Y
M_FS\LSO_ '^I\OR04445ZAX04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >C_  '_ .1SN/\ KR?_ -#2O?J\!^ __(YW'_7D_P#Z&E>_5YU?XS*6
MX4445@0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7=?#K[X_P!Z
MN%KNOAU]\?[U>3F'P1/L^&/X]3T_4]TT7_4K6VM8FB_ZE:VUKPC]%'4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9M2_U;5XS\1O]
M3+0!^=<O^L?ZFFTZ7_6/]33:_2EL?B#W"BBBF(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /JGP/_P B9H?_ %Y0_P#H K<K#\#_ /(F:'_UY0_^
M@"MRO(ENS![A1112$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &C
MH/\ R%(J]^\)_P"I3Z5X#H/_ "%(J]^\)_ZE/I7S.,_CR^7Y'ZSD/_(OI_/_
M -*9VT'W14U0P?=%35Q'OA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57N/NU8JO
M<?=H X+QE_J'^AKX*_:1_P"1\@_Z\U_]&/7WKXR_U#_0U\%?M(_\CY!_UYK_
M .C'KU\K_P!Y7HSYW/O]Q?JCRFBBBOM#\Q"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH AF^[7&^*_]0]=E-]VN-\5_P"H
M>@#X?_:H_P"0AHWUG_\ 9*\'KWC]JC_D(:-]9_\ V2O!Z^WRW_=8_/\ -GY9
MG?\ O]3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M]'^ _P#R.=Q_UY/_ .AI7OU> _ ?_D<[C_KR?_T-*]^KSJ_QF4MPHHHK @**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "NZ^'7WQ_O5PM=U\.OOC_
M 'J\G,/@B?9\,?QZGI^I[IHO^I6MM:Q-%_U*UMK7A'Z*.HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *1J6D:@#,U+_5M7C/Q&_U,M>S:E_JVKQGXC?ZF6@#\ZY?]
M8_U--ITO^L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ?5/@?_ )$S0_\ KRA_] %;E8?@?_D3-#_Z\H?_ $ 5N5Y$MV8/
M<****0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T=!_Y"D5>_>$
M_P#4I]*\!T'_ )"D5>_>$_\ 4I]*^9QG\>7R_(_6<A_Y%]/Y_P#I3.V@^Z*F
MJ&#[HJ:N(]\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]Q]VK%5[C[M '!>,O]
M0_T-?!7[2/\ R/D'_7FO_HQZ^]?&7^H?Z&O@K]I'_D?(/^O-?_1CUZ^5_P"\
MKT9\[GW^XOU1Y31117VA^8A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Z_^SU_KM=_W8?YO7D%>O_L]?Z[7?]V'^;UC6^!DRV/9J***\TQ"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ],^''^JCKVG2_]6OTK
MQ;X<?ZJ.O:=+_P!6OTKXP_=UL:JTM(M+0,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "LSQ-XDTWP;X;U;7]9NEL='TJ
MTFOKVZ=2PA@B0O(Y !) 52> 3Q6G7E7[6/\ R:S\9/\ L3-9_P#2&:@#S_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'U3X'_Y$S0_^O*'_P! %;E8?@?_ )$S0_\ KRA_] %;E>1+=F#W"BBB
MD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'0?^0I%7OWA/_4I]
M*\!T'_D*15[]X3_U*?2OF<9_'E\OR/UG(?\ D7T_G_Z4SMH/NBIJA@^Z*FKB
M/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ5>X^[0!P7C+_4/]#7P5^T
MC_R/D'_7FO\ Z,>OO7QE_J'^AKX*_:1_Y'R#_KS7_P!&/7KY7_O*]&?.Y]_N
M+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>O\
M[/7^NUW_ '8?YO7D%>O_ +/7^NUW_=A_F]8UO@9,MCV:BBBO-,0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /3/AQ_JHZ]ITO\ U:_2O%OA
MQ_JHZ]ITO_5K]*^,/W=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IDT*7$3Q2HLD3J59'&0P/!!'<4^J.
MN:W8>&M%U#5]5O(=/TO3[>2[N[RX<)'!#&I9Y'8\!54$D]@* *__  B>A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#-
M]VN-\5_ZAZ[*;[M<;XK_ -0] 'P_^U1_R$-&^L__ +)7@]>\?M4?\A#1OK/_
M .R5X/7V^6_[K'Y_FS\LSO\ W^I\OR04445ZAX04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >C_ ?_D<[C_KR?\ ]#2O?J\!^ __ ".=Q_UY/_Z&
ME>_5YU?XS*6X4445@0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7=?#K[X_WJX6NZ^'7WQ_O5Y.8?!$^SX8_CU/3]3W31?]2M;:UB:+_J5K;6O"
M/T4=1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4C4M(U &9J7^K:O&?B-_J9:]FU+
M_5M7C/Q&_P!3+0!^=<O^L?ZFFTZ7_6/]33:_2EL?B#W"BBBF(**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /JGP/_ ,B9H?\ UY0_^@"MRL/P/_R)
MFA_]>4/_ * *W*\B6[,'N%%%%(04444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 :.@_\A2*O?O"?^I3Z5X#H/\ R%(J]^\)_P"I3Z5\SC/X\OE^1^LY
M#_R+Z?S_ /2F=M!]T5-4,'W14U<1[X4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M5[C[M6*KW'W: ."\9?ZA_H:^"OVD?^1\@_Z\U_\ 1CU]Z^,O]0_T-?!7[2/_
M "/D'_7FO_HQZ]?*_P#>5Z,^=S[_ '%^J/*:***^T/S$**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0S?=KC?
M%?\ J'KLIONUQOBO_4/0!\/_ +5'_(0T;ZS_ /LE>#U[Q^U1_P A#1OK/_[)
M7@]?;Y;_ +K'Y_FS\LSO_?ZGR_)!1117J'A!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Z/\!_\ D<[C_KR?_P!#2O?J\!^ _P#R.=Q_UY/_ .AI
M7OU>=7^,REN%%%%8$!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MW7PZ^^/]ZN%KNOAU]\?[U>3F'P1/L^&/X]3T_4]TT7_4K6VM8FB_ZE:VUKPC
M]%'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9M2_
MU;5XS\1O]3+0!^=<O^L?ZFFTZ7_6/]33:_2EL?B#W"BBBF(**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /JGP/_R)FA_]>4/_ * *W*P_ _\ R)FA
M_P#7E#_Z *W*\B6[,'N%%%%(04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 :.@_\ (4BKW[PG_J4^E> Z#_R%(J]^\)_ZE/I7S.,_CR^7Y'ZSD/\
MR+Z?S_\ 2F=M!]T5-4,'W14U<1[X4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[
MC[M6*KW'W: ."\9?ZA_H:^"OVD?^1\@_Z\U_]&/7WKXR_P!0_P!#7P5^TC_R
M/D'_ %YK_P"C'KU\K_WE>C/G<^_W%^J/*:***^T/S$**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O7_V>O\ 7:[_ +L/\WKR"O7_ -GK_7:[_NP_
MS>L:WP,F6Q[-1117FF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'IGPX_U4=>TZ7_JU^E>+?#C_51U[3I?^K7Z5\8?NZV-5:6D6EH&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,WW:XW
MQ7_J'KLIONUQOBO_ %#T ?#_ .U1_P A#1OK/_[)7@]>\?M4?\A#1OK/_P"R
M5X/7V^6_[K'Y_FS\LSO_ '^I\OR04445ZAX04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >C_  '_ .1SN/\ KR?_ -#2O?J\!^ __(YW'_7D_P#Z
M&E>_5YU?XS*6X4445@0%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7=?#K[X_P!ZN%KNOAU]\?[U>3F'P1/L^&/X]3T_4]TT7_4K6VM8FB_ZE:VU
MKPC]%'4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %(U+2-0!F:E_JVKQGXC?ZF6O9
MM2_U;5XS\1O]3+0!^=<O^L?ZFFTZ7_6/]33:_2EL?B#W"BBBF(**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /JGP/_P B9H?_ %Y0_P#H K<K#\#_
M /(F:'_UY0_^@"MRO(ENS![A1112$%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &CH/\ R%(J]^\)_P"I3Z5X#H/_ "%(J]^\)_ZE/I7S.,_CR^7Y
M'ZSD/_(OI_/_ -*9VT'W14U0P?=%35Q'OA1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ KU_]GK_7:[_NP_S>O(*]?_9Z_P!=KO\
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M<?[3JE 'S9^S=_P2C^-'PK^,7@OQUJ7B'P?9Q:%JMO?2VL5W<S32QI(#(@Q
M%!9-P!W=37ZVUQ?@GXU?#[XE+&?"GCCP]XC9P"(]+U2&=QGL55B0?8C-=I0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!#-]VN-\5_ZAZ[*;[M<;XK_P!0
M] 'P_P#M4?\ (0T;ZS_^R5X/7O'[5'_(0T;ZS_\ LE>#U]OEO^ZQ^?YL_+,[
M_P!_J?+\D%%%%>H>$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'H
M_P !_P#D<[C_ *\G_P#0TKWZO ?@/_R.=Q_UY/\ ^AI7OU>=7^,REN%%%%8$
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5W7PZ^^/\ >KA:[KX=
M??'^]7DYA\$3[/AC^/4]/U/=-%_U*UMK6)HO^I6MM:\(_11U%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U>,_$;_4RT ?G7
M+_K'^IIM.E_UC_4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#ZI\#_\ (F:'_P!>4/\ Z *W*P_ _P#R)FA_]>4/_H K<KR)
M;LP>X4444A!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!HZ#_ ,A2
M*O?O"?\ J4^E> Z#_P A2*O?O"?^I3Z5\SC/X\OE^1^LY#_R+Z?S_P#2F=M!
M]T5-4,'W14U<1[X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[C[M6*KW'W: ."
M\9?ZA_H:^"OVD?\ D?(/^O-?_1CU]Z^,O]0_T-?!7[2/_(^0?]>:_P#HQZ]?
M*_\ >5Z,^=S[_<7ZH\IHHHK[0_,0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *]?_9Z_UVN_[L/\WKR"O7_V>O\ 7:[_ +L/\WK&M\#)EL>S4445
MYIB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z9\./]5'7M
M.E_ZM?I7BWPX_P!5'7M.E_ZM?I7QA^[K8U5I:1:6@84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME\$/$VK)9:UIWB?PE$Y %_?64<]NO^]Y,CR#\$-?D]^SK^S)X\_:C\83^'O
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M*D=P*^=/C=\"?&G[._CJ?PGXYTAM*U5$$T3*XDAN822%EB<<,A*GW!!! ((
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#5K]*^,/W=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AF^[7&^*_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+X.>)O"FKVNN:'?Z1>207=JX93F6(E6'56'0JV"IR" :^>OVSOV,?%7[)_Q
MO(9;.ZU#P+>3LVC:^L9:)XR25AE8#"S*."#C=MW+P>/G/<=H7)V@Y [?YXH
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MQB=^A\'ZM'^+6<JC]2*^1/\ @BS\4K+6_@GXJ\!R3HNK:%JS7\<)<!FM;A%
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M44 %%%% !6!?>$(;Z[EN&NKA&D.2JD8'Z5OT4 <S_P (+;_\_MU_WT/\*/\
MA!;?_G]NO^^A_A7344 <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU%
M ',_\(+;_P#/[=?]]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__ #^W7_?0
M_P */^$%M_\ G]NO^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A
M_A7344 <S_P@MO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_\(+;_P#/
M[=?]]#_"C_A!;?\ Y_;K_OH?X5TU% ',_P#""V__ #^W7_?0_P */^$%M_\
MG]NO^^A_A7344 <S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A7344 <S_P@
MMO\ \_MU_P!]#_"C_A!;?_G]NO\ OH?X5TU% ',_\(+;_P#/[=?]]#_"C_A!
M;?\ Y_;K_OH?X5TU% ',_P#""V__ #^W7_?0_P */^$%M_\ G]NO^^A_A734
M4 <S_P (+;_\_MU_WT/\*/\ A!;?_G]NO^^A_A7344 <S_P@MO\ \_MU_P!]
M#_"C_A!;?_G]NO\ OH?X5TU% ')S>!;?;_Q^W7_?0_PKD/%'@F!87_TRY/\
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M0_PKIJ* .9_X06W_ .?VZ_[Z'^%'_""V_P#S^W7_ 'T/\*Z:B@#F?^$%M_\
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M;_\ /[=?]]#_  KIJ* .9_X06W_Y_;K_ +Z'^%'_  @MO_S^W7_?0_PKIJ*
M.9_X06W_ .?VZ_[Z'^%'_""V_P#S^W7_ 'T/\*Z:B@#F?^$%M_\ G]NO^^A_
MA1_P@MO_ ,_MU_WT/\*Z:B@#F?\ A!;?_G]NO^^A_A1_P@MO_P _MU_WT/\
M"NFHH YG_A!;?_G]NO\ OH?X4?\ ""V__/[=?]]#_"NFHH YG_A!;?\ Y_;K
M_OH?X4?\(+;_ //[=?\ ?0_PKIJ* .9_X06W_P"?VZ_[Z'^%'_""V_\ S^W7
M_?0_PKIJ* .9_P"$%M_^?VZ_[Z'^%'_""V__ #^W7_?0_P *Z:B@#F?^$%M_
M^?VZ_P"^A_A1_P (+;_\_MU_WT/\*Z:B@#F?^$%M_P#G]NO^^A_A1_P@MO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(9ONUQOBO_4/793?=KC?%?\ J'H ^'_VJ/\ D(:-]9__ &2O!Z]X_:H_Y"&C
M?6?_ -DKP>OM\M_W6/S_ #9^69W_ +_4^7Y(****]0\(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /1_@/\ \CG<?]>3_P#H:5[]7@/P'_Y'.X_Z
M\G_]#2O?J\ZO\9E+<****P("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KNOAU]\?[U<+7=?#K[X_P!ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L31?]
M2M;:UX1^BCJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H S-2_U;5XS\1O]
M3+7LVI?ZMJ\9^(W^IEH _.N7_6/]33:=+_K'^IIM?I2V/Q![A1113$%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'U3X'_P"1,T/_ *\H?_0!6Y6'
MX'_Y$S0_^O*'_P! %;E>1+=F#W"BBBD(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** -'0?^0I%7OWA/\ U*?2O =!_P"0I%7OWA/_ %*?2OF<9_'E
M\OR/UG(?^1?3^?\ Z4SMH/NBIJA@^Z*FKB/?"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#D*BL <,:_,#X<_%+QA\'?$@UWP9XAU#PSK"HT+7-A,8V=#U1QT9<@':P(R
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7=?#K[X_WJX6NZ^'7
MWQ_O5Y.8?!$^SX8_CU/3]3W31?\ 4K6VM8FB_P"I6MM:\(_11U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O\ 5M7C/Q&_U,M
M'YUR_P"L?ZFFTZ7_ %C_ %--K]*6Q^(/<****8@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ^J? _P#R)FA_]>4/_H K<K#\#_\ (F:'_P!>4/\
MZ *W*\B6[,'N%%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 :
M.@_\A2*O?O"?^I3Z5X#H/_(4BKW[PG_J4^E?,XS^/+Y?D?K.0_\ (OI_/_TI
MG;0?=%35#!]T5-7$>^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>X^[5BJ]Q]V
M@#@O&7^H?Z&O@K]I'_D?(/\ KS7_ -&/7WKXR_U#_0U\%?M(_P#(^0?]>:_^
MC'KU\K_WE>C/G<^_W%^J/*:***^T/S$**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O7_ -GK_7:[_NP_S>O(*]?_ &>O]=KO^[#_ #>L:WP,F6Q[
M-1117FF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'IGPX_
MU4=>TZ7_ *M?I7BWPX_U4=>TZ7_JU^E?&'[NMC56EI%I:!A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6/KG@_0?$\D4FLZ)INK/""L;7UI',4!Z@%@<?
MA6Q10!';V\5G;Q001)!!$H2..-0JHH&  !P !VJ2BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9
M^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** (9ONUQOBO_4/793?=KC?%?\
MJ'H ^'_VJ/\ D(:-]9__ &2O!Z]X_:H_Y"&C?6?_ -DKP>OM\M_W6/S_ #9^
M69W_ +_4^7Y(****]0\(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /1_@/\ \CG<?]>3_P#H:5[]7@/P'_Y'.X_Z\G_]#2O?J\ZO\9E+<****P("
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KNOAU]\?[U<+7=?#K[X
M_P!ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L31?]2M;:UX1^BCJ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "D:EI&H S-2_U;5XS\1O]3+7LVI?ZMJ\9^(W^IEH _.N7
M_6/]33:=+_K'^IIM?I2V/Q![A1113$%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'U3X'_P"1,T/_ *\H?_0!6Y6'X'_Y$S0_^O*'_P! %;E>1+=F
M#W"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'0?^0I%7OW
MA/\ U*?2O =!_P"0I%7OWA/_ %*?2OF<9_'E\OR/UG(?^1?3^?\ Z4SMH/NB
MIJA@^Z*FKB/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ5>X^[0!P7C+
M_4/]#7P5^TC_ ,CY!_UYK_Z,>OO7QE_J'^AKX*_:1_Y'R#_KS7_T8]>OE?\
MO*]&?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>O_L]?Z[7?]V'^;UY!7K_[/7^NUW_=A_F]8UO@9,MCV:BBBO-,0HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /3/AQ_JHZ]ITO_5K]
M*\6^''^JCKVG2_\ 5K]*^,/W=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *KW'W:L57N/NT <%XR_U#_0U\%?M(_\ (^0?]>:_
M^C'K[U\9?ZA_H:^"OVD?^1\@_P"O-?\ T8]>OE?^\KT9\[GW^XOU1Y31117V
MA^8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z_^SU_KM=_W8?Y
MO7D%>O\ [/7^NUW_ '8?YO6-;X&3+8]FHHHKS3$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#TSX<?ZJ.O:=+_U:_2O%OAQ_JHZ]ITO_5K]
M*^,/W=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_
M_P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&;[M
M<;XK_P!0]=E-]VN-\5_ZAZ /A_\ :H_Y"&C?6?\ ]DKP>O>/VJ/^0AHWUG_]
MDKP>OM\M_P!UC\_S9^69W_O]3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ]'^ __ ".=Q_UY/_Z&E>_5X#\!_P#D<[C_ *\G_P#0
MTKWZO.K_ !F4MPHHHK @**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "NZ^'7WQ_O5PM=U\.OOC_>KR<P^")]GPQ_'J>GZGNFB_P"I6MM:Q-%_U*UM
MK7A'Z*.HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z
M:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (9ONUQOBO_4/793?=KC?%
M?^H>@#X?_:H_Y"&C?6?_ -DKP>O>/VJ/^0AHWUG_ /9*\'K[?+?]UC\_S9^6
M9W_O]3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "D:EI&H S-2_U;5XS\1O\ 4RU[-J7^K:O&?B-_J9: /SKE
M_P!8_P!33:=+_K'^IIM?I2V/Q![A1113$%%%% !1110 4444 %%%% !1110
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M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TSX<?ZJ.O:=+
M_P!6OTKQ;X<?ZJ.O:=+_ -6OTKXP_=UL:JTM(M+0,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05
MKIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** /3/AQ_JHZ]ITO_5K]*\6^''^JCKVG2_\
M5K]*^,/W=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0
M/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M '8?YO6-;X&3+8]FHHHKS3$**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#TSX<?ZJ.O:=+_U:_2O%OAQ_JHZ]ITO_5K]*^,/W=;&JM+2+2T#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A__P @:;_KX;_T%:Z:
MN9^'_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&;[M<;XK_P!0]=E-]VN-
M\5_ZAZ /A_\ :H_Y"&C?6?\ ]DKP>O>/VJ/^0AHWUG_]DKP>OM\M_P!UC\_S
M9^69W_O]3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ]'^ __ ".=Q_UY/_Z&E>_5X#\!_P#D<[C_ *\G_P#0TKWZO.K_ !F4MPHH
MHK @**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NZ^'7WQ_O5PM=U
M\.OOC_>KR<P^")]GPQ_'J>GZGNFB_P"I6MM:Q-%_U*UMK7A'Z*.HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO
M_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** (9ONUQOBO_4/793?=KC?%?^H>@#X?_:H_Y"&C
M?6?_ -DKP>O>/VJ/^0AHWUG_ /9*\'K[?+?]UC\_S9^69W_O]3Y?D@HHHKU#
MP@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M:EI&H S-2_U;5XS\1O\ 4RU[-J7^K:O&?B-_J9: /SKE_P!8_P!33:=+_K'^
MIIM?I2V/Q![A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'U
M3X'_ .1,T/\ Z\H?_0!6Y6'X'_Y$S0_^O*'_ - %;E>1+=F#W"BBBD(****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#TSX<?ZJ.O:=+_P!6OTKQ;X<?ZJ.O
M:=+_ -6OTKXP_=UL:JTM(M+0,**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9H
MHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** (9ONUQOBO_4/793?=KC?%?\ J'H ^'_VJ/\ D(:-]9__ &2O!Z]X_:H_
MY"&C?6?_ -DKP>OM\M_W6/S_ #9^69W_ +_4^7Y(****]0\(**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /1_@/\ \CG<?]>3_P#H:5[]7@/P'_Y'
M.X_Z\G_]#2O?J\ZO\9E+<****P("BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KNOAU]\?[U<+7=?#K[X_P!ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L
M31?]2M;:UX1^BCJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H S-2_U;5XS
M\1O]3+7LVI?ZMJ\9^(W^IEH _.N7_6/]33:=+_K'^IIM?I2V/Q![A1113$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'U3X'_P"1,T/_ *\H?_0!
M6Y6'X'_Y$S0_^O*'_P! %;E>1+=F#W"BBBD(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** -'0?^0I%7OWA/\ U*?2O =!_P"0I%7OWA/_ %*?2OF<
M9_'E\OR/UG(?^1?3^?\ Z4SMH/NBIJA@^Z*FKB/?"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AF^[7&^*_P#4/793
M?=KC?%?^H>@#X?\ VJ/^0AHWUG_]DKP>O>/VJ/\ D(:-]9__ &2O!Z^WRW_=
M8_/\V?EF=_[_ %/E^2"BBBO4/""BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#T?X#_P#(YW'_ %Y/_P"AI7OU> _ ?_D<[C_KR?\ ]#2O?J\ZO\9E
M+<****P("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KNOAU]\?[U
M<+7=?#K[X_WJ\G,/@B?9\,?QZGI^I[IHO^I6MM:Q-%_U*UMK7A'Z*.HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *1J6D:@#,U+_5M7C/Q&_U,M>S:E_JVKQGXC?Z
MF6@#\ZY?]8_U--ITO^L?ZFFU^E+8_$'N%%%%,04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 ?5/@?_D3-#_Z\H?\ T 5N5A^!_P#D3-#_ .O*'_T
M5N5Y$MV8/<****0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T=!
M_P"0I%7OWA/_ %*?2O =!_Y"D5>_>$_]2GTKYG&?QY?+\C]9R'_D7T_G_P"E
M,[:#[HJ:H8/NBIJXCWPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/N
MT <%XR_U#_0U\%?M(_\ (^0?]>:_^C'K[U\9?ZA_H:^"OVD?^1\@_P"O-?\
MT8]>OE?^\KT9\[GW^XOU1Y31117VA^8A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Z_^SU_KM=_W8?YO7D%>O\ [/7^NUW_ '8?YO6-;X&3+8]F
MHHHKS3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TSX<?Z
MJ.O:=+_U:_2O%OAQ_JHZ]ITO_5K]*^,/W=;&JM+2+2T#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_
M $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@"&;[M<;XK_P!0]=E-]VN-\5_ZAZ /A_\ :H_Y
M"&C?6?\ ]DKP>O>/VJ/^0AHWUG_]DKP>OM\M_P!UC\_S9^69W_O]3Y?D@HHH
MKU#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]'^ __ ".=Q_UY
M/_Z&E>_5X#\!_P#D<[C_ *\G_P#0TKWZO.K_ !F4MPHHHK @**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "NZ^'7WQ_O5PM=U\.OOC_>KR<P^")]G
MPQ_'J>GZGNFB_P"I6MM:Q-%_U*UMK7A'Z*.HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *1J6D:@#,U+_ %;5XS\1O]3+7LVI?ZMJ\9^(W^IEH _.N7_6/]33:=+_
M *Q_J:;7Z4MC\0>X4444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!]4^!_^1,T/_KRA_\ 0!6Y6'X'_P"1,T/_ *\H?_0!6Y7D2W9@]PHHHI""
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#1T'_D*15[]X3_U*?2O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q
MFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** (9ONUQOBO_4/793?=KC?%?^H>@#X?_:H_Y"&C?6?_ -DKP>O>/VJ/
M^0AHWUG_ /9*\'K[?+?]UC\_S9^69W_O]3Y?D@HHHKU#P@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H S-2_U;5XS\
M1O\ 4RU[-J7^K:O&?B-_J9: /SKE_P!8_P!33:=+_K'^IIM?I2V/Q![A1113
M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'U3X'_ .1,T/\ Z\H?
M_0!6Y6'X'_Y$S0_^O*'_ - %;E>1+=F#W"BBBD(**** "BBB@ HHHH ****
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ME_J'^AKX*_:1_P"1\@_Z\U_]&/7KY7_O*]&?.Y]_N+]4>4T445]H?F(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>O_ +/7^NUW_=A_F]>05Z_^
MSU_KM=_W8?YO6-;X&3+8]FHHHKS3$**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#TSX<?ZJ.O:=+_P!6OTKQ;X<?ZJ.O:=+_ -6OTKXP_=UL
M:JTM(M+0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^
MOAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9ONUQOBO_4/
M793?=KC?%?\ J'H ^'_VJ/\ D(:-]9__ &2O!Z]X_:H_Y"&C?6?_ -DKP>OM
M\M_W6/S_ #9^69W_ +_4^7Y(****]0\(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /1_@/\ \CG<?]>3_P#H:5[]7@/P'_Y'.X_Z\G_]#2O?J\ZO
M\9E+<****P("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KNOAU]\
M?[U<+7=?#K[X_P!ZO)S#X(GV?#'\>IZ?J>Z:+_J5K;6L31?]2M;:UX1^BCJ*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "D:EI&H S-2_U;5XS\1O]3+7LVI?ZMJ\9
M^(W^IEH _.N7_6/]33:=+_K'^IIM?I2V/Q![A1113$%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'U3X'_P"1,T/_ *\H?_0!6Y6'X'_Y$S0_^O*'
M_P! %;E>1+=F#W"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M -'0?^0I%7OWA/\ U*?2O =!_P"0I%7OWA/_ %*?2OF<9_'E\OR/UG(?^1?3
M^?\ Z4SMH/NBIJA@^Z*FKB/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\
MKX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH AF^[7&^*_P#4/793?=KC?%?^H>@#X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TSX<?ZJ.O:=+_U:_2O%OAQ
M_JHZ]ITO_5K]*^,/W=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"&;[M<;XK_P!0]=E-]VN-\5_ZAZ /A_\ :H_Y"&C?6?\ ]DKP>O>/
MVJ/^0AHWUG_]DKP>OM\M_P!UC\_S9^69W_O]3Y?D@HHHKU#P@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ]'^ __ ".=Q_UY/_Z&E>_5X#\!_P#D
M<[C_ *\G_P#0TKWZO.K_ !F4MPHHHK @**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "NZ^'7WQ_O5PM=U\.OOC_>KR<P^")]GPQ_'J>GZGNFB_P"I
M6MM:Q-%_U*UMK7A'Z*.HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKYG&?QY?+\C]9R'_ )%]/Y_^E,[:#[HJ:H8/NBIJXCWPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *KW'W:L57N/NT <%XR_U#_0U\%?M(_\CY!_UYK_ .C'K[U\
M9?ZA_H:^"OVD?^1\@_Z\U_\ 1CUZ^5_[RO1GSN??[B_5'E-%%%?:'YB%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7K_ .SU_KM=_P!V'^;UY!7K
M_P"SU_KM=_W8?YO6-;X&3+8]FHHHKS3$**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#TSX<?ZJ.O:=+_ -6OTKQ;X<?ZJ.O:=+_U:_2OC#]W
M6QJK2TBTM PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F
M_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9ONUQOBO
M_4/793?=KC?%?^H>@#X?_:H_Y"&C?6?_ -DKP>O>/VJ/^0AHWUG_ /9*\'K[
M?+?]UC\_S9^69W_O]3Y?D@HHHKU#P@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ]'^ __(YW'_7D_P#Z&E>_5X#\!_\ D<[C_KR?_P!#2O?J\ZO\
M9E+<****P("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KNOAU]\?
M[U<+7=?#K[X_WJ\G,/@B?9\,?QZGI^I[IHO^I6MM:Q-%_P!2M;:UX1^BCJ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D:EI&H S-2_U;5XS\1O\ 4RU[-J7^K:O&
M?B-_J9: /SKE_P!8_P!33:=+_K'^IIM?I2V/Q![A1113$%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'U3X'_ .1,T/\ Z\H?_0!6Y6'X'_Y$S0_^
MO*'_ - %;E>1+=F#W"BBBD(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** -'0?^0I%7OWA/_4I]*\!T'_D*15[]X3_ -2GTKYG&?QY?+\C]9R'_D7T
M_G_Z4SMH/NBIJA@^Z*FKB/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO<?=JQ
M5>X^[0!P7C+_ %#_ $-?!7[2/_(^0?\ 7FO_ *,>OO7QE_J'^AKX*_:1_P"1
M\@_Z\U_]&/7KY7_O*]&?.Y]_N+]4>4T445]H?F(4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__
M "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (9ONUQOBO_4/793?=KC?%?\ J'H
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'0?^0I%7OWA/\
MU*?2O =!_P"0I%7OWA/_ %*?2OF<9_'E\OR/UG(?^1?3^?\ Z4SMH/NBIJA@
M^Z*FKB/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH AF^[7&^*_P#4/793?=KC?%?^H>@#X?\ VJ/^0AHWUG_]DKP>
MO>/VJ/\ D(:-]9__ &2O!Z^WRW_=8_/\V?EF=_[_ %/E^2"BBBO4/""BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#T?X#_P#(YW'_ %Y/_P"AI7OU
M> _ ?_D<[C_KR?\ ]#2O?J\ZO\9E+<****P("BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KNOAU]\?[U<+7=?#K[X_WJ\G,/@B?9\,?QZGI^I[IH
MO^I6MM:Q-%_U*UMK7A'Z*.HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@#,
MU+_5M7C/Q&_U,M>S:E_JVKQGXC?ZF6@#\ZY?]8_U--ITO^L?ZFFU^E+8_$'N
M%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?5/@?_D3-#_Z\
MH?\ T 5N5A^!_P#D3-#_ .O*'_T 5N5Y$MV8/<****0@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH T=!_P"0I%7OWA/_ %*?2O =!_Y"D5>_>$_]
M2GTKYG&?QY?+\C]9R'_D7T_G_P"E,[:#[HJ:H8/NBIJXCWPHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *KW'W:L57N/NT <%XR_U#_0U\%?M(_\ (^0?]>:_^C'K
M[U\9?ZA_H:^"OVD?^1\@_P"O-?\ T8]>OE?^\KT9\[GW^XOU1Y31117VA^8A
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z_^SU_KM=_W8?YO7D%
M>O\ [/7^NUW_ '8?YO6-;X&3+8]FHHHKS3$**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#TSX<?ZJ.O:=+_U:_2O%OAQ_JHZ]ITO_5K]*^,/
MW=;&JM+2+2T#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFJ/.D5KJ&SSD\J9X6W;&(Y,9(P>A%>E4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,WW:XWQ7_ *AZ
M[*;[M<;XK_U#T ?#_P"U1_R$-&^L_P#[)7@]>\?M4?\ (0T;ZS_^R5X/7V^6
M_P"ZQ^?YL_+,[_W^I\OR04445ZAX04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 >C_ ?_ )'.X_Z\G_\ 0TKWZO ?@/\ \CG<?]>3_P#H:5[]7G5_
MC,I;A1116! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=U\.OOC
M_>KA:[KX=??'^]7DYA\$3[/AC^/4]/U/=-%_U*UMK6)HO^I6MM:\(_11U%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2-2TC4 9FI?ZMJ\9^(W^IEKV;4O]6U>,_$
M;_4RT ?G7+_K'^IIM.E_UC_4TVOTI;'X@]PHHHIB"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)EL>S4445YIB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z
M9\./]5'7M.E_ZM?I7BWPX_U4=>TZ7_JU^E?&'[NMC56EI%I:!A1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_@H4/VI5N_!_C."RTGX@V$ GB:U)2'5H1P[HA^[(O!9 2"#N4 !@OS!\/\
M]B&W_:;_ .";O@+6_".BV7_"T]-N[T6MV9%MVOK;^T;A7@E<D*0%;>I;D%,
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M44 %%%% !1110 4444 ?5/@?_D3-#_Z\H?\ T 5N5A^!_P#D3-#_ .O*'_T
M5N5Y$MV8/<****0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T=!
M_P"0I%7OWA/_ %*?2O =!_Y"D5>_>$_]2GTKYG&?QY?+\C]9R'_D7T_G_P"E
M,[:#[HJ:H8/NBIJXCWPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KW'W:L57N/N
MT <%XR_U#_0U\%?M(_\ (^0?]>:_^C'K[U\9?ZA_H:^"OVD?^1\@_P"O-?\
MT8]>OE?^\KT9\[GW^XOU1Y31117VA^8A1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Z_^SU_KM=_W8?YO7D%>O\ [/7^NUW_ '8?YO6-;X&3+8]F
MHHHKS3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#TSX<?Z
MJ.O:=+_U:_2O%OAQ_JHZ]ITO_5K]*^,/W=;&JM+2+2T#"BBB@ HHHH ****
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MP _[ZVG\*_H$K^=G_@GZLC_MF?"@1YW?VP"<'' C<G],U_1-0 4444 %%%%
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M/^IP_P#*9_\ ;J/[2PO\_P"#_P @_L3,/^??XQ_S/FJBOI7_ (8T_P"IP_\
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MS.,HKL_^%=_]1#_R#_\ 94?\*[_ZB'_D'_[*CZY0_F_!A_868_\ /O\ &/\
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M?XQ_S.,HKL_^%=_]1#_R#_\ 94?\*[_ZB'_D'_[*CZY0_F_!A_868_\ /O\
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M_P"??XQ_S.,HKL_^%=_]1#_R#_\ 94?\*[_ZB'_D'_[*CZY0_F_!A_868_\
M/O\ &/\ F<9179_\*[_ZB'_D'_[*C_A7?_40_P#(/_V5'URA_-^##^PLQ_Y]
M_C'_ #.,HKL_^%=_]1#_ ,@__94?\*[_ .HA_P"0?_LJ/KE#^;\&']A9C_S[
M_&/^9QE=U\._O#_>J#_A7?\ U$/_ "#_ /95O^'=#&@8_?>?SG[NW^IKS\97
MIU8I0=SZ?(LOQ6#JSE7A9-=T^ODSUS1?]2M;:UP%GXR^R*%^Q[L?]-<?TJZO
MQ$Q_S#__ "-_]C7DGV9VE%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
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M'_E,_P#MU'_#&G_4X?\ E,_^W4?VEA?Y_P '_D']B9A_S[_&/^9\U45]*_\
M#&G_ %.'_E,_^W4?\,:?]3A_Y3/_ +=1_:6%_G_!_P"0?V)F'_/O\8_YGS51
M7TK_ ,,:?]3A_P"4S_[=1_PQI_U.'_E,_P#MU']I87^?\'_D']B9A_S[_&/^
M9\U45]*_\,:?]3A_Y3/_ +=1_P ,:?\ 4X?^4S_[=1_:6%_G_!_Y!_8F8?\
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M'_#&G_4X?^4S_P"W4?VEA?Y_P?\ D']B9A_S[_&/^9\U45]*_P##&G_4X?\
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M_P"HA_Y!_P#LJ/KE#^;\&']A9C_S[_&/^9QE%=G_ ,*[_P"HA_Y!_P#LJ/\
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M>].U>C@*T*-=3J.R/&S?#U<5A73HJ[NOZU/CVBOI7_AC3_J</_*9_P#;J/\
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M+"_S_@_\@_L3,/\ GW^,?\SYJHKZ5_X8T_ZG#_RF?_;J/^&-/^IP_P#*9_\
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M_P"HA_Y!_P#LJ/KE#^;\&']A9C_S[_&/^9QE%=G_ ,*[_P"HA_Y!_P#LJ/\
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M'['=Q<,@8V.O6-PI_ND^9%G\I"/QKZ<_9[_Y(%\-/^Q9TS_TECKYU_X*V?\
M)EOB#_L)Z?\ ^CQ0!^'G@?Q)+X.\:^']?@;9/I6H6]]&WHT4BN#^:U_4;7\J
M]?U0:>LD=C;++GS5C4/N.3G S0!8HHHH **** "BBB@ HHHH **** "BBB@
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M_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
MORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_
M -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+I_\
MSX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GP
MM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\
M^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\
MGPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+
MI_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_
M /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8
MNG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L7
M3_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH
MI?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_
ML73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@
M"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_P
MH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5
M=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_
M  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A
M5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]
M^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_
M*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\
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M_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\
M^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ
M?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/
M_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E
M_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q
M=/\ ^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *
M7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C
M^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5V
MB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\
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M_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
MORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_
M -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+I_\
MSX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GP
MM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\
M^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\
MGPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+
MI_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_
M /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8
MNG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L7
M3_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH
MI?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_
ML73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@
M"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_P
MH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5
M=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_
M  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A
M5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]
M^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_
M*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\
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M_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\
M^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ
M?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/
M_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E
M_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q
M=/\ ^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *
M7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C
M^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5V
MB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\
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M_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
MORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_
M -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+I_\
MSX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GP
MM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\
M^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\
MGPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+
MI_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_
M /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8
MNG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L7
M3_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >,T444 >@?#_ /Y TW_7PW_H*UTU<S\/_P#D#3?]?#?^
M@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(
M?[:G_!.OPG^U?,/$>GWJ^$OB!%$(O[52'S(+Y%&$2Y0$$D< 2+\P'!# *!^2
M_P"TM^PK\5/V5=)M]:\96>FS^'KF^&G0:MI=^LL4D[(\BKL;;*,I%(<E /EP
M2"1G^B2OF_\ ;P_99U7]KKX0Z1X/TC7+/0+FQUV'5FN;Z)Y$9$M[B(H O.29
MP?\ @)H _)C]F?\ X)L?%#]ICPII7B[3+O1=!\(:A)(B:EJ%R7E81R-&Y6%%
M+$AD8 ,5!QUQ7ZV?LA_L/^!OV1=#F.D%]=\67T8CO_$=[&%ED7(/E1(,^5%D
M [0220-S-@8Z7]D#X$W_ .S7^S_X<^'NIZI;ZS>:7)=.]Y:1LD;^;<R3# ;G
M@2 ?A7LU !7EG[1O[-_@W]J#X=W'A/QA:,T>[SK+4;;"W5A-C DB8@X/8J00
MPX(]/4Z* /Q!^*G_  1Z^-O@_5)AX0.D>/M++'R);>\CL;G;GCS(YV55;V61
MA[U@^"?^"27[1'B?54MM7T#2O"%IN&^\U35[>90O<A;9I6)]L#ZCK7[N44 ?
M._['?[%7A#]D'PK<6^ERMKGBK454:GX@N(@DDP'(BC7)\N('G;DDGEB<#'T1
M110!^;7_  4(_P"">_Q1_:>^/%OXP\'W&@1:3'HUO8%=3O9(9?,225F^58V&
M,.O.?6MS_@G#^PC\2?V4_BEXF\0^-)]#EL-1T8V$(TN\>9_,\^-^0T:X&$/.
M?2OT)HH *^'OVVO^"9.@?M+:M/XR\'ZA;>$/'LJ@71GB)L=2(X#3! 6CDQC]
MXH;(&"I/(^X:* /P0US_ ()2_M*Z3J$EO:^"+/6H5) N['7+)8WYZ@32QO\
MFHKV3]G_ /X(U>.=>UNUOOBSJMGX7T&-@TVEZ7<+=7\^#RF]08HP?[P9S_L]
MZ_8NB@#%\&>#=$^'GA72_#7AS38-(T/3(%MK2RMUPD2#MZDGDDG))))))-;5
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!^>O[8O_  2=T?XT>)-0\:?#/5+/PCXFOG::
M^TJ]1AIUW,3EI59 6A=CRV%96/.%))/Y<_M#?LN_$']E[7M.TKQ[IEM8RZE&
M\UE-:7D=Q'.B,%9AM.Y<$C[P!YK^E"OBW]OS]@S7_P!L3Q)X0U+1O%.F^'DT
M2TGMY([Z"20R&1U8$;>F-M 'PO\  3_@D5\3?BKI^B:_XDUO1_"'A?4K:*]C
MD20WE[)#(H="L28094C[T@(ST/2OUH_9V_9M\$_LP^ X_"_@NP:&)F$M[J%R
M0]W?2XQYDS@#)[!0 JCH!DUUWPU\*R^!?ASX5\-SSI=3Z/I5KITD\8(61HH4
MC+ 'H"5S^-=)0 5\V?MD?L-^#OVO=!MY+Z9O#_C'3XRFG^(;:(.P3D^3,G'F
M19.<9!4DE2,L&^DZ* /PC\:_\$DOVB/#.J26^DZ#I/B^U#?)>:7J]O"K#G!*
MW+1,#TR,'KU/6M_X3_\ !'OXV>,-8MQXR_LKP!I <?:);B\COKG9GGRXX&9&
M;_>D4>_:OV]HH \V_9^_9_\ "/[-?PXLO!O@ZR,%G"?-N;N;#7%[.0 TTS #
M+' ]@     *])HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\
M\@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'__ "!IO^OAO_05
MKIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **_
MG\_X*,>(]6L_VU/BA#;ZI>00I>6X6..X=5'^B0] #7S?_P )9KG_ $&=0_\
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MHOK&RGZ\B@#^AZBO'OV6?VFO#7[5?PKM/&'A]6L[A7^S:GI,KAI;"Y !:,G
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M],]A:1J?X"L;!I![R,Y]Z\9M_'OB:SO%O+?Q%JT%VK%A/'?2K(">IW!LYY-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]*K2OVTK\2_^",/_ "=?K?\ V*5Y_P"E5I7[:4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT/\ PO\ V1?A%\)/!MKX<T;P'H<]O'#Y4]WJ-A%<W5X<?,\TKJ6<L><?='0
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M-K'AW2?$,7E:KI=GJ<>,;+RW248SG&&![@?E5V"".UACAAC6*&-0B1QJ%55
MP  .@ H ^ ?^"GO['?P^U/\ 9]U[XB>'?#6G>&_%GAH1W33Z3:I;K>P-*J2Q
MS*@"L0)"X<@L-F,X)K\9]"UN]\-:YI^KZ;<-:ZCI]Q'=VUQ&<-'+&P9&'N&
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M4G)"JH4?H* +-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;[OO,J*!O;U9CEB>Y)KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M))K@VL> +2^4AIT5>R/O$@QP"SK@ "OW$K\R_P#@N#_R(/PL_P"PG>_^BHZ
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M>?\ I5:5^VE?B7_P1A_Y.OUO_L4KS_TJM*_;2@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\5;%%9FATQ=0^7KBVGCN2?RA/X5_/#0!_4GX3_Y%;1N,?Z%#_P"@"OA[_@M
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M88' 8C\'O%7BK7OB1XMO]=UV_NM=\0ZM<&6XNIR9)9Y6./\  !1P     !0
M_P <^.O$'Q.\8:GXF\3:G<:UK^J3&:ZO+@Y>1CP  .  , *       !7Z_\
M_!+7]AN[^#.C-\4O'>GFU\9ZO;^7I>FW"8DTRT<99W!^[-(,<=43@X+,HR/^
M"=W_  33A^'::9\3OBOIR7'BLA;C2/#MPH9-,[K-.IZS]"%Z1]3\_P!S](J
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MEX[T\VOC/5[?R]+TVX3$FF6CC+.X/W9I!CCJB<'!9E'Z%T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLY9%.V19(6^XQV[2R[7X'(P*_H]K^>C_ (*.6.FZ?^VQ\4XM*5%M6OX9G"*
M//>UA><_7S6DSZG- '[<?LJ_M(:)^U-\'=,\;Z/#]AG=VM=1TQI-[65TF-\9
M; R""KJ<#*NI(!R!Z_7Y5?\ !#?6+QO^%OZ6=S6"?V7<KSPDA^U*?Q8*/^^*
M_56@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0
M/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAX&;X=W$OAOP3X@7QO+;LL-IJ0@^P6\Q7AVE60O(@8YP$4MM(.S(-3?M2?\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? '_!:O\
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MA_\ \ IZ_6?P;H<GAGPAH>CRRK/+I]C!:-(@P',<:H2/8XH V**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=C=)NCE0]CZ'H01R" 000#7Y:?'3_@BOJ@UBYO\ X2^+;)]-E?<FC>)2\<D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'
M_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OA
MO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#QFBBB@#T#X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:***
M /0/A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'__ "!I
MO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_ /(&F_Z^&_\ 05KI
MJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /&:*** /0/A__P @:;_KX;_T%:Z:N9^'_P#R!IO^
MOAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#QFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_
M]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /C]'_#??P^_Z _B;_P%M_\ X_7P+11_96&[/[P_M_&]U]Q]]?\ #??P^_Z
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M*/\ A?\ X>_Y\]3_ ._4?_QRO **/J-$/]8<=W7W'O\ _P +_P##W_/GJ?\
MWZC_ /CE'_"__#W_ #YZG_WZC_\ CE> 44?4:(?ZPX[NON/?_P#A?_A[_GSU
M/_OU'_\ '*/^%_\ A[_GSU/_ +]1_P#QRO **/J-$/\ 6''=U]Q[_P#\+_\
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MU).23U)))ZT ?!&H?LQ_M#> ;<ZMI/B"XU">$;S%H^M3&;&.1M?9O[_*,Y[
MUV7[/'[;&JKXA@\(?%#Y)7E^RQ:Q)#Y,D,V=H2Y7@ 9XW8!!^]W8?;5?$7_!
M0GX/VEO;Z;\0].@6&YDF6PU,1@ 294F*4^XVE">^4]* /MVBO$OV._B1/\2/
M@=I,U[*9]2TIVTNYD9LLYC"E&.>23&R9)ZD$U[;0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XN\6Z5X%\-ZAKVMW:V6
MEV,9EFF;G Z  =R20 !R20*^"_%_[4?Q6_:"\6/X?^&EI?:38,6\F#3<+=/'
MT$DT^<1?@R@9QD\&MS_@HE\3I[KQ!HG@2TE9;2UA&HWJJW$DKDK$I'^RH+?]
MM!Z5],?LT_!JS^#7PQTVQ^S*FN7L276J7!4>8TS#/ED_W4SM ]B>I- 'RBG[
M(7Q]FA^WOXIC2\X;R7UV<SYQ_>"E<C 'WNXK;^#OQX^+_P +?BEIOP[\>:5J
M/B(WDJPQPW&)+M%/'FQ39Q*@ ))9B,*?F7!K[KJO)86LUY!=R6T,EU K+%.R
M O&&QN"MU .!G'7 H L445\V_ ?]L;_A=GQ&?PK_ ,(C_8VVWFG^U_VGY_W"
M!C9Y*]<]<T ?25%%>#?M)?M2_P##/>J:)9_\(Q_;_P#:4,DV_P"W_9O+V,!C
M'E/G.?:@#WFBL?P;XA_X2[P?H>N_9_LG]IV,%[]GW[_+\R-7V[L#.-V,X&<=
M*\>_:2_:E_X9[U31+/\ X1C^W_[2ADFW_;_LWE[& QCRGSG/M0![S17S_P#'
MC]L3PQ\'MFG6$7_"2>(Y(P_V*&4)'; C*F9\'!.0=@!..NW()\1T/_@H_K$6
MK*NN>#K-K#S,2+8W#I,B^V_(8CTXSTXZT ?=U%>9ZW^T9X%T'X867CRXU<-H
MM]&6LXXUS<7$@R#$L?7>""#G@8Y('-?+>N?\%'];;42^D>#;&+3-Y"_;KAWE
M<#W7 4].,'&: /O"BO&?V=?VF-'_ &@+"\BBLGT?7K%0]SI\DGF*4)P)(WP-
MRYX((!!QZ@GV:@ HKYM^ _[8W_"[/B,_A7_A$?[&VV\T_P!K_M/S_N$#&SR5
MZYZYKZ2H **\&_:2_:E_X9[U31+/_A&/[?\ [2ADFW_;_LWE[& QCRGSG/M7
ML/@WQ#_PEW@_0]=^S_9/[3L8+W[/OW^7YD:OMW8&<;L9P,XZ4 ?$G_!23_D:
M?!/_ %Y7'_H:5]A?!O\ Y)#X&_[ 5C_Z3I7Q[_P4D_Y&GP3_ ->5Q_Z&E?87
MP;_Y)#X&_P"P%8_^DZ4 =C17G/Q>^/W@WX)V<;^(]087TR&2WTVU3S+F89(R
M%X"C((W,0.#S7R]K7_!137K^XF/AOP+ +6/I)>SR3M]6"!0O';)^M 'W/17R
M!\)?^"@NG>*-?M-(\8Z''H(NG$4>J6DYD@5R< 2(PRBY_B!.,\@#)KZ[GD\F
M&23&=BEL?04 >3_M.?&;4/@9\.8?$.F6=K?7<M_%9K#>;MF&1V)^4@YPGK71
M? _Q]>?%#X5^'_%%_;P6EYJ,3R20VV[RU*R.G&23T4=Z^"OVE/VN(_CYX2T_
M0+?PS)HL-K?+?&XDO1,798Y$V[1&N/\ 6$YSVZ5T/PA_;K_X55\.-$\*?\(1
M_:G]FQO']K_M;R?,W2,^=GD-C[V.IZ4 ?H=7PEXJ_8=\=ZU\;;[68-7L1HEY
MJK:C_:C3L+B)6D,A&S&3(O08.#P<CM]9?!'XH?\ "Y/AKI?BW^S/[(^W-,OV
M/S_/V>7*\?W]JYSMST'6O*-8_;&_LGX^Q_#/_A$?-W:K!IG]J?VGC'F%!O\
M*\GMOZ;N<=: /I*BN#^-WQ*N_A%\.]0\56NA_P#"0+8O'Y]J+K[.1&S!2X;8
M^<%EXQTR<\5A?LY_'^U_:"\+ZCJD>E_V)=V-W]GFL3<_:"%*AD?=L7AOF&,?
MP&@#UFBBO!OVDOVJ[7]GW5-%TU= _P"$AO=0ADN)(_MWV;R(PP5#_JWW;CO]
M,;.] 'O-%9/A+5[OQ!X7TG4[_3_[*O+RUCN);'S?--NSJ&V%MJY(S@\#D5XY
M\>/VOO"OP4O'TB*!_$7B15#/I]K*$C@ST\V3!VG'.T GID $&@#WFBOA%/\
M@H5XRM3'?WG@&S_L>0C8RR31[O7$I!4_]\U]._ O]H;PU\>='FGTDR6.J6H'
MVO2[HCS8L]&4C[Z$\;A^(% 'J-%%% 'P5<?L_P#[3KW$K)XUU0(6)4?\)3..
M,\?Q5P7Q8T'X^?!;1;/5/$OCK78K2ZN/LT9MO$=Q*=^TMR _ PIK],J^2_\
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MD@^66,8)+$G@$[N,5]Q5!)8VTUY#=O;Q/=0JR13L@+HK8W!6Z@':N0.N!Z4
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M9]\-)^M?H%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?
M#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLF.NX3,G/OA!^E?0-?+O_!/?Q9!J_P ';[1/,'VO1]1DW1]Q%* Z-^+>:/\
M@-?45 !7YM_\%!+..U^/,,L8 >XT>WED('5@\J9/X(*_22OS+_:VU!OB=^U)
M<Z-IC>?)'+:Z)"5&<R\!A^$DC+^% 'Z0^&;I[[PWI-S+N\R:TBD;=UR4!.?S
MK3J&SM4L;."VC_U<,:QKGT P*FH **** "BBB@ HHHH **** "ODWQI_R.6O
M?]?]Q_Z,:OK*ODWQI_R.6O?]?]Q_Z,:O6R_XY'Q7$_\ !I^K_(QJ***]T_/
MHHHH **** "BBB@ HHHH ]E_9U_YF#_MW_\ :M>S5XS^SK_S,'_;O_[5KV22
M1(8WDD8)&H+,S'  '4FOF<9_'E\OR/UK(O\ D74OG_Z4SX4_X*$^,Y_$'C/P
MIX!T[,\D"_:Y84/WYYFV1(?<*"?^VM?9OP_\)0> _ ^@^';;!BTRRBM=R_QL
MJ@,WU)R?QK\R[K4O&OQR_:$UOQ3X'LIM2UJ&].I6>%C;R(8G5(&(E^4[0(A@
M]^U>T?VQ^V+_ ,\[K_P#TO\ ^)KB/>.2T*7_ (9U_;=FM6/V?2+K4FMR.B_9
M;O#1_@A=#_VS-?HS7Y3?M >&_B])=6?BKXH:?-%,X73X;YH[:,'&]U3$&!G[
MYR1GCKP*_1SX$^/A\3?A'X8\0M)YES<VBI='//GIF.7\W5C]"* /B+]I#39_
M@%^UC9>+[&-DL[RYBUM%3C?EMMS'GU8A\^T@K]$[&\@U*SM[NVD6:VN(UEBD
M7HRL,@CZ@U\S_M_?#O\ X2CX2VWB.WBWWGAVY$CD#)^SRD)(/P;RC] :ZK]B
MWQ]_PG7P&T>.63?>Z*S:5-D\XC ,7X>6R#ZJ: /$/^"BOCF2^U;PIX&LRTKH
M#J5Q"G):1R8H1CUP)>/]L5]8_!SP''\,?A?X<\-*JK)86:BX*]#,WSRM^+LQ
MKXF^'4)_:,_;8O==D'VC1M-O'OP3ROV>V(CM_;YF$1(]VZU]]>)4ED\.:JD'
M^O:TE$?&?FV''ZT ?GAI<$_[9'[54ZZA<2'PW;M)(L:,?DT^%@%1?0R%ER>Q
MD)[ 5^B.@Z!IOA?2;;2](L8--TZV79#;6T81$'L!_/O7Y7?LV>!?%WQ#\:7^
ME>#/%LGA'55L6N'N([N:W,T2N@*;HN3RRG!XXSVKZ1_X97^/W_19[K_P=ZA_
MA0!1_P""@7PKT_0(]#^(>C0KINI37PL[Y[8;#+(5:2*8XZ./+8%NIROI7U3\
M%_&DGQ$^%/A;Q%.0UU?6,;W! P#,!MD('IO5J^4?$'[%_P 9O%U@+'7/BC'K
M5D'$@MM0U*]GCW#(#;74C(R>?<U]3? OX>WOPK^%.@>%=0NH;V\TY)5DGM]W
MEMNE=QC< > P'3M0!^>O[2D>J7'[6'B6VT1IEU>YOX+:U^SMMD,DD$:!5/8G
M=C\:^^/@9\ O#OP3\+6EG96=O<ZVT8-]JS1@S32=P&(RJ Y 4=NN3DGXK^)/
M_)_5I_V-6D_^A6]?I'0!'%;Q01>5'$D<>2=BJ .22>/<DG\:\[^'O[._@#X8
MZE>:CH?A^W34+F9YOM5P/->$,Q8)$3_JU'0!<' &2>M=QX@UZQ\*Z%J&L:G<
M+:Z=80/<W$S<A$4$DX[G Z#DU\13?M!?&#]I[Q9>:'\,(?\ A&=#A_UEV&"R
M1QG(5YIR"4)P<+&,]?O8)H ^TO&?AW0_%7AN]TKQ';6UUI%RFR:.ZP$YZ$$_
M=(/((Y!Y%?GM^R)J$WP]_:L?PU;WWG6%Q+?:5-(I!2=8A(T;<<<M$N"/[Q[&
MO8M/_P""?\WB"5+SQW\1-4UN]/WQ;J6*^H$LS.3]=HKPGX%^';;P?^VE9:#9
M/++9Z7KM_8PO.09&2)9T4L0 "V%&< #/84 ?H/\ &+Q+=>#OA3XNUNQ.V]L=
M+N)H&QG;((SM;\#@_A7QO_P3S\#Z=XF\7>*O%6JQ)?ZCI2P+:O<8D9))C(SR
M\_Q_NP W7YFK[G\2:#:>*O#VIZ+?IYEEJ%M):3KW*.I5OQP:_.KX=^-M3_8G
M^.&NZ%K40U?2)PD-XMFZ[WBSNAG49X<*Q^1B/OD9Z&@#]%?$?AS3/%VAWFCZ
MQ91:AIMY&8IK>9=RLI_D1U!'((!%?"W[%FO7?@']H?Q3X!ANI+C1IWNX1&3N
M7S;>0A)<]B45P<=<CT%>H>/_ /@H%X*T_P ,3MX3@OM6UV:,K;QW%N88H7((
M#2$GD#KA<YZ9'48G[#WP+US2M7U/XD^++>>TO[Y'BL;>ZCV2N)&#27#*0"N[
M&%]06.,$&@#ZT\2:];>%_#NJ:S>';::?:RW<Q_V(T+-^@-?GO^SGX)E_:J^.
MVN^+/&7^G:=9,+VZM6)*2,Y(@M_:-0IX[B/'<U]H_M))+)\!/'@A^_\ V3.3
MQ_"%RW_CN:^!/V8?ACX^^)D?B&+P/XZE\(M9F!KN&.^N+;SP^\(W[K[V-K#G
MIN]Z /T^L[.#3[6&VM8([:VA01QPPH$1% P%4#@ #L*^ ?VRO!$/P-^+WA3Q
MUX2BCTI[]VNO(MUVQI=0.A9L#@*XD7*]\-ZUVG_#*_Q^_P"BSW7_ (.]0_PK
M%\2_L0_%SQG' GB#XDVVNI;DF%=2O[RX$9.,E=ZG&<#IZ"@#[;T'5X?$&AZ=
MJEOGR+ZVCN8\]=KJ&'Z&K]8?@;09O"O@GP_HMQ*MQ<:;I]O9R2IG:[1QJA89
MYP2,\UN4 ?-W[?O_ "0%O^PK;?R>H?V/_#MAXX_90AT#5H!/IM[)>VLT?0E6
ME;D'L03D'L0#4W[?O_) 6_["MM_)ZN_L(_\ )N^E?]?MU_Z-- 'SI\"?$VH_
MLH_M%:GX'\1S%-#U&=;.69N(^3FVNAZ AL'T#MGE:^J/VQE+?LV>- !D^5;G
M\KJ$UP/[=OP1_P"$X\#IXRTNWWZUH$9-RJ+EIK/.6_&,Y?Z%_:N-T?XOO\8/
MV(_&=C?S&77] M(K6[).7EC61&BE/U52I/<HQ[T ='_P3C_Y)=XF_P"PR?\
MT1'7J?[5_P 5+CX2_!G5-2T^7R-7OG73K&4'!CDD#$N/=45V'N!7EG_!./\
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M7%Q&@5IH9%<_.1U*LJX)_O-7??L+^(+C7?V?=-BN96E.G7EQ9(S')"!@ZCZ
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M"WQ?9W$236TFI[7C<9#JT"!@1W! KV/]K#_DW?QQ_P!>2_\ HU*\>_X)P_\
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MC'PQ_96BM;2R-<?V3/;8=0-HWN2.?2OJRBB@#\SOV'U&K?M*65Y<#=,MM>7
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M'HNGZM8R>=97UO'<P2#^*-U#*?R(K[@_.R]1110 5^;G["/_ "<7-_V#[O\
M]"2OTCK\V_V$6"_M&2@G!.GW8'O\RT ?I)7P9_P4D_Y&GP3_ ->5Q_Z&E?>=
M?!G_  4D_P"1I\$_]>5Q_P"AI0!]A?!O_DD/@;_L!6/_ *3I7Q[_ ,%)/^1I
M\$_]>5Q_Z&E?87P;_P"20^!O^P%8_P#I.E?'O_!23_D:?!/_ %Y7'_H:4 >X
M_LJ_L]^&O ?@?1/%$UO'J_BC6+2'4)-2NHPSP>:@<)%G.W ;EARQR2<8 A_;
M>^&^D^*?@KJ^O/9Q#6]%\NYM[Q4 DV&15D0MU*E6)QZJ*]7^#?\ R2'P-_V
MK'_TG2N=_:D_Y-\\<_\ 8.;_ -"6@#X]_8G^"FD_&#4[_4_%,TNIZ1X;:-;7
M1I6)@>24LQ+#/W04R5 PQ(SP"#]_:EX1T35_#TF@WFDV<^C/'Y)L&A7R0F,8
M"XP/;'2OD;_@FQ_R _'?_7Q9_P#H,M?:% 'YH? 6"?X3_ME1:!932-:PZM>:
M,^XX,T'SJI;\51_JHK]+Z_-S1_\ D_J3_L:9_P#T)Z_2.@#\W/V$?^3BYO\
ML'W?_H25^D=?FW^PBP7]HR4$X)T^[ ]_F6OTDH ^#/\ @I)_R-/@G_KRN/\
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M!= T^^T#Q/IBVMOJ]U+)::C' 5#S84-'(Z@_>&'!8CG(YX%?47[,_BBY\:?
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M,X/<&OSE^-'PWU3]D_XS:;-H.IRRQ($U+2[Q^)-H8J8Y0, D%2IQPRL.!D@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9H
MHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,P_Y]_C'_,^-Z*^R/^'=_P#U4#_RB_\ W11_P[O_ .J@?^47_P"Z*/[2PO\
M/^#_ ,@_L3,/^??XQ_S/C>BOLC_AW?\ ]5 _\HO_ -T4?\.[_P#JH'_E%_\
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M\531D,L%T5BMB1ZQKRW/8L1V(-?2MI:0:?:PVUK#';6T*"..&% J(H& J@<
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MS?P[\!:9\,/!>E^&-&\XZ=I\92-KA@TC98LS,0 "2S$G '6NDKF/6/(?VL/
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M_8)\ >#[V.]UJ:[\6W,9RL-[MCM<^IB7EOHS$>U?2D,,=M#'##&L44:A$C0
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M@_9A\*+\:O\ A9R7FK)KOG>?]E6:+[)N\GRON^7NZ<_?Z^W% 'I7BJ[O-/\
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M&4'_ +Y%>C?"O]B?X??#6^AU*YBN/$^JPL'CFU3:8HF!R&2)0%S_ +V[';%
M'T#1110!\W?M^_\ ) 6_["MM_)ZN_L(_\F[Z5_U^W7_HTUZ;\7_A)H_QJ\('
MPYKES?6MB;A+GS-/D1)-R9P,NC#')[5+\)OA;I7P;\&6_AG1;B\NK"&6259+
M]T>4EVW')55&,^U '7S0I<1/%*BR1NI5D<9# \$$=Q7YC_&_P?J/[,?Q-\3Z
M5IT;OX6\3Z;/#;(Q.QH).B9_O0R!?<@#IOK].Z\]^-'P-\-_';0;32_$7VJ
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M;Z4VRW@\P#-G8H<O*^. Q+,V,_>95R>*_3#3["#2M/MK*U016UM$L,2#HJ*
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M)?\ #)/A#_A;W_"QO[2UO^V_M_\ :/V?SX?LWF9SC;Y6[;_P+/O0![;1110
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M;:.Q<36T3$</)*IVD#^ZI).,<9R/ OV+O@OJWQ(^(C?$SQ(LTNFV-R]U#<7
MYO[TDG>,]0C$L6'\04#H<>S>!?\ @GYX"\-WL5WK=_J'B>2-@PMYBL%NV/[R
M+\QY[;L=B#7TQI^G6FD6,%E8VT-E9P((XK>WC"1QJ.BJHX 'H* +-%%% 'DO
M[6'_ ";OXX_Z\E_]&I7CW_!.'_DG?BO_ +"J_P#HE:^F?B%X'L/B5X,U7PSJ
M<MQ!8:E$(I9+1E651N#?*65@#D#J#7-_!/X$Z#\!]&U#3- N]2O(+ZX%S(VI
M2QNP8*%P-B(,8'<&@#T:OSY_:<\$WW[.?QPL_'_AZ C0M;>5I8$RL8D=2MS
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MV_PKT?1]7L_$&DV>IZ=<)=V%Y$L\%Q']V2-@"K#V((KYE_X=T_#?_H-^*O\
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M'09X H TOAWX'L?AOX(T;PSIN39Z;;K KL #(W5W('=F+,?=C71444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\[_MG?
M >Y^+W@6WU31(//\2:'ODA@0?-=0MCS(AZL-H91Z@@<M7B'[)W[75C\.](3P
M-X\>:TTZU=DL=2,;.;;+$F&51\VT'." <9P> "/O>O&?BY^R;X ^,%Y)J-]9
M2Z1K4F2^I:4RQ22MZR*5*N?<C=[T =='\<OAU)I_VU?'?AS[-C[YU2 8.,X(
MW9!QVZ^U> ?$K]O33;'Q=H^C?#_3&\5HUVB7D_ENHN%)QY-NN-Q<D\,1C(
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ML?B)X.U;PUJ4MQ!8ZE"8)I+5E655)!RI92 >.X- 'R=_P38_Y ?CO_KXL_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFKF?A__P @
M:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_P#\
M@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A__ ,@:;_KX;_T%
M:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /&:*** /0/A_P#\@:;_ *^&_P#05KIJYGX?
M_P#(&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_
M -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /&:*** /0/A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:**
M* /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_P#\
M@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A__ ,@:;_KX;_T%
M:Z:N"\,^)K;0K&6WN(IC(92WR*.. ,<D<\5K_P#"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
M_%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P +
M T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_
M /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">-U_WRO\ \51_PL#3_P#G
MC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"P-/_ .>-U_WRO_Q5 '34
M5S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*__%4 =-17,_\ "P-/_P">
M-U_WRO\ \51_PL#3_P#GC=?]\K_\50!TU%<S_P + T__ )XW7_?*_P#Q5'_"
MP-/_ .>-U_WRO_Q5 '345S/_  L#3_\ GC=?]\K_ /%4?\+ T_\ YXW7_?*_
5_%4 >?T5(MO+(H98G9?4*2** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>cdtx-20231231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9>!5P# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9EPBYR45NSMO$WC;0?!K:8NMZK:Z;)J=W'864<\@#W,[L L<:]6))[#@9)P
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M+O3;W4X[ZXNC+I<LDD.V0@J,NB-GCGY:*/O4[U-[+[]/^"%;2I:&U_PU_P"
M>ZT444 %%%% !1110 4444 ?+?QM_P""B?PX^ OQ*U7P1X@T3Q3>:KIPB:6;
M3;2V>!O,B61=I>X1CPXSE1SFO5/V>?VA?#G[2W@>?Q5X8LM4L=/AO7L6CU:*
M..4R(J,2!'(XVX<=\]>*_)G_ (*1?\GB>-_^N=C_ .D<-?<7_!)O_DVK5/\
ML8KG_P!$P48;][1<Y;I7_%+]0Q'[NI",=G;_ -)O^9]J4444 >&_M*?M?>#O
MV69- 3Q7INN:@=:$S6_]C00R[?*V;M_F2QX_U@QC/0]*S_V</VVO W[4'B75
M-#\*Z5X@L+O3K3[;*^L6\$<;)O5,*8YG).6'4#ZU\I?\%C/^/SX6_P#7/4?Y
MV]<G_P $@?\ DL7C?_L C_THCHPW[UOF_O?A>WY!B?W48N/7E_%V/U;HHHH
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MLIX)Z@U^9OP;_P""C_Q;C^)WA^3QYX\:Z\'QSF34X%TBR1I(51B5!C@# D@
M8(Y(K]%OVXO^33?B9_V"_P#VHE?A5I]A/JNH6UE:QF6YN95ABC'5G8@*/Q)%
M<M-R>(<5KI&R^<CHJ*/L4WIJ]?DCZ)^-?[?7Q<^+'BBZN].\5:GX,T02$V>E
M:#=O:^5'V#RQ[7D;'4L<9S@ <5]%?L>?$7]H#XD? /XM:Y9>/]4N[C1+15T*
M34(8;V5[Q/WTJ;YT=FS& F&) ,H(P17U7\%/V%_A1\+_  #I^D:KX,T/Q7K1
MA4ZAJFM6$=W)-,1\Y3S WEH#P N. ,Y.2?8/AS\+?"OPD\/R:%X1T:#0])DN
M9+MK2W+%/,D.7/S$G'0 =      *W<53C.G%ZVLGY]_,R4G4E&HUUO;R[?UY
MGX^^'?\ @I/\>K#Q!IMSJGC7^T],AN8Y+JR.D6$?VB(."\>Y8 R[ER,@@C/!
MK]GM#UFT\1:+8:K82B>QOK>.Y@E7H\;J&4_B"*_"?]LCX0GX)_M$>+= AA\G
M2YKC^T=.XPOV:;+J![*2R?\  #7Z<_\ !-3XK#XC?LSZ7IMQ-YFI>%YGTF8'
MKY0^> _38P7_ ( :JC)5J'-;5:_HU\G;\2:L72K*-]'I^J?S5_P.M_;C^.U_
M^S]\ =4UW0[Q;+Q+>7$.GZ7,T:2;)7.YGV."K;8TD/((SBOA#]FG]L+]HSXX
M?'#PEX//C]WL[Z\5[XIHNGC;:QC?,<BWX^16 /J16S_P5O\ BG_;?Q*\,> [
M:;=;Z'9F^NT4\?:)_N@^ZQH#_P!M*ZW_ ()$_"'GQ=\2KR#TT73G8?[LD[#_
M ,A+G_>%1A/>E*K+5*_X:?C+\&7BO=A&G'=_KK^"_$_2FBBB@#G_ !]X\T/X
M8^#]5\4>)+Y-.T7383-<7#@G Z  #EF)(  Y)(%?DS\>O^"G7Q+^(FKW5KX'
MN3X$\,AF2$6R(]],G0-),0=A/7$>W&<;FQFO7?\ @KQ\5[J*;P=\.;2=H[62
M)M9OXU)'F'<8X ?8;93CUP>U>)?\$ZO!OPKU#Q]K'BGXI>(/#>G6^B)$-,TW
MQ%J$%O'<7#EB9=DK#S!&%Z<@%P>H%9TH^VDVW:*O^&_XZ)&E27L8I)>\_P!=
MOPU;/';7]J+XV:7<1WZ_$_QI][<IN-8N98B>OW'8H1[8KZ^_93_X*@ZVWB.Q
M\,_&"6WO=.NW6&+Q-#"L$ELY. ;A$ 1H^F64*5ZG=V^X-:^/7P+\2:/<Z3JW
MQ'^'VI:7<QF&:SNM=L9(I$(QM93)@BOQ8_:8\'>%O OQN\4Z3X)UBPUSPFMP
M)].NM-O$NH1%(BOY8D1B#L+%.N?EYK2-3EFHR5T_Z^1FZ?-!R3LT?O\ HZR(
MKHP96&0RG((]:_)W]J[]N3XV_#7]HCQQX8\-^-?[.T/3;T0VMK_95C+Y:>6A
MQN>!F/)/4FOM/_@GO\3+KXF_LM^%Y[^9KC4-(:31YI6)+,(2!&23W\IH^?:O
MRV_;H_Y.U^)?_82'_HJ.HK1=/$*">EG\_AL_N8Z4N>BY-:W7ZW_$]T\:?\%0
MO'9^$OA70/#=['+XUDLRVN^)KBRB#B8R/MC@A"",$)LR^TCG &1NKYON/VJ/
MC9;ZK]LF^)_C&*Y+>9Y;ZO<+%U_YY;MF/;;BOO3_ ()3_ ?0+?X<WGQ-U'3K
M>^\0WM_+:Z?<SQAVLX(@%8QY^ZS,7!8<X4#US[+_ ,%%_AUI'C;]ESQ3J-Y:
M0OJ>@I'J%A=L@\R%A*@<*W7#(6!'3H>PJL1^XO4^;\D]=/1?UU%0_>I4^FWJ
MUIKZO^NAXE^P3^W]X@^)WC"W^'7Q)N(;_5;Q&.E:VL2PO-(JEC#,J *25!VL
M ,E<')(-?H57\_7[,EU+9_M&?#"6&1HY/^$ET]=R]<&X0$?B"1^-?M)^U[\1
MKCX5_LV^//$5E*T%_%IYMK653AHYIF6%''NID#?A6M>2C05:VNJ];6M]][$4
M8N5;V5]-/QO_ )'QO^V1_P %+-9T3Q5J'@OX2W%O:II\C6][XE>)9GDE4X9+
M=6!4*I!!<@Y/W< !F^+_ /AK'XT?VI]O_P"%I^+O/W[]G]L3^3G_ *Y;MF/;
M;CVK@O!?A>\\=>,=$\.V'-]J]]#8PENF^1P@)]LM7[[?!?X'^$O@3X)LO#?A
M?2K>TBBB5;F[\M?/O),?-)*^,LQ/KP!P,  5$*3C3YY/7^K^B+G44I\D5I_7
MWL_(_P"('[=WBOXR_L]ZO\._'D,>JZK)<VUQ9:[;Q)"[".0,R3HN%/'1E Z8
M(.<US'["/_)W'PU_["#_ /HB2OJ;_@J7^S'X?\,Z/IGQ1\+Z5;Z3-->"QUF"
MSC$<4K."8Y]HX#94JQ ^;<I/.2?EG]A'_D[CX:_]A!__ $1)3PDE*NG:SYE?
MUT_2W_#DXF+C1:O=6=OQ_6Y^X'BZ^GTOPGK5Y;/Y5S;V4TT3X!VNL;$'!X/(
M'6OQHT'_ (*,?'^;7-.CO?B&HLFN8UG+:-IRCRRPW9/V?@8SS7[(>/O^1%\1
M_P#8-N?_ $4U?SFUA3DXUVWJDEITW9K4CS4;+1N^OR1]R_M3?\%+_&?B_P 4
MZCHGPOU-O#'A.V=H$U.WC7[9?X.#('8$Q(>JA,-CDGG:/GOPU^V'\;/"FJIJ
M%G\3_$US,ISY>I:A)?0GV,4Y=/TK]3OV%/V7?#GP9^$/A[7;C2K>X\:ZU9QW
M]YJ5Q$K30"50ZP1L1E%52H('5LD]L9__  4*_9O\/?%/X)^(?%<&F6\'C'P[
M:-J$&I11!99H8QNEAD8??78&(SG##C&3FZB^JWUNUN_S_K[A4W]9:LK)[?I]
M_P#PXO[$/[<%M^TQ8W/A_P 0VUMI'CO3XO.>&V)$%]", RQ DE2"1N3)QD$'
M!(7ZO9@JDDX Y)-?SW_ /XD77PC^,GA'Q9:2F'^SM0B>?!P'@8[9D/L8V8?C
M7[ ?\% OBM<_"S]E_P 17FFW!M]2UEH]'M9E.&7SL^85/8^4LF#V.#6N(DHT
ME52U>EO/3\[K\3.BG*HZ3>F_RZ^MK?D?-7[67_!3[4='\0:AX3^$/V54LW:"
MX\47$:S[Y <$6T;90J",;W#!N<+C#'XLU;]K+XT:U?/=W'Q3\71RN<E;36)[
M:/\ ".)E4?0"L#X'_#"Y^,_Q:\+>"K:4V[:Q>K!).!DQ1#+2N!W*HK''M7[Q
M?#GX+>"?A/X3@\.^&?#EAIVFQQA) (%:2X.,%Y7(S(Q[EB?RJ8TN6'/)ZO\
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MCZ<^-G_!1#XO?%[7+Q/#>K7G@GPZK'[/8:$QCN F>&EN%'F%B.NTJOMWK@O
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MS_V"/BUXK^-7[/MKXE\9ZK_;.MOJ-U UU]GB@RB, HVQ(J\9ZXS7Y>_M^?\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:]TS1_#&E7ECX1T-WNA+>*//N96 3S7521&J@D 9)^?G&<#,_P"":>HP:?\
MM>>%%G?8;BVO8(_=S;2$#]#6V%YI5)-]>:W_ (#;\S#%)*G%1Z6O_P"!7_!'
MZ=_MQ?\ )IOQ,_[!?_M1*_%OX$HLGQN^'RLH93XAT\%6&0?])CK]I/VXO^33
M?B9_V"__ &HE?BY\!?\ DN/P\_[&'3__ $ICJ,)_OR_[<_.1IB/]U?\ V]^2
M/Z%J*** /SY_X*W?!_\ MCP3X:^(]G!NN='G_LR_=1S]GE.8V/LL@(_[:UX7
M_P $K_B]'X%^-6K^&+^Y6#2_$>G.P+MA5N+<-*I_[]^</RK]1_C-\-[3XO?"
MOQ1X.O0HBUBQDMU=AGRY,9C?ZJX5OPK^?J3^V/ 'BB[@#S:7K6FS36DNP[7B
M<;HY%S_WT*RHR=&I."ZIV^>C^YZ_-&E6/M:<9=K?AJO\OD=-\</B%=?&;XT>
M*_%6'F?6-2D>VC RPBW;(4 ]0@0?A7[A?LR?"=/@G\"O"'A'8J7=G9+)>D?Q
M7,G[R8_]]LP'L!7Y&?\ !/\ ^$/_  MS]ICPY%<P>=I.ADZU>[AE2L)!C4_6
M4QC'IFOW#KJC%4</&"Z_DM%^-_N.>4G6KRF^GYO_ "7YA11161H?D-_P5HL;
MB#]I'2+B0-Y$_AVW\HGI\L\X8#\?YUX?^SW^R;XW_:9M];E\'2Z2/[(:);E-
M0NC"W[P,5*@(V1\C?E7Z$?\ !4G]GV_^)7PWTOQUH5J]WJ?A7S!>6\2Y>2R?
M!9P!U\ME#?[K.>U? ?[(G[46H_LM?$:76H[(ZMH6HPBUU33E?8TD8.5D0G@.
MAR1G@@L.,Y&>&Y?>A/1Z_B[K_+U]#3$<UHSCY?AH_P#/[NYZG_PZG^-O]_PS
M_P"#)_\ XU1_PZG^-O\ ?\,_^#)__C5?3_B+_@KI\,K709YM#\+^)]0UCR\P
M6M]#;V\._'1Y%E<@>X5J^!6_:J^-OBSXAW6IZ1XX\2P:MK-]YD6E:3?3BW,C
MMA(H[<,5('"A<'\:M7E/E2(=E'FN?JC^P7\ O%O[.?PCU7PUXP>Q:_GUF6^A
M_L^<RQB)H85Y)4<[D;C'I7Y<_MT?\G:_$O\ ["0_]%1U^SGP(T?QCH7PG\.V
MOQ UE]=\8?9Q+J-TZ1KMD8EO+&Q0#L!"YQSM)[U^,?[='_)VOQ+_ .PD/_14
M=37;>)BF[V37W<J"C;V#:ZM/[[L_2O\ X)A_\FCZ#_V$+[_T>U=Y^W%_R:;\
M3/\ L%_^U$K@_P#@F'_R:/H/_80OO_1[5WG[<7_)IOQ,_P"P7_[42GF'\*?^
M'_VT6#^./^)_^E'XT?LV_P#)PWPQ_P"QFTW_ -*HZ_6__@I%ILVI?L@>,_)!
M8V\EE.X S\JW46?YU^2'[-O_ "<-\,?^QFTW_P!*HZ_>7XE^!;+XG?#[Q%X3
MU$[;/6;&:RD<#)3>I <>ZG##W%:XB+EA(\NZ;?W<K%0DHXE\VUE?T=[GX3?L
MLZI;:-^TA\,[R\V_9H_$%D'+]!F95!/T)!_"OW^K^=CXB> =?^#WC_5?#&NV
M\FGZWI%R8VQD9P<I(A[JPPRL.H(-?H;\'?\ @K;H5CX+L['XD>&=:N/$%K$L
M+ZAH:PRQWF !YCI))'Y;'N!N&>1C.!49QJ45ROK?[[?Y$2A*G6=UNK?=?_,]
MD_X*B:I;6/[)NJV\Y7S;W4[*" -UWB3S#CWVQM^&:_-[]A'_ ).X^&O_ &$'
M_P#1$E=%^V-^V%K'[6FL6=IINC3Z1X0T027,%B6\V9V/RM<3E1A<#  &0NX\
MG-<[^PC_ ,G<?#7_ +"#_P#HB2L\&FJZD^LD_P E^A>*:=%I=(O]7^I^W/C[
M_D1?$?\ V#;G_P!%-7\YM?T9>/O^1%\1_P#8-N?_ $4U?SFUS1_C2]%^<C=_
MPH^K_0_HN^'-[;ZE\/?#%W:R++;3Z7:R1.G1E,2D$?A7/?M$:I;Z-\ _B+>7
M1401>'K\MN/!S X _$D#\:_.3]DG_@I5'\%_ MGX(^(&A:CK.EZ6IBT_4=+*
M-=119XADCD958+D@,&!  &#C-9O[9'_!1E/CUX*E\$>"=%OM#\.WC(VH7NJ,
MBW5RJL&$02-F5$W $G<2V .!G.^-_>\ZAKS7_'_+_AC+!_N^3F^S;\/\_P#A
MSXCM87N+F&*-2TCN%51U))P!7ZU?\%3M%NY/V5_#DH+,-/UJT-QC)&#;S)N/
M_ B!^-?"W["_P'OOCE\?=!C^S.WA[0[B/5-5N"N8UCC;<D1/3,C*%QUQN/\
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MDG&,5TM_Z5?]3[4_X*;> ?$OQ&^ .DZ9X5T#4O$6HQ^(+>=[72[5[B58Q!<
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M'^IR>];_ (W_ ."@7QO\07&OV-GX\N[+0;ZXN/)MX+2V26&!W8JBSB/S1A2
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !117/>,/B)X4^'=O;3^*O$^C>&8+EBD$NL7\5HLK 9*J9&
M 8@=A2O;<#A/VA/VH? G[-N@"^\5:COU*="UEHMGA[NZ(_NKGY5SU=L*/4G
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M,/CC\*/$FK^./"L6NZC::T;6&=[NXA*1>1$VW$<B@\L3R,\U=+]]!SCLE?\
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MS\G]ZN81DI*Z_JVA\.?#/_@K%\3?#M];Q^,=*TGQ?IN<3/%%]BN\>JNG[O\
M Q\^HK],O@G\;/"_Q^\!6?BSPI=M/8S$QS6\P"SVLP W12J"<,,CN00002"#
M7Y%?M]?LPZ)^S3\3=+MO#$]PWA[6[1KNWMKJ3S)+9U?:\>[JR\J03SR02<9K
MUG_@D/XOOK/XN>,/#"R,=,OM&^WO$3\HEAFC16 ]=LS#\!Z4Z+C7BU;77\-_
MR9-5.BT_3\=OS/U9HHHK,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *^.?^"DGP!\>_'SP?X,L? >@_V[=:??SS7,?VRW
MM_+1HP%.9I$!Y';-?8U%1."J*S[I_<[EQDXNZ_J^A_.'XI\,ZGX+\2ZIH&LV
MWV/5]+N9+.[M_,63RY8V*NNY25."",@D>]>P?#C]B?XT?%+PIIGBKPOX,_M/
M0;_<]M=_VI90[PKE&.R296&&4CD#I7-_M2?\G)_%'_L9=0_]*'K]=O\ @GO_
M ,F@?#[_ *XW/_I5-6V%DW1CB.JY7Y:W?Z$8C]W7=);7?X&E^VPC1_LA_$9&
M&&72 "/?>E?C#\!?^2X_#S_L8=/_ /2F.OVC_;B_Y--^)G_8+_\ :B5^+GP%
M_P"2X_#S_L8=/_\ 2F.HPFN/3_P?^E2)K14<'RKIS?DC^A.;_5/_ +IK^;O4
MCMU.Z/\ TV;_ -"-?TB3?ZI_]TU_-WJ7_(2N_P#KJ_\ Z$:PBVJ]UV7YG4OX
M$O5?DSZR\$_LQ_&W]O*>]^(M]J6G6.GNWV6TNM9GECA*)QY5M&B.1&G3)P"<
M\LVZO#/C[\ ?%/[./CQO"OBM+9KIH%NK>[L9"\%S"Q(#H653U5E((!!4]L$_
MMS^S!HMMX?\ V=/AK96B+'"GA^R?"C&6>%7=OJ69C^-? W_!8:-1X^^'+A0'
M.F70+8Y($J8'ZG\ZWQ"]C65..UVOP>OWHY\._:TG.79/\M/N/G;PC\7?C+\=
M_!'AGX!Z#?7&IV#7#+#;QOMDFAP"L4TI/^HB 9@#P ><[5 ZOXS_ /!.'XH?
M!7X=WWC&_O=!UK3M/427L.DW$SS01D@&3#Q(&52><'('.,9(]1_X)!>'[2\^
M*GCG6)8U>[L-(B@@8C.T2RY8CT/[H#\37Z'_ +2$:R_L]_$Q74,O_"-:B<,,
MC_CVDHQ/[NE[5?$TV_E=?H/#_O*JI/X4TOOU_4_%_P#8]^-.I_!'X]>&-5M+
MN2'2[Z\BT_5;<-B.>VD<*VX=RN=X]"OUK]XYIH[>&265UCBC4L[L<!0!DDGT
MK^<+P](T/B#3'0[76ZB8'T(<5^Z/[9WBZX\&?LI_$/5+:5HKEM*-HDBYRIG9
M8<C'?]Y5UY.&&4^JO^EE][_$SHQYL3R=[?FU_D?E[^VS^V-K?[1'C:^T?2K^
M:T^'FGSF.QL8F*+>%3C[1,,_,21E0>%&.,Y)TOA#_P $T?BU\6?!]IXD,FC>
M%[&]02VL.MSRI<31D K)LCC?:I!XW$'OC!!KYB\*ZI::'XGTC4K_ $]=6L;.
M[AN)]/:3RQ<QHX9HBV#M# $9P<9Z&OT27_@L@L:A5^#X55& H\2X '_@'40A
M"G3WO+^M?G^%O0N<I3GV7]:?UO\ >?&OQX_9M^('[+?BBPMO$T"0&8^=IVLZ
M7.SV\S(028Y,*RNI(X8*PX/3!K])O^"<G[6VH_'7PK?^#_%MT;SQ?H$2RI?2
M$;[^T)VAW]70D*Q[AE)R<FOC[]J[]O\ L_VHOAG%X5G^&ZZ!<V]]'?6VI?VU
M]J,3*&5@$^SIG<K$?>].M<K_ ,$Y?$D_AW]KGP:D3[(M26ZL9USC<K0.P'_?
M:(?PK7#\TG*E/9[?=I^.AG7Y8I5(;K?[]?PU]3]N:***R- HHHH **** /GK
M]M[]I1OV:_@[+J6F^6_BG5I#8:2D@#!)"I+S$=PB\XZ%BH/!K\8-%T7Q?\<O
MB)%8V27WBGQ=KER2#))OFN)#RS.['   )+,0 !DD 5]D?\%>O$T]Y\8?!N@[
MR;73]$-VJ<X$DTSJQ_*%*V?^"/\ X+M+[QA\0/%,\*O=Z=:6UC;2-R4$S.TF
M/0XA09]":C"P564JD^E_N6GXO\_(O$2=*,81ZV^]_P"2?Y]SS/Q'_P $L_C;
MX;\-OJ]N?#^M7,2>:=+TN_D-WZD#S(D0L/0.<]LUX)\7/C-XL^*ECX8TOQE)
M+=:KX6MI=,6[NMPN7C\S(2;/)=#E<GD@#/()/]!5?BS_ ,%,/ MGX)_:HU>:
MQA6"'7+*WU9XT7"^:^Z.0CW9HBQ]V-3*34XQ>S_!V?Z7'&*<6UNORNOUL?47
M_!'O_DG/Q"_["UO_ .B376?\%:O^3;-%_P"QEMO_ $GN:Y/_ ((]_P#).?B%
M_P!A:W_]$FNL_P""M7_)MFB_]C+;?^D]S6F.Z?\ ;G_MI&!Z_P#;_P#[<?FU
M^R_\5-)^"?QV\*>-=<M[RZTK29I9)X=/1'G8-#(@VAV53RXZL.,U^C__  ]T
M^#W_ $+?CC_P!L__ )+K\RO@3\)Y_CE\6/#_ ('MM1CTF?5Y)(UO)8C(L>V)
MY,E01G[F.O>OJ/XF?\$G_B-X/\/W.J>'-?TOQ@]M&97T^**2VN9 .HB#;E<X
M[%E)Z#)XK2I)QIIRVU_X)$8J4VEOI^I?_:T_X*60_&GX>ZCX(\%>'+S1M+U1
M5COM2U:1/M#Q AC&D:%E7) RQ8\9&!G-?-/[+OP.U7X_?&30?#EA:22Z>MQ'
M<:I=!"8[:T5@9&8] 2!M4'JS 5YSHDECI/B&U?7=,GU"PMYQ]KT^.?[-+(H/
MS)OVML/;.TXK]T/V05^%EY\%]*U;X3:+;Z+H-\,W$"@FY6X7ATN'8EG=3QEB
M>,$<$55&*IOVZU:_I?+T_"]R:TG+]UM_6OS_ *Z'M:J(U"J,*HP!3J**R+VT
M1^)/_!2+_D\3QO\ ]<['_P!(X:^R/^"0W_)#O%__ &,+?^DT-?&__!2+_D\3
MQO\ ]<['_P!(X:^R/^"0W_)#O%__ &,+?^DT-/!?[O+_  K_ -*B7B_XL/E_
MZ0?=U%%?GM^V!_P4*^(O[/\ \=-7\%^'M%\+WFEV=O;2QS:G:W,DY,D2NV2E
MPBXR>/EK-R46HOJ"BY)M=#]":*_(W_A[I\8?^A;\#_\ @#>?_)=?:W["'[3G
MBG]J#P+XCUKQ58:1876FZDMG"FCPRQHR&)7RPDDD).2>A'TK51<DVNG_  QF
MY)-)]3Y5_P""PW_(]?#C_L&W7_HU*Y#_ ()5^-_#G@;XL>,;KQ)K^E^'[:;1
M!'%-JEY';([^?&=JL[ $X!.!Z5U__!8;_D>OAQ_V#;K_ -&I7PGX/^'_ (H^
M(5Y/:>%?#>K^);N"/S98-'L);N2-,@;F6-20,D#)]:QPDG%-I=9?BVC3$Q4F
MDW_+^%F?O;=?M'?">SMWFF^)O@](T&6;^W;4_IYG-?D?_P %!/V@]!_:#^-T
M5]X6E:Z\/Z/8)IUO>-&4^U,'=WD4, 0N7VC(YVY[UYA'^S#\8I'"CX4>-@3_
M 'O#UVH_,QUZ_P#"G_@FK\9_B'J5O_:^C1^"='8@R7VLRKY@7/(6!"9"V.@8
M*/\ :%5[/GDGV_X8/:<D6NY[#_P1^\'W,_C3Q]XI:)A9VUA#IJ2D':TDDGF,
M!ZD"(9_WAZU\_P#_  4*\0S^(?VN?'9F9BEE+;V42M_"B01C ]MQ8_C7[ ?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "3GXA?]A:W_ /1)KK/^"M7_ ";9HO\ V,MM_P"D]S7)_P#!'O\ Y)S\0O\
ML+6__HDUUG_!6K_DVS1?^QEMO_2>YK3'=/\ MS_VTC ]?^W_ /VX^"_^"?\
M_P G??#K_KYN/_26:OW,K\,_^"?_ /R=]\.O^OFX_P#26:OW,KJJ?PH?,PC_
M !9>B_4_(O\ X*C?L^Q_#GXIVGCW1[7R=$\5EC=+&N$BOU&7^GF+A_<B0T__
M ()9_'L^ _BQ=?#_ %*XV:-XJ&;4.?EBOD4E<>GF("ON0@K]$_VK_@G#\?O@
M7XD\*B-6U,Q?:],D;^"[C!:/GL&Y0^SFOP=L;W4O"/B"WN[=Y=.U?3+I98VP
M5D@FC?(/L59?TKCPLE2FZ4OA_1_Y/;Y'3B(NK!5([_JO\^O?4_I HKS?]G7X
MPV?QX^#GAKQG:[%EOK<+>0(<^1=)\LR?@X./8@]Z](K:<7"3B^AC&2G%21^)
M/_!2+_D\3QO_ -<['_TCAK[(_P""0W_)#O%__8PM_P"DT-?&_P#P4B_Y/$\;
M_P#7.Q_](X:^R/\ @D-_R0[Q?_V,+?\ I-#4X+_=Y?X5_P"E1-<7_%A\O_2#
M[NKXR_:4_P""<5K^T5\6M2\<2^/IM!>\A@B^PII(N GEQA,[_.7.<9Z5]FT5
M#BFTWT!2:32ZGYP_\.<;+_HJUQ_X(5_^2*^IOV1_V6(OV4_"6MZ'#XD?Q*NI
MWPO3.]D+8QXC5-N!(^?NYSD5[Q16BDTFEU,W%-IOH?ES_P %AO\ D>OAQ_V#
M;K_T:E97_!('_DL7C?\ [ (_]*(ZU?\ @L-_R/7PX_[!MU_Z-2LK_@D#_P E
MB\;_ /8!'_I1'4X'K_V__P"W!C=E_P!N?^VGZMT444%!7Y8?\%;/@_<:3X^\
M._$>TA9M.U:V&F7LBCB.YBR8R3_MQG _ZY&OU/KD/BU\*] ^-/@#5O!_B:V-
MSI6HQ[6*$"2%P<I+&>SJP!!]L'()%8U(MVE'=:_U\C6G))M/9Z?U\S\??^"?
M_P"TQ9_LZ_%V5-?F:#PEXAB6SU"8 D6SJ289R!U"DLIQ_"Y/.,5^T^EZI9ZY
MIUMJ&G7<%_87,8E@NK:021RH1D,K X(([BOP]_:0_8C^(G[/.J7<\VF3^(?"
M2LS0>(--A9XA'GCSU&3"V,9W?+GHQKRCPG\7O'?@&Q>S\,>-?$7ARS=M[6^D
MZK/:QECW*QN!FNCVJJ12ZK^M3!TW3DWT?]:'[H_M#_M#>%OV<_ -YX@\07D1
MO#&PT[2ED GOIL<(B]<9(W-T4<GL#^&5Q\7_ !BWCK6?%]CXBU+1M?U:[EO+
MF[TN[DMG+R.6(#(P.,G@9K)U+5O$?Q&\1)-?WNJ>)]=NV6-9+F62[NIFZ!02
M69CZ"OO/]B;_ ()S:U>>(-.\<_%?3&TO2K-UN+'PW=K^_NI!RKW"?\LT!P?+
M;YF(PP ^]-.DW/VDG;]%^K?]=RJE1*')%7_7_)'W)^R78^,;/]GWPA)X]U6\
MUCQ1>6OVRYFOSF9%D):.-B>250H#GG.<U^4__!2+_D\3QO\ ]<['_P!(X:_;
M6OQ*_P""D7_)XGC?_KG8_P#I'#6=:7/B(R2MO^AKAX\M*:;OI^J/LC_@D-_R
M0[Q?_P!C"W_I-#7V-\3OAWI'Q8\ ZYX1UV$3Z9JULUO)QDH3RLB^C*P# ^JB
MOCG_ ()#?\D.\7_]C"W_ *30U]W5UXJ*F^5[.,?_ $E'+0DXKF6Z;_-G\ZGQ
M+\ ZG\*_B!K_ (2UA#'J.CWDEK(<8#[3\KC_ &67##V85^S'[ ?QZ/QT^ .F
M-?W'G>(_#Y&E:EN.7DV*/*E/^^F,GNRO7RW_ ,%:/@3]CU70OBKIEM^ZNPNE
M:N47I(H)@E;ZJ&0G_80=Z\(_X)W?'C_A2_[0%A97]QY/AWQ1MTJ]W-A(Y&;]
MQ*?]USMSV61JRPLG4BZ,M_U6WWK\_(O$Q4)*K';?Y/?[OQMYG[74445)0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!G:]X<TGQ5ILFGZUI=EK%A)]^UO[=)XF^J."#^5<IH_P#^&/AV]2\TKX<^$M
M,NT.5N+/0[6*13ZAEC!KO**%H[H-]&( %  &!2T44 %%%% !1110 4444 %%
M%% !7$>(/@;\-_%E\]]K?P^\+:S>ORUQJ&BVT\A^K.A-=O10!B>%_ _ASP/:
MM:^'/#^E^'[9OO0Z791VR'ZJB@5M$X!-+10[L#X@U+_@K5\+=,U"ZLY?"WB]
MI+>5HF9;>UP2I(./](Z<57_X>\?"K_H5/&/_ (#VG_R17W/125[:CE9MVV/A
MC_A[Q\*O^A4\8_\ @/:?_)%'_#WCX5?]"IXQ_P# >T_^2*^YZ*8C&\%^*+;Q
MQX0T3Q%9Q2PVFK64-]#'. )%21 ZAL$C(##.":V:**J5FVTK(F-TDGN%8_B;
MP=H'C73_ +#XAT/3=>LLY^S:G:1W,>?7:X(K8HJ2]CE?"7PI\$^ 9Y)O#'@[
M0/#DT@P\FDZ7!:LP]"8U&:_*7_@J]_R=!:?]B[:?^C9Z_82O@S]MO]@OQ_\
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M'Z^6HKHJ**8!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHKXE_:P_P""FVE_LK_%Z?P)=^ ;SQ#+%907GVZ'
M4T@4B0$[=AC;ICKF@#[:HK\PO^'XF@_]$EU'_P '<?\ \9H_X?B:#_T274?_
M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
M\9H _3VBOS"_X?B:#_T274?_  =Q_P#QFC_A^)H/_1)=1_\ !W'_ /&: /T]
MHK\PO^'XF@_]$EU'_P '<?\ \9H_X?B:#_T274?_  =Q_P#QF@#]/:*_,+_A
M^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\ \9H _3VBOS"_X?B:#_T2
M74?_  =Q_P#QFC_A^)H/_1)=1_\ !W'_ /&: /T]HK\PO^'XF@_]$EU'_P '
M<?\ \9H_X?B:#_T274?_  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:
M/^'XF@_]$EU'_P '<?\ \9H _3VBOS"_X?B:#_T274?_  =Q_P#QFC_A^)H/
M_1)=1_\ !W'_ /&: /T]HK\PO^'XF@_]$EU'_P '<?\ \9H_X?B:#_T274?_
M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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M  =Q_P#QF@#]/:*_,+_A^)H/_1)=1_\ !W'_ /&:/^'XF@_]$EU'_P '<?\
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MT3S3_P#OY)_\51_PP-\!O^B>:?\ ]_)/_BJ^@J* /GW_ (8&^ W_ $3S3_\
MOY)_\51_PP-\!O\ HGFG_P#?R3_XJOH*B@#Y]_X8&^ W_1/-/_[^2?\ Q5'_
M  P-\!O^B>:?_P!_)/\ XJOH*B@#Y]_X8&^ W_1/-/\ ^_DG_P 51_PP-\!O
M^B>:?_W\D_\ BJ^@J* /GW_A@;X#?]$\T_\ [^2?_%4?\,#? ;_HGFG_ /?R
M3_XJOH*B@#Y]_P"&!O@-_P!$\T__ +^2?_%4?\,#? ;_ *)YI_\ W\D_^*KZ
M"HH ^??^&!O@-_T3S3_^_DG_ ,51_P ,#? ;_HGFG_\ ?R3_ .*KZ"HH ^??
M^&!O@-_T3S3_ /OY)_\ %4?\,#? ;_HGFG_]_)/_ (JOH*B@#Y]_X8&^ W_1
M/-/_ ._DG_Q5'_# WP&_Z)YI_P#W\D_^*KZ"HH ^??\ A@;X#?\ 1/-/_P"_
MDG_Q5'_# WP&_P"B>:?_ -_)/_BJ^@J* /GW_A@;X#?]$\T__OY)_P#%4?\
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MOH*B@#Y]_P"&!O@-_P!$\T__ +^2?_%4?\,#? ;_ *)YI_\ W\D_^*KZ"HH
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M]_X8&^ W_1/-/_[^2?\ Q5'_  P-\!O^B>:?_P!_)/\ XJOH*B@#Y]_X8&^
MW_1/-/\ ^_DG_P 51_PP-\!O^B>:?_W\D_\ BJ^@J* /GW_A@;X#?]$\T_\
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M_P"*KZ"HH ^??^&!O@-_T3S3_P#OY)_\51_PP-\!O^B>:?\ ]_)/_BJ^@J*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?J\!_8'_ .3-_A-_V!(__0FKWZ@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OQ(_X*D?\G[67_7AI?\S7[;U^)'_!4C_D_:R_Z\-+_F: /V;\
M"_\ (D^'O^P=;_\ HI:W*P_ O_(D^'O^P=;_ /HI:W* "BBB@ HHHH ****
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M^T%_P4!\&W?PEC75+?3 9M3O-*7Y&0. \C%>H)/7WK0_:_OA^Q;^U=+X_P!
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M2/\ D_:R_P"O#2_YFOVWK\2/^"I'_)^UE_UX:7_,T ?LWX%_Y$GP]_V#K?\
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MX8L-&OI(C"\]LA#%"02N<],@5=\;?"WPG\1XT3Q-H-GK2H-JBZ3=@=<5U5%
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MGP]_V#K?_P!%+6Y6'X%_Y$GP]_V#K?\ ]%+6Y0 4444 %%%% !1110 4444
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MH ^+/^'U'PT_Z$[7?^_L?^%'_#ZCX:?]"=KO_?V/_"OM/_AGSX6_]$V\(_\
M@BM?_C='_#/GPM_Z)MX1_P#!%:__ !N@#XL_X?4?#3_H3M=_[^Q_X4?\/J/A
MI_T)VN_]_8_\*^T_^&?/A;_T3;PC_P""*U_^-T?\,^?"W_HFWA'_ ,$5K_\
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M1_P^H^&G_0G:[_W]C_PK[3_X9\^%O_1-O"/_ ((K7_XW1_PSY\+?^B;>$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<J>OI69XQ^&?A/XT?M)^)T\=^*-8TEK31DNETVSU>YLEC.Q,/B-U4\'.!ZT
M?>&X=<\4!@>AS7Y.:'\1/%/@/]E6]M?#LNM>)]*F\>7>G7:QW<DMT]D+>,A4
ME9MR\D]&%=I^SG=:I\/_ (O:!?:1\.O''AO3M5\J$S^(=::^A:*0@;MC3R8.
M#UQD4 ?IA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?(_[,G_)XW[2W_84L_P#TD@KZXKY'_9D_Y/&_:6_["EG_ .DD%?7%
M !7AO[<7_)I/Q1_[ \G_ *$M>Y5X;^W%_P FD_%'_L#R?^A+0!3_ &!_^3-_
MA-_V!(__ $)J]^KP']@?_DS?X3?]@2/_ -":O?J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *_$C_ (*D?\G[67_7AI?\S7[;U^)'_!4C_D_:
MR_Z\-+_F: /V;\"_\B3X>_[!UO\ ^BEK<K#\"_\ (D^'O^P=;_\ HI:W* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JMJ7_(-N_P#KD_\ Z":LU6U+
M_D&W?_7)_P#T$T ?+?\ P3J_Y)CX\_[';4O_ $&&OJVOE+_@G5_R3'QY_P!C
MMJ7_ *##7U;0 4444 %%%% 'Q9_P4@_X\? ?_81/_H->Q:U^SGX.^-G@?PO+
MX@ANX;F"QB47.GS^1*PVCAFP<@=OK7CO_!2#_CQ\!_\ 81/_ *#7UC\._P#D
M1- _Z\HO_017A87_ )&.(](_D?J^>?\ )&Y1_BJ_^E'+WW[/O@_4;'PE:36U
MQY7AB]AU#3]LN")HP0K.<?-U.:OZA\%?"^J?$R3QY=6LDVO2:7_8[LS_ +HV
M_F;]I7'7=WS7=T5[I^4'A5C^QC\-[#7KW54M]1>2ZE:;[/)=[H(F/_/--OR@
M=O2NJU#]GKPAJGB#2]:N8;J2_P!-TVXTJ!S-QY$VWS >.3\@YKTNB@#R6Z_9
M?\"W7PQT[P(;2ZCT;3UD6UECFVW,0>1I&Q)C^\Q[5'X=_9:\#>&?!NH>&;:*
M_ETZ_:)KAKBYWRN8W#K\V/45Z]10!S.M?#S1_$&FV-C=QR-;V2".(*^"  !S
MQ["OE#]JCX8Z_K_Q$BN;7P'J'B?3UCCBMKC2KP6KQ,$"[I#L;>HY^7CM7VK1
M0!\W?LL_LM1_"KX,:GX5\1SKJJ:QJ,NJ&(Q[6MMZ(NS)SEAM/S>]=;\-_P!E
M'P-\+?$DNMZ1_:DUX[,X6^N_-C3/]U=HQCM7LE% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?(_[,G_)XW[2W_84L_P#T
MD@KZXKY'_9D_Y/&_:6_["EG_ .DD%?7% !7AO[<7_)I/Q1_[ \G_ *$M>Y5X
M;^W%_P FD_%'_L#R?^A+0!3_ &!_^3-_A-_V!(__ $)J]^KP']@?_DS?X3?]
M@2/_ -":O?J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_$C_
M (*D?\G[67_7AI?\S7[;U^)'_!4C_D_:R_Z\-+_F: /V;\"_\B3X>_[!UO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!\C_LR?\ )XW[2W_84L__ $D@KZXKY'_9D_Y/&_:6_P"P
MI9_^DD%?7% !7AO[<7_)I/Q1_P"P/)_Z$M>Y5X;^W%_R:3\4?^P/)_Z$M %/
M]@?_ ),W^$W_ &!(_P#T)J]^KP']@?\ Y,W^$W_8$C_]":O?J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *_$C_@J1_R?M9?]>&E_S-?MO7XD
M?\%2/^3]K+_KPTO^9H _9OP+_P B3X>_[!UO_P"BEK<K#\"_\B3X>_[!UO\
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M (3";_GR?\C0!U%%<O\ \)A-_P ^3_D:/^$PF_Y\G_(T ?*G_!2#_CQ\!_\
M81/_ *#7UC\._P#D1- _Z\HO_017QQ_P4)UI]2L? X:!HMFH$\CK\M?4G@/Q
M7+#X(T%19N<647.#_=KPL+_R,<1Z1_(_5\\_Y(W*/\57_P!*/1:*Y?\ X3";
M_GR?\C1_PF$W_/D_Y&O=/R@ZBBN7_P"$PF_Y\G_(T?\ "83?\^3_ )&@#J**
MY?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,)O\ GR?\C1_PF$W_ #Y/^1H
MZBBN7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7_P"$PF_Y\G_(T?\ "83?\^3_
M )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,)O\ GR?\C1_PF$W_
M #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7_P"$PF_Y\G_(T?\
M"83?\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,)O\ GR?\
MC1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7_P"$PF_Y
M\G_(T?\ "83?\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,
M)O\ GR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7
M_P"$PF_Y\G_(T?\ "83?\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#
MJ**Y?_A,)O\ GR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^
M1H ZBBN7_P"$PF_Y\G_(T?\ "83?\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W
M_/D_Y&@#J**Y?_A,)O\ GR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\
M)A-_SY/^1H ZBBN7_P"$PF_Y\G_(T?\ "83?\^3_ )&@#J**Y?\ X3";_GR?
M\C1_PF$W_/D_Y&@#J**Y?_A,)O\ GR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_G
MR?\ (T?\)A-_SY/^1H ZBBN7_P"$PF_Y\G_(T?\ "83?\^3_ )&@#J**Y?\
MX3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,)O\ GR?\C1_PF$W_ #Y/^1H ZBBN
M7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7_P"$PF_Y\G_(T?\ "83?\^3_ )&@
M#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,)O\ GR?\C1_PF$W_ #Y/
M^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7_P"$PF_Y\G_(T?\ "83?
M\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,)O\ GR?\C1_P
MF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7_P"$PF_Y\G_(
MT?\ "83?\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y?_A,)O\
MGR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^1H ZBBN7_P"$
MPF_Y\G_(T?\ "83?\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_Y&@#J**Y
M?_A,)O\ GR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_SY/^1H Z
MBBN7_P"$PF_Y\G_(T?\ "83?\^3_ )&@#J**Y?\ X3";_GR?\C1_PF$W_/D_
MY&@#J**Y?_A,)O\ GR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\ (T?\)A-_
MSY/^1H ZBBN7_P"$PF_Y\G_(T?\ "83?\^3_ )&@#J**Y?\ X3";_GR?\C1_
MPF$W_/D_Y&@#J**Y?_A,)O\ GR?\C1_PF$W_ #Y/^1H ZBBN7_X3";_GR?\
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MC_Y/%_:6_P"PI9_^DD%?7-?(_P"S)_R>-^TM_P!A2S_])(*^N* "O#?VXO\
MDTGXH_\ 8'D_]"6O<J\-_;B_Y-)^*/\ V!Y/_0EH I_L#_\ )F_PF_[ D?\
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M?6/P[_Y$30/^O*+_ -!%>%A?^1CB/2/Y'ZOGG_)&Y1_BJ_\ I1T5%%%>Z?E
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!\C_LR?\ )XW[2W_84L__ $D@KZXKY'_9D_Y/&_:6
M_P"PI9_^DD%?7% !7AO[<7_)I/Q1_P"P/)_Z$M>Y5X;^W%_R:3\4?^P/)_Z$
MM %/]@?_ ),W^$W_ &!(_P#T)J]^KP']@?\ Y,W^$W_8$C_]":O?J "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /D?]F3_D\;]I;_L*6?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK: "BBB@ HHHH ^+/^"D'_'CX#_[")_]!KZQ^'?_ "(F@?\ 7E%_Z"*^3O\
M@I!_QX^ _P#L(G_T&OK'X=_\B)H'_7E%_P"@BO"PO_(QQ'I'\C]7SS_DC<H_
MQ5?_ $HZ*BBBO=/R@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **X?QE\2+GPGJBV<7A;6M94
MH&^T:?:M)'SVR.]8/_"\+[_H0/%'_@O:@#U:BO$;7]J+3[W6I=(M_#.MSZM$
M<26,=J3*I]UK8_X7A??]"!XH_P#!>U 'JU%<IX&\<3^,ENS-H&J:'Y!  U*W
M,7F9'5<]<5U= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;6?PZT>;5[(@Q%?]G%=A0 4444 %%%% !1110 4444 %5M2_Y!MW_P!<G_\
M035FJVI?\@V[_P"N3_\ H)H ^6_^"=7_ "3'QY_V.VI?^@PU]6U\I?\ !.K_
M ))CX\_[';4O_08:^K: "BBB@ HHHH ^+/\ @I!_QX^ _P#L(G_T&OK'X=_\
MB)H'_7E%_P"@BOD[_@I!_P >/@/_ +")_P#0:^L?AW_R(F@?]>47_H(KPL+_
M ,C'$>D?R/U?//\ DC<H_P 57_THZ*BBBO=/R@**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2
MEI* /D_X>,?^&N/$W/\ RV;_ - KZQKY-^'G_)W'B7_KLW_H%?65 !1110 4
M444 %%</XTM?'DVIQGPU>Z?;V6SYUNHPS;LUS_\ 9_Q>_P"@IHP_[8#_  H
M]8HKP/PKXH^*GBO4M:LH+_28GTN?R)"T(PQR1D?E72?V?\7O^@IHW_?@?X4
M>L45E>&(]7CT6W77)89M2 _>O;KA"?85JT %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\C
M_LR?\GC?M+?]A2S_ /22"OKBOD?]F3_D\;]I;_L*6?\ Z205]<4 %>&_MQ?\
MFD_%'_L#R?\ H2U[E7AO[<7_ ":3\4?^P/)_Z$M %/\ 8'_Y,W^$W_8$C_\
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M6%_Y&.(](_D?J^>?\D;E'^*K_P"E'14445[I^4!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2
M4M)0!\G?#S_D[CQ+_P!=F_\ 0*^LJ^3?AY_R=QXE_P"NS?\ H%?65 !1110
M4444 %%%% 'D?P5_Y&_X@?\ 81_J]>N5Y'\%?^1O^('_ &$?ZO7KE !1110
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M(W*5BP?TKZQ_MRR_Y[C\C7RS_P $Y=/M8/A7XYABMH8X8_&FHJD:1@*H"Q8
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M^1JS]CM_^>$?_? H^QV__/"/_O@4 5O[<LO^>X_(T?VY9?\ /<?D:L_8[?\
MYX1_]\"C[';_ //"/_O@4 5O[<LO^>X_(T?VY9?\]Q^1JS]CM_\ GA'_ -\"
MC[';_P#/"/\ [X% %;^W++_GN/R-']N67_/<?D:L_8[?_GA'_P!\"C[';_\
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MO[<LO^>X_(T?VY9?\]Q^1JS]CM_^>$?_ 'P*/L=O_P \(_\ O@4 5O[<LO\
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M/_O@4 5O[<LO^>X_(T?VY9?\]Q^1JS]CM_\ GA'_ -\"C[';_P#/"/\ [X%
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M\"C[';_\\(_^^!0!6_MRR_Y[C\C1_;EE_P ]Q^1JS]CM_P#GA'_WP*/L=O\
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M (*D?\G[67_7AI?\S7[;U^)'_!4C_D_:R_Z\-+_F: /V;\"_\B3X>_[!UO\
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M *2EI* /D[X>?\G<>)?^NS?^@5]95\F_#S_D[CQ+_P!=F_\ 0*^LJ "BBB@
MHHHH **** /(_@K_ ,C?\0/^PC_5Z]<KR/X*_P#(W_$#_L(_U>O7* "BBB@
MHHHH **** /)O@O_ ,CE\2?^PNO_ *)2O6:\F^"__(Y?$G_L+K_Z)2O6: "B
MBB@ HHHH *Q_&'_(J:Q_UZ2_^@&MBL?QA_R*FL?]>DO_ * : /GW]B'_ )%O
M6_\ KJO_ +-7TU7S+^Q#_P BWK?_ %U7_P!FKZ:H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9J^FJ^9?V(?^1;UO_KJO_LU?35 !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\C_LR?\GC?M+?]A2S_ /22"OKBOD?]F3_D\;]I;_L*6?\
MZ205]<4 %>&_MQ?\FD_%'_L#R?\ H2U[E7AO[<7_ ":3\4?^P/)_Z$M %/\
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M_72V_P#1U?6M?)7[57_)8O!G_72V_P#1U?6M !1110 4444 %%%% 'DVL?\
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M -FKZ:KYE_8A_P"1;UO_ *ZK_P"S5]-4 %%%% !1110 4444 %%%% !1110
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M\._^1$T#_KRB_P#017R=_P %(/\ CQ\!_P#81/\ Z#7UC\._^1$T#_KRB_\
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M** "BBB@ HHHH ^1_P!F3_D\;]I;_L*6?_I)!7UQ7R/^S)_R>-^TM_V%+/\
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MO^28^//^QVU+_P!!AKZMH **** "BBB@#XL_X*0?\>/@/_L(G_T&OK'X=_\
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MK%?/&K?#?XMZ+=6PT+Q=>:A:H@#1W4T8 ..G0<5+KWQ8^)O@=8DU+PO%?*N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/[B_E0 RSF>XLX)778[QJS+Z$C)%3444 %%%% !1110 4444 %%%% !1110
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M:8,VDVKL3':N@.8V0<%#@C%=Y^V)\0KOX<_!>^N[(*9KZ=+#+#.!(K<CWXH
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M1_:EG_S]0_\ ?8H M455_M2S_P"?J'_OL4?VI9_\_4/_ 'V* +5%5?[4L_\
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MXO\ DTGXH_\ 8'D_]"6O<J\-_;B_Y-)^*/\ V!Y/_0EH I_L#_\ )F_PF_[
MD?\ Z$U>_5X#^P/_ ,F;_";_ + D?_H35[]0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7XD?\%2/^3]K+_KPTO\ F:_;>OQ(_P""I'_)^UE_
MUX:7_,T ?LWX%_Y$GP]_V#K?_P!%+6Y6'X%_Y$GP]_V#K?\ ]%+6Y0 4444
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M/_GWC_[YH_LFS_Y]X_\ OFK=% %3^R;/_GWC_P"^:/[)L_\ GWC_ .^:MT4
M5/[)L_\ GWC_ .^:PO'6F6J>"]<(@C!^QR_P_P"R:ZBL'Q[_ ,B3KO\ UYR_
M^@F@#E_@=IMM+\+M$9X$8[9.2/\ IHU=W_9-G_S[Q_\ ?-<;\"_^26Z'_N2?
M^C&KO: *G]DV?_/O'_WS1_9-G_S[Q_\ ?-6Z* *G]DV?_/O'_P!\T?V39_\
M/O'_ -\U;HH J?V39_\ /O'_ -\UXG^UQ8V]O\*I6CB5&\X<J/:O=Z\/_:^_
MY)1+_P!=A_*@#I?@)IMK-\(?##O C,;1,DCVKT#^R;/_ )]X_P#OFN(_9_\
M^2/>%_\ KS3^5>A4 5/[)L_^?>/_ +YH_LFS_P"?>/\ [YJW10!4_LFS_P"?
M>/\ [YH_LFS_ .?>/_OFK=% %3^R;/\ Y]X_^^:/[)L_^?>/_OFK=% %3^R;
M/_GWC_[YH_LFS_Y]X_\ OFK=% %3^R;/_GWC_P"^:/[)L_\ GWC_ .^:MT4
M5/[)L_\ GWC_ .^:/[)L_P#GWC_[YJW10!4_LFS_ .?>/_OFC^R;/_GWC_[Y
MJW10!4_LFS_Y]X_^^:/[)L_^?>/_ +YJW10!4_LFS_Y]X_\ OFC^R;/_ )]X
M_P#OFK=% %3^R;/_ )]X_P#OFC^R;/\ Y]X_^^:MT4 5/[)L_P#GWC_[YH_L
MFS_Y]X_^^:MT4 5/[)L_^?>/_OFC^R;/_GWC_P"^:MT4 5/[)L_^?>/_ +YH
M_LFS_P"?>/\ [YJW10!4_LFS_P"?>/\ [YH_LFS_ .?>/_OFK=% %3^R;/\
MY]X_^^:/[)L_^?>/_OFK=% %3^R;/_GWC_[YH_LFS_Y]X_\ OFK=% %3^R;/
M_GWC_P"^:/[)L_\ GWC_ .^:MT4 5/[)L_\ GWC_ .^:/[)L_P#GWC_[YJW1
M0!4_LFS_ .?>/_OFC^R;/_GWC_[YJW10!4_LFS_Y]X_^^:/[)L_^?>/_ +YJ
MW10!4_LFS_Y]X_\ OFC^R;/_ )]X_P#OFK=% %3^R;/_ )]X_P#OFC^R;/\
MY]X_^^:MT4 5/[)L_P#GWC_[YH_LFS_Y]X_^^:MT4 ?(O[,*B/\ ;$_:6"C
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M'^T)H%DNCV*VC:3<NT(@786!3!(QC(KVFSLX-/MH[>VACMX(QA(XU"JH]@*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?6/P[_Y$30/^O*+_ -!%>%A?^1CB/2/Y'ZOGG_)&Y1_BJ_\ I1T5%%%>Z?E
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MCF?#\5Z@CK(H92"",@B@!U%%% !7A_[7W_)*)?\ KL/Y5[A7A_[7W_)*)?\
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M"SVNE65O.OW9(K=%8?0@4 :E%%% !1110 4444 %%%% !1110 4444 %%%%
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M>:\7DE_:?/;3DW^9^G?6J'^I'U;G7M/K%^6ZO;DWMO;S/8****]H_,0HHHH
M\FUC_DY+P]_V![K^:5ZS7DVL?\G)>'O^P/=?S2O6: /$?VQ_^2%:C_U_V/\
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MY[QIXBU+PWIR7&F:%/KTS-M-O!*L9 ]<M70T4 >5?\+8\7?]$SU+_P #H?\
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M:M13=E\CUZBO#?\ AM+X2?\ 0TP_]\G_  H_X;2^$G_0TP_]\G_"N?Z]A?\
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M^@BO"PG^_P"(_P"W?R/U?B'_ ))/)O\ N+_Z4C5HHHKW3\H"BBB@#R;X+_\
M(Y?$G_L+K_Z)2O6:\F^"_P#R.7Q)_P"PNO\ Z)2O6: /G[XV?\G%?"'Z7?\
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MD?\ )^UE_P!>&E_S- '[-^!?^1)\/?\ 8.M__12UN5A^!?\ D2?#W_8.M_\
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MF'E0BZ\K2ZZ/]$?R;Q%X6YM1S2M'*:*E0O>/O15D];>]*^FUWON?=%%?"_\
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M^%(_A?HB^";2>R\->5_HD%S$T4BK[JW(KOJCM[>*UB6*")(8UZ)&H4#\!4E
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M[)X@TJ*\"C]W("4=#C (*D&OF.^\,_$_]E"ZNYO#4\_BCP*/WYL[A0S1.3R
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MH\(**\3^,UC\5[GQ);MX(OOLVE^3B1=J'Y\_[0]*X'^R?VB?^@O_ .0XO\*
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M/^O27_T T ?/O[$/_(MZW_UU7_V:OIJOF7]B'_D6];_ZZK_[-7TU0!\ S_\
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M0/M</_/5/^^A7DWP-\*I>_"CPW,;F1"]HAVCH.*[K_A"X_\ G[EH W_M</\
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MPA<?_/W+0!O_ &N'_GJG_?0H^UP_\]4_[Z%8'_"%Q_\ /W+1_P (7'_S]RT
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M "#;O_KD_P#Z": /EO\ X)U?\DQ\>?\ 8[:E_P"@PU]6U\I?\$ZO^28^//\
ML=M2_P#08:^K: "BBB@ HHHH ^+/^"D'_'CX#_[")_\ 0:^L?AW_ ,B)H'_7
ME%_Z"*^3O^"D'_'CX#_[")_]!KZQ^'?_ "(F@?\ 7E%_Z"*\+"_\C'$>D?R/
MU?//^2-RC_%5_P#2CHJ***]T_*#PK]L7_DD<W_7=/_0A7<? O_DEF@_]<%_E
M7#_MB_\ )(YO^NZ?^A"M[X>^)(/"/P'L-5N)H(5M[/>IN) B,P7(7)(ZU,I*
M*;9K2ISK3C3@KMNR^9Z7K/\ R![[_KA)_P"@FOAS_@FG_P A3QQ_NQ_^A&O(
MOBS^W)\0O'%\D>EW2>%X(!)"Z::<B<$D9;?GMZ5X[\/_ (N>+/A?=3S>&M:N
M-+-P5-PL.W$H!S@Y!XKX3%9SAYXNE5@FU"_SNC^K\A\-<VP_#V/P&(G"-3$^
MSLKM\O))MW:75/2U_,_:ZBOE[]DG]J[4/CA>:AI>O6^FZ;<6442P-'*1)<L0
M03AFY/'8=Z^AK[QMX=TV5HKO7M,M95ZQS7D:,/P+5]EA\52Q-)5:;T9_-F;9
M!F&2XZ>7XJG^\C;;71JZV-NOSY_:(\;R^-/B9J@EM5MO[-F>R7:V=X0D;OQK
MZ1\;_ME?#KP-J/V.YU'[9)C.ZR(E'YKFOD/QQKVC>,O$6J>(O#WVV73+ZZ>9
MI;J(J%=CDJ#@4X8JA4G[.$TV1B<AS/!X98S$X>4*;VDU9.YSM<%\4M7:WMXK
M 1@K,N\OGIS_ /6KO:XGXF:&+RQ6_!<R0C:$49&,]:X<V526"J*EO^G4^H\/
M*F#I\3826.^&^G^+[/X_(\JHHHK\D/\ 0T^@?V(O$EEH_P >/#]E<:/!J%QJ
M$QAANI3A[5MC'>O'7 ([=:_5VOS0_8!^#X\7?$J/Q3>->6D>@_Z3;,L>(IW/
MR;2Q'/WCT/:OTOK],X>C..$;ELWH?Q!XPXC#5N(8QH.\HP2EOO=O3ILUM^84
M445].?A9\E?M5?\ )8O!G_72V_\ 1U?6M?)7[57_ "6+P9_UTMO_ $=7UK0!
MX'^V]_R;WK__  &G_L1_\F\^'?\ =;^9IG[;W_)O>O\ _ :?^Q'_ ,F\^'?]
MUOYFO!_YFO\ VY^I^K_\T#_W,_\ MA[S1117O'Y0%%%% 'DVL?\ )R7A[_L#
MW7\TKUFO)M8_Y.2\/?\ 8'NOYI7K- 'B/[8__)"M1_Z_['_TJCKUKPO_ ,BU
MI7_7K%_Z *\E_;'_ .2%:C_U_P!C_P"E4=>M>%_^1:TK_KUB_P#0!7GP_P!\
MG_AC^<CZ[$?\D[AO^OU7_P!(I&I1117H'R(4444 %?E#^VMXEL=:^-6L6EMH
ML&G7%E<21S749RUT<_>;CV_6OU>K\T?V^O@ZO@WQX/%-H][=1:U(\MRSQYB@
M8D84,!QG)ZGM7S'$$9RPEX[)ZG[IX/XC#4>('"N[2E!J.^^[OTVOO^9\GT44
MHR>!R:_,S^WS]"?^";_Q-N-8\/ZUX*:RCCM]*"WJ7(;YG,AVD$8_V:^U*^'O
MV._@=J^F?!GQ%XDT>^O])\4:VGV2))8P@A6,[E==PSSN/7CBNL\,S?M'?#/2
MKN74K?3_ !9%"K-NNV)D*CT"$<U^G9?B*F'PM*-6#>FZ5[+I^!_#7&.3X+.,
M_P =7R_$TX-32Y)2Y7*5ES--Z6YK]?0^M:*^1O!G[:VOI>7,7C;P/>:9'%TD
ML+&X8?F0:]%\'_MC_#SQCJGV"*_;3[@-M*W^(<'WW8KTZ>8X6I:T[-]]#X?&
M<&9[@N9RP[E&.K<;27WJY[I16+9>-O#VI3B&SU[3+J9ND<%Y&['\ :^>?VL/
MVM+_ .!.KZ7I>A6>FZM+>6[O.9I27MVS@<*W''/-;XC%4L-3=6H]$>5E.09A
MG6-CE^$I_O)7:3TT6KU9P'_!1+_D.?#[_K\'\Z^RO"G_ "+.E?\ 7M'_ .@B
MOQG\;?%[QA\1;BUF\1:[<ZH]J_F6_G;?W9SVP!7KGPG_ &X_B!\/&N8M0GC\
M46\RQQQ1ZED"W"Y^[LQUR.OI7QN%SK#QQ=2K--*=OE9'])Y[X9YMB.'\%@,/
M.$JF'Y[J[7-S23T;71;WMY'ZHT5C>#_$<'BSPSIFJV\T$XNK>.5_L\@=%9E!
M*Y!/0DC\*V:^\C)22:/Y/J4Y49RIS5FG9A1113,PHHKXF_;&_;"O_"EY>^"?
M!TS6.K0RA+O40")(2K X3/'.,'CH:XL7BZ6"I.K5_P"'/I^'>'<=Q-CHX' K
M7=M[17=^1ZQ\:_\ DXKX0_2[_G%7T#7XQZI^T!\0];UG3=6OO%-Y<ZCIH86E
MPX3=#N(+8^7O@5[-\ OVX/%OA;QC!%XTU277M$O)!'/+<*#);J?XD"@<YQU]
M37S.%SW#^VES)I2>_;1+4_<,]\*<Y_LW#^PJ0G*A"2<5>\O?E+W;KL^O4_3:
MBJNFZA%JNGV]Y#GRIT$B9&#@C(JU7V6^J/YJE%Q;C+='CVL?M5>!-#U2ZT^Z
MEU 7%NYCDV6A(R#C@YK$\0?M9> =2T+4+2*74?-GMY(TS:$#<5('>O1+[X(^
M!M2O);JZ\-VDUQ*Q9Y&W98GOUJ#_ (4)\/\ _H5[/_Q__P"*IDGS3^S3\:/#
M7PLT74[;77NDEN)%9/L\!D&!GW]Z]H_X:_\ A[_SVU+_ , S_C762? GX>0Q
ML\GAFQ1%&69F8 #U)W5\$?M/?&#1M&\2:YX.\,^%M%M+>W=!#K-G([S?=R>=
MQ7J?3M7!C,;2P-/VE4^MX;X8S#BG%O"8!*Z5VV[)*Z5_/?9:G0^%_%NG^./^
M"@FF:QI;2-97%RQ0RIL;BV8=/PK]%Z_#S0_&NN>&_$MOX@TS49;/6;=B\5Y'
MC>A((R,C'0FOL']F?]MSQ3J&OZ+X2\2FROH+B9O-UB^<I* 0,#.0OZ=Z^5RO
M-J$*DX337/)M?.VA^]\=^'V:XG"87%8>49_5J$825VF^2[<E=:KLM_(_0*BF
MQR)-&LD;+)&P#*RG((/0@TZON3^5PK!\>_\ (DZ[_P!><O\ Z":WJP?'O_(D
MZ[_UYR_^@F@# ^!?_)+=#_W)/_1C5WM<%\"_^26Z'_N2?^C&KO: /G_X._\
M)S7QA_ZX:=_*6OH"OG_X.L/^&FOC",\^1IW\I:^@*X,#_"?^*7_I3/KN*/\
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M#_CA\0/!WARST>#P1<3Q6P8"1E()RQ/I[UOV7[2'Q$N+ZVA?P+,B22JC-@\
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M]"6@"G^P/_R9O\)O^P)'_P"A-7OU> _L#_\ )F_PF_[ D?\ Z$U>_4 %%%%
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M_!OX2WGPQUMI?#GBR]\3>#]37S)(]4N%F^RLOW%MRH&%.3G.>@KVZ@ HHHH
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MOWV^9]A>'/#>G^%-)@T[3+:.UM8A@1QJ%&>YP*U***^@/Q\**** /*/VB_\
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M P<?A7TE7R!X!_9D\5_!?P/9W^E:D[>((9&-W;QMNADCP-H '/7/>O9_A/\
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MI/Q1_P"P/)_Z$M %/]@?_DS?X3?]@2/_ -":O?J\!_8'_P"3-_A-_P!@2/\
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M:/4K..ZT%8'N9".&$N[&WG_9-?<'P4_9!\$_!F_BU:SCNM0U?RTS+?.L@AD
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ML[S*K*NZ%.5HKMUZG]F^%_!F HY53S;&TE.M4;:YE\*3<;6?5ZO[CTGX:?M
M>,OA?JMI=:;JUU+:V[,_V"2=O(8GJ2O2OT._9/\ VHQ\>M,N+'4K.2U\0V>Y
MYS&H$#(3\NTYSG'7BORHKV?]D/Q!J6D_'OPA:V5[-:V]YJ$<=Q'&V%E7/W6]
M17#E>85L/7A#F;BW:WJ?5<><'9;G&5XC%*E&->$7)32L_=NVG;>^OSL?KO11
M17ZF?P0%?)W[6W_)5O __7N?_1M?6-?)W[6W_)5O _\ U[G_ -&T ?5T/^J3
M_=%/ID/^J3_=%/H **** "BBB@ KR37_ /DXKPO_ ->-Q_Z+->MUY)K_ /R<
M5X7_ .O&X_\ 19H ];KQS]KC6K_P]\ _%%_IEY-87L4*F.XMW*.OSJ.".E>Q
MU\__ +;WB#3=-^ ?B&PNKV&"]O(E6W@D<!Y2'7.T=^E<..ERX6H[VT?Y'U/"
MU'V^>X*GR\R=2%U:^G,K_*VY<_8Q\0:EXF^!FF7VK7T^H7CRN&GN'+N>%[FN
MB^+7P1M?'D9U'2Y$TOQ%"-UO>+\OSC[NYASBO/?V"?$&FWWP1M-,M[Z&;4+2
M0M/;(X+QA@ "PZC.#^5?2E3E\N;"4W>^B-N+Z/U?/\;3Y>5*I*RM;2^GR['B
MGPL^-4_]H?\ "*>,XGTS7[==JS2#]U.%XRK=23UZ5[2DBR*&4AE/((K@?BG\
M(],^(M@)<-9ZQ;MYEO>VY"N& X!..17F?A7XJ:[\)]63P[XU3S+$M^XU%E*\
M'CECP:] ^0/HRO)/%O\ R<1X/_[!5Q_Z-2O4H]2M9=/%^EQ&]F8_.$ZME"F,
M[L^F*\-\4?$#PW-\=O"U_'K=D]G#IMQ'+.LRE$8R*0"<\'B@#WNBJNFZE:ZQ
M8PWME<1W5I,-T<T3!E8>H(JU0 4444 %%%% !7R9X(_Y/'UW_KXN/_15?6$T
MR6\322,$C499FZ >M?'O@OQ)I4?[6FKZDVH6XL)[J98KGS!L<LF!@]\GB@#[
M%HHHH **** "BBB@ HHHH ^1_P!F3_D\;]I;_L*6?_I)!7UQ7R/^S)_R>-^T
MM_V%+/\ ])(*^N* "O#?VXO^32?BC_V!Y/\ T):]RKPW]N+_ )-)^*/_ &!Y
M/_0EH I_L#_\F;_";_L"1_\ H35[]7@/[ __ "9O\)O^P)'_ .A-7OU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?B1_P5(_Y/VLO^O#2_YF
MOVWK\2/^"I'_ "?M9?\ 7AI?\S0!^S?@7_D2?#W_ &#K?_T4M;E8?@7_ )$G
MP]_V#K?_ -%+6Y0 4444 ?+VAZ9\(OCI>>,];CT9=$C\-:BUCJ\LMM&B3R!%
M<NVW.X88#)]*Y32?VWO ?P]DET[PQ\*O$Y\&VMVMHOB;2;&!-->/<!]H!WAO
M+YSG;G /%>0Z'XC\=_"?3/CIX/;X3>*-:;Q5J\US9:A9VTGD[&@1 <A#GE?6
MOHKX7_#UO"G_  3[LM!UW1TM-3L_!,ZW=K<0[729;9R=P(SN!H ^BO"WBK2?
M&NAVNL:)?1:CIERNZ&YA)*N/:M:OGO\ 8'Q_PROX)QR/LU?0E !1110 4444
M %%%% !1110 56U+_D&W?_7)_P#T$U9JMJ7_ "#;O_KD_P#Z": /EO\ X)U?
M\DQ\>?\ 8[:E_P"@PU]6U\I?\$ZO^28^//\ L=M2_P#08:^K: "BBB@ HHHH
M ^+/^"D'_'CX#_[")_\ 0:^L?AW_ ,B)H'_7E%_Z"*^3O^"D'_'CX#_[")_]
M!KZQ^'?_ "(F@?\ 7E%_Z"*\+"_\C'$>D?R/U?//^2-RC_%5_P#2CHJ***]T
M_*#PK]L7_DD<W_7=/_0A7<? O_DEF@_]<%_E7#_MB_\ )(YO^NZ?^A"NX^!?
M_)+-!_ZX+_*@#L=9_P"0/??]<)/_ $$U\.?\$T_^0IXX_P!V/_T(U]RZK&TN
MEWB(-SM"X '<E37Q]_P3_P#AQXG\!ZAXO?Q#HEYI"W C$1NHBF_#'.,BO#Q<
M9/'8:26BYOR1^I\/5Z5/A7.J4YI2E[&ROJ[2E>RZV/LNBBBO</RP**IZPM\V
MFW TUXH[[;^Z:9=R!O<9KS+['\8^^I^'?_ )O_CE #OVB_\ D5]$_P"PQ!_)
MZ]2MO^/>+_<'\J\/\7> ?BGXVL;:TU'5-#$5O<)=)Y-HP.]<XSESQR:VUL?C
M$JA1J?AW &/^/)O_ (Y0!ZI>-"EK,UQM^SA&,F_IMQSGVQ63X-NM!O-#CE\-
M&U;2C(X4V:A8]X8[\ #KNSFN%%M\2([+4V\0WVC3:5]AN/,2TMF20GRSC!+G
M^597['O_ "1&Q_Z_[W_TH>N652U>-.VZ;^ZW^9[M+!J>55L9S.\9PC;H^93=
M_5<NGJSVNBBBNH\(**** "BJVHBY;3[H63(EX8F\AI!E1)@[21W&<5X6NF_M
M&;1G6_!^?^P:_P#\=KGJUG3M[C?H>Q@,NCCE)RQ%.G;^=M7]+18O[;W_ ";W
MK_\ P&G_ +$?_)O/AW_=;^9KD_B5\)_CI\5O"5WX<UO7?"ZZ==8\PVM@R2<>
MA,AQ2_#?X4_'7X5^$;/PYHFN>%VTZU!$9NK!GDY]2)!FO$YJGU[ZQ[*7+RVV
M6]_4_3O8X+_5;^Q_KU'VOMN?XI6Y>6V_)O<^I**\#_LW]HO_ *#?@_\ \%K_
M /QVO<]-%TNG6HO61[T1+Y[1C"F3 W$#L,YKVZ59U+W@UZGYCC\NC@5%QQ%.
MI?\ D;=O6\46:***Z#QPHHHH \1_;'_Y(5J/_7_8_P#I5'7K7A?_ )%K2O\
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MFF2B:PN0,1R2J>1U[&O3_P!D_P#9/\!:[X9T_P 8ZC!>WNI17,L?V>:93;,
M !N3;D]?6OL30] TWPSIZ6.E64.GV:DLL%N@5 2<DX%<F59++FAB:S5MTOR/
M?X^\3:+H8C)<MA)3=XRF]+;J22ZW[]FR+0_%6D>)5E;2]0@O1$Y1_*;.UAU%
M:M?)GCS]G'Q5\*]0NO%OPMUN^DFCD:ZFTG4)#<1S9.2JH,=S76_"']K;2_%E
M];^'?%D*^&_%*A8Y8;EO+$DA./E4\\FOJ*>-Y9^RQ*Y)=.S]&?A6*X8]MAGC
M\EJ>WI+XE:TX?XH]O-71]#5\G?M;?\E6\#_]>Y_]&U]8U\G_ +6W_)5O _\
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M4 %%%% 'Q9_P4@_X\? ?_81/_H-?6/P[_P"1$T#_ *\HO_017R=_P4@_X\?
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M1Y(HYT,;/"VUP".H/8UXK)^R#X8DD9SXH\: L2V!KCXY.?[M<]656-O9QO\
M.WZ'L8&A@*RD\97=-K:T.:__ ),K&I^U)HM[XN^#U_INCP_;[Y[RS=8(W7)5
M;A&8\GL 3^%>E>'I$M=!TV&62-)8[>-64N."% (KR#_AC_PO_P!#3XT_\'C_
M /Q-)_PQ_P"%_P#H:?&G_@\?_P")KB7UA575]FKM)?%VOY>9]/-Y-4P-/ /&
M2Y82E*_LG>\E%/[?]T]Q6ZA=@JRQLQZ ,*EKQ_PI^S%X>\(>)-/UJU\0^*[J
MXLI/-2&]U=I87.",.FWD<]*]@KOI2J27[R-GZW/DL=1PE&:6#JNI&VK<>6S[
M6N_O"BBBMCS0HHHH \._;-_Y(+K/^^G]:]A\/_\ (!TW_KVC_P#0!7CO[9S!
M?@+K))P-Z?UKV+P__P @'3?^O:/_ - %<$/][G_AC^;/KL5_R3V$_P"OM7_T
MFD:%%%%=Y\B%%%% !1110!Y%\<_VD-'^!-YHEOJFEWVHMJLOE1FTV83G&3N(
M_2O5--OEU+3[:[12B3QK(%;J 1FOBG_@HE_R'/A__P!?@_G7V5X4_P"19TK_
M *]H_P#T$5Y6'Q%2IBZU*3TC:WS1]]G&483!Y!EN848M5*WM.9WWY79:=#5H
MHHKU3X$**** "BBB@#B?%GQ4L/"/CKPQX7N+2XFNM?\ -\F:/&R/85!W9.?X
MAT]*[:OG[XV?\G%?"'Z7?\XJ^@:Y*-24ZE2+V3T^Y,^AS+!T<-A,%6IKWJD'
M*7JJDX_+1(****ZSYX**** "BBB@#Q5_VI-#3X\Q_"S^R=0.JO(8OMOR>0"(
MR_KGH,=*]JKX!G_Y216O_7TW_I,U??U>3E^(J8CVOM'\,FEZ(_0.+LGPF4+
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ME.0:?7&_"'2=!T/X?Z59>&=0N=4T6*/%O=7ER;B5QZESR:[*@ HHHH ****
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M*BL_VE_A)I\ AM?$UG;0@DB.&TF1<GDG CKM_P#A6?A/_H6]+_\  5/\*/\
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MDUH^7\C]/S[$T:G"^4T833E'VMTGJKR5KKI<T:***]H_, HHHH Q/%OC/1O
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M3B/!_P#V"KC_ -&I0-.SNS N/C]X_M9&63X.ZO&-Q"M)J-JN>>O,E>;>*/\
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MA2S_ /22"OKBOD?]F3_D\;]I;_L*6?\ Z205]<4 %>&_MQ?\FD_%'_L#R?\
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MC[#J7_/ZO_?-:U% &3]AU+_G]7_OFC[#J7_/ZO\ WS6M10!D_8=2_P"?U?\
MOFC[#J7_ #^K_P!\UK44 9/V'4O^?U?^^:/L.I?\_J_]\UK44 9/V'4O^?U?
M^^:/L.I?\_J_]\UK44 9/V'4O^?U?^^:/L.I?\_J_P#?-:U% &3]AU+_ )_5
M_P"^:/L.I?\ /ZO_ 'S6M10!D_8=2_Y_5_[YH^PZE_S^K_WS6M10!D_8=2_Y
M_5_[YH^PZE_S^K_WS6M10!D_8=2_Y_5_[YH^PZE_S^K_ -\UK44 9/V'4O\
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M!D_8=2_Y_5_[YH^PZE_S^K_WS6M10!D_8=2_Y_5_[YH^PZE_S^K_ -\UK44
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MK_WS6M10!YC\1/!OQ#UV\LW\,>,+;0X(XRLT<L!?S&SP1QZ5R/\ PK'XU_\
M13+'_P !&_PKWRBN.>%A4DY-O[VCZ+"Y[B,)1C0A3IM+O3A)_-M-L^8M%_9U
M^*F@>*=;\0V?Q%LDU/6%B6[D-JQWB/.WMVW&NA_X5A\:_P#HIEC_ . C?X5[
MY164<!2BK1<E_P!O/_,]"KQ7CZ\N>K"DW9+6E3V2LE\/1))'$^!O#OB_1]$^
MS^(?$,.KZAOS]HCB*#;CIBN@^PZE_P _J_\ ?-:U%=\8J$5%=#Y2O6EB*LJL
MDDY:Z))?)+1&3]AU+_G]7_OFE%EJ7_/ZO_?-:M%48'B_B;X>_%K4->O+C2?'
M]GI^G22$PVSVQ8QKV!.*R)OA7\:9X7B?XEV.UU*G_1&Z'\*]_HKAE@X2;;<O
M_ G_ )GU-+B+%481A&G2TTUI4V]//EU/D;X:_LA?$#X3WFI77AWX@6=M-J#%
MK@M;,=Q)SZ5WO_"L/C7_ -%,L?\ P$;_  KWRBLH9?1IQY8-I?XG_F=V*XPS
M/'577Q4:<YOJZ5-O3_MTXCP+X<\7Z-H*VWB+Q##K&HB1F-S'$4!4G@8]JZ'[
M#J7_ #^K_P!\UK45Z,8J$5%=#X^O6EB*LJTDDY.^B27R2T7R,G[#J7_/ZO\
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MK:<^WV2#%?7=?(_[,G_)XW[2W_84L_\ TD@KZXH *\-_;B_Y-)^*/_8'D_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]A2S_\ 22"OKB@ KPW]N+_DTGXH_P#8'D_]"6O<J\-_;B_Y-)^*/_8'D_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO\)O^P)'_P"A-7OU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^1_V9/\ D\;]I;_L*6?_ *205]<5\C_LR?\ )XW[2W_84L__
M $D@KZXH *\-_;B_Y-)^*/\ V!Y/_0EKW*O#?VXO^32?BC_V!Y/_ $): *?[
M _\ R9O\)O\ L"1_^A-7OU> _L#_ /)F_P )O^P)'_Z$U>_4 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#Y'_9D_P"3QOVEO^PI9_\ I)!7UQ7R/^S)_P GC?M+
M?]A2S_\ 22"OKB@ KPW]N+_DTGXH_P#8'D_]"6O<J\-_;B_Y-)^*/_8'D_\
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MI/Q1_P"P/)_Z$M %/]@?_DS?X3?]@2/_ -":O?J\!_8'_P"3-_A-_P!@2/\
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M )$30/\ KRB_]!%>%A?^1CB/2/Y'ZOGG_)&Y1_BJ_P#I1T5%%%>Z?E 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P">EM_WP?\ &C;K'_/2V_[X/^- &K165MUC_GI;?]\'_&C;K'_/2V_[X/\
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M_P">EM_WP?\ &C;K'_/2V_[X/^- &K165MUC_GI;?]\'_&C;K'_/2V_[X/\
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M_P">EM_WP?\ &C;K'_/2V_[X/^- &K165MUC_GI;?]\'_&C;K'_/2V_[X/\
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M_P">EM_WP?\ &C;K'_/2V_[X/^- &K165MUC_GI;?]\'_&C;K'_/2V_[X/\
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M_P">EM_WP?\ &C;K'_/2V_[X/^- &K165MUC_GI;?]\'_&C;K'_/2V_[X/\
MC0!JT5E;=8_YZ6W_ 'P?\:-NL?\ /2V_[X/^- &K165MUC_GI;?]\'_&C;K'
M_/2V_P"^#_C0!JT5E;=8_P">EM_WP?\ &C;K'_/2V_[X/^- 'RY^S)_R>-^T
MM_V%+/\ ])(*^N*^1/V7]_\ PV%^TMYA!?\ M6TY48&/LD&*^NZ "O#?VXO^
M32?BC_V!Y/\ T):]RKPW]N+_ )-)^*/_ &!Y/_0EH I_L#_\F;_";_L"1_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4 %%%% 'Q9_P4@_X\? ?_81/_H-?6/P[_P"1$T#_ *\HO_017R=_P4@_X\?
M?_81/_H-?6/P[_Y$30/^O*+_ -!%>%A?^1CB/2/Y'ZOGG_)&Y1_BJ_\ I1T5
M%%%>Z?E 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^C@]2_\!8__ (BOK&B@#Y._X9K^/7_1P>I?^ L?_P 11_PS7\>O^C@]2_\
M 6/_ .(KZQHH ^3O^&:_CU_T<'J7_@+'_P#$4?\ #-?QZ_Z.#U+_ ,!8_P#X
MBOK&B@#X?^(/["/Q1^*4=C'XF^-]]J:64GFP"2W4;&]1A*ZBQ_9>^.FFV4%I
M;_M :BD$"".-?LR<*!@#[E?7%%0H1C)S2U9U3Q5>I1AAYS;A&]E?17WLNE^I
M\G?\,U_'K_HX/4O_  %C_P#B*/\ AFOX]?\ 1P>I?^ L?_Q%?6-%6<I\G?\
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M]G'P3\??CO\ ![P_XV?X[:AISZI")3;+;1D)D XSL]Z]+_X9K^/7_1P>I?\
M@+'_ /$5T?\ P3UL[C3_ -DOP)!<PR6\Z6BAHY%VL/E'45]'4 ?)W_#-?QZ_
MZ.#U+_P%C_\ B*/^&:_CU_T<'J7_ ("Q_P#Q%?6-% 'R=_PS7\>O^C@]2_\
M 6/_ .(H_P"&:_CU_P!'!ZE_X"Q__$5]8T4 ?)W_  S7\>O^C@]2_P# 6/\
M^(KRS]I#PK\?/@+\/[7Q&GQTU#47GU6TTWR6MHP )GV[ON=J_02OF#_@H?8W
M.H? G2XK6"2XD'B?2V*1J6.!-R: ,33?V=OCUJ&FVEU_PT%J2^?"DN/LL?&Y
M0?[GO5G_ (9K^/7_ $<'J7_@+'_\17T_X:4KX<TH$8(M(@0?]P5I4 ?)W_#-
M?QZ_Z.#U+_P%C_\ B*/^&:_CU_T<'J7_ ("Q_P#Q%?6-% 'R=_PS7\>O^C@]
M2_\  6/_ .(H_P"&:_CU_P!'!ZE_X"Q__$5]8T4 ?)W_  S7\>O^C@]2_P#
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M!ZE_X"Q__$4?\,U_'K_HX/4O_ 6/_P"(KZQHH ^3O^&:_CU_T<'J7_@+'_\
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MGQ!\._'WP3\=?AW\/5^.=_.GBNWO9VNVMXP8?(\OC&SOO_2O6_\ AFOX]?\
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M32?BC_V!Y/\ T):]RKPW]N+_ )-)^*/_ &!Y/_0EH I_L#_\F;_";_L"1_\
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M#=@>PKS+X-_';QGX"^)^G?"GXJ6<!U#5))8M$U>T9G:\9%:1A*#@+\@/W<T
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MN!-96,^8AJL:'='))$?F!W#OZ5]7?%CX3Z!\9?!]SX=\0V_GVDN61P?FB?!
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M'X%_Y$GP]_V#K?\ ]%+6Y0 4444 %%%% !1110 4444 %%%% !1110 4444
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M;2!1Y2R/T0LQP,]:^BJYWQ]\/] ^)WAJXT#Q+IT6J:5.RL]O+G&Y3E3QW!H
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MY,MC&%,<Y[%L\\?UH ^$/A!\'?AY^UQX\MKWP5X8T;PO\+]-=99M/L5$,M\
M!\MQ#G.!)R,^@-?I#X:\-:=X1T:WTO2K2*RLH%PD,*[5'X5S7PY^"O@_X3S7
M;^%M'ATD72JLJPYP<8_PKRK]KC]KJR_9[\/QV6C6'_"2>,K[<EMIL1R(< ?/
M+@[E4YXQUQ0![[#XBTJ?6I]'CU*UDU:!%DEL5F4S1J1D,R9R ?7%:-?G_P"
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M.G-93 >4KJX<R(>ISTK[UH **** .;^(6I:QHG@S5M0T"RCO]5M;=YH;9_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG?%?=&E:5::'IMMI]A EK9VR".*&,85%'0"@"W1110 4444 ?,G[>GPS\?\
MQ+^#]]9^!=2NK65(B;BUM9RAN%!!*X'WN,\5SOPQ\&_!O]I?X#Q^"M(T2QT#
M4=( F^P?9EM[[3KG 5KE4^\FX@KO[Y-?7AYX/(KP;7_V6[*'XQ:)X^\+:E<>
M'KI)6&J6UMM$=[#M.$;C/#'- %;]G_X5>//#W@S5_ WQ-:S\4^&#)-;VKWDP
MN9)K1AA8Y >VWC!]:]N\-^%M(\':3!IFAZ;;:5I\"A(K:UC"1HH&  !T %:M
M% !1110 4444 >3_ !V^"_\ PN*3PY#?:M=6WAS3YY9]3TI)2+?4$VC:LR='
M"L-PST-?&OB3XU>"+[]J66PMX+OQ!X0\!06DNBZ3X;MS<M%=HI,BK$G0[E _
M"OT@DC66-D<;E88(]0:\2^(GP]\/?!+P7XL\<^ _ NGW/B^"WDO(HE1LW,P!
M(!P<\GTH ^4OVI/VO/BK9^'1::+ ?#KZ](+33=.MF,6O)(PW*WD??5< Y/K7
MT;^P=X3^*/A7X*R'XLZ[J&NZ_J%^][;OJERT\\%LR(%C8MRI!#';VW5Q7[+/
M[)FJ+XC'Q:^+-W_;GCC4(O-M[(C-OIZN0XV9&[<H^7FOL.@!:*** "BBB@#X
M-_;?^'_B"/XO^'?'/B.TOO%GPETZ2*34O#L2&ZC,:@>9^X[Y//O7IGQ7^"'A
M?]HCPEI'CSX4:A9:9XPTW9+I^K:1*L32 *!]FF=>B@'[IZ$"OIS4M-M=8L9;
M.]@2XMIEVO&XR&![5XQ\$_V;4^!_Q U^_P!&UFZ?PQJ%OMBT:3;Y4$QD#%UP
M/3(_&@#<\&_#>\\:> =%M/B]HFDZ]KNFR[XVD5;A58 8D!(X8XZ^U>HP0QVT
M*11(L<2#:JJ,  =JDHH **** "BBB@ HHHH **** "BBB@ HHHH *\-_;B_Y
M-)^*/_8'D_\ 0EKW*O#?VXO^32?BC_V!Y/\ T): *?[ _P#R9O\ ";_L"1_^
MA-7OU> _L#_\F;_";_L"1_\ H35[]0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7XD?\ !4C_ )/VLO\ KPTO^9K]MZ_$C_@J1_R?M9?]>&E_
MS- '[-^!?^1)\/?]@ZW_ /12UN5A^!?^1)\/?]@ZW_\ 12UN4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5X;^W%_R:3\4?\ L#R?^A+7N5>&_MQ?\FD_
M%'_L#R?^A+0!3_8'_P"3-_A-_P!@2/\ ]":O?J\!_8'_ .3-_A-_V!(__0FK
MWZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ(_X*D?\G[67
M_7AI?\S7[;U^)'_!4C_D_:R_Z\-+_F: /V;\"_\ (D^'O^P=;_\ HI:W*P_
MO_(D^'O^P=;_ /HI:W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F
M_B/X%TSXF^!=<\*ZS&TVEZM:M;7"*<$J:_/?0_C]J'P[^#?B;X0ZS<:E;?$.
M_OWLM!TYY&%V+? V.O.0ORL!SZU^EE>$>.OV-/ 'Q"^-6D?%#4QJ">)-+4+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** $Z\'D51L= TO3;V>\L]-M+6[N
M%FN((%220#H&8#)QD]:OT4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7AO[<7_ ":3\4?^P/)_Z$M>Y5X;^W%_R:3\4?\ L#R?^A+0!3_8
M'_Y,W^$W_8$C_P#0FKWZO ?V!_\ DS?X3?\ 8$C_ /0FKWZ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OQ(_X*D?\G[67_7AI?\ ,U^V]?B1
M_P %2/\ D_:R_P"O#2_YF@#]F_ O_(D^'O\ L'6__HI:W*P_ O\ R)/A[_L'
M6_\ Z*6MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%K:>(B!,;V^=!G&1P.:^/[S1[G7_  Y\ X]?B,L*?V6ULK?Q1"1=N[UKV?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5Q_A?X2^%O!NO>*=9TG31;:AXGG%SJLOF,WVB0($!P3@?* .,5V%%
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MR2:S>2J"1CE6E(/XBO5/AW\+?#7PJL=3L_#.G#3K?4K^;4[E [/ON)6W2/\
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M)"DYXZ&@#U:BN"^+_P ;?"OP-\,Q:]XLO)+/3I)!$C11[V+'H,5Y9I'_  4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB49+E5)Q^.*TJ0@,"",@T ?+B_MA:TR@_P#"%77_ 'YDI?\ AL#6O^A*NO\
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M'A'B;_HF]W_WYEI/^'A'B;_HF]U_WYEK[:_L^U_Y]XO^^!1_9]K_ ,^\7_?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSX#?WO$/_@ G_P <H_X>^? ;^]XA_P# !/\ XY0!]NT5\1?\/?/@-_>\0_\
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MOGP&_O>(?_ !/_CE 'V[17Q%_P /?/@-_>\0_P#@ G_QRC_A[Y\!O[WB'_P
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M>(?_   3_P".4 ?;M%?$7_#WSX#?WO$/_@ G_P <H_X>^? ;^]XA_P# !/\
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MP&_O>(?_   3_P".4 ?;M%?$7_#WSX#?WO$/_@ G_P <H_X>^? ;^]XA_P#
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MSX#?WO$/_@ G_P <H_X>^? ;^]XA_P# !/\ XY0!]NT5\1?\/?/@-_>\0_\
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MR_\ !_=__'*/[<I_R,/^(5XW_H)C]S/W.HK\,?\ AHKXK?\ 13O&7_@_N_\
MXY1_PT5\5O\ HIWC+_P?W?\ \<H_MRG_ ",/^(5XW_H)C]S/W.HK\,?^&BOB
MM_T4[QE_X/[O_P".4?\ #17Q6_Z*=XR_\']W_P#'*/[<I_R,/^(5XW_H)C]S
M/W.HK\,?^&BOBM_T4[QE_P"#^[_^.4?\-%?%;_HIWC+_ ,']W_\ '*/[<I_R
M,/\ B%>-_P"@F/W,_<ZBOPQ_X:*^*W_13O&7_@_N_P#XY1_PT5\5O^BG>,O_
M  ?W?_QRC^W*?\C#_B%>-_Z"8_<S]SJ*_#'_ (:*^*W_ $4[QE_X/[O_ ..4
M?\-%?%;_ **=XR_\']W_ /'*/[<I_P C#_B%>-_Z"8_<S]SJ*_#'_AHKXK?]
M%.\9?^#^[_\ CE'_  T5\5O^BG>,O_!_=_\ QRC^W*?\C#_B%>-_Z"8_<S]S
MJ*_#'_AHKXK?]%.\9?\ @_N__CE'_#17Q6_Z*=XR_P#!_=__ !RC^W*?\C#_
M (A7C?\ H)C]S/W.HK\,?^&BOBM_T4[QE_X/[O\ ^.4?\-%?%;_HIWC+_P '
M]W_\<H_MRG_(P_XA7C?^@F/W,_<ZBOPQ_P"&BOBM_P!%.\9?^#^[_P#CE'_#
M17Q6_P"BG>,O_!_=_P#QRC^W*?\ (P_XA7C?^@F/W,_<ZBOPQ_X:*^*W_13O
M&7_@_N__ (Y1_P -%?%;_HIWC+_P?W?_ ,<H_MRG_(P_XA7C?^@F/W,_<ZBO
MPQ_X:*^*W_13O&7_ (/[O_XY1_PT5\5O^BG>,O\ P?W?_P <H_MRG_(P_P"(
M5XW_ *"8_<S]SJ*_#'_AHKXK?]%.\9?^#^[_ /CE'_#17Q6_Z*=XR_\ !_=_
M_'*/[<I_R,/^(5XW_H)C]S/W.HK\,?\ AHKXK?\ 13O&7_@_N_\ XY1_PT5\
M5O\ HIWC+_P?W?\ \<H_MRG_ ",/^(5XW_H)C]S/W.HK\,?^&BOBM_T4[QE_
MX/[O_P".4?\ #17Q6_Z*=XR_\']W_P#'*/[<I_R,/^(5XW_H)C]S/W.HK\,?
M^&BOBM_T4[QE_P"#^[_^.4?\-%?%;_HIWC+_ ,']W_\ '*/[<I_R,/\ B%>-
M_P"@F/W,_<ZBOPQ_X:*^*W_13O&7_@_N_P#XY1_PT5\5O^BG>,O_  ?W?_QR
MC^W*?\C#_B%>-_Z"8_<S]SJ*_#'_ (:*^*W_ $4[QE_X/[O_ ..4?\-%?%;_
M **=XR_\']W_ /'*/[<I_P C#_B%>-_Z"8_<S]SJ*_#'_AHKXK?]%.\9?^#^
M[_\ CE'_  T5\5O^BG>,O_!_=_\ QRC^W*?\C#_B%>-_Z"8_<S]SJ*_#'_AH
MKXK?]%.\9?\ @_N__CE'_#17Q6_Z*=XR_P#!_=__ !RC^W*?\C#_ (A7C?\
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M_H)C]S/W.HK\,?\ AHKXK?\ 13O&7_@_N_\ XY1_PT5\5O\ HIWC+_P?W?\
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M#^[_ /CE'_#17Q6_Z*=XR_\ !_=__'*/[<I_R,/^(5XW_H)C]S/W.HK\,?\
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M_P#!_=__ !RC^W*?\C#_ (A7C?\ H)C]S/W.HK\,?^&BOBM_T4[QE_X/[O\
M^.4?\-%?%;_HIWC+_P ']W_\<H_MRG_(P_XA7C?^@F/W,_<ZBOPQ_P"&BOBM
M_P!%.\9?^#^[_P#CE'_#17Q6_P"BG>,O_!_=_P#QRC^W*?\ (P_XA7C?^@F/
MW,_<ZBOPQ_X:*^*W_13O&7_@_N__ (Y1_P -%?%;_HIWC+_P?W?_ ,<H_MRG
M_(P_XA7C?^@F/W,_<ZBOPQ_X:*^*W_13O&7_ (/[O_XY1_PT5\5O^BG>,O\
MP?W?_P <H_MRG_(P_P"(5XW_ *"8_<S]SJ*_#'_AHKXK?]%.\9?^#^[_ /CE
M'_#17Q6_Z*=XR_\ !_=__'*/[<I_R,/^(5XW_H)C]S/W.HK\,?\ AHKXK?\
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M&H4ZM6HIJ;:TNK->I^+G[.O_ "<%\,?^QHTO_P!*XJ_<ZOPQ_9U_Y."^&/\
MV-&E_P#I7%7[G5YV1_PY^I]IXJ?[[AO\+_,****^E/P\**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(;I8A+);0L_EQB)""#)(X8#(. IXR01,I6LDKMZ)%1CS7>R6Y]FT5^9NF?\
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M[_[</_2"WK]2OV=?^3??AC_V*^E_^DD5?-9=_OM?U?YG[AQE_P DSE/^&/\
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M,/\ PHGAG[8_[1I_9F^#MQXDM+6*]UR\N%T_2[>?/E>>RLV]P.2JJK-@$9(
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MS1;;QWX,MO#7BG=Y%CJ&KV\%];1,S#")=%0\>XXZHJ^K5Z=_P4A_Y,_\:?\
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MM?B#XIF\>^#]3?>6N[I[U+F)6 D$<LH$L4J!@=N=N2/O"OU _P"$CTY?#?\
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M0NQ9F+%MC8R3VKX@_8Y_: ^+OP7^&=[8^ ?@MJ'C;2[_ %&2ZEUFWTR\G5Y
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M;^Q+\4;GXN?LS^#=;U"]EU#5X8&L+ZXN)#)+)-"YC+.QY+,H5B3R=V:^(?\
M@I-^T?XVT7]H!?#?@OQAKWAZQT'2X1>QZ+J4]JC3R$N6D$; '"O$,GUQWKT?
M_@D_XNGT*S^)GPVU9OL]YHM^+\0R'&P\PSCZ*T4?_?5>6?"_P%)^U)+^UC\0
M&A^TM=6<T&DLPSEA*;B-5]PEK O_  *M<1)2J*K%^ZHN>GIM][:7H9X=.,'3
MEOS*'X_HE<_2OX,^.$^)?PE\'^*4?>=6TJWNI/:1HQO'U#;A^%?&'PX^)7C#
MXY?\%'O$EEIOBS7+?P!X3\[S=)M=1FCLIC @@P\2L$;=.Q;D'(6M3]A?X\0>
M&_V$/$FJWDP,W@7[>@5NI!7SX5_%I=H^E)_P2?\ A_/;_#KQ?\0]2#2:CXFU
M,P)/)RSQ0Y+-G_:ED?/^X*Z))?6I26T8\W_@7P_<<\7;#1CUD^7_ ,!^+[S1
M_;2_; \;>$OB;H_P<^$%JDOCC41$+B^:))7A>7F.*-7^0-M^=G<$*I'N1QDW
M[&O[6FL6C:E=_M 3VNKR?/\ 88->U". 'KM)C4*._P!U".*^E/V@OCI\$_V>
M]<LO$'C6UTR;QF$,MBEGIL5QJQ4J4+(^ 8P1E=S.H/(R>E>!:A_P5HT?5[M;
M/P/\+/$7B:]<X2"XG2!S_P !B68GZ5R0MRVWE=Z_HO0ZYWNND;+_ (<P?V6O
MVI/B]\/_ -H^+X'_ !EN&U>:XD-I!>7 1[B"7R_,B83+CS8Y%[MELLO(P17T
MY^VC^TH_[,?PA?7;"UBO?$.HW T_3(;@$Q+*59C(X!!*JJDX!Y)4<9S7YXV'
MQ&\7_%3_ (*%?#SQ%XV\)R^"]9N-4T]5TB>"6*2.%3B-F$H#$D<YP >PK]!O
MVW/V:KK]IKX0KHNDW,-IXBTR[74-.:Y8K%(X5D:)R <!E8X.."%[9JJG/+#1
MF_BNT[=DU^-F_/YD4^6.(E!;635^[3_"Z1\O^$?V>_VMOCIX;T_QKJOQKNO"
MIU6W2[M-/M]3N;4B-QN0O%;*L:9!4X&XX/(!R*D^%O[2GQH_9E_:$T7X3_&[
M4H_$NC:M)#!;:M(WFN@E8I%/'/M5I$+_ "L)1N&">,<\-X?_ &KOVF?V0])L
MO#GCWP,^J^'=+5+6*XU:S<!8E "QQWL),;X&!EMY[5[M\(?^"@'P4^/7C+1;
M?QIX.MO#'C!B+>QO]8MH+V!&+?+''=%0Z98_Q*JY[YKHCR^T7LM8WV\O\S&7
M,J;]KI*V_G_D?<=%%%8FI^;'[;7[2'BGX$_MH>&KRVUW77\,V.D6UY/X<L]2
MEAM+QRUP,/$&V'<0@)*DX'? %7K+X'?M@?M :9_PFNI_%!_AY)?+Y]AX>M]0
MNK 11GE%>.W7"#!'WR[_ -[FLO\ :P\,V7C'_@IC\+M(U&,364]OIK2QL,AU
M2>=]I'H=N#]:_2VII17L.9[\TOEK_7I\QU)?OG%?RQ^>G]>OR/SR_9Q_:X^)
MOPI^.47P6^/;-=75U,EKI^LS*GF)(_$),B@":&3H'/S!CR>H7WO_ (*&>+-;
M\%?LL^)-6\/:QJ&@ZK#<V2QWVF73VTZ!KF,, Z$, 02#SR#7S%_P5XTZ+1O%
MGPK\369$&K[+N'SH^'Q"\,D9_!I'Q]37O7_!12]DU+]B36;N52DMPVF2NI&,
M%KB(D?K43DZF'4W\2DD__ E;];FD8^SK<JVE%M?<[_CL?-GP5;]I?]L;P!ID
M?AWX@7?@GPMX=A6PDUB;4KA;S5;P#<[O-'^]DQO4'+!0-OWCFOKKP;XC\3?L
ME_LQZCKOQK\6/XOUC2Y)7\^&7S6D#,$M[>.1D5G+'!W.,@N<G"U!_P $Y]-@
MTW]D'P.85PUQ]KN)#_>8W4HS^0 _"O&_^"OFM7-K\)?!&F1N5M;S69)IE!^\
M8X2%!_[^$_A6^+E[#FC'=M)^K:N_OV\M###)5>5RV5[>B3LO\_/4X'P;JG[5
M/[=#7?B70O%H^&/@5;AH[3['=2V2MM."L;Q+YTQ'\3,P3=D#&"HD\7:[^U)^
MPG/9>(O$?BD?%+P%).L5V;RZENPF3@*\DJ^="QYVL"R9QG)(4L^$G[6W[0'P
M^^&/A;PYH'[.FJWVC:;IT,%K>1Z+J+"Y0(,2Y5-IWYW9'!W9I/BY^T[^T1\8
M/AKXA\&:I^SAK<%CK%JUL\T>A:DSQ$D%74%,95@",]Q2J?NF_8]._7UOW_#S
M'#]Y9U>O;IZ6_I^1^A/PG^)VC?&3X=Z'XRT"1GTS58!,BR8WQ,"5>-\?Q*P9
M3[BNNKX;_8'N?&'P-_9)\?WGB_PKK&F3>';F^U6TTO6+:6QDGB2U24JOF)D*
MSJXW!2 2>#BO._\ A\E_U2'_ ,N;_P"Y*NKR*HXQ[)_?_5B::FZ:E+NU]Q^E
M%?G'\8OVJOBW^TA\<;_X3? .?^R-.T^22&[UV)@DDH0[)9FF(/DPJQPI0;VX
M()W!:]?^!7[<<_[2GPU^+.I6OA'_ (1.Y\*Z.UU$W]J?;/.=X;AA_P L8]NT
MPCUSGMCGR?\ X(]Z';?\([\2=<9=]_+>6MH9&ZA%1WQGW+_H*S5/FJN,]HQ4
MK=[Z+_@ERGRTTX[MV]+*[_#8FD^%_P"UI^RW9MXXC^(0^*NCV"BXU?P_>7]S
M=R20KS)Y8G4D #)W1L&X^ZPR*XW_ ();Z['XH_:4^*NLPQM##J-A-=I')C<J
MR7BN <=P#7Z?LJR*58!E88((X(K\V?\ @G7H=MX8_;$^-^D62".SL5O+:!%&
M L:7X51CV %51D_K"3_EG;[M5^5OF16C^XYE_-"_WZ?K_2/I+]MG]KZ']E_P
ME8V^E6D6J>-=:W#3K2<$Q0HN T\@!!(!( 4$;CWP#7SKX=_9S_;!^,VEP^*]
M?^,%YX*N+R,30:2NI7-FZ \J)(+95CCR,<<L.A /%>9?MV>)]:_X;ZTF33M#
MD\5WVAIIIT_0XXGF-TRCSQ&$0%FRS-D <BO9/^&Y_P!IC_HVO6/_  2:G_\
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M_P#83^ _Q0^+&F:QJG@7XFWG@?2]-U*!;ZPMKZZMUO#MW9*PL%;Y05^;UK]
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MU>.K#1+[6O%$;%-.T7PK-J$[V'VN:W@$9^S[]N S%L* 23U&2:]W_P""3?\
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M?*4)"!=V=K'+8P!U(\5_X([3)_PC/Q-AS^]6\L7*X[%)A_0U]+?!7]AOX1?
MN^CU+1?#[:IK<8PFK:W+]JGC]T&!&AZ_,J \]:M_L]_L@>#_ -FGQ%XBU7PE
MJVOS+KBJMS8:E<0R6Z;79D*!(58%=S*,L>&.<GFJII0E-O[2M]SND*I><8V^
MR[_>K,^/_P#@J5>1:/\ M _!_4[LF*RMX%DDF() 5+M6?\A@_C7W_:?$3PK\
M0O">MS^%O$ND>(X8;1S*^E7T5R(]T;%=VQCMS@XSZ&L#X_?LU>!OVD_#]KI?
MC*QF=[-V>SU"RE\JYMBP ;8V""#@95@0< XR :YG]GG]C?P;^S3;^)H/#&K^
M(+Z'Q!#'#=)JUQ!($V!PK)Y<*8.)&ZY[5S\C^KSHO^\U_P!O&W,E7C67]U/Y
M'RU_P1T_Y!?Q0_Z[:?\ ^@SUTOB#]M+QK\$?VU-3\'?%+48;3X;3;EL7@L$5
M8H9<-;W+. 78+@QO@XSN./EKZ._9K_9+\(?LLV^O0^%-1UO4%UEH7N/[9GAE
M*F,.%V>7%'C[YSG/;I71?&K]G7X?_M!:5;V7C?0(M3:UW&UO(W:&YM\]=DB$
M-@\$J<J2!D'%=56=ZD9QU2237R2^_L<].-H3A+2[NG_73N4?&?Q;^"?B+P;-
M<>)_%G@G6?#4B%F6^OK6Z@D&#PJ$MN;@X !.>G-? W_!.W1;;7/VS/'?B#P)
M:W%E\/+2"]6+>&"BWEF'V:(YYR=NX \@1G/2O?K/_@DS\&+745N9-3\77<*M
MN-G-J$ B8>A*VZOCZ-GWKZE^&?PI\)?!OPQ%X?\ !NAVVA:4C;S%;@EI'Z%Y
M'8EG; 'S,2< #M4T[0FZG6S5O7O^A4[RA[/S3OZ=OU/SZ_X*Q3+I_P 6/A%?
M7&4M8H9F:3!( 6>)F_(5^@>A_$KPE\1M!U*;PKXFTCQ''%;;Y3I=]%<&(.K%
M=X1B5S@]<=#Z5S_QZ_9R\$?M(>&[?1_&5A-,+1VEL[ZSE\JYM6888HV",$ 9
M5@0<#C(&.3_9U_8S\&?LR3>(G\+:OXAOEUV"."ZCU:X@D50A;:R>7"F#\[=<
M]:Q47["5%_WFO^WC25O:JK'^ZG\CY3_X(]_\A#XN?73?YW58G[5UOJ7[*/[=
MWA_XR?V?/=>%]8E2XE>$<$^3Y%U"#TW[/W@!Z[AZ''VG^S;^R-X/_9=F\12>
M%=2US4&UWR/M/]L3PRA/*,FW9Y<4>,^:V<YZ#I7IWCSX?>'/BAX9NO#WBO1[
M77-&NA^\M;I,C(Z,I'*L.S*01V(KHJ2?M(5:>\4EZZ6:]"=).K&6TG_3.4T/
M]ICX4>(?"Z>(;3XA^&QI31B1I;C4X86BR,[9$=@R-S]U@#[5\:>$?C[XU_:B
M_;NM(_ASXFUNT^%^BB)KU8)I([2XMX26>1XFX!FD/EC(W%<=,''I.H?\$G_@
MK>:LUY#>^*["W+[AI]OJ,)A _N@O"TF/^!Y]Z^E?A'\$_!?P+\-_V'X*T*#1
MK)FWS.I+S7#_ -Z61B6<^F3@=!@<5,>5351]-EY^?H3*[@Z:Z[OR\C\R/C1?
MZ"O_  4QN)/C$H;P?#?PIMOE+6PM_LP^S;AT,7F%2W;E\\9K](I/CE\'_ GA
M=+N/QOX0TK0XH\PBSU&V$94#I&D;?,<=%4$^@K/^//[*OPY_:.M[<^,-'9]2
MMD,=OJUC*8+N%2<[0XR&7))"N& )) YKQCPM_P $JO@EX=U1+N\?Q)XCB4Y^
MQZIJ*+"?KY$43'_OJLZ=XTHTGTZ]_7S-*EI5'477IV]/(^,/B9\>M,^/O[>_
M@7Q;I,,T/AVVUW2;"QFGC*O/#%=*3*5ZC<SN0#R!C.#Q7W%_P5 _Y-*UG_L)
M6/\ Z-%=9\6?V&/AM\5M0\(78.I^#W\+1>3IL?A=K>UC11()%RKPN,JX+ C'
M+-G.:]"^.OP.T/\ :$^'-QX+\27NI6NF3S0SO<:;)''/NC;<.7C=<$]?E_*E
M.-\/&E'=2O\ *Z=_G:]AQE^^=1[.-OP>GXGG/_!/?_DT#X??]<;G_P!*IJ^B
MJXOX.?"G2?@C\-]&\%:%<7MWI6EJZ0S:@Z/.P>1I#N**JGEST4<8KM*Z:TE.
MI*2V;.>C%P@HL^7?^"@7Q7^)WP5^$^G^*?AU=0V<4-Z(-5G>S2X>&-QB.0!P
M5 WC:20>76NI^ 7[7WPZ^,WP]TG49?%>D:9KQMD74M)U&\BMYX9@H$F$8C<A
M;)#+P01T.0/;=7T>Q\0:7=:;J=G!J&G7<;0W%K=1B2*5&&"K*1@@CL:^2O%W
M_!*_X)>)M3>[LAXB\,(YR;72-00Q9]A/'*1] <5SQO'F3U3U]/+T-Y6ERM:-
M?C_P3Y7_ ."D%]\)_&GCKPAIGPLM](U3QK<321ZE/X96-HIS(R+#&[1?+),7
MW=,L!P>HKZS_ &Z=/OM)_8*U6QU24SZG:V>E074I.=\JSP*[9]V!-=W\#OV(
M/A/\ =4BU?0-$FU'7X@1'K&LS_:+B+/'R#"HAQD;E0'!(S7H/QL^#VC?'GX;
MZIX)U^YOK/2M0,32S:;(B3KY<BR+M+HZ]5&<J>,TI0M1]E'6[3^Y]"H2O6C5
MEHDK?\.>)?L Z+;^)/V'/"^D7B[K2_@U.UF7U1[NX5OT)KY6_8M^*=M^Q=\=
MO'?PI^)=Q_8FGWUPB1:G< K!'-&6\J1C_#'+&X._H,+G R1^BOP7^$>C_ /X
M8Z7X*\/SW]]I6E^<T,FH21O</YDKRL"45%/S.0.!QCZU\[VVH?L^_P#!1N;4
M=-NM&U*'Q-H,0#37,8LM1MXR[+\KHSK(@;/RMN + X!-;U)\V)G4IZW6J[KO
M\O\ AS",?W/+/2SNGV;?ZGK_ ,5/VN/A;\*?!=UK]YXRT;5'6$R6FGZ7?Q7%
MQ>-CY5C1&)()Q\WW1G)(KX%_X)A^)KKQI^U]XX\07P O-5T:^OI@O0/)>6[L
M![9:OJ+P;_P3=^!7P?OI/%.J_P!J:_;::INV_P"$GO8GM+<(-Q=TCCC5@ ,D
M/N7U%>#_ /!,VU7QG^T_\7_'-E"PTEX[@12;2 /M5YYJ+_WS$>/:E0Y57ON^
M67R5OU?Y:=1UF_8^7-'YZ_I^OH6/^"MW_(_?![_=O/\ T;;U^E%O_J(_]T?R
MKQ+]HG]D/P=^TSK'AO4?%&I:Y83Z")!;+I$\,:OO9&._S(GSS&,8(ZFO;T4(
MJJ.@&*FG[M%0>_-)_?L.I[U;G6UDON/S5_X*W?\ (_?![_=O/_1MO7V!^V-_
MR:?\2_\ L!2_R%1?M$_LA^#OVF=8\-ZCXHU+7+"?01(+9=(GAC5][(QW^9$^
M>8QC!'4UZ1\2OAWIWQ3^'NN>#M6GNK?3-8M&LYYK-U694;J4+*R@_53]*QE%
MO".BMVY?CL:*2^LQJ]$H_@?,/_!*?_DUM_\ L/7G_H$5>,?M&_\ *4[X:?\
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M[5S#=VX/99!U7G.U@RYYQFLHWISYXZW5FNZ_X'0U=IPY)=[I]G_P>IE_%?\
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M82E*":CJ]K_UU-C0H]"_9L^ NF0ZS?):Z)X2T6**YNV_B\J,*Q [LS#@=26
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M9U/P;\.?$7CK6+:2UD\42Q)8+,I#/:Q;CYO/9W<X]0@/0BO/O"O_ "E^U?\
MZZS?^FL5^EL,,=O"D44:Q11J%2-  JJ!@  =!7B&G_L@^#=-_:/N?C5%J6N-
MXJG9F:S:>'["-UN(#A/*W_=&?O\ 7VXK7G_?JI]E1:^])+_@F<HOV$H;R;3_
M #/<J_,_PK_RE^U?_KK-_P"FL5^F%>&Z?^R#X-TW]H^Y^-46I:XWBJ=F9K-I
MX?L(W6X@.$\K?]T9^_U]N*SI^[64WM:2^]:%U/>HR@MVU^%SW*BBBD,****
M/QS_ &_O^3M_'?\ VX?^D%O7ZE?LZ_\ )OOPQ_[%?2__ $DBK\M?V_O^3M_'
M?_;A_P"D%O7ZE?LZ_P#)OOPQ_P"Q7TO_ -)(J^:R[_?:_J_S/W#C+_DF<I_P
MQ_\ 3:/QS_9U_P"3@OAC_P!C1I?_ *5Q5^YU?AC^SK_R<%\,?^QHTO\ ]*XJ
M_<ZC(_X<_4/%3_?<-_A?YA1117TI^'A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\.?
M&[_@G#>:K\1KSX@?![QO-\/_ !'=RO<36N^6*(2N<NT4T)WQ!B22FUADG&!Q
M7W'14\NJEU17-HX]&?G7??L&_M(?%)1I'Q*^.4,WAML>;;V=[=W@DP<C="R0
MHQ]"Q.*^S/@)\ _"O[.G@.'POX5MY!%O\Z[O;@AI[R8@ R2$ #.      ,"O
M2**T4K)I=3-QNTWT"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR(Q459!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\<_P!O[_D[?QW_ -N'_I!;
MU^I7[.O_ ";[\,?^Q7TO_P!)(J_+7]O[_D[?QW_VX?\ I!;U^I7[.O\ R;[\
M,?\ L5]+_P#22*OFLN_WVOZO\S]PXR_Y)G*?\,?_ $VC\<_V=?\ DX+X8_\
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MET'/W858O[.C?;T/>OV@?C7IO[/?PKU?QOJMA=:I:V)CC%I9E0\DDCA$&6(
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M,/B)X9AU3X')IW@O7KU(8KI[2\A>V@8_ZV2X8E<!<MDQ*&QQUHI_O.7EZ_\
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MW=E^.YK)^SIJ26LG9?F_PV,OQ5\;/VSOV:[6'Q7\0K'3_%7A5607:_9[-HX
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M&C2__2N*OW.HR/\ AS]0\5/]]PW^%_F%%%%?2GX>%%%% !1110 4444 ?/\
M^WQ_R:+\1_\ KSB_]*(J\Q_X)3^$;31/V:Y]:CC7[;K6KW$DTN/F*1;8D4GT
M!5S_ ,"->G?M\?\ )HOQ'_Z\XO\ THBKD/\ @F'_ ,FCZ#_V$+[_ -'M2P_Q
MUO\ "OS0ZWP4O\3_ /23WSXP?"?1?C=\/]2\'>(9+R/1]0V>?]AF\J4['#J
MV#QN4<$<XKS/P+KGP-_8]\%P^ XO'>BZ.EC))--!J>J0-?R2.Q8O*B88MC"C
MY1PJCM7(_P#!27XQ:_\ "']GO/ANZFT[4=<U&/2VU"W8I);Q%'D<HP^ZS"/;
MD<@,<<XKR/\ 9#_X)[_"GQS\&_#GC;QFEYXNU37K?[8\0OY(+>#+']V/*96+
M#&&+,>0>!13O+G<=$FD_-VNASLE!2U;NUY=&RM^W5^VA\%_BI\!]>\&>'-9D
M\3:]=2P/:/#I\R16\D<R,SF254'W ZY3=G=CH37L_P#P3(GDF_9%\.J[%A'?
M7R(#V'VASC\R?SKR[]NWX2_!/]G[]F?5[#0?"&@Z-XEUF6"UTN00B6^.V:.2
M5EEDW2!0BD,=V/F /W@#Z;_P3#_Y-'T'_L(7W_H]JK#V_?6\OO\ =)K7M2OW
M?W69\K_"'P'IWCW_ (*E>+8]4MH[RTTO5]2U002J&1I(R1&2#_==E8>ZBOU6
MZ\'D5^:7[,__ "E&^)_^]JW_ *-CK]+JBE_NM!?W5^HZG^\5G_>_K\S\Q/V0
M]*@\)_\ !2KXF:1IBBUT]/[6C6",!55/M$;A !T .,#V%;7_  6+.+7X4D_\
M]=2_E;52_9G_ .4HWQ/_ -[5O_1L=7?^"Q8W6OPI'_334OY6U9Q;]CA+;V7Z
MG1#_ 'JOZR_])/!?C9^U'%^UI\5?!WA+6M7N?!WPEM;R"UW*@:3H$:ZF&<;N
M2!U$:G."<Y_77X;_  ]\._"SP7IGAGPK80Z=HEC$%ABBYW9Y+LW\3,>2QY)-
M?+7[27[$OAWQQ^ROH^A^!=%AT_7?#%K]OTE(5^>Z9D!GB=CRS2XSDG[ZKVJI
M_P $U?VGF^*'@%_AWXDNF/B[PQ$$MVG/[R[L00JGGDM$<(WML/)S77&W[RDO
MB3N_[R[_ "[=O)'!K:G5^RU9>7_#]^_S/<OBI^V!\(_@GXJ/AOQIXM_L;6A
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MW"O#OV(6#?LG_#/!S_Q*E_\ 0WKW&NZO_&GZO\SCP_\ !AZ+\CQO]L+X;?\
M"U_V;?'6@QQ>;>?8&O;10.3/ 1,@'N2FW_@5>+_\$L?B*OB?]FN;1+B;,_AG
M4IK;YVZ02?OD/TR\@_X#7V5(BR(R.H9&&"IZ$>E?D1X5\>-^QS\3_P!I?P.T
MALXKO2[I-(!./WI?_1"!Z^5<EO\ @-<:FZ<JB7VHMKUCK][6B.MQ]I&GY22^
M4M/PW.5\1>")?VC-%_:5^,9B:X.EZC!+ITG/^J-S\^/]VW5/P-?H%^SG\=H+
M7]@W2?'=Y)YLGAS0)X9PYY:2T#1(I/JVQ/\ OH5RO[!GP4MYOV'[G2;^$(WC
MB*_GGW#GRY5,$9_[X16'UKX$TGXV7?@K]DWQW\&IWDCUJZ\4P#[/W6$ F<#Z
M2VT0(_Z:5<XNE">$A_+"W?F^%_=>Y,6JLX8F2^U*_P#AW7WV/M#_ ().^ ;A
M?!/C;XD:F#)J'B/4OLT<S]7CBR\CC_>DD8?6.N#A_P"4PP_Z[-_Z9S7W-^S7
M\-5^$/P)\%>%#&([BQTZ,W0 ZW#CS)C_ -]NU?#,/_*88?\ 79O_ $SFNK2.
M,C".T8R7W*WX[F";EA*LY;RU^\^C/^"F7_)H/BK_ *^[#_TJCK<_X)[_ /)H
M'P^_ZXW/_I5-6'_P4R_Y-!\5?]?=A_Z51UM_\$]F#?L@?#[!S^YN1_Y-35A1
M_AUO\4?_ $DNM\='T?YL^,?C9X#T_P")?_!52W\.ZM;K=Z9=7VGR7-NX!66.
M.PCE*,#U5MF"/0FOU6CC2&-(XT6.- %55&  .@ ]*_-'Q%_RF"L?^NL'_II%
M?IC12TPE+Y_H:5O]X?\ AC^1^7UY9V_@[_@KM!%I<0M8;J^5Y8X\*"T^F[I3
MC'=G9C[FOU!K\P_&G_*7S3/^ORT_]-BU^GE*CKA*?S7Y!6_WB7G&+^]!7SWX
MD_9G^$_A#XVR?';Q-K$FFZS%)YK3:UJ4,>G1R>7Y2/B11M*J!M^< $ XS7T)
M7Y+6^CW/[=W[='B+PSXWU^^T_P -:+-?)::;;RA66"WD$8BB# JKOP[MM).&
M]L3'F=6,8;V;OV2W%*WLY.6VBMW;V/N_Q3^W9\!_"(/VSXCZ7=OV72UEOL^V
M84<#\2*^!_@_\2/#_P 3/^"GFF>+/!T4UIH6K:A,\8FA$32$V+K*Q0$XWN&;
MUYR<&ONCPW_P3_\ @#X/9+F/P#:WDL2Y:;5KRXNE..[))(8__':^&OAGK'A/
M6O\ @J)IL_@>VT^U\*QZG+;64>EPI%:D1V+QLT:H NTNK$$<'.>]:T+?6H=[
M/[M":M_J]3M^NI^M]%%%0,_++X*Z/;?M)?\ !2SQEJ?BB%=0LO#]S>W4-G<#
M?&1:RI;6ZD'J%)5\=RON:_4VORQ^"^M6W[-?_!2SQEIOB>9=.L?$%S>VL-Y<
M$+&%NI5N;=BQX 8A4SV)^M?J=13M]5HV[:^M]?G:UPJ?[Q5OW_#I\M['Y8_M
M[:';?L]_MA^ ?B-X91-,GU-HM2NXX,(KSQ3;)F/8"2-@&]3N)ZFO=/\ @K,X
MD_9IT-UZ-XDMB/\ P'N:\*_;TUZW_: _;&\ _#OPS(NI3Z6\.FW,MOAPD\LP
M>9<CC]V@4MZ$,#T->[?\%9U$?[-.B*.B^);8#_P'N:YW_N</\;MZ<T;?*VQT
M1O\ 6Y?X-?\ P%_\&YZQ^P;X#T[P)^RSX%6QMHX;C5;)=5O)54!II9OFW,>^
M%*J/917C'_!7+0K.Z^ _AC5Y(5-_9^((X(IMHW+')!,77/H3&AQ_LBOH[]DO
M_DV/X7_]B]9_^BEKP'_@K5_R;9HO_8RVW_I/<UT9A_$DNTE_Z4D8X'X5_A?_
M *2STSP'X\N_ _[ ^C>+$<RWVE^!4NXF;D^9':?)G\0M? W[!/[1?PI^ =YX
MI\3>/_[2NO&6I2B*VNX+/[08X"-TAW$C#.YY]0HK[P\!^#KGXA?\$^=(\-67
M_'[JG@1;6 >LC6N$'XG _&OD[_@E_I_PR\8P^+? GCCP?X;U?Q9#=?;K+^WM
M*M[BX>'8$EB0RH6^1D#%>V\G'6MZE_KE>V]O_;G>WRW\C"-OJM*^U_T5K_/;
MS/?]0_X*?? /5["YL;[^V[NSN8VBFMYM)WI(C##*REL$$'&*^</^":OCJPTG
M]K+QMX<\+RS_ /"%:Y;W<UC!<*58)#-OMV89.&$;.I^M?H'J/[.WP5TC3[F^
MO?AAX#M+.VC:::>;P]9*D:*"69B8^  "<UX'^QY\=/A?\8OBYXBL/ ?P3T7P
M@=&AF=/%&FV5K$9(#($0'9"CH91EMF3PIR3BLJ5O:MK?E?W6Z^G3YV-*EW2L
M]KK[[_K_ )'JOC7]NGX'_#OQ7J?AKQ#XW_L_6M,F-O=VO]DWTOER#J-R0%3]
M02*D\!_MQ?!+XF>+M-\,>&O&O]I:YJ4ABM;7^RKZ+S&"EB-\D*J. >I'2H_&
MO["WP/\ B)XKU/Q+XA\$?VAK6IS&XN[K^UKZ+S)#U.U)PH^@ %2> _V'?@E\
M,_%VF^)_#7@K^S=<TV0RVMU_:M]+Y;%2I.R29E/!/4'K4T_L^U^=OQL.IU]G
M\K_J?&O[;=KXI_9W_;/T+XX+H3^(/#D@MY(FEW"!)4A\E[=G /EO@;U)'5L@
M':17O_PZ_P""HWP8\:K';ZY+JG@R[<!675+0S0%CV$D._CW=5KH]:_;0\.Q_
MM.M\#/$7A5K.*Y?[*VK:G<QFVG9XA)$HB*D,LF0HRPY(&#6G\1O^"?GP-^(Z
MS22^#(?#U[(N!=^'9#9%/<1+^YS]8S4T[QI15KPUM^O]/_AZJ6E4;>DDDG\M
MOZ7_  S_ -F?]G?X1^ ?$6N_$+X8:[)K::]YL<LEKJ45Q91J\HD,4:Q* NP@
M  Y*CBOE;]OK_D_+X*_]<]*_].4M<O\ L=:9J'P'_P""@6L_#3PUK4VN^&6>
M[LKV0-\CQQ0M*CNH^7S(W C+>I<#&<5U'[?7_)^7P5_ZYZ5_Z<I:VIV=7"2B
M_=;5O)>\3*ZIXJ,MTG?SU1ZC_P %9O'%WX?^ VAZ!:R-$FO:NJ7.W^.&%#)M
M/MO\L_\  :]Z_8]^&NF_"W]G/P/IEA;1P376FPZC>R(HW37$Z+([L>Y^8*/9
M0.U>$_\ !6+P'>>)?@)H_B"SA:9?#^K++=;03LAE0QEC[!_+'XU[A^QM\4M,
M^+'[.?@K4+"ZCFNK'3H=,OX5(W07$,:QLK#MG:&'J&!K.A\%;_%'[N7\KV_
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MB7'XK?CI^EMC],=+TNTT73;73]/MHK.QM8EA@MX$")%&HPJJ!P   ,5^7_\
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M-^NJ6\DR16[AE#@)(F#YGEKDDCYNE.M*'(HVM%627S_S_JPJ49\[E>\GK?\
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M2 B29W7!=$;HPSE1S7LU%3'W.:WVM_D7+WE%/HV_OT/FG]NW]FGQ/^T]\.]
MT#PM?Z387FGZJ+Z5]8FECC*>3(F%,<;G=EQU &,\U[=\+?"]UX(^&?A3P[?2
M0RWNDZ5:V,\ENQ:-I(XE1BI(!*Y4XR ?:NHHHC[JE%=6G]RL*7O.,GT5OO=P
MKRO]ICX#V7[1_P (]3\%WE\VERS/'<6E\L?F>1/&<JQ7(W*<D$9'#'FO5**F
M45-6949.+NCX<_91_9%^/'P!^)&B/K'Q$TW5OAS8K<1R:#;ZM>LFUXWVLEN\
M(C!$A5L;O4]>OIG[67[#/A7]IYX=86]?PQXRMXQ"FKP0B5)XQT2>/*[L<X8$
M$9[@ 5]+T54_WB7-T^\F/N-N/4_.;_AB/]JU]-/AU_CM;GPRW[IA_;6H&;R>
MFW;Y6<8XV>9M[=*^B_V3/V)_"W[+=M=7\5X_B/Q=>Q^3<:S/"(A''G)CACR=
MBD@9)8EB!R!P/HZBJ4G&[6[Z]27%.RZ+H>0?M,_LR^&/VG_ R:#KSRV%]:.9
M].U:V4-+:2D8/!X=&&-R$C.!R" 1\BZ7^PO^T_\ #RU;0O!/QRM8/#2#RX(I
MM2O;8QI_L1"*18^IX1_QK]&:*S45%NW7<T<FTD^A\=_LU_\ !/FV^%OCY/B)
M\0?%4_C_ ,=*_GPS2[S#!,1@RL\C%YI!V9MH'7;D CW?]H[X'V/[1'PCUCP3
M?7KZ8;O9+;WT:;S!-&P9&*Y&X9&",C()Y'6O3:*J?[R*@]D3'W)<RW/A7]EG
M]CWX\_ 'XE:!)J/Q&TW4_AQ8/.)M!M]6O2CH\;@%;=H1&&#LKXW=03G-?=5%
M%6Y.22?0E12;:ZA7PA^VU_P3^\6?M$?%JV\9>#=5T#35FT^.VOXM8GGB=Y8V
M8*Z^7#(""A4<X^[7W?163BI--]#12<4TNISWP[\'V_P_\!>'?#-KM^SZ/I\%
MBA7H1'&J9_'&?QKX:\0?\$U_$&M?M:3?$#^T_#X\!3^($UJ;3VFF^V,N\2R1
M[/)*?-)N'W_NG\*_0:BM.9^V5?[2_P [_H9\J]DZ/V7_ ,,%?($?['_C)?V]
M/^%VG4]"_P"$5\QF^Q^?-]NP; V_W/*V??.?O]/?BOK^BE'W9J:W5U]Y3U@X
M/9GG_P >O@_I_P >OA/K_@?4KF2Q@U.)0EW&@=H)4=7C?;D;L,HR,C(R,CK7
MR1^S9^Q;\>O@'\2O#\A^).FWOPZL+QY;G0[?5;U$GC=6#$6QB\L-E@V-V,CK
MWK[WHI0_=SYXA+WX<C/D#5?V/_&5]^WC;?&R/4]#'A6-XV-FT\WV[Y;'[.?D
M\K9]_G[_ $]^*^OZ**(^["--;(<O>ESO>R7W'QSX@_8Y\::M^W;9_&J'4]!7
MPM#<02M9O<3"^PEF(#A!#LSN&?O]/?BOL:BBB/NP5-;+^OT"7O2YWO9+[@KX
M=_:/_P""<U[XX^)EQ\1_A7XN'@OQ3=3&ZG@F:6*/[0?O313Q9>)FY)&ULDDY
M&<5]Q45+CJI=4/FT<>C/S\L_V%?VA/B)&-)^*7QXFD\,D!)[+2+VZNC<IW1Q
M(L2G([L'QUP:T;;_ ()TZK\+_P!H_P "^-_A?=:+;>%-"^S-=V>MWL_VR=QN
M6X<%864LZ-D<J QQ@ "OO*BM(RY91DMT[_\ #F;BI1<7LU8****DH^>_VK?V
M,/"7[4FGVUS>7$F@>*[&,Q6FN6T0D.S)/E3(2/,3))'(().#R0?FNW_8?_:H
MTO3QX<L/CO#%X67$28UB_29(1QM5!$=HQ_ )-O:OT8HJ5%1NEL^G0IR;M?='
MS+^RC^PIX4_9EN)-=EOI/%7C2>,Q-JUQ$(H[=&^\L$>3M)Z%BQ8]MH)!T_VX
MOV=_$?[3'PCT_P +>&+W2[#4+?5X=0>35Y9(XC&L4R$ QQN=V9%[8X/-?0]%
M54_>)*72WX.XJ;]FVX[N_P"*L</\#O ]_P##/X/>#?"FJ2V\^HZ-I5O8W$MH
MS-"SQH%)0LJDKD<9 /M7F'[<7[._B/\ :8^$>G^%O#%[I=AJ%OJ\.H/)J\LD
M<1C6*9" 8XW.[,B]L<'FOH>BBK^^;E/J[_C<*?[I)1[6_"QP_P #O ]_\,_@
M]X-\*:I+;SZCHVE6]C<2VC,T+/&@4E"RJ2N1QD ^U?-'[2'_  3ETWXF>-I?
M'GP[\1R> ?&,DOVF81JPMIKCKYRLA#P2$\EEW GG:"23]GT4ZC=2?M'ON*'N
M1Y%L?G)J7[!G[2WQ)M8M!\??'"VNO"^0)8H]0O;PN!R"\3QQ+(> ?G<\]Z^Q
MOV=?V<?"G[-/@?\ X1[PRDL\L[^=?ZG=8,]Y+C&YL# 4#A5' 'J22?5:*:DT
MFEUW\R7&[3?0****DH^9_P!KC]A[P]^U!)9:S#JC^%_&-C$((M4CA\V.>($L
M(Y4RI."3A@01D]1@5X''^QA^UJMF-$_X7S N@_ZO>NMZ@9Q'TQ_J<]/X?,QV
MK]%**F,5&Z6SZ%.3E9O='SA^R;^Q/X;_ &7H[W4QJ,OB;QAJ$?E7.L3Q>4J1
MDAC'%'EMH) ))8EB!T'%<?\ M.?L?^,OC3^TQ\/?B)HFIZ':Z+X>2R6ZM]0G
MF2Y?R;MYG\M4B93E6 &6'/IUKZ_HK3F?/"?6+NOZ^9"5HRA_-O\ U\C/U_0=
M.\5:)?:/J]G#J&EWT+6]S:W"[DEC8892/0@U\!ZY_P $W?B+\,/%]YJ_P&^*
M3>&+*\;Y['4KN>V:-<Y"-)"CB91DXWH"/<\U^AE%9\OO<RW+OIRO8_./6O\
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MO>#==GN+.":74[BWO+5OWEO.DJ;) #PP&2"IZ@GH<$?KM7Y[?L]_#'QCHO\
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MT/3;33M/MHK.PM(E@@MX5"I%&H 55 Z   8JU113;;=V)))604444AA1110
M4444 %%%% 'XY_M_?\G;^._^W#_T@MZ_4K]G7_DWWX8_]BOI?_I)%7Y:_M_?
M\G;^._\ MP_](+>OU*_9U_Y-]^&/_8KZ7_Z215\UEW^^U_5_F?N'&7_),Y3_
M (8_^FT?CG^SK_R<%\,?^QHTO_TKBK]SJ_"CX#ZE::/\<?AW?W]U#96-KXCT
MZ>XNKB01Q0QK<QLSNQ.%4 $DG@ 5^RO_  T5\*?^BG>#?_!_:?\ QRHR6<8T
MY\SMJ=/B=AJ]?&89TJ;E:+V3?7R/0J*\]_X:*^%/_13O!O\ X/[3_P".4?\
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M^S\;_P ^9?\ @+_R/0J*\]_X:*^%/_13O!O_ (/[3_XY1_PT5\*?^BG>#?\
MP?VG_P <H]M3_F7WA_9^-_Y\R_\  7_D>A45Y[_PT5\*?^BG>#?_  ?VG_QR
MC_AHKX4_]%.\&_\ @_M/_CE'MJ?\R^\/[/QO_/F7_@+_ ,CT*BO/?^&BOA3_
M -%.\&_^#^T_^.4?\-%?"G_HIW@W_P ']I_\<H]M3_F7WA_9^-_Y\R_\!?\
MD>A45Y[_ ,-%?"G_ **=X-_\']I_\<H_X:*^%/\ T4[P;_X/[3_XY1[:G_,O
MO#^S\;_SYE_X"_\ (]"HKSW_ (:*^%/_ $4[P;_X/[3_ ..4?\-%?"G_ **=
MX-_\']I_\<H]M3_F7WA_9^-_Y\R_\!?^1Z%17GO_  T5\*?^BG>#?_!_:?\
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MZ*=X-_\ !_:?_'*/^&BOA3_T4[P;_P"#^T_^.4>VI_S+[P_L_&_\^9?^ O\
MR/0J*\]_X:*^%/\ T4[P;_X/[3_XY1_PT5\*?^BG>#?_  ?VG_QRCVU/^9?>
M']GXW_GS+_P%_P"1Z%17GO\ PT5\*?\ HIW@W_P?VG_QRC_AHKX4_P#13O!O
M_@_M/_CE'MJ?\R^\/[/QO_/F7_@+_P CT*BO/?\ AHKX4_\ 13O!O_@_M/\
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M#^S\;_SYE_X"_P#(]"HKSW_AHKX4_P#13O!O_@_M/_CE'_#17PI_Z*=X-_\
M!_:?_'*/;4_YE]X?V?C?^?,O_ 7_ )'H5%>>_P##17PI_P"BG>#?_!_:?_'*
M/^&BOA3_ -%.\&_^#^T_^.4>VI_S+[P_L_&_\^9?^ O_ "/0J*\]_P"&BOA3
M_P!%.\&_^#^T_P#CE'_#17PI_P"BG>#?_!_:?_'*/;4_YE]X?V?C?^?,O_ 7
M_D>A45Y[_P -%?"G_HIW@W_P?VG_ ,<H_P"&BOA3_P!%.\&_^#^T_P#CE'MJ
M?\R^\/[/QO\ SYE_X"_\CT*BO/?^&BOA3_T4[P;_ .#^T_\ CE'_  T5\*?^
MBG>#?_!_:?\ QRCVU/\ F7WA_9^-_P"?,O\ P%_Y'H5%>>_\-%?"G_HIW@W_
M ,']I_\ '*/^&BOA3_T4[P;_ .#^T_\ CE'MJ?\ ,OO#^S\;_P ^9?\ @+_R
M/0J*\]_X:*^%/_13O!O_ (/[3_XY1_PT5\*?^BG>#?\ P?VG_P <H]M3_F7W
MA_9^-_Y\R_\  7_D>A45Y[_PT5\*?^BG>#?_  ?VG_QRC_AHKX4_]%.\&_\
M@_M/_CE'MJ?\R^\/[/QO_/F7_@+_ ,CT*BO/?^&BOA3_ -%.\&_^#^T_^.4?
M\-%?"G_HIW@W_P ']I_\<H]M3_F7WA_9^-_Y\R_\!?\ D>A45Y[_ ,-%?"G_
M **=X-_\']I_\<H_X:*^%/\ T4[P;_X/[3_XY1[:G_,OO#^S\;_SYE_X"_\
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M^&BOA3_T4[P;_P"#^T_^.4>VI_S+[P_L_&_\^9?^ O\ R/0J*\]_X:*^%/\
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MX4_]%.\&_P#@_M/_ (Y1_P -%?"G_HIW@W_P?VG_ ,<H]M3_ )E]X?V?C?\
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M=X-_\']I_P#'*/;4_P"9?>']GXW_ )\R_P# 7_D>A45Y[_PT5\*?^BG>#?\
MP?VG_P <H_X:*^%/_13O!O\ X/[3_P".4>VI_P R^\/[/QO_ #YE_P" O_(]
M"HKSW_AHKX4_]%.\&_\ @_M/_CE'_#17PI_Z*=X-_P#!_:?_ !RCVU/^9?>'
M]GXW_GS+_P !?^1Z%17GO_#17PI_Z*=X-_\ !_:?_'*/^&BOA3_T4[P;_P"#
M^T_^.4>VI_S+[P_L_&_\^9?^ O\ R/0J*\]_X:*^%/\ T4[P;_X/[3_XY1_P
MT5\*?^BG>#?_  ?VG_QRCVU/^9?>']GXW_GS+_P%_P"1Z%17GO\ PT5\*?\
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M6'_Q^C_A@'X]?]")_P"5BP_^/U^QE%']B8?^:7X?Y!_Q%#.?^?5+_P !G_\
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M_P K%A_\?H_X8!^/7_0B?^5BP_\ C]?L911_8F'_ )I?A_D'_$4,Y_Y]4O\
MP&?_ ,F?CG_PP#\>O^A$_P#*Q8?_ !^C_A@'X]?]")_Y6+#_ ./U^QE%']B8
M?^:7X?Y!_P 10SG_ )]4O_ 9_P#R9^.?_# /QZ_Z$3_RL6'_ ,?H_P"& ?CU
M_P!")_Y6+#_X_7[&44?V)A_YI?A_D'_$4,Y_Y]4O_ 9__)GXY_\ # /QZ_Z$
M3_RL6'_Q^C_A@'X]?]")_P"5BP_^/U^QE%']B8?^:7X?Y!_Q%#.?^?5+_P !
MG_\ )GXY_P## /QZ_P"A$_\ *Q8?_'Z/^& ?CU_T(G_E8L/_ (_7[&44?V)A
M_P":7X?Y!_Q%#.?^?5+_ ,!G_P#)GXY_\, _'K_H1/\ RL6'_P ?H_X8!^/7
M_0B?^5BP_P#C]?L911_8F'_FE^'^0?\ $4,Y_P"?5+_P&?\ \F?CG_PP#\>O
M^A$_\K%A_P#'Z/\ A@'X]?\ 0B?^5BP_^/U^QE%']B8?^:7X?Y!_Q%#.?^?5
M+_P&?_R9^.?_  P#\>O^A$_\K%A_\?H_X8!^/7_0B?\ E8L/_C]?L911_8F'
M_FE^'^0?\10SG_GU2_\  9__ "9^.?\ PP#\>O\ H1/_ "L6'_Q^C_A@'X]?
M]")_Y6+#_P"/U^QE%']B8?\ FE^'^0?\10SG_GU2_P# 9_\ R9^.?_# /QZ_
MZ$3_ ,K%A_\ 'Z/^& ?CU_T(G_E8L/\ X_7[&44?V)A_YI?A_D'_ !%#.?\
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M'X]?]")_Y6+#_P"/U^QE%']B8?\ FE^'^0?\10SG_GU2_P# 9_\ R9^.?_#
M/QZ_Z$3_ ,K%A_\ 'Z/^& ?CU_T(G_E8L/\ X_7[&44?V)A_YI?A_D'_ !%#
M.?\ GU2_\!G_ /)GXY_\, _'K_H1/_*Q8?\ Q^C_ (8!^/7_ $(G_E8L/_C]
M?L911_8F'_FE^'^0?\10SG_GU2_\!G_\F?CG_P , _'K_H1/_*Q8?_'Z/^&
M?CU_T(G_ )6+#_X_7[&44?V)A_YI?A_D'_$4,Y_Y]4O_  &?_P F?CG_ ,,
M_'K_ *$3_P K%A_\?H_X8!^/7_0B?^5BP_\ C]?L911_8F'_ )I?A_D'_$4,
MY_Y]4O\ P&?_ ,F?CG_PP#\>O^A$_P#*Q8?_ !^C_A@'X]?]")_Y6+#_ ./U
M^QE%']B8?^:7X?Y!_P 10SG_ )]4O_ 9_P#R9^.?_# /QZ_Z$3_RL6'_ ,?H
M_P"& ?CU_P!")_Y6+#_X_7[&44?V)A_YI?A_D'_$4,Y_Y]4O_ 9__)GXY_\
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M_P ?H_X8!^/7_0B?^5BP_P#C]?L911_8F'_FE^'^0?\ $4,Y_P"?5+_P&?\
M\F?CG_PP#\>O^A$_\K%A_P#'Z/\ A@'X]?\ 0B?^5BP_^/U^QE%']B8?^:7X
M?Y!_Q%#.?^?5+_P&?_R9^.?_  P#\>O^A$_\K%A_\?H_X8!^/7_0B?\ E8L/
M_C]?L911_8F'_FE^'^0?\10SG_GU2_\  9__ "9^.?\ PP#\>O\ H1/_ "L6
M'_Q^C_A@'X]?]")_Y6+#_P"/U^QE%']B8?\ FE^'^0?\10SG_GU2_P# 9_\
MR9^.?_# /QZ_Z$3_ ,K%A_\ 'Z/^& ?CU_T(G_E8L/\ X_7[&44?V)A_YI?A
M_D'_ !%#.?\ GU2_\!G_ /)GXY_\, _'K_H1/_*Q8?\ Q^C_ (8!^/7_ $(G
M_E8L/_C]?L911_8F'_FE^'^0?\10SG_GU2_\!G_\F?CG_P , _'K_H1/_*Q8
M?_'Z/^& ?CU_T(G_ )6+#_X_7[&44?V)A_YI?A_D'_$4,Y_Y]4O_  &?_P F
M?CG_ ,, _'K_ *$3_P K%A_\?H_X8!^/7_0B?^5BP_\ C]?L911_8F'_ )I?
MA_D'_$4,Y_Y]4O\ P&?_ ,F?CG_PP#\>O^A$_P#*Q8?_ !^C_A@'X]?]")_Y
M6+#_ ./U^QE%']B8?^:7X?Y!_P 10SG_ )]4O_ 9_P#R9^.?_# /QZ_Z$3_R
ML6'_ ,?H_P"& ?CU_P!")_Y6+#_X_7[&44?V)A_YI?A_D'_$4,Y_Y]4O_ 9_
M_)GXY_\ # /QZ_Z$3_RL6'_Q^C_A@'X]?]")_P"5BP_^/U^QE%']B8?^:7X?
MY!_Q%#.?^?5+_P !G_\ )GXY_P## /QZ_P"A$_\ *Q8?_'Z/^& ?CU_T(G_E
M8L/_ (_7[&44?V)A_P":7X?Y!_Q%#.?^?5+_ ,!G_P#)GXY_\, _'K_H1/\
MRL6'_P ?H_X8!^/7_0B?^5BP_P#C]?L911_8F'_FE^'^0?\ $4,Y_P"?5+_P
M&?\ \F?CG_PP#\>O^A$_\K%A_P#'Z/\ A@'X]?\ 0B?^5BP_^/U^QE%']B8?
M^:7X?Y!_Q%#.?^?5+_P&?_R9^.?_  P#\>O^A$_\K%A_\?H_X8!^/7_0B?\
ME8L/_C]?L911_8F'_FE^'^0?\10SG_GU2_\  9__ "9^.?\ PP#\>O\ H1/_
M "L6'_Q^C_A@'X]?]")_Y6+#_P"/U^QE%']B8?\ FE^'^0?\10SG_GU2_P#
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3,?Q'"G3Q<8Q4+M<J:U?>[9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>cdtx-20231231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g3.jpg
M_]C_X  02D9)1@ ! 0$ G@"?  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'E >0# 2(  A$! Q$!_\0
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MR,/PH\=?%#P]\.;KP_;:[>&VGU[4$TS3XU0N9IWZ+QTXY)[ 5\^^&_@]XS^
MOQAMM1\'>"E\6>%HO"EAX?CD75;>RE62!W+2,K]2V[)P.I->C?M!?"76/B)J
MOA;4M$DNH;W24U$B2WU&2U\MY+&:.$@*PR?-9 3Z9SQF@#VBBOC#XC? 'XQV
M?B;3)O#^K:SXET)_#TEA]B/B>6QDT_4F>,B\=Q(#. %;Y"2!Z<FI-/\ V<?B
MS=>+-;OM9\0:W+!<ZUIS0FW\37$4?V&.P\NXVQI* A:< X !/6@#ZYUOQ%IO
MAN.SDU.\CLDO+J*Q@:0_ZR>5ML<8]V/ KF=4^-7@W2/&D/A.;68W\0R3QVS6
M,*L[QNZ&1 ^!A<J,\UP>J?![Q5XR_9F;P;JFK267C.*W8V6JM<M+);W$;L;>
M4R@[BRC8=V<Y[YKR72_V;?BGI=CX3\01WSP>-M9\3RZ]XS-EJSQQ")X)5CME
M^?#QQ,ZJ%''R@XXH ^SJYSPS\0-%\77_ (@L]-NO-GT&\^P7X88$4WEI)C/^
M[(I_&OEKXQ_!GXU1_"'P_H/@*ZU2?Q"\<LNI:FWB5TN([@.#& TKE3&1NR%&
M>%Q@9SW'P/\ @CXST/P;\3].\47"V&J^*;I)HKV&=96W'3K6"1SMZ'S8I/J.
M>] 'IWA/]H+X=>.O%L_AC0/%NGZMKL+RQO9VS,S!HR1( <8.W!S@]JV?'WQ,
MT#X9VNE7&OW9M(M3U"#3+8A<[YYG$<:_BS 5\W?"GX4_$;P3\*(_AT/AOH.@
MSZ1I=W8V/B[2;^)'FF\LHEPB@^;$\IPSDGJQKF_B9\&?C;\;-<T"^UG0(]$L
MK'6-&NWT[^W4F55M[J%YY5VM@,51B,?-^- 'V)X1\::'X^T5-6\/:E!JVFL[
M1K<VY)0LIPP_ UM5\!?"/X%?'[X3?8+73M#_ -"%CK5A/"?$H^SB2YE@>VNA
M'OQO58Y ,<C?]:Z+6?V<_C9J&B_%6Y@\2ZS;:YJ46G1Z!Y7B.4*J1VD*7"HI
MDV1.TJR'>1SU[T ?;=%?)?A/X+_&.S_9=\>>&'\4:[%XYU,W,FE7&LZK#<7-
MN7!.Q;B$ *"Q)!S\F0!@ 5Q$?P'^/YTOQ)K^C7VJ^&=;L19R>'_#M[XJDU&"
M>=8FBG>:621@4(=G",<%E4D'% 'W74=Q<1VEO+/,XCAB4N[MT50,D_E7Q#=?
MLT_'71?%O@6:#Q_XDU?2(=/@35EL]9CB*W8F\R9Y1/N\Q&5MH$>,!#ZU['\!
M_A!XN\+^ ?'MKXQO]1OM=US4]1DM_M6LS72I:N[_ &=8]SD1#:1\JXQ0!Z;X
M0^+WA3Q]>VEOX>U6/5EN[!=3@N+=289("VT,&QUR.E=E7YG+^RI^TGI_P#'A
M/P\][X8UBTT2TL($LO%91&N([[S))$*R8CS#QQC/2O=/"/[//Q4T.[U@Q^)-
M7MWGU?4DLKF^\0W%XD%A+97"6[&-Y&R5G:!L8W#;0!]>U@^-_'GA_P"&_AVY
MU[Q/JMOHNCVV/-O+DD(F>F<"O"OV3_A=\5/ 7ASQ5;>/?$.M7NK7444-C=:M
MJ%O?)&ZB4&6)47Y5)=#MDR?E [5#\<O@;\3/B!^S%JW@NZ\2Q>,O&-S<QR1Z
MC)!!9+L#9QM553CZ<T >B6W[4WPHO-!OM:A\;Z<^FV-Q':7,PWYBE?&Q"NW=
MDY&..]=EX#^(GAOXG:'_ &QX6U>WUK31*T!N+?.!(OWE((!!'TKYZ\0?LA:[
M;:E<Z]I?CG5-3\9:QK6GWE_XANK:RBDMH;<QC]W"L0A8A4SRA)->L^ OA3=_
M"+P;XI&E:G<^*/%.J27.I/>Z@D,!N;ME)0%(U6-!NP,A1UYH [;0_&6B>)M0
MUBPTK4[>^O-'N/LE_!"^7MI=H;8X['# _C6S7QE\(_V3_B1\(O%'BO6_^$F/
MB"?QEI;IJC&58)[:Z5BT!$BX+D>=,N_).%3G %2^*/@Y\:/#^EZCI_A>35M2
MM+R&S(D?Q0WVJWF6!$G:.2=V !93\IRIZ@<F@#ZBUCXC:'H?C?0?"5Y=&/6]
M<29[&#;GS!$C._/;"J?RKIJ_.R']G/XI:?X5\'ZA\2?%5QX=70;#7(+SQ7J7
MB%7N;!KFWG2WE\Y&#$*\B=#P!3/"G@?X[?%SX"Z'XML]7\27OC*]U);AEM=>
M&G6S6\,4L<89'(&R42[FV8.54@@C- 'WU9>,M+U#Q=J7AJ&5VU73[:&ZGC,9
M"A)6D"8;H3F-LCMQZU/XH\5:1X)\/WVN:[J$&EZ38QF:XN[AMJ1H.I)KXI\3
M? OX^ZYX:NU^TZSIEW-8:0B6F@^+&1H;B&6_:YVRW$CD@K+;;B22V .B#'K5
MK\*/%OB[]DI_"'CKPO:ZWXD>.;S]&NM9EF^T?O7*;KOS,AV4ALA@JEL
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M5U3_ .1Z;#_P4,^"5Q"DL6MZY+$X#*Z>%M3*L#T((M^17NFO:#I@T/42-.M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8WC3_D3M=_Z\
M)_\ T6U<;^S'_P FW_"K_L5=+_\ 22*NR\:?\B=KO_7A/_Z+:N-_9C_Y-O\
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MHK,\O5O^>UO_ -\'_&CR]6_Y[6__ 'P?\: -.BLSR]6_Y[6__?!_QH\O5O\
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M\O5O^>UO_P!\'_&@"'QI_P B=KO_ %X3_P#HMJXW]F/_ )-O^%7_ &*NE_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% 'CGPS_ .3B_C5_N:'_ .DLE>QUXY\,_P#DXOXU?[FA_P#I+)7L= %#7O\
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M -)9*]CH H:]_P @/4?^O:3_ -!-<G\!_P#DB/@#_L V/_HA*ZS7O^0'J/\
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MW3RV@7RWP0Y'G;L8.<8S[5VNH?\ 'C<_]<V_D:Y?X._\DI\(?]@JV_\ 1:T
M=%]OG_Z!\_\ WTG_ ,51]OG_ .@?/_WTG_Q57J* */V^?_H'S_\ ?2?_ !5'
MV^?_ *!\_P#WTG_Q57J* */V^?\ Z!\__?2?_%5Q6E7DW_"X?$;?8IB3HVGC
M;N3(_>W7/7_.*]#KA])_Y++XD_[ NG_^CKJ@#JOM\_\ T#Y_^^D_^*H^WS_]
M ^?_ +Z3_P"*J]10!1^WS_\ 0/G_ .^D_P#BJ/M\_P#T#Y_^^D_^*J]10!1^
MWS_] ^?_ +Z3_P"*H^WS_P#0/G_[Z3_XJKU% %'[?/\ ] ^?_OI/_BJ/M\__
M $#Y_P#OI/\ XJKU% %'[?/_ - ^?_OI/_BJ/M\__0/G_P"^D_\ BJO44 4?
MM\__ $#Y_P#OI/\ XJC[?/\ ] ^?_OI/_BJO44 4?M\__0/G_P"^D_\ BJ/M
M\_\ T#Y_^^D_^*J]10!1^WS_ /0/G_[Z3_XJC[?/_P! ^?\ [Z3_ .*J]10!
M1^WS_P#0/G_[Z3_XJC[?/_T#Y_\ OI/_ (JKU% %'[?/_P! ^?\ [Z3_ .*H
M^WS_ /0/G_[Z3_XJKU% %'[?/_T#Y_\ OI/_ (JC[?/_ - ^?_OI/_BJO44
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M?X(\.>(OB1#!K.N7'C75[/1--UO3+X:@9H;"R2;=:6C*&(,D; /N/+9R2<T
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MO$9SD_E0!TE%>7Z?XZ^(.I1B6+P1 8O,:,M_:,0P58JW\7J#7I] "UP^D_\
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MMMY,/VH:G<"+:"2<&U\AAR1@CG- 'T]1110 4444 >.?#/\ Y.+^-7^YH?\
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M:HJK_:EE_P _</\ W\%']J67_/W#_P!_!0!:HJK_ &I9?\_</_?P4?VI9?\
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M+^5'DI_<7\J?10!A>$8D_L=OD7_CZN.W_39ZVO)3^XOY5C^$/^0.W_7U<_\
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ML6\ZRNF3=Y;^A'H<8([T_P $^+H/%^CBX4>1?0MY-Y:-P]O,.&0CZYP>A[4
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M[#CCO7A?[*,VI-IODZC?6MU-!IMO')';Z*+)HY H#!G$K[SGUQZT ?0E%%%
M!1110!XY\,_^3B_C5_N:'_Z2R5['7CGPS_Y.+^-7^YH?_I+)7L= %#7O^0'J
M/_7M)_Z":Y/X#_\ )$? '_8!L?\ T0E=9KW_ " ]1_Z]I/\ T$UR?P'_ .2(
M^ /^P#8_^B$KF?\ '7H_S1[4/^174_Z^0_\ 29G=T445TGBA1110 4R:58(7
MD<X5%+'Z"GUS'Q)UT^'?!>HW2()9F40QQDD;F<A<?D2?PH Q_AJUSJ'A?6=9
MNP!-JEW<S#Y"I\M"8HR0?]B-:O\ P=_Y)3X0_P"P5;?^BUK:L+$Z7X5M[,C!
MM[)8CSGE4Q_2L7X._P#)*?"'_8*MO_1:T =A7C'[5'@74_&GP_B;2HWN;BQG
M\YK9!RZ8P2/<<<>]>ST4 ?GU\%_A?XA\1>/])VZ==V=K;W"RS74T+(J*K<X)
MQD\'BOT%K$\(?\@=O^OJY_\ 1SUMT %</I/_ "67Q)_V!=/_ /1UU7<5P^D_
M\EE\2?\ 8%T__P!'75 '<5P7C*SF\(ZU#XMTZ)?LP.S6(44[I8<8$@ '+(<$
M^P-=[6=XCU(:-X>U34#;&\%K:RS_ &<=9=J%MG0]<8Z=Z ,];N&^\4:7<02+
M+#+I\SHZG((+Q5!XL\6/88TS1XUU#7KA6$4","L.,?/+S\JC/U/8'FOSTN/'
M.N?VP]];ZE>6;K*7BCCG8+%\V=H&<8R!QTXK[N^ \<%]\.=*UMK<KJ6I(TUU
M<2G=+*^XKDGT^48 X% &[X/\&OHF[4-4N1JGB"X0"XO2N /]A!V4?KUJA\7_
M /D4[;_L+Z;_ .EL-=O7$?%__D4[;_L+Z;_Z6PT =JZ+(I5U#*PP01D&O/K[
M1;GX;ZA_:>@VYET"9VDU'38^71CC][$/SR/88KT.DZ\'D4 <!\3]9LM>^"_B
MN\L;B.Y@DTF=@R'.,QDX(['V/(JS\$O^21^$?^P;#_Z"*^>?VN[ZX\*Z];Z7
MI#MIVGZO:>??0V^56=PY4$CH. ,XQGOFM#]C'QIK.H:IJ?AZYNWGTFULS/!$
M_/EMYBC /I@GB@#ZMK!U_P )G7KM)_[:U?3MJ;/*T^Z\I#R3DC:>>?T%;U%
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M1_Z]I/\ T$UR?P'_ .2(^ /^P#8_^B$KK->_Y >H_P#7M)_Z":Y/X#_\D1\
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MSYO(A/VVV_>-@D ?O/12>?2NY^&OCCQ-XNFOT\0>";[PBD"H87O+B*43DDY
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M %]VW_I-%0!ZC1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA:UC5[F"42 N$&[+ ]<]:XC]HWX17_Q7\/Z='I<D:WUA*[HDK;0P8 $9_P"
MBOEG_@F7-??\))XPB5ICI_V>$R*,^7ORVW/;.-V/QK] ZZLNQ3QF&C6:M?\
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M:6']FJ5]6[MN5KK1;*VG??38P/&GVC_A#]=R8_\ CPG['_GFU<G^S'_R;?\
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M/AZ/4-.L[SPVT<.D7D$*"U\G5+B"9B\;MN>2>.63T ? )Q0!]MT444 %%%%
M'CGPS_Y.+^-7^YH?_I+)7L=>.?#/_DXOXU?[FA_^DLE>QT 4->_Y >H_]>TG
M_H)KD_@/_P D1\ ?]@&Q_P#1"5UFO?\ (#U'_KVD_P#037)_ ?\ Y(CX _[
M-C_Z(2N9_P =>C_-'M0_Y%=3_KY#_P!)F=W11172>*%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>-/^1.UW_KPG_]
M%M7&_LQ_\FW_  J_[%72_P#TDBKLO&G_ ")VN_\ 7A/_ .BVKC?V8_\ DV_X
M5?\ 8JZ7_P"DD5 'I=%%% 'G_P <KKQ39^ YI/".N:!X>U7SD#7GB2(R6GE$
M'<I =/F/&.>QXKR+]DE-;TWQ-XFTK5SH\YB@287.@^'7L+*1G<L3'</<.TO7
M)7RT ;)!;K7MOQ3^$?A/XU^%3X;\::2-:T5IDN#:FXEA!D3.T[HG5N,GC.*J
M_#CX)^$?A/+/)X9M-0M/.B6!DN]8O+U B_="K/,ZIC_9 H [JBBOG[]HKQ]K
M_A?QWH&FVOB.Z\*Z!/X?U:^DU"U@BD,E]";<6T!,B.,,LDS8 !/E]>#D ^@:
M*^9O&'Q9\3IX,^$K-K<V@Q:I<0Q^(=:M[=&E@S$K("KHRIYN2Q.WC'&*]9^'
M_B+6M0^',%_$K>)+P3RQP37$J6[7<"RLL<Q8+M!9 K<* <\ 4 <Y\,_^3B_C
M5_N:'_Z2R5['7A7P;O=2N_CY\9Y;_3$T^Y(T4&!;D2@#[+)@[@HZ_2O;_,F_
MYXC_ +[_ /K4 5M>_P"0'J/_ %[2?^@FN3^ _P#R1'P!_P!@&Q_]$)73:])-
M_8>H_N1_Q[2?Q_[)]JY3X$R2_P#"D_ .(@1_8-CSO_Z8)7,_XZ]'^:/:A_R*
MZG_7R'_I,ST"BH?,F_YXC_OO_P"M1YDW_/$?]]__ %JZ3Q2:BH?,F_YXC_OO
M_P"M1YDW_/$?]]__ %J )J*A\R;_ )XC_OO_ .M1YDW_ #Q'_??_ -:@":BH
M?,F_YXC_ +[_ /K4>9-_SQ'_ 'W_ /6H FHJ'S)O^>(_[[_^M1YDW_/$?]]_
M_6H FHJ'S)O^>(_[[_\ K4>9-_SQ'_??_P!:@":BH?,F_P">(_[[_P#K4>9-
M_P \1_WW_P#6H FHJ'S)O^>(_P"^_P#ZU'F3?\\1_P!]_P#UJ )J*A\R;_GB
M/^^__K4>9-_SQ'_??_UJ )J*A\R;_GB/^^__ *U'F3?\\1_WW_\ 6H FHJ'S
M)O\ GB/^^_\ ZU'F3?\ /$?]]_\ UJ )J*A\R;_GB/\ OO\ ^M1YDW_/$?\
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M -$)7,_XZ]'^:/:A_P BNI_U\A_Z3,[NBBBND\4**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&\:?\ (G:[_P!>$_\
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M<:'%J6EO^Z)*202#;+;R#K'(G5&&0<'GD'O3(,G_ (57I_\ T&?$G_@]NO\
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M@SXD_P#![=?_ !==G10!\A_M=KXM^&NI?""+P/K'B?RM<\96>EZUMU"XN/\
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MFJ>)M3T2]TH^'?$TD<FJ^(/$D[RW.EL?W;B.)$Q+&5$86/='L;<Q9MV!ZO\
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M21@22JFXHK-U(&]L9Z;CZU=HH **** ,OQ-X9TWQAHL^DZO;+>:?.T;20/\
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M6VU.RM[^W6191%<1AU#J<JV#W! (-7J* "BBB@ HHHH **** "BBB@ HHHH
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M[7SR]SGC#R><JX() C&6;M];44 ?(>I?L6W%O;^!_P"SK;194T'2]#M[RQ>
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M_P# Y_\ XBC^U/BO_P! +P__ .!S_P#Q%>FT4 >9?VI\5_\ H!>'_P#P.?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>cdtx-20231231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g4.jpg
M_]C_X  02D9)1@ ! 0$ G@"?  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'Y >H# 2(  A$! Q$!_\0
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M\R:9SSM1!RQP">.P-:/PF^,7A+XW>#X?$_@_5HM4TF20PM(IPT4@ )C=?X6
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ME^!/$5MJ^A_#/PO\0_&FK>!?AS:>#6O]-GT^>2U2\OS<2!P\J?>* )A3_?-
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MZ?%%C< K?=4=0 #Z@"K:^$="30CHBZ+IZZ,PVG3A:Q_9R,YQY>-N,CTK6HH
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MY5E>-"&]10!]*45!96JV-G#;HSND2A%:1LM@>IJ>@ HHHH **** /F+]C_\
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MT/\ ]C@O_I+'7T[7S%^Q_P#\E,_:'_['!?\ TECKZ=H **** "BBB@ HHHH
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M/?\ X&S?_%5MT4 16UNEI;QPQ[MB#:-S%C^)/)J6BB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRU"BBBK.8**** "BBB@ HHHH **** "L_P 0?\@'4O\ KVE_] -:%9_B#_D
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M^O:U_P )%JT'BU5GU+[/Y'GM]FC^;9N;;^9KZ[H **** "N-_P":Q'_L _\
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M#:J(, #T I]%% !1110 4444 ?,7['__ "4S]H?_ +'!?_26.OIVOF+]C_\
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MBW_]"KTRO,]"_P"2_>)?^P1;_P#H5>F4 %%%% !1110 4444 %%%% !1110
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MHHH **** "BBB@ HHHH *S_$'_(!U+_KVE_] -:%9_B#_D ZE_U[2_\ H!H
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MTV5)8[V9N".6- 'SCX6M-;\ ^,/V>=6@\9:]JR^+%FL=:L-0U"2ZBNV.GSW
MG5'8B,B2)?N@#&17NWQ%_:#\,?"_7TT?6+#Q1<W;0+<!]'\,ZAJ,.UBP ,L$
M+H&^4Y7.1QQR*S?!?[+W@_P7XJT37TGU;5KK0(&M=#AU2[$D.DPLI0I JJN!
ML)7+EC@]:]>H ^3/V%?$UIXQ\7?'O6+"*\AM+KQ<KQI?VDMK,!]EC^]%*JNI
M]B!7UG7S%^Q__P E,_:'_P"QP7_TECKZ=H **** "N-_YK$?^P#_ .W%=E7&
M_P#-8C_V ?\ VXH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-XGF6_D;B)%V[L@XZ8&:ZZ@#YB_8_P#^2F?M#_\ 8X+_ .DL=?3M?,7['_\
MR4S]H?\ ['!?_26.OIV@ HHHH *XW_FL1_[ /_MQ795QO_-8C_V ?_;B@#LJ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S/0O\ DOWB7_L$6_\
MZ%7IE>9Z%_R7[Q+_ -@BW_\ 0J],H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_Q!_P @'4O^O:7_ - -
M:%9_B#_D ZE_U[2_^@&@#RS]C?\ Y-/^$/\ V*VG?^DZ5['7CG[&_P#R:?\
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M5.[VK"^#WQC\;S>+K'3;F'X21Q:E.&U"?0?$2/=W#XY<1K]YR:[_ /:+\0?
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M[MVW)(OV6/D&OK*@ HHHH *XW_FL1_[ /_MQ795QO_-8C_V ?_;B@#LJ***
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MU=64,I!4C(8'@CUKYY_;;^'>F>*/A#J&OWDM\E[H8BDM5MKN2&/<UQ$"752
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MIW_8XSUBM\_ZJ,_W5XKTRBB@#YB_8_\ ^2F?M#_]C@O_ *2QU].U\Q?L?_\
M)3/VA_\ L<%_])8Z^G: "BBB@ KC?^:Q'_L _P#MQ795QO\ S6(_]@'_ -N*
M .RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,]"_Y+]XE_[!%O
M_P"A5Z97F>A?\E^\2_\ 8(M__0J],H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_Q!_R =2_Z]I?_ $ U
MH5G^(/\ D ZE_P!>TO\ Z : /+/V-_\ DT_X0_\ 8K:=_P"DZ5['7CG[&_\
MR:?\(?\ L5M._P#2=*]CH Q?%NL:;X7T.[U_5(F>VTV)IF:*!II%7C=M506)
MZ< 5R=Q\>?";>+=!\,Z5<S:_JVK@R11Z7"TL<,04L9)9<;(Q@=&8,>P-9WQR
MT66STB_\67?Q)\1>"M"TJR+W=OI$=F\3*I),A$T$C%B"!@'' XKYU^ FI>#?
M"?C_ $VU\/>*?B?#)XAUJ[@>WU;0K6"TNKR(2//$\@MP4VA'.Q2 -N  * /N
M&BBB@#@?B1\9M#^&NJ:5I-W%=ZCK>II--;:;81;Y7AB7=++SA0JY4<G.6 &<
MUO\ A#QQI/CKP?9^)=&N/M6E7432QR;2I^4E74@]"K*RD>H->#?&O58?A'^T
M=X:^)FNVUY<^%/\ A&[[199H83*MM=2W%J\2X[;Q$XSZX%:W[/VIQ?#?X/\
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M</>70??-<'!+.!*YPI4 XX[4 ?:E%%% #7C61<.H8>C#-&U<@[1D=..E.HH
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M*.C_ !K^$NCVOA'7O 6G#2)]5N[Z?5$U3<\*3RM)M";>=N<=:^NZ* "BBB@
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M+147VJ'_ )[1_P#?0H^U0_\ /:/_ +Z% $M%1?:H?^>T?_?0H^U0_P#/:/\
M[Z% $M%1?:H?^>T?_?0H^U0_\]H_^^A0!+147VJ'_GM'_P!]"C[5#_SVC_[Z
M% $M%1?:H?\ GM'_ -]"C[5#_P ]H_\ OH4 2T5%]JA_Y[1_]]"C[5#_ ,]H
M_P#OH4 2T5%]JA_Y[1_]]"C[5#_SVC_[Z% $M%1?:H?^>T?_ 'T*/M4/_/:/
M_OH4 2T5%]JA_P">T?\ WT*/M4/_ #VC_P"^A0!+147VJ'_GM'_WT*/M4/\
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M'_#&OP0_Z)?X<_\  ,5[+10!XU_PQK\$/^B7^'/_  #%'_#&OP0_Z)?X<_\
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MAB0 *BCL   !6C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 C*&4JP!4\$'O39(4EC,;HKH>JL,C\J?10!%';0Q-N2)$;&-RJ <>E(
MUG WWH(SSGE!UJ:B@"$V=NV"8(R0,#Y!T]*0V5N6W&WB+<<[!GCI4]% $36L
M+MN:&-F_O%1FI:** "BBB@ HHJ.XD:&WD=(S*ZJ6$8ZL0.E $E%?(FO_ +='
MBS0?BI:?#Y_@1XBF\17T$UY96ZZC$#<6\;,#*!LZ?(37OFB_''P?J&I:7HE]
MK^EZ3XKOF:(>'Y[Z,W:S*I9XMN<EE ).!VH [^BL+PSXZ\.^-+2]NM!UNQUB
MVLIWM;F6SG65894^\C$'AAW!KFM0_:"^'.F^"==\7/XRT>7P]H9*:A?07:/'
M!)G:(R0?OEL*%ZDD"@#T*BO.]#_:(^&?B32X=0T_QSH5S:S+;LKK?1\>>7$(
M//!8Q2 #N4;TKK-"\8:'XGN-2@TC5K/4IM-G-K>QVLRN;>4#.QP#\K8/0T ;
M%%<UHOQ*\*>)-'O-5TKQ%INH:;9S&WN+NVN4>.*0$+L9@< Y(&/>L#7OVA/A
MUX=T#Q'K%UXNTM[+P[@:I]GN4D>U8@,%90<AB""!WS0!Z)163X5\6:+XXT&T
MUOP_JEKK.D7:;X+VRE$L4JGNK#@BM:@ IKHLBE74,IZAAD4ZB@"#[#;?\^\7
M_? IQM86C"&*,H.0NT8J6B@"%K.!VW-#&S=,E!FG"WB63S!$@D_O;1G\ZDHH
M :54L"5!.,9Q48M(%+$0Q@L,'Y!S4U% $:V\21F-8T5&ZJ% !_"C[/%_SR3L
M/NCMTJ2B@"(VL#-O,,9;.=VT9J6BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /EWQUX,UR\_X*&?#7Q-!ID\F@V?A*]M;B_5?W4<K--M
M0GU.1^=<-XH_9QCUZ\^._BU?"BR^-7U'=HFJO;K+<+"21+Y + ?-&7&,C.<9
MK[;HH ^$_@[\-?\ A6?@/Q_/H.E3:X-0\.1M)H<7AF+2K<S@OE) )W\R8@C<
M0,$!?FKS_P +?L\VL/C?XAZ+;^%8];\*7G@F]B+V_AF/2K2]O4=9H D8F<R.
MKHI#.%P0,9ZU^EE% 'Y[>#?V2_"/C+Q7\0I;_P  Q'1+/PMH\&@(]N8TAG!N
M3.(E/1@Q7)_VO>K_ (T_9IU+POI7BG3_ (9>%_[#GUSX:11WRV*A/ME]YK>:
MAR0#*R<<D9SR17WU10!^?WP?^!]WX8L?%%MH9U,Z9J^AP"^TVQ\-PZ39)<BX
MAV[R+AV>=5\WD(5P6.[H#VGQ6_9)\(Z39:HGA?P/;Q_VMX:GCU".&,;;JX4$
MH\@[R$L>:^S:* .6^&.D>'="\#:38^%-+CT;0H856VL88#"L*X^[L/2NIHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MA?BQ\6+7X1:!)K.H:+JVIZ?$,RR:;'$^SG&"'D6J<7QX\+6_B :%K$EQX>UA
MIH;>.SU&,;G>5=R#,991G@98CD@#DU>^-'P]N/BE\.]3\.6UW'8S784">52R
MK@YY K.\1_"&+Q!K&O:@YLS-J5[IERDDL 9XUM9(W*D^YCR/0X- '2^'_B-X
M;\4Z]JFC:5JT-YJ>F,%N[=0P*$^A( 8>ZY K$U[X[>"?#M]KUC=ZSF]T2SDO
M[Z&*WE?RXD0NY#!=K$*#\H)/M7+_  O_ &>[?X=^-(M;V6=Q+!!<V\5Z)KHW
M++-(KD.K2&(\K_=R,<8R<NU_X&WNKZQK4MK<Z?I=CJ5O=Q2I )F>1IHF0,RL
MY12"VXE ": .@TG]H/P!K=]865IKX:ZOK7[9!'):3Q[HMI;)+( #M!.TD-P>
M*WH_B9X7F\.ZAKZ:S;MHUAS<7W/E)\H8\X^;AATSSD=017E6M?L_^(=<UBSU
M*;4M)%W#.T[2JMPN08)(0H0/L.!(2"5+=>:]"OOA;IT_PI'@N/3M-DL_L@@:
MWDB9+9WQEF*QE2-S$L<$')- ":/\<O NO:7=ZC8^(8)K2TL)M3G=HI$,=M%_
MK9"K*&PO0C&?:L>/]J'X627%S;CQG8B:W0O)&RR*<!48[<K\Q"R(<+DX85Y1
MK7P U6'6/"NG)-<W-^=4NFU"ZL[5ELFTJ8M(]G,[ EU)V_>8NQ R3SG0O/V.
M8;KQ'%J7GZ3LAU?4-1A5[++1I<6MO B ]BOD$Y]",4 >H:+^T/X&UKQI?^&(
M]8CAU*WFM88?.("7?VBVCN8FB()RI251EMN6X&:C\0?M'>!-#TW7;J+6%U:7
M198(;NTL1NE!EG2%2FXJKJ'D7)4D#ZX!\@\%_L:ZIX9M9[.YU30[F.Y70DDU
M!;%OMT2Z?:6T)6*0GY0SVY=?[NX=Q4-Y^Q5J=UX)T/PVNNZ7;QZ%;):VE]#:
M,MS<J+RWN&^T/_%D08P,#.TGI0!](^-?B%X=^'=A#>>(M4BTR":011;U9V=C
MV"J"Q]SC [UE7WQL\#:;K&IZ5<^);.*_TVTDO;N$EOW<4:%W.<8)5025!+
M\<5C>//A)>^(/B7I'C73KRSEN[&P?3SIVL0F:TVLS,9$48*R'=@D'D*H/2O,
MO%W[(VI>*-)\1Z4NKZ5:6VJ:EJVK17J6C?;(IKV*9/+W_P#/-3-C Y*@C/-
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M_A$:?7'.:Z:@#Q;XN>+/$$OCSPYX;T?7(O#EI<:==:E<71CWR3M&H,<:9(P
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>cdtx-20231231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g5.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '4!!D# 2(  A$! Q$!_\0
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M/"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KU7]GS_D-:W_U
MZQ_^AUY57JO[/G_(:UO_ *]8_P#T.L:W\-DRV/;:***\HQ"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^/:***]LZ HHHH **** /5?
MV>_@O9?&K7-;LK_69M$@TVR%X9X85D)&[!!!/0#FM+XG?L^Z?X7^'L'CKPAX
MN@\8^&&G%O-,L/E20L3M!ZG(W8!! (R.*[+]A62*'Q7XX>>+SH5T/<\><;U$
MG(S[BLF3XQZ!\3(_"'POT'PS'X&\"WFKVYOT^T^9++ND!(W=@3CDDG('0"O)
ME4K?6)*+]V-K[6M;7SOV/H:='#?4X.:7/+FMO>]TEY6[W/GKS%+;=PSZ9KJY
M/AKK,7PUA\=M]F_L":^.GJ?-_?><"1C9CI\I[U]EPZ7:>*/BAXE^%NI_#'3=
M,\!V.GEK;6(K,QO%A%*S";&,DDXP=P*<YYKST>+5;]BC3+)K+3A;3ZS_ & ;
MHQ?=B\QE^U#_ *:X&=WN:/KDI<O+'=KKT=_Q%_9D(<_/.]E+HUK&W?IKN?)?
MF+NV[AN],\T-(JG!8 ]<$U]_ZYX;\!^$?%$7@J:UM9?#::7NDT&V\*SW=U."
MI_TG[9&I)8'N.GUQ7E/@6^T+X?\ [-/C+Q#::%I?B2?3O$LD&FSZQ9!SMWQ+
M&S@@-P#G:<<U4<<IJZ@];6^?]?\ !(GE3IRY95%HFWUMR[Z)_P"7H?./@GPG
M?_$#Q3IOA_2#"VHZA(T<'GR;$W!68Y;G'"FNMT'X9Z$K>.[+Q7XNM?#FM>'5
M>.VL\"07TZ%@R*3C(W*J\<_.#T%?4"W6G6/Q\^#7B2PT'3K*[\7Z)(+V..(!
M(V,22B1 .CCE=W7:<5S<%Q9^-/$G[2-[>Z+IJS:=8O;6^RV4[3&+A?-!(.)&
MP"6'4UF\7*6RLK+UOS6-XY=3IZ-\TKM=;6Y.9?U<^._, P&(5CV)KT3X!_#"
MT^,OQ$A\-W.HS:=!):S7'VBV578%,<8/'.:^@-!M;+X:_ _X:_V%\.K/QU+X
MM9/[6N9K4S-EP,IN"DJ>2JYP%\L]Z[*WTBQT3]N33[;3K&WT^V_X1=F\FUB6
M-,EFR<* ,\#GVIU<:W&:@K:2L_3R%0RQ*=.525TW&ZL_M:[]=.Q\(:A"+.\N
MX =PAE>,,>^UB,_I7TMI/[)?A:^T/P6]]\09=)UOQ5:+/I]E-8!TDD\M7:-6
M##IN'4@GM7S;KG_(6U/_ *^9O_0VK[SF\=7'@GPK\"FM/ X\77-W8QP+<QPE
MI[ &*!6>-@I"Y#'.2,A>M7C*E2"@J;U=^W;S,LMHT*CJ.NKI6[]7;IJ?#GC;
MPK=^ ?%NK^']1>-KO3;AK>22,_(^.C#/8@@\^M8JL&&001[5]TVWP;\+^&?B
MM\5-=O+Y=5U"QLH=2MGU2U.H&R><2M)*T*\RE2@VC&0#CWKS3XR0^"M2T_X>
MZVME<:]K<FHQI>MI_AZ?3(M;M-Y+!$90ID& ORG)W'MC#IXU3:BDWMKYVO\
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M*K[6[2/.QF#^IN,92NW=_+H_GN)1116YYH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!\>T445[9T!1110 4444 =#X,^(7B'X>W%]-X>U%M-EOH/LUPRQ
MJ^^/.=OS X_"N=7Y<8XQTP>E+14\J3;2U93E)I1;T1Z'JG[0GQ&UKPNWAZ]\
M5WD^EO'Y4B$())$QC:T@&]@1P<GGO7,OXYUR3P3'X0:_8^'([DW:V/EKM$IS
M\V[&[N>,XYK"HJ(TX1VBEUV-95ZL]93;TMN]NWH>CV/[1OQ*TWPRN@6WBV]C
MTU8_)3Y4,R(!@*LI7> !QUXKEH?'FO0>#+KPFFHN/#UU<?:YK(JI#RY!W%L;
ML_*._:L&BA4J<=HKOL$L16E\4V]+;O;MZ'8GXP>,&U#PW?'6I/M?AR$P:5)Y
M4?\ HT94)M V_-\H ^;-06?Q2\4Z?+XEDM]7DC?Q(&&K-Y:'[5NW;L\<9WM]
MW'6N5HH]G#^5?UK^8>WJ[\[^]]K?EIZ':^%_C3XX\%>&KC0-$\1W>GZ1-NS;
MQ[3LW?>\MB"4SWVD=:D/QO\ '#>-(_%IUZ0^(H[7[$M]Y,>1#R=FW;M[GG&:
MX:BCV5.[?*M?(?UBLDHJ;LMM7H.FD:XEDDD.YY&+NWJ2<D_F:]+TO]I;XF:+
MH]KI=CXJGMK&UA6W@C2"'Y(U "@$IG@ 5YE13E3A4TFDR:=:I2;=.35^SL=1
MH?Q1\6^&_%D_B;3_ !!>Q:]<9^T7KR>8TX..) V0PX'!'&!BI_&GQ>\9?$+5
M;+4=>\075W=V+>9:-&1"MN^0=R*@ 5N!\PYXKD**/9POS<JN'MJO*X<SL];7
M.V\;?&SQQ\1M%ATGQ'XAN-2TZ(AOLY5$5V'1GV@;R/4YK(\9>/->^(%Y9W7B
M#4&U&>SMUM('9%79$"2%^4#N36!11&G"-N6*5@G6JU+\\F[]WVV-[P9X[U[X
M>ZE/J'A[4&TV\G@:VDE5%8M&Q!*X8'N!^5$/CO7;?P7<^$H]09?#MS<?:Y;'
M8N&ER#NW8W?PKW[5@T4^2+=VB54FERJ3MK^._P!_4W_%'CS7O&=GH]IK.H-?
M6^D6_P!EL49%7R8L*-HP!GA5ZYZ5A0S26\T<T,C0S1L'22-BK*P.001R"#WI
MM%-1459(F4I2?-)W9ZC-^U!\4KC1_P"S)/&%TUOLV&3RHO.9<8P9-NX_7.:X
MS4O'FOZMX6TCPY=ZB\NBZ0YDL;4*J^0Q))(8#<3R>I[U@T5$:5./PQ2^1M/$
M5JGQS;Z;O8]/7]ISXHK]@_XK"\;["I6+<D9SD;<O\OSG'=LUB>"?C-XU^',E
M^WA[7Y]/6^D:6XBV))&\A/+[&! ;W KBZ*7L:5FN56?D/ZU7NI>T=UYLZS0/
MBQXP\,>++OQ-IOB"\@UR\)-U=LP<W&3G$BL"K#@8!'&.,5G^,O'&O?$+6FU;
MQ'J<VJWY41B67 "(.0JJ  HR3P!WK#HJE3@GS):F;K5''D<G;>U]+G0VOQ"\
M0V/@F\\(6^I-#X<O)O/N+)(U E?*G+-C<>47C..!2>"/'^O_  XU"YO?#FHM
MIEQ=0_9YV6-7$D>0=I5@0>17/T4^2+35MP56HFI*3NMO+T.R\ _&/QE\,%N8
M_#.NS:;!<MOEM]B21%NFX(P(!QW'H/2JL_Q0\4W6AZ[I$VKRRZ?KMV;[4HF1
M";F<E27)QD'*KTP.*Y>BE[.%^;E5Q^WJ\JAS.RZ7[[F]XB\>:]XMTO1M.U?4
M&O++1X?L]A$R*HACP!M! !/"KUSTJ34OB)XCUCP?IOA6\U::?P_IS^9:V+ ;
M8V^;'.,G&YL9/&>*YVBGR1T5MA>UJ-M\SUT?H;TGCS7IO!</A)]08^'8;G[8
MECL7 ER3NW8W=SWQS3O%_C?7/B5K=O?^)=4-Y=B-+7[5)&H\N(,>H4#(&XGI
MFN?HHY(IW2U$ZDVN5R=M/PV^X]F_:,^*&C^,%\)^&/"E[-?>%O#>GI!%<3(R
M&>;:%9R&YX55'/JV*\9HHJ:=-4H*$2Z]:6(J.I/=A1116I@%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7JO[/G_ "&M;_Z]8_\
MT.O*J]5_9\_Y#6M_]>L?_H=8UOX;)EL>VT445Y1B203R6TT<T3M'+&P9'4X*
MD<@BI=0U&ZU6Z:YO+B2ZN&P&EE;<QP,#FJU%+S*YG;EOH:6E^)-5T..2/3]1
MN;*.0Y989"H)]<>OO45GK5_IUQ-<6M[/!/,"LDJ.0S@\D$]\U2HI<J[%>TGH
MN9Z;:[%_2=?U+0F=M.O[BR,GW_)D*AOJ*(=>U*VU)]0BO[A+Y\AKD2'S#GK\
MU4**.5;V!5*B22D[+;78MQZM>PV=S9QW4R6MR=TT*L=DA]6'>B^U:]U18!>7
M4UT($\N+S6+;%]!Z"JE%.RW%SRM:^A+:W4UE<1W%O*T,\;;DD0X92.X-.O+Z
MXU"Z>ZN9Y)[ESN::1LL2.^?PJ"BCS%S.W+?0T[_Q-J^J6BVMYJ=W=6R](I92
MR\=.._XU7EU:]FL8+*2[F>S@;?% S$HC<\@=NI_.JE%+E2V13JU).[DW\S3;
MQ-JS:FNHG4KDWZKL%SYA\P+Z9].:AL=:U#2[Q[NSO9[6Y?.Z6)RK-DY.?7FJ
M5%'*MK#]K4O?F=]]^I>DUS49M3749+ZX>_4Y6Y:0EP?8]JK75U-?7$EQ<2M/
M/(VYY)#EF/J345%.R1+G*6[+EOJ]]:V,]E#=S16EQ_K8$<A)/J.],T_4KO2;
MI;FRN9;2X4$"6%BK 'J,U6HHL@YY73OMMY%^QU_4M+O);JSO[BUN923))$Y4
MODY.?7FE/B#4V%Z#J%P1>_\ 'SF0_OO][UK/HI<J[%>UJ)64G;U+<^JWMU8P
M64UU++:6Y)B@9B4CSUP.W4T?VK>_V;_9_P!KF^P;_,^S;SY>[UQZU4HIV1//
M+OY?+L6DU2\CTZ6P2ZE6QE;>]N&.QFXY(]>!^5+?ZM>ZHL(N[N6Y\E/+B\UB
MVQ?0>@JI119;ASR:LWH=AXT\666IZ+H>BZ2)ET[3XLN9EVF24]6QD\=3_P "
M-<?114QBH*R-*U:5>?//R_!6044459@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >L_\ #%OPN_Z!=Y_X&O1_PQ;\+O\ H%WG_@:]>ZT5\W]<Q'_/Q_>?
ML_\ 9N#_ .?4?N1X5_PQ;\+O^@7>?^!KT?\ #%OPN_Z!=Y_X&O7NM%'US$?\
M_']X?V;@_P#GU'[D>%?\,6_"[_H%WG_@:]'_  Q;\+O^@7>?^!KU[K11]<Q'
M_/Q_>']FX/\ Y]1^Y'A7_#%OPN_Z!=Y_X&O1_P ,6_"[_H%WG_@:]>ZT4?7,
M1_S\?WA_9N#_ .?4?N1X5_PQ;\+O^@7>?^!KT?\ #%OPN_Z!=Y_X&O7NM%'U
MS$?\_']X?V;@_P#GU'[D>%?\,6_"[_H%WG_@:]'_  Q;\+O^@7>?^!KU[K11
M]<Q'_/Q_>']FX/\ Y]1^Y'A7_#%OPN_Z!=Y_X&O1_P ,6_"[_H%WG_@:]>ZT
M4?7,1_S\?WA_9N#_ .?4?N1X5_PQ;\+O^@7>?^!KT?\ #%OPN_Z!=Y_X&O7N
MM%'US$?\_']X?V;@_P#GU'[D>%?\,6_"[_H%WG_@:]'_  Q;\+O^@7>?^!KU
M[K11]<Q'_/Q_>']FX/\ Y]1^Y'A7_#%OPN_Z!=Y_X&O1_P ,6_"[_H%WG_@:
M]>ZT4?7,1_S\?WA_9N#_ .?4?N1X5_PQ;\+O^@7>?^!KT?\ #%OPN_Z!=Y_X
M&O7NM%'US$?\_']X?V;@_P#GU'[D>%?\,6_"[_H%WG_@:]'_  Q;\+O^@7>?
M^!KU[K11]<Q'_/Q_>']FX/\ Y]1^Y'A7_#%OPN_Z!=Y_X&O1_P ,6_"[_H%W
MG_@:]>ZT4?7,1_S\?WA_9N#_ .?4?N1X5_PQ;\+O^@7>?^!KT?\ #%OPN_Z!
M=Y_X&O7NM%'US$?\_']X?V;@_P#GU'[D>%?\,6_"[_H%WG_@:]'_  Q;\+O^
M@7>?^!KU[K11]<Q'_/Q_>']FX/\ Y]1^Y'A7_#%OPN_Z!=Y_X&O1_P ,6_"[
M_H%WG_@:]>ZT4?7,1_S\?WA_9N#_ .?4?N1X5_PQ;\+O^@7>?^!KT?\ #%OP
MN_Z!=Y_X&O7NM%'US$?\_']X?V;@_P#GU'[D>%?\,6_"[_H%WG_@:]'_  Q;
M\+O^@7>?^!KU[K11]<Q'_/Q_>']FX/\ Y]1^Y'A7_#%OPN_Z!=Y_X&O1_P ,
M6_"[_H%WG_@:]>ZT4?7,1_S\?WA_9N#_ .?4?N1X5_PQ;\+O^@7>?^!KT?\
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M%O\ H%+_ -_Y/_BJZRBCVU3^9_>'U'"?\^H_^ K_ ".3_P"%5^%O^@4O_?\
MD_\ BJ/^%5^%O^@4O_?^3_XJNLHH]M4_F?WA]1PG_/J/_@*_R.3_ .%5^%O^
M@4O_ '_D_P#BJ/\ A5?A;_H%+_W_ )/_ (JNLHH]M4_F?WA]1PG_ #ZC_P"
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M?A;_ *!2_P#?^3_XJC_A5?A;_H%+_P!_Y/\ XJNLHH]M4_F?WA]1PG_/J/\
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M!2_]_P"3_P"*H_X57X6_Z!2_]_Y/_BJZRBCVU3^9_>'U'"?\^H_^ K_(Y/\
MX57X6_Z!2_\ ?^3_ .*H_P"%5^%O^@4O_?\ D_\ BJZRBCVU3^9_>'U'"?\
M/J/_ ("O\CD_^%5^%O\ H%+_ -_Y/_BJ/^%5^%O^@4O_ '_D_P#BJZRBCVU3
M^9_>'U'"?\^H_P#@*_R.3_X57X6_Z!2_]_Y/_BJ/^%5^%O\ H%+_ -_Y/_BJ
MZRBCVU3^9_>'U'"?\^H_^ K_ ""BBBL3N"BBB@ HHK'\8>(E\(^$]8UMH#=+
MIUI+=F%6VF38A;:#VSCK32<G9$RDHIR>R-BBO%OA[^T@?%OB;0=&UCPI>>&V
MU^V:ZTJYDN%GBN552QY &W@'],XR*S/#'[5BZUK&F17WA"\TW1]2U0Z/;ZJM
MVDRFYR %*!0P'S+S[]\5U_5*UVN7;S7]=&<"S##-)\V_D_+RTW6_<]\HKRG2
M_P!H#3M0^..H?#=M/>"XMT/EW[3 K-((ED*!-O&%+<Y_A]Z@^%W[1VB_$N\\
M8*+;^R['P[^\>]FG#I-#F3,N HV@"/..?O"H>'JI<SCI9/Y/8TCC,/*2@IZW
M:^:W^X]=HKPS0OVD]4\3ZA:7.E_#G6[KPI<W2VT>N9QP7">9Y80_(#U.[C![
MC%>XLZQKN9@H]2<5%2C.D[31I1Q%/$)NF[KT:_/?U0ZBF--&BEF=54'!8G@4
MLDBQJ6=@BCJS' K$Z1U%-DD2)=SLJ+ZL<"CS$W%=RY49(STH =13&FC6/S"Z
MB/\ O$C'YT^@ HIC31J6#.H*@$Y/3/2E\Q0X0LH<C(7/)H =13?,7S-FX;\9
MVYYQZTAFC4D%U!&,C(XSTH ?131(C*Q#*0O!.>E*K!U#*0RGH1TH 6BN4\)^
M/4\7^)/$^GVEDXL=#N5LCJ!D!2>XVYEC5>HV94$GJ3[5S?PZ^/>B_$?X@>)_
M"ME"T4^C,1'.T@87:J^QV48X ;;ZY# UM[&IJ[;:OYG-]9I7BN;XFTO-K<]/
MHKY_C_:<\1-XS'A@_"W55U;ROM)M_M@WB#=M\S'E],^_XU9\3?M03^&M?\2V
MY\%7U]HOAZ[CM;_5+:[0^7O.%;RRH/)SWQZD9K;ZG6O:WXK_ #.;^TL-9R<M
M-MI>O;RU['N]%<9I_P 2[:]\=6GAUK5XHM0TM=4TV_+?)=+D;T QE64,IQW!
M/2NQ:1595+ ,W0$\FN:491W1W0J1J7Y7MH.HIOF*6*AAN')7/-$<BR*&1@ZG
MHRG(J#0=13&E2-E#.JECA03C/TKRRQ^-&IZQIOC2;2_"DNJWOA[6#I:65O=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7)?%RUFO?A;XNM[>&2XGETJZ2.*)2S.QB8  #DD^E=;151ERR4NQ$X\\7'N
M>$?L[_ _3M"T'PSXKU235KWQ%'8!(8=6F)73PP(9(HR!L&"1@YZGUKYX\,^#
M]5M&M)M"\-^)HOB'!X@>:TN);)QIZ0''S2%QM'(//ZU]_45Z,,=.,I2:O?\
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ME47MJ?/:R4KKW4M.O>W-=7;;L]D<=<>&[/P3\0O"T%C'>69N)G^TZY=W#/\
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MV>Y6V2*.4$QC+ Y=@"<8XQR:R+7XDZII?B?QPVM68AT+1H89E*2HSQ9CR%P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !4%]?6^FV<UW=SQVMK"ADEFF8*B*!DDD\
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MZ]B6I?N7HF_NWM\]NZU/HB/X@^%YK6:YC\1:6]O#&DTLJWD95$8X5F.> 20
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MPJ1MR^MG]XM%%%<QVA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 53UC2+/7]+N]-U"W6ZL;N)H9X7SM=&&"I^HJY13O;5":35F4]
M'TFST'2[33=/MUM;&UB6&"%/NHBC 4?05<HHHWU8))*R"BBBD,**** &R1K+
M&R,,JP(/..#69X9\+Z5X-T:'2=%L8M.TZ$L4MX0< L22>>3DD]:U:*=W:W0G
ME5^:VH4444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KY>_:N^-7B[X7^,-'LO#NI+9VUS8
M^=(C0))EA(PSE@<< 5]0U\2_MW?\C]X=_P"P8?\ T:U>)G56='!2G3E9Z:KU
M1]%P_1IXC,(4ZL5)6>C]&<3_ ,-<?$[_ *#L7_@'%_\ $T?\-<?$[_H.Q?\
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M ,/ZH^%XN_W6G_B_1GI=%%%?HA^6!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5P>E_'#P9J?A#7_%3ZS#IOAK1+^ZTZ[U;4B+>V
M\RWD,<K([$!D$@9 PX)4@9KJO$UW<6'AO5;JT&ZZAM)9(AC.7"$K^H%?-7[/
M'@W0/$'[!7P];4M,L]8^S>&3JT1O85F$=Z\,KO, P(\S?+(=W7))ZT >]WWQ
M8\'Z9\.X?'=WXBL+;P?-:QWL>L32A8'AD ,;*3UW;EP!R20 ,FCX<_%;PC\7
M-%FU7P?KUIKUC#,;>9[9CNAE !*2(P#(V"#A@#@@U\C:;-%'\$?V'TU/:=!D
MU32!<^;S&;C^R9S:!L\9\[81G^(+WQ7KGPOC1?VV/C<^G8-DV@^'QJ/E_<%\
M!=X#=M_D>5GOM*>U 'T317P=\4O%7Q!C\-?M%^/;#XE>(-,G^'?B4QZ#H]L8
M?L(5;>SE=+A2A:>-O-9=A("Y)')R.F\=^+_&_P"S_P"*O'MA!\0M2\2";X8Z
MEXLBN/$PB>.SU2VE2-9(E1 (X6\X?N<%047WR ?9=>8_$']HKP?\,?$>H:1K
MLMY"VFZ5#K%]=0VYEAMH9KM;2!7VG=ODE9MJ@'B-R2,5XG^R[9>,==^)\?B&
M;7OB)-X'M?#40NXO&MY&$GUEVS*8XU',:Q\Y7$88C9D9QY_\0FD\;?LH_&OX
MN21F:7QQX@L'TI68(3I-GJ-O;6*@G[HDV2S9Z?Z1F@#[ZHKX7USXW>+KSX+Z
MWXLNO%NK:;XMU;QO8^&]6\*Z6L:W7AN 7026QLU<;6NF@S)]H<XDW;DP @KV
M3]DW1?%<5QX[UK6M6\87OAB^U*./PS;>,KL27:6:0IO=DQN3=.TP!<[BBID#
MN >Q_$#QYHWPO\%ZQXK\0W+6FB:3;M<W<Z1M(4C'4A5!)Z]A6]%(LT:2(<HP
M# ^QK\\?CYJ'B#XI?L__ +1/C35_B)J^B_V%KNH^&[;PM'+ NFBUMY(XD@EB
M9-S2S@^8)-P8>8FW@8/KM\WB#XM?$KXQVD_Q,U[P%8?#ZWLK?2K;1+F*WB3S
M-/6Z>^N@Z-YREW*A6^0+"W&22 #ZTHKX6O/BOX\U3P+\,_BYXZU#Q/IOP[F\
M*:?>ZM<>";N*VDTS4&?=+=W=LR[I[:1#%A5W;!O^0Y#!?$GB[XU_%#QU\6[C
MP7#XH_M7PIK[:/H%OINL:=::1;^3##(IO+>=A).)C(69B"-C*(\$$T ?=%>;
M>(OVD/A?X2\=0>#-8\<Z-IWB>:6. :=/< .LL@!CC<_=1V!!"L03D8'-=YIN
MH"ZC6&9H4U&.*-[FUCE#F%F&<'OC(.#WQ7SA^U%9VGQLDD^ _A:RM[C5M<N;
M34O%6IQ1KY>AV$<R2>=*P'-U+Y(CB3[Q&7.%3) /IRN0^(7Q/TCX:MX:BU*.
MZN+KQ%K%OH>GVUG&'DDGE#-D@D81$1W9NRH3STKY>^/_ ,4/%W@?]H:/X?Z1
MXUN+3PSXW;2QJ.K-EG\%EI6B"QOL*I]N$9CC\P_)*&?H17HE]8-\8OVL;VUC
MN9H=&^&>@-;1W4+?.FLZE'@NI[O#:*#[&ZH ^C*YS7OB!HGAGQ9X7\-:A<M%
MJ_B22XCTV$1,PE:"(S2@L!A<("><9Z5\,:#^U-X^AE^%\VI:X4L_AW/_ &5\
M4WE( EDFOWTJ*6;CC:8C='IPP-4/'OQ0^(-CH_P<^*=G97'BWQ)JVJ^+-?T;
M2+CD6FGR6<@ME1%PTBQVRI-Y:_,Y+ '+"@#[SUCXAZ/H/CKP[X3OI)H=6\00
MW4NG$Q$Q2FW5&ECW] ^Q]P4]51R/NFNFKY$^(4\-I\.?V:M<T_QE<^/[JX\?
M:3)#XHN"N^^2[CN$G954 1H8Y7 C ^15"G[I-?7= !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?$O
M[=W_ "/WAW_L&'_T:U?;5?$O[=W_ "/WAW_L&'_T:U?/Y]_N$_5?FCZCAK_D
M9P])?DSYFHHHK\L/V4]8^ >D>%O$EUKVG^(?#2ZS+::;<ZK%<_;YH"HA0'RM
MJ$ AC_%U%9E_\&_$>I^&;GQC8Z/#I^BS6[:G#IBSO+-#9[L;P67#*/=MY'.,
M<UROA/QCJ?@J\O;K2WB26\LI;"7SH]X,4@ <#T.!UK5;XL>(I/!T7AJ6:WFT
M^&W^QQ2R0 W$<&[/EJ^?NY]LX.,XKTH5</*DH55JK[)+72UWN^IY-2CBHUW4
MHRT;6[;TUO9;+H=IX8_9SOI/'^G^'/$NHV>G_:].GOA]EN0779&&4$LFTC)!
M)7(VAL'BN#\'_#G5O&W]L/8S:?#::3&)+N^O+I8;9<MM0!SP2[<+Z^U;;?'C
MQ:9='9)-/@3289X;6"&S5(U$T?ER$J#U*^F /2L#P7\0-9\ IJ,>E/;-;ZA"
ML-S;7MLEQ%(%.4;8PQN4\@]J<I8/FBHI\MW?OLK?C?Y"A''J,G)KFLK=MW?[
MU;OJ;^L_ OQ'X?M=:N-0N=)M8=(O([&Z>2]VCS7C610F5^;Y7'3N#V&:Z?QS
M\!X?#5_XOT[2$DUV73VTM+2X6_421R71V['B"8<LW3E=JE3SFN&\6?%CQ%XV
ML=2M-5EM9(=0OX]2N/*MPA,Z1")2#G@;!T]>:GU#XS>*=2N-;N'NK>&XUB2S
MFN9;> (RO:X\AHSGY2,#/K5\^"CS*,7Y=]I?_:D>SS"7*Y25^J5[;P^?27X(
MZO0_A"GAN;QU8>(/[)U>_L?#5S>0II]V+@V=TDL:X?;C;(NXC!]:YCQE\$O%
M7@/01JVK6L*6R21Q7"Q.6>U>1=R+)E0.1W4L >"0:-6^-?B;6;W4[N<:;%<Z
MEI\FFW<EK8)"9HY'5W=MN,R$J/GJIXO^+7B+QUIB66L36T^&1Y+E( D\[(NU
M3(V>>/0#)Y.32J3P<H.,4[K;;\?P_$=*GCXU%*;C9_%OV6WX_AYG'4445Y1[
M(J_>7ZBK>L_\AB^_Z[/_ #-5%^\OU%6]9_Y#%]_UV?\ F:T7P/U7ZF3_ (B]
M'^A3HHHK,U"@]#@X-%% 'MZ^&?#/B+X1^';O1/ R#Q3KFIOH<$HU6<A940'S
M]K';ECG*G@"N?_X9V\4MJ5C9P7>BWC7LMU##-:Z@)(BUNF^4%PN!CD<]P<XZ
MUR^F?$C7M&T?1M-LKF.V@T?46U6S=8QYB7!&"2QZC'8BN@NOV@/%UU=VMQG2
MX#:M=-%';:>D4:FX39-\JX!R.<GG))YKV/:X2HDZJ=U;9)=K[?/\#PO8XZDV
MJ,DTW)^\VWUY=^FWXCK'X ^)=0TV.^BN]%\J:*YN($.HKYEQ! #YDT:@$M'D
M8##KD= <U<TC]G3Q/,=$N]2CAL]+O+BS6[;S2);2&X8!'?*[1G.."V"5# 9K
M<\#_ !RTCPK\.;32K@ZA=ZE9:?>V,-K)9P/'^^!"[+GB2.,9),>#D@<X %<1
M<?&KQ5>:?IEM<7%K.]@UNT=T]L#-)Y!!B#MGD# SP,XY)JG' 0C&3NVUM?KI
M^OX?(E2S*I*459).U[/;7;Y6^?S1KWWPWL?#_BCQYI?FPW\&GW46C:=<3.&
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MLGEM@;=H&[LS XYQBMJQ_:(\::??WEY'/I\LUSJ']J?Z18)((;@@*S19Y3<
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M5_Y']S#ZYA_^?B^]'%T5VG_"F?&7_0$?_O['_P#%4?\ "F?&7_0$?_O['_\
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MV\T?%<55Z57#4U3DG[W1^3/0J***^^/S(**** "BBB@ HHHH **** "BBB@
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M<^P444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV-NQE1C:,&M:=/G5S&I6]F[6\][?<?<11@,D''2DD_<QN[C:B*69B.@ R3^
MKX7^%-]X5\*>)O!*_"G5+R]ANO ]Y>^.K+0;V2\CAE6R5HI<,S+'=>?N 4$'
M/&!WJ_L0Z+IWC<>,O#>HWBZC8ZGX=TV_G&BZK<R0"=GDS)=/Y@:.^)V[T0A"
M%(Z5M+#\J<K[>1A'%<TE%+5WZ^5^Q]UZ;>V^L:?:7]C*MW97<*W$$\?*RQL
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M)VE_]^V_QH_U7Q/_ #\C^/\ D'^N&$_Y]2_#_,^ Z*^_/^%%_#S_ *$[2_\
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M2J*;G'3U_P CGQ'%F%K4I4U3DK^G^9SVT^AHVGT-=Q_P@'A[_H&+_P!_Y?\
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M,D@E>U73X1"SCHY3;M+#UQFM;:0  N !@ #  ]*[C_A /#W_ $#%_P"_\O\
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M!Q?B3_DIW@O_ *X:A_Z!%7:5Q?B3_DIW@O\ ZX:A_P"@15VE !1110 4444
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M0"N0<'.:]0\?_ _Q#>?$*?QU\/?&:^#/$=_:1V.IQW=BMY:7L:?ZMF0GAU'
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M!-$W1XW3:P_$$TNH'B?PQ^(_QD^)DWA[Q7#X:\,Z=\/=8G5ELIKF0ZK'9,Q
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MME(VQ#@R(H)]A7I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIM)Q9O>H"7M5NBGDM, #F,.6R",9!% 'HE%%% !1110 4444 %%%% !1110
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MIV@ZX^GVS"+3<&-3_P ?$GI_N5W;?=/TJII;!=)M68@ 0J23VXH][^9A>/\
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MVN?\\M-_\")/_B*[2BCWOYF%X_RK\?\ ,XO_ (1[7/\ GEIO_@1)_P#$4?\
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M=3G.<FO3Z* /-)?@U)JEOJ=UK'B*XOO$=W):20ZM#;)"+0VKF2 1Q<C =G+
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M6@#S#PKX/UOP!\/O$7B+5M(7QM\0=:']HZM86TJ(L\BC]W96[2G:(H4^1 Q
M8AF.&D8UPWPSUS7/"M]\7_B!J6BZY'INK36;Z1'XHM8[;5)[@*\:V2I&?^/=
M9'B2(L V99<EAAC]$?VU9?\ /POZUGZM'H>NFR-^([G[%<I>0!BV$F3.U\#J
M1DD9[X/4"@#POXD>$_'7@?3?A3;>%YM=U2ZAUCS]>M]'Q'#J$TTB//+<SYS'
M&"T[ ,K(P.UL$(:\[E\'_&R7PMJ%S_PD'CM=4N/#6N:@(([B,;-4MK[.EPH"
MIVAXF.4SB557<>*^R/[:LO\ GX7]:/[:LO\ GX7]: /E7Q8?BW-XSU&1D\=C
M4WU[2FT[^Q3;+H:Z/YUK]H$H)W"7'VGS/^6G]WY*Z?X$^ _$/A[XK_;]1T6Z
ML+#^SM=B$\R )NEU^:>)>O5HF5Q_LD5]!_VU9?\ /POZT?VU9?\ /POZT ?-
M6K>#?B;KGQ*O)FU_QEIVBWWC*YTQXK*Y2.W@T-M*5Q-'\I*'[6@590=REF Q
MG-<'-_PO:X\-:(VJ#Q]_PE(\/6D?AYM$-NEH-57S!,VLAN""PA)+#88RVS]Y
MFOM'^VK+_GX7]:/[:LO^?A?UH ^+OB;X<^-&B+J+>&[75K#1+SQ;JE[JO]BI
M-]JG9X+46LD?DD2^066?.WN$W#;FNRL;?XH?\)1X*C^(-UXTN[<Z3IRVUUX-
MC6WM#J1>3[4VJ1QDNHP;?C)BP)<<U]/_ -M67_/POZT?VU9?\_"_K0!\>:;I
MWQ;\;:1H6G>(M%\3%?#]GH-CJPU()LO]4BUFWDN+N#:Q\U%@B=C+P-K@#G(&
MG\#K?X\CX_3MXRO=032EN+XZI%-;ROIDUN6;[(+1BWEH0/*.8QN(#"3YCD?6
M']M67_/POZT?VU9?\_"_K0!=HJE_;5E_S\+^M']M67_/POZT 7:IWW_'U8?]
M=C_Z U)_;5E_S\+^M5+W6+-KBQQ<+Q*2>O\ <:@#8HJE_;5E_P _"_K1_;5E
M_P _"_K0!=HJE_;5E_S\+^M']M67_/POZT 7:^;OVCO^$J\7:M:^$]#\&:Z;
MA=8T[48+Z*&WFT36(XY(WD34'R)(ECV$XX8F-"N\?+7T)_;5E_S\+^M']M67
M_/POZT ?.>M?L_>(-0^-4>DZ?K&I6OPHN-2'C+6]/N(;=HI]3%PLL5O;3 ><
M%,\7GRJW PJJ?WA"_3-4O[:LO^?A?UH_MJR_Y^%_6@"[15+^VK+_ )^%_6C^
MVK+_ )^%_6@"[15+^VK+_GX7]:/[:LO^?A?UH 6/_D,3_P#7"/\ ]">KE8\>
ML6?]K3M]H7'D1CO_ 'GJW_;5E_S\+^M %VBJ7]M67_/POZT?VU9?\_"_K0!=
MI&.U2<9]A5/^VK+_ )^%_6C^VK+_ )^%_6@#S7X:^%M;U?6M8^(GBS3WM_$&
MH1/9Z1H<[K_Q*M.#92$X)433,JR2L,_\LTY$0)XOX9_\)/XN_:"B\4W'A/Q!
MX;T>T\.2:5=Z?XD@MTATNX\R K%ILD+'S4D\MC*QRO[J':P^[7OW]M67_/PO
MZT?VU9?\_"_K0!=HJE_;5E_S\+^M']M67_/POZT 7:*I?VU9?\_"_K1_;5E_
MS\+^M %VJ6E_ZJ?_ *[R?^AFC^VK+_GX7]:;HTJ36TKHVY&GD(/_  ,T 7Z*
M** "BBB@ HHHH **** "BBB@ KBOB/\ $"Z\&MIMEI6CG7-;U$3/!:M<"WC6
M.% TLCR$'  *C !)+"NUKRSX[R>'EL]%CU*77(M=DFD723X:B,M^6*8E"+@@
MIL/S!AMQCOB@#:\)_$Y?$E]X8M9-/:U;7-!76XG$H8(<Q;XB, \>:N&[\\5W
M->(_ ?0[#2]6(.F^-7O[;3DL;>_\56:P106J%0((=O SA2>,G;UXKVZ@ HKF
MOB1XP'@#P/J^O_9_M;646]82^Q68L%7<W\*Y8$GL 37"ZA\7M<\*2:YI>LV6
MF:AKEM:V=Q8?V9(Z07#7,YMT1]^2A63!)YRIR .E 'K]%>1W_P 6/$/AF\U/
M0-8L=-N?$H>P737LVDCMKC[7*T2EPV67RVC<M@G( Q@FN@\)^/+X:EXGTKQ8
M=.L+K0O(FDO[=S':RP3*Q1_WARA!1U.21P#GF@"QXD_Y*=X+_P"N&H?^@15V
ME>;7GBW0_$7Q3\'1:5K6GZG+';Z@SI9W4<K*-L0R0I.!7I- !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>7D&GVLEQ<RK##&,
ML[?YZ^U1ZEJ<&E6_G3D\D*D:#<\C'HJCN35&STN>^NH[_5 OFH=UO9J<I;^Y
M/\3^_0=!W) (X[*?Q#(EQJ$;06"D-#8/U?'1Y?YA.@[Y/ W:** ,'QKJ=OI_
MAV_28R;[BWECC6.%Y"S%#@84'UJ?POJEOJ>CVYMV=O*C2-_,B>,A@HXPP!K7
MHH *\Y\4?\EX\ ?]@?6O_0["O1J\Y\4?\EX\ ?\ 8'UK_P!#L* /1J*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I6
M_P#R%KS_ *YQ?^S5=JE;_P#(6O/^N<7_ +-0!=HKXR\77EQ\:/VK/B1X'\8_
M$WQ!\-M \(:7I]WH6F^']9_LA]06:-GGOWE',JQN!'MR47N,]?-?A[\<?$?B
M:X_9N\3^+-:N]6M--UKQ?"VL0*8_[;T^SL)O*NFC7"NS+'Z8++GO0!^B]%?&
M.E_\%)M,N/A_KGBF_P#AYK5G;V^G66I:4%9Q!?+=7"P10R7$L,<<,@9T9L&2
M,*25=\$52\<_'+7O#7QH\/\ Q USP^VG7.D_"WQ'K-YX5M-92[A:2VNX<*+B
M,&-B57[^W*[L$9!% 'VW17RQKW[=ECH^G^+KRU\)2:M%X?TOPWJ1%IJ2,;C^
MUYEC6)?DP&CW9Y/S_P"SUJ+0/VX-4O/&5GHNM_"C5- M%\7/X,U+4FU:VN$L
M[]H3-;A43YI5>/#,1@)D %S0!]645\*ZY^W&_P ;?A?XHTBR\&W/ART\1^"?
M$NK:1J_]LPRS?9K2 HDCQ1#?#([,WRL05V@@MD[?3/V/_P!I0_$9=.^'NH^'
M[C2=4TGPEI>KVE^VHQ7RZC9R1K&)G,9/DR[U.8W);!R3VH ^GJ*** "BBB@!
M&^Z?I572?^07:?\ 7)?Y"K3?=/TKAOB1XFU?P9\%?$NOZ!8_VEK>F:'<7EE:
M;2WFS1P,R+M'+<@<#D]!0!W5%?,%WX+LM'_9WU[XB:5\1O%'B?7KCPE?7JZ\
M?$$YMKR5K.1A)';*_D1!6^9!&BE-@YR#56UT2T\#^,O!/A6+QCXANM!\6:!=
MW/B'2]2\0W4\NGQ0P)*NH1W32>?:CS#Y38D"-YHP 4H ^J:*^7/A+\/;6XT/
MQAX];QCXK\&>$M:LOL&A2:IXDNIWM;+=_P A(F^DD6.:<D&/(^2,1\;G:M[X
M!ZI+X+\:?%WP[JVH:W9Z1X=EM+NULO$6J/J;P6;0R$WBW3N[;)C$[>2S9C,;
M< .  #Z$W L5!&1U%+7S=??%K6OAA9Z7JD7A$^(/$OCQ=1UU[>XU!;,6=O:V
MZ20PLQC?D6^Q< ?ZPM_>)%76/VQ)8?AWXOU=_#$VCZC!I.E:AH$/G_;9+X:F
M)%L]\42;ED5XW9XDWX1<ACR  ?3=%?%VE?';Q#X@^%?P_MK75;[7/%^@^/;/
M0-2EG$FC/K,?DS-#++',%9(YXS$Q#*<LKA0Q !^DOA#\4+GXD6OB&VU315\/
MZ_X>U-M)U*QAO%O(%E$4<JM%.JKO4QRH>55E.5*@B@#OZ*** "BBB@ HHHH
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M+^&.T4_:HL$>7(2"73!/RDX&3QS78?V8?^?VZ_[['^%']F'_ )_;K_OL?X4
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MC+1]JO/^?#_R,M %ZBJ/VJ\_Y\/_ ",M'VJ\_P"?#_R,M %ZBJ/VJ\_Y\/\
MR,M'VJ\_Y\/_ ",M %ZBJ/VJ\_Y\/_(RT?:KS_GP_P#(RT 7J*S6U*Z6X2'[
M!\[*6'[Y>@(']14GVJ\_Y\/_ ",M %ZBJ/VJ\_Y\/_(RT?:KS_GP_P#(RT 7
MJ*H_:KS_ )\/_(RT?:KS_GP_\C+0!>HJC]JO/^?#_P C+1]JO/\ GP_\C+0!
M>HJC]JO/^?#_ ,C+1]JO/^?#_P C+0!>HJC]JO/^?#_R,M'VJ\_Y\/\ R,M
M%ZBJ/VJ\_P"?#_R,M2V5V]UYPDA,+Q/L*[@V> <\?6@"S1110 4444 %%%%
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M*YR,(2&.1QR*C\!_'[X=?$[5Y=*\+>,=)UG4XU9S9V\X\UE4X9D4X+J#U*Y
MR,]:\P_9W\0?\*E\':!\,?$'@KQ%9^*;2<P7=]9Z--=:?J<S2%GU'[8BF/$I
M/FL965U)8$<#/!_#&VU/QMX*^"7A"S\&^(M.\0>#]3MK_4]=UC2)]/@TR&'>
M)XHY954S-.C>3MBW*5D8L0%Y /I;PK\:O GC?Q)JF@:!XLTG5M9TP,;NSM;E
M7>,(VUS_ +05OE8KD*>#@T_P+\8_!'Q,OM0L_"OBG3->NM/_ ./F*QN [(I)
M <?WD)! <94D=:\"MM%E^+7QETBPC\'Z]H/A&U\/:OHNI:1J6BC3(M#:X"HT
MMI=1_N[AY\ 8C:154;\H<@ZWP1^'?BGP_P"--1\4^.]8#>&_ FFS^&O#<T^D
MIIT\]FHB:YN[A49@R?Z/&L9&U2J.X1=ZT ?0D7B6RG\3W&@1M))J%O:1WDP5
M"4CC=V5 S= S%'PO7"DUJU\ZZW8^-)_!_AS6]$GU/1];\:>++.YU>?3[9)I[
M+2Y%94C.]&5!'"L0+$85RQ[X/$^'?%WQN\*Z79WMR?$7BC4]1T#5K.*PO]*1
M(8=1AU&*UTV5S'$IC\R*1II68E65&=54#% 'U)JWCC0-#\/W6N7VL6=OH]K*
M8)[UI08HY!+Y11F'1A)\A'8\5N5\&WOPK^)?PR^#7Q ^'E]X<^VVVKVMEK.F
M3^%Y9]6)OH[JV6_+F6*+$LS;;D1GY2QGP< X^@_V?]9\6:EXN\:07UYXHU;P
M=#]F.G7_ (QTM=/O1>$R?:H8E$41>W4"':Y3[S.%9P,T >WT444 %%%% !11
M10 4444 %4M5_P!1#_U\1?\ H:U=JEJO^HA_Z^(O_0UH NT444 %5-3U:QT6
MU-UJ-Y;V%L&5#-=2K&FYB%4;F(&22 !W)%6ZY_Q['+<>$[^&'PW#XN>51'_8
M]R\20W ) (<R J% Y/!.!P"<"@#>DD6.-G8[549)/85@^!O'WAWXE^'TUSPO
MJUOK6DO+)"+JU8E?,1BKKST*L""/45P7P<^$.N> =9N=1N]7BTS29[<PQ>#=
M'DEFTRT8N&$J//E]X'RXC$4>"?DS@U@?#;Q3;?!7X<^-M;\7V][I=I+X[U7R
M4:U=IK@76J-';&.,#<XD,J%2H.0<CB@#TRQ^,'@G4O'MQX)M?%.ES^++=2TN
MDQW"F=< ,RX[L%(8J.0#D@"CP[\8/!/B[Q9JGAC1?%&EZGK^F;C=Z?;W"M+'
MM;:_'?:Q"MC.TD X/%?-WA_POKLUOX.^'/\ PBFL6GBG0?'5SX@OO$DM@Z6)
MMC<W,QO$N_N2//',L7EABX+N&4*N:R=#\#^(_%G@SX;_  ]TSPAJWACQ3X+T
MW5;;5=:O+-X+2*633[BU!@N2-MQ]IGFCGS&6P$+/M8 4 ?4_@GXP>"?B1J6J
M:?X7\4:7KU[IC8NX+&X61H^2N[CJN01N&1D$9KL*^8_@_:WGBGX@?#">R\%:
MQX-M_!/A6YTC6&U33VM(Q-(MJD=E"Q %PBM \F^/=& $PV6Q7TY0 4444 4I
M?^0O;_\ 7&3^:5=JE+_R%[?_ *XR?S2KM !1110!4N=6L;.^M+*XO;>"\N]W
MV>WDE59)MH!;8I.6P",XZ9JEXO\ &&C> ?#=]X@\0ZC#I.C6*>9<WMP2(XER
M!EB.V2*Y7XR>&[CQ?I%EI$'@K2?%WGR,3-K=PL-MIY XER%:4MD\>4 >#EEX
M-<S)\,_$/@_X#?$#1[SQ#J'B[4+[2KXV=J4=UM-ULRK:V^]GF==W3S9'8ENH
M&  #UVQU:SU+2K?4[6YBFT^XA6YBN58;'B9=P<'T((.:Y3PC\;/ 7CRQUB]\
M/^+]'U6ST<%M0N(+M-EL@!/F.Q.!&0K$/]TA3@G!KRSQC=O)^SGX;^%<9N+/
MQUXN\&3:?I=B\;(?.ATY3*LK?\LAR$+-@!G ZFO-OB!X<UCXV6]]J/A;X>:S
MH]GHW@Z/2;S2]6L#I[ZA(M_:7)TR)9-HD5(K:X3>,Q$W "L06H ^F= ^.7P_
M\4>$=4\4:7XOTF[\/Z66%_J N56*UP ?WA.-N001GJ"",Y%;/@?Q_P"'/B5H
M*:UX7UFTUS2V=HOM%G)N"NOWD8=58<94@'D>M?+OCC2]6^)WBK7OB'HG@K7E
M\-6,GAO[5I-_I;VE[K?V&^FN+@I:RA7<PI*FW<!YC1E4R ,^M_ NWN]:\?\
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MKKQ'X/ZYIWC3QY<:S>^-+7Q3XA@L&MK>UT_3Y;2WM+=G1I" ^2S,RIDD\ 8
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M?_?8H^V6_P#SWC_[[%-^P6O_ #[0_P#? H^P6O\ S[0_]\"@!WVRW_Y[Q_\
M?8K-\2:5I/BS1;K2=39)["Z 6:%9BGF*&!*D@@[3C!'<$@\&M#[!:_\ /M#_
M -\"C[!:_P#/M#_WP* %^V6XX$\7_?8I?MEO_P ]X_\ OL4W[!:_\^T/_? H
M^P6O_/M#_P!\"@!WVRW_ .>\?_?8H^V6_P#SWC_[[%-^P6O_ #[0_P#? H^P
M6O\ S[0_]\"@!WVRW_Y[Q_\ ?8H^V6__ #WC_P"^Q3?L%K_S[0_]\"C[!:_\
M^T/_ 'P* '?;+?\ Y[Q_]]BC[9;_ //>/_OL4W[!:_\ /M#_ -\"C[!:_P#/
MM#_WP* '?;+?_GO'_P!]BC[9;_\ />/_ +[%-^P6O_/M#_WP*/L%K_S[0_\
M? H =]LM_P#GO'_WV*/MEO\ \]X_^^Q3?L%K_P ^T/\ WP*/L%K_ ,^T/_?
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M-;\FK647F;[RW3RQE]TJC8,[<GGCD$?6@!GV6]_Y_A_WY'^-'V6]_P"?X?\
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M6=E?+#//J-DTBQ*8A"[ 3>8\2&%B&5I8^QR #V/[+>_\_P /^_(_QH^RWO\
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M:_\ 0Y6?_@E'_P >KKX[B*9G6.1)&C.UPK E3Z'T-24 >=Z#I7Q"O[&62_\
M$]G93K<SQK'_ &*.8UE98W_UW\2!6_X%6C_PCOC7_H<K/_P2C_X]79T4 >=7
M>E_$.'Q!IUK%XFLY=/FAG>XNO[%'[IU,?EK_ *[^+<__ 'S6E_PCOC7_ *'*
MS_\ !*/_ (]79T4 <#K&B^/;/2;V>S\5V=U=Q0.\,']BC]XX4E5_UW<X'XT[
M3=$\=W6FVDUSXLL[>YDA1Y8?[%'R.5!9?]=V.17>44 <9_PCOC7_ *'*S_\
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MUWBTN5KMI_M-E)]E9"P5A%@PQD+%$%90"*^H_P"T_P#ITNO^_?\ ]>C^T_\
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M -.EU_W[_P#KT 7:RO%&GZKJFB7%KHNK+H>H28"7[6HN?*&1N(C8@%L9 SD
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M[%]EB(&4&7MYY/ER(S+@'DUZQK7Q[T72_#?C?68M-U.YM?"LKVD\AA$<=S=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-#U8X;&*ZF;XE^-O"_BRX@U'5(]6TJT\3G0W6+22LCV[:2;[SOD)+.D@V*%
M#*,'+'- '?\ A7X$^'/"/CZ?Q?9RWTVKRI=IFYE1P!<RI+*"VP._SQKMWLVP
M?*N%XK-NOV:_"U\VK+<WFL7%KJ#:G)]DDO 8K:6_W?:I(AMR&(9@,DA0S8 )
M)/F(^+>L_$CX)?'$+<7-U#INC/)I5_Y"17#K-I_F[<6[LI97S@*=XSM8!EJ+
M_A:WB;[1:O:);>.!H]S*VG7\-F\9N9O[#N;AK=0AQN65$3N<2[#\XS0![.GP
M/T.'6);^&]U2!?MMQJEO:)<+Y%K?31M')=1@J2)"'D(#$H#(Q"Y-9=C^S5X0
MT^W\J,W_ "=SE94C#,;]+XD(B!%S-&O"*J[<@ 9S7F>I?'3Q9I>AWU]:Z_8^
M(-&LUT^]N-5MK:*">3S89VN;*U1SY<D\9CAD$;$.5E9,[]IINI?$CQCI8\3?
M\(\]KI"POXGU5M^F/*UQ)9K:- K!G^7?YKAL<GHNTC- 'K.K_L^>%=;CN4N6
MU#%Q+JLS[+C'S:C&8[G''3:QV_W3ZUG>,/V8/!_C:WOX-0EU(17TEU).D<Z%
M6^T0PQ28#HP4[;>/:ZX=<MA@&(/G>M^/O$VJ:A/I&K"*_DL[T&&^CM'A>-;C
M0+NX*IM; *2+M#')PV#EOFK-M?CMK_ARU\):-I-S<74T/AXQ7EK>V2%8YH]$
M-['*&W^<Y+JBEBOEMO90=ZF@#Z"_X5/X=D\,^)= N;>6]TKQ#<S75]#/*3N>
M4*&VD8*XV@C'((R#6;>?!Q+]]&N+CQ;XDFU/2)GFL]1>:W,R;X&A92/(V$%6
M)R5W9YS7#>(M:UI=*^%!\7:[*GA[53)-X@U.WSI\0F:VWVT+NC Q1&1F'+#)
M1%9CNPW$^-_$%O#JWQ!?0/$FJ/KUEI>EOX,M[;4YYGN9V27:L<)<B='<*KLR
ML-I)8C&0 >]:3\'?#FB77A>>U2Z_XIUKN:SCDN&=7N+G/G7,N<F28[Y?F)_Y
M;2>O%BU^&=DOC*T\2WNI:EJ]]8K<)I\=[*ACLEG*F4($12<A54;RV ,#%>*>
M.M2UF\^).KV/A/Q/#I-QJ&A:M!)=P:M-=1V-ZHB*3WL;_+:)&5D2-DR27]*9
MI&O:TOPI^-=Y';?:?#UI:L=&MY]0EU2!I%L@;A(YR0\L?F^AQN+@$'( !ZE<
M_L]^%;J/5T=M0QJECJ&GW&+C_EE>71N9MO'!\QCM/8<<T[4OV?\ PMJEO>0S
M-?[+N[U*]DVW&#YE] \$^..!L=MH['!YKR#QQ\2?&EQI/C>UDNU;29KCQ!H-
MO9P631O!%;Z7)<0S+*#N+[T*YZ$.,#<,EK^+O$RV>F>'M4D76/L4EF8+\VK0
MRQK/HE[(P&UL;EDA #')Q)@Y.#0!ZY_PSSX;.IW=T]YJTD%S=MJ#6#70-N+H
MV8L_.5=N0PA& ,[<G=@M@A/^&=_#,:LL%UJEM^[T[RS'<+F&>Q4+;7*$H?W@
M50ISE&&<H<FO$?AW\0=?U'PS\/=&DU"#Q+:PIX99]0:S=7L+J9)DF@;YN9(U
MCC?]YEE+G>#N6F^$_B]XRT'X8Z';R^*6EU"W\/7FHB\U.T6:>_U.&8(-+8<'
M?TR@_>GS!@_*: /HGP?\(=#\%ZZ=9LGO)M3D@GAGN+F4,;AIIQ/+*X  WEP.
M@       KMZ\U^#GB3Q)XNN/%=_KUPL4%MJ\MA9Z8EL(_LT<:H3N?DR-N9AG
M@848'4GTJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>cdtx-20231231_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g6.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (9!!D# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH YKQ%9P:AXDT*"YB6:%DN"4<9!PJ$5=_X1'1?^@9
M;_\ ? J#5O\ D;= _P!RY_\ 05K?H Q_^$1T7_H&6_\ WP*/^$1T7_H&6_\
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MC*,)/LZ1%-;55/7,E]U_Z95M^+O!_B"']E+X?_$B[N9M$7Q+\2H_B!XGU+[
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M+_Z&6;_OVO\ A1_PT]\2_P#H99O^_:_X4?ZR83^67W+_ ##_ %3QO\\?O?\
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M_P"$V_\ \ET =[17!?\ "._$;_H=]$_\)M__ )+H_P"$=^(W_0[Z)_X3;_\
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MC&S3[=NTQEPPY*,!@-Q],?\ "O?"O_0LZ/\ ^ $7_P 31_PKWPK_ -"SH_\
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M?7)S2444 %%%% !1110 4444 %%%% &A)_R+MO\ ]?DO_HN.L^M"3_D7;?\
MZ_)?_1<=9]:U-UZ+\C&EL_5_F%%%%9&P4444 %%%% !1110 4444 %31WEQ#
M:SVT=Q+';S[?.A1R$DVG*[AT.#R,]*AHIAON7-+UG4-#G:?3;^ZTZ9T,;26D
M[1,RGJI*D9'M5/DDDG)/))HHHN[6%97N'7J<TNY@P<,P<=&!.?SI**0PZDD\
MDG)/>NI^''CI_A]XJ.M_9?[1<VEQ:F-Y2N?-C*;MV#TSFN6HJX3E3DIQW1%2
MG&K!PFKIZ"*"L<:%F94&%!/ ^@[4X,55@&8*WWE!(!^H[TE%06'MGCTHYXY/
M'3GI110 K,S,69F9FZEB23]:-QV%-S;"<E<G!/KBDHI@'/3)QZ4NX[2NY@K<
ME<\'ZBDHI %%%% !1110 4444 %%%% !1110 4444 %>F?LU_P#);?"W_7S_
M $KS.O3/V:_^2V^%O^OG^E=V!_WJE_B7YGGYA_N=;_#+\F?I/1117[*?@044
M44 %%%% &!JW_(VZ!_N7/_H*UOU@:M_R-N@?[ES_ .@K6_0 4444 %%%% !1
M110 445Q'B_XD7.A:E)I>C>%=8\3ZJBJ[):1K#;QAN1NGD(0'V&X^U ';T5Y
M3_PL_P"(-F5EOOA+??9>K&PUFVN)5'LGRY/MFN_\+^)(/%FCQ:A;VU[9*Q9&
MMM0MFMYXV!P59&&0?T]#0!IR6\4S9DB1STRR@T&WB9D8QH63[IVC*_3TJ2B@
M!DD,<Q4NBN5.Y=P!P?4421)+MWHK[3N&X9P?6GT4 %<#8_\ )>-<_P"Q:T__
M -*KRN^K@;'_ )+QKG_8M:?_ .E5Y0!WU%%% !7$_!CPMJ'@OX;Z7H^JQI%?
M6[W!D6-PZX>XD=>1_LL*WKN+7FNI#:W.GI;Y^198)&<#W(<#]*RM"O\ Q+K>
MEQ7@GTJ+S"XV_9Y#C:Y7^_[4 =;13(M_EIYA4R8&XJ,#/?'M3Z "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH AO/^/.?_KFW\J^>J^A;S_CSG_ZYM_*OGJ@#Y9^.5C<2_&#Q<Z02,IU
M&;!"G^\:X;^S;O\ Y]Y/^^37ZT]*6OC*W#BJU)5/:VNV]N_S/OZ'%;HTH4O8
M7Y4E\796_E/R5_LV[_Y]Y/\ ODT?V;=_\^\G_?)K]:J*R_U87_/[_P E_P""
M;_ZX/_GQ_P"3?_:GY*_V;=_\^\G_ 'R:/[-N_P#GWD_[Y-?K511_JPO^?W_D
MO_!#_7!_\^/_ ";_ .U/R5_LV[_Y]Y/^^31_9MW_ ,^\G_?)K]:J*/\ 5A?\
M_O\ R7_@A_K@_P#GQ_Y-_P#:GY*_V;=_\^\G_?)H_LV[_P"?>3_ODU^M5%'^
MK"_Y_?\ DO\ P0_UP?\ SX_\F_\ M3\E?[-N_P#GWD_[Y-']FW?_ #[R?]\F
MOUJHH_U87_/[_P E_P""'^N#_P"?'_DW_P!J?DK_ &;=_P#/O)_WR:/[-N_^
M?>3_ +Y-?K511_JPO^?W_DO_  0_UP?_ #X_\F_^U/R5_LV[_P"?>3_ODT?V
M;=_\^\G_ 'R:_6JBC_5A?\_O_)?^"'^N#_Y\?^3?_:GY*_V;=_\ /O)_WR:/
M[-N_^?>3_ODU^M5%'^K"_P"?W_DO_!#_ %P?_/C_ ,F_^U/R5_LV[_Y]Y/\
MODT?V;=_\^\G_?)K]:J*/]6%_P _O_)?^"'^N#_Y\?\ DW_VI^2O]FW?_/O)
M_P!\FC^S;O\ Y]Y/^^37ZU44?ZL+_G]_Y+_P0_UP?_/C_P F_P#M3\E?[-N_
M^?>3_ODT?V;=_P#/O)_WR:_6JBC_ %87_/[_ ,E_X(?ZX/\ Y\?^3?\ VI^2
MO]FW?_/O)_WR:/[-N_\ GWD_[Y-?K511_JPO^?W_ )+_ ,$/]<'_ ,^/_)O_
M +4_)7^S;O\ Y]Y/^^31_9MW_P ^\G_?)K]:J*/]6%_S^_\ )?\ @A_K@_\
MGQ_Y-_\ :GY*_P!FW?\ S[R?]\FC^S;O_GWD_P"^37ZU44?ZL+_G]_Y+_P $
M/]<'_P ^/_)O_M3\I9-.NO\ A'K<>1)G[7)_#_TSCK/_ +-N_P#GWD_[Y-?K
M3[TM5+AI2_Y??^2_\$B/%SBOX'_DW_VI^2O]FW?_ #[R?]\FC^S;O_GWD_[Y
M-?K514_ZL+_G]_Y+_P $O_7!_P#/C_R;_P"U/R5_LV[_ .?>3_ODT?V;=_\
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M_P#:GY*_V;=_\^\G_?)H_LV[_P"?>3_ODU^M5%'^K"_Y_?\ DO\ P0_UP?\
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MR:_6JBC_ %87_/[_ ,E_X(?ZX/\ Y\?^3?\ VI^2O]FW?_/O)_WR:/[-N_\
MGWD_[Y-?K511_JPO^?W_ )+_ ,$/]<'_ ,^/_)O_ +4_)7^S;O\ Y]Y/^^31
M_9MW_P ^\G_?)K]:J*/]6%_S^_\ )?\ @A_K@_\ GQ_Y-_\ :GY*_P!FW?\
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MC4#)9F/  '<UD>$/'WAGX@V,MYX7\0Z7XCM(9/*DGTJ\CN41_P"ZQ1B ?8T
M;U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &!JW_(VZ!_N7/_ *"M;]8&K?\ (VZ!_N7/_H*UOT %%%% !111
M0 4444 %<Y\1/#I\6>!=<T<&W5KRU>(-=$B)"1PS$<\=?PKHZX?XX)92?"/Q
M8NH7$]I9MI\@DEMEW2#C@!<C.3@8R,@]10!Y_H?Q(\3QZA86%W\1OAK?N)8X
M91'.PN)N0#@"3&\^@&,GI7O%>'^$9-<\G2%F^!>GZ4!Y0>:.\LE\CIEPF-PQ
MU Z\>M>X4 %%%% !1110 5P-C_R7C7/^Q:T__P!*KRN^K@;'_DO&N?\ 8M:?
M_P"E5Y0!WU>.?%+]I;1_A=XH;0[K2KR]N$B25Y(F55&X9 &>O&/SKV.OA/\
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MQOPD^!GQ*UGXPV?Q5^->M>';WQ%H^FRZ7H.A^%(IA86"RD>?<%YOG>60*%]
MO'I@ ^DJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\>\7^X/Y5^6UA_Q^P?[X_G7ZDVW_'O%_N#^5 $M%%% !1110 4444 %%%%
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M )^$_P"_7_UZ/)NO^?A/^_7_ ->K-% %;R;K_GX3_OU_]>CR;K_GX3_OU_\
M7JS10!6\FZ_Y^$_[]?\ UZ/)NO\ GX3_ +]?_7JS10!6\FZ_Y^$_[]?_ %Z/
M)NO^?A/^_7_UZLT4 5O)NO\ GX3_ +]?_7H\FZ_Y^$_[]?\ UZLT4 5O)NO^
M?A/^_7_UZ/)NO^?A/^_7_P!>K-% %;R;K_GX3_OU_P#7H\FZ_P"?A/\ OU_]
M>K-% %;R;K_GX3_OU_\ 7H\FZ_Y^$_[]?_7JS10!6\FZ_P"?A/\ OU_]>CR;
MK_GX3_OU_P#7JS10!6\FZ_Y^$_[]?_7H\FZ_Y^$_[]?_ %ZLT4 5O)NO^?A/
M^_7_ ->CR;K_ )^$_P"_7_UZLT4 5O)NO^?A/^_7_P!>CR;K_GX3_OU_]>K-
M% %;R;K_ )^$_P"_7_UZ/)NO^?A/^_7_ ->K-% %;R;K_GX3_OU_]>CR;K_G
MX3_OU_\ 7JS10!6\FZ_Y^$_[]?\ UZ/)NO\ GX3_ +]?_7JS10!6\FZ_Y^$_
M[]?_ %Z/)NO^?A/^_7_UZLT4 5O)NO\ GX3_ +]?_7H\FZ_Y^$_[]?\ UZLT
M4 5O)NO^?A/^_7_UZ/)NO^?A/^_7_P!>K-% %;R;K_GX3_OU_P#7H\FZ_P"?
MA/\ OU_]>K-% %;R;K_GX3_OU_\ 7H\FZ_Y^$_[]?_7JS10!6\FZ_P"?A/\
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M^=?J3;?\>\7^X/Y4 2T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% $-Y_QYS_ /7-OY5\]5]"WG_'G/\
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MUK_L(_'KQ'^TE^SSIOC?Q5#8PZO<7UU;NFG1-'%MCDVKA69CG'O0!]"T444
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M\.R0>+M8T[0_%OQ'U?[/;W$4R>&?$&DQZ;=7#QL&C62;_EL R@X0_-BOI"@
MHHHH **** "N!L?^2\:Y_P!BUI__ *57E=]7 V/_ "7C7/\ L6M/_P#2J\H
M[ZOA/]KK_DLEW_UZP?\ H K[LKX3_:Z_Y+)=_P#7K!_Z * /%:*** +%A_Q^
MP?[X_G7ZDVW_ ![Q?[@_E7Y;6'_'[!_OC^=?J3;?\>\7^X/Y4 2U3U:ZNK.Q
M>6SLFU"X4C;;K*L9;GGYFXX'-7**3V&M&<1>>.=>L;JQMY?!\XDO96AAQJ$!
M&X1M(<\\#:C?I6YHFK:OJ%PZ7^@OI407(E:ZCEW'(XPIS_\ JJIXH_Y&3P?_
M -A"7_TDGKIJQBI<SO)Z>G;T-YN/*K16OKW]0HHHK<YPHHHH **** "BBB@
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M:/\ 8RT175D;^U;_ (88_P"6U?92QJB[54*O]T#BA(UC7:BA5]%&* '4444
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MX]\9XS0 S3=.M='T^UL+&WCM+*UB6""WA4*D4:@*JJ!T    ]JLT44 %%%%
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MIW@O1;[0_C=XABOM<O->D?P[I[+->1Q(R#[3>#:/+11COR,T >JU\)_M=?\
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M.U7_ +"]_P#^E#UT]74LI-)&=/F<5)NX4445D;!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 0WG_'G/_P!<V_E7SU7T+>?\><__ %S;^5?/5 'T
M715=KZ)&*GS,@XXC8_TI/[0A_P"FG_?IO\* +-%5O[0A_P"FG_?IO\*/[0A_
MZ:?]^F_PH LT56_M"'_II_WZ;_"C^T(?^FG_ 'Z;_"@"S15;^T(?^FG_ 'Z;
M_"C^T(?^FG_?IO\ "@"S15;^T(?^FG_?IO\ "C^T(?\ II_WZ;_"@"S15;^T
M(?\ II_WZ;_"C^T(?^FG_?IO\* +-%5O[0A_Z:?]^F_PH_M"'_II_P!^F_PH
M LT56_M"'_II_P!^F_PH_M"'_II_WZ;_  H LT56_M"'_II_WZ;_  H_M"'_
M *:?]^F_PH LT56_M"'_ *:?]^F_PH_M"'_II_WZ;_"@"S15;^T(?^FG_?IO
M\*/[0A_Z:?\ ?IO\* +-%5O[0A_Z:?\ ?IO\*/[0A_Z:?]^F_P * +-%5O[0
MA_Z:?]^F_P */[0A_P"FG_?IO\* +-%5O[0A_P"FG_?IO\*/[0A_Z:?]^F_P
MH LT56_M"'_II_WZ;_"C^T(?^FG_ 'Z;_"@"S15;^T(?^FG_ 'Z;_"C^T(?^
MFG_?IO\ "@"S15;^T(?^FG_?IO\ "C^T(?\ II_WZ;_"@"S15;^T(?\ II_W
MZ;_"C^T(?^FG_?IO\* +-%5O[0A_Z:?]^F_PH_M"'_II_P!^F_PH LT56_M"
M'_II_P!^F_PH_M"'_II_WZ;_  H LT56_M"'_II_WZ;_  H_M"'_ *:?]^F_
MPH LT56_M"'_ *:?]^F_PH_M"'_II_WZ;_"@"S15;^T(?^FG_?IO\*/[0A_Z
M:?\ ?IO\* +-%5O[0A_Z:?\ ?IO\*/[0A_Z:?]^F_P * +-%5O[0A_Z:?]^F
M_P */[0A_P"FG_?IO\* +-%5O[0A_P"FG_?IO\*/[0A_Z:?]^F_PH LT56_M
M"'_II_WZ;_"C^T(?^FG_ 'Z;_"@"S15;^T(?^FG_ 'Z;_"C^T(?^FG_?IO\
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MQ^P?[X_G7ZDVW_'O%_N#^5?EM8?\?L'^^/YU^I-M_P >\7^X/Y4 ><_M+?\
M) ?'O_8(G_\ 0:_+NW_U$?\ NC^5?J)^TM_R0'Q[_P!@B?\ ]!K\N[?_ %$?
M^Z/Y5^;<5?QJ7I^I^B<-?[M/_%^B)****^%/KSZK_P"">/\ R.'C[_KTL_\
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MA'22T\D?NSI]_#JFGVU[;-OM[F)9HVQC*L 0<?0U8K!\!?\ (B^'?^P;;?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH P-6_Y&W0/]RY_]!6M^L#5O^1MT#_<N?\
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M8?!X2IB(5)-Q5];=S].J***_.S\X"BBB@ HHHH **** "BBB@ HHHH AO/\
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M_!W+1_P@/_4U>+?_  =RT>RA_-^ >VJ?R?B>S45XS_P@/_4U>+?_  =RT?\
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M -35XM_\'<M'_" _]35XM_\ !W+1[*'\WX![:I_)^)[-17C/_" _]35XM_\
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M"E@%0@NY+KP", ,>V*RK#4K+XL:?J_@GQMHJ:?KMM&LEU8+(7C>,DB.ZMI<
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M3K5/_!A:?_'*]BHJ?;+^1?C_ )E>PG_S\?\ Y+_D>._VUXN_Z)UJG_@PM/\
MXY1_;7B[_HG6J?\ @PM/_CE>Q44>V7\B_'_,/83_ .?C_P#)?\CQW^VO%W_1
M.M4_\&%I_P#'*/[:\7?]$ZU3_P &%I_\<KV*BCVR_D7X_P"8>PG_ ,_'_P"2
M_P"1X[_;7B[_ *)UJG_@PM/_ (Y1_;7B[_HG6J?^#"T_^.5[%11[9?R+\?\
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MW_1.M4_\&%I_\<H_MKQ=_P!$ZU3_ ,&%I_\ '*]BHH]LOY%^/^8>PG_S\?\
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MOQ_S#V$_^?C_ /)?\CQW^VO%W_1.M4_\&%I_\<H_MKQ=_P!$ZU3_ ,&%I_\
M'*]BHH]LOY%^/^8>PG_S\?\ Y+_D>._VUXN_Z)UJG_@PM/\ XY1_;7B[_HG6
MJ?\ @PM/_CE>Q44>V7\B_'_,/83_ .?C_P#)?\CQW^VO%W_1.M4_\&%I_P#'
M*/[:\7?]$ZU3_P &%I_\<KV*BCVR_D7X_P"8>PG_ ,_'_P"2_P"1X[_;7B[_
M *)UJG_@PM/_ (Y1_;7B[_HG6J?^#"T_^.5[%11[9?R+\?\ ,/83_P"?C_\
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M=3MC=(Y]3@  <     5O444 %<=KGQ:\*^'O$\'AZ^U9+?59F1 AC=HXW?\
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MQL_/EM+6>6W$F9&.R,!F55)4':>KDUKXL>)/">D?VOXR\16%Y:?#K7M=BN=
M>>+[9/;7D!L#,9((F:3R^&'EH91NXVL:^^Z* /AG4O$WQ'T'3_$EO)XI\87&
M@W@\,ZKKNK00F>^TJUNXKDZ@UBHCS&H:* %45C"K.P&>:9HNH>+?'4WA[P_X
M=\>^/&^&M_XTBL],\4W#2P:K>67]E74EU$9I$#M )T14F=0VXD*3M4U]TT4
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M>TRQN(KFRLUM;AKV2TC>/S$'GFV265$)4%R.5)'V]10!\ ^(-#MXO&6M^./
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M_P# 2+_"C^Q=9_Z&*7_P$B_PH WJ*P?[%UG_ *&*7_P$B_PH_L76?^ABE_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3 "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>cdtx-20231231_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $G JP# 2(  A$! Q$!_\0
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MH-Y>9)G0@>=C %N^>>Z\'G&;_P -]_#[_H#^)O\ P%M__C]$</C(KEC%Z?\
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M';31DU*\U2"T010RWPB\Q(P %3]W&@( '4C/J37@O_#??P^_Z _B;_P%M_\
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MV&Q$N2E--G=5A>-_'&B?#GPO>^(?$5\-/TFS"F6;RWE8EF"HB1H&=W9F551
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MW)X>0>#K>#^T?$DOAUS_ &A=-B$"$B?_ %@_?CS.O$?7]WR,+ZU'6R?])/\
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M1LW(MJ@CCQG,K,5[-LP"_K__  @>M_\ 11O$W_@/I?\ \A5$J*C&,G-:^O\
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MYP5)!]02*L-K^IOYF[4;MO,MULWS.WS0+MVQ'GE!M7"]!M''%>Y_\,4^+_\
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MQ8]G<6C>)]9:UN'DEF@.H3%)7?.]F7=@EMQR3UR<]:]A_P"&*?%__0P^&?\
MO]=?_(]'_#%/B_\ Z&'PS_W^NO\ Y'H>(PSU;7W#6#QL59)_?_P3Q3_A,-?_
M +&32/[;U+^R41HUL/M<GD*K,&91'G;@L 2,<D TFK>+M=\065G9ZIK6HZE:
M62[;6WN[J26. 8 PBL2%& !QV KVS_ABGQ?_ -##X9_[_77_ ,CT?\,4^+_^
MAA\,_P#?ZZ_^1Z?UG#WO="^I8RUN5_?_ ,$\+NM?U.^^V?:=1N[C[;(LUUYL
M[-Y[KG:SY/S$;FP3R,GUKH_ G_(L?$3_ + ,7_ISL:]1_P"&*?%__0P^&?\
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M_P#DHOQV_P"QSMO_ %'M&KU6O*O@W_R47X[?]CG;?^H]HU 'JM%%% !1110
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M+IK^'[NUM!:/:_;OLH2-TA682@,K*6D8%A@@AN'RZVO_ %I^#OH)Z*_R_/\
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MI?B?1KZ']E:'X8:XL1+Z[;V/AWRK&0QD.JS6MT9V4Y*!EB&0W(4$X^AZ^/\
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MG_*_N*%%7_[#O/\ GFG_ '^3_&C^P[S_ )YI_P!_D_QI<\>X_9S_ )611_\
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M*O\ ]AWG_/-/^_R?XT?V'>?\\T_[_)_C2YX]P]G/^5E"BK_]AWG_ #S3_O\
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M_P"&?!^AZ/\ \))X;7^S[&"TV_V%<2X\N-4QO^V)NZ?>V+GKM'2MC^R_'_\
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M"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5YMXT^''A_XB'3H_$NFVVN:?8R-.FFZA!'/:R2E"@=XW4AF4,VWTW$]<8])K
M ^S3?\\G_P"^31L!Y!_PS;HT;?9[77];L=">..WFT*W6R%G+;QW,MQ%!S;&2
M.-&G9%\MT(0*,Y&:-8_9OTG6+E9&\2:_;P6MZ^HZ5:Q?8VBTJZ><3O+"'MV+
MDN&XG,JJ';:%XQZ_]FF_YY/_ -\FC[--_P \G_[Y-:>TE=.Y')'73^O\O(\D
M_P"&>=/CL]EOXK\26=]<?:QJ6HV\MJLVI)<N'E25?L_EH"1PT*1LN6PP+,3Z
M?I^GV^DZ?;65I$(;6VB6&*-<X1% "CGT %7/LTW_ #R?_ODT?9IO^>3_ /?)
MJ7)M6Z?U_2[7?<?*D[]?Z_X%_1=B.BI/LTW_ #R?_ODT?9IO^>3_ /?)J2B.
MBI/LTW_/)_\ ODT?9IO^>3_]\F@ 7_CW?_?7^35YI<?!&TFM]<L$\3>(+;P_
MJL=XIT.&6W%K;272N)I(R83*3NED<))(\:LV0GRJ%]/6WE^SN/*?.Y?X3Z&H
M_LTW_/)_^^333:V \[M_A#&=)UVVU+Q5X@UG4-7L_P"SI-8NI+:*Y@ML']W"
M(8(XDY9SO$>\DC+':FVQXD^%</B:XT^&77M4M/#MF;9AX;M8K-;*1H)%DB+,
M;<SKAD0X251\@XZY[S[--_SR?_ODT?9IO^>3_P#?)JN>5[D<JM;^OZT7W(\H
MU?X(CQE\/X_#^NZO-:37%Y+J6H-I]M9W*33R2-)@?:[:4 1E@$=55P$7D8Q6
MQ;?!S1K72X;!;O47BBL]2L0\LZO(4O91),68J2S!E&TGWW;CS7?_ &:;_GD_
M_?)H^S3?\\G_ .^31S.W+T_X%ORT*22DI]5_G?\ /4\1\2?LG^$_%7BB^UR]
MO]1^TW=K):$);V/F1J]FUHVVX-L;@#RV8A#*8PQSLQQ7=6/POTK3_#T>C1W%
MXUJFL-K8=G3?YYO#=[<[<;/,.,8SMXSGFNT^S3?\\G_[Y-'V:;_GD_\ WR:;
MJ3=DWM^FI/)&UK?UL>?:I\&-!UG3Y;.ZFOFAD.HL=LJJ0;R7S9""%X*L 4],
M<[JQ=8_9QT+Q5I5S:>)-:UKQ'<75RUQ<WUZUM'+,#:36JQLL,$<814GD( 0$
ML<L6&0?6_LTW_/)_^^31]FF_YY/_ -\FIYGW*Y5>_K^.YX[X=_9IT7PCH\-K
MH>MZAHM_!>M?0:KI>F:39SQ,T1B=/+ALE@=2I/\ K(F;IAA@8G;]G?3)X]5M
MKGQ-X@NM.OK34;1;"1K18K87QW7+QE;<.79B6&]G"DX  XKUO[--_P \G_[Y
M-'V:;_GD_P#WR:OVDV[MDQBHVY>AY1X!_9T\+_#?QQ?>)](++=71G)ADT[3P
M5,K[W/VE;9;IOFSP\S#!QC 7'J]O_K#_ +C?^@FC[--_SR?_ +Y-20V\JN<Q
M./E;^$_W342DY6OT'&,8Z117HJ3[--_SR?\ [Y-'V:;_ )Y/_P!\FI*(Z*D^
MS3?\\G_[Y-'V:;_GD_\ WR: (ZX.3X06$GC ZTVLZNUD;]=5_L$RQ?8?M@0(
M)Q^[\T'@-L\SR]WS;,\UZ!]FF_YY/_WR:/LTW_/)_P#ODTXMQ=UO_7_#^J3$
MTI*SV_K_ (;T;1'14GV:;_GD_P#WR:/LTW_/)_\ ODTAD=%2?9IO^>3_ /?)
MH^S3?\\G_P"^30!'4D7^KF_W/_9A1]FF_P">3_\ ?)J2.WE"2YB<97CY3_>%
M %>BI/LTW_/)_P#ODT?9IO\ GD__ 'R: ,?Q)X=MO%&G1V5T\L<4=U;78,)
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MD3YCMHF?SQ)O#%@* /TB\9>,-(\ >%M4\1Z]=_8-&TR!KF[N?+>3RXU&2VU
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M#=_\1?$'C/1=8\,ZSJ$MMKMIID?DSVMUI<<3QM:6<#?=O)@0Q8'*\ BO:Z*
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M(!^B=>5?!O\ Y*+\=O\ L<[;_P!1[1JZ3Q9J/C[3K+2AX5\/>'M>N&C/V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-T^/?^@1X<_\!KC_ ./T?V]A?YW_ . _\$/]6L;_ "+_ ,"_X!]F?\)?9_\
M/*?_ +Y7_&C_ (2^S_YY3_\ ?*_XU\9_\-T^/?\ H$>'/_ :X_\ C]'_  W3
MX]_Z!'AS_P !KC_X_1_;V%_G?_@/_!#_ %:QO\B_\"_X!]F?\)?9_P#/*?\
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M_P $/]6L;_(O_ O^ ?9G_"7V?_/*?_OE?\:/^$OL_P#GE/\ ]\K_ (U\9_\
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M !H_X2^S_P">4_\ WRO^-?&?_#=/CW_H$>'/_ :X_P#C]'_#=/CW_H$>'/\
MP&N/_C]']O87^=_^ _\ !#_5K&_R+_P+_@'V9_PE]G_SRG_[Y7_&C_A+[/\
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M'/\ P&N/_C]'_#=/CW_H$>'/_ :X_P#C]']O87^=_P#@/_!#_5K&_P B_P#
MO^ ?9G_"7V?_ #RG_P"^5_QH_P"$OL_^>4__ 'RO^-?&?_#=/CW_ *!'AS_P
M&N/_ (_1_P -T^/?^@1X<_\  :X_^/T?V]A?YW_X#_P0_P!6L;_(O_ O^ ?9
MG_"7V?\ SRG_ .^5_P :/^$OL_\ GE/_ -\K_C7QG_PW3X]_Z!'AS_P&N/\
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M8*22 ,\56_X6UXE_M2UU%Y]/ENK2%;>V:;2;1UMHU=G41(T16/#,<%0".!T
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M4 9GB3_D"W'_  '_ -"%?/O[:W_)$O#O_86M_P#TFGKZ$\01M-H]RJ#)P&_
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MH7B)P.48<C/7FKCBJ?,KI\NKMZOX5KLDM/G=-&4\%4<&DUS62OYI:MZ-WO\
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M(_\ A,O^G/\ \B__ %J/^$R_Z<__ "+_ /6HHK@]M4[GJ?5Z78/^$R_Z<_\
MR+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\
MB_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z
M78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]
M:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\
MUJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^
M$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A
M,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**
M/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z
M<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\
MIS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.
MX?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\
MR+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\
MB_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z
M78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]
M:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\
MUJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^
M$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A
M,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**
M/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z
M<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\
MIS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.
MX?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\
MR+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\
MB_\ UJ**/;5.X?5Z78/^$R_Z<_\ R+_]:C_A,O\ IS_\B_\ UJ**/;5.X?5Z
M78?]LO\ Q%'Y<$:VUJQV22;LGU([=B.WXUNV=K'8VR01 [$&!DY/UHHKNIJZ
>YGNSS:SM)P6B1-1116QSA1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>cdtx-20231231_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g8.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *=!@(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$.J_%O7/&^I/X<FN]/FU"*.-M/E2!VWQ[1UR1U]!7@<-_P#&_P"%7[*>@?M
M6GQJU#Q"_P#9UOJNH^&?$5O$]K<1N5!CC< ,&^;BOLG]H[_DU'XA?]BI=_\
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MX9-Q.%'&<_I7V;7QC^R/_P GF?M3_P#86L__ $4*^SJ "BBB@ HHHH ****
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M[6WC34_@[^W9\.?B&O@GQ'XOT6Q\(S6<J>'[0S.)'N)L#)^7C()&>AK[YHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBH+R]@T^VDN+F5(((QEI'.
M *4I**;D[(:3D[(GHKR?Q-\<(X6:'18!+CK=7'"_55[_ (URH\3>-_$66AEO
MI%;_ )]HMB_AQ_6OBL3Q;@*51T<.I59?W5=??U^5SZ6CP_BJD/:56J:_O/\
MK\3Z"HKY^^S^/;/]Y_Q-ACGKNJ2Q^*WB?0)Q'??Z2!UBNXBK'\>#7.N,,/3:
M6*H5*:[N.AL^':LE>A5C-]DSWVBO$;S]INSCCQ;Z/(9<<^9*-N?P%<SJ'[3&
MN3 BULK6U/8[2_\ ,UO6XRR:EM5<O2+_ %2%2X7S2KO3Y?5K_@GTI17S)X5^
M(GC?XB>(K?2X-5%GYAR\D2J@51U..]?2>GV?]GV,-OYLD_EJ%,DIRS'U)]:]
M;*,ZIYS&52A3DH+2[LKORU9Y^9Y54RJ4:=::<GK97T7GH6****^A/$"BBB@
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MJ_KN?AV997B,KJ^SKK3H^C_KL24445[9XX4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7<5JE9?J_4E86;M&;NF^:7F^B]/SL4_'WCW2_AMX?;6=76X&GI(D<DEO%O\
M+W' 9AV7U->*_&>ST[P_XV\&^.O"6J>=XFU74(;1;..X\Z/4+9^&*ID@ #G*
MX'XU]#WUC;:I9S6EY!'=6LRE)(9E#(ZGL0>M<GX7^#G@OP9JS:GHWAZSLK\Y
M G5260'J%R3M_#%31J0IZN]_P?DR\30J5_=5K::]4UU7]([.BBBN0] ****
M"BBB@ HHHH **** "BBB@ HHIDLT<"[I'6-?5B * /'OC0Q6VU3'_/N>/^ F
MO%?@?^SWX0\7?"_1-6O_ !CK&G7=RLC26MOJ4<<<9\QAA5*\=*]G^,5S'/9Z
MG)"Z3)Y##<C C[I]*\2^"'[/MYXQ^&NBZE;?$6XTH7 D86$=M$_E?O&&,DY/
M2O3C)14;R<=.AP6<F[13]3T'_AECP+_T/^O?^#>+_P")H_X98\"_]#_KW_@W
MB_\ B:/^&2-;//\ PLS4/_ "*D_X9'US_HINH_\ @!%5^UI_\_I?=_P1>SE_
MS[7]?(7_ (98\"_]#_KW_@WB_P#B:/\ AECP+_T/^O?^#>+_ .)H_P"&2=<_
MZ*;J'_@!%0/V2-<'_-3=1_\  "*CVM/_ )_2^[_@A[.7_/M?U\@_X99\"_\
M0_Z]_P"#>+_XFKEC\-=$^'+74.D:[>ZX+B ,[7ETDY3!P "H&.IZUG2_LIZM
M:KF7XI7L0]9+*$?S-6M'^'+?#\WL4GBIO$[SPAM[1HABP2,?*>^?TIJ<9:*I
M)^3_ .')E&26L$AW[(/_ !]?$?\ [#*_^BQ7T97SC^R',BWWQ'1I%#G65(4G
MG_5BOHZO+G\3.^'PH****@L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >/_M":5XAU'2(7L!YFD0C=<1Q9W[O
M[Q]17S2X*\$8-?>K ,"",@\$&O$OBM\"8M0675?#T0CN.6ELEX#^Z>A]J_(>
M+>&,1BJLLQPK<WUCUT_E_P ON/TOAO/Z.'A'!8A**Z2]>_\ F?.;5'5B[MY;
M29XID:.1"596&"#5>OQI::,_6%KJCN/AK\5M2^']\ &:ZTR0_O;5FX^J^AKZ
ML\*>+M-\9Z4E_IDXEC/#)_%&WHP[5\,-TK<\'^-M4\$:FE[IL[1G^.(_<D'H
M17WW#_$];*6J%?WJ/;K'T_R^X^0SSAREF:=:C[M7\'Z_YGW+17%_#CXI:7\0
MK &!Q;ZC&/WUHY^8>Z^HK7'C"PD\6CP]$_FWRP&XDVGB, @ 'W.:_=J..PU>
ME"O3FG&>B?=OIZ^1^,5<%B*-6=&I!J4=7Y+OZ&[1117><05&UO$\R2M&K2H"
M%<J,C/7!J2BE9/<=VM@HHHIB,[7=!LO$>GR6=]")8F'!_B4^H/8UX]=>!;SP
M9<7@BOIXY901;74#E#M_#C<#V->Y53U72K?6+-[>X7*GD,.JGU!]:XG@<+4Q
M4,94IISAL_7^M.QT_6J\</+#0FU&73^OQ/.?A=\5I-6O!X:\2.D'B*-289L;
M4OD'\2_[8'5?QZ5ZE7S_ /$?X?R&58I2T4\+>=:7L7RLK#HRGLP]*ZCX2_%N
M76KC_A&O$NVV\10K^ZGZ1WZ#^-?1QW7\17J5*=O>CL>?"=_=EN>L4445@;A1
M110 445FZYKD.AVIDD(:0_<CSU_^M32;=D)NRNQ=:UJ'1;8O(=TA'R1YZ_\
MUJ^9_BQXJU'Q;XQ\.^'](N9+G6KF[4_9E)9$AS^\=EZ!0.]7/B1\3-3O]:AT
M/0+=M8\3Z@=EO:QGY8Q_?<_PHO4DUZK\'?@W:_#.QFO+N8:IXHOP&O\ 5''+
M=_+3^Z@[#\358C#T:E&5"M%24E9HBC6JQJQJTW;EV.H\'^"[#P?8^5;+YEP_
M,MPP^9S_ $'M70445R8?#TL+2C1HQY8K9(ZJM:I7FZE5W;"HVMXGF29HU,J
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M+D1'RY9<-\BGNWM7N=%:2Q4I-NW?\7<QA@(PBHJ6S3^Z/*?+<?AKQ/I7PO\
M@L+;PS=7^I:3?B6ZT^2,J8QAAE\_=Z\$]\5U/C2ZUSXS>*/"VCV?A/5-$LM)
MU./4K[5=4A\I4\L$>7$?XRV>HXX%>]T4GBFWS<NNOX@L"HQY.=V=KK3HDOT/
M$=!\.ZK#\5/C#>2:;=)::A9P):3M&0EP1;X(0_Q$'CBN:TWX7^(-9_9L\%V,
M=A)%KFAW4>HG2KP>69_+D<F)@>A(;(SW KZ3HI?69*S2[?@K%?48.Z;WYO\
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M!MJ3O[V_](****](X HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P_XU>*
MKN/Q"NDK(T5O%"DFU3C<6SR?7I_.L'X9>-+O2_&VFZ>)6EBU"4PO#G(^Z3NQ
MVQC^=>K?$KX4V'Q&AA=[J;3=1@!6.\MP"=I_A8'@BOG'QUX8\1?LN^.O#_CI
M;N;Q1X7?_0=0,D(#V;.<!@!_"W3/8X[&O5IUJ<J/L;:GQV*P>)HXWZZY7@FG
MINEVMV_0^QJ*XGP?\:/!?CJZCM-&\06EU?.@?[*6*2<CIA@,GZ5VDDBQ1L[L
M$11EF8X 'J:\QQ<79H^MIU(58\T&FO(;/*((9)",A%+8'L,U\S>(/&VHZYJ4
MUT]W(B[LJL;D*H[ #->D^//VD? W@OP_JEZFN66I7MHN$L;>4,\LAX"C'OU-
M>+_"WX->.?B1X9?Q%JNJ0^&X]3G:>VL?LQ+) QR#UXSG@'MBO0PKC1O.HCYG
M-E4QCA1PDKM7;2?YO]#L_P!GOP'H6H^//$OC.X,VHZ^'2%);E]ZVZE.=F>C'
M]!C%?1-<K\.?A[8?#?P^--LI)+F21S+<74WWYI#_ !'\, #L!755QUI^TFY+
M8]O X=X7#QIRWZ^IXQ^T%^SW!\4[:'7M!F71/'NF#?8:HGR^;CGR9<=5/8]0
M:X_]GWX*^)=4\3S?$;XIQ-)XHSY-E8W#B3[,%^7S..,G'RXZ YZFOI>BDJLU
M'D6PYX.C4K*NUJON?9M=6N@5A>-O!.B_$3PU>Z#X@L(]0TR[39)%(.GHRGJK
M#J".E;M%9':U=69^<5]X1@\!^)M5\/6US->6^G7#P1SW&#(R@\;B.IP<9[XK
M2M\[1C@5;^)7_)5O%/\ U_/_ $JG 2R@=J^LHZP39\W4BHR:CLA\V=O!K%U+
M[IK9F'<>E8VH_<-:R(1YEXX_X]9/I7UA_P $S_\ DD/B/_L-R?\ HM*^3O'&
M?LDM?6/_  3-!_X4_P"(S_U&Y/\ T6E>)C-CU<+N?7EQ_P >\O\ NG^5?G3,
MW_$ZU#_KXD_]"-?HM<?\>\O^Z?Y5^=%P3_;>H8'_ "\2?^AFC+_BD5C?A1IP
MM\N#Z5'<'@D#ZTZ/G'<XIEP>.M>Z>,8>J'Y37DOQ%_X\Y?H:]9U0_*37DOQ$
M_P"/.7Z&N6IL=%/<^^/^"?\ #'%^R_X:9(U1I)[MG90 6/GN,GU. /RKZ,KY
MW_8"!'[+?A7(Q^]N_P#THDKZ(KYB6[/H8[(^8/CY\(_%/@OQI%\3?A1:.VMW
M)%OJ^EVZ@BYW?*LX4\%A_%Z@ ]JZ[X#_ +/7_"$W,OBSQ=,-<\=7Q,DMU,?,
M%KGJB$]_5OP&!7N-%:>UER<AQ+!456]O;7\+][=_,*^:/B/X&T?P3\7+_P 1
MZ,UQIU_J]H!>0PR%87?/,FT?Q$  _3-?2]<-\3OA;!\0[6%X[R33-2MP1%=1
MJ&!4]593U&:O#U(TZBE+8QS+#U,5AW"E\6C7]=#RGP%X^OM'\6:=:O<236][
M.(&B9B<YZ$9[BOH^OC:2QU'X"_M >%3XRN(M4\.:C&R6&HQH42"YZ,'']X @
MCV)]*^P;/4+74%+6MS#<J.IAD#@?D:UQ<HSDIP6C./)XU*-*5&L_>3V[)K\B
MQ115#7;R#3M%O[FZN$M+>*!V>>0X6,!3\Q-<)[[=E<Y/6?C!H^DWSVRI)=;#
MM:2,@#/?&>M=5H.O6?B33DO;&7S(6.#V*GN"/6OBNW^(NBZA9M=0WRRQLS*&
MP1N(.#CUKZ+_ &<;/4E\(W>H7T$MI#?7'F6L,RE6\L# <@]-W\A7IXC#TZ5-
M.+U/E<LS+$XS$2A4C[OIM\^IZU1117F'U84444 %%%% !1110 4444 %%%%
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MPV8_68SJ5+TE:_1;ZW1^D6B> ?#>A:38:?8:+916=F@6!/(4[1ZY(SGWKH
MH  P*CAN(9N(I8Y !_ P-2UY#OU/N8I)6B%%%%(H**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPSE/$'^K:N<^ '_)V'P__P"ON3_T6U='X@_U;5SG[/\ _P G8?#_ /Z^Y/\
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MQ.X]3WK+^&__  3[^!7PM\20:_I/@M;W5K<AK>XUB[FOO)8=&196901ZXR*
M.-_8KL9/V9_V,7\3_$+_ (D22/=^([NWE^4V\<S;TCVGHQ&,+ZL!3?V._A[K
M?Q4\::U^T=\0;9HM:\0J;;POI4X_Y!6D@G80#T>3J?;G^+CWKXW_  *\-_M
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MU>=BO@9W8?XT?JY1117SI[@4444 %%%% !1110 4444 %%%% !1110 4444
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MNHV4^AZ'IT=U)9R2W5R\CJZ$!L(JG/7UK["\6^*]+\91W=WH]T+RW1 C2*I
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MWFCGC89#QL&!_$5R5*E67QG53ITX_"2@8& ,"EHHKF-PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH YWQMX!T/X@Z7]AUJR2Y13NBF'RRPMV9''*GZ5YN
MNN>+O@;,(=?-QXO\#CA-8B3=?6 ])T'^L0?WQSZBO:J1E#J58!E(P01P:WA5
M<5RR5UV_R['+4H*4N>#Y9=_\^Z_I&?X?\1:9XJTJ#4M(O8=0L9AE)H&W*?\
M ^U:->2>(/A#J/AG69_$GPXO4T?493ON]%FS_9]]ZY7_ )9O_M+6UX!^,-AX
MLU*70=4M9?#OBRV&9](O?E9A_?B;I(GN*<J2:YZ;NOQ7K_F3"NU)4ZRM+IV?
MI_EOZGH-%%%<YV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110! ME;QW;W2P1K<NH1I@@W
MLHZ GJ14]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P!F/P[(YW,UQ=DG_MN]?1-?+2T;1]$MD%%%%2,**** "BBB@ HHHH ****
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M*[BL)1E!\LD==.I&K'F@[H****@T"BBB@ HHHH **** "BBB@ HHHH ****
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MBEHH 2BEHH 2BEHH 2BEHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(;= BC\!5VFZW*K4E;SZ_P!>A*P[F^:N^;RZ+Y=?G^ V.-8HU1%"(HPJJ,
M= !3J**YCM"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKY[^/WQ6U&
MUU:3PSH]P]F(D4W4\9P[%AG8#V !&?K6U*E*M+DB95*BIQYF>XZEXFTC1_\
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M33Q2F^5H^N****\X[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!T_P J_.JX_P"0U?\ _7Q)_P"AFOT5N/\ CWE_W3_*OSJF.-:U#_KXD_\
M0C2R_P"*0\;LC2B V@XYJ.;.TCI3X1\@YJ.X!PW%>Z>086I8V'->3?$3_CSE
M^AKUK5,[#GDUY)\1/^/.;Z&N:IL;T]S[[_8#_P"37?"W_76[_P#2B2OHBOG?
M]@+_ )-<\+?]=;O_ -*)*^B*^7ENSZ&.R"BBBI&%%%% !1110 4444 %%%%
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M2DY.\G=G9&,8+EBK(****DH**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTC?=- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\Q+=GT,=D?+_ ,?OA+XI\#^,E^*'PIM))=<NF$&KZ3:J,76[Y1.%. 6'&[U
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M,@<#\C6N*E&<E."T9QY/&I1I2H5G[R>W9-?D6:2EJAKU[!IVB7]U=7"6EO%
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MUW<?\>\O^Z?Y5^=%Q\NN:C_U\R?^AFOT7N/^/>7_ '3_ "K\Y[C_ )#>H?\
M7S)_Z&:,O^*0\;LC2AP5ILN-M.C^ZISTIDW?C\:]T\<PM4^Z>>*\C^(G_'G-
M_NFO7-4'RFO(_B-_QYS?[IKEJ;'13W/T _8%_P"36_"?^_=?^E$E?0U?//[
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MCO\ 6OJ2ODO]H.\M],E\/W=U(L%M#K=H\DC=%42@D_E7N;?'[X?+D'Q38_\
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M]D:O.Q7P,[L/\:/UDKX8^.__ "6GQ%_OQ_\ HM:^YZ^&/CO_ ,EJ\0_[\?\
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M[IKR/XB\V<O^Z:]9U::-%8LZC\:\<\<:@FK7L6CZ8CZEJMXXA@L[8;W=SP
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M?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'R/+^U-\/MS%C]O/7_<:OU:KYO%V]K='NX;^&%%%%<9U!1110 4444 %%%%
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M++R(XPA&2>W)%>XZ7^P7XV\1,/\ A*_'MGIMN>6AT2V:5R/3=)M ^N#7TO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU"RL]!TB2\D:$8R2JG((STKH?@[^T!H_QJ;5AIWA[Q3X?&FK&TK>)M'DT]9
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MI&5% !GBSDDX&2.N<D<9%>UZ1\:O">L?#AO&\.J1#1(X?-E<L-T;8^X1_>[
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ML_:BE^$WQ.\.> M*\ ZWXY\0ZY83:C!;Z1+"A6*)L.3YC#IQ0![O17C/@/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\L_:F8K^SC\22#@_V#=_\ HLUZG7(_%WP1-\2O
MA?XH\*V]W'8SZQI\UDES(A=8BZE0Q4$9 SZT >5?"7XP>#?@W^RC\+=9\;^(
MK/PYIDVB64$=U?,0K2&$$*, \X'Z5F_%_P#;&TBU^&WAO4_A/=:=XWUKQ?K:
M^'-"E$C"T6Z()=Y3@':B@DCN<"O6_AG\,+;P;\)_"G@[6$L]=.BZ?!9M-);@
MQR-&@7>%;.,XKG/CM^SCH?QF\#V6C6TO_"+ZII%\FJZ+JFFQ*C6-XGW9 HP"
M""01W!H XBY\9?%7]FWX<^,O&_Q;\6:'XYT;3=.:[AATG2C83QS@@+",,0R$
MG&X\BOF)?^"AWB?P_H]OX^O_ (L?#C7H)?+GNOAK86LJ7-O Y&Y(KL\R3(IS
MM8;201FOK?3?@E\0/'_A3Q+X8^,OC#2/%6@:M8-8+9Z'I9LB,X_?,[,QWC'&
M,#VKBO#_ .R_\6-!73M"3X@^$V\+V!CBCO&\)0-JTD"$;4>1LQDE0%+;<GKU
MH SO$'B*T\7?M[? [6[!M]EJ/@74;N%CUV.Z,/T-7?\ @FK_ ,D-\2?]CCK/
M_I2U>G^(/@-<ZM^TIX(^)L.J6]O8>'="N]';3! 0\K3,"'5@=J@8Z8I?V6_@
M3>?L]^ =4\/7NK0:S+>:W>ZJ)[>%HE59Y2X3!)Y&<9H YG]J[XO>./AIXL^$
M.D^"9+!9_%&O2:;=QZA"'1X_*W#YNJX//')QBN-_:$_:2\6?LM^ O"&@^(?%
M'A_5/'WBB^F@7Q'J5J;+2].AY8RO&FYF"*0 .K'K7KOQN^!]Y\6/&WPMUVVU
M:#3HO!VM-JLT,T+.URICV;%((VGODYIO[0G[/L'QKM_#^I6.IKH/B[PW=&\T
MC5)+9+F)&9=KQRPN,21L."/Q% 'SI\"_VW+H?&KPU\/O$'Q,\(_%JR\3B2.T
MUOPW9M93V-RHR(IH>5*,,[6!SD<UWWAOXO?%S]H+XE>-$^'%]X>\+>"?!VKR
M:*\^L6;W<^K746/-'RL/*CY !'/-=I\(_@S\1?#_ (PBUKQOXG\*W]I;PM'%
MIGASPW%9HSG&)6D;<X88X"D#DUDP_LS>,?A[\2?%'B#X7>/+?PWHGBN\.HZO
MHFIZ<+N..Z;_ %DUN=PV,W<'(S0!YQX9_; \?>$_AG\:/$'CW2;*Z\0^&?%,
M>@:1HUD D1DE2(1(9!RREWSN/.*])\)^$?VE)-/OKC7_ (B^$M^IV#F""WT$
M_P#$HN&7*%3O_?JIX(;&:P_!_P"P[';_  Y^*OA#QCXKN/$L?C76_P"VHM46
M,QW5K*$38Y.2"ZN@88P,<5WWPE^'WQC\-:M;0^-?B)H_B/P[96Y@@@LM(-O=
M7'R[4>>0L02!R=H&30!\;? 74OB%X#_8?^+?BK4O$6C>)--L[G4?L.DW^BI*
MD=VET?,EDWDB1&/(C(PO%?1=Y\>/$7PI^(/PEF\27FG6OPM\8:'#:%UM4MTT
MS5!$)%)<<".1> IX!'%6M'_9"U32_P!E7QK\)&\26<E_X@N[ZXCU06KB*$7$
MWF %-V3M''!YKM_BY^S3I7QH_9U3X7:]<@>78V\$6HQ1\PSPJH650>GW3QGH
M: /$;3]LCQC;?"7QO\6&M+;4]!U;Q!%H/@'16A$/G[I/)6XFE'S,COEO8+Q1
M\>/B+^TK\ _A'!XEU+6_"FMS7.IV4-U)8Z:8VTQ)955D568K,OS;=QP1UKW;
MX@?LR>%_''P%M/A9"TVC:5IL-L-,N[/ FLYH"&BF7L6#+D^N3ZUY)\5/V3_B
M[\:?AW9^&/%?Q;L;A+"^M+J$VND&%+I89%;-SA\LQ"\8P,G.* .%^.7A_P")
MUY_P46^&D.B>.]/TM;K1+^?3EETD2BUMD"^?$XW#S&?G#G[M;NE_M./\*_%7
M[46NZSH^FW%EX,U&RM[&'2["*VN;R26(;5EE49D)<CYFS@9KW3Q7\"+SQ%^U
M!X%^*L>K00V7AS2+[39--:%C),TXP'#YP /0BN2L?V.;'4M>^.Y\4ZE%JF@_
M$VZ@G%I;Q-'-9>7%L!WDG+!@&! &,4 <+XD\>?M+_"OP"_Q<\2:IX3USP_!
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M)<:EX8^,NC6\>HW$4FJ;M$:26ZC5]S)O=B1GG\3F@#]$J*** "BBB@ HHHH
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MB"TU+4/%/BR^0PR:SJI!D6,G)50.F<#)ZG% 'TS1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCY_R6SQ#_OQ?^B4KF+?E!7??M2>')_#7Q,DUJX5ETS541H[C!VK(JA60GL>
M1]:\\MKF&:,%958>QKWL+).E&QXV(BU4=QUSG:>YKD]?_P!6_P!*ZFZD7:?F
M _&N.\2W]O;V[M+.B#'.6K>>QE'<P_@'_P G6?#_ /Z_6_\ 1;5^KU?F3^QQ
MX'O?B-^T-IWB.PBD;0O#N^>XOMI\HRE2JQJ>Y.2>/2OTVKYK$M.IH>]ATU!7
M"BBBN4Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHK@?C-\7=,^#OA";5KT?:+V3]U96*GY[
MB4]% ZX]:J,7)V1G4J1I0<YNR1WU%>$_ _\ :&NO%6K2>$O'6G/X9\:1JLJ6
MMRGE"XC8;E*<^GOV/>O=J<X.#LS.A7AB(\T/NZI]FN@45X)\=OC#KO\ ;]K\
M.OAU&MYXSOANGG5L)8Q=26;^$X[GIGU(K1^!?QXD\875UX/\6VW]B>/=)/E7
M=E-QY^.DB>H8<Y'6K]E+EYOZMW,/KM+VOLOE?I?M?O\ UN>%_M ?\EDUG_MG
M_P"@"N5M\[:ZK]H#_DLFL_\ ;/\ ] %<I!]WGK7TF'_A1]#S*_\ $D,NNAKE
M->_U;5U5P/O&N5U[_5O6TMC*)ROP._Y.M^&__83;_P!%25^L-?D[\#?^3KOA
MO_V$F_\ 14E?K%7S6*_B'NX?X#X<^/'_ "6GQ%_UTC_]%)7-0_=%=)\>O^2U
M>(O]^+_T4E<U /E':O?P_P#"CZ'CU_XC&7/>N3U__5/]*ZNZX4XKE/$'^K:M
MI;&4=SFO@/\ \G4?#_\ Z_F_]%M7ZNU^4/P'_P"3J? ![?;6)_[]M7V3\4/V
MEM?NM?O-(^%VC-XF&B#[3K%]"H>-8TY:-">"3@].3CCUKYZO!U*MD>HL1##T
MDYZM[):M^B/I6BN3^&'Q(TGXJ^#[+7](E#PSJ/,BS\T3XY5AZUU;,%4LQ 4#
M))Z"N&2<79GH0J1J14X.Z8M%>%7'[77@^/XJ6_A&.0R6CO\ 9WU?GR!<=D#8
MP?KGZ5[HK!@"#D'D$54H2A;F6YE1Q%*NY*G*]M&+1114'0%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !39)%AC:1SM106)] *=45U;K=6TL#YV2(4./0C% O0\JU#XZ"'4BEO91R
M68;&YV(<CU]!FO3-%UBWU[2K;4+5MT%P@=<]?H:^9/'7PK\>^'X-3DTG2[?6
MK>")Y(7CG"R.JC@;"/O8[=Z]2_9P^(&@>,/A;HO]FWH-S"GDW-O.X$RS9)<$
M?7->AB(T>12H_,^<R^OC/;RIXS2^WRWL>KT45F^(M?T_POH=[JVJW*6>G6D1
MEFFD. JC^OM7GGT;:2NSAM:^-5II^HRP6MI]JCB8J6+[2Y'7'' ^M>=?"OX?
M:U\6OB!<?$OQ]"BP6<SPZ#H^\21P*K$>:>V<CCN2,^E<%X5A\4_$?37U;P]X
M:NI=*N+F1+2ZN76,.@8@.<G.*^H_ACX3G\%>#+'3+N9;B\7?+.Z_=\QV+$+[
M#./PKTJWLJ,+4_BZGRN!EB\=6Y\4OW:U7:_3U75?><[\;/@?IGQ>TF&02G2?
M$VGYDTS68!B2W?KM;'WD)ZK^(YKQ-OVGO&/A70[KP#K6A3-\5HW6SLO+3=%=
M*W"W"G^(8Y]/7&#7UQ6?=>'],O=6M-5N-/MYM2M%9+>[>(&6)6^\%;J :XX5
M.56DKH]ROA74E[2E+DD]&UU7^:Z/IZ'G7P%^"X^%NBSWVJS_ -I>,-6/GZIJ
M#G<Q<\^6K?W0?S(S4?QT^!-O\4;:WUC2+D:'XXTL;]-UB,8.1R(I<<LA/Y9R
M*]9HJ?:2YN>^ILL-25'V'+[O]?CY]S\[/$6M>)]:\5W<OC#3O[,\0PE;>[A&
M,%T &\$<$,,$$=0:M6_W1W%=7^T%_P EEUCZ1_\ H KE+?&WT%?3X=WIIGAU
M(\DN6][=R.Z^ZQKE-?\ ]4U=5<YVFN5\0?ZMZUEL3$Y7X%_\G7_#?_L)-_Z)
MDK]8J_)WX%_\G7_#?_L)-_Z)DK]8J^:Q7\0][#_ ?#OQ[_Y+5XA_WXO_ $4E
M<S#]VNE^/G_):O$/^_%_Z*2N9A^[7OX?^%'T/&K_ ,1D=RWRURGB#_5/]*ZJ
MYZ5RGB#_ %3_ $K:6QE$\T\%^$[OQQ\>/"6A66I/I$U[=-%]LCSNC4H=V,=\
M9'XU^K/PW^&>A?"OPQ!H>A6HAMTYEE;F2=^[NW<FOS,^ ?\ R=9X _Z_6_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCVR36]1714KSK)*70\W"Y?0P<I3I+5A1117.>D%%%% 'P_\ M"9_X7-K&/\
MIG_Z *Y.W_U8YKV[]ISX1:U<:X/%V@:?)JL;QA+VTMQF52HX=5_B&.H'/%?.
M=OXVTM)&@GF^RSH<-#."CJ?0@\BOI<+4A*FDGJCP<13DIMV-NZ[@?C7*Z_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB#XT_&3]I/XT^!O#WQ(C\%^&/#GV-[>YCTZ*YNHY'1BL<>_@(2K%B<GA0.]
M'VC>745C:3W,[B."%&DD=C@*H&2?R%8_@;QMI'Q&\'Z5XGT.Y%UI&IVZW-O-
MTRI]1V(Y!'M7Q%??M,>+O%W_  3M\3:QKLL5SXXN[RY\&175DGE_:YWG^SK(
MJ]F*,3QW&:Y#PA\1-9_8W^'?C[]GRXO9+WQ:HME\$22 [KU;XA'"_P#7*0L3
MCM0!^@'A+XE:'X[\)W7B+0)VU/3[>6Z@/D+EVD@=D=5'<[D./7(]:K_"+XJ:
M+\:? &F>+M!\Y-/O@X\FZ39-"Z,5>.1?X6!!R*^9/V /#E[\"O%7Q3^"&J7L
MU[+H=Y;:W8W$_P!Z>&Z@3S6'L)5(^N:[S]D=3HGC/XY^&(ODL=,\82SVT0Z(
M+B))6Q]6+'\: /I&BO,/B[\>+/X/WVG6MUX2\6>(S>QM*LGAS26O4BVD##D$
M;2<\"N"C_;7TF214_P"%7_$\;B!EO"\@ _\ 'J /H+5-3M=%TVZU"^G2ULK6
M)IYYY#A8T4$LQ/H #7Y[ZS_P6*\,V?C"?^S_ (?:YJ7P_M[K[+)XG3Y0><;U
M3;C'<*6!(KZ;_;0O;R[_ &0/B1=Z='-%<3:#)((V4B158 L".Q )R/K7R]\'
MT\%?\.BM4^TBS^P_V+>&]W;?^/[>=N<_Q[MF._2@#] /!_B[2O'GA?2_$6B7
M:7VDZE;I<VUPG1T89!^M?.'[77[>>@_LPZUI?A>QT"\\:>-M0C\]-'L"08HN
MS.0"<G!P ,\9J?\ X)I_;/\ AC/X?_;-V?)E\K=G_5^8VVO%/AJUG)_P5R^(
MG]O^5_::Z&@T?SP,[/*BSLSWVYZ>] 'T!^R'^VIX9_:PTW5;>UTZY\->*]'(
M&H:%?']XBG@2*>,KD$'@$'KUJYKO[9'ABQ_:2T_X*:-H^J>)O%,JJ][/IPC-
MMIRD;F,S%AC:N"0!W ZFOB/Q)\0(?A/_ ,%$/CIXM\*1Q2)I/A&ZN;I81E/M
M02($L!QD2$$Y]*\E^"WA3XX_"#X%^(/VJ/#7CG0HEU*X:XU'3[U!<7-XGVC:
MP=F'!+G.P$$@ ^E '[3:]KEAX9T6^U;5+J.RTZQA:XN+B4X6.-1EF)^@KYA_
M9)_;RTW]K+XD^,_#VD>')=,TO0T\ZUU&:?<UW&9"BL4Q\N0,XR>M?+W[1'[:
M'_"\]"^$GAO6]&U_1? &O64&M^+I]%LI)Y+I03BSB*C[A9#N.>A'I6;_ ,$\
M?BYX1_X;D^*-OH>EZA8:5XH+1:-;"Q9!;1QDOMF _P!5\JXY[\4 ?K!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9^M=C\./V4?#OAO]G7_A47BHQ^+=$D:X,SS1^66\R5I 5P<JREN&'.17LO\
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M[P/\1M4MB^O^$A.+-@!M<2+@;_\ </S+Z$UZ=10!Y3JWP?BL?V@(/BY'K/\
M9\4.@2:1J5DT8VW$:N98Y"^>-A+?G7GW[#TY\7>'_B#\1E4BS\:>*+J_L6/_
M "TM8\0Q./9@A/XU]*30I<1/%*BR1N"K(XR&!Z@CN*K:3H]CH.G06&FV<-A8
MP#;%;V\82-!G. HX')- %RBBB@"IJVEVFN:7=Z=?VZ75C=Q-!/!(,K(C AE(
M]"":_/C4O^"._AVX\5SQ67Q%UVQ^'T]U]JD\,H25!SG:&W;>.@8KD"OT2HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>cdtx-20231231_g9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cdtx-20231231_g9.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (W @P# 2(  A$! Q$!_\0
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M&_'4]*U_C5\./^%P?"3Q?X(^W_V5_P )!ID^G?;?*\WR/,0KOV9&[&>F1]:
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M#\:?!_P%\'GQ1XWU1M'T3[1':_:%MI;@^:^=BA(E9CG![5X/_P $U=)M-!^
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MGCSPE;:>XTO4(KA8]8TZ,*'8(QVF:$GDXW-ZUZIX-_Y20_$7_L0--_\ 2IZ
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M ,1:?=>'Y+FQ6:-3&MN\1G.YF"G:%;H><<9KIM/^&WB:']N[5O'C:6Z^$9_
M,.CIJ7FIM:[6^:0Q;-V_(0@YVX]\U] 9QUXI: "OA_X?ZA\:_P!G_P")7QF&
MF? ;5/'&D>*/&5WKECJEKX@L;1&A=411LD8M_!GG'7I7W!10!\J?#?X3_$;X
MR_'BP^+GQ@\/:?X/L= TVXTWPWX-AO$OY8C<C;<7%S*HV%FC^3:O&#VQEO0-
M2_97^&7A/P]X@O?!/PU\-:+XGDTF\M;.[TW38;><-+ \>U7 &-V[:>>AKVNB
M@#X=_9_^(_Q\^"OP7\'^!9_V9-9U6;0=/CLFO8_%.G1K,5S\P4L<=>F37V'X
M#UW5_$W@_2M4U[P]-X4UBZA\RYT6>YCN'M'R1L,D?RMV.1ZUOT4 > ?L5_#;
MQ)\+OAEXCTOQ1I;Z3?W7BS5]1AA>5)"]O-<%XGRC$?,O.#R.X%4?V[/ ?B[Q
M_P#"30(?!?AV7Q3K.E>*M+U@Z9#<Q6[2Q6\I=P'D8*.@'X]#7T;10!\<?$KX
MG?M$_&+P#X@\$:7^SJWA6X\06,VFOK/B#Q/936EI'*A1Y&CCRSD*QP .OKTJ
MBW[(^IZYX\^!GPY\1Z''X@^#_P -_#<DU]=W_E/;:MJK1B%(S"6+E4&Z097;
MR1FOM6DH ^/OVG_V*O#]O\-[?Q!\$/A]H&@?$WPWJMGK6DOI%I#927+0R@O
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M! .1S]*_M[> ==^(G[,GB.Q\.6#ZQJ=C<6>JC2XP2U[';7,<TD('<E4; [D
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M?L:VL*V>TI]G$8$>T]1MQC'M1+I]I-9?8Y+6&2SVA/L[1@Q[1T&W&,<58HH
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M%F;HHZGD9U/AY\0M#^*7A.S\1^';IKK3;DNG[V)HI8I$8I)%)&P#)(CJRLK
M$$&@#I**\CL/VI? 6I>/(O"]O<ZE)YVH/I$&N?V;-_9$^H+G=9I>;?+:8;6&
MT'JI7.1BC7?VI/ 7AWQQ)X9N;K49&M[V+3+[6+?39I=+L+R4J([:XNU7RXY6
M+H-I/!=0<9H ]<HKQ'XF?M9^'?A/>:NNO^$/'BZ=I;A+C6;;PS<2V!R5 99P
M-K LP4$=2<"O8])U!-7TNSOHXIH([J%)UBN8S'*@90P5U/*L,\@]#0!;HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /)E=O10!Q'_  L#7/\ HF_B;_P(TW_Y,H_X6!KG_1-_$W_@1IO_ ,F5V]%
M'$?\+ US_HF_B;_P(TW_ .3*/^%@:Y_T3?Q-_P"!&F__ "97;T4 <1_PL#7/
M^B;^)O\ P(TW_P"3*/\ A8&N?]$W\3?^!&F__)E=O10!Q'_"P-<_Z)OXF_\
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M$'_(JZA_V']9_P#3E<UV]<1\(/\ D5=0_P"P_K/_ *<KFNWH **** "BBB@
MKS^3_DOMO_V+,G_I4E>@5SK>%7;XA1^)?M*^6NEMIWV;9SDS+)OW9_V<8QWH
M Z*BBB@ HHHH **** "BBB@ HHHH **P_$'CCPYX3FAAUSQ!I>C2S*7BCU"]
MC@9U!P2H=AD?2LK_ (7)X _Z'GPW_P"#>W_^+H [&BN._P"%R> /^AY\-_\
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ML=)\4Z+JEZ_B73F6VL]0AFD8"8$D*K$G YKV*@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \@^.^OZ79ZEX:T;_ (0:S\=^)M4:9=.L[Q8PL2(%:5R[
MJ=HQC\O:N,M_"7B5;B(GX >#X<,#YBWUME>>OW*Z#]H2;5;SQI\.M*\+P0V_
MC">ZN9['5KIRL5M''&//1A@[PZ'&W';\:MP:7\>5FC\W6_!;1!ANVVUQN([]
MNM 'LPZ4M%8GC#0+KQ-H<NG6FLW>A-,R[[RQ"^<(\_,J,P.TD<;L9':@"]IN
MLV&L?:OL%Y#>?99VMI_(D#^7*N-R-CHPR,BN:3XR>!9-0%@OBW1VO6E\@0"\
M3>9,[=N,]<\5P'[-^GMH?@;QU8:3&TC67B/4H+2.63+,4VJ@9SW.!DFN(T'2
MO$_P+\*Z1J/BSP/X4O="L9$%_J$!\[5(WDFYN&8IM.&<<*21QSQP"3OJ?1?B
M3QUX=\'M;KKFN:?I#7'^J6\N%B+XZX!/2K>K>)-)T'23JFHZE:V.F@!OM<\R
MI%@],,3@Y[>M>0^#?">C^/OBU\4KWQ%IMKK,EM<6VEVT=]$LJP6_D!RJ CC<
MS$DCFO./AKIL'BCQ5X"\*:O'_:&@:+=ZZUM:7>)(Y#!.(X=P/WMBL<9I7 ^I
M]"\0:9XHTY+_ $C4+;4[)R0MQ:RK(A(ZC(/6M"O&_A[I=IX1^/WC?1-(MDL-
M)NM,L]3:SMU"PI<%I$9E4<*6 !..N*Z^?XO^'K>:2)X=>+QL5.SPWJ+#(.."
M+?!'N.*8QOP@_P"15U#_ +#^L_\ IRN:[>N ^"%]%JG@>XO(!*(9];UB1!-"
M\3X.I7.-R. RGV8 BN_H **** "BBN5^(OQ"M_AOHD>J76BZ_KD3S"'R/#NE
M3:C<*2"=QBB!;;QC=C R* .JHKPW_AK;1?\ HGGQ4_\ "#U+_P"-50D_;4\)
M0ZY!HLG@SXE)K%Q;O=PZ>W@G4!/)"C*KRJGEY**TB L. 74=Q0!] T5X;_PU
MMHO_ $3SXJ?^$'J7_P :KT+X:_$RT^)VFW=[::'XCT)+>;R3#XDT:?397.T'
M<B3*I9><;AQG(H ["BBB@ HHHH **** "BBB@#SM[6&Y^/DOG0QRX\,IC>@.
M/]*?UKNO[+LO^?2#_OTO^%<3'_R7R;_L68__ $J>O0* *O\ 9=E_SZ0?]^E_
MPH_LNR_Y](/^_2_X5:HH J_V79?\^D'_ 'Z7_"C^R[+_ )](/^_2_P"%6J*
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M4 >?_&+_ (\O"?\ V,VF_P#HX5Z!7G_QB_X\O"?_ &,VF_\ HX5Z!0 4444
M%%%% !1110 4444 %%%% !1110 4444 >=_%3Q]J_A_5/#OAGPQ;VEQXG\02
MRK;/J!;[/;Q1)NDE<+R< C '7]#YOH/QW\6VGPQ\->-M7BTZ]TLZG-I^M+#&
MT<B*;CRHI8N<87'(/7(Z=:[?X[:';K#H?BN'Q'IOA;7M!G=[&]U9@+:42+MD
MAD&02& _AY&/QKY]\#V\4^BZ3X2\5?$GP7!X0L]2.HS6NDW327%\YE,HC=F
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M7XL?]@9O_0TKZ!KY^_;^_P"3-?BQ_P!@9O\ T-* /S(^'O\ R(/AK_L&V_\
MZ+6N@KG_ (>_\B#X:_[!MO\ ^BUKH* "BBB@ HHHH AO/^/.Y_ZXO_Z":^VO
M^"37_)E'A;_K_P!0_P#2IZ^);S_CSN?^N+_^@FOMK_@DU_R91X6_Z_\ 4/\
MTJ>@#[$HHHH **9+*D$3R2.L<: LSL<!0.22>PKDO^%Q> ?^AX\-_P#@VM__
M (N@#L**X_\ X7%X!_Z'CPW_ .#:W_\ BZ/^%Q> ?^AX\-_^#:W_ /BZ /.?
MBI_R=A\!_P#KQ\2?^B+2O=J^8_B=\4/!EQ^U'\$+R+Q=H,EI;67B$3SIJ<!2
M(M#:A0S;L#)!QGK@U[9_PN+P#_T/'AO_ ,&UO_\ %T =A17'_P#"XO /_0\>
M&_\ P;6__P 71_PN+P#_ -#QX;_\&UO_ /%T =A16=H?B+2O$]F;S1]3L]6M
M YC-Q8W"31[A@E=RDC/(X]ZT: "BBB@ HHK(\6:)=>)/#M]IMEK5]X=NKA-D
M>J::L1N+<Y!W()4=,\8^92.: ->BO#O^&>?&?_1P?Q$_\!]&_P#D"O.OB-X!
M^(?@[XC?"SP]:?'OQW+:>*]6N["\DFM=(,D21:?<W*F,BQ !+PJ#D'@GOS0!
M];45X=_PSSXS_P"C@_B)_P" ^C?_ "!7:?#3X;ZYX#N+^75_B/XD\=)<HBQQ
M:]'9*MN022R?9[>(Y.1G<3T&,4 =[1110 4444 %%%% !1110 4444 %%%%
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M_P#HM:Z"@ HHHH **** (;S_ (\[G_KB_P#Z":^VO^"37_)E'A;_ *_]0_\
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M$Z_;^(+*RG^RW$L".GE2[0^TAU!SM93^-*S6XU*,MF=K1112*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R[XQ>-/$%AK7A?P?X
M3FM[+7_$4DV-0NH_,2TAA0-(X0\,V#P#QQ^(X_Q-/\1/@5!8^(]4\;+XT\._
M;(;?4K.\T^.WEC65PGF1,A)R&8?+T_IK?M(3Z):_\(Y=:CJ>J>%]3LYI+C3O
M$UG8M<P63X562<#^%\CCO@]@<YGAOP#K7Q=DTR^\3?$K3_%WANPN%N5T[1+:
M.*.XE0@H9F4YX/5,?E0![]1110 4444 %%%% !1110!Q'P@_Y%74/^P_K/\
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M\"Z$ S ?95[^YKH/-?\ OM^=<[\/?^1%T+_KU7^9KH*_0*/\./HOR/Y\Q?\
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M6/K_ '5.>]>WZMXXTO1?%NA>&[EY?[4UI9WM$2,LI$2AG+'^'@UT% !1110
M4444 %%%% !1110!Q'P@_P"15U#_ +#^L_\ IRN:[>N(^$'_ "*NH?\ 8?UG
M_P!.5S7;T %?/W[?W_)FOQ8_[ S?^AI7T#7S]^W]_P F:_%C_L#-_P"AI0!^
M9'P]_P"1!\-?]@VW_P#1:UT%<_\ #W_D0?#7_8-M_P#T6M=!0 4444 %%%%
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M37_)E'A;_K_U#_TJ>@#[$HHHH YOXE?\DZ\5?]@JZ_\ 1+5^0W@/_D1?#?\
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M +&:'_TWVU?&U?9/_!,W_D7_ (K_ /8S0_\ IOMJ\7-OX"]?T9]IPG_OT_\
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ME'_#'\D?S)F7^_5_\<OS84R;_5/_ +II],F_U3_[IKN/-/Q'^'O_ "(NA?\
M7JO\S705S_P]_P"1%T+_ *]5_F:Z"OT"C_#CZ+\C^?,7_O-7_$_S84445J<H
M4444 %?9/_!,W_D7_BO_ -C-#_Z;[:OC:OLG_@F;_P B_P#%?_L9H?\ TWVU
M>+FW\!>OZ,^TX3_WZ?\ A?YQ/M*BBBOE#]9"OS UK_@J)\5;77=7M;3PMX-^
MS6M_<VL?G+=ERL4SQ@MB3&3MSQZU^G]?@%KG_(S>(O\ L,:A_P"E<M?6<-Y?
MA\QQ4Z6)C=*-]VM;KMZGU7#N P^88F=/$*Z4;[VUNNQ]9_\ #TKXN_\ 0K>"
M/^^+S_X[1_P]*^+O_0K>"/\ OB\_^.U\@T5^B?ZKY7_S[?\ X$_\S]"_U9RS
M_GV_O?\ F?1WQ"_X* ?$_P"(MUX1GO= \'VS>&]<AUZW$"7>)98XI8PCYD/R
MD3,>,'(%=A_P]*^+O_0K>"/^^+S_ ..U\@T4?ZKY7_S[?_@3_P P_P!6<L_Y
M]O[W_F?7W_#TKXN_]"MX(_[XO/\ X[1_P]*^+O\ T*W@C_OB\_\ CM?(-%'^
MJ^5_\^W_ .!/_,/]6<L_Y]O[W_F?K'^P[^U5XJ_::C\;KXHTG1],ET&6S2$Z
M/YP603)(QW>8S<C8.GJ:^I:_/7_@DM]_XO?]=]*_]%3U^A5?D.9488;&5:--
M6C&32/R3,J,,/C*M&FK1C)I!1117FGG!1110 4444 %%%% !1145S<16=O+/
M/(L4,2%WD8X"J!DD^V* /'/VAO#-MXBET5;GX=:AX\6-9<&RU$VJV_*\, 1N
MSV]-IKPZZ\+>%?#>I:4E_P# 76M.DN[J.WMI9=<DV&4\JN[.W)QP">:^EO%_
MCKQ2UAI.H?#_ ,/67C+3[Q'=[EM12W5<$!=N?O9^;Z8KS[Q=H_Q7^,FF6OA_
M6/"VE^$])>]@GNKP:D+B8)&X?Y O0Y _^M0!]!TM%% !1110 4444 %%%% '
M$?"#_D5=0_[#^L_^G*YKMZXCX0?\BKJ'_8?UG_TY7-=O0 5\_?M_?\F:_%C_
M + S?^AI7T#7S]^W]_R9K\6/^P,W_H:4 ?F1\/?^1!\-?]@VW_\ 1:UT%<_\
M/?\ D0?#7_8-M_\ T6M=!0 4444 %%%% $-Y_P >=S_UQ?\ ]!-?;7_!)K_D
MRCPM_P!?^H?^E3U\2WG_ !YW/_7%_P#T$U]M?\$FO^3*/"W_ %_ZA_Z5/0!]
MB4444 <W\2O^2=>*O^P5=?\ HEJ_(;P'_P B+X;_ .P9;?\ HI:_7GXE?\DZ
M\5?]@JZ_]$M7Y#> _P#D1?#?_8,MO_12U^?\7_PJ/J_R/T_@;^-7]%^;-VBB
MBOS(_7@HHHH **** /M'_@G'_P DG\;_ /8YWW_HBVKZOKY0_P""<?\ R2?Q
MO_V.=]_Z(MJ^KZ_?\!_NE'_#'\D?S)F7^_5_\<OS84R;_5/_ +II],F_U3_[
MIKN/-/Q'^'O_ "(NA?\ 7JO\S705S_P]_P"1%T+_ *]5_F:Z"OT"C_#CZ+\C
M^?,7_O-7_$_S84445J<H4444 %?9/_!,W_D7_BO_ -C-#_Z;[:OC:OLG_@F;
M_P B_P#%?_L9H?\ TWVU>+FW\!>OZ,^TX3_WZ?\ A?YQ/M*BBBOE#]9"OP"U
MS_D9O$7_ &&-0_\ 2N6OW]K\ M<_Y&;Q%_V&-0_]*Y:^\X._WVI_@?YQ/NN#
M_P#?:G^!_FBI1117Z^?K84444 %%%% 'W]_P26^_\7O^N^E?^BIZ_0JOSU_X
M)+??^+W_ %WTK_T5/7Z%5_/N<_\ (QK_ .)_F?@6<?\ (QK_ .)_F%%%%>,>
M.%%%% !1110 4444 %8WC+_D3]=_Z\)__1;5LU5U33TU;3+RQD9DCN87A9EZ
M@,I!(]^: /F?X+^/?BGIOPL\-VVC?#.WU;3([4+!>MK441F7<?FV$97Z5W%O
M\2/C%)/&LOPFM8XV8!G_ +>B.T9Y.,5Z9X%\(VW@+PCI?A^SFEN+;3XO)CEG
MQO89)R< #OZ5O4 %%%% !1110 4444 %%%% '$?"#_D5=0_[#^L_^G*YKMZX
MCX0?\BKJ'_8?UG_TY7-=O0 5\_?M_?\ )FOQ8_[ S?\ H:5] U\_?M_?\F:_
M%C_L#-_Z&E 'YD?#W_D0?#7_ &#;?_T6M=!7/_#W_D0?#7_8-M__ $6M=!0
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M-U;PKXE\=>+-1T+5(?(N[7S+*/S$R#C<EJ&'('0T ?E%\/?^1!\-?]@VW_\
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MO_D>C_5/'?S1^]__ "(?Z[9=_)/[H_\ R1\*T5]U?\,#^!/^A@\5?^!5M_\
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MW6;.PD\R^A/[N60*V/W/7%=3_P .Q/A+_P!!+Q5_X'P__&*/]<,!_)/[E_\
M)!_K=@/Y)_<O_DC\L:*_4[_AV)\)?^@EXJ_\#X?_ (Q1_P .Q/A+_P!!+Q5_
MX'P__&*/]<,!_)/[E_\ )!_K=@/Y)_<O_DCR_P#X)+??^+W_ %WTK_T5/7Z%
M5X'\)OV.?#?P/;6&\%^+/%FCG5C"UY_I%K+YAB#!/OVYQ@.W3&<\UZ%_PK75
M?^BC>+/_ "0_^1*_+<PQ$<5BZM>&TFVK^9^88_$1Q6*J5X;2;:OYG=45PO\
MPK75?^BC>+/_ "0_^1*/^%:ZK_T4;Q9_Y(?_ ")7GG =U15>PM7LK&WMY+F:
M\>*-4:XN-OF2D#&YMH"Y/4X 'L*L4 %%%% !1110 4444 %%%% !1110 444
M4 %-95D5E90RL,%2,@CTIU% $<%O%:QB.&-(HQT6-0H'X"I*** "BBB@ HHH
MH **** "LJ\\-VE]XDTS6Y#)]MT^"XMX0K83;,8R^1CD_NEQ^-:M% !1110
M4444 %%%% !1110 445QGC7XJ:;\/[Q$U?3M873S'YDFJVU@\]K#UX=DR5/'
M]W'(YH W=4\,V>L:UHNJ3F47.D22RVX1L*6DB:-MPQS\K'\:UJR_#GBC2?%^
MEQZCHNHV^IV,G FMI ZY[@^A]CS6I0 4444 %%%% !1110 4444 %96M>'+3
M7KK1[BY,@DTJ\^W6_EM@&3RI(OFXY&V5N/7%8_C;XD67@&2!M2TS6)[)T+R7
M]A8/<PVX!_Y:;,L/P4UJ>%?&6A^.-+74=!U2VU6S;CS+=]VT^C#JI]B : -F
MBBB@ HHHH **** "BBB@ HHKE_&WCZV\"K;RWFE:Q?6DF3)<Z98M<I;@8YD"
M_,!SV!Z&@#1\1>&;/Q1'8)>&4+97L-_%Y3;?WD3;ESQR,]16O6!X.\>^'_B!
MIOV[P_JMOJ=N,!_*;#QD]G0X93[$"M^@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $9@JEF(  R2>U
M><7/Q9\$^.-2N/".E>.$M-<E.Q)--D7S0P.<1NZ-&QX/ SQFLG]J*^OK+X7_
M +E[B'29K^WBUF>S!,L5@6_?,N.>F ?8FN5M_BGH6H26&@_!OP;:>)+ZQ&V/
M49+0P6.GY4 LTC ,6(/."">>2>* .AUC7/B)\'5^WZI(GQ!\)1\W-Q#;K;ZG
M9Q@<N57Y)5'? ![G KU7PWXCT[Q;H=GJ^DW27FGW<8DBFCZ$>A'8@\$'D$$5
MYO\ #SXA>+5^(%UX&\>V6E+J[:?_ &G9WFC%S;SP[]C*5?D,">^,\\=S%\.]
M)7X8_%KQ!X1MB4T#6;?^W=+@_AMY X2YB7T&6C8 < &D!Z_1113 **** "BB
MB@ HI"<#)X%<7JOQ7T?0_'.E^&]02:T&J0>98ZI(!]DN),X\E7S]_&#SP<@=
M2* .T9@BEF(50,DGH*\3UC]J;P[IOBRRMDM;J[\(S%K>X\3QP2?9(+C=M"[R
MNUD[%E)Z^@-=%>:Y?^/O$WQ'\#IML;>RTN""&Z0G>9+F&0EB>P7C 'H:X3P#
M\6O"'AWX<?\ ""_$)(/#^IZ+8BQOM,OXSLNHU4J)(L#$@<#.!SD_0T :/Q$\
M%O\ "^Z;XE^ (A''&!-K>C6A'V;4;7JTJJ.!(H);<.O)]0WM&BZO:^(-(LM3
ML9!-9WD*7$,@_B1E#*?R-?.?[/>J>(_!-YH/@WQ%"\WASQ-:75WHD-UDW%C'
M&23!*#_"8BC#T+8]A[C\-/!TGP_\&6.@/=_;([)I4@DVXVPF1FC3WVJ0N?:D
M!U%%%%, HHHH **** "BN+\;?%;2/ -WH?\ :D<ZZ5J<S0'6(U#6ML_\(E;/
MR[CD XQP<XQ5/7/%UU?_ !.M?!-N$BLK[0;C4'O4),@;>L2!>P W%L]^* .6
M\5?M/Z'X>\3V=M:V-YJWAY)7M]4UZU@E:WLI 0%&_9M<9)W;6XQW/%0?$;P&
MWA]_^%G_  V$,>KQ1BXO;&T/^BZS:_>8%5X+[<L&')^N#61\*?B5X>^'/@U_
MAW\0!!X<U+18Y+=TOH\6VH6Y9B)8CC#A@W*]2<^X&/\  O7=<^'NMZ+IEQ%,
MW@7Q?>7G]A6MP"+BP",SQY#<^7)& 0.V0>.<@'T3X3\36?C+PSIFN:>Q:SU"
MW2XBW=0&&<'W'0^XK6KE/AOX)/P^\/SZ.ER+BS6^N;BT0+CR(9)6=8O?;N(K
MJZ "BBB@ HHHH ***X[Q]\4=*^'5MIE[J<5S)I5U=_9)]1MD$D-D>0&F(.0N
M[Y>G6@#L:\:\?_M,:-X-UR&VLK"\U_3K2Y:#6]0L()'BTX =W"[&(/WEW9&/
M7BNJUSQ]-#\2O"/AJS6&6QUJSN[R2\5MQVQHNP(1Q@EP<^P]:\S^$_CS1O@U
MIUY\._'4L>BWEE/<RV]]>KBWU.W>1G\P/C!;YL$'Z=<@ &[X^^'\.K6\/Q*^
M&<T,'B>.(72/98\C6(< M%*HX8L!P>N< ]BOI/P_\:6GQ"\&Z5XALE,<-]"'
M,3=8W!*NA]U8,/PKYV^$?B#4_AWXHMKS3XG_ .%7^+M>FL=)L9E9)+5FYBFB
M5N1%(0_'' !^OO\ X \$GP+'KMO'<++97VJ3:A;0*N/LZR[6:/W&_>W_  *@
M#JZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ***9)*D,;R2.L<: LS,<  =23Z4 /KP3Q#XDU+XV?$[4O &FZE/X9\
M/Z)A]7E1_)O]0.>(X0>5B]7[@CL1FX_Q"\:?%_5[Z'X;366D>&M/8Q/XDU&
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M\M<[I,<;CT[5Z?110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8P<8/<5B:#\5]9^$<(\/?$ZTO)TM_P!W9>*+&UDN(+V,<*) @+)+T!!'/ZD
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MR:Z)(;'5[A[8WP(V6S!00SCKM.>HZ=37;PS1W$*2Q.LL4BAD=#E6!&00>XH
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MK8)&1[&IZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX66%MK.F^0'O9M0L].O$#/8QO(6B7!SM8 Y]06->KTA(****8PHHHH ****
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M]^.%I&:)3[A"M>HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991775536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 12, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CIDARA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1537286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6310 Nancy Ridge Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">752-6170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">&#8220;CDTX&#8221;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag', window );">Document Financial Statement Restatement Recovery Analysis</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,235,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtRestatementRecoveryAnalysisFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtRestatementRecoveryAnalysisFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992269328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992344896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,778<span></span>
</td>
<td class="nump">$ 48,670<span></span>
</td>
<td class="nump">$ 50,430<span></span>
</td>
<td class="nump">$ 47,976<span></span>
</td>
<td class="nump">$ 32,731<span></span>
</td>
<td class="nump">$ 53,078<span></span>
</td>
<td class="nump">$ 24,637<span></span>
</td>
<td class="nump">$ 36,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">16,246<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">26,121<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">6,097<span></span>
</td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">3,712<span></span>
</td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
<td class="nump">6,530<span></span>
</td>
<td class="nump">5,779<span></span>
</td>
<td class="nump">6,706<span></span>
</td>
<td class="nump">5,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,855<span></span>
</td>
<td class="nump">58,461<span></span>
</td>
<td class="nump">62,674<span></span>
</td>
<td class="nump">79,808<span></span>
</td>
<td class="nump">45,094<span></span>
</td>
<td class="nump">63,899<span></span>
</td>
<td class="nump">36,546<span></span>
</td>
<td class="nump">52,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use asset, net</a></td>
<td class="nump">782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">3,788<span></span>
</td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,030<span></span>
</td>
<td class="nump">64,144<span></span>
</td>
<td class="nump">68,339<span></span>
</td>
<td class="nump">81,975<span></span>
</td>
<td class="nump">47,487<span></span>
</td>
<td class="nump">66,721<span></span>
</td>
<td class="nump">39,362<span></span>
</td>
<td class="nump">55,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,772<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">4,244<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">14,177<span></span>
</td>
<td class="nump">11,772<span></span>
</td>
<td class="nump">10,022<span></span>
</td>
<td class="nump">9,108<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">8,567<span></span>
</td>
<td class="nump">9,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">18,040<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">11,534<span></span>
</td>
<td class="nump">11,314<span></span>
</td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">5,034<span></span>
</td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
<td class="nump">4,922<span></span>
</td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">3,464<span></span>
</td>
<td class="nump">3,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current contract liabilities</a></td>
<td class="nump">25,095<span></span>
</td>
<td class="nump">14,679<span></span>
</td>
<td class="nump">14,975<span></span>
</td>
<td class="nump">15,790<span></span>
</td>
<td class="nump">14,614<span></span>
</td>
<td class="nump">15,249<span></span>
</td>
<td class="nump">14,730<span></span>
</td>
<td class="nump">14,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liability</a></td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">67,418<span></span>
</td>
<td class="nump">50,228<span></span>
</td>
<td class="nump">44,770<span></span>
</td>
<td class="nump">47,482<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="nump">44,255<span></span>
</td>
<td class="nump">41,933<span></span>
</td>
<td class="nump">40,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">16,504<span></span>
</td>
<td class="nump">17,551<span></span>
</td>
<td class="nump">19,386<span></span>
</td>
<td class="nump">20,525<span></span>
</td>
<td class="nump">24,398<span></span>
</td>
<td class="nump">15,351<span></span>
</td>
<td class="nump">17,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liability</a></td>
<td class="nump">575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">3,002<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,240<span></span>
</td>
<td class="nump">70,038<span></span>
</td>
<td class="nump">65,922<span></span>
</td>
<td class="nump">66,868<span></span>
</td>
<td class="nump">61,925<span></span>
</td>
<td class="nump">68,968<span></span>
</td>
<td class="nump">57,905<span></span>
</td>
<td class="nump">58,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized at December&#160;31, 2023 and 2022; 90,601,999 shares issued and outstanding at December&#160;31, 2023; 72,470,440 shares issued and outstanding at December&#160;31, 2022</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">433,212<span></span>
</td>
<td class="nump">432,315<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">399,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(441,431)<span></span>
</td>
<td class="num">(438,218)<span></span>
</td>
<td class="num">(429,111)<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(404,903)<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(8,210)<span></span>
</td>
<td class="num">(5,894)<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">15,107<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
<td class="num">(18,543)<span></span>
</td>
<td class="num">(3,705)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">67,030<span></span>
</td>
<td class="nump">64,144<span></span>
</td>
<td class="nump">68,339<span></span>
</td>
<td class="nump">81,975<span></span>
</td>
<td class="nump">47,487<span></span>
</td>
<td class="nump">66,721<span></span>
</td>
<td class="nump">39,362<span></span>
</td>
<td class="nump">55,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177082314656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177155664832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 26,107<span></span>
</td>
<td class="nump">$ 40,744<span></span>
</td>
<td class="nump">$ 6,216<span></span>
</td>
<td class="nump">$ 7,269<span></span>
</td>
<td class="nump">$ 33,604<span></span>
</td>
<td class="nump">$ 13,485<span></span>
</td>
<td class="nump">$ 44,854<span></span>
</td>
<td class="nump">$ 54,229<span></span>
</td>
<td class="nump">$ 59,570<span></span>
</td>
<td class="nump">$ 64,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,335<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,718<span></span>
</td>
<td class="nump">7,497<span></span>
</td>
<td class="nump">26,107<span></span>
</td>
<td class="nump">40,744<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
<td class="nump">7,269<span></span>
</td>
<td class="nump">33,604<span></span>
</td>
<td class="nump">13,485<span></span>
</td>
<td class="nump">46,322<span></span>
</td>
<td class="nump">54,229<span></span>
</td>
<td class="nump">63,905<span></span>
</td>
<td class="nump">64,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of product revenue</a></td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,389<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">18,869<span></span>
</td>
<td class="nump">20,283<span></span>
</td>
<td class="nump">16,630<span></span>
</td>
<td class="nump">20,381<span></span>
</td>
<td class="nump">36,425<span></span>
</td>
<td class="nump">37,011<span></span>
</td>
<td class="nump">53,814<span></span>
</td>
<td class="nump">57,294<span></span>
</td>
<td class="nump">68,532<span></span>
</td>
<td class="nump">77,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
<td class="nump">5,339<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">8,496<span></span>
</td>
<td class="nump">10,681<span></span>
</td>
<td class="nump">12,928<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
<td class="nump">18,333<span></span>
</td>
<td class="nump">20,546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">22,208<span></span>
</td>
<td class="nump">21,595<span></span>
</td>
<td class="nump">23,326<span></span>
</td>
<td class="nump">26,553<span></span>
</td>
<td class="nump">21,969<span></span>
</td>
<td class="nump">25,723<span></span>
</td>
<td class="nump">44,921<span></span>
</td>
<td class="nump">47,692<span></span>
</td>
<td class="nump">67,129<span></span>
</td>
<td class="nump">74,245<span></span>
</td>
<td class="nump">88,388<span></span>
</td>
<td class="nump">97,951<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,490)<span></span>
</td>
<td class="num">(14,098)<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="nump">14,191<span></span>
</td>
<td class="num">(15,753)<span></span>
</td>
<td class="num">(18,454)<span></span>
</td>
<td class="num">(11,317)<span></span>
</td>
<td class="num">(34,207)<span></span>
</td>
<td class="num">(20,807)<span></span>
</td>
<td class="num">(20,016)<span></span>
</td>
<td class="num">(24,483)<span></span>
</td>
<td class="num">(33,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(8,877)<span></span>
</td>
<td class="num">(13,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,462)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,339)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,488)<span></span>
</td>
<td class="num">(33,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(379)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="num">(272)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="num">(10,611)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,718)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (13,624)<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
<td class="nump">$ 14,246<span></span>
</td>
<td class="num">$ (15,759)<span></span>
</td>
<td class="num">$ (18,474)<span></span>
</td>
<td class="num">$ (10,611)<span></span>
</td>
<td class="num">$ (34,233)<span></span>
</td>
<td class="num">$ (19,718)<span></span>
</td>
<td class="num">$ (19,987)<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">78,640,086<span></span>
</td>
<td class="nump">70,217,985<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">87,427,439<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">101,189,396<span></span>
</td>
<td class="nump">88,592,568<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">87,427,439<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176974671072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Underwritten Public Offering</div></th>
<th class="th"><div>Public Offering</div></th>
<th class="th"><div>Series X Convertible Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series X Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series X Convertible Preferred Stock </div>
<div>Underwritten Public Offering</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Underwritten Public Offering</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Underwritten Public Offering</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Public Offering</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 398,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (384,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2022</a></td>
<td class="num">$ (3,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2022</a></td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(34,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2022</a></td>
<td class="num">$ (18,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2022</a></td>
<td class="nump">69,238,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2022</a></td>
<td class="num">$ (2,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(404,903)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="nump">71,181,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,414,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,584)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Dec. 31, 2022</a></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Dec. 31, 2022</a></td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2022</a></td>
<td class="num">$ (3,705)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2022</a></td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(15,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2022</a></td>
<td class="num">$ (18,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2022</a></td>
<td class="nump">69,238,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,664,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">14,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2022</a></td>
<td class="num">$ (2,247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(404,903)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="nump">71,181,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2022</a></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086,000<span></span>
</td>
<td class="nump">6,158,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,256<span></span>
</td>
<td class="nump">8,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,255<span></span>
</td>
<td class="nump">8,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of stock options</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">3,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2023</a></td>
<td class="nump">$ 15,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2023</a></td>
<td class="nump">90,024,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2022</a></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2023</a></td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(429,111)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2023</a></td>
<td class="nump">90,251,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2022</a></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,718)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2023</a></td>
<td class="num">$ (5,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(438,218)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2023</a></td>
<td class="nump">90,415,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2022</a></td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2022</a></td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086,000<span></span>
</td>
<td class="nump">6,219,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,256<span></span>
</td>
<td class="nump">8,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,255<span></span>
</td>
<td class="nump">8,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="nump">25,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of stock options</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Dec. 31, 2023</a></td>
<td class="num">$ (8,210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">433,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441,431)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Dec. 31, 2023</a></td>
<td class="nump">90,601,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,601,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2023</a></td>
<td class="nump">$ 15,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2023</a></td>
<td class="nump">90,024,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2023</a></td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(429,111)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2023</a></td>
<td class="nump">90,251,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,107)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2023</a></td>
<td class="num">$ (5,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 432,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (438,218)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2023</a></td>
<td class="nump">90,415,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177082503936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of costs to obtain a contract with a customer</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use asset</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(10,413)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(6,097)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="nump">3,735<span></span>
</td>
<td class="num">(2,440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">8,886<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">6,506<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="num">(5,799)<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(973)<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(22,432)<span></span>
</td>
<td class="num">(28,473)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(505)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(505)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from underwritten public offering, net of issuance costs</a></td>
<td class="nump">17,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">8,707<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of Term Loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,593)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">25,984<span></span>
</td>
<td class="num">(951)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">3,047<span></span>
</td>
<td class="num">(29,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">35,778<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">797<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment, included in accounts payable and accrued liabilities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance lease right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">788<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of shares pursuant to Employee Stock Purchase Plan</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets', window );">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrual for Taxes Other than Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_OperatingLeaseRightOfUseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_OperatingLeaseRightOfUseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock In Underwritten Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses, Other Current Assets And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991936720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">THE COMPANY AND BASIS OF PRESENTATION</a></td>
<td class="text">THE COMPANY AND BASIS OF PRESENTATION<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company&#8217;s first commercially approved product in the United States, or U.S., is REZZAYO</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Melinta Therapeutics, LLC, or Melinta, is commercializing REZZAYO in the U.S. The Company&#8217;s proprietary Cloudbreak</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> platform enables development of novel drug-Fc conjugates, or DFCs, that inhibit specific disease targets while simultaneously engaging the immune system. The Company&#8217;s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting multiple oncology and autoimmune indications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December&#160;31, 2023, the Company had an accumulated deficit of $441.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had cash and cash equivalents of $35.8 million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s consolidated financial statements relate to estimated collaboration expenses related to the Company&#8217;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#8217;s </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">collaboration and license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restatement of Consolidated Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the indirect taxation consequences upon the first commercial sale of REZZAYO in 2023 and determined that it had a liability for indirect taxation in various tax jurisdictions outside of the U.S. based on its supply chain activities in 2023 and prior years. As a result, it was concluded that in prior years the Company did not appropriately account for indirect taxes which led to understatements of accrued liabilities and operating expenses during the impacted periods. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $11.5&#160;million, an increase in operating expenses of $3.9&#160;million, and an increase in beginning accumulated deficit of $7.6&#160;million, for 2022. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $7.6&#160;million, an increase in operating expenses of $3.7&#160;million, and an increase in beginning accumulated deficit of $3.9&#160;million, for 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consolidated financial statements (as restated) also include adjustments to correct certain other previously identified misstatements relating to fiscal year 2022 and the quarters within 2023 that the Company had determined to be immaterial, both individually and in the aggregate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Impact of Restatement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See below for reconciliation from the previously reported amounts to the restated amounts in the consolidated balance sheet, consolidated statement of operations and comprehensive loss, consolidated statement of convertible preferred stock and stockholders&#8217; equity (deficit), and consolidated statement of cash flows as of and for the year ended December 31, 2022. The previously reported amounts were derived from the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. These amounts are labeled as "As Previously Reported" in the tables below. The amounts labeled "Restatement Adjustment" represent the effects of this restatement described above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">61,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(406,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(418,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(14,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Operations and Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">94,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,857,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,857,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">398,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">398,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">404,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">404,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(377,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(384,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(406,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(418,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(8,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(14,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Cash Flows</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,052)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The remainder of the notes to the Company&#8217;s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts from the restatement discussed above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176986668864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, and product sales. The Company records accounts receivables net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#8217;s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of December&#160;31, 2023 or 2022.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to materials, third-party contract manufacturing, freight-in and overhead. Inventory is stated at the lower of cost or net realizable value with cost based on the first-in-first-out method. The Company performs an assessment of recoverability of capitalized inventory during each reporting period based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life, and writes down any excess, obsolete or unsaleable inventory to its estimated realizable value in the period which the required reserve is first identified. Such write downs, should they occur, are charged to cost of product revenue in the consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the Company did not identify any excess, obsolete or unsaleable inventory.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:f-404">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Codification</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC, 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#8217;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#8217;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in selling, general and administrative, or SG&amp;A, expenses in the accompanying statements of operations and comprehensive loss.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company reports deferred income taxes in accordance with ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indirect Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in research and development, or R&amp;D, expenses, and the related interest and penalties are included in SG&amp;A expenses. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#8217;s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed in future periods. Indirect tax amounts on commercial sales (product revenue) that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included within inventory.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a License Agreement with Melinta, or the Melinta License Agreement. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment and milestones achieved to date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 9 for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta are required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represents a distinct performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price to be recognized as revenue for each performance obligation under the Commercial Supply Agreements consists of variable consideration which is determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue are adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration is included in the transaction price only to the extent that it is considered probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections are recorded as indirect taxes liabilities. The transaction price will be fully allocated to the single performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that the performance obligation is satisfied and product revenue is recognized when the customer obtains control of the product, which occurs at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#8217;s product to the customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shipping and handling activities that are performed after a customer obtains control of the product are treated as activities to fulfill the promise to a customer and any amounts billed to a customer represent revenues for the product provided. Costs related to such shipping and handling billings are classified as cost of product revenue.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or research and development expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#8217;s stock, (c) the expected term of the award, and (d) the expected dividend yield.&#160;The Company computed the expected volatility data using the daily close prices for the Company&#8217;s common stock during the equivalent period of the calculated expected term of the Company&#8217;s stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#8217;s losses. For all periods presented, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,044,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,764,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,323,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,826,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40,025,543&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the FASB issued </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Update</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025 and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures, or do not apply to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177082171248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176986668864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s capitalized inventory consists of costs incurred subsequent to FDA approval of REZZAYO in March 2023. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred. There were no inventory write downs during the year ended&#160;December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176993596592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Depreciation and amortization of property and equipment of $0.1 million and $0.1 million were recorded for the years ended December&#160;31, 2023, and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992265152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $10.0&#160;million&#160;from the Lender, or the Term A Loan. The Term A Loan bore interest at a variable annual rate equal to the greater of (i) 4.50%&#160;or (ii)&#160;the Lender&#8217;s prime interest rate plus 0.75%, and matured on July 3, 2022. The Term A Loan had an interest-only period through April 3, 2020, which was followed by equal monthly principal payments and was paid in full on July 5, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992288816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald &amp; Co, or Cantor. During the years ended December&#160;31, 2023 and 2022, the Company sold 6,219,741 and 3,414,926 shares of common stock for net proceeds of approximately $8.7 million and $2.4 million, respectively, after deducting placement agent fees. As of December&#160;31, 2023, the remaining capacity under the Sales Agreement is $37.1 million.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2023 Underwritten Public Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 7, 2023, the Company completed concurrent but separate underwritten public offerings with Cantor, the underwriter, to issue and sell 11,086,000 shares of its common stock, including the exercise in full by Cantor of their option to purchase an additional 1,446,000 shares of common stock, and 286,000 shares of the Company&#8217;s Series X Convertible Preferred Stock. Cantor agreed to purchase the shares of common stock at a price of $1.267 per share and the shares of Series X Convertible Preferred Stock at a price of $12.67 per share. The total gross proceeds from the offerings, including the full exercise by Cantor of its option to purchase additional shares of common stock, were approximately $19.5&#160;million, before deducting underwriting discounts and commissions and offering expenses. The Company received total net proceeds of approximately $17.3&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On August 12, 2020, at the request of certain holders, 52,241 shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of 522,410 shares of the Company&#8217;s common stock. As of December&#160;31, 2023 and 2022 shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 10 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#8217;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#8217;s common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the Company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC 480, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had 200,000,000 shares of common stock authorized as of December&#160;31, 2023. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, warrants to purchase 17,331 shares of the Company&#8217;s common stock were outstanding with a weighted average exercise price of $11.54 per share. During the year ended December&#160;31, 2023, 12,499,997 common stock warrants expired unexercised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, warrants to purchase 12,517,328 shares of the Company&#8217;s common stock were outstanding with a weighted average exercise price of $6.82 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had no intrinsic value at December&#160;31, 2023 and 2022. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,044,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,764,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,323,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,411,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,469,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">987,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">806,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38,225,338&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,302,480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992287600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY INCENTIVE PLANS</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company&#8217;s board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by 4% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:f-535">three</span>- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i) 1% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii) 490,336 shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to 15% of the employee&#8217;s eligible compensation.&#160;During the years ended December&#160;31, 2023 and 2022, 309,548 and 363,596 shares, respectively, were issued pursuant to the ESPP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, total unrecognized compensation expense related to the ESPP was immaterial and is expected to be recognized over approximately 0.4 years.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the year ended December&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,223,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,515,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(490,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(151,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,098,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs and PRSUs granted by the Company during the year ended December&#160;31, 2022 was $0.83 per share. The total fair value of RSUs and PRSUs vested during the years ended December&#160;31, 2023 and 2022 was approximately $0.7 million and $1.6 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At December&#160;31, 2023, estimated unrecognized compensation expense related to RSUs and PRSUs granted was approximately $1.7 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2 years.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the year ended December&#160;31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate<br/>Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,099,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,233,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(641,417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,666,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,666,015&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,236,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the years ended December&#160;31, 2023 and 2022 was $0.72 and $0.51, respectively, per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, total unrecognized share-based compensation expense related to unvested stock options was approximately $2.4 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.9 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes the Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted to employees under the 2015 EIP and 2020 IIP and the shares purchasable under the 2015 ESPP during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2015 EIP and 2020 IIP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.58% - 4.61%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.39% - 4.02%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82% - 83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70% - 75%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.50 - 6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.50 - 6.08</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2015 ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.29% - 5.43%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.57% - 2.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64% - 147%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75% - 98%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.50 - 2.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.50 - 2.00</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992288816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS AND CONTRACTS</a></td>
<td class="text">SIGNIFICANT AGREEMENTS AND CONTRACTS<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Mundipharma Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#8209;bearing license to develop, register and commercialize the Mundipharma Licensed Product in the Mundipharma Territory, subject to the Company&#8217;s retained right as described below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#8209;exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#8217;s territory.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s Retained Rights.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As of December&#160;31, 2023, the Company retained the exclusive right to develop, register and commercialize the Mundipharma Licensed Product, Subcutaneous Product and Other Products in Japan, or the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Mundipharma Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;As of the execution of the Mundipharma Collaboration Agreement, the parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#8217;s Global Development Cost share of $31.2&#160;million. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible to receive double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.&#160;Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSTORE Trial and the ReSPECT Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company&#8217;s patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0 million, plus the research and development funding of $31.2 million, plus milestones achieved of $25.1 million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the revenue related to this performance obligation in the amount of&#160;$17.9 million&#160;in September 2019 as collaboration revenue in its consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In November 2020, the Company achieved a $11.1 million milestone under the Mundipharma Collaboration Agreement, which is recorded as current contract liabilities as of December&#160;31, 2023 because the rights to consideration is expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. As of December&#160;31, 2023, the Company estimated the uncredited portion to be approximately $10.1&#160;million in December 2024. In December 2021, August 2022, and December 2023, the Company achieved milestones of $2.8&#160;million, $11.1&#160;million, and $11.1&#160;million, respectively, under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones achieved as of December&#160;31, 2023 in January 2022, September 2022, and February 2024, respectively. The Company determined that as of&#160;December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#8217;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.</span></div><div style="margin-top:4pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In January 2024, the Company achieved a milestone of $2.8&#160;million under the Mundipharma Collaboration Agreement for which the Company received payment in April 2024.</span></div><div style="margin-top:5pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur.&#160;No&#160;royalty revenue was recognized during the years ended&#160;December&#160;31, 2023 and 2022.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs based on the Company&#8217;s Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or Phase 2 Study. Unless otherwise agreed by the parties, the Company is responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company is the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified CMC development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen will assume the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continues to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Following Janssen&#8217;s Election to Proceed Notice, Janssen, is obligated at its sole expense to diligently continue development and commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#8217;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#8217;s DFC technology more broadly. The Company&#8217;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company was eligible for reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting Research Plan activities. The Company was also be eligible to receive up to $695.0&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In addition to the Company&#8217;s right to terminate the Janssen Collaboration Agreement for Janssen&#8217;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, upon 90 days&#8217; written notice to the Company, provided that if any clinical trial under the Research Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after completion of the Phase 2 Study and before expiration of the Election Period, immediately upon written notice to the Company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after delivery of the Election to Proceed Notice, upon 90 days&#8217; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million, plus the research and development funding of $49.8&#160;million, plus milestones achieved of $10.0&#160;million. The transaction price includes the total estimated costs related to research and development and clinical supply services, which can increase or decrease as costs to continue the research and development efforts become known. No revenue was reversed due to the change in transaction price as revenue is recognized based on actual amounts billed. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $26.8&#160;million, as restated, in May 2021 as collaboration revenue in its consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The research and development services to be performed represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company&#8217;s initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> In March 2022 and September 2023, the Company achieved milestones of $3.0&#160;million and $7.0&#160;million, respectively, under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in May 2022 and September 2023, respectively. The Company determined that as of December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#8217;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur. No royalty revenue was recognized during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Pursuant to the Melinta License Agreement, the Company granted Melinta an exclusive, royalty&#8209;bearing license (including the right to sublicense through multiple tiers), to develop, register and commercialize the Melinta Licensed Product for all uses in humans and non-human animals in the Melinta Territory, subject to the Company&#8217;s retained right, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Until the fifth anniversary of the first commercial sale of the first Melinta Licensed Product in the Melinta Territory, neither the Company nor Melinta, nor any of their respective majority-owned subsidiaries may, directly or indirectly, itself or in collaboration with any third party, develop, manufacture for development or commercialization, or commercialize any product in the echinocandin class of drugs in the Melinta Territory without the other party&#8217;s prior written consent, subject to certain provisions in connection with a change of control of a party.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Commercialization.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Melinta is solely responsible for the commercialization of rezafungin in the Melinta Territory, at its sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s Retained Rights.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company retains the non-exclusive right to practice the intellectual property rights licensed to Melinta in the Melinta Territory solely for the purpose of performing its obligations under the Melinta License Agreement and Mundipharma Collaboration Agreement. The Company also retains the right to grant licenses under the intellectual property rights licensed to Melinta to third parties to which the Company has granted licenses or rights to market, promote and sell Melinta Licensed Product outside the Melinta Territory, to make and have made Melinta Licensed Product anywhere in the world solely to develop, register, use, sell, have sold, offer for sale, commercialize and import Melinta Licensed Product outside the Melinta Territory, subject to the terms of the Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Continued Development and Regulatory Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company is responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that includes, among other activities, (a) completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the FDA of a supplemental new drug application, or sNDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the Company&#8217;s ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain CMC activities for the Melinta Licensed Product, and (f) all other development activities that are required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company will remain the holder of the rezafungin IND and new drug application, or NDA. Both regulatory applications will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated sNDA for the Prophylaxis Indication, after which Melinta will be responsible for performing all activities that may be necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta&#8217;s sole expense, subject to Melinta&#8217;s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket expenses incurred by Melinta.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Supply and Transfer of CMC activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Until Melinta assumes responsibility for the manufacture and supply of the Melinta Licensed Product for development and commercialization in the Melinta Territory, which it may do by direct purchase from the Company&#8217;s contract manufacturing organizations for the Melinta Licensed Product or by having a manufacturing technology transfer to Melinta or its designee performed at Melinta&#8217;s sole expense, which, in either case, will be no later than December 31, 2026, the Company will be responsible for the manufacture and supply of the Melinta Licensed Product for development and commercialization by Melinta in the Melinta Territory, and during such period, shall supply Melinta Licensed Product to Melinta pursuant to the terms of a supply agreement negotiated by the parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Upon execution of the Melinta License Agreement, the total potential transaction value is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestone payments. In addition, the Company is eligible to receive tiered royalties on U.S. sales in the low double digits to mid-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Either party may terminate the Melinta License Agreement for uncured material breach by the other party. After July 26, 2023, Melinta may terminate the Melinta License Agreement at will. The Company may terminate the Melinta License Agreement if Melinta or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the patent rights licensed to Melinta by the Company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million, plus a milestone achieved of $20.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022, therefore the Company recognized the revenue related to this performance obligation in the amount of&#160;$25.9&#160;million&#160;in August 2022 as collaboration revenue in its consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company is required to provide research and development services, at its sole expense, as described under the Melinta Development Plan, which represents a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company&#8217;s obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services. Revenue related to the clinical supply services performance obligation recognized during the year ended December&#160;31, 2023 was immaterial.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;In March 2023, the Company achieved a $20.0&#160;million milestone under the Melinta License Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in April 2023. The Company determined that as of&#160;December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#8217;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur. The Company recognized $0.2&#160;million in royalty revenue during the year ended December&#160;31, 2023 following the commercial launch of REZZAYO by Melinta in the U.S. on July 31, 2023. No royalty revenue was recognized during the year ended December&#160;31, 2022.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $2.0&#160;million upon execution of the Melinta License Agreement, and capitalized an additional $0.5&#160;million upon achievement of a milestone, in accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company incurred these costs in connection with all the performance obligations identified in the Melinta License Agreement and allocated the capitalized contract costs to performance obligations on a relative basis (i.e., in proportion to the transaction price allocated to each performance obligation) to determine the period of amortization. The Company recognized expense during the years ended December&#160;31, 2023 and 2022 of $0.5&#160;million and $1.8&#160;million, respectively, and is included within SG&amp;A expenses in the Company&#8217;s consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the remaining balance of the asset recognized from costs to obtain the Melinta License Agreement was $0.2&#160;million.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company&#8217;s contract liabilities pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the year ended&#160;December&#160;31, 2023&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:86.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2022 (As Restated)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total contract liabilities, December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the aggregate transaction price allocated to performance obligations that are unsatisfied is $11.5&#160;million, $3.8&#160;million and $3.7&#160;million under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. These amounts are expected to be recognized over 2 years, 0.5 years, and 2 years which represent the remaining research periods under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the Company recorded $13.9&#160;million, $1.9&#160;million, and $0.4&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. As of December&#160;31, 2022, the Company recorded $0.2&#160;million and $5.6&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our collaboration revenue disaggregated by collaborator and timing of revenue recognition (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestones achieved</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,421&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon transfer of license</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestones achieved</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980315440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The tax provision for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current tax provision:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax provision:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for income taxes under ASC 740. Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation between income taxes computed at the federal statutory rate and the provision for income taxes (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal income taxes at 21% for 2023 and 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nondeductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(19,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">162m deferred tax asset limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">382 NOL and tax credit limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expired stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Current year tax expense is primarily the result of capitalized Internal Revenue Code, or IRC, Section 174 research and development expenditures, effective January 1, 2022, creating taxable income which can be offset with net operating losses and credits that are limited in use by IRC Sections 382 and 383.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">84,586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(83,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(76,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized inventory costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had federal and state tax net operating loss carryforwards of approximately $153.8&#160;million and $131.2 million, respectively. The federal and state net operating loss carryforwards begin to expire in 2035 and 2029, respectively, unless previously utilized. The Company also has federal research and development credit and orphan drug credit carryforwards totaling $9.5 million and state research and development credit carryforwards totaling $5.3 million. The federal research and development credit and orphan drug credit carryforwards begin to expire in 2035, unless previously utilized. The state research and development credit carryforwards begin to expire in 2029, with the exception of $5.3&#160;million which have no expiration date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all evidence, including a history of operating losses, management has determined that it is more likely than not that the net deferred tax assets will not be realized. The valuation allowance increased by $6.4 million in 2023 and decreased by $19.7 million in 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Future utilization of the Company&#8217;s net operating loss and tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to IRC Sections 382 and 383, as a result of ownership changes that may have occurred or that could occur in the future. An ownership change occurs when a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards through 2023 and has adjusted the attributes for their estimated limitation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized.&#160;At December&#160;31, 2023 and 2022, the unrecognized tax benefits recorded were approximately $11.5&#160;million and $11.0 million, respectively.&#160;Approximately $9.7 million of the unrecognized tax benefits would reduce the Company&#8217;s annual effective tax rates, if recognized, subject to the valuation allowance.&#160;The Company adjusted the uncertain tax position in the current year on certain attributes related to the IRC Section 382/383 analysis performed in the current year. The Company does not anticipate a significant change in the unrecognized tax benefits within the next 12 months.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2023 and 2022 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Decreases related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(13,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by the U.S. and state jurisdictions where applicable. There are currently no pending income tax examinations. The Company&#8217;s tax years from inception in 2013 are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#8217;s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties since inception.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992862320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company at December&#160;31, 2023 which will have, individually or in the aggregate, a material adverse</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">effect on its business, liquidity, financial position or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#8217;s business.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease Obligations</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a finance lease for lab equipment which was entered into in November 2023. The finance lease has a term of 36 months, monthly lease payments of $25,009, and an option to purchase the lab equipment for $1 at the end of the finance lease term. As of December&#160;31, 2023, the Company was reasonably certain that it would exercise the option to purchase the lab equipment at the end of the finance lease term. The useful life of the lab equipment is estimated to be 10 years. The rate implicit to the finance lease used in measuring the Company&#8217;s finance lease liability was 8.0%.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s finance lease as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted finance lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of finance lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s finance lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net finance lease right-of-use asset</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of finance lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term finance lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the weighted average remaining finance lease term was 3.1 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of finance lease liabilities was zero for the year ended December&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Finance lease costs were immaterial for the year ended December&#160;31, 2023.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has an operating lease for laboratory and office space in San Diego, California which was entered into in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015.&#160;On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional 36 months and increases the base rent to $133,371 per month effective January 1, 2024, subject to 4% increases every January. The operating lease expires on December 31, 2026 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of December&#160;31, 2023, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes. The incremental borrowing rate used in measuring the Company&#8217;s operating lease liability was 12.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s operating lease as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the weighted average remaining operating lease term was 3 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities was $1.3 million and $1.2 million for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $1.6 million and $1.3 million for the years ended December&#160;31, 2023 and 2022, respectively. These costs are primarily related to the Company&#8217;s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980269232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
<td class="text">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restatement of Interim Financial Information (Unaudited)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Due to the misstatements described in Note 1 above, the Company has restated its unaudited condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit), and condensed consolidated statements of cash flows for the quarterly periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(403,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(415,487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(395,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(403,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,662)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and March 31, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at March 31, 2023 and March 31, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at March 31, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at March 31, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3) Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2023 and March 31, 2022; 90,024,562 shares issued and outstanding at March 31, 2023 and 69,049,247 shares issued and outstanding at March 31, 2022</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,478&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(429,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(408,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,997)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,961)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,543)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and June 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at June 30, 2023 and June 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at June 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at June 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6) Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2023 and June 30, 2022; 90,251,746 shares issued and outstanding at June 30, 2023 and 69,238,508 shares issued and outstanding at June 30, 2022</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,620&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,932)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(438,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(393,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(404,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,932)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,894)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,858&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,721&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and September 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at September 30, 2023 and September 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at September 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at September 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9) Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2023 and September 30, 2022; 90,415,944 shares issued and outstanding at September 30, 2023 and 71,181,197 shares issued and outstanding at September 30, 2022</span></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,454)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,281)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,281)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share (10)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share (10)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,640,086&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,640,086&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute diluted net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,189,396&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,189,396&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)  As the Company was in an income position for the three-months ended March 31, 2023, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,831)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,098)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,113)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,753)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,208)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,475)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,759)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,357)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,624)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,759)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,115,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,115,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,133,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,133,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,854)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,317)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,999)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,400)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,148)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,400)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.46)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,409,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,409,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,638,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,638,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,555)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,490)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,942)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,877)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,172)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,172)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share (11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share (11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,217,985&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,217,985&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute diluted net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,592,568&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,592,568&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)  As the Company was in an income position for the three-months ended September 30, 2022, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,409)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,807)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,451)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,941)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,320)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,718)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,390,446&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,390,446&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,444)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,444)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,266)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,266)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(781)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,615)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,615)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 270<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//270/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980313456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the Company&#8217;s special meeting of stockholders held on April 4, 2024, the Company&#8217;s stockholders approved a proposal to (i) amend the Company&#8217;s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company&#8217;s outstanding common stock at a ratio in the range of 1-for-10 to 1-for-30, inclusive; and (ii) if and only if the reverse stock split is approved and implemented, a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the reverse stock split ratio, with such ratio to be determined in the discretion of the Company&#8217;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#8217;s board of directors in its sole discretion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On April 12, 2024, the Company&#8217;s board of directors approved a reverse stock split of all outstanding shares of the Company&#8217;s common stock at a ratio of 1-for-20, or the Reverse Stock Split. The Company&#8217;s board of directors also approved a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the Reverse Stock Split ratio. On April 22, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Amended and Restated Certificate of Incorporation to effect the Reverse Stock Split. As of the date of this filing, the Reverse Stock Split was not effective as trading on the Nasdaq Capital Market did not reflect the Reverse Stock Split.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All shares and per share information presented in these consolidated financial statements does not reflect the upcoming Reverse Stock Split. As of December 31, 2023, adjusting for the Reverse Stock Split will decrease the total number of the Company&#8217;s authorized shares of common stock from 200,000,000 to 20,000,000; will decrease the number of issued and outstanding shares of common stock from 90,601,999 to approximately 4,530,099; and will decrease the number of outstanding warrants from 17,331 to 866 and will change the exercise price on these warrants from $11.54 to $230.95.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information presents the Company&#8217;s basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(22,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,371,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,492,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177084756848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December&#160;31, 2023, the Company had an accumulated deficit of $441.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the Company had cash and cash equivalents of $35.8 million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s consolidated financial statements relate to estimated collaboration expenses related to the Company&#8217;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#8217;s </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">collaboration and license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, and product sales. The Company records accounts receivables net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#8217;s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of December&#160;31, 2023 or 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to materials, third-party contract manufacturing, freight-in and overhead. Inventory is stated at the lower of cost or net realizable value with cost based on the first-in-first-out method. The Company performs an assessment of recoverability of capitalized inventory during each reporting period based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life, and writes down any excess, obsolete or unsaleable inventory to its estimated realizable value in the period which the required reserve is first identified. Such write downs, should they occur, are charged to cost of product revenue in the consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the Company did not identify any excess, obsolete or unsaleable inventory.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:f-404">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Finance Lease and Operating Lease</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Finance Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Codification</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC, 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#8217;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#8217;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PatentCostsPolicyPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Patent Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in selling, general and administrative, or SG&amp;A, expenses in the accompanying statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company reports deferred income taxes in accordance with ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock', window );">Indirect Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Indirect Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in research and development, or R&amp;D, expenses, and the related interest and penalties are included in SG&amp;A expenses. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#8217;s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed in future periods. Indirect tax amounts on commercial sales (product revenue) that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included within inventory.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a License Agreement with Melinta, or the Melinta License Agreement. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment and milestones achieved to date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 9 for additional information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta are required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represents a distinct performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The transaction price to be recognized as revenue for each performance obligation under the Commercial Supply Agreements consists of variable consideration which is determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue are adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration is included in the transaction price only to the extent that it is considered probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections are recorded as indirect taxes liabilities. The transaction price will be fully allocated to the single performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that the performance obligation is satisfied and product revenue is recognized when the customer obtains control of the product, which occurs at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#8217;s product to the customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Shipping and handling activities that are performed after a customer obtains control of the product are treated as activities to fulfill the promise to a customer and any amounts billed to a customer represent revenues for the product provided. Costs related to such shipping and handling billings are classified as cost of product revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Revenue</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">R&amp;D expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SG&amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or research and development expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock', window );">Preclinical and Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#8217;s common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#8217;s stock, (c) the expected term of the award, and (d) the expected dividend yield.&#160;The Company computed the expected volatility data using the daily close prices for the Company&#8217;s common stock during the equivalent period of the calculated expected term of the Company&#8217;s stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#8217;s losses. For all periods presented, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:15pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2023, the FASB issued </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Update</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> 2023-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025 and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#8217;s consolidated financial statements or related disclosures, or do not apply to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PatentCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PatentCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxes Other than Income Taxes, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176993631392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Error Corrections and Prior Period Adjustments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Balance Sheet</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">41,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">61,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(406,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(418,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(14,438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">47,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Operations and Comprehensive Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">94,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">97,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,503)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,527)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,857,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,857,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.437%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">398,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">398,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">404,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">404,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(377,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(384,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(406,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(418,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(8,469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,904)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(11,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(14,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Corrected Consolidated Statement of Cash Flows</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(29,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,052)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980279744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,044,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,764,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,323,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,826,119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40,025,543&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177104592128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Instruments Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,778&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980303024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,097&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980276992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,817&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Computer hardware and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177088480736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">21,044,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,764,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,323,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,411,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,469,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">987,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">806,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">38,225,338&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,302,480&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991985728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the year ended December&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,223,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,515,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(490,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(151,115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,098,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the year ended December&#160;31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual Life<br/>in Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate<br/>Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,099,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,233,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(641,417)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,666,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,666,015&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,236,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Black-Scholes Option Pricing Model Assumptions</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes the Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted to employees under the 2015 EIP and 2020 IIP and the shares purchasable under the 2015 ESPP during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2015 EIP and 2020 IIP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.58% - 4.61%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.39% - 4.02%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82% - 83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70% - 75%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.50 - 6.08</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.50 - 6.08</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2015 ESPP</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.29% - 5.43%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.57% - 2.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">64% - 147%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75% - 98%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.50 - 2.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.50 - 2.00</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992282112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company&#8217;s contract liabilities pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the year ended&#160;December&#160;31, 2023&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:86.676%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2022 (As Restated)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total contract liabilities, December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,340&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our collaboration revenue disaggregated by collaborator and timing of revenue recognition (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestones achieved</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">16,421&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon transfer of license</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">License of Intellectual Property - upon milestones achieved</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,256&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177084863936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The tax provision for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current tax provision:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax provision:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation Between Federal Statutory and Provision For Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table provides a reconciliation between income taxes computed at the federal statutory rate and the provision for income taxes (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Federal income taxes at 21% for 2023 and 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,029)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nondeductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rate change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(19,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Reserve for uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,423)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">162m deferred tax asset limitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">382 NOL and tax credit limitation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">37,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expired stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Net Deferred Tax Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s net deferred tax assets are as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(As Restated)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">35,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">42,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">84,586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">77,151&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(83,086)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(76,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(214)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Capitalized inventory costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2023 and 2022 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(As Restated)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of the beginning of the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Decreases related to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(13,472)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance as of the end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,520&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,015&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176987800304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Finance Lease</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s finance lease as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted finance lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of finance lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information For Finance Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s finance lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Finance lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net finance lease right-of-use asset</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of finance lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term finance lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#8217;s operating lease as of December&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of operating lease payments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information For Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company&#8217;s operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Finance Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Operating Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980276992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">the Company has restated its unaudited condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders&#8217; equity (deficit), and condensed consolidated statements of cash flows for the quarterly periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023.<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,007&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,899&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,338&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,478&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">430,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(403,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(415,487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(395,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,942)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(403,390)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,730)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,107&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,957&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,662)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,705)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,736&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and March 31, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at March 31, 2023 and March 31, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at March 31, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at March 31, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3) Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2023 and March 31, 2022; 90,024,562 shares issued and outstanding at March 31, 2023 and 69,049,247 shares issued and outstanding at March 31, 2022</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,546&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,770&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,478&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,933&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,997)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(429,111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(408,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,582)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,414&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,997)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,961)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,543)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,986&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,339&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,524&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,362&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and June 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at June 30, 2023 and June 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at June 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at June 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6) Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2023 and June 30, 2022; 90,251,746 shares issued and outstanding at June 30, 2023 and 69,238,508 shares issued and outstanding at June 30, 2022</span></div></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Balance Sheets (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,858&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,620&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,049&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,255&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock (7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Series X Convertible Preferred stock (8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock (9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">432,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424,286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,932)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(438,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(393,589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,314)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(404,903)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,038&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,932)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,894)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,314)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,468&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,858&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,721&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and September 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at September 30, 2023 and September 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at September 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at September 30, 2022</span></div></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9) Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2023 and September 30, 2022; 90,415,944 shares issued and outstanding at September 30, 2023 and 71,181,197 shares issued and outstanding at September 30, 2022</span></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,370&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,454)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,281)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(677)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,281)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share (10)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share (10)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.27)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,640,086&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,640,086&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute diluted net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,189,396&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,189,396&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,138,116&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)  As the Company was in an income position for the three-months ended March 31, 2023, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,595&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,969&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,831)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,098)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,113)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,753)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,208)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,475)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,759)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,357)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,267)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,624)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,640)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,759)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.14)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,115,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,115,859&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,133,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,133,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,485&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,681&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,921&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,854)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,317)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,374)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,207)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,999)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,462)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,400)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,148)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,400)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.46)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.50)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,409,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84,409,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,638,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,638,651&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,718&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,555)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,490)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,923&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,942)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,877)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,172)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(732)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,172)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(935)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,107)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(582)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share (11)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share (11)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,217,985&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,217,985&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute diluted net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,287,441&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,592,568&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88,592,568&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)  As the Company was in an income position for the three-months ended September 30, 2022, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.</span></td></tr></table></div><div style="margin-bottom:18pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,322&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,229&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,409)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,807)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,451)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,941)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,320)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,718)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,987)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.23)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,390,446&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86,390,446&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,474)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,953)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(844)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,004)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,898)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,608)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,111)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,303)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,567)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(483)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,324)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,412)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(595)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,444)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,444)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,266)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,266)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,430&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,718)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,662)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued indirect tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(781)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(778)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,471)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(327)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from underwritten public offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(720)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,976&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,615)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,615)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,195)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:24.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corrected Condensed Consolidated Statement of Cash Flows (unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Previously Reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restatement Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As Restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment, included in accounts payable and accrued liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176980296000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following unaudited pro forma financial information presents the Company&#8217;s basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">As Restated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss and comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(22,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(33,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(5.25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9.61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic and diluted net loss per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,371,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,492,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991988992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 438,218<span></span>
</td>
<td class="nump">$ 429,111<span></span>
</td>
<td class="nump">$ 415,487<span></span>
</td>
<td class="nump">$ 404,903<span></span>
</td>
<td class="nump">$ 419,149<span></span>
</td>
<td class="nump">$ 403,390<span></span>
</td>
<td class="nump">$ 429,111<span></span>
</td>
<td class="nump">$ 419,149<span></span>
</td>
<td class="nump">$ 438,218<span></span>
</td>
<td class="nump">$ 404,903<span></span>
</td>
<td class="nump">$ 441,431<span></span>
</td>
<td class="nump">$ 418,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">47,976<span></span>
</td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">24,637<span></span>
</td>
<td class="nump">36,488<span></span>
</td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">24,637<span></span>
</td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">$ 35,778<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">11,314<span></span>
</td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">11,314<span></span>
</td>
<td class="nump">$ 18,040<span></span>
</td>
<td class="nump">11,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 22,208<span></span>
</td>
<td class="nump">$ 21,595<span></span>
</td>
<td class="nump">$ 23,326<span></span>
</td>
<td class="nump">$ 26,553<span></span>
</td>
<td class="nump">$ 21,969<span></span>
</td>
<td class="nump">$ 25,723<span></span>
</td>
<td class="nump">$ 44,921<span></span>
</td>
<td class="nump">$ 47,692<span></span>
</td>
<td class="nump">$ 67,129<span></span>
</td>
<td class="nump">$ 74,245<span></span>
</td>
<td class="nump">$ 88,388<span></span>
</td>
<td class="nump">97,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177106545632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 3,788<span></span>
</td>
<td class="nump">$ 4,050<span></span>
</td>
<td class="nump">$ 4,307<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
<td class="nump">$ 1,354<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="nump">$ 1,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,030<span></span>
</td>
<td class="nump">64,144<span></span>
</td>
<td class="nump">68,339<span></span>
</td>
<td class="nump">81,975<span></span>
</td>
<td class="nump">47,487<span></span>
</td>
<td class="nump">66,721<span></span>
</td>
<td class="nump">39,362<span></span>
</td>
<td class="nump">55,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">18,040<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">11,534<span></span>
</td>
<td class="nump">11,314<span></span>
</td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">67,418<span></span>
</td>
<td class="nump">50,228<span></span>
</td>
<td class="nump">44,770<span></span>
</td>
<td class="nump">47,482<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="nump">44,255<span></span>
</td>
<td class="nump">41,933<span></span>
</td>
<td class="nump">40,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,240<span></span>
</td>
<td class="nump">70,038<span></span>
</td>
<td class="nump">65,922<span></span>
</td>
<td class="nump">66,868<span></span>
</td>
<td class="nump">61,925<span></span>
</td>
<td class="nump">68,968<span></span>
</td>
<td class="nump">57,905<span></span>
</td>
<td class="nump">58,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(441,431)<span></span>
</td>
<td class="num">(438,218)<span></span>
</td>
<td class="num">(429,111)<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(404,903)<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(8,210)<span></span>
</td>
<td class="num">(5,894)<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">15,107<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
<td class="num">(18,543)<span></span>
</td>
<td class="num">(3,705)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 67,030<span></span>
</td>
<td class="nump">64,144<span></span>
</td>
<td class="nump">68,339<span></span>
</td>
<td class="nump">81,975<span></span>
</td>
<td class="nump">47,487<span></span>
</td>
<td class="nump">66,721<span></span>
</td>
<td class="nump">39,362<span></span>
</td>
<td class="nump">55,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,131<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,468<span></span>
</td>
<td class="nump">67,986<span></span>
</td>
<td class="nump">81,736<span></span>
</td>
<td class="nump">47,593<span></span>
</td>
<td class="nump">66,858<span></span>
</td>
<td class="nump">39,524<span></span>
</td>
<td class="nump">55,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,620<span></span>
</td>
<td class="nump">31,420<span></span>
</td>
<td class="nump">35,663<span></span>
</td>
<td class="nump">29,972<span></span>
</td>
<td class="nump">33,049<span></span>
</td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">32,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,430<span></span>
</td>
<td class="nump">52,572<span></span>
</td>
<td class="nump">54,899<span></span>
</td>
<td class="nump">50,497<span></span>
</td>
<td class="nump">57,791<span></span>
</td>
<td class="nump">47,485<span></span>
</td>
<td class="nump">50,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424,286)<span></span>
</td>
<td class="num">(416,114)<span></span>
</td>
<td class="num">(403,757)<span></span>
</td>
<td class="num">(406,966)<span></span>
</td>
<td class="num">(393,589)<span></span>
</td>
<td class="num">(408,567)<span></span>
</td>
<td class="num">(395,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
<td class="nump">15,414<span></span>
</td>
<td class="nump">26,837<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
<td class="nump">9,067<span></span>
</td>
<td class="num">(7,961)<span></span>
</td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,468<span></span>
</td>
<td class="nump">67,986<span></span>
</td>
<td class="nump">81,736<span></span>
</td>
<td class="nump">47,593<span></span>
</td>
<td class="nump">66,858<span></span>
</td>
<td class="nump">39,524<span></span>
</td>
<td class="nump">55,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">11,534<span></span>
</td>
<td class="nump">11,314<span></span>
</td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,608<span></span>
</td>
<td class="nump">13,350<span></span>
</td>
<td class="nump">11,819<span></span>
</td>
<td class="nump">11,428<span></span>
</td>
<td class="nump">11,206<span></span>
</td>
<td class="nump">10,478<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,608<span></span>
</td>
<td class="nump">13,350<span></span>
</td>
<td class="nump">11,969<span></span>
</td>
<td class="nump">11,428<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
<td class="nump">10,420<span></span>
</td>
<td class="nump">8,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,932)<span></span>
</td>
<td class="num">(12,997)<span></span>
</td>
<td class="num">(11,730)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(11,314)<span></span>
</td>
<td class="num">(10,582)<span></span>
</td>
<td class="num">(7,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,932)<span></span>
</td>
<td class="num">(12,997)<span></span>
</td>
<td class="num">(11,730)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(11,314)<span></span>
</td>
<td class="num">(10,582)<span></span>
</td>
<td class="num">(8,662)<span></span>
</td>
<td class="num">$ (8,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
<td class="nump">$ 353<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="num">$ (106)<span></span>
</td>
<td class="num">$ (137)<span></span>
</td>
<td class="num">$ (162)<span></span>
</td>
<td class="num">$ (184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176985903888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Operations and Comprehensive Loss (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 26,107<span></span>
</td>
<td class="nump">$ 40,744<span></span>
</td>
<td class="nump">$ 6,216<span></span>
</td>
<td class="nump">$ 7,269<span></span>
</td>
<td class="nump">$ 33,604<span></span>
</td>
<td class="nump">$ 13,485<span></span>
</td>
<td class="nump">$ 44,854<span></span>
</td>
<td class="nump">$ 54,229<span></span>
</td>
<td class="nump">$ 59,570<span></span>
</td>
<td class="nump">$ 64,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,718<span></span>
</td>
<td class="nump">7,497<span></span>
</td>
<td class="nump">26,107<span></span>
</td>
<td class="nump">40,744<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
<td class="nump">7,269<span></span>
</td>
<td class="nump">33,604<span></span>
</td>
<td class="nump">13,485<span></span>
</td>
<td class="nump">46,322<span></span>
</td>
<td class="nump">54,229<span></span>
</td>
<td class="nump">63,905<span></span>
</td>
<td class="nump">64,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,389<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">18,869<span></span>
</td>
<td class="nump">20,283<span></span>
</td>
<td class="nump">16,630<span></span>
</td>
<td class="nump">20,381<span></span>
</td>
<td class="nump">36,425<span></span>
</td>
<td class="nump">37,011<span></span>
</td>
<td class="nump">53,814<span></span>
</td>
<td class="nump">57,294<span></span>
</td>
<td class="nump">68,532<span></span>
</td>
<td class="nump">77,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
<td class="nump">5,339<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">8,496<span></span>
</td>
<td class="nump">10,681<span></span>
</td>
<td class="nump">12,928<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
<td class="nump">18,333<span></span>
</td>
<td class="nump">20,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">22,208<span></span>
</td>
<td class="nump">21,595<span></span>
</td>
<td class="nump">23,326<span></span>
</td>
<td class="nump">26,553<span></span>
</td>
<td class="nump">21,969<span></span>
</td>
<td class="nump">25,723<span></span>
</td>
<td class="nump">44,921<span></span>
</td>
<td class="nump">47,692<span></span>
</td>
<td class="nump">67,129<span></span>
</td>
<td class="nump">74,245<span></span>
</td>
<td class="nump">88,388<span></span>
</td>
<td class="nump">97,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,490)<span></span>
</td>
<td class="num">(14,098)<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="nump">14,191<span></span>
</td>
<td class="num">(15,753)<span></span>
</td>
<td class="num">(18,454)<span></span>
</td>
<td class="num">(11,317)<span></span>
</td>
<td class="num">(34,207)<span></span>
</td>
<td class="num">(20,807)<span></span>
</td>
<td class="num">(20,016)<span></span>
</td>
<td class="num">(24,483)<span></span>
</td>
<td class="num">(33,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(8,877)<span></span>
</td>
<td class="num">(13,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,462)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,339)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,488)<span></span>
</td>
<td class="num">(33,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="num">(10,611)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,718)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (13,624)<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
<td class="nump">$ 14,246<span></span>
</td>
<td class="num">$ (15,759)<span></span>
</td>
<td class="num">$ (18,474)<span></span>
</td>
<td class="num">$ (10,611)<span></span>
</td>
<td class="num">$ (34,233)<span></span>
</td>
<td class="num">$ (19,718)<span></span>
</td>
<td class="num">$ (19,987)<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">78,640,086<span></span>
</td>
<td class="nump">70,217,985<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">87,427,439<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">101,189,396<span></span>
</td>
<td class="nump">88,592,568<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">87,427,439<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="nump">$ 7,614<span></span>
</td>
<td class="nump">$ 25,990<span></span>
</td>
<td class="nump">$ 40,744<span></span>
</td>
<td class="nump">$ 6,216<span></span>
</td>
<td class="nump">$ 7,109<span></span>
</td>
<td class="nump">$ 33,604<span></span>
</td>
<td class="nump">$ 13,325<span></span>
</td>
<td class="nump">$ 44,854<span></span>
</td>
<td class="nump">$ 54,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,718<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">25,990<span></span>
</td>
<td class="nump">40,744<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
<td class="nump">33,604<span></span>
</td>
<td class="nump">13,325<span></span>
</td>
<td class="nump">46,322<span></span>
</td>
<td class="nump">54,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,330<span></span>
</td>
<td class="nump">17,135<span></span>
</td>
<td class="nump">18,715<span></span>
</td>
<td class="nump">20,041<span></span>
</td>
<td class="nump">15,255<span></span>
</td>
<td class="nump">20,166<span></span>
</td>
<td class="nump">35,850<span></span>
</td>
<td class="nump">35,421<span></span>
</td>
<td class="nump">53,180<span></span>
</td>
<td class="nump">55,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,556<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
<td class="nump">5,780<span></span>
</td>
<td class="nump">4,074<span></span>
</td>
<td class="nump">5,204<span></span>
</td>
<td class="nump">7,608<span></span>
</td>
<td class="nump">9,278<span></span>
</td>
<td class="nump">11,164<span></span>
</td>
<td class="nump">15,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,273<span></span>
</td>
<td class="nump">20,445<span></span>
</td>
<td class="nump">23,013<span></span>
</td>
<td class="nump">25,821<span></span>
</td>
<td class="nump">19,329<span></span>
</td>
<td class="nump">25,370<span></span>
</td>
<td class="nump">43,458<span></span>
</td>
<td class="nump">44,699<span></span>
</td>
<td class="nump">64,731<span></span>
</td>
<td class="nump">70,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,555)<span></span>
</td>
<td class="num">(12,831)<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">14,923<span></span>
</td>
<td class="num">(13,113)<span></span>
</td>
<td class="num">(18,261)<span></span>
</td>
<td class="num">(9,854)<span></span>
</td>
<td class="num">(31,374)<span></span>
</td>
<td class="num">(18,409)<span></span>
</td>
<td class="num">(16,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,718)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(7,942)<span></span>
</td>
<td class="num">(12,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,999)<span></span>
</td>
<td class="num">(31,400)<span></span>
</td>
<td class="num">(16,941)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(8,172)<span></span>
</td>
<td class="num">(12,357)<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">(9,148)<span></span>
</td>
<td class="num">(31,400)<span></span>
</td>
<td class="num">(17,320)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (8,172)<span></span>
</td>
<td class="num">$ (12,357)<span></span>
</td>
<td class="nump">$ 3,209<span></span>
</td>
<td class="nump">$ 14,978<span></span>
</td>
<td class="num">$ (13,119)<span></span>
</td>
<td class="num">$ (18,281)<span></span>
</td>
<td class="num">$ (9,148)<span></span>
</td>
<td class="num">$ (31,400)<span></span>
</td>
<td class="num">$ (17,320)<span></span>
</td>
<td class="num">$ (16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (USD per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (USD per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">78,640,086<span></span>
</td>
<td class="nump">70,217,985<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">101,189,396<span></span>
</td>
<td class="nump">88,592,568<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (117)<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">1,590<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (935)<span></span>
</td>
<td class="num">$ (1,267)<span></span>
</td>
<td class="num">$ (196)<span></span>
</td>
<td class="num">$ (732)<span></span>
</td>
<td class="num">$ (2,640)<span></span>
</td>
<td class="num">$ (193)<span></span>
</td>
<td class="num">$ (1,463)<span></span>
</td>
<td class="num">$ (2,833)<span></span>
</td>
<td class="num">$ (2,398)<span></span>
</td>
<td class="num">$ (3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,785)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176987407040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="nump">$ 15,107<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (18,543)<span></span>
</td>
<td class="num">$ (3,705)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="num">(10,611)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,718)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="num">(5,894)<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">15,107<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
<td class="num">(18,543)<span></span>
</td>
<td class="num">(3,705)<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
<td class="num">(18,543)<span></span>
</td>
<td class="num">(5,894)<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
<td class="num">(8,210)<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">399,678<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="nump">432,315<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">399,678<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">432,315<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">433,212<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="num">(429,111)<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="num">(438,218)<span></span>
</td>
<td class="num">(429,111)<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
<td class="num">(404,903)<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
<td class="num">(429,111)<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
<td class="num">(438,218)<span></span>
</td>
<td class="num">(404,903)<span></span>
</td>
<td class="num">(441,431)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="nump">15,414<span></span>
</td>
<td class="nump">26,837<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
<td class="num">(7,961)<span></span>
</td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,172)<span></span>
</td>
<td class="num">(12,357)<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">(9,148)<span></span>
</td>
<td class="num">(31,400)<span></span>
</td>
<td class="num">(17,320)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="nump">8,038<span></span>
</td>
<td class="nump">15,414<span></span>
</td>
<td class="nump">26,837<span></span>
</td>
<td class="nump">9,067<span></span>
</td>
<td class="num">(7,961)<span></span>
</td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">15,414<span></span>
</td>
<td class="num">(7,961)<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
<td class="nump">9,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Additional Paid-In Capital | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(406,966)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
<td class="num">(406,966)<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
<td class="num">(406,966)<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
<td class="num">(406,966)<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(406,966)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="num">(12,997)<span></span>
</td>
<td class="num">(11,730)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(10,582)<span></span>
</td>
<td class="num">(8,662)<span></span>
</td>
<td class="num">(8,469)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(8,469)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(8,469)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(8,469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="num">$ (13,932)<span></span>
</td>
<td class="num">$ (12,997)<span></span>
</td>
<td class="num">(11,730)<span></span>
</td>
<td class="num">$ (11,314)<span></span>
</td>
<td class="num">$ (10,582)<span></span>
</td>
<td class="num">(8,662)<span></span>
</td>
<td class="num">(12,997)<span></span>
</td>
<td class="num">(10,582)<span></span>
</td>
<td class="num">(13,932)<span></span>
</td>
<td class="num">(11,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment | Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment | Additional Paid-In Capital | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,749)<span></span>
</td>
<td class="num">$ (11,534)<span></span>
</td>
<td class="num">$ (7,749)<span></span>
</td>
<td class="num">$ (11,534)<span></span>
</td>
<td class="num">$ (7,749)<span></span>
</td>
<td class="num">$ (11,534)<span></span>
</td>
<td class="num">(7,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,534)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177155676144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (13,624)<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
<td class="nump">$ 14,246<span></span>
</td>
<td class="num">$ (15,759)<span></span>
</td>
<td class="num">$ (18,474)<span></span>
</td>
<td class="num">$ (10,611)<span></span>
</td>
<td class="num">$ (34,233)<span></span>
</td>
<td class="num">$ (19,718)<span></span>
</td>
<td class="num">$ (19,987)<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">639<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">895<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AccruedIndirectTaxLiabilities', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="num">(2,412)<span></span>
</td>
<td class="num">(3,956)<span></span>
</td>
<td class="nump">7,154<span></span>
</td>
<td class="num">(5,799)<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(595)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
<td class="num">(781)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
<td class="num">$ (973)<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,172)<span></span>
</td>
<td class="num">(12,357)<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">(9,148)<span></span>
</td>
<td class="num">(31,400)<span></span>
</td>
<td class="num">(17,320)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AccruedIndirectTaxLiabilities', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
<td class="num">(3,956)<span></span>
</td>
<td class="nump">7,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
<td class="num">(850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,153)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (935)<span></span>
</td>
<td class="num">$ (1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">$ (732)<span></span>
</td>
<td class="num">$ (2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AccruedIndirectTaxLiabilities', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AccruedIndirectTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Indirect Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AccruedIndirectTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_OperatingLeaseRightOfUseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_OperatingLeaseRightOfUseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992542864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - obligation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Janssen Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborationAgreementNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cdtx_JanssenCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cdtx_JanssenCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176986057520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">33,826,119<span></span>
</td>
<td class="nump">40,025,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">17,331<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">21,044,720<span></span>
</td>
<td class="nump">18,184,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options, RSUs and PRSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded in the calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">12,764,068<span></span>
</td>
<td class="nump">9,323,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177082121488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">$ 35,778<span></span>
</td>
<td class="nump">$ 32,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">35,778<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">LEVEL 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">35,778<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">35,778<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">LEVEL 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">LEVEL 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992804896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">3,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 6,097<span></span>
</td>
<td class="nump">$ 2,901<span></span>
</td>
<td class="nump">$ 2,388<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177091812352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991866624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(3,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176979153856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of property and equipment</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992096096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT (Details) - Term Loan - Term A Loan<br></strong></div></th>
<th class="th">
<div>Oct. 03, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowed from the lender</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Variable annual rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember', window );">Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Prime interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176983941456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NumberOfVotesEntitlementForEachShareHeld', window );">Number of votes for each share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CommonStockDividendsInArrearsOrDefault', window );">Dividends in arrears or default | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember', window );">Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,331<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,499,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants, aggregate intrinsic value, outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember', window );">Common Stock Warrant | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants weighted average exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of series X convertible preferred stock in exchange for common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued for each preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion', window );">Maximum ownership following conversion (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of series X convertible preferred stock in exchange for common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember', window );">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,219,741<span></span>
</td>
<td class="nump">3,414,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_SaleOfStockConsiderationRemainingOnTransaction', window );">Sale of stock, consideration remaining on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_A2023UnderwrittenPublicOfferingMember', window );">2023 Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Consideration received per transaction | $</a></td>
<td class="nump">$ 19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_A2023UnderwrittenPublicOfferingMember', window );">2023 Underwritten Public Offering | Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (USD per share) | $ / shares</a></td>
<td class="nump">$ 12.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_A2023UnderwrittenPublicOfferingMember', window );">2023 Underwritten Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">11,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (USD per share) | $ / shares</a></td>
<td class="nump">$ 1.267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">1,446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CommonStockDividendsInArrearsOrDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock dividends in arrears or default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CommonStockDividendsInArrearsOrDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfVotesEntitlementForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitlement for each share held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfVotesEntitlementForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_SaleOfStockConsiderationRemainingOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Remaining on Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_SaleOfStockConsiderationRemainingOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_A2023UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_A2023UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176987789808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Summary of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">38,225,338<span></span>
</td>
<td class="nump">45,302,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">17,331<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">21,044,720<span></span>
</td>
<td class="nump">18,184,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options, RSUs and PRSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">12,764,068<span></span>
</td>
<td class="nump">9,323,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember', window );">Authorized for future stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">3,411,463<span></span>
</td>
<td class="nump">4,469,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Awards available under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">987,756<span></span>
</td>
<td class="nump">806,968<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992481504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee stock options granted (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember', window );">Restricted Stock Units and Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs granted (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs and PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP and 2020 IIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic annual increase in shares authorized for issuance in equity incentive plan (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term for stock options to be granted (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold', window );">Voting power threshold (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP and 2020 IIP | More than 10% of voting power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP and 2020 IIP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP and 2020 IIP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 ESPP | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic annual increase in shares authorized for issuance in equity incentive plan (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Employee payroll deduction under the stock plan (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,548<span></span>
</td>
<td class="nump">363,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 ESPP | Maximum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Common stock shares outstanding (in shares)</a></td>
<td class="nump">490,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177082044208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details) - Restricted Stock Units and Performance-based Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs and PRSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,223,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,515,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(490,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled (in shares)</a></td>
<td class="num">(151,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">2,098,053<span></span>
</td>
<td class="nump">1,223,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning of period (USD per share)</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (USD per share)</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (USD per share)</a></td>
<td class="nump">1.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Granted (USD per share)</a></td>
<td class="nump">1.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, end of period (USD per share)</a></td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177082440224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">8,099,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">3,233,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(25,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares)</a></td>
<td class="num">(641,417)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">10,666,015<span></span>
</td>
<td class="nump">8,099,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">10,666,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">7,236,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (USD per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (USD per share)</a></td>
<td class="nump">1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (USD per share)</a></td>
<td class="nump">0.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (USD per share)</a></td>
<td class="nump">3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (USD per share)</a></td>
<td class="nump">2.23<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (USD per share)</a></td>
<td class="nump">2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (USD per share)</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (in years)</a></td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">5 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract', window );"><strong>Total Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Aggregate Intrinsic Value Of Stock Options Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992519632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Black-Scholes Option Pricing Model Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP and 2020 IIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (as a percent)</a></td>
<td class="nump">3.58%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (as a percent)</a></td>
<td class="nump">4.61%<span></span>
</td>
<td class="nump">4.02%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (as a percent)</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (as a percent)</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP and 2020 IIP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP and 2020 IIP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (as a percent)</a></td>
<td class="nump">4.29%<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (as a percent)</a></td>
<td class="nump">5.43%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (as a percent)</a></td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (as a percent)</a></td>
<td class="nump">147.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 ESPP | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 ESPP | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176978688256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 3,061<span></span>
</td>
<td class="nump">$ 3,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">1,592<span></span>
</td>
<td class="nump">1,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="nump">$ 1,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176972777056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 03, 2019</div></th>
<th class="th"><div>Apr. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,250,000<span></span>
</td>
<td class="nump">$ 7,497,000<span></span>
</td>
<td class="nump">$ 26,107,000<span></span>
</td>
<td class="nump">$ 40,744,000<span></span>
</td>
<td class="nump">$ 6,216,000<span></span>
</td>
<td class="nump">$ 7,269,000<span></span>
</td>
<td class="nump">$ 33,604,000<span></span>
</td>
<td class="nump">$ 13,485,000<span></span>
</td>
<td class="nump">$ 44,854,000<span></span>
</td>
<td class="nump">$ 54,229,000<span></span>
</td>
<td class="nump">$ 59,570,000<span></span>
</td>
<td class="nump">$ 64,448,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">1,772,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,246,000<span></span>
</td>
<td class="nump">$ 3,178,000<span></span>
</td>
<td class="nump">$ 26,121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,178,000<span></span>
</td>
<td class="nump">$ 5,483,000<span></span>
</td>
<td class="nump">$ 26,121,000<span></span>
</td>
<td class="nump">$ 5,042,000<span></span>
</td>
<td class="nump">$ 4,833,000<span></span>
</td>
<td class="nump">$ 8,783,000<span></span>
</td>
<td class="nump">$ 5,483,000<span></span>
</td>
<td class="nump">$ 4,833,000<span></span>
</td>
<td class="nump">$ 3,178,000<span></span>
</td>
<td class="nump">$ 5,042,000<span></span>
</td>
<td class="nump">16,246,000<span></span>
</td>
<td class="nump">5,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementCostSharingPercentage', window );">Collaborative arrangement, cost sharing percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Related Party | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion', window );">Revenue from collaborative arrangement, excluding revenue from contract with customer, uncredited portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Related Party | Milestone Achievement | Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Related Party | License Of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability', window );">Revenue from collaborative arrangement, excluding revenue from contract with customer, noncurrent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Related Party | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice', window );">Collaborative arrangement, termination provisions, required period of written notice (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | R&amp;D Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | Development, Regulatory, and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | License Of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Related Party | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | License Of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized contract cost, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract cost, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized contract cost, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="nump">$ 460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Related Party | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Related Party | Development, Regulatory, and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="nump">$ 430,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Related Party | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Related Party | License Of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics Inc | Related Party | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementCostSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cost Sharing Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementCostSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Third Party Share Of Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTransactionPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Transaction, Potential Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTransactionPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PaymentsRelatedToCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Related To Collaborative Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PaymentsRelatedToCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer, Uncredited Portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=cdtx_LicenseOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=cdtx_LicenseOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=cdtx_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=cdtx_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177082077552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward', window );"><strong>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Closing balance</a></td>
<td class="nump">$ 29,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">25,095<span></span>
</td>
<td class="nump">$ 14,679<span></span>
</td>
<td class="nump">$ 14,975<span></span>
</td>
<td class="nump">$ 15,790<span></span>
</td>
<td class="nump">$ 14,614<span></span>
</td>
<td class="nump">$ 15,249<span></span>
</td>
<td class="nump">$ 14,730<span></span>
</td>
<td class="nump">$ 14,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of contract liabilities</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">$ 16,504<span></span>
</td>
<td class="nump">$ 17,551<span></span>
</td>
<td class="nump">$ 19,386<span></span>
</td>
<td class="nump">20,525<span></span>
</td>
<td class="nump">$ 24,398<span></span>
</td>
<td class="nump">$ 15,351<span></span>
</td>
<td class="nump">$ 17,229<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="nump">29,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward', window );"><strong>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Opening balance</a></td>
<td class="nump">35,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance', window );">Payments received in advance</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable', window );">Payments receivable</a></td>
<td class="nump">1,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized', window );">Revenue from performance obligations satisfied during reporting period</a></td>
<td class="num">(9,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Closing balance</a></td>
<td class="nump">29,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="nump">$ 29,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176981971232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 11,250,000<span></span>
</td>
<td class="nump">$ 7,497,000<span></span>
</td>
<td class="nump">$ 26,107,000<span></span>
</td>
<td class="nump">$ 40,744,000<span></span>
</td>
<td class="nump">$ 6,216,000<span></span>
</td>
<td class="nump">$ 7,269,000<span></span>
</td>
<td class="nump">$ 33,604,000<span></span>
</td>
<td class="nump">$ 13,485,000<span></span>
</td>
<td class="nump">$ 44,854,000<span></span>
</td>
<td class="nump">$ 54,229,000<span></span>
</td>
<td class="nump">$ 59,570,000<span></span>
</td>
<td class="nump">$ 64,448,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,421,000<span></span>
</td>
<td class="nump">14,256,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | License of Intellectual Property - upon transfer of license | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | License of Intellectual Property - upon milestones achieved | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,252,000<span></span>
</td>
<td class="nump">3,252,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">484,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | Royalties | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,303,000<span></span>
</td>
<td class="nump">9,595,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Mundipharma Medical Company | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,000<span></span>
</td>
<td class="nump">925,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,283,000<span></span>
</td>
<td class="nump">23,496,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | License of Intellectual Property - upon transfer of license | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | License of Intellectual Property - upon milestones achieved | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,347,000<span></span>
</td>
<td class="nump">976,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | Royalties | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,011,000<span></span>
</td>
<td class="nump">18,814,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Janssen Pharmaceuticals, Inc. | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,925,000<span></span>
</td>
<td class="nump">3,706,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,866,000<span></span>
</td>
<td class="nump">26,696,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | License of Intellectual Property - upon transfer of license | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,885,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | License of Intellectual Property - upon milestones achieved | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,257,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | Royalties | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,441,000<span></span>
</td>
<td class="nump">811,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Melinta Therapeutics Inc | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ClinicalDrugSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ClinicalDrugSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177081309488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Components of Benefit For Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991835968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Reconciliation Between Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income taxes at 21% for 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,723)<span></span>
</td>
<td class="num">$ (7,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (186)<span></span>
</td>
<td class="num">$ (247)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nondeductible expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,076)<span></span>
</td>
<td class="num">(1,877)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,373<span></span>
</td>
<td class="num">(19,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Reserve for uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519<span></span>
</td>
<td class="num">(10,423)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount', window );">162m deferred tax asset limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount', window );">382 NOL and tax credit limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount', window );">Expired stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, 162M Deferred Tax Asset Limitation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, 382 NOL and Tax Asset Limitation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expired Stock Awards, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991988176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Significant Components of Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 35,506<span></span>
</td>
<td class="nump">$ 42,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">9,747<span></span>
</td>
<td class="nump">9,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">25,871<span></span>
</td>
<td class="nump">14,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DeferredTaxAssetsLeasingArrangements', window );">Lease liabilities</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">5,951<span></span>
</td>
<td class="nump">5,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">4,114<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">84,586<span></span>
</td>
<td class="nump">77,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(83,086)<span></span>
</td>
<td class="num">(76,713)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(214)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts', window );">Capitalized inventory costs</a></td>
<td class="num">(244)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(1,042)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DeferredTaxAssetsLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Leasing Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DeferredTaxAssetsLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals,Taxes Other than Income Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991949376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Research and development credit carryforwards, no subject to expiration</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax assets, valuation allowance</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">11,520<span></span>
</td>
<td class="nump">$ 11,015<span></span>
</td>
<td class="nump">$ 23,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact on effective tax rate</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NetOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">153,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards, research and development</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NetOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">131,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards, research and development</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177117408048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Summary of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance as of the beginning of the year</a></td>
<td class="nump">$ 11,015<span></span>
</td>
<td class="nump">$ 23,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior year tax positions</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(13,472)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance as of the end of the year</a></td>
<td class="nump">$ 11,520<span></span>
</td>
<td class="nump">$ 11,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992188752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2023 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of claims and actions pending | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Lessee, finance lease, term of contract (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeFinanceLeaseMonthlyRate', window );">Lessee, finance lease, monthly rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment', window );">Lessee, finance lease, option, purchase equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Lessee, finance lease, discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease, weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term (in months)</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseMonthlyRate', window );">Lessee, operating lease, monthly rate</a></td>
<td class="nump">$ 133,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease', window );">Percentage increase in base rent annual (as a percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NumberOfOperatingLeaseOptionsForExtension', window );">Number of options to extend | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseOptionRenewalTerm', window );">Lessee, operating lease, option renewal term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lessee, operating lease, discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost', window );">Operating lease cost, variable lease and short-term lease term (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeFinanceLeaseMonthlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Monthly Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeFinanceLeaseMonthlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeFinanceLeaseOptionPurchaseEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Option, Purchase Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeFinanceLeaseOptionPurchaseEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rate Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseAnnualRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseMonthlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseMonthlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseOptionRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseOptionRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfOperatingLeaseOptionsForExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating lease options for extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfOperatingLeaseOptionsForExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177084770336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total undiscounted finance lease payments</a></td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of finance lease payments</a></td>
<td class="nump">$ 793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176986188464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization', window );">Finance lease right-of-use asset</a></td>
<td class="nump">$ 788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net finance lease right-of-use asset</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liability</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liability</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Long-term finance lease liability</a></td>
<td class="nump">$ 793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176991630928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">4,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease payments</a></td>
<td class="nump">$ 4,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176986450688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 3,788<span></span>
</td>
<td class="nump">$ 4,050<span></span>
</td>
<td class="nump">$ 4,307<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
<td class="nump">$ 1,354<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="nump">$ 1,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">3,002<span></span>
</td>
<td class="nump">$ 3,306<span></span>
</td>
<td class="nump">$ 3,601<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 621<span></span>
</td>
<td class="nump">$ 920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 4,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176971503328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,778<span></span>
</td>
<td class="nump">$ 48,670<span></span>
</td>
<td class="nump">$ 50,430<span></span>
</td>
<td class="nump">$ 47,976<span></span>
</td>
<td class="nump">$ 32,731<span></span>
</td>
<td class="nump">$ 53,078<span></span>
</td>
<td class="nump">$ 24,637<span></span>
</td>
<td class="nump">$ 36,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">16,246<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">26,121<span></span>
</td>
<td class="nump">5,833<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">6,097<span></span>
</td>
<td class="nump">2,901<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">3,712<span></span>
</td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
<td class="nump">6,530<span></span>
</td>
<td class="nump">5,779<span></span>
</td>
<td class="nump">6,706<span></span>
</td>
<td class="nump">5,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,855<span></span>
</td>
<td class="nump">58,461<span></span>
</td>
<td class="nump">62,674<span></span>
</td>
<td class="nump">79,808<span></span>
</td>
<td class="nump">45,094<span></span>
</td>
<td class="nump">63,899<span></span>
</td>
<td class="nump">36,546<span></span>
</td>
<td class="nump">52,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">3,788<span></span>
</td>
<td class="nump">4,050<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,030<span></span>
</td>
<td class="nump">64,144<span></span>
</td>
<td class="nump">68,339<span></span>
</td>
<td class="nump">81,975<span></span>
</td>
<td class="nump">47,487<span></span>
</td>
<td class="nump">66,721<span></span>
</td>
<td class="nump">39,362<span></span>
</td>
<td class="nump">55,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,772<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
<td class="nump">4,244<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">14,177<span></span>
</td>
<td class="nump">11,772<span></span>
</td>
<td class="nump">10,022<span></span>
</td>
<td class="nump">9,108<span></span>
</td>
<td class="nump">7,672<span></span>
</td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">8,567<span></span>
</td>
<td class="nump">9,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="nump">18,040<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">11,534<span></span>
</td>
<td class="nump">11,314<span></span>
</td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">5,034<span></span>
</td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
<td class="nump">4,922<span></span>
</td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">3,464<span></span>
</td>
<td class="nump">3,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current contract liabilities</a></td>
<td class="nump">25,095<span></span>
</td>
<td class="nump">14,679<span></span>
</td>
<td class="nump">14,975<span></span>
</td>
<td class="nump">15,790<span></span>
</td>
<td class="nump">14,614<span></span>
</td>
<td class="nump">15,249<span></span>
</td>
<td class="nump">14,730<span></span>
</td>
<td class="nump">14,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1,169<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">67,418<span></span>
</td>
<td class="nump">50,228<span></span>
</td>
<td class="nump">44,770<span></span>
</td>
<td class="nump">47,482<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="nump">44,255<span></span>
</td>
<td class="nump">41,933<span></span>
</td>
<td class="nump">40,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">16,504<span></span>
</td>
<td class="nump">17,551<span></span>
</td>
<td class="nump">19,386<span></span>
</td>
<td class="nump">20,525<span></span>
</td>
<td class="nump">24,398<span></span>
</td>
<td class="nump">15,351<span></span>
</td>
<td class="nump">17,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">3,002<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">315<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="nump">920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">75,240<span></span>
</td>
<td class="nump">70,038<span></span>
</td>
<td class="nump">65,922<span></span>
</td>
<td class="nump">66,868<span></span>
</td>
<td class="nump">61,925<span></span>
</td>
<td class="nump">68,968<span></span>
</td>
<td class="nump">57,905<span></span>
</td>
<td class="nump">58,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">433,212<span></span>
</td>
<td class="nump">432,315<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">399,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(441,431)<span></span>
</td>
<td class="num">(438,218)<span></span>
</td>
<td class="num">(429,111)<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(404,903)<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(8,210)<span></span>
</td>
<td class="num">(5,894)<span></span>
</td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">15,107<span></span>
</td>
<td class="num">(14,438)<span></span>
</td>
<td class="num">(2,247)<span></span>
</td>
<td class="num">(18,543)<span></span>
</td>
<td class="num">(3,705)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">67,030<span></span>
</td>
<td class="nump">64,144<span></span>
</td>
<td class="nump">68,339<span></span>
</td>
<td class="nump">81,975<span></span>
</td>
<td class="nump">47,487<span></span>
</td>
<td class="nump">66,721<span></span>
</td>
<td class="nump">39,362<span></span>
</td>
<td class="nump">55,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">47,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">24,637<span></span>
</td>
<td class="nump">36,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">25,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
<td class="nump">4,833<span></span>
</td>
<td class="nump">8,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,712<span></span>
</td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">5,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,779<span></span>
</td>
<td class="nump">6,706<span></span>
</td>
<td class="nump">5,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,704<span></span>
</td>
<td class="nump">62,240<span></span>
</td>
<td class="nump">79,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,899<span></span>
</td>
<td class="nump">36,546<span></span>
</td>
<td class="nump">52,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,131<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,468<span></span>
</td>
<td class="nump">67,986<span></span>
</td>
<td class="nump">81,736<span></span>
</td>
<td class="nump">47,593<span></span>
</td>
<td class="nump">66,858<span></span>
</td>
<td class="nump">39,524<span></span>
</td>
<td class="nump">55,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">3,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,244<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,772<span></span>
</td>
<td class="nump">10,022<span></span>
</td>
<td class="nump">9,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">8,567<span></span>
</td>
<td class="nump">9,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">3,582<span></span>
</td>
<td class="nump">5,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">3,464<span></span>
</td>
<td class="nump">3,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,679<span></span>
</td>
<td class="nump">14,975<span></span>
</td>
<td class="nump">15,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,249<span></span>
</td>
<td class="nump">14,730<span></span>
</td>
<td class="nump">14,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">942<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,620<span></span>
</td>
<td class="nump">31,420<span></span>
</td>
<td class="nump">35,663<span></span>
</td>
<td class="nump">29,972<span></span>
</td>
<td class="nump">33,049<span></span>
</td>
<td class="nump">31,455<span></span>
</td>
<td class="nump">32,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,504<span></span>
</td>
<td class="nump">17,551<span></span>
</td>
<td class="nump">19,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,398<span></span>
</td>
<td class="nump">15,351<span></span>
</td>
<td class="nump">17,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
<td class="nump">3,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">679<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,430<span></span>
</td>
<td class="nump">52,572<span></span>
</td>
<td class="nump">54,899<span></span>
</td>
<td class="nump">50,497<span></span>
</td>
<td class="nump">57,791<span></span>
</td>
<td class="nump">47,485<span></span>
</td>
<td class="nump">50,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,315<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">400,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424,286)<span></span>
</td>
<td class="num">(416,114)<span></span>
</td>
<td class="num">(403,757)<span></span>
</td>
<td class="num">(406,966)<span></span>
</td>
<td class="num">(393,589)<span></span>
</td>
<td class="num">(408,567)<span></span>
</td>
<td class="num">(395,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,038<span></span>
</td>
<td class="nump">15,414<span></span>
</td>
<td class="nump">26,837<span></span>
</td>
<td class="num">(2,904)<span></span>
</td>
<td class="nump">9,067<span></span>
</td>
<td class="num">(7,961)<span></span>
</td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,468<span></span>
</td>
<td class="nump">67,986<span></span>
</td>
<td class="nump">81,736<span></span>
</td>
<td class="nump">47,593<span></span>
</td>
<td class="nump">66,858<span></span>
</td>
<td class="nump">39,524<span></span>
</td>
<td class="nump">55,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported | Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="nump">434<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,689<span></span>
</td>
<td class="nump">13,431<span></span>
</td>
<td class="nump">11,795<span></span>
</td>
<td class="nump">11,534<span></span>
</td>
<td class="nump">11,314<span></span>
</td>
<td class="nump">10,582<span></span>
</td>
<td class="nump">7,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,608<span></span>
</td>
<td class="nump">13,350<span></span>
</td>
<td class="nump">11,819<span></span>
</td>
<td class="nump">11,428<span></span>
</td>
<td class="nump">11,206<span></span>
</td>
<td class="nump">10,478<span></span>
</td>
<td class="nump">8,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,608<span></span>
</td>
<td class="nump">13,350<span></span>
</td>
<td class="nump">11,969<span></span>
</td>
<td class="nump">11,428<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
<td class="nump">10,420<span></span>
</td>
<td class="nump">8,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,932)<span></span>
</td>
<td class="num">(12,997)<span></span>
</td>
<td class="num">(11,730)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(11,314)<span></span>
</td>
<td class="num">(10,582)<span></span>
</td>
<td class="num">(7,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,932)<span></span>
</td>
<td class="num">(12,997)<span></span>
</td>
<td class="num">(11,730)<span></span>
</td>
<td class="num">(11,534)<span></span>
</td>
<td class="num">(11,314)<span></span>
</td>
<td class="num">(10,582)<span></span>
</td>
<td class="num">(8,662)<span></span>
</td>
<td class="num">$ (8,469)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="num">$ (106)<span></span>
</td>
<td class="num">(137)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment | Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992125264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">2,156,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176983651712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="nump">$ 7,497<span></span>
</td>
<td class="nump">$ 26,107<span></span>
</td>
<td class="nump">$ 40,744<span></span>
</td>
<td class="nump">$ 6,216<span></span>
</td>
<td class="nump">$ 7,269<span></span>
</td>
<td class="nump">$ 33,604<span></span>
</td>
<td class="nump">$ 13,485<span></span>
</td>
<td class="nump">$ 44,854<span></span>
</td>
<td class="nump">$ 54,229<span></span>
</td>
<td class="nump">$ 59,570<span></span>
</td>
<td class="nump">$ 64,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,335<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,718<span></span>
</td>
<td class="nump">7,497<span></span>
</td>
<td class="nump">26,107<span></span>
</td>
<td class="nump">40,744<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
<td class="nump">7,269<span></span>
</td>
<td class="nump">33,604<span></span>
</td>
<td class="nump">13,485<span></span>
</td>
<td class="nump">46,322<span></span>
</td>
<td class="nump">54,229<span></span>
</td>
<td class="nump">63,905<span></span>
</td>
<td class="nump">64,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of product revenue</a></td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,389<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
<td class="nump">18,869<span></span>
</td>
<td class="nump">20,283<span></span>
</td>
<td class="nump">16,630<span></span>
</td>
<td class="nump">20,381<span></span>
</td>
<td class="nump">36,425<span></span>
</td>
<td class="nump">37,011<span></span>
</td>
<td class="nump">53,814<span></span>
</td>
<td class="nump">57,294<span></span>
</td>
<td class="nump">68,532<span></span>
</td>
<td class="nump">77,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,432<span></span>
</td>
<td class="nump">4,039<span></span>
</td>
<td class="nump">4,457<span></span>
</td>
<td class="nump">6,270<span></span>
</td>
<td class="nump">5,339<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
<td class="nump">8,496<span></span>
</td>
<td class="nump">10,681<span></span>
</td>
<td class="nump">12,928<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
<td class="nump">18,333<span></span>
</td>
<td class="nump">20,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">22,208<span></span>
</td>
<td class="nump">21,595<span></span>
</td>
<td class="nump">23,326<span></span>
</td>
<td class="nump">26,553<span></span>
</td>
<td class="nump">21,969<span></span>
</td>
<td class="nump">25,723<span></span>
</td>
<td class="nump">44,921<span></span>
</td>
<td class="nump">47,692<span></span>
</td>
<td class="nump">67,129<span></span>
</td>
<td class="nump">74,245<span></span>
</td>
<td class="nump">88,388<span></span>
</td>
<td class="nump">97,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(9,490)<span></span>
</td>
<td class="num">(14,098)<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="nump">14,191<span></span>
</td>
<td class="num">(15,753)<span></span>
</td>
<td class="num">(18,454)<span></span>
</td>
<td class="num">(11,317)<span></span>
</td>
<td class="num">(34,207)<span></span>
</td>
<td class="num">(20,807)<span></span>
</td>
<td class="num">(20,016)<span></span>
</td>
<td class="num">(24,483)<span></span>
</td>
<td class="num">(33,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">1,995<span></span>
</td>
<td class="nump">191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(8,877)<span></span>
</td>
<td class="num">(13,475)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,462)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,339)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,488)<span></span>
</td>
<td class="num">(33,312)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(379)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(443)<span></span>
</td>
<td class="num">(272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="num">(10,611)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,718)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">$ (13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">$ (15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="num">$ (10,611)<span></span>
</td>
<td class="num">$ (34,233)<span></span>
</td>
<td class="num">$ (19,718)<span></span>
</td>
<td class="num">$ (19,987)<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="num">(2,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="num">(2,931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,377<span></span>
</td>
<td class="nump">$ 11,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">78,640,086<span></span>
</td>
<td class="nump">70,217,985<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">87,427,439<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">101,189,396<span></span>
</td>
<td class="nump">88,592,568<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">87,427,439<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="nump">$ 7,614<span></span>
</td>
<td class="nump">$ 25,990<span></span>
</td>
<td class="nump">$ 40,744<span></span>
</td>
<td class="nump">$ 6,216<span></span>
</td>
<td class="nump">$ 7,109<span></span>
</td>
<td class="nump">$ 33,604<span></span>
</td>
<td class="nump">$ 13,325<span></span>
</td>
<td class="nump">$ 44,854<span></span>
</td>
<td class="nump">$ 54,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">12,718<span></span>
</td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">25,990<span></span>
</td>
<td class="nump">40,744<span></span>
</td>
<td class="nump">6,216<span></span>
</td>
<td class="nump">7,109<span></span>
</td>
<td class="nump">33,604<span></span>
</td>
<td class="nump">13,325<span></span>
</td>
<td class="nump">46,322<span></span>
</td>
<td class="nump">54,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of product revenue</a></td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,330<span></span>
</td>
<td class="nump">17,135<span></span>
</td>
<td class="nump">18,715<span></span>
</td>
<td class="nump">20,041<span></span>
</td>
<td class="nump">15,255<span></span>
</td>
<td class="nump">20,166<span></span>
</td>
<td class="nump">35,850<span></span>
</td>
<td class="nump">35,421<span></span>
</td>
<td class="nump">53,180<span></span>
</td>
<td class="nump">55,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">3,556<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
<td class="nump">4,298<span></span>
</td>
<td class="nump">5,780<span></span>
</td>
<td class="nump">4,074<span></span>
</td>
<td class="nump">5,204<span></span>
</td>
<td class="nump">7,608<span></span>
</td>
<td class="nump">9,278<span></span>
</td>
<td class="nump">11,164<span></span>
</td>
<td class="nump">15,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,273<span></span>
</td>
<td class="nump">20,445<span></span>
</td>
<td class="nump">23,013<span></span>
</td>
<td class="nump">25,821<span></span>
</td>
<td class="nump">19,329<span></span>
</td>
<td class="nump">25,370<span></span>
</td>
<td class="nump">43,458<span></span>
</td>
<td class="nump">44,699<span></span>
</td>
<td class="nump">64,731<span></span>
</td>
<td class="nump">70,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,555)<span></span>
</td>
<td class="num">(12,831)<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
<td class="nump">14,923<span></span>
</td>
<td class="num">(13,113)<span></span>
</td>
<td class="num">(18,261)<span></span>
</td>
<td class="num">(9,854)<span></span>
</td>
<td class="num">(31,374)<span></span>
</td>
<td class="num">(18,409)<span></span>
</td>
<td class="num">(16,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,718)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">232<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(7,942)<span></span>
</td>
<td class="num">(12,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,999)<span></span>
</td>
<td class="num">(31,400)<span></span>
</td>
<td class="num">(16,941)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(379)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(8,172)<span></span>
</td>
<td class="num">(12,357)<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">(9,148)<span></span>
</td>
<td class="num">(31,400)<span></span>
</td>
<td class="num">(17,320)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(8,172)<span></span>
</td>
<td class="num">$ (12,357)<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">$ (13,119)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">$ (9,148)<span></span>
</td>
<td class="num">$ (31,400)<span></span>
</td>
<td class="num">$ (17,320)<span></span>
</td>
<td class="num">$ (16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="num">(3,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="num">(3,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="num">$ (8,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,532<span></span>
</td>
<td class="nump">$ 11,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (USD per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (USD per share)</a></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">78,640,086<span></span>
</td>
<td class="nump">70,217,985<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">101,189,396<span></span>
</td>
<td class="nump">88,592,568<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (117)<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost of product revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">421<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">1,590<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">876<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">1,150<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">$ (1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">$ (2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">$ (1,463)<span></span>
</td>
<td class="num">$ (2,833)<span></span>
</td>
<td class="num">$ (2,398)<span></span>
</td>
<td class="num">$ (3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,785)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Allocation of earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Allocation of earnings to participating securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="num">$ (935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (155)<span></span>
</td>
<td class="num">$ (582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-65<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176972263872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Cash Flows (unaudited) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (13,624)<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
<td class="nump">$ 14,246<span></span>
</td>
<td class="num">$ (15,759)<span></span>
</td>
<td class="num">$ (18,474)<span></span>
</td>
<td class="num">$ (10,611)<span></span>
</td>
<td class="num">$ (34,233)<span></span>
</td>
<td class="num">$ (19,718)<span></span>
</td>
<td class="num">$ (19,987)<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="nump">639<span></span>
</td>
<td class="nump">476<span></span>
</td>
<td class="nump">895<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of costs to obtain a contract with a customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,427)<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="num">(10,413)<span></span>
</td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,388)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,901)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,097)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,120)<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="nump">3,735<span></span>
</td>
<td class="num">(2,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
<td class="num">(1,037)<span></span>
</td>
<td class="nump">8,886<span></span>
</td>
<td class="num">(2,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AccruedIndirectTaxLiabilities', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(1,277)<span></span>
</td>
<td class="num">(1,324)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="num">(2,412)<span></span>
</td>
<td class="num">(3,956)<span></span>
</td>
<td class="nump">7,154<span></span>
</td>
<td class="num">(5,799)<span></span>
</td>
<td class="nump">2,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(595)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
<td class="num">(781)<span></span>
</td>
<td class="num">(778)<span></span>
</td>
<td class="num">(973)<span></span>
</td>
<td class="num">(1,052)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,608)<span></span>
</td>
<td class="num">(8,076)<span></span>
</td>
<td class="num">(35,444)<span></span>
</td>
<td class="num">(9,710)<span></span>
</td>
<td class="num">(7,471)<span></span>
</td>
<td class="num">(22,432)<span></span>
</td>
<td class="num">(28,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="num">(505)<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from underwritten public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">8,706<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">8,706<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">8,707<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,222)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,593)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,593)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(611)<span></span>
</td>
<td class="nump">25,976<span></span>
</td>
<td class="num">(1,722)<span></span>
</td>
<td class="nump">25,976<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
<td class="nump">25,984<span></span>
</td>
<td class="num">(951)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,303)<span></span>
</td>
<td class="nump">17,699<span></span>
</td>
<td class="num">(37,266)<span></span>
</td>
<td class="nump">15,939<span></span>
</td>
<td class="num">(9,195)<span></span>
</td>
<td class="nump">3,047<span></span>
</td>
<td class="num">(29,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">47,976<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">25,007<span></span>
</td>
<td class="nump">37,970<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">47,976<span></span>
</td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">25,007<span></span>
</td>
<td class="nump">37,970<span></span>
</td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">25,007<span></span>
</td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">35,778<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">651<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">797<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment, included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of shares pursuant to Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet', window );">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">720<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets', window );">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,172)<span></span>
</td>
<td class="num">(12,357)<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="num">(9,148)<span></span>
</td>
<td class="num">(31,400)<span></span>
</td>
<td class="num">(17,320)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">2,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="nump">664<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of costs to obtain a contract with a customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,427)<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">2,978<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,467)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,120)<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
<td class="num">(2,567)<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
<td class="num">(1,662)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
<td class="num">(483)<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
<td class="num">(1,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AccruedIndirectTaxLiabilities', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
<td class="num">(1,277)<span></span>
</td>
<td class="num">(1,324)<span></span>
</td>
<td class="num">(402)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844)<span></span>
</td>
<td class="num">(2,613)<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
<td class="num">(3,956)<span></span>
</td>
<td class="nump">7,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(276)<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
<td class="num">(850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,153)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,608)<span></span>
</td>
<td class="num">(8,076)<span></span>
</td>
<td class="num">(35,444)<span></span>
</td>
<td class="num">(9,710)<span></span>
</td>
<td class="num">(7,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from underwritten public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,256<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">8,706<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">8,706<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,111)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,222)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,593)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(611)<span></span>
</td>
<td class="nump">25,976<span></span>
</td>
<td class="num">(1,722)<span></span>
</td>
<td class="nump">25,976<span></span>
</td>
<td class="num">(1,615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,303)<span></span>
</td>
<td class="nump">17,699<span></span>
</td>
<td class="num">(37,266)<span></span>
</td>
<td class="nump">15,939<span></span>
</td>
<td class="num">(9,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">47,976<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">25,007<span></span>
</td>
<td class="nump">37,970<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">47,976<span></span>
</td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">25,007<span></span>
</td>
<td class="nump">37,970<span></span>
</td>
<td class="nump">50,430<span></span>
</td>
<td class="nump">25,007<span></span>
</td>
<td class="nump">48,670<span></span>
</td>
<td class="nump">53,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">651<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment, included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of shares pursuant to Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet', window );">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets', window );">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Restatement Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(935)<span></span>
</td>
<td class="num">(1,267)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(1,463)<span></span>
</td>
<td class="num">(2,833)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
<td class="num">(3,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Non-cash operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of costs to obtain a contract with a customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(323)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(434)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(434)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AccruedIndirectTaxLiabilities', window );">Accrued indirect tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
<td class="nump">2,993<span></span>
</td>
<td class="nump">3,155<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from underwritten public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment, included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of shares pursuant to Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet', window );">Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets', window );">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AccruedIndirectTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Indirect Tax Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AccruedIndirectTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_OperatingLeaseRightOfUseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_OperatingLeaseRightOfUseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Common Stock In Underwritten Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses, Other Current Assets And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176975259552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (unaudited) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="nump">$ 15,107<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="num">$ (18,543)<span></span>
</td>
<td class="num">$ (3,705)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
<td class="nump">$ 13,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares)</a></td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="num">(10,611)<span></span>
</td>
<td class="num">(34,233)<span></span>
</td>
<td class="num">(19,718)<span></span>
</td>
<td class="num">(19,987)<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="num">$ (5,894)<span></span>
</td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="nump">$ 15,107<span></span>
</td>
<td class="num">$ (2,247)<span></span>
</td>
<td class="num">$ (18,543)<span></span>
</td>
<td class="num">$ (3,705)<span></span>
</td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="num">$ (18,543)<span></span>
</td>
<td class="num">$ (5,894)<span></span>
</td>
<td class="num">$ (2,247)<span></span>
</td>
<td class="num">$ (8,210)<span></span>
</td>
<td class="num">$ (14,438)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares)</a></td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares)</a></td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares)</a></td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">8,622<span></span>
</td>
<td class="nump">$ 1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,699<span></span>
</td>
<td class="nump">$ 2,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="nump">$ 431,519<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">$ 399,678<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
<td class="nump">$ 404,055<span></span>
</td>
<td class="nump">$ 398,013<span></span>
</td>
<td class="nump">$ 404,055<span></span>
</td>
<td class="nump">$ 398,013<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
<td class="nump">398,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">795<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,061<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="nump">432,315<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">430,585<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">399,678<span></span>
</td>
<td class="nump">431,519<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="nump">432,315<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">433,212<span></span>
</td>
<td class="nump">404,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="nump">8,621<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,698<span></span>
</td>
<td class="nump">2,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="num">(429,111)<span></span>
</td>
<td class="num">(415,487)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(419,149)<span></span>
</td>
<td class="num">(403,390)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
<td class="num">(418,500)<span></span>
</td>
<td class="num">(384,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(9,107)<span></span>
</td>
<td class="num">(13,624)<span></span>
</td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">14,246<span></span>
</td>
<td class="num">(15,759)<span></span>
</td>
<td class="num">(18,474)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,931)<span></span>
</td>
<td class="num">(33,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="num">$ (438,218)<span></span>
</td>
<td class="num">$ (429,111)<span></span>
</td>
<td class="num">$ (415,487)<span></span>
</td>
<td class="num">$ (404,903)<span></span>
</td>
<td class="num">$ (419,149)<span></span>
</td>
<td class="num">$ (403,390)<span></span>
</td>
<td class="num">$ (429,111)<span></span>
</td>
<td class="num">$ (419,149)<span></span>
</td>
<td class="num">$ (438,218)<span></span>
</td>
<td class="num">$ (404,903)<span></span>
</td>
<td class="num">$ (441,431)<span></span>
</td>
<td class="num">$ (418,500)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares)</a></td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares)</a></td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">2,104,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Underwritten Public Offering | Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares)</a></td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="nump">164,198<span></span>
</td>
<td class="nump">4,875<span></span>
</td>
<td class="nump">293,073<span></span>
</td>
<td class="nump">278,519<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
<td class="nump">541,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,520<span></span>
</td>
<td class="nump">828,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,548<span></span>
</td>
<td class="nump">363,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares)</a></td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,086,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,942<span></span>
</td>
<td class="nump">6,158,799<span></span>
</td>
<td class="nump">1,664,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,219,741<span></span>
</td>
<td class="nump">3,414,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140176992554848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Apr. 12, 2024</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,601,999<span></span>
</td>
<td class="nump">90,415,944<span></span>
</td>
<td class="nump">90,251,746<span></span>
</td>
<td class="nump">90,024,562<span></span>
</td>
<td class="nump">72,470,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ProFormaMember', window );">Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,530,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,601,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,530,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,601,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants weighted average exercise price (USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140177104534240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (13,624)<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
<td class="nump">$ 14,246<span></span>
</td>
<td class="num">$ (15,759)<span></span>
</td>
<td class="num">$ (18,474)<span></span>
</td>
<td class="num">$ (10,611)<span></span>
</td>
<td class="num">$ (34,233)<span></span>
</td>
<td class="num">$ (19,718)<span></span>
</td>
<td class="num">$ (19,987)<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (9,107)<span></span>
</td>
<td class="num">$ (13,624)<span></span>
</td>
<td class="nump">$ 3,013<span></span>
</td>
<td class="nump">$ 14,246<span></span>
</td>
<td class="num">$ (15,759)<span></span>
</td>
<td class="num">$ (18,474)<span></span>
</td>
<td class="num">$ (10,611)<span></span>
</td>
<td class="num">$ (34,233)<span></span>
</td>
<td class="num">$ (19,718)<span></span>
</td>
<td class="num">$ (19,987)<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (USD per share)</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="nump">90,287,441<span></span>
</td>
<td class="nump">90,115,859<span></span>
</td>
<td class="nump">101,189,396<span></span>
</td>
<td class="nump">88,592,568<span></span>
</td>
<td class="nump">69,133,700<span></span>
</td>
<td class="nump">68,138,116<span></span>
</td>
<td class="nump">84,409,667<span></span>
</td>
<td class="nump">68,638,651<span></span>
</td>
<td class="nump">86,390,446<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">87,427,439<span></span>
</td>
<td class="nump">69,857,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ProFormaMember', window );">Pro Forma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,931)<span></span>
</td>
<td class="num">$ (33,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.25)<span></span>
</td>
<td class="num">$ (9.61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share (USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.25)<span></span>
</td>
<td class="num">$ (9.61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Shares used to compute basic net loss per common share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,371,371<span></span>
</td>
<td class="nump">3,492,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net loss per common share (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,371,371<span></span>
</td>
<td class="nump">3,492,884<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M@UPO$'%:_$6/JW,')QT49*D2R3I8WT$2\=4G?5J#>!'@DIH L@X@KP)POR;
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M6KE::;_:46)9K#V_%4J)I-A<,!HRF9^@O[\30FUV\@ML?^\P^A]02P,$%
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M4'$F@.T#V*4!?!_ +PT0^P!Q:8"]#[ O#7#V <ZE >X^P+TTP-L'>)<&^/L
M_]( 2MZ4(]L,VDF^S9<@K=/[V[)XM<H6W_"U'[9)MXUOTB3+V_;Q4)?-7[,F
MKKX?%WE5++-Y6LNY]35=IOE,6@\M765=6W\^!-;?/OS=^F!EN?7'HMA4:3ZO
M;F_JIN0V_F:V+^7KKA1VII1 SCY:G%Y9C#".A(_UX0]RW823L^&!/CS9Y-KP
M4!_^6UIJ+SZZ_-X9$CZY_-ZQ\.GE]XZ%QY??.Q:>7'[O]#3\IDG40[:R0[:R
M+1\_EZV;LI1Y;:55U23H)RP1=P0")VA'FT_5.IW)NU$SG%2R?)&C^U]_H0[Y
MC*6E2;+ )%EHDBPR238Q238U21:;)$L,D9TT WYH!ES'?C].JX75],36K/T@
M_]ID+^FR:1=HS[RC<K=4[6SIY9[;KNO=WKP<9[J*$I[CDE-4H*)L(CA A0B7
MZ[O.*2I"KHNYG)ZB)DB)G,"KGZHH)ASNGJ)BI$1'>( KT5;]0&'%05BA%?;+
M;%9L&AV;F>=,-J(^+B4FZ8[$.;H1ZC0W#"1549S"F@M4D"T\#@150<RA#$@5
M(50>!U03!$0$ W*J(*$PQ2K(<^&5)]KJ'BBF?1#3UHH9YR]-FRS*GYB$MG+U
M#O%!PHY5$/,)J/8  7&8U*'V2M\[7*@E@AY@THN8]B)BDY><&"([R0/GD >.
M-@^^E7*=9G-+_F@6M96LMCUW42]DV4SQC^<S6)XXJKHN%R!/5!!W*6A4@0H2
MW(4M7079+H4-704Y-AP$)AB3ZX,L0)A< OJQ&&%B-JB"1"O!0('=@\"N5N _
MBCI=7J"EB[1YS[:!F"K*]H0#6SW"Q1P7U$JHHES?(Z!SB%24L(D/N"9(B=SS
MH:(JBCLV')IBY!X9(:#[2[2U/E!3[Z"IU]-HB[4LZY_;QMK.L-:K1MPK*Y<U
M)JVGWI ->W,$X\$)EHIA<%0($0R<J$4(AH$.8:)B*.P/I@@/'(!B!,-!6B3:
MRAXHI7^0TM=*&67YUM58RK225MD:9M?%T_6F^;)MJV=%]=76XX%*'&N+?N\*
MT219:)(L4JL"]O<FBYN:)(M-DB6&R$X2F9+.K"/:5/YGTR>E=98_GTUFU)LC
MR/P 3A''"$H0&W90&(K#GCM$4!Z'"T $1 D<4"88BL/A?XJA' (::XRA/#@X
M)7H-AFI\9,A2O<;;F>'Y6<0^_+3:A*(FAK(Y5!-#P;E&>!$J0E$N''0P%/-M
M*"?&1>$*$$?!H4=?W4/E[!Q+JG6"]I-#C9P,FP/#Z?08@PDJ!!04@35+9Q\J
MJL(\ZKLVE%2%"5=X+M04*=1QH3\P16#<YX[22%68;5.X"$GTU3Y4ULZ!H_PB
M)WJ9I8_9,JLSB=O1U)"=M,\"DVR!4;;0*%MDE&UBE&UJE"TVRI:88CMM%IU_
M22\T,-?ISW/N)46,21<.%&,,Y2C+8 1%E45IB* $8<I\!.$20NGL$"X&^^$I
M=O7$ARLG!,4\>(^)OLJ'2MJYF%1O8S:2EALY/^[I4%551X\*ZL)%, :CBOH!
M!B,$+F%#!.93Q=] 4*ZCSDQ4E$?AZ#3%4+8#=QJPZ_(5STI?\4.%[6Q)JO<E
MWX3-\GE6REEMU>F/7I55,XYZ1"BS%00F',^'*B,P+N >4(C!J LGC1$*LZ%9
M.D%AG"HM&($1&Z[_8P3F^G!#(]$K,53ISI^D>H/R3>E9L6HMZ'1W,BF?6X\R
MET_9F8DI8M(1Q7I&4$) ZRM 4%RIRQ KT1,<RHR4Z"OF%H9JD@:*C%R7< 34
M&$$1Z&4G>@V&:MSYE51O6+Y-2&=%7I?IK.YMR8AM9Q/8J,8(K&G)\.8#%*8L
M*$(,9KL^="_Q0F$3G:!L3$!+&F5SX0HK1F',(5#F_X>523LOD^K-S#>9UT6Y
M;<7%D_5TXF^^R8[N.E+5QV-4L0Z,>II&V4*C;!%2'=#6-%K@U"A;;)0M,<5V
M>K"KLS:9WMI$$KL ;J<VM1GF)BIV/8+RE5,N"$B9E8<8$X,=&791#%H9$PQ%
M'=B-H2@&4#%:#;"#3?1:#-6ZLSB9WN(\W3#M&:B8ZO(YKE!Z+01F-PL&>-X%
M@35K/)@"(09S!4RG"(-106 G@A;*X,[O%&7SE8,O&(PX< V2Z#48JO'124V]
M[_F/(G^^KF6YNGA&PA"WD0DX(4%0U+$)-$(QF&O;2BM&8#[WH#6 P!BQF0UU
M1F""^_"T&E:HS>&UQ>@M,-CB$[T.0W7NC%"F/XO8Z?R.><B>\_1TB**T4;/3
M*%MHE"U"JD/I0HPZF$;98J-LB2FVTWSN'$RF=S"[?'[?] ,S_. &Y!A#<7C@
M*<!0#CQV$2(H9?K1"YE@95%E8%)!#MS>B1&0,B%*])4_5-S.RV1Z+W,W\>@;
MAQ"[L%E60H\+@Q'"E0D'<M+35OR*$(,YG@.M3 Q&?74@0F">#]FF"*Q=C=M0
M603F>13NF^OK?JBVG9W)]';FN%BMLKH]I;4[8=E..YK&*_/9.9T'F'(6^I2(
M(:+ %%%HBB@R130Q130U112;(DJ&$/7G?6?NLIVQ>&XG^J$N9M\7Q7(NR^K7
M7SQ&W<_M Z+9+*OQ!Z0,^93[W#?)%AAE"XVR14;9)D;9ID;98J-LB2FVT^;1
M^>*L[R"O?))E*>=6U384M$4,L'3Q@< 046"**#1%%)DBFI@BFIHBBDT1)4.(
M^C.]VQI@/5L#S02HR'=I?F5](!\)(=1:IZ7UDBXW\K/%"+DBNW]6M4C+]E&4
M3;THRNR_3?-(:RN0,[EZE.7NHMX>>=[.IMKG?S];/KEJ%B)7ON^_$615U>XL
M;A]IV=15W7QH5TQGR3Y;+KL2+KD2@@SDP)Y#_LI4*]^'$_9>2- /"?LA$0*!
MITCZ(=-^2-P/2?0Y,_0YU<[5YWI7_\M\GK5V?K/J:I^!NLYR:Y:NLV85ACZJ
MBATNY@P^RC1&<4Q9MP8HCMKPB&B(XHCMP1,&&(X( HW<"8ICCK(SB>*(#<\O
MQ0B.^[X#'^9,]&(,%;NS];G>UO\RFVU6F^7V51+[&2BJLNI?7PM!E7,?8Q3(
M/67',D"!S%<.C88HD-K*D=8(!WJV8NVC0")\ I^DP1E]"I,BQADY5S9Q]&H,
M5;LS^/DE!YNK\ZL/5'O5T[YN@J"W@L%L#SZ2%B P)N ACQ!!-7T ?&8APLJD
M0D!#9X+A&(/G!*<HG6?#XRPQAN,N]&"2/>SXX77*Z=&VQZF*1V\2T-OWBB.V
M'8;?JZKJ7V-GV#$8<H8=@R%GV!$8=H8=@6%GV+%"D3/L" P[PX[ L#/L>FV&
MMN#.ZN9ZJ_M!EJW@_['&1?XBRSI[7$JK6R\]G%LOZ6G?ZR 890N,LH5&V2*C
M;!.C;%.C;+%1ML04VVDSZ38-N&W48.,FWUPP-LH6&&4+C;)%1MDF1MFF1MEB
MHVR)*;;3YM'MNW#]OLL%!MN>X7CRHLP->B%!/R3LAT3]D$D_9-H/B?LAB;YF
MWZO<S=%; -MW6_Z6EL]97EE+^=30DX]NDR?E[G61NR]UL=Z^&/"QJ.MBM?VX
MD&G3S;6 YN]/15&_?6G?-7AX:>?]_P!02P,$%     @ $8>66/_C"82?!
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M&[&\@C3.ZK_T>_./V!,0\X3 : 0&5#!H! .HP&P$)E1@-0(+*K ;@0T5.(W
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MB6H"U2I4JU%-HEIS^2.IT(*:TKH]H<UG1NY\INN&[LB6/POCM)_"=)<8?2*
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M/_YG"388BG+YD1L0"A_ZR)+=1<%R%<O5+"=9KF$YQ7(:XWJ]XB1O&HQ>E'M
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M-^]?3? JF!T69,OR/V@F#[>SU0QD9(_K7/[*7OY%VH!B[2]EN3!_P4MK&\Q
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M/"R^1@A "5G ]MJ"(=NH3A5!VHJZH#\EGH+M[C ^$.T."D@5@Y#G)Y"( )%
MYT56J^)W^*<%)W&S(KUC1]=\W9,B@2.!LPSKPH-P_$6::MJ,=V8=$%\VV(ML
M0I;2:QC-@&4XCFE%65?&6\I#UP&I30'D4*BY61G$T7.S(9W+>EX28 $%^.P
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M?XVB;FBZ1X6MO7;(G6U.W(^H65H53.KK' *3K4&'D8\O9T)J>5O;%,B+X<#
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MDJ5<U, >E<XS:1;BV/%TFDHS QO.?7$R"RQ$"J+,A5I.QT0IXM8LD:2U/GN
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M-1O^B*("T^(%^GW9D..@7S" _[.7W_X_4$L#!!0    ( !&'EECH[YJC, 4
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M""%Y!WY?&N/N#1]@_*RM?P-02P,$%     @ $8>66,Y.$ 'M"P  ?R(  !D
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M6DF80P/P?EF DO@;6J#]S<G%?P!02P,$%     @ $8>66&X;4V(\"0  -1L
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M9+4;1#%K ND0GPASA!E@#H>=%'Z1J7?'RN@\V3<%C%/;S/SL(\9]OOV[L6<
M@,V0"D1@T+MAPV@W0.6)ETX3@#((J(;PDULA&??8R7OLY'\%=K+Q%?TZ> ^#
MO(=!?BT,\AY@"!X04Y+*75@30@O_6L/6'S\>&32ROY(.FG!X(+X3TWS-<MH%
M@[I[L,QSHN>FLLV(1'</#FD]*@U"8JC[!):QX+9L<^JMN;8N)-R[LL?(-%YW
MUWGZJKF<:=/U=4-,&;@$K&?QVRZL>Q@B%EUIN[D[P_4*5S5(9I%*KL3OCVYU
MW], EQS(H^:S<-&R!OO/D3FVL>A7^ U\;NJNE>DP\998@U'OE7@#S>S?MK>-
M-]YQQE\.KG]X29E4IK/6['0&W#*/CNB7YC8/57I.#3+SWR%<JM;C_ :7C183
M;P4MT;*LQ'KH-I01)D\RG>_0%[;7I#@)\&^6FN=E$-BW6KX-;J[;""Y"QD@P
MSUE.:$E$N@F.%S"9&!8'HA1<(D>-5?=J-&X5V#(NVG32*4^(+"3.ZW]P^RR3
M7C0G;+D-[V2U;A:O9C%7"YUUP3V66*5[ '*NP]S%=%$=P[] <4!J>J!(.][_
M%@99^"4[-53#GIO>"HP0J?Q-[=J>DD;O13)V^4-;9YC2:K7C\CTL'Z[0CYR]
MXP2#;J1]<'XG^!NU/GUFN.7S/3RMR^+NQ HND1B%4@9IUW%P_K5U;E;L%[N3
ML@RWH&+@*C<()<Q=AFV/'S7VB!*-^8D'HH!N)9(-EARH)$"CW5N"E-G][',5
M(S3Z(Z)QQ!/ PX@KG\\-UA7MZ*AC(PA&@0"+NRZLY2R"SM:@ *$V<Z4T+ DA
M/1=-@74ZT$@/$<B]>CIJXW*;NZJI"S6(ZK8T;[FJ>H0E$&RRD$7T@54/Q7Y/
MC\Y6:.P]85ONA?Y3[GP^]R9[!\IM(=D/9_L8<1,DS]908-M72FNOL?_V];1S
ME=8&D+?^\'K:G#O9YM('28OW(0%$:$X*EFV,?LI!8)I+6A]ZER:?@0N$';(3
M=RTYW^ZVX_YLN$E\\S7B5^[%8#G)OO.6&=[(T'.1-DN<_VT@?;(9 8'G?7=G
M#P;9=#Y\OL] X<I#4[5APIS,X]E[VY Q<'$4@N;"UQ[06K]EZ.QW'WL<N*!?
M& ;=8 ^&DDL-]+@Y#>"*5BXL0" >1<Y#$@P";(X'A+=YVX<,TM"V WPW12UH
M]T7"2%=7*@E*4EAOKYU%M>:C"BX?].J"J%9NIX>TACOW[!<M24-'&UJ7I;>%
MH._"<W?+.=+2<[WY'[CW?.4Y?QI>=^[\A.? V@]Z-_%R?H60J*TW,MC A<"/
M[FJ2AUBB(:0102*$=T DP>BI=#>?(,8##VDD\!F6#O:#"TC#0QO=FT_PC@9>
MQL0V&O#U*RML: (#NV"S,I?PTID)S\-R=<?NGI^9L".@.;;I=3N)Z3]L,;R-
MYFH4%K@DQV5RGH51+=_UYP!KO44[+,&&+=;<^Z,O.T@G?#];VZ--HC66?T-Q
MG[[S-9\0-ZA%)OTFUE;QI(7SF39.8?E4FU77+(^P/&4PH^WJTN/^.SKZLJ3_
MUWUMA'*3IF:N:L:7*9LBI,9K/RT]@X1XW&[?#^EB4F%':<X2N$,([3-O'92L
M <EV[VC>7%?:[0KCT\?!!9O>%<;AW9L=-"TRS>!&3X,'6W]D8AM4=,/9#Z5[
MT:I8N J*K# I_34*+I2:?4XAZN1[C3WP*")*Z3KC "^Z_<+BP7STMM<43\D!
M^B75DY$;_C83F]N*M][%.S@ WL#;&(G[VW?O>/ONAMMV#7?#\XS?VV6Z_OT.
MX8VX.Z#ROK]6[3UV[#\7.[;!W]VCQK[=?:Y-N!3<*5;],<"Q1^$EKAX)WP=:
M+*@$&KVF.CK!C+:#R09JAD$KJRORW9K@U][:>G^MZM==J_K-KE/M]$[^_#W]
MM[U*]:+/_&R8<U"DA\ 4@U@*-*1J93. [9C"(0"A" .O_AM=!V/Z[P,9Z!%]
M#PN\AP5N)OQ.%_RZ"^).[E%_]ZB__P+47TM'K X^.&R=(6\-NJOWFKM;=,A=
M-N6Z5("!H_L3+M[\XQ_3__G84U"ETEMN<()VR#L %0>H.\:6O<E4/]H_YWAF
MC9@!\)S17ZB'EX(0W082+M,5?G7*:Q=N*;5E])<25"6X"/#@."B+WK(TVQY-
M9/[?X8$=?12.W9)QKUXSZCOD.[T\BTY.#T?F+PI.M98F:7\M39+'[)ST\ZIR
M?\6A'RMUZ^!A,U\]CXZ2Y_'%^2FW>QN<O6B\._O\AVHB)\2@)MYP5?GND<I.
M=:!_KGUNR1DG8QF!CA)W9H73?.F)RSV9M_=*W1JD2]FQ+QQ\(;=_S"H\3T(U
M)MU8:7.Q_N7//XA5\7SJQ]M#KN<KLNF-!<W&\\Y$:B\,,E4/6?GLHLZ:$X"=
MM!6-C&\7)XVQ^-6+>'!_/+-'7M/+NW0-P7R##770CF%F=8.J@ANG-/XM_I#U
M]B.26=):_XN#ZM6+ Z7AGQC^*_,;^%<OI:Q>BTJ\>@&6<2'/(-35?/S\Y=[1
MGO<I<'S^<F]Z]./T>.\ WFP>?_6B$ L)6<L"H7.IG,.KAY,GC_:XX&U_J?("
MA\0_50AFF'Y<0K0K2WP OI_G$&&97W "O(*.R'OU+U!+ P04    "  1AY98
MN5:'P_D*  !='0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM6?MO
MVS@2_E<(;W:1 %K'DOQ*V@9(TRZNAVVW2+KWP.%^H"7:YE86=205)_O7WS=#
M699?Z>[A@-:Q*<YP'M^\J-=K8[^ZI5)>/*V*TKWI+;VOKB\O7;94*^GZIE(E
MGLR-74F/GW9QZ2JK9,Y$J^(R&0S&ERNIR][-:U[[;&]>F]H7NE2?K7#U:B7M
M\UM5F/6;7MS;+-SKQ=+3PN7-ZTHNU(/ROU:?+7Y=MEQRO5*ETZ845LW?]&[C
MZ[=#VL\;_J;5VG6^"])D9LQ7^O$A?],;D$"J4)DG#A)_'M6=*@IB!#'^T_#L
MM4<28??[AOM/K#MTF4FG[DSQ=YW[Y9O>M"=R-9=UX>_-^B^JT6=$_#)3./X4
MZ[ W37LBJYTWJX88$JQT&?[*I\8.'8+IX 1!TA D+'<XB*5\)[V\>6W-6EC:
M#6[TA55E:@BG2W+*@[=XJD'G;SY\NOOEXWOQY?8?[Q]>7WIPI/7+K*%^&ZB3
M$]1Q(CZ:TB^=>%_F*M]E< E16GF2C3QODQ<YOE-97Z1Q)))!DK[ +VWU2YE?
M>DJ_,C,K);[()_%.NZPPKK9*_.MVYKP%(OY]3.? <7B<(T7)M:MDIM[T$ 9.
MV4?5N_GANW@\>/6"O,-6WN%+W+_ICS].+;XLE?#0N[+F47,0(8:%#@;! ^5$
M9A!=SJM<F+GPV#\W!<)4EPMQKDNLF-K),G<7UP*.4:N9LJUSZ",1=[6UJO2[
M!UV+GU2NK"S$F4BO4GPFPZEX\-(K,1K@A_AB/)YFQXC%< C>DP0GSA6>YZ=X
M__#=-(F35^W?P']_-9R4'^5U8O/NGC,6Z(Q%(I/>F54ERV?DD\S4I7>'5JT1
M"U;</MR)R7#0W^JQW22D<PJDL*THM)SI0GL-2@ELYLHKBT@' :6;7-05I,CU
M'%Q4F6'73/FU4G"G+F69:4AL566L)[<11SJ 2!UY]=1)^$VGK92DB, ICL@)
M ZI$8#2FLC!I0RS7#H^E1X(J"L@ =82"4!E6EJIDTJZ4Q%T]52KP,I#Q45FG
M^FS$+<Z\G!4JF#LG*NP#*C/(*3EM;Y3=P^VJJHDOQ&'8-I!P@$#MC7UFP8,Q
MENJE"-B'^3^5M$TV.P7Y\ULG[A4=I?*+%HT[7"%6$G_/IS$="<*T9^)\&$V2
M](*^3:)!<G71X'9+'XD2Q1BNVV@U4Z6::R_.X^GX0IPGP\F%^&1(Q!HUC<Q'
M=B[)X<EX((;QB/-=!K=JN/X\B083(HRCZ02D]W1<MI3E0HGST?!"#*]B<1=^
MPQJ/LJB#Z27Y" A38AREDQ0,KJ+Q% 3W(>VQ?C6>6R_)C!0VQFFB=6(47X%@
M$ U)V7B<K'9CD&$)1*ZT#X?%R51,$Y'B_Z=??FYQ')3H;MS$:CJ)1G$JWC]5
MFIBB4F9?A5Q+FSL13X8BC@:C1/P"_\,)4U@AOA ?MA'8F&PGO#?)[!D@V-FD
M'3"DT;7HXID1A<2/LD].RF0%R0K].V3X4")T2WCL'E@O:\H5N8H$K/3A_BX2
M#TTG0M)1Y9 V6[*B.;87IEK1V7PD5$90NJ@),/0MXJ^RK-$UB0#%)"++2!\B
MZ(ECJ$'0>JG!-I,4.A!P3G9>:[\,J*J **9")71-:&^ PM%-8<O6YH2%M*#$
M[)GDWXCOV$=$ET[3OGC0BU+/-<[S'):F5)04FWK2)$OVV>258QD.<1"2A71-
M6CB,RC\4B>\.^5Z+3\>41E4:1:/!F)R/X(#_N_%R%4V&$WRFR80\BKB@& .H
MTC& /!!W'8_?_R!7U:MW(ADAMF(1([C!]H&Q2-8 >AIX(Q (D^ET)'Y&SE4[
MV3B.8K12R62T5<(V$!I%5Z,8G^-D(&ZSS-;LEQR8ST+A[/(9@L]0)-$XGC3(
MGR0CBH1X>JP0-L:?#J/1="PFDRC&43\KYXXF@?-I&@TX TW&T21.CUJ\35['
M.,0P.O)3.MVE[&AP+3ZCEDF=;U,: G=(R6N*5-DUO2YA(,[UF7&<YH;8M\D.
M/%W\:.8_$H ;/9$ !\.$,RAX';%'UY3G+"PV0]P+AM$QTYVU!VZ_W?I#O$;=
M:!!+F;?)G0*)$<QL#V,4D6SM,S)MR&Q4T2O4LR=D(Z^0C<[B4=J?8C0H"C8V
MV)W%:=Q/-DL1Y9HJ9)'BN2F_!X=_\^"96E!0&G(,P$>Y(1FDHTUIN]H])D)=
M* A(:)$?-0(9DM9>L^?ZNVU4X0P,XEJ93F;&IA30LK$5ZI7(;;W8+.]*Z\FY
MI,G957^T8YR@[K<..<5MU$\WW'8M^7^1^H2-OVW,_T6IHX>1'[E8<"/XE*F*
M0QBHZZK>U)BE1%TJ&P8AUG/(T1<?98F!GH^F..&<2PSEH]1%Z/>X3W@,+5JI
M%I)_*.H!*5&05,XSQ(6>"U?/46$T\9O75!D/:E[3DB[0*5'GQPTG17Y0 R,.
M>>]( /?%6^ZQ3>A?USS$<Y"!X4:<B(XIZIS[:[$$-\HZV+1?6"),YJWFA.E.
M+\_%%4Y *[$R7&._*FXF@(C2^/"<9#A5(EE'VCDC3\N.]X^E6DAL%:N&ZGTV
M[@];WP4_IPU(NKOBJ_YD;UO2%S\%BP? R0T<3A7WO1RRU\;MA]6F/SGNU95\
M)F5=/?N-BYT!._Q#'U1T&L)(5+5U-?4?V'&J48FHO9"=OLVL 16WU%73"C?M
M#YW)N#893Z<4M>$)IKTB#\M"![@$L?OBMCQ@%S:Z,!I)3+JKN@@@S]I.>TL#
M>1@4C(;1X/N6&J&HB=XOK5(_<E\* VNSET0):]1N%(J'HK)K!K+")2R 95D\
M8]R'$1:P_V;<Z[36$..$#_]DOEQ:4R^66YR1?#+_K>:K!LX$WEL]JVFXG+.!
ME;9MR.<=F7;UI-D0[>;O/"CRF-N,1G-K5J3W\6DD>.&/!-^6HLDH#C)+#F >
MP]631#@WN-MF!9C'%'4 '24/%K5@55"M$:R.8$2=Q2)8&A4\4R%ES+H)R*ML
M6:*9+C"86TWYJ3.R;(>K%:3"#OA*'E>H,51("D&U[2B1<[=A0B)I# I '>M;
MVLDU-#!UN27HVM\Q(TM#\UI1*[_7HL1[19A6!J<:E-M=XFY2:A+/:3'6'*26
M)F-U-$<UZ6-KC/:6(Z)*L^4;=?../YYE]SJ9+L!/ +%)'%EWT,3R9F\G+#;X
M:4Y_,: 1KW0]'R:V??Z[0N8&O DAR)<HJ15?DPC7'>+:_/0-4X?<%$K6D\<
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M-N#YW!B_^4$'M&]4;_X+4$L#!!0    ( !&'EE@:9\#(GP@  ,@7   9
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M##6I%)OQ.3R6$#"7:<656I+DVE ^G1JXYK"# PDGC(2?/)T+,EMD&;H0 X8
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M-6A#*V3'4CK;V#Q&"MLXTLDM6R>Q'F@#W:S:&@"W2<32LR090FPEV?X&^QX
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M;F,]'*W=3Y+N,9&[1D)(2DT$^*?K[*\R[)=IWH<,IE<4L?=/F^&<.B/IO&8
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MLQ0JC1[ [Q=%4;<$-=#],[$7_P=02P,$%     @ $8>66*<8EXBE!0  ) \
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MS#1WLJ;C=.7O04OM<*ORS1S76&%H +YG6KM-AQQL+\87_P!02P,$%     @
M$8>66+\OAQ-=*   JHX  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
MS7UI<]M(DO9?07@W)NP(2I;4[KO;$6K9[M'$N%MAM6??W8W] !)%$F,0X*
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M,K*&#80(2VNWY=Y/"JNZXMP(&5^7"7^(,6XV_:N$+I?;!JAW[XU\R0MI5^R
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MP3QTZA:K-ZR1C#E@G//9=53YKRVI&9H#QZ;4@XJ5YD/6#7*/\^E.4;[+2VC
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MJO$ZM=VUX-@*)(#O2Z7J?D &MG\P'/\%4$L#!!0    ( !&'EEBMQ_$,8 ,
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M:C3P0'=]KIM8M6M[RUI9ZE2M6=*O ;5SH/V-4O9YX@CZG\WL-U!+ P04
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M+Z)NN,*;/U76 -\OI32[B=V@^2\Q^@M02P,$%     @ $8>66'=QQ?H-!@
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M,\]/R##PQ@F:7M-RZ9*7"^P%<32 :!+ 6?V,V;CC>56GGE.->)D*&'EA$B+
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MB0X!&L/)CKC^2CP_)AX9XK$E3B13)LHV8+)Q%S.2OKU_UPW\\ -VMFN*FZ:
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M/*V=.;(D<(]R<RVY#WQ6V%[NJB/*P+Z9:& S(X,QX"P]#37<],5H+\'Z8V/
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M6G(_ *L<8]=2"LMF(H&&5*#' *QF-T'3%ZA-7\4L![#AT)< @P)\DF"?/ J
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M/-WYP"S9%*6"3;%;24%%4TPGN9I#Q5$3<E@F0B@!^T= LEOMC8B]:W',T92
M*HDGHYC<VH!D@>^9+M)T1 R&8%CSPT:17S%!N_@R"8G!)%%TW&P2N4$,)N"<
MCTZI>.MDXJ!#DN#6)10K^D7!*/*C^TE!.OOH?,Y(3Z0KQ.1><G!W'6]W2,$8
MPY*X?88BL<&/-.+^6I\I\?A"D(ZDXT8&,E>'S)<)K-W0<G;8\7;8<W=[&1BT
MHD\UB= T">T_B R,83?["<<W.TG ;@/8;73@)D> WHAW9Y^G_M3.%SI9T,,S
MRBX+-E<4#L5FD_6^+&:K:=W5$[#OMC\7<ZGU[S71"CT>!4Y92S;M](YP)L?$
MZTE1\:PLUUA2<>^,=]/KW]M J@(*A1*F5,R^(#\,A PE)66LMB-4@K5Q1#<U
M0L6GI71Q W(=>+D+9!K#IW1FI$0"?"P9=]D+/X&(4(LTJ':7+PB22I,O88(Z
MZ!.Z@0*W2<8#_T7DR <1),% *(^+X@9$.H%_E'9DJ=8CPG>?4C?])5MD;QO!
M;GL4>S&Y9#AR+>Y[)$,S*G*E&GB87&H/)\X.UQ.8"2+I#';@;V#M#JZG36Q.
ME.>3:XA,&$CVA"R2N_J?V@X<-ETX[#K!DB!F4W'"<4J']I16W\[_U&H-OP7,
MK?^(O;WX,K?U/^U1X_W]3Q0]$\/>Q8YWDA&2 05::3?Y$/ZG\?9B[.5$>MK$
M;I*'X"&\3V.70__E@=KJ@7J7+W;#CCT>^C/:83 P8#<, 46;I4//-_UQ#TBZ
MG_: 0",TL-;ZLX>&;)JE1ILF?U60H947 !<8%5(R#D(.G3"23EX)-42>3,)M
M.(.B*4S8Q/-3G*FD$RC/9]LNAAT7&"_16PQ!0Y'> 1T[)#'%D%*H-D2;EC[%
M><$HC4A]Z4W^L)A@.ML^BMU@0$:QSSXBF+0ZX+MAVFC[BQ^8H[U!Q]A4.Q<8
M9;(1>.PNN9?7"P,7!D[7R$NHDJ9K4CI=PR\)W;D;0Q\J<@V^ 747KQ>@J&PM
M.F:+CX<(,]MDP]IAQ]QAS]ZM+;ZF)>OCLHG6#T:Q/P]A\1FZD0A59]PDN;JP
M!F.CW>2O?\S.P9W?\5L8?FOAVDLE?E--$_)W$_0=-H>AA\UQZ&%S(+K]0+%O
ME $IAJA83'/ QF[FD$MICG+E"0?6*$9YXAB8)U:+#\+XR+G>V0,A!<?11>!^
MFQ+UKE@\X3;6P]':_23I'A.Y:R2$I-1$@'^ZSOXZPWZ9YGW(8'I-$7O_M!G.
MJ3.2SFL&D#QV'^1W?51V'(J+.B5,U<?9?<[K*Z+YU3M8S*%SD\9-W]C:;;_R
M5M2U'=I4PKEK(DZNTL7'S.([&V=*_1L/_G2BAGGC\_&W3!H)C.%CN172(:UC
M3C"]'@_LC08#>TZ8<,--'$D[#W%(X!0ZQ+6X&OI&>"K/T4CHJ>(35EC.2"12
M&"?<D])[QYM*>D& &P +RYG^=L>8DC.T"^JC6#.Z5:@&76+Z9"S\<A*0J4I1
MVLK0[7CVDQH^'*$+\T<W8I4'A57 :YNFC%V*$9$4:ZFEM?%V[D#V ,9)[++;
M9,#X)9?QP!JV&10\7MW8RN]7$)XIH02+?4;"LV$MADY]1/ ; ;H<(F[PG8\T
MMU=-S2N*UODLBVF6S1I\LH)@+S_#A*ZSA5BN+H#KP?]E5J*8!0CH#05X\?4"
MN]GI&#)Q0\H'Y/KWL+VU)JP$<0/@QIN,^9"SCZ4F2OM.F#O2PX:R+UDYS2NV
M@ZQ=4RPM#@N<<-]P"]O0%?F203$V8?>RH7.*_WV[[1H>[6&R.=?I;F*Q.#[E
MI&\OOD)5VED^$I<CLT4^+*F<&ZV6G)A!_2;H71HE[Y+)++.I(\&1M)NN77#4
MMA.C;\D)Q3O[[A9N,S9?X$AK2(2/^6+13*I][1*]C2-R[G V)%WTC=RC5B:W
M5IZ1&.VJW?%Z(4H,W;1-UMD*EBM#!\SKK'\+V> E4@[$9@GOUC.6X@.Q >DH
ML+6M^W4O.>'13,Y7,[O_TWUU ;WM87A)QA[5#1W6IF=O;,FA]\.M!U96'*][
ML:K%HJC%U\P.S)VY5&MWX==I>M>._?PUSV[_$/CU(<ZR?A7\"@:4>_F'*$DV
M;2_+F-J)88UAA7X$LS\1FISR%#T?8J-OQ[ .$$(R<BX;1/?"L+W.<9*_"P1+
MUY][^ ;]*)U7DR'=WWEC2,;7')0]?E;QELL==T:ZDK"L,]]$3:2]*]RK%DOO
M#7@E1> [E1(U"6-76S&U_TTK=MO;S[Y:.M6WG[L1\(1O+@T4/M/X5C(<Y#,]
MCH0E=N] YUJ:[HMHV<%BNA4M=\!B0Q8$U-!$LR6C*8@G!&K0P?ZP./;\R#WT
M;^@)15V$;I_:C'N 8NF[:(8I^R8Q!Y/[>P/C/6M[1' L=2_EULA' L?N"U8L
M];L%QUC.4A[=H.\$CC4#OF[36A*[+!JTT-!W \@11_DXLTGD1-%]"3-P5=J,
MWP] WOH^(LTOFQRB5LYZ%("LXG6R]_UF55N'7GLCZ#I],[459N]QR=EJ>RM+
MLB]3UKI\ +A^J9/\@G&X!EIOY&QA<!QHM\*1=Z%U#R]7)6WMFL#(F^OEO/B:
M919D]4^_GV-_T1W 83@RO\<B&>8ECP_FMT^]A?)#^K<Z%/Q# ?Q[G5W\*@@?
M,DFYKU.5?#!&<;@.. .U$^&STY"\U'&B1908>IGC$5;*+B^U<R>=[J.[FHLN
MQ]\=XSMO,N#7& SN]C/UF^![:<-D%)TO 1S2.RZ</E/:0?C\6@L'X2<N*GI
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MTAXBT1:1R(K(=3HW']W_ZMVG2_.>/%^A,KTU;_6SHJSN-<_P'A/Q"T33#K>
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MDLIL=2\S5%7U1_8):K;YJ<!8\87-Q)=QI#5#"RF%"&)Z\VD#912'VO=CNC"
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MD">NAL)'A*JA[&"<O&<%BFNKF%)U=D'9LPL_JF9/\57K)DB1$D,*,@@--7M
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M-T>C9K^_%'5=7&]_O<IGB[S<!#3_?E$4]<,?FP[NBO+K=O>/_P]02P,$%
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M22?0MB.8MN9I!W@?5VF15//L>;,(F%?SM+RD1I<-1J<QS0+ILEPET_1Z4*^
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MAI*0<GV!.K]*4_FVHV]0+P\:_0=02P,$%     @ $8>66*X'P-'J P  *!
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MC'H)I<DTQ:X)4->^P"PT4KGRS9*^#V#<!!I?:HW[P-6L]HN3_0)02P,$%
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MSLV6,$9RT:FY7IA+YT436(NQUS#V=.K1T\E;$UB+M]_P]G]=C_Z1S'#@./A
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M0%F2?OR[-6JD:ZJ)^>N=]6\QO(298$Z&-/CE3\6B9[0-,"4SO K$(]W\3;9
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MGOAI:$I583B.Z235W,75H(IJ(%)Z@=P(, M<XN8%3&4M]8=>_=TAK>(GXK2
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M@8(1TY/XG:&G/:JEJ"903:*:0C6-:@;5+*IEJ.90+=]ICWN8)YJ7\%%.*#Q
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MTMJUJ8FA)@>?X9Z@X5)42U%-H)I$-85J&M4,JEE4RU#-H5I.:>W:T81+$V\
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M-.#GUX2PUT;IH-TM,_\!4$L#!!0    ( !&'EEBQ5H\TM08  +PW   9
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M!;=J*%Z4=\1'KO2-LWS<$[PAPACH[UO.U7/#7#N;?S,L_@-02P,$%     @
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M_ @JO]%BF1W*S(36(LTN(V!8,)H&^'XNA'Z[,1T4!X'C_P%02P,$%     @
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MF@#/C\_E;R1;FO-A,R8E2\W+!241Y;J!^GS.F'QYHP.4AQC'_P-02P,$%
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M"*:<="R B1D\B 25H:,WSF+ ]!*NZ)PUS)7,X(H+1A9PC50W.!PBF:;Z"QP
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M)7WT4%D#>C^7TKQN[$5<?4;COU!+ P04    "  1AY98M(X%C0X#  !""0
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MW3;VUN!'C%NU-P83R5R()S,9+GJ.9P1A@I$V'AC]-MC')#&.2,:?G4^GI#3
M_?&K]UL;.\4R9PK[(OD9+_2ZY[0=6."2Y8E^$-OON(NG:?Q%(E'V"]N=K>=
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M54)I#&A_*81^G9B;LGSGPK]02P,$%     @ $8>66!+TI'?3 P  ?1   !D
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ME0#Q?$<(?VO(P]7Y'X?I_U!+ P04    "  1AY98Q,S;FWX8  !K]   &0
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M:[?Z=+Y?3<9N&'P@!OHAW2\ E!='+M4I$2R)(GKW0+ L2.F3.X#Y;N1'U,\
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ML4,*.Z04-5O9.ZSLD-H.::3,'@:#EJ'3,1^6-02#J :=HB+@-$40@ ):CK0
M(%;2MP0@M  @%%\ $(HO  C%%X#O(;2F6FA-@U%'#[8*DJFHQBK*EHNR%:)L
MI2B;$F6K1-EJ4;9&BFTX+;3*G%HR[D=4D#133)X25DTTMT,* *&U\DM1NY7=
MJ,H.J>V01LKL841H13BU*L)C"D::628'A?T3JW9( 2#T;?=2U&YE-ZJR0VH
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M=5#*IO=9".9XD4>U F!:*Y^*!<!\SZ.C"PP:T:$J1K"J(VNJ%PYSW4@Y5#
M%OB1HH+A,#]PZ,U4!F"!JUR/"H;#PE"'(14,AT7!2_FU!:,:P2BC8&IGU/JZ
MW]T]B6:WQ6)1+/[KR(WH^B2".:X=A50M'*<"VC5G .6X3N10L:"@7D!%%4-<
MZ-)UPP7$.=H)J%X KAJLZ/)"BG!5/Z.X#.-LNL:00UQU!\X&&50_[=FZ0S2-
M=^68S:M_EK?%WEH?S?5?K6U1PGMU1]3&$F6;BK+-1-GFHFRQ*-M"E"T194M%
MV3)1MER4;2G%UN[^C:7EF#VM9%L6%6]Y&@&L5Z=9QB_'L0 .!2Z_9#J:7CL
MB%[*IP"DZ.QV!D">1R\:'/.:+N8BC++IU8*#0AHM@4P^O4YP$%C71RU %W(1
M4T2G;$N(ZII1-)Z68S:U3E-0>HF LN#F I % '%9<!"0!0=Q67 ,EP7 <%EP
M$) %8F*R&&3WH!9@L@!,0!8(U26+QO5QS+;/<:+YI?BZVQ=/XT:Y^NOI!@6J
M@QL-K\,PH M_".9H-V W*,;ZC;[D W>FFMW[5$ZH<M74E-W(2%9N :/:KJ^H
M_ "NFL#2N]44\D7L[CW#N(BNR^4(IY3+;WI0_;1V5(<8&[/),:YL7R3#!!B
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M'=97]9+OX_W+?;%_[G;UYEKK5;W?MO[U^/47V/\>(T0O]6;_YM#NAU%TX0_
M[-]L>A\#4=1ZG>.0=#DZ[H %M+O@ R!L"8;1!\&'52WK@-&EX@X8:8\EAG4]
M#*X:BTF9+:;I>O-0;_7^.16Y@U2$44Q%'(94A%!<13 D5Q&&,17A V J@C"F
MHD%5RSI@3$48QE0$89TJ:JPH9;:B/CYNYG^H,P@\7OSO*U7563C, ]3Z].F
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M+1%E2P>)(^L_ ;EHM992;.U>U7C%>LA^/5,R%,V]3Y0-!<#   U0:( &,#1
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M5%7-^1]= ]^K^I_]\#_]/U!+ P04    "  1AY98OGE;@WP2  !%X0  &0
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MMHZ=<T!I$9060VD)E)9":1F4ED-I!9160FD5E%:C:/U1HDL9<5XL9<2!IHQ
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ME*[_AK^: [$7P#EP@-P$R&* >B) :0*4K@%J$Z!V#=": *UK@-X$Z%T#C";
MZ'J4S"; [-J#U01877N@TF;FI*Y]T.UD'\VV?BID,]VT\WS3S833>L;[:R_6
M1K;#,AQ<Y=D+R2L]YU4;=374\=R_45H5[K3,^;L1CRL'T_N;J?/GO?/E&W&^
M\]<I^42F_.PP7\6,9(_$"?,T2I\*<L=R,EV$.?M(;L(BFI$PG1,[BE<EFY/W
M-BO#*"X^\.C[J4W>O_M WI$^*:J @D0IN4^CLOC(&_GVMT6V*GAX<=4O^1"J
M1/JS)MV;=;KRB705,LG2<E$0)YVS.1#OML?KK\7[[?'6:_'C]G@JMP#Z?.ZV
M$RAO)O!&;B5.V?*"*-)'(DNR B1TVQ[NK]+6<+L]?!+F/)R>#'>Z)R\#X</N
MR4/AH^[)0^'NVPZ=][;D_;?->_"V(S]N#[?9K'7>)]W#Y98B4+9G,:7F*:=&
MLWHHV,\52TOB/%>O?X^Y@G@E2XI_H+/,&J?"N.K+TF6Q#&?LNL>_#14L?V:]
MP>^_45WZ ZHP3)B-"7,P84-,V @3YF+"/$R8CPD+,&%C3-@$"790^^JV]M4V
M^N +O[J)LZ*HOY#,LH1WL:@N+)Y9W0Q5_QIHU,#JRN9Y\,FBDG'5?]XO:T!%
M%5U6#V7VL4R1J'(H<HY%5)55_5 UA'K4#,TZE(T@F:D:0F(N))-T2@]E'B!3
M5%D11N!#-,N@YJ$L &66*1S;,2"394L1<IM N2F:N1OI@6.TK6,T;,=HG1P#
MJ"#'',L QQR+(,= /0*.@62 8R 9X!A !CD&H@&. 67'C@%DD&.@W$X[1M\Z
M1F]US.8Z)]TX9\FOAKASDBQ=7^.0]]5E3]5:[WZ /+3NPMI/3;H0\K^%19K@
MH&.5="&)#H)$5#00V)\LH$:P2I@B%\Y=8'F@2AB@WRFM %8)YA_#*N% 3$"5
M:L*^,;:^,5I]L[Y2?I-KC"ZN@46B:XY5@&L@T9%KP/Z.7 .K1-? N8NN 56B
M:SJE%< JT36P2G0-J#KE&G/K&K/5-=/U79-5P<\X959_0O&S#YF_?A**FJT"
MM-*Z5WTO64N234-513M!0DHU4_Q<L8^%E M-2[&$ ^4<*TV.DS5=^#@8'@MU
MBRJ*(4F"NP"A2163BF9U@:Y55;)T77"B!Q%UQ=0UX?CX %%7+$D5/YX#<#"&
MQ)&"VP"BH<J&J@A'? (13<W@+[#GK*WGK%;/W>49J>^$0\9I#3WW:AD39F/"
M'$S8$!,VPH2YF# /$^9CP@),V!@3-D&"'=0YE78W_"7<>V4-#ZG\46DV*LU!
MI0U1:2-4FHM*\U!I/BHM0*6-46D3+-KAF6#OT1_%O@_23CS[7(!)LU%I#BIM
MB$H;H=)<5)J'2O-1:0$J;=S07KTE!>E:[DE1>5>_,GK]MA+/KE],FHU*<U!I
M0U3:")7FHM(\5)J/2@M0:>.&]GK] KJV^MT]M*:MS\5P[BJW]W%V1:,^RT:E
M.:BT(2IMA$IS46D>*LU'I06HM'%#.[@=JUW(FEC0@,RZT"5K_]^)XMX]E:;M
MCZ41;OVW]W!V:6/2;%2:@TH;HM)&J#07E>:ATGQ46H!*&S>T5TL;D'4M[=W/
M!VC[[P=./)]Y>*WBVY_.M'=Z=K5CTFQ4FH-*&Z+21J@T%Y7FH=)\5%J 2ALW
MM/W'7*IB4/Y?K/=CH:):LGGRR_GN%Q^T_2<?_]=#V/9NSRYS3)J-2G-0:4-4
MV@B5YJ+2/%2:CTH+4&GCAM:AS(^%<)GW]U;")"Q_JI>$%;Q 5VFY_H'@MG6[
M[.QSO?A&:+^AER,*M+OTTH/:?7H90.WC:EE;O5)GE\YZ3=PDS)^BM" Q>^2I
M21<&/Y7EZV5FZYTR6];K=AZRLLR2>G/!PCG+*P%__S'+RLU.U<%VL=_@/U!+
M P04    "  1AY98/+^D+TL#  #P%   #0   'AL+W-T>6QE<RYX;6S=6%U/
MVS 4_2N1&1-($VD;2)O15MHJ(4W:)B1XV!MR&Z>UY#B9X[*67S]?.TT_\*T*
M#X,N%<3V\3GW^/HV,?0KO13L;L:8#A:YD-6 S+0N/X=A-9FQG%871<FD0;)"
MY52;KIJ&5:D832L@Y2+LM%IQF%,NR; OY_E-KJM@4LRE'I!N,Q2XV[=T0-KQ
M)0F<W*A(V8 \G'W\/2_T]8? W4\^G9RT+EH/Y]>[R%D-G9/0*WQU@# JBXG&
M![DUUQ[#YL+DNX?)[Q/'I'O;TG;ZJ1%RQ%.,EGAH)LJ:"1V$W&T=F*V]R;+B
M85U,PWY6R'5-1<0-F.@T9\$C%0,RHH*/%0=61G,NEFZX P.30A0JT*:8C9TV
MC%1/#FZ['M1YK9-S62@;VT5PO\?U]!U@U0.#7(C&8(>X@6&_I%HS)6],QTZV
M@\^@H&[?+TOC<*KHLMVY(FN"O9D@XT*E3#5AVF0U-.P+EH$=Q:<SN.NB# '4
MNLA-(^5T6DAJ/:P8=</(3I@0=_ 0^)5M:2^RC7VUNRJ;IC%4-YV,ZX#^IIK3
MWI2]?)5N4/+'0G^=F^5(VX=J8;>*97QA^XNL,8"IMW%U6I9B^47PJ<R96_S!
M 8=]NN(%LT+Q)Q,-2F5B!I@BP2-3FD\V1_XH6MZSA5Z5TR+#/7>.T/._S?.4
M2::HV#1M:O\]9_G5CNNWYEMXMH^57<=>DU'W_7NL3PGOW61\#":/8KM[QV R
M.0*3W3=[:K[@"?0^$QG6)Z&-X];68:L9#>!0.R _X0@MUD&#\9P+S67=F_$T
M9?+9F<O(:SHV?\YMZ9OY*<OH7.C[!AR0=?L'2_D\3YI9MY"(>M:Z_1V6UXZ;
M$[6)Q67*%BP=U5TU'=MF8!HF:GT!81>YL9<?P3@.\R. 87$P!QC'L; X_]-Z
M>NAZ'(9YZWF1'LKIH1S'\B$C^\'B^#F)N?PK39(HBF,LHZ.1U\$(RUL<PX]?
M#?,&#"P.1'I9KO'=QBMD?QU@>[JO0K"5XI6(K13/-2#^O $C2?R[C<4!!K8+
M6.U ?'\<J"D_)XI@5S%OV#<81Y($0Z 6_34:QTAV8OCX]P?[ED11DO@1P/P.
MH@A#X-N((Y@#\( A463?@SOOHW#UG@K7_^,<_@502P,$%     @ $8>66)>*
MNQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q
M%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(
MMB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!
M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B
M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MX-&AN/M$5,S/VC?+JPJ6 ; ,6JR1/,Y3D<A/3]A-G,;9FK-F9$L%T 2 YMD
MV<4\5B M &E](&140]1O*%F^8;.=-@-M &F?#5)>>E$@'0#IG \R+I\5R &
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MJH4<V'1&O1:"Y6MMT)&%'.JU$,34!AU9R#EG@X$^Z,A"#G4!#F*J5=<!LM"
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M2P$"% ,4    "  1AY980I4XC.\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  1AY98F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( !&'EE@,!992AP<  /LP   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  1AY98O/O95SP"  "]!0
M&               @('+#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ $8>66/;]#^.S"P  P%,  !@              ("!/1(  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !&'EEC_XPF$GP0
M $<=   8              " @28>  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  1AY982+O.4KL)  !X/P  &               @('[
M(@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ $8>66 PO
MV'$$(0  6C$" !@              ("!["P  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( !&'EEB/5UKWU <  .(D   8
M  " @29.  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  1
MAY98WCH:"%H1   .,0  &               @($P5@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ $8>66!+- 1S3(@   G,  !@
M         ("!P&<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( !&'EECH[YJC, 4  +(,   9              " @<F*  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ $8>66!Z@24@A P  K@8
M !D              ("!,)   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  1AY98,V\OAQ #  "U!@  &0              @(&(DP
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !&'EEC<S;@.
M- ,  .(&   9              " @<^6  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ $8>66,Y.$ 'M"P  ?R(  !D
M ("!.IH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  1
MAY98;AM38CP)   U&P  &0              @(%>I@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !&'EECUMZ2/E!T  />%   9
M          " @=&O  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#
M%     @ $8>66+E6A\/Y"@  71T  !D              ("!G,T  'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  1AY98&F? R)\(  #(
M%P  &0              @(',V   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+ 0(4 Q0    ( !&'EEA8H"(&!!@  %AL   9              " @:+A
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ $8>66*<8
MEXBE!0  ) \  !D              ("!W?D  'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"% ,4    "  1AY98OR^'$UTH  "JC@  &0
M    @(&Y_P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M !&'EEAU, IF1@8  &P0   9              " @4TH 0!X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ $8>66*W'\0Q@ P  ^@8  !D
M             ("!RBX! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  1AY98V\+O>N,"  #3!@  &0              @(%A,@$ >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !&'EE@:&Y2I@ (
M '4%   9              " @7LU 0!X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ $8>66/]V58/H @  (P8  !D              ("!
M,C@! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  1AY98
M<@[90B$#  !X!@  &0              @(%1.P$ >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( !&'EECQGK^WD 4  &$.   9
M      " @:D^ 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ $8>66%MAH\7:!   5PP  !D              ("!<$0! 'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  1AY98=W'%^@T&  #.#P
M&0              @(&!20$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( !&'EEBSN0O6,00  -<,   9              " @<5/ 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ $8>66)@ZY$GN
M%P  TFL  !D              ("!+50! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  1AY98L6\L>R<#  "X!@  &0
M@(%2; $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !&'
MEEC.:+D>; 8  )XQ   9              " @;!O 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ $8>66-*8!R9,"@  \$L  !D
M         ("!4W8! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    "  1AY98ML)_GSH/  !Q<   &0              @('6@ $ >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( !&'EEATYD6>%1   );;
M   9              " @4>0 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ $8>66(*.<$'J"0  CU\  !D              ("!DZ !
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  1AY98GJ;U
M/>$$   J)   &0              @(&TJ@$ >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( !&'EEBN!\#1Z@,  "@0   9
M  " @<RO 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M$8>66%JA6758 P  10\  !D              ("![;,! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    "  1AY98+&'BZAD#  #I#0  &0
M            @(%\MP$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( !&'EEB5!P30)P(  )D$   9              " @<RZ 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ $8>66##,\?ZY!0
M/S@  !D              ("!*KT! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    "  1AY980B99E#P#   T#   &0              @($:
MPP$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( !&'EE@^
MF9XY:@(  'T&   9              " @8W& 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ $8>66,7'?96P#   (Z4  !D
M     ("!+LD! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !&'EEC& L(<[@0  -X=   9              "
M@1;K 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ $8>6
M6)O%Y8D^ P  E L  !D              ("!._ ! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    "  1AY98<"TZFZ4C   *U ( &0
M        @(&P\P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( !&'EEB5Y17HDP4  .TG   9              " @8P7 @!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ $8>66)W%SID7$0  Z#P!
M !D              ("!5AT" 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    "  1AY983OQ#1Y4$   Y(P  &0              @(&D+@(
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( !&'EEBQ5H\T
MM08  +PW   9              " @7 S @!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ $8>66,D_9YE>!   <A   !D
M ("!7#H" 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  1
MAY98B(Z@$2X$   4%   &0              @('Q/@( >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( !&'EEC0N\YN!0,  # (   9
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M970V-2YX;6Q02P$"% ,4    "  1AY98$O2D=],#  !]$   &0
M    @(%M5@( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M !&'EEC$S-N;?A@  &OT   9              " @7=: @!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ $8>66 @$'1!S!0  /"0  !D
M             ("!+'," 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    "  1AY98+U:_VD\6   ?T   &0              @('6> ( >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( !&'EEA*[TXF$24
M )"A 0 9              " @5R/ @!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ $8>66+YY6X-\$@  1>$  !D              ("!
MI+0" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  1AY98
M#,?]#ZP%  !$,@  &0              @(%7QP( >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( !&'EEB<T&'KQ08  /@W   9
M      " @3K- @!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ $8>66#R_I"]+ P  \!0   T              ( !-M0" 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  1AY98EXJ[',     3 @  "P
M@ &LUP( 7W)E;',O+G)E;'-02P$"% ,4    "  1AY98YKM2ITH%  !0,
M#P              @ &5V ( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M$8>66+?' S!" @  0BL  !H              ( !#-X" 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ $8>66/C# AT& @  3RH  !,
M             ( !AN " %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %$
,40 N%@  O>("

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>369</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - EQUITY INCENTIVE PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANS</Role>
      <ShortName>EQUITY INCENTIVE PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/INVENTORY</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSTables</Role>
      <ShortName>EQUITY INCENTIVE PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/EQUITYINCENTIVEPLANS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/INCOMETAXES</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - SUBSEQUENT EVENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTSTables</Role>
      <ShortName>SUBSEQUENT EVENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Operations and Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Operations and Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - INVENTORY - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INVENTORYScheduleofInventoryDetails</Role>
      <ShortName>INVENTORY - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - INVENTORY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INVENTORYNarrativeDetails</Role>
      <ShortName>INVENTORY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - PROPERTY AND EQUIPMENT - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/PROPERTYANDEQUIPMENTAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBTDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/DEBT</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - STOCKHOLDERS??? EQUITY - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - STOCKHOLDERS??? EQUITY - Summary of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Summary of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Black-Scholes Option Pricing Model Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Black-Scholes Option Pricing Model Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Revenues Disaggregated by Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Revenues Disaggregated by Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - INCOME TAXES - Summary of Components of Benefit For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Summary of Components of Benefit For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - INCOME TAXES - Summary of Reconciliation Between Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Summary of Reconciliation Between Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - INCOME TAXES - Summary of Significant Components of Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES - Summary of Significant Components of Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - INCOME TAXES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXESAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - INCOME TAXES - Summary of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Summary of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Cash Flows (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Cash Flows (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cdtx-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - SUBSEQUENT EVENTS - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  cdtx-20231231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="cdtx-20231231.htm">cdtx-20231231.htm</File>
    <File>cdtx-20231231.xsd</File>
    <File>cdtx-20231231_cal.xml</File>
    <File>cdtx-20231231_def.xml</File>
    <File>cdtx-20231231_lab.xml</File>
    <File>cdtx-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cdtx-20231231_g1.jpg</File>
    <File>cdtx-20231231_g10.jpg</File>
    <File>cdtx-20231231_g11.jpg</File>
    <File>cdtx-20231231_g12.jpg</File>
    <File>cdtx-20231231_g13.jpg</File>
    <File>cdtx-20231231_g14.jpg</File>
    <File>cdtx-20231231_g15.jpg</File>
    <File>cdtx-20231231_g2.jpg</File>
    <File>cdtx-20231231_g3.jpg</File>
    <File>cdtx-20231231_g4.jpg</File>
    <File>cdtx-20231231_g5.jpg</File>
    <File>cdtx-20231231_g6.jpg</File>
    <File>cdtx-20231231_g7.jpg</File>
    <File>cdtx-20231231_g8.jpg</File>
    <File>cdtx-20231231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2371">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cdtx-20231231.htm": {
   "nsprefix": "cdtx",
   "nsuri": "http://cidara.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "cdtx-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "cdtx-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "cdtx-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cdtx-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "cdtx-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdtx-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 318,
   "keyCustom": 45,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 37,
   "memberCustom": 27,
   "hidden": {
    "total": 7,
    "http://fasb.org/us-gaap/2023": 3,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 369,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 553,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 2371,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://cidara.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://cidara.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://cidara.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
     "longName": "0000006 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION",
     "longName": "0000008 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "0000010 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://cidara.com/role/INVENTORY",
     "longName": "0000011 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://cidara.com/role/PROPERTYANDEQUIPMENT",
     "longName": "0000012 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://cidara.com/role/DEBT",
     "longName": "0000013 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITY",
     "longName": "0000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANS",
     "longName": "0000015 - Disclosure - EQUITY INCENTIVE PLANS",
     "shortName": "EQUITY INCENTIVE PLANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS",
     "longName": "0000016 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://cidara.com/role/INCOMETAXES",
     "longName": "0000017 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000018 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED",
     "longName": "0000019 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://cidara.com/role/SUBSEQUENTEVENTS",
     "longName": "0000020 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables",
     "longName": "9954472 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Tables)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954473 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://cidara.com/role/INVENTORYTables",
     "longName": "9954475 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://cidara.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "9954476 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9954477 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSTables",
     "longName": "9954478 - Disclosure - EQUITY INCENTIVE PLANS (Tables)",
     "shortName": "EQUITY INCENTIVE PLANS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables",
     "longName": "9954479 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://cidara.com/role/INCOMETAXESTables",
     "longName": "9954480 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "longName": "9954481 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables",
     "longName": "9954482 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://cidara.com/role/SUBSEQUENTEVENTSTables",
     "longName": "9954483 - Disclosure - SUBSEQUENT EVENTS (Tables)",
     "shortName": "SUBSEQUENT EVENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
     "longName": "9954484 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Additional Information (Details)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-267",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
     "longName": "9954485 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Balance Sheet (Details)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdtx:AssetsAndLiabilitiesOperatingLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails",
     "longName": "9954486 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Operations and Comprehensive Loss (Details)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Operations and Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R37": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
     "longName": "9954487 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (Details)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
     "longName": "9954488 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Cash Flows (Details)",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION - Corrected Consolidated Statement of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "longName": "9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-66",
      "name": "cdtx:CollaborationAgreementNumberOfPerformanceObligations",
      "unitRef": "obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails",
     "longName": "9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954491 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://cidara.com/role/INVENTORYScheduleofInventoryDetails",
     "longName": "9954492 - Disclosure - INVENTORY - Schedule of Inventory (Details)",
     "shortName": "INVENTORY - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://cidara.com/role/INVENTORYNarrativeDetails",
     "longName": "9954493 - Disclosure - INVENTORY - Narrative (Details)",
     "shortName": "INVENTORY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails",
     "longName": "9954494 - Disclosure - PROPERTY AND EQUIPMENT - Summary of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://cidara.com/role/PROPERTYANDEQUIPMENTAdditionalInformationDetails",
     "longName": "9954495 - Disclosure - PROPERTY AND EQUIPMENT - Additional Information (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-279",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R46": {
     "role": "http://cidara.com/role/DEBTDetails",
     "longName": "9954496 - Disclosure - DEBT (Details)",
     "shortName": "DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
     "longName": "9954497 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Additional Information (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cdtx:NumberOfVotesEntitlementForEachShareHeld",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails",
     "longName": "9954498 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Summary of Common Stock Reserved for Future Issuance (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Summary of Common Stock Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
     "longName": "9954499 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
     "longName": "9954500 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-131",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails",
     "longName": "9954501 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
     "longName": "9954502 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Black-Scholes Option Pricing Model Assumptions (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Black-Scholes Option Pricing Model Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails",
     "longName": "9954503 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock-Based Compensation Expense (Details)",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
     "longName": "9954504 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-152",
      "name": "cdtx:CollaborativeArrangementCostSharingPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
     "longName": "9954505 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
     "longName": "9954506 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-214",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails",
     "longName": "9954507 - Disclosure - INCOME TAXES - Summary of Components of Benefit For Income Taxes (Details)",
     "shortName": "INCOME TAXES - Summary of Components of Benefit For Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails",
     "longName": "9954508 - Disclosure - INCOME TAXES - Summary of Reconciliation Between Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Details)",
     "shortName": "INCOME TAXES - Summary of Reconciliation Between Income Taxes Computed at Federal Statutory Rate and Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails",
     "longName": "9954509 - Disclosure - INCOME TAXES - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "shortName": "INCOME TAXES - Summary of Significant Components of Net Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails",
     "longName": "9954510 - Disclosure - INCOME TAXES - Additional Information (Details)",
     "shortName": "INCOME TAXES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails",
     "longName": "9954511 - Disclosure - INCOME TAXES - Summary of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "shortName": "INCOME TAXES - Summary of Reconciliation of Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
     "longName": "9954512 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "unitRef": "claim",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "unitRef": "claim",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails",
     "longName": "9954513 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Finance Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails",
     "longName": "9954514 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Finance Leases (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Finance Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdtx:AssetsAndLiabilitiesFinanceLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdtx:AssetsAndLiabilitiesFinanceLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
     "longName": "9954515 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Summary of Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails",
     "longName": "9954516 - Disclosure - COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Operating Leases (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Summary of Supplemental Balance Sheet Information For Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdtx:AssetsAndLiabilitiesOperatingLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
     "longName": "9954517 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) (Details)",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
     "longName": "9954518 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) Additional Information (Details)",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Balance Sheets (unaudited) Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
     "longName": "9954519 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited) (Details)",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
     "longName": "9954520 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Cash Flows (unaudited) (Details)",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Cash Flows (unaudited) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-279",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
     "longName": "9954521 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited) (Details)",
     "shortName": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Corrected Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (unaudited) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-2",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R72": {
     "role": "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "longName": "9954522 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)",
     "shortName": "SUBSEQUENT EVENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-366",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails",
     "longName": "9954523 - Disclosure - SUBSEQUENT EVENTS - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "shortName": "SUBSEQUENT EVENTS - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-297",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-367",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cdtx-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "cdtx_A2023UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "A2023UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Underwritten Public Offering",
        "label": "2023 Underwritten Public Offering [Member]",
        "documentation": "2023 Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r656"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued indirect tax liabilities",
        "label": "Accrual for Taxes Other than Income Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r61",
      "r628"
     ]
    },
    "cdtx_AccruedIndirectTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "AccruedIndirectTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued indirect tax liabilities",
        "label": "Accrued Indirect Tax Liabilities",
        "documentation": "Accrued Indirect Tax Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r158",
      "r510"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r388",
      "r389",
      "r543",
      "r711",
      "r712",
      "r713",
      "r769",
      "r792"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Issuance costs for underwritten public offering",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r109"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r394"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive securities excluded in the calculation of diluted net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "terseLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r160",
      "r187",
      "r229",
      "r241",
      "r245",
      "r255",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r430",
      "r432",
      "r449",
      "r503",
      "r577",
      "r656",
      "r669",
      "r730",
      "r731",
      "r779"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_AssetsAndLiabilitiesFinanceLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "AssetsAndLiabilitiesFinanceLesseeTableTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Balance Sheet Information For Finance Leases",
        "label": "Assets And Liabilities, Finance Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Finance Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_AssetsAndLiabilitiesOperatingLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "AssetsAndLiabilitiesOperatingLesseeTableTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Balance Sheet Information For Operating Leases",
        "label": "Assets And Liabilities, Operating Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Operating Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r166",
      "r187",
      "r255",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r430",
      "r432",
      "r449",
      "r656",
      "r730",
      "r731",
      "r779"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets at fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://cidara.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://cidara.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://cidara.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675"
     ]
    },
    "cdtx_AuthorizedSharesForFutureStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "AuthorizedSharesForFutureStockAwardsMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Authorized for future stock awards",
        "label": "Authorized Shares For Future Stock Awards [Member]",
        "documentation": "Authorized Shares For Future Stock Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "THE COMPANY AND BASIS OF PRESENTATION",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r97",
      "r99"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property and equipment, included in accounts payable and accrued liabilities",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of costs to obtain a contract with a customer",
        "verboseLabel": "Capitalized contract cost, expense",
        "label": "Capitalized Contract Cost, Amortization",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Contract Cost [Axis]",
        "label": "Capitalized Contract Cost [Axis]",
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized Contract Cost [Domain]",
        "label": "Capitalized Contract Cost [Domain]",
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_CapitalizedContractCostGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostGross",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost, gross",
        "label": "Capitalized Contract Cost, Gross",
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized contract cost, net",
        "label": "Capitalized Contract Cost, Net",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r156",
      "r626"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and money market accounts",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r94",
      "r183"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "terseLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r94"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r161",
      "r162",
      "r163",
      "r187",
      "r213",
      "r214",
      "r218",
      "r222",
      "r227",
      "r228",
      "r255",
      "r274",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r311",
      "r312",
      "r315",
      "r318",
      "r326",
      "r449",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r565",
      "r586",
      "r604",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r681",
      "r707",
      "r716"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r227",
      "r311",
      "r312",
      "r313",
      "r315",
      "r318",
      "r324",
      "r326",
      "r537",
      "r538",
      "r539",
      "r540",
      "r644",
      "r681",
      "r707"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants weighted average exercise price (USD per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "cdtx_ClassOfWarrantOrRightExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ClassOfWarrantOrRightExpired",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants expired (in shares)",
        "label": "Class Of Warrant Or Right, Expired",
        "documentation": "Class Of Warrant Or Right, Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding warrants to purchase common stock (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_ClinicalDrugSupplyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ClinicalDrugSupplyMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Drug Supply",
        "label": "Clinical Drug Supply [Member]",
        "documentation": "Clinical Drug Supply"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_ClinicalSupplyServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ClinicalSupplyServicesMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Supply Services",
        "label": "Clinical Supply Services [Member]",
        "documentation": "Clinical Supply Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborationAgreementNumberOfPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "CollaborationAgreementNumberOfPerformanceObligations",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of performance obligations",
        "label": "Collaboration Agreement, Number of Performance Obligations",
        "documentation": "Collaboration Agreement, Number of Performance Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementCostSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "CollaborativeArrangementCostSharingPercentage",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, cost sharing percentage (as a percent)",
        "label": "Collaborative Arrangement, Cost Sharing Percentage",
        "documentation": "Collaborative Arrangement, Cost Sharing Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT AGREEMENTS AND CONTRACTS",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134",
      "r147"
     ]
    },
    "cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "CollaborativeArrangementMaximumThirdPartyShareOfCost",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, maximum cost share",
        "label": "Collaborative Arrangement, Maximum Third Party Share Of Cost",
        "documentation": "Collaborative Arrangement, Maximum Third Party Share Of Cost"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, termination provisions, required period of written notice (in days)",
        "label": "Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice",
        "documentation": "Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_CollaborativeArrangementTransactionPotentialValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "CollaborativeArrangementTransactionPotentialValue",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative agreement, potential transaction value",
        "label": "Collaborative Arrangement, Transaction, Potential Value",
        "documentation": "Collaborative Arrangement, Transaction, Potential Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r70",
      "r504",
      "r564"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r268",
      "r269",
      "r621",
      "r725"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "cdtx_CommonStockDividendsInArrearsOrDefault": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "CommonStockDividendsInArrearsOrDefault",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends in arrears or default",
        "label": "Common Stock Dividends In Arrears Or Default",
        "documentation": "Common stock dividends in arrears or default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r661",
      "r663",
      "r664",
      "r665",
      "r666",
      "r711",
      "r712",
      "r769",
      "r791",
      "r792"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r565"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "periodEndLabel": "Balance, ending (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r80",
      "r565",
      "r583",
      "r792",
      "r793"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized at December\u00a031, 2023 and 2022; 90,601,999 shares issued and outstanding at December\u00a031, 2023; 72,470,440 shares issued and outstanding at December\u00a031, 2022",
        "verboseLabel": "Common stock",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r506",
      "r656"
     ]
    },
    "cdtx_CommonStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "CommonStockWarrantMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Warrant",
        "label": "Common Stock Warrant [Member]",
        "documentation": "Common Stock Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "terseLabel": "Net loss and comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r168",
      "r170",
      "r176",
      "r499",
      "r514"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer hardware and software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r136"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r632"
     ]
    },
    "cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Controlled Equity Sales Agreement, Cantor Fitzgerald and Company",
        "label": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]",
        "documentation": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Of Stock By Unique Description [Axis]",
        "label": "Stock Conversion Description [Axis]",
        "documentation": "Information by description of stock conversions."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockNameDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion Of Stock Name [Domain]",
        "label": "Conversion of Stock, Name [Domain]",
        "documentation": "The unique name of a noncash or part noncash stock conversion."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum ownership following conversion (as a percent)",
        "label": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion",
        "documentation": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series X Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r315",
      "r663",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for each preferred stock (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r53",
      "r79",
      "r107",
      "r321"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Product Revenue",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r287",
      "r313",
      "r475",
      "r629",
      "r631"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r710",
      "r767"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r418",
      "r424",
      "r710"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax provision:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r710",
      "r767"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r185",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r299",
      "r306",
      "r307",
      "r309"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r75",
      "r76",
      "r119",
      "r121",
      "r193",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r457",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r708"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime interest rate (as a percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowed from the lender",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69",
      "r284",
      "r457",
      "r640",
      "r641"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable annual rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r285"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r457",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r708"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r193",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r457",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r708"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r53",
      "r56",
      "r67",
      "r68",
      "r69",
      "r71",
      "r106",
      "r108",
      "r193",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r290",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r308",
      "r457",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r708"
     ]
    },
    "cdtx_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction, Net",
        "documentation": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r766",
      "r767"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r117",
      "r144",
      "r423",
      "r424",
      "r710"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax provision:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r120",
      "r412"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r766",
      "r767"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r765"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r765"
     ]
    },
    "cdtx_DeferredTaxAssetsLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "DeferredTaxAssetsLeasingArrangements",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets, Leasing Arrangements",
        "documentation": "Deferred Tax Assets, Leasing Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r765"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credit carryforwards, no subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r765"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r765"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r765"
     ]
    },
    "cdtx_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued indirect tax liabilities",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals,Taxes Other than Income Taxes",
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals,Taxes Other than Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capitalized inventory costs",
        "label": "Deferred Tax Liabilities, Deferred Expense, Other Capitalized Costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from capitalized costs classified as other."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r765"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r765"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofSignificantComponentsofNetDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/PROPERTYANDEQUIPMENTAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization of property and equipment",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r46"
     ]
    },
    "cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "DevelopmentRegulatoryAndCommercialMilestonesMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development, Regulatory, and Commercial Milestones",
        "label": "Development, Regulatory, And Commercial Milestones [Member]",
        "documentation": "Development, Regulatory, And Commercial Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY INCENTIVE PLANS",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r352",
      "r383",
      "r384",
      "r386",
      "r651"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r677"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Restatement Recovery Analysis",
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675",
      "r677"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per common share (USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r199",
      "r200",
      "r202",
      "r203",
      "r205",
      "r210",
      "r213",
      "r218",
      "r221",
      "r222",
      "r224",
      "r443",
      "r444",
      "r500",
      "r515",
      "r634"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per common share (USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r199",
      "r200",
      "r202",
      "r203",
      "r205",
      "r213",
      "r218",
      "r221",
      "r222",
      "r224",
      "r443",
      "r444",
      "r500",
      "r515",
      "r634"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "cdtx_EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "162m deferred tax asset limitation",
        "label": "Effective Income Tax Rate Reconciliation, 162M Deferred Tax Asset Limitation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, 162M Deferred Tax Asset Limitation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "382 NOL and tax credit limitation",
        "label": "Effective Income Tax Rate Reconciliation, 382 NOL and Tax Asset Limitation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, 382 NOL and Tax Asset Limitation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate (as a percent)",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r403",
      "r425"
     ]
    },
    "cdtx_EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired stock awards",
        "label": "Effective Income Tax Rate Reconciliation, Expired Stock Awards, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Expired Stock Awards, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period to recognize unrecognized compensation cost (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r385"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated unrecognized share-based compensation expense (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation expense, options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards available under the ESPP",
        "verboseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r149",
      "r172",
      "r173",
      "r174",
      "r194",
      "r195",
      "r196",
      "r198",
      "r206",
      "r208",
      "r226",
      "r256",
      "r259",
      "r328",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r471",
      "r524",
      "r525",
      "r526",
      "r543",
      "r604"
     ]
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r224"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r447",
      "r479",
      "r480",
      "r481",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEVEL 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r340",
      "r345",
      "r447",
      "r479",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEVEL 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r340",
      "r345",
      "r447",
      "r480",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEVEL 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r447",
      "r481",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r479",
      "r480",
      "r481",
      "r640",
      "r641",
      "r647",
      "r648",
      "r649"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease payments",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r466"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails",
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of finance lease payments",
        "totalLabel": "Long-term finance lease liability",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r469"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityAbstract",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease Obligations",
        "label": "Finance Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails",
      "http://cidara.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of finance lease liability",
        "verboseLabel": "Current portion of finance lease liability",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Finance Lease",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails",
      "http://cidara.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease liability",
        "verboseLabel": "Long-term finance lease liability",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted finance lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromFinanceLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails",
      "http://cidara.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use asset, net",
        "totalLabel": "Net finance lease right-of-use asset",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated amortization",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r691"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of finance lease right-of-use asset",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r465",
      "r655"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails": {
       "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForFinanceLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use asset",
        "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization",
        "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, weighted average remaining lease term (in years)",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r655"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r673",
      "r674",
      "r675"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense",
        "terseLabel": "Loss before income tax expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r89",
      "r123",
      "r229",
      "r240",
      "r244",
      "r246",
      "r501",
      "r512",
      "r636"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r267",
      "r589"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r589"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64",
      "r115",
      "r116"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r397",
      "r404",
      "r409",
      "r416",
      "r421",
      "r426",
      "r427",
      "r428",
      "r542"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/INCOMETAXESSummaryofComponentsofBenefitForIncomeTaxesDetails",
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r145",
      "r207",
      "r208",
      "r232",
      "r402",
      "r422",
      "r516"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r400",
      "r401",
      "r409",
      "r410",
      "r415",
      "r417",
      "r536"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate change",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r403"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal income taxes at 21% for 2023 and 2022",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationBetweenIncomeTaxesComputedatFederalStatutoryRateandProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cdtx_IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued indirect tax liabilities",
        "label": "Increase (Decrease) In Accrual for Taxes Other than Income Taxes",
        "documentation": "Increase (Decrease) In Accrual for Taxes Other than Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r705"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r705"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses, other current assets, and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "verboseLabel": "Interest income (expense), net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r182"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/INVENTORY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r627",
      "r656"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r155",
      "r164",
      "r260",
      "r261",
      "r263",
      "r485",
      "r633"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/INVENTORYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write-down",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "cdtx_JanssenCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "JanssenCollaborationAgreementMember",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Collaboration Agreement",
        "label": "Janssen Collaboration Agreement [Member]",
        "documentation": "Janssen Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_JanssenPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "JanssenPharmaceuticalsIncMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen Pharmaceuticals, Inc.",
        "label": "Janssen Pharmaceuticals, Inc. [Member]",
        "documentation": "Janssen Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, finance lease, discount rate (as a percent)",
        "label": "Lessee, Finance Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "cdtx_LesseeFinanceLeaseMonthlyRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LesseeFinanceLeaseMonthlyRate",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, finance lease, monthly rate",
        "label": "Lessee, Finance Lease, Monthly Rate",
        "documentation": "Lessee, Finance Lease, Monthly Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LesseeFinanceLeaseOptionPurchaseEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LesseeFinanceLeaseOptionPurchaseEquipment",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, finance lease, option, purchase equipment",
        "label": "Lessee, Finance Lease, Option, Purchase Equipment",
        "documentation": "Lessee, Finance Lease, Option, Purchase Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, finance lease, term of contract (in years)",
        "label": "Lessee, Finance Lease, Term of Contract",
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease and Operating Lease",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r464"
     ]
    },
    "cdtx_LesseeOperatingLeaseAnnualRateIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LesseeOperatingLeaseAnnualRateIncrease",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage increase in base rent annual (as a percent)",
        "label": "Lessee, Operating Lease, Annual Rate Increase",
        "documentation": "Lessee, Operating Lease, Annual Rate Increase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, discount rate (as a percent)",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "cdtx_LesseeOperatingLeaseMonthlyRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LesseeOperatingLeaseMonthlyRate",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, monthly rate",
        "label": "Lessee, Operating Lease, Monthly Rate",
        "documentation": "Lessee, Operating Lease, Monthly Rate"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LesseeOperatingLeaseOptionRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LesseeOperatingLeaseOptionRenewalTerm",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, option renewal term (in years)",
        "label": "Lessee, Operating Lease, Option Renewal Term",
        "documentation": "Lessee, Operating Lease, Option Renewal Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term (in months)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost": {
     "xbrltype": "durationItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost, variable lease and short-term lease term (in days)",
        "label": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost",
        "documentation": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r187",
      "r255",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r431",
      "r432",
      "r433",
      "r449",
      "r563",
      "r635",
      "r669",
      "r730",
      "r779",
      "r780"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "terseLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r122",
      "r508",
      "r656",
      "r709",
      "r720",
      "r771"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r154",
      "r187",
      "r255",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r431",
      "r432",
      "r433",
      "r449",
      "r656",
      "r730",
      "r779",
      "r780"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LicenseOfIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LicenseOfIntellectualPropertyMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License Of Intellectual Property",
        "label": "License Of Intellectual Property [Member]",
        "documentation": "License Of Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LicenseOfIntellectualPropertyUponMilestonesAchievedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LicenseOfIntellectualPropertyUponMilestonesAchievedMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License of Intellectual Property - upon milestones achieved",
        "label": "License Of Intellectual Property Upon Milestones Achieved [Member]",
        "documentation": "License Of Intellectual Property Upon Milestones Achieved"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_LicenseOfIntellectualPropertyUponTransferOfLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "LicenseOfIntellectualPropertyUponTransferOfLicenseMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License of Intellectual Property - upon transfer of license",
        "label": "License Of Intellectual Property Upon Transfer of License [Member]",
        "documentation": "License Of Intellectual Property Upon Transfer of License"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of term loan",
        "label": "Loans Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r48"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of claims and actions pending",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r727"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r347",
      "r483",
      "r523",
      "r555",
      "r556",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r623",
      "r638",
      "r644",
      "r650",
      "r658",
      "r732",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "cdtx_MelintaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "MelintaTherapeuticsIncMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Melinta Therapeutics Inc",
        "label": "Melinta Therapeutics Inc [Member]",
        "documentation": "Melinta Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_MilestoneAchievementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "MilestoneAchievementMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "documentation": "Milestone Achievement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r347",
      "r483",
      "r523",
      "r555",
      "r556",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r623",
      "r638",
      "r644",
      "r650",
      "r658",
      "r732",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "MoreThanTenPercentVotingRightsClassesOfStockMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than 10% of voting power",
        "label": "More Than Ten Percent Voting Rights Classes Of Stock [Member]",
        "documentation": "More than ten percent voting rights classes of stock."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_MundipharmaMedicalCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "MundipharmaMedicalCompanyMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mundipharma Medical Company",
        "label": "Mundipharma Medical Company [Member]",
        "documentation": "Mundipharma Medical Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "terseLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "terseLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "terseLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss and comprehensive loss",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r96",
      "r124",
      "r152",
      "r167",
      "r169",
      "r174",
      "r187",
      "r197",
      "r199",
      "r200",
      "r202",
      "r203",
      "r207",
      "r208",
      "r215",
      "r229",
      "r240",
      "r244",
      "r246",
      "r255",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r444",
      "r449",
      "r513",
      "r585",
      "r602",
      "r603",
      "r636",
      "r667",
      "r730"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) attributable to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r199",
      "r200",
      "r202",
      "r203",
      "r210",
      "r211",
      "r217",
      "r222",
      "r229",
      "r240",
      "r244",
      "r246",
      "r636"
     ]
    },
    "cdtx_NetOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "NetOperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Net Operating Loss Carryforwards",
        "documentation": "Net operating loss carryforwards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued and Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing activity:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_NumberOfOperatingLeaseOptionsForExtension": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "NumberOfOperatingLeaseOptionsForExtension",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to extend",
        "label": "Number Of Operating Lease Options For Extension",
        "documentation": "Number of operating lease options for extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "cdtx_NumberOfVotesEntitlementForEachShareHeld": {
     "xbrltype": "integerItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "NumberOfVotesEntitlementForEachShareHeld",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes for each share held",
        "label": "Number Of Votes Entitlement For Each Share Held",
        "documentation": "Number of votes entitlement for each share held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "netLabel": "Operating expenses",
        "terseLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r240",
      "r244",
      "r246",
      "r636"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease payments",
        "totalLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Obligations",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails",
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "verboseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails",
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r466"
     ]
    },
    "cdtx_OperatingLeaseRightOfUseAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "OperatingLeaseRightOfUseAmortization",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Right-Of-Use, Amortization",
        "documentation": "Operating Lease, Right-Of-Use, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSummaryofSupplementalBalanceSheetInformationForOperatingLeasesDetails",
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r655"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash financing activities:",
        "label": "Other Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income, net",
        "terseLabel": "Total other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Paid-in-Kind Interest",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "cdtx_PatentCostsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "PatentCostsPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Costs",
        "label": "Patent Costs, Policy [Policy Text Block]",
        "documentation": "Patent Costs, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Issuance costs for underwritten public offering",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "cdtx_PaymentsRelatedToCollaborativeAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "PaymentsRelatedToCollaborativeAgreements",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments related to collaborative agreement",
        "label": "Payments Related To Collaborative Agreements",
        "documentation": "Payments Related To Collaborative Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760"
     ]
    },
    "cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preclinical and Clinical Trial Accruals",
        "label": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]",
        "documentation": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666",
      "r791",
      "r792"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r311"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r565"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r311"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "periodEndLabel": "Balance, ending (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r565",
      "r583",
      "r792",
      "r793"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r505",
      "r656"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prime Rate",
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProFormaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProFormaMember",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pro Forma",
        "label": "Pro Forma [Member]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r682",
      "r683"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from underwritten public offering, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "cdtx_ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs",
        "label": "Proceeds from Issuance of Common Stock In Underwritten Public Offering",
        "documentation": "Proceeds from Issuance of Common Stock In Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets",
        "label": "Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses, Other Current Assets And Other Assets",
        "documentation": "Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses, Other Current Assets And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r486",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r625",
      "r645",
      "r657",
      "r693",
      "r728",
      "r729",
      "r733",
      "r790"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r486",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r625",
      "r645",
      "r657",
      "r693",
      "r728",
      "r729",
      "r733",
      "r790"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment By Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r137",
      "r142",
      "r143"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r157",
      "r511"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r502",
      "r511",
      "r656"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r137",
      "r142",
      "r509"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://cidara.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]",
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "QuarterlyFinancialInformationTextBlock",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITED"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)",
        "label": "Quarterly Financial Information [Text Block]",
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r225"
     ]
    },
    "cdtx_RDFundingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RDFundingMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D Funding",
        "label": "R&amp;D Funding [Member]",
        "documentation": "R&amp;D Funding"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r339",
      "r347",
      "r378",
      "r379",
      "r380",
      "r482",
      "r483",
      "r523",
      "r555",
      "r556",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r623",
      "r638",
      "r644",
      "r650",
      "r658",
      "r661",
      "r724",
      "r732",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r273",
      "r339",
      "r347",
      "r378",
      "r379",
      "r380",
      "r482",
      "r483",
      "r523",
      "r555",
      "r556",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r622",
      "r623",
      "r638",
      "r644",
      "r650",
      "r658",
      "r661",
      "r724",
      "r732",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r472",
      "r473",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r582",
      "r584",
      "r609"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r472",
      "r473",
      "r474",
      "r475",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r582",
      "r584",
      "r609"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r778"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r472",
      "r473",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r582",
      "r584",
      "r609",
      "r778"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal repayments of Term Loan",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r540"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r287",
      "r313",
      "r475",
      "r630",
      "r631"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r396",
      "r787"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "cdtx_ResearchAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ResearchAndDevelopmentServicesMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Services",
        "label": "Research And Development Services [Member]",
        "documentation": "Research And Development Services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment",
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r205",
      "r206",
      "r224",
      "r442",
      "r443",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r696",
      "r697"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r224",
      "r257",
      "r258",
      "r420",
      "r441",
      "r442",
      "r443",
      "r444",
      "r458",
      "r470",
      "r471",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r224",
      "r257",
      "r258",
      "r420",
      "r441",
      "r442",
      "r443",
      "r444",
      "r458",
      "r470",
      "r471",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r706",
      "r788",
      "r789"
     ]
    },
    "cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units and Performance-based Restricted Stock Units",
        "label": "Restricted Stock Units And Performance-Based Restricted Stock Units [Member]",
        "documentation": "Restricted Stock Units and Performance-based Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r109",
      "r507",
      "r528",
      "r533",
      "r541",
      "r566",
      "r656"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r194",
      "r195",
      "r196",
      "r198",
      "r206",
      "r208",
      "r256",
      "r259",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r434",
      "r436",
      "r437",
      "r439",
      "r442",
      "r524",
      "r526",
      "r543",
      "r792"
     ]
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration revenue",
        "terseLabel": "Collaboration revenue",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r768"
     ]
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Opening balance",
        "periodEndLabel": "Closing balance",
        "totalLabel": "Total deferred revenue",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "parentTag": "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contract liabilities",
        "verboseLabel": "Current portion of contract liabilities",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "parentTag": "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term contract liabilities",
        "verboseLabel": "Long-term portion of contract liabilities",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments received in advance",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Revenue from performance obligations satisfied during reporting period",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative arrangement, excluding revenue from contract with customer, noncurrent liability",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments receivable",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable",
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative arrangement, excluding revenue from contract with customer, uncredited portion",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer, Uncredited Portion",
        "documentation": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer, Uncredited Portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r239",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r337",
      "r338",
      "r486"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r624"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, amount",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period (in years)",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues",
        "terseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r187",
      "r230",
      "r231",
      "r239",
      "r242",
      "r243",
      "r247",
      "r248",
      "r249",
      "r255",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r449",
      "r501",
      "r730"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Adjustment",
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use asset obtained in exchange for lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r655"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for lease liability",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r655"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration received per transaction",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_SaleOfStockConsiderationRemainingOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "SaleOfStockConsiderationRemainingOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, consideration remaining on transaction",
        "label": "Sale of Stock, Consideration Remaining on Transaction",
        "documentation": "Sale of Stock, Consideration Remaining on Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares sold (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price (USD per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "As Previously Reported",
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r150",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r208",
      "r224",
      "r420",
      "r441",
      "r442",
      "r443",
      "r458",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r690",
      "r694",
      "r695",
      "r696",
      "r714",
      "r721",
      "r722",
      "r770",
      "r776",
      "r777"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r348",
      "r682",
      "r715"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Net Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation Between Federal Statutory and Provision For Income Taxes",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofCashFlowsDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r205",
      "r206",
      "r207",
      "r208",
      "r224"
     ]
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustments",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Instruments Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r447"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://cidara.com/role/INVENTORYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r86",
      "r87",
      "r88"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
      "http://cidara.com/role/PROPERTYANDEQUIPMENTSummaryofPropertyandEquipmentDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Selected Quarterly Financial Data (Unaudited)",
        "label": "Quarterly Financial Information [Table Text Block]",
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Black-Scholes Option Pricing Model Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Units and Performance-based Restricted Stock Units Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r106",
      "r108",
      "r109",
      "r161",
      "r162",
      "r163",
      "r227",
      "r311",
      "r312",
      "r313",
      "r315",
      "r318",
      "r324",
      "r326",
      "r537",
      "r538",
      "r539",
      "r540",
      "r644",
      "r681",
      "r707"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r49",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r56",
      "r79",
      "r80",
      "r106",
      "r108",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation Amount of Gross Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r763"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r248",
      "r637"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "cdtx_SeriesXConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "SeriesXConvertiblePreferredStockMember",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series X Convertible Preferred Stock",
        "label": "Series X Convertible Preferred Stock [Member]",
        "documentation": "Series X Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Automatic annual increase in shares authorized for issuance in equity incentive plan (as a percent)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Number Of Shares Authorized For Issuance Percentage",
        "documentation": "Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs and PRSUs granted (USD per share)",
        "verboseLabel": "Granted (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs and PRSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of period (USD per share)",
        "periodEndLabel": "Outstanding, end of period (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of RSUs and PRSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee payroll deduction under the stock plan (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares outstanding (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options canceled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of employee stock options granted (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (USD per share)",
        "periodEndLabel": "Outstanding, ending balance (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Voting power threshold (as a percent)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercised (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options canceled (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted (USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r356",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r390",
      "r391",
      "r392",
      "r393"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term for stock options to be granted (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price of stock option as percentage of estimated fair value of shares on date of grant (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r184"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r161",
      "r162",
      "r163",
      "r187",
      "r213",
      "r214",
      "r218",
      "r222",
      "r227",
      "r228",
      "r255",
      "r274",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r311",
      "r312",
      "r315",
      "r318",
      "r326",
      "r449",
      "r537",
      "r538",
      "r539",
      "r540",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r565",
      "r586",
      "r604",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r681",
      "r707",
      "r716"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r26",
      "r149",
      "r172",
      "r173",
      "r174",
      "r194",
      "r195",
      "r196",
      "r198",
      "r206",
      "r208",
      "r226",
      "r256",
      "r259",
      "r328",
      "r387",
      "r388",
      "r389",
      "r419",
      "r420",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r442",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r471",
      "r524",
      "r525",
      "r526",
      "r543",
      "r604"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r226",
      "r486",
      "r535",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r565",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r662"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r348",
      "r682",
      "r683",
      "r715"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r226",
      "r486",
      "r535",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r565",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r588",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r662"
     ]
    },
    "us-gaap_StockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockCompensationPlanMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock options, RSUs and PRSUs issued and outstanding",
        "verboseLabel": "Common stock options, RSUs and PRSUs issued and outstanding",
        "label": "Share-Based Payment Arrangement [Member]",
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of series X convertible preferred stock in exchange for common stock (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r25",
      "r53",
      "r109",
      "r300"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r109",
      "r537",
      "r604",
      "r616"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for restricted share units vested (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for exercise of stock options (in shares)",
        "negatedLabel": "Options exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r109",
      "r362"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan",
        "verboseLabel": "Purchase of shares pursuant to Employee Stock Purchase Plan",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r109"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r79",
      "r80",
      "r109",
      "r543",
      "r604",
      "r616",
      "r668"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r26",
      "r109"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://cidara.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedBalanceSheetDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance, beginning",
        "periodEndLabel": "Balance, ending",
        "terseLabel": "Total stockholders\u2019 deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r83",
      "r84",
      "r100",
      "r567",
      "r583",
      "r605",
      "r606",
      "r656",
      "r669",
      "r709",
      "r720",
      "r771",
      "r792"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedBalanceSheets",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedBalanceSheetsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r186",
      "r310",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r328",
      "r440",
      "r607",
      "r608",
      "r620"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r456",
      "r477"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r478"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofCashFlowsunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flows:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards, research and development",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "cdtx_TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indirect Taxes",
        "label": "Taxes Other than Income Taxes, Policy [Policy Text Block]",
        "documentation": "Taxes Other than Income Taxes, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_TermLoanAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "TermLoanAMember",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term A Loan",
        "label": "Term Loan A [Member]",
        "documentation": "Term Loan A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Term Loan [Member]",
        "documentation": "Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r733"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r733"
     ]
    },
    "cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Aggregate Intrinsic Value (in thousands)",
        "label": "Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]",
        "documentation": "Total Aggregate Intrinsic Value Of Stock Options Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r252",
      "r253",
      "r254"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred at Point in Time",
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred over Time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "cdtx_TwoThousandFifteenEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 ESPP",
        "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]",
        "documentation": "Two thousand fifteen employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "cdtx_TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofBlackScholesOptionPricingModelAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 EIP and 2020 IIP",
        "label": "Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan [Member]",
        "documentation": "Two Thousand Twenty Inducement Incentive Plan And Two Thousand Fifteen Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "cdtx_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofConvertiblePreferredStockandStockholdersEquityDeficitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allocation of earnings to participating securities",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r219",
      "r220"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allocation of earnings to participating securities",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r219",
      "r220",
      "r680"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails",
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Balance as of the beginning of the year",
        "periodEndLabel": "Balance as of the end of the year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r405"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decreases related to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESSummaryofReconciliationofBeginningandEndingAmountofGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases related to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact on effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "cdtx_UpfrontPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://cidara.com/20231231",
     "localname": "UpfrontPaymentMember",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront Payment",
        "label": "Upfront Payment [Member]",
        "documentation": "Upfront Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r133",
      "r135",
      "r138",
      "r139"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/INCOMETAXESAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in deferred tax assets, valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://cidara.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSummaryofOutstandingPotentiallyDilutiveSecuritiesExcludedfromCalculationofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r660",
      "r663",
      "r664",
      "r665",
      "r666"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, aggregate intrinsic value, outstanding",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r622",
      "r623",
      "r781",
      "r783",
      "r786"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute diluted net loss per common share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r222"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "presentation": [
      "http://cidara.com/role/SUBSEQUENTEVENTSScheduleofEarningsPerShareBasicandDilutedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute basic net loss per common share (in shares)",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://cidara.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://cidara.com/role/SELECTEDQUARTERLYFINANCIALDATAUNAUDITEDCorrectedCondensedConsolidatedStatementofOperationsandComprehensiveIncomeLossunauditedDetails",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONCorrectedConsolidatedStatementofOperationsandComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used to compute basic net loss per common share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r222"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "270",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//270/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-65"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001610618-24-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001610618-24-000041-xbrl.zip
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MBH HU(<3SH+(Y\=2NQU]NSY1/U=?J;_Q]\NAU-(+2NUJO0TD\$PH!2B1@@5
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M;,1&GC:B=H'CDC1U(\TF;I'9-%('E^9$FEWM(N0E:>I&FJW-I6:>GG57NP1
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M\U$O9]SO9IIVJZ5OY$%GNMB-2[$C&FGK&QS1*4^Y*^R4 13=,50&4(J$K3*
M4@@TE0&4P@50FCD67K;+ ,H.@%X&4':,@#* LBO(ZQM T4#>S%L$.UBXT6KK
M&\K03#CI@*V.OD$%7229%F@J>G3A;9K9N97G=(H>NWA!,SL_H!<]!+$C,SL_
M!!0]N/#29G9^D-?7K=<Y'_6BQOTNIK]W](T\Z$P7.W,I=D(C^@9'-,M3[@0[
M90!%=PR5 90"8:M;!E *@:8R@%+$ $INA9?=,H"R Z"7 90=(Z ,H.P*\MH%
M4&A[D8*Z6F.4;,^Y]+TSSY^P+4.XT<P-PMJ%(G2 <(L@G$^NO:N=([\S",_W
M*FX^4S6#CN>9L-IY[GJ@XU&5CSFB0U\W/1H$_*\(E>LM_-?-;,JS6G7N@BWC
MIXTI\T9S$_S,7;HI?C[8]T<^#[S(-WD@_AQS9M'A+?OV^$?X+T*;/:C7#SN-
M>GU_.&BUF]8!:Q]: ]:H-SO=P4'[H/-_T4U,?A.$,P?0-['=ZIC;HW%XU&[6
M]CO3\..=;87C([C3?^]E+V7^"*X.O>E1=QK"=\&4N<<_#OP/<%_Q;W'[Q8<D
MOVS# _#-JLRQ1^X1,%;(?7DO=;GI.9Y_](\Z_=_'(8"B.F03VYD=_:OGV\SY
M5R5@;E - &1#\75@_\V/&G J\>>=>*%]^+4#)I9ZP4837^G;U_.;TQ/C^J9W
M<WJ=/7CJR+L]X_5I_]O5^<WYZ;71^WIBG/ZG_TOOZ\^G1O_BRY?SZ^OSBZ\K
M#Y[%TK9@?5CK;/0BO[-@#,9MZ+D5XZ36KQG->J=]N,GA.RL.'S+PU-7U \\'
M5JC"2SAL&O C]8^/EAU,'38#(X'.1#_Z*.\^\,+0F] #R/,WF2,?0L\37TLN
M:!_6]NO[R @A<%QHJ0=+'JG!.WY8_/SPH'987_Y5O=:@SS_0_7SUI01:B_@*
M?@,O@B#Z::^U-_>N")O&-#0"S[$M0R%NRL"=<T='=0.^B^__@=[[!:G[8".B
M.+NX^F+\")+,]=ROT01N8AI2X%WQ(6J@QI[A,M0N%K>/3CPSFDAAOT>R;@@7
M'#?JU=]('B9W.39*RMH19>5"/YN1S[LOS/_^SW\TNO6/%RY_OR'*7QS!AT]"
M<*?6/CQ8B]^-2:59:]6;FY#**KI0J&].[Q'Y::9Q^' 1!-XT)S%2?X@.A&WR
M: G2<]V(.6*K\9XQ1 ,^!,OI/CP:VO?<JH9^%$N8YM[Q/_]QN-_N?IP7,C'!
MA99ND-M +1/H>E^_?NM]-JY.+R^N;HS+;U?7WWI?;XR;"P,LCQLP+P1[-5K&
MQ971Z+RSWAL79\;-+Z=&RC*)K9)>_P:^EC\Y;+4S -J)(MK4/ $?S@C'W!C:
M 6##F''F&V"9<^L)ZNF2+/A38==GJ<N"3ZH3N,48?U:UV*R*CZIR5U%;^S'D
MW(]\'QYX1H?^ VZTZ4.3Y[7VCD^X25Z0P!MZCEDRKQCHY#])P[9V;WA>7)5Z
MH8AZX7>X,=X\>*:$>X)YZ</S*"6R6D$,F1/$&J(C-43[-6J(FZO>U^MS5 7;
MTA(&N %T<>I1EZ=7YQ<GQMG5Q1=QX:[^&U]R5\\NCOK$Q*T=8(3..+-!A +]
MQPIE<P8\I6@;WD#\7O%7%X.(#8Q&8MAL!8>5?MZKBB TFQL1WF.)ZXJ/[" $
M 1]^A6\4@>T#!9^?]*YZ*(:N>I>GWV[.^]<5X_QKO_84@M,@WO;N])Z9(;V_
MX0V-Y+T-%AC!E)L8?[<,VS7L,##,,?/AB)NZT"4WY1\U>5GP=1K-6E,:O<OA
M)TZ[\$6S*WZWW,Y\[!<'>=ZL5:L_^C>KOC@XH!1(3B?+\UZ-3HZOV6AU'L;
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MI^'CK+VN$3D\.@\BTYLR"(KUFY@.9&'(<<X'H@"P@;.4)LQE(\K[Q9T!+ A
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M*30C=A*,.QQ9!+2!-R);LE1T6\4R,A;>A3 R\KT[ '^"#7*7T$/%V9KDR*[
M1T(#:9+!(>?2WY*W*/&6(]ZH70SA;G&<^878$F V&/#J-,0>LCF)'"1NI1*A
M)4JV(S"5[1XP1ZH_@1QI/HHK;62=NS&GD23,\5R.$042@O *H/$P.^'Y)=_D
MA:24T9+RDF,;XYMKBX8"(=0 %]]JUS4AW89R7@-5S_EVJ81R%693[M- GI3,
M"L>V;U6GS \Q=#&=.K;J X'+(HQ\@5E1\D:^MH P\R@"A V!)*Z$Y6;SE/8
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M(0I-!1S!4L5KK @#+XXM8M/NP[6=6C+W'\G+ 2U;&_$/\9MG1@*,%/R]0U@
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M3D@:"<,=JX=$#\D2<1!''U-%3LEEZ1$;JJW8\MD=JC-5UJ;\0Q$7CT/5\=U
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M]$5B\_TCWK*.[R@9I*C B*-1GU0TZFW#0]!$/XYX9*#19&\-'#=8J_P8:38
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M4+L'I,40:8Y<B9)QHX<B:\F3_TTI(6P90.^VQ[=@-YR4H__.5W7E=\)[P'O
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M[MN823L\MU+N2)^%L+^NT7;J&H0>TG]6M<0*-^L*:1FG=+'4$ Y**MD.1*:
M([Y%V0 )S5;,P:$[UYPH%47;?(-YV!N]$09:\1X;B9J1T\K;>9:G%Q1O:_H-
M0#@SY]1-BD)N<-MXT:,$;%ZV<+297!%&0@ @D6O<I90)1V.!F!@I%J96\8JM
M)^2V)F%9%>L,A>7IKY6FRYFE.+**$BX[LPE):%H3A!#Z \EV$HA#:&GQHDSX
MR'V_R+4O YD-Y4'!W4E@LK1<>\63=%]>J(,Q,8G!>O([,.B%7X,&PY,HS,T-
M'0%<9>84FE.,I.]%F_'$Q^U6/Y?5=1F6PIY7%&V50RK%>WG.72FH$P@<0UY!
M@)I^Q@L[-XCL2NT-0%RO,]P!*81AB^[!F"_&HM/CY%-DN9U&EMNY$+;V#)RM
M/$+>\+XD6Y]]E.DE;2X4.-8M%8!G2=<) ;0+'*JFYI"\'-[7A$MJ%X, 2Y9"
MOLX)8\K'.PO[P.5C(+:=3KC*I!50%"@TPZ)NAH+NW IE_BT+X10P=O R4G7C
MTDVHYP$KLJV8I]$W//GSIBJ@?+E3G8G2&HBYV_ 70'O7 7HO\\OZ7TLK;"9Q
MFC;+2IU_*,5V"20!/7X\=\=0[Z9,]<P(%1W8+O(Z$'E]M8N\WDOD]5L&1J[3
M&$A&93-3 O0@819CPP",L7$SQDZ&8);U;R=KIO17\%[@2/R<K3WU_YV"L?]K
M^4R^(OUY:B.1,-D-.YWVT]U1*-T;Y@T)W3$747@/:3>]]S6]Q)R:,=H6Q>O3
MJJ&J A^G<W*]%G2WTRIH'.)#6E,PA^R6XIZ <9HFYZX7:+JPF]O[F=MC1?I[
M0)PMTZ)8KG( ;V?0\\2V4*%_O7US"+?T@D(?4>9-C PQ)N"Y_JUU5MN<FMNH
M8^Y<]3=207-:5X2R0=#B;R=O3I/16T)??*K3Z6?>]Q_K)36>>5.W%WNXI/MI
M_$@?&='NO*ETPW&&S?Z!=*LAAB'D.6@=LB_3HFT\1Y'OBN,CTG")W4_HK9ED
M.BU0Y?L>7;<I)QRFQ;-0GQW_XQ^'?_\X' \/T3LI-I<H,G^>ITW.,2%N]05_
M!D8:I0EKZJ=B8G3VSE_12N9;2='QSSQ9QZV3?RH+/:H61+='L8H-,F47^TU8
M[.&I'9I+CG1NNHUGN=I_TI6/2#BZ]9P*<T72"15$4N#/']MJ+C3]4=GQ9?)>
M!-/6&6ZU8! E&GE=66#F3>/RC9&40 NC6P+V5H,$AVDP5+.O)&I8!F$]]1>?
ME%>4 +M(Y<&G15HRD/GDE+OY2'K*!ZG/VP5:N[G!R6X>'5VF%'-T@N)N-64@
M]/GB] B[YDTVS183MT/#QCE^?^C7W<\2K:YNHEQEY^YK'O;/W<*>?SBRXMW)
MT?&'\^/1X8<WHZ./[]X=_O#Q[/#3R<</H\,?SXZ/WQ]_^'3^4 *V[ZDZBZN/
MW'XNBG122?CQ\*+.4+*XE3KI8SDZSY8KED<GC-1YC(O*2V9$8(B@D[<[O"%O
M*WLA^!M''..Z<)MK&OW0UC@ROG_AG/*<P,@1"@7(%5#TIE=92:<GU;!(J5DR
MD@UAG_LNGU(WO5DX7OO;9H@&[]_"/?P>B_>U24T[O]\BI:=,RQIBOX/40-RX
M>QG*CW.IB$(;4(VJ4':'%"O@0Z.4?CL;7135I%-RM%1M33_ZD;^W)?&LS1FI
MKR@#*INM2D[XGV7GGSZ>'3O[*P_GU,V2I96WYA:GQT>?ONH6H;12ZLC=MS^^
M.QV'$ZNL2C+JG[S^OD<'20,X>G\4S8,@B7-)8-XVA+WH6]CC\5HLLYKV',[J
MHMCPJ$3"8VB4N&'RH\NQ#I+K+#,B!*9SE*)SDY5V\53Z&UM)JD?DW5Z.?&:D
M+&4M8-S2K?^:+M-A_?$IJVO"*J\3XF@QW_CT9%,5&3SPAZ(:9%:^2:*?M<)I
M6S<MR@ON?*) -ZAA9*\G4AZQ "E96*V=/["6#3)QIB+WJ,$;FV,F@9_9:,0E
M/G!N%2.QP3;(B:&^)FW )+!DQM-$C#CZ/*WS":%AW%BNM]-'(3AIT52;YIS]
M*[-#_2+H;#=WG>[.^6Z/=,Y,M9-INTK+C,Y[Y:FIPY%_;K^/E#$GS1>^%)WN
MQHJ)BE48@MJ_WT=<(3<"KN..JZWN#A:Z"0L_68]:S(:>78MVU:*6;//QU5';
M**)?RI"85\N6K PNDGN<[ .S00)RSVR*0+A^!^%G8F-=LNT4WI^=)2?$H3#K
MR,63GCVU[^( 0@PCB\ RWN68OD4BLI36*JV=/VJ]>/H%"Q]_%RLNBJR,-;#!
MFL*-A(=89A<5X:OC#9?:%22 #^6BQF*PBJB,'IES^&;+8V@7<7PIV@Z/^:AF
M><1[H+6T;'=WOHYU5#))YI7]D;G2R7HH1R9Q*IWI=C[#]OYVI^<OF:@6X?53
MO<M2<T]GW)T%@M8Y-I^."(S@Y-&:3F6LF^R^H/;268WW\2<'(W/,+\8@4G&F
M 6VD;'I9,E<.W?>?SM9>%>MQP+F;"^XX&_<V$X/O+W4'D9J-%'I'IP8E_5#V
MQ]N\)'8?IWC<2R^^X=XX#&G[+]FT57_^JQS0CJS*&4WG^R4YI]F_^.Q^]/S)
M?SQ_\EB<TH8Y/^_BZ[AM,G#9$=TB,B=2:M](L,<AKV/#'62,;B3?/=U73/TB
M8.HS20&8,A["L3,J<D04'1DY?=\]?_%J[UGT:XMO%2),9 DH1LISYSYMEV.N
MS5FF:_YPP+29,W\1:P7=^E'Y9W#PDLYF';G1$!-%F36!6HK,U*S(+^"C@JMB
MFI%"G%7$J3*>N6]6XAGD66!.R;(2!?'NPUK*D5#<4&8K+FO80: &(%"O=Q"H
MK85 ?:76)EV=E]\X0GB<&YN8(D K&57?1MD4;"8'J2VGH(>A@B*$VTCZW!$K
M3 ?&"HTC7+_MB831=VHQ"32G'$B<1[_V]VWN?..<*Q^YS1&,ZYQY( %.HWSP
M5>X4AYYI^$11(+:\*XY>*J8_"D@FT8#H=:)B">JYF*<:]4.ULAXMFTZO.+:!
M%L90TK]MCCN3"28Z+C2B)\WG>9%C:CE"(*8CG:^>D;/BS*/\I82#=)?595[/
M6!P2/EVXZ*1<<Y4 2EJGZ'I<+555<ZNR#"<@\AL4&N6S.K%E=O2"[B3-9RB,
MJMUBNAF<9H%6*?'WE6>B,4XCMHI8T3"/F;*4&),*3 IYKR;W2H<GZB=667]$
M,EL4@G(20C,J<8E"#5RWRF:&,2K.SE(@QIU*5P 'PX&F.YEK'TSYQ%_=[9JL
M?&B9.(93/-VG--S!_G :[I978X'0BVY,L-G^WF!G]578'8[2I;-N** 6DF@F
M;=:KRS)D[L%T%&+O$A35+U]ZI_'4Q[;(2/6-JTII#7B'%[9/66VZ!ZFA1J:@
MY !:+QZ; "+<:6"8?5GF2KKJMG1:%SG%5<()BJU*F1MN607RIC1G%FHJRIDU
MIM[D)Z=YQN=39PR.SXCMLT+=\:JF)H\"/V.F_D/.=.V_?OD"R:%T0;U$9YBV
MG\[/]NC_#,T@#9S#0[Q^[YWFW3]@*?*GP&V",\FF[C&F>9A47C7TZ>S&KCG;
M9=]\\QPH'7YRL.I(LGA?YAZNDM&63Z(N;U$\V"U>ADKEP:\]=3R.28EQ2Y1Y
M+!YL8#U'PT7S:\]M2G*%@#=LIZE3 XQ*&>023T2@T]Z3]'6DN&5#4O9,K^)4
MK*<1JK#Q('ASPQN,B,DPJ;D>[>R*+]QAJ3NR.[+32X+:[8=)7-$ZA_)_#KCR
M50>=JQC[(U^A8P':/T"[T(1?YR#,QG/$[$2)N?0,@2!,^LGMD%#% R[3*]$9
M]"EM==(J0RS)K,8Z+Q)T3&=ZZ6(S"KK"W71TR66I\Z$UZ=Y\;_0#V9?R4AM?
M2+(<3'3*WGW(9:/"KUF19Q^U>56=3$&^9E,F9,/+[?GMI$.BG"RH^OS($HFQ
MY8L)NJ(<.<FITT3: 3#S'4AVN.S/%&$)?<"XFH^7U9009QSMN0;^JP6+E4F*
MQS-H!D\A^^FTJF>LJ;E:M2N?DW9VD7V[3/(M->)8>K9)*<8"OL&<" "4,U"L
M\[/_DRZ6W[]Q;].@OS)4RE];MR($=/.K157"!=K;Y(B>KL22 *M^XYT1OSP=
MA6<Z8W)(UE TBQ^5!YBM$M4O\V56@"B[8Y2XL[2ZSM#).+=8J'C([K=7;(>Y
MVQ\78HB[$9^R<S#Z4*VH7P;)%6MDT.<Z?1#):-HTK90<S5L$A*, V-#6"!:;
M5+,&T?+:?]*N>!YGC:>9FV?LOHGU#W%V>N1"\9A^3]UF%R#-)/DDN7'&#I[U
M&Z^K^C.(W:*[=(U1T=(\ ZJ44<[,^C4=U-!!X\@V9HX-4I"*N=F@.<S\$W?(
MW=YX.[?A6U]6)L/W,>'-XICHM8GZT?" QQQU":N9@+64I8-<^!4[_H1P(?I"
MQ5 X1Y;*@-"<0U:^:ZOTY37C0(^[85:(EQM.[3 $R- E]7Y>&;\>;K[;-/E%
MR0XV2_/>Z&3N5_'6JSFH;M]V17AA;KQ$?D'8"TH%<;N3!7)]:N/%.MV=% 0N
M8*_\KFUEML!6_I:@H-'/2W$Q?IO?9P 0?I-'R76?3_, H?%OA 8%5,C-*!\#
M]MAH$ Q%RS8!.X;>ZR:80 L A,>7ATB"&YA>QZDNQ!4XJD#D&:"VINT\=^H7
M1GCJA7UI8%M,5VQL7.G#8CV=CG/3\P;<R!%N& "RUQU +EER><V8OV9=3M?(
M75WESF,6JJ@;)@.^.SO$O1EY*/OS0U6.*;%,9^81,;VD(7KUC5Q:'@0BW]25
MB*@=0ER(#6*8NFY--NV!))06_9:M+V+.CMM\&.43^X.DZS=O2,'OBI$'](".
M8/"W<B$%>]RKL$O!P+,X1(T)(U[O#:'I1S9RU8E2RQD-U\B-M:KMT2D<NGU3
MJ_MS#8\_#EJ.B ]Q';F!=%Z&7NM81E.38^I08$#$.I'N01$%I$ F.=F>(=00
M=5OCAH8(8(,3$C06=;K,6FK1HMW>1)24"0GL1OX0MYI5X5+>0?":AC@,$2ZP
MZL6IKZ4VDM0>2F0Q4N]-TYA3@N6T>.4%"T6H5*2_YFT-2T9F$M6,TG/-($\0
M305G9+'>0U,VHD"9RA;VNZ=S @11H>58*[3+3Z]A"N$&/K[=&*46N,@"6M$"
ML%>@PS.+T KM2)4%NGDTS#9\3+U6W -W>2C*<PO@*?^NC:,7+--\%C3-J%U&
M> L /PY>[CWI #]N@,7<Q;H"8R,=QBNAB/<.& >,UU9-,MO,=\]?=> G(R#W
M-Y@"'%)!/(63'#:*M$EA\V&4W00!D<&\>/V\,R>CS9B3C9 3G>4FJM,(P)*;
ML"2D['C7AJY.^6RL-/D$46DTUT#[.OYFAT3I;ZF#)SLDRO^#2)2];Z"=K=OE
M'3JU-F+DPFT6*1W!W;C,/,T+0.LKM1BYA'=S]-##/FS:<1[_ZA19Q>1.H_(5
M;L2.X\Z.692YA''3A.KL#H8FL6@ 0ELPF3;(\NJR6XV@0^F#/NXR==Q*(P?X
M(FV$0FG'F71?]!L1G.B/\XP@5:^?H(6T[(K1=9VOG*%-]B=)O+NAIF1ZF"JR
M@.-P\*9,$#==XDBP,%8K907\ 2/U"7_2N:]&F#4^/1M*VP0@P=ULJ.]WXGL_
MXLO-A6*Y#0D$2<HR63_W*;^#^LP7TA7)>5N0TTV"^;W3?;N%O,^%]-JDNS8#
M^8NO4R$2G31GG-06WS&NU(5A4M2E1$5=6Z[J]7BR'LL_@0G@H#!]JM4A$W"M
M/!24W'O*B*Y\Z<OVX^,XE_P"(=R##2P5F]Y)N"GD:SY(6%YL(:5\G0X4MMX,
MIO,U/=)1FTO6$09SI\B2(^.V/XL6G<?C->5'N>6<ZES]Z:%5TGW3/%.O[GR3
MC"2WR<)ME>:/8BRB=R9"CM+'<#V, ;&#Q\E75?!M$!J?%F\;!D.@(R/;<12&
MY :-:9DOTM"YLB=3MR2YDFVJ97^HZ92?;\]@W%BGS%]NE(/-2UM*/EYBB:43
M&+DJP1\"'W?7Y+7BRO.KT/)C7%V7:)4[:8AFJLZY/\ F^'UB$O^WI"P4E^\W
M@:V;),&.<HAU'VJP(4>QC.=D@-=7&D!MWA$^Q;^ILID=+#5,G/9OH$W,/E)(
MG'&Z.=I9BO$CR##NAP"&/$;%,>Z*2U@>R"X[ZJ[,-PGNZ"KFS0 NT&>'^H 5
MI)TM-<6&G32 DGDH"S10U_Y-EB@N::<3:J"L?8GF'=-,,E'.8R-_H>6,XC*C
M-.=0A8NN_J8M+3+1R1*B55- =8+6:1 UM]G.[!82;T*9C91JQ4R!?VDN ^H4
MQO^F"8#-H^HU9[X&;_<BR:H&CT51!>04YX,1GEE4 AYI* >R\?!1MJ4-^P;W
M_,PWPO,7Z>P&D\:I<$ I=24!ZM'5&[*9$K)^$HQ1&NVXBZET@DC:F54E)6!P
M]Z1 OI<RP;_UQ3JE(U&H:*.X/!25<22(OUF$Q:=9.PL9M,.0H_M&ZF0 G Y-
M31O9:NJD"UD/I'((.6RL7M"%O(53SCUT04VXI5V 0;X\2A\/A+*ZW'$<VGHZ
M6N97*-SOQ"M#'59@4+ZY%YMR@9)[4$D#[QN:VU$F-5]*XZA0J^4?=N*I7=T;
M31X3; L0,JT(<WM!*6UE.Q U,)<U?G#_FM_B_NINW_C,Z>-10YW#@"0?DVWF
MD0N!Z^B1(7X[<F:?F_I0\<"5LG><Z*_E+O:3%KHV1<.?/?86H3OV!AG]6'3L
MMY$89>$.Q/TWQ/>W,;1 MW\T?\P(:@MJZ>*G(=-,S2@M9J7"A58S<!(-8(:&
M]5YO?8>FQU?E#"_^QB-].W';JI2DVQH2_5Q\(U-DC$V"9-'+NQTB13<QYV'A
MZ91Q2X_S-\<]XI7^BQF#.CDB2JNG%9XH[%NEJ]:?4*IY5E'IN'./JBGW^(WV
M[:9]R1%>MB]T2+=70'$%94?LAF@A/1?D!\-$?KO$_Q[2QL20_&E,"NF/&&,0
M="\TI$T<N"%T2("4+--U*I 6>KA2"ZD!"-2;/*89/2(L%Y+&")VGINQJ1K9G
M36=12P<995&HNLFY_N#3?AQQL<353O[V'IWCMKZ\QD,Q6LY;H.GH)3_IEJ"C
M(-*7W\14X?B/#S&B+,B0KC)E@(JU#83PX8K7NDW%=F,FP_49F^6;=W'..W%6
MT?IS6(><I2G.30]J$@GU\JVXU4Y)4U5?I*4\^0[;EAI7K[4T,NW<R])]#2E"
M+G^2ED]9J*R\?=_BQ;D>EH-E7!&K>JRL1@7ZJ %EV866O[BQZO-W7\ZP26_2
M7 3#XUED0C))BC;$9J'CV3@0,\G+3F3=^SRIWB64$?CZ@VZ9[ [E-H!RV]^A
MW/Y?0;EU8,C?YKQ9HB"FRXVW.1&&W7PGSKAG+YYT0+819]SHNZ?=[WOP9=)'
M ME]UK^Z0_U]&TJW7TT%^KX!E#!EWBBK99&\X 9GZ*[HS\(YQDPI9_"Z!.(%
MD]Q#,86^-=3R-KZOC>'4KV7Y.H0'8I$"3Q-_^Z]YL)!];:*RVO@[(K *-LB.
MO.HWD%>Q<;"1O$IF%_S:6]K:YOWAAY_?'AY]^OGLY,./VQJ7<#8]N8[4FQV+
M2Z51PI@AA=#%FB/HSN2EL"!4GU.W1$C27/)RQ4:Y^Q=)C%9IA-LXDTT,3S*S
MIUK0Y?D#^'M$)CK)BI@^EX(@7,MEP30T$$-8-4AR(UT4Z5+A7N@32'#%UE !
MGAU&W>!("2_'-_+DIC#^^3.?MN!')LS+9KB$AX?*6H_9M/D7V6",L$<#X[S*
M_%=:"#>?3./'_"<RP@G39E!$1>_@% EP<CW7*O]7>Y-M_FVY$.IH^363%:'!
M+')"?)&ZIN0Z4VQQOKWPD4IJUKMAL4V5X #H(-@Z(IU<">1V28V0J!Y:3OXF
M;?$94 /@)U: %D,(Z*.E=F(1?EL1'%DN'"($(\WG:ZU(_!?Z"O*?H5%:;^QU
M!D&,EY@KK[@2O*'-()N1M;W,&,9RIYG5T\_,JW(I^%..PWH7U'BY--ZBA>)9
M,FSE].%)G4G"QC^Y#5SS :DUZQ)QPN.]T<?\IL?$R8=/Q^_>';MSXO#=Z/3L
MX^GQV:>_;^66^R39)C>9.-&=(=2"%I15GNT,2-7"=G>"H\;]YX>/SXB* #EU
M6&Q4IIML)AL456F4%7WRN:RNQY?.)L<>0<96 A#TK5(/07*=T'UF! $&IS?T
M[^"-)#6SQ.8P+V/;87*N1[I.TE8KULSR,TJOTKSPVA;="!&<=D\BWCP<*LO*
M;80U>4PT(HJ;T&F _$D2XMI\),PSFE)K 'E8E*E[YLCF?U D75VT8ATL)8G-
MF=,T449ZG1#>A!I&2T#K77)L+M0_R[[VJ:"P!]W3H@6@VW6('GIK(H@'LG1+
M<BAGM$S3.EO%4?^OOJ\[.\F6@<) .Y-42[H#8YD"'3IF9T29FH&D7"<_RKD0
MPFO@ET.74I&]-H#I&  $LG.#I3,K&JP91/:%ND;Z433J1^B?=J)\FY&J]RQ;
MU1)6S.G->5N,&(H&,1><2UC\)%YY"(V7DKW16UC[.7^!>G?*9]?9)?D#0.XT
MGRF67:0R,+[[ &XE<;L=[%QNIXY0J_#D^S/WZ]%;4!XTXS/<ZBS<BG;2B;W5
MJ=QJ#S_?OVO-S1\,76_1R@?G.!9EEI&@V<)[WA T4^ISK:I=_=L]U9T,=9/3
M;>LS[=')$!UG7Z4GKV%*$>J@WGP\[4K#[FEEY:QD.Q8A"\RSVIXP37S\4MT^
M5J.[-;BWZM+,W4_86ISLS]E/225RA 6)3OKO:5UVLW]/NHW#-I%Z\7CUO)R3
MMZ?U*&I B,7NU9T$V> )&WMQ.YU_[Y)J' IDN1IVB7H9M#D!/X=,?HZPW."E
M1.="EV8TMHAZ3D(*_A^E7SET#R\XHW' G-S/$DO/3T?$W#D'5>@KOO]DA!F3
M2%>T; /6IC&UKM(:M*<I3-1>G.SE/=Y7)@P35?IX+:]TN/M7W1%SOYU21T8O
M[-BF(1"L3IUYH4Y 2L.<E]*N0UD=$+4X>/+T5<)E9=)9:6U#.!0888@4SR'^
M3F?_;+GG4F-XNQ#1,U?YL/RV[MZ.!R52Q-/D]I9T>.XX.^X'A%V%2VO.=PJ]
MBL,6H^/ 23C11>#UL;/_[(# #KC*/9D]3BSL;E&P**($_^A5>;IUJ_*_&(%R
ML$.@;"T"Y<:5>P\TMB]:1K\^SO"&ZJJ V&8DJH:1#+S;0D.)5<,M@>''%\X@
M8(0-YCOE7$8^#ST "&4,Y(9@R"6HY#;](J-L!T5+Y?&)WD^WJ\5]M,ZDK8'O
M-UR)Y'=[>G)+9>DKEQCJC!XF-#)UY_%)'F"^ H>#E0PT'*CF>S,IW<LH&DZ9
M\]7E\&42X&D4:KU:+U&$8"^1=T;TDLG;D6BBF/7 #:LR2AT:8U1"T";>O)5G
MS"<1*]L#UJ1[&*<I)P5UO"E''^LE )9NV9+1WT[>G$(DWY(Q]:E.IY]_<W&&
M\H14%YE:^,0\--H_ "JZ"6M*(A'M(V/I<[,T?94.[=!;@T\'((E;.S$:Q>\P
MEM_9Z.SX'_\X_/O'W_Y"6MTCZ3=E2*VH?F24%I*SN(KNC$[NTGA)%R9J_;YI
M=6B4FY9#"Y*H8E-3=-*H3C)]PM)TMRHD7BA9GX::Q+N7&-,B&?R)Q.&'5TPV
M,XTM<%=#$W#V5&!??JVV=N\<MQ3I3HF\9J&E51OVDMDXHS=AY8;%ZX8-XN?=
M^:.=C1'/L8F6DBW8./&CL@-B6)I20(*E4C\.6E<.D6[1D"DG8J6OJ78MU3 A
M/7JEZ\I:A#>-%*DY+KIIL%TPWB68H&HGBXJM0(%>GBIK3%J&O7IZ<BKI>7'6
M12><+TZ/L-,](#QL]N/W YM=?G?\\U>LB]_GVRFG;YDB&?XO)U\I[$?K</\Y
M50T#<:H-4[CA80UU=Z'2/E WV0HY(<'P/TQ"9;3HKBY! \Y@H NF8*^V[--=
M. \%1?.I25UW?DA"YH8TZT*E\%I:S4Q>D@ZO-W"\;,03Q!*5C Y;8HLNY,PX
M2LMT=L?NC7\X!N+HX_O3XT\GGTX^?MA*H2;E.\FKSN(Y)493#--ZZKYR)YZ[
M_Z]L0L.<:P3;LR[=8*8CI@#W7*/*)%5FUR&4J+ N&[%<@2H=@+I#PV9B#$!E
M3)<,(W6S6M_ 5 7SF=G5JY$2DT.X?=[9/Y.9@VB(_A.3?'8_MOLT2CY#IB=9
MD6=7F48+_ &E.+Q;(7OT6HR5Z*;1J=JX*+)"T_DH\)[F $BYV>[N10HYU*L\
M8(;<P5_,.*JQRL=2*'U%& FU!ELYMOS"D:=!;>E6*2%F"<8DD(&L;DP7*3?D
M>3JUAY1=>APX&OMLW.^G66,Q9.Z O!#>ITFV<C(UIK[I%'&,Y"_A(C^BHNI]
M@]_FE0E03U&=Q0B0P&"-H8 1WTT83*((.N:NG9+B<5\2$7R^:@4<P @N0'O=
M?=P-IEYN@6D6$7:.XLIT ;'WV,[3ZZP#/G.OX(:3%^MXEY# 2'T]Z(.RP4XF
M=ZP2EQH[MB4(([0F?G@W];]6A4RJ)2P2<]W;$A-G_#%EJF[/N8(S<EO"RK<_
MHC*4F5OY1].T658:K&8[20L\:V?)HX^;,S3W'B>CXQH5L8^<_#C+(QWZT>G<
M3;.3_)-RNL<EI>_7TY0JCD>/G/@,_N:P(1"'&\LI8_5^/I??XPUKAD"J<!(S
M%D-PYE'76NWU(=G>:*:,8BK1W)5/=N2(:)EH,]/4V<W9<>*,QHKKL(-;%^I,
M5G[4'(S0L7MB0+]H<T8 B7#$T^)W*A?FN?GY(?U"!0T_96ZO7T[I_D?")XC'
MOE\3_RW-'";^QR(K817\R(]O\%7$1A$7R,![TI%Y,8HS&+'REC2;V1$WG$DT
MWO1:&HCGY7 7TXDM;L#3]>7G5>-TDO,4E_F7T:/3M^,G+U\].WCUY/ECOW4:
MIR=-![B^1/+N<Z?,%[Q!5B_-;Z-%X86S[@E^VG\"=X\<L,_=H\^GZY(.4G[X
M5BJZ7^*UE7Z%=EFU^8>?GJMTRI[</.KL@H-<KZ&C8+5!&7(+F/##P$QB#[\R
M:VO2&Z2DZ*2^S">$WPV;X9/[UMTB(4@8MYBF$9QF]"OW""DP*&=5V4X9639P
MD_^IW"U^33N!-S68-B9]??.=8;SJG7IC\\W]9,@4>,BWWRGIJ&SA0]*__?SR
M*9*Y<_1"O*6P+H($#0<!VSD-;ISR(Z)%1XKGEE6GHVY**'6],6R,QAH1W0$=
MO7GY=+PB(P:6I-N^[KJ%.\RF;<&!EVC%/SH=-7[^].G0)J;OY'@(QHW?T?]J
MLX4S-IQKOZ+^0_V?']939V+]D%<P"V%F\8_#X)U2K*8%QDVO.JEF>6R-T;B+
M=I%.!A] +M8_G)Z=IJ/3=]V4P);L]?<&5ZI'747&G92VIX4<J$IQGE-NAQ E
M%W1X.85<PA9D(BVN6A"D\06.T=J9TE+?FDCAR%0(1)ANU%F ;.9RO?PUZH[2
M'OI1[P9+G3L!B*F.IK @C.Y:]80RZ&U41573>FD>@_?=P"'.H!?=HDW/76)O
MB(CAPD6P4!I)(9@YA5?$T,"(G( )@;'%FN"L#*B071IR( WY=)>&?*!IR(P\
M6=Y2Z?1?;:[(*]G6L8L*GW$PQ"(,LXHV(%:.*VHT4H&62G4+ZV<T)RFAOF9B
M\Z9\!A&5EC]2.\I0-[3=R\B$1%8NP^OK;%JW^4I+L)B[D?[2=,*L&X9P.C"]
MD$Z:;CXHH,CJT0/8,');WK<&MUFC3&H@$<K*NBJ*T#&E4PZ8Q(<RSWC,D^(#
MV[XLETIN*4?D*9:XTQ_G&2^<4>6FYEQFCXJ"T[I8CQN*?QA'A=8&L\7)6$Z+
MV99RT;$#$]_9 G0K;U(96F *LO3*]! 4B>=,/#<,83M/WF!P&1;BX!EM#M"9
ML)RDC]%6@&NM#*O@B@2'3O(Y3?24&"C1HB>)VNF0!3DCFQJGNEJEVH.!PEUH
MM "H#PW)MTGLQ"P](QB[U5H7WND)QS$E'R RAZ\MJEVF:]IV6[EL']NHS+!"
MW6=;YJ@%%@ 35U0BOYI1KK6$OLE[BN7._0+([*?%<[L/>LTW"Q3#:YY=\Q8L
MT*^1 HVTQV9Z)6U_ E1P,8XL/OB3Z&/\B-F-<H[&EL,R":(G'C(7K?4T(ETA
MU10@=*PWFU;J$.5U>! K;>>@S+#[V1PT]XQ^ZR;31\AXZL,1T)WH2)>F9,%6
M*+U%!M#7^4E[&(U+"!T(SG.3>.P3B%C'R: PR%4(_ED@B,*6 B0@C12A\PP7
M>;O@T+$-*_=C19(Q"K5 7B5(W5>*=>?TXP*=DM*&&][GJ.>MF[ X_:V'[!P.
M!WI]-[DUZ72:@I8YD+LCVM+<T8\?__OX[,/[XP^?1F?'/_[\[G!KLT@_&ITH
M2*;@I4OR3L*/\VQ&^<H$T"D^]HJ*CGK6SQP&D*4-.4W!0UPQT3EV8S9\7DC^
M&V'YQ/I3Y+\A 11Q[T=L/CW"!^:KQ\$^_9Q>X,>-VY).GJ@*F#IH?<ZR)3YW
MQP95:A-+PNP*Z1C\P<S2V&LS.J7R2<M_>1Q 0EO8V=^J'=Q+H:[;&V&DHW&=
M4#@+SP3]DWS$V*X,NU<C0NSAB5H(_7T?3",?I-(!]SC4*3KEPNFMW LGW8PU
M'24JLXWT8@B4YV]Y/XS>5L11QW P9+6K9I$1SNB0.&V=MGO[YN@PT8H\MG*9
M"@-W#F@G0ZD00@6#P0$U>BCPD?VKS<2:)6B(=H4SH(3.SDUDV])-%$#):$@Q
M[<W %!RI.$T J*7"WH9=.#>!.WI6,>\$[8W>AI:3&.<Z=*XSJ$J(2XS&9",5
M-[=(2 FN1&S8/'E).*O]=-9"_QKVJ3NKU']A#$W!)R$E'9 %S=B(M!;J%<)1
M_VP).X2N)Z4&BL-VA<@$,M5LWC8T-SZ5,0A 3S 9LSJ]%JQJL#=8<8B5@/BK
M]Z\N01Y/.'3M:G^=UI"8 OE97LI6NR3+AXF?.Z<#G0-E/FBR_%>W1J2(P:]6
M,745LVDTRT"J)#_ 7W5'->;E/UL_+_,<.4.9!FYT'HX;)37!%3X'"UU[4=7B
MF?+CYCD#YJ?Y58Z!36M8MP7-)W.D;:?1;G?U$%6U&'ZIIKEA0OF\FP4D<8=X
M4!N45]3]E,6-.Y*Z5=_59-]3W6*'&'9N(AI*\@3\5:QM+P@K&O]4^X/@"/CQ
M_6EB]>JNR/>>EBMN66#YJ"1R0P<GF8]@&:$&8Q%1%86W94W\YP/+V]7L6&[S
M@'BMW^W6^G=9Z\W-&T!1KS[YHFU6B@+S 0M5M9S[Z?*3L>9U:[%;JWM:*V]K
M32B&3C%S5)Z B#(@KF E7N79]6A2I?4,V^?D[ >XG&#2#,J7FFIH&UWZAOL!
M*"V/\[M X;Q;O_LB3V!:\M2':IWUHEX_A?/'T@:.;,OA/370J1IJTU^G2I.;
MDOQX=)I$-(Y2#H7F[O";)9SLB3B=>U,1H92OGX)<!)C,3A;^ +W[X<WA;I[O
M:YZ=V#9S4$RM.[V84HYK.]6Y%-B_KTD9H#D%56Z@/ 5EL"\R\GTG&^4"!<X(
MB-&F9_DHAO$& Y?W[U1,7.N]EWIGSR8&G\4/+*%2R\MJIO@&:!2NP?0*![1P
MALB%=KNWPYC1A5)+S@E%W6/""4]P>+4U_NO)=J;K'</+/8HK1\=P>@>\7:B6
MHF9!=PI4'GQ[%O)3XS><&_? 695;&5<X'>#=532U<4LR8L-/5W'<9C2]S!8Y
M:D0Z'E"4J_]]I.PKU\79$%>Y4PK?@AF>BT$BCS&HR7ZU'U('3080R$HH+:G(
MB[P0Y, ZUDTZJ@6;Z#NP*)"1DET<$99&@%W7UB]Y8WLY290W"M]R.#?H9)LT
M<7YJ="VWH"1[ZS]6U9=\R@ 8>195^: /&/K&$-"=O"Q8!JNH<M%;9V&XXG[[
MNF8<+/%9LD.8]1%FSW8(LX>),,M+N$Y:&YP6:T[PS=)5RISPH08D%!ZDW)C!
MV2Y$G*9-F)C>/D)6K82U>S"'&NSSM$'\/L1']D;GI(P*]ZLQB&:Z>Y0SE2:I
M"N6'W<N(&HW\<\6947=LOZ7U-*>B"'='&%[DG'O>,T[!T.!(B[#F6E!?\IE7
M+6GK=FR*N2JTCJ\Q(9RG3]PLK1NY%;JE+%<FG)Z,VA*8$HD3L,69+S*3S4MS
M@B.(6PE87LT4NL0JWR,#D^N()=.4]WC/L^ORRH)-)3C/(8JJC),V@'%PRD@:
M>.FDJ&K5[!X-&&J6,FG%%;>-I]:AJY2S2'[\_H6S;J-0HO1%9 NT;ZFHZ<0V
M0O4"@@4C I. 9_'")&F&WBLK[;H;R(.Q]H[T'3[A';;2PCOJ15.0]>&4:8R;
MDQ.W6_% Y;$(C;@EX@B-V HVA]VT2ZH&5SD(8-%P-X+E#,1R?CPZ[5@64<W@
M31 /_R,!F16F6-V/4<M=&:G%*A7@RK+A(.+HNF:\:Q#^7%*6TWSIFP@"@Q1-
MYMZH.[E,'PY3BQHM,_%_3<JI%-PK5>Y74W).9X2L%;3(AC>L\ I4M:MK@YOP
MEU0@O,A6T@-A F03HZ4">"1$O:1V)BA!T&A.ZQR]&^0.8N9#D_J1AHA85R/X
M%^WQ0Y9KBRCP=W+C+6?LTDML/2CO#2>.J+0.9(W4S-D//KAK L%VW=P$R,@Z
M(Q==V/$X>4_0.<EV>&^]54#RE6U/),)GQA!X/&B0>)C:W]J$ G@,>CZ;Y_ZZ
M_J V2T<L4.(G]*3;6Q"RQK(=^%1B*+;L%#X^=21*NSJ0Q#)HENTM=CXQ;^X<
MV7;E";MZ.9N>*-);DLO%;6:G./KGM-L:E=(/JAQ/9-EYBW(1*Q,%<:GXS)V-
MF38F(V'YXX,N,+QGA%3#(/X"M417_>D_KZ^O]W0Z>#;V+JJK;^ D[XU^&HS]
MDT)=K9=BR74T3IT1"PMT#.W.Y25[QY*\(]"M,RV+=(DVJT#T3ZA)] [A<$]Q
M.VXMO_\7J#"FQ6LD@\;XDI6&A=%5YQ*;8]VU(9C:,@_%$+!X46!)NP=%KNB,
M4\X,4-_9%%*GK#4!LZH!QK<JG.(J*85.?GJ]%*BE.VTG59$WBRX(,_M"G-UR
M8P">G4V.AK;P@BZ86)]K0RSI@#2]BP[4NZK"G6C=2;0.8M%2<Y5)@PAAISQP
M(D!NY98*PG#?:SLIOZ#!V>2B JX_8AL)33T2R1)PS0.H,=0F4NNIFSKTK8O#
M:0'9I7PB2Z_/7_@^]3U993R\$U7RD_G+G2C=JR@]O464J'GLDKE&!H0)M&0W
M)*X'G%G&V:W(K""AP1T1FH'=10FZ53C5YGF]B 7,2.: K 589R_178$+K( \
MCR=N$/-\Q=#'(NO>*O7=DN A^5>T5J-6_2NVO7./[33^3JFZC[&2A)$WSM90
MB/EV@]#9;<2V0#-6ME@TZZW0L8%XSKQF:X0Z/;ISY/SPV#UC.FWKO9&<E8G\
MXX!Y'5@T!U%$TNQ)LK=4=6G9K\1"A:/%>H<$5[J<DX# &]X;"6$=C2[$KI0A
M5@/P #$W:-A#7_DVL&G7_[$H:K1(9I:GBQHL;W%7Y'G.H26?K>U[YF3<<5DK
ME3(T?B>V9>I>=;E"7).M!HCSWNB<&1:YTR9\E2E,B:'!1Z2]_1>AL]OZC?F0
M+)"JX(60*%DP/[MA#''W#&;;)+")4V3NL\Z@M9QD1/C7--646\9S"6[IJ<-)
M]&ERJ;0#FU1LI <3''OO22ZU9F,K5<5AT[0+;FZI^ZL#F3"Q)JOI-<Y]2\[J
MAFZFW4P6*ZEL%NE?SD]Q)9O1NU[.?!*V4],40!#"MX<-9BJ4!J(*J-*\)2##
M4!U,",] V&DQ);4]KVS0V] /[8U^1HA,$XY%>IUH.8H)*B\JIWG=0SN32,,(
M79@5[:$TJ<7:IC33J,;$\FC/LRS$:U0EVN()-Q/TI%P*1.U-<1AH*3G=R7N?
ML=_J]")QU(!PAL^/[3PV/\ERBZ*C,'\PAM<:G*+)*0I>$#F'@,;):[=,+Z+4
MBEE'K5" 9I>#F#F%YG(P6P/Y^C(3R<S6(I9J114>TL28'OK%*BPOJ$5#9 VI
MCW2M\FIY=*-=ELKCTE*&J((>1H@8)*CGD*N*N-QQ$[4;2!O84)+$VH<>S(.T
M/[ W') Y1;F&/ WV)X;<4&32CO<CG4Z=_43WQ-7B/L\E!ATJ22Y +D=&[WCF
MKKN\<6Y!JDW-<3F@:&T1#_N\J 3&R:I2A8@$2#7 "OP4N# ,A>Y-@5:OCN2W
MT ><^(IZ4H(-O!POW<%9"VTSB[%(Z?X3BHVO+@54@=OT[N!_+0\+Q90<YJ5.
MI:C?\X8-#=5++DQ.,G7*;G&T::+'!=(=-M)UXN..^1<9*-,-Z')^"M.GM4 "
M6T9M["PN">+^X]RG3T.?5N21"786W%REK<XNTGK&47,3.RV<ZN(X,\>-91V#
M2,4;3?J?SN-V!;HZ5-_+TU>9JGEN9BJS-LMIIU/:,&12J490G*$Z^$AL+3J?
M/F\$Z A1(4O7JUZGP5+B(Y$8/5)*C9PA>2K %CX%F4*5RLW0.8OF.;'()P3E
M=P"3 8#)\QW Y&$"3*A^G1)9,Y%P1"[,V1N=1M*Y:!+H6</.5S^)'$%50O'-
M&S6J!K;KA#KYK;RZ$B;#[N^)&U2\7R)+7Z2?F;%NFF]QYRF:H)4:RA;<VJGF
M;'I%T."]T5K_@6)HX8),)=>Q2C]G3)3!_0&T0CHC+ODWP 2A%%P;9WLSFK#7
M5P+OKC/N.X.="52(M--AGJ<U1T4:F'!"+G+E+$,^,]R.6Q)=E-8B&UZ3F=.!
M[GQ#N)8U/TRH8=99>YK0:-  POCS3H8P003M89)A$_#XA0E$P/D!VA-_G* 1
M1DW!A5(2Q,B3-H@#<%MJS'<3D64.MZ1!="Z;$K8J<$O%M-%:8C\P$3(#C+)M
MY9 //2$L <MV"O6AAV#96L88)"S(;4E+WZG: $#^E5E]-$>S9>Q2?8X%#UX
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M!&;2!JUA9"I 3%8(0H72 K&?*9D[4R+4[6FS:<-)M$,9U4H;6C=FLW0 ,^D
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MW/X#:?"5N_.*&]Y>C^JJ70UT1U5$!K^*4[,7Z']$Q5A)&)8[+YTYT62Q+\/
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M^T\8%1'?Q1J4]/-C-XL\K6=$EDEG#O\9W4<06^P#T&T&GII("1ML,MH1.@W
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MN$E^:$H$'9W)=JK5G>>86GQ^F6DW),G$MRCKS*0W5FA-[LQ8Z@ZO<P)X3VM
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MNCLL?I[;M*1/\"22%#!O5'TZPC5[94IV;4M.=+*(/L$3Y.62=Q(7PSV)R3C
M2.@MWNO, %-GF3LV\H7WG6"KTG@H?937'3_D)O+.NQD43_?_]#!.HX:*<91L
MD!RN(.NGV@>>9O]#)N@NLS9'*8C-'TIF[9>,,]26@,_VXFE+!7XAX9\)/MT&
ML,%2]VOJ+KW(2V4A5(#\T9NGKUXEHZ,?/CX[V/<A.59Q1T75SF!+?AW4XUL
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MON;.:P3DGDV* PR\5MH/M*.:APN2@=^0.>'L(E,U0=G#Y2H5+&'KR5QI9##
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M<TUJ_U_VWKW)C>/('OTJ".]>AQ31I$E*LJ15["^"'DHV=TV+EY)7O[C_;#2
MPDR;0#?<C9XA_.EOY<E'974W,$,9E,!=1&QXJ0'0CWIDY>/D.8-N3=5$\7W*
M@  -NT8/=Z2*DJH)1\#6';4V.Q479)KOC\1F:[3ALDJ20Q(4"">1?+7#\2X/
M!8'&*55=U7T]J$@]YG5\[WUS;W:WWPJGIK MC2ZLB4:O1DI@C@%A=*]5ZDVS
M!($[?B1L[S[%%KWD'=& 8F]UBS9(B32I_^EE.6OLG 1PY*#N>V<]J_&,GWQO
MG[)STAWS7&MB4O%D7=Z)(70L]^QP<]L)TQP)DU,QUCI;*MU'*>1;&(.)I[)N
M+M1#J"J=%9FQ935W+@U<;2YV!J=J=&EY>A7I22+1@.:=\U:ZIY*8[['W27P[
M;MS3>U'NXC\_K^Q-@E^CHQ*H[LH@O.O'.EB'+&+':Y&#:N=IJY(/*@JPC,M$
MP94)5;1+<N)L6D'+IWZ4.S^8FZSTF!4)Y;Q_\.4LV\36! ONKL(Q1:D'MU,%
MD-H1,\['4P[\*9BP7H]4D5>AE8,H3L&Z 9XP;@XI4]$_MCLM(6 CQWDC4OA=
M2&.62?^1E!O=)2N,C6YA\H<-A12!P7*B1?F31RL:5*Q-K2-Q+E>5X87.TNK]
M,#6$=^\S"Q@' KV19TY_8L:&9X^_5HP;IN1?/_OL\>_M+SJLC ,]QEZ%'[./
M[OG@'PC$*P$OZC<B,[,,Q"O%G!*??_[T\><SG]1= INE+R]5T.70!]JV59RP
MBK22Q>3Z5&BGJ<U1^I([$JI;I,S7Y4+A"7J5:+!:\!:J65LWI'KNM#8\D8<%
M%4:=,5&5^66K9\QIWGHV0 <Z]D 4H?1!QRLUQ)8'CH-N"&N9;(45"#-]5^ V
M/-0CD',.N&'K[* ZP.C@)5(I?,):N*U@C>!H!S,MT/>S(@3ZU:TC2>9H\:F5
MA(KVF1P10J._,T<^/9'^$[R/)"(9_T;_GV=B8 "SSG680FM==Q:0A+Y6[&!3
M??S207ZBW@06RA3R3?%?D,VXXRZ5O#$I+I>7?WG1%>KL(\+XKFFX2O&"?O \
M<_KQD^]>/.>UGY":T@[%V3,L^VD)0/Y=7)IO1P00MHOBGZ-Q:UA8L!*]8@F,
M1-VS8='BW1!B1D3SEP:H4ZTE;Y24YV_ ELD9.0LX)IJ>+K-Q\ME@QK"IP1Z?
M/--I+ND*LUB27'O>FCK/ _PHPN])W1LZO/+#]#+CI[+E9";'/4;=H%=XR =Q
MC'SS,C<GFIO4Q._34<PYAA1[IN,[Z/:FPD5;6M9&$G2.WLQ+&GOF5.@L2KOA
MP1ZTRQR?:(XUOD;+(8RC]6YK*#O5N4VEV%43H[W+1)QH(FZHCN*RHP-V!3U_
M/ MK04$+MX,9>1E<3] ]HV!/73(4R%XVS*GF*?XQ93!H/E([D#",BD:#:GQJ
M#8'GP4?)]D?/WJLFT;N7E\;V$\[?A^I@_U^,[OK\@N[Z.-%=/U(?.VC9N,BX
M\9GV-2=P-WUGUHB] ^)Q[J7.G-%"NWC*&NBYU\LE^E2.13'_Q,=9218M[S%"
M.1U]G*M^C>[6&6IW(I2Y)H[,G [26U>5")@F:9AD8C"ER#'_0"+VG"!$D)1D
M-\5O,&)SSEUF4G_BE&XS^?/<'Z:$YD&?6/).T=ATS&4!#[OI=H_2=SWQY:#H
M@J'FW'?JIDO"UP7F73@]ETTQ12ZAT+&=L'%FI0ZBNR9MTU S@KOQ'!*NM,/5
M!Y!V<D<R+X7#JU3J=\L@&5B:0H*@*/\Z?>@4<QQ2ETO2QD=JM28NQ1[0 P^K
M%>F?FL.<J_"T*<V=USH>SYZ;MI!4*ODA$^Z;E KD>4%,RPU[)$(4G_4A&D0?
M2V7RKPZ6(M0(UNKM^M]E*(:X[WLUISRC2=;>^="RH3]*_A;-7[7:_\)"&OV!
M-Y QF8<)%2Q*)?-67/M1E,66C?->JBS^DQ$C!3-T"_G Z$N+MB+5&ZS1AU!4
MZ-T4#SRF>* =TI%!"0(P73<0+[>E00P T8K6"7Z\N_<!"QFQ!* IX[YKJX &
M/E'J$CAL6E0YSF)D,28:4\!D2!A"%O+QI-,#_D(Y[^+_ 7*R$,7B7=N')+&M
M>*)*"IC">VS&9:DCE?8-7I?&\([2GX*PYB-+)]W9%BIVB*5SC=C25[V7X1*J
M%WQA[R;3MUVC#J<:/Y/:@XHBB,< 2'M2+<VI[I$K2/?BU\9"T7Y!>\,U&HDF
MZ5..F0VR_0.S<9[X@?_)3#$MMZ83 D>*; /2D;.CDC$F%5HX:7S(G_5R#/0:
MP*<AVN?ZP@=AH3G;)?NR:\NP?O2G<D-E[K(U= ,MCC61"<S#[BY$^_B&I"H9
MV/S7MV1_@FS6=2@9'F<+M4!55"TO_<*MZ3C^LD]T2ODX6_:4?]:&L1&'BS,$
MWB_[CN;F74G10G$(^?& 5RG2FLC1@I)<2'_$$O];# >Z994X,U+2>\O>-,.&
M-M$F)W,?)VOA^''>(64DK>G4@E[2J/F'XW_6UJJG,J,DOQ-(+\TMU/SB>E71
M:I>QTU:^3=RKO'&G>O]5Z28H^'M#S@D_2Y'S]/<UZV#*HMD_S.N3(RE&@92Z
MIH.T1FL#,9MTNQ@J/%1?^0R\8<7IU<TL.@9 $PQ8>!'#YAI.&E][-+X"CW/,
ML<0/(H>KI57F-C&J3>G]N:W.&F"71FHWVQ-?5-C$10;$+\/3,EU!QTO(F5D+
MF%-@FZ@0:21<MF%"6^E'A=?CH*#&N,[Q_'G%+$J$$!I%PWEKJ@'-(_,B*)4J
M UGA/O('TZR"CZG]MXM'"'9-(=6S8 8$>LE)C5'F4UZ(]H5-;<:6U0'2!W/#
M[O0^11@<Z@/Y-X,KWCHPEJW4UGUOLGBNY?91NN4\UY@C*M.,2W1OFAYM07TM
MJ+/:X%]%VFY(0"'ME-!' 'QW[AA(UDXMGPI.6X=<N:9[P8-?4\)'U"TY8</:
MGD%;'I(G$[=!+=JW+)QC*07NU$\9C56SD':,E'4HMRR?L])"!!!WD_IDH\00
MA3;CN8? I5%V#I[&,7.FJZ6$E$J79LD_$@+:A:U!-4KWRA^-L9_JC/"S*.D[
ME0^BE43?2G'?6O@$,PF;."1_*;ME^?=BS"%@^SFN)I(:6WY469#L53+'@5^&
M@FWR3_CU5=V96B\I*DP]#=U^,V_6JJ1^]>+'_YLDSREAM&04J*4 H3LO8YW2
MX%,S13'4IM\,ZH!*=G1TVI"OW<7_):@?5K_&R%3/E=2?!]P[@D/_*+[S:;!P
M]+[I-N=I=6U;X/7M'=-['7LG7O4'>$QTX%R#&^\$4-1DSK^3SKQGYLA;.+SL
MR/+9NIA72T>(LJ-8)ZZD?WWZ^,D3J@#S8R=Q0OG5'^*O7N-7;])]^0"@.(#5
MQN)8<9^GM.;]61[U_R58@/7M_;"++K2^ESPPLX;(XZJTH9D0SR3TE4HL&O Y
M&UTZ]BF(5RI VS[WO I&\+,GR"1 5R"Z=98P6L8CDZ9FO0:(G]EA.C0N0J);
MNNBN65*$SML2&0C_X%]K]X)[ZS^%DOL'7I=4=;?AZU,O$+T/7QD==GIMUP-P
M]*U\%Z5KB:0'XGN^:FKJXXV6B>CFC'GL:R=M.?PC=SP&WALVW_)*AV>E 1P$
M8_2S)XB^=6R24%D+2";94_]^ZE6>?JGO(L^MS? ];96;($P0Y#;82 \G[5)Y
M'U?>O[A4WC_.RCM; V^PN-WJ<TZWZ(ZX*SL-9=G7&7Z=B[[^@Z_T@\.&3S<?
MUSEC3-GQ=A\?>L>\JUP"%TJW8J93(]:KZ,U_:0\T8;0?:%AY5-(Y0,7E9&JU
MCUYX:L+2EP.T1HNND:X3"@;]"?)BU6;6;T5RJ#D\;D@M5SNVQ908IM"Y$!X&
M&[$)&B^._]MR*4,J5W\HPS;H./BH7I$&*KU1GK!7_V+"_4=F]/[J-S%EZ2O@
M<;-G1,D(#\I^K295M4CIJ@J%*:*"+DN2_;M,>U@[&U/U@$XTR]QQ;A,%@!"Z
M0E@\^"=YKPS7OILV,9&A8A+B#+F#RO<.(+;M:XDW7_+@ M%RX"BE5(T$3MG
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M&R]1F8.L\JR4(/4T'"+ C=P9T=#:7X=A?.>+,'H5EV8#2IS#]$/P_K&@X\%
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M1059E%Q8T-Q"633M2UWLLLA/Z)18K^7[.A_7!'N\>!\?>GZ$U@*5&Z9RI50
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MPU(%1D]\7S=4%<P.5JZ4T#5-[50 Z8Y3=/U4ILDIYER>9O#4&<2G) AV8_S
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M-O7P?DM>.+W[^V9D&Y<>!/9BZ"I#T9UOR P/,QZ6M(%RKFP' BF=]^EN*41
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MDY7/?JIQON$.DA!] G(!B"25N<*HQ4,Q@;,?PH*CL8G34O=?IY0OFZKK)(E
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MES?I>\TY97%#3DX9U#W:W5 U2RM;,!-,F6@Q1AQ=#.&9[I&K_9R6Z*Y<O$6
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MEI)MBMM?%BI-45*6>8 A8_K3(9+=EY&UP]@!P-*?XL_CJ;5L6NM#%EDPZ23
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M[_EB]^D47M%?[:XB4/\6"4CZ^Z>/9]_Y/,4DZZ-1-$YQ#EJ6FK,2;A4+^_-
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M.53R'V:C^9@=;>K1M@'J$E8HI$5^?^N)4P[ 6SWHU7V=:X]H:UVC.1(2DA4
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MCX>7EZ9ZYE6)]A#JAU:!Z/*3Q.GP&L#5C)P"]+@KY=L55I&8?=/U$]L#5:J
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M@[E8)6D0@2&4N&>?I41^-3@2W(8(#-1;?P[;<4-'-*'<YJ/?"K:A9#O5A @
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MDVX"]VFT?2.)L"T%G;89Q$Z8095WATB=90;1$#.@+ZX+U<YAAEX3:<M; >[
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M,-VV^#UDKM!:/"-[)3F,L=$<C$R&P41K:*T QR;RG)C+-6A82BNK<:KZX+6
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M=S5BI#]OE\G$VA<C8#9>@IH9(3!J WOW)1!NZ?B43<4<^U+3 (/@?\N,)R[
M#F,NYG_,>/FJQ&B"P&)3ER((QDC1QEKP4#58<@9NJ8AI2LK0%R.\>_ _7GDJ
MGC!)?,"-.@-?-.9*RQ15)E 1DY-+BIG#D]=82LP8^--&*C):%0''=2+@:'S1
M\#'%>B@F7S"=#R:3$K6]:,Q9R&W%JA&T2J,B7%J?(X8(*Z]UYIDY;AX:%(H[
M4P;EO3U0A;X4!.C:$9,ZGB););-?YF ZZ8Q[)E%B,79R]?]3#8\DS2C#[VY+
M>S9OA:4\3 8K?VVX4R1.C-XY_#<<N"6G4O!T;.2E]@F] 8=XQ<L@YJ0OCLP:
M!>WEK/(ID>I+IF\?^+O?]EY[+WE_+OF:8]/<D ?D,45>=\"3?R,@:YU$S"?B
MO4^%5YRU4MR8-[0.CZ145?NY(]Z.Z@Z&N ;Q92/#^/1?DJ']U_]Q\NS1M^);
MDW;5G+Q_M+7$[34-1QME3:!2>Y?!;_HU%:,%*AQ%'Q#4=@.-"00%GFH*#L8\
MF"$Z<,GAN&J;_O**'80H*Z'5W]&+:N D\VXY/  %=)KY+!E(4L19IJ))&-&<
MSBGE#[_M)KJ4@A,<.X%L],-Q3G4DZR['.+67X>#ZNZHH%<VL7RJ*QW/=X> M
MVTMRQ G4CM\%7R_I7,E_A:O2KAK6GHB2!X(JH,?5K"H+^X3C$FTE/6J5,U@4
MKR,"*$H'&NB6B0@B.W!2V8#5W0B@8UZ6"TWM ) Q)9<]"M'3^93N4Q4#.6 %
MMK$"3PY8@?O!"NS!$?=+*:'3B/176I.,\!K\(?%T-]E8M!^<F889CB(0B!(Z
M0HVDZ2!A2]U?Z=2SL?>]&1NXK3JS*S-K0(H2>MXFL1/7>S4"3')A$MY?Q)#,
MEQCHSR<O'C_1I)9\-1-U4Y6;9&9R=40I$Y*" 3B[DKD4#J)((>/75-N0+7W+
M"1T#6TVV@),7>3O-PW>.WGY:E!LNE#C9X[9?R)HAZG)VIHMFM8XY97[B6T"6
M:2R'2F'G^V#'GB!\'N@]-YOI/-0CP5T$N\2#V_C63"$/D619*SXR1I*N"+DU
M?#&YZ]INXEG*/"ZXI#7@!/> $RBH(OW8AY$[?73RB$?]95,41Z]:@CS_0A['
MQ;JEON'WY+^S^/8Y%1S"F3YY%UL0SD0H87 %_)J*9N&MN%[V >4G+.O$D(P\
M+P<SZA6"32:X!;B=5B'<E$EZ([TY+V7- .F:H&0<K90$I]2K%*7GBC7A8-;!
M9'TV4W3I<FC4AIA)LX628_^TD7C]F'6(U#U#HWNW%+"%X=C+^KIJF]K6 ?UU
M00$>K0)'Q ,_Y#K!/%K^H^7Y240:G3DE_HN$!+<N_*IJPD*\5+H_MA#^2IX-
M(-KCB-4DY(&!;<$.4#E. *U))&: /D#\Y+&Z,Q83[Z>==\JJ9(]'5T[*,CRT
M".IS1QW1,3 LX]^&.WYD_$T_D"#%CDYA22$WG:1'*!(N]:"A;U**_+6FSQ,+
MQD@FCFL,M"0^[T#3<Z#VG.HK&E4;UOLF*:3$9-QO+:@X01BG[2D!%0^-Y22C
MYEL-#/Y,H->)'!S]"<4@16FGB6,1B.,K6[;/]'&3Q>TO;;BJH49,PI4V&K&-
MKRQ^*\QWM>8I-A5C?G;Z%7L19#@C%$8:R#2N8Y^#@VVKWQ+VVTOTQEJ=KV6(
M1[,%W/:%/%20<Q[HJ)_$; !CLGGT_D),P6MO2;X1#A4K-B:&B&XHC\?/PQMI
MU=2:7!JL;"Y,B[%J1M>^R\+N&.$XG",J\T.M77R.YMCT^J9-WA:#Z#K^?J;U
M;XZCNY&LR(-)BEUH?WR>GD2&$NZN\G9W!_U.W4V#7;!-E;J$P"<-EL37X6H%
M58Q(+G4O#Y/7MTB,0L>3RTC!],U$!P).HDK/\2?\ /.^&1_7L:%C;^3S>GQ)
MA4?PO<7DQ:/LV:.3[,6+%VX^4]U6EU%+46:<P5.HV3'_^,NPS.9E-;U")O,O
MT.Y7/4PVM24I=S("X2&6VR]NHY702&LKE_=98T7K1)E &M70/5(_VA7R4HH*
M(,$0B[-KB^TDX6%1EDN/(=/,'R/P[!B]Y=& Y)%GVVT-!J'ACF5FJKEEA9,9
MBEGT6$"I,\\&<2PK36Q<E"$2,!*;O#6R2RISM$1=3D\JPV$R7 SDP\8-)W:S
M*4M)-:]%?EQJ5/ TRN!<5RHEBR3HJ E39,"GM= *XRBP:#8-3U7:$N53,ANS
MJ^"@J+_ D,,G3^(/7S\Z<>A#ER4(49+L//,&W2F[8[ 1OX7EIR7N"I"-J*&F
M\*R-U>KXT_=G?_9R[YYS@\O$:5 /RN18H,%.KQ>B*0(&@%%].4::M,/"&$_(
MSJD,@?K6URA=<?O73 Y;PQ X;_P=+&*@6]J2,%8T4]A8*ENGY6JZX:X;9&%9
M$Y4_;P&^\%6YP.*.A9MQY&Q8QKM?ETJ/QL3C!IHWS;#L<=<0Y$XK\L%X8J_8
M>/$P(5X7,S9^SI#MXV6)R%5$3M**O.,_<$@DV$,^8\(':)V3QCS9P^VN3V=D
MBFK1>T3\;5+L6\75!^OX_4)'QJ(J";TS]2T">LA;.,G088,(11TP")73&- _
M:."OPQ0/D=9=/V?<^)JA4Y)_=RD?J^VO;\H%*;"'9[_R3<)P" Q:Z;2)CR<7
MGFEZFS12S3_K1R1I#Z=>CH2)+]N*I*M?9R+'NJU_AK45]1/8\ DH.&,T!-W:
M&.D8%AWUTER^1',C +,U!$K0;KA;BQHAKE3>3'EOP[C"M4FW3G@1RJ_ (7 &
MRZJALH%2EPQEQU82.EX1/E]K=D$Z-7)-P?G^#T[/:$V%_JNXX_MXP SIQ=AZ
MQEN2FLZ-X2:XY<0%7^N#AF>^KA8EI:N[LJX85K4[#M*BT?A?)4&A]IQZ/\BB
ML.O$=&I6)6 K>"C7CI1KGQ[*M?>E9?K'SMR[P1%\^NCDZ>1[WJ6O[1Q^AU-$
M+#U_Y/6[; 1Y+5#*O[.]!ON_>@82*>E>E=!G"ZGC6E(DMJ#$VYTR/TG4-0BW
M_(/SR1(>M2%UXAEV?4SGUI,?\[K/VPW?_03EM#P8@DTX PR5PQ93#YCT&\A)
M/,W(@CSY%W5,ULWZM@R6G'G;:8_P/,.<A_DZ)#;'!QR=W45X/#PC&L"(D83(
MRX<W='U]DBG;3BL&U]B.8Q(,6M_'#,35I5$OZEN3=^HE)HOL^XMW88']<1/%
M=3,,&96[_T'3]N3%H^SQXV=RE^/)SS43RXS.$B.NNB@(ZZH&6P^<4V8KUT2"
MI"1X?\8Q&]DJ6E/D^=CRHH<M,=N.>=H*\U_WM?<A*%)^@BF8A:@6VI9P'27Z
ME5:[FZ;]R-,<6="5^J<'U;D7X=C/2.-M:N*)K6#76TO9TI?\!B-P//E.NW_G
M?IF"/(HH_2-_AU(S(7*)OBA=U*DU#:X??/ZP'\+IP94@^B"-]S5U=;LT-S5[
MD4]+'XYQ Z/*N5'R>#)X;^M*P5MNQFYN96D\LCZ$MU@)T'R+L\E5AIN)[I+A
M/30*NVM$HL1W,0:)$"$Z5Y7B78X"]\94I,*K(F0;/H<7CYF-DR4=3]Z5; LQ
M*5V9Q8H;O?6N,>R" [$^H@G/W/@<!5M5E)GA*8^F)0//4Q:ILO,,])UMMTU%
M":,\O.]UT\(,1LSY%AY3PAOK-N"G;>\Z]=)QFZ!K,>TV $H'$0POQ? R[PEC
MC@FUW\EZ?DEF<Q\,Z!DQSJWSCR7PYRX['5V%X!,03,RA@VD]OPRAU TE0JF?
M4[.Z"Z:74Y!O+F@FSCPS.-F/(IH([M14:1;;X8?G;<\Z6  X+%>L7+5U,**>
MO%KDLY+K <OFNDPR-'&K[:_A!W1;2$&,BX>8F)"U64L_N0*P%%TQ^JWI!GK:
M-!_"?Z)3CCWS!5,9YVD%HL?6@]=V>$J6_TJ=%QAU"C@J6G5F&XXG%\W2T0PF
M2#'TW'US(/'\PCOODO<9FRUN'"*W'>6,-H0*("Y$PJ>]%G*#RTMTTN+O1^SR
MDZ2,YZO >4V=#_###9K)M]3T(KQH6JYK9,HHP77@W;VWZ0U[YZJ:,O1*S:J#
M-*)>PH':34LERQK[$:UI"=I8]C#-YO8UJ- TH>.DYJ(SJ=4XB@&_Z0]3>V]3
MZ\!/@JI8E?!=9/BYK.8-[I22W(L%RA748,5A=S#?%;&CIMLSA3GQYZIROHUJ
MHA. *H'<"B3APUCH[G)3=N7#<KBOY5!<P^D-)K>:#8!Q\P'!>>RO(A>!*+AK
M5TS2/C)#_V\MA\.D_7Y[N&[DM#1@ZO;Y;*!.<FH+@>]B,XZZPJYZSP$,.--<
M&1>A4"VR8-0YZ0"CX8+!<<PB$L<W"-+YOF!VCS"0ZYOF* 2K+3,2@QK9)>32
MQ)UOSZ3+U@FR H\@60U;CH<5^+NO0.9\N_?I;3@DP1J3.(2*>]NN")<2^<,X
MS$BQ/<5.(?2X)0)"'P=G? ]KY'[6"':]4'1L=CL)R(%W75]*P9BLA^3E:U&;
M3&L?.RZCT*2QYFB&M<,O'=Y$H.1@9!$(3->#2:HU5!;_6M[  ;WV'UF:H"B5
MPO%&J>RL!0LH LW19/H!;D/:A484"B+>,Z>/'NOX6*KG+Y+#/+=&K[_2B1!;
MC33&F A)M.\B,19$ <HE)U-S WJ[DZ?_8@").[;RY[L26 GEK^LO:WZG=,HM
M_1P#MZMC14:11>"&]U925=+=,4BQC&P.P,G12EM:[&7HV69%[8TVS72L'AD@
M:?M:$8&%G@E+_E3+55D 9">]_\C+2R>^2$5\@B3+FCOLKYL%D@(N+:3SY";!
MWRIR "37TOZ=6T''<8:'"3^X"GZP),L_NVJ:3DA2>.<PKIK6CUPJ-C'JJ-*M
MB)M/.5*&N3'E2!W)D#F0S]W28SZ[?*>\Z%U2SO_$:)AG!S3,?QOR@IUY<#'!
MIF LL/5P3/4M7-ESE(%:<UG !<P]+'*R:0J2H?O!=]"FNW[)UCNI69++:RIR
MTW)]0U(M?02X>7.4C50\AI\1]KT1F3A?)_NU+\"!XQ[+'@(G:I0K]6UITG&&
M?A&%^NRG:_-[3G#5[9Q;YL,RE.QF)0UOD=_.B5=(7<RN2T_8HW>[,<L<_O0-
M0ISPR>J:M9;C(1 O1O7[G@H?VE587N6+^;?XJGR><NW"$#XA"Q46$I7DJZ(/
M*R'<M.C7FYU?F"WR:FFZ0;0^6]9J]VCO6QT\NB)<O,\%6[KP>*:^18WVC@^%
MV0S3,_1-C<\OG\_SBHH1S6S=HFL-;$+A+)=#D:?2'(SPP;)S" $TT5/E6X>;
M' 06,B"^[IY[J6+K+&$$7,=.RO$M+\9O0:N'=S?64/"56O2T]NVZ4YDN76^>
M']VH&\BQR8SZ\_1TA/^#^CKXB;@56[PX?SD&$LG=H>2!Y2_/ ;\8V7JJQ@RN
MK"(.X8<PF[0H"646SOTKN0CZUD=>++D_!G0M+C]N@_$19,/NB0([ 2QB[NUA
M)".-]G#:^N4#RSBPA[R.UE2Y)Z([,YN_P4X*0CH"(V.$XQQ6O*B*22;;3(Z!
ML:L[AA@SQI.S!98ZHSA 4YKS8(>XC0DPZ:4D];YK,*6@RY'?SB!'3"F-*&TQ
M1W! 38:U[ MA^@=5\DRP8[Y'6ZE;NQU] Z/H>]+VXO" &3AF"EGB\4@$!#(5
M5/.'YY"%^FZ4-'MYU/UR1:P\B>WUNVLH^1#-R,[YYZZT>2XL>=?!J2+1A"1Y
MPNIZU!9P52*=UY7EQQV[*T0V?6F40I3UNR+&'"8IUP3#V)$:GP@MGYAKVADY
MLW&7TJ46$5;7U643+'-'\XJ#0N%954&;'P0RNBP-E7;[G354^N(XWS'5*7'$
M[[;&%='9@D0!_34-L^.C?F->CGLMJY3S>'#CG9B*2J=HY%8/!H[T>CYH5C&%
MR#P,^H:&7,!@:-[IKB+^KFGM=\$*J/P.K)K'FBE:;TJ9Q92D9 CGPORD@O,/
MH'WU@^MZE/3!*&4BUA)SC$]$852;)A-,H_*!<6'Y,Y.C,\##&P_:"$4DI@37
M!B5;V2YP<]4POP@!%<-<W]2 &W9N<N)$(Y5R+U.-HUU)$48?L7,/.2,0:6<\
M*"- *,(5=L89A&7*H]@@4&0FF)8.^Z)<XN22@1IT20.N:OX'HZ1&H8<C:_4!
MHA$1 4:GKR<AT[]'8I^(G07%SRQOVTT8N'!\%I+$%!]4CBU2&EJ'F&$*WT^*
MI<)<O)^;]V=$E^KD<[VUAO#=S\<7Q^:);P]&>#]&&.O)'-Z=H%B4GPAO@^PZ
MDEM#=:B3K[/8:!H.Y:J-I ] B;1MQ6TD-,R0)9A3XAF>:AA8;-^B1%=G/)YQ
M^MWZM.&4=1S2SQ]QGT?^25Q/HEP(.Q&1H6E.PC-F7J ;=HM LJ L"CC?Y9 D
MRGRB4B/?61X# C?!^1TP47! ?Z&4N8^?G^(>CY];_>.U1J+O2_:*SIL"F_[D
MQ?-GK.;'?H:Y[C$NQM4O&X# E7$NMD-S9*F\<W\6C#ADK[A]'GVJEPC_Q U[
M&D9* M(_3S<,9_X*.E+!NB@U2.RW1O#GH7DLJ?*5 'GBDXX%7=P:08F7\DCN
M>:=MJ&47^]9@)U)^:S[OB,6+KAX\*?U@9/5B>;'!GIV<I2REBOJFMMV4?S-I
MK\71Q?PR,^RM$")7X&<$\I] $>*FA?UPFK'"&@G7L;).!6Z5:X;O#^9.+HXU
MIYQ47V+$M%^9Z''6Z5"B$8$& )42U]NS_0P#NI=TD'S;[%4U7UO]08Y3O1I&
M=R>Q3Z:Z<Y\Q1(/EH$""3]J#\3]/GCX^?L[7#G9S@3TH>N-=C/C$T[VL.+O
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M=;9QEL>=W+=REF;CA*59Y&_YC+'Z)R[%?WTHQ3],8HH/CL9U+GYYL+4K5 ,
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MPY .(C89!8#574JXRJW9/ V-!D1A7U[(^<-/B.]MQ0JKRX23!J><9?H07H_
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M0 8[X)%S)A&K0KR."%SULRS^I)NGK5!0>8(^'Q+>&MF(O\54G-UP6=F>"5N
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M)PY4)18M4 ZZ+CCT990[=4-:N#GO:XE4'0$225QP)-$ J80Z]( UJU:51VX
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MB?CMFFYNXX3<IG1RQ7J76F!QEJ3+IRY8PX3H#WQ7<#H 63/P]\#M#(P9;:J
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MCN\K^CO R@E"!-J0C*L45)F?FS"M$D3H*0LA1'WK8+!1; ]>E#7&HQ+$L85
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M2D^XEG'GH>C(E,>-1NZ.YU2I#T-GH"?C@M*RHLV<\V.B!:HP?RS)2>#AH_^
M#USZ"^'<XTS%G-4/P/JI\"[]7J2QT_&(AXE\7OR+=H4><HL]$<Z % F=VG0\
M),#J_5?6Y&ONA2"G%X:4Z/_ '*Q@AZ2GL,H?ZL=O:I,D36S.;.%V!39Z^9S(
MHP&I#5\1,)93_FGP2,;\GYR(8O3*A"%]>A+.$"<3F89HM8D[0@N\X%O3Q9VS
M 1G[# _3QYBX\]/7^ 30=.?3 VH:/@-C[X1/MF0=R;]*DYE>T:!E]-/\8WKE
M*3.CE=S\I[$D22!/654':9>V#'!^5,@0^: MB*Y_.JUAF!X9S$VO"OR#1#L3
MPG<AU7 Q+KQ..)D@>WJ@ 8\>MU+$K(=U&:-1$@K=C*)@Y.&JI<.&@>(>GX>%
MGM.T7^<FFVYQ^);P]9'U(T1SIIM]P>&B%59A;"J-G170P8'7$C(M/0B?62@X
MP6#I6A#AG8C+A7J=Y%61U"PRD.6JI<[O$&&*CS-;+%>&EV/-U-8Y'T3<5#0J
M&9MC#LDQ91(]J*1E$;Y%;"_8Y7JZ2AI8,&D01"W0 '#/:$SXYR**&6I^$_)-
M"(9[N!)QLS6Z.TYFD#[T%*LYNELBZ9H513;5Z80^<H5G>?M Y.K[0,A6DG\K
MO\R!O\W5(9!DJ![P>M^*$6\YGDJ:MB^%H2=YY4 N6U&"ICAJ<Z6ALI)LWN*E
M)&>$P0WE650 )V\=CNY\N$"O*STFVDW,Y<Z #Y8,JFM2EE>\7BO.7-)L6X52
MY@,](C!-I#M\"!#V4OZ/W!@X+FD7N5@PVJ6>*G<J:$B1* <2',KI"(&\!U+1
M_#WI<:U^I!P+_"02'Z ]J_Y]_QK*,1#HK5EO#.ATPQH@K 4BYU'GA<[Z^J>2
M37F.0!H=EU$@3QV950!;"?\5W_$_+'6<,0*PZJ<_ZBZJ+6,VQ<6':4XDI?C2
M"0:?YIX0.I=A!POS5P$\6M#QK>PZ_XKR:-:;C>(U%ES?B]=7/+2CM5WR2;.N
MJZSK/Q(^.4"N*]FZQ,%N?14&.K]A)47[;C9KV<?,4JY28I%;@"7AL(5"S#50
MH-C*UD\O&UW1V,N5*5UP6U!L<A=47#+=;!8:KM'@B*/+*[Z<]<SFZ^#D5XF)
M-8T;%O\=ZC1Y<*()"@JYV .^)IFYTME?]AZ;G ?MYB^]7/0RR<\N"#G*A X-
M0=9YH7=-%^;R>C+%'N9GZY^P.'@, ,:JJC>11,;I]T/MEB<\V)%D8I>5:5P:
M] VX)F4*09;N2S6Q92>&%^GB4$ZDJ,N3Y9?\FC5)&5KUT+].UJIH6DTYP7PY
M0=N4$^QG.0'&6H7^Q[(O +,YE&6:N]A&XEJE[2LMS4D',=?GN[4-^;*]K%&>
M)S-N)\""JX!8:D%#YDV'21AAS&:MPTEK0="#'C+:$Q/'?(E85I#*8E](3(^*
MP?W\%)>.JI(.Q:4BL1%4J^H^#P:\.+.51J3D^MAZV Y3DO.1 C@BM?R:3+F5
ME$I@I$J>4W9!I),BG/!"B ;&4-X_FS@0GIJ;DKR:JZD5Y?DR92*Y0*D6+*CF
M*EYSQQMKNP?22RHLY\;2HY2K2"O@WYN.M$N^9M(HP(8[D_]R@Z7TIX(AO9*K
MA!SHF384T8@C^P7UMG09BAXZ$_3%HSO@TG8%2V9IFT(F"C?&:B0TI%XX2J90
M?0#' _+$4YS,B47._7O1.# _I4E<4E@542^C*R^_GIDB]8=F''3LT,2O@WL\
MS.PVO'+J-43DTPV?TIH3=6@$X:WCBXZU"*-J9U??H6DT,SC^[7L8T:V,GA,'
M9MH'FGW\6-YU](;?2VD\Z*28+Q6F88-AQ, >B[2&>\FW+.VF**L8)Q-!22BS
M!I*DS<8A\G'SKZOR!9F_U*YWN7FFQI9*%& ]1>6(17TQZ:WX(55$2_7JR%@V
MY#-%J%,NA#2:XH*HW;14L)>-Q] +0N<L*I&X9,B*$;SB7/!I!E$$!(PX"BI3
MSK03I34OB2]<'S4.:JGESH!,C*:SDLH2ZD3E#TSJ6(8)4INZ)I94@TDQ%O0X
MX40>A.>0)ANHD"4C68U"'BC-&6[PK+H[N+6>],(US._=\CN)GTTZVYFT"]9;
M+T.Y$/-7B1_JJJ'C7C:(9;N9] NGJ^R"WL&&EU"\[CZJI_#*IEIDQ7ZO6=?)
M, +..W"AQ)W6TTT$#"]-P<PW1@E[YPC;OGE?::=R?:57Y]>_?;VYMKY_L;Y?
M\CO)S<7W;ROUDU;A+#[CIH@[B%$::7KBBACEJ&$(^Z?5L"'^V$(EA4!D-5N8
M;C+%TX+&*9E"SSCT6@CXFH+N6!GN6$<"!TTOU1G4FLT=,3DU:MW64B:G%7^^
M,WJIJ@ZJ7?PK^2K#4[4"_\J*C#7/+H4;?MY'UC?V8%T%4\??4AX%*&R&IHN&
MM1?Z;&BZ=D_3]6;D<8:^]#J;WY"-[>=*KTLV5I%U/F"@Z;.B8D)#9+8_;%.=
M@=WIU:O$!V&(S Y$M;IMN]WN&]5Z[74X0-5ZW[;[O?Z<"_#<6G7 I#.76033
MMT$NT[9;K741W VYS'-'/?K-1O.3695*K<HK[I2#OCT5PD>_$7I N]-L[:UW
M>)AKLIGQ-:MRL#OE@#W>JY+BDK?A^FY$Z66\K I22IE%>>980]_N]UJKQQJ,
MV[M,HBN0WKP1%[C/KU7&!Z[6HC3K=L?0EE=L4=XW[69C#2-LW-]E$M4)A;*T
M1P?M]S;LP<!X6!5;DT'#K$BU5L3NU]LFW+MCJ5X041I0YHE6DK?AYKYOMU_^
MZ#:N5*DKU6N:U:C,:C1ZC==Q:U<A[:X>N'(^15:E%JO"D5H/3D0GZ;O.H-:%
M1M:)['I]UVW7VO(G]- &W5:V!M$_>=+@;+17+7Y3#@&I'.\3^XK]VX @7->
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M_<G]!P"H)R(-=2:[7$/YFY[*]@MLJ)DXF<OVS67H!2$!D,Q!]ML(C2W&G)E
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MCL"MU+];AVA9NUV5!JFWD;&51"1EW",FQ;:2]0<9?DU%N.$.@&[JMMWHF3+
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M;*QOS:.30<\>=.:1O_9&WTRZ/Z=@T'-HC<-@*NU]X)ND_YJ8.W.&O@1S1^W
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M*FH?XD,F+/D*8<D*J6^[CN'-5@&IV3ZHKZD)7A38VLEQM'>UG-N=.$4[E>]
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MWSQ37;KEBY+3O:.31KLJJ6FC.ONSH4T9RZL9AY>R#?TJV88#SKWA8AP/^4K
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M-+.=E"N"*F_O5CXD2][*T=@V<3"O/<_RB(AM0V,^4II5(RI+=>U-&739$SH
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M@$] TZO9[_RJ;7'!ZR+]!X_]94Q#!U"9CLUR_F2DU7[4GF?69(;@M!P35HW
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M<*+9^(V;QH<5UF)U*1"':0DQEG0PK)7 7!'RS+,LN"*,>34>F5/&3X[#: :
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M)O(:A4Q>!M!GS*N M5E/,B]"(:7_S]=&CH-.*NX"0GO@*]9Y-!NG_UQK <
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MME=">)"WCO[).38YW2955M E\=;WUR0TV#H%#5Y'0:]<2"$!#8F LAD<;T]
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M;1PUXQ'H@.A%USSWQ; Q55^#)3BD4L*5"\\U0WB\#_COGVDJ&6+[5<_$;62
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MOP\ 3PUDKQ>N2<Y\%.J[6>72-9%9-;J_T+5!IZ57 TZ<A-X0&!P6"55)^K*
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MD77(@Y=:K!6$?"EP,0]'X#MS;J,8;.J=/-_,)_.%5C<V;)[H@G'A_/?P9(U
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M+H_JJ>(OD$62I>)JH<@NE9&N:#WB8NRIXLD_%)?#&/BZ+?NP">!PS3LE3<+
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M5_[&3+*3Q0+H:<KO2=4**UBX+)3.>^33^,__3HZP!Z%B\:!W?.(GZ>8[O1-
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MS.HX===^T2.5<(PQ+*F?Q,5N8/;^@)<_8=$D7:O09XAI%-\CA6/9DO2BY8C
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M4Q6+9(RN:EK8SHK]9).0MVN.-D+K!J&%K4,Q&R312TUQCRYLPW&DZH^LV/5
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M5N'"?:2IY&G-E.>+ :T(5C,>H1R-IX^,/5F]2-/D<0'4G5N96Q_-E$TG^TV
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M6-M/Y(5-2!X!:_,\)$FK6YB.:*)//3@S:AV_U&7"Q9BORJ-H6M;<^!.% SD
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M-W03_H[^P5'!K:C(.6#I:@*)M10F5<M4.DC<J]KV>%4KR-:N&BNDN(ZG(?W
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M<>RP@ X^1N-QJ%U#!'S9=+R=@MV$9YK,>(>2JG$?V:C?F6H#=320O</BDI6
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MU00VOY#<,?.0ZLN@SMDD@13D-MW+!54CE9#G 4>ZSG#5CI#G%1CY^P,\3[0
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MPOC<M.5#&)^Z5F)\9K8?6SY@T#];L/?%%KLUBG<;UHQP-OKF.B]E>[_ZQ<W
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M9(D\>ST&BR=2+QQV\!'7U^D"6'#+PJN( O6T[/5JQ3M_08?=LFYD!91:V-O
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M$=#8^)<%6=)JVQ ]BEEQB>[C."P?Z7@G6"TV&;DYJQ!3CAC1*0"$=C.PY*C
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M;3+ 3 ;! F^W</K9,?&V)2[O7G!YU6WI\7AXOI5I'S&P?'.NL0BMJD)B^::
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MEUV#U L!63\]?L8(.054"[/@P \OEN<E@ "^?9TQ[X&6F5#ZWP3QZMU\G<6
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M_XCVM\W.DCNB_1PB;*F9[D]W&^BI;H,6 TVABGRO9S+$8:=1OS/5!VI?+RN
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MYK2W_?T9+:ZE8AV:"QP=C7#KH\2P=AW'8F#&#]8+V8Y,6RJV/+O?5]!3Z%Z
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M%IFA/7"&]BQ,QJK)Y=*4S(O;$HQH$<*LV$*IJ7I/%T0<2P7?"L4)FT8>]7I
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M]A,"G,J^B)UEZE\<9X&#3V?V(CY7]J<B@L=Z=?V,#&M),$TE9T."&2*PP,[
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MHD@X#%K)2K5[.WM*2<E9>B7@$F,Y2T_.TDL <91#;AQ^D%UE\RK[.49S038
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MYL/Q3VDK&W[@*4\NP>=@=Y*]67D4=8']G;^.-^HM[O%5J"GH!QX;C<[;Q)E
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MJ"D7.C@@-8W0F@=J,O+6O*2FDZ2FNN&#?5#3N#,=J1,C/SU:TM))TE(NO'!
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MXY\86:K!Q9Y,O>IR^ M@(@0F'&UUSFJF*+_0>MORP(\P_-!L><X$N:15@^M
M8;[0!#$N5!5CG]M"Y6%<' -6*D$YX6K5<]8T/M$TCE:%1X)*6D%CN'D&.M3+
M=K0(W]/W+^-HWBVK 7-/L-<<49Q=X X=/IC;@IS=7G1=!R^Z?-CL1=T8H&YD
MXX9J$?(AQ\S)T:%^6B)R*%'?_@L5OW9*@(TXV- ,0SX*QQ9+X1Q+;6N].3A@
MJKL8#]_^6%NV)QZ]L+>JV&67;F<R=5S5]\3/YN?@2P3I.5;I:56(7"L@I-S%
M[KWX@70(@ Q(1_?Z:O:5Q<,KBZ>:I@^R [(CK>RT*QMGEQX?+SN^:AM'T98
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M+]=D6CY<6TS\7V'V>+9.\>.C9"-(KYW%B$0H+-5W;4&\-N %',XZW2]]E'T
MQ#,D)$\$[MIH/0^TGG3L-1G#XM'GY_2YI@;TR4-?@Q$MTIIK:[#F2DA>@^TM
MG-ZS=<'T'L5F7X3I:AF\DH&B9ECA*G&NDKZ*>>.$6<5)KACB!R7>G!VL+,GA
MP6]NF5<(_;,>0_OA%.:JNJO1:,9DZEL041.:$<9NYA7?2:L3W5O10HIXJIG
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M 0#<=\Y[$X"[$_!L$\K?)(1OWVGO?;2?!=I//@#WG?G>!T![,C4LU?1[>XH
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M/.DI_T[OZI9]R+^;)P0X1O7 1U  H #D5 !M,W=Z*@"OMPMT'PK ;\P( @4
M"D!.!= V]8FCH#F:UMNQ/82:<C2]*:4*Y!_D7T[Y;YL[UE.RF%V ;<?%52^9
MC3EI(BL :9O?_!:DX3R/8BS"Y3I#"]+PI@AMK%!"0AM/F*/T,4@J^6H,59<F
MGO)%O+Y?(DE5&N,CCTVG7:/DEB! "2,8C2KD/$@B_/3IYHN^%["]:0AM2T-0
M/)G<QY*+0.U([,E4.]&Y^BK80#ETL+[%_2V>A&=S<E ZH'0^NB[Y*!V*^Y3[
M6)J5CILKG6K%G^Q*I_OHCU.X)99OA[=,47RCW$>R2]/XN7QS-7^861GUOD*\
MK04H(,D4D,==['6*/Y;[6!J5H:X3!533A5!T!21M,FG^OE)EG:*%DL5Y.BG&
M2+GO[IKI4,U;/'9E8]A3Z0FB!AHE+Y^]E.)*T#[+VE_Y=Z/%##]8\ -=KI_N
M47+U4(I_\3JOUEF:X9>'IZ>=DW1;1'>Y<KD.N3+64FVP#MB<3'U-U75;]=IX
M=KN=7\"+U$.7V!_Z?E *W92"?5BEL,LORG7(O)2"#4H!A')HH70.2?@NKR'7
M ?/3(J1!M*_JIJFZ6HLDC.,6RD/?#TJAFU+P#BMCN]R-7(?,2X_YLBN%W'?P
M:Q;@[\3_7H3/Q4.1EQ!&Z^#],3]^@B_</%8)I&44_856<1J2:TX3M,07/Z-O
M/\-%]K@!=NO&\GFU]UN"^S0FJ#7>\A0D/\(HGPOGHT#.$6D&Q4?V_!.;)GT&
M&9E.?$7EJRYF;NN?C\EF%"O,Y=?[! 5_?PT>\"!/@^7/X#4EL[_]:/BY/DUE
MTRSL[;'=VL<^N_@^NYDI=_\\OYE=G_]Y=W%VJRH7EV<G'R=#G %?QAE*B0/I
M+([RU*> ^(Q^#Z,@FN-O5VXS_,$3'EBJE%7B2MF?#"WJ7O G:2BUA>>:7^U"
M?>5WSK+-I^5FJ/8>H_8>([^G"GXI,CI9';9D@?PWOCZ7XG?IRM4&GMIEL$K1
MZ>:';YOCR\(HGZG\IF\?OY],ZR>-D;_"XM<EE[Y_8C@^0;-T/99_N*3V!,_\
MK]7/#>O$,^I_I9WHM9\W?96NG3B>P?15S9_;I@.#:O6YZ?DPJ/V_/FOG5U%"
M #OWTKI=N:YFQULH[GUN>2O*O(@)A"_*O_!5CZER'BVP'O^O=8044U,50]M:
MCS_[^X]O+HP/<]$2$ %"0?6/>A8G"9J3=1LOS0O2!V;Q<3E_6\25^$%Y;RJ:
MAXD^Y&DK)(E<^;*.@O4BQ'=6@GEU1FK;_&D1*9FERG6"GL-XG2Y?E1NTBI-L
M:V/3YZEIMOV8I^T&I6](S1;_7J<9^1&FC4Y;.7-M$#N2&0'Y _D[L/Q)6ZAS
M@YX1MIW3TS9H,!^$QH+-'C+^8' P. $'QRD#3>@^]6?$@8:GI?#?)876877U
M2Y<,6_=<8PJ4U=;_^KL[DI8K3G&.Q1L4SVB6)$'T(]^QG+_,EVLR(Q^NC3+R
M]_\*L\<SO)V)GU#"7"9L:).I::J.5BV^ZQ9\$B"J#$(C@=#XVH&$9F?K7\?@
MU_H7! 8$AJ? Z *O,@:L,B T(@J-(;#0%(<ZFD:U1!F$!H3F@$)#.3V,J]#4
MR(6%Y<*I9L^!4(!0'% H*$>G'70EL8OCK3U15A**?V^34H8'BIIE#*X2YRII
MHT%W<18L-][9RG$SK>H'6#S@HRT0Z.'W9._ :#B\S$G6=W/H?A[ 67=78<KD
MY^-^3"DP-FK&VGG7.N@R#W09<,;JD.K F<_+FP2<R<!9.Q].6H>2J7%QP !'
M,G#4SNW!KJ],G9?/8A^<2=LRJZQ\B'XHJ#@NMV->Y!B: ,#]QW<_>"(ENXJ3
M)U+HU-$;E*(@F3\6/0OQ"KN,5SN+&8[V+'BJ![*8R%FT^/X^C>7!\.Q;%I+E
M0GIP\=H:CVSW*R5"=.?B3H1J*#$G4]OEM:L%1 1 A.H;Y*IE+*QE'-7BYL@!
MA 1 B.KVXXJ0G2]4EJ$#0O(@1/7H<47((0?,VSYL=20BB.K+XTJ0BY60JVJZ
M*$KH&(H._Q-%* F6N>$8+)["*$RS(@^M3V=[*:6!9CO>HB7^"S_*&<4R,?LP
MGYW%PIM,7=71/$%2]7@ZZ(X5)9H-V1:E&EK\R=3S@!6)6*$8DP.I'4O#(*F6
M[P!*\J!$,2J'0DF?3'W5<$$K2802Q;@<"B6#6)F65CU#"U :+4H4*W,HE$@U
MI:8Z7F]S<S\U,&,OF8@KB2-0/,'3_'Q+S"D%@CW#RK(F4\M4+;OW0@V9?!(
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M2$S_]_=I+ 6!V:=IDCB@JYIF[XIAR!,3!R%J9L).A&HH,2=3VP="Y"&$FE?
M5<E8A9+Q "&)$**F#'!%R)Y,#4W5K.K9 H#0:!&B9@.PKE,.IL0R !%9$&D1
MS.>J9=Q<RQA>]>ST42>X"VT9_B>*L%6_S W#8/$41F&:%77Y$ YDM UOT1+_
MA1_EC&*9F'V8S\YB0=S[JFU73QP'5]MH4:+8B&U1JJ'%GTP]%UB1B!6*M3B0
MVK&TR=12+;/W?@Y0$@<EBM4X%$KZ9&JKKB=17T1 B6(]=E_!+ ,K'A]8D885
MJADYE-HQ)U-'-5Q14)(V)[RHEXXKF>%]HHM'5SG1/MNT/NS>1B"LR=30L43P
M<K (4:K#R8%WA,"US5_=E7QHV9.I;]H % #5/JNUNP8C(09#-31>+<  N%$#
MUS9/MCMP)"9AJY[!*_()P(T:N+;9M3N73&\R=?O[U0"H\0/5/N>VNP;SL09S
M5-L>Q:9?VIYBFX.TE_E!V@])_+0QF.,(6HQ]Z6DIIWC8^*=&Z2EFGQQBSBP_
MMC:9>EA\JB9.Y0QTZ&PA-W85>YD%NQJR]'K3&;@Z,JXJ9O.0ZLS T*EU\17
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M"NR#9JM590:7/3;3ZQAS,J&D7-&J.2A<,6RT3-XGD0)S(V6.5O#!KLLLT&7
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M@U T"85[2*'PCUHH ,HF*+T#0FEHDZF+H=1=U?=Z9\N-#LI#WP]"42\4GRR
M?0N%/CJAD#9.UF Z+!C"9YR.FCD>Z>MH/)1F>$4(V>7/X+E3 N_;H,VECTDL
M.ID/_,3"/&JQ "RY&A#\L"1]0SS5]@W5=JJG3\B.Y:'O!['@:D+P$PM[=&)1
M&A&;46QFW\#0"91H*[9%?]Q3(_#0#GT_R]346_,.LSE?:'._QJ[/_SN,%BC*
M3K&R6@F@WTF2JZ+,4B5[1 HYKB6(7I6?0:J$D8*'4+;86\5IF*M_K([S*[/'
M!*&OV-C/'E,%X2=:*+=HE2&BSA534Q5#,PRUN/1G_'6^#-)4>4+98[S(O[U%
M4)(X%(I$7'*H[?;P\'S-UTO2R;'>(_%^)_Y:_$L\;G+[4YR4+@QR+F[\H'S!
MCYZ/,$%!NDY>E;Q78#E,54D0?CMIPZ\5/!'A P8A(J\0_Y'-7?CA@M5JB5\J
M)DTEEWTQ?JF=B),/ZU!.WZ]Y]T+\[T7X7'2/),MK&*V#]WZ2'S_!%WY:.2SC
MQ+7QN]^\L],$X;G"C_SM9[C('C?K^M:-!76GVOLMP7T:DXEMO.4I2'Z$42Y7
MSD?0YQANE/!!V#^Q:1 ;9&2Z8;W-93%S6_]\?%M:5WC'\?4>O\V_OP8/>)"G
MP?)G\)H2V=]^-/Q<GZ:R:1;V]MAN[6.?77R?W<R4NW^>W\RNS_^\NSB[596+
MR[.3CY,ASH OXPSEI_&<Q5%>S9_+\.]A%$1S_.W*;88_>,(#2Y6RISVYDM".
M%G4O^),TE+M SS6_.L7&-+]SEFT^=2?-]QBU]QCY/57P2Y')=?B6+)#_)KNV
MO ?IFW3E2Q">VF6P2M'IYH=OBS!=+8/7TS#*9RJ_Z=O'[[>K2T3^"HM?EUSZ
M_HGA^ 3-<O$J_W!)[0F>^5^KGQO6B6?4_TH[T6L_;_HJ73MQ/(/IJYH_MTT'
M!M7J<]/S85#[?WW6SJ^BA(1V[F=UNW)=C6.@4-S[W#E6E'G1@1E_HORKV &>
MU^\ S<8@T+'.B%'=\]%A$2!,6/_ 9W&2H#E9P_$RC:V:M/CI?6E_6]#)=OL*
M[\OS-3?-=_0?SH942$\BY<LZ"M:+$-]9J92H,_K:M@<2D15L<5UC R.,U^GR
M5;E!JYA8$5R>FF8KCWG:;E#ZAM1L\>]UFI$?8=KHM)4SUP:Q(YD1D#^0OP/+
MG[2U!S?H&6$[.CUM@T8+Y^W'5RZ"9QL&!X,3>W"<LA/S<(9;.$*%TS-GQ)F&
MIZ7PY26%UF&-[\I:PSCF*L5J8H&^N[MMN>+\GL1/6U \HUF2!-&/?,=R_C)?
MKLF,?+@VRLC?_RO,'L_P=B9^0@ESYUO#F4PM2_5LBU/&@0"I-B T,@B-<2"A
MV7EHL6?L.+08! 8$YH "8PJ\RGBPRH#0B"@TEL!"XT^FMJ5J3K6K&@@-",T!
MA:9R NF 0E.5"U.;3#'^(!0@%"()1>6L4'%6$E//5Q+#$&4EX10\$-J_=YW$
MB_4\:_+LO3UVBY+^T5?<]/:*587@35AF:8KP_Q9WP0N[8!AX*5&M_N4VG,Z\
MWW.K"#FY8G$<=>%JMX/(-+DYB  J<:!B<:X,I:PL4%;2<<7B?QA 6=F@K"2$
MBL4^'P J!Z"2$"H6^W8 J/C%W3A!)6T'K;LX"Y8;LS7EU RK.>E'+BEI9]2F
M[)L_$D%S5-.HG@'.^83BFKS4$;7Q.1;.VAFY*9.*]7FG-@!CHV:LG<W+KLLL
M#709<,9J W?@3.<<0 ?.1LU9.[,XK47)X!ES!HY&S5$[2[B#OC(YAVD'Y4S:
M K"RV#OZH:"7%:D,[U<*=NC*&[@?[C_"XJHT;]RPXI"$T38+:Y1K&<5?]:8+
MR82FLVAQ7JK$VO7+FDQ-C]?IAR/;!\F)!\7-M ./]GXGBU\0$M 1!QV*]XA-
MLSB@623#@^+TX:-99"S6 W0H?AP^Z'B CH3H4%PW?-#A'D<3Q%4CM,5W@U(4
M)//'O$'? IM[RWBUL\'3T2;R4%,4BHG$]']_G\92$)A]FK8VF=JFJGN]?>>0
M"R8.0M3L@YT(U5"B3Z:.V;LX'! 1!Q%J\@!7+6/D6L;3 2&)$*+F!7!%B 3?
M;-5R>B>E $+B($0-^7-%*"_0\4P@2"*"J,%^K@396 FYJN&+LHX=0ZSP/U&$
MK?YE;C@&BZ<P"M.LJ,V'<"&C[7B+EO@O_"AG%,O$[,-\=A8+!RM67=4=B=I'
M 4L4(W(HEERR2+N DDPH48S-H5#RR/EMJF_P.JT56!* )8K5.11+/F;)5C4;
M6)*()8KY.1!+CI;;H;X)*,F#$L4.'0HEG=0]J+ZM"\*2M%GG1=5U7,D][Q._
M/,+:C+;YK/6!_38284RFCJ6Z9F^)8'U)(W !'B%P;3-DNP-G3J:&:OJ\VCX!
M;Z/FK6U:;7?>+*S@7%7O7X4&P,D 7-M$W>[ V9.IJZFVP2M%"( ;-7!MTWN[
M T>J"537L($WX*U]3G!WWERLX"S5L$8!G+1]S?)SNA^2^&EC9<<1=#?[TM.\
M3O&P\4^-0G,1S>,G1*:>76Q(>,53+:VZ$:V<L0X=-^3FKF)E#\F=WV1P W9'
MAEW%V!X0.U?#V&FJIU7+7(&[(^.N8G,/R5T1XK%J0CS W9%Q5S&]A^3.(%:X
M[52-(L#NR+"K6.!#8F?FRZRF.X)S)VVD^RI[1(D2YJ]052*407LUN%^>^X^A
M9.("Z^\$I=FV%$.Q!&,NRF82B\6L]"Y?QM%;#M ERMB7-UZ'1$'NGS@@47),
MV$':W<#$A89L,E)$R1P91ATYH(ZD XF2$=(.I!I67&R9B7)",8 R?"8']W4+
M>K;)2!$E/Z.SNO$%4C<4HW$1IJME\$H&BIJY@JO$N4I:[UU9I_+9AS=(F8JD
M"HU6HT+F=EN!?=!LS%MP3^-[;'2[MS7F5$=)L:-5JC!@MWL?YNF\SVH%YD;*
M'*U:A;.J,T#5 78M:E8HV-609?(P%@"K<6-%JTSAMX):L(("<ZVJ4]A5F3T*
M529M&<HERI0E*46Y1U@AH-*(5K+@9=/S 8I2ABE*><\:^SV)G\[PMX31&L_'
MU5LYT&_Y*RFNNPM>4'K^DB4!GM(P"I+7BPP]I5C6R-]/XKS?RL;YR+Y5=8K&
M*A9DW1X]OVV+6X3BUX4B&<"7J4A&*'Q);:&OFB;4%AX]OVV+;83BUR^*=HQJ
MKWG@]\CX;5NT(Q*_O@;%/X O4_&/4/CJ^?;!KSF25BQ^C^'DOPL^#I21G6+2
MUT=2)UQ8:$K'X6\H0@]A;=Z43^HVW3[[9CC>1ASW,K6TH(&+]K$,W^0=RP!P
M1- HU'*"]AK% HTB,AB<JP/Z:Q1^]4D CCC@4*L%^H/C #@2@D,M$.@/CBL:
M./*'Q\EQ?/C%K1+TB-]:^(SRC[E9UW19$&,^_C'0$PLH]0.%_<^V(2J4 8;L
MZ@%K!';'C]<[V;]AE'A(/;K:^"0>X*IF30_M 3U4(KA700$<K0)HFS?!40'X
MFM;;PS*$ O"QGFG(QP#Y!_F74_[;)I[TE"RC=]'+/O22F4>D7!T4 "B 8U$
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M:#"TD0Y-VIC/!5Z-$KQ^**L@9 [KR+KWD&J'0:N-W1!PC0&X1$RY^:Z,9T8
M]#) 3RFD[0.]C,== /0R0$^IO.T#O8PG=0#T$D!/.VRD GT-W.9D:O J]P:N
M@>M]5.SV4>8RGH$"T,L /26=L(TRMP52YM!>7K*KI(TZ7,;1USR\$$;/6,"V
MNL>_]HHU'-K)"_?#_0?UY"_"YWV>K;Q.YH]!BO(#E5=)O,*C>LUK.D@YQXI$
M%572B'*Y7N2G16 AG^.'S5)E%;P&)/Y!KL4?)FO\^V48W(?+CP=(Y,\# 0*)
M-EWTYIFK, N6YR\K%"W";(TW8!?1?)TD:/';.KN,L_^+\@U9[6[,F4QM479C
M8&4 \.VZ;+8%GL'FYG>V!D@#2,->^W7V4/\>J'\ 7C#@:1&#7L#[DZG.JRX'
M@ ?@]]/\D_]^QX/4() &,:6!VK*@N_K'DB:.^H?@@V17P0N5["KYHTEU9Q%#
M/ GNE^=^4,J2704O5+*KY*W=2M,U7ET1?JHT2TE8-[=2E/MUID1QIKRBHJRK
M9\078KWR&+]-L=[Y(GLY_8[NLPU39P2IC=W[?9W@&<";.K*GNTJN _S(P;+\
M[[L$C[WXVPTI>=CBGIK]S_,&/Q"(PAZBP!Q%@<%=ROWX1! 3$),AP\/#KA@6
MK!@@"J*)0E/@^# K!O?>JR F("9#AIN'73&<R=0U>+6M E$ 41@RUCRL*+@B
MB4+N??LU(YZFM^H!/# R46&T#O*1U7R"+]P,K9Q^RSAQ;?R*5G$:DFM.$[3$
M%S^C;S_#1?:X>3U;-Q:#.-7>;PGNTWBYSIIO>0J2'V&4]X1R/HK3')':0SZD
M^2<VC36#C$PWG$]U%UO_?$PVHU@%/]#7^P0%?W\-'O @3X/ES^ U);.__6CX
MN3Y-9=,L[.VQ*]'#_+'/+K[/;F;*W3_/;V;7YW_>79S=JLK%Y=G)Q\D09\"7
M<892)8N5LSC*6QP&&5HHOQ>QSV"IW&;X@Z?\))5RRT:N)+2C1=T+_B0-I61[
MKOG5*U1,?N<LVWSJ3YKO,6KO,?)[&L''O\LE]EV2\E9I>!J7P2I%IYL?OFU\
M[6&4STI^T[?RNTKQ(U/X23ODKZOX=<F@[Y\8CD\P+!WUY1\N"3W!L_QK]7/#
M.O&,^E]I)WKMYTU?I6LGCF<P?57SY[;IP*!:?6YZ/@QJ_Z_/VOE5E(#9P'&Q
MN_ )*]-+]%.YB9^"J-=FK7[+\_9,NMWFH8H5Y?!)-;?AB_(O?-5CJIQ'))CW
M7^L(*::F*H9FF"V2:G;F/D@T%\:'N3@LS?T?]2S&-@%I[DSV# L4I<5/[_N,
MM]T%J?G-SW#[G;0(5KZLHV"]"/$EE5/EZXS3MIV:1<1AEBK7"7H.XW6Z?%5N
MT"I.,M1\<#O+4],2A<8\;:1Q^(:=V>+?ZS0C/\*TT6DK9ZX-8D<R(R!_('\'
MEC\)$KWJ'_AJA9)@NR=/YRQJVK$,% +$\"E3=O4='>XP?S!_4LU?UR^'P75O
M%E5?H%.$YPJ?NW T7Z),6<9I^WS?FF>4(@!9]UP"!B"_L$4@*^E;*1XV_NES
MV2O&X"*:QT_H#\P"\\%1GC>9^JIN>96H8\7WT$5VAHB][R@( O1E0-^OI&L-
M@SYI^:%:C@GH _JBH%])P1H$?2QA4UU3'5T']H%]4=BOY%P-P[X^F9I8[VO5
M1"M@']@_$/OF?M@W)E-#]4S8\@#ZPJ!O[0=]$ZM]2S5$8)]3O$-H[]1[6"Q/
ML$P0?NWS<(F4J'1;D4_)SWF[F75:U+C'O ,FAW9;POUP_V">:5=$P;_-XOG?
M7^\#(M%86Z]0E.:)S8U2;+ ]?.U*+LC*U]/#^W&]NWT,$O0;F<>SK6ED7_BL
MW,UE]N[F+,[&[^C1J7I(V='97:7J\ZM2!6[$X8;24)B7RG% Y4B'#J7[+B]T
M7.*AT/KWX@5TQ$&GXMSBOEIYL%I)R$W%,S2,RO'%4CD\O4-"6HAO38;?O3U+
MA%^C@DCK]A1ULA3;=E<8HR T68IY-X*W'.,_R!S>D+]Q]?!GBF9/,7[&_REE
MHH(]'L9DZCB6(-T&>+IE),*$<^),/V#TV@.:VWO/ 15A-$J3(=@/$ -K%-,'
MC2(/)KO:X'3&Q)Q,;:,:A@-,!,*$<_I"/V"LR=2J]I2$A4<,5+C8=/T L0D@
M(SF^:?P1ON]HE>!76+0KRIO0;[T?"/,QAOFV9W,6+:BLDX.Y>S?8!2^7,'S0
M8GD[^6CM(M4U?N=8 SSBP$,)Z+$J%P^4BUQ\4*)VK'SXDZD+?$C$!R4TQVGQ
MT?D=*@SPB ,/)3['J%QT72#E(GT0;OMMD/YSQ5%D6:S$]UE 3AO+WS9Y"<K/
M,'LD_[U.\1A1 N$Y1@NO/)@:__7%63FGI&TX51Z,R=02I1LX^+Z&M_1:<<*P
MZ,IX-!5 1+'XNBH;"Y2-7)Q0+#_>RD;&4XT (HIYR!LB!R"2$"**F<@;(GZ.
M[OT$! ]_T#9<-?#!Y&.+\+YEZ(:D<3!*LUZIN3+[P&BV_W40+BZB_PXC_,]B
M*IET&=0U2,@,S0_0DQD?F)&0&8K9WX\9 ^(S,C)#<0'4,5/#ACZ95ML$ A6C
MI8)BT_?4) 9H$@F9H9CP+36)*8XF 9M<LJND#]B?/0;1#Y22+FE!FJ(LS5.O
MEV%P'RZA3QK<+]G]7$_P,$X,,9LDSN?X$; H)VB.PF=R"#-XV+H>A'$1S1-2
M-_0=%?^^B#;3^_^S]Z[-;2/)FO!?02AFW[!W(38!WNWS*D*6Y6[-L24=23T]
M9[]L@&11Q!@$.+A(UO[ZK<PJ7$B"%P@@580R8L9-D;A453Z9E977NV1U<]62
M]LE9JU/:]TWJJC*0V69@VPTI!0X]5"RMCBC:M1?#JP5/EP1/S2"S:PN#5T.F
M![GSI8NV$&34@<P6<USE>Q6Y%.N(HEV+Z+]:\ Q4$CR5%M!7]7!XY3XQ-_3\
ME_>0<%&V.>(VE,>+:;.@:(% HP7=LO1!9Q7]5(+D&-%3_'BX@)X<@!@G9^T6
MP:,F\-@2:E&Q<,&63*U^F0:LA!YU%+$M,1<%P+-9CV]1=E<=X5/X-/A:^+0)
M/C6$SY8XC>K@HURZU[OP%][Z;&[9XS@:/] U+YPR7QM%OL_)* ,#=(P,$+^(
M;\BI6)U34=+@*YLPONCC2T&*<W=\ PM^CNM=7 OL@A9HF.0,J _&BA\SBT-K
MBY2FFF]UQ-7K_9+[D5U]DEU'@+&RS=C?!EO8FZ73+5/]F6"ECN@J?+RM>DML
M4Z;3<>"J;!/Q-Q%7;4,9<?4N7*1)_.S<>@'/M:A&/AKY$5L(C7\/'M0].U#C
MI;X5*PWU',4Z?T^7N3B_H/.CWZ/"4_6!UNN#;W>'UI8]GEPC=<158;?L?D16
MFT36$4"K[&FW</C<9I#EX AZUO17NV"1UU\- !THB+>R/8]*YQT'KLJ>:_<O
MF'J*"*9WX=&5--%L=VS[;!1JH?6K],GUR$P]U?5"EJMY)1?SP?KU6G%*61(U
MQ,ZZHVE1[.QR3!A S'A_H$H_"X+/GILF5PN?3I/@4SOX;&JF7-G.U3%HYZHA
M=M8<,/<A>M F/QB4;M!-\%$'/INZ+E<,GY9:\'DO?E \18Z\&;BQT\[,0^:R
MB?W* .!:6U9*1 !?SN:.]\+8'7.LL)PWH=,&/<_,:7M'=F U4+5GW^>N6-JB
M]"F7CD%HVDLFZIO(J"[)J%JAZO7.SBI1U0-4M7)*BA"JU$#5GCV@%>U\U1GJ
M"4T*R:C7^SVKE%$#9634NW"&QNW?WIL#]& GUWB!_[+#Z85LYQTSR$MA]N@V
MP=33-<K$"I"14)TMO/#AM0"<-N_B77):' >@#G9^K5A2F22I:@6LUQ]A*P86
M>CO,CDG J@>P5HZQ50$K!SM@^^^NYA$0<HX2.:\_L58LDCH@DMJ& B+I7?A>
M;^;,MT(^7,T!<KZWM-.#G5V3=?X.?V^6K-V3LVY./1*R+*N!F3T?2XL@I<>%
M98<LQRJCY6!GSB*XZ9^<=0:KP"$)<Y28>?UQL@AFH(5"9T"8410S>_9W%D!*
MKWERUBX=^D]H44C"O/YT6 0W!I<PI0Y^A_%6OGVW8+IJS]V5-U@0>HV>D@?Y
M:Q9J(RN8:E& ";F:EYSL@8^>2KNCAYX_9OYIZ,T_P5H$GF./-9A,387>SH=]
MOO(7?.%O?>_)'K/QEY<_ \A'2"3?>;+\A:UA/?/DK*\W>]WRUK#=R'<$!MCC
MQV&E!H37HF^S2[M771$JPI]J^-N326*?<K!-<O#=XW!7,\<^<=B!GL=ZNUTF
MII* J!H0*[6=[&E#KJY"%N%/-?SMR1JS3T'8.P9!6)$'_RT/^[VUS76#I;/]
MI[6'^QUFO)T&N=Q9UJ)*(Z.1'=_(R#Y<LZN(H#6[JM)\,T4-_K>1/YI: 0LT
M;Z+-?3#WAR]8-H7].[+G,^:&E'VVW:B_J#+?6B^P<,&#=S[BJ^BS6[FPMX[E
MAN?N^#)>VURM&'J)-8VW#UVEF.C]&]Z+0*7 .7] N61'@:6R1O0JY4Z_27*G
M1EC9TKRP)%:,DS,^*L**HEBIU!:]GSVJ;](>=118JK8+84FYTU)$[E29UG4T
MP6!VCL&X3'[7>_.YE T&2PSV69]+#I.TRRIRA>AS! '5QP^T0T1[Y<*KP(9>
M>0%.PI\R^#MLM->N@JY+@NZ= ZUD.->N0.N553L):*H![1#A6F5WU,H+>Q+^
ME,'?8<.U=A5T ^4%745>6?7"L;[9KN6.J@C'VCDDKG"8RRZF+QH9C>SX1E9I
MG29%#7I\4^"#'@?:Q/=F?+_A:_/LVV'(7&T>#1U[I'F3"7^R^ZAK+@LA),0.
M@HA+)<;7)'@?+72JC021*_Z-+_B57,J;R84WFWGN?>B-?A:.F1Y 5\2>;G96
MLYBH-L*QPFAKE$@Q&&T^50RJ*S1,$%('0MMB0ZJ71"9)HOK!:%O82*62J+K\
M<(*0.A#:%DY2*83:!*$:0FA;$$FE$%*N<>"[2#Q8.(LN'3_AY#E":O*Q<')6
M>1P]LNBK2HZCV.-X*]-<N7]F3 *W2)(;29'BVF$7BFWTFJ650PKN4P9>ZXZI
M5<-KB[SN4>!H#;&UYOSZ%J*K3Z*K=O!:<ZZM EXY"((RQSEN5,+/T>)GS:'V
MH%N?V6S2UE=#;*TY[>Y%-IE-0R79]/[<KNP7\T=VP. XBX=;S9L# <BY6L:Y
MBJQP(Q;R4J[P.!?^X+58K3=%ML)C14D1W^D:E!38@,EC44<(%?"=[BYHVB1H
MZH62 J[1\H)&.:<$0>BPKM'R$*JNV"M!2!T(%7"-EH=0=:9VZJI#5^5=]3Y\
MW;8[LN>6H_EL+NM?P/'_@?DS[;MGN>3(+GCTOTO6\6;RW7,?826_LF&1 C1F
ML[KL.C*F*H.<;>: 2I!#Y?7JB)PM5H JD&.0 ^<XD%-ML;W=H+,]-,$TC),S
M4S?-,OTM"3CJB)PM]H!*1 [5V3L.Y%1;9Z\ZD=-21N30X;]F5Q%!:W85$;1F
M5Q%!:W85$;1F5[VK2L1S6=9*&[YH'V19XH_:)*=RTONN2URIL7U-2;&D7M7K
M.T":!I0J[NB#G)[,5.#N/6'PE26+MV)PBVV$2A83_G8R_N]3!G9)!M85@X>M
M9EP)&J'4L=XK9>XC'*J&PT,4.RZ[%U.QX_KB[[#%CBN1@X,CD(,UJ(6\_L!O
MNR.?60'3/G RX:>/T(0([0#0H!8_0)?:)TX[MUPUF./GL$I/_,!4\/_+='7O
M6!#Z]BAD8_CAW!TO?I&Y\I:/W^-<*&CV5=*._^U$L)*7OT93RWUD=U;(+B<3
M-BKNDC1%#=3N8%"11_OM=XJ*?-WO#,?;K 9OB>/-VHY971%6PO!Q8WB+Y4%U
M66R2+*XKCO=DO5 =T:V3LU9/-[NK]KC"$4\$9F7 7*D)1&'%HKJ"N(1AU3"\
M)S.*Z@*Y<PP"N:(X#/5L,1?K#"Z:%6I#]FB[KBS9.T<H4!VC13YL;XG4+L5]
MQ9FIRYG)U'NMU;:I5!3@6!'6.1C"MB@?RM4+('251M?AP+6+^.J3^*H;P+K[
MM.(61]C@Y*QKZF:O10BK#<+V:6,MLD&VJLO_)G2I@BYCG\:BPO*K92@FOVH;
MI+#Q8,SX]VN/Q'NT5*FQ-'_;TXR/7%*8':5L 2T32H'K[595U<"5-A43T[U7
MIE/%/-*JKGHT,9P"*"2&RV<XI?:X-NUQQ'*U9[E.5RFFZV!*6[/9(Z8CIJLO
MT_5442RK*_5.#*< "HGAUC!<7ZE=KG<TNUP-@I-ZN?"YC^9SAT&=0\O1QG8P
M<KP@\K&Y&EIE)X[W''Q:&Y*TPQ)DB-+B*S_VHJ'#%JF2ZPPIZTRAH='0CG1H
MM?7X7/'=R.?[AS:W[,).G;KJ'K72,+9EQL8(N.4 N&:%(O-;=>PW0:"O >BW
MI=&6 7T=6V40Z.L ^BTQ825 WZYCEP\"?1U O\4WMP+Z'' ;)V>M/N&:<*T2
MKK>$8)81YG7LGT*@KP/HMP03[B+,6PH)\QH8J=>9C4;>C&FA]8L%Q4Q'NT;-
MJS'/W=DQ;U['SH[;34> @@< P2:.A'BE?FF65"<[A+!= VQOMQ"M8KN BE5Y
M&7;"/>'^,$:BG61ZEV0Z85LY;&^U!962Z74L!4&XKP/NM]J*2N&^\C+VA'O"
M_6',1:5P7YVCE_+.-\<\7GON*08WVNX3"T([[7OW\KI(QPV&8KJ?[G^S^ZE7
M:<VN(H+6[*K:NFQNYLRW<&MUL <-ZAJGWN0TXG]80<!"S1N&%K\/6M!J3%:Y
M!85)WN'8UM!V^)Y,SIX:*M/;G#UW\.";R9\!.P>PW$BL7+EQ/>1OGI]@[#L
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M<;PGZX7JB!Z<G UT8U!&\R<LJX;E2BT@ZNH51G6IQ81AU3"\)RN*XO+8,(Y
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MC#_#]YY7W+]'OGQIGI,&B4ZG5ZXF4YW^8^C_=E8XCHN6=W%Y1Z-H%CDHFJ5
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MXY-C _B?K@T6.ZF]/41.8*FIH=PD8IAO[39[BA/=-TH]=&L*LJ"RD1@)%Q/
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M5F.2=8LX@"QL_B:7,7-NYO/#PN!0[PC;U+^@CA)P6(<C*,/]&, ?D2/WR*'
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M8)_B#Y^YF)X[ULLGV\59XDV?Y;.D$0:6Y ELI_RX)TT):%40/TM+Q( O7=<
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M,0443E&\7MAUH&4@] D1UH<[;!8EWI<:_$4Q^EAMB8]H<6-(Z*B6'1M:!.P
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MPJ.?*TQ$:2.NXI4R].!C90]6+*'\\)$$0UDEC>80_0<%&LHM#\JQAER:J->
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MUD,1LF8(TL5.B5HK%R.^@NWW/$Y@PEN=40/,J8BY6B,,UBL<?WD1=OZ_S\]
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M@NA!B TD"#%(RH##BSZ+ N ;B>2J^0<VO+M^0CP7.(;6GEBPXWXDPZ ZAZ3
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MRFFP*_?JJ>=LY!V[ E4SGE T7VIR((1";F0BT5]G5VL%0GL35(Q5TM&JS"<
M8!HHS5:FD!5[#$EYA))+&8WR0V9\2J8<(EEG(3'Q.V^L)-(#:P)2Y737=!94
MYV6IJZ2N2D&@4[NIXL7.I&6KGR]?(1EO,(Q5:N=5@JW<H-2?P)@YC,5=--8!
M*$]%D4A:HQ.(DDH\?XX[\M!Z5HQ!G4 E<J&@]=?4E3M;2])=Y]Y5DZIFW8V\
M2!<R2>^.\E9D=XX\ZX!^RQDV( F.PXFV[&PJI:RP3H8:T=*3,85SI5"_C4A1
M\ZB6J. ,)"<G9T.B!WLI36QMP>F:8F7"CE0^9C0&BQ@81Y8F*'$D Y':XT@
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M(YTNDLY!YQV3S?(_ORY0[4F<V]@+4S%Q%K$?Q4X:.:?P;X'3;7<&SKV(A7X
M@"7@@9G WWK.9>"%KN.%$R<JK>1-4WAPK64&M$S+*6^FXEN.!XOX\[F8^%XJ
M@@='_!#QV$\0,TZ2C?XEQBENWW-BL<CB\0R4-8>(VYF)8.*,'IPL<9W[F3^>
M.8&W2$3B> E](YG!VHES)Y+TD:WP?IV1&$=S4=@!+_4@%[F!QP$(\\2)IN5C
M ,3RE?!0$Y&,8W\$WQJ)(+J77\3)IMWVA_/_R?STP?E5A&+JI_12TJ+?.A^<
MTR!P!#_@W7OQA+X.!.CXB0F2,=")'V;P :"C.W\LU*[@ .,,E=Y649G=)0KO
MUE*X.I.YF^6+/Z7_^_#,VT2"\.;PW12H+;H/$4,3@20"CQ)QSK,@]1?! Z(/
M<1-F\Q&0 6 J"Q&M\!00:1K[8_S7)(W&W^$7/TVJCOG,IW$=8!5- N_5];>$
MF=%"Q-,HGGLA4+F%5]V&+AE@0'9_;[>.3ERBN'$ MC!0'S#NG$6<17/8[\/_
MEP 7F<^C4$(2_N6C& LBT2Z\_PI 1;.4-QYX"?"YV$/.Y$R\A]+>:4;TT8?$
MF?H)J#C.@_#B)B%CAYEOKY;Y7C.92&$Z\^Z _SG3*(L/$?Q:4"7CF9AD@0#!
M[*<SISOX-_T3D!@B,8*/TBM>&(*DBA,OU@A6CR)I"KCQ\(\4"" 5S N:A&2X
M.ND,M!;8=BQ80_)#%-Y D'XXCFGOH"[<264#_N#Y(1R.P=D;.K1"LL/$TM^,
M6-)9+$0=M6A%1\%0PK=)*#?P^HQ8>ZW3'0QJT7F*NFB"QP^RB7!(V  ZO934
M74,Q-83U(3I7)\:-#B<^DP/>9'I/(G^";^)SBD-XXYDO[OCR V.X\\"2R4!>
MP9[1I*4%QE&\B&+@# Y  -X%K@+RS]@*L9KI%"1?K.7%LMY,3,H0+4BD47;+
M?TN\U$^FWABWC1M),K T3'TD/U3+.2730,O07N?59&B3KHSKA( 9Q=X+L(M]
MX)F^Q]:15I,315[$-$9"A(H<)O5W3GZRWVT=X;:60P#W_B2=2>^+^:*,4;3S
M5[Q1$@596O]*Z7X;CI<QT*N(7Y8'=_HGI;"%\<]9K':Q\&[A0H*<^GY(HNJ]
M%]Q[#PGZ0\RCP;E*H%P#"IWN2X+AJ!(,9Q<?3Z].G9L_SJ].+\^_W5R<7;O.
MQ9>S5A5P]H)9#S>RDI_;6A,+,,U(WTD*DE_Y7$"J@Z:(;I(3Z8]QSG^,9UYX
M:WI+Y%.+./KQ  L!<R<1 "Q#OMUM.Z=AB-K!9R%8IYPZI&O,H@"XB'8'2?L:
M%IQF0:#DRM2/0<A4J)VT3=(S]U&N'^T+J9C858HUJ)1D_R72X.C\TMNBP?%D
M)=_I]G=?OS^N)1P#B[6Z8.K/GZ0$^J%$JP(S<((@D( .G6NQ2%G%ZK1=Y E=
M^F=/^F&[?5>J>;>D/H;;4 2]Q2( S1/=PNHHS\PLGANU)TU$[6<OAMLMT=JC
M?_856@<6K>M$A]J-QVN?_CE0>!U:O*Z#U\?#?K4Q.5":=)SJ*7$N_?X.1;8Z
M@V= $2WTW@?2]L=KV"12><%[YX_AI,F:Y/>RI/47(-6?@)6>.B*\!3,1+S->
MJ%COVP5-9N+#C?28TD ='Z,)'P3J#U-Z _X'-;?0FP/Z-+[494[D;89G4F /
M(?GV38I(G$D6JV 9Z6L"J&NB72K2;]IAZ; S9' I8CADXJ<B>>_\(;P@G;G.
M7R*8XGW".WD%E@PKDNKJ-)-2\ 8_@F+B$2+P;WWD+.@/]# +Q5^@GTXJ]F*^
M"*('@;X=YA,+Y!.N="Z2V@Y/85; V M<!UDN_N\=@# *70<MJ(43^%/0T"?(
MPOR * AETWCL\^/PE@?R ?\(S\R)? C ()FRF-Q/^JN.\$ XC3&Y0$J?!$[G
M@!3T*9\ =Q.A_J]WGK0 ?XX7)!&:JG?P3<=S^NW.P?=WM"P>W#SITN'JP.?B
M]V##XRQ)V!*B[0AV0#+'A5/X*<I>R73E=RGK0O+:1E(/\IF(V(R&&;(, NPB
MOR+(7. _DR@$+$H*211 Z^!&^)A$KC.+[@688B[0W0,['.%B^1E(,_0AH%PC
MRC'(0)*((J/\!WS!RRF^%I?C+(Z1LFKWMBM\RB"DIA(0VM:IA_()+OB4\BQ0
M7P"%)*,;HEE+G+/4!64U1:P,&6=TM5O)N-9??X*WE=;?@)G<E-[T,=*2LO"#
M[Z!*[4\?\'7/2;T?A_P''U.\\''6P:Z92["0E*OIJ/E$%+Y"K\EK* T!8H+Z
M1 "W.=P@#5QD<(LH5G&0F4_WE(ZA  )ZY4*$"6D$K@,L6H9@T(V7I5&,+)H\
M=X$_]U/ER;F'0_T=+/A!NTWXT%"1IT)]9-"F6TJ/]JCHK_2H\1 Y8@ 9I"&0
MSFD22 *G L8S>C!/*A'K,R>*Q2& N/06L@+T_=!/DN]> 1H5/ M/NTKCA?V*
M0%"RRDARH_RKC ]&!.8,P38RXG-S[[L@&8 T#%PP?B@M;_"?N9>.9])(,[8K
M>9JQ N :^.@AIL4M/=YR+D*VM.\%P\?3-RFN_@3!GWPN^L8IP)%"4P<:I)VI
M/P4^.R;3D- (&'O(UYE$H%7&##BX?<$#WG0!+-:T:0K7F.B);TKB_T!HCF7<
ML 1RPYK,294V/,UBPKZ9= C"B5:6*FXBR \-!Y.XO, @!PJI*S@!&"QP <E>
M6;[.4D+@42*@5A2!P%/D493@@4_ZH;*ES_R)%WMZOZ  @&*<^F)WA,F7*,RY
MU$>%P3,#\(V4,5]DK'*ECEO6:6.9WS >4S;@R M0@4 >CK'/' R5(HO44%R#
MI4+Y!89;@6#Y#24*A<R#9;+[-4++&EDW72"24E+;(LFC11FRRJ(88H_*XQO>
M9*M:?Y/B<9JE&>;\3AU0^W6RI)1 DX@20B(6?[3?$=\'> [^907QO^'P[Z!M
MP[];"?\V@6O>@ #]*"89B#XI%H 7G6L.U'CV^<W41)W.L'LP+RBAI(<7?W9+
MS,WS29*3.BH9L52XQJC;(4=6'$OI6:R__A@+,0$-L=.2/2'@6 $MB9+6^T&^
M3O(J 7^Y!<84@W7W@%SL<")!#@]D82 2KB$H[$MQ.M99@(>2&8+>ULG4H^#@
MA+8@?;$'N8Z&2\D3+"='F=]0Q]'+O"M\:QE,BRQ.,E35J4;B'C0$L!F<D<^>
M-6+:WICT"0'JQIB<ZU\ B)SBBUZTSA%) M1(0,_#9!P$"3O[8'?,[3GJ2:E/
MFSC17]HWE<ZT^_^LK-_]D0'0G3-O@3<1?YXCK#"(( T$]#A+[W/B3YA@''].
M402I4V,@ R080#0B"T.)+_)BZBM:M((VV@SYDX(H^@X?2Z6,Y<^1/ 2[@+SE
M*989C,D9QG(<M'R@#Z;9:2!^^+E&J61_@7:FTA8NYU+7ZCMD;\.>X<HP@)(4
M%6P=@;F-8.MU&=K5H,&=P>69TP'PM:*D+RU&3_DJ8:"4Z8'*CLI+Y/,BF.CF
MF!\D)N&S]FW<=ZG,JP]-F SP3_(A>)7,@**5+9D7*UV;87@%NNCB/53L&TU?
MH+24[Z?I&QA18&2^ .,DCN9K;[Q&!:-+7O3UHVU<A?0RGD=9@NL @)$-KV>G
M/&,8K5J^GO_7MXN;?SJ_GG\Y_^WBQKG\=/KE>E<L*HK#782 6_9K782H:.'%
M:JS'#KUI;)%XDVA!-GHAH.B;)2?PUU<3+;6HJ#[7N?)Y45JT<P7L>.%34OAK
M9/S^3B%?[3$K@GB> 5\=H9T*T/0G&7+J^UG$P6)VQHL[3*X.'@Q3$)CGQ(\%
MRYXB+R85#E= Q@"\+(M) J+*1J_+A+T@B.[Q[YXSBD+/F:(4 O7'CR:X'BI=
MQN-EIK(K=,!%#IP;_RJHORG@6CMTE83GK$:&=VZJ%[+N7/F?W@((8>RSS*$:
M6_AIJ=J.P[05/V 9GO[53/(NOE=(__:2F8K[YNX(\WDB*G75#&\O/H\$K3BA
M4EW) R@S]!.4762(<DU)D3YWE>!.)ZAP NP+)N +$AQ'2!1/Y\V@BEA@.BUY
M)4@U&ZW.20']2WK>4<7\5Q1+HS=5SBRM8&#RS4)0!H[# =U$174J?YINI'VW
MG.MBY4AU#HQ+!BF?7W[<R\#RB &(9,WQ:GA#I#\,ED/K$'5H!A.Y_+T<D5'L
MFGI8K(6)2^86[8$@Z!I%Q'QETH<%_UZ^-0;0E8+-Y^'"&9W0)8]7O*1%TS5G
MVO!??IQG#N5A=S.-5J6&F2E89)X:WUB"=8V?'</=;@W,V'0CA5H#3Z4)X?X$
MU[PB>XO][T)5P,:.;B2@:V(EV)8 IH"K;$*ICQ-TR?Y6;)8/U4@-[*8:>#-)
MBY)V"]:'F9TC0<,75V?@\QVONR^%QVK1AZP!U8\8C94BYMP<1U%<PI_,,S*V
M:-"5"T:(C%M2=M*J9\DKH@H0$)&AN"_= Q)0VMM=H *.)V.@+L]AD%5BRLY,
M8^$1.27<OX)3J20H<_>3-T9GCYBHZ(&LU@Z!"01"I;2S-RI,9%B++.()YK%C
M>,PCWP[&@HW@XH[(,U:@9 +CJXBS+U&8!ZA+FA'@^,OU5TS*,1(K3:>;^;SC
MW<9"5@,H:T=%?9?(WPC^%J]%P2 O,S-.22E\E0E$1E=6L7CC1DHU<<*D6O$9
M)+'BV7)ZA9N%UQ98H/23PA$P.J"^,_5\O-SQ=V#C=UZ0Z6A:N=< >2HP@J;$
MV^H^+4I?H BIW#85?R8+$)BDU]9#>Y=8<XD"*&5)2_ARJ4P%A%3J!:I3/_QY
M1F^C7YAJ9%K.M]S!K5DV)JO0RNQ:R^/.E?2=1Q21[]T3Q_97+"+3>#D6![N?
M^0MF:QG?,2-S%'@9J!6H]0#[%5XB;1G.1O42]$<3KR6RR[.V7)GN1WFI&>Z'
M<LB-W9!4R*E8$SRN+$O%%&SYDIEJ#^:U<RF/8=@23P9(>KHVV S_2Y@1]J06
M+'Y(KYV\K9@UD*K8A=R.O$3R[?QC9-5X#E-&^8LH;0 E,W_D2Z9CZ%YYZH 3
M>/<<:,[0?RW=W++%QB*"%QY:SL73\%B+1H5%Z5<U$NV(U#U,A:5WB]B:^#(>
M3:YG%0&1.,G!4@7_"MP30CD4#18N\/FG$T.GJRBA@$7XI92*VCFN?1!/33DW
MA3\7L3O-25G?>;UA]6"Q>5:VB'(Q8%")-)"D]R=?F;801G('"!*-!>E5)JA@
MHO]#)'5B\6/AQWIE2LR$CS63OYZ29N5Q:IJIP2NU/=<RIT7IY"<)UA]H@)K7
MLR08R0H9B5+CIQJ=E^H)C6B%;N6&FB8PO)D8?P<=U@N_.Y/8FZ9(N+ K@9=E
M@DFMNC,6D',<?1?QH9>08WY"RBHQ]ER+UJU<F"A8AY^JUFA58MGP!4;WQEG,
MVP3K]O4N0E''O+AZ4G>48+8=B%LO*&$#'4_1W=/$]UM.^^C8M(]M5?V_=(Z$
M5L J>(3VX1K*U;($\*3S'EX*DRG\D3RDE#> ]PBYDNJC=9^PT$DH*5)FANIL
M+E>Z1(P\@DDT1U_..!?TS'Y:SFFXK%/!PH!\CQ*$#1%K9.)CK( 2TA2?J-1P
MRFQ&JQTL+G?$GKW*_>)LVGY#OSA[0U_%O+VZ_J9][#5&[ I?_H8VK?&QDN>7
MTE?*,AC5+8P&('U62 :B-[VD6C$1*16_C!X<EIH3$?B40:R,)!<UQF@^,E0@
M#C6$.HJ!5"4PV8&$#QB]2+^U!Z,[(FOB9%:&W'7Q3+GG4JI\:T$6CCEA6QUO
M-I8TX?V'O6)E'%C0!'QY^'$,VIZ$)RR^H)P>+=%5?M2(-#D-N19V3T#&X!E,
M)7<"R+T:)D-I@ZY1+4QYKLAXI)JLU!\X]E30SK325)EW;>KK,NT&^SHITZ)H
MZ^W*I3_3C:AND!VS'_!UKGO9J%"64^XD06Y-V1WP0-Y!*S4V7NNR54[CO+*
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M^:I'+/V)RH'*C$ GBBR]F<\E9,V@,-4/K8O<4V;F](PS711B!A'Q5\JK1'V
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MJYHR.'V'>U!-1WBRW@0+TE3_D22;J\J_<;Y</IUOHJO7U)2ZN?"2C,?C.0L
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MIN<+UWXR1@=7U6Q'8)OJ]JRO->[I[9\F9)0830N)T6$7^]?O>R]30MS"A;&
MG(BI-B#E]>Z7[UA"P^^LFFT(B3;H*]-V&%IUZ!-Y IG$0+9RX?Z09FK>-EQL
MHJ7FZH#;9!V^ GN6T@AL0]"J2&P\H7@$LW.$ZIWP'H(=+3UX:-R"I.J[GG2>
MY1QNN25U0:Z&P,W D@8<PN?TEFD2_[=!>7-03 1SCW:^]T3AM\D[UO0[KP-.
MQ;2&MH-./++NT7A&AB*<C5AV#V4J.5G!9 U!WH#=3QA+WXU3CT)NEWB\'LR<
MV,_9%J.D-Y#[U$!1Z/%1C*=#?LGO<>K0DFKMM&\A=WR1&"</Q_QY%G-%O:/G
M;S$ON[V[/>W<W%_?_='IL,NKA\[%X]T#N[B[N>_<=MN/5W>W935OAC;JC0A"
M0&S_E ]'7C#FZ(0. 0F"<$;1"X 4Q^@_!-KBF0/Y/, J8E.>>W@;U3K?$2]*
MY\D4LT1T^S4!0F,7]LB5M=E 5XPYKZ!]DLX6A"Z<$"'*$^\!:C/>[TL,)45)
MK]%8KQ/$QX7A?+0PC26CK:Q*P^FR*P:8MS[W36OV&Z-*W]S8(6 UF8LGHLQY
MM^<2@\#Y'GEOX .HG\>3R:8._O/<L/K<-X90)&>^-3=0&W>(>1/PYOG5W.*U
ME(G+LHK<AE-<C*?$F^%O[@HK(>?&FT)A]!W"JE_P<D-B!6')V\K%E^':@:14
M??>VZ_1)@&U1IZW;2$,^J$&L9T<#  FR%TZ%,G^RJAHLA$393PWZ.[N3N!C8
M+DK=E"@)*%\54+8'%$>4'L5."LO@TQ+@^:FAU0 TPB[-H)12#3D)AH)();#:
M>.N49Y3%62KY  ,P8T2[!_SX"[H0?/(_Y!Z<Z"7>6.'%;O%";TK$T&N$#H09
MS468,4O&N\8,=@(RQ'-YDEW89P)5HFRV,3(+/B]'I6/V4+24AV(K'@K%@PKQ
MH#2V1X:'/&.A<C0>1PFHS6!6L*;@.Q29$N7,Z.$DN,2?V+/P^W)-,;N322<%
M:R8 (XCN2*3!*NT&<F+K9^;^7&.$SD=<84A6*Z'S(HN=2XCTW3"*4;3 )L+(
M#L?IXRFH!+33N*60HTF*[\\,!WR=_QO%$\ \'I#7( *)X8E[-*J)C^_[0%LL
M?@W2R)8H>?H7P!TA:_=ZW.-A9OOE1NXG8#V0F6@SZ5.!!WHP4QAX7W%Q2N/8
MMGFPE-@M@]3/#8E=/B<'I^<&@8<.MB'G".<(W6$N/(EPI^"SP.=Y+$J'!<0!
M#2)3;C=$8,<>8^P<FC7!U&.XNFRL)6MD ^XYL^ZY=(JM('/9_0&X@9%G@X8G
M;^'HTCGQ8]<3;@*"U*RC8.+L7>LG"!+/48Z"4G$"Y2@H%5 V=11HJ9=@)PZ#
M0B8A_K+.PZI<"B5R*6BI/V$GKH5WPJ$M.A\4TBD;4MF0RH94U*YL2&5#%HUF
MD%8@)M8-GY(PXBE#!NBDQ[>0H6>Y42[\&]H@S#7F!<YSJB&(EG0AMR/0:C!O
MBG]'58,C"O22,)1I+"#J14?0%%VFC)0LVI54@NG?RGFDCU/FL>Q^SD4F68Q1
M.I@:.41TQG"=J:@=0)4>IPY^J28TT<W(1L=P#: 27T1KY,EO"81R4;G(EYD(
M&4C= "+05N9]FD6-])GCG$_@[=/_OKY7:K'DKE,YQ6N$PZ)+D9WWI:_5]4W[
MTIO-BEYM;*U?M[6=UMC-BF6N;HVM%C59U.K)]ZG _.(>F;?MF\Y1-07]UNET
M6:?]<-NY9'</[+Y]=<FN;ME%N_OK3LYA9;&*' ]\KYO@0H=T=X\1G*S]>_OA
MLLM.?OJ\13VX5FFNO8RNKK+E] 4L>V++G>B?9RZKCP&K'^\>V]=Y0+U/-]M5
MM4K+487E/ "+ S1,.XH\S,JZ'U0N*P4(^P?.8BO=;0ZVRDW!'9>P_DW-0._9
MEMO:[+K@DD+?8T5?<WUG&H6^"GW+BK[->AG1=V.-2GI32J\W7=J@-GGL/ F?
M>:XTQ28*T\Q6"Q'F@N,Y"/);M*\2$EGK+2K.8I1^-TF@T&KOT.I-JH="*X56
M:^IR&V_1";:$5^_0W:4<:')AARZ&#/FVQT\?!]S^,XH#7W5[V8X"7G::LBB>
M4=6.5FCU\1J 0BN%5FN< H9F?A1:':SI_^@.@W@P9@\5]BV$80)?8S=OO351
M:O7>J=6UUAM4 &6M*;123@"%5KMW65IO4 &4#V"=]__%Q:0@S[,'6XF:4$KU
M_BC55O/M<0[*5E-HI5P "JUVZ@+X,+0Z6!? Q2 <1S:[@1\"9?8?AR)=JRNS
M_^.A<'!HI<Q^A5;O8?;KRNS?ON=_P ,'"^0_5%BW-P@#[O!0F?W'H4C7+67V
M?SP4#@ZME-FOT.H]Y'_S@\W^@KW(/Z(T0;-F;EJ:H-6LM*JK$^ZEUI/^F/94
M$EM<3&ABKW+UQE3F1751RLX!'JPA7MI2(0-C*X4,6E;%T&OO5,A@(>T S';)
M'/(YW[O.W1=;)=S=I=X^WU1==DD7[<Z?GT/^C%601)4E*HC4M]V0O=A>,JG^
MA-W#X[%H3B\>Y5E?R/4U:?INA'U;UY:FH88WJYI??VMWSUF[>\$:>K/"VE&4
M#&4+ZB2:-)6&N7II+VM12"B:'(--+3M[7B*;ZMP&,1>K:*8;FNH:O[!;?'X
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M[MGU]86V= AV=96.0B^L?N,QM*G<"[UYUV77]^*U>SN,J681?A<[<C 8Z=?
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M3 $%OQABKQ-4L?KPK7Q'!(--!IXY\T1@/)PPK9TZ'WHPBD]A M,DC!1OO]C
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M%?8[,E'/Y2]<W//$!&0"N7@[R@3D"LRD"Q$.XT?(T=%K$0,#DI[>D!,\_YT
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MUU:,KK,E=9>$>A9A<>,N",PIF=[4N(FOA[;K]R4E[X&3L$BB@4U \I^A!<+
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M76]\N=UY<7,E["B IIFNX;S:_#K(:N-)=>,XU97NL+@2N "3R-E4+-*:#T9
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M7&:?2BUY:+ZEO'SV[IOCS1;#0!2#2I="*EIE4-$B1.$=&%J@6AD6A>UH&EK
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M,=GRLVFMPWP>9L/9"YR'X6BK@]F=XMGM3/?^IJK1<?"E;;M\](OA+(TF%="
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M&P?7!M>G+<IF[%E5[]%65,T+A*[#.^_I>J[T*48A?4]>80&ILB1U7V^N*E:
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M4:2,@17#P,JJ(HVB:"NX"-DQYP.Z+'3K3/.^W,L53QC(4)*,QH 7K"9SI:4
MDUG@7'$>$;DVK<^!KX#R*-W%31AS4XVV$,E^#/7*BDG+G0A&!I"+N^CK+@ I
M>#(E(IGB"@^^^06(6P%]E.[A+MSJ7IR]W\R^/OA^;&>OP-27#>UUIJR135ZE
M_%+0F6F-@-'7VRYBA* 3 C/)>L4BCZ9U6F,M>]1LA%<V4BD:L[H4"S:@KK?]
M(81ZCR0JJ3&6DGCSAN?W@NJ3%6[!D36-[I92:69^5\"ZV%9U68M"^A>T#PE4
M2(["]D*6@0*I[*--0K2N+;P;49\,ZAYILHT\UC24YZ_7+Y$>^;>__']02P,$
M%     @ $8>66/J>-%L=B   @G,& !4   !C9'1X+3(P,C,Q,C,Q7V1E9BYX
M;6SLO5ES6TF2+OC>OR*G[NM$9^Q+67=?8VJIYAVEJ)&45=U/L%@\1$R#@!H
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MYYI#VSH)Z4RVU3/TMR@*?2.D6Y*$=8C=W/=]$<5S8(+( ,1:70;99U,"-88
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M]J3QGA&^7<[NNJW2;#H?W%A E^2MI1)H,%'47!(L$B2<16T!F!0!P%O>+_4
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M+446+DA6$A"6SR]O&&7H_>RF$8>G46 OH@_1<.%DD*@$%6O/Z3*2H\1@@X3
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M1:54UB,$F58"?%L XIX[GW< 3_+=B?77&]R !&J=)HR:S@_CB6?>DZBS,%E
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M.;]75VUO1N-]R0#Y=!YFPS3TTQ^?_-6J.BO-66\H12H%#6BE!5IJ<+Q$!5Z
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M3$K5[X9YX"G/F?%U2;B$N1N[9B_%[6B<%O)V\T3#,XM[U2T4BKTC%'$>#6L
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M1GY3B%R%1'"7EW;$GA-7S%UE+=-:*V[%UCTF>R.WZQ6_[YW8KL':VHV*-B^
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M"IR[]=#M7;$;D7U2@V855:D.R&*8R040H3Q$0QW)%.T26=IPEX1-DD10%E_
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M3*%;[%V(%\IW'Y URZ#Z MM^D=3F/)QLBP$[DQ::#14I9B(@(.+@T"(/+I*
MJ[!&\JQBKZ%'^RTE#U1B[4A(UJ%[[1K^W\_':?@5;9XS_SND8?2C8O;X\8_+
MHA9 6RH'36CP$LUW/#@]2$,\R]8S1O'4Y(_9#7T>M.7BGS:\F30B;.VJ^?^#
M-^,,QA\Z=!'.YP7>['@<KP:,QAQH2(27_$))N^ 2VM4A6B5#4&"%[<7T1QYT
M<$RO2=CJ.QWPSW/_^12F_FL'[08P8TKUO]8D&2O*(2>)CSX29;C(-!G\0[^N
M" \]Y>#878VD#9+9/\*HN+,^E+7>5(5_^W'SG>Z&D\SZA$HPH=E:4GQHQ,LR
M%B?BCS8ZF5UMEW9_="_<_FC,SL:"=['!^B!J%*V_CV8W(?I6_'M 3#8@?I-P
M[#UD62ENJ'*$V^[<Q2LQ1&:(592Y\A]7M:O"MB4.CP3D=R<-Z]"\L11<W)-H
M6I76,I'80 TB$ID$6IH&Q12HU8P;5GL*VWT4VP]^;<J;!UC]!,)6;B;Q83I)
MYW%^,KT([2T,:7PD)!H)A]+=Q'E&K-6*:"N<TUI8(6NT<EGV[!>N1%1A2<5J
MLAMXROHO$,TN?68]0%5T6JX$LGTGY>8\NL_P2@2N[)1<#<[3,N_#4:*=1OE.
M)7Y?A+Q4UZ0 T9B[OH?GP/4'G(Y;8OHZ=*WN>AB.8#:?C.$HG@[A6W>R75K)
M5*9L\%;2V:%ZPT29&5&RP$06P(125-S)#%_E>%CYC.VZ'2IQ8%*??+6]B.]P
M;>,9WFVEI<5H!'%^[D>X?+P?KW20Q$&PP(#P; #7S /Q$96;A!<72-1S3.SG
M5^KQL&?/Y]H$;:&_3W[XT148S2!Z#8$$'QV17''B)+X$%4!F2T,PM0>2WP+P
MG#F^.46WYS3LKB273"AG"N$LE/1*9XACB9',HL05 HV^=D;- W!>N$9?FV$-
MZN!70+O8,GW ;<$E> _87GD'UV=C/_'8@ >-?4+W0<8LF%56D#()#?>$H22
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MO'_]ET1_'&ZGR'=#J'N*@;=W\FU%AQUXJ,.6M"ELYA3MO*@6X[1$G354O*'
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M>O:$ZF#X#N\H?XQQ=#M43S;PPJP#XQ2"0MI"O40-1B>+.J#0KO53^3TPCH8
MVYKXKM=M^UN2 <NR%!8<Y))H>TK(P EK@#DA&;)49/.B^",.5K8T\%V7NX.+
M3JX]!S"R",K,("7GZ&BKN;VMC88V9719>7E;('&' <H^'V*ZWKD=FF>[/_#>
M!]#ED%BD;Y6BDQ*4K;6D.F)M9)/TR\;9VT*,O>*6H^59'V?T&%AX984!,Z@Q
M% 719=IMA:*PRAD%@8BLE"<HIN.ST9$RX*D&[O $_'K\_?MP_M95J\XOY9<J
MM"ADB(6V*C$K06:9-JUH(A01C Y*1Q-:QZ\/P#E2+K1R0(=4]X$5JRQ#TD4
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M?71'7U32R5$=$K452.O-Q72%881'C(XQ<,)J4)X,@X$I,,E*0=$^_6]'U'H
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M.&;3]XG%+]<? D[S__Y?_Q]02P,$%     @ $8>66$VX=08-50  ]%D  !0
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M".NQ7N_, KI?#$=Z0O$]4]M2))K[FQ[KC?D7COH_3CU&>E40L)X1O#!9'+P
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M@ZP+B:_7P&^4X >+*:#'YX W)G935<73C>V07C&O4X35I%NO;S7OHGC]G:M
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MD5BV$3+!Y/TVZ,S-S_Q'=.%ST1:3Y8HT_[?NMS>DM(7OUW+B30Z&(%6>*G9
M^%OR_2 ^PIA<O/J3;\1B(W0^KZK2UYFIR++D%SKO/[:\@>9H7WOK!I*BS!;6
M1]>IQ 0),W@7R%P4M+<SOK6L,;DJ++-WGA^1]6'7%(CLF^R6?07<1+#IB,\H
M_SA\$)9LHNXZ+-N_"3CC*NI@./L'ZKQ1^ZJ3OA',8KQAE&)Q?[*L'6XR0[9<
MJ];=-YX):H9(&-F_#VZ[Y<0,,LE8N;O@UF:02PN4/ &F-(/NA]TDQ.'EDA4K
M@C74NOE!?8(JX\HCX;C: 03_TFW#SU7XI?8?WVG\FO2'JYZ9:[FL@(?0U,N>
MM1=5B\O%260?$VN.3(FA(M$_O=1]RDQ*;$LVCNQ+R5]E?KQS_G*]X/Y>*CY;
M!^AX8971MA^)&UK(.;)*U2[E^J0_*IP_-3LH6_G$SR6E_J&X/5-5.7U,23#G
M_]PF16ML;U WW]@VIF#1@)H)6OSNA-D;_RF.X,,&2^%;;]_(>I?VY"VKOE(_
MK"<95Q+-=4&4_I-HK5+/RDC"CE]0(<=>".B9FCHRCBYNG5_ W8$6^;;JRJNF
MV_=K[__?UHYU0G GFHM$EXCG(5G;^:QJ("'\.\_!?J^?35_2>>K+">VZ';(4
M_OP%PT'%S3X(/]'5$-6"M^Z-3,X.+U5A#Q.V,'81$'AB,Y$O-8[(9K^S+'&C
M*2941)9:X?._*RD7=S C'JV-L6A-*;7[GYKB5I(K_BPJ";-ZSK>ZM]<BNEDP
MF\VQW!.!K'5G'P:W$69"Q[I1EY).C"86:M>#Q]K?A'303?X22%'E\"O?$Q)\
M39+XVR,J^G5RT=$N//!^U?&HK4LP\P]# 1%=FDNK2=$,.Q';[<%8#9%]4YQ)
M\L^0/Q01W$PB;?_<+%LMIB@H,G*L+B:1\*GT^'5=\HAK<P"86U.4K$.T#Z":
M46*AWJ5PS"JIO((&5/0',@D))@PJU@%_%QNRN[LRV)^5'R+6R]H2+M]EO.E3
M2];$JX,7ZHD@+-W'C[!G"WH>=-E5&)W*W7F!%V7VQ1(CNZ62T3CTHWK1V[!_
M#-;!3;#4<X#7!!59-!<<V\$_^3O%D*^JJ'D>K2F.GEDP9-'4#TI\&J2CX'SG
MQU+]0%_6OMA]84.R!E[\]"V:>KT:9C'IKZY2X=WJCOP]EQ+:-OX%89.ULGPJ
ME3_9P'G/\IY%FJJUEL/%Q%F<8/-VHL*-K28? ']U<IN4V1M5V6!N>_K5\HLK
M#+Q1BZF\X4X?^9Q^-&)>Z_ZUP?XK!:OKM<GB<"M*5[IB7IFC]?8Y0%N$NV]5
M;NPXZBB[X.XVVH2@5S=S^'M"P"@0AAW)OT.9($A"S>022MSI['/DXVUB@*7F
M^A\U#:)Z:$(Q$TWM\ VN+^U$O0V?P  _3XE).5>2SF;L=?CMN\NB-"\X@\5$
M6:G^F!@>=RX8624=[_<C'EP!UL@8H\U+"A3GR5H(NB=^Q99-;QYR36Y(,/="
M_>'(HGY5&.>_&WD+>^&59RP?+R+, W5IPBH:SYU,ND-$]0EQ?4'-(%>9C<N(
MN8P^39>X'4&F31UIG>-O/@_Z'EC:*-#>B':1GC@'K.5JRN&M^XY>1?SH8^':
MG?L;/)@$O3^O#'[6@@C.G9OK&7ELRSBF.,V]ZGS]6<Y(@_2=KT]-D-%3PC0R
M,,\+J^!TBQCXR3N47ZD#R>2-(GRM5V3OES?F>.<O^#!=8FL8X=@EG\$;1D]F
M-^E6UN0Z2X:"*C!& >*#B<$:VI9HVQS#0:GQ.6=7*BW&+8SN<P.UG-3G]P'"
M[M99T5.KQX\;X:1KY)OG@(JK^4Z53I8D(]B0ZA3H(!!72"E1#08$.ZD2O4J@
M#TDLA.H?"4#-P<X12@]>J+C$?Q6EZ?']1_(HJ5C@U&_$52 5*DV(/TOM8"2.
MK$?]$F8EFV%36'KG&K0#SY#51))IKL"5T#<&](38OKF]L6U>E"I'8H(#.W-D
M;2I:H)+8=@!:<%+#T\=T3'2.4GI>/\X^5&O:&"6YEPXH']Y=0!TUA0; 07/1
M5&$U1^;?D.\[;H>]MIE#@R(P<5D\24'Y\AN/4T-1N;,K-K[55=N9ISP*L9>"
MJ')LXA@;7]I/P=Q!5#NJE@4Y98[$C<?3OA^-?.S53!*<KB?QBN@PI!<!<0R?
M/P ^/ 4 :@UQJ#@_=>$/F%UN#F\>;@2IR>"SMS5_;/=2?^J?GV(9UENI*G>Z
MNG@!5%M.'&?_(&NIB=:ZN)5$? .6%I%<O*!=_GTQ*OM^YE",Y-S=Z<!=]SR&
M#^Z)-Z]E^,Q"@<5.83 MY)?.^6 6#L?>MNB*SWK^V1Q;R<S8%<DB 2T&Y0&T
MY/AC \"?HM.N#J'IWT /\_C^.3NMMHND&(+$^?7=GK@&EVQI=JGAMIV_LNTD
M]W/FH=$G)F42*%6398>B,%>%U- Z6#T8<4M+;GOX/A;59E_&,*JK4A7YF)ZZ
M("#IQ-AGK29K?5G/9F8;OQI+5IY/-RERV#!(FE/F,?RY;2K+J;0O^A"Z(E\Q
MZG9[<978L#X8IRD2-F3NIV>(G@WZ%+0=><4Y:1N[<K>6>Y.;%B4R+'KK'ZJ!
M:%^7=URES,!G'7:0'Y"A++.5OZL4(=!6+=%O;E 0!UFSJL3M8]UXF 5?[T08
MQWWT\8MN,AL,#)(M0V;QC-KFY(BP*CKSW^V1&OCL1AW\0A7^$LJG'K'<V*'2
M')OC#_30_>:OU6$@*Y@%U-K>*9U>#*3/R<B[*_\V^!Q 'TWCO7I54T+K.=ZF
M*;[D^QXW8G[?]9JURH,]'ULS:'].3L8-:EVVXK<B5=YE]U4L4P+7V7#C+=QM
MX1N'PKV57@%*9V^ +GY^0C"%T?"?'TFF25XT3MX-?6EU)XY#.U13A6X=GI7(
M6P8:D/+"WT2A[G5A#J\"J4G7UJD:)RSO4(Q.[A7@=I(.]0LCSJ1:@=0KUJ:Z
M>M>2UO^_GLZ/K( C4[A;\5Q-M5@!9EA?:Q9V;Q[N 2&8BWIF7#9X/9KV8=$/
M%7)P1T_TVJM$?";%4*ZKD'3M)^RWT)QW05-T(0S<-W!+YT5U]M8T3L,J2;+$
MU.P_-C7^+_HK)<R_VQ0N["LCZ29%!YQP#F!5O[4-&YP@FX":R.2HB3^,@Y%;
M?B.PBN-3_S^GA\8=,&SA JDOMZP]N-9'B)H(P@OW92\:A;T*(A4R>"/D^-^D
MVARQ>G.@/] LB*BSL&24VB;2@4H]/[!DP;"0=?#?NRQQ_(SG@.]J ]'!0^>
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M%J(W!\0AHL )TI$D0N6D"V&<L<WB]]W_L?4Q]RM)'2Y8/2'HE42<.0E=#-0
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M<>CU6$9= \ W^GB0<0W@JT9!L3VC.#%5LR@_[N$0JD55A%C.G9% M^N"@;;
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M-R/+J.[SUHL3IJ;&J)P+^)U&IA]/K9U:<6>T]B+VWAX#]Y-QV7!R:D$OGOC
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M1@@]_?]X7?3?&0K7B_\%4$L#!!0    ( !&'EE@JL+E5&.0! *X" @ 5
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M_TV+=QIS<(CQOUS+Z\G$F,6:CNAD**I=S*H0\Y.H$_8.5&FS*YD0G,PV7?.
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M>!?WDJJ/,E/4[=OK=OE;S9(*IW+Q;_19&JVP5''!_[29JSEC*$5$:!'7)7L
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MH$+8*&\RA*JPCZX2\ILN?$@8@\S9N#3):6A5M>.7%F!4K"BE=&UM,/(W^,[
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M]QVWI/82E_3&9]N#R&5:Q7^ZE+VA-=#0X2!W/3KXA"CF^O-+_*\90\FOQH+
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M3VGEEA/M*U6)?[@$N==]4%J(H:M799VT+*7XPEROZJ:LBYA\N]90UPB9G.5
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M$RR9$(([4#8_6;5Q346O#/P/!-&WW[QF?R>K']CP:*__4&Q-:O>CYQT.CV_
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M(/F4F3+KE&?]!F[*X1-_X1.UAV(H#3\6-4LW^@V]Y%S]T"I#^IG[# H!L)2
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M"C*(>]6)<\,2 ;Z& ODN'!$T@6N*Q V-(,WAHIU)PL'\(7%]Z6[OE<VBHS-
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M<%Z(9! ;':* 66K]$E+TQT6;JYS.3(;^  'GAU^M_CD>_SU@5]I36@<2U\X
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M9P \?!TV!72E]J/(;A"DGR!ZOPOZ]WK<-.+R4*LC7$[R*;8X_[H^MFM:Y\K
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M\&^!Y[P[ _R"_89,^@;73T&.C0^*_/N8ED7P#EU/3,BZG0,W<TZ.ZNHB-X]
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M%?GF:X7J#XML$P6OCGOZ, _3J')W&*WS:.0[+AMY6J%2(I[15#,MRYX!MLX
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MQ6766<_5RL1["_?6#PR^5:JM8 /1745Y,><6@A6'S@#5@<;O2IJLTHY*26<
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M@2C/$[]+=295'@H5KVE/[GX6"^]B$!#%N'2XLUAW9&7#+)$Q.4D3HJABL5_
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M/[Q -1G[P;",8_PUX)QS*^^/*K)?D[Y]\U43?SH&B-/_:@TX_=,:8 ;\^B1
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MCSWFM5_?;5"2+'D-8+H2U*'[NR%U3WFRQ,3V2$C#>N=7252^1GRZ??->SL7
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M0Z3^OBF\^YS^A='[U^(WEXNKD7OH^Y,^HS/C?S#'J,>^O!?21(/[^H[[>$=
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M"-KYWE83+3;_TQXT(BC &9(_,]G8[D7LRI1,XQ*"?YP@>]L+SDS3VE!2V3R
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MQQ7GZ"!#)>_STK+V#Q6"] !"WX2:P:CAN>Y%!D5#)]X0'JK2OLN%7&,]H82
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M[PS?3%^/KHASQ2KU:(@H@*JW:0<\^WI28^(%1[PJG>7QU^5*I5W7Q=14AM*
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MXIH'$>)(%X@KK>-^D/!"A3N(X9[NUWB3L/  =OP4:,9K[>PK5 7%&_,OG?C
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MLV(?/FYAZGC:=[+@4 4V(27GI\KY!HF7)3D48TC\S<@R!?6_#CW@8_DF? O
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M@&/FHDHMA??WQ$HGNL7X[J<ABW%?,/OT<=\4"^OX%W]$TEPF6091',-U+<U
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MD=JCO'3GMGT]!0I 3T:2OFFZ[W_J0;=)71)=Z$)O ,AL<1U]H4=.M%21*CK
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MZ;C YZ#%N%+/,B@]I6=]AA^8QN>:@TF1?P57R8P+[[!P[=)GKR3]564S./&
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M4OXYN)NQKVGWG?[/KXEU>P$6?E9=,Q:6.OK#&DNM#>.7^7G\G@D24/Z[_H5
MX52V!B.>"XV#V7:<F,QW9N#$RF0TPUK\QKP',OO6:3>??Q2O65.#>SRO!E\4
MH0O7/[)\BIPS0-(F9KA[Y>75ZR71E'G$QJW(!T56H*/<D[Y^_]D(U% K,.>L
M2#MK^/=:[=)R+O.\ABU-$\ZU(Z(;K7'6NP;RRC;2/396>=>TN*O*KY?210Z_
M7T3K*,S+.GS:J:.Y=5FN'[7=:;UM_:%X=+'C_9&;3B.H:0^8NJQ(94( O0K
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M<PYQ9)'C[XG0VA2'0W;$@_NB)1?ME)[=(OY3503)$W6<XA<O%EH3>#<"[J3
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M_D//9[B!'-<.;,LK73()=\8T#,M-J*48)#="@6'E[CX?'^=R+\JK[HE?3X%
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M:VM;ILCR3^_JS-]\UM*0\^3XG\F-O',TM?L<$VEBB.\YN'NF-F;O8"<\]&A
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MF-RVE[%[/Z$X.@]DD?Y/X[Q)^UCN(]E3R8]1/YUV0(P4K8TQ)=XMQL"J X?
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MKSP.46K]9):SO>+HC!.[NT/&9:)3,:%:^?9;/F_0/+@7K:G7;/47;@YVM3M
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MGI53)XO]Q?U]U"PW27FHYFM!\4JOHC_VH_5HF74Z6@3&X/U#\U!213'-.]0
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M*$>NG!6B'/<UI#ONF'FR-V_KL*6CY-@FE.%1;?$ZIDG&,'\EN/%LLR];T]C
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M"Y>[-. G(8G%7YH06+IC5!*>=PNPGN86N^@\3]_6<3$BU,/:-MIV7]%4PN(
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M7=>Z%B%X%TGW-'#QJ3VTQR\U;X;:792NILZ#3SO)$)KPFWGDBH^K'"("9.=
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M7:(7CK+JY<4E\%#E:I*0ZLG'@16S']> Y=DE];RVS!^0]HNSXI_5L[FOFWC
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M)94T$+6/H+5/XZII&,.@M> RFU^[:*KC:(V-X!E>$!8^,4G]EM^Z]%^'#&_
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M_4N)]$5X',6282,QL^--@_UJFB/'H?JVG%@V55D1M#IWP9,/0O7*C.13P3Y
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MO_N41?%_DH[Y)__D/X%S9Q/_ U!+ P04    "  1AY98PTYS?^AL 0 $KP$
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MB>GJRZ@G@/\MQ.8S34T<_>FD!>BJC,1@G .6_Y]&OL]MY'7[V<]]%<&7UEP
MK:[R_XRK\+Q!7V[>'5I[3Q_U\B".^,65]> 9N?*#!X?94MM7;W@6MQ1D3 %/
M<F9$XP[I_TW)E7' [PASU4G[ZMJ_P"WPWV=]6-H_]22K]?/@7DVYKC)M^+]O
M)'ICZ]DIZB.5MB,@ZW.Y93[M?]S4[6OK',</F0]AM/8Q0P^RHK2V9#XK, -,
MGPP$>*H9"^E' 4QY)0LWV@]R?UZ/>K;E1W'[%#5T[3]O_;^%;XR#3O^>^9]
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MQ.+]X/D='11"^W[Q3DL842%PM?02P!4<ID=+S[EM:)B_6[.&<>O/E#S7(]B
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M?J[: XIB:TI1 KHJ>)99,+M8:R'$QMH[X#[J6=<<3U##-/IZ,\FB-SJNF:K
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M0AV[0F=_J.5#2D<.^87:86&P:M]P;Q8XJ>F5,9%?DGTQ8WW+1K9B/^)E,E^
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M]]WKXRT<2PH=5 1[6#@[Y4BS:/:T)??6!_XJWB<$ T%MF:K=K2"@+#Y33<X
M.[U8%)1^)CBO._KFYLQ=A$:S Y^\2!I^^4,X<U@ =&9DU<AP"N,\^#W%3I\A
MLGUT936_'RB[9WNLBI1(4R;^(N^'V'AZ4L "U-[:ZQX],%#:7Y>C1HN?WEC6
MQ,@N6J CO+0XNZ:$/AQNJR5/OVRLI4"'2/'K(*CD/2WUEW1NG<L1/IUI^KUV
M-!HW2O/)XL[4K:F1TI'@%KS&N QSG[]9OVU+'!B.?;'JE?:OXIBF^BMB,*AF
MG4_K>7\^7/N4NVBJ'P^R<F%YI>E8QMRVZ;(F:_.E;=K\E"0.')MG*3!4*^%[
M?24F\J56,Y&Q/ZAJ62?6="T!=Z"))06QU:2W(^R:(2S3B0.W2#4BLD+EI99=
M'/R2B#HASRX!<*J+O,/U9+V67[I-6HJ;+E9]KP^*^BUSN>!DXGM6RI732LLF
M):ZEPW-FX*S7,(%ORP^ -K+:@<LUZN <JZU[S>.UDI+"R..<<'H[CDBZPWR,
M.(YRI//*#B[V,9L;&K[;&NKU#BZ-2+-_Q9@0KT(B/4BW@W@Z*C8?UA@146T!
MO$K:1[%IM;%IS89_)8TK$^J]G:;;4]B3^Z(HL+S2=1R]-CZ'",GP-*3=E-2<
M*TC7P&RTT 2<!F1F.JP.^"'-QQJJ@YY/C;GFE3=&32)V!LE)%>* V]-NI.?2
MA ]G&IOH1H'.\,(W>#W+V4FSY1Z&)[]Y[9#0E3A"62?Q@2,UH<E\Y%P+1]5^
M&A&18U0+HZPIUW<F SA,(\ CW2-:5SH9KZ,9L%M]V,23%S 2E:]<UY,STC)>
M6UD9<#K)0?(Z!;\_VU?^AS:I;X;?O=!>X1G0 9D6G)Q+&#&M'MI%70)4XU;#
M<CM<&BQ%__[!#RC<.97%^WX<7$3_MJ*!JM6,V(Q!E6AZ::W1(+U?=P"[UP:N
M=G=J6%O0VZJ<53N6VN-A-]?UJAADD!D5\W#L3)JZ2_'417RJ]]VG!^I?E8/
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M\6F7S*HWU08)+61.%W=:L@^_'3DJY4%W"-W'F#5PB6C\]II_KP@Z6KL$L()
M3O.L\!V>4;$S"PGR>VVW2GM%3BH2C8^N2I2ULF<[^?/O%SF<]CZO^T0,"@.9
MDUP?#[52P%R$Z/UHE"/41G=^XKB_\]UG$N3B??ID(S?<EZK4^MS^HD \,^;5
M9DJJC'+&-QMKCSIU5NV!G>6Q>$6"4;3N\[97,1=9<=DIUE')0C9\L<C3DTR#
M/Y> &]=QI/>0C-CPM.=/S"_*M-LOIA::6<X,(41R0L22&\TTV%"_<^EV2F#3
M;;;RDFSR2NUL5OQ:LTK4UX5RG-835_.JE[8S=GQQN&FW??GYI76,_U+\IU/R
M#9_Q=WZ^&E]=ZC6-!+BV+U =%%36X\V/HH !KZU5Y*K'$I!6U$8T@@&H)GD;
MY8M?XG<9%C*RL;-B@2;.<'IE"/Y;:'3SQW?U2,:C7(+ F0H$=M/K0D<KO&W>
M'"74 &'I9M)EQ/8)4^G^H5L9?2TGSZNBZS[<U*IOO"Q"_<4^O\0@-=^F&KO>
MZ6+T&R'7@%,(7=:ZD?>Y;H(NIGSG,8_H=U?SPT.XWR4@G#A.1#81J>]*GFG:
M#U;[8^KRS6T4PB&K,GQ.UH[CX ')"B]/"FTV*=2/I$-BZM]-Q$.H&IKXQ"]<
MRZ&#(7QK,WQB6&5BT6HW"T_WP=K+60CCFJQ4T]PMK#^4_&;B@N\.,$]$U[S"
ME%7O>_YC:=G:@,S.S/BZ2P ]U&(1$[RG5CNR-IR@)V6=_,.V(_V$RWV0=O[3
M/#N<^-CO0!&G/)#D8@WZ_);7C:)DFZ>;)";QZ5,58&]!B4U$+HN)2UW?9HI@
M\TE#+DYL/MV,O6599TI6%Y?9&4]%V'6A'Q_?5C4PWD'9VR:19AC'Q"&2/RWO
MQ08@8X-Y\^,%?FE1&48JK0I4AXU10*I9/XMF+,\U[T=Q/O_BXKA3ND^+\]ZR
M2C-K.C_+5"=$X.?0S9H+31CFO?8 /T1S=:"T&TJ% U@V_J9^8=]O /B5 #G3
M=<H@Q\: &,:K!10Z&]D:;DX)/(,.+:P WBFR9R0O>1E"R!15DU6U^E>_O5T5
MUQU\73KB-GH8'S//6A,?RX#7"70 YX'QP,KQGF&_F,#:IP%>&\#^C:S&A[=&
MHF+H$J6*QGZ &Y/9IN\\R2KI=W4=5J8[#X<%E7Z,>I(CG&OH.&EB7%S84_G]
MGJJ2NC(@B/-J#ZH:HL08O5KO;WPF1#[_1;]2;_1.QHWTGDZ+NP(K0F$0EX9^
M64GLBE"K&%D!/S*>]Q3A9,4".#3V-8 CA=_>%J'PHC^6]\^/Y=),M._$NI7H
MYX.AEP"!>!C!ZLP2$GP;>V[*7I.'7)('T4V2_SVS>\U&F_3YMT^_+@%YIJ6.
MTVRO/:6KB_B)$B.4V31RV_;2*WT&D ",(G25^BKT<G=8+V8;7;;K4_0_QL)*
M5'[D!A[-M]3*^RZ386[[XC30[6#*'Q>Q[EFMW^@Z].G?3C\C=>\22?/MA,>W
M+Y.%',Y*&@YEQQM73-<9Q%F:Q8",V%C@X\T?HP;\=I2U@\%6&>AI,V<(11.Y
MSN3^\YG46KCF;M##!?@TLQ45P4P;)6YUQV3++;^KPFP@AM9:A?:SXI]CNE4%
M!I P!,98L](Z%J7H<@OH8G,;9,X7<+2%;"BCC_*N(*0=CC$G-2LK\;=9;S4>
M_@*#&H_F9L-/U"\ZSXLWX!'S5P+L?['WWE%-O\V^:! 5!1$+16I40)"N%$$@
ML='%" @H+2(B34"D0R!([TA7I$AO0D2JE 0($ 01J9$@)0F])@@A0,KAW?>N
MN][?>\ZZ]^Q]S]G[KG5_?\P_29[YSO-\9CXSLU:^\X!#MA&G#/".RJHOGVVU
M?GN!WY-0U]U%Y"Q]^DRM^*6G9N3C?A=F=CI218J'Z)6SSXAJH1G0JV%ZQ 3.
M;6NY'B[.Y>'J;X:5&>G8YK">H>UJSUEWC!J( _3Y6[%<.?UC;)17BXKK8*.F
M2]]2E0WXO%1?2UYKPV$8_^I4>W%.241 :9VM>?//[Q2">YV5H=RU!=W!I/LI
M\*H KH[-Q,."LZ--_XG25&:6=\=Q(B0[)U&'? 2T&HC-,;*JJWQ4J&S\H5;'
MWOFP2)J2JFF%WET),J',GGO\.P'<T4#9;3QAM)!BFZBMV/X-D6$='_\]H$;B
MCU*:&37;'F:?XV0S':5R7A[]U.2Q'^Y@968A("H6>4./X!X6(!&2F/'YR@>9
MUQQ#<@;KIZ\U"@4Q <-Y9 YB6JX&U1Z?=$(EK2&NX).47'A+/-+*!GK?([=^
M/LU(QM[_2G:C'BP#G<C*Q<=;6/O:<F/7H0)VB;H')Z$-44-NV[\T;N/[B<W6
MH,6"F@OB$!2_2&<US)A*9TMHE>:*K -S.#$$A\8:&S-BAW,]0W[M:0<04VW
M6L:89SSRM@,;ZUOK06L&_9^K4>-"FJLSU?3U^L&/,-$#BRE'!EO]3^5-S@EJ
M^MHCV>+NH:, 5>OVL%ZAYS[5@83==9Y <F '[K!5*M9RTBQ">O[NHJEU7.#X
MY;EOGC1D+H/AN1G<9]+JZO:!'RW5,5*YCN?0WUU%E6#*8+>I4Q))A^V1>\=
M<57!TO?X?^RZQ>[Y<B*( F>'=X$3C?T.\*51&I=QQCBYI'G"DD'3MWIV+XRP
M2[_DI^)XA)Q+/T$/K%53]^J"W^LM#-[-(&AZ;8<K!BI81(TA,0'HX NNLB\S
M==B/M:=ZI)YL+%$M9TC" KY2X_ (=B>/Y9F)UTLLIWR-^K_F9"B$;!-+7/HD
M"Q[W;2VT(L52MRW954\IJ:G9D1K&#]H8?Y8F@3@";G\&<IA#0KWHOC:?;WU>
MN1>B)]Q[<9:NCLW[17O=ED3D%@$UC\A:..IQV#H72';.AEQGD\C5F\.^-[*
M*'2-SB]D_#B0Q9K/+-A#I#N-%^:BNK*FUG8-K$$Z%18TKQ0L,7SF+/B+::ZV
M'05XXTT:QV[-NH4(/[V@B+39(^N.@?^J5'=V?#BQ]^MD-IQ7;=GFAM9]CU_1
M+>5!U6X?=N6>^/#J_P Z9/J2JB/6 Q_=7/A:MG(%+#EMI:>6I#;Y-0:S:M-!
M*J5\:"9QA<V1>A#YD]14'6/#5L^WI_P7G7HO5L.ER +24JI93?[-:?,O!FHN
MW+Q0X9S^>%IZ6W,0DU<OO)@4+#CC9[9XIZ'6,D91J&&@_E*\BND1N\^$3#QP
MW;",ID[J)2U4%:$)LB*@BWJ67.>8 ,^WMZ$0?5*S=.&!#L^ZJ1O<7]KKUSRC
MKZ-9+JIVUQ)E?9"+@!_<61FB6;D++64\=))[9N!92E_*%;^ ^X6!ND4VN\?.
MU(N!S\'X@@HP>(,@E14FP+&I[30'K$A$X7J +^)(0<KW:U**4:"4-LHJJK2W
M-!TOM#PZ-\[;0%?9V<O=.W0%RJ<FTF:X*TR= .&R]"OYT7]DW"#T1D%2\XFG
MMS$(*W-^<B QHX;L:?7E:TNHNK!*>]*795)>NAJ_V*X$, 2A4I!&IF:EI?-#
MI@Z9/PHBVVG\:;63-Q5%;,OHW0'&YPF)4;]Z?-3?-SYTJFMK+/8S"Z\UFY8?
M4(?(?9 X7$F8W^$WJ FGSU+]J.]SP <WS3.,C#3L [)IP]0JN/I+:XWC ID2
M8J[? MV+=S5'NH "8H=+W=O-W8NKW[UTRP^1^H8*?LZF*8U#JL."H9% ;M&1
M3=H-!X2ECI/PP*<O(5<:WZ;F?+H].QMT#7I^8AI2.G77TU7ZM@='5.(]57O;
M7M'I:K^PKF9$+")BHZ8,4FX=<7+12F4!=_,4-A^B7,7NB9U)?;#O99VD4F)P
MI]@B('CCFC-NQCQH\-XHRE'6THK:7>JW^;!.#UX[0P<^T+ET3N$T-]!&[TK*
M*K$N$RA\G@"FZ%>6FU"X;B1>/DM?"WS16A$[N[]Q:5.^?N#/1H"!/%HVG^(/
M7Y^>&2\M6@$*5&^ K@T2#X+D1@UE8A<ZE_QKTD]PQR=C61'.:ZUV!R:<)IT6
M#3%X!(<%U7%5/#'?X_SQZVX78(";R3TN'9(5B>"S/.+\,'-WMY9]6'2&9<2'
ML#30T92QM094H']NO@NYV0#ZY@]-G=%GIO?\#VAJ80OTZM=DDC,?T2N.=!LI
MS 38E]^5>$_9O)&':A'TL(%JZ6"EF8 ;$_-[/DK[D<"]8"P8&H?:R=] <M%+
MM3+#/QUZSB;'!/7+( 0S(?[NS666GT)S0EZ#Q:_!W"#E:9HVV2RG4J?XL=.9
MY:*@C'')]*BC\$^J>\TLB2'FV4:F&CZ7BY7UC4<>3*E@@TZ49N"=3+WS.:T/
M)JVW)TV6YNB(PMKZW%T(Z4&.'>']>L2GK#0)9U?ATS_5O;MAJ]X>XNO?L><;
MWRO]&%8767N@1UNY*77M0O.O#U)?VE#5D>]>G@8>GUOJP>[ WV\"3S,!SH%Y
M['X"X%,NN2+U9.4<!&_5:_2\\)W/%Q?9\E>?, '<*">7F5@HURQI:B'A6';R
MCUK!:"!'A 3[>:%39\#LY !IAW>$'/"SQ0W<E(K"$[/3RFW-46V'=<F([5#O
MS]X4^5/Q%YX[O/6$WEM"U7^_:9U31:2*&L*Y+2:#,F3UA>ZU>$S=F@UDWQN.
M17/%5D6X#ON@2E>\GGU^="U&BMS6BJ,E65#M#F[;4%D?DQ^4>Y=65_DBRO^\
M^S:_9I>KL[C_"'R"<5./A# D*Q<L2Y?!7:\>BV_1^%3)]2!XQ]^:QZ.'<*F/
M*!])V=O<?3\HCWYD8AS5[;))\3E(>DA5)S=#PG&^,;(F^M8Z!\_D96HR'3+1
MI[87-XUITM09"33P%#5/U_"J>T_=IQ(3N1EI*?/2X/KY4>/(ZVT@4W[8C<;!
MUQ5/%7;4?A/)$VT[#9@R/P.B5RXOU0#A=]')Y556H:(@6NY48 U-=;%8 -BS
MK 0-#4"@AXIERF%K,VY_7IG(5>UZ#$[17?J7\NVDN\6*O\SO@4)(%_Q5?ONF
M9$)C7@ZZ4@T.[D_!-$GQTQ?&ZAYKZ!7.U9VU4J!//]#/#F5?S'/..V1:\9DD
MD#"4:A9T9+Q'/88EUL ,][;G L^MIK7CBC9\6LZU0H>5HS]]TK)D*M[&-,R[
M#27Q#X!0=J,:]H='P <3)^V&"NI;>@W??VYS\OKS7Y]0OD)!*UO[DM7Z]:5/
MRA_Y.EG.):XH7<43B'I/5&8&-@*9@ BXB^6 1#LEZW@COD7^[+=G^:YR;HFW
MV!5:TL)Z=WC"R+Z4>!2U'F_-9] \8MRS"<EQ$]CB.]C@3N2C!BRT!L2N9MC%
MYH#MKQXT--Z-Y#<[G0-U%?!)W\3">_=%]>B?\,TC7MUD]["7,+V*Y0K>F8>P
MX\0+8F?\B7D!^$D,KK$;'+]O]CG33(0;E8(_-_S<\'-[^[QO<O]SDMX.0OZ0
M@G=6RGJ*JE,A]>L+]<(:M9Q:?8\*7XQ8#Z.>;X/ONBM#8K[XU=X>F4'?5.^9
M%UCM&D>T&5_JKXCD-T8WHGAFF0 !I)0%59%2D-25<193";>?E#EW[XNM0=I3
M;?QR<^L5^6@1B="NB<-*WE3V6I*8C5ZC2$Z &8>B;O?[N&MJ,A@Q;''LP)2C
MY$C;1L[D@W$<+M@A.:QWC#W1U,(EO>>;<N#&-&)#QX#,U3-,_8/)RHO)X/IL
MX'_]^V6=P8Q;@*<,GC4+Z+K3L>F\$B:@\\EL/]=9YWWGB,9109:F)=V+?S"@
MG3]M///&/=A"M0?GQBW7$;V42GNJ,RE"#:.[5.]4_:$*HCL*TG#9!7(7D@?2
M5++LMZ%2%I.8Z/B@(7+HQ*!$58 F=MVC5&H&^HL&&EZG:06*?$,4H2O/J8G9
M22Q/(U\55.?:QI0.]&M.[;O/],]IW4><-,_, K(WK#M-3'JO&/I[B^_,[5Y?
M__/")YE29I3R^A7;[76;=)(E<;R<%&PP:5\;9S[D_C6WT_--RX7?I8W".G</
MN?/U4)5QA);9A[KD"2B7P5G#H4K![FU-- &^#O8ERI]LC/3B/#W9N:^$H8O+
MDI%&6,=VP)& 7>5!0W+-/%44B$:MU9](B3EDZ3^[C79NTM\EJV.(-3QBBU>=
MQY#6B1;^;KS9HB?0]_::-V<&%[B-M%Z)O/WGV5&'PA*AQ6V^0Z8=_<LDKWB?
M4(B^Q03))C<+%5\G?=4_D;!_87+)RMBM;UY;SE#+6QT1#65S!0G#9$D-]>4K
MQG<).8[O>]X^.M/0]5QM6S2IVF6TE>- \)=?_^QZ:>R/^L#35=[/=O4<:\J3
M7DW5>V+96/]4*U*&QT1VB:;SF5.-(Y_R&T-!?2IS!&11%(85+Q\1S+F<JF!@
M".G_TL3YDRWN4M)0-&VUL\JBN?#!P^#M:H996U(EVO;5EZ[Q!-V#MWJPC73&
M'^+,Q.+L!Y@SN7XZV==#)<_6SFUX"L(>NC2!JU#$2(#3']$_(KDG80+4$-RQ
MXCGL..I%(EZBZ>&%C1\Z(N'F8P/X;?H[FB*9M>ONR]>K K_UGGH.IFTT 2L9
MIEW!OP3$ZYF GJ1(\UT I_K#K:?O![6[5EX%?V34/R*_+H]N#B8^F"Z_TEN5
M:5(8YN&R6UZYKS),J_8$LL/MS,E\D4_)P 3O0:IVW?*H 6<33DPR@.^%JE5B
M6)41=?Y @0K'S[QY07:(I)G3:^Q/E0M.-F .,*'"D#_5_0SV8^70#G^\YF45
MOVVS4+U3!EVN%U4!B50K\U[R-,3=2;;(\YOPIR[^B^:7A!+#$7<M\&UMW@(;
MQ:G+;E&@&ROO] Q.E%L7DZVG*=.8G\$B]#09V5;18I=@#7(5*BS/'"?C^CR>
M]\53]DI>T=3DD1(M_\&>O-!F5(=A (>PMA^B2HYX'6?3L6MO-&I7PX,@E1H/
M,22IPST8@F]<]8A.;1+]S*#'UMY[@/9IT$.=+<1]>G/5#H*JURHO,*FMH29<
M%G<_]_CO8=#QV2#&AJ:6ZFCEJ7M./\S;]I_X6^Y<\7JU\\H8H<\[_\5B:N^/
M;,J:%A[\*]O:+]"PC>P0AR=-YY<?.Y -N??B-_K2R6?7IU1YB&!^T-D5U#&:
MC9?F@\<;&;H1W?6C=SF4GB=G^UP,/4%!U,-NEU!U;$B[:(.D>#Z59OE85PNU
M3^O$9DD!H\:P-[UB<@%/#QMJ)L#M"K:86N^V7]7JX13W0G1X+GQ.CY?P.)6^
MWD7>_J3P+JM>6G)@:7/$4!U4^L+V#7H(K3:2D#6_,CGF\KW9'PBRM!@,O(YV
M/9IY_L94(K<<9HGM2AT8?QX+7SI6 9_E1M$,76'BHZV0(MJMX>I686=YF X_
M_$O[4 SKN? ;?;J#_;D[VX,TF21<*B-"%TRRRJ/YM+&/%3\P2T"ZS>03;5_5
MK=[NLYJAK+FA%.<"$5PKXPI*NQ:F.W4<N\598T,ZH\FQ^5!]VE-R(Z8-BE^H
M=")"N+KM\.5'X2XY,AG7FY+U:1T_0$_;*A=2?X[7.=],;JW:\E7H-DK@+^L\
M""IVV.70"HHJAUVCWI[-"T.RD:-BMOU;^Z/Q_OFU,A84[?MO:?2A?B&[8FMJ
M,2EOMC1$.XS8ORI=]%/YF%;8W2]',:_6;K")JIER9,=O>5C% 8\/&P5,N8Z)
MQ/4YEWU5P]S[@'V^OP:#:@6)'IC#A$FH,#B>FWPCW'6\7QO+7FFA#<GL-3-_
M&.!F_%H*M?Z&A$(#.;T'3]S&MTEI7A=<$@N,2'BW>>GGD==!)VFKSGY-C^:^
M!.\P 9P_G">"+$!#WQ"O9T"NGV#K.J6J_*O+4%.8,_7&8:[BH$[B-1/?%VHY
MN53IQL$%:H&JY][_@'Q=7C5#.?WCW=$3#)XE7'%&CG/#M PRE.]SK>%:PXK0
M<8_!8Y$;R/1LC\^IH7H',XMV3^:]G2I2TC*_(MO&MFE),M0A4E3G#)>&,%[3
M_"[Y^NH-7-'M#=?=2CLI03_6C9 'OP7(*_L2E"2J)1[.2E.G!I8[!MSWX6O.
M=G:;UQ;K?S>6^#I(#V% ?4/:G"WM=!7LR)I&X;\YI-!%XY]8M'"GO^>N^W+$
MGR-OO+8T]F&XN[^:S23T;L $K,(TY^O3@L(@ZWJ;J&XO\Q%HG<[:9I$3ZFPK
MG_MLEZ4@D%?WDL$KO42)V0VK;>-2U1V>E7.,'\A3I!\UI7X0!D]B*4%=CVCD
M31C48#W?: RR'1&.XM]\1-Y.LY-;,.J[=JY<5:5M/'UGM>$;$] .XBEHXR!B
M.E%4$]19=Z43BX&5LG$>+C)Y?CU3K(&)Z<O +X>_FCGMUW]WG.9"O#/L%Z@G
M4_GR0L3;B@V?EZ]O+2<N-#M$E[+;3!;2']STDZJ_QL59E[XY8>FY:"']&RDF
MT<D$Q."P$5Z(B/W[S2+%_C!7-S/=)Z*.O7O0H]G9"VV>9B2'=G"X!>7]+.3,
MLJ(S;HQ0,%AQ_].T"9C=X(C*'(4UMN]Q/3>"S7<8M^1^JMGD=;WN5J6<R]+D
M4AW(@FJ.#X0(PG1)&V^"MW0<RJ8^G:N3.,T=Z@=J-=M=9R.M&E)-R7>8 '36
M_=1^NZ,*O56O)_/DOFI@2P9)/N!0)J ^*E2I7PU'U&MK,6B1>#O?:?O&3),4
M.(9*G.&:(42MAQTZ$.Z':\J6(%SEZ75CY209'>0Q^YT(J3Z]@^PJQA4FP#CM
MU7!XX4&W,K!]+S3VP)QQ9F:",8/A(-5LZWVPLJ5X5EYSG0Y6;/P^.$V[EBL=
M234Y "WAX.O7JJGGN\;+JY8S?,Y9=2RDW+AZ[=VOV1U<3Y5=?M]DG)GYCLT]
M ZF*X@L]1KZP9LT\A_P_PCS;[MV;D2"69O)F)%*$RI*N<0OW:7R_"BT-E%$P
M+D_M.!DY&V!>?6-M<[:-U>H+Z0T56K&:<?UR,2:N=99=G:OU^$;(3CMQAKLX
ML?1"=]W.^+3US@E[Y0I](V.S./W]>M^1>Y35(2"'$=1@"?SECN'!':C?3<K6
M$PTU>[?FF"9HQI.GSX[HY YDA\(GE!T(N>4'H&6HZ\]M!)<A;U7Q]+T$;_?S
M:]EB%5<,N[_V;:Q_J]R?$Q>_("%=N3Q,_\X$U#IKG\MY(OFDOG*J:LTO+P')
M1<W$;[PI=+DYT*KPR[F_>:SPG9IMW8V+7K.QA-6-&5P!L3,@J@-^ZHE.B:Z[
MLGBD/%?#:=F8+<:N!BS;]Q/7&9HX]1))!WU3.X985MJ&]7;<PH4[K\OHA%C[
M9%\^XO<CP%Q3QGLVF[#W(4#\UWJ7O4:]O8")_C6]AAGS$3=4,KF^Z$Y@TV7W
M%K'84I%P0EL>Y1U5/I\FW$SZ'2"#]90K=AXQI)1R1A[U(I8J3P:/HMAHET@8
M/9+8-/]G7;&6O)=8YZX/(4?.8"2$YG(UG0?7YYF 2UQ'F(!?FDQ UIC.^?4*
MXU=#(/?VF*?!57?/"I2KZ61"3>;UI8?A#C,19VG/J DN^;]_4/9A'O4#(QCT
MGDM2.N29'BMH9Q7,+T8]F;^<>Y%4DI!OZ$KX<")+VO6.Y._(K\(\V;G: =G/
MFDNCXZ6D]%1HS0'9W)^-R[6PKXT2^S9]YV M6D$)P$ZN<# K0V!I%W7.=6[,
M.\A9P;>@I?5>F=U\17+(Q_B:S<?@.M\.% L5.+L9N8-@MY!)\O<^8ZV7G9G+
M9XSV?4D4;C&[AC%)&S4.:)$8RE'LJQ@IO=IGU&J*0Y;MV<0>0 GFG4F' <0)
M.U^R&O C.\.W,<O)P/+Y-,$E,OKL)0 %'*7\G:9&52.MXDL[XN2!,,,OKC:N
M>J;Y7]#7/]IM296)RMSZ)E&OCQE)4QNUH5BXT6(S3,R4-3]D>YF['<@K=@>S
MT-1_(B7\R%[N9US O\9M[O95"QL5V])8/KQ9I9J+$@T%!M%(N7&E-M">M[J@
M>F:D8/>R5!@:GJ>_SXI/"@_F.ZRN"@QS8PH4J7>L%7XH';Q=GO_!,O4F>]9C
MNH)V_I [W+F#AT6D2>.E11C?@B>";]P=OW>8N. #A$B2?NG\?<9M:2:-.Z.\
M)T=+V5_-MZ1:80/^09FO"I XDCE:/E1$Z1_30D2<<,)H9XKZKY41M:F<7Y=Y
MV4+"WX2J=?LMML,G*&@,]&RKH2V!HYSO+FD$A8N7<('41[-J1AXWM/*HPZ6F
M.(\'[*TYR%1_21,]7OP=-[0VOJMQ.?9 5(<*)T$H(;58+ZZCR\9^<.B(J+R[
M%T_J#\#LM:,Y?;J+*+5J XHI51T/$78":4#YG,B_(45]3RTS9!E)$4_7 !JS
M\7^6#58_/TPKYLUV]<9:1]$SS4POG=!3EIXH+?F0=]T(^H(*Q@,[H/%03F5;
M_*1+VY4@3LK@ISXNG)#D[^>BJO;V;(E2H31YJB$9,@N/KI<_NFPNX%/\49H)
M*+4Z)Y&>[&N_ASX.V']$#^:KC3/S"7 -BF-\JQCVR+8><;%>;VOC>NN(* ]F
M@PF23D>1(AA78'I)ZQ1%A][:I]T\BO7!IA=K4T>&FPT]\5R=AG:S$K$P5SRG
M9O5MG:QQ@Y1.@QNG/F+J<@%JLXM5CVI&B2!+S?7@S"O\ID]&3!9B?1;J=QH#
M17B\26[CJ[.:I4G;KGJ;U:X;%IPV YE'9B38S9=[(+#8K>9]40KD?3WB%,R8
M]'WNF[UO?GUO?"[O(S,T? F\.P!;^U@1$I#(Z:IMO)@MMNE 54P]^T"D+_VQ
MM*=LD$DCL:G.2,L[^S\P,-A8X%_G!>1>(/TH) J_QNH,/SUXD/]:-U:VP_>,
MXNBX=2!D+18G17M>PQ@[+U@K"'?PO[7^IV4#X_IUU?JQA7Z;GW'J%U?1)'Z+
MQR\U]8?,/0QS30E)IU9L.+'5VZXV7+7.*I]X'1N/X_0CA9*>2<LA&ZE1AY41
M*^P.O4*FCC=RP[)\W*1*;D'KNHS4T$MWPZ8?T@/$0^]?H)<[D&XW9C+.[K2<
M/0$;0;FG(':;Z0079(.EJF&9$G&PMWYU<7\OUPVH$J'O-!IG/+<8X+6%W=C2
MN!.[;W";>@EO>)>2-4;C4_ZT>+NAX;K.F>Q-SL_ -FR5CP@?E8_D:4V&QL#.
MNWO#_0G2KL/\3]Z;_78(3VB^9A6_/V;2YS**,[)H6MFO[AK[01IMC,]K+BZ8
M "%,B#CI53@+[035L,HY8"9DYF';*,W6CM]I!W#*,2$WV4?]]77I_F!.VM$X
MS,S9^BE1LS:7(-';#@?/AX24WCP.85E_>QWB_..)O1>>Q^'? FIY7P"CBM97
M%I<N/II;@86\:(,(%"!K1AAG:,+4;O=/CHRCN7\@Y-,9X44IM<<^L/&C@^;%
M[$2+/5&U\/8D3I@V:3!>C*SAJ154;%-?\5OGFE:XC/\S'9A0KC/J2Z5^D>WQ
M/.6UD1'#7O]Q$:528X\T?U>O\>:U-1A>RP?.]PEVM<0/YP(]-A74<CMVFL<R
MH;NQCV\W2F*Z#4*QIU[%N\<BSY,-9Z*/#@W:2R8*OEN0O&0B0NCR4M7XLVQ5
M]\I;F@!"'/^ K<[RSZDG;Y.H]K%E68E9EM:PI%Q'A,\(Z!35D@#IZ2)AP[Q5
MX!R3%F*-YBO=4['QH),;EB2$813%E>00Y[X#/3WA9]YE(]A4FX#\AIA"+KD]
M%GJ>2-PW-Y6I:'-I4F[+:*F?I$TE=UO>1#_\DN7[Q=TP=1,Q6SV8)/TKF(UV
M=@0IY>?2;9&S4>QI?R5)A$I\PQT#TG;SW*ZNG(6OK18[0TFIJR#0N\EE&V!3
MROAC7L/80:#<=QU2HJJP"PYTS@G*A2>!$[WEH["UAJ76EKVI.,/L]E5!+\[>
MHT*QZ_U;C5=[O-?[-@L#EG(;=C1H@ZKQ3C]R^9'/B9OB&ROCF=L@3K<+27>T
MQ -1:&@X4HA\HQUZ@5K!F'885\*F6?;6\AB%%-D';AGJD1SP7)&M3J0;/4B)
M,=F23+-AQA#%2?1=176_MW??[EX,XCI_D%.3N'N G,&02.L??>[1WZF[SPOH
MT$&[#FEH9_#Y,0WWZMN%2^,S+J,2O^WB7EG-/M\*B@C$=*#>V)Q-P@?2[E)C
M/"\O&V:$XB2D5([C.%CZ%154C=:MH1UPZB,XJ>73%5(8="]UHJ8N]N&LEL)4
MJX+F\>]VFJLED4^NZJ=6BO.H.P6]W/\UW^5P)MQ%ZDQ:MGQ5VV1UYM:*'QP]
M& 8A0&*39E%GG3GPD]$\W]?37_PNO,0G<32;";@Y'WS1[QG7,>J(^<_U^J-C
M%VNRNS(]B.>XT/$4U0WI9<AY/XD.\%FP\[*2+0\Q,M1\#)!< '9^J"LY_<%G
M&W'M)X.M@^B.X[ @N>6(95@H1XP.R'R:G$L\^O(5Q$SL#75LO+T),S$<ZY[3
MK;Y"JSHL6[G>7S7 C:<:3)0KN_+E[&(+-%[$[J\,XG7:9P3\(@_:FX6[=Q#1
MZZP5TYO/1+3P(79;2/5$=2PK27'6+9T C+,1)V7&$E+FO<JR68^6:'Q^Q?K<
MY^+XN;[5JYUG4V _L ]65@MO)'I&>2VJ:1O-F]>:^00J^0GS[.R&!Y^DB9#G
M<B5))>'[X3A&AJ5/ON+;NT?,Y]8>J;#L(%*\!?F5VK17^E[R5Y7X085O2/.
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ML7[=M?[/+/77;VTFVU16^?V9E>^N\C0@HV+DW>JFW,9$%9?7F]B>JSULY_K
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ML1Z 3=3R.%*FH*X\(N*!N4^6V=Z%H>]21@MFAGK3@U\W\[B8 $?#&_A-C/1
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M0!Y2J?GG8#B<QOIGA''!@0"AWX&39)@ LM)?UZ/N+!7^VS/8]MO"_APP ;/
MW+R_&E+XE_7*^WQ:0-RO)/DF\-@:,&^&"0#0MO\?=R+)&._R#^I@()[2&$P
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M=A,[*>1\,\.NG8>@ FYT:#<TZ J[VTC-R]?\HW#/3NVQ=4S/T"5!O<$V0.#
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M'1BQ;,I@P+[#['0IV:$[EX?,.=C-Q>6(Y$,UOVY^D5HT]:$D\KS(B2R;B+@
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MGVY[.9+-\+Q"U&]L:"JT:B>DA6N9P*:B)^H48->%>>3]AN:L628Y(?^)#<4
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MT&\P@)M,)M_/)(*YKGBZA#W*@E+83A"L[8CG<Z*+C6Z:W:N:5C!IUM*[:RH
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M7UDSGM_C6@CF03T=;-%">K@CKCBZ*DX5.XHMFV 3UA]EK@1H"/]"QZ%GW\\
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MUM>GEPP-CO'E?;UXTO4K W#>C+E%$P!A'U:_6WF@:DR"<D'*#?Y^ O[X.0;
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M;VKAHG2W0J.>6=O"B%CVU<]H]^:\$Q955=F"D&QS?WQ9S.Q3WOLN=,U!J.L
MWH38W-W>R #6&0 W4A5W:T3C8C!>0:384Y==S/WE1\FW\Y]8<X18OB.U3,#B
M/1A-B0+O.J2G#$:WXJ)]4'2)06_-:UO@_9HG]SJ6[J;'9/*18/IP8_IWJ&3F
M'&1M9W93:G7 M6!%(K3(9NICW)FGKW+7>^;DC;N;4<5[%^D_@B7VWS( 1XP
M2I'2E"8![RAC7[S]N9(\B;_FX0/5--+L\SA ,@B:2_"$F]*[,-P^T%!L)32D
M28MD8Q!N%3=1CE"18VF*?.R;4#CJ]_#Y1?[6VIK=\ B:N499A^7IS(A+2:)\
MA3M*4Y9VMA6AQ^+X!9'%L@:Q>C_XOT4!#,"L)67T?X^3^S]<'/+D ;K!'F;O
MD!US'BR4U]2KA:%_J3&C\/B5309@I.%3]<_Q6R_NT(07B9HI)$18L AEYEV9
M]02&>R8!;SI/AU/?GA4^:R"*UN+LK@FP7.(-=F.2.UVU/!<94="O;$7OJ$C9
M@R Y]_<>QTV^2A6^H7C6!K 0I,[D\ SP!X\1/I8&2(= V[\JVSTP=W5NTOW<
M](CO;LO-M8"="JP>*YC62C_-Y&NQCE]$7 M![8WQEDR75!*+5."X0R\=\D9+
MF&P9*DGGG&8 AV8R0W]T;QQ._,"=Z\UWX<CVGV;/[D+AG>XO[;,OR6GM1D1L
M(O,MZ 269$Z]U095"G3TV BF;E2Q3 ])6+NJKGE% >!OZAIH0JJ(D!$;V22-
M/?I(_AE;G[@^Y^;_*F ,1A,<,QQF $^FG2;Y9PS[!:=F_S(:5CV)]Z] 25)4
M0E^9>OII5"I[%O4H",\2/J';(0+.D,J-VG<N%K^6M5/:L:]M[\<LLM?O_Y2H
M64G\\3U?PGG+L>LW2A<,)<*.('-)4C,R(0S .(Z2E^AHNV&+>T=S A,=*)4P
MT/VQ= ;>V<M4+/N;GN %<6$'. ,(W<Q?;EALJ_U1,+*NH90D>,?IES#G=CF&
MI+7VDD0X2),E-U-#^2=U+^=K#R@K]5];%'Y:_7ZF-XW.Z3&4B;.[P0 BLP6&
MZ%STP6R1.G+^Y^5@]Z0_D?PL=?G[&)3P>]0C"JYC<E/H7GFQI\176><N7T]\
M.0I"YN] XUGG##$DF(339Z?=X$S$O%NB[\91!PW,G!HG[?9^!ET6F=^DEF-<
MYMQRE$> 9#IY[EZ/^KK:S[29F;"119'2VATT[X#Q?BCJ6@LK&1LO^Z8IPR+E
MV4:BFOQ=P2^%M&M,#A&-A%B0@['Y1ODKQ_USD,(9LK4*49O8A^B074P(77KE
M#E@^SKWO<D=];$-'IJL1&PTYB.)&D!<[_$X22X33W>9]?&(>2?F4%P9?K2A+
M7%P>.%'3J.M'YXSW;@AOB_589N'4V#O/0="@VJ&8.']P,/8!Z%#1+38IL:(L
M''1!@WI1<8W_'V.L8:E1P)_?U*_5%(V=]K1*<E<L7['7,U2MZO//+[L,4'Y!
M>SRK:%YO+ ^(T_^\AXZP?YRTT8<[==9?K&+$PL!#_+(,*?F;?>AEF3>E%[.R
MAE<P-%:$TQ__ "D&\'SH)TJV0++WVEIY#/>"_I'G0G,92\4'2%EVO--3K4XG
MG)W+)P4RQ;_TH23W+J%;#7WB7Z$/([PE89PP3U=$:UW2N9>;UQQG7ELNL%70
MA"OM6])%<&U09\F0VM3ZSN 0FC@8PX3#)M9",,3DI/H?U</G]$_-OKRTYG?7
MS$SGT&AZG+"A<8Y1%Y1\-Y<!B(@W:XTMT@05Z*8OC1E >1E<A0&T7L>ZZD $
M9Z9HYX=EHQ9F^!XUZ+_5\C1#MUY@ &Y%NN=DDLFUMVKBQ"1@T]-G6N7&_'9B
M]7IV"_B<G:,F7Y]]6RS.CK$6?]O=P1]N+=I!X._+!4-Z$&YY8HJC?^09 !O/
M?B9*F@SMD#B ?-+G[M"<?K6(XZ$K]296C0',ECG23\$XF1+:B2E5C]V1][YK
ME[X5OU:[)\64CY@PU 72I+N\W.ABM7%,A_?#<W#+4Z]8C"YW/H4R(_9\' BC
M-\G2S;M07OOEN@)D^[8-I=B;DLT^0A%58*9JW_C#C!_L9=FM%<CD&^2^F-J
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M;.N6PNORUS*FF;\^-QT_-/TVF(Q7\XHF0)!NE*A;P#XH!X@RH_1&>=Q/O3V
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MA0.".*5##4'(A:JW-?<"3S%\#] T^=KI4GUT-R:3/&K@-KO.:PV4M9YQ$ZJ
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MY5.59G/=[M"?8%[&\%@[ELIK3RE^,B/2RV.<W5DR5YXN$0M^73QUQ!0ZCH<
MF-TV//? [U!CHW0=?&UL?:U?4U=CP/%P (06/G]_R1SS:B2AFSU>+BZH^E8
MHG-S,#0^$K.!3ICF*T9QT;726_TKCR\I=&AX!_'4W+F<<!<SAQ=G#(XP_B@<
MB^[X_B!0Y1H./1Y;/%[".,4F\;OCDMC'MQ=^GY<@5_GSW75B5WCE?FTB?WT^
MI(COA_T9X#M*B"Y;1H7%%V8-5AAG'@HV24]]/.=HD#3!G5L1!*8K_TQ8]1"P
MJP?@WI (J[5=\^WT5A>@-)#NC:D-O%;!ZVWC44N__.;.MT>;-K<\:?A>O9_C
M\Z$N>H^QG Q)5RQ?/=0+YWI+*66 )^%D.(_.;/Z%WWS#1)D/Y G'POYIMO;L
MVS-KKV_J\4E&\,WOH%O!)R:1SGA*_91 (%*1"_=.K&+C_C1+[-X$CV''3<PF
MIJ:IF;B<EZS^LB! +'[Z$?.+1_YJP7K8Q-HY5([J,6\;$L[Q?-[S^;BIX"Y+
M-^HAZNN_& H[BQHTJ]=#!.3H4L5(\[*A-7'B>KUV?H?\F+/"1>OW22AB7.HA
M/JF3X9@]*-[15B1<QMFU]:&-LI#,A<<7IY6WZV"M7J,M/7Y>HXIMIG>>]]+/
M<#'!K@WR  6VLD5*..ZN2#]=17FF_BUE7&Z\A7BS2SZI^N0%"PFY%93R6@5U
M:\62*CY3%5_O00[QBH2P>=6SY"_2R++7?LT:\8>O@R<465I<N,IWG/%-F0?Q
M)GM96J?MD,%4R?5&[($E?]K(>H4&@@Q7TW'S?XA"6'7"E%O#8\&U;&?QI3CN
M$<(#^%.MTR,57/;[(!(M72OKDRE1U?) MD6:OD29BJ!CH@DH"+;*D;FP#^+
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MSN(QS, [(_-4)=$WR=<>%8D9%63-)HR)T RI<N6UGN])#0[FU*LO"O24\;@
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M.-*UKI\A1\)&I!8Z!Y9X[#UAW<:;^U >[<&N>' XBFRXR W:G@G77HUE#/Z
M>IG$@@\P]E#'#:B08E<JMRT%\M8S]]>8I!%,1C:C./HGKZ5Y1!GC9W>8F:)G
M.076.IZ873'>CHVTU6^#"@\CZ"THWNAG9IJ2U2F&]=(G3 ]"%1]_!CLB^/9L
M=O&3=D'5-:U+YA.[H$7<)(;/+1 [3!C,>VDG^V;/A>_=1;EL7[3P[67,D>RC
M1)K0IS/;<,"AL%2?M-2N(B#T+&CNO+W3&?#]F^QS@_Q;WR;AA P<?IQB HX6
M4^]CW"7HQ\,WBKW$+?#"RELB74D2KON\/N\QG.NO,J) :8G "V?R> )SST"8
MI/LNB/\^0X5DN)$);;<U;O!X9O\T;M^YR.=K1*D7"T/A4-T"3"?\R2ZHJJ8-
M3O!L1AT)$T2J4_FR*1F-GP:0GI,<IV! &C'F($^!^/ZOXF\6'LU[KK<85X9P
M:@P1C&(4)*(D$TK/T%>/GK=I[+$%5?S;I69U?:2CI)(2>?;<#7M!"6Q?(1XF
M<[V=S-B1(D4EJQPV!I^AP?)MNRW%A:0_3K++H1N+$_]2&@5,LP<H6-&& S7]
M;R(LJR&6 ]HMB54)=).P/K&#@"LITZF%P'SG5674H7;K'6[L*[ED\=H8+AOU
M104[]>K/#Z4S8&6XI3N465+:HXU038=!XY+!MC5#X4G-YRFQ.T<IV)C[2(>W
MA'G"_2RO%]_A,=0!L\3/FRIN[[^=UE-<+-"^17Y%*T#-?D2-7RZX6FEI4W78
M$S'F+N]D\,/Y9=EG_F_?J,6?*5][L3'KT_X795P=I=FJ"X;<AK]S\'V:KYUI
MTM_!H+RUP1.X)P. RS;>:E">_=O45Q&O,"\W5 VNS4L<=PP1:WS7AO2B)C0&
M_7V_B>)9W8K-J%J6;1%KERB.F2K+Y45V-E=X4R'WPH_%,DB]J/OH1"BX$M'_
MV5:Q?9^C0^O2YR,AL0,_6+D]2A31L5B';X>)534EM_A5+T$&S>>&TM3NK!)]
MAY@RJ"_7&B1)04[5E-)L:$QIAOHMB^QI6!:T2AY+%9BL;AA3'=+2#G+*R]XX
M7P=^%BJ[<9@TWH(:7B&-J'KFC[A5C%ZJU^U<+58*>8UOAE%,31)M(S&MMRK1
M!SV/=[W1\$+(65X+>YXY;!3*C=;BG@@U:<^2[C]W[D/>Z\9FO27A>V=,S&$_
MHC_O@MBQX4Q^(/!J$@-77773CM*%@C Y6)@&#)K?.ZN+I1_KD'8'NTF5A!4P
MM'<:S_2'B0)AA[W8S*ARY$O[!T<>)*N%\>7<XZV'4 LP9X[3*@PZC\JDU-;Y
M89XT&-*MD*[ ZUX<9?:+M>I[A8WWRXK8[C+)FIUBB)SNF9@"(IK+]N/QD$]$
M]CGK3E>G+H@62RM:*,H*N;J6M*,QI/YA29(HXEI0&L)BE&*I(.H(%'T_<7?0
MJ=\(K1YM[])D#/20P$<!)[)5Q?N%TZ%7S*.,/W9;9+:G3&1'<U50[73*L?TS
MJ=V>3VQXGD\\]@AZ%2R^'H*#4<QZCGK:]#?LGR!V778_E!OHR2-C6&0+;5$@
M:-)BTV=,>!9\ 6OC)+V3\4DO5#:A+;N@)TQ>"CQZ\4V?GZR1Q6H2=G#O\.<5
MA[JB=^%OI-?W%G4MRSOW@OD1KDR.3)(<U-!ER%^VQ-72[24\\]N>IPM="-U-
M!B\7DTR;N;6QD]00_[7V%\<<K'# ]+N\"W(_G35I?U&=!F2IBOVMP5&YZ2\J
MM6\G76$#K >:SN^D-@D#LQ8:4<6D^B#OC.*3!.@I1XS1Y5C^X8G@Z$4H)7FU
M^Y9Y2Q*Q/IZ#)]%B.Q8HII%WGB'E*%=(ND.U=TI&#/VQFP$5WPW$?UK/1P:A
M<"PO:D%5LD?CC:A[+UQ5UW=\%W=J36EK(FKIB(Q1N,$<S(?%CE*8  ),SFK\
M0$"4#HG,6821U>X?@]DH,'CS2<D%8O?'-[N"\S]G_\QFF6;/QOM!/[\@.#22
M&&]F@%Q<![.%]83M 0)G=T%W$<%#;&KC8X]V09F!QVW%,M]/$7X2B2GXCGAY
ME$RCKHW4?JKX!#P"(A>:S>0-%3YA0-P%%<MK6!]%W45%3#DQ>43LK>M,KWV5
M[_;\C.):YXZJ4YQS%"LSAK3=N&K85V<K_?Y4Z=OGA;]:#C3=! IW0?OF@%"J
M4;N XZD&]SMUG]3]1>/Q0\IFP@&0D[N@:'.&RKG<D>L!S\*60ITI':3J%Q1,
MLVJ66!]_9&;=A+=ZE__S2IN3M7KT*_U5<EC/\II:8G_74[4UC"QU<[&&TM]N
M[NB1GA^U-%V_:C>C4_F ^XYCFW'RA7/WXQ4_G-<]#WV='4\X%RS09G+TISOM
MH:[S_OY<#[X)$&MZV+>N@H?( R[MVUW3%>G35Y]V?)FR7E[.H\LQ+@SY<V#@
M6F==53H[;::<IU+&$A1H-H!3CL=-V#!@U2U2<./7E.64<*+95N+X9Z9('T.;
ME*E!O%$>U<?W"'1KDJW*3_!]BW +;WN$A_1GONV*\W^'[J6^.##WNL)3@DZ_
M"ET2^U'JC-J<PPF^/:0(VED (L#6;/5IVSJ(,CG1\Z3I6,LY1\&^G'[QE)6#
M=#Q<5_;4:"2?Z?5_L3[R_[QC6 * GC!>KJ6;(:Z0/WJ4M3F]_946;)'N$_]*
MTAW-)7(1%'RW,?GO-<BB4?!=4((8&]H2<'JG%E<9.:0,$_UI[V%U9DF+>'&
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M4 [Z<<:%>HKK8LF$P^%6@EN$J>I[&KF=%/1H.B#ECMB;\QB/!DII3(&'J8>
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M:&+E9\F;Q%V0$26JQ,7)'.[IRV=F)%+WV$%PZC5O(/@:"$^!_J[[%4?0XIS
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M Y7A.^WZ.)!+H%^[^ >49,YP: #/006.CTQF?YQC*:KMT 8<,*Z\@*,]<:)
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M@7RJ64]SDPB%/8;[B?+AS$MJ,?YQ1MEGMC7/0Y9J"6%.WY9^6#?B$YB#8YQ
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MTI10@#>X$ *?=7-65U2CML4'$GGU$\0$\MNC,EL&4"'15P)X(91/*6:#,U*
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M2PE4>E&;4QA93Z9!\E"U%\!I?!&/ZATS:(?<'8'Y25RR[J5>)K^!;.Y3>S(
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MAU&G^W[\G#TZW7+U_OGC6NX)92\U'DA[#V/@R@$&^]H8(4,\"L5.(B=6;N+
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MCD_.!?V28UNM;S<GB0;:X13$3E 46W3F>-@8F\G0E,XT%\ZM\B-49H0TBF"
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MJ<GE,#GY$#1YD/^FXOB!1+,'7."%QEO'58Z/O;V$[3P&S  ^6,O<[V#P=*G
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M>*4^?KR]"9208"RS@US6#6<1^AC:4E=O$&/YS<Z65%;= TGU;%,B<;7$BS)
M%Q]?C,^')<>YC,T2I$A6_QCX8#^__G%$QXFP$V1U]6.2,QA;8L<@DE'L$EZ7
MU!JU8_QZ\>0!CQD>'_GG_@0,2NEB\F++G*9D"JY2;0-*#&E<7#?K#3)O^.]9
MB;9%@AP:*RT_R!IBW6*@5 1IK$87Q"!:,%#:&A3CZH)JGH9]!!R[W-<!*O"^
MYHZ@MWC.A*MP0Y]%'(IS,ILY8L$J0K12,6E+G9WUJ8LW@^B0$7?O'L5 =Z6*
M1G"515:U8<P;><^LU0M[LA\64^"9F.6QBL8*/+]]*2E</%@RU%^&]5/K4+]'
MIQ6/+- "_?'E%<ZI>,C<)$&Q8'OJZNXX:M(&-JG^NLS4Y9V,L.S;2J;AWP/=
M_I+)6!H+9I["5 _4\%V'\A)'1^]')6L/Y^:S'U+HO#21G>;^T*KLW;09[L5)
M:V9DNG,ND53D87-E6U?OL\WU8NFGH7MP1I&G,^5Z'?RXJU;AZ2?P@JV16L=-
M7[HOZ>J&3H*;48&T0"8$/O9G6]C2%#NU1C7+^V'V7W5-&;\:!&3O2S_PLQ")
M_FVX&G<6MQ$HA!G^97Z[*7.W<XEYS$LC-GT@S0PX],QH6KKCZ2T5Y\*2+Y]R
M1]!E87&/BQ__*X\R_)M_\Z]P/?L?4$L#!!0    ( !&'EEC-)M55/ZT  !.X
M   5    8V1T>"TR,#(S,3(S,5]G,3(N:G!GG+H'-%Q?^R\^6D2/7J.WJ-$[
M0?2(DN@MB#(FHT2ODQ!$#X(@B-Z),D891"=:=$;OO8PZ8HSK>__W_?W6?]WW
M7>O>^YSSK/6LM?<YZ_F<_=1]]MWLW0K@D;:ZECH "PL+\.;^ MS- U0!.-C8
M_]SWA'M_XSW$P\/%Q2/$QW_PD)B0F)B(D(B(A)3B$0DI.2D1T2.:1^245-34
MU,1DM'0T5'045-14_[P$"^?^&5P\ CP\ BH2(A*J_VNZ^P4@?XB%AUV!@\4.
MP";'PB''NNL&L   6'A8_Y, _XNPL.]U?(#_D("0Z'X"]!$ &PL'!QL7YQ^M
M[T>#[\<!N.1X%&PBR@\H#6SQV3VH1#\FYC[D4*GIH#8<.^$4LWL?2D!(0TM'
MS\#%S</[A$]<0E)*6D96];F:NH:FEO:KUT;&)J9FYO9O'1R=G($NGE[>/KY^
M_@%AG\(C(C]'12<E?TU)3?N6GI&77U!85%Q26E9;5P]M@#4V-7=V=??T]O4/
M_!Z?F)R:GIF=0ZRNK6]L;FWO[.XA3\_.+RZO4-=__\&%!<#!^A?]6USD][BP
M<7%Q</'_P86%[?O/!')</#:1!Q3*!OBV'I3LHA\?4JDDYM9T$'"(&9Y0V[T?
M(Z3A%%_E0OX#[7\B^S\#%OK_A.R_@/TW+@2 & ?K?O%PR %*@-M7>=&\@/^/
M3R&(&+-)<98PAN&C-(AWT1+G%[RFNO3<1.44Y:XGN&^9O"N!K[P=?S2G&Y>4
M3*1HC$E=,=>H!;4@S>\ KU&@-5ZP.,NC_3BW<C\[3&"F1:7QVL'\ %5@?F-<
MH8_?P+O84*R>]P$\GR5N575:B4I182]%4!0Z@S'!-B;9NU"9MS:HZX\ODOCP
MCB.,&6M^>EHE=C2IZ>JH^]<.47'O-KIDM5?OLC@9V$B"&*#[00HH[+&E!?HJ
M;P6E(7Y^UZ_^/#+;6RLY(S7YF6I(G\BUG,_,4O5(_"B>,>_R$GO8N#>'VVTX
M%0\ALAC!WD5>GR0E(KU>^=P=9N*FAY)DJL/-X8MO.2ZLR-RYN52LR(/KK/=]
MKCI?GH/O-3,7EB*TIR_U\+81#'*=L6.GIT_P_?&W6$^URJ:MA9"DR6MZI'X:
M71E62U&0\BZ%BYZ9.&&'*<UX3H-OH59M4F*D\CV]!//]0P)R'EOMD"Y/_[5U
M@E/H&&1CN*"=M)+Y4,V?[)!DK1+2J83K!(\^]%IT=&R -K5.#()AHK(5U?1*
M3W%X\$OZCRV+>UCP$4%D*+VRO1#2R0M=Q6W#0%!@2^\DUU<Q'3X"(8R/G .'
MDNQZ]<^\;)8L#:NW!^UD9]P-8G,R@3 #$X@<8G!S(YA2+6AY30]_-H@6%;;B
MAE*](%&9@^['?+NP4)]T:+1 ;M#<Z)37!:U&^,9Z'UH;%:#UD6[A(?0+:N5^
MR499\EK82T"&K)[S.'$I<LO/6S S@M\1+Y[2'P3KNA$SEB1_JO>YA?#;_-DN
M3><3[*T0F#IV\L[3!15=Z8!'FYRKXS%\H(P*3[0;N0MM-*NLC&ZR]&FOND?8
MKVH#5&25]2S:$>5R.:$KM,ACV!CH_>4P[5$IXP?YC8\#%9OA+HBCS)LD2&E=
M'U=@GV/:,@_+^';3F WG3JV?1QLS*G#-*8:R1_:HM53S-X9MW%M/8/>]EH@:
M3'.X$_Q,B_'Y.QF9_>AN5 JR_$4=ZEKX,V6WH9K'#Q?CO\_-WX;8Q@>*TEDK
MKK1@+0UVO('X+D>/O2GD7J<-M"DVFOA;,RPP3K56+)YR.),_?2/<9#-YHQY]
M?=JG18:\ZI95 86P)6O4G:!E"Z$U2)(SUN_](2&.UQ_IKE^:($I"?LM&1J&U
M[$&E('-KJ">H87T02;T=[=08O?DI_+GC0 %?(SUC]!V -'#:L,N<M%C*K6_+
MJXMNV^#5YB)T"BW(,S%:F7B>0KUN7A]7$3).J:$HZ1Q"D[0V@9.2"O2INWE<
M!E!,K^:<D  [Z=[F!"FMSP;IK>$C95WVF>?C[+;\W%XOU(?H*'/4DM?5EB@)
M ?L(-Y+;+M%N&)72>/VM*]<4S,Z<TNC)P@UV]'7=*BFT;"]C.>Z"<=Z-:I\2
MV#RU9V$- 2O-@E,H^2DM,E,61Y^QVYZ1O:1<)>NRXECS[>*%>U3O,:26KP4;
M,B;Z^LR<AI_"&B4C!.?E<Q-:8-4<3&]2Z97;@&"',]^STSO !^EU+H.23EK7
MXT#GBA;_O_XYV@;6X!OI?5K9[0X;(DNKIB2_P[B:]^]-U0\9DH_#J7<E!J2;
M/=V#2?>,J,T]2IH+,"=YT7PD*M&\/[#_$Y?;6!-)=_1:M>V42\15BMRH$"/K
MI-&ZKXWF4K2D>W>4&IPP!Y#$.P##?TNY:FZ_XUF BIMW@,/T.T +RP:D-^&_
MI!(##3ZR_Z?!IL?":_CA%Z.4+HI,$W"M A=FM@D3[\MD4#!5FD]^O$.4:3/9
MM^ 5V03SY?P4\]5#GD#+]MLZI2M[= )J[%_"M-74I(]QG>6+>;9PXOA9'L('
M6K\NJWBZ6)CD*=?YJPDM=O[.S',C7V8*U>17S_'H0<W5]>73WS(^==!+N:Q9
M_+4ROAGC8S-]!]C ;,\J%!P&W@',(1DWH]J8N9R;&HP&VOE?@DLXU;5^H-:5
M\!W@W>CM[!V  R,.^9<DT6_C=Z4R$00N0*EOW0PB2<N!"A=9.<EL9[:??J3
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MC?)W9WP\KI/GAOU9$%3@)?PDTE/M+RKAG!MOF*)[]>)2&0J:#5&0+D4^I$!
M+%C Q#A /G5Z+U.U7'PFY(6? P^0V#/6FS_+B"_.)DTUVS3:(*A*^[;Y=CX[
M1LU_4I$;E59AMJ<+7 GF4$E\F\3/4;7?DQ6AY"O6XT8<$Z^NKTU&+!8KTKA$
MC6PH]*>T01WQ$VFN>VSZ!:I%+VZ\-P')+;3V=WY8X*OR?9L-*#XX1&H)]YTV
MML*D.F@PQO=>5N$K,8H*6R,+A_/XI68L1WD%,QRN4U0PA*/UY=@X'Q >$- ;
MBAT$\W_-7"$-JP VAZ=%>4,H_1H8]\/DQ_::%SM[!H@?J>)H/%)S6'@P0O82
M@%-^<@?H.B;R>XD\.M<C<?XK,=]K!SR_>?C#1T69SXR*0O3'^FR @8M..63F
MXH_EU.:EX?7R"6SO#:1S_X];9=#A@T%+Y,O]A#H5A&*B^\G+3ILGT5:RE4UJ
M;[J;O@I1?1^[ Q"DQ4-)[ \0D*[V&M.'\EV!:R2N1$$#+<SFA3^;>$(?VG_L
M(GTJY7MN,(Q7'W*%,6:I*Q6.]CG7N6C:^H+R7"MJ*MI=-T)F1ZX.IC126!5'
M>CFF9S_5%"F8$:V-^ZV\8/O[Y^-G<O7G=P"B1;_W?Z^/@K3*4>'5A#KW<5SU
M 1N;SYH(E4$X+M^F1VRH.Y&(0H\]2 EYWGY$MN62HL$#$FZBF\RG4[\"7S?<
M 2RH^%F,D3[)N2!S]>1@WPT7AKK^5/UKUR40>X3MEX>6V(I(ZAHUY\K@ER:!
MSIX0<KB1_THUWI[Y=$Y!&\S7I<1PP%R-I&E*1R1>AHD]0JB'PX>P0J5FK:E<
M*4[2??<R!V&<J /AE+4<\2+J::NU#9;K(HA8[;:VPV+4'#((>?G,OL<[1/3$
M.F>]4E#\5GO=N.$C%^6#L8N85E&[7^1A@A4U33;?T(4-R:'JS_KHUT;G)CH5
MV6(MS1##!?LTS6Z7(>G>)(L=L!I^XAK5IU"*"EU.D/@'&2N4G10 I!1HX6OC
M:[./H9N6K]:X!;NE>7Z9O . ]?!V0FAUG8S'H5E4"XSVM@X56O;V@FC/[M."
M1/B5%B%)8K]FJN8\'\#02LJKN?@0ZVU#<\'/7?.&%&"Q%?"RS@61\M5Q>:1)
M<GCC8=N?I'0:N2^FAYW4;G 3>^O:^S:7K'C7>-IX&M%3IZR$H/B[W&T>:](T
M6W,@I>/.+0)^CDV!,25LM,;S@N40P\5*3/4</ LY+V&TXRYB:ISQSV$4_/PM
MZ&5)H\\(/QPZ'!Q2$Y/-ZQ!&C)*<5S.%AP_8HOWB2CCS()Z][_)+W23#^$,X
MY5I-Z;+E?(]]$5P2I# IIBH_M@AP]>DCUP%J4=1J%@#Z">AGD#R]MJL0)A"#
MX':$M\:X>!:#@O6^=:B.[V=ZYM?Q>)%#9^D+G7LM^IL_I7$9_IRX=;@]]",%
MF9UG*>Y6'9HA^%LU#)O;O]/$<<BDKIF\QV8O"]4TZK?$]G2ZKXOEQ=8&%^V.
M7]4W9X#-.Q4DSWY/NMIJ1$@!.?BBV,LT8X>,7V.KC1(_&83XCIY.(&?.&T)C
MC*_@[0H0$J7R[_(Y]5LY(,+;E@Y%@9\M&G!:8[?'7VO-N6H^:'%\J\JBHVF*
M,[)W\@'_$E+G4Z(.F<IF.N'YQ&B!5(PI0[GNW[S8%7'^"UW*=/,0WR<<FG<$
MU8#J.9C-/9(*U4W#Y<QA!S>K*2<O*W-W:"01X.'#@M1R_Y KWT#?$5=F#7Y/
MIJ$M8U%ZFK?)/A/MFW0)G7> NMZP C]:M3\2_*W:IV<OFQK;9*LRRY:!,Q26
M>APZ(F?YC6*U8E+\ N,TB,*Y6=?"2NCIS7%EFX[3U/&/VT7T\B)8B5%8[7UJ
M&O*OE6<?01ZD4Z)TAX8(0IVW%Y!G4;OH.H&XF!BT^"C8PNDH:C;V863\Q_<*
M<YM#Y<)]\P ]IY5EJD%?]]0K&O- #<?D)?-!RM]")M[]FNNOXP;]AQD3ON)Q
M_9%R67X(%^2&E>^-VGMR'95QTJI=,";3G[%I/DX2X^Z?RX^CJN5+ALF,2O0&
MV=YF>BU'(8(K4^)ZVL(89>+_KG"M6^J\>V-*+"(OY1[^0*)#R]CYVP=S[FT^
MR^F)P3M PTVSOTW)^J#W\-FMX#[&BC3'&M4.SD>9=#6WMD=*#-O=6(<[U?TY
ML/_HYG-M[7D=899$=\FS),A+WQDZ]$P^+:)-WD61;09M4:E5J%N$EO[C-0]D
M;\H8EW&]("K-C5_Q5Y=+^BU?FFM J9SJ=+/."&I!]G5"2(*>UTQ4>K?H%"?H
M+0@B^@R::MPK,IDE0?[DV9*6#^*BU'_U2U-G_O-W7W)PQ<JI:XFG,=(2[+*E
MDZ5B)4L@/EOK4P'"+JCD9!>/YC+D%""V#<,9;YM$S!]@S.\ 5HJ["5W,X+^8
M@! K*3'H<8(!RGA"*]B^@YEWXN@8?.3F5&-KSYD17$'Q/$G/?6Q1W!82] G7
MUT[L=(-<'Q5VF3#FQ:C#GW*?.#Y[2PO%G6<[Q-4+L#= &S6YFL'CU4=1B68B
M:=[X+LD??*!W@+!FQ\)5BUOVSJV]\;UC;5E&%]C,JSU:'<>1%]&<V<:.[^F1
M'&*/?"@;6<WSE0[N *N9HX]V:=,(W+WB*%_63YRWTBSMK1$YTQ#0G[%SY@I1
MU^ /\-6&86=KK>Q5P]!*:+(V\W+6B90K3/OP'6"%O^7I_&7,H]WA4I=LYDFX
MF -S:V!!SV4!K#794,?YZ$4<89='LZCU0LE"Q7LCE:R;M(J9-@'A3VUTBWZC
M-B<CU;F%#?*+W'_7.H3L'SS[F&W@!4Y\J>KJ_POG^)%?WO&*39CP>6:6Z+9N
M<_;(&J@E-*',*C5:)XWBQ9A49C.%E:IPJHGM@&[!]^4I#,U.P''8 5K,7['Y
MKU$IWHL0MDF.IJ^ KG<S_-(9#FSQQAIO_/JEZ7("IN]35]@M>",:[E\]?GS4
MEG,">14#0UV[+Y.G=>5WR89/)=-G'UV;C_.>>T4@QLV"+J5TMP]!];C=\+<?
M6%S7TU:7YW$ZK9^>H*;%%80-I]XY3*V,'3K 6B?D6](=#<=24JIQG;NQ;J(>
M"V%Y/7ADI7PNC2%#:3_69IP];X@WS6^)'-1IFB;@:)K?+DC$/]UX5?.TJD!H
M#.;*%ZN$'<1/$I_Y=MPO>F]4K^GFM>15&]^4D+WO[T>U%6D"W+%T,^1:3;3?
M>1?F2L[;T[:K?\][3RW]I2R$7Z#KKY<A73_]ZM8E(C^A;1U^2$:5[ZEH@5=;
M)@]Z&NLG$':=;"*I;SV_Q'8_3Z(V2 60?[?"OXP?1RNOSK<:DQ&ADFB-:@-)
M%)W!X2,E,/\;F8_/-TU\ID>_CU$#ZL V&<V/ U<2PN3UUOJ0W,6%.I[E\B%F
M;K %3IG3MY%#CRI"1813^(LS:/U>Q<WBT$@<?V*F0C*G2\0MAG<;Z$BT]F79
M0SR=/)B^L&IFR.0F<B:XD+1S$(?.C6P-58% B\$S,]O@9E#5#.-F<\,T&C)P
ML5\4R>^$7--AP=I59)\.4O)+WF<X0"ADI^->NO_^9*E#Q:[%W62JD_AHE4LN
M_4.LI)KRNAO"2>?$+4J"A$'I(2K')NFW&7AI7R=^M!^8!]4IM2>1&/*;(SH2
M^,7*X7BX:=0,0PFO<H\%R>3W.?@#\U$0YYJ)=Q<6+8%69:_+AJG>?VK4-] T
M"_LXRO1]H0UELAJL+=?=-"$_!8^_?')?&'(Q3A^[(0*D\!IX^S>?=1[2%QU7
MP@]1%A=N(UTQ<1-IH\@[P(=6(?=L]MO"BGJ4-Y;M:J6K\^I$557>E%,T;BWM
M(T1P8>7BB[7WOZ@,C44_9KK>_OI8)]6S6T^D1+FX3T,2R)Q<:NK\QWQ7Q''M
MZ,BO,NHY&>NKF\$4'$XP84\"?7G[R0\TX1)[^PRC6I*N.JHFI:"]R3G9LX?C
MVH!>4JUU)2IGT&C)9&OD98#$B5!$F[5 VU8>XN?M>>3M$YBCZIGG53P5.C\6
MZV/DE#\" YN^[X8W0RK"&UK*T>?C=P#QMJN-!)$_=P"7.'Y+:/I,A[4@M)$W
MQZX^@TA5*)??4J(]F68P5;_3=,'M2X&#09;5%[<BOZ[+O+$@QOP=64RIZU_U
M1%]P(-=B52$7W,3 4M63I&S>/\+#-=;I:ZE/VF G)9QWT2J^\$2X(Z,HC>13
M!G@*KM\!<B.>EBU<K.Q^\FY<7-$2J5W+@2/>Y/!FB"F"TT/OG\-Y4OKC8/&M
M"5=!V[J&B/%I*R7#YOI&6#RWHRK3/[,W,SW+'[SI%F%-?'5L/MJ^BO&],+Y>
MNAT!55:B[@!I-OLO74<OOXY#!?$DREF(_")N=!*TP=:8([(:N@/V.0[UJMYM
M2O%0CI_SZ5\CXF"XWO9*W60)")M0L&-K$[[>A->A;?VM]NDUEC*5#TD@?S?U
MJ3L@80MGN[^#CL?Q9L7FDS=_^=P1V]1&X*&,5PL4LSR);=E96F-N1'F8] 9.
M,$NOCK7\Y8D@!@?%/M.UFU>4+%+[RI/5:=(U&R+I0R;>Z\GV=6@H%SX^WQ74
M\7'K>W6U\.#T7YO?RS/&^8.%&(C/_LB-EZ@7&8)'#<G3V8YZ62$.-M\;J,Z?
M^/&S/FGD*+"T((M5F?BGI0(\VOH9D4"WT RQLCJ.I!NBI>,2(S45Q,\%O9[R
MBN%NGLR/L-#:J/NB7LOH&RJ# -\!X&H4 HX41R5<0CXS>7-HI;%WY\$<+]ZV
MMC>,NQH?C4%UU;<N'=)UJ'TS@,Q:#Y<\6C.9[(]BW[JPX,GSE.FM$0B!+R03
MK%1@TU&5RURE=K][37^8?7+7:5+UK^%3/&@X2-();/'':"_''9_"+ I!H%L0
MQAA6?NIT[TLD:C\0J#/E$^/B7!>$5/2%&H56_N(BL-+3GI&6?(#38[%%LX+#
MAWM!9[-D43A5ILR'!<H9<'5)L;-,%F3D+UGI#R36MPJ.GL*,*L#K"OO)/*Y\
ME(7[M=L'KIZ]%9QT8<'VTJM9:DLLV4=8UTBF"V4]1F=<YKYO<LZ0R/"S7G<8
M^LP8F>:Y^OH!HPDE"K(B%18DYE;$%9?]HW9W9J!4V9.[+I 3\[[;5G]<OF>)
MC9Z7S<Z>T)V62O#B&&6#AO]MYXXR1_C<9+4/8U@X2/?OK0O\%MX7CM:19TL1
MG\L/G6?HN+'TB;MT$(O$<LP0:7;X3"TW67MFI=?E%OTH2!OLKIRWQR 'I(WH
M7/4FBI%A&35(4VFXHJA_UV09I4)!;Z;ZY$&9,PL6G'PU<]W7OM"2/ORW5<]E
MJ_;>)GB.?HZ&.M78U-XX95:-[C5N&(R5O&5E-/*OT@?P,<>X&CK.7SC+PZ/,
MQ=<\KCN6BO<!*)TSV1D'RQ?,M$*<H=\NW-Z.ED(SHAL(S#''%[= 5-9C*H/7
MFO]LQ$P:J%'W!_[W<43J-1L&N,/:*/;><%G7X\Z=+V5P7^,3784*/LDHYH/G
M%;^CM1S?O5$7)36J*90.U #-;G;/_(7++%B<HT?!>7G0YHB_TXR9P/Q&6#J-
M9E%4&$<I/7&!NS(^:_2I7@RSW/2!O*W]#V>"8-_W/S7>(X$^[X?&ZOK[(WP)
M#1X=2A,_N[:$ 1B>=$RF"1[0Q:IT35S&26U G?3\D0G/)C"L+ 2+@A?UJ_EA
M-X86CA9DT/YL.W/_[03I7J/.<[:O.(V'E7J?%65K4(&K3=XZ'=LCIX*5<=&2
M7&W-7PZCE]@6%QM7F(B3?TG8_ K!">N"D)P?$[MH2KQ B+K8@!.K>C;&-X_,
MU;\$K6DQJ\L @F9_,1';X*+))^!L:VI31Q*ZJM:R06#@#XN]]^DFZE!WHAYR
M'J&-S:#MP6L=)O_.&M\CB)5:P*4U)/+Z#I"3NF1U\\QO3AY\DJ:9:D%?'VPW
M81V_;#AVE/YB^M5GGM\B^,0%MHE]I+$5TA)K.!B%OO'6J\O.DZ(4[H1_3L+=
M1M%:1M^*WY?)0D9+B_GI:%@?,4[5YHAVTHU'ZY4?]AV@KWW5^NC!TO!\T]::
M_]=#!3T^5-<=@)5Q^8KLM+J]30XRT+1\!YAIC<0DA+8!4-V0-=5 S"K&Z.K^
MT81K*;D[P-^KGW> L1,327[43UGWY:[$4V@U.C"A\+X\@FS0>F!6J]9F, HS
MNY;"W?;W*K7D_/-F<PC!5I_G/EF8$I-X CZ:'>6=+QB'^7D9@)<UW>19K+:E
MEF?>S-<GT7%@]AD<)L!AYL#AXGE.]CE(IQ"EI]PR#0W<\;H5FE:2!)5F/BS_
M$ZS%"<#G_/) BWH[IQ8:WI9S(X-6C$9014B-LZ6G/,#R95QL*_R6?%&"ECIY
M("C</9W&4/W9];Z4R:+P:3J9B71=57Z0QD'AVT+J2FS&C^5Q4Z#4C?(X'4UI
M6RX]Q/R5 T%2VD?/VI,GX"<VL15P[[P[ -!,U1O8 &1-'=6/'&CZ.%;38#KP
MFT*RD20,.KF>L51-BVI:O49SK*FNW4<L8'.M"T,%]HQ)\O-XL[9Q.S[PDBG'
M@),1!>M7(9]5^I_DH EYLDI85!#EZJU59J +0W#KF!U@P&^JKN_QC<?S'U]?
M3RQD&"V4_?XT 0\X#\DI;5)[GT,>Y+Q$,+;:%$^="MP\32P<32W&:^I[]<%=
M5"Y["M)AS1?6NT1?/PU.'HQ>Z6^1<NW0HF?,1I>67K[7?[7C4D.U:?1';TG[
M\E2*-^]':RMLXMUV2TLVOX6.'\*L.+V3TSE?8*CO P W*<"N3I9@IPI[?WWF
M@^UDA=>-&\4\2.JJ!1UC1< YN0D.\W0 IZHT,IT^>/;.2SJ")8:AH=JI5"<O
M2!IIM&\QP/E4,O=Q0T8::3[?+\L7M9_G.;9/1T3]^ODM AFRC%J]T"-N%6-S
MVI@,C(D"3?1J>AN7BTDB7\^J#2E"P/7MUX'[RC$A9397$O&);CFYJ>XTEE37
M<?@$UB-[F55B ;H#4%Z,GI<.?9:7 X&+!,@W1'OC:K4B'G+X9B8UXLLG\8$.
M_]FBFT#BF]O8D=P.G@$Q^(4SC!5!;T\4(^6G9Q2?3'"V1WNX(+R_KVV=#%FJ
M<UCXP31'&]>=#35D=ES2T+P0[.$*B,L> \OE[1T@\=) ZK/0]N1E7XO/%*TP
MJR73EV?]"TO%"JD)>;N8QQ.V$^?E1%:BG4S7/@WN%0;<6O;0UP!1+7G2@K&;
MPD4,RQ9+>YK#53OF^<;,6LSRD@YIPLHRM0NRAT$^#5_/2@'+KNL-;>VS$?6%
MK.AG"TTRTA6SWCDQ#)C,XD'\"+C8ZI."1A87*Y/7:0:IO,IL-4PBO;$;MI''
M-?&D!+__6E$%:E;FM?G> 2+06./?VYZTIZ3M0KI7!(,HURTJM2^WC5")GDRB
M!S<*V>'Y"/.>!P\8N5=='U\Q,9N^.3IXAJN$@Q848 @*:'8)>7+#3*_Q&6J1
MB2KXPJ;*WR$00;$A]OX1P/00)_IX)W]>+Q]6E/,EV#H-87(!QOB*P.56VLG\
M5 ]99F5ITO."\]VR;K.<'K=GPN1\WQE\=WWG5*17^6Y,[>U\<HM4[&NCO(K0
M:-X"_?_#<U%]4^VKK!C$N%+M': .4NL[<%MXV2XV.E__[M0'W33BV0+3GLUK
M?E77M 7UMH]'=10-E@>)(CEI!DNU_ 0*DJ85V"_WQC>W#9JYS 2SN.C=?QS:
M)G[Q&_;G";O0HT21]9AD4]3 D-G%1<Y7,(9/5QD%4KZ[GBX9[VQ9=>9_'/+K
M>!VS5[SLD:^-?,/&N!#DM"[(LGH<(8Q6K5Z\C=2L>78VPNZOB1?Z@9PZ/<H.
M8(2;] R[9$^)2EZX !4_KP*?9H--5HGO>GN;:)R.C\N[96AY;/;"D:T1/@UB
MT)JL-GXY*XN+]M5;TRD%ZJG[2OI#SA9\(B0 ?;U&1AYD=U(4"H8^MN]!Q/5,
M/NW_&QF)E@%Y>I#LU &MI^?PRM6_R%=2^,\0KFIK%JD)M'C)$Y7Z'>NBJLN7
MK ;6Y/K7U)--:I.[MH@LOAV>[^29L3<^Q1(_M>*OU7!CU8^=3TZIMD3.]%5C
MHR4:GR-I/Q^(SV)Y-S:G;HE0Y_-^.OQV]+N.Z-M#N@&*)SN>)MOW\8R1J"C&
M $F37,@Q2MU:,9-16,:UK\7T,H]M*Y7S&@F@>R(W^4'U"8?EB'$@YG'E]O7?
M/4$P8S6*[^\=0,=-EXSZ-F<;E>F&I& AW1_U*/#S?#X^SETC27E-F["ID1ZT
M_=-TJ)*__SK^XN0#&\QX:1]6YM>UQI7SZ:(\<_1PGXVYDCD:EN$:(73,$>Y:
M=";Q4'":5A0_ZD><5ERB=CHAU8!B3DF0Y4EV9/D2\.\(S/['@%LPZ;>D/9B'
MA8:WMX .GS*!+][&[)[/QVR_8= >L^3)46*E:KX-".&06BU.XLV<X^'/Y$M&
M&"'(WFOA\8P\ZLU3R1S5E\9 +]CU\ND=X.GTX3P$Y3:*SAK-J):HCLY0^@ E
MH^QSJ+3RRZU?%-.]L<XO9FGXE:0G?S:X@3 ;J>13DX _[P/S57S643<RAU5Z
M*\6RSVNV,Q250VYS'F1S_DS0CF8K^[TO?J48. BD+#&%?PMCM\!<OS00VR0#
MCK<]\1.V^M-;5X1J5YX4]R2^4D+0-'\7G;_6?\23/&3,WZ PV%H7WC\B9N;;
MSMS&N)L1WVX?O-Y.NGMES7(:49:6\?4ID; 4MM+3%D!+#"_3!:NW="%7ODD#
MS-K:.N[(,!@\/GIB$U"+J8;P)/=92T%/6#X=>563^\48(_&C):3&,P0A7:5%
M@[;R#2.^/6"N>M'@[,5UH!CW:3^C, \U%$FI_S_8>\^HIL)N730*BDKOO4A7
MFDJ3(HA(%Y%>0E$ZQ!"1%B 0!*47 0$! >E2 B*AETAO(E(CH810I2?4  $.
M?ON>N[^][[?//6>,>\>X8]PSQGK^K7>M=[4YGV?.^<Y%R'ZS< Y@=;?21,R7
M12*W*8$/PM-H$@X0BJ"(#,?LYPS4(X,<D05T!;E3[^E*+K=HJK)"Q4P(RK6K
M"%?Y8/Z1EW%CB1)CM'XN;J*:]^BS")USFGZOBBG1T3]&SA[ Y"=@#PI!M:W*
M^'778\1PU=?F9./P^UL5E]K"[_V0U\F9X]JYOUQJN^L[? [XOD3:/H*47)\$
M59(4TQ;3Y@]\E3O,"&F=<:QS*B4EJPSKQUN%<N5\H_L2$"U0D*G,3F^E<FKJ
M!,T WPO1V*"H7FI&'?9+:Y#KT(4>*_!^2D]4#?<+DE*AJ_ YP&1,4D;-(WFF
MA[%_F!5Z,RC;A)#J2?YP %SSV&4PO"7,@O@NEQAH.H:0!?Y&ULO,*,CJS6@>
MF(2/S++Z:4@)W*%,YMQ?H)Q(4F6#*G5A'GOV(/X$3*25=B?R(Z;EZ6P%^Z>8
MJ%+>:Y<2N<)OS+QR]XO1V08%3:-BS%?]EG)U^RJ<UG>1K5:J22K/(SJQS#7P
MJY-K?B*=BJ==L57NCX+4VQ/<\=9:3OS6UQ LHHNI,A<B1?;YX,UPF]@%5V[6
M:"D5OK5SP W+\BV80<ETATH9O&@]("T"%V-IP5^5R*?JS.)^,ZO"Z0CP3NBN
MU",]ES_Z#CVSK'ALQ$WTOAW]*H?9F]ME&J6V=AK496622V)B=XQNA&K2JED:
M$*IQBP'"N>6H!-B=1I6L5Q)2/E<G)+I:RE?8HG7D-[44>,7H_/-T5" J6;5H
M].,TH.MV_<(M2;.),@+6H.LL57EWOJAI'D4!D\8C4M^4$-'&V?.SZI(-Q7\\
M;4$,C<"TT%O\(&,F:K%-LR0+4Y-;9J(_V$SKFXGI7C@LNROF@[QB^42 V]=0
M4-8]EC"CAJ;PWP(;],S>;P9[/E[^<!/OA7RW-Y43:TL[>B&3; SL1O=\XG>H
M53BS='?8;C;79S!GW/_L#)]5T%)'OO:C<D8BS@2@3W?-QF7JE0WR]4M67W=0
MGWX*>*LO^RGIJT62"?7'R=\AN2'BVF2R< ^#P+VSQO4C&,[V[KM&G[/630BZ
M'WO?<AJ*[F:=%4%E=W2FF9LU,I^E@PK75;CTP'(_U]:6[SN$SUA-R_9K,=W>
MT>ZV^*@@^BC5% 6I@)ZTV_*&<]+201,,)WS. 2QK5LPUV0V%':R_Z8[F,5"Z
MJ:[66=&%>'LU;[X[Y*>8 P1PP2ZT6=4?EE$9)=-RK[M;*&G=K*4UE%/4>DCP
M,DO*ITLBZ51ER#U1+</H"X?R-K\-$Q$E8X&JV5/*"EX;KI I.'DBY2.+#)%6
M)E/*D*,/U7WUR*7FB:\5-G]WXARPG 8$!>^+]&^,EV^E@26.BXZ]?Q$2,%I:
M8S65+-  /<ZFP:=P2C=SQ6.WNZNIQ[$0Z+<.ZII1()N5%K1CNK>,WDR"A?%3
M6#&^>V6>-0JF5=CE,R_%)/(.03V^/;7?0C/1?V@2\^.=!*Y>LR:A;TGJNFFT
M@G+MVZ3K??N4E-ODJXT3^:66!I^MUC#%29!*B5GR[&W0:3:O;,\/(JRS*:H#
MEI]]6S18'&KP+#%-#[V'<'HQQJO?'$C]=+PK=I4K25$_78VJC-/IJK7/%/+N
M#9[- BQ<__#(M<FMXD#7/.D;,.@DN+'UN*C&BHB-RYS/.HPB 47>%C;BD9H;
M+35=K5%4B$#A=24]N$)!2%K4$[_7"A3P#\.XX8<"G%:$B"YJ5;.O^*Z<:)B>
M3[GXX1!7<<>=(8G^TP:^;ZROM5[>K*MS#-_\\3'&VQ$<]-MA,R.B9RCB0(6S
MFD 5+#D,(3WPA(G37)!C8)\+>390]TFR?R83N5&/R'V!>/>_JV;YH8Q=LW<F
MD-NTZXV29?- 2NC5?.[8X;Y7[]_;<B_YWSKI%DBZY/4K@Z_!W_1@^&@?M5^<
MNO"I(CNUM6R@L/GX:!;S)X&7F#)O$%FKPC=6Z3#1[%0 ?;UNG-W]$]N1S1;Q
MK#[\/CC_=S]U^0_EDT1)X0]L;V&PPI3N&&CU_%8*#LNJ_^!M6F-W1)%'G=DW
M8<SQFJM$UA-[T1])B";*K'8A^ZG0D*T[#^0-B./X0_,)B;U,7AZH\Z%I?18B
MMZIN0F(QV])4'>G^YI#EACHS&1^=>Y#Q?$(X<M*[OKL,%' <\]B>)8U>Y7=!
MO!L#KM7CIACD+O;7$3AV;JS0M<7/C"2_OWZF'3"[I03:02TY05JV0;#A\O5S
M )//=H25Q[N2-96[]0WH\JT4X5'E^XY)SJE.(<!9?<G,EQ+S\=*"/P8A+S?*
M\^1>O^U;M>-LMIM'2'7;\N#K0FL>F#]MM%'^,7%L&RZUD.J2+;II-F\6-8*A
MKIIA=;Z58L2<$IJQN<>;< Z@)>GES8(P\!@9M^:[+AYITNL]QK7 ^V&Z!/!K
M1VKVZ;=.XR:+@,Y%:A O-Y%CMS/N2EHD3%4U4K(\R8N+]:OL6&UDJ[T*F8=K
MBLLL[<QEZPOGJ.B*6*H<  8-0/2:9A(KRBH-Q##G /AL1<TP<"4.V(EE5#8M
M B7!P<03C:B*S;S6^)Z.RU='!MP-BP:H)R 2_92&8CJBTKE*[)8FW^+ QEU8
MM@)BS *0\WHE8L.[B:)FY'FF;JI%I9!CO*ADU@5#3A6&RZE+^YO'YLF(@L<B
M? [J@Z5)JHTCWBU&O-Q0=["T:>,)38X_3Z7'KUEK%YXGDKPODUSB2G6&W)<A
M<#<#2@RQK".;(U0>-;&?*3/&\1-K/.IG,=54X-EW*["0AKO@6:O:A[H7O?UO
M_<$4%>O;YB19T$#PDNUADBT\#L7=XCO;P\Q22+B![C([XQ@G 1<HQ5@:FY)Z
M.EEF.>H^S3(YFH:O/?X&E?A,_J1MTL'%/($AJQSX"^5R\9BA,3W9E^H(JI&V
MVN> FEI])S?!6[S)ESNC4$OL+\3*DR_#PTW9V+J\,?!89=Z%&5XK(#?D,8$G
MQ7UDTCT&XD<]1O?5;K9#Y;KI38,?B-\[8L+8A8@.(?QI=AE%)^WU.)IY+R=0
M$$\UZ,!-6*/O'9?*".Z5;]A[)4.#&;. )BDBW#QO=U_8JN7"Q>*Q%8T5![^V
M_E0$[\ZSOO,^!]#I?)Z!9FK5H@6JP6I[?97S>BDU[#^6^:?>.E!(Q37[5/@:
M8'AQ,'/%EQ3SO.&6^P*O)#@>6%W5>4(F#<!%AV;M0//^F+GD&EK.\A"$D^<W
M.=#FOVKT)$ ZC483A\=![0;D_=?)"R)UO_8*A&&0[K5T_[W$Z3]%UJRENJ28
M@!TX.)UK*L>'B5FAIM&BT*Z7XQF.]4ER%KKO'YI/F\1^.U @R]@JBT*K,*QR
MG -B<M%;DI6I&JZ+27V"ZF E$4"]H\0OT9L69$C/ 1<K6%KSSR>Z"%&K=Q6'
M* ^4=-L9??"@*A.)=HZ6S4IOX:/W V/3B%,R_1''70D&0T;JG0%!H05G9U/G
M=^I7XH!>W+FL!\!A'X.0@.)X;U7>WL:@L1$K&\O3I-^#;LI7!(WO6=_><I:L
MB&,L_; S'M+94%D&BB&@VUOD>]!WIZ>Q:XH^[8^>[XH[JC6\UN[U]GRO]SQ$
MNNG3G(./'4:NM(7G0'G5:9V6S>!JRQ_7BIGR0Z4[Z@"U7IF:*W$?.,!9+85(
M/>J:9A"38>5C#39 $(#Y@6<V#I=3<TA*1O">=3P[!_Q)7U].N="4\/;6U-/*
M<\#BIS_G@ ..F'/ XR$[Z7^$JH*NVI%$UJ#U0_-2ZOVM=\\!O9=W3SOL/J-X
M51=G]U6/<4[G@'Q<Y5!.;,[.I>8+;7H.N'UZE7AR#A ^+(6C*:5.>:F]YB]N
M--E+57P!+,<=/OS/\2YJ/SD480NEBPL6@/=*KIQVV#:?,0Z&KV!SJ@U(F2L=
ME2> R8MY%E;J5LJ<9L 79\^XS@&_KPZ= S0D FQ@L74N(XAXKTX4'9+V6G-)
M*5:VJ8<VN_^]WJW)H?L:"LH\%"K3T4?  Q\BZ$0-RK(-I'8JA/KIA_<69J<A
M;,0/S%FI^=__ZG(3YC,U??Z4-4+CFO_=4]X%J3 K^;C]HC$(1);2DU^+ZZ#V
M=8'G3Z9/6TJ4H0-OA2RX1#$FNS:;WH':[2SAVX%G$6GBLD\TX&Y #=[P0<0A
MZ@\LYD3Q3\!V)R0J^$[8 D^49'&Y:^TO1%QQE*&C=N=(OW,JANQC.GN>QFZB
M]M$C 8=7E:4^$G+.^-.)G +KHIA78"M*I<@Y<Z#F;S-Y^D]BY/>5#"C8*LCF
M>SJ"O+HY$"W+"7)9;\"+.MR[S8':]NJ7OTQ]XR)TR\4W+(R^4.?2CA/0[?_,
MSLL.\0JY&AQB:*9KEA'0FA5V1=?$Y(^.DD3!S'3E2FLFCRG.[JV*B(50W848
ML/&R"^<\D@2/ZG]T*Y.!\'B*/<I[4:LCU"X^=;G<&B 7=P(/Y2&/!Z97--]U
M*)^9UA9,W;4V+K%6N/'E4L9<T]QM4<HF,BX:?3\9D_X:S>W  +<C;L_VX>@Z
MB5,?>& 3W[=O=:,OYY#(T+]1M G1Y^\N"[KFWRC-#P$  (KVQ7G1W]=^_P]+
MX2X@]D\!$*!L6OGWIWT/!1U @0&F'5XW^O'.-@YKL_0C/C,@[?%*A/*INHX_
M3S_D+KK?Y5GYJVO4[REFK]:*5GR8MAE>KB\1D_%JO8^'!=\?V=@[B>HT2\1.
MV1JP)\ _?>W_%GD<ZY3HOU*LNTLI-9E53A+R*U*-BMM"J(3YY,%!-A9+D1\>
M1UNR/+LA:(;O%KBBTU&[^;.[I3OZ+2+P@J2*!=OYKAL=96?;X<\!^-.# ![6
M<P#5>H7U]7W*(?;)66(\J'=[<.'/.W"JFC_XU1H?,&364D_)]0,[Y24ZH4_)
M&2J"I]FR.4RD)^-2PF/E]K\JC70DMRJ06*2UM<2/JO*#7_+9*C_-*,7N_WC'
M=<>W/6STS^U;/3-+=7I3*Y"=1^ ^'97BM\3, WL506(R>+X/]C"I;%9/+O>%
M)_-:CY?'YC6Z2Y# &W=V-G%Q;U>5(4LE.ST_.,L)/6THXA,'0G,.YE4;?%Z,
MTT;Q5H4X"W3S<TAU^=/,L4%.'<'"M-=.UE_X2..K)D;?GIE,],(&^P9*YH[K
M-E;FN=T?U]<36I)LUGC=;(*UO?E9MA0*:B6XO]7TL?0[(*,9FW[:-_"5P<9R
MZ,\!SC-V/1G[!_FL,;BOEK(IXXA<((AHQ34I5! ],KG&,J+T,F'I9LK#I(=]
MPFIV_GE9*4F;9VYGH..'!:.-RMO?450^4M>@F9V8F'4S!X.Q_&A*;A&]JHP)
MS,_[88(OA_N\;LODRMV$)M&UWVUXR@KAP%9GU\FEX((4[5A6BR9ZU.QHW-]Y
MLS#83$;1?P0J-*HZ^S,SVV3^I "$%-PX=!>UDCFNW 'M))^52\;YG0/>G&GO
MG -X8;QCRJ9?[-8:?9N<',I:EK.\7#&IJ1!PGMZ]K<0^AD'V]_Y)?7Q.WK>[
M%#=7DL94G<Q:,F:755FG@79:8 _J3E]UU9>LQOH/,-1$,Y^&+'I_"]*/G#NP
M8JQK87\:%IZ=L]B*VU7"]F.EUDFU]WDY2,)U!/WX"!<7'YYD<![0NJ>XLW;6
M7DT:4X.4OM2@M96D<Z?ET,?:G/E+\&":5=!XRM!;9;4B8C"(11O,LJM^XNA;
M6_8\%<3E+I+P,I+%3.?Z;>458TZRC$-%T0\F#95HN.HZJ4VG>V(U$'8.P"5D
M%YTF;J*[K(1+(/.T][K[?IA;!<W;;C8@+Y-;J YOO] \'4?>164G=Y]9);,=
MA7G7G@.NDHQ!^&,XM4B,MV\JUCS&9%3*KF/GA:]-3+G-YR9>5U_/I#^_%G?K
M:@*O,-LTUYZ,DD;.*EC]4/NG[K!=^8T:1 <$)!&1,,(-OAGH[Z.'H!=VMN3_
MI"/N*FP:#[^WMJP!8[93^)!/1;_.PTCT<<,9T+LK(HVO9\]W#^C5&0C>JJNI
M-9_DV4*DI6IN'H;TL#_P84I-J[-;WX<',GJ8H0R(O(NM"QT2<">B/8'[9[%4
M5 6'4DS,43;;IJF%^"@[PM"B"@#LW=&F&;%ZA$@!E+TVAW_+.@QO96I-OYJ'
M.2@N+H@#T>2 /,6L@Q?5R(5\N)\^M->>Q3VQ<XV_5]TZS"Y8-\9D\J60XMJ?
MC+KU0VS%DE>=D @B@0X/;SN%=_(PC50VO_"#@.?AM6L<G24'UZJH%PG-+",O
M=;),/]<]SWR<M-N3,>579SZ'?9>6?7V49%[\>_T5HNC+USB%U+Y4$!GW![/\
M0/\"7< ;MA<./7PK"CQ1&O),1RG(I.H](&5Z48XS=G;K',"3R?.@X&SPV#;"
MQTDH;M%W&*-C7R7NZ_"J%ODME1+JQWK&7A08\ONDA^WL=AE^Y2!H7%G@BYO?
M\5",Q'Y9EAS;7(W> X&-5^WO,;(U]:;2VMC; Z]ZO.26LZJ05PPWO8W36@;A
M-?45>SNCBU 9>'4V"H(_L[G!R^8V4#KH4KP:5WH.<)S16L1,EAW9/NH*3M*0
M_[AL(*/[2N=(6X"=%5NM4K=P0("U"DP@Q 7&*Z2HFPW=>C:?=,M61P=F?MRZ
ME,(Q<?.DOE,\SX]S; $RPF0H6+"(!6)7+FRFN?1H[X4-I2%=(O"^71R5]$:Q
MNB7:2>;X.)38V+B9IR5-RU2PZ5.A.=XF:_%=9ZA*U>D0O_OFJ^CEFIPVSFU&
M]5*W.OI9J+'V5WUIK='TV5LNC;6CG97,[4>OOVJX%9H_6VR]R?G>A6S6M6"^
MH,$6BP>2IG;&=/65*M<A.[8!/(XH2MF!H5!C**LA&AD6>"!;%7H.>#K,,SML
M_S"7?M-J^=&:J6]CE/GKI*O].]N,,$;">%WT7B!(; 6=/V&K-F_CM)>IO<DR
M"^Q=SF"KL[W^?(9*CX9<7BE%X$H^7Z]*=E[IYIBI[3E@(D>EI1,94?T'*E=X
M(AEGUS4K-[8MN]<P"GO"*Y>L%;#ST-%B/O-2I7[=X&7E2PNU\0\30C?D(6,$
MUN]!5NLF3:W#RFH%DRV+5K'R=]PQXG6OOMEP/K]\S6/.\19S@=O[R0>:LRD;
M2),O!4D;B)T-<^5*N!+IAP'Y'WD59GQ\0O[L6O*ZN:]<59MD[FOK/J7;(=9I
M?EXYYGZ0;6FNJJF\Z-HI/V<W2\N_R^A?:#"[8_4SYA\LN,=/?9/>'DG9;-"5
MM!((B!:M,)ZX(9H7\I^A##\HPB]M1ZJPE=?>:>EPJR/8#E#=12;)!-K*84JO
MW]\EXVDS37 _DL0:UM0CS>.718SNL5O3@?;$C,;%]X#L$,A6[C=DY.7=GSCZ
MUP_91<;>JQ2UOB:L1 8SP'31DF:\5*N*V=7\1R/KYHV/^7Z6,%*W.H;]L,_G
MHH^5XA8;:S=/D9G/]_8G9A@F+[^N5E$BOG'P7*#\ I/-?81I197()[L46[U8
M2OFJL_ MA%*:Z_87\4Z ?G LR15?,]N"!UF/B#,7-\9/*##(:KJD]7F_+RT-
MU;L3&P)8?"_VXQS@A(W,H?:6BLAF'T:>Z/%2@N196*("@CNXO[0V +VIQ7K#
M0-)T#]VNV3^]FR2]IS\^)F<V,FVM^Q[8'JXCE!*:)\HNKC,'4.@K]V0NO%6T
M .(8+F9K*]CVVFW_>3R3Z[C[7H==]$\/53G--;Z=:WQXT#MB%)S\*R6;W:8\
M^LE7H!4P3'"T?\5=BT/2,CT*($J>]$ILDS:21YQH0*"T/1NJ_R6#8E@',VKP
M('P*U6^W?]%CVG7DK KY_?M&UHQ_N>KDR3QK>P+%ZJL.<(';+,N$L^&5[C*>
M="9**%4<,CV?7?0JS>J=SW1>MF^K3+E4J)^*_@K-Z<G=@).1E()PO&'!%,,^
M]SG01E7#8+[&.F>SN[I?OW@+Z5" '!T9[J_;M-R[9>0ZHCWC&/?=R4>!BO81
M;:%*,^/O?_66_-^!'^1JD63_R$ PA2DHE?=H@?=TY[;5K9F8%%_^$W'5W6[5
MDT7# POX2BS\L+?$-6]#P=Q>ZEO'.4#Y0F6T:O Z19Q!>\X!L.C4:,F._SWF
M_^MC!(#0_.<#'&(![RX7Y$6KU;9=B/L[_]XV^O\$69<J2.+1B@'1OS!2&)H4
M9"M:I'&?021%&OQBVL-4U92B!C9U\,7QK4QJHM(Y !I]+';0>I_HGW<A(-VE
M3ND?P"94%Z:#Q/Z\ON _JL9=W7#Z !XX =C):$$,WMT8[J'=ZIUSJ0F:(929
MM-2>9E=N3<QK;PLBJQFT$>'@G?9O9/$_V-]PM_&C5,[N7.CBJX=G#3E+=L$D
MWW- LA?J'% 92'O*>^7?Q*^U/'X9UG9ES M8DC%Q"\C=]9I'$<UK,"I)C:3O
M].5Y6)&*/GL0,5(/B43M4#9<*!QTI=3;W7P"+RQXT"^-(^*[%,#:1B')97AS
MI^<7']E>5X"I?]I&WU^5C=\]^YZ*.A8W+T+W#O@&B?NJ:?@7HJ.;+0F7UW:&
MV@R!KAE<T(0SAD$CULS-*WE>K=U32XS\R=<9FR*G)&H<R63E<O'R&@2)K/VZ
M:!\(';%"J8]Y*>'9>&$HEZC^%[[:NX\ HIQ;+IZ"22 [YWR2%J3K'& GG3FE
MZW=@B,H<#JY< ?'$:'BB\(5GO/!?4;@<$N/4.8# K&=$I,#O&I^(P=L%BMQV
MK::%QE@5G]@]SU9@5;+0NZ0U]VGA?B_%%W+]DGW(!8T)-4[Q2+0+/ <L/CV+
MQF7BK*QF-7SRB95=5N(QG#W\<9;;(\^ZGNK:1HW1UX4_+%Y^KG.U^J4W*H:'
MZ^Q'Q FD0T6VUD!^,VE-+FG5W.#3QX-F85>B",6A^ENRI*ZP \^T#JF_C# R
MR[+KY%=PF>D9_,VJMWF6%B$#JQ5]=T&5=IWG>O) W3WKV7;)E\Q+]IG!Z$O0
M7V)SSL:\5,4 'J4X7JM1DD91QQ<W\P-,UMO)G:WR94M[&$,QZ!;?7.C]!VHE
M*0I:9DB2R@[.BID[;W\3O37=I,%DYMSV/^I+]_\ZF!>Q=*VR^G.5[!IYB)8R
M:7\>F^;RQX?!#L^OM3Y7<>ZGH?U1O&KUB"8?^=2=&/EBOM@8-+7]P#E:;$A%
M%&;&2^N!X)-;C4C89##PUGT\'*K.+W\809Z#HVJ@\*%[6ZJ7JA3?$@!U]T"8
M.\:7KG1;,>=$;S1+JR! K)%2X-DMK+[;PPR+]R$_64<KT2#Z+$24LO$\0J1-
MA:<5+3M%]!X4[E:5FU_S>J?VZ5*/8-+#&Y?$M0$,#ROOX;'?3T6Z>&E(YP"&
M-D_>F/WE,"L4FE_B:KY+,--'*]:72#L7&H>XNTC)?2=^'3(]G!TY<:#S3.AK
MSOPC-_/:5A8X,57'D6;0;)M7,@^?]%A(X'D9^[29L?0M#+\SK&K[U)\]4!<[
MT#IKB\K.SH9\."UL-BP@HB^8N,\,Y;,(DQ&I?0N7VJ8Z<!\_F\AB $\GCQHY
M%[V=ZC]"8@&'FVKXGU+7NEA:<K$/PA/+URGE2CYO##:G==_2;HG)F='NYW9Z
M)M>OV]!1EJ[\!O[7R,Q\GYIL\E,FZ:6IMM:<U9RAN(=N$3L]/\^> ^KA*4$7
MWPOV3+__''#6LJ&Z!V,^.B4DG#UDS=GB7;+[C.(9HYU<,;9^Q??M;S49^A_5
M9%^Q[8D[<1?SH?U;389:9/7Z6WHVC3D']#2>BKTCQIT#^/[&UP)&B0;WE'+
ML$N$G@B2%%X=1Y-6MLX2X)N/<$N=:/1!=.;R+!O2;'ZAM64Z$Z0IO[0:+ 63
M'E<1U<,-B,I^1-KP=V]65@IJ*Z]']=J)/BS%-NW,WO)@/BP+2[G"KG<#!W>!
MOU5A0ZNZV%$+-Q1U(/0J_OC&!#X865:G,W5UT.3JYL>\TP7?_*5SN#/NJWH5
MIDD8 \W!6=GV+O2CVU',,[1X99T-,1M[/YSN*L^DY=V#I&#GEP6.^:R\TNRO
MAS(D!WEJ;-TZD@H\LB=0\\=^J %ST/$Y('Q?[ %0K:IQ=!^Z?Z(523XVGZK
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MNVP;CDJ=SN*-)4&=-Z;P\#8;QC85^9PN.7FKMXUO,<P)$1BE*+I.B<TGX7(
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M^)GG$+5H^?@W?0_7^^Z3% &CWMRRS\0E/&_/F0PQ?X$Z\#&>N1M1@.TKDA@
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MOE+PC#OB.V;BCZ0DI*!6;M:F5,&W 10EG ""&'SBYQZ,C5T0&6#7MVQ!F\X
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M_R3;&]R@]FZLN/?Z$)M;^W$>6'(E$V9U6KA/2]=7\MOM^&IQ,=%+DT ; 2Y
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MMV,/U$%F8&;@R1N/XJ% UW[MA$^YL27?.^86Q54O3&24S*GO<8\-T<O) 5Q
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MJC&4A#C=LE-N'RC(XKZU\JN%C:C/V#-Z3]&MOVL_:% _GZ%D'18C>MZ@'K@
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M^SVWJ!G:(AC#!7N7MXS%7K80I;MJ2S<R552L1;H^4S7DA4-)M>*0W:<T+EG
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MOUD,,W(@. H'D%*U0=*3G^JZ/YD_I+6A3GP(H)HM_,7JID/667"@MVG&I"[
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M#X-<P/$^88QXJ556X7Y7W&'>C&:W>9/DM;2/U7FB7V4'&'<5P9'J%  :BZ4
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M_A1 ]IW>0_M/G+C>T]PCDT"X\5S^R>PC,'S[-9 ;P84/7 5W+3AW(&Y4?Z
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M/AZ5+5FG 'K@T?S1G:RQ" F,^;=.(Q+SHZQ>@Z>&%2V\41]I1Q26HVN82-0
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M-N/MTEP\W=\",2 .+[+BKZNBA4%.J-EAZXE=K_M:UZ?>COD]+]FP*C1KMJ<
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MB!?"#G<":_6ZYN7X@J0>J<X][9!O?5W5CW8">+U_TC^WD]RK?R6"D8Z#2 %
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M)PMX*$OCY4_YA"--J0T87@3^'EI# 3C#>'8\V0R4Y=AJ[_XD8+N\N4'7DBD
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MR?>;$:[NUN_.Q]SQ@=['GT_@25I7B!I8B4X8KYL6-]8KV2=OYRPLUW;HTXA
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ML$8]%,"/_5YW.397W7 Y\(BW]>)9I^[U:T_#:^9^,3R];9@\\T;O"O]B3MD
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MNNNU?W47+*2.IWEKZ4),.^:#$5W'C3B1Q[[/X%Y;&ITCE;&GCR\D A<1F5(
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M'WMC 1<"(01[)%,"<4+.3,&$?U;6KV7O5)#J1QH4'<K@6^+;XI5@BN(\8?\
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M\)-94NC\J%&)$I(;CE$Q*V  7#LRFM\;4U[,=X-BDWZK;=&\T.GY3,GP&3Y
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MKXQC'<6:E92DAV5'OB^0ZD.HNAV6,P#1]\AX!N!.P"(KG>L 3WV")#_>3F(
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MD"HBM[0"%7Z0-/^WE$[5_Y^G^+0.J7M3E%GMCS0DT"H:[_5O[?0CN"3 H]@
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M\ $2SD')G8H6#:!?H"";=SWOY:WHD<[D<L3V5-0P)[XHJO^A?O)^V!_<PB&
MRK-"9DB:C?9B-LYPAJ.AT\R(TX^+>TN+9:YK^Y(^=YRX$R(7A;\&?Y)D4\LD
M=<W I '8BE_!KLP+0 0J06780C@9I.*Z+_Y=>@JVRGL:68!JP7+N[C^S_]ZW
M@-W#;=&(,RV.[="S#0I?+LGYV)B,=##14W]]/9*%Z[M4'FP;4Q.P5"'>8CPR
M@RQK(R,I B_K$_H.)/<%N[T=9%(Y!*A5]XY0 V*^[\^<W]>%[.(/ 6Z.6X<
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MCM0$,2&G,I "B!M6X\L#_G8/B=5OW-QF:X,-S<N]DZ=DW%G=W#TDUB?XG=C
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M\^+1.=/\5' 4W.A <B5#C!@1X1-_SJ4.D^G@/A(H_[HZ\52RL>(UO>%(Z 1
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MM3&)06IB#@?J]#Y-3MHGNJB5OU;3B(ZPO:;;Q/8?9>7!=TQ&BH#K'2+'FD,
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M9!M,$.YK4C.;5]KJ)A<53:FE9RYL[A=T0&]M>Y7OC0A(JK@Q]*JEN;SQP7,
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MT8V%.@=<Y3RFI7:Y% =&!,C.1[3S)F*>C;H6"0L-2T8SP]0('RD,](M4P-4
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MV[<&KW&=1SW!TZ>S?>5IIQ;_UM1C_UA;[W<>@]^0#WMKW#V_V=7\/AX@O,G
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M,<L1VHY6A\]5 _<N$U2H !MO\+*S$:_PZL4.I[*D153/#*GC_:.]+Y4N1E2
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MF'!XVI5EWI0:_;G> K&479LT&D!^0V.UD,?*H*OP\6P:4F6_32"RXH3N5^/
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MY=@T>H1PL7+>5^)]HY.,?NL3,#XUQ=%W<Z^J $JQ4(Q\%^\S11I4G_\?5W>
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MYQE-\'<).G.Y/L.J_(0)<$X5R_T,/>EAE5X^8NG<V0[F(070<JU/D^>-LTV
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M^7Z-Z/,3OO$.UY?,U),O%[J>;MEU\.G=HT#2/&KL$AM.5-YHC?-! @M$1B0
M/9LF_,2QJM [BIK$==I%_(:Z#*6"S>S]'L;:B,V<[\#I8VT8CA_\DQQC=:U3
MT49!-.'SX[H/.G3O#-R8KX+M$[,)C2J#GI @SS@7X)_M8VHUG.$"8\I4]H?M
MK'MM(WN)14VLMG Q^1/?;Z#?M2"?0>4,=+VD672Y3N8<4^3-IIQTE\/[6C,H
MA6XQ3@,.ELBL'\<EG_T=YZ*?DZA6B-A^<:T40<:UM-EMPR8[M>G9KAG[_4?$
M"K95CGJ*Z6<'[N==,8R$7"KYL5XTHZJ%*+NMM,3AX@/GX^X+?^][V@;3D_@W
MOA<O[+O.O [2CQ(&SU0B^S]@S5-GRMH2[R8&N*6[2O_(K7-45+JXW^O&_.40
M1L>FT']*@&+L(:A;9G_?=4YZY4$CF=S 7<[C%5>NB/^HNG#H1Q6OWL&%>0*-
M=86AQCKEM[V^M*QB8L;'ZIESME*_2!/=V%-T,OBNAU2AT.H?0:CTH0/9-097
M+TI8WMK:T9T-I$6VT<2)]F-FB-FDT:S#)=U>P]?<#V6ZQ=5+[O!!&5QTXH5;
MYE"IB'6F*=0C(W#[:=Y][P+=-8NSVP/I?K]LE [^NF9_ 6%P4?0^#QH#5N]8
M:36ZR$DOMY7^P>G]CADS?B&WI!:$Z\>T\<^U KBF3@-0 RQ2B-1X@=/#&L?H
MV:UMQ1J_._C^^R= \-UAH!4 SSZS6#+(8.LRZO.<2X8>)8_A=[F([]B_+WBV
MKV;1,N.DJL2URX_X>B0#IVK144RL/(8@P/@UM-OCIVF67=K4[-4@5,9[Q;47
M\0TDL4H9TSMH-"WVD4,LYP2FY8LA>A5W(X:C.,,%!FLA@6H:>LPPW]5YXLL@
M3L[OPMB^2,;[V2T$W\@)"9^%$MO!!AZ;GT&H>_OS=,84ZHF"V+M4\9<3"+Y9
MC]FD?4PWXQUA$8VCD0:S,5G!65G=F[Y(_L/=NC?EY2%F14FSLTZ4W%3#A&N9
M=R,D][>H'2$#/'))0%*RW&-)M2\;#"24&@'$)?03L,2(+993%_"S(MOO$CFW
M:QJ'+/4)1HOZW_BU$$XNXGFPI;%?.'@J6,"+$+.,#N$",J!S$R+<%:LS81:^
MIQ1!R:E/^:FY>S%M_%+1*[IP$@#%CKT\M-?XIO=3A0O-T_=VRCR4&<>C6S,_
M4Y,G8N?)4S:55%(T#OGV_#M.H= .30_%IR<?W'UA$_]*>) ]-T<:&(8$ZL>)
MFS%,W]!*530J JM\=\XM9>]SH^$B]BN^YT$<MCTC8JVJJ<7>&>#$I*7F5Y;V
M?"!_*4KYO?] GZ5C:.W;\-J#S;7!FW<''RA+2,>DSZQ:K/9OO39H5=?=[J'S
M,&9_C[CC;5T D(OO%N6YG9XTKN@MK!2Q+4% 8@ P/LJ;,MD_H4*!Y<Y&&UI8
MG7( %Z@%-WM+Q?+[Z?,Y@25D*0UADWSOFVH;P!'!L$:Y* KR ,.1S-? !6+#
ML489#+7ZT2./R-LTWN5F)AVCGM%QDUNS"4;P1,"#R_BRQ=+C3+_N"2XP#XX+
M7DC$J3)<_7>/B*6D"W58?W]/P\L[+/XT[WY^77$%1>?A L%/JEDF:)4'6$]7
MYS0&=%0HH52SM8!D<44B,!PWF8JMY]D=].TP#\#[J^SO:^[NYF01G1<VXYJY
M@(@CS2A282GO[8CXR_0:LHW+]@=/PG7V?U6:O''BUYD-O#UY&KGZ;3.N694E
MCW[DETC(7_%,>;%A*ND+NDTK#%+R"YD(HX2.F4GYI4Q1M"MSQT>TG8^\CE,9
M2N/?)O(U4NSXLCFZLX;3>5SP'ZM^_MO@^^G.%@<AIU5. XK>0%3+66Z$!%%<
M0/T^-(%DV:-?]OSY4?(_&189N&_$Q7LH =3\G2YPN>#@DM4R83 1.F\T9L2)
M3C*#$@R.(SM:_^P,=QWK^%> E/Q=@!LUV8(]Q05NZ,'3U2@7IP.UH38G3_@^
M+N8"0M9U#CW$,>D>]WDQW)+-<,WM:+XO+^A@U1Q=%A(8Y +RUN-(%C\<\YAZ
MF*4<B!]64 H98PNL32Y(YIYL7BF(/XSV&!+;0?$8"\]S7/3";\]AX!84?HP<
MV<0;\W*I:T]*=1(1I[C6RLG7WV$#M1&+':.6]8[J/10/R*)GQLG9NR=N>&NV
MJ1:JNOYYY12Z$@WH'[3&NC$4R>V[AN_P6G?O^9QT=,TRJV$PG0L$G<DC4B6!
M98']>3LFLNH%S8))?.4W)AZ/9"HC3),HLIX/E-YXB((63](X5D$H42+Y'7*G
M'*.:98W1OA*5ZYW)N+*]EAY7O^3VDA\3Q<.V\RP+P"MCI@@QH-!MAAKME 75
MH5N\HNOBD&+YJ_&QW''_(/HV-9[YC?<MV-OGQ@))E*VL6XQ[@3::;URS1IK&
M ^V<-_FNG9>[6/L&H7/Z;<"1#RC&?I"=DEB/9O%G0>&102AWT)ZP!F?M(23Z
M@1D\TU3:WY$M9@*=\VTDK0R;<H$N5L *:F .,D615SF1 8Y0O)'=-3AV7>0"
M\=*T58Y/-[A<.1J$4D:1$U&+@: 0\1?< YDM91PN0*A",/:UL_'H6A56!)PF
M%OPB@M- GL6X5@UQ,]:&NLQ$1I4?RV+$FKP44-?JX%-,F2;Y2W4^"][\5:,7
M'AL/T=0+A %Y]T$SFR(:,E3X9Q9UXDI\<PPFI-)6<R)^\FR54 YP]M@DY;J_
MA!L7@/@565:S2 2D8(W=V[\PZL[O%S?H5?P2LA8^M3'HW/*UCY>S(=6']DIF
M<WR-A(=,L%$EI%*9JIDAJ2O9^O")89?(WE?"'<UZ70:&R%_]2]9ILT.)0=@;
M-]X-NQ7W+ELS?MF/]!T;>W)X9KJ%>8%O98^!/4.GKJ]2@QH3,2ZUS30AUWXC
M6V+N1XMD&12E>#-H=V5E:?>=/)5#/TWN6_L-7;O]NP*>PXN4*L 4/(J4KMSM
MP@6*'2DZ!$R9EZKM*"/=RD1O;V_AEV:ECU8&\SZ;JU=;<76P*JD\"M;@.<^]
M<[7;)IK[?N]W,'"UVNS;'F_Y'[29'YO.T55S<7 242VK+Q ; 1;UL_?M^.A?
M9A9,$4DU$7KW)?[(\+M59,63^S7[>4]! KDLC6'V5II"K;*%T4-AF;E:GR'1
M@O<3WJT/G;?XZ.?R/R:@E7/F20PYH\98QC5\8?FH(/'3DC=APW=! R'<[?Q$
MS^%2]H8(>_I60FZ "ELTA_R&T<M2\$O3L=2E.-:^H&T,-T^0W^A^S,CSA=5U
M8'88LPA"_$3:%"2*HAB/-2T<THU%,,+AR>YB/;PY1TWE^9YYS;.R<BF/B9E.
MO,Q-:?]/Z6G>M31.%FIRLE(1;O+@[YW:;A6K-"X\?(I5Z"V7O*AIBZI+V=*)
M-7"AL$&GPJC6M?.%L:GP1#\&,\ ^&AIJ:+7@ B;["&4H=Y60]#KD1[[Y,9I,
MFW _3IHZ&I<U^C4=7_#=LC;_!5,I._7^-R?>!<3 C@F T<_:S]ANE>2N<[F@
M2-+P37S"$H7H=:UB1$R."Y0\7U;&G0.KM^,.<V+1-%*MX&>:].0!@C,MOVJ;
M_$ >L**4R\,TQ*RD! DPX"2\GI8,B8'S.=E./H5K5J51;I?.A!^H%?1@M3QB
MBII+<(&\7GH@;@_<?=?U56/#D449Q(?*"DM>[9LL<W,.OB(,_114JKL?NGB!
MU>#$.SF'#NV_B!7J@61-RG1V8HTP8RSW7RVRPS9F6N,/=G,!XG.Z.WNK$73^
M4@.2?J"5"V0D%.>S[+#P[X3"V%#/4$DU<Z<'6LW5'9XM>W(CC&5:_[HG*O=7
MY$44Z[8B$MH,<YC"@0D$2_0G//5;K !.*N&G/1WNKJ<<F@K4X&K"!<Z^)<RD
M$%_&#LE")JMU1)9$L0KGX-,@%(X+W'1?4P<?HNG*U\#I#,(=PG9.!'&R$]H*
M#A0[<(&TA(J"($47*X>4XAMZ,6^<-ZX\FRNPQKSH.S-YJ4?UX^Y8>_1C+D"]
MHC) K"4"WKD[&D<W%MHJULKL^7S?I&*O_IZ"+X(5V+BA8Z+'!CO/[KI['#V4
MQ";"26P/UJW3N@:WC7')T5.Z[S,GK8S"]BC(+XK>^_3H<U8.ZM4W/AOY@,-?
M^63A:V#,>./O/H$,1XID).+PWC>35LK/^<58CNQ^]@#J:A$!YUX0^F;9L?#7
MRF,/5'ZB9<5 <J8B(ZI]]5Z"SI;@AR1CV:0+Q%\?/!RA,D0 Y^[?;_U2N1<V
M*,6ZP-*;I1J+F/%5M9JU.U(A:=TD42NH<7(50-+S=]WRO299.4*0X:01'1!A
M^&+EA&C7B3G!EOK.;ZVW^GP+K%]$?=%Z*CI6((LN%SG6: 6P88H(O@.U!* I
M6K3!<9JZ_$2-_JX2R81TEYW97VZ.W0B*^WK5]=OH^ZBC;9C5LIJ:X;/YI04%
MI9%M;:,:D5)^6^0\TJ(.OH\!X#^".">9"]CCP\""7%)XGBZ_2(8@YIU;(@;T
MGWHP^?*LZ-<-VW^6^.OQG??\I<YC<:EK?B57_V>M>5$PU/!3,_*^=7;?F8R3
MAZ\\?R"T>588MQFL-N8"MVU5Z"Z<U)3AVKN!R34I>XLE2_ N^I0WAYJ4!,"R
M#U\2.VV-CK;BV/WCJVSQD''QY'&S(=Y:NYWY+Q4^4W]&;:2=1'FK_[JU%>^Q
M,X)(25U-1>2CR''$G2JX?;B6VI,]4YC'I,TNB(S3O^XU=*0U 0J<)^T[ERW[
MX+,^XG?E0;O8O%WEVS.^:U1P@>A#*5(1LG>T!E(%NE5VL7]1WZW83E1X$JFG
M28(CSG#/L[T)IE+[2C+R<LLW$F.;'I@<IG_[U)ZM_WR5"T24(\;:I4[LTM_;
MH5X1L'.I0.]\L\YSFR?G>=\U[L:=#$*)$,DOT 4EB:PS6)>*'MU+MS00?'X7
M-R^H*$U*Q/P:&PC? U[6D;NGLW;?3 BS>KNYF61:&-S5M9GB>MT@9O^>XQ'_
M4*YGXH_/[3SL U3'F@%"&M4]5-U=X%3@WA9/D<?V8F_OE>5UU-M?4.4K]K[,
M4X/%,!3'S&))"&\S/@;1-)(+G"^/3CAV]D!2E\V6PI-UTD\/3&[])7("GOC'
M=N"'01Y]M>]Y>*\^: \55S8CW/#=]5/QJZ"S4YF3DS@QSAZV)2-GC!B,1ZS$
M2O@57H@]W^GU]5R!SM;*JXTMHM?Q+[^/73&ZB%FKJH1&.&_T-4?U7]YTTS68
M4/8QOE$<*^>_JI;0<!] QP_\80H+3;P(UA99APBKW$G3W;]-&7.NI,?\\B2/
MNLENX/>.@6EYF+&LD'2&+W6J9E0LM.^,E][!_G-&YD%7=R8</DY9Q62D(J*X
M@(L[XR!?K4J0<O:T'?*9WVH#G96FJ>T9FS]T5O6(!^I<2.]VSUM;?%8(C5Q
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M /6V*-1<!*&SF?W[9N(CK%DYYPWJ3OM6*V>I%:E S5F4H/.6QC9Z1/-AN\;
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MC%XJLE82]8"MXS]N>WZX+LZV%7,SM>RT<I[HYZ9=;M[(<,(&.%\PAV./:*4
MVX^FGS\1NV$V1;+[$%9+^:V6Q=<W,I<\W:HW\4^Y'&$+X][!G8#;R';C/()T
M&8\G4+'>MEICN"_^66C,ZJIF_]:&9(>(7])Q8:T=P8@)=.6S"WQ+N5Q B(]U
M"NQ4H/%QF&;0P5C&==20%!2!"D<M=(&T*QQ1./UN@^!V;ECBI*TH/A!""7@_
MNZ>6'/9(;"ZV?)&'U%=1.&;&WMH^H?*8,.8N83L-\79KJ;S^::N\,GJT[>N8
MO&K RA.<!LO9 /!7F!]DJ3"0=$OJ,>I4B-+DB Z_^XI) \(W</=.85E@$R!W
M,%M ]:ZJL7[I_QUY?Z#98I?(%@V$6*14T09J[(,5]RT,,X/./AW_^6?JH%."
MH7.LW(V/^0?H)]#O_U\TJ91]&$D1Y@*G\77(U1D4XSUJ+(@+.+DSY:#?#SL;
MPWFQQ?(E P#+]_M>(T-J@A2LCV"$82:(@B2_F^,0U&=BN?#LP/.K6D*&_--G
MV',+>B;GB_O46<F"<TX$I;PT)\?2U[R-2G<V._S>E'EWR-Q5IU1$(W%X.\2O
M.(X6FO.%]C.47; GQCX_-E-X%)5J-_#TWM5MC:N=,;7ZU\DWF/V-/C+ZC"66
MCE*21N7GB86P?&L\_ISS@M+-D\:3-77[FQ1>><L3W_Y^E+TD^11CCG5^[DE%
M?6*,ONRL8(V)AW3O=.AY5$1!/N$\V6+::/X2W(R7GZAYGS/])B:,2Y(6VTZ7
M%5"?%SU6Q^PEY]A^526$M"<\?%?5LO4YH4=R/\\!)YAKVVC2Y8EV,KV[0X6>
M-F$.[HW)B-S"-V6E?H&/;%%-&'"?: NA)5<-Y;VA$FV+NN>+65+)CR-D3?/K
M$C>W3?V<!A2H!-*)CHN=__$PM;Z<\R<OYX@MP2-?9;B?;%8-2L_BA&F),6!^
MN7'F&AI3 'TEXEN6]AI?FHK<=.I9'$+(XY7,";'EC3A89\"\/\G2EP>_JW$!
M4Y]G/,QW7 !AR'E!G,X$?_!>AH6("VILFE2X@R/:SDYUP;.CT4'P.%I89>M)
MT6]R@;277."9,#Q*X^!0&I:.^X9>OH1:?/ >7-3  ?"$)9*HR^Z#CZ%(1^B"
MAAEDF [)1+..@)WGN$#S)OBWOO8R> T '!< :SN)MU68!_!KQWM1:Y*QC "M
M>5AC&<!^[9?,X@*R%F1A41X69]V]=??6W5MW;]V]=??6W5MW;]V]=??6W5MW
M;]V]=??6W5MW[U]Q;P:2@$AXGLHC?A,F5/"AKB^',*YG^MI5B9B_0%X2,.S2
M:I<3"!&(\K_1W4=\_9[I"_'CN8!"+94(5:J@EA^-!Z%2_WZ_JW7\>T"I_>6+
MRNA,U%_<'_S'58'_-:A0I#MP@?@XACD7L+\=SP4RXBR2^O]R!1J 'CG]-U3/
M:.\GX$V[W/+L69T-EC@Q-@7Z;J?RB4:B7)J@N,QQL/WB-)DC=3X?ZU"GQ3@(
MOQS(H,((^E2Z2)@2I&?"K0BF$3BX6([X,Q[$_-*8H+ND7Q>]8:Z&"U 3C&12
ME@15-)WH6^7LOWT[G]LP?OB\OMMKQ6DTXX*5$6<KFIW2 S(XWBBJ@5^7V5!R
M_9Y>&[!&PNMN+6J18X\N(MX*@?P:N0!6 &##PR-TXUNP4XP+-%&,N$!L)Q<0
M$#P#$X8B[,10+!= $KXO%)S@ KKV7*!R(W+==MUVW7;==MUVW7;==MUVW7;=
M=MUVW7;==MUVW7;==MUVW7;==MUVW7;==MUVW?9OSQ9RJ-1@^" %V(8]1<.!
M"&CKUS3+,]W8)G3+M[.#WZ):VSR;%FQCY]'C+;&\4/<H3U\NV#\\\C6G <?>
M9@@::<R U"NG+;F &T+Z8/85EGYRU4XND+A3L9YX.W9-14:("Q#&N$"J!@ :
MZTOUR/6J6YN\TV?G/]*]^OHF0P4R<%6#/A$6<]__Z07@_Q; ;N4"P>U<H%6&
M"WQJA ;Z?WKC7OR+C9O_] 79_W3\Y5NT=IB_\C)$-B]3XI^4;OBO J]"/7I1
M>1:U4D]\#AY%%VNQ7^V(!N>6P>DBPO3JO_I9*N(]D1R)7_0:/0![K#K'!4P^
M8.B91+&_=O3/O^+K^ \#Q4LDOR<M8O6U8:X+U.("9ZX31#E)J,ER/S6(& 8%
M]5)@CG1?TT=*@_V5R5S@[6&+2%PK<M%.5X(+H&NYP'$7 'I2OH,+["UYR05L
M+-:N]OX?<B.A#3'L#IG0L[B G0^1J601<H%OOEZ,T6X X+Z9HZ.6_]F_SY!_
M@)-%C!U0K0_(/(99P?WIU_2_O,_^O$=&#EPQD=G/<\ '?S9?IO[ZYI9+>*GP
M*S_37[2_>&=P/O\7I5[5LODZ7</B@/'63@/1YO_6*[/.L^OX'XO_@3S+)G-*
MN, DT05<F<+ V79]P.I\*4N;K<>(ICYJM*;M".,"11K'#CE&3[%<ZZY=N2?J
M:BSF)],[SP6VHFXC>-GFM--#T)>-RTD/\]_>Z;#=V2]P^&ACA@]>!))QX@*"
MY2HB#][(=<[0SBP>;-\35]"H@,\%_+EPPD^J03)%P<4,^)_&;"[P2(=QB@N<
MC(4N$U",E?L:5Y,O%98\:=3XOO6,=L[75.AT!U\<6"O-WL,%WL#ZX* %GAT0
MR[ G/D0MPQ/[Q]DE6#-8?. "KLXP*7(!N"U@(ML)&NKF E-0/\0%5!@=?/%_
M^0V?S1XC"X@U"T+LP[3;N9D,^_FAT)A$3T]W+7IH]WR<[.VKM6=/5/,&;R:\
MV52<E;)Q)1^U,@@VI-$4PBBZU\8H)@9$D3[MT/*$PO!AC*CWP0&]&&$ =PW+
MSP6>=I/1+.%!+C#]@]#+I"&%H4:B2+G"N+26U<>2'G&6V:>86=Y]8PXB41+W
MCGS]2G#[\Q_(^R\&XAOIG[_A;#$3^\\VV,G^+V'BK,;53YF7/R+Q!-&4NI:;
MO17OGA=LLLIKRMH:A4@6LS>+$HXJ=\R]8RQX2" /%%@Z>-7C>>S>O#T-5XT.
MERCI4ZO2QK_+*:!"O6=NEC:+R>[C ._+&D,)">H.#R)+4S],1#Y^>M%'-4;S
MD(N:SU$LMFAHX!.5PJF\1KG%6RKV7,Y54,S[X.C*[$D/?,VO^X??\;,/3< 3
MKZ/GOTMQ*?[E^]7^N?^R9DPJ8OKV?\,($,*+@5]+X=G>+PY=88_A>DB+=^TT
M8#*$U7Y:%S&=]&]]'*3_'M:.!\&F;K\LJ*Z%P#F43QA*8E_]*P?_=)G[_PM\
MH%C465U]^-Y;^7R[F7#'B(T<G'Y6AF<7$<6= B8;E+6N=:_P&U&M1HP4<6=-
M'2COENYY*M(K,T<;TF.U'Y?>=\*8&XB]"_\_+1[#D.8"&^%1$#]&Z^?<GR$R
M3VWTRYJ'A\R^B6K\"ANUO(D 1X/@'+")RIB#*I9)G#W!Y9?H<'1Z2B.W,R$D
MD_<"WW(HF;@F5M3.'"<VE^3LJ 87%9WQ*_7@<]?_3UL=\-6@B\,H>GEHO]*+
M5-_08@FO"J293W'YY^+ @I%S1[U'CUV^]+Q*]NB=R>N(YQ*/C\A-IAAKI(^?
M.D83SW8S/(3K54G2D_)OGT-CV8<XC\LWOO5#GT^N2\(F0<5*BLIU\=^-=YV9
M5[UBOE-(:$+YJ4>*-H!HMU)<Y@*0A F<^_+W$1E;47^W!YYJ8DTL<WLN2-T+
M0H=@U>!EMB9L"?;7@<PMA(&RQ?#?);M\EN3R&?J]MPR%<J=:J_EV<Y@K 7_^
M\/IOP)]Z-RIK[\(=WU1A*<4& QO/R!6$D+-RSF"C9GOB3HTF/XMJ3Y?\M>3S
M]:S>^4JI+CCE+_*Y;%M3::11WQW\(Y,S,>99[JV->1J_FN>+W@QM'ISM-,ZV
M_6R)FPTU?XI)9\11N8 9=31Q5\GT+3O#G4*=U,1QN^2WS@7.S*B637V'/H#/
M+S'J:9[&7[I-,U^K?B\1.:_3_V-;@B-:_<?S[^Z+^8R'4Z]NJJ5<.W 4_</]
MTK=<#8KXK,,C^E=IHHK5%$X6J]*U$KO<*A0>\_U%T*Q+YH.WK>]M_1=J\EM]
M!?*=%H!M.T[6^F H#@K!'S+"DHEN8=-/GQ7,GW9\E+V6:#*"/#*;9%-F6GM"
M^]GS@)#+F.\X7;^+R,(AE[XXFKX)A2!"J&RA/98.BW8@HB\MSQ-V%>Y2PN0R
MF:&BYG9Q<Z'_'5N)_4^JJ\83/TY8$U]!,L=)S<17*D/)T'G!!N(*$[5L9;%\
M_U_][ )?+YIJ8+:F[2[*!09>>G.!C#X-UB5T).FO'/W3-V[[7P_L,"ULXF>Z
M?X[Q6/MF$[D;MQ;E*DHE$AS;- UBCK=+A<DMKZXL1-G)Q]> (BOWIW=FM!A-
MGJ[-=M2YIU<E!XE-( L((6,]WJ8F=1;F:]&W3XO7A_$,;*.L5/-"&S 3A2XK
M-,MF?SM)F_+F1<Q]'^A+7J)^][[:&U2&U>>2@[K-DH8JCBHSA/KGNGHL%;_'
M=4<XI;:]Z5T_DJ<.-KLY-L$*Z=LFD&SX>EQET,RZBV(U8=1+[GT;Y;9H)^N^
MI]%A[<7VE;V5;].*L"H)+'V#';A57UA35<6N%*K37\V>);4TYT)@Q))*M5ET
M4DILGL$8*&JB_K$<[_CH_H>UDD5'GETI9]IW+2)*S3)S&BKEH/8#$X2=TC>[
M+\4:7;-'H^YL,G0^P:IR\&@XUFYN]SG+NLDQ:_B$^L^?ENF7G<.K[VT2M"_!
M%,IG1;\Y[X>]_?Y09Z+WVLS4Z(B(S:\27M&9\;LI\V\K&(/3T%S@:%9MA]_5
MA0;2MD-%UA)[(F=_SKK&WJV_X/J]4>Z/ -ZA+T3&+3@T@AU&!ER N 32WK<Q
MS."ISNL.:VQ?-'/#<_I&K-NI./*2D&RNK<Y(+O(-_1K]?E2+8G=ZF$L;_RPA
ME[2&E!W%M1.WE,LBA]6;)CX]125#^[1B"A >3QY"N_J-J/'T!SWS*^%8U/B4
M<[KOEGV3M7<^5MX51YNGJ/I++PW/6*TET[.IY\1W],G(%<>V8 JNEPUW?)*X
MRHQ[ HZ(34]\%%/=^<'M#_<$94^#+YGX%?=ZM;:JVT_:9P.-5(/+XW\\O0KK
M7/3DJOZ+-O]=D59C.'[&4S-1K%;7H:Q[JUO?E,;%7KQ :5K=S<OHQWAXB+TN
M+VS?6R]TUG;2/NC])F.%;K'59W,G<_?W/5ZU(C;EX'G":]L1=E[[RJW1/H]4
M8G0=[<DH$9O95<JBH6;CEJ/.MU#>?)\Y@$(Q=H;J.ZX5SK:F!73,2M9/)O1O
M<L0<T0GG^WKF#UU*%?-*Q<G9)7H,XT5" D5.7[S[_+7/$K&ZI:R%*,1QO<]U
M#)2C.)Y&M3Z>\G^Q]QY 3;_=OF^P@(4B H)4%90.@O06A3\@(+V#$!41(4*D
MMT! !*0+"$A7BDB-"*$7J:$(2 V$WCLDU)!Z\YXSL^\^=^_[GMGGG+W?<^[=
MS#PSS.\W:4]9Z_M9SWK6[^FU(4].R;SP9Q>#_4'WX;&_?XP_V]7L&R8?E_MN
MEJ<1%?%J5\6_AO9C9;9*42=NAH3B(L?M\5P[RS@H!+=!/O_Y-5JD2^)';X-S
M 5?J)/,!L7DRWG^!_JVG?3](E2F4?'LL6)K!T^8=^E K%;MGM_Q9;ORF5+$)
MC4HX!R :'[MF-:6>3<\VFEF51!"M/["^J\)2KC2Y5O\LTQCF?')X=*0PK<P4
M2Y8-<?%!<:*2)7^7U9:^*F.Z5>)FH/JK"ZB'ZUJF ,+Q2U:X=#>(>-OOU(:0
MBU.PIJ1C5=7'\#(D-^-%?[Y=U:*IIU!%@GX['%V^9[JS%WQB&V&\\W!0-=Q/
M8>9;A75DZ@.&J%P5;U]?0_QA_9&"V%:\0U0\$W-X9%7FSY_C(%=8'[(0YPNJ
MPFK%.)<X'_C7I GQ<'&H+<1W\HKJ-@6>//6?7FR,@HV+K[R3/'U[F0) UEJD
M(0W9_-(Z\&[I3HM^&7HD+>T/GY]+ZWZAZ3OA"4A$(H* )]$1(&[OQ\UF=JD5
M!S4Q:T-II:FMN\(+PCK.]Y(#K<'P'E@W)/8&C,DK75S\I<XQX?T=#K/U7CJR
M#;#HQUY0:2[I,U2S!!>I.5$P+BO:K/57O5&<K[*NF>L@[=);T2%9IA!T?/)"
M-J2+5ZC):6R"3T[9^-X)H]6Y$:!G[T)P4.E/4A)LY7P%%?/Z*("-<RV@R]'=
M$X//CPM[LKB,6_KMB$?D&C4X2]BOQ0/=_JL2_L)WA6U]O\W9Y! T62TWZ-;_
MKO!>\"6RV9(-(Y&@X_V_/4:6GFTIMTJ;F)9 "T-1-=$?SF8X^4KYWPZJ+L/Q
MIZ.PHX@K6,.I?+(>,@RXC8-M,#SD&V%_1P&L6(P"MZ,I !%T&>@B!=!3_@V&
M8B.;(_Z';#]?+E^-_"]PZSE<PWZWTAM]^4A$9D2JCS$%P)LFH>,(.;%:*3X6
M"'":"CY/GN)E'6L2+=R8N]_LRFY;%>HZM[=XN;8>?9\O8!U\39$>,*0Q*-H!
M S.AKUK@0I<93#LX@T9M<+9/ZL .%\1#_05<(Q)["!UOS[0-:+9!JG_HMI!$
M&;H.")Y71I+(:(C-)W.>7ZPE,7&RD^D$<:A5558:/((/.13)\KBR*.Y(WN>V
MN>;6R^3I<M]QW&8>K,>E@]S"3^VX\."N/__P"G+_ >T_M.JSPNWM>"&::K-2
M&A>/Z2S/,[/#._Z)%]D<7:_RY"7I65B@:9T];WN61Q^/^=&U'^"*+.2P$B?F
ML]'KP8/D+%0@QM<B\Q%6QI>9T3V"-U^V*[Y8X7F1".BZ#:^/HT6AREV=85S2
MGZ-&.WXR<[]WC>AJ3VY0X'@F@XG/S$=B\=:L<(O@6,&X]W9,%?/CE>Z+&FX5
M-0:5<5\3YN!#WEFL)6Y#?3M;IJ:E6-7?K@;:&9MI ]2%,"6;)I?@W203AS#$
M2E7$\S&5)=V\\:2G*:,?)2M,O_VFS]ILJ9G37&),. ?!6=ZKGO;;5KE>YHR9
M^6=+7CD(O.LMX%Y2^2Q@PJYKQ=TVI'*Q<ELO;X8K[I$1_'> N9)SD7%Y= I'
M]5:?,L_N\6I-\4),C/.RM&YB-N)0<R+9(UGG@ZU+EA<\7Q;<'\1O,+FE,L$A
MFG%X)G$K0^O>_>B \579P@A3]_BXC)=^4<_YC=OE8[.'A,'.EB7,QI;E5M.;
M[ :]X@V'W5NE9= 'M=DVMHHHP8_O6N(5LV4E;**1$TB%@J)><X4<D*:S2P,W
MWBQ<P.32<1GZ.%]HP%[L]+;"V--AWT>:K.:IK"89NO]N6/J?(;O_;/_+&W8(
MG:<-BCA9#-YV88[ O_'4WJGBE.Q(3P\^!#VVW49H'YRK;0'Z!34]PG286:&@
M$YEN8["Z8 C1JY(H&DI*5M'DVFP8C-B/<OADUUW4\./*))Z-+QMJ!O/LA.3N
M=AAV$--/O2B H [36/GW>Q0 TZ%:6%ZTZ*[A^RNB?2T24'=0A-)X>*P--""_
MGT5/)=@WM>=!>%O;D5O^2#-=.WX**QAY1#*:5LU%+UJ_E[YFK4$?HO]VN'L1
MR^:DG@47@K3D?MVP^/5"R"CB7H'KY9TCU&K]06X[[$R!"X8G-% =E #\ARA5
ME+VG  [>RE$ QZ=4M/VB WIF.? VEQ@SC\O="#)DA[684"<G^/"Y_2."<8E\
MAYGD:2I>NLD730&,RFX?'U( NXY+0@XC7D$,=C;^=^7=LL?-V$QQ2?,I =R:
M)C('?4VS;UI9_;E5#<P?Z(JH\I ?3Y%2!'QP@7YE:N:M;UOU/\#29:.PVTL,
MZQ^\/ZC0++:/S!J*('VPN4W( FN>2 M\("<*YPGQ7X!-K6T;A9%XR7K.<./T
MX+W]NDG58+MO+<$8R<XXC5]*78.ESLZ.,)A2R@-0?OW3K$J[BJ:<E?5": N0
M^\?D$PD[Z[INHYA,6_3\E6-$[E90#A/-\6\D^V=378/K+L([J[-GXD,_U&X2
M@=4XST4_F4FINQW!!VO+W/VWMX+#OIRP';:VMYXI1,&VM_;/5/4H (;G2_MX
MNM>MITL0LK*][R(%P+?%RXW-],M <SFU.@LD]Z=8=:4-^M$SP6Q6N]<5KJ1@
MDCIFU9-1^JF904@#4/(KF<58OU+%\1@]^P82<L[+,@/*B$LI)CX9]K[:;'+U
ML4!MW<%'&WXA_M<J>Z_6,[:)CLOB#WXU<*._%<NG77F;")<4]='DZ:4 MC-(
M=W*DXYY(=QW:,-COZS/]%GT&'NYLXHI;RRY#C V/R]KJLQCFX,E+RGJ/V;V2
M'[\M$5V5_& O,T96P0WV:_SYXE[TUXIM_DM:\M%( 'VPQLQ80$WSTC[Z0>>[
M]G862&'[]'N:2H:&'/F>^<YY$I01<03J@(3C+3OL!'=.]-;G^FCJFC]"#W(-
M'7DB#U50O;KF=?$NUPPX7AX'.;G-@491FB<RFT:+GP-=3G*$R_E'V+>(%$#A
MS#C&,%R\B64QAH=S+"U^ZOX(<W_E:B968&*5U7)&2X39./JG=MM8L4B5][V]
M.?C8(ED.UBN*92>]Y<-SHK*#>X$'-"C8]BKLB,8^!EM%U@%]:-T.H4[LB:;M
M$QT*X"-C(Q7Y1*F3^LK9E?D#8U/J1(:5)52V4P"]BA\H $X*8-HPB+KD=@RC
M_P_;A?XOL=@ K'YY5T+4<2#XA^:8?+*VQ&)8DR)#XO% <!Q1D?2IA1MGV9%J
M/+-QH^&8T%ZN>I*GLLQ_[;)(T:IQ3@ACMLXV2"9X*O?2KA>(8P[7H=Y475_9
MFD:^)_=QAE\/[)WU@'70IW(%+W5K^4XS<"%RMW(Q!9.37> WIQ<G:EH9+DZ>
M^ZCR9T8DI&3EEA@\M*?[08_* B PC?B  J!J9^8C22*-(=7Y4GN *IXOX=G)
M@"*<!118O=X^E<_8(C,: IR?*SH0S8 199#M^W@>KR'";FM[B"02P[38*2T6
MM1#'P//8\?G+] N^FW;'_@6@ZK2.FP6/E[$Y&8,K(M]]5G+""@/L_N$/*_R/
M:,&O_D6(O?7)_S.;Z7\^WJ;#'?AA*:/$"B.J/C=_&B1R5\)4L3^%+>[KEMJN
MY)368GQ*T++(M+9,MRLBLMH)6/WFC=QK6\'H@';Y-\ASF<G1]9>0$U6?TF,+
M3F\?,#^ZDYAO5W\^(T,3L,P]%L/!3!CS].;/++:9A?DQTC6#4F?=ZS6=;.%X
M8V/;5$QMZB_ZZ,&R>IM7YH5]H_7Z;TX3P]<:@>$^]P7CQ.YD/XJW/E>C7>[Y
MS1R1H-IE]T=VK6I"?"\QV._S?3CP>I%-[")O<8Z%E!D\LMA U51[',C<=/5&
M$MFQO,[O+D?L<BSJTZS5[)36:KY(R"%(BZB*=<O$/NBXT2_"XGE.,B-6ZI F
M-LS$+VRQO"*?OK*]I[&>IB&:Z'0UL_^B9.D+5#-[^=#Z#J^_2@N$+CYF+::J
M_I"G>>RC5=/';VN"%Y8SFK]L.)DA<M9LWP[$KL!UMV3WK[0M6G^HRU"-G7[+
MH+;=A0:%'YGK^;#(+$0@7?#I+[*MBB+B9G+6T7H<VX]4!-Q63E4H #*SW+A$
MEE;L?4.7YJ]^ :JJ%2^S 1D"8N46+W"((N<3EH?BDS.-SZV$NNZN?94)9LDX
M@?+_[E(_;:N8TF-%W=7LR]3QSWE?% >>&D\0<;V[YC\4A:AM:O!)/&4>S4))
MR178KC!D#9<\=4N<5N&SZ8N+$OCHKPBO[5A<OG37X>B-!*?,9J%K')>_ /?^
MK?6)&J]9D^4A@$$'Y GGFJW79[2[B>UCS.]S26#=3Y]&Z\MUK^3Y*D_EUXPO
M)KJ-ZYVX?6LBV&-V4A]<CSGP9D- @I2> I979(<GT5UE':M]6@%7%HL4G\WN
M[^5X*R7WS\ONL_1,Z=9<:BNH..W,H<D95.^[7Y3XU&[\?6J9!F/*OG'G*)RK
M+5<OLFNDLTN7OER3U=(8_>]6UWP35"5)S$IH3R!PR>22Q**;)OZ50DM&=$</
M_I>5=;]), R> C%0 "])(B,0COFG3[=.^^S[U4?RK>%.#]^"P-(EMX"=.U\6
MPF>T1*>\!UZ-=C2(DTMATM.3D].]WNX/WEZ7,?F-W*"!=\!#^1B/@3AAW]WL
M)1Y(-SO*V,_;^EA?HU?A=5EBN^W47P'W'ID//16M%>\-'S I*62R($AN40">
M6[:K1?KCN7F'$#PH0"T>A)/02B?]X(>$G3KHSH=YJ*A_"VIIL9RJ69^&+8-<
M@G_#:H =">@.G<;<MMK#Z:T)$=Y3C7%^*[CK6!8=^F;*J(J;UJWK-&VWC.5W
ME#&TD"NY3/+MP"M7F01[#I,--)NF8YUV-4X)K>CYQKE6034%')T9E6F<R&@;
MQLI%KNWB)J5I63TFF=5OE8E3$F(KJMPA9?5'4K6TB/=?=]F$2>4LAX?DUH5U
MH:&IAL19M]8>TEA>\0:^N>B#3""/2;MC?67S.^5,_^2"Q(8("][.:RZK][+L
M<A9O"M^]6W5%Z#M$4OQH6G%O;SU^8N(2VMHIO5W@=;[8;V0(X$)2D(BMCEU*
MRX=%-56H&V9_9Q\#M\6BHE:?%VU6$E.QS&NS3Y#,;1RJUIGG_] GAUR&<Y,B
M@:[[N#?;0/:GL':J4[\$.[F0.KQ+'B?XYJY?9H2-==7R@EH\I]G.1@G/H2^Q
MH-TS+'_WU8618:(HSJG0WB7/^?*UWY6B;O5O&%]^#DDLW@C) ?J!9RB A4C@
MP45</54T<$+(8>[FD09Y6>O$6KW^#-39-ME2\!HI5\RA>8?D&@BMI@ B@,8;
M>=$:?Y,HTE!SJKB8RZ>*"]LSR\-P@BFLM\T/16[5)L?HDA/^WET OI1\J9B*
MROI+N006B=:CANY6%S#6]E]>?/WOG?_Y__=V3OD#?\.[QZ\TDX19\_/I(TSN
M/R+^C= X_2SM<$S+/<=V8G4_I%.KZ_D]E'@K=?;C+^W')D J16H*OZ'!-SQL
M0#8=_N!;'1U*=%KX,'M&<$I9NU2VHH=91&7:!@50S@03&BA,-= U7B^2==:N
M7\EA)WU7$2^Q*3KYE:O9>/5P[5[&'=B4T&7BKT*L]NZC13N)<0K@I]IPN1W;
MV;G.82TF@N8OX$=9B!4I'<I2W-MR">+5:EY5WP,\Q<AO/AF!O>*[Z%SEGUQ(
M_@9<SY[]=96JP,?U_=U4-(0(HJ.@N0D* $5J".2>D1W8+3<E*MGB*8#:!#8,
M\+TW/#Y'.=-B7+XF=RVRJ:'-#.!PK:CEOM2DYV;NC[RXYW'\FE>BSY7$_S)3
M\LETSI]".CNXLF67.5RF%V*VW+AH#7<0Z;^=:N*^MI:5O4*H0@X<6K]*X7]]
M,/JNVF&*C\4/U&61<QG7@A\_\M0#N_J^M1,?8U<.^_Y+@+' %_ZWQ^C^P"20
MSB/@!"P3!<!3D;>]P!>R7U%8EZD^+U-F-[V;=EX@*SGTKB8%0'^((9##*0!B
M=AT%L)QR:,4-5^[?#.1D$T:?4G\?,>JH;F::_[<CY^<,;^XD/3WQUMW]!Q]0
M0+"=A+(/IUJ4O\H*M!S:>SUL2SU5<#/1WG>AE19,_<PFYWM5I6=A^M*T#8UH
M<[GX1,W]T(3GO;NY>3+S[WAI1PJO/UKLMWP^NBMVF-"G=:?12GP)$7X[0B9"
M@,M"84SD^Q' JV)C!=?D:C4V("JL);$E90,:@O2ON5, KL_>LJYRE\3$KI0/
M")8<48?4KA-1$STX)W3[$;>4T%^:' ":$!$;(7BEVIW3\7!H&@9.-K@#PN,;
MR88@&\N[A5!A3$74$G_%E'.P08G=S$Q0GL59IG+\2)=_[ZX]X_.0TIBNYZ6/
M2DU=&XDUH_T]>'JX5.&[KU&%QG);VBDVT]LM+<%.UB!6HBTN)/B6W^;<DC^+
M)B*M)_2Y4=<+.OJ%ZS0.L0=!M'YPQ-VX5W'+[BG/S!:6P^S]YJM0'2<O#$*3
M_(&;M7Q$C_H',XTWT[58,0?1T;[.M:6;/P/<O-^2'</ZM@9K[DE[(/)?9C?N
M330&"](M M%7%T_?>5EY#8AJ33RK34B"?M![/#N5D-DK6_4W<%_DP].!0:=+
M?&1E.S[B@Z&.?3S5CA_X4-=:O/&_&.4!;C68@<C];($TJA)8,>C[7,%;*J@X
M6C(].PL[T-KOF/^0X=N9?2=(^\F[K4NW/__J]XDNKQ-2Y+*NZV \'IL0?$]D
MS_?C,TSJ_ZN*P%:==-,&*+O2?XW68\?PH:A;2\6[DF)-2^=!]#3XC.]NM-==
M&T/ZC$B]?<B#2-P4!2  [P0=_X)M@.V]"0(40 ^='15"4ZB0>S$PN#9ORB]&
MMV[4FR-XV/%MHV.,I\3BQX#B"Q[*G(.8A) CR7/30[21#B<<1<\.)+,%,C]P
M# TBV9;'?IFG@ND]P(D::8.G$$0YW!.5_WFDZ-/XK^JS58&)B9H<W\W)>2H7
MSZOY_5T 9?SO9(E9(JC<8MZZ@H-Z4P#V> CY8YN],$$&UNN'<2+!F$@TW\_C
MU3$@8C3:B>0.6K4UC_EG.67_0[FMYP_ RY;$5$->V&0P!4 !Z I42+?:5;3P
M^)G@M\"9N?2O4>PLBDDZA:-+3CZ"=S^G] H<)E-'O/T'!D*Z8L-'OOJ< EAZ
M??Y +IKD00&$/U^8Q[-6 XDWJ!#?^;<3EAUMK4?"KV$X\4@*(.H+4V\Y"UG#
M@N\8RT=^+WHB45^(<UK 34KC3#4L3#]J95^Z10',RX[\LVT@M@/@KCA=-TEC
MZ>YJZ[OXIA9.@HJ]]<C,7XU]##COVU6Y 8!C$#IA:36M@R^"LT#8)P:^]5$V
M.ZZA[I#FK7DATHA91W&S\?6^/0L%<('06M^$%8R]<'I]\,;(3"A_*G)P#G%X
M&M=RC:B!(<4-MB[%T9F^FY&.@L/CE^L_&-='"20]9ML'80SYSFXV.?[MH! %
M@.?Z0S?S7R@3"O7"M6$93Y=143*&E\'HA7CE2C#XF[-'#]++O:3N\6B2KRA+
MZ+85$$T!5#L1#W'4/@A)@Q'UO8!53$1+/D3A7@,LH%0NO\1ME]#>Q[1^'_Y'
M%T!$DU&D?.!Z;B>0>*&1VKO@;<FI&^O=I_: <5ND@PWGE[%)#5(]=[%D\JIF
M7-Y#QMGIYJJ,4R6A<Q6E)3:O QSG\F%*Z"F;OT:'9')]9(STI$X G#CVI=Q=
MV^7<&#415[I?'B!GFZ>C_A9OG:/[@[SC8P=;I=<O[)H >#QC40CR'*]:9@>,
MP8L"8+(96#6$/TV4&^VM_4#KOIM&G:ST\<>)A M0>40E)CY_6>\SVS'7)GIP
M0HL;><[!9_XTESJ"=4+G>_A.H*0OKF\&2\I+2/ENA]P!"_(<R"]IR3N,?INV
M(#K@&Z8;?DR=_5^@&H%Q>D^LPZL/YI U!VVA;6+N];^ ?G*V?TZ  :@N/HP1
M4Z3/A&\&4YSX;:O"1H>BN9^Q=-XFPU*G:&Z6C=+-AWS.MD\U_2%LG=<+_NB&
M+B?)T5<4O+RF;:2I9\] N(&;(MIA=/M&_.G3;,3VBZ3<6JQHEHGGZHS)JX$#
M__ XQ?_^,8X;;["'KZI?]"UJ&R#27=IL::N_O.@,L)35'U2JK0>_7N>N$?D>
M7I"\=^ R(\*?G),RMM$@YNO1)0SZ= Q7*W34M,MQ?*K>@4S/VLLL1'2&/EZK
MKE !BE>P?2SF/H*;#ZNP Y(4=2N44"9S3+43QPH?\RY-AB:"9&V5W@NN0"/X
M/WPU*$HS78^J/K 5\#2#L^]L_]H=:08O1;Z;;L<71+%J]^X\7&K*P6_(1"@"
MX$X7HZWJM IDG^#I6V]R>RM,%)59@PQCW1AG\!,SEO9//YOW(4PJ0SC&;O4.
MN$XY[XS0:R8>E6\;R(]M=)K%32>FW#G;LW3;R9BH_I/#9BU5>Z]F5"M^V/?L
M6?UZH<C6Q;?Q=9HG<"6KM+LN@;QF6#>7L1IE>(2:6NZOJA? SU)GD0YVM/78
M0^-XLK-#4&94.RIE$#O367[5%>;2UA1OG@FNDE)K0KT_*).X5U5NP9ZL]LI:
MXNK-#W[1?PP,/;]BY6.])5D&TE=?W1QXJ?)3!Z ML#R1K^=3FW [RF';)'%=
MO<2 #]WL9QHN]'W4XO%I\6B1E@CKB+%6<,S7H5(PQO9K7]4[+=7M&35AG*,,
M[-)TS^@YN>]3^]%++3<VUX"LMDTQ(4P6>%0%U!!#1"/B?H:,:-=!F[5USV;Z
M.<FM6@QHH;,GR_?!#SI&/:H=B@_8MF^N/&-_;?_)MGTP6QH\#GV$(7VI.[MU
M=4LJNJL>,W02<.;(^L 39&<H56AR]1.AP;_\RH^GV0;J$UTQR_UB0:(V^FSB
M#BS2NZ]VP"6U(UK)ST_B,GL55E[5[]H0!H%2"UYL5YE%1DY]'L1+6$6AN6X<
MQ00J3SP2">URV6QX7/M[V.-K0_32U_$;BK0=[Y10SHMVSV3:+M/RCQOJKG>9
M%E]8J5&4^E0R&I,T75E?FOQ]\^O'L[(PA+]6.7A==PN[6&6__+S<:K,V@2^9
M2]V]UV8%:H]V/5X,?*EYX1 !CJ3YD")\X*'LJS)3Q:[$QJ.F[53BE/#4N:3D
MX<+:=ST7[&%L@LT1@Z=.=<3\8/@!.(N@WGLYYK7"?C0>KY!FHM)#^*TF/I8@
M8^!+&U<T@A@9-N[6>K1M]%3K1W9S*<),?XKW74GFSP<GV?5(UI+8F=",^I7(
MVE_;=I!P_I])U].DM!MK-!UMF7>^#H _HSH)'(KH==%"F\[#1,_P)^X9\._:
MW+Y/*KF+WEB"ETJ5Q8<OL3W<K[84+9N:GOYQOV9K,!SB,G9LN>$8V2DR8&@>
M'&'':FRW_NW_V/@.711YFK-J _93NZOQ^\I!+IFYOT?##8GO^0TCR!N01)>8
M<+?GPMQDYF-LAM<V^HNLXY5N6<^07R;T6$[SU4ID>$.FZ)9F:%3:6_CJ/TL"
M#P:@@_-[J&X@1J-Q,K,#>*/\?/ 91&93=R5H)#D$)BM#E2PQUA2 !Q!O2KKX
MH?5G08-G:Z\MMA(?!DK-Q3RUXY4;#;[NDM[9+U?XQO+UJNYT+>A%:WEP(6IU
MB,C.8ASN)?F^AD\>S;MNG.7>_>>')*B4J:\>3(J!4%4;':9^7&,I+9_8^IL
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M<"_X6"B X=_09U1[WPDBNB7\BRLA:B5Y+:(8IC#B<XSER03&*<PM6,)O&AE
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MJL3D;G\_= F\/GC?KUCH,!#)%I T+_77X/A1&7C@QNOITF>'L1.DM<(;\8N
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M'_V(X?V;VDC3*\"-P6LX  !MHS0JG< BA"2EC\^$5G@@;&7G9@UABU$[^\O
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M>=,G\\(7VD76 CJ>NW[NA7)X)Q8H=@9S;V<^8&N[ @0?*U;C!Y$'\G\1D7[
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M6TBT(C#0;8[\,LF^P6S\6BIL/!!:R>J5!(?T8#=!1=J3AWRMT-_;^U( O*?
M)X@@M%G\KU-3P6-C,%8R2;GHY@LT*.?[<W3(\NG!"X+X8'2Y/]#M+RZ0" /Q
M75)T<&NZ[)_FT!$=Q#Q[H81559*2OJF95+RK:>I=/[)7(.[K%9HV44YYM)Z
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MQ(2/*8T 2?TX[\;V>&^P8=+PRIGR-)G5VZZ&.&]#^$+,<N/'M?J(4O:@,BS
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MER"7R+&L%)"NFZKP;:%1DG$T1;/K=&[CWNF^R< HKPO-H@23>3E<.,_V)6K
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M/=GFC@7P?KL;S4VJZVS!YK;"?65J>U \HU[')?1RP+GN%H&Z9VI+VHF7K*G
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ME,#%Z&81=W+4V4H-U8YV>4F7$"65TL/H7<62(RXK]WO3Z(V\^.9B?KY7Y>3
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M2C FWWK;6\#V4(98=N9\K1YIFQLR6I5P=*NYS_6&#FAKC;D\^"AM]MFM5ZS
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MP$[II:R^-RXZSL5QGK:ZB1((GA@YSY*K]?8@M#U_]G:G$_\S_!M.A.<^+L7
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MH7C(^6#FTB4.>1I>Y;#=(\:N%QV9A?ZZR9.WW8O]OC21'1N'I='5C3LS5BL
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M?CO+!CMM6(1RL'YI:;I>65<UN,4<. [S_$UN/9=3_,ECNH^7N!<7F,BE!TG
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M=$M!NN61]X$=ML<]_:WM*S&7H<_]M5P9/W6#KT&41?6-7N_4]%/WLW&T^4>
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M3,-J%2+@7'U:X- ,WX#5PRFAWXB _@>:7F L*OXPT6]BRJB#$G8]#9%R?>2
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M_':1X0V.D:1#JFF<SI30]F<]M\GX19Q%5H<(_.>9^[4PJU)Z>H?B$<:[>4#
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M1?-7IN<U??JD_>A/'7C[OW[XC<YP(1433D)PK'@,MO4@#K?RKD%P7L.<\?[
M=E!V<?J@L^W-A_;>C-&2ED;1TV[]] L6V'W7"5-"2*'%Z36C7S[OOJ015?Y.
MNWR/#^^2+!0/.^"G5XB D,+ P=D]>9(1FX-W_AL)I3$XRT:N^E:2."A])!'
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M;'/:55\CLRIH)4OEGI8IQRY6:IZ6+Y0BNR?]9@UWJ4N"Q"A^N]G/BY_0_ST
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MN63R%(3:K7FCW-G) _&<JAT^,MHF<"W7@ W"/%5X\#.+R'GZ9]CB7X[4 ,X
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M44U]W;KPMB J(H(@TE6J(*!T:5&1+KU$:D2D1D! >HF"]"8@(#72.Z%WB("
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ML"(U]_6:G(8[V04.C;ZGC)E$JJNJ0YYZ_F6[9,$#SV!"U KIAASL_ D#N,*
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M6]<8O/YAOO.B./V%2)%FM F'3\.>?,TBM65;7+%1C_ X@ZL&+K]DO;;UZ?8
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MPMUT-GH=L^Z1_VI^VPO=@?C;);C33F:;$%^Y_(&B3>-/FPYV-@!+CKOLE32
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MJ0UI(P$8LNDXED6$<1Q@[4A CC9XB_=/IC@/$H,@=E(+DP 5%*(;B>.#X3/
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M%(<^!Q?P.>0<>V"$-6AYC'[1)P:^6__.]+J<6(*5&6[HZTXF"5"1<'3YQ()
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M$]$,N30IEITP]RXN\/:2 PM?R"G8(6(!WFES,7UY6S7\C$3L?O1F[<G94>*
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M_3HA?_.'S:#=E6@(^BXPY0-X58)PRZXI^OC,)'RF"4X4CD5;;K_]D97RL-J
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MEVL&#;9G7ME2=G[[&O?TVA?MAPDH\V )_T.0AF0/7G1R0=[YJR.(ZEG-(*L
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ML=PPI=[@"_)@"40C(.H,\CI0QMBT5V464<Q.MSI!6(P:E^O<%,XD;\?9VY(
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M"BXW\DFO3%KJ_/1=NXCLEK]!L2]!Y+2:]3FEK[$[/9B>-2@'8:QF'PVXU)$
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M,VA.TVH#;W>=V-\2X-AYJ#,1K5U<C8,5#-A=-$T3P1! 7QJ_C+9S.[VI3.[
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M-;/9F0B;8O9W$K._*#I1J6@.)O=QCLD;G$E-?[)$:^\8]TVZ[GHN,ZG%1N@
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MY=V_I@2PTOR]AP&*>O^-8G+(<S K$&9WN_3D$-3&=KJ)L<4#F';K@0=D)7A
MKR)4Y2WNG#<LYB2)<"!:<J)/JPDPAR\U)8"][/CUK]UO1!<>@&&/QO:%G@3"
M-A*\_<!+,"Q5.\Y<]K01>=#U&B2V_"OB)?X5!^[#<SQ .^F12H8T+E_R;=*O
MQP&>G7@ ,0,FS&6[^4 ,O8%+$M.?7KW2F"9UMX2:S/^&"(^79R&S%Q^4'@^H
MU1$'.<)QC5/WH\8$(TX$CYL.I*&;%P>I3TEBDNK*[4%UI3)]WL$$>3J;2H%]
M,K1ZL%^2Y+^]A;UF>R"SO=6T166)DT3#XRX7$A0>>3M=?E2TTYN9\BJCJJ(
MUY?!@MBT*T_?@5Q(#GRIC4M][OK?8 E[G,)0EW4;0&($C85N/PFE,R_$BF!\
M9K9$P#K%@\:#55'B5=>>%-B<+=,.).EW/QY>\7%W+EH(&&M'Z^%$O>DH)$.J
M^CPF"20.*W TG05^AQN&?H.^1UJ$^A[[1N>8'_1@,J8FNX(1',\,])X2L:4W
M<UX7/'M'F&'I+1$]6DO 6KU?JF]+@/W$;X/#"N7AOQ19DF:?$F5R_RO@NH&
M,<VC73&W@UTQUC:U<(*>^; #N@Z;"<<#KA5#?4'%:37G*\WO%*(%BIL27,R:
MWU>4@J,$&4_:%]J2#GJ&-S:\2;WK79*VOR)G4A-O#15AXO4AEA6).40TK->E
M[1FZ9QYB+0_A%>7IXA*L ]J12$1C\8[(A#'I/B,Y05>>W?GAXV[I^37"T8H&
M8P/=0T_M;1>@73<W"-?/?>(YZ(_('T[V8XF__B7+V54$YFXF-D$H +;^M(*@
MW-9H3[,1C;8_G_P'=1IAS:N]R32C2FRH<&25/]JZS.Y;@_08O:RL723^*.MH
MF((V'FY)6V;1'3-*;VT1W_4C7.C[XL^2R!SL#1 -")IQ5U!]J;HB0XAAV=/]
M3F>^CJA7.RKLUCH#!??':AZ?IDLR< <@&+[V+W#5/:6"8&EWT2.AN;T.^HDF
MQ@$Z"I<5O3\D642[AS8B;G(\N,@$"+]%0B?K?MR-"O5M?HN]3YX70#SDH#+#
MWHDT11 %*MTS?+S*$W'IF9#>0;1U\UB5.+.0DH>NISI?B\.X[%ID#>NY<!KJ
M@C6EE(!UR8F_OEN^+WT41<:([QS=<>&P+/=3VX*8SFW=OJ"GKVC.BWVMG8EN
M;KB0WSXV_L"QW^$ SE</H:E$D^_(LP$Y0UQBL2<B7?<AF0,\M*V;O<>O'H5I
MU&O@^CM.1_+5O12&HD1K$*^?O!=RC!TNPNAG07E,J+=:$9#^HC@OR<&[.P/?
M0E+R7^<>RK!;@4A[OD6QV3QMIVHJB[Q_FY+R:AL&6LN>DLS'PB6V#R^(+[XC
MDH8HJ$.9/UO)T=0*V];I>&GE#-:_LL5 4-AYLS_SJ['RLCH2U$V<#^??COST
M>%K*VQHNG//UL>E'%KAOU_@ZFFBJPF[O:,&EH!.2R60]\#6W^''(@)JT^U(X
M9=$G54;)$R7+*&()RWNK@_E02["*[EA^:0S-,U[+@&+J5A'.KC&!M-C D;J4
M^-YOIZ@ :?7)\Y;M$@]8,H]4^JT995H/?5E]FGJE*5\[6;QX1NST2G"66D96
M.*^3:[BC?FC2W57OE<'ZKKT UQ&!]5--V/D(/KG&1:'@3'FIM:)W])MZ\@?Y
MCRT7ET6'-J@ZMK=MEA0:E-@O^3X@G;%75U<SO'5[?%5$_S9]Y#R4KH8VTY]_
M//@QBU0%PJ:*=+_"NH'=S:9'N.WKXK=\!8%D%&/251GA )OXBJ2+6$;,&VX"
M:KS^L+1QMC3D(2F/!!&B6%QH+IBO\6->U+#:#:.$2E_+.F\.[TY$EH&!1:S'
M%P=%O^%\UU)?K$H^EAU]SMH]XH+6MHP7&LHG4VQ5 NG*.?1( GYH +<QKULV
M;=LZ;I&M717=!M'6EQ6$G^V);<'8HBT5T<4Y,C8W1 ZV\R>&/9CN1 NW2*PM
MB[#.&G>?]YJZ=2.=F$4L]5.(8%C):T=%)O*;:H:D.CGR-3F6-S"A#@%+431-
MG/L2%V8ITU*"]%BRC4K=:I9;X (N*6*W2N:U+,@EY2\(SR98OMBP+XZFSL?,
M76W*#8D<E@F5_";"#I[O8[1&79$!4 MGF[,@U,SR0CDK?]1=9_5CJQY,+I-Z
MLZL5P,J?EM<6%&_8V]V<T=)OW4R3O<5?(G=X>;"PR+F9?S2ZPR=ZJ-P;<2Y6
MU+O@7F^;FL:4U'Q[J-[;JHQRPYC5^QWPMP$L:3R$O_GZOQKPKUF"CHZT5],Z
MO<?(F"@V6"?>)^??'L495Q D\VXL*J0NX%#ETK]WBJ"2U5+JC:W6VHIPKHSM
M2JG2X\_8X.^R"- X#!T*KV*<^'-6<L$RLX>KJN.>94P^YQG8O663'*X^H50N
MW=2O?R0A@94.B\5[(E0OQA,M>W\D]=$G,F*LEK/-62V70W^B2?[)"KK_ 8KO
M*LX.?]_RHRUM5*&9UG45TZTHK!A"F/BZYDV&RXVYL+79MS"\PPRS$B#U*9H=
M]][+$0\ )&'9]Y^7=U-A9;:1;R)5_,0?99I?JG=H=G;(6@>-JKL OZN2+(*Q
M?(<-B..K^]W8,[#M5!S-R2SX],+Q$HX(A %/1R45?ZCKE-(J[K?"JAQ4KL7T
MC5&G%I375W[5NA5D9!\NTNFN73ZKQ%[/,]Z9:W'CV$KH.F>1NJ$<HW;8&[88
M\1<SLZ]!#_B37D.OH@;STF#G+ ,"1?D>?/,$4+_80PR,/73@%:$L^LV!';\0
MD%#SLPR[GP?2_"4).?V*:, #QNMQZN:@DPI;7%BZW1QRD@T/\(5&2#Q%G.(!
M%#^2]%;D-K-2 G#.(,0O!P#]10@%YVD":('%FX) 3GOQ@(P2Q$0 5NCG<SB?
M-CQ@@@7V%G2L  K;[3ZBG46NS>,!>QD$R7<W]?N)<C_R(2!-PEK#5%#<I]ZK
MH&.N*:2*Y<_)"L -^-,881/7GX00#S>VOX+Q#^*8JG4([S'H[=][E@30WR0>
M;T$E0*P;1O_T)&F!ROO04XAP2-Q0H2?$X[#E=$1F+>P,"-1QVNT+F]=2Q$T1
M\$Y,;R_A+O!Z^&LW^Z<D!/F$?1>)(R7 1?Y4W.STB>E#8,+>_W#&Q7_7@$D5
MP')5DC/[[_Z1G/R&RE-;?I#S?37W7&]!MA/+*9+2++751R:2U[Y)L\E)^'4]
M6G\(]PV(D5;FXAV-I!$N9JX )8+H7/EFN['7,P]\=*W@F_S!RKV31=4FPKOF
MN;H1$[=S<\F_S(FPC6Q2#H\#+\%F2O4T5K;KT==1@^LW6U[+>Z#B/D6)Q)5?
M>:K:)%'5?#R\7$H0U?<UES&]*+<JL3G8Y1%,J&QT4N&4;,2M9\'HLGJ9F>N^
MCZE-WT$O8Q\3="T[EGL8;EJV'1V(E4()AAUR%K<U9^DW@"I>OX\ ;LDU3_FU
MI3W_(J&^=NH=Z\;PR8C5L5FFU9D;P_FA%I-O6(0'G'>=6IRS;:?KK(YG4?GR
MLMR!I(;<T_A$%U:K*NYUHN#Z:JW.72:&XC66SDEP<G1LHKAQ<A4/<- ]0&QV
M ^_F+'UL_$"UYQN'!YP3^!JPH:^*:79TMDZ*%;.]S,$EFVQ280?:BCT&S7S
M7EN:L:WUTIX&1RA4HTL*;6;E;#Q5>%4H.<3R+OC3U,[;:C/LD(-,:;"VCQS;
M@*0#VR ,$W ],M=5<%H-TSQ;+:HD.:=9='+SPP9<P\IWM,6<2R'QH5=.=ORU
M+Z$RYW!QZBRD@+, .T!Z?HY*0BX[<PKO>Q%;KRF4-*6VS)M?$2=X7B4 .:\_
M %L+A+'A[) 6MD?"W+1XP/ RX;B:0WNW_L:W#X%:L%HJT/Q*E08>\/SE,"Y:
M9WA#R9O]%R;_(0).%0I??3PFJ#+;:-&"T[L!!T*J3K1ZFXT#FO+*GQOI>1;P
MZ78$E^VGI03,B'_]RRLQLRFN4.ELN3!]\=+TU1IN'5?!-M=A"E%6&G+=@6Q2
MM<6X;[RYVI3&W6JC]/;H_KD(<^W=E0J[:;OI2D;A57N(R/82Z@ Q1W&M-JLK
MQD??8Y-I2"#O)NAJE4T$JZ3^4YH/$+[8$XJZ"O),W[W/ZH."E5RW8X_.+83D
MK&IZKXX<&5R^D>'B[VR!G&R,VJL6Y*3O$KZS4F1Z6RM W5$>$G-L]?P+%?7Z
M#^7Z5XHR(+(LKJZ\RA>ORMK08&61;E-NO4G=EO:) 3[*V=CPRCZ&69AJ$2>$
M>9O5--6]*%R[6% %G5M+>#Q?;U[GU*P76"]YKF(H[:9&Z24'&?;=JGH1Q&>E
MF9U![_531?86GB-#@=#.A,HGV2CDQ4E,P%)WQ*F^H+)W\?JQ<NCY0(N/#41C
M#^+55T2?TDKD2)/.G8TMATI'S ]\&W&4L) 8W2E?]-(7S&ZE8^7\2,#M>Q_:
M?M'TH5/\+7S%MW=G@+0RGCO?^5@B8/Q[6HA<IZ9Q1^=R_T%XZ>.W&&L%S^;%
M8XV[VXLOZKW&5LSRRZ^NG$+H@FZ%7FKZ6B#3?C!;OA;H4AQA&02&Z4 8^NME
MERZG9*CU+=<57\B:8EDT2QW93RD0__[S]\<*<)[-U*>)HX:P>4DV=(V'6DSJ
M#&H"Q, O.4!%X+!6;23C-Q;S$HCZIDUQZD/JE&J6QD>Z]%;SBYN$&SR7X0^^
M%1HI AO18Z'1,Y04D17WIKHMJFE?L COU3T1%O*@]9 ?&V8XN>3Q)N=PS#72
M(<'BE/-R_(M\(YFTE"W')%'-2L<0B_*B, -6J@%-)9N@4<;8Q:@;H!>K(6R&
M<NL,.W?.CN6I;4@[-SKD,H:HQ/QR)ZU]H]Y//(<()DSQMDQW8ZQS0\F(?M"-
ML[;N^P$.I>?H'^59]/F8E2D94FM_4;E*0AJPC"%9Q]W%2.7Y)UP,UB?S!:&@
MC[%LIRD,:(I(\VP3UBY*@",D;*[;EU8V:"^F3R=TK.#SB/$[*)WK' J7O=UM
ML)M_^$"[[6,FU2Y?)I0CFI]NQM-+02<^T7,O827) SZJ*LK#)N,^X/B869U"
MX8B]%@\HZMQ,,*74"[=U!M#;0^)0MF,>TH/P\"DYTD*Z\FD\8 CQ/-'8-R?<
MIKE'K?-KL?66;B)\C/?&&IC3^L:H7=6 GG+QR_S'S %.JC)V2B:8P&9:6U^1
MA"&5U.>5ZNE*CHD-:/J%!4[RQO>V$Z(#-?*@AE0T@A8MM,'W9>4K5<"9%W@
M# _(AP!GN\>D&DI+@XYEVREL+L)I1Z/H0_6/Z;D8A>IZ3@RF/HSA ::@*6A7
MK!$CYA-.8#L)RR\;XIGWP@8/L,,#@JTQX(,(-%5\;X+.^8<RFQ?@KDO4KS9,
M'&0EZUI',T(+ \+D(4HS26-B3]!*#:^>7[_=85^&Q /TJDWNZ?MI:XIHSX,1
M"L6B[;%QY9N]#>H-LK&??A"B_. ?@)"4UC?I(#3&?=##&FA_BFJT4M,1Y?E4
M'BNDE4F]DRIJ3<^+9%TLO-^_X!<1&E4A*ON(H?:V9C?%Q8TO=@W*8JL.3MI1
MJ<\9VQ$*G0@N.Z?)F)4Z"XME@HB^_35H\Z^.TJ(X&)O$5'&P+3"&@:IO'#ZB
M"K:Y(63S=+:AK?V3UP_'Y^*?3C/O7)P+_<"Q57Q37<1HL$T(1&O\SG$_6^/L
M1E3N\#MFD]XMZ<D?&0G_D88N.25%V2*;SQLRTR-9*O:^@NPE4OR-MB>?VT%N
M1\C;,I,!N'A*7(T!6&L&%/M<Z15JJ5.;925??TPVDCY,45X1JFKWK^$$\BP\
M,?3N!R,I,N@O;Z<WC^ZWWM7E=B:NM7QB%/ED+\SWLL>9!ZTM&(6=G3G5BJC%
M53<NFY?/=Y3XHEV,!\+=[E50^"<RQC5.7ZF2S^L:3]Q5C57K>JB^9!'ZK.SL
M"C0YB0@/,$DB]13?3DQP]DH;MYBZ6U$:HE]9N?R^1O_K)76>^@M$PBTTPDL]
M &]O3VX"NHY&<9^0C<&6YQ'P'ZX>;X8=<6X4YQ4AK!=$R;6=\*0?&;I/<:!(
MSZ-9EB'NL::-JX_O8IJ)-)\1'71%'E]'WT<!?6HXS*'/T?31=.-LO+6O4JT;
M:SR:3F49;CM</O\HF2(49HP'C(FI;F_Y$9#5V;5#%9<OJ]<N<)@DM%J*A%YX
MG31C[#,^\E'6_:0+R5"E^\7 ]593;$V(Z;TU>634@(%L)'/*QRS[E4,']OW<
M>M',@VG?O80GMP/;Y>!\N./SN"*BS-^:F/N+E5)^[WGTO[3G$30!#]@&<Q^E
M P]O$,BYZ.F5OW!- ;Q=>O^!%>/^T8.8L\<D),'"0S^TL&3]C->J2-KN"],F
MLMM]0_.34T,TTI0:+/]_O53/,%O-M/?K0226]&QHYN5^)\Y[H_ MKB#K^]&T
M01'%CTPDOU_ST-YW.]PXNYV&M<-PSE$0P;^<AA]OO!MC7@GLN%+ D$O5TM)"
M0W-;V_GV)Z89^$9FMIV:@X(^/1T>0*%Z&H-<3NXDT#A.*3P@2.WG4^ 6Y/9<
M-0P7,$10[6_E03^21G_ZV>S1_C!60NK A"!&[X1P%XHI< ]D_W("2F#"]2'[
M>, QNYXM[B(305 '=[@W#$]NN$X?R*(%TNB9M :QW)XG5E72F4U/KH>UR[3!
M!MO.*S>)O_DH1W)M/D)^GU6Z:&S9>Q1+>5KB38[KF>*,JY<\BS:V%)W01K@/
M?3,OU9ZNT-8R(>=0R"0>?NW8K4SND>#M!*M] 'L1"L! CJ?GP&]QS!.N76.[
M2G%/1:W&GNNV&_$56=]5/M=G-,!RR_U*[1N&MS#I-?<PU6]KPUNP]""C^^PU
M"2"$OL__TMJ+O-KCMX 6@-9AYT>F]+6M=\M*C!D+Z1T<P0*!OK$[#^49:-,A
M7O*.?&VYDN8_LFJI?^+<YYJ&L#*%<<Z:,PD#3*I@3=.W-YST_3>2RU1X)1\T
M.@XA2*\NQO%EZR7068@Q9F"RT=> %Y=W&T)2O,I)D J8KBEKT]E0/_'LS(_-
M['.ACMJ>7G/!LK/WJKX_W2B;88LG/<0#WH$N6^])W!W;G)V4[E'U-NKT3+#H
M[V ;]60Y@NB:?NXV5<)MBAT%;B-G.NC)$K@6.-F-4[W8!Y1%B=XH=%>.:%CV
M9"KSS[5?WWLJ>"/J<FRZM"YAY7ITOYR;R6YTT]&.772M0?M&CDM'<JA[E_,=
M)8B#W% "6V1"=B-22O:N -<$$40+S=>HLLB9QAUI4Y:+8\?X71N2LTXC<:&A
M:G2UE2]#"WY%\)@SKLHCNG>KIM>4GO$H[T2MGXI]< !EWX]9).T-:26<'0HL
M=6F'S>:C,/D9VGT/?9V\YU?KW@#VLO@31"78&I\%/SP;6PK5BGQ9M+-Z]2WD
M4-O3Q#E.J].>-SY]TPE"6#^XR/.7JX/)ZXW9!!]D$#=3,GL%!AE,?IP$*@NI
MVQA]%QB6J;RJ^8HZ*]]:?8@GAX1*PDE&/.O K/_ GG!_9$VPB7RYWJ3F*RTO
M_<#&?JPIUOKE1&I )WSUN-,&-28KT*:4UE8H3+;SKM&(973932"KK&WYB[2H
M3@=G$5IIK>^;R)F :MM,&N,):<U8$-OCFDB;:P&5=Y3D1R^E!+ ID/+(6A38
MFNV4M<P)?'4J&WO0+%#$TI92P9-@UO_*Y,D-:_Z7/BK6&3%,M3/:C=45XU]4
MV0R3G0!@*[M>;:NY*.8UHX]U7Y.UJ#-[I5]9IP@?_BB;\/0_DV)[)I=*A"H,
MX2HEAV;BX+;J,[^ BBW.MGA)Q6SB_TDS,@T>>F$(^=(+I%GA=L?$1V>>+0QB
M.$<Q"M^M76%>"&[H6&DY"T1!7VP93?2_"*$9R.MERG'_8# < ^:L']!CYVO.
MCT!9Y#.:3F#.-#?BA+?W0J^4E5VHN@PZ'L#85!G-!4O?2?1X^Z$&=#QX@,N>
MD0!JG@S=F#F1(59,=152Z!DXTM8^J?8LB-V-TE#'PE,7Q-/#M9 <.34:"YPW
M#\QKT)0Y-O!,NJ-F#+@0PWW@V(L%662[7:BP!2,@5QN!QV61H$GJ] DOR_[4
M:-64+<O"X?H%83V*N*AUU(?:)'*WUP3,*AO:5!Y*Y=WI+NL7J_*M^4#U^YRI
MQ<&E)#VM5Q#?BI<^J0+FTG01M4:K7+J/@&<P[:A3/*"NVLB&<R%,F^;1A,<N
M9&N[^< _9+/KEF4!O291V7 V5A9CFXE]V/>BM,Q?RE@L^AV4WS7NP+VRCU8J
MP]]7U,H8<N[K_C;5[:_'C4G<XESW.7*6?(8HONR_BIZC8]0LU56:,)/KXM.S
MA^I.Q$N)MB9^%M@^EW@-71+*1\2\FI(H:9(??'^.Q+^*@LVM3Z&)KR4B,4EO
M3 3)%?FLM_?28;3"WICDQH.PL0B2OBJR[["BK\.T3 /I(0(2R@#XKBJF]XM^
MT5WVEA;C7<^Z:E=C%LU0WK#-_F943GTB;\\>+7LP+! "Q'7SY<][-)\\3DC%
M:O<(4#X_#-L$;I .CZM7EX<AAUA*;5XX[X&Y+=%B#RNK+)TJ@VKLSJ,,];CC
M:$4=\GC9Y=KX,(:=1L(#&+H6KCO7932'15PH(AX8V!MJ/&D?*W06 SUP83G*
MO20MZ3IIXV*TZJ#0;7P^(&QC/C1GP'E^M51"LW_D%^'#EZ^!Y664,NV\FU*1
M:41_/]*0E<CQ*937@3U9K?AAGN$-T%14?OU0M15O$07[M2VQBP3%H=OR)Y(D
MQ"9-F?):9$/M50=;I-F:XLF"0 *$6<LBZ&!%K/:'PJ?]<X5_8=IIV'0&N)]1
MUG2240D"$-B]P* /CO>\N_2/V$#=/Z_N]\]9)FC>M*&;O',&#_"#,/::*H6^
MA/%+A9!NB>EX4-72-]4<G28AS1&DKL.UHB^C"O)&EZ?N%I3(<>5O+5[)2S\_
M_8#&C[SLTL?+,BHV*MPG4.].,.S*6TQ]W5#3'+343];-F/ZL84/J@O-^F"PU
MC@%P^S5%;>F-G3$5INL-VYVWJ%SGU?/2G,_1^[Z6 !O6E%:=YG#9S)0%>,B+
M0Q>9T&4O7@@]\[TDS'A[L68'$WGRQ!6(@@?:.SO#1Z'3.4)A&:-/"Y78WWQ,
MXWIUMKECA.K(_.&Y>**(A[2Q"?N'054J+AYWW<:B<EUW>64D][Z5,U'D"GA7
MN,*4<(T]3I.@.S6MUG0ULE(%9PBH'M-_H' :+< (UW&=:QRR-C8WFWJ5D#'Q
MY5H[PTFA:%)%CINJ&]/9GDNGI;\YIO[WFD#_EVH">;O@ ;4&R,5/L G"9ENM
M[3U&BN$!,W#HK@)HDQ,/*'$B.IK^;ZJJ\#\]2/;$_IA_Q,N];[Y'>?P;"&&A
MN.*L(7=M#7! H-,!1\XMUS]C&5<Y'GWQ]H.L=C[Z[Z1*:?"F")N6_I0:3SS@
MPVMO H?>T]H#GJRJX.Z&8EQ)UK<(\@1]A ?4I.$!LZQ^QY?+M@*G23TET*6H
MKM*9[NNCS)L1.?I%W.6/S)* 3%DJDTY6O(D-X"@""?L.,H4=LQU3G.X3CMI5
M"/!$&E:K7T/I"JP3#2ZMMWZL<AM3H3/%+A/0IV-EG;;,%"5/19;5]3!(<-V8
M/3XH9[0V VZNC&W--)Z'8IBG&SJA,Z$;/MF>'.55YGO6KRRK[RTR@RI.7F:%
MI<;(/O<L5;%GZ'X$+2[&$([ N<+M\X5HJ8.V/G&ENYV.EJB]BB$!L:%SH;QR
M4_R7IJ?,F;K$?&REH)610P.1M)!^77T"813#YCEZU(QE%F)L3[UO$(!J@<"O
ML>S\BW1XR]NPF%L_.")@'YI&1WJ6@1O25UF/?$R%VJ^+AB\$FHJ(N454NL>^
M/!.P&\KT[X$U?QCSADWA7[&.LSKB]U&MB(6/7%,/$MUI8^2E123">,/?&Z1_
M$^\^\,$DUM#U:7>US;T<G2QC?S9;\WP[]*T T&\LLG-6EJFK>_?V];%,M$FJ
M"UJLF8(9OO+\W"6*;$06CMI5&42&>35\U6_Q9;O[<)-F1/.P-9;EB$.07G?Q
M05OF]JP]E,+[PO@R@JYQ(TO_O4@[M\#Z!U*>:A9SLC]RKL$4[P\^=6JU]:.]
MV@28KIWY[!?CB82&P\Q+%MT^$]-GA!\?<PH.R2\XJZ:*#X=@^ILH\B<N6"OR
MFD;J;3M:C46!%;9TJ\/V8NXIZ@OGMQ6]G8S&ZJ*OF43.%7W^M+(3NWBGIQAZ
ME>?9-\&M?"=)TNW;AQ&RSO8T5Y>8!-P[X0FVSY-EWLCM4:'+#')O)B#SC-/F
M;GZ3/*1)F'%UX^ R)&;-'UW0 ]63)3WP'B:CW"H#IRV+DM=\L%%GTNHV(!WD
MO:Z$*/[^ O.T4H\=LN6XBVV7;%K,C:K*J^3TN<__20TRNEO[BXJ"BC//Q-+'
MX 6MU/3CH<B,XH&V1H?($:DKOCS)STA#N@:MGY.>)]>!?V[^=&#6ISG\PYXH
M^V_.)F8 )QDPYCM-YSTRN^38B=Z]G=SJX7QKA;AL=D;:8BKAR7B@'[^N]O*5
M#R2)G\:MN9B#;JA55/.I]_?-GJ_#CL"O+4[FF[!,.AHBR&B53Y+8 [-9Q?(O
MA#VQ+'+**=7S='PQMYCKI$'@/#%+3<I<RXMPCBF:"\U4QBH%O'(TT0OY)?Y,
M"[[F6H^WB1TX^#41/:NN47,V*4R6P$G*519X?]!/Y/$?-#CE"JTWCC4U57G%
MVH6Y\8"AE*0L^/V&)&)/L5GJ>?/\YV[4P!FJ2?4AC4S2@'[P@VR9!"WSIJ66
M*='3&.=SNY?#3%".S5&137JXSAH.LY<NQ?$;-"<9-5N[(0_&/@I2(HR'JOP7
MJ-W:XS1=M7@Y..4=+4)?IV"89[/OG]".=T=MO%.;]+R#EO5='-M6#IHB($+]
M6TYQG1>$CF=CG--UIWG,4R_)9N7!"LS'Y<7BIU=/;YG?=]P=5M_N*IZ)00UP
M73,;4TG0><N>#AU3;(PJ:+PDY$)O8$%I%&IQ(M:02-PO+F51H'BF3.W-1_:H
M?DF2Y:&>ED(]F8Z&L.]YH&]K?9%9RBU+N*:&W@@=]ZBG.Q1$N'Z-0MG38M>'
M6XL2'KZ!Z-QZ]PZVYQ7^G]&'/FXW&RA& ^;4P^6+,(-7XE]3DZ*WKGGRH('U
MR]I0+O48W&58)%"G:68O^Q8<M9]7?S9=9U?:67++!S7(&>[:5F7#^T#W<.R9
M-$=@<U^-&>8^>E/BS(VBH7LBVM_!) &'DWRS)?YPF4KN.P0X-O6,?2C=_TN
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MR^,6BO]%^=S9A4I0K 4>< V21WB/,H_^WK-T)?VM9+-:X#@%3AS+B3OMW@E
M>M3<P@-:Q;>;3]]N(/?4A_MGD&^ 28O>2_6@';9T F>$K3Q=7DX)V)1,_K7[
M_!>I9] 4JB/")V(KGTTFC+)?Y6<\P/(9Q8EC>DF>TKBVMYO>6*L+BUR3?.Y8
M] >XT\C@I+?&5/72@1M&<"QM3G4P_[,^W/ZCC!=;Y@:-=<8RO&1(X;5-<SN4
M\[1<.>/Y5WZML<D]2>[3%^E@ 5UKXHZAK2^[&Y1J4$VOK'\"7O/3H?C1_+\$
MHL\>T_V1'OV68GQ4.T@L9663-]_VS?74_%7<^0%G3D:=$%PG4TV?X5R9[W66
M2UK]BZK*/7+K<EM0337=@7?Q5@G%T'?(N0*[:/;JT*5;.-K2 \*92DE%GR40
MI4,85@NX/8@L IU2 ?V &*%*/& V]U@DI8@!9X]$Y<+,8,=LH"N@;5L7/*"1
M0-?)]4^D"*1=#?.&P*H\D#@V9&HLR]FC)CS -__T"X%696$?$B["ZFD\@$H6
M*V"[04%@W+*S)#CR30+]S<&%F"53M%)@F,'-%$'0JR!S<MFGZ ^!51JS*A3P
M-_;\7]? C@92E&]U'@OO7B2=" OKNH@8.F;)9^9Z264=O3J]^L2X;;P&#YC_
MD:438_0KE,&_0FY8:]K5)IW^-3Z]"IW\!$??QGOK\*<)D5V*>G$;-^'?YTVR
M>LM*[T=(NP5/3NS<JOS!"/S_I)D4_26[33F:@]^)9.9$2; '8C+G+$&DRX[2
M3,M,8<*WRO-6E30"/P6M:@:SB+2N>^:>/'(-5[GA6COK*W5OZ.)KQ_Z O>G7
MDL1OFQ4]5E!GYHTOM7>ZFKYS&D^Z[KJCF)#/Q&W7+"$C!!YUETR,A210FE4Z
MI J@RYS6!B/=@*"/1KA2_T3!E-%HNE)::TIPGG< X8'._/1^S7%/++!-JZ_1
MI00^W543:8HW6%P/2Q=US&6^P%YBD"DX\JF2GMA>*(F*'R/% !+J*^O4;]ZU
MH']6.J69^'VX<[8L\.P'R/Q1T@LO")E/(8=!-<:!:WT0'=I EDOW6"=O\<XC
M!FN+6:[B7.05%4K'0LDEFFZ)-=FZ,?*N\AQ&I>M&H=I4*V,N;^X4E(%=!S9$
MZ-AG65&.MX\JX$H:ML9[>F4=N;ZIM*07!Q6=JUNQ%,GP8!/@,_6U%4,ZTB^,
M6G3$5,<9MR@N<5+W^K9@]:G\$WFK<@=^E#=BSYK_CV=,E^L(+G).?@[0F7'.
M#5L1N@;74I:,K$Q?7J/-;>'3)Z--)O O*LDE9W%NWJJ0RQZZUB'_C[WW#&BR
MV]*&@X@%*5(B'52D=P$1!*(B74!JZ$AOTJ1(CXB A!+I2HOT3J1W(EVD]RY-
M>DNH 4+XXCES9IYRYK29^>:\[WM^[/RXL^]DU[76M?=:UV*D>+8-G)G6[7 F
M [-_+L:*\I1P?3GIGQMMU6I1 I%E>\#-QL+EID<;D](^6,W<=EMKL[6M!)F'
M6_B.>!<+&JGF>[I%OYPN8H>3?)C.V,U2ILU8O;RDPUG0O[[TF#N(EKI<_=&_
M[8]8P,MIXM47^Q\R@_1BK=?T)!P*5"265(77C P5ESX!U^8Y\XPUY%.@^8LV
M;1'!,\_GY;CU.1%&=\KEHZ?^0.3T[J<F@"[,.%X/IBL6,!YJ[!"ZY<R0N&W_
M0+?DU%"O70$8I[#'2OQY.;1)72V1)EA'1T,\&YSJ]=/;X[=VY?]T(7#5F\P$
MU4T7]-AH6ABA/TO'4<$D]45RQ*ZR1QJ-*S/(K=^KN@S=@]_ ,@U**OHF4$[)
M;0IC1=?$!,M?LL0>Y&V^R/Q8*D?D>3=CBX45+,4HRWT?ZE$8(Q^("3ST'<(U
M(TW+31XT#A<:<1SZG,[:59PXZI_$+W0<W>0\#C+K+I5K%12-,VRDGIF4M%FB
M)1Y<>585M>"MMGF65?AE6I]=>,9^4%)J3HJG><X/>E%S]IH1@9F=L@*VLWE1
M1#/M2GDZ3#78)*CY='BNV,'6!?=#NI]\L!C9G:EY2XU?L/SDY+Y\/!=C'%L/
M!VOB\.U=*TGWW'O)UHQ@-=%\E2XRVP)KYIXZKV(Z4X,8VY22-C;J1/'$P&<E
M(5HE\:/NI(R!%RD2)Y/DHS+9/(%F3!QFV!;1O@.O+KF(+'TX?^TT>@H^<0YH
MJ>K>8LJTTEG9)D8+A+)</H 0K5OM]DXJ% G%<6>2\6SE\HY2)3\?R+7UJ&V]
MQ)#;&A9)0)>;"E;-?""\5'+LR !DT("&;<-@TC18_^%RNO@6S=JHFQ&5K[<F
M&_-1)I$B.PQZ(:4?+=T-*X<248A(R(7N)(1;ES,UOVHW.-$7B!YNO(JV\'8?
M*E=F];)^I;28\:[H37[NV*A47VK+0@F=NV5(JSW-\&E(%IM,SFQ3OEZ;"&7F
MIV)%F<3$1KB?^J'MK!9>! G^+6;_[?KE:>AR-NW[,35GX:O%CIL.'\;@4 /A
M@>:& 5)J=6.O[[^4TJQ^0T;PUY#1Q$6&[<1-+"&N?$R'!O.5;HVZ/+;BP.J7
MAMSEN5=_!<$T('#$1>< CI9%Q,G1$&0_F!BM-I&!4^X(!&U@(*ND#UD&:=[@
MU9S.$&@#>@[@GBPT^27@^?N]RY)9*F>Q"5MJN/HMR+YN$6+"_C 6U=?$0F(O
MX5%G7F#4Y^5915$))U%->TS4-'M[+VI-%_G+-Q"7/I$CSP'S<RSDH%72!2<L
M4=4Y8!%O+F\QH&64, WHNQ *F]&C^%$- YDKD<<4=Z9?OW$N;&&)\ JB)MB'
M;):=*GC:S_D'%.MN5$I43%>-*8HXY,A0Y3[[<*OJ:_W*D.@V"PI%'@+?OX06
MPUV8.@>@3S 7H("SBQ5GC=(LWXUD+MC@V,AYWA(5.:"C7?IV-M:4L&X#H!^B
MIN< $PJ\W?$8:;;Z=]M@_Z+Z^W^(ZB\<Z>1 -M1J0B5]3<_X'-!1![&/%AYC
M,5MH[$&\/@?,Y24>= 2[P]Y*!!6\2&4M #IA+Q1+6G*-MFAEJ4RJB, _KBQ3
MVYD)QMD,>,2F#_HER78&Y82XZ27>'[UFX/GQ$$$88$*(51ZS0,N'%BN)VXQ,
MT4D?;-4F=-CW46.8=5DL7DKZW+&DY3L9ZU7FQ U^G(IH/3@96ZGGB]/^TEMA
M^/CH$,0WUQW?:"1Q@%8^2N+/MCA<9K[:F5L@HVE3>H$\J2:?.*M@OUH)70<R
MSN'@G F5I=9._'OEP#]S8>G?-%D?6N7:_XH<R>G7_)MW,R$:L0C><D*'/,)C
M]'=&GM9JF(!"?<^78VV5M8;Z3S0XRT^%NRA+170G)TC\K8AJ-DQ*XS LIP\A
MWU0KU$Y97B#W?45/Y]6#CCZ+6!Q!EBA&AVBT^9!S7WEV=^8@6&K-A3$8TE%!
MFMZN*)WERO3&T8G)1-IGKCLN3]C'=52FJORW7JH^ZES,!JGSH%P/]<X!L9]L
M(8?WUY&GKJKQU=^>^3S X;?^7;NUX#RVVG, NS]Z0!8H\_<<3_T?<"M4K-P&
M9G.\1[R>Y5!24DQE6'TJ.\0BHZOC$=IC-'E/>#4=.B_9_Z?*6=I\@] LA/UU
M3U?EZ)/YRO9Z]\/,2:5-E=R"LFL=LQ0BYP#"M6Q%*TT>PEVR"G05K-XE#ZN%
MOA@U(<\J6^=DS#W;MD-OA#D'M%\:;2TS<.OU4T3881Z@=,8>#3P?%B"S3%II
MGSQ6.K"S C)QVE[T== ;[14B)U=6X/LV>PEW TZVYMSC1M-KBDRMWS,N5P-X
MN\AWT;]]5 $.@"I]3[D_9%@"DF\VM9U;X]8Z_',>>'>BB^I5>$.NU"<:V'44
M>,BJF&O %$MLI_<7ZC5;]9?&0D4?Q]>E>#_7.6HUH2U:YN,+Y51CS\&8SVMT
M.['1R4E:@)<GLKF]VD4M,;8^81ZPT5)?)LD0@7CK,-@.2_/'I&RL4$WC&W&V
MYT&UV\4M\AAKTK<W'V0D;GD4VI>  1K@05-/'\)@.\,JO[[H=A=5RW!526S)
M)C31/^Y2"JW6H^I70.<2D5CP0///'(&%L-CD)0U5UU=X,.#'_8YD^,VD0UTE
M4V/%*Y5!B]KW-VB5UFG48)V[?4_-LVPRNMTU6VJA.S+!AY+JB=^'):5]OYBM
M<"3J8L4_A)KO:2Q9G!(G5(23#!BLM*29\Z7:DRV V*UD)F-4'*TE7N:@20I.
M^&H2MU3O]SP[G293<9<@3?VJWG<I67O"S;Q/V!1LMY B"QSTP>,"C5\OH9BI
M!H/*H:P/^POY0B\]%#XJRAK%R>E]%B]R ,G=Y?18*)I<M?E@YE6D]0P*V#+.
M(F&ORO6J*-'7O^@\Q<LM*)Z7F][P)'J V=SA9Q:J_SC+SMQHRDI_+>0>06M8
M( $@==G[<KA+[1(.SAQE+TL+"[)60ZX9CG#-:KW4R>HI5+T'35SH-3!I%.2F
M7QR?&_^?\-+[:^7Q:/[F52!W>Z[@)2Z;+ NPL#>15F,Y%?O#Y:+^V;M12HJ*
M>F\M%K8CU8<+XG82AP<=U&8EM7JR"E3J1+TYG_ $&(K8W._=?9 _IA&1KJ@H
M"UQE]ORY9C4&_RAB*6;UL_'S5O^::9%QK&.64?KZ+,81LQY/X56 =!6!M)B8
M:S.]>E*%)DN02EZOCG*)%H;.M\V;0T-X9M.6%S\_:Q]:\BF")31>P#I(6!X=
MWDLWDH$USESB6>]2_E#!8UE=Z<*K@GW<R('I0C7OS./*$PY91.C8/I#0;_A3
MX09F)R2\=>VXNRCA#8EHE&='<$S+@O<+3UU&W\^NGH8&%976(\-Q+;9(QGH.
M'SO880)YI"?+(K@(Q^]IMFM*#>8UJK4@1R/\P)F'T=(I9C;*MAD%Z4E.(J^<
M0\V>?Y63E:Z4N)@.]6[7_]"N<5!H0N$YI(3*JNO)55*GMMAJ*I9;.7R'LIL2
MEG6_Y>NR"T,7<NC'B=DJLB9Z0D5F<D0^KAD;>&LJW*XG<YKT43&()G#BD7(U
MAL^1OTN$1/*F&EC?*998*,N!9N@8?H[/UG(IY^F*IJR3^,8UI2*T'$E)*/'&
M;Z-PZP8TYMOQ(Y),9N\AXJB'K?@U>/U/<B-<C O8:T?H,, \,ECD.EFZL JW
M6V@3>+GB"#SMH<Y-A^Z1/_V_Z5+EOUJD?T=M!_ZS+E2_/[)&@P[Q/8I-5,-M
M_V35L#6I_%V,3#'CJ],L$U37KG4>WGA&XD>H@^6,BVF$6MVD-^?@SX>'_L;+
M90E9EH/-(F\Z!_S,Q#$Z<AIE$GP.^-VS_AJ3TR!RE/PY0%%^5]KK',!J"#[S
MA>-B\8(*\13]:UCQ^]"7L;4M?U-(DPOHAR9&&6_TU\)P856?R%E_;8P7]OW&
M6,?4./8M)R);$PKP0QGU_J_U92]G*^0<P.Q_XQS@OW(L:](P2XH'GZF>YK@F
MC]D3+GN4_%\.F-G'",S)KQS#:U!]6&@>9&KV1%-"@C.]#I;[-\_X;W+LC:T&
M_29&9I5PKH$&?"II1>,4APS.GY'S'?5/:;/F 3Z7-4I$6[\5D -VK^WV)4JI
MRBO'^PX8Q%F8L[HM%\JR1%$](,]ZG&3>PFS+GOS-KTZGMH&B(FG@Q9/I&+QR
M#T[[)PB)^5\/K<$"SG)%NP3PJZA)7E*E<%W3#ZXZ5&_K\,I5\/'4[4C=E"GB
MJ_>?J0)Z_/&RHV489.5TPBD,F0O#H\Y%X-ZKK9_!]TGHV78(S)@7W1>$-9V?
M\A,VKJ:!6XUTHU4N!CUT.YM6+:RANWQS+]PEYL<LZL<Y(&QV7\*3 W<.^ [9
ME3(/7@ZF3^$2"/*_IXB3BXNU-'9G'<-.G:G5(N?76<K$SJCID"C97 @:BDW$
M7$.'-?M?/:OCE6:UETC2]Y06H+2C#UR_, F^?=7W+&(I/V'%&UW%*@D]0F)>
M0MIV3I@D\8 =L@,Z9H;]]D$%=*F OLOS') (24MN6'^9>0A!0;I/"W#,::?"
MD(%'/^GQ]/&;@S;C=T\009!Y/,RF0:ZZH=3.S@'U^#WC#?K]H^?^\;Z49Q72
M9+@!:>YJU.QK7]W)W@HGNS&$/7N*^PO?.$N=YX.MG^9J461>:Z,-S4@IT',X
MAOT<$(&TA$6(&=]#@T/=2%6'UX1U91PRZK>7%9F%:\*C/A%?8/XH?AOY>$.1
M,XO9>/)L9[^$XJ4C^-CO9P!<][^SQQ6#%\3:U"[[WNY'5OK:+C@(M-#;FH5*
MY[B]#]6]X"%WM:N2X($6I<M@>;WI0A'H2R/5J*]\@?(/6V^5Y+$Q#8@'9W\=
M2S$!H@5YU5-F00T+-#E,'A7EV5)8G63ZM,=>'2/\*%V7YC:#9PQ/H]P*+,'U
MLFND'57LN@^WSS8VX0"RX>/[.7M=S2$A"8>4.:#!"ZPWT;B>Q,//B995;3RT
MQ7K04($7 GS/O]Y?MC75_7+$!ST1D!]U.P=0V'I,QL?Y.>2MC2G<>;/;:QE/
M]VS?POV.X-$EI(2D)7X6E#!^H" K6'.J))HO(10HS-1>=NB3).8L(>+2QI#+
M$1[B4-/+0"L-Q%<]PLPO@B9X#E-K,-<61Z-):;2&D:4_/L<[#(S;\<'8;=14
MHI>T%@D",R#D#S35\T"6$*^ME3-_CP,AN,BM+?\^$X&-DTW_;G59(%$0-3C$
M?XBE4JP%,F']R <.7.]R+5:DLP>1C0M&'_Y8A"6 ZM0.9PF'. (IH]_4<>,-
M6GEM=-7A.XS7J?BJ!SVR58VB8W[JVBFL=$J\,G5IZ3V7V87'D>. E^-?OG;^
ML*X?=%<V<E4J'2ZTW-M$W%)^QS8)]G5,BYU[+?>(D2+Q)YJT4YN4:9^M$( A
MYX71^E+9J5-;Y7X2UV<MR@)TJ1@MSHZ6E)$Z=YPOC;#T=S0[';/YX\7Y9[X$
MW#NET63#/*7,\E?Z7@]V5G+6BI?=[V3H"$;F]^W@]2EHP[S@3ZZ*__2@4^Z!
M5B*@('?ZBL.4E(LQ1/@C^TM(O;UK:V*2(D=\#H-G(?%\ ;^UA5=%3O=/4L)"
MLN=_?,_PK8['O)9%_T7ZB'U]5;CH9L>1"VFK-7 7W"$0<:1_UG%HG-16P_$R
M,&;-J&\+B/8Y%5!UD&B793<OJ3Q \&.H4#U8\P7R+;Y'^KHTT45#,29BD:V]
M%;)!G\[48KI+W(6 .N0D1].K(&OD6ZKU!$2AG9>-;D0^&*Y_8OYLPMH)F,GZ
M0IV$0)_>(\9Z_I2HJOR=#"T3D9FQDD6U;_*>450:(Q.1ZH.R];OA),[OEPP.
M\&"&Y\/)PU^34 L0%W9\_D2X9*P[1SS7R.I9;7N8?46!#3,W(L#HN:#L?'BX
M"3RQ %-EKQWA[@S?IGDP<[57 =&W%[Z74D]&*L:1U3=4RLQT:"<>*95U9<-Q
M:><2QMB$PN0L_>53UMPV']6DG+8L?5X*$LY\8_K^A?[-^@IC73)[G8;I!.Y@
MHT?B G[;?<D+).M>Q;?:!8Y<)O#8PD3.]]//MKDOU$I1*07[O!P,KWBNG_/1
ME?XD<:O0 ==WA;#!ELC#PS0O3VDSFL&MRO#FESR;]$HIAY^&K!E%%+1U6(2E
M7$'O/GL59UK!MK6$2VYAKSX+:7?,&P.>_>)$VK="0<:Q)UR<N9LJ$NHYG_%_
MUO-'&YC;P =<_5P(FIF<\CY)64>F\P<9YTK_F'+.FE ',Z.C]('@X/S>U8FV
M5[R,DZHK5&U-]R(U[;WIQ?>+6TZE22 %0/+#IP9EE4E-:C4\=,SMQ@E9QU-&
M)SK['FM7FJ%NZKP\%7)$T@W<6N:*!GDK(T7<L)_R=56\^3\AH2-),5=6?D<;
M\)6NF%UV@E4@RULK;%FN:UW(4+4FFT%/C/,K>PV/?/[]DNNG"IWI";;;0HJ&
M.5?^MQP9RF/_S&D<=TJ.2.RS2V)0289L3&W/I\;P:NFX.6G)LWC_X;9]:QL:
M1+>PR5/-M^&7A-M<QIK56R$4C/?#24DTSC;5@I/F3$+W:Q*I:WMG#]4PHU8E
M<[-4&/FC9;/-#/%)2'LCRN>:(FU9<V%'7N&9>;.^3H45JL<FO%LHU?Y;O-HU
MG^@R2<4?(IMGR8G6/2#B<X#MO4&'N8I1S6[+YDHRGM4^4LS14[1^@4%M6]U[
MNC)C@L6^"5-*141A=K10=!,-R[RQ%.]W 93*\CA'M4*&-/S,;B68!QAPQ-.^
MNI03T6XY&LPN%GID$BJI;3IO0%-;'66A1??E!3C8,^$PNR1R,ROV#L%[?SM4
MD4$',R>Z_KTN0^A'W?G//(-8PE.!>PUVCCOL<0:!@3!4?OP#BK $?J >4+(+
M& EG)[LGGXJ96I N0S,\L]?=O?E^JWE%<F1+X- 639;E1-+IIG./=8D;WWTH
M"KZYDX5QQ#T(-=][<]VYO<&*P<!'M]6YG55VE4A"S[! 3%)S.%^<MZ!*DW:[
M+Q(K>RJ\3D\>8MT8_Q*GX0@2. <8ETD38!\Z7<7$CJNT,I&II2'*L(^L1(O(
MUMN.]30=?)71#^93T^;AU *'%G?]427\&5GF8<UG2LY%CVPB?3VNG4ID\LS'
MA[FNDU/X>@Z()&D\=GR9['NVL:Q&ZPM!BQXB'ZQ%2G]C6#*D"C@>]H8T&T%:
MKV=,3QN2)#\/P &W?LZ*M0$3^\C2</],><A-Q<GDG/ .4>!VVK=LTX^*<M+K
MDE,MD/+**FMZ_O2Z=QM-P'7<];.<<@=]FR+VUZ%)A![G %R%P1C(*H55-ZK^
M'39BYMY8+X1:FL(0*S9L&3^J>*&]-50Z=HG7XZJKX@R9:W?I01]'#]5V$D_N
M 8]V];LE6@NMBCUX,PBFR QW,/=4?T>@+*9_5$3>>J_Q)LRO'HJU7D+X![.G
MWN9J6_>3HZ%1!EZ<.Q"QR<HL+BO_:>[J-X^,'=4437:,TC2XFHD&C(1X?,2#
M 7"D=],O>$((_OVBC_9/P5NUGY'M#_L4LC*S$ 6_BD,!$2+G\F=W?:4E\-#-
M[Z<CVW,$]5DBZ$>]IS .&8)[/;(%^6MDCP#<^_I?<3>:801PL@["N&K$;E'^
M/Y;IIQC2GBJ-.FIIX#E5;O5NJ(RQ3>91G16&/U&/-]_\E(A.ZILJF(\KWV)T
M*#3*/0?$?YX Y.!.GD/P2IP>>MR'8^B81V!18R 4*0BSQ(+Z#B*%K 37G ->
MV^(A,R?AZC>>%1\G_$^TC;0^NT._?,QX>[E'*-H9M)3E1_$O#HQ_<6#\BP/C
MOQ>H_\4IE<<1ARZ$P4C\VZ0?W!L4T5@GM<Z)UW@TP=9MVK$0$'#(7A^&NX*8
MP^PC)W;:4F\+?:H9P3[L]WI-VLYY$V;#,9$9 X-X[X#FBG4&#?W;)88R[A9*
M5+R-)KI,TN@XS?+B,^@9#RONRM+MJLVPN\%$":VOTEY+PF::O3*N%K16_4#N
MP_;,6NNX*8RFL&PXA=-$)!YXS2$DQ%$T6P'S?< U&]X=@7)[J8?3<N-6-6]L
M6<E<OMXR?V=]%F52 <1,G .(2J,,%L<"S$E(PN;K8R^_)^T>OW_4A"VXJCA4
M)*<^HWP.<+"6O9^G64!3!L--P\:-R-7IV\-R9A$SM561>%1TX=GL*$*')D ]
M P4*B1HNX$]Q)/[<=/F;,8]'G;VL7&$&4XPUD$Y<(\QG@LB7R0^/"A&HHU;8
MI'([A,K_SD:(SL"!D?9.(58T>SN4B4R0GWV^[F54 .YXS<1S0/=.[(AJGNC1
M%#9BRI&,B07+L@?""^ZY4F/@0#WY8E^0/DW(?IT*C5P)"CM@H#O>7")+&1;8
MG$O+W/@CQJ0(>17Y(PXCAOM2:7)RBV<7CKOF?@Y@<YWO.'N]C)=7@28%++^L
MP=E<B:I@P+TZ[DY^K$QU$9FP'S R($O=#MR5WPI #RU FF=9;"5>O1%9KA^R
M'J)<L-:]^"&VBSLJ&>(.WD,4K8O?BI1)B# \*0U\R/*1OF/+'8U;5*Z-=*!\
M1"4GPU)*!H_S?XXU'!4EO^ZK,%9!J@/B4:].%ODJ)SCU<&W_ C)K!ZC?= ZX
M\CWC],,Y8+@*!5/"N2#M+*^=/L0,$P0<#@SA:K( ?N#_'Q@7M:645O6_*-[O
M,2PV:*-I>OV.6?;)TK=B:PW#DIJ^&<45(X7C7A79A^GU0YUX-1SP,TGMM@B
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M"9>HN''?!KMBN/V*4F8X='T^R.P9]7-P1E!:[W&FLYG]2W[MZJ5G80&#*;+
M+6;!OQ,"$1"UY1MRD=RUCQ@M+[,7XK[?:U^3/Q;/]8J.I'Y4^U9WN)WFBGR*
MNOY)\;O1HAJ"VZ5O[PJUMR3.N[AX6"=Q5M<)E6NONGVTHKL)C=Q0C1ZII>1Z
M66<H;E2LG1[I$ZZN\#>K_?^E0B!_$2R IFIZCQF2J:YT(Q<R>1_5/Z:F5 C.
M>K*00T/WXFLRJP8_Y02<<1;7J=\ZIG&W$0AC3#1 3("T*H:4J>()10_ED\\!
MW].R[G*!CQ,&ZV&;X0+FS;CFIHT,D-2+"BFG^=[RDN"H&QPK,8,-P6.'"0J;
M&F*\%H0QQEV+R#<GH'"^:?D7G[MG+(PKEL\!J*_QC58[TD_]6>:-O9L6!;?:
MPVHELUYWS-]9#'D5^N.[*&:F<,/Q$IPWOQ&JXGJOBIESC*8[:EG\@+TQ#X78
M7,Q8%;N@_,%_L!%F_-KWVOS4 ^?/:RX<0R*\513Z>P4/O.@U.]&ZH:[@//,%
M'LB%C<2A%U'PH>21'IDYZ9QLO8JUSB\S)D9,EU4J/]87/)'9TNBQ=W(AC^,U
M791T*#;)E;?J<Y04>-1Q%%TG?1_%T6I_#KAB%R7OMLVW^)PXQD03H]D1+\T9
M1*R0K_M*=(6%4OK"I-V.Z-('&X*NBTKHJW?0Y*]WQKI2+8+9]]=YKO1F4TSJ
M9_1DO&NW$#YT'Q,5WFIH#!&91,T2XOK#O!@]CM0[JIUU5T0W)U5+G(KT,U'W
MG[> ^+QC-Q[G'^D=T>+'B(%A(*XK5EW6T?O"OP,XH<:UXKXOH T5=U-(>$#J
M'[*%Z5C\\H[#_S+D+V9?+I@\!_SE*ZAA@K-;GK^X46K[1;)FK7_D((( !=O*
MFH,0SWJ^66EK9$;SA_ 7(@X=S.5AZB%;TG8IJ<]A'ELM#$8N4>6,?NNKC0#<
MY*1.Q'P*J*510OG=G9*(YX'@-\+<]4H =6Y8DC,A0RSC8C*S6O<L/?)'J><>
MKN7H''"BSN822W#RBGS+&I6X(+BQ2'L!OC,Y?0L;_GP8CAI!$H-672KP5I$7
MWOZ&8K_@H>4ST[-\:>#TTRCYQ6LZ4>/<B"BQ.\D$1SPC&^BA)^> ]R,A9[[R
MYX TXK.PO]_63?B)M+BH,>;G +-[17B@0 $>!OZ9Q,Q_QL'QM_=16T&_9?8+
M8<*M@;%WL1_7+2$[& BZXQR@).\N2PW>RSOS_UO<Q[V<-M?PS9-!07ZJ=M$*
M_Q_@>>3O'NWS@W'S,E@*/&14Q\)2(5_'@'C AT? 68)XT#,D^?!7P.9W?'T'
M)SY_YM9JE? K]C=4%\*_IL)HY#<H.\Y&H-E^^NAG6ORUOOBN_<4+*"S%7R;Y
M\Y.^AJ$XQEEO^PKC6Y5O<GB$B^V-A'(6+Z[_S1/^F_LH]Y-;OZ7U V!W_JOB
M/(-:,PX:N/.0]#^O1&WUFJQ"8&+*RD73X-@E/-5.P>E"9\VPPQJTLW-?[F[,
M*E2%04!=I>C!Z=N/-':OI0I QYKA26#SM\EQD_1R7%R;R#C!D<2;/P^0N+Z0
MZSO09=[\TV'2?W^)32,4 <3^VR3^X_F<ZPT..S$CH,W3TWN8L?9*-KDB6SN^
M_;.6FT9/-ZA5(N?U6LRK-8V'3.C/ 4WZ^Z=).^/(5DJ#8*')=0^JOBJ<UW&3
M^.'TAN%X\,@#_B*!ALQS@+ W2ZO*_M@V&"0%>LXR[N@TQ=$ZN1-6;Y\_:X 1
M4ZV;\I&\:[6C5>^R+&(F=]F&(/#!>\7O@!_Q)I60%[#QJCEX$V)\;X$Y:UX@
MI-8XI4!W0I:M,HLK>GG]WMXB4;R>W@?*JXS,!ZZX*U,+I,+J9W%.^UV/PW+7
MOM^LH2G9[J*Z+3=0PQ1@$@NI]MO HX*Y#)9=2P@U<J-9X(P36M6!6P\+%RD'
M+\0(?:G2*;>4<A+XIB/M\9.7\!S028K'#V?A>+V5.0!>=:S(F/0,D6\</+A"
MN=Y\<I6O^-9[2XN(X0(NYK>4/'M=N"OX+7A'#"\\#H40N!A9D_2]I_%HR=+:
M#GHN*X_[Q)?OQ*P9+&A9;/$5(O=C34,<>#I\D&=<\% 3E*K/!.XR?D!E=K#$
M[*\J:I)T4-,='.0_:*)H84:CB[@3T5,7DZ#9TL@BEE:\O.76SGDG@IC5G?7,
MT!TQBZ)^_D5C::2ZG>"BO_MIAB8-EZG--Y\I'"GN$+>H#Q5JTPZ_ASQ&=.+7
M'O>EOT6:_7,BF@O"#AI^/-%H]G3#MW*+DJ/9B,([0K4\IB70Q>SW7;?,7 TK
M<K*B.HRSDW.M-_"R^]:7/_0GQE#6^IJRL,,SX1XIL+OGSA;+(FR3G+0-6#C%
MS^#LD),Z$F27'R&FOB^.!L8SQ^9WI7W!];,PL$?.EV_=\P\K?RO:@:7 : J$
MN5\<V5FT%5,PW.Z5&!5KF@W9\U4<8V](9(<?P85,4YL;1U!](0Z2/%DM]K;T
M[4# \PS&Q<3C:5&ZQ?4SLZJ6_N.GS,S9U@8;VCCF=TA;<[*/+SX;I+=#!8%R
M1-+Q,1C%0T2N=)\#A:8&O/,M3'\EM),=81=S7'C)FS[-6.ZV[U"5^7@:F2[>
MUC=<>:@N2Y@(X+H3==/PJS./L#&:J#'$H1&L?<<EQEB^V//P'*!>%W4S+O&V
M<YV*[Z%UROSNK(=W5ZET!N?\IK'3CLS,F_6^IV.2#@[9CA0*62&#]2M@3)Q?
M7MGCB'#T+C0M&P/2&&/72Q2S,(]Y;S_H9A)R[\8Z3(3[#M-+GB6I8J>4JLUS
MP"O"K89(V99.'Y/OP]B/R[5JP0=,CFO^ \LB+[PZ1==2F3#NEIFE*N5X+5#1
MX^XQBI[(51@&2!$IJ-JOEN*86YZ?G:1B3\N67%6YVJU8ZK).JSV,GFCK#G-S
M/I.ZA)=H)S$+>'65_8?9E[,IB)<PK'HKJ*$3\4W]I8=L"F5'[T>C!!XCN]P(
MCX  [4V'&Z/7/YD#K6IOUZAO#N1L+N#G7KW_UPM;\>$U!3_.&3"OVS%'G.I5
M_=RVG@DJ+LZ",DV9UUY>K(D3N7R?KG\"F.4@,K+(K2_"X 727I7X5U^8_2,1
M97<5XA\%/_-/+\A.(E8P,,-I.T)U'I?2WHKPO@UKSJ@NBYR_8F'R+2?]=4D0
M*-C4XCZP^_M:J5[-L;_^O@3BE373#TM#JY(X-KY(KX'P^)#D9>CJ 8@,2!<$
MNJ7[<ESE,LF58L5'':[!6DM,7SESROD+HKFE1BY>DV5?-^R_^5]1B__3".H5
MQ?<$'XCGD,VGRX[2%8QA-:02"1@50G'[8GY&GV%MLV./&2DPXH*^8L8,K#GH
MJZ3@M!2IJS\_BNSCP@;-&P//_JBCN(>B P/JG'D\=^TT@VRJM<!/C]4Z9HE,
M6AXL#[5"+XOKB%K/P5N5(\A6;5VGA;%+:A]<9[\WI@QO9@P7L@4-"YE&QJ''
M6G>(>^:<@(HNU X4UM^OT&[T>![D^>DK94G!^EQYKW46R-,%#4JI'SZWB!=U
M$[]H%5T_.S<;F3%6SN"9\T&JBY.6(W$_WB@'N*&9F >\X[?-0$&BS3D2W&W_
M>[H*#QK,US6IV_'1\8V%O_(/PI+]%3)Q,-["_HO@(Y?PY/$OT(1VV"^HQW/_
MD?DAO.UT916LJ2@RR9_"6RKT*FJ+E;=;5?%.I*)('^:QK]0YX"$3?DL#%L\!
M"_9?_N 1GPYY>S2 L6ZAF.I;N!&N[.I^_WL\=-;]\=%+\9775^968'&B+),Y
M"\4Y0M$FM#.MKLU3;=3<H(N/UAZRX*T#U%N,#^ZUA#6. *\X6P?P$%$M!+E*
MF V98X1@5?RMS@$MRMAG>-@PIGD.:!S#<IX#@A,P:>< F>*<<X ? O/L\IH;
M#HCJ">=SN0?+G&ICZ1[LM*?,/XV6!S:81$^&M#I18U8,A_K>23[*75_G-^=A
M&NF2M'M%%IJ2@0*>#/W+6>Y?SG+_Y,YRA$>$ 3H.6Z-6QY$ H&;Q_9SC+' D
M-[U'_S?%J<?*A20$@Y^RS*N78P#/#[++=?AL"L5=,<\ZE>FPN98@)8FP/'R7
MM73_XI&"_CWZ)U7J'STHXTC;TA0]\EWT3A6JOGU,J B+@?H N3WY],W;N)NU
M:V@+#H7B^FB!PBGQ;X?SOA6';[PCX;@(:TXKJ(JJCV$D@69_TYJ#5M>ES_V\
M-N?N^7MA/A%M9@__=X+,3X_PW19,_P?9^OZPV3I]]3#V6;YF&/L%-2)[T\B/
MQ;J=UCP<WV'.QT:029T6<G?@Z$\ETM9N<#>#XRH7WP#V#./4#J(%S7T$E3,7
M/.<;Y4*.&.E^9Q4-KK*B/7Z9=SE'HSCG)>4W2(3:X&RY !9H\ 523K/9LG .
MN*@\SW+=TZ>M=B3Q,92$YA[GQEWQL\-]7U,U;"EBB#P<3H EPD.)%I-Q8RG4
M"/S="ZWXH&PB]BIS6"+7LY!PE'!Y>"29/! %@R'GWC62C@@\_4Z&B2GT]+[$
MVSZE,[0X_+!/5D?^[6NI(Q9737Z[V+,X(YTQOI?-.14Y&=]GQP[6?<_PC=@Z
M:VADQG6"2'RUTS!(9?2-C%P[_<^-KVTJ/RNEFD2'!M]582;3.D'K0.S5,#QJ
M[Z1%/=4T4$XM9Y=,+GE"GLE5-0P7;U],#.KF%1S(5:^\WG+KL^%[3]->O[NS
MN"O6 HF-D'8W"FNX0,MECJFDVA.&N1 LY:NYG&8CU2GPZ"TD)K#@4<5[^\W@
M3D8(Y=3M(%-<=_8CS.@>M @KGPT/#A9TA*%&D<N>$"S%RJ'VB._]6GB[$^6X
MLIGH-4W3>0P_=4$GX?7!F>?G@&L.VC+33E)7. Z(/S+:DM@RVI2TO^;.#P=<
M?G@Y2[HX\WBRLDOVS/_.8\8J)P_\;%O8_!\*:[01V_&CEUZZM.D56[<FM-BW
MI'IKJ1KF+[NS=3$D;_UH7YA/$@>2$F8!EU-5Y_$OW,S*S/$*)=YYO_5HN)^(
MU+7UGC_=9Y^"C^H/F:XBWC7>]>S$NBRJ\7>YH2Q(<Z]NVY>>I4MS*DI7N&=.
M/A#Q^19LG&+G-+$RMSF9V:';\&Q G);O^!R@?_S"TG;1[DP_OLMU46@\=%FT
M,4?>XD J:4[@35\0EL_^Y<"QD\0V:X.W/6.)2)>!6TEYY*0TI5  U-V/C=LN
M3I2H_V22.H[8)8<Y0'U:@36T;$U#QZ/$I9*1L.</.<&T[^\ILMZ0FV']2548
MM/R3AD(3D#^9FG8CSF;H6]/#Q<14V_A)*IYDSAUC9?2UMO9#4]L7RF^\VCPG
MLBU):@-S9QL&F''*L<,])=RQX+J1#_X\HVSH&Y\U* ?E^PF,=@*PUYB*$M5>
MT:=@PT?%6F"7OPXR=(XM.7Y$:&E1W)0]36\T8?WV_;:34#O/-P-V/QC%BE#S
M4*3V:X_P5S86-]#ZN;H)-GG7J!1E_5]'0TM!@@Z=,W7_3K_WLW!I/XT(N@BW
M4U4C+'*COQ$+&:W>4.&IH]<,S..Y'=$8(I+$PDB_7K@55,C]R1P:>SL70!:[
M_EU(7<K;35OJ#90S7^)WPBZGI$J,*JC]D2AQAL*X>N)J>9%D<WZWH'UV$(>&
ML;R4'339MW-Q<$&;SMANV+E09HDVCQ/A+QCN(1_$]<T WSCNK_\=L?Y413)L
MR1I^2SUJLA>F<R<M2*K'><3KI1M='LA-CRX!^;FBYVGZNXW(R'G?!(K*+;;X
M!(P3N8EH.(=1Y=#T[_7(J$5_>WHW65MIYT!%U"FC0\90^Q#.EMQ-C&V(<!G.
MZ2IITDD*K!TOD*76X;C_O^V\]Y^6\0%9@*G= ##&W7ITNX0\,8,Y[G%[4Z9?
MMR"1EZ@MTM[">SA?P-H#;*!'YUH^_,3AONC(%4W':? #OZN15HM0[OY#6Q'J
M A^Y 2/5(4.!-B>BC@4^9A\XKV1^O?=^\5HL0AWZXGU8;KA*_\D8]4)VLI[[
M:@>5DE96F;00QKY(#6^5T3Y)>&H6R@8H</G>^'4($:-5HOSAJX5IE D'UAGE
MUQNU\""LFG7J0HU#UP'"%,.*OD#JI!:HLB=\NUC\$+@T;[F9O:: "8>6?5FP
M>\Y]U'^@<YI=YP1(XU5QT3#5#KVO;L3RQM<R3;?GT/;@RF*U8U3RC[$!4[ZM
MN!E839Z&R%C]IG<#GXR]._#';05#">:%;$0>X!=AC_]\69%^.O+_ +4*4*@M
MS#)A O6JWW?R'>P/6:2^KIF\_)F6<)SX!*1X%K2<-/\V]6;#V!+]XEJ$']E'
M)\=[O*EZ;J')R3']E("F7F$3 4QPV_X,1+,L2DG1R97W:4XN]P^*$_ &^'6]
MK.E"']%J;642KZN>D;[<JKDXX1*=YJK6C^M>%Z_;$.[BC4!X@,AL*)Q2!$&R
MGK"W]MF.V8RME;CP20!=['4?INJ3*!,9SSW<U7. >\YJV0Q&LU4E;_9)5C#<
M[T*[58?E^WN$WA>$MGF:1:V< EG*B;JC;NGNDWIVTG.>]F=.O3X'!,C#>I'J
M^UN/\0; %J)PV2!,^<.HC57XDA&MI:X/O@E[PH>.(4TJZ,=#BNCMV#UY%\'@
M45L.3YWO/QBYOWT*SWM!YLUH';ZXOXOD:I0RL3U"TON:NV=*B,:L:Y0J7CW6
M*]O[++U3O?(=^:R>-5^Z9EZ*1CUV6;F+DY]VD;'>KN.X_U+#7[*,K3<:;P]B
M!7(:<"5Y^FLZ"LYC-#&\ZF^\2;L?]E5881^C*V M<*)UW)WA2 <W#$FVH+.%
M8RBM=&&;EI_]7C:M+^34R%<YR2+5M^,N!6]XI;>;.(!@S&;U/M&'O3[VU]([
ML,/W&'.VB4KF>X-/ B-Z[@WO8"T<MC:P&_TO1*\9:?3RU/%\<.*S9,A(_?YP
M=7%8< Z*J=W 79W-+4YIG&T_+)W=.@>H\R=WWG 9ZJ:DBDS>0G"CX.%8U],[
M6*4$9:3>C0D+39]LFADGKZN2BG22%N%;+F^N-&V7$YP8R5IAG%IUI'E1.'B1
M;8S7B1_VJLO%#TW<+:RL)0=,$?^1B.I?R:7^E5SJ?S"YE,:<0Z]7)K[_7&I.
M^DJ_0L9&LRGBE]0J[B;09M[:XR0/$L]Z=OE[=MQBHC:AD^@=MSM1WHQF,1BO
M+!8>8@NHF(5;YJUDUU[;\IT5E0*YGW:-^7^,;481@%IC2R3V#W^I.6\T=%-J
MG'STHU)11<"^^"<U\S66RY@+WW>^[,X <B+M>RH:Z'G$+&F)[%WGD6TWAO8G
M1";(M(/%\Z4%*8RY4L6:-E[;SSNC6@?:AB.L,[Q9DN9M%P4QZY];0>X-Y%(C
M[-K/\\7S7@AD$&M'JEC-\)07*G D1A@*,/%L^B4Z*YSN6&01464'%>%Z=\4)
M(WD^UKC<Z99_BM807:2M],C?7]/\X5 RD+$YY;"--^G=F![]O:JC>O^7AUW_
M,+I<A%>RPQ8$KOMWG0,HR\\!5UM\7!?H]FWC!YG$7&JBJMG,K^W=X*8%B(MW
M>!]*\$B\/WP?*V!?0*-J&*.Q"9%FN8;?ZP*35(>N(P:*S%S#B%ME,18X%K2O
MFEM45$?\D^KXFZ#:R+@C4!,$PR<?>+!3-HY5147L!!4GV4D7I%=-.0C#/DZR
MAIJ;6.ZI^"VAA>?@K_V%;9&FZ(ZW(C"J+_DZ]X;Y@$LAK!<[V,7:_?H#32A]
MS? J6M#W'EH]<6=^)U14C="HY-N$,?D6PTVA([ K;T$,5D[^1"=UT,36Y.3T
M''!7G/70"%:.H\;Z8EZA6U1/K0,DS3,Q<1>NW@GNG?-+!TI)?C6@E-]W!\Z"
MYQ):9S'LR"TJ%,LS(W.% 3:TR+VG["%@E%%7C^13<B(S GY"LAJMF]XCLV_Q
M.TCS'#!)..>'&L ^RH713DP@8^Y]7-CPL*_^[&^YUSX1>'@V[POQ2'2.#YTZ
MP=5>S>O009Q!C-2^$_/\@(R/X8CYYD&3B\;PYK7Y&9GF1O[*4OMC/O8X?C[+
M""/M^KS@T3M.&C*W49X<EQJK<SBK)\]DZ;B,9_!6=Q[GWW)^UHD&8\.\86<N
M3DLFO31;*N< #J)%DY\'9WP\)U+_^9><A.L(S.T<;(H8%++YM!8O/3?HS_(0
M;4Z_?_AWNC]P23PCM'HO%Q3AK#]\#K"IM[H</GK84'C,EFY<\4V81MRQHD,?
M/, (7(&X7\4+-*'VGTN4DR&2)Q*3L7@-0HKQ6-(K<2F?\P>.*]ZL"EAVJJU/
MQ&S@U6O@O9H%13Y>!HKP6W1]+\#PR%9>J1LG95W=)<I7'W45W'>ZM 8&4=:;
MD2SN=,+U3Q.^X%C4B#&.3%):OCD>+IL\'>< :[5@YXG5RMK"_"=+A(PPNZ-.
M!A>6IV!VO6"WO%,][-.%3I1CA( #""ICRYG>4+;ZY!5%\>)@35U7H$C(8$6%
M<L3GTLB*P+$BK^J\C:\P95)2\9\ZI_D5$7=XHA(BSX0M*#.RXS(=D/(/&:+Y
MA>(4.>4]7L*O2SY+-+RK'[@GN+6/D$8YAO+CQZ.4?,:],[]V.4T *MHA<W:6
MP:)_ +N <7?SDTR@<WW#LT?L K]NY;N+HZ8[)06K!=^%6+,L:NEC>]^T]TK=
M&WD>[OQ@>#AS.1KY+%Q+(USG'=9#(W8J-F4*+R9SW_]);'P:T)PP2"H(,AXF
MY:F[O0S+KAA.ZYL!CLI<>2,8F"5C:E/Y?MYG)'\UW$M]2STSKZ/[SP1?!1$E
M$18)4@9U,1* '?8_6J_<9U$:*QO(B'CDKU]K.[^NY<,X(G0]1(.4X^FQ3.=H
MY9>VVW*LSRXKN?O$KN6[E$KJQS$I&@51J^M__!_AA%4?%OFZDY!*)L5]0)VH
M)L<>HV--GFM#95 C%%YD>3?N!7/%FH9<*?\H(Y@-@3?RK:WCI'?T?^0I368$
M%S$;F3T?4! ^&^2R_[!(S+GR6023YI5DH\%)VPWE,0.1J-W>GCG1HEH5GMI5
MA1 W*GH(3'25I,@JLM5'N5_>S5V_\L=HPO^!7OT#A31:B$.?-<*<EGJ=BVS'
MU*X^WE:HBSX5JL)1/61OEM*>&%U,<,;#OM!6-'X"EM5VOW+T1,5U)(..)T6D
M0(F/W0O<1GXI!RH)<HX*6"EE'MG=":PH@(4P"T:R=[8FJ=W?@9YJ.T^0W$>D
M^(O["MRP.RGZ).VX=2:UL>3BEAIG6BO)> X@?-#!%())J]F8#(GD57NS4B??
MW2RYT.B*@KVK4*/!J@4X3 1H.-=%2D 7+="I-8=B);>@%.7A]"<"APH8@[,T
MSY.EYKM=S$+5WL,#L>B*>54F,4GZZO6:T=L1G#QL-0<Y+:?*!2!R&:;QUGKF
MQI'!(=9'C'89X22:&_OO.N*Y.=8$87>T?/"#H:/[3PT'5]2V("A-#91 *Y]R
M:V6E$T=PQ<>>;]/M=S_W8CL9%K>72ELDKSM+T.\@YU)=9E4*/1O5*@PA5E-3
M7^"6>PR=>W>L;AVN,)30T6T$FEBO2SADEYB+QIT5BE6Z\D\X;+-2RFVL?I.[
M<C(F-J<6Y$^+L>;/Q]$/42FK*#V)7^"<@3H^>SAY]8$\1T"'%"?A FPJ8WZD
M(\2?DR-T(2@RJ;@Y*(MPR>#=,.NM_6_Y8HT&_6/0M7, 4-(\"V.)E;)><-"8
M>N*L-=[QLHM6\RB6!)7#<=/YI>LH4JO><JZ(9N%RR+:($40M3'TH9RD]YF8!
M67BAN [=W!M2WXU\2!-(\I:KYZ N)D2W-"#2]^/%EUN'I.4^!ST 7[4YY)5U
M:4FTSL=/ML\^(A#+NN8 2AHIHP:@G&[J%_HSUT&W\7(__MYFDN-[GS.OIM9I
M/X;U@^&^-\]2?5E1>E8)3ZH25S13/)3S3.Y[?3N8K 9PKWPFO$_'<:'A[E^V
MU7^2C05Z-A7Y@N9A)#)<+"]2E3?>:L+B!8$$AVSC9YJ3M3OC!LT4JR:7>DO-
MVWJKO.ZT/Q87:G^J@'S8=0L/?>E1B*E=S+2OV6!1QTS5@!GM.< V^P-\"'@
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MZ@&P_*A'$A;&_CU5R;[HR?U?JBS_N>(N> MAC'1\+XI69,A68E/68Q,RZ E
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MG VQM=7UJZ?!"V5C*F([?%,I@G(2V$3V:@=S&?X*VA.+D(,O6DX!G;9"926
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M$.1AN?[<L85X?G&/A[2VUH4)C;$TB7M>.:47'<*J?]ZZ0W;23_TDHCT.0JY
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MIEM<-L%^:SCC5X&C^BK?VVDM\Y^@VIJ$5W8BM 'BBLS*?FV(3NSGQN$/@,_
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M9G5,9Z2G7]9J4@%5]%&MH'+K>2%\*$IWR)WU<0D$R=_?U5J3WX/("V"B /=
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MBJ7-TMY ?M=2)N*0 )(D!2_(AA'W-^;*Q!_7848O4>76 W]0S)>28WZR.9K
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MB!'QH;0W\<+;YP% Q%[JJTN%>X6X9.J,R'"5>/0M!=GV?H9HK04A0B(=?8J
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MN$T72AZ:9:?V7'#_,?WZGNG2] +[UO O]N<\;!\ 2";35FRELRV=\JU=J@\
MA5]5\<CX<GR2X<,L>J"9P;1313W HH?P?:C7.\WY=U$'LC4_U$01J"P;B^C3
M;E -2K3E3D_F\LYD.*'$>-[KY#7.TE-@0:R=$RCI2/L]E0R4<ST-R)_,5+J?
MV+#WPZ45GZPJ@"MI0 GVMJ&,ZZ#*/AGEEA..0D<X</?&0^EY3N]$UA=L8Q];
M#*JSTCCOU: 6'# 3'_I&2R!K?T'^[ ICC24A1KV$H6CP)_2/)M&"EY-JRP\
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M@A .E YSS*-V^V>X^[DOV$?GH+K*^B,3!YHR:Y<+[<$X-,RA^*PA.^.AQ3T
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MOSA$'+]585>+_!8%<"=P-HSZO]A[RZBXHBU=M!*")%@@D."58$$"!'<($#Q
MT,()P=U=*B0!@CLD:' M*DCA$H([%%*X5.%>:.&7<TZ_V]WWC7[G=(][WSWW
MC?=C_MDUQEY[K[UJSOE]:Z[Y2</M#(K,ZFM^$+BV_^MI NAPUDS$J5'6LL?<
M7>8^QV.(4;(:B".HVMQ1FW=<X_$5= Q-?]IZ<':ZAXZ.*I43TR-L_<97Z+3P
M_8,")X/AB72=9HP<#:IHV\31VZIC!K>3&*^SV*9*JM2ZX:NLGI$,^_W7HPV9
MH45LUEB'RHKC>WQ&&L/JU6#./;AY73 ZHSR24FT-.S#;'Q^SF7/E<-#36&4!
MF^1(ND-?*F9'?SH"5F\.GZ0++OE 8VX!MES3GN!@A)MW0KMSK]LR:Q;/6Y[A
MP@I)C\;OO1OS#73.!IUBV*A!JV5H. ?_[J.-F46#K!*ET'TY%";Q#/BM#3""
MN]U,OB[Y(%# NI5:C*TA.O//HL8G-I/-@6D_'[SK]TN[CC<=C\6I_OF8.BP^
MC9*G&[QJNLI^&@WDH[1DD(PI\6+6R'@\*AL 5O1)(5T:U:&JBNYH*L7N5"^E
M)4.D%OH-@J!-7KPT)!_D65.Q-@[AM*Q1<"A,HLG6YV?8-&(.*YPR,L9.(F,]
M+0]4IG28=0_W1.4;5378F3#]%M)9JV-_*709>>3R<#QB)7D]QY;NB07<W$XW
M0BJZ#OIDXJ>=WZ9VR@/^ +,E23H;KYMG AH_C[@C209]=)H/UB]-.DA[GTZA
MO.;N'4.S^GE9U4LU,ID%:HW7^\W/JP].MN!=\LFS@N-'K5B;',5VC_=-YHM[
MD<T,R,!\&XN\-BL\HR42$#\A77>;R,,XI8C/+G'&\B6V(*I.=%P$^;#O\>8M
MX$_RBX]/8V.0?F19IS5L0OEY+VI_%"^+.]H]91.:7VAD=WB39U%K$2-<+J\R
M:E$7^5CB>WFHZB@G&<4T-8(/;=RGX5J'+OE:L!H@C>K@>#T=U"@T[ N'N^MQ
MZ9D\Q]JP(WX_Q@B+K9!FZXKP811DDR$OMVGS$X5["K-I&O<=TT;570EL>S,F
MN=RO942H(&,>;R3[&@IX/J2)/]#[MN*BBVA(ZLK'"U/KC78QK"EV_)4I<0OP
M/4+)(E\^T]X=#2Q,>41,+M37U$(7<?)J4846_B3(T+'8)D3,7.>*]_$GSWWM
MO9W(#35MJ..74\[N4=/%7YX;KAR4&K9 +D?%;7VOI_;Q9C98X^,FED0*,\H?
MF_/5@3)4X0C>B31GBFV=W!#%U^1V(+41_^'4=RRT48X!F2P.-5WW&&9^%8=%
M&N6X3G;)<8Z.K^\>^ZQMU)\6[?$I?O2O7+K0&1<D+37++OX*KPX5"U\_G7@B
MW%*APWE!$[$)9[5D<\M2"I'U_CV?>EPJ]+&NEIW^4W>!34H+P(9CL$-6R5=#
M[RO]KJ:T6:HTSVII]CJ!&B[L7:L$L33;[EZ$FQD#;MCG]2_1[&)[\[ &4#ZE
MG"W:"DK9E=.D]Y')L7 2 ODCUW2HAE/UHZ9\0BA?+25YY6)<26SV1Q_-;/QK
M0@8!9U:XQ,2CW*(2N&)],VM;.Z?4IG9_A7^C82#J2OY^XM44;0G%U"';F]^<
M]U8T?_%Q'O+D!FD:*(@(0N2$-=34X06U1DTHB!6[[I!.A=5.CG0K5X_?6&OE
MJ6*ZN2<D0]PL?MB2Y[=E^>;AV_[5'AY9'SB496&>F,W[A]RI 8UYR=9 OF?D
MA:9GS4ZM>&DIXA4JSDM.J%MI3?]UZ9??P[Y;^7I:44-]_$FZ)A^K)]<]70['
M;8!#]TR2JW4D4X1[]MADHP4,B]9J3I-'-DYK='BFI3:$\KM +R'Z_HXK'_.B
MU%,H?A<.9ZOFQV4 "6-YU<X;@\(S(&>2-(\4.6:XQU9+U]Z5NT_K+6]67X[E
M&@UJX&#[6G[7*G<6+G0MG^:!#D@8LS(;7K7'J01%.*OHQ3V,>3X)QN<)W.9U
M?#C;+8PL1CE*E2* G"Y:TVJ.)V.TT3WB.$=J4=%+HD3';)%FF.)59P!6:N7L
M*X7>VB^3\<S=Y*0_W_..CZ>U2->7E9DYX*UX<@3!2WLGLVK=?#49NU'Z'3,B
MA#GA;(-_SVW=\WFNTR@].0/N6_0^+@L:UZY)U4/-J&KI:*I,_<DSA$Q]%HJ,
MVE6)DZZX'U?'EY1=GJT:#?JV2E%\6C &Y^E3(1YPG!QW3^%1_*S8LZ_NVCT^
M5DM#7GC.S#^G1E;]=O/)!<6_.W.A;OJ/(;QI1H7$JLJ<Z++N^Y]HM4\()69U
MQO;LG5XHIRE_3Z7,CK4PEWO $S?W6"'W4AIQ$VAZ"VC]<F5],W*7#F=]!^\O
MW0*H5%C9Q4/25#<PH4NX5Z078Z?NUSF[-XP8.Z3VP:C#PM++4&KE>YD+6A:/
M%=W6:;?RBH>3'TXU$_.?\8/^W7TDJSG ZVO 2XQD5\E^DDS.5!JG%6?9U<%U
M[2U@*<D*!8J$-@4<-*J/':N1V'):3O 9R;M[UKIF-8NYLM6F,(!)DV8Z]OK2
MUU$9N#</&2YEMR[^3,]OB$B$V2OBOF^9_. M1VPH;9Z0=<9^!OH/7V:(1.O8
MP)-3PVUBSW_VDN2F_09X'=/$[JMS[/VER_>7>K&='!>'-)$.GE:\SFL?QO2*
M%=2CTN,)6?)QW@J209JOKM*_^#D<6(4;JU@Z9?7ND,U[W7_&XAURZ"T -8?
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MR08Z!8Z"JPKR#]0,+V5;?X"7#>KQJEL8F'D1?2FT%$2AN??BYHC'1/++-AK
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M F2('F[K[0*3ZFH7&"#.7;8F^&)36AJ@""Z,1<X8\]QBL D:%+Y:$R]0G?*
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MA&=&93KQ27P@$B9C._=/Z/;=) ZVBB1_:V\%SVTZ"#A^WWC^LA^+7_F)RN:
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M680QX26IM_^V"9T]9\TJ7Z-H1-?QJG_V19\DV[$)AB5XK*9J*<WMC*&V(39
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M\$.8;]%!=][3/M_KG>N%N=(TI=^J_%?GWY7SW[X:VMP_8QET]PH:\=ZMZM)
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M,CFK\SP8>8?TY3F&,$,;[[87#Q6MKR UIFEY0O.>(NJ;8?:P88^F/L04ZOR
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M=,RT?WJ#\G64<MG&^:+9ADU#J RK 6VLN2ZICHS/)_F!_:V:F?Y5!%9L>A?
MXXLE 12%TP0.:\"!+<#(]P=T&^BP-Y%9L$UEZZK!K/=N![%5IA.[EC5@] $R
MF #:YO:& %VYVQX!=%.= *+,QHP30-(E=000EA8*V[3P(8 (H NEN(_(A5@"
M:!:F!4 0]P^;NL?"?0C\U'>YZJN^/7!&7BS5-#-)G<X5V" 5]+O3Y^&1!U<C
MA(,>5P[.D"J6+9QHICG@-.%$0W?O8(0/)3!)\_502BQ#^84")^L^#6-FV;6%
MC_I1@2\E\DXK\ETE:3+8+>]2X9$=+3H<7S2]GI* V#S\VXV;).;AIL&)S5IJ
MQ-LBD.=]3V%\NW<W@2/L>^LXQ+LINP=U+E!C&V$A%ZIWMW+1T3_!NTXSUY@;
MEW"9F'!?5T2 +V?5*3^[5&/ES1>J;>=83DP7^<K!OE/Q7(N<'@^Q9Q"TFD*/
M]?@N,2PQU_BXA[9&LW0U5. ^%E=;(7%%I!YM0)JH(_:-^9KBT1"S7)ZKW:N/
MBXK>B-L\53<+I%/CDGWQB.ME#0@$HMGG)H!(/^"2MI%DRTDTF*+)9;KMX> G
ML]LXB]7J^SQ=&1%GT9"@+$7ZBA7-_CB<(^(U<B+?W7'$MZ580('.ZM$&3[+L
M:,_'=,T#*B/,.Y'-GJ4XK('JEA@'VSI9@2I:.7EA?)!RJA#)"'F""!B[7>YR
M\[-/&IM'/E7$WNU(BG9,"R.XL>I5-=",O7K8L>7;($6K:_MVY_Q]VA"_55ZG
M_4BHJ6[JVY(B.[?^]?X=B0-PG5(QW.6K[A3E*O6F[R ,K6F.-MIJP[T[70!^
M\Y.;J<G*6F^46O*=1>DCV!#-H0_T'?CK;^$VXVC-[.7]R!^6/6Z'&8,UI/K1
MOIX33'>PR]$1&@W=&KTW. V[QM&Z/Q:RV9ENK2;;WSE</QC$A@Z!R3&Z<FCA
M-]NK)/>Z<[>#:57\[59OY:JQ.38FOR#;65)@VX+"P6B]]<%Q^7XIZD%O@V[7
MA4<;+.\]SB>E>] -]0MI1+Q#@KTB-.G(,G0?_Z3P#>D'CGQH#241!X@I[-WR
M7=-[T=&;><_Y1Z6U\*=TI;A4PWN>I\.:H%7&C),1\UI]*%4DMN0.9"(&>25/
MBAO?G,1HN!CGHU3GHO1)E;58Z9:X ;B5_KH)K *JWS\OC+UTT\/A9;74VV(S
MU4MOM)ND[;Z@-FD.!$RB60UBUB+W"^.Q*N0,TJ/Q4!<K4B_:1KXAO^]0$NQ]
MJV1,M-=497D1K=/;L-L#QF$>.[((8\1U3,,A'X9[.N MCV#HY>\2)='%7[H$
MJ/P920I"QO)Z?[BRF$V!,1RTM=E5%W;IUM:%6Z@X<#\)( ;L ]PG;QFK*510
M$F?OBI)@:N]/SS8*)EMU'/?N5CT$K3KNKQ/'O-(Y9.(0<O/Q82>>!A-P> _S
MK+L61B^AF:+WQE#)\%/X&U&1@?2#GV3]_]%',_P+']@ EO#M@M$7\05<85S)
MK=QMF1;!1VW>0A:SO[-/M;03=Q"9#,7H+L""I:@73"1#GV13R4,&6;'<?I!\
MRCJ\DZ40; P\"55^76^A&/B&-_1N:&33HRW%HH2OO65F Y@^\-"TL05CSE?8
M&&12$[%JE;-70  U 2OV'@2L/)]H1(7;<6#E,-KGH /+M=EP_K.44N.3QDQ8
M*0)HCO'@$"6\Y#5C7/5MBP.7*VA<*A2 /X!,*B*+0C*3[%1QV[#:ZJ3(77%T
MC/BC,%]6+"<<W60"[#3ILJ\9EJ.$D@!"O:K.38*AIN?> /,%P3R?L2B,)F0R
M5U!65"A@"P($'CJP7@O;JE7] ?/GP]X9?TT S;^&?R2 R!&8>P00_.1!GA=L
M"B[(M^J1Q0<V$SD@@':RI<'#AGHE:E?J1 @@0*O]?<X10!1ND^#]2?8Y2.T'
MWR:32[^"X-;K:_ZTSL"&4P5J%YZ.&D>/Q"TLFA% H;"=3,AD61$!M+\! (+"
MZ/Y\?\CL^0#OJ;0?BDXE@-Z(HP.PAVW (->W+!*&^G00[4$ 05238)-EE?<)
M("D(9A^($EC#[2]KC*.;?"^BL,_;_E@$=KQ(^LY(/-Z'K,<%N7_@O4H G6]#
M .@$X"5@M6'XD;%KJX^!F.!HQ)>F%0_@I+F_%[,%GE0"MN4QL;Z_%TD<+,<*
M8P\H,^9A6YA]%)XQOAZR-7DT*:UDM7T*O(\^CJ$3J-PFW_/ =KT@=_#4L#IF
MC##>)Q7;A-$\6%,& O=;$AW'XJ4<@/!F-VBQ&-CT/)83V$>E+&06\"XPD!4%
M JB.!2-P/$T-8H8Z;8F7)'ZO<;#[ER5L@266-OC^6**\$HA8"GP$S($AGF[O
M.VQKE9B2EX<LGMQ5A4AB7F$F+4".FV&6\U!@(^EXQNSZ 6 ;E%AO()/L6&'=
M=\CY&@)HW!++O1B*,1LGA:%RCB9"CP?'JT@A(P'\PO"H#N3\QA8GKKQ2>>AX
MUE$<JG_&X8*G._P.V5KF ^*((7Y/#_PV?1@ C0^,'4#I^J\U*(%?'0A98(&M
M%^!IF) EEH&OL.4PR#J0%( IH5B S5+Y *4X._%-^-.C6P9MH1E$ A3RP_8W
MP8/[_0 @P*]]L[;Q9GW_-$ (8TJ,UO3NRH8]9 :,PKD"L!K ZJYYDCA@O=K@
M>P$8+?9="/K*.F8[!JP.Y,G*?!UO1'DH+ ;$--^B?.CA6>?!X #> 93*7Q!I
MST<W%NRGTH2E(/+]&3*?M@Y7.=A& /E0HC.OX\*Q)\Y9V,ZB#NNP'/BNE@,U
MVET3U[T\;U>(K2I]#4!<RWG\:5AM"G08WBB$91:'H 7P-+M*^-;J4^&.MK--
MP#RN GPSDG)&5,@9@/$!L$QW*[3A'FQ0OQ9C [\*J_/  /C^$": KH/1V<4$
M$ "0GN^6ZJ^(3,:)<M1W/)<KL6G%9\)LC\<"_/8((F<@ EX97'PB8M_7^SMD
MM7?*44J) KZ'PFB?A=BOTYV>5I[&;>%I=HR1@"B]W%NU@! G5H%7_";.(P43
MD'L_CZ'V)(#:P@F@)_,:!%#,?%,^?KB:KVKZ$ (F[H<6*S@>Q+;O_XX J@8*
M8=#J\#H6\B#<D@^W#:E-APXJU03>OC4+_&< 1A/?TZI;]QMT4+0.DPVG?W!H
MY=FD3(='H8YV RW"57CK_9!HAY <1=6#S(>^>'+X^^Z"^U=@$[*:LT.*E#V
M:JW>^F+XDW*E<DY<5\H: !@ZW!Z..IPGJN$HR]55\R-";=/C0K#7*O"2,TW
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M'!'G*)X9(E,@!2[$>#[ @%8']O-X6AI\N*(1O'WAF/O]8& :B#@-^4MD^0*
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M2-&>^6?Y<@4QQRK;_#LEW2D25YS(;-.(1YS<4S\<B1,)#4GSVZY)L.])]HD
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MI_CZDY;6G0R8;.7FS#:I[4YB+V =2Z,OSSB;-?X,T$],+)#XMDM*4H_F05)
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M/3-5W,&H*I<LG9V7H,PZ X>%5 7FXN!"SA/J/#69_T$A!!BP]/>VL\Y:_IX
M+0 F;_S?*<J6^?YW^U__D!'Z#X-.]+7-35XC"]HVK1NYI'N(L]"?,QL3W[O\
M>S.T[=K@J\=*\X<IF-,P@[$1Y7AE))E*-0-3+ <KK*OF(PS CG50K16C^(NP
M^+EFQ"<NI!.BXDS#";]J*:*1SL;@W0?+EO&GALDO)_K^K--I_ED8V,)5.4;N
M%I]@A4 A1D()V4 D2S1CZ[;IXTT!F28T?,&8SC?=Y/=E&41O"R238+(LW=H_
MMJWI]2@^1)F^YNSMWWGXY)3>6?XG2=\= !]3JHU6:;*%VR26VU[&%QV$V0QO
M/-S2C'HH03K51+?JA.):,8E,0/C%[\CE;'OD%Y\)%7N 1( "\+3&3;L[P$/)
M(853X-\GW,(IVRY*$<8=(,]B("+50W[OP*2";Z_?\S!031FLKV!__=2!;>"Z
M:/&71 _-7LNBXP*N:,]65%SVK(V80W5ZGGZ'I;G])Q&'Y5=?:*,^WAMKK#AS
MPHPBA\/2"*JKQN#P$P>E]T'/ZD;-VHLY<;#>B7?[0-VD\BHP/PZYWF$TD.)P
M'\/:HY\1#F$43 .U<4!N&_&RZX]](H 1W/XEM"J<3>Z++TL!>Y0DU"J)$H&S
M;:J:37D'<(\&'@AZL>UU_)F-)FF$5]3FPG/$J*QTOGZGE^C9^E_-O+[:4U(O
MO'YO&D\F]S_P]J@.[<RI?)*:W]SD"G)5."LM;#%;"AC;.HOU?37E,. I'$/M
MEF]A\L-,VM\1ZGA5=#NT.AH$\'/_7RAMA+N9B$H^3#KHO@,\XO7EL7;N_VGC
M^EV?V9&MGEX>M5NY#D!]@H75PV;SSJ0J#ZL#2,)\[7G)0 U&4V+VO!]LS259
M8D*>@M !G^1$VTI3;[FV/?7Y.@\H9HV#J9[O)#[MW^3Y01U\_N 1Y,"XR_K*
MV:M?">-CAMRE(Z#S4YQ:<)#]U=JPIU8E'W'=@,9E8RKMW[IWP(-N6=[<:UA1
MD##+-Y&@(J(4N)': 54JD+G29+QW9$8+"Q,,,PEN-K/^,:Q!1G< 6WZ,3[LS
M ;8C\\2F.7?X;M7S1[<\)JR[BT\F)72*E OLSL]ITS)$^^<->XWFYMAJ?FYQ
MC0L 9Y560*&^3,*AIB/-P_:AEE%3^Z\I!K9P/)FM4\QS]\CF!.Z=";?"$!VO
M,7U> CY%LB,2LEI)XG*) V%(.;9^7\)?]/%,(MLI]&:W$^GE\T R!ZM#X6"S
MJ*4NYUS+ .>B?'8&$K,G#'0M;V>B ]PDK0XZZB>C"LRX7OM8BAF^?7:JHTU(
MLL%U]OCW*BK!&51CG4S;/#[')/*39.!@]H\'@M-RJ-.#\YBW4EE8(87AS9]_
M&:7+H.*;/:S@*KTL"3*%*3\)->B@?_VCG5UUJ.O[LCOSJ<!71(>]Y?,.>ED=
M?H6R5XN= -W5@F4(2OT_MA;6/Z,VUG_%6+R..^_8;#97Y U[CEF$N@:UVB!G
MQ%C^D.U#H<LD9_WW%'0-JO#@C9@G\S&!@S1,NW)<:1RO>%[A4VVL6:RD?5]T
MY:#:M+>FSN&)&P^+Q7U$]\ %%/RA^-ZV6@.JFZ.WY;F@I" +7)!/8L8L*CA0
M^/5YF1;EVY'+R2"Z,MVC;-.5A/7O#HCEV#P!"%ZW]Q!GU^=@_M^ MGRKB^0\
MFA*?&B[)*&.KM?&9>?1NOU^^P6QW#[^(X0T8!0SQ@%J%9[79$HXFM[<T[D&V
M30AG=A[;GBL(L#WF>$"[[\MW2* 5?"V-H"Z3:N):>[E76&+V((.+!5.!%$EF
M@2=I**;4?:@ZM9Y3!A/&.MG$I%]UO18,6"DEG+&C=!UFMBOG-'W$-7A+B]E5
MG7#/9ZJKYR%+S=&]KMKV%VD&,Y!_4^^:YU.\3LI]W$Q 1FN(:.Y9H7#6C6BA
MP9?X\WOH]LG86D6#V6-+S;,#+;<[@)BW%L/S']=%)4ETD8J'WV2;?,(&)^V[
MP[WORW?P Y&27">T[A>9!2UA/=LG91*CFCF'NF,.K.SV$9ACXA?5=:%3&X,(
MR]_54)UB#+0?U# >/G3ML&P!U<%;)=@UH$CLQ7(>=#9S(<Y14*\:%L8.CU<L
MS_@]QY]Q&#_ B_6X6&37X"NFD"54Z:79H;&"4*/$AC<)S2TMR]1&+5<ETJ7+
MY[B?2=S6?'O'XK# R:,GQ\Z8M2KV_N\9NPU>P8W&SE=KT&G^6 6VP\><7NK*
MK7F[!AIMXYE187I^G/A=<Y'<\PJ-'KD]^+,I3Q<7JT:%J.2&R(5$)7=QVFXG
MYO1@X8PG2'5UE:MG!9/?5@[*!9FJQ-*BN42'8^LH?F2W%VMI^O; W>'6#,UI
M:%FD)Y^H1-+@R+4P9),*VV,S;"/2*[^OQG)D)>H9)YG#K)OX()920_1;%@55
M.H\#N_5&F=*+6 DI,SKH]&OO%0ZW!6X]SE^G]CHI1K+3.K%DL202.LF!F3LJ
M6IR^T6SW7D\4<%95;VDT/C,=D#+UF43A=A 4PYK"(#89&6_I5B?(C$P^N^7#
MD2_[F-@UHK]-%YF0[FT+XQ:@/K@H1E)N-X$DIR4XS_9Z"V+%=9Y?2HP(<[65
M.C4;*.V.9>6^4" )0!T,R8N#WFNI#_I]TZGBC/+8:O,Q[Y*(?8ZC0+ZQ5&L=
M&'9F</!@FU:F,?:W[J\]%\,A./)&[$@@:1"MD\]:7V#EMM-$5@-ICG*1;:A7
M61CB'>KZ$2CFLFN \$]"/7>NBZK:$\@W4A@FC4B#C@,[U0P,O5VZ,_QV[#ZP
MJ54]D'FON2M,:[>6J,Y326/V*VR3CXV*S.\@<:K2G4AWY[']0\ 91?*S'RQ:
M>$,^^&[FOTMY>D("/S76, <JQ>Y:)]31[.H39?69"X!BFZO&MZI_Z6^'[>/^
M"!MN#E6HK?Q!U N8YINR%*V%QW2=]FDFA\W2JB_--\=23FE_:(RG:+-;9&TR
M");U,(01@XO1J GQ["CD[Y(7;<6#L+;#>7GK@!_QT>1F-_&T)8*/?J5U!UGC
MEUW,;'Z8R)G(#:-R]70_RYEVQ^/^]$047VSB[):VH:JV5Y8;:JI%!)%I.)KY
M'>NOM=LU%O\N3EMR1NQQ8:Q=M\Q9&>O/WN0^QW;X#*+?45O! .MB7&"0RCX@
MVY!QLD;PQP]%2,Q8O9WF9[]>>P^M(A5@0W!7TUO=8[A9L.B7!WY+BJ5F>3]>
M=BM;SW;_,N)VA,1] MF=+@$P*I):66&LLMP=+-&":Q^*WF(KWI 0T(7F):JY
M;KE>&B<\_5R9SD>OQ>!H>S^(T&5[UT2EIL/AZ<FHPWK,$^ N9 @\>&V"KN>1
MXO=MO<W6&3"#-$I"F\\V>TPQX01?X =&+[MX-HX@5$8=.:YB05^B%/2"J?(%
MM^$9<D[B9=B?#@U)(LH(![("TN+/9L1^N_,0YVW5^;FKPS,FUE@NDDNGTNE0
M1EDQJA6N'<>93^N@AR8@!Y)?U9\&?KJH-9KC%'O[U-+?V#7P#<G:=N:7-X]7
M?13-EED.5&^T+FO-1\M1%%1U0Y3SK/-S)[/>_7%]7_RC\G_ D3V3G?$MCI/>
MELF\$8VM_Q!MLA*=%>OV)3Q?"W3\=+ O^.<L)OQMW3K*B4S<X &N++7-_'WG
MK;>$*:1&6N1)ZMHVMK4-64@>\]N'XV@ZS2G&LSG5PX08^^%:VREH-M']B$T;
M_KG&[ZC^N(,T\#;?1UAY:0=P-@^4MM1J3!OROK[N-<-4GGCE>>(34^2ZJ[QA
MQ)XAK_><<8V,ID%8.4OVPHS.(+"*;0\7?756?6@5MP*DVF5D'7=RZ^?[]9;Q
MB[L3N0/CF>^O!#P\^[*M5SUVE\9A(12LR5OZ<0HY$YO-#!C&'F3Z1U]1) .O
MP9>3!0*5FG&'G 9+VS01<]V).BU5W2":)_?2VDN\BMJ3A*,DI/TRO$(4*Z9.
MP%O71<D$6]HVEH:!P=H/Z!\]/'G".%DD8[A4Z3!LL/_.KY]]VQS90@5K8_"_
MYQ6GY=. )Z&#M*&[-72+5!?^[+;E:/8G9CK</T6E5RSMR:'#SZSK;T?0GL'G
MX'5:UFE!A<C!C?$V_)[U"-*VHTE7L8VFE;!G\VZO;E#M8>S9S_\, Q9;E\D1
MSX[T:5=+/$S$I$KX.H4J$K9[ MNJ+-TZ_U?;?I(4MBR'I1^Y+7+< <KX=^\
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M5VIZ"DPQH*'%^X>[:A>ILOLM'6\>),V$. V\Z+;C^!;< TU[1?6 V XO^R(
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MWN+_68_9.E9++\_'82?!^(>@V:Q;I9Y Z5T,;(OH%7",ZM,=8$U[7'HW[ [
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M0MN?\4SYT[?&TA(7WM6=[;SRJPQW]QJQBK[\)GY66[Y2'CQ"+^/89;VX]5:
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M9Q7*A/)2GFHIHXCYT>Q'$'8)'[/RTNC5("*27,XYF8WP 6F^?;RG@"6!J:+
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M)5P]9/48/FY9A:G2>WG5PD3Y/-..\N> H-SG.Z1Q)GD^PLWN!#W*WA;<)'A
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M+'&"1_!;.4H2<04\[:2C/(NQ+1.B*G@ +PEQ4'"0;+*#0?YA"0(4S5?P*2M
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M>3KVA)9VKLA>6HH!/GC_6EFDHQ[.M=?(&,50S8<L']XH-+T$@ .9[?\(XP&
ML;H@<;="%!1W+QGML/=(HU0A8[7X5:*JP'V!M/P7JSI62AT)0X+5_G?E'I#^
MNH2M).(!-='9E#+J*#N#*#Q@X 368&32*)E1C:MQL+I]A ?LU:-UHR U!K85
MP:FF8.#FQ'I27*UWWJ3?!!X /ZU7B$2)(_?;%6NI(Y;-$:2?^8.4+,GO;#\\
MBG7R8WUB\[G=FY.(/G14:L3O#&7 GAH%6TF!U1=\O5_25K#:^-%3X_$M([WQ
MK?@R_T]29$]4=L?7;[J[@[WY77-;ZR/6[E+9<SQC\WPR^",A_MDI2]V%G:9!
MQ)BV"@PZXBURD2.I%7B\!X-.-O)3Z+PV_H]N":1GG? N)JM?_[4:YW?"+ L;
MM!9H$T>'&V-^U*))SF/F,$>Y4$6UNTV39H4'],TZT4UZ[PXZY3I/9 ;GKY,<
M7*K_P=U713R?V+-77*5#'BSI_?!/V#TW-26BI6TA(EJX]P7';(10PH6[?6)&
M"53C 1N#EZFXNT T8Y \-D^,F=EIF2Q(9.E)575CW8])\*2KBP';W+&DT,N,
M6#HF$@\4?!$/^.M;,I5ISR9_),T,8/>V>#R*YZ,F#F!H07#'4QQ3R$RVV%2+
MZ"HQ??>5#S;\\Q1[DFE=0Q0K30+Y/:MLI68!F5#A;*?=)F3<!TCU6"?I++S;
M*/VX:_D.'M"I6+IDDB%]I%A[+.#7^<:L<K;0AUFDI)]VO<(=@M")FY-!G[MA
M,\[X59\W4K5QPSG-F34@BF(/]GK54K'Y,<8E!SVD\B0^I2J9%+EU6-/)4X&O
M[-*U2Y#$>EB)W3H<0Z&WDGIP46%N'P#_)" ^]F@NJX%.,=(%-RW&W\]S].:=
MZLVW>5*6"?&\GU >UY'MBB)8Q[X10P\=>G6XL7Z,!9,9LSSO/AV.5^-Z=H1^
M>N2T 4%QQF'((Y^C+E>942:*E-8ML%_0[03O$;K[D>%0B<8WG-D&3\Y3'P ,
M==43M81(FW&3$,1+:,3<=J@/L=(J8PS\(^:-Y0U-EZ(Z#-PP=5/EE=NV:)/T
MC7N#[83^1,6<07)N1A:5BXK0#$PXO:&+WF3=%1X %+0HVE&..:LOL7'SM_.@
M7"SH=N*3?"@%VE"A-31D>/CLYB.XN'R(.;B#'NS KV=@'KC2"_.=["F<KR_)
MN3SPZZ)QKYF_3O([=D8Z\R*^NU=?3/4_Q*3/7@>O^8-53MX27O&\:S/P0^SO
M]Y+T0_UB:+6CRJ+8N9F;#C;I=G<2<J-K1)D  #*UW2C,,K9:<:6<3B72Q7\%
M^GX"W*F\Y@0YM46*>1S7U=E>@L>_QBT/C!''A*[$8'FEM<:2'='4-,M&N0HY
M2-7# <1Z)QY0FQ*'>%%840IJUDF4HEO7BJ+EJV!W-U8535,J"P?$%_]>:#TA
M^E6'N0SI;U+\=*HXO[QZ6/0EIZ4!*82\-U2L6DSF&K2MXBNRL>W/GY3MJ>4_
M GY6UV*%_C327+^\B[,5,*K@JD@$0B]O!8T@]W'WN!':YX$SKK7R;MW4=-N?
M#K7F8YB[9O  QW2J#4H_OFK6#T(ZF4+]_91 W#U!M"HP9.2Z=$44E-@;L<![
M9!:&\AV\[+;>9QD/B%QC3RA[>_XN,CMR]5_C)4X)A5YE1:JNE:>FSE&>G@AD
MY'6Y(^J.X+QL?P;S%2960^\-JNFJ]1+T,DS;L#.R,BY#W/9/G6>":M>I^<WJ
M@=#MBP#@OEND(L+P.)1)83I)NZ45'D1U(O5R&\GX@8U/N_S?(O2@C'[?1;=W
MZ61TC;=9]M.,L>MC=V1_M$AYN=3C#W=8*YW^K)^GXP$?E#$2<+D;Q8[,=PY<
M6SC7AFCHG%SDH5M-M3 >$2NP=-9X/XVA(8"\7UZ5% ^XZ8K-K]/41O\EKKS_
M_^.J3L$D]C60S.@,. 'V*_A3,J+)?4Q=E(>#51Q>Q0!%@P*NOS<JB!R;?991
M06J*O-7;N":K5[^NBCB#S16&-]XR'^)[N1)-8?= 1.36L^MTI,+F06&V>,!L
ME]Y4+6^"TUJ6J\V$6&/-GZ>CY=9IX+F7TU6!PGIC2H@^#'D?[FY?#B88D8#*
M0QIJ#!W>N_*GUAQ?_0DRN7"B3/3?U&5V<&^_9<-6PK8.6"=Q_)$8FQ![/-9P
M=B7AH&#B\26ETE00_@?=*GC6T 5!\?JUDS([#A0M6>RWW?=G8/-"Q7:047'.
MO&3[^O@B^+N?^+G!7[+1ZE^S,>O_(QLOD6A-< <+CFX_FV!*G/1CBJ0%.=(\
MFEB\/AO^Q]P$F$PK#,L<W=EXP,L+N+O!E!=Q38TD;L*D,-_G^,,5=E*;*L-U
M+CMRNWKY@67GF*LHYDF6N:KSP'SAU*6C]+,@-> T6 V[E#I:)"Y6U&*1'7>%
M:VC8D[_N0Z___AX4E(PV!7>H*C"&#%<MV]?K%47+!3-9T3%&YPW5)3&?G''U
MQS$OT((M,S]]G9(4$/;\?<H\EW3>CR ZB,O?N0@1H4O&CE:(JCH5VE?W\(\;
MT#JHJ_&]52&AEMYK!_CW58/<+!J0JI'>([;C;+'PUW6Q1VS? 'NQ.:%O[])V
M;-^$__%'/P.MKVGWX 'D\T&JJ-@&%\G/CY8UT^VC7]/;_PY-Z0]XGA]_9R6K
MCV\^!OQBF>BZB26!!''M]>"K)[PF'JY?B^2/4@NO0FZ+L[666Q*7XP':?V2N
M+LG7\0 ,Q?ZJT<$V4E4?0?VI%DCE:-*;'E_[Q_[<]X=IG(AX@KY8ZIWN<$M(
M:D6P'_ 3A#3H?AYN%HC0@U*9H/*T9<;"K:?%N8_YU].-P^;FRY1N6\<D?[56
MZF>5EYW1V<JRGX@SX+PPGCWI_%JJD:=QC =$- Q?_?F;CKN#H__+/V452#&O
MD1>1+:P%(+?>\ZN4QF 2B O_9DQZ9^++#OU&T\(GGO[MG'/-@G^S4F,&%H8'
MK&3":OI"6PSR47'/48'GC$[JC;$GH]MH)YVDP60:D7KX3Y[?C]V?,4W72ONG
M*BR^LAL9O)3<">:T4$/NGY>A+-%BNPCM]67RKD+SA9Q <Y&;3E^&0D4'NT.K
MS$KHY^]F2]HVNWVVD*E"62(NND/XI\:N;G^V%,<,95(]RG'Y?I4(8-J"48!M
M8>_;.*Z#-#5D?(D;Z19;5_;%G&1)N7GZJ$+[F+"1Y;ZL2_M' OW0E[(&LHF\
ME".Z1361RKYHP7T<[<+LR631(>=.JA_6]*KQ0B'N.K6_HHA+G>[:>%FN\[/,
M?BN9<A/[:7*+=N^%7LNW*X[@L@/%"!A%"R?R2Z?O$CO"HM5NC9]D)5FC6;+_
M@?!7'REKCX3DMW?&6-I,D6 ,F?:Y/QS#*Y"1;T^7&B&NQ,0R4W[FE+9E="/"
M?LLOYKW\4YWE6P%QX3#K91H4])P(^U- @0H4>VG]J\[\.3^]GO([_LT_[BZ"
M#YF;P*!(SMSF&Y,Q)2>C1=5H;3=%P;WES:^7.=IS%2E8..0,#R!%NRBS\S][
M]C_<')XR<AU"_09%U!%P\;F.3#DBSE(>@PXXB)+PO;%\7T>:2WG0E"6/6IJK
MS]<#R !S&(L U\2F$6_'80R<<@?<[]97&S@<'0EGZ])T29M%NS[F8K..NO2
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M5$;*;Q>\S/+I#6)E3RL6Q=_9#/ULWVII4=>+*:A>6V<IHM>P>C[:R7XML&.
MX.)=#?K[GY5;6.TYF9)--/WU/ZU;B$9G)]O.O/WC^@P]N6M&IH?*]_\1/;TI
MOF.'"E-WHNS8CG7*:I@;5N&=*D1IKRV3.[@$VQ6,># C#OM&3@>V6@;W9M95
M?R8N'1%]V#0N8XU^9&XLIRPS[AX]E=^@=N#[5EB_^J'WJHZZDW=ZTY.?K[^_
M/>&A=&VD/1V1T6JN\C\KMK;(4@Y(,&&:,DQA[,QDKK@9UL\P]4863!=PN/''
MR$J#A$;EP8)P49G/=MCK,Z;F4@.SE7.*-+X0#0:TA\4J6K:/JB+$N>!^:RS
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MZ3U&*YGOD7U"']X%</YA:9O ?GH2")XE7Z5[V6R*>S2DTNO5\51U1]G3$GK
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MBHMO]J(2S+.N=)<=2*&.2@HMQ]N>Z0DMV/?Y0PZEB=S,;5M+#[D'=S68:.<
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MY&X;<7G(79,,BV\CBSJ"BNK-W],GZOC8F%N=E1P"T3C5-]HHMZE2K;7 1HF
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MKW.=G0GBFFHI2'+($:SN+^+\BEY1O99; 8A-KW8?(A#&#/,*%RTCXNSP\SM
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M+(OQ%*_VNP@?;S@8@-N7 Z[O %U@2JD<2TOFL@/ZH^M/.AS9P[PB:*E"<5S
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MH"9HW&HE_$Q$G%%,;(%WTHD WG@TE-#N_X0(>"H.48$V<Q(!R_O"H.TK_D3
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M/\-03KJ8K[^;N^C)T4_@9 J<H=:9,T6-13LY"]R\="U".9Y[+\3(+@U<\!K
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MB.T2K(X2^CPK] JF#/D:?=^^;'S_\7E$'CMUUC<HPE1)_' '\D#H']S<B3
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M+2$:1&CL_,UX3O0\S&VHDUESHD@UH8JGUYA&.(+!N#2=U^KU[-)P4)S+[DM
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M&#JDH[R_]KOTY84MC#56$'.VUL%!/XI3^VYW8-#XCC!;'V"P&#%E&%KX0NF
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M"!EFBC@E#KMYQ!G-0K*\LIJG7H[>J6L$XB^1LY5]9KC;74FC^1$'94.%D+E
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MU)E#RJD+\5RUVKO*IQQ]KA]RX+!?;/_Y\]A'E"B2H@G>//8L976;RZM!!)X
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M83+48,RT[-7K47O,_V5#"&.""(F.T@NK"ZM4&QU69#'#V5K>X/\-.#M<"[.
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M#,T]_?(1]B@SPWR9 9[<_I2([]0]N)]Y- V:8[PZZ-=J,5NY*4A6+@@\1LO
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M39;;::>9+J1O%2X@N#>OJ5?4ZMG[A==M7_MC'G3IM4EGM8*J_,6/DUUPKA/
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M=R>CO\D252I=^MP6<=NA5[9&[>ICU*^.U-:4:1LSE2F* O3-4.KD5 87]1+
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M'%./TF;"G'4_S>;YH.LEP/*:KF$;\P<\S926!U^>HPO#IRI+3@#K5T/WO+O
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MLEQ@5'XJF@9<*\%NYM& .4<2D@:<=L*NSF)W^$O2@Z^@2:8'2#*QA@;4I]&
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M\&AR=(TJQ4^;!KP;#H8 __:U/$:\/"66'J/Z#IBV[Y3D?_(D0'E"?U:7VHX
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M'8J<]AA#SLZ"RPLVM80/I6,?5%*+DIR.>SPT]E15?23XR00A^5T;VW@=G]2
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MR>]>>2%%,YE+FTDP+KF ]:'8]/1SM$X9%CS'$F[7U[2,9-^.4K#./F^Y?,N
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M;,YO+9S,8UQ>'U^9G8ALF!I%S#)G^SPJMEG.\*X^C>&[)V05^\(QHO=)JFD
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M:+ 5V-HO.A +'K.$,9H-F@Y@?C ^^6&G-E$"'=#)V!:D ^WQQ',;\=L;C$L
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M+ AZ]:6RE24?AL?R#]\_XP1>BBRN$0U]=^JE)_@C6A9B+T\0DTVK >TFE#7
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M@,=WB?=N_:AVPF1-I0@:FU!BE67G2H[3SWNILWN0JU!I[N%7/T(PX@5)/Y.
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MD1XN?XR3KD;N=SOIFF-_=N<!1\,+F<F&MT<8&2Q#'WE9/GLV] SZE@H(@D]
M2;:XVH&>)@&S8YAON7G#R*,'M8&$)6TQI&&XCTFR?RCN-2JKP!8U+RP'3I4I
M8MCD;5I#S#XAE4> :1=K0<\7_&-!<QBM.K^?^&%C0JB .L:*Z(QHW%]*J\]$
M9_(^C,!_I]U0+S.H@*A\/)F](YWV3S%4P)^2-FMUJW-C,-O!(+]KZ8[#V\&2
MJ'TB>A5BH55&FB5B![+-XZH0VS(6NVG28#.0\DK<^_YT,X]<PVS^9)M2W:9U
M&^DTM)8*[!S:A!#'$?7E1./.E0U5@]5KZ&?+SME6MI*^>A4"&37'MW:;+"G
M#4F/:/EIFT0262T0<S,H4<;P!"F#T"AC<,C9IGFKC4GE1TZK&34=ZES+H%/P
M,H(\Y?(R,Z7\",W2.D!W47XRT+6%\:7Y9=?::9_9R=P%6/F?#IB)T$I7 =&
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MP43+L=4EA90!N\*=B(B46)H2CKST7F+$4/#$+,&\>^7)YH":8,3;[$?W3M[
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MWSJD>K',?F'?\ V5E!.PNNB1-AY)K0?)AEBBR#KZFP'Y(S&)J=6'\R:&&AB
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MCUSR_+A;:?X(,A[[U1M\]1TD,+6_%9@$?9Y:G_^$M;91JV-SEWRZ!F*ZZ'L
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M[FW]O1:6Y^.M\UL_0%' _ROX^25OTF7PA_!QSW((1WI\H@_I['Y^<"U./CV
MI%--J!DS>RK'7N%D]*A[\,'<0]2D.A7P%#9<S9K29$EJN1B^(I&FFF+Q2"O(
MMO'VJDN9SI+V9&<8.!"CA8<O9%CQ$-"R2>K. _1U1/^.6>9'U[8B44?P9@OT
M8\BCMFHAEFJ<IE0@VDMV8Q_B.N(E(O,83I1C_6#H\X<:3:0ATI$9'%H"46LE
MGH#>($;/F2S"V3UOXWI\;[Z&&A3DV;>^:#?56KT2!?9&,>']%E)2#):"+K?G
M.$E+[_1(7>;=>MP$2MP'/:G"JSJ_6#<0JB;:>+8[#BKA/RJHKLY_FG4#NTQB
MRJ[&Y1R.*AR?I$P0K CQB:-#?<H-,,%!/QW*AR+;39-45"050(QC*9>,S>SM
MA;ZTBB^C.Z2;5'C93.63XPOF/*07^ZW/H]/(3\\4+I! 'B>?Q5GS=L@B9B@2
MXTKQLJ*1"_P4Z#CBD<ZC^;=RV?4\1K")S/-O.3/G/(ZBFV+&BA'$]O.WMKH_
M9B=6O!*:B!)"H*TF-X46G?:B^P/NQRMT)=]K6)%8DW;9VUUW<:Y%43@(0H'&
MX*6+N>[B^ 4O25Y<RFR#95,8TBR11U:#!+.Q,5YGR6)&F9O(Z0./8J-K*TQN
M?NA+=A:-C]N]06HEZ%["!&I8=OX:8MS:S?0T;UX(>59V20A^ $NWG%43DG_[
M04_A.,)\AD""!CR5&;0,WXS6:K*C H-A07"97-LW40M&ZMM&.7.%U'/KJ)RT
M9\&'@W7"<#KVX1EG^66+'"YN@6X(:&[O.[!5OI_9EW6ZA#OSK7BXU&E_ZP^_
M[@'ES=O7AQ*\K+4>V*O(&]-IG1,UXJ&=>8CU-*N2B\G5QS?>!-[[MQA??@8:
M?Q!\ST#CCX?&WZ)=.<]^XR%\=!/@/@?*+T80\C1VU1*RW0S^JPI:6R0DX? :
MF7FSE9G&1AI( BMW%5D@)9[?JU?JCJ\J,_VU,-8$^&^;UO\UJ#)5@AKK7(/'
M$-D8R.W1!)--WD1$0EH'[S3_6K/+GVTD^I<@D='9G;#?Z!OQK2V1;U*1PA32
MM:TD1BI0C4PB(9ZFOPDD'R7I?2]!)S#/]+=?__8P^<-)JOD(?@R"MB%U:I!+
MCZC /E+;7XGA=K#KTG]0CV6&Z9KI'T"@_@')+2<L :?32AWT2S=57#,'O878
M4L437+(R0^Y)O0BOW-$98?Q@3*1/L@K&/!@M\T524J"A=QX.VUR5==6BX%E#
M5#NG<RSS5-SBVA(AS,(&HH]@JE/9C<Z9@V\UWB;#ZZ @5^QZ![IDB-U/7.>Q
MN]#'-\0X"CFQ$HSC-188;0VBG,?GK'5)]&<(#647"$TH(JX&><.Y>EKO2?GN
M55-UB5MN\UHB(3*J<9B+184V]%.9Q.C-I$4XAZ<G#N[K6=LIT00O.+N[;P ]
MXS"MXX!H8!W!G"<7JMD&U<3R2CXH[432T=YMBK+%NMS"NJ(7>KRNJ_UU KH0
M[D&CJG/OT"(^2=F&+9O3F F*]2))'U]3C[DP6-RW4*M+6YR$N\W>(WB>".]C
MV@C(.11^0^-,MOZ,B\L4F6=@'#1(1[<R8[0;.<R9@7MX6L]OX^9#\(BQ]?F2
M^>K;'X2-;6TKXK.OFQI%-H1].+]L2&[2BLQD*_-J6;FWAP?JQ,547R&F1O"P
M8MM3+":YD;*)O8%,<9:Q]1FW2U#VE@&D4 DUN"\3.2>=EPTH8-Q4\VA)T2O'
M&BUL7 <.BF,Z_@['/5&_?_$=TR*J>6ADJT<KA21;A-A5W5&<E<:[/&-<ET("
MF]:;D 7>M6-X'@<W;$':1Y8]>4 Z^S!+4 +H\;)4U@8HL%U'&F(^0P48\'(N
M-W"&>6^S#-GSTBNSISUWUKDA5E'V':3]84_)0S,&X:ZZ4F^(OLNHNP+F"/JB
M@=YE;(#GX1-/*3<&(_$+V[0#%N:ZI'SM;L3$O-4PO;<[I&T</[F.%.DD8'CC
M_/**-[ *PMSB(I:EW+$HRS)>EH4WF!A%WI$O_<<-[62U@X[^RC+NV; 4W+I^
MY=^=2NCX5C4*FV\%RZI,L(-FL[#B2'BIYJI,.F8ZXYP4[4+@R=KW,JC\;\)W
M+<LU1P7\GE/:H:O:A4RDG0548$P<7O,>;B&R=<[ C[+# (Z/!2A/^5!3* J/
M E$%WJ;9"<8Q=E"!X#8JP'2"G(R=SK $$>@MJ$"].=T6RQML/);@QK1PFC8\
MU&Y2@4H!#8J8,DG.;SV<M@"EI,.'6=.H $<"T[1F(&F<"OC<H'1 C\#-F0YY
M*A<3?$>;$(=K4OH^-YKF5^V':<DV<R&$V*49*QS:L4K3?W928T?X;YXMH_V_
MU1&]R? !_L>,WSS3'[G1VB88=WINBW<EGI<*>" (D,GJ0#Z4W>;WVA!#]\=5
M]Z^DYP/\6WG!5GMH0\8L%1!;%V0BIHC@&I:5%4!7-%*5/VG-O5S\TX7\OP(K
MK8SLRT?+ON'16C7^5CE1*S5"V)H2*Q5X"E;>!.V[I<BZ)4IX][U8-.2KA-_V
M,/G;L^3W"KY3'ILDG^D''IR@L&\F_97 TIAICL=_5! =9VKS:_L!1,$ME5@+
M=\#KC.69ER+NJ-/+*'>@Q"#)PGM)SQWAGUU =(D?'94Z<24J7(DQ<^T,&E$/
M*H3X>$I@I K9NH59QCYT:#6#-GI/@,](M!HR*Q]$Z:K*I^GL%_+4+C6O:MSD
M_7(?K;.DOQ$[?C$7'7XM]TUPOF@E76<LH;QNJ$C#OU =;VY@4Q3!/*PNO3*Q
M%1HH_^08'GG$E5AK?.$YIC!K8)9.FKGIQ'+5^I6G(&_4JUI[MF/Q+[0B: R(
MPM UX@IAAQ@LWX1ZD,1)&B6>)L0;KKS5_6,V1DX"D6/O.Y3C87%^'YBZGKK"
M@[#6"_>(GL:@]A/O%)X+B^A]H (WDP!0AN4F)G S2\DK.#L9=&Z9"H ))G-V
M: GOFCGQ2=(Z,7K.(0T/J5UB(73%$<UNEZ,#RJJP]Z$;"W;8% ?61+.$H:'A
M.FLB'$T%^,A6B1T4GD;A \U#N*/*:^"1VX[OI.8=2SL-L1"*]5)VS(->1S>N
M]N)K5"!<:K;<+,EX]NBRT, +*L!\%-K<DSXCOZ/X249H)QME):1A;88 N9OF
M>D;?_@4XTNL@Z%D\(1!YFF)+0D35V3_JWZ<Q);(,G71=1^(H;N\>FC*"RP\U
MDEJ<8C5JB.;.D84KG,1V$DVK?7;$^J4438+;R[E%1F9SQ$ S4#6_#SA7F[N[
MAEQ0DYY1 C(-]U8S;J7TFF.9.O$#LE6:*@5NGEX"6>T4GGP344KDO+NM#R\"
M=';&Z'3TTS$$Z#A*#\_$3WOT[4(S/,6IS/9QNQQL:15UI;A-4\ZS,)$U$&4)
MC,]["G"Y;M+;])L'\,@;].KM7,_8Y9K *#HSG6"O(['/2:^5M:!)/Q:YE7^9
M1P!_6$YAN^*LT\^^X_\#L%W_7 ?5%S$*G^^A HSE%-:& .P(%Z6/TDF$;]%G
M][P>)R-H/R_HD86&N+,#]2X.K_9O%S)7A %4H*8-:S&TQ8_<O$R;/#>/(0CN
MD@NRM,?$:+^?8U":(+G)L+3&2J"C$1(E<AI\.A4^0:=&!<8MP2/30P5+9)96
M4H(%G!1R&83MA PSD2YQKK^FD9$8*O#B@ @5"$NG<: D6 =V50N\_#B%1J<D
M !@5N*5/X2Z+(M9L/6A>P%ADWPOK!QX$[KS!4)K-^#\F];E-!U;H*%P.B52@
MS9#&W)1!5 "4JK'=OA1'SKJ@+EE'G$X,44.'FX>]??LX7$4,!Z ZSVU"*8SV
M8_U+ *P>)AVG'IE0WB7?FNR6^2K+H3GS/!5XK#@I0F+T!C/)N0U[,5'8ZAJ>
M8#@LW?U"YX\M"(K/3>8M/^@T/25\[ZE^:+?)T\;&HU(<E<3,$3,2LT*]P7JT
MK<?8$/?,X)%XQ8-]IC'F3GM-WA,19PB?SB\5NX[Y6+V'#X?GFB]3>OL8UA.T
M'I4]6+%(] ;/R*NL+4VX#0ALP+S!?)ZW:!]!MB*T3U].&F\Y.#E\8GEA39TY
M\>KG80Y-L^-'*%4-%9X'\(AAID"L*3) E\)!B$G\<GF'&H(0/7#<<,[HLXBM
MM/*M5^>;3IR#+:^C9HRQ,O#A(EUW 1(#3FB@*MC5!\R\J6LD&>=<]*(UE.AR
M&F,_9 .X:Y".0(>154-[2& ,(0 79(07SC0;??FF"%.(YVY!AW]NH9,^GU>S
MW^,VQ\%'U\[=\MMU9-T&1EO JY@I)Z &I!L$WV$3?IL+1&5U\U]Z3YSV<1T1
MQ,1%C9OUW-N"S$W\Z;'-G[G&'Q\_<XW_77E$22V#R[*?Z&;$;DI4H]RSA1,R
M![U%..B5.IXNW?Y8,:8N5K.>[9 ^U*]GB-)_^$"O9^4,&EH/*F)XXFB$MTB=
M,BKA8LH_\SY_<0'1<B5'E?#VZ /W#K6M>><1G-XKPT+&A]#HH=Q5\>(/%7,@
M"-XH%&&Y(5G\7+\_;3!V]+*_?/(K2*VQ,#F;9():0EPWM-D]4+*;=<6T@3@O
MNLF'.M%-4GQ+")_^,EL6TIT$)JV612;S?KZ/DX]<>1G*FWB 3[&1W$1JS:K&
MQ9])+0E(%VZ"4*!!\KUXOP6;X5:FS;#> ?7L+RA.02U^Y$8_HW+9)!I,H]?L
M@6O9^.GNHC*NL\E/W%:8ZIX-D9S1;)':^<!NE6EZSVY>N?I1<<T)8^A4Z=IG
M8^XF7-\'N27BT$1N]BB(?0XF6+)2&**[I.DY[O5&\P-V$76%P/@^VPJT;U;R
ML\".  V\VC+E-5QU>G7([XJ_Y&%T&C$W)&DEBV_BY;S)Y+C[FCO,_37K2G#Y
MSE+I[M>\J(DW4I8=>;C!1"^?J/E >*#&"UCA;)_RXS?%#6&6Z?"*X.))MYQB
M=9Q@./,+B557V+' 'F9-BAII:!/$'SC:>^E\P<)?.>]KW$)R56E,'/GE,X9)
M>'79 F^E77_D^;YTVZ6P*%*+Q\%('(Y4BEC-:5 CP#+_&OJ;%V8W<.PB+E+6
M/4,%+M:/B6?>ZL]K\WJ/;Y&M7%8+3LPI5B6XWOA">_*[&<J^T//R&NUEG. #
MRCSRJJN(4\L+(B-;V_39R/3U\,NQAL8MB)MM\BG73<M59\N*=+J7^;AF^[%Q
M5I1M4K+KII717;K":T=8=MR09;W1=??NOKZ4.B% _+0PO_FO5/-':.+T]WF7
MG^5!_DF@HJF #>*S<\/Z1RKP1&P!(UR"*R;QPFUZQ_6R6Y'K"%[IIIP!S.6U
MCTN66SZ! *F2QDJYIN&KNFM,).8&*M P_?4=<ZL4M,-Z,#E;GA/65,;0C[;*
MSG)_DAN=_VD^5X@\!2UE4V(_'K*HPZ#>6YG Y!]'V>.6>#+*-JAX-N%^1&(#
M;2$,FQM!]/D.#U51 1_WH&GYO804#[Q [<W&O(GYU<^C'=GO8 \D=^JN@/K.
M:SM$[;+)Z5C/HSWUN><U<NJQ)<7\2#3[L,I>C?E+,O?NEVELN<4!C91AQM<7
MDH-[FHT/X1Z6X^EJ=0V8GA4$M;@8H+VBUB\>*LA[[Q6I?%GZ; (040>8]!3
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M7J:8S-GU6-?ZJRU\^X<645H$1CS345AO'_TS0H' OFQ3X\M1&JNNF-+CN50
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MD,W#[+-&C8(VIQ)\P"B3%N<M,.G0M,1JZUN2H6BO6_;$%;/$Q><-)0L#O#<
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MH/(V!;A&=8<WT>1?U0C2Q17[?#N":0-LARF:?$@!UKZ1!W$\I&-I%* :0Y
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M^CH(?3INOW[=&SJX6:E[RG"T;B62GQ0VR]J8UV"?YM)W^JK46'Q\"!UT+/Z
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MY52:8Z$S70U@8"1T%\( []*I*/C9Y\+[K2S%Z.Z-E7.T"\\4 Y2OW&=C, 3
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MLY\/9724C=JKC2ZH*'@NVN5U?=X-/@*X90D-?(,P=KD.WCSKMSBG-](UT]P
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MQ&7J^1%%XM(KES!]O:)<)6_ZBH$N+1[W=-'!(J<@8&!$-F"$\\%XV'ZN^T<
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M\( K47C8VP@5^FWR38MC*@.>Z9\Y$-8!M# JH#@Y"C]MPL44XL':L%&YGCT
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M+]#WK1/T,&>"B/7!$1#8X<V!TP^<-VOX_2XJ"9>75D1:!_.\E-0( QC=5 8
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M$J_6G-/E%;UP-_[0%2GVAOB0F^I,^_B(8A@4B4MLRCYPT\]9T>(#=CN2B_&
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M11JB[@KUC#Y$SB?:KP"_*ZX/[0S#FBK@"4U>B@KG^]RVWK#W79?:2?A'1%4
M2C($&T=A_CKIRDI(P=?W\S?%#5OJVF0.?5O<,/OP'C(_I/NEV?-^1&-(I<33
M/H;9R"M3B<V15CTKKO7'?=[AA]1#@J?,JF+X%[.PD!?%Q=5?D2O+!2LSM755
M\=;!8QPR(A_.T1G==C>-!3#DRM$1.V@0I0!71@5$4 $V(!;1#&%=T6A/SZQK
MPIYGT:+SZ!ZC1G9;SJU1'\7EBUBU;;P?^16)'R-H!I*R-+4B&D8?W_$^5A63
M\6GB)6MNS LO>_DUN1]BE/P#*;O7# ?D"T%-U;:M6?G@H85DS^JUY-5UVV#Q
MQ*^ISP%^<6 >TB,:W"N#\A),\.% EC8/G)AYM*1P3U?\O8*+\GT11]:.?A)G
M6*E>AT>"RTP:D=_7OXZCU<[WE>9_K(G3B6S?[KU_W[DB6N8I>9)^XS,GX3NN
MC\(<@VN:$ALZO;EB!P(X&-I>2PS>OG)1QGE;)$D;;1E$1UF!TFZ#ZE9[!?=Y
M;3<W*>[8.Z8E-4+:(NO:M.W4SQZ%P)KE$U&ECE3 016AA",">4MIIYIC=UUT
M'(:=8OJYO(3RP0@X-\A!YOFXX!:HPF>CE2_[^:AIK=?V>>?R9XB=.?I))2I@
M0E*J*W]+!N]'NT!9\\5=JT0DZ28N7[6N_]Q(420FLV'H"P]35;SOQ$0>>BEX
M[1(':B($M"X/-:<A*FE%*D##PF3)Z#&R0?\[&H->7LO4S2:!L(5I 15TUSIZ
M71)FYUR\=DHNG)DXVOS_L??><4UE7;_X0=2 @-B03E00D*HBH ()C-)%B@)*
MBPH(B(@("$I($*0W 0$%*4I11 A(KY$.(KU*"P&4+@DE!)*<_((S\XPS\_[N
M^]SG/G/?^]X[?YP/YX1S]CYK[[7V*F?M[]IV5U& *6'U[3^U3DKPM[9ZGVWW
MJBB;+"KR58B[^O5N,)]XJ]R)<8!))/E9+F("TX!F0QX@P-(FEGAO=<X,<85\
MU?[28F>];AVN*;/@N8M)%"M!!^PCR5+W7T^V0>NM#A*@CZ06D"IOKUHX=+SQ
M##"-F]/*T A/NA$<>\/IW5TV+3F_#AV AB!@ZB-9/><<@RKE)Y*XZT\.OW%(
MZRYBN6,F+P;DA4<PU<S/6@JBS]*!?#JP&#D!'5QOX.O/>CEC=A.[LV"[R7K<
MII]6V$&%FPCIKKS74JZQ=T9,YS$+_G1@!Q\!LFCL#@V<*HFI&5.Z]BF!8ZK6
MIMQXQ_.<K[M>71 7R3*^[JMZ:+\J]&J7NJA+R[C!MB[$=K +1S!U#DQA69O'
M<GJ*:29.*&#L%[D:1A1_&K@8HGK7^.;0XK'M0H;WDX]/OT#2@4PZ4'-7^:K@
MJMX;I$Q7KE0=:EG)Z>*5=.'/(<<A<YD^<,LWF$2T+7QX %^R> UZL<NVM!-I
MR7[S:J7*6Z?])W=CV"+CC'FG>:[WOA$8Z+[\B_S=]$RL']+W.\5&<[7JS7'S
M%FH45NE;6W@E?EVM[WDD8+ SB6NCA)@(LNF-+['/E?!YU*5 +,D-A^^E# W%
M-@TZI4 ;!+SX-!#KC^V&*EO5&<PV[AFGHB&<397NSKTM%[RO]7(<+^KE<P$4
MSW2O 60^G N?\GYI,9RP3GK?>>=.I;"'2F;^C9"A /^L0Q'?>O?[C.S+?;SJ
M+O:FO=O%:OI?5GU_XYO]<\?_%GRSF%- X=-^Y.63%A+KJ:RM-](>^*Z_FT\R
M%.YHL](C0DA/"/&/J(,W>]5IFT22$KO.^.:)]CZJ%JSO'RDN=NH"*A87-L0;
M6C:$L+#4J&G1T@X^Y.5.9<Y;-_O=S;VXA"4B/D?1@5&U..</ILU"RK1WE<83
MUB)\9U\'+@P+N]E]2@JLB'K$<'> 2#.BX_Q\DLZ<;F)K\)W<7Y)<>F-:,$\;
M7 3%O4KM5V!+ZB ZBE0J<R#'J+NA-?:^&19K2TZY0*:06N.LCV+]W4;34JM[
MX0F-G%/:5,GI#B[/:2MB$6Y(OLIHT@#YQ42CW@&<XXQ%,UTQ1NMW+KG_I!QD
M;D==O<.]LD0V;>EOF'0]MJSP9:J8$D4J/'Z:/5-@5GQX405<WSP@X6BNC1'Y
MO%U/\J%XFP<?O*[HJ-F7A/O@! $[X8CM0NXS-A9^K)$R:OP!8\=65_36:S#P
M8\4=.M""$O,/GWBG(MG$)N2!LP6="<H5.@2.AA:3<K04NN/TAG/'ZY7<%36"
ME,G@LG1MRE)4'#S\(2J40"WNMJ9),EK>EE7XC"$L%'89<_^:^8M\ZP^Q\YUD
MJ9O.84T.)J@E6X;3[[=2]B5!T6?LI[+(U5S*>3**^P[CV>Y"+$L3"U1LUE(Z
M.2#JT?+ &\]IKG2R]!'F*6BL^WV88(0 L@C+$9TJ8!P;)'L+>.F<F>[Y(3O_
M W>1;G&2*H=Q \=?!6SW;XK._IUF_G>:^7]!FKGI-)QZ@ W<98E!=6 /2%$A
MA&YI(3IP.<^O;>".NSB?6X@FT+!MAWO=CHUG+VAK GL<9Q&#=A/Q]8AP++"Z
M)(C4#-4KQO;G'DV\6-(C;;;#7/[PWF=R^5*?<C\0EV,GJP!OB'&1M$Z'>L\W
MYS6V-U*WG:P=7I>7/=$\H)4FM?!)U1C8ISUN*DR,F51\C-KFN9O2 ,KWI76[
M.5H<DE[154X7S#^?9*514QOQ(<:'%?H46MA!Y9J_0L['(PZ0)6O G?G=E;(Y
M@Q8.KE;SKLKK&/8W!N7IM[/V+UK[7/ 1FLX 4.7D2Q-B_LJ> Y)XS/X9\(BC
M0:9+.J[![<9H4@6U6,FU*#^Y%!;;.;#20.$'A\8.T\+7,'M&9L:@/<KJMACI
M<JMAG')4\W;1GY(OA]PM6S%7BBUGMWX!5H'-6(*!?B"N*(A/[ZTV'B$@XB22
M+%#]5,O&F->NY)E$\-/=:;OJML<VG6):X_JN"4W;H"7ZB['7*8>HBD78XI*B
M/JIM=MO4[%F]UN,:QH=:3R5J'3EE!($<3=*\\(1IM8IK0YL@"^Y:) I/O&Z,
MW$96-" X^^=(N=-N=5Q(GABTV,A/[Y&0DYG5&F$6L-F+R';;PI[5HQBB:RY7
M"R"! 8SR"3R%M?H0^6W;$'_I[=SM!^]'[V:_=]&XY+2*,5>^+^OV&SZPSZ^P
MA_'?#:HR9ZY,,N)55>;"LQBCYS:2LY4O>=>'R::?4]Y'4@_8,>P]W3=->++1
M9"WLE+M4@M";N=HIICB*<AV;Z,Z+W5QYK+M410#OJ^I<1&[J@5!2.KF*(MZ$
MA^[Q/,*Q>[ZV/"NZ<6'NOJQ<C6>9VT:<.GYR]%$$NW3'$1_8Z*OJ+9/.$QPV
M0O6/0?IRE'7B%&"PSJ]M7XI">"9*B^XALR8U;FCL-@RXR'*ID0 9N/R?^GRF
M_J@>AHU=XH-U="9K8/&G$Z^$@GOI0"$MDB(Z>Z@CY<N#Q'5A.]I/UCQ-\M^*
M5AC&N"7%T5.8I$(''IN#^Z4EZ_E2J"*(6Q0Q$E?EO@4*/ ;[:>5F).]*#T^'
M1OOI9D@(':A+1&U#=TR'P0D.W'2 )PT4&";L!]'*##O+;PMZQ!9=-P>RH#MS
MB S[9T<_G/I<DPK#C ?2=N'VP F6U@R-^I0I^WN2&.M6DMCQK20Q!/5&U>MQ
M^((PP9KDWIO65RF)-TZIWQLF6I3]:<!#>TEH*5INX%F?]G9?ERVSBC.;?)CA
MPY;4<U*W:@,LVT()FUA?Z*HD4I71FGLD'1 U@.!63:/(KJ0$ C9X"XP.I6@V
M>(M(-E(1G;^BX'IN3_6RTZ=' ]>>9*Y\4=A)O7=2'5GV'S0,>-,!==.>I1BC
MGD7,$?9\B_/OW[CX,@,:WAO9_YT<=LC*":(KR9<<3L1=HGA$*E]_ZQG>%]KD
M[*HP;*]-!Y+OR@A'@MM>E>&V4^%$Q?JD.RK0VF1H;Z7F6^WN'MTBK^ 3+VS\
M(<R]R9"'2]7RJ!;T0:S=9QN8(L'D9>;LW+"I\2/UMM"'*/!D,^O"NW->IDED
MW<;D0X3=10<Q^"170P(IFWNDJOM;\I@M:?=C 2\#R AB.\.3CD!S5;J3O'!"
MMQZBZ]I.$-KNU",040,T"Z<ON9KKZ<W?BDC%#']B>QM9D' .'Q]<Q-4I0HP,
MDBX,+=M_F2CB.VGC"SD<O6>[KE_S439VSL0JI"+A$LC&1/3#3W]>H-HZO:9J
M=,<P)1/5,PB&@_I\B\H>GH,I9A3=<PS92T?N(W<1!NK++<<R/,8C]XPZ<!L>
M#:@Z.)@>]?(:E\Q^-YM]JOP?]\^J0H.X:.>1#"&)@M3!2>S%#--$%]%:A3:$
M<J*GU @=-#]I[*I1)T3MG]3]D(E(ZD'H)"IM4G:(#QKH8M&<P/G8Z;!=D8F2
M2%7RT><9PB^/'#NBEIP"@Q$Q<K1H] TQ,HWP>D*_OLKC4FDW51JO!R,,-=SD
M;J^N#AGL*)!BN=++LRY@LP181TLQ%D)EX0=X]+!I8[RB>*MSCIIMEID2\TJC
M4UIP4(>%-GMHT[IC)QVX#A]FJT7O9H@&+A3!@KR.+#\_E)F2965OVIUUO.U4
M_TW1XOM0E^#SXOK;"[:I#;% 0E'-T/?L=*"H.(9XI$>GSUR/J!A82)8M;$XZ
MIW9_H7MGP,7YBEL^XX2'OF<]/1[+(K7Q:#Z' 5"0XIX27%A1E-SW;M+:A9V8
M=\B?^0S[6>LAK#IZ/!"W#-\*YN79QH/AT5@S-YIHD_;5@XT?QSYI-8R8UV>5
M!8O$/&H1B4EY"'Q![2)_0P?C6)4/3U14'"N<7S37+2DO+T@6#1Y/>O+@C;&/
M,&>IUZ.$#25P5Q=%"X'D)7/;X05WS@PY@@K1YHK)BI(B"B?>TE)SSW+C!-#?
M*B:C$*ZF$]S4@_#&DYY^)$Q15_T[IU7!;?W#'SL^BD2E)R4*9=B$H3^H \A0
M AI_$4NLF[!Z-.[,?DY@J+_ 9>K<M,+@))-N9<3=NV]"VN^RUK[8YHFI1,FB
M:WB1:N-P_X>!097RDX-4XPF.DUW?OITRZ0Y_/R*1.WU%9.5*'""P$_%BW2JV
MG;%B<2./[<90=#UCS+:6PT&0_UFM%B6Z55F<!_UA>QJX U%T@(E:2A9K?-A4
MA^6V!\4(M-6$.R7IHYH>#NY[OXB<BUJ#O(3XLD+\$-VF"VO$ASV3 S7Z$/)F
M^ZE'[A4[DNV%G5K9YW3T>%1J/T9@"7R@!QVP[]@U3.8G/2+'XN=/Q[%)R]8G
MA&<4WCI^4*0LRAIXZ+0->P4['EI]TMN1Y$04"_SZI#)!+,CVQ#%E$;ES^WW@
MBZ\^H?D VK:MQ#1,@S-94G'Q^ANJ%KG G?#Z?&4<KA;&]50=+>#LC^T%=K0^
MZKO1_H%38[?W"8KLA-/#X=HQ@3[W[+KB'KW"N&7KF:B7]VE,F"_S]0FTZ1"J
M^EO'AV$YL)=9EKH/7"4%XN,T9190&<&IG)ZT"#IP \T-#L)$J@.URT-5"8WQ
MA;=@A\J#/D8I;3,2GV3/O+I;SD?5L$58@G^4#CARDD6^8@B<>%LZ$$&5GF2>
M9!,\<D(AR]KEFO3KB+T^/1KGPWA-STC<_<GWG@OB&F,FX,J:XXC/D:2]A,@@
MJM.$M%QM,7BHO++O9L+FM7 789VNU'#4:OA4'??'U!>[8\>PU -RI*ODYW8/
M\%ZXH'+WT8!LYZ-)?<4Y&6/#YGKLH?E=8_9<VY[4"^2-)P!4=5H*J.A(!PJ:
M&L(A34*"I=&22;#KI%#WVT='\X7;'C6YNT\.+E[W38V<-?^I/T=9^^7L9M'C
M9/=P6J6'R3+G9'CO2892M+(;=_Z\-.YVUC(N&P\/1&V/:\1O+QZ*2TR_^K'@
ML$C U=C=Q Z(V%"527\_/[]]SB(^8FSLP-XF=AVNO:H?#"  4^,.0/=?=%O^
M_H#]SQQ_W0?L8\?8;O@(:I>_>N"[_C9FCE7HGOVV>2W(PQSIB=1Y"\UPF*0G
M^@,IT\G.N"1_NZWU_4^1O^Q.<B:N+SX_!=K^&F(Y2S,YCCZBC[>Z+WF\CL'Y
MH2I>=\#)OIHOGI6NM$^GOJTBT!M04T<A\??=TB)EE>4!W6,GXA,<MAVA,3R7
M1TA56IZRRJN-N,T#1HX#UL*?$*/#65M[G4K&CWL[3F&Y/"=_'[;9V$_KA4J
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M:$AM.O"23[P?.R6'I@.(?>@9C1!@ ?S=3LU<NS]NY?P?SD^$IW!Y@-;-<-L
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M&[<S 0@$+FQ:,0=R=,>)TNK<MC8#@O(K TV<'%?,R)?,HT\_.WOU4]VTV).
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M.'[Y,>"KQ-?S[P?*$/W=CE[Y'S\$^"C!&6[9\LY$L)J?#JB9S68_)S/N/.2
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M.0A6='-?&GI@ ;YYXI9M ?,\8P0K8U[\9:GX;PE0*@J:<Z_HEU!AY:<ZLNX
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M"VWH#[]#__QP)V3UM?H6VM $)$2><PMK*/1.I7;V"#D'R?_.DN.^XZP5^4+
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M.OT?%(H5%![^N5!LW=[:[X5B15Z]BXQ]^B)IN$)Y29VP+W,+L-<ITU.#X7#
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M/^;*,K(RWK766YXYY_,^$^-;C\.PTYU>S$A&"_AXF5,-\##8$GJG8:'Y+$G
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M 3G1E+4C* RPPT84_X0XWD\L!VW%3G*'EICA99=2" +W\-0<KPPG&06_-N<
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M'P@7&=X*G&;B:;1Y(:G..[L/[49Y[J43);&5B+>P*.:']5A\SL@04#MSA@8
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MHD52HTX$@:U22HC*&6H[^FR5TR+7YBICS4Q7T];M*Q4B^NTO<2JW4E2,QVF
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MXSX>=1'<X"\C',RC ](58H[O>RM+33<Z[KMDEJHQ&G#>U326!A#+7T8,^4S
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M_"H'B>"M2*+M>RA/\[>OP[H$S9-#U5G-I;GU<:9OXH,J!7B##@FRJ9W#*-$
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MBMWNW7D,V3UR<Y<"+(KOK/\=7)OJ_;V>*2H.8B+TLSKUSQ(J"C*1"BW("*8
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MOXAN2,V&H^9P4$G+ROX:43WG\G-X6!H%2"I\/.Z[ #&>6B\6R[OF)+/D)8S
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MFDKJC3L]N]OJP QP/IAL]PG_:T4UZ"@*L&+@G'NCWLG^4/CY.A&:6ZY$0)J
MML-ODAE3"%J>3C@'4O)LG[*EYY!'0'&>D(/H'*'5BVNP/;+M:&@F\^$*B3A@
MNKU#3?<&]?KA\&YCPU4I@H;ITAAOI?<XXT+_#5MCJWH!36&F.[-OQ  U6\&[
M,C*W.;#=O@J@;TZ39N@FZ%#AY$  *L]@4\?A$A2J?G(M_+)$5X:K,ZG_\ ID
M?;H:GO(]+PK\R )9D!2C%SQ3&.2&9+&3RW-PSZ;SXTD]U,+U9.545_Z2[][
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M$T"DLGD_&)&GLT8)WF=^&#,>E*Q3O4]:-<7C_@I0873/VB@B.Y:QS./ZJ.+
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M3+N8 DR[TA#;NJ ]6L2SXW4=>T))("H7.DA=V7PI9)[U26L2NQX]!9@(&*
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M3[<004E@/&D2>LCX%"XL9W'((;%=\MTL>-5?X/ADX'7O0PR+9HA Q$3@F9S
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ML@0'?H+D<]=Z0R+&BW:>$D]DJ\\O1(T4SZ4=N\QF<H'O*C9*@0;'L*&PN[P
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M-<5'O\VY4TH\--<W4$<!N"6U':+,;?.?)LED/=(#8T[L&<Z-K_)/92H[$R[
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MO<[YE^7*_$X_6'3L18O_8$7(BFD'Y8J\#]ZX]O/J2.DQF2^]7"J0R(O7/23
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M-$-QR +7QY),U5K7>:= )$$Y4N\<BJ*%7/&@ \\-&.>KAA@C)9%&DP23U>E
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MSY!Z^]1P=*#(JEH[-@:5#ZKEV]R7%7!BT9QL&+%W;.Y2W+5=^I,5.(O6-#&
M8L$0E==AQL;$XED48>14[W;1F;3W[RML_>_RYK6PO\T_=@"&;;=%S?4NR4&:
M>QE*BQ04PPWW3H.A:WK-7D$'E :&;,V*M>W,AYR.6$2]V3?%Q9&-:/M;?X82
MN"ACRPK#ZFJ6O2?YXG:S.!>6%B5/]5C6FQJJ'A]1EI3E]&MHZ0G4_8K^A"$I
M]=Z]Y:<+HAPFZA]W)++9O!QP?Z^W.[$?YR8B-)<Y\9[C^0-\%OIEN0,=8%>A
M/BT'.>B,XP2T6JJ-[+6/2#7AOIG$Z$Z]TQ>1HQ:?F3)$&".^0(I"L\D.L/6F
MV:LOVR@[TV3J7DZJ')>LNJ'3."83+#-KO_EH"+"C^0!'.;)J!SK'D?JB'.K\
MO+)1(^1*\BF$W:3?U1TRO5OI0#:BI7=LA,)_""O8DAB)'PE/\BJ_#M&Y+84J
MN2[I6)O_;ED\69#-ZZ'78&S7":;@9PI^IN!G"GZFX&<*_C]=\/^MHK(]':C2
MPXPFK;^**C=Y0S$C&7@(UE$7Q9_95D>P>2B^2DKI2RC(!SU.TVS\8A%_M'<L
M+*(<E$,2MGEB3)2*S'05*P!/7_76MBI^K)LYRM_9@<D2:^HM5WA!>CTRLSX<
MZ_!6/TCG#=GBF=]T3=!>UC6/\_NK+(0N7P>FH-/*_9XTKC*BZ4IH3_9^;SOY
MQ0\I/&M74+8]2C8:B8?:;(_VN9E(BM^5-'4!:-\FP+QP8>SAN )S+E<MU9IO
MEN\Z+]T)D_YZ]<P7Y:\*F:E;H=CBF@H>K/(=57,.DG/C5=4C4OT>'L\EGJ6]
M.4B3NVQZR-=9KN)6P7]^0GD3GN?X,X;]+!TX,7%E IK2B^G"= 3JGON] _T2
MXG?L!G0C';BC#&D'/26"R%^0U1AUQA3ZAS5MR/K\OMV=]?DW6.4UL0+/=6H8
MX_&43A9="G P%+"*W[C-X6<_>H[E+Z2&QX^07+?IP./EIVJT-64"ID5J[6<_
M^K/?U#H)GOB3)?R^[%,9A<#E:="4[21$"PYCZ#I@Q@RB]]&!)5NK]ML-ZXGK
M5I]14N"OYKV8Z28D5:@[6QEGW"UB11.@@K["E1@C-=& J]H@W^#F[UI(+H?
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M<8D&@9;5H9-%Y]1NM*$G)9='@F%I"T.:ACN<\:Y$Y):#0@T[;M"!E2\^B73
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M 9<U7=:XU8V_,KG*;_A6'_NOY.3>=_SJ^T#G?QN_8M)=ICF8YO@IYM GM;%
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M*7MYNUE^N<%C.Z*3$[0Y,X+T^*A:%W<H8L,5A _K%0NY79;.*KD1L&>?*17
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MYJ9/4NU$[GK 4Y>\-EDR;N&VI^1EY<O]ZQ,UIR@+ C9OWM9]XGX-49R0TYR
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MEU,0F1ESJO5AA]N(F'Y':[:<C$TWJ27JZXK60_DKH0E78.,>#.?'9]<>^^+
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M@@H5.X53WV[&AG ?HTAVJ@H366OIP):E!3R$RR].CR@>)UC>Z7&A(MKYL:5
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M7]<A%-N7WKDVV$EW(F"/7$YPJ>"/SUP(&TT:67?TB!A&M-O+1N<[]V9:Z4N
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MYN:AZ#:C97QP$ /!@JYLA&'_[-.&&5^C&R4^%PZJ*E1CC<Q-^,*G8CI'VJ,
MQ@V*_9(5^4&]U!\9@=44TP9']VQ1L;3N,/<QF[VRK[B6X4U\XV1("RZ&*+:I
M$5GCQ^8YT=9(C3TI[TW]Y2'49,D2ICSNA1\G78F";^:I@O,&Z[M0G!P3!UC
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MQY-A5G4[PB$-*/# 4.,KR!1J*8HT#FU,(X]XW6WS>Z?^$MA1^?1!\(]D0.;
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M:+4/L +"+X(P,JH9+EN[SRM3D'S[V79F.6),PW(RP151@CN5:-+FNLAC!;
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M+BT,!5E#R@5<(U:$>,W=77N^<@U_(]9<^&Y7\?XS@6]X6D=$ &K)C#Y-@(V
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MN(%0F!K7R15E%E'BZOXMBA'R7_N&,(WN%'E%6BHK$QC!VM%^8WZET$"I&-S
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M[Y$6"O8(M.?O:]K%UPI7\QIK DD@#7+96_HEL=%#-YD 74)N+Y3P6 \M!B[
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M+JAEQ];8$X8\1[K2Z1)RM6]UZZ!&2\!72Z)V]R^()[RG8EE]6KC:G7H_X,1
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MU _9ZN&&EX^+'V_QWQGY8'L^T\&]SQBE@2]N#2^HE4$.00][#5G$&ZWQ6O;
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M3A"G AP,Q-.$/@P?Z+_3J3PQ''#9M".X"#(NAOH4TA,LH;1<OHFW;! ZH)N
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M#U. [!$ 2*;D))I;*;25(/"#1$/0Y$F-5)U2K^)+LQ'CN@C"\%@#(_A4Z\J
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M7]KD/'S9.@0//& UVR,D\#:+ #T'UB36Q;YV'C;L!)Z^=Q-_5"G,,,Q\_]E
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MD#F>_899/:TMJN%N.6*@C9$T$D%)(MX"MW"44!#5$*#WB"27UYSS4^TZX_A
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M#^*RW>B6,51Y$:U?PP36@+Q5SIF+/UM%D0_?W^K0=%HOG)Y:+B1A9CI>T05
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M+]+#L\C9^LX;]7O6UZ#B\8X',KAM_L6^_*++4O4'&GA1BB1XK+(C>WA$WK?
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M#]&_MOR% 9P:)V;1V^2D&,"5F0RH,G//OV#.82+U.@/ R6!H,B'X]&[Z,P9
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M!(!ILL;?TX+-P)I%&4#4KC[V-[*GF90U:?(04*U%$THDCWV]6!V^*&#GTP[
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MXCB7LKCQW\IG2Z["^2?LN]W>61N%*/PAN\'[^8;2;=Z+V3_C7,+79=K4872
M2?M"XT52Q6S%8;.TZN_;Q=SK%8;2M ',8-BI;PYJ5RLJL];M]K(C3SRL^\3S
MYY=L@3N 0KOSM-.I<$0Z'1 *AK7CN +\\H(KVNIKHI3TGKKQJ_;&53]_V2VA
MV<UGYR$Q/2<JW%59B3:ICQH>%CKGXQJ0</K6E3[)Y^$?6*12M "K233>1GY/
M[1F"S'\'N^W=$?H(CZ9=14> JQ?=Z$!.?[@JEN2\ <&%;3V:!#@C'T8'.HOV
M#?N'<@:\^5X4R9YF*VMA<9\M,=6"][JM.=$!Z6N$Y[0N#>A@H_>8 ,@)#.E
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MW^85"C'X=TT'(ZU%=&E*8EUK37BV88%4VCF2P8>X9/%\D9KI#X:(<,R"<"Q
MG?['N YSDA!^KLVJ@A34SM*5==S\Q(A1_\U4IY +FZ^D[[,69CH_[DV(]<)O
M=#E>'-(\01IP(%RO.5\[M%,TAEF?-PUW2>ZI9KGU_-/J>1DUPQ\;%.U"[?RE
M0!755,K"'<OJI,J/G_TRSQ9(93)^#\04-C-#.0-:1M=!N2QRFW\PNU:@>&#A
MK'5OPX?=,W?\9#+O[UD8[T;; A&T(VB\)1V8I0-K+C,R!6MCE2#;]6:)P7-W
M SOFR]P%-%046]5A6EVD:R@Z8)6(ZL%]W'B"<$%$FY*<6@E5'5]7*SP?=+0^
M\BNX?EBE6G,YX4KVC/:ZT07B_^T\^;^=)__GOK!2_^@\X:J-[L!QJ%L6UO?_
M[MPP"F)<5[\G%7MD]Y@RXJ<G]0[F!?2M/!R#&VF#++?BMU16N;\;Y2Q,?6):
M:NM[1O3:T77_8Y^UQ&QNA". E?W3U$>A7BR)""=L9-#W+RDB&L)R9[7R7WC9
M3ZQI1G,SDF)I 2O;=K0C:F37)3CKCH/.##)^1W"[CVLEZ,J&P6"I';>=8YEY
M<*Y3:^XCDZA+;%_\=S<!A'-!KB5'=D12"-.-[RP7"&JSA]_@\V?ZGC:Z%!WV
M5M,>R!]T,_B,.]$967T.?%I>^3 9BN&2!^@AE(%4/J]%D_$]O'PO2;-C]F7S
M9P8HKTU77NHK#B=;?3OHRYU@,8QN30GEQI>^%5LO"5&\1TKQ"IJL3M9KZ1],
MI@-R0D,VT?@/ .3Z\)3[#%1CCP<E:77Y+6"^HQUN]%O#;%U5JG."[H[E#6WX
M5<HX]*\XP_,D+WRKDAPQ<&C]59=W*]\$:;IFQ<&*PHV9INY&H!A7FI4'TX+1
M'>G3UFV28ECG&H['NHX=\Q[:E^;UHI-C?QX\U2)4[74'[F.FZDZEW2]\<Y5W
MV$6&%+EYF,\<C9PFN6T+4!"8Q1XB;U5-!341Q:-_AU=OG+DQVG--9)0?[/+S
M>;B#65#&^H'3*0BQRHT87(4#YK%+@S')4%U(-NWCA!IJT\A0RD/B!6P]?DU
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M3Y.HS^1;>CXZ[-N.(9V*7MTA*!B6GL3+HD2:TZ77'$5J'QZMVXXT3D%L_ 1
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M&H17F0W#M8!QXC!"1];<N>A"G4#"VY8TB=$T!$G4983&C*S%X6]L/$;@Z^F
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MK\"T]EC3@:&V&8>S2OOL!N$T"TJ?U?:/OU68OK-D6_UO*DSC]13+@_H#=-1
ML!VMO0=)/=><#8O1_+>%I^43V'3P7]>9O/9CLF$+030V;MD!U!B.+R-T0[C
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MR]S_@[WW#&NR6]=%7P2I(D4!J4&*J#1%FK2 2/N09J%#E":($ 61T!($Z4U
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MYRNZB_O@>/6U#>2$+X7I^CQ;B'\K,BK0[1.BJ1DGG6_EL9 YK9UGW75:.]+
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MS*^WS*':I1CA$FLG_3.)RV7U1C$O. 6 [R,:9<!++11>Q+3)(6"<YK-W+["
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M!B&[%ZF_(ZB6'@*+*=L*/SY6!RWA2V0FLA*S_P_VWCNLJ6W;_UZ(B*@8Z8I
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MMZA0H?(G@RJWJ%"A\F>#*K>H4*'R)X,JMZA0H?)G@RJWJ%#YOT!;1*^XSN:
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M0.&6;Y':\&3X./JHYV5,%(DA'>.ACLDMJ7YNQ+D3ZZ7P35 :JB/ZUG7]R>I
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MQ^I7RLLK74Y\YVF;2;B*\?=52YX>];#Y$&LT\.! [[?VDTX7F=_WAN<H8I5
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M&(SP1\<($&^Q$+ABGW8IVHT&"K)UN7 ]YHGL5)ZYSEBD*O\MYUM\"6;V[63
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M#JJE C?1!%'X"Y1[?X3UCU ?Q!'7('#-X+;ST,ALQZP>SYASF&JV(D=;-N5
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MV;D-?M)@X OI"^#5 N"&#RVV%#*"OJ:QU9\7-,PFZ>-\WSE<,O(LM>/?Z>(
MA1Q9!AUNF/MY\VPF^!=8^9B2_@@/DI4K)WBQ%I_"^O;YO3LO=,3ZZ[XP;'BR
M[;5C(91CD!DO5KU#S]O0S/;^4FOO\TP']:%68/,[@#X'WDADI)&,5420%'%R
MK8GC5"!4H0=\8G&4_OSTTE9Q6?R4'D,8S]!,]&RPTA]=0_*KIN1_&(P5) 5N
M'';*H904=00)P L2&]X:4P'SX3D("VJH1QV<<I\*%,,+<@=I-VY)!4P,D .)
MG;.@>YD18B_^_'&*]R7E3KE;)^2F.=#;3D]]CM$X&K@DZ'2T4+6+S\(06X,Q
M;\ ];L,MUK(>[6-XX^TCQB_AOQ6R#H\YDSJ,IP*MD&^HYD;ZAD$%FXFB-2^;
MLE3E_!^/5%X;F][L-E?X01>,>5/4WS;G>JLR?K1L9>;^9VWEZ9#*QS3'BNV,
M;.0@%&%6?<O]$9JU R<7RUM&CQ[>_/")0[4<HC2_LF,RV]GLQ4QR&BQ>4[F<
M!%WT6/-2R)ZVZ; $.C,8UJ/3MY$O&R%!75QI+8\YJ]9.KNT@F740%S\!'ZNZ
MZ*6 5BG=O;#SJ>HKM@3;CI3'V@'Z6.4'3(G5IW?$'G^!PC_O;4:((F_NO:=9
M8>A,VNHMS)0#9CVE@# R37"W:)H,3+WT6>V*P2Y+F!I>S2%5>]6WU%9;.)5+
MW$PIA:#"YO%P4NSA.LQ(ZW'>FB/V>2N:@626:>GOJ_QB;7TU^9%66X?F!UV+
MD(![$BTK5\T<K(]F^SIQ1)QJ-4O@7 ^)$"V)IC7$FAHK20#'T %F81:Y_.1>
ML&KO]S%+ST%BG[KJ8[HNTG%^XTC^>9$[46*#*5:B&G85+S,;M["CJRPS/<=,
M*>/#.W;6&R%K]$+U]C-2(Q[P)I1XT>S&-_:6W6HIF&+)LI(C]F AFNU#*.+F
MO<*>G:Y]KBU(E<SD2!T1X4=DX.GI[6Z01NZ!CQG9*;89/N?:;4&?-,@@A RN
MCKHH9A5,L7X*4/$D787+:!P\P%CJU*#;I2>F-<7+A!&_?R^Y0D.+U>P$J\4(
MI$)G-3[7?ZMY8]:0L_-A]6X;W-E&0RP\TN%2PH?%SG6$1NI],9IO&.ML1AT)
M.C/NK@8.V51>4A ML9RT?</NH"/!R[CRBNU'8 "B&B\16(]P)HJ<?(^V]C6J
M(JW"TFBR*-._^2]J2Q@^!/7 -[E&(%//]QH"NS"0';'MGSSEB-IC=@>OMY*F
M&[]CT_9?[5NT+D W3&A!B&PH0 7NY6V1QB8T=K4,;C33_K&_M?Z[RJT_"A8?
MB%6WBR8#QX&9^K\E- -7_N8,E]%NFEVPR%+S4Z,"WD'YFS3:;_Q":OM= _5O
M5CGM_HL$D5+:P09F&IN<5LLG@_X\!?3IMVN@DF;(^8T-8J[L.9)_O _[1V;V
M9B UG2^D87+$,R3SAL%QK8^>G&M^VO>:A1^&:5(!F.[PQO GF#WA@2/N,<8K
M@L26KYCDBG2M^":?5:SU)=1[O20,?!6@>%) )+'1H(NP:]C=)S %UOLKUL/]
M8Y@M/9:. TF/S@3KFFHY7SR(,3R,,H5!J,!!;2RKDNVQ4M@5',]ZSI,?^GD3
M$Q,MUP_[9A4_8_I19-&"KA#^J+CJ2/3V]VGDG[B00 48U_.\<]W&#B6R)A_A
MVVKNL)81LM*@7]"(?3>Z#;J5;^.6>&&WVD)FVFI2N[S5^RYF+I;#T<KRGL:9
M$%'ZF9_S-9M!^UQ!?/"9CDZ:EEC\MTF=)WY.ZJ2)8"8/^-[Q1BJ0&:SF0$Z"
MSZ3!C].$!HK;+4@,&U8Q&ZA_8TA^85 (85-;DWB66__,L_QHQK[5MOHX[2.S
MC>_^SG[Z>TC>1@TJ$)(4-)0J0TZB@!9'IX^<ON>NM)X^[H</';)WMQ8-?U?O
M$F1, A0/,&0@D47]C5*P@UB13I?MBS"_=,U9956NQ>EQJRG=6?#% KN^"/68
MFVD)Y?6;S !<M9&3\ #W%/\>E[.0D;U(X2>$(J?TWS9<5]\2K_&Z@/FDVR$#
M. %,=% 'F"CMKY#PIP)M+)H^<U2 8TGM1&BP@V-NVWA4]W[1F6RWP.%W%BOX
MY^E+J9P#)94-X.N5 P\G[FS.5)0]N14FQ,-FI'Y4-;AHFPYK\10R$TGK'Y4\
M<>[)R B8D4S'XH^&Z'%ZA%:$S!QD(WF;&TP0\EKM=RD5PA[<S4$<#O2[<2CH
MK0ATI+&2UGP:PY"95Y"*NQD+CWB/HP85 88QG[J.L765+C"R,6 TEH"F,+[%
MHDVWP"V-RCB1Y]DW[]5&WG!C.8L_RN_Q<*9,;6=?@2;[!4BFM%M2@CEC;>7L
M_,V)5W!KF7>*+\2_56YA@$MYB,P(BHPW>F/AT8VR0>U4@"5R1,06R_!"0&"-
MRS?C+D[+CT-5*$RCVE1E9F:G.^:>^[YV*716I&6#D62-)26+1)(NY1*2]&%4
M(&OYPHKH96W%LP*BZ#6Q@[[R=%%$-9@FBE"%56Y*E1OFJZD:JIKBG;CQ,6Q(
M)EPP3N;SB?."4GI-@FD/[)]:!C%@[6.Q/YKW(:$DB)M'I0'_\+G5DLBHLQ&"
M'&:3;65-/'K"-?^G7$+TH[FJ,+T<GVC1H;JZ,X=NR.JE@\Z1,U"N&\_1%0RA
M)C:XD5)/@V;'\D%/D]Z&AIN7++,^]<G*?C;3UK:\X[PI@E^A/:JHB:#1U(/O
ML?9O9A[!+N6X[G\.J+2.FLX43O6,,3AA'NYP],U6%V9B'6&O]IB<'Z3F#JY,
MZD">((R:I>K4?$C)&)2T)%4G7NWL"M?Q$.O:<7(8&G7'2>!E1AM/!G51V A=
MLS8X=Y_90/OQOE8-RR"7-:'J#V^<$[HPKR]G\YV1N/,N)9U^T>M;/.5H5'I0
M'_Q()2AL6@RKG?$H9REN4F9DNZCRD6ZRWZN%J6&=[CL"_->]!U"6:BRT]G7N
M]&*8(*0UC>]4-V1?]95KT8T[(G,DVK*/2Q% ) 1?Y-OF&]VB K/0,<TV+L@J
M$@..3K2(=>/E'BYU+D=5,9I[JMWYF,SQ;0?$O:>Y,!-V\WP(<P"(= J"#QMJ
M9 P:Y.4=B-I(PGBQ3[9G+2>6@V/JXJH'J$!YEP2RESSJC>:CWQV)D!!IMS_W
M%<:,(?8^:+,N20W/&LM[XQT(EVUETE^V>@&>4V=7,+@^J#5X=^<8\<7:.<^S
MCWY\>%.=;528Z.3P#3@B,HXZKT %"%)"H=%U^1.N4,8[P_(?[MZ)'MF'GGP$
M\CYQ^Z0F>(S[EF/SQ(>YBUTK]@94X-"AGZ%#L6-%&?D\[5BI5#$,).PPM/-<
MDVG\??]^I<F6(&_&^_XOP1^9]U;4P8-IS8;A8.R'(!:"9B=X##T&QL:XQKA!
M;FW1;(_ 9_4)E=ZB.LX.W\A]"W=[,2(K%>C*(IVE F5.M&BK)?G8[G^1S7=4
MI<B: 78.?QM+"DB+KAJN2,7H50R46/0UUG="Q?D"CJ^VB7[J88I8;SSKCS8@
MN,] 3Q J+'T-I*^\3[OQ42*JXV+,QV.IQ>I-/%ULI F8/V%X%CP.FLVMFT.<
MM%5)JGVU^M5F0Y+G'9 F-:VR?<6>H:!+)<Z%?KN5YD5",(2[S'J#5PE&A?;?
M'KVVVE!XL38OAJAWL,P&?A#\8C?&&Y!XFD4(*83Q$=#%5HM*!?4$^.RQ7);6
MX]6?/!9BWAW43[C8M;8@?@<KJXOLIP+!:=BKH CP&36.,?\!.P<=;$)I 6A<
MOD?UQM5!VRO:QA:,>3TZ,P7?$RY-1#K/2[\$'R7I84UF3U?,H$Y;ID#L!G(W
M\R)Y/LT$=_$KX@3$S$TF66B/>HH-FT8ZZ8?/:B2,88.(S6H"=7%;;12FS4S]
MNN=30E.1;Y^=T_M>Z<@E"Z^;_R&83"S_9;]_V>__G/TFLY)?JISRQ*2%X ,*
M.PY1/IY+,NF*]I6H]$9^.22Y\T"GPPNQ2V$A-,_ Z5P*N/0+W$[K&-7&TK,P
MU="I9#,$7PWK\3WHP!";0^0EQ*';P'3;HK?O.0_:NTL\8UA_'U-.<5F$<_41
MNH@0-*%NCB%$Y7%FURG]7/08W&5<=T)?DZT%E?P,JVL\9C_#]*"9D#N#\U%%
MI9'HM[<+BVOC6N"^^+6A(7*&VD4[TJGA>O;[?-$K.D-23L]OA#_O$^"UYP$Y
MV7WV_K*]+5 U&B3L?TA^[.8PR8@FI<JFKAAA/J*>G^QH/>@IN74 =,VB#X6]
M@=RC]Q>A-$JAMCF*9FM76QVQ;5^>;3@C%QZ]7ITM/<9FGO Q,1%EP-:+X'2M
M5H*\5'@I*;6IJGDM9-VTJC:\YES9864.L$^[2"A)H(0P:FJ@K#&P7N4^\J.[
MZL5'^N$7&)V/3<41^YT_7PQZLY4VS.GEQ9X-4Q;E_!X;4AB\$:>W*#'=9N8?
M(.5NCHAO_A(MQ\9EJ"5"DSGK<&?XMV7IP]/6_DD=C0;K%:<%:P:20,Q%.TQK
M7R=]Z><9WM4<##2 7H!YDBM@JC,3ERHW& P87E2-= =FR(XD=A+;G^^W+K+.
M#>'5ZK F]BB<3@O\V/)X2JN=&WNBGOR6#%"7JM<T$\2VR9'S(C\A@/P0BNU<
M_,9Y<[$+(U,[9H?:"NR/1\VDPS?5" Z4YBB:(K%N-$<6PO_ZJR9XG3KA#)J\
MCT0NAD2((M5Q+:CK*">OL'LP.8)AML;WO8#4K)-H=%W@G$#^65"Y%#MO>NK.
M7NN,'8<_HF.:=T#W('3Y CZ;-TVE$#6"LEWY(1<1I2T_:F=8B:D]:E)@M5X)
M5>VG11!7^'BJU]. AMPGZ4OXVN@:0?Z%1])^'#<OZYJ-9Y]V" F(9/+IYT)5
M**[QH\]([G S&W>CKX^NLCG=J9*<-V2Y.)T1+A'6Q!>_FY3J3YC 9PY#+0F[
M<T?>Q<]/27Y@>!\M;TA.VBG9^(8RC3<DI\M;LD24[#0,USV9NB(I#)KC(.4G
M'HYKWK*9KMH@/)-SVY##PZ;GDB0;?6G,$&A!O 63J\&-MMBL&9SM*TF7@-I\
MRDH3=>C37'M_=S\=V:=$?CY4S#_\<*).K./6QW",-Z5'C&%;@4 .=-D/7&LO
M1JWPQ69Z!!3P40'Q^M2LA$LF@1 3-8'T#&NVI'%SN#3A/M=._UC1S#L4)\SO
MC(51+<'ONH1:ELRGR8][MQB(?1J\3>=7)7I5+F'6--N3=Z(1.1-5(QF/Q5N9
M)*;"-Q89C!\#!D&9L+,$QUP8.P'NGMF$6P^]MKO;NQF>*R!]5B0S\J9S9GYI
M?2O;3@"LC)"V\Z"_:Y,*E)K_2-X50*4E[:545=6;^^)LFKE:#^J>O#AW@XV5
M"0 6 60*Y+=;:6;0SH]B[SC6?WK:,EC>4XWL46QSE\N4\9@N?/JV+D^8\D+]
M[E\LQPX;.7TR[^4SQX;^ZL[A4(_&[*4UIR#X5RVV79WYL[_2+;_2+?_DZ19;
MADYT1 R)A2 ])\UC<'*2!V20N"XJ>-'*B9Y%V_#F "NT(UAE$)]-K@OBH'1?
M353CK_\PHF(B?]L2IIPMWO7@_?8C_1-E9W<<XBZ9>7"1_,D?(!Z[Y/)Z(TRO
M(85%"/N.BZ=^Y*LF.0-?_5JW>^)-?25 :@!4 T:?^<>WV?,32N;>3CF8?:@=
MK3<HG7XC%!.R.6DH</,0_5#,@2?!,D#'H<>0-4\B[S*\7#4M6+)JS4E2'XIC
M>S9:4UW]=9;[M+;Z68NN+<;)^]_H50]?X@-[!WVF EB+#7I77DYL4@C)#Z.J
MWWK#-?'"N 5^/G(6SUQVI2S\#L*MEKY&D"\&$4 6QZ(B'L*Y_8,Z[;"4/-?B
MQ=&OX9Y>Q4Y6M]XH.5I=!_$A;C,B?SS&QY)?J6@2E18I]*,;TF>'ZQ7G5(5Y
M]*\WAAZ5O_NE4S#F:CTFJ=?VA.ZM3\W=B%+43!2X4CLG!Z8^3 $M^^7:@<RJ
MDTP';KWZWOJ(=U!<9Q%YPD]@Y%SDW=OJ$*AHYH>TEVE<*NQ8Z19%7B%<!\HU
M?<F;OK*/"C2D!/<GL3HLQ/;OFIXBW#@ \R#49,&.$"QF#7E6UJC R:G37TN9
MQ)NM'UVTQ!C#PR<+0;YL>_VN-"_4230;DJ$"+0D3"TJY&X2K6Y'OG"DJ1?.(
MB0K\]BC$W>N$3HZK]^0BY+C\$JQ'4MC\@$V!NL :N[+>(:RNZ<%G!S?U!$G(
M;%K/-^^AU(E0GHG2[Z?2[#6]0'NJU%<8 V:"#*<9N]SPS&^="Y-H]%7^"*$^
M6<O].(!'C^^X >P83HYR3!\[VJK45FU_'!M=-7>1W\DDWT#6%:L7':;:O6ZZ
M7WX6CWR#FBD%5S%3@3:O2&/8N8&[WU^V-++XV'R:NW]R]X8CTVJ3#\OAS295
M[L^J[3 J0!0.:J=<(B,5>J^B6XVMEI0N))Y:VQ_)MM0\=<&WXXF&]%G@'1/
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M<P YW."W<G_N:?**!:ZL4][QR+7Y#\UUR6-*KFL U3U7#22?8S/F2<AS,OU
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M-@T^(G/E"%]& 20?"]6(S#BC\W(-HU];&*GXI:D?WDD&_^80;@+>_Z ^"?H
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M-!=:!2T,SXR=0Q3NWRE0LC/>/IXZG9^6OVRJ!VVOWWE>#[H'K#:#C33J!+"
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MFK;!\. G@UK9N,C].WTU@YC2R$1BUGWEI2$>UXJPL&)_;W[)T>>W6G'<A_?
M/V=)Y'PXNEF-@W&$;1'E4UE J_AZ'I@%^UDT]>0B;(US/6&,%THU;T&0X7-]
M-8@^'.%)EY=7!%3$*8X%.$[MY;EGB'!RFMVN/V I7"IR_=8F !N"NXGKCR9%
M5R/ZW>N\!S=0+M<G)[[H[>GYDO[U&JF&6!G_]-/Q7H["@Q>FBIDV-PDFW%,^
M?Z<M'C)KVHYF.XXH'JNU5,]5=)_&['"^D;#6'?WV5FE\T#Y**>4DS2)')^H5
M9*!I;5.@HL5$29*]F^3S5QKW&STL9#9O67HOZ/#?OT/SH[JGGZN4.J5\&[,3
MK8!T)+0$>2%$D&]-HPU;[_30FV9E1V+/"6[75YHV,#O?)&O"W8(0A!&>P "T
MHFNIV.=!T0IR=]KM4<.AVD2'[B,B2[J&_&*8E8N.LLF^V%-4;IH$2HZ19)\T
M]9XI]!!O_OSL[<F5@G==PWLG7^C+7TM6S=XIP1?LB[VK*P-6WYP#BV9WD:&U
MKE>O1)[43-[USB'6K&70Z1H@+UG9L(878 &0(BH;=!]7N<L"YIYAF4?UH+E#
MXKHB_2@GJCYI;L/ Y8!@9= XZ;VMKZU[[T#GO42'TS-YQ24CCB(?IFR/T?8R
MWP_Q@]>%W."G0\%MR J+SQ>0868\#J=@OM)Z&G7IMSP29(+K/!  6#NCNY>]
MWAX06 !M=(H%1)__/>4%C\T?H9N@HL7P/H%E7W)8G:1#0X=QYU+VK)2KM>3@
M&5\?U1J-6=EY&>ZXSJ2EM;]+4O:*GMC+92^U6:W(A)L$I^\T96Y9P:(D*0W8
MX3E@W-0%QK\D[]I$Z""I:CS8]<G@882NQ:'8U[IFW,X-.TMKC+RTK)IN%!J4
MM&M]((=JBSX^<$DF55H;\+^IFXE[J47_RG:]U2A!<G(B6>4813Z4#DGOI69.
MU7N3+[OXG4N4\/$\WIUXXY-,0^I3H]W09SI!>M!8O-1^BEPYD2%?L^ J]GPY
M_*J,)$S?-5QJ<(NL@\/!$\]??F[NE;9/4%]C;U&N ;:"V]1@N,@$5+!J[X2
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M.%5Y[.',\'U7*'^E=H TM-)5O'SFKH071^5GSTEC9"-="UQF(X[4$^P-6CW
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M+KA]+(!0BA!X/0S;J@NU_DSI-2@5^S9]M<K28CN?*'2:!:2#0R?:<6:*%!;
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M>>NTI3'%+0MGDM:DRJ#1&/YGPY!JN#A5[LB%+4M?=H]^W)(N:C'J]"$J^DU
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MEA'_"T<XY2]S*8BG)9#]?B$\5R__D89@^8CXV_D2.@3X._SA:=CR]2V$#L5
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MC).<X?)$$GY&OQ<S+OVM2,3?L=N^_$B&GTC11F&(J$U/;*!W84H!>]!9;!#
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MM?JD1F1MJ;:KR[="7\A55 O&6'HUD[HG&S\Z4S_&K&J'DW[A&0+7S=9VO+\
MZ;M@'ZD<XZ1@ES07BM',^H>1?M,.-7,-]%NF4O;SWS*9_GMDM=6'0RXPX"_@
M1AK;J%58HGN5)P)FU@%;@,HT9W^\.O5I;%$GTN'[>RG&E?9F&/X"R?2('5R
MH'7O$%7(TNLR5RE.\0IF6[8238?705)PJ^C[)L3FFK[]N&4+RYL7!]K32A[T
M+\.*Z)X>5QU. YBTB>$NA22K"7"H#&)I^4.MBUO,LI5K\TO/693])BH,@M>,
M":&"5Z8),8_A&A/S(4W?<R_Z>A1N3VD_EYPZB.[8EF)L1W!2VS$<""8[U&T\
M.'@-PR$FI2M[_-6(VPGP:J?GESADS;.^5S^ &_BYN/?O)#\7]WY ^;FX]Y\A
MDC=!AQ,C +($/4H\0M0+CBW,$QB-"%YABF\_$F'9(P*Y-D776C-T9HX,&H%=
M+MA:^7=6:'GMDL8)4K.6<F]7ER2.3AQ8.CYU+4[S6*CVM1,:+$%[%F%GB6CJ
MWB[2&>^N:XFDJT3SMYHN8DE."ZTO7C!]GE\Q;XDXN[8K )*ZJ'*EHE>)S4&(
MS13M]."NR:V2TLC/XGG-K!%IUL_B ,;X9$H;_;ZLJ4U>J$)(_8ME3F))ASF1
M!C2TH.X5W\D9]'@?9Q4L!E'AKL+[+MQ\%[^,VHNQACQ$,CX87:VA[NI45-DX
M0/*.RBR_&GG;YFEAEEK-+9#ONB] +J8W.V6ZE0RMK<A!OG]A_!B]F?AE9P<(
MH70AF\1,OD3)5-6X+2ZH.18&Y[I[W6?"\3RC\&'US$_&M2F?OO-/,44U:B+/
M^6:&K54]T/-1$CGUE:IWQVQW>:"X/->)2XDL#[0S[AFRG,3WC8^&X9-J?,'!
M9"6;DK.B,?8E)1W1'X43K4:>A]L\6&C8S$O^/UA-^(-RC!]<?A9Y_L'E9Y'G
M'U%^%GG^SY"/[5'JI\J)MGBW9H1<?I!0]C+HN_)VT7X+V]8XG>.3"49XC<%+
M@+-&;=[7CW(Q5.[N2C\\>$([U/V>,<ZDMU+IG5V)8<5#D&IO@;9@HB0KVPD!
M55: _/?J*K^A@NT(!M2',!8:,*8,(_M69E-%("1=9,>K'4[($MT*T70HQ(':
MH808[E!"O.A94K,48\__J&PS.DE=#=$XQHNQ07'8;2_'%*E8RNEC*D@\7!I9
M&LYFEI'$(2$N]1L/##)<8;NH +%K(X;PE,J//Y+"D9E3>W=SF;WOZE!6B CG
M"[<G)\LOXM"*#!MA9/6N"11E3S6(!E0_P!#7P;\K2=TS!<//TH!!/6K(/@@-
M8/%$D5VK?8AM>%@C$H![N6%I@*!)8Z9#+T%;]<D%Y_@L77[7E.\ZDV S@-)*
MSPX0U%[UPY2\:D%B3$.J^+>U*L'YRSU?4<)F)O%6DO'"+Z(WK%Z6"8O65:>C
MOZ*)AV'D)W(BR/XOR+5$5@KO/VSL/Z)PH?0TF"BUW.C$2^:G)*ZC>+SE3)+.
M]Z5A"B-4^JVTK;6?2;.?_3#I!^WJP<&*2Q<6:< ^/;RY(9Z%+ [&1_KGS8W.
MD+078 Y#4SI@IZ1I[9<X@9'F*@ AA:S_A+23VSYF%D9E,$,2DB'CDY"B) KO
M\0LT ,B%$-O\ ^F#0YX&O!^@ 8GT$>/9QTQHI>X],QXSL#R>BL;%\)$]'?RE
M#<[Q29$ERQV>OW@T'HX8:LW'>@K'G6,* *'^ID4P?@5,-UU$(MT5!!BCR#:5
M75C)A54<;!#:'#YNL&LVV]]7[.2PQ3 DP<ENST$!&X1GGLX!(.X*<*2:2$?N
MY/TS)F5=5OYN$^O1*0CM]MVHM*KA2_[I?H_"Z>.%&8#3(Q+HT,YP?F</)C+O
M$)SNT4?N$VHG;.U&,8B\:X??I+3&TMA./#S3(+?GNYN]Z&Y"Z O<P+C0"_W4
MCMDD+G;W&/<"+8/"LQ0_:-,8"UD:ZT:X(\=.OO4"AJ]^\D"P;FE5GS-]V['&
M/R,S^L;]UQ\.U=3+2;YT/ BN!'] -AAPPDTH\7#&"0R?O:N#^L'N.Q4.V;-7
M.3..^J@Z/ F0JGL=S6*_.;B*H7?A[A@\/W8FE+PWS1YZMCHFO5%R )TW(*B;
M:)IZ/R[@J, 3'&,:[_>G?WH^\'.5Z=])?JXR_6#R<Y7I/TBNG62Z]N5\EH#X
M&N_6)ND.#:B%5A['ISC1/S)R5:TGUK]<F]M:56S=_=VYA@:DZZCQ++!D"_.F
M<8"I;"X$T"78'K(J7M&+LS57%RF;KU1><O/ -3&NDQRU@]K-Z,31!"P&KZ6;
M"!EL-38^K>!]C0"=WWA\G1R(?@SWP8WM)U\AV+R90/+:]YV=KLKZ/#T\9GG*
M\NL)%N%C 0 KL/,#[4/BM2GV0WJ4_..YF1ZZ2B*LV[U L]!+'U>L;TK^&;(4
MX^99S!XD-A>UXKMSP-<'&SK@?LV,6(9BT61>-^.2'HBC$U^SX[&6^PL+Q]\.
MNO)I. IQ$EEX&#;0?[O?"DGF/#6J24F%.SI#.74GDC2=C,WU7+6IJI"SE/U_
M2KKTR[A>@5#9/ B,AB^:QCC@' 4%=L;;[H/=L;+G6Q7CBJ3:^A-,7H(,Y*L<
MUNLPLCOEC&C [O5]>KIXY8;Y Z)^QQ5U7\_=?Z-^Z5.=GI=ZA'G;-5_K)UYI
M'!74/<\=TN5JD"(6-=PD3P,N'R_'P(I/YO<N,ZJYE&4VEREM'X>U92YTD:YZ
MXS:,"$758GCK+TR66@<Q77*QZ<55D<*!AX,X-+[V7MOS>88I>%N(_F1$6;Z0
MXW'(!_!CW8YY=0%C ]N5;EIMPU&$5XR9PNM-WI\!BCJ:GG,3I;527M,SWY('
MU>ZHHP]D%8<$UL4?,91\;XQV&6XZ;#5?H;2,I(-A;,EV%#7&PQ8+"KLZ"UTY
M9%*L3X?KB[NXM$?W'Y82=XNL5MBM(0R=SGRL:II+/D\PSIC8YTO%F?1YF(=^
M+*]XN11G9S*9"CD(U!P  /ES]*P&KS?V*(D&[*<!5L@])1G2!AZO6UW>^.2^
M+'+&+(61=Y^*0F*5UD/@FR1&,F^W^BYJJ_H^?&\AH]E\9_.1C"SZ:^ KD.DF
MF:A]Y]%54'GR-M>?/@/U<T;JWTQ^SDC]B/)S1NH_0SZ0/7#[(.-C0? +$[GF
M;8+&89D6]EZ(\T[QGT./Q&[D:5WI.2W2]@":@.B%K#A !" +EWN1:Z'V -F=
MD@_!9J2>H628+==7@U<K>?%;X1<RS=NH"8B4DQZ'UZ]!IN+(E2LPH*_9L%ZB
MX5LCCZ-,P8D;40PR7ZX @(?2/*RP>2&; -Y()?!O. 4I*J=V2K+YY(Q,2[.I
M;L99B+I\;62?*4BF/*7$(K$O(2"D#;A@OO05W!8W:8@L0;_:):VUO&%RY:(M
M-9D+EL<:9!R@;D!YAL0FEF>,+<SCVO=[SU_A&U4CB(8IB@I]6^I@Z3+?I3.5
M)#F9J'71PODJ&V,K+ZP-PT%\W !FAUO;YMS;3$* "4>B/*8OJ/I$.]@]P0:!
MG#68=6HG.2,CJ*_G5Y<W!FA $+0?[DE0H@'15*$Y8X0 P6-5H%CDU);I?:<I
M-1OV@*)KI021G+PK5[K*GC%./D=B"S BZ?C/75 #_$/?P,>MU '+4TY%C)$^
M@>Q-Q[=FEAQI@$VU&$$R7,G@@'?PU3ZEBMEB-=C5CW[9%:VA(^*=93)?FKOC
M8==T:0#3>TH&KCNU!\[B*,[:J#DW7R)ZG=T#^ )F&7%;A%U'M&+PV@+N_HCF
M!IB@DKG(^<&!RAY\7ER;N-L)B-3'EXM;VN[GW)K;(X,8UI+(7,WCCIOUH '&
M^L5WYL49RX^69OH&^0_<%J[@XH,L:_)<47L&[3,2WJ_MP.Y<+]C(;L\I%G7^
M?=8!@*&#X=H_C@K_@)WU%NT-!N$(?J+>N$^E-FZ??5_]MK""^#6899R8L5L(
M"["N:LBB;RHJBX^.PK6SSR%$"!PIN]&O[0V5BD<26I:B3?IO!<_.[9G<OZ>6
M=TI4B%*BOMN[ON'L@Y#7Y,O?E$1@USY&=W9V"@A7=JDP7X0EO1,'-94O1]
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M$M%[4Z4;OAFOW^DD=*&K(\[H4,D1!6B':I N9/%5&H?*!&K1FN"%D\U5VHR
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M4<U*>8?.(*BCO.$B.-P![9Z##W6=X#RW-1M,!6Z=>*UY**!&)< 0 H;8M0]
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M%7<V<(*HU@FU6Y@',*G!]6\5O1MSL5H7'N[5=LGZKW&DMBUSS:7?N[0;Z89
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M&]=^NLG65_6$XUB0L[F<XXY/1J:/'0[LJG>Y7D3$R9XM6CI)>,L623A5#[&
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MVX9T<]^>9W\LX M\BU,$7T(T?JL]A.A.BX"@#=G( #B#!#Z+/D6"'21L]:]
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M>$<B&2@3;#73M$S&!+?2%U_!*Z!<05"S*(E^U V %'L>.5],XFB=0Q!9M4/
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M2,&&M -Q;CM?"ZWL$H-+7-F^NE29\X5O?JZ2=K-(M133CBY@E%C4$>Z7:*0
M,>KR'=WAN_+QFAKTLXC'A3MS(_*]INZEW6)B984G>142U!;T_=%U!3O]9,9Y
ME+%;$ZBTHR66NU7=>"VRR+KIOO.[ 9';$H^#5];J>D,<CUM>.K"@%\S]Q_<K
M_HVQ??Z+*J[DX]]Z:P)!H%]O:5X/_541,6['DU $A:6!9+Y0@*FE(*08E8P'
M1#[\D1F? -!OVF?2_$8P-V^.__3F_14]KM ?"HE_[CKTS^WGKD._L'_G78>H
MX*=\>'?5[T\2QB?F<'(W>+ER:N\)60SA>16_XEPEL^O[V7[Y>.&I%,"S.U)%
M2 W/<3K'D</8'S66-!"=U\5SNLP83W]C?O04^,(UOR-86UVQ4_J)9X\]@WR[
M_/&C_@&1+3HS7Y$"W:8M]7>5L^'%!WL),D0#?.!,K &J.K;"DV-1A@I%+[ZW
MG&'9MCG$RS_R+$F[=?@=^6LFWR9KW*08)N61DJA,H)(W_>S+I;-C)G-U2@XS
MS"=;F%5%<&JT0[#;(+P$ KZ_U*^8J&@!KUC\VCG*W%=T=RSQPV$-MJ*,T$>B
MN9_!1R%=C7:B^, "N72T+3OA;(/#!KOT5RO%Y025$YJ*WPX_?=H6-#YC%F.K
M)LN[^U:HBE78E"?5=+LOP'<XQV $5IFR>AT5:S3=EMOR_>#2X66K<%)E14#X
M1.D$2X5+933#PI=/T:J=M/<O>=LQ$OB(6C7X4((NQ+Z+"FL,TGT#\W70R@\C
M+I(<UH>QA9DLL%N>T>##QZN3-L%X@WLU9VJ0@^/G3F?<+8VI$[BK?5FK#1I-
MI,73HKZ/4(!F]S>W"27?URY\@!5<?&5T;UK FRBI>#]O,?&#6.+(I70;/3W3
M[#*#R*BVFXKU8N^^NOA<,M^8*B0=GL#GM. F93!?BK,F8T:6S!(M/S%LBYV)
MW56 M\*/0.PO8\!1E<8,UT.+MP354:NYL9'Z5V/B+P>$C;.Y;1]#W"(5@>S3
M/&/7A=GQ'K>5D#SMH<<WUH\.'-;GLHFOG09HIS& Y@VXG6)8,9?D6CSWL4\W
M'^1+^:;GR#6\^ 3M0%;FAN7@K[Z%6+?MKE:%%2UXDY+5Y*>ZHM'C'+-)/HU2
M[\^\GI^E<]:$@%<'">=N(WGJ]7)N0X_4JHP>B1;SE[]^X4U;R[3@"UZI@O<L
MX^7VHG0[*E$@)UAT!F=# A596JW$1.ZWYE>I>[01&G6,N8'DEHWW)? '7<>'
MYW4P8MJF(N]4KR83;&.+CR@LES8^14Y+P0YNO#%K."^EF3MPM6GV:]#9#JG'
MA1/6=AV&!%JB<DJ'L&#1EK^(<Q]1C0/\65S;1/7!DY)@/_9I6/\I<+[O/(B&
MS+"021/$<B3T=7+-^Z?UA-4S>BT3%W7H2XE20#/\YI*A1&_A<',O3FG';K[5
MZ>ML7&OM4[S9(_SW#C#FBKM&DY *EC52N'';W#-G284OT$8NN^"XPH7>9-HN
MU2_C,UK+XR!G4#P;M =Q ($51,2+/TJN?;PX-VG9VA;=QIE6Q@6;+U&(&\1X
MM@N/J*"['Y'E(%-F_4&\OKZYX.648;/^XE; D&-<0Q1PH',\K[D[/ Q^!V\!
M<01)X0T*%[6E^QQZMW@K/Y3D/# WD#U<77UY1%_TNRAK<TW>-;A4R:FQGJUR
M9CFP"5W!9;=,DTJ8K5PP+S@-B3&%<VCG8/UT>KFVK1=3=9[!MQU3S64I0%P'
M%_2I^;S?JC]!E7@)GXC=:.6;"T49I9OH)VA8K*XE0*[;R-;??,?;Q!/<\G2T
MLCU?W2P:D2NN*W6YW6<PP5"BKCIEZ3H%>' ;?\T5Q*EI!%=?,Y8W.K),_I1X
M_B3L^_.74.5=%; $M!%)3[3$Q!MC<R#E>BGZ-0-.%6QB9?JS0\HI$M_L)R]M
M;<6:L<MQFKI=95ZK<)O)E=1XXU"\2+X)EH<UZ2H)LXT''2L;WF0Y0^XF\&WX
MKMPW9S= 3.IPEM.#3@\?WEI@U#0?4+:^UB^K7'QZV019';?V<4G\0:"_^5U#
M_GV\Y]<.B)GKG0\\K[JM.7X<5C <[F;WB6B!]\-*7\4'8_G/8(-,CF^MI=PM
MOY-A]BF_$]+E2Y/T'-98N&72#*J,;(9S0^[+6FJZO%ZT3KR7;%7<9VW3.C'0
M_NV(*.EEV-?4'8Z9:B+'<&O H7S??*(:4\E"F8)OWYOGQR>J3"9,O\E$:PA$
MK#[P!VE,!-'@TQQ]<?Y0(7S.Y_%K='UR @JT$BX'SD*Y4/U)0:+>LS6[1\3C
MP"_;E;F,E!<#[[MD5!,\H'U\GNW?.5U232*^^1-5LOW#/5Z<)A7XB9S*TUPY
M^(IY^F5INP+U(=SX'NZGK8V?LB_6%%L@\U$ D_?/XI]]?B"B VNHF]_5=ZUN
MI@!?P6B_5I8SXTL!5R$&YYU(JVM%^SH+I^[P3IJ\/1,?0!+!ZV(>4SD$O2:W
M&ZJ;M:F*A^R_]IKV2^TSTJ*8:+YV.@ <HG?3C[VP%5RLYW#7OO3K'23#EJ98
MR:J[<N6V^[8&->@TM&S\ME?(?YR$=.^:4?)C:63&Q+?D/KX!A I&EI027N]S
M3+BJR9?W2$ .:^U:)V.<C9>-M$=C9_=G6U@+>(30BF1$3J=.BN*=?=\H39Z"
M,;KU=-UT:/9+74/)O1 ]\S!2XI,>SW);<+ > -,,D"!R5.-BADOZ)J=03L5,
M[[XL+]ZHU-$:M>1DS;7:A>/\J3-+ ?^  EPK']0^N3Q4:_8L,G"!3V#2=^ K
MF5&BO;.CY/.WN'##3I)W=HBBI@1*2[@Q@[<_2 M%4F>1T.N_0:5LTHYC E?R
M&FEW]V)-@IO=[[P7/ZA<GNA%_9?&7/N,L5V-ZC>=3HY!O,8+<"S'!PI,T$?!
MG>8KP5!#6)-G/8</:XPV+[[!WJF\YEU-G\.3X($$-;H\UCK&3.$UX0O 5^II
M=,E=" "[W>+)&70.&QFA-,6YY%:4+MXL>&M0[D9EG.2MI-?GQ[DF/Y_D?R3F
M?]:%5VW'AWS0'0-MF8:ONA>W9'W5?7.[=K"XJMK1V?U@![-UD^&^/'Z=C:QG
MT\S,Z 9/,J,]P?,V;-]</=X:37![TTO4*^SP>>MJYO4BMN%;H8"X&EM0FX"8
MA12C*2N=@F@?;+IZBM6:+!L?=_-1$@6XT.OQI@,@ENO44(#&^(\AVGUX-XS]
M=$<'[ 'T,%;P>_,4_80U/DR_"N$M%'DGEK_K8'FXHTYGTV/F?+K#X 0*4&7>
M%$B=K]RXPKY*DTBKI"]I-X^)U[VZV,>=,#SOD##Q@;!TL Q57JM"4\T^LNM&
M9J1R<GH>O#=F>#HXMP4>M?MIDK\60S FI>=]<%'^I&+V954R?OO\2DGX2T#_
MX J0V!942#V"CU1TSW.T?.9X^'9XUGN3@PNG]9O;T4NG!%+NV-0GWM$L2*R0
MU$3IBG"$T!!<"!I$AS+2*^V#$*,.G()LF9O9+<OBI.H#<EPQ/OJL7F6B>5J-
M^QOX]DJR'IPM[B.WU[J\9S[F[D0<6_O"'#@@$.C)NCL\^NP/3Y/]E+3^4W;Q
M4]+Z4]+Z_W-)ZY[A-W!]I.?UWMB.CE2A8A1$YDUY13^TZT1M[>'3%$!Y+,1
ME%EZ15U:JF+&3+/LZTKSK8(;!04#U;:?* #K2-?;!77WUXV,Q:O94;B7L1]#
MA ?,PCG-(D7]_*AG?_[@]]267L1[DPO4<>GR)"N2=!OBE[ *W[+M6UI04?'8
M2*?YC\Z<_$#[86TSNZC#;F2^!52QW=QPMDE(@EV/[E/UD90A_$91R36V1'&(
MF,<-W:6BEIAO ;&<-/A*#!4$(+'6T]]78S%]H,,+H%$R6^5PPDZ0P5MA]<\)
M8[[-+PPF'Y9&Z8L![&.ZKJ0SI&*D<QIH%#9MAYRVG(_[2+Y1;>6X$B;MZ2]T
M\>(X1\5Z;&AZR==YKI5[EQDV1+&!T[ X*!TD.YBA0T@ T>-I?__\M_>/=KA%
M!#PCP'7'8!6OA_;ZKQ-.$L^0W@29N^5 3NF^KZERV6?KQJ'_P=ZA9G8VC8>'
M5T/?LC2$$;YX&CTI_=Z.%VV8[1T1I\=<I'5 R^5FN"SZ?+9>G-CE@D<G.0\!
MM.]>'1*=]FS6DIXV:#9APC/IV<M&1#I5D0,ES3+.&!F=H,WRYQV/-RM9^N,!
M^&_M9[GWWP_IG^7>_XK]+/?^E?UO+/?^;R])_8=)IJ]OL9P9,^Q?\X2+&[EI
MW$YU>?L$9:]'5\[Q%6!\=8A_QJ\CGH[<+<28V2:D-I3==V_SXUGNJ?=UB;R'
MS_+,CN\> KX]H5'>^8R5)C/Y>I/>B(%8$0)Z./HO7=WLMIFG+T'$>2YQQ^_>
MG@BNP?O@ZDEOE>&C.3-R^>C/NM_"SL?&EL2^33Y^9V4PKBG^>_64S\1S',"4
M20NZ20%BD!7ZJ;XF!R!GG'IIFI=&G^4[NTNHDL;.ZR8*XO:WJ\V%:*?V@::K
MP%RH>J=!3=;IL2[C<3VGE/OK--W\H_[[ WRJ2[=FJ&%O)(Q\,!S3@GLT)$-4
MR3_K/2U\9!QULVS0R:"BY@D%Z%+UV$]S*T"Z@.,)MT0T<17+3637P$7VK!BW
M53W-6H[A\*_NKX2TACVX3]X4D8AKW>):-XBN%RV!L+9R!T@\JDB;8+(L#T[\
MNL2F=$H_>#!$=$!HDX9TOA=\:*_O"\B-Q6#F>W/@=T9(QOPJ5!ISMX5A3"RH
M*] !]=!4&[J1=29F@GS&WS[S?=X?FD^II#+M:=?A43#QA&>IG8V5?^:8-3'*
M4L5^A><+JY;)/#C_.CJS(G(E$K.!H]+]AWYDCC'W,S,$AE7A6P065'5'YJQ_
MVCLUJC]\OCD_% )*A^&-E+MWF9>$\5P2>VU"&9UJJ->6?I8"['M- ?A(B'^R
M4Z4D+?4O^V<?<IAZ))G><*_3IF4)K,>9ZDX:\T'M2*<@JB>A<\0KE+CX,:)6
MG5LG^0:B;S%^'O#SDKXOS__*2:AI>$EZPPY$OT@!2BG JHH_BC4F@[$4BPBW
M5]<-]NB6@;H7HA+6!GL'UKZ>I;\3MB$*Z%^CQ0F3&0M]M;97## ? Z->OW^1
MU3 A5F09OQO<^2UUU^,],DQ;$ ,.AQ[!>[2@)AH:JA\8Y]7V)0P9)(@RMW[B
MM?QPBZ?3.I%X??2/%V[^QGYV_OZUQ.EGY^]_T7YV_OZE_=MV_OYU-N+;K];U
MAY01^R]6::52.8O2#]T^?,\VNW^Y"E-OC>K8S5L>O8?<<MN$QX#\K/D*C<Y7
M5##_T5FEOW&=1J1G/)L)*O/K/+IAM;S^+B(:EY:CJN'L&X[$CK $KOI'KFI@
M1F$QPN53K<(,EK'#NU6QWES9V T;>OD#VNUZNO@>AHWO!%GBZ7=X).%<D!;F
M?N&7I$(WMK,!:1]Y95L\DF@/Z3J87390.X9\/2%O5-ZSV66L<:DRXF/S%\[J
MZJIJG:=M?"$%T3DA  !H2>\\Q,C'*,>'@]F40!R+-ZS=,H0';B)"/=A03A$Z
M3;80U8_3\+=Z4!PU.&(NQX=-"=6?<O&:E.H/.HY68 ^N/C-<DC!T_HV(QV'-
MAS(?7J*>S/-TFGKK"%\<GE<A'@F<)D<6!O'W:(L=KS@)23L_@.X76A$LUGI9
M>'0]?CNZDRNE1RGC+0(U3%8/4L441]4/:0:CTA4'CB9^JAU<G:'W?AF#!(5#
MS\*:C)&>+$RX!'?11BA-@A&2?I$;-LJM7M13H;^[(MV>857%<^[1]R[  JG#
MR4X318W-P5BZ4=!J&/VS.V2SXBRPU?G"EVQ9XG3DDW&(2L(+< P,HS<5X1>P
MW8%DQP^BO-_@809N5TY//1L?5W]H0P&&5><DR+3+X/)GORL5_^-DC'-@XI%X
M-'=T/0,%..A'/IS)OBPD2##'=8^"RCQG*S>J2)$>%$ V8L7CCO/;F64=X;?/
MS#=D*0 +(]:$' V. 6&"?2E !Q7@1#S$YU( /?EV8;QV+068>49#4AI&21"Y
M$M%^$60)Z."G25YD]<!TSZ9UL-#ZTF!8^_8)I7559E7W;,>S<>'G5\$*R\*\
M"!%(].=B9; @).5JY8VSNOZ%XQ<>"KTJ5./ZY&)U?:ZNP,JEUK=H>#1\O)"^
MH;B6.\&2)_S:=8$$0X"&>G%U% !SP80;#"G$*6!:S?LT/[^>G'0I-92XRO[1
M=G\PIV%%H*1@X?(NA@)\+9\.'E[Y3E#&JS0%)!0L7];9#D@MW,_D>ZJB3-R
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MJ<6UZ3V)?VQ]"!$D=(.='\)9*#F6#C_:K?FJ Y3KVO2,[2ZK2#39G0(X(4?
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M:%G5/D$!>AY/4P#"W#(%B*=^QEJQ5Y%U1CZ, GQ/@Y.UJ-Y7K7IFBDB&@"C
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M9H=C/%.D:JL*^+ZT"GTJG?G\)/"P\!!2+.CF3#P;\<RP^%"028FK]M'!MQ3
M,C!_0JNU>+7F@ZI@I*ZM<[/\2!?:N>-QK^>TR7Y7Q%%;@M :SWVK]G&O[4-F
M2IJ;3IPT(T'W2#7:IZ ]$>BI5O+)VJI>ITYUH?@T#<%<O"7;''6(V5IV-T"4
MH1E!U,?XX,2R>N3(=X04OD_P&&U$L'"+VWQWW-(P._"HA?3L2>!0"I'S,4X7
M?Y6@1/Y0JXF@QU2<5B]"B%=49UK4/BV1=SKK?N_""YOT@@OY4J'7D@2\=833
M*0 -F6DYLT*E+9T6M1TI)U/L&^OXAJT[K_/#O@-9_B]+K]LWZT_0?&B$#U*
M4.J8U$=&3+(0M+9;;3T(':/1J-A8Q!T9FLVC%A_Q6MMYJK/^;4%48D3WG@(D
MKN =*8 WB*0\,?Q]"["'@)IJN5NFF+]" ENLC-]&9GT]&C=F4OI(CUFGU#Y<
ML(N]=4LLP5^Y_%^=\'9NV"E<-(9[90PECS^OZ5]B\,;ZO*6L^Y6+U>8)-.E/
M6M7L^R7";6);:5.)STAU5%+WA@^\:CBM!6J:9,<@X*@N(T%7K2N^C[NV#-]>
MB[C]T(FGB2E3XWY02VS(C7D16MQ0-#&$](AZ7+X=)YX#DZ*+]YO)9%ZN/I%K
M[ 6KWB0\K'6AZZ^O@;S,NHQPFN3]P/1$;0Q< &,B2^,-9D /W8-,IHL#^EO5
MCW<P^;B.Y]Q@3SC:HC\C*MEXLK/SU:&R:*F,TB(+",RH;F#+:"Q8Q;@BZNW[
M^KJD6]$\ X[I$X\.OO(50X?(70$?()I2'WYK$"]&N_AT&FJ,Q:=#\<PLWX9)
ME$BYF(!@V86F-.31DX$<%F0J<WW0&W1\N-*A LL=$62(<O,_L(_0%;<NMNT5
M(\"Z?3V>ZLS"KEC8,6*'(\EB$*>N5KLC0S);JX>V_,:F+#Z*Q6*\] W.'! )
MZQ1Y0,-5]]<B5A4L+5HE0IL3;_>]%2H_+%.OE6T5T^4?+*G7[7AE\#GN.GW4
M-*V.X'&NG>T9&%Z6NUF6X4K"< N"'ZL2?4R_8XSNBM69F8RK@9Z;A,X&U_D6
M,%XFI6F*VQ7[%9)R?IC(>3PX'^;+;FM%Y=9W6HW@VH\,\CEIMMNX,E$4@,TE
M0ZKW3F4L]^6JP7N%7Y,#W<;4S"R<8F(BJ)2?8< L_'_WDKBI[YOL$"VF:9NC
M]?9>H,4_;U7AE=H$UG2J-]G3[IG_5;N'2(*K(]O/!KP<G(Q.<)XM@5W&U"*@
M5IOBCU2N7)\M-UNUB3N1JE\8-9.:\C  !;HP6\G*5.'?/-PPX2(M#K5J0V"6
M##.32Y-.U6:<*.ZF3_@RU[V6&'^V,TL^!'U=,C@@>LO8J/EF^3HTZ:.K'8?T
M2XE%L%I<YSN+L=HG%77%PD3A%]N6)MQ.EHXY%XK1B$^5X#F$L<!N[?N/3UI&
MDU_X9AN[MKZ=U1X$KW*<;<U_'Q#' H7%HBX:\W>QR/F..9--=GM(8=)86MKH
M"H72>[-3$ J02LC,A^>Z<:=>3%N5$PN9%SLQ33(X:UOR&&MF4?4V:S]U=&C=
M7,;G4P"^C><E]FEKU: )3;[D^HO:-Y_/<GR+>>F.LYOR(;'F=CC4R+.;XBJ/
M\DZMME&#=ZC\AZF>[57^MBKULC#WNPE"RR]/[H9]]M"#%$\BG./T8\-$.6]V
M.JH>JW471HOGOW6WM+%KU3#:1GZ'8S\'KS'$Y%_J;6])VK:"U_GB,^/GR#RW
M3MB]-3=/A\E4P"3*=]8S<&41"RZHPNX*DR@KCZQ*L2>C1J21]\)A]TH04U<,
M.=D:P_I3"2NG3['&1&H+N1IU[?80_0239A1',[IX#9OMW& &Y3M\SZ[?>\\R
M^<:\I/_CN]T3*J8]_T]LZ"<+^LF"?K*@_T 69,=*N @=G6*B ([6$'ML1+[R
M4)VW<+K[*Q>%*+CCQ2<"^8[7+H9M:,AY>;\\#(Z?JI98_40!*C.CZ]5@60L!
MD6%%F];^Q<U5;^:TAI\O-;VX<NTH38!C[=8KUJE4Z0TPSH6*$NJ"E"-;M-DP
MGK&;6L[-_1865HOQQ0S68V=N1=EO.(K>B>;W@!BT^VLZ(?7O"<(N8B_%.Q<N
MC(:7%+ZQTQ>O:BA[X1CAH,4K:,BLU0: LZ.+\UW- N0R?6!YMKKV]N[\1EJ#
MGQZH9NLH6KYX=!!8,@8LLQ$"^%(JM@["2V (US*->^R'@OQ]F,JTOCS=9^#\
MWLM;INA-1("B](DEQAE-6 1HNG**:4O65"/8L\E.HO?.>"BN\R*WKMK21\%+
MH(D/N%>LO>K23_"66!\JL>+7%'5'>]*YX3*.]CIKZ+45"O96FR:( KWO.S^^
M9WC:H3S<0Z/G#'G<&F#^\)[&A+/-@/N]6/&/IY0_;VUV<9Y\M?1I18=V&<P<
M1!W0#SX$"6+BBF4C(Y5@;)"><[-\NT-BE95W!!SY]"<G=E\)JKUB14C"0Q""
M%*#)29L5GV-F),]^&WH4<^_NZ2/DVPEK$P8"R&>3-Y9'^-\$]Z(\N6Y/JF)(
M<76H5=-^JUYXSH8[O,C)\F92@*/E)5:1^%L'7K%8_4M3H,0(O1TGAK?'9+8C
M%*)[?1F#M++MEI9OK_O?\J%CE3SS5>/LG78O[XQG-$.]X 0DANCN0XX2SZ0
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M?Z9=QAT&DBQP>:T=56;4;,O\330%UGW,BGD,E:*89J>KLO*NL'W$T&MW(28
M1O U[7V@:&AF1;B/*SR^6&/^/%'?LZ?MC806D[V:#F? .]7V(D0ILE$6>5O
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M:EK20(R[EOL%9CT]7A?]_'%C:^-YB56<H5F*M'%@1O?L)B)O9-J3G/KTW<9
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M:#0R9($,I3^I"I60*,DO2!>CZ%0::+_FT24[X3Z+\2T/]1-#T=[A,^?664=
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M-VBY<B3$R5#SINOT!>6GKL8:0PGJP4^A.XL<'G5R#^%,@EG/KN9$Y5FM%_'
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MQF5]*?_F]Y$?2\8W;4_!B]W.F,P5Y&-#9K^$-LK&S-ZS7-'%O<8K7P.V2*I
M9_/P!6]+OYSZUXK$6)F4(\_L6L*GU[_)?8H*>^!C>6<B2#. G@9UJ'W6J%8Z
M./2K#*G5#=B-J)P:N1LU.NT@=:Z"/6(]E&,[YD%<VDK]S6T("H,WQ3Q)K6G'
MM<_8X)2(_JK>RF7]*ZM2LTYSX9F5\8\MF(Y=*3K-9 FEY\T PC+<DEAARYHS
MYC[MRKO:WBD6D7*^4@*1>><9LB$VL)(>XSV TUAW#NK7W?86585/3NHVV()H
MI<@;4>=+NXY4'A\KDVY>$UO3 GF%O+(7.W5B3Y>L(J6(=!6N;(Y/C5FP0?'!
M'<1GJ3T_=Y.S!-Y:,L;+GMQ_]\*:UD!Y8#LT'(G7"W2SE21V]+O:!S[-_SE,
M3)2!R(59E>PTY:&N4@;^2[GK)><F 7$D3A^R\@E_PA_'?B^^S7IS<J1&]O[X
M; E/R@Q+Z%S>-4)=_ZF8J-THC" =2U3:G:JN NKP"UJ.]HZ.F8;^O#-S;(K-
M0@EKT=[D<!#"UV8,IJE(.!9UP+U\W->T2EB77:.U:^";OOJ1TD_L1I[ZZ,(
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M4$4^<.0\'6!6W&R-BL(D6KO8VN[U[$T@Y-ZN/Q)TO4.+^RZ'/\!R1L91NXC
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MZIM%1( ?(\*MV*IBQPSP%TI$-9#%IH.*W1+M82<.59'?]JE"7$)R?N1WS$^
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M?X)QTH$3CQG+E]5M!KC:4R;%6<-8RD[9(39G.&G^4D^KPIR_[^)JPU^*J_\
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MX3V)7N\_^%-*VA\F=_STO\BN6^?VG?.KQ>/"<87?8.60>)GQ\EUGA>(XL P
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M)NIU P@#(LN#'= "\&X(&TS#?0I5:+$PN&_#4S?+3'VZ9%#!M^R&_S+GV[4
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M+ISLN=UC9UE15@*+N,;)]E2IYBZBMD!D7A-WUC_-+0W6@&)]E'_^C)WX*;L
MFM9(]Y0H]/=5A"U N$_,0T''66#]D!,7"D7P@=F$TU:2'P.319A8"R[S/72E
M89 \9D1$7TRBVW X1!#'A-<'I@;4FI\84- ^[ZW@>2%!>EJ,8^9&3IA(.O$M
M 93DK4Q,AO'@'!HDLLU!?=+E)B;5'9_50D_Q&MD/MS,+1)2A4L,9<!9J:/M
MFY0%.;/$T-2A4V'T7$=.LC_0'M16/N +?M\&QG+BR$"F50M.=2JU>I04<:^3
M,B+=YX?2*HDOX-:B2GR"*%KOVU]-[/D*-C5G7KQS[$>E<)ZEWHW$(*HU Q''
M[!Z6833KUEG<G[9+^I?U;GF]HDPZ5,@SM9W#<6B':8,0I0.XN::&1/K^,]VN
MMPP.11N^M;=HOZU[QE'0J@R140.$+Y:I]1L.\EQ+.2KQN5F@<V"2D< *G0SP
MJV*#]3$Z3"R;F,F)&JCYW>UU6;YX4L2K.%+/+N.2QD)$2W%?"^D<0 PGQE7)
M+R(*8FL@Q]QW;H>OI&N]2!M-=+*S?_TF7NP).S?OTMT=I#:R/1S';Y[B)EN-
MX!E4,QPTP86H'U,_)3E\G9MJ>(V/ -TR_Z=1AL*C_9,RY=^:BTL1OS4G9_R)
M-0*W3J)SQ=^U!>?#J_%>C QFTK$AWD92,3)LCN\44X\DC=Q!K/HN!'EQ7',U
M5Y8!VSC@A(5J-0?+=4H[T\M+,/#@>P?54Q9,N$U0.U9O7T<@]+C>N9FK>-M-
M.> NT 2M/8+C5*O8%H9<%!Z3>GK3RAV<G@J:P34]"20<!)W0B.!1L 0%>',D
MF^-BS4J^(7E*VAN:&<Y_$:<+C.%P._4PS GZF9@"M@3QD%IE8: "S(BQ3^58
M\<'BDVC#48_9DS)T-<U<5UJ/O>BD69.MA0P]V&P8SWL'X?*^\G%PV*PI&;(L
M*^>3\.4JK/U1K?"#>GLFJG8/\$L+TE=P\7J=PU!IK'IW:@EZ/:2;6FJ,I[=Y
M["O*)^FU=_Y9;)U%I*_!*V]Y='JP@BL9..C=0U"<\+F@855?EA@L6G!26RVB
M(*+H ^DI_6>.C8JZD)G$P^K(9B[Z=18"'V;$0'\] V?04,8P=O=+867?^UK>
M*SI4.HP'F9:.)#$NG0S:H(#3J&D5U"HM&E0SIO0<?$;#N%56:_J _-O!#^]5
M\?R&XS0E->OFR?_^4ZK?R4]7YW^/J_.?=HDNB@D" C_0%!K$MT$*S5(;@'MF
M"YFGP&=SW730[YRI-V#1XP4>&0^+]5>5>86SW1D$_\,[X_O(=7B:CZ1C6FI<
M<_8M,L"PC]23&".E'0Y6> 7$1HPP-3R1&ZAKYLX7M'M,R@L#BZ$;?**SW$\+
MTNSL6\'GZR:N/0!WEV9-9DQ9M!H+IR 9@Y$O8A5I2U!BR[K3;;=JBX<\!(40
M[*2S>R2]D"LT!^\-="<*HD7J<Z\:!.)ZKL8TO.][4E<E,H,QE:7U^FYCTK*Z
M0P;J$'9^4RV-70VU)"B\W*%Y=BFM/];!-;*ED Q4O..<*D $=9UDLHWYR/S.
MH],)%;0-\H<6]A1"%8U!$NUS\B_6\TI!VKTPZ<WM)QXQMW2'I,^"YTQ\EC>L
MNKN:9@@JMP:%. .)<:*P>62;S]SC/='ZRQ<_Q\'+W*4UVZT3'@=I5[(_*(L/
MLQ8H,?O"7T(&K T&+$<<@Y*M+?@_75A6)6FBMY7H9= #U(&5MZOLWY2#/<%S
M53L+]\Y7[V124^O;2['B^S=8P*/V*E9M# V(O>_-D/5C*K#WL9ACD#@C[4P;
MN @%XM?LFA(@,I,*PT(5>2P)S_':_6#_<:E@*3WK-6JWS!AEZ$)'^.<]8<E;
M_]<L%S^9+?Z,_&2V^+7\=V.V*%D/@3 \AHE[BV @SZ79-G*D5V6@S#*CC2==
M^ 2I2V\,U8VJ/)72HMD\A)&<1 4JT1.N]!%.3YD(NU3"54LO?@T0$.3.CBCF
MN,%N>;_WN(J/++J81%>)V9E,C'+X:&H;KQDJ:M>IRNP>W_8Q[NY1P#)PV@V\
M>MEB20-6!NM&Y(W7:0ZEJ*EY6Z9*>394P/024>D7_?<&G=2T<'P]@H0P#M@#
M99IXPA(N@@(L-##M"1Z"B0<Q<P&YW[<-"YMG\]ZK[CAS?LWV=+HYWZEU4!^,
M-D&\<FRLW9P<][?R)GRD7>,'O)ZWQ4?.D^A=I^=>-J#JPAD:9-$5L0;'4I:H
M. @-[NUIE)*3B:G9US\RTAC:RA]C,8$^M8 KJL;QDTH6]5;@$]&0@LJAO-CJ
MI_TJ=PYTY'X_,3;]L&VOD\9J.AQWWJH)PF+89I-JXFY1R]=X<EFC9PSZ8L(J
M;B9"$>Z'FH:PX_SJS?EPT5.M[PT,JZHP;*^V37PM2TJ>)D[-Z9^B&HGJ!!1]
MD645])16F.#*<TUKQX0PLOX*X@^:3GA(M/HX^?7>R,B KT\@*\F Y3A.B*:V
M8S!^;]PLC*/B_O39.PN%;??9B!QY_6-,&XWP(?EWSO[ E*\T&9A(1.57SJ\,
MXZ47RGCS@6*,3([(LER!X6YRO)[6Y^*R&Q&9JR4R(HO&_\(8YZ#@8>I.I=]P
M:N1:_9YTXQ\K;)@.$KU#AIDZIGB2&.R/YU;BM4EIV?5N*GVM1),K$ Y^"6LT
MF#<@G+R&]:K"S-<Q4$^9!UL/R,).V)SJ.W'Z=%M(FEHL3[V.F-)S?8M:-!4-
M@4GR6N<'G,!TSH,C4TJ"B'J097FL]>:A+R;UG;GP\BKUC@&EZ!DR@#8%[8*J
M3L*_2U VS1M-$#;8-W@A) QN">+41+K+38VIB6G?[W7)FA&S\^)\EW'O"%^L
M$#3SH+WBE5-82!%J-1F\&I'MKJE3@GX#8TFX6I@X&".J/'J>9)%ESQ$H8V$O
MOFDUG ; 4/ :6=1,"^PD&1B(;B)%=T 2P&@C-9=+<"C]X1Z!4&EA!5GKO<Q7
MC/%PF2<OR<#PQO5KQ,XWZR_@:+T<^(3#RO)DAW\5*UHT>&E(,?7S&50F1"HO
MQB-1HW90VY.F28([(E*\!C?0,":*D6UD!$&6AT9'.UXIZ.:.KL?KE*>5Q#7K
MZ>EQP^D^953OTYAKT:P&$$[P>\6A+,Q$A3JB3^;#7L-+YPZ#<7A%GW1S23RO
M-VLLUH>80&":2"CIDC:1!X-UOE]C+/S6=KZU'/<\_PU-EXK7GTGE\]-U^G^B
MZ_2?DM.B+$!W(5<M5T9F1A(=LV'V>Y6'X]8VYQ Q91J%W!'/Y;1HHMV#:]4%
M'2CP>[.C?OWPIR9AVN6AJMJ^'+T/]B)U56=L/G6V-@ PHW'K5#6<^=P74JNC
MQ<486D%_O05,G@Z8R3S:(]T_ K<&/;>LQH"(J5IR=SW]J  LG![L&-V3?^-I
M%$;R;L_3)A_.\?I+(S CL'@-077:K#%T.D? >"C3$>O10<@KV66<\ 15#R!&
M%][#C)O*N@:=&[SOW*]]RVTV>P1_V2UL_.FX:WBW1.ZE;Y]E7JI[&>[;FH4=
M=D9V@D3J"U L4"50;8U3]U7P;,BX'(FG:3)HU04>%"-K8M'+!Q66\PC>;"()
M;"/;'4?$PFO&[@X4[(?L/24#KAT#$NW27S?IKV97OBF_Y4"@=ZAJTG-.&1YQ
M8OL*7Q<"I3UJ2S,S>9B^WD-,1$7;&9M?\3D2,V0]_VK+_?M%XCG;#JKZTD3#
MW<N['ZJ^45#_\RH*@/UH4S-XP1EDL[(K2.J5(BBQ[4"^S<9,V]19&KH>3C=Z
MEM,:?,D^]D1CSOKX9G9KZ*'8! _XA!A)>N^166,)MT9RX)UW53@B&9BKLIHV
M*@[@B#FV?5%#/SPF$I\8/C.\P7>40>Z3^KQQT9G0J/$\@LWB)?OMG=XL7>0A
MG3=OHI;>=^V:>2L^EAH]U^D8.2IMM2/1P-+PFM/5WOE?S47Y$Y?_Q.7_K^/R
MO^*1_R*8=HZK7$V:WBC'/CEL;NBA]:S_PZ.1?.SGJM%7#CYGT% !8&:D7A!:
M]4AAF_%F/>C0MI?&:2L+ 9R)@=5Q >8HK$?C5$H7]SVX]U$J#/P5>.(=J, M
MP#Z1EL1NRW9/INL"PM7.*73MJ!.O4@GRN\.0$):$D\=+C6NDN0>;)AA@SBNS
M=;JPOVSK]2 #B2^^-''4T$!+'G/[0F=&G4GTH1],1M2D'%YXOB3PH<-]<M.R
M6)MTL@Z^O;P:M9W$^%J!E0*K:XDI"E:N)T"4O?B><2D54CH+)]JMY!CY;.CJ
M):$7"CXWX*JH!_L)/!C]X8^(#WH:S<5Z[V-BPU8;ER$71(LXH60 QGJ_3)WF
M4H1OH[O6C:7-\2/P&GL%Z@QS0=@9G-L4PXG#U9(V UKC=AU..;/<C(_?/5V%
M.'@S$Y-A(%@7+T^4$9HQT,YUV?IFSK>SG/+!^@)\EH'5+NW':-DO71*BX(2_
M\J#O)ZKZ'XBJ_BZ_"DF"3,F1YHRQH;])T.S2QBX![NUS\Y6U+?P;)VQT)^'&
M7ER^T>%5HQU.P\<8,RHMF] CTL>$XV^DJ'*X?O!#Q.3E%NA(/C,//)UAWW=S
M6D-_U?!FD)6I. .OA[V#2V#%L/I,<52_C  88KRT%1X4&U-NT;OZ\JM;/+<(
M22"9>.Y6#K<,S+BQK$MN$EK3]!!WV[.(/]X!!:FT]=$WJK^TDC=.K]?P=-2G
MXUI/ 9S5QG/B0/_B[722(>HK99-?QND7NI]N?(,I4CX5%IV3BILV[KH8*C9\
MBMO#C>.!4F@_2K8);:EF;GAY_$<,&)4G FD)X^O.M'[$LD(&XN6]>P;6'#JQ
M-[26]'SO>3X749J^]MST;>!+U.#BKOZQ<(SDK=ZG:?VK2A9D0-%#$[\ -S4P
M8<F4@@K:?Q$XZJ_[&LZY>Z15LGEI]+(NW(\(FO+92HYRE.92OTIIZ^Y-\+,.
MC?11XPW=-LUUU8Y%;54G1L^E<X7M" ?7;Q&AXV/F##[]D";=T.3P=/BE]1V[
M'>D%V/T$=XN;;IG1?;/P5D6#K[?T-C5[FXRNI/NS+&Y=3IZCV63#Y]1\TA"H
M'K:\$8H:8D?V/.%HI)$PJ+NK@1TD=NABWO4$;)Y/U&_4=C3;"=[- >O,LAZX
MS>@9;<J)94S\O"0L;/-/N<S^=(G]Z1+[/\ E]@D$1##*=*>? ->',UOWB%;E
M?<!!=7JS/[H<.^%N]S!2YMP-]L-:3]REJ,:Z(,_'T5C&H5LD?R*8@B!B$ 3[
M<)P7S3X3[S48@J)6W=(DR2J#*J4,)HH)BG[[?+S)*$TR4',ZG0QPI9!X:_#J
M\,YQRI>)R!XR$-I)LZ[!NIM%*:J%6%AUGM2-XE10GQP'08O*/D9;3NZ*308Q
MR-$[Y=,GN-?9AUX1>!S:= ?:CK)'X<ZJ-HX_(P.%!J$$YDE&IL'O[FZW\(R#
M=K/=JW,/-\_;S7F7)UO$1G0(59VEWJX*PDV3:$/QJKAU; SNUE2.6]/0.[F/
M:?=S$LX*/N\6>9+GP:0DTY@$BAN.6H98=/Z;O$\Q3026'FP1BAA'8AQ<3&0K
MPPN%$NYN&'\?O4!O9)($49J %\E^0";[C-<%X7E1/.")XN.CR,:.@)[+%/7.
M@5'N.G@QJ?1URYZ4"]7N "DN9PFR,4;!)Q4)Q,S3\08.]?GB8!T-+U0 ^!YX
MB*W!^+%;/YC.M;?X]6%(\?FG]E<6GMY>&$_S>?_#Y,HQ.?IHO&&<I5#^$K*P
M36;;)50TC:^J"9\6:<3J)4_+=,T5N,BC <O1HMF$8D2PUW%MZ(#;"3H8J[I0
MMUL]?%P?429PI2&^D-G95U_.[D68=M3 0WG/XPYA:#0PX7Z%0CV%4)E9#W'3
M>K7QHYD$Q\_<X<GLIYB(,JTG-+B:^,]'E)QKKN-[MG1D"SD_3:(#HPVNXECQ
M=W%^*NBV;$_8RPR3FBP3P_H;K0Z70!+2H-JJ!Z5Z*ZE4C6>I=\ 3D(8VL>FF
M6C"]^\X-79ZPXD?%O+=DI@\FO8GA]WH3849+!AZ5E^'*2;1L##.0O,37 U=>
MG+#=6866<+-75!]3+ Z4<VOS2?G/A2A_0GX>G/_7/CC_O:CU%H0J<\3__XD'
ML':_09VNK:0\TL>$.[\D(T#=- &]4J0HVA_YQ#6L:_835:<6,PQ]TGC 56BK
M>]-/]VNPCO7\!9?7HUG\RRHT8-&G;4>V/G4/40#JS7BKVR*7$IU=4U@[6'E"
ML6E)+55?Y]0NMV@YI2^E^YG--L9S%5J:65?/!TWDO'AI77(WR&;+,_$C%TCG
M1=]-'<?(I?=Q5JJX7(/'GCGIQ>\=B'<IZSG.P"%MN8BSUVLE-P51JO6D;BD]
MPES#]<-V;;^)X2WHJ<@SUC.ZKYO5!!:@$_G'&&L-*CZO#[:N0]QVP1%[809-
MN!7IY*";V=Y;L6/%N\BX]3>#_.JQT ]E>Q?;/"Y$8;@,NHO2.LVN,@W= 9'V
M0 /2PPOCQZ5"(;8<54V4Y2S&#20V,\H \PB9)#1=\"84W\IVI>POX?U.).&O
MSM9X)=>3I&];J 42!0NG."8U#EISU\/+/%C?2^>T(?::-Q#CYBHN23,/G<XB
MKXE-$9JHK?M@W8IIJ''4N'-S6PG-V6](.7&LI(]%<;N\3__E5W\[(]>?5R\N
M;1&>1>U$!;4A5$N+Y_C/0%JRME;*@[^LN*;HF+>;I16/%X];8$*&?9V]BS;3
M0';',./S/*3E/7\545WF-P]RZ2XNL=_K;;THC<U[\_#-A[7PMOD[=X=#HN//
M?(AGYW0U>OMG8,2V)F5WF[G=20:6OX*(@/[L?1R(=+V-D5213-'M#MD;1(@.
M^NT[@%_]*V&3U&\\4:E^8]BKLN(@>'BC!+;?!9!4MDCP/5UY:Z6%S$_LE(^L
M5SO_Z1:BK!&?H;Q]  H\,9>@['*4(0LY!.L&;RA=H2!T*!E(X:W:_M_2&BS/
MPM=%NA#R"'@)ZJZ'!HLVQ!KVX*]<$'_CBCKP^M>6/<-^'(?$=ZSMV0\5/7\I
M9<*^3:M'Z=?F.XS#K]U4JRX21Q_;YHCR=W=>_(OK_=?##6Y-[3R;P;U'(QJK
MC@6MNNQZ7_M@ODC_%+/[G%J!\;A3*=?S]78)R;#"_GZKP KUCSC9.L\B5/:H
M:%AXFK&&CY?+DN&U@VKFJJ<.J-&EHFFG?,'GP)--<O-$ULI]>.H$Q^S]_CO>
M8#\#A0Q%-]&A % TW?I_Y*!(@"]DVI !W"&W'TDHII XQ_92,J#BL(]?N1$$
M6/CO_U'51P8"7I/:4%MW"\@ X4 Y&9B6@M<UPQ^-[YTSAI.HS,@ )A[8#/\.
M)=$.9)":R !S(9)US'UJH!ZSQ"F_^*"?X7).T,EX#K<U"1G5M;P0MUQ);"YE
MF=-;0A6$-XVS$&X4X8*MDJ_E^,3:(RZ\V90RU\B^R%T2[1QU<LV/H\''!AV
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M>!@QY%!G_+A8IR5]"&=.FU3T2,G4X71;<T2TYX%:J8,[WZN>5UW&J6#J&LD
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M-YK#IQ#:J[(][Z ]LUD^/<8.^!%!+TW$*Z;XMP'OUWCU!H>4HL+=6>VU(BN
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MS<JGC*<?6)M@;@4S/:??_NE9J8&*K&\)A7EOIIU.VT*LVE&,5;13RXG(A+!
MY84\\&4K%:7<7'J^LKOL9DY*+M@H8[Z^0%@RWV>Y*_ZP4.SH98M&DT8V ("T
M]$-[,DUXKM<O]D *FR\Q\0_/2Y]6TVCNG8(F"0V3(QL%W!,QYQWY-);8@%PW
MRJ-OTM(D,>/K<$E7QC&%1:2,^4PK!QNHBTE@ Z0/J$T@LZ&2J@)6'_F/[\V_
MQQI?.F=;?QVX/G-)AG>@R^'+:>5@AQG%V_S"&HK>1Z:X]B=^*@]=V1FH=W-9
M8EEMB@N1&#/A^>=Z2_9)/N1'-1O5]MG--OZ3B8G+FOA9S3@U:ZY#[;<WB-T1
M+1CC[54K=T6>;W9X)WC;['S':YD!?[!F:&^VJ? [7[<M(!MU1\SKS%ZZEQ][
M,SAC+?DKP[B-7V9,+_PNU%-.R$0Z8##=ON-G''@=TE$.&#VMM?%57L0'0G'H
M;]S:ZBHOCLPU(U'X/%8E3='0=<V?#7A$,+3 ,@WBAPZX.@W>QA=IQ1JFFW%W
MT2-<UM!JE1VT['=[YHI*[KWV--0;F4\FJ91[B!%/7@;IAVRW 1L0"D8+V(2S
MYJ_T:I8VH#*?T.3-2TF#H:-^U3K#R>)+5G9?"IBZ6_ZCXP+J;GD:-12CL?)V
M)O2QB+MY!JO+L$H9K[*X1@,#5A@OSM.#JU6<),PW]FZ$6$HCYK^R$J=_OT3=
MJZ->3!V2K.Z(7)UBY%*&_[#G4XQ5LZLA#'\MY7 \;$532!"$#LR!Q_*Y*?GB
MQ#HC9[<P.66OJ,YLIK\11\VPX:KY>M(4/R8DJLL"9E^$)37\7PM;I2<<R8W#
M_=;W74AP.5R>9IW?_)*>ZT,:W!;*=2;!11*:(=] S.RT7.868@/1V8SVQ 9:
M*V2JPP:V@6/>VR81QNB+'J267)\>B#.42WI&#KF0B1=?/I&NP["F*]S.(<\>
M@FF;0PPJSC]APNTD&Y U&K3-\8)I9&.,=VU'N=MJ4JM(_A(3][/U]85#L88_
M6WODS_IM;'Q+UV(X6*O<:D;<M9P[7,,Y69SK_G,GV-AEG:-:#4>.IB,-O+]X
M0'DX:XSQAARZS_,6^:7;\Y6"AZ3=G)/!J6R@@-OD%F5OD\E1#B^ #;1)B;CX
M8I;6J>"8=0YW,YP"KAJ,65V$-0F;+YOI]8Q2P#M^B[(;Z!GZC$8QKJ<KSA>E
M\ZEXG7= /!T\M[7I2S$>;KGE93@!VT+G\^ 23%!.83=PUJPT;PUQ,JF[7,RQ
MSZ1JQU%K?C@[DE%ZREH'S8JU7?X/'QB*TER0?3W("=!9WE0A!O6C?,6[?JUZ
M-6D^8Q8#4R&BI1L%\MM$LNB?V$#8;S3=;E$$=(7;^)<E&QB91:T&[!Q@U;Q[
MO<S9[CTY.+&!*H,U&EKU 7'DQI$]L%Q*CK,!AR2F;1HKK?Q$'!NH&CDXOW:1
M0(_%KK[C)&.>LX'S!I6%$(U!V4 FH,A<LUJL1-P@OJ6;]:U<+)>'#>PY+E+9
M0&$#H;\-68GJ)U0.>:&=(EH/5*'6M)MIIWB^GER7798W%0^=O<A:9 /AJ.LM
M7W&#+!L"68LUP^QW#!M$O3SM=0=\[TP$4,>D,I@6M*:0>W2\X8XX9L%-SK%]
M5T=,43=01&:SP.Z1XB[L**0YC5E+!-WT03OQ]8SE,^C@>/GP=TC^V1A59G'(
M+Y_+Z7FX ZIZYZ,CJF)+BF::O27%V8#(=PJ/_K0N:^KWLU"'?*/^UDYBAB9K
M6!<B81F_-US%WRD4Q97&MGQ9\,A]H"2^FMYA)["LY"Z;]<3Y=ZRA&)2/>)O4
M$3T*#X_MSUYM=F/H"";/ZNG9W:@@ YM2/2L'QLGB-Q>@V1O;\(U:ENYQI6$=
M2C--SVTB/XWX=(%+CO1=[P(8)#90#S+,5_<[(JV[YW_J&C9<F,U?.("<-#A%
M3QK.>-DG&R1?V"=(7@\/8,XNBP0'5G5.:WFS >H^@=UW9N^S*%1T1R\DYZ8^
M\+-Q))/_0LV5\H3=%]E >?I7-B!<>M#AE^([^9=B5F-EH81PA8T2#4MZ;(&V
M'4W!5/1JIM&ZZ(H92!;]]<?9?2.?52<9[Q>0WVR_4O)JB8SG'&ZQ79.,MZ)L
MX"2^55D*>6C$XPH*NQ%[YE#E:IHLD8EM.X(EXX;[#P^,*#QE \^[7T):!N*L
M3'61JP66!6*]T/B'463L7OJI8%C@LE_-UU%; O>;5?*>W5K^F,6M$:A'W7H]
MW2^ 1=:CR(]\^HY]XA4'A_!K'^"XJ8>9/4;$E;OJ)VK4PQF$H=@LOE]G<ABD
M#:0=FF'CIJRP\_1JS-NY*%J(S_.]:8KS^<,6>F/3RIT_/52?I;+$%&C)?)]&
MN)UGRD<UB(+/IZ#EN3T$^^8#$DMYPEI]:L))>AO^MM\I/UF^F $W!UI?^X*!
MYL0V_'OK5/<UU :I/U1@GT7&'*H,9]#,<)(PK1[6$BX384HPF;D&IUB%9V)V
M8RNUL3/D\$<;[E?*,8FY[A,/V<#XY!"A[O>SA7N$<=*H[+)Z5/1:_^_>W5BB
M82KKW8-<1*-U^GN(/'CBR0DU+K3FG+'689_[?,O)? BE6L*&)UUV2?[^?F/"
M> /<J7"7ZAG6;D5_O.IX\=JG.DH?)3.27L]X0A^Y)G4Z[ZXX/6K0%-MB3 TV
MT*\%GL!@V<X<QRRS?'>R,8D-G-&;?^Y#BE=S.09:'D=5_6P.WR@S ,G$$1[)
M[6O->Y#N]@*BE-BE@X[21W?WX]9U+][O/_?+7Q_LER?DG8/-=_1[IB8K)DK3
M0X\1/H-FZ'M=MSAFIR<I>N1UG)((&WB97C O0SOY(6#$L.+P2$L_.*^\G/!M
M\-RO_#C<Y@18&2_ON>2T)HUEK%"&-;N=!;V+6$N(= LG..$7T-1GHD\;[D#O
M#77QHHJ5,'@<S/E]A]9:V[1;7;(+M9@-\36 #V=0RY.*+*H-A1HV@UF>%)_6
MO&!^!L;^]0'14EAM.]A2*+*!82>W4>A-LPD;V$YAVA8P91""\* \D,4&AAH<
M(:E<U+!@%QN8;"<L)L/V%&2>\, S-]G V#7XFUJ8N6PNJOCR_%(JJ]AN\I C
M':VJRP:N\F>R ;\<>' UN$M/NJ_F8@?W;4=92 '%/+Z9PJ1A&'-WX(RYNPA%
M2-:Z9E?N'K"QR+L)E2=7!P__==Y33<K)LX=T^\?@X=H0SN9[T_VWXF)+6G"J
M]"LNR$US-N"-I":K<Q+T(L20ZYU;TUF6YG#QSGP$GUJTPPW4KC0C;;Q,C.:W
MU2E69&QMKAORTATM]#J?*O/]Y_NFID_KTH!R.$OZWI.BUYJ-0C"<E%U6FJ'M
M-[JNVIGU?@/N5UUZ9AX4@83ZFNCCPKEGX01"R\\^=_IZ2&T!9.R=,U7XA-IP
MIM<R6]5H;S2%:<B-TVQ@@Z<]%:_@^*[3X6+'!X3[6]@VV5Z@YWO<F^]\Q#%0
MGVG$-8&''H!C< '/"]04"9%SP:W%\Y49Z4:3D9KDDO'LGQQM"ZCN1,=@<LUB
M5$<3XDH8N&;[^]DW:ZB!T?ZJ</3DG\OG\7@-=VDO/9)@SO$\O2E16$A)CF^-
M&4>QN5]6#H)O,P5V3Z W?."VVB4WVO39OHD-S%/HXG@],V7*0=4KM2?<2+V/
M,#-2BK3UH)XQL[FU>Z)0ALF9?4T8<N#@5BWVN/E]R$Q07,*R 3%/!;Z1YE'P
M8'U]UV&PY!!B+*^&YAKTI$(YA,AJXUSB2QQJ<C4.9X)U-6;'QPF6'Z I-K"D
M^5//3&3P).EKC8M*.#0[NG'7,<ONO;GRYTGFKI?(NNY&_VQOVUK:V>B@0I$/
M%G0P9N&#T:L+*=^U0C<C1\V_3??#N,O<U%:?Q>C[MC(@C9PUSMJ#[\YAX#8^
MZE0]5>PE$IA[P/#%NT:^.8-:ZPNGG*#.B)N>2F.'7UHBYP_9&53PS&+@T1:N
M=XC%B(;Z1PP3QP;RU5A?[]7<]\<Z!X<NRHP*VHSJS;3L=#O0B>R(*S;9-,SP
M(YEJ0K!I[SNL4Q78R<4&(MC 6DK)A4QSH7&\3)='S%W0.+3T<G)-D;UVNV;:
M9\U5/$+HSJ8^&WA"2+8M/($S;EW 3#R2/22U\K>5]GG[D5!A(W&#'%'R,&(U
MM:]Z4RI-_.[/VCQ?4DC6']"'X:2"Y*>%XHCN[P2./6[8X.DK*$\U[U+'!*GW
M+A).\Q$LJ0LTR#==J\M(I+T(BAPC:CIJ8^8L5S*-=@QM=D4/0]</T8X@.SZ@
MEARA&ZL7Z*'#0WL$QAB[Q6!L FM>]!< 37ZB7LD/:^_RR783N)ZBX,M\4P%?
MR(:U93O.^IRP=+2^@Y$$ES23<,%"AW<LQC'<#0[2,Y+ 5A5XH'A:RP;XS$!6
ML+<D^*,5KJ2BK,GREM'D1@;=S^B+^/,6)7]7D/HS+ZR[@+)>"<)PBBG3K )Y
M91%H%%J6A+45(V\X :?=^^R-"1._:(G YKJNC1#FNUS@5 ID4%/"*-::E"S=
MI!UL.X-F,%'TV'$V .=UT=KG=_KPZ5S(F\#<BYEX2%]4\C3$T+G!NBG"\#/D
M)DR"QEK9P",]-E YB(/\M-@ ""LLSSWSRVLIX$.&3V3.L&DFV(BKP4PXERNV
MQ-.QS"@D\^UW'QFSM<Z$6L9$$HI?037N'MGOSXT60JT0D0U8QLG+KMD9$)4>
MPX,(UR((Y]MX$5P^!(U#&DDTD_O]3G9/.!W#X;Z5'L*\3=I3%]SEN;N/#6S!
MVA^:R2H,;@_#QL#G<!7.G'AT1J8YN?P4Q@VLK"/UYA;O%/&7A<I<,=SY\,C+
M:VKV;B3GM,G>]%13JY<>WM)!#Q"LV-56WTW@O;?I/",1R8K/''/W$G6Y@GI^
M<89VW4Z"L)8&C\DW5V6YR1_--0S(25_XIH3<5 QSY)O%KH:=>["S5(77*.76
MWCT:TF)>"AY9W^.^+O1:2':]TS$YZJ?!>_L?G3GX>\]_J^=L_&>"8ZN? "9/
M<:YB!+=_^MD1W('[.WZOI!I%O1_AQLEHKL>?%S,?J/;FT0# TYOJF6EN:$Q.
MUPKC;5XS1K=(YYUG4+V6_41H@#3BNB' TO#>QWCBTX-F/)BF[)==%3Z>A^>Q
MOB# [Y$6%&#O)"IW\+3I^%5[L02DY! _O@/9QP7M,1H&L;&K;"#$:U\:<0AW
M>) _:FGPWKMITE)<A.C.C<3PMQN?KW*0+$?N008^';B<:"S* G7 )A8==J*S
M*C9.7]?*Z=O GI&8@_[98[O,;C :E-LX.U%YZTQ>9UT::8XX# :8;<\N"T;-
M/5 G8KH=;U]'U@>?;;L4(Y;V0O!EWZ]CVX\H3*"HNK*^RH$UB^0 HBO%PHJZ
M^"I+E*2@$G7%W/!M@4D56K=5"M\X8-"JHNM1.[=U%,Z;1J@:D+Y"$P]1O?^5
M;D543OZNV*Z1PEE:_E[P@')HLN'%>L.C"T^=(R]6L,SH""IG!9@+^LXS3PZ%
MGI\3\C@7Y3[A*#>R<*?[_M=?_;7 RZW+?[==.LP&\C!S^4-H<H1&ASQ!V(1B
M:FQCA'!^>MHA9(?*F<[WG*)\0W#/GG+LG83\!H^Q@0JX5[WVSM  O& ZOO\-
M*QZ<$AY!,(^BZ$9CK?-I5-PE^A'&+3?*+T@@;$2&4^M]K_W[&?/3OFI?Y7[>
M6]WX:@N%S2Y-KOV"QQE3+P/6%]!Z4= -)F;EQZ@N4:'?ZQW6J+:N!4[]$F'=
MAS]Y).>F;B0]/EOKK_YAVRB.>I/04SM<,*\[C#Y*H2_TZ1<6=LC:?\F_H)@)
M[*657+AT="F1\$"=FWF<NO[+\4TQRL]+4KA*>5?DI'?,F6]R=:J]\5:-(@35
M4/KC<F>X ,Y0;;D<ZP_FN5%=E1KE^-=IZ$PSDWZ3GX&J'>G?K6<JF#WF%8W<
M#X48NWQ1.#Q=DO.7)\&/D"\>+&COE<E1U5E>DMR0-"9]GC_V7 _OA^+YN1+$
M%>DVU% <6# 1R9"JS7+3K.DN()EQ_W;8N:*H[+''(KN8?+#^"O&Y<KK54?\
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M=\)-MAQ(8A;#<:(WXN&^P.4%MJFQ@<6I/VOT, +RPVWYO\G&*R?F>.E]0FW
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MS5I.(*?H/4=<Y)U(U&TWA9XMUU^?+]2FDZT*/CNR[L*RI=\5,#[[E)D?X93
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M8;)A?__GI)HX)_!(_[,RB_8& QV#.U&EAD?+&P9?[&2MAT]#Z: 5TZ=!U?@
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M/G0^(UPMZ=,E&!^EYX_E@WA?AHDRMBE!Z2Z%SWD-=*9L1;S.M<71T>C=US0
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MMT&)T:C>AM$BS,@"AZKXZ]37NB5]!*[HX\D#R*PG9B5O>)EN;Q<<\6>6&8-
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M:\%K?* 8,9JNW8N0M>]P"L_RS%?T@MCG)/DD]#OL%6\=3CVX'6I#CY>X9FA
M?L_:G"?E"_IISP,C#+45/O/S$"'C;I!7\@O10?1E6<>N#=;=/W73PD8(1H*2
M1N4;0%ZC)*($0:4/>[%=;G="<C@MO[UCK>":R'/7 WO2C:"$APU[R)*@ZE@4
MCVF_QAU7W-P.DF%8G\W1F+*]"Z+J0@]8E'<JVC$2)HA7:("_+[6M@@DDX&E
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M)WN_7R+TQ?9M$$?D#>0PMQHY'R'0EJ/AS(&:K))LX&\*CX[??;+S?9IH#'>
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M\81/4."P/D?DL36RKOV<B(=<VW&_CU&JBV?.U'0 )G^?8^#_=&FRZO#-#]S
MH=6\:+S4_;73;HZLM89Y^7G27QKXZK;=!@D\U<":E33Z.1#@CO@(##B"M-NC
MC>?JXE.E\-;10X\^W/M,!0*J^VE_/C#?<P#C#%"#I4U;8QW*PAK>+C*O.(ER
M\5XM[Q[(RX1R!C .3&'/S%AH4($=.6?(<8K'-(0IW&=AY(/5^4U4@,]+PPC'
M'"&+9(?WW['?ZHQQ/YPT6ASTY+/ZL?H1Z]L:VZ^';\&P&@OU[OBE];.XE+HE
MGJ$1;2R('5Y:MGL."'VPU2JN_>3<XYBWE]@* F^K1I:>:Q$".U#>(PNA 53
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MK&_FKSSH8^CIMI BFE#Z! ^08R@\(X0RLZC\I9?(0ONKEW1*M>=2TX,[.?J
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M9ZVE7Q(/!#HW&@$00CGR@V@\0Y(!SSK2;.,<RMV4*^A3XRU5&4Z^C*?<\52
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MWEENC$4R@H$V$VIW2_7*2UDR_"(?7F*I'#OI.2"JW"L@X[:X//0/9<[[QU3
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MFJC,Z EOUPL[.NV.KBA=)%LPU@L^0#F./GLJ9L_++OEVU_(>0 5J3<WD-[4
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M2\O#@&G/M\8>/I@9*S%>WRG#I9R[AKS;60>'UV]1Q@<XUX_K\:*B3K./H*F
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M,$)V!X.'UFB^:1ODM5C0Z6KB1H'@3XB_</W=+VDTYG_&Z$G]DSX+.H;D%RR
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M(_G;A5:?V'/]9E)/[SH+9 ')#V-:D!^\W==K4:<BOV'?/.KR.))FKJ!XM^P
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MVYH4M\"(I!?%]S.4T1V@T<2. (TM47_Z@0$%Z[);M@]&KKGD0>[?R=V5QS0
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M$.068VAD+I,@4T55F'1Z^/["Z,MCX;8++-5N3]5']"4R@=0=+ O1;=!K(4Q
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M\T+%I@CL>7_+@[=& QHJ)4$<>W-RDD3=M[V40 3]'HCVF0GL&H1BR*G">TR
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MC!Y <"_76\^\!HL%0>_W^<NJ/'"S&+#J$2X9N:.BP_7[RIH>*Z@\I(I2%&;
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M17D2!&R&@FB6$09=#?JJ=7R>&=%;!X+C4LT5K^@>JI=7O$(;@\BC6DVQ#UG
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M?-.8Z=L05 4VDFX]E VJ,#T6  G=OD1QG64X=,HI-%L9F S?.WOGCJX2^WN
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M80Q,WAU'YWXU#-GMK?2;8^ZVS2=O1G-S/7?!@!V#XB<=11Q@)/JA5@QW22R
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M2CJ8J0Z7?W8@YJNYI-1%+DFW<?2-C[E6>N8V;UUEX05,!P:7R-J%/D<G)\3
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M#QSYX:,7<PO'1=:.LV\_^ JBV4VKC../\(.9.2S"Z*)."^+T$V@I4+]QWA[
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M*BODJ<T55Y[PC##A!ARQ%A^V_P^,CH/JOH.$9014@KC6]=[0H"C@Z3GVGUB
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M%,*?+,O/G;1GF/_WQCG;]9%:Q2W;I"OE+FB#27KB7Y.^_$*R(QW[<2 -ZR5
M.85/:+2:MR0(S]V<)>*C?:;SG.]>Q(1%)$:NWA$4@LP!\(TK/P>WKZ73G!">
M@T&7L764HOE>)=,IH<V;V7]D:)WR9P37'42S: 8()50R1*I1:1:C.??<KI$O
M0!45IC9X-2UULU):CH*9@7'2M8G8]@'>"W,8_K_V^O9QAY#7JR)%>1<D%%E
M<_>W<^9*"MDVA2NMUZC8->I^\DV]Y5X?**:1[LIX#WU$@)/3*- Y[&%*;9<&
MQ3S0^<K4NQN#''[.'?<?]'<9+SY-W4/:YB8DR@TS>1S "F[% AZK##!XE4=
M'LI!_G"$M.)E'N:J$@O?B67DA;ZTR!([UU\KH;[0JBCRN&2UA2!SH#RY)@.D
MI%*0@< 5_"JZS(P2E;A]ZMJ-FIP_V)(D[$4_0;\7KN'E:J!(AE16.PB3O!=
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M?A=3;!Q_E]*'$\Z0N',(.'AQP_ MSH &5NK>*80V./W/P=H3IV(HY=60OJ8
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MA2B#$FHXD_<8*%5"2%S,^G%0C3X0W1:@"W8S0CKA>X$#RT$P>^0,U9"ZO)Y
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MR0#+30H>-I5_-Y=F &]!#M=YF<4B?!W6000QB0P-#'^(,^PSK,_CT^G,>H;
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M/$JM[PPY?VMY=_-'CX,7X%1*XC? $VX5_L_X: ZCTK;$'IFRR$UX&S J2X2
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M<3Y6MB*91=US=H(?NSP*FK=]N09JL9]/MJ1$/GM]M\!,E:B*7.\EA?F,)VA
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M&_D'L@U$D*0"2)D';<BCPZ_'UT@6'\C7?88S Q5HZ1S/@YA]T$6:'RC$5&[
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MECQ,_-TM<2_6S8@X75U,!;">P0I2HI805 !<C J8*QYK8*$"+H(C41O"'E1
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M&22)X_N$X$><UBCK%Q3:E^PX40%,J TF(.7UR/;PORR__5OZ ,5/HSA ,T7
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M:?I$KQR4#%@KOY_#$$R18>F'PNR5L+O)3XEW8KH5$W>D1;%?U"!&X2 V? Q
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M;%U6%N(<MS],0*_"ZC^6V,XH\E(/$Q#1]>>L2Q:U)-Y\\O3=QU,Q_?9R/.\
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M?]<:=/22+&NW N(!)F0S>5^O:J!2<LH%A95[9VQDI#8V2G*;(=P:APFS'QA
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MSQU8$1F?CKM)*KT6I"? ;!THCVS/Q)>/ZQ@ PIH!<*U"[C" 4"U.(BH [H7
M@SCL1&88 %7:)P;A\*G\K<OA4<%C"K,F#T_"-M',K^%06H(,X*,* 4G?58P@
MCP/P6W^D"<%M@'D@<U>&$:M+"!R4^5^K%ER> 60ZX\!47G,&0*R%_$\2,D<0
MC!$A=';"!]1D4C]<&$>3Z_G$]6[(_/;>5<L&48>8J&U%7'BK8A#]$&$EV=9Y
MLI<-Z_#P<^OA-H,L"Z7HQ(61RVLZ)4=A.==X34(;1?UE!J8>G9E<>Z'@]#6E
M9/II96'BF'^5%K,OPC_!E9BP7-V2 6!*F6(&$[:18:AU&4?,)@E"0!<H]^Z
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M6S U9)%ISY<&UP?AW7^P4+]2BP^;.11PRH:HDN JIR>=Y?3T2*N</@O[<P;
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M14V%KZ.J,8HF4C5^;Z@35U,;Q/CPY[]88>VKBQ)WKA_F^_J"ERF)55!(%IS
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M0VC"[$%A(%13";*G]U/GY"N)*VIT1> 4M=4(%53?^^YXL9$C6#MZ\99I$ N
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M4J,WS-PZZ.L)0@;00;:EAPXU,[RVPK"$-SK&.J)B":,+=8(? 3%CUJ->AHN
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M<5GI$E8!T[<TY=<*YZ"V<3># (WC)Q;P!G$?/1._?I5X,!R^/\H2GVDZB5[
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MA7D%5MY2S'*S8?#(^[5VX22DRX8,1RKQCK7.SM8/FG%EAXM#45L)K^T9GI"
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MY[^6>L.#RD'4M_FZ=,PR8C-'=0OU9[ERE"B-\?F9()=_7D/,A_[Y&J(O80\
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MW=H$6N?BTWF[T)F@\1R=PP)^-YD7%+B)(?7@4?][O5L5Q433Z<5R\T<U;J)
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MNCZ8+G5/>T*A&I*]LT&DD 0)<PT,)K6+?)WG79,]&WRE? *_[W$3,7DB=R!
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MSG]7>_P8,I(;<S"#+P$>M:EN+"JQQ'.^)E,EP):!])TWF"],&P?; (GCLGL
M%V="]Y->>;TG;:>FVQ;%I]W#$8>\]@#! ;($>J2CO^17BW<.NKX\!S7AE0+#
MD['_JD@ \(MD3,Q(8D,*6_@D-/Y>[(>'>E*?3H6%":EH+ W'7G/AUN$ZND_O
M#VF"G.VAXRYF7>Z>G%VL\!G;MR[-7/N^+ +W4SFR="^YLX](1#O*'C97T=@U
M?[^$+8E%-4[PW!TNE0S8,$X99?X@'*08H=+*!M:YPS-TR<7,TV+B6HGEUW21
M\.I+&E=2V3N[].G3=] IBZMF*;-FHC.>T:T9AK>KHCY5Q ZXV5^MAU\7%!]
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MX>^]/6TL*=J,]8WZA/C^@'UF:]$,2USCH03NW#R$^)=#XS_WYJRS;$:NBT.
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M=90#LF"'#O]U=A'D(>:7\4:E![:>_3'&*.L?4XU^'H<+MTO^-6]VV?UO+?D
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MSPL^$N+&I<I+9>G4.D:8$U%V.=P7M_8*L^<$9\&NI:YW#1\==]5W8GVW[@L
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MZ&9SB&$[B=AX<_[+ #JV;/.P'PV ]Z3>A\ZP4)[^\9>GC_8SBEK$*%<09BW
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MIJ[*PW,Y(#C0"[G-DF!.#&C=:)[7(WPTLJZJJGH[U::;X<FGX($,J77!(UM
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MBS/I_2S!290++7?9*M-A2D*]DJ94O]8A/6UNZL(;$A.78PP*NLBXS[PWHG^
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M_8A;/<[ M[&F=OJ9ZC>MN;NEC$.GNC^BEK=A[6I[EO4U=S/14BCM@65UR\/
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M^]#!P>VNN$'Y$<&8XY%I'^@?P#CUKCS%#8M+%.D*&\^?"0(ZYV\:<]84=?1
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M3M5[[XQ!S=2#[/^]4O%_K%R&_RCXQ]0(E/NO"I>M@_]5;C3\WVUM:?U?;V?
MZ=/_F/<:0$K_L8/FVXA_Z+'Y[Y/\>[-$ 7,RXL#B])E1WW0U>W<I^?<."R7;
M,437UR<,GESG_@::$?YN92#E28*,CS5 ^%QH?-/B_<Y#$K!+[X+CK!7.OO]Y
M[[WRK2'A/!(AU D,8$CC>@J9KOV3OU4L9)O'.Z[E]YWL2JK*^%1K=YIKKII
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M@+,.C5,5S*C328]4D:&]%67AHI,/7GK=!LUL96268<BKV#V$>@J$";)D:1M
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M&64U<KWL%_\()LF]*HV((D"7>E^_&0AC=@X<X?WX(%/^VTCU5Z8,DP1CD>E
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M*X+!&>#\WZX^7^@6+N1E'3+6<<ZJ9)G]O622[8<N=L%7.%-!YG/.H S3$.@
MBX2X\D9:^;^)9N8*TE6<I>GN=EJ"KKJP"#73=,+F"]!:7^8N'..P@6:"/TJ+
M ]72ON0BXY^;0H/^V)96^!Q$?5DZA=W&7A'A5DED94[&58WF&=HZWUL<W'=-
M5PXH83FW551/C1QYC!_*6T0LM4M-T:!UX [O2TX\GCI_[$]]((CGCG])#,A\
M^Q%A8R3+9>/*^4.)="T^U0\F2/N-XB0\^0@+ZDTJ\6X<Y/-?#0OA4;8@]C-[
M+J)O4EC(CI'72'%84J3QP^7*"\,_NR7S1<UH<MX[G$%9HM&W+AA9LP@RIT)P
MX+G=13DD22:D\YUTBM0KPS&NY?3;<C(M;R\:;)Y#AA$:*=QKV))D74/%2JA8
MZU+6^Y]I)>LY-46ECP*>?>NY;$#[\8;E@:P,>'.K48WF3 > _8,4=C"PNY1#
M*LAN%9RVJ-)(1:$A(V=(2AWZ'I^71,^_VU6_>HOKRP'O[N[9<*G)_VS]FZ+3
MVN0V1T@RCR&<VV&XT.4[7W.TP\M27[!_Q<O-ZI^GC:"82$Q?S(M)T@;QYO?P
M?G[ODQLU)9^KF'77,$FSYQ5( SR*22MX\'_43_K"FV)L!(ZISYY%;@/GOUD6
MFZ0/GV?8N)CUK>2O(X-CQ85.-2G7GH? &BUISKRL;N6E^E-NSNITP(6P$@H/
MAF;)M'1,]6^F \9*RQF6-"8[DG\"I0 ;Z:4##.LSCAWQ0_^+NN^.:NJ+UHR"
M(-($0:0C1:2)(@C2(BI=0$"Z$)$.TJ6'!$% 0;J0'S5*$1$A(DUJI#<!Z9TD
M5.D))032)KXU[[TU[\U:;];,FEEK_KC_9"6Y]^RS][?W=^XY^YL>[VJ6:5BM
MG^Z[:3H?]6!YA#7R##808YQ!BXC6)'3%A27\GL'HQ"AO+:-N?DSOJ& 7]Y/]
M]<+D6_8E7@FU'OH]Y8W$W7??IHJXLG$AVY)$]U"Q+M1Y,!##SA4:U]'1*OO;
MNVBLN<(,XSV*%^=_GBX90'?G]YFGN[V25T0FZW>RB2]#O3",'<1!M9\%U\>"
MH&]XBK7=&\%I#G)1O7**R+ S=+$Z*UF,5QCJ6V5IKGZ7P@*VF2R=6!U%-,N7
MS=]-7X*RS<LU_NHINZ6J_BRC3[I(,B,G$6-"NA2#1K:W>++:OQQ\T&4;V_16
M;@4GV#^4=O//0[VW_$[DDA="NHJ?%D+"_BSBR1I0S%<5"6U;U3DO"G*J8F@/
MKXUC[ 3QD-A&:(3A[6@W172"V5Z7;[:B2:+J9V+X=;I  .@#YN?/K@@-";DG
M*R771K]?X_"W]%G5<#*,>3HJ7S-7LN =1C?7W_IY\TE*;PZIGIQ"D= FLE%^
M%R@3G'#2.B.'2<;6HW*6+J+<Z7=\10,BM*7OGC1*T:F<>4-^@I EK!(52!KD
MPI?3WB2WCQ43$XV9M>,[3SM"?-A=4H,< FMC;H1U>UU?S#M9KIC(V46B7RH%
MY]V56-S 0['AV5!N*L +$8N\ &8/6>*'7_DS6Y-X)GW8>'1OJ>%'"QB<R%=T
M*=H?1BRZ>ZV5AK'1%H2$K2Y4C4GG0C A)J)L(]UAN/[3R8V1.:$9)Y .@8?"
M%((U;[,EJ9;\LEU/ ,/8!0N:(OCGXAC%I+A,]X2WJT2.&5K4T'O;&6A4-/!2
ML\TRG'UQBW,3(GZ@/5&Q\BW7^L$O"5%QO<SW9V\J]- =5$C-<D<6[4AL!)T>
M'>H$R:L^36P&5< W3N&"T#9=,#\"+$S^V,R.F]*N]DJ\LE)K%T^W8M@4TE^>
M]EO_R@5V(NL.R)TD1Z[0Y"998_,KZS\1!G2_A;S1]R_U#!FQL[=5QLFF-9V]
M&:#,4M:M)=JBW%G -PIV_+CH/KN6[UWNH9SV3Z7LGBBGMO2I0@$[8MRJ#W*-
M9@5STJ6I6MVF:ECGHE!L,J3GD^>M&IG#@Z4T*@"W.92/830IF7.P0IU2"C)J
MBK\$?3<9FH."1@_V9@/_OMNMPGFU+P+(!4<1WJX4?5+NP%R$>^7.[EK V0?\
M"JFF]V1'K_8 (U:5\(BDBB!V@GDXN?:P/.P+%?!L7E<]]=-$EF_UM^?ETY>'
M&%O\X6>1SL X8'5S4@A&XWR^JQZI3"E?Q]P_>&"> 2A--R_Z6=U-!>'BPBEE
M>28S[KQ8C$&)DC1G<?Y<"PKA*WXQP\+"T+VB].0$G@/"&@@G%+!A0:^;@XH)
M\5U\.J\^/_6\?-#&5A8A6)6M_KW!:,6G#?VJM_>(:X^&FZ^"4'%P/A(3;OA^
MK5>BH55=PIHV?;&5Y7ZVZ**N=IKQ/(W&Z_H[S"W+$R3JV^"70W/6;>IR.PMX
M;_>ZWK&5VY;Q23;6U\[BO? .S_IJ^@S(PG/QRIBZ-F;F4,YU2-#-\$?,]O'E
M*=S7,E4G>M6TF#RW4MO)@("5<D')RRV*EA1D\</G'P>-MGA!4U;0K=T#=21&
M?B<(6[UT_+I"*1_8=6J<ZX=C;!P],IRNV*W@%U9H5*.+"EU4**U"P*@ 3_C<
MG'T3(1/C>P8RW-A5UU"N'R#6TEQ=G[#/7/8T-GGQCHOTSX!??_Q[3WYX'K)S
M0]ND*4R$Q"?I^X,D?<R/O/7M<,LBWM>1ZH021RH@TJH"S$1.T>2A#/,P$-L;
M^0TKOH=Y?]T,R$UL*?UL=L_Z /6\,F(-UB0E9?BP$0+;(7OR=<O)@:!;B*,/
MJ%D'00,4'H@CV79UAM@VAIIA?"5C[XAGG&?#6VPSNYUM=J(P*5,!UR:^0*>[
M JF PF>(KQ"QT,L=2R%11U0 DV?&T[F-V8GW=<J<,]^_]J=+F3W^_HTUIEM+
M:*(/,@RLGHH'NL+IAC$@%H=-V"QX"@$>]1SM$2_4?6)V)EF1WR^F+OS F+-F
MLX]<#*,8^1LHQZH@OL]1 7TOS,F5R)4IBA1TNNGOGMR<9N'_^T]B\&_+(#\V
M(T8^P710BU]#]TC<=!0C&1N:2V6F4)*X9REMR'UW)"MRJ]N$?#VK"9$B3'<H
M/\N/69B*4=<-^3SC$7*I2\VHI$\@D"&I_OJYD2G>K?W)TG:3.%50&SQ>53+Z
MT"YQH$)>[^W':*]CW?SW37?G32WT!X02I,R/G4R!M>*4/],6_T9L^6@AWTD%
M]"*PPQ2D//+P?/D&:I:=\@C1#<5+TLK@X@DH_CWY?;,$T<S:W;) 9CRH0E-#
MR,8EZL]!!X>3R.,Y4F]Q[XG.K>2C!4(/IC)[&1K'!W\E7]J4J#>NV#U:DK,P
MX4.OHQ&;F9"YD+RJ-^S9DTF\4'/:MW&LZ%/<4BMUF#!%!9QMV.\A<?I2C,J?
M4 %5">M4P,,V!UT,Z,00CZ "[%VI@#%KQ ^@&WQFJP->;?)J'8N(DP\RW-'T
MFFKU4/)P2C<5^R(%Z.%C_:$UIQ%6&6)"3@7S?Z*,' /Y"L=KNW%/MG]->JL#
M'?DK.AF95GV)14 HHIY[=JVUBB^?R_9DO^14 )RRN5\ZT4\%)$++=BU.X/_A
MYF,7L M O!;6)Y>H.T_R3#2;XN\RK[YM4X,EO_:IOR@@F8G<?4>FM,Y;*I)G
M^WV]]".W'G@6'/%J^<R2;H!GJ(!SSP@/RCW#Y5^W2KI_T[^%)2I]^O"[TO9*
M=D>'%!7@ O*3K I"0,EY5("W?#R47YWID_T"(=?P-]@X]8NGJF9)<-9^<9L.
M_MU=(6?G?=[ *#^_ )D_S -JD09#$88_Q!IK\_FDGF73%;_1N?"]X+P(.@9T
MC7! 88K &G;GU,#P=;-3KV=U;N!/63?%)=[V7;V6?"^&G/E3,%9;;<R8OZL)
M(3FU=R,XUWRFQ->""@ L0;U!<SAUOD;=UZTLH0G#-KC8KMG<\H4[*@A,G&;T
MN?[OZLF=+#<,=L2BM2//+;''460(743)Q5#=[C%:>+5[5;AK^ZPDW!(P=>!H
MX:&+XFBG2]G-L '240&.H-?(,T'N0?F7='Y,U!)NKVS.KBPMN0<N<$EW)U%&
M/_@T'X"TS-^+;ACDA@0LX$<G09-+[XJ_Z!2.P7"3QVYKM(JN%)\^TGJA8TDX
M!G[IQE@[7]*G4MG)P,U?5]^*B\A.[JLY/HXSZK=&[XK=[88DDBN!+U+.@F4(
M)@@[#R'),24DC^>= %N/64CV2QBGSKZ4J6PNTW0"VUXN?]6KG"V(!J1;F!GI
MGECUF0#3S1FPOW")Z*7WWFY!(1D08)'^" "X\?4>FN-I2#N20$N7;<C8\&\3
MCM43ZOIENAF^_HCYXO:9-V+A.FF%EWE[92NBSUP1_52J%!HP'&$S5YEUP@:7
MXSUXX(4:(PW_+3DT:%!TEQ!+LXH7E,SI=<C9'(+W)L/498@W_C0.P3#V#ZS'
MY8[L7C=DU[XMS)S(#([ZI%($<!KGPTO_*9.0L@\&1>NUYSUU<EN@R&5KRH[:
M.6 KJS^)G-M[\:GN3*/+LLOZ >(7E'!-N-N7#<R+ Z6 F9:3=.;:CX_'VI_!
MS%.U>.!GTN]>=7LA7?_K)A-OFZ ?^V80> <W@&<A&.$.GL*>3BK.#?(XY*TM
MF_]VLPN[H;%B:9642ZYH2N%5M^1H44W6M]>W(1_KC!KXF88K[B+->?#-Y(IF
M5C3T->7J[QH@AS4AL3MG-2_'-;?XSQ1ST,UTEUOQ_KQJ -:T NLH@-(2"*OK
M9]4.ND2S$V5 C#(S +I/ND2.UN0D,4\ :VN25(^MI[AM'">4!F(+O"([Z+N_
M)/+5 1-=,1G#2F-_M[E]1[ZFQ0]1,'RJO3&N^K-NA9' ,:-U@=2%[PP 21A7
MJ/"MH<#9FD_O!>86]>4;%E'9W/)*]']W/.10 6)KR(N060<E@AC1TQ/"1BCY
MW.&!G?4>>(ZU%OWZ>""NOL$-T'2N+0GKG]\C+!>IO0Q,A-*3M-$SE>HF2\/T
M6YI\:<P**)#M@I9(&^9QUOR\ (!IV-CSN!LQ,X6A G;.E=C-A*+N)9I[V7=/
M[BN[^W@?3#F_>? ,:Y!7)N(L8#4T"<7JPV,N-R;,]Y41&G>YO;N'O.^?N<1^
MWW(!)*PSW.+"1<XIE9MRH+2ZIGOE#VF$0V%I:"#6>.'RW%-RM7K($OM9VWD;
ML'I-]-'SQ2O7Z[,<\>[)87US/^AZ.?(.*Q/_XQ&(4SKL,,;D=2LKX;D\.T'Y
M0=WOFF+O-1D_0STR<^^VH=HS]NRW*H!@A"H.L1V#WA,D1?ZFW$!MVJYHBH\,
M-FEY>:O+N"[J2RB7O6D8,O9;QE84N8]_]"ZK;25#?W5[#.5'["F25:%I- #_
M'WK66WD1&6B>7DBZ0P4@>(&'A;:[K>I@]M](=]_X$ <6G.!BD4O)O G7SAV8
MN/\OOCOS'WATG[HA!FSA3)I7-J ,$($_!<PC/O(W:EI$K\4Q(1:$@LVVU_VU
M+21EPZ]_+MWM+H1ZZI-'JOX]K8'_8X/#.J0SZ,)<Z!:> UL:MZ=2,W$HT\1K
M4M@GWFN":6RQ6N[Y26;&QQ%"@M##' N;=VSM.W'&8QX!N@)M1=[]9UX&=8>3
M:D,P\(Y!&;15>\OM]L;;J$T^XQ@OD=C*;*$UB_G1BP9?I%Y4T46I1GHI%I99
M)AD5CYT$S,#V5,=+69=R3A84(2&0-BC?5Z0SC4L5J!"T</?7@*Q?I]H^MC:I
MR2TU:M7L!;87OZW*'.*YH !Q!+T NY._07C!0EB-W5KY1,5(M\?[S-,>JMZ'
M(9<6>K6FSWX4OZKQE/0A9,?!Q,67J$[#(OV*(Z;NS,]M2W*759:S-E)M/!]W
MK];MEXP^[*]G_2&EP1#6@-XC2")_PJ,4GA*F+"@C4U='EKU0:ET\:?K>GA<O
MWS!36=;I!KZ[.:0R)+UY5P5R,CM@M8J:1%W5UC9J-#B.",,?DDQR@>B,QMHA
M).Y@Z4YIZ-SNWLNLANRJ=TT+8K=(?8CQS7]I+VWJ\9T0LQ3?A> 59Q5\W9^J
ML\V^F!/R'C%._Y2L#<F<1!@\R; $-P5/5"N1;"N/C^OW"N\BWRIX?B.IX1[F
M7'2='#-L]+H(#QT2]947(E:!8'#LHT@OC&;^TA[W((YM6;<>EU@C5[P0^K:(
MJ5Y^[<17OE]"UDI]5ZP49[6E >[ 02E,(]B09?8WE4%SN8*&';85\W%V9<W
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M9JT9.9L*6+V.ND0%+$X@#U\$A5"8+RO;DJ2$#\?,*)83>79X%4-?E]/\BU1
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MO8(:1I+N'B!)W,JTH>XTFZ+9$VR-<TZ[DSX@,B)XWKLDS(PZ2JM_4=4AE?G
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MQPN>N J>[@.\<VY,/EK0]$6TVN^H0>V)87E^]>.U<_-D*!M%=Q**/=Q[A3S
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ML6=D48"FK@<3HCM/]ZFHS+->V@A0[-\%;#'&9"%Z,LU\.C;L#N,/_&1S_+)
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M>?(UE)CH')NA,>,GG7_*6E\;7ON97:PO!*%:_8,:@Y?API@0E]BW_D!PS<6
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M7X]MTG"S3BDZF_'(?\+"T<;U2(2XJ9 G:#7XWM+-L#7P\5J$?^OM -6'F C
M%0I*(W%\=6?:20*$KHC0(.0CY<(=WDX' X?T*_M]9R/G@XF7ZY]F^%[N&NF[
MX]EOG"]CF#VHAPID245T.1 S*:S>#,3&*X:D(*M6MPJHW['?8E^9-16>+M6L
M0CP0KF!I]@:UE]!0)D1$1PS$$K3)<>Z9H-?(KT"V,(PT]>X8J?.79$J,P(/J
M8Y=&]HER6N&]+.,2HK(NK:6S&E[G+/^Y;[6I):U(!Q">2WL"VD\I'G)-,'1W
M+K01Y&J^<C+X-6?,OJ6[B;<TI^H4P4-4;EH R$&2N)I\"TS[/(:$E?:?G-O4
M#[6H?>WQZ;?DKZ]A;368QT,_A+27M[@C_@E((,?A:1').&Y][&X&+]4<]4/G
M.#W/2].AWS%!CR3VIG3(+:DD-%Y5ZY^9:_HIXGZC[ZXNZ-U"/2BCA\)<$>R+
MJP0\%ZO'AC8=T?IB5A$ 2L9<K#_R1GJC%18,Y:>H_NO>39E,^\_!!60.]1RC
MOIIM9;W8<&K<S0H0!*=T'R9OM,PVN>#6_^E+<O)N/ZQWN6%2X1:J*#.BY\[S
MTA6GS$3\,\P1>A[. ;KGO"I6ZEIJF.4;TW#_J6J'!8^DJ]_%'V]CE;0VL:>"
M/O FH'TRR]Y;8%6B/MAV[_YRIG(Q^C*$67*8(/('I=' %FR__UPRU8XA9!_V
MC/^8WNAA6+##_MH.\EWZ:]I%JH;KZE2ZJ7E"J_BEEP^K$YOM'JA]K]N-4+JW
M?NJ=@Y-DU*2" <R\VUKOE@(]8%O9T\0FU[X+]P0:.A+;@GA3=Y$8DJ!:5)=3
MN-AC;=/AO_*U 'MM]FX8](K;6WJ$SCZ6D$* 2A.\)/FYM, \L5L!>'7#),/3
M0TNO.-N%16FYV%S5]?<6;>//W?*-UWQ$:V?Y*)KTI;VZISR]/A+)8*>ZD4);
M(TD'ZE$2B/W@BE+'>5+H/0]'L^!D+P>M.UX=Q2]BOW](W0AG0B8S<&)UY^WN
MW:,] +O$<P@%^I8GR3[)5K^'UHY;1!]X9[#)/:7\9VM/G]CS'W+$>@2]_U 1
M\ '3R(2$V$%!V&2@8B-*L/2DAAY:_,=@P8^VI+A1,#W&4.=SW5-Z'<P!*LCH
M&Q3G!(ZZ6HMGJ-RMMHE=39F+]$E]/%K6$7&3"2FX_%LCIF)[E6^>VIHCOW,$
MYE0$O8X& PC46':0K<E:;+1%:B+ML\W]F\1X>^?_?M<G*J_U"L6J U\A0#M!
M'ISFB1:88GM%TYLX1!IR3+H_S?UU[&<6A\+"#]_LQ>0'\U"?RZID+KXEU 9+
M'P0DF 1<>BY?9+^9 8#2F#9$I$#229B CG);GJ]K=W]P;?IL_V:EYMM$B2LS
MQ[6:OD5M:<NMK0<S(9PU,")03X&_I5UT..\5K:,=A[&*BY67P)(T1>,#35Y:
MW'VA4G6[RF.MZ[?BB"*#?9.4.ZW>AC[F2S4E.0>O3'W[?E^E3.V3#W]+X<57
MIP\X5AWI*(<FQDI^Z#<%'\-'V1B1>(:=1AL3(H3IB9"[I'M-EL/!1>:R83LZ
M;0!6 E\-.+1=DX#TW3QMR)\.(UP8X)X]>/S"H_D(.A>)+:0<+^#[G'I]8.53
MW]9WJG=E=46ZC^27)DX><+O(2'9F]]./ ?3<-<MDC3':Q@!N,@UZC"'H6[IC
M!9X@69IR68]CU:RC.\F%X1_>^CVR.@$Q;)T1W-'JQ["S>K@6?'I=:,0W=KJK
MN0II3W:"DA1*OF4 JE>[DN=_\K6)^^>?6FXP_X5ZW6VDLUH]ZK9T.6!P$=5B
MJVA<]F=KU$33M#+B=V./U!L.7PM97>%7_!;<KR"'9?OYS-VQWI+QEE=U^>X(
M_B_>^?O ^?_G7S90U@P\?L.;H<F$8'GHI["8/LSP(,-DAQ!+CZ# &?&Z<-5D
MH&YP&TBAA@H![<KO]QZYH;A#8X!_]P(H(&9-ZN2X9-$\01\ >,F5&(T)VUI<
M4RB6Y&WA='LAHOS]1/#M?9(9$'ZJ'!/"Q4_,943X! '$/4O!-EFE^ZTJ\YVK
M>;U3WL*U2">AGL^S3VH3 I&QUS)K=AC"<@13.M_Z8=;\VKO!%F/V'P/(+= K
M8'-P/Q!+1JDSD!TLS@O,^//SS^.(W?"CP$*NKSH3PD9&TY['@D\PP; M\QH1
M)B2(:LJXK%^92^M8YUFA(6B[R7OK9'YLR<IU 83,.CXFI/L6$<'@686!L]#_
M&,C==#=Y CH,XG<W%6F'F)"X!0NK#%8'U47*,"&9Z9-X&G0$(/V$_?M(XB/H
M3<4:6!D)MSD'!SE8$NO/%PRK]89$@.9,B*YF PZ$E3,AT^^!?Q]*>P^C+^ \
M#<QWXH@"#/U/9G8!_W$MSOT?A@IP!3KKB(R][=F[4H!)1=K_VPM[CMS'A*0$
M$NCH:"8$O6>V =\5#];U6Z>I6#6B*3(37*P.2\]E0D2S_G.TU;U5A-0F*HQU
MK74<F9!7N WMHQ&;^/\(P7\.-FK.<-P)_1O,O\'\&\R_P?P;S+_!_!O,O\'\
M&\R_P?P;S+_!_!O,O\'\&\R_P?S_33#_:Z=.6C8=6Z.;#9:1/Y(^%WQ:\O;_
MG>Q)5CQ+-?UF.)G@_O[HJ"V[><@=;IZ#O",X2R;DWU8PDZW7HXH'?7;1)9[9
MCMPB/[.DG+*@=+783MQ)H$$3I?)DXG1=>8_696[<9WTYCL!K7+<&I%*UTK.S
M2PMD6I6.+(]M%Z+!A]!8^-898/;QWJZ2@RN._-_;G_V:6%^'S_C=)L$THBQL
M-3S&'SABQE5BVV#_^Z>[F1#. Z1EQEM36N$]@$2A1V4FD\]"=W- ( X@\2FC
M=[>-62%#,R%G49=9EQ!"\V="/IU@0N1.0FFHV/_X:C[@\2,F)!4>NLM&T^6<
M9P3>8669,Q/2CHX!B/4P<=S"#2;D9TLH$P+-8@BR30_2CZ!W[WUEI?4V54@7
M.O0/,)=,8%QE0GBOL[X.;8$C"C$A&\[3:-H%GC8,A1>V4<(:OVV!-2WV@=M,
MR#5IAN5Y&$A'M9KI_X_S?@<TW_X-S/<KT@X#M!1P_M\0P@BO4-K GW F)#&2
MAP&#E[PWHX>',EQ0T!GH7\!_ ?\%_!?P7\!_ ?\%_!?P7\!_ ?\%_!?P7\!_
M ?\%_!?P7\!_ ?_? 'C;?N_95'#5QX]3"523.S?SL,A3!^-TYR)]CEU.3><5
MVI5N#WH2](C0IBX.T"57P"3+Q;O:\P,G.^>%PH"2=2PLVLO""B5PP/CPZ.=1
MW(N9;T&1%VGZ1[U(GE$6"H.R;E83JVCF\'\#4$L#!!0    ( !&'EE@>*J8L
MKWT  !:?   4    8V1T>"TR,#(S,3(S,5]G,RYJ<&?LNV=8%-NV-EH(DA%0
M<FH5D"0@.=,82")91+*(BM!"B^38B"2)"@**Y""2)6>0#))C$R1T@^303;*!
M#E^OM<_>>ZV=S_W.O>?<\^QZ>OZHZEDUYQASA/<=LXHP15@$&&YK:&L )"0D
M0!J0#@"$6> F0'KFS"\_XD%&_)VE/'N6C.PL-04%.24M-2TM#34-#=VY\PQT
MYQC/T= PL# P7F!B9F:FI6=E8V%B.\_$S/3+0TA(B?>0G:4Z>Y:*B8Z&CND_
M?1"^ HR4)#](EDE)+@-G&$E(&4D('0 ( $C.DOQZ /]QD)PASI&<@I**FH;8
MH8H!.$-"2GJ&C/2761/_]2?^#Y QGCU_2>(Z^05#6XK++DR2+]]F4O+>*&ME
M-AI!\4D]?!%$1<W"RL;.P7]%0%!(6%I&5DY>0?'F+74-32WMV\9W3>Z9WC<S
MMWOT^(G]4P='5S=W#T\O;Y]7P2&A8>&O(^+BWR4D)KW_D)R5G9/[*>]S?D%Y
M1655=4UM77U;>T=G5W=/[[?1L?&)2?C4] P"N;3\8V5U;7T#O;=_<'CT$W-\
M\HM<)  IR1^/ORD7(U&N,V1DI&04O\A%<L;SEPZ,9&<O29"?OVY(8>MRX;+D
M2TJF&V\SRUJI>*6,4,P/7XQ0L_!)(_C1OXCVJV3_FF!!_X\D^Y-@?Y9K!J E
M)2$N'BDC  9PQED1@L#?:T50-J^^6RCZL)VJ!49' P<.]<_DOGWQP;%\)/&'
MEZLAO6#'EE#%O"[QEP&74:'13*XVCM:WA?LN1GN\-DR/Q_=(DTQ88&U15O!H
MZ5W*=J0.NY_.YZGHVV.ZIOT5%HSI,AJJ.R)EI4,#<D<JF*YY:2>_A:EUCAF'
MY$^Q=L77K]IN.75HGPTT>/]0]E:1/_L@!**/ 9_>6 =3F&I(82+OP7?%X=MR
MI@&"-19]@NIU5I-[GW@O]L8FJG53J'AGT-=#+I]VSJA^++J2X/[Y)GG6T:BU
M:$.*1*@RU&6K(30@J_E.#88*';/?8<I1?%15F*V>\_2YN48:7X+=Z1VYMRKK
M7J-J4>8,BV4@69?Y)KFC+QBS)2C(S,O.$.-[U1!R9'KAOM4':^G!CVX%8FKV
MW#!W1K;5". 01(V]APJ+/A3?PE'85$R(!WRK:=9MB/,+]5"/S[O1TX[*[K9A
M4E9!K6RV'\UL(ZK3K<<OW!E;NBOV)/5$G%M^.>VKZ5 S)T9E"1S8PN94!:+P
M$O(S0SQM%+)%8):M[LU_,XFC>#$JV6(T6_Y<,=XZ^O2Z'_^DZF7'9I;Q2FVQ
MS*918\/+.OX:.C:BRV7)\EK4[0(#C\A.[)6?!*ID16#:D7)?05$> 5?&KJ#P
MQ468I!LP>FW;(UZD][-'8X=7O'H:/<^3RI-8+/.]7._-ER8 T]W( 7BD3,.V
M?0?']R^6F^:N-YRPNBY,,-N8]K[:68[;9UA22 -)5)Z2;J9".\RAH4L5\<:-
M,;WB8EEE+W/ FP()U=UL/^V^EMC?Q4PLSO%VO<'H.3V10]/&=S^;O%:HU+43
M>HO^9<BWJ'U+GGR4;Z>U).[#Q];Z3\7\25'(&KO'!55].OQ-'<Y=\\:"2I&"
M4Y[V"KO)>U;B1TZ8O-PIC'X'XX(RC^RDG[Y8TY+4XT)E%\HTJGM*CX]1Z([!
M B:7O5<Q@J1;&ZO*4FA2=;0[ 0B_>C!;*NM/OK_%B@@E,_9VN"*%WXJ <1Q#
MED"MZ=&&V$LH_*M%D6(C&$/CB[Y\1R>DJ4[X#NDK-CJ1!(FW#9<TO"P?V*MT
M?R4 0:I2PUA.-%@/K=XVY=@L5*^=U13JGE##K3A)Q;6]YC>5<Q+C.TR1YZ5_
M%(1Q7RIE&4)$DW;6!Q27M.UU'7GT][=F\VF1=)W[SK5X5)P.\KLSK,H^LV[*
M@9NNC#0>OS@F&FZYFV;/V-42>8UYW[,M/03,V'@!E04.NXEH?I4QE./@Z2&K
M*C8*16HF0Z]F65Y^M=*QER(5YU-6 D7:$T5IX909.'-J-LP[<K7(/9IC^V!W
M>_R#B=-.IO</J^+ 3L/P[@',,,54&B/Z4]C2-K,,E-[1P'$&HJ11([O\[FH>
M+9C4P@3%V@9^:0-JON ?!-<;)@##(3%5MLH"'=E;2)T/#WPAF3Q8J$F,FD3/
MPF%)I!DN!2_KR"'>:?%>6:=H%I+\SMS-AR(!J7"C0-.!VE)8*/Z1WFA1F#?7
MX:X:R&G$AA^CO]C2I02>]NQ.8X,Q0<J\5HWE)!U,.08+Z3H'ZI[K==8& QEE
M?%S8#\ #$LM;,!(\.%6\(QD?[5^ L;<H8WGA!6NO:1:.-PSRGKP2X9ELQO?
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M[WKE"J%KO3L"2'9Q@M;*?2(.A[;HQ/$OJ]-_(F!M@:H!4(R@9JN)D5Y9*:#
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MH^?"V!,  59T(6Z GAB$'Y7:E?[UI0QJCG\4#DHJB,#E#4\V46.CL+4K=>!
M K!WRX^$ #S@!.$8$OH)0$P3:"76$;0G0L0[-I>(.NS?6<N*6%<V^$>;(?^7
MC93S'^83#VMI(E93LB)F?RH"<&!ARGDJ08R=-5@BM"TS)>*M4:W/I*/$60+H
MA9F\3@,O4T34D]U;HX<-W#<-@]I63Y_73YEW(2I<GO<4W9.9D72)?6]ZX50,
M$[$'XO&*;!N!)'M&2',ZJ7+V^=^\,<&#;QN)?'=Z6<*@+,&$3",'F\-SN$8
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M@=H,[^SI%EQGR96IO&Q6O*7E*EV6_Y@SE)7;YT!F$,N-_E2!3.=Q?&VKFE^
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M >RN%;3\R?)@CF:PH>_@GRB#LP7"I4>Y25A<.P& G07]V38=(PI_(YOFG_L
MYED%!."/#S#\32<UEL__.\9@4OZG95Q3PR45HWX,V.K,QOF 5C"V$K0_4)CT
M=ZH#+](9&GWM%W54N*QFOUOV%3L:K!WE.T=T#R98YC_H)Q_YLII,Q,<D:[(!
MG+B,*E\+XL#57A'Z=->%3L4^<J>63@>,7:2@WC+7181=?'[6PX85*X!HX? R
M5U'J\"D]XNA^GG3/_)VG-E2F^)O]HS*I'YYTW9]YXSMML9=0>M'9F\EIE?/2
M4!ZO+"1959)1\@IK'*>)@E;"0T!XI^_\=?X/=:2!)!M5'Y!@^AFO/,V/NLWG
MG'*?SC56S[R(*6G$W;V7RD3R%0-'<& F[3W0L9%NZ@X<-WFB"W"I"B96M3,!
M-DGRAT]4-F'M 12CRE(("S!]*_2H6'7Z# 'X]- TH?X#'Y_?X$"B %><+G1$
MC4<(E:=?68;+5)6^Z02A:[SN=H,WXEJ!%.2*UYFF[%[]'?$?UL1(BM<37S(]
M30;AXWJMN]78ZP^$<&&?L9&_1$)BUG\$%T+Q\(')&L_<%@)/R:JTK >96OVG
M@3'/;9@+3%CY'1Z)OWLBDH/6\!;"=6(_[QF?1AX;KV60__[TG V2/JH23(+Q
M0!( L[J8R2O&7) :<5[&KP:*!.#V#P)@O\#Q-$ 8XYHU-679+7/TX3%=U40#
MK:)D!MGB(3NW^B\UHDR$O^/^O=&J6J<?'V_55#+T78Z[IT ;\T+S69#"40G-
MD:E%-!A9'>\K%#>K]^%)X+?I^\NNG&?O' AX@#F T\)?U:,9E_[=YENZ.F#K
MI<&'[X:^A2UM+-7@9'UF?IWJ/7 P>/G<PN&A*P'(3JM>.T,36E-9D^A=K4E[
MVVHNC#KC4?JW1LUV&XY&]GP_QXE$;CWPE:.VT6_SGC?*&LMZE:[U<KE<WGLN
M4H3+*N$ O3K!&MX9L;+D<[G!\&:P2YU?0Z'78*'8CSYWO<;>JKJ*02M)1_(5
MI] ]F_?N!QGT8[O\X-J6A#]HMCB[G;\YWH[I>_^;R\UZ 0\R0),E!N3,'<3@
M3940UM."_@&&'B&+2W^]Q>X[K.>'+='CB'QHS>7>'"#UJ["6^IUKPUYZLY39
M^"LG4.B)?VA#\E^!I8QS8[_7C(L->_9U5'KG\N57N"276?R'Y-C%E*<!C)A;
M[XQ@%;;;^)[\9BE8+S\Z#!=4 CXP^XRG@O7RHF)QKX@S&%8'/-)^:QJ")/]_
M."6E[WHK@+TTLTM4+ (,/7DRT1/PEZQDJ_&?!C8#BMP1(C_HQZJAK$.6;.@M
M9S>3>3X6YTAH\U'E3ZN[E?56(A(>W6-?GVFVP44V@S!#7\$7E-6A2#H)\H^J
M8=#G]<4UH5MN?0Z/XYZX1RB(9L3VS])HUDK(^\^)K"U$XJ4;4*!0N_&'(V*'
M?10I%@N=ME#^#M37C>L)=E$LS^5[#/151-(P+,/^J7%PJXIQT?.#C,S1S?DJ
M'8GY+ZNLV;W#7[X,(F%KY3*@*/X?Q&5<0,QQ<*.18FF+N)+ZA+8NE!3#HW#7
M*]=\SPC'MH-I',R'6F.IS2RG-9>U/\WV^V7^^/(FJ^R-Y&+8D-++0>]/<V;?
MO5XAHP^70Z_GK9E[!_%_I^9\36(OO^7!MOF753KC,3]-V.*<T>PM-%.D3$I?
M>9_ILG<4_?>D+WZ>BURFGBE["LRF]T:=9 84D6TG9'65J1[:G%%!(@/*ZDLZ
MZ2_K?9JK;>ZB9A4B1I$7[Z"XZ,K GY473[F.,L[MMH'V** G)W4$8&1(,U+9
MU $A*E%2XJDCY??%O+L_ON61X?=X:^Y%V$RAYGB"FZ\*!ZY*Y_7RZ57]FF>E
M?%'?ZBAB&Q7A91C/UD\+1OC9R<<6..]7@N\D)"PRP1M(BIV8Z0W?X;/Z]!B-
MI;O-L39H(:D- 7JH;<LUL^<!&P?BK_JXTN^XWF]!O5Y7A'<.L=QTS9M5^*A>
M)BKPKN&G=,W%ZBU[@8>N^)Z#4KT2$#&&Q/4A]4_/K!. $\6-0-#BG(7A:)5V
MHT1Q'Q><98WG&XJ+\[W2(Q#2.OAGER\<8KD:W2B&OUP6:J%@!+]?!E7\MA[O
MF8@/]N%Z$'-  ,@P]?2L:TB$YEM_&F^YQ.CVV7[Y1[R;*3QA58 .$8GR)H3A
MO(8(0&:GA?OKWY^[ :8=1!YBTTWG>Q==G9UQ_[M*:$+N7#"CH&7CB/SE&U-#
M\P9JI<7*#DM\J*I&QNO/3F(*W9!*$#9O3[XEEP/#[P>EZ:H2 8,O-GCL(Z#N
M6@\GH(<T7O8U58%\-*MWWNY0L/.Q]@K$1P [X,>E$<GPCG3Z349(O'_)KE[B
M-3$/8193NL ;@?+3\/FFYD;CUF82V/1@EW>QU6$3S][]SJT@+DLU#3672K\>
M2=<T#<TF7_[498Z0(E/9T2+4[8:X6PJTJI4DO=@G1(7J+!$)N"5LK<(0>YYX
MJHD G9(3L5)&1/R2'#;.AHUH@TM$&R0&TR1L')B2 $S)@G!D!A30/]5L_K5&
M+O>/BR?_>I@:PLRJ3\C@V)W<FKP;E0122E5FU/A=*0>7+;],Z8/DY+MO6OYL
M'SKK)7(3?JAB<Z/IE2GZ[+(0\TX6W$&EO:O%Q;+T@7]A&?I,S\FYG#)8L>QH
MR)+REOQ2DY?-5K9LS@PT_O."^9PN^4<HU]O9M:S>[#>"M.P=I8VK<)Y*D@/^
M7]XI^F5/4.$O\(KU7UY08Y+9/2;9 !]N"^"#(/$8>@+ I_D5=$121G0U*JLG
M_Y '?B  W#[@ 9YQ\+*I,;Z9R :U/\R-J#./>OU:6+R3;!+$^G:0F:GLA-K?
M%73>?0RQ<'9#3BO([,,MB2YMS@\]E@&WTML")? <58-$_&%OU@#H%EA][U>]
MD==WXV'4&]A4-)'*_K[>-_.E3-$FQ&FKI[6F_'ZLP@]CT&A9P#DB[15"$5-F
M<<N!^3"%K;7$Z5TO5F-T7COFX^WH'>>K]OO)TQ1B[UMYO[MT-_FJ,)$<'Z)L
M$+!P/_4EG(!SJJ<]!/J\?,!=^FI$1/$@59<^103N;)'^[QC@,,F_5B6T9(TJ
M6D'%5-%'NJTE;7W=FKRDKI0;QG8>H+@:1G9*:K5M[Q5KQ"$75J6K-LO9"H%<
M)<(S[L<S(=5N*BXQJ6ND*LZ(9K1&D@M9Y%7)]7U%Q90@FDX#KXK.6-MH*<UH
M=SH?Q'WU,]=$SDGL]PU]RP8;3_% ]D>7NA57C]H7+#9,$YW+DR+D5Q^4^4W/
MD+M$O>S6$]G9#42W^J-6;T_.?"_)S>?5=7<1FKM:6ENB?7"L 2P:D.^^PG*<
M7-F^>;>.(R]<C($F<K26%!?,_2Z@R3&LDP <,VVW;(E_(F:K9S*S<$8T#*^N
M!#VE66\YL: #/$HB+R>XTQ9=N\Y.WGARJEZ'@7Z&.:S)KEB=L7>0X995M6);
M^EE&/\0[];#I7'PIQ5LU+HH.W),^:XPXLJ&/,WSG0;QVZJM+@U+L\KQE1\H1
M%2@=O#8H&+;%28\/$EE-G]DY66JK/VQ.RE%RF DH=5A=N E-,/NN8*"U)D\J
MW^6[4@FV W% %$/S\S$^*]NKHT[/^E&WL,=.*X)?5=\+1  GU5_<B; NU8=H
MX3,3!]OY%=_&=AISE./C9-.\<6>A1"\Q6013SV$BM9MJ&]"FX5%OB%HL+,>0
ME(N$18/#2B:8-R(:[M+&OXQ*J^K$\A. MS!CHC7.$WE4[@LXY%='^U<:V_P_
MK685EO_#TJX:3](O,0H6#NH;=K^RSW)9-%=I5M[FS7YWKE_G*0@RL 1F=N3X
M.HE5^3'[]%Z]P\@!YX+\8,_RQ^,W$C1\'V;WZ=J!\Y"Y9F$_I49,6'8K]!,F
MR0!5DNV\-;+@L,I72"LI&1]JW&US>T65&BM=A['(U\G94%6-[^0(.W+C<_C)
MT,GT5J.X9H!$#YD35,?+3@PUFQ-]7DM(F[!F[NXG[@T(J.AR(5U5/=WHM\Z$
M !.N-S2T)T_JDU=5+V(>VK!YW5O5"=)"))M==(\S\(B.YPO+^WQ#\ R8RT]]
M)("G/4^V5#K(2>.'T]5MIR7)(1<A=LIP!;N#8C ])JZO8T99,>'CEYHW"2*2
M[[RFM>]I&G\K_W+QU7"0R$M,(:KA/GHHO%&D=+W&0S8Y/=2=O+[<(GI%8<G=
M\+)VH!;?YU:>A"N9*(V^+AN:%51LA%A)D+6U:J;[E6A/_L*KI5)W3/@L98?[
M-6NYALGUV]F96YZ61O/?9ZRYM0PZ<8]KBGU^6/JAY<G"JQ-0.WT4B*U1)7LH
M?\"6YNE>H2/KJ.5 4O6;E(8XK0/NPC481G.[I4D.AY,&<-YA1SS90]B&7W=+
M?JB2?B$ (;R+YV K?X!NU57;Y--N*K=V/N)5E@E 8M[IISJ;ES[<C0MG_<BW
MQAY7BEQVN42*NV$JA5<\@"6K?(;UE.3A_,+P\5*C-?3F<O3F P0@.&#V= RV
M,*:)Y3U:F/^(QR>O*QOK/#_,?GY8M/"GN<#:P$ZX]9;=]0PZ>@5P<TNJ"_[:
MN-.NGSXBE99>T<S>=]6 5#R)@=J3_LZWE@2OU<[=:7B[*BO*J:LX;X/G8LS^
M]M&U':>''E85UC<O1+'@MZ(/2F(1]E]52-O!#%4XG\$EH_?F+S]9%$]@R\N?
M\QAY\ESO]SIH+1&<*!9.B0NR<-^%B?-N2+ 'F.E3EDF72<8[:POHBC[,FEM0
M*O^96!T05K5!J]KN.H2M@"Y#$C'*FECA=$HB2[SV:RVOU#_#@H;S53WTUU*>
M?F:)/8+G-52N;8%*:T#PR>CVZXY@^D.(55Y?*AZQJ8'8-&M!Q<["?*"G)T__
MK" UYD;>RR4QTP_ HR6*Z2?/#BM6!7["]TOYZC&LB*%P@YN^!9:.:%W:)(;/
MY>.Y+SU>+RN'R ND584L$H#I]#9/D$-]W&F'N&A)MK++JEDZI]V[$#+GU4#5
MJE[AA'?'=F3P4BSIVA>,<ODGT,Q$QS=)BUQ=&<^ QHU3#Y7-YX<E()T'+>S*
M6MH S,X!1XRD51-N^8C9^R-WI3&&+S_H>H?6H8:TT/".6$8'Q:@:]$Q)4IX>
MQ^ V(OYYXI;_#X7N*K?>7O7:PHJ.; ZC?+;)^"AHX>UM<9U"W-K1'U94Z;D*
M92E@,PUK$UVB<MOW1XI7B ;IL9XZ^NT2O3IU/M#TR]-FJK$#[BM#>M5QV\7;
M#^_;25E*U9FPL3]\H5]7)*17-+L:8:.$#S_8IQ6CH&?#W:O\-%_?GMA[O*^U
MEPHYLD/=RUUZYQGT%%D?8Y%_*<:HL%:1EI:'HA\R*SVG.JLUMKU5S'M?U&E8
MDPLR<I>6Q'*[*X2X7E3^$3L?00]3"$ 1>"&B&H8 5>,/%GX>P+61R19AQ2Y@
MUA[B(NG-IA]'_II0W-+_N'B0*$Q5UFP[PN+)O23PS,SSE1L^\S<$24<\_[[M
M _NE,R*(H]?(4@#"4758YZ]YNRS9URRA1]A$YT'@<PU_2 Q&!#$K'LI!$>JG
M[71!);'._KRCL=2C5M[%;'IUT1 "\-(T&_M@1!2!,45.,^=>K;=J97_S%E\$
M'VP6PW B-F'3H5"6;O>BD@*WX/H9&06_P&5:I/)VMXK(1T8CMP>K;//S'CAZ
MB&"K[3[7W6M5&_7.3GSCWE7.,Z<CY?OPX5/^)]%?A3>^[EUSF TK]IM&)2U.
MAB!L&)\NS)C6CRWT.G&OI+K+YHO'J]IQ+@GJT8BYQBPNN\D<T/])Q'JCE"7O
M0K_=$]YTD"9=6.$6JHIK=*YV;S/@^^@I 2!-P=PAZN,D';S/.=YR4&*^3537
M?DN(CVCC#'F.66[/9!4_\H:BU3>1\C\KT(+'(<O*M) $,[(B\#-IOT2GHX7F
M ,;LGS(_\%G@;0-T>I='K';PN?>ZM>GB;HC/O0HT:5>][L1.T:2/58?$K/#&
M^3.9F9H*"JN)TB0'+(@-P>\J$!IME%5H=%Z[/91_3)VA[8,S^RQ:H-CB-P[)
M05Q^SK!B(KS_8W3*QC.>0G=U"0!,%W!PYJETYJGZ2  H<34_B>"CY5/LG^(9
M26ZMSTBMSR3T3VH!_]&NALD3_T$0^.\8D\%K).R7Z@=X[P^[7"U_L<OEQB,Y
M[)34>K).)\=R(?TP#^]=10Q]?^L- GIES'J15^%-%'BFD4<<7!4P<;[B_OJ;
MC7-ON7;MF&H8SF1'O5F.^08)Q_!G?M](OU %8]T@ (Q.?K;%W#RB EL,:Z(Y
M394B2GU-V=Y6'Z\N.W_E<I?92N,?V3D<4!$M.H2DLF,G[&LK*!\)2R5P3@0.
M<2U5N<+H\1P8^];DE1I8GK9L-E+IT]T)&:7IJ!I)+G)UYXAL,H;/&9Y=3TGK
M_\>\V8<(D,5$]+7!Z'8/G33O1)I65M=5B$*DWAGI?A<N3>$Q#'?9R2K!BHZ)
MN2V0SWP<-=];G]\PLO 4ZR@%[VR70([BJA1;VMFEGR*\5R=D.&G<HLGUSG[7
M6^5YR1B+L/[PV/GJUF*-30,3A U++D*V4!6W_OBX8CR?S?_&NZ3.(=4F!8=9
M_1;KEDOU?W]W:MP1A%XB+K+E[#$' L^(B;Q=@[% "/X8WUIZ*]WP^)%O,!DC
MQS)C\G1EC?):F_&H\&J&H1F*V*WVK5VD<46BAOQ=G6 ^'#GD1O#8%#_536T1
MMM]M,WN&BF4VU#0_=4H<Y\=U/"MP;4J\09/NH8R77O@MI]%<//46W9:Y),PD
MFF\E/S=WI^@ZML"F(WHQJ>RC[US )]SS$WULHLUYV!0K$8^.P$VFOUNU/GFY
MFBS/D$+^-BCJQ-7R7$+1??HH5=XW\[/ALQIC7Z$RS[42-WD5?H)2S;ZY:[M3
MH8.K%YX8RG_1IAL,>/A)@U-BC5( 79R\*@H;5781_7Y+QW'&\7)_,/-5?K^H
MB+6-2^,;'7PI3M,!FNQ+T38&P] 0?%+.0,E">U[_P[%%=\WW'VS)SG20!&HO
M'Y5*U^,R&UWMB^X[&/M=FN0=%X\S$\V0JYY^:S>[PN#7[]+D<P(O^UWQUE0!
M&:VZ HNR)FN(8?6%^'*;/'Y'GT!#XY2!\TC_5N?"F)^3*5MM;E&X?^>GI ]&
MOLZHTS;;6/O;GJO^W"L'W_*("DC5X8+=341WI,PNRWJ2*0?1CYT;!5R8YBT]
MX*Z:O+<;KL]32[#U\J;?SD:7.(ABS\5U,J;=G9!>T7H7:!G9HV68;KXK$HYI
M(0"74VMP(0<+.-'0^FQ6MNF&YM40ZR+A2?=+NC?$MPJG_;=;.A9+\4I>!$"_
M-E1(E7Z3=.AC3S"N>O9G=) :J/' R/N@9!51&J.LBUPO'>O@H6I&1:A]MO7M
M"\^]$*>G-M7-]G5STR) J";.=_><]--!WO%7=:"VYCO9 FC>_9*@NORQSY^^
M%\@FZ8)[?DJ\_\Y]1]I.AX+RM@Y2+]MQ*'=E,M]=WS4*0TRS?$E=H"/J6J(!
M/*FEJOHH3H_O]:B/R<YI+YFV6'-1KO?;,11@ PE=Y HP6?A]L<;Z,5)4=O,^
M+OK>X#>*^OJ/UU_;A4HDVH4L4H\QS&3+UE1@8ZXF7TM['!JM^;2N[616[[&_
M2?)A<UB^(P>M]364:K)35DS7MA.BKLQ9J_K-16&2@U9A_]>%JE3H.\T7*Q(7
M# +-(!ZBR_,S.Q1TT_ )M@>O,![%]-0=1WC6$>3;VUJ)SPN%-BC5*$N%<!G*
MC]*IG"M+F1U&;KA'%DWWTGZ8=3F_/TCY0X<+=%3X%"NX#YDV2;::GO7[*X9G
M(XH?3*\T/0HM(R:&P2K(V<;ZA(.?#%8=G:;]'V9NLANGQ&VIK=:>P,<3-"Y9
M6Z%6\;?A'2TGI]7$0/>T<!S2U\Q%#'[FF"0"8..Q<*++#/A$_W_)%^4B_4P<
M%N=8G&[OB!0FZ)V?[")/0WILO>UJD2H[X(*SHA:0JA^1T N.;TI#_+0131K8
MXOXXB/FS2;2E4[2!DSV))YG)MQA-GQ%,WU(#%/"Z1U-7155Y6CC;L_6L>>C1
M3ZA,>R%3^.5\7B7]@1@):]W3*^U7\@L<\;SQ'7C^B<$\VC2GQ,_<6TMI2A]X
M$[)<1Q(FLBA/+2^+W:4&3N[]S_ED XF]GH^!WPXS:*BI&GY<5D//]U#G=4?4
M*[Y'9%TNNQ$ F@#,Q",3D[(AYF)1)X?-L9Z?YLPV[JRLM8O+&6I\H^2]V,[7
M$;M3Z%&:>>#OV-[!PCB_7O-F8;KWF[XS8J0YV'298ENA:$-QM1O$_-W1Z=E^
M\:P&W4>6R*?KE6E:/V4.%K 7X,C* %;43F&&5]RQ]-SEO4,+K;25RV]U7&HN
MY*5H?%_J:8M/\]JU$0H;5/FD>E> 4[1T'3:$C5VC76K/?8509/_$49AOK%V;
M6_\YTYW3\=@)IF>?&UOO3H]!UQ& $B=LM-]NL9\4RC?@FWEHD9]09JHIGE'(
M.>"[VYH? 9#;RFT<./5T'E*J2(%7;+:@WNNZN[)\.!<Z>:[!SK?NDYFW]0MF
MRLVTPU55P1&L+@+TLKXZMK@]>\[+5W_X<763K\+*Z9W$=1)3B:"7G@D4[!?M
MN> CR$OLHW%Q:T-=+_S4+655H_*U2WWD*JIP/_(^5*#L$.FO%E'T(57R6*',
M[GP:^676R+P;5^ABFUJ<77>3#QU75-EE/F+!J%.'7N'['^6Q">F<;4O14RJ0
M3UG!O-0NAE:,:9#PPO"NB00SN=W;<,_JTIN)HX?;<NW6+,D$P*2Y9JPHN[YV
MP<7UXBV;!; 1!(0P[=BEPR!5]$1Y.Q(5Q]<_6[Y)_*DC0HGM$HKB^>@2ZXC9
M/%K&Y'[:3#LWAA7-MJZ:&TPOM)+]7'9C1?[%CVQR2Z<A%9*A8B_05J%<Y"7,
M)B(=<Y.W^J.YY)>]7;:K5[C#!J_JV_+@/Z@&II@.(EW3[:)C>!A7S$7EX#69
MIZK:B()^^8<ET/"B];N.1K=OC]R6<^AM,HJ;Q#&GY6V6%&>NSQS6M^:O']5'
M4<].BM3>,Z$+DB0](Q7D_;/(6Y7;2Y%M1EM9(C-+L$_* 15(43I71 ]&PK''
M7N)$X"]& # 3WIK;NJYH[0 R3.EV=1I;K-ZIJMB"?EWJ)\9'CSZ[D98HK31]
MF\J]G5+PHHGY""S2M\=N5_;N>4F3S)!@%[9W9F?6_6##!Q02(.('_HADQ?+B
M06C9L!^1$DR*3B']MF3SD"0:CA3GU11:>!$<H9(3Q_]=EY/Q"OI5VG'IE!/+
MTM(%!Y8G&]VM;:O?;*3Z&^KH&KA6GSVR7W.Q5C5-[N,<S*-K@-2=@'F>G^7A
M\'*P10OE?RJ6S=KE=&R8/SG:KYO]?;+^B.E&#H6Y+<3P4(W:=-[SF*X:/[\Q
MM/WR^MO&EY3N0WQOKWP_D56: +-;^9E&63=ZI+'I_!@5I]7XMK'60\[Z#C?O
MU[\]HP+9@QJG'3GI;>C\?+_PX?[@V&K_OB31RA4&775D!OB##:)LF^O7*S12
M2+ZZU49X152AJ00%F+(=(/*]5B?.#14_M;BB8M2)//4O7K")#>BM66 6:Z;R
MTBVY./JD;&J3*WG\IY#O,A6;YM[Q8X\MFHH4YEGK=&0317>:\.A2^5MEI3.Y
M$TW#[FDO7)EZ!4&N=7<"9'9M-W$/4QS-"G,.]\%7!B5KXI<<%^>TAN*,HI$$
M(&'6.6E+&RV%S M5OE#L]:+/%*V:GFVI[<>-J&VX_R%K+X?]8IJIBTTW\YR#
M3W%:C1WS3KH[\X^<=C?7-L3;L,^76]CQBKI(H68QK_S&>V7=I;@Z_/B;!,'B
M+MEM^2Z)T>8&7*"S*C$,ME5-PMNK3YA.KDUPKDRL)G#I_M"L%4\L[II+A:Q>
M\^XO8ZLS<#N P_76<.GAC3+9[U XKL$T485<SOEO].DV'J;K_G+U6_X0]$>\
MMG@4>(O9A9B/!KQ9HY5MZ8-A=H4.2?<Y5#-.N"Y/WJK=>RP>0FI+QH43R<;D
MRG5,8ER0MOGF7KK$;+=UC!^>K#'5%=0-\_@Z$FC!+>EBDP:K+(:_YIMH%#WW
MQ<JM]D 'NM5Y\U)8GZ <\W=@+L5Y]@V=#WN:# )5GAS9,%:-TW^[:,T6XY(^
MTCY>S,P6@)[.MTDH]5R%?]O"&6.@2']PYSS5R"&=G%&824BQG6E=D.%%,0;G
M/E*X"B0<EQW :(,U1>%3>9+X(/ZV(O5\Q977'I 0R4M@Q+$]GBI)YB>6+^W:
M:W.[/%S:A<M1Q[Y[LZZS\G.Q72UJFX5BG<I/.&22JPC S:]+7!'*"JGW^C*-
M4S4&E"R0IA4'+1M^]BC](RB:;K*)O,G=_5QRLM56)*.&&55MT(W&V)TP:W_U
M7SYAH$JL0EC<4A4<37ZTKUP!R\G6X:'7>/3CG4]\MXQ F\TQZR'XE&[#YL14
MU"/8/DA29%15<&A,6?T31/;)QK<3SDAW=OOH5IK#@U)1C U25_@4N=HA4S/N
M]$F.]=XVI3;)/A DP^>S1XD5$3G*1*FF@X)DQ,^;71>M+OA\*1ER3Y#_=3B?
M%L4\N\FF#1?&?-.@ LV3*OL>?@8G<"]R*S.JH0)[R5M@70V4-WY/+E39-@?3
M-E#B5EA52]G)]_JE]L,'STV&$>].&81WBN";>?UNG36^.\I5#4_NUT?M"%.M
MIP4%BAE:<LW4Q-J.%Q=%IX?1QG?MB?A_6@*$#%SW8)4B12.<)I"+[FX5.HTI
MD:P>L=QU#\X]);WQ'SCA;S5:Z#_Y%,ID^I]\8)=!K_,+<^UO5KU9]-T+>LN*
MMQWM%2=1I.9.8\:LH^EX7G?ODKT:&W?*:EV1?M +KY*Q#BI[%_[4U5>KPX@F
M[6=+T49#!@[W=9Y2:\U6?R9+6XY/WL2+^:DV86(SUJM9%,M&K<<,0T]T6_L]
M!5^^#%6+B3*IH46$W4;BS^"'6%O(#GWKX!TVT+&2XAW2]9&.]?/ZH@=PDF&I
MZC/=PK<H+#6HK@2J5$<(5QWE.N1VE,];W73@E!W>[V&XL![G,WPV6;AX/M\^
M;R;R8V&M:/$L6[(#,\-J'A\RMZ8^=(\I>?YN&BN[&>^#;YIE3"3+X/^.-Q*8
M^R$M%Y1%$*G:5V5T/0:_H3'W'\?3P9E?%P<,P\XI*_A=/11G=[B7I)ECI#NT
M;J&7(U0X,#N^C\+<T9#48W-\\=%\1J@&^G;-9"]]F^)4VS'9N:;82^=&S+R2
M>W3QD^:Y>MW^6O]LS.TXS8"$64N_V_!FA3E'#E [LMXZ\/6/.:\"!,VC=$3U
MG:AJ<'@<N2;S*IBQQ6ZS25P_R6C8'5;]/EM2G_GX>);T:NM)&NZ%OJM96];G
M!;$Y M"ST?%@GIK1/;5 Q=LG=][JXUI-=<F,33@J('Z1 (2G4SM+BY126<QY
M1>K4C^5:?"WF@TO(;#'V;\><\CWP?ZW\L'DH#-$=LHU5K>?R88YS$'Y1G77I
M"P^Y9N:BZ[8U53865(>YA&K^:0YI)?H]__9*$NF LQ9#Q\\C!))"_N*KWNX?
M-OJ3U[)ORSSN8RY?7QDROO#A"7/YB5BQ@W3!7<B\[TQZK_F)18/RC'[(26DH
M= >*!2&%MK(?<;I9H%?-G$E!XI?BY;FPWY>1S7:X@A;'75:,SO5:%$L> J(B
M9SIQ]4E-2ZI8/^KXQ9G #@\A!>.4-]>\6C=M7L![%JI7M]H6&*5Q-[N/%%NF
MG0^<%+7S*I)5>J^Z9-I51CG)6Q^7@B6SS=D<E'D=#JVM/''TI8M1W:(=]FZ\
MZ5V2L=/Q>MA9=3E.*YNB^,F9F57PJ7# A+4H&A_MNC@ ;K]7']KPR6%MTN@#
M]KVL2('4[><=)(V@=W)W/'M.\"J&TCB>$65-;UM[;VF+)S;*?,^FCH-86GF3
MCPN/^''OES'&SLI0_R*:V6W(G?N)@VQ'.93])=>?I78+-D9Y(INSQMVLP/?W
M.G$A5:A8)=41ZMX:%9<W+L,!)B6F7#?:U9'6+:+U7%S>-H*)KN9I.F3Y>9[\
M T7-H_ L_\2?<_?WBUDU,+X%F!NZ/#AIA:U'=2E5C>7=^P''*'T%8I8*!E-@
M>1>OC#L?V-!-K\O!H'7JR?(]L*M:WS(NS$)!M[<U@[#*.8P9ZT2O@:? L+J:
M")I\YV)WE@_](3(BG^&>C\WNDV"H#[B% T8E?YA::_88=R^QG"]F-K>,<]S\
M,+U;/XT=V C=&:4Y=7#:>:B]^-:C\87@XP>^#(Z.(AGH_]/>6T?%]2W[@TT@
M$#RX0P($".X.#2%8",$27$* ( UT\$8[0(#@%B X">Y!FL9=@CL$A\:]&VU\
MN//F-^O.][Y[Y\V\]]9Z:\W\L?_HW6N=LT]5[:K/9Y^J.N-.'LK16RU52QW[
M. B7'5%9HO'2=361=#9]U0<67 ?2:=;4Y4:U=<%#E(F>%@'D-+:L[XMD<Z:$
M/;0S&=0=-IB>V%;\9MFO[5L%QE!4N8$(]X@).P6&\2.$G0NL@)J@C$AQ'75Y
M(YW) :?O)98KW.^417^6NB]F"GVK13D&^YA\6#48/\-_[@^&*4<<1D?!-C+8
MT,K+&F0^]LB/I>"5?3'M,#5?Q8.#TA%5FF3I0,JC?+K@<Q;9O*:0V\>9Q- 1
MG-=W@%;Q>[":LNYF;P.DE";.W:[H,<\WF=F)&P8YT';'2>([E,@Q**U>3"#,
M<=M<BG=:A%W7:DO>T)&(!:>&?RKT%JT^<_:5<FS<\R)WRA'(<?K90PLH*N('
M, #(=SC*LENEJQ"9;5!LR*H9\NQ'"<2T7Z=!K%W"&A*URI3P].+K?BT?^XC>
M#QM9AG%IOKRN_&U*?MLSK9L_#B.<8;F(\,+2<A_I"I7?57;,$H#;9T=6XL"O
M3 E@/>GG[4+?LAD,=A$5WXO^& IS3L1_T:ETJ(;YBIJQ#-T*0N)5P<&R?##:
MW-CZV\':Z%XJW!;W=M'](9>,R553X)B/&.)PAGELT:;$3=UY3O&K87M)^:<X
MPGR\K(-A!J[MYXU,6?.OC_I_VH[ULU!Z>*OT"TC'O9$0V32K)DHR7P$&-G-,
M5CO(#JM/[#L0Q)@8S2G%*<W0!^!@YU-0]WV9J*FZCCS"2RC\^,= TSVI.@@&
MVN<M-O+@M@7BEIZ4!]<_R_\BBM:]G>(H9S%RG:.O\H1P\>^\390XV=TW A+=
MLJ@AN$*K&?RF9)BZ=05"^82WU@25ME3QN7GE%B,#_SR6IUXF&T>;>O(V"N6H
M<U$EJHF;_#EES6*=8HIN9FA;Y5AI@-7ZLG=2ILW:)2[CDJ7M@0^?RKR]I2YX
MNR"<KUQS[TI[4_MI"$Q>?1/"*8ZW\^[CO?'JXRM:<*S/I_J_0AK8"A!?EM]F
MD6149 '8;9A0%EZ@O^-1J>["^R%@4ZA!.A8SOEJ *T 5T<32!J5LI$-1JK(@
MI[_NN26ST"7S6/9BB@]QV4SGL_</E,\5;K[M0U5OUQ]$I(N /=G[K:LV8##)
MU%2;<IZU ,B4C26=H1@-EA>)J0@2WE;_+*1KF G6G PFJ:J'4U[IW&CR*_6
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M*?Z*.C,0B.R1*'>\ ZB<AA^)K$'_$:LGE/MF7Q%K;0#19_$5M]MERLO@V3O
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M<U_TX[I'B>"R/W/AZB>LY57FST^1&J'ETJHKJ80:NF.6R/V%)779'<TQ7D]
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MXP%V@XF70+^VJ%)X8\_@(6]J&S^]^0'HYJ7X)%HH : _&?8"H"+-5AS+E^\
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MS8E*K-'-PK:2PZ_[V%Y4MM[+ZKMB#(WX6]I>NP;"F^=C1R<IVK.4]47L'R.
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MW=Q_C:.O.Z0Q1B?.CLVC/PYUGRW7D9:>=(O@1SUZ0I\VK: (\$PZR^^"7F)
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M >(&=@6<P0E ("OR4!\*NDS4<2$H>Q@OX--P!OA[DU<?!*C4CU$9WGINH)4
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MA9N9GK;Z:;SPO*5D7!,(*P<0#^=H)Z&IUB,P9Y7([;XIQKY# _-M)%12P0%
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M([PKFP5'*>>P0(Z4@[4#9&]NDGX8"6N^WXL%7MXZVM(%O9L^14!'-4F_=SV
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M9.DT%W;AWL;GQ B\?I=0]#[GI]=9:?>PK]E&TM+>?:%4S '\PNC%[C@=B(X
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MG[K1ZL/P!2/_+%&U3,HA<9H[5FI<ZKG';=T3Q=N 3]'0?UZ<>39%<CL'DB@
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M,=AW(!A23SS"MM(?]VS3#'AT=,;MFO%"E8;TI-)?6PR>,C838F[7>L;\Z<T
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MKJ%VJ&+=9R]4UGV1:=<,>XR+&(3)OIL;$1O;;*+'W9V_5GT%?J\=:2_0!%7
M'EV6;!H3D]=TY&]GVSD;6\\?JAR6*+V<E)1#WTS,P+MTB?*.E#O5-(_5[LLZ
MYMP*-_"<G_<&7X+Z[_H?JG2VT@[,ENFT[X[;BQ!XQDL0Q9/F CE*.2?#Z_-E
M/]T73V7T?PQH%5.O??@+1.[0@<@Z=>?P$;UTHC6%<$*RC#-FKM/[#ZO=RB4M
MT]AES)O.!Z\_*<MUWY'E/,"M?![G2S$:\)7(%NZ7H#-Y^4QR)1.8RF^1/DK3
MEFG#>?%"=<P(*AT5T7-=5AB7242EYBV(FX=#<>L+6!O=I*\_4\H<L^KUU]L5
M;^&GR$.MS"W<*^_SB:U=&/.H.JL(3\OA@^!$)\<K]?*#:5Z](9I%NSK'7O3J
M\+@7^3[;>F B$JP!EB"C1,\/:T+FV)(RQR.*]3ZX6<$O6(6N3R'%XW:M]^E:
MJO\_CK2CB-C9?BN<9+L.#Q&BUYQD-K9C<E*VS+/PX9V$+[,I><^U0UN\ZXG@
M(,E.\W TGBAM1-3SRALX8[?,XNLA\JVX:_HJ;SI.Y>R<>.3IRL>?.H-Y"+9=
M+7)XY_ILR? FQFF5=.R4IYB=\2/R-T#([+I7HYKVRT[8'N'$  [=;1X-9OPY
M"O_]'W=.OX.Z=%!;-C2EVIB4]<SWB [FGUV4>[U8!P0_^XT"SQ%,/K/#+/"\
M)=B@K$\R#J.\2I#HYPH2$SQ$^J.O<"4%J,N=NKJA,I_^@%)9&5G3IJJLJR]^
ML,<6=^0V(FEF??M]:F_0)Q9]-C6T)&9CV02AN5U(^U.?\.W7'Y6.MTM;QU=W
M$!03*C?]OGP7J;%_5@'3P+?&5D0L5.6Y8;*_7^;/7)YX\#@OA<YHJ8>TDI\?
MHFU]%.?3J,7730%J>;(C:BW]DJ'-EJH.NL5O5ZOPP!+XUG]\%OX?G_+]B5!_
MW9;;EYL^>XR?]5O)$?:O[/\:0?SW_;V$&IAW&MKP;=;XC5Z>\NLJSW0[FV77
MN[:2.M[\'EUJDN.?[.AQEE7!Y388NQ5[ #J?ZF3H4-:403_!GM>S^[[5K5GE
MT&F6+7&UM4YL2//HTE7RX*M><8'NKT:GGA'149/DK_ S0RV21-9#U(%VDDN!
MF_K1MSK?#T=O;,S/XTZ&I_=Q"#AS&BFG0 '14:J=G6,4P6%G=]F)VM1;T0]?
M,9UBR?A6DEK\<&1L[,6EY[?C(^E#M2"+N9->V.E7N*1P]<C6 -E-^U^.YV0M
M,>M&3C_0'"?L;H>0? :$T:4V4W9Z^'??3"[6@"G  X,AL=R6::,\UMB^>R-U
MTC'W:UOK&G+D=I)1EQHE5>>I.^TKXF!RV&RNMIR+1R]WV)BGKV765]9@EN7+
M)G4F/1*SO!6,I<37M=U/3ZV K5<PW=&/O,(#P5&.8Q[U)UR"+]\_7?VD\1K(
M\^ETB";;GV0M&7AGS=0]XC$4"4W9''M4;MNY;$_[PHC]*%U;!5#8MQK=_N]E
M=>UNW:X9\MG?J%AWK*F),.E1_,9SFW4^L^XN7&K8$0W3>&]M"N%9OF?;!+^*
MFG]R.X3E>H6+1[]K\;6".^:1R^2H)*+8;@M>,KXIN SJ[6LDRSDT)+,AX5@U
MS?5\TG@I#%FND+FG=+]7P.B\P641%I@.WFM7" T7)=T8A)F6EF>4+I%]*KP=
MGVAWYUA$J3Y/?-D=>/CL]OD0.F"6ROXA^!;/S2QH\<2,N=ZZ*HK^^6R5#_;Y
MN.^YC^4N0>7.;U=WZF9,?8;;A_1YEG-I_CVE_EO^,#J 7/FK+ P$N/QM5#0]
M_1,.3%=4FD !.C.>GIUY!FX73*]YMY*IU&-;PF(YWFO[*NK$\,S75^);1FT_
MZ ;Y86,X,!U,!-=,WY4CBO2*S.7=UCH_-BXO439G$I3%S\[,@B^;Y+7XQ8T>
M:A46PF)<_;P(5!X8>;'@$(5:?XE[S*7,X:I.W5-BFE81\/Y="L OIRWF+ACY
MHN%= C[2[0$D2$ZD(@MVNR?M\))4 NY*L^:(G,CA(#UZ^]A@!^A<6Z!+AP[C
M##3H;J*QS^1@_H.87GG,\ARS^I/\O"PL.=6[& I?&P\^$.:TQ>2]")?Z5:Q7
M8?C9(GY[<;SAVG&^(M$?JA*IL:TQZ[#+^:X6>A^^6.LI%B&^SVDY(@<.B@?V
MK&*W>Z7RV/Z$/JC[_RD9R@SF71'TBMC6:$;<CLF9-(UY]S"6+E/?7L7C#FW,
MTF>>GA^P 'P6%'D9_RWMJ7)KB?ML#W?@/5F9QQW<52EWO:OEGPV]E%]E<8$]
M&7*N&98CW?4G2';8,P[6EIS9\SNXZN?%=3[E>K@I3;QU*!U5-W7L/GI6HG!V
MYN1Q2C&MP^_%PB51DM&^)1]%9RP'R^[7-C1%&VUU;#(]ON5JJ,$=HCP+2%&O
M"Q[;K J* 0G4ZD0VO$LKF.KT+UX)S#15JL]RX-VWY\_PJ=Z*8/QDT?/-FNKU
M^#&<U?0N(*ZT[<+/#I5KCQ7:71WNEA@N^GG6SDB+L;HZ>9D%JM+5; D*1]3Z
M1[9(0.K1&=K<QW=Y'NJGNSI<*JL;1?)6<,[5$[CB#V8MD:M'[SOQ,[,4('*;
MC1T#MG''S&,ZC^HS*WDS>B ]19\M!O>?&GB3QX! N1#X>1,"(_I::S6^OL+C
MK?N-N&@EC4@D!_^$OS0/9\9B$G:CW[^.8/79VR6/9(<?3\#'61$>%LU^D?R(
M))B6EX%>.3M73X//Z56O)UZ6BJ=AIE/H#'; R9U<%IPB?JPC6):]-6"7G%A-
M/Q$>"O?*4593V^GFICI6[4].!8-WI:LSS D;:]1>2O]/>]\9%-6W[#L($A08
M1'(:,BA)<LZ2Y ^(2DX*$H>,2 Z"Y PZ*#E(DBP,.8<!07+.S(QD!V9 AI$P
M/$Z]]V[=<^^K4_=6G7?KUJOW87WH7:MZ[UK=O?K7O7KU_KG\/@W7J=K2<K?S
M&C!E]Q,%"%7K*O_W>-/G//.]\<6 SM\J4Q;7JFL7AR,=YO4N_JR6Y4P2=V)+
MP*5_>/??A.NQQXOM$.1$J%R^*T(:0AM;(L@.N>+!$<;\:^'"6B_E%^)PR+XN
M#HQCO$B5B(AO?\$>6K#)@Z((DG7$';U*SVS"T ,:,J-?9URX?+[M'WT,I$JA
M=KY7M/= D)DK@):0SO[NY+"IS^(=P-F2)$I)R$6(Y[#82M/4_$TSW_9KHEM:
M""U6E[X-B\Z?D$HQYD^3VAABYH\Z[-2*E, M&\6A(O\4JQ,%HS!@K.NE*CBP
MVMZ]227-G1)&+G5LQIA2JE+Z'=Y-Y>PCDB0H=*G#%W=88M_1F,X2Z3%\A]Y=
M3"I"!B]5  QM6'"5I'B"[5O?E_40C$^(-3G2:E4GQQ.]J:0[:SJS]L@0T_W9
MFJQ713G/JOI;\F0]OPB7W8_%6G-'BU#I(N07>?!3S?'#;L+[5O2':#JU8CYE
M_J\+; P8Y?X;>'//-%@]L*W#9N\:X!03D+SY#=XC, /6R?$S^ENI7))WO_4W
MZ;?T#WS<OREH:@P3I,77[4Q6T.Q)5C+\SIP=FW4TT$X<\RP3J"//&+(6Z-E&
MG\4V!M1TR+[NXLA0FT6\U_6E*-",ROZ9<WAW:$2:\H\+V-_1<C(XGV2/#L]Y
MH^<.X$9G85XH-5$D6+Z<Q__/' WA4A(@Z/R 3J^DM!C[:3 !QG._O@_%Q7[R
MU[SD 1"X/.13;EE21:W+<@>5?K>=2'6H\A$H*?B\BQX#BMT.(SV@ A_ Y<U^
M^K8FK[S*4A!X7'QW*4LEZ*60:8PJAJU3LNM=>5FL[53C,*^VNT,CY73;%KO;
M8(#\V]:C-!60JJ5UK\NK^W^E,>9HL6T3!E%I$\YN@D8JUPZ:Z.1R(;F*LU[6
MZ^['',H!V,3\F?FNP&;T4%P7^^-FM@<Q \;/]NX!?_UNCG&X"-??81?YZR%!
M_I&DZ>R;L/L'4F=X?E'P'L)"I@@_#LT:=AOA]U,_/FG30W*!A/D)=Y51 C;-
M5PFH>U<-CI]_NC-C?Y(C9])TZ"J<%2_G#5>YUOKBCQ^7\1",DUTF!5^!HD_;
M#U)P>H<H!2U@?.$G03I,'_&!)6JYWUT<FF#'^N+%,Z<N(?1L'2Y;AXV]?0[*
M#,'/-:8/VQ>-+V*#NQ\8$2H&\(8KQ33-NGGPYC$(<V59O%UZR'7KZ3GHB:"O
M@)6./=ALVC=>_7ZC(_NC7JY3VI.ME*C3([*B@Z9'N/>X!-,(U4I!XPN$SM)=
MXCLF!1E.2)R/A=)M=&VL A^B4D]L_,2"C;6KR;F&.V].O?\M*3=$(*FZ!8MG
M NS]&Q1O"8O9U);PH+4!H\JMK3>L+4H:KHH=)K]Z/Z+5DIR9_-^PC-CW&A G
MD2N,'.Z<$ZS:6>D>;6EY[-8*\S30UU(Z)5\7F:S>NJ=;[3RE_4)JJ#V1M:RP
M5Y$BP&<O?5=)"I.SSHV^.DMX;FB4:=#2/!.\E;SZ.B3;$_2 *#DPK[O?&KP9
M1FRU&P94,"P\L+X]!Y\_<B]M@;8W0:7MX:&V!I+] ?;$-.4PJ9W.@(Q!?;%F
MD= KY1\754KJ494ZXT9Y.=G>2R?N<\MOHR<,6LX##6B=ZM8DJ[(ZW_L]1$A%
MU3R5L9O2'O<.X4\99))HOK4F&42?4Z]*O5IHVY\NFK.SW&4X&4IWD&73NW(-
MH'!9-HBMN;16']SN=V-)_2X?\CUJ*K%ITE-G#29JN!;\8.&PBVP/S_1M^E+=
M#?%3R<Q9:,HV647'\<(DLR4"N+XVH3\7LU!ICI^X<;^;@=< 8T7E4POA[:US
M1+.RT.]FH>ZX[GY<F/]YUP:,B6)V_87<>JY$B\,QLCTI^V[N$ #;.U'Z8!)7
M^[@EV23!=&9+.^-'6OH>J08>T[L9M/ ][)X2PWX>+\ZC>'<9&!/\1!)'+?X@
M:UR>?^IIBJS"::(X/4'X]S_-A.-.N,_H6BN,9B5<()]R=YW3PDI,6?S%"2I]
MLE'68+5(\.5?2XS]CH<7TQ"Y;YT5Z_.78<-ME@*9+SR?P;Q/9,N"G$<; J\Z
MBYO:+<]ARHQ.][4DT@ZRP%_8&1G=D1P$C+>3_8=/RYKC&S6:P9%5IJ2T YK/
MWV2KYR7D()7FCB=2E%C7P>MRZ*ZR+_Y! V,ESAG<6<7?RX9<IS55^*EI$\GB
M_8A ^G-TA>AN\PSD&VM>/;X!/3AI7^^C"^Y0\$3C.W[H,?8C2=)%T'8%\FOI
M0D-7TS4@<C<1WO<G>/,+)KBZ=V1\H2U0/2S>HJ8)K!GR B\\B6S0;9I_<PI-
M^^$L;Z5Y[Y/OTZ5>I=DDQ-4=&8CQ_.^MN"_'D=DM/2(S[CX+RUU/IT/I#XQM
M&&HO]0**_9,N67V8^YVIS8:XI_2.#]\VBJ*>KKZ*2&ESN>KN;S\(2_+#<^2K
M8B3RF+)D4*AM"X9EC58 H6C3,?8K6O,R:#M]R"CL^*BZ>_,\S(3,L\N&;GIP
M8W5[KRN_?0-A%;A[-;,/PNDVBI(_9P4;4(VUCV:@#%'!OKT3,D?QKGBQ22%C
MJ6S+&5LSJI$DGE471A)C1H64P#\)O=V4OHHB",W.:A<FD[C[_<OA7'I&,\AT
M[?AK0-4&06*5Q7%+#^.R2WX_*/H,3SO;8:@<&RR/>.51;JGG4_K)U:Y3P#5L
M*X-+,[A4D+&)'/B)_+GI<G6M]T+WI?)$05D?CA3F9EL[4C1M/#?J7^V7LKSA
M6*14E3UHSM-P.]NT+BZ^,OQ,F^SYY'$@2R*3CH)98;]R!F]#V9>5B#]NO@RN
M>9&,^^ MCQM\3"Y92^DO,M#$QCX=K"%5[/]-\8NGN=8;)CXB#<:T8IX[/U_?
MDCI%TM)'X^GWSVUZVR> +DR@V*'X'#$'>=.=>!V&;>D+G<1O49:W_+Q2 G59
MC;Y<Y6O>F$_PD!+]*/*!ANV1LZ:T\9SB3^BRHI]YM>%I ,8XMCG_M=Q@>/NZ
MW;'2;)X#?.[MCBRVS )7K-F>/1)I7)]E*;K$.B+^*A33H]A^;C(<.-071K4:
M3)/2]_V+?W08<T0:<TH#9^].9<1,2!WO50?=^&&@7]GE8YPN0H3&']C/9!+5
MF$_E?+[U98]GU$H-LL>B_>5)D;V*92L7("/';Y ON2HC=*(H#*VHQ]'W^4T)
M0X>+SHAA.S3]R7[0I=C>C%;EXODTB,%)^O: ^7HVQV,QJ=&6\3E6TY,>9+4.
M*%["N3#+Z32(/IJ*R8QNZTZ!PJTA!<(C&_Y+31RXW#]]HX^L".<W,,TJ]SC?
M4,>UN.$:H/548?@C1'2[X57X\[S6(4G0 #!*B0-#,N!! 39GRT80H=>SZ7R=
M'*"Z 8Y$2?&I5:_L'P:P1R8^_Q<+'ZV0:+$0J?@^EKBU_<P=.Y/Y^G0]2,O-
M?/6\,]BJ4()"[L#<1ZUVJS%B7[&P/O?+3@TI<CU.P:I0@TG[?#XGK?W37-;^
M(\88(Q*%M,C!X/:OP?*SCKBU(EP6*^& 2>B]QN9CX<+T08ZT&K$GW4N01S4%
M5-)VB@V#;T)9T9=9)D- &G_(-:"G[4,>W:QM,H4205DC[,$"V^L\35$&6X:C
M(=FSRF2QXK>>34T'S6'Z,4+ZS+UJ+)@!627](&&;^+T@19M!CR WR-#4O%Q4
M385+II3?H[65[K4L,L+"\WN#IC7T<-9$2)9UL^ATZ92;B*19C9O@3N+  =EC
M0M'\UI'F$:7.@[9:_9P<Q)>)&)AA,EM'A>J:R$&96\0_S&A64XK_Q\KTX'CI
M/3;6A:Y[N%H#C!O2&<_44I<F<IB:.C6X]HYE9\]&$.=HC#89$(D%D9_&E6'H
M\HMND.%NXZZ(&V>4A6E3M'])0/Z8&"&_F0VS+%\.F\"N\K+=(/[N5"B+M7\8
MS"U L3:.*\,@P6"&P_GP4(P8R0(^H6I]IKV79DUQ(1HZD@6%%<*[&7$IB&S_
M:T ?5OHLE&.JZE6]KN=9INK9F*>GK@QU:]]' #)YE@!;0F.H0N$_K]%?_FJW
M7\+-,K+Q]1MDB5P\P%8S;<?VX4Y&HYW$^7\Z,OZ_.?Z9!3\D5T4=\LC/"E[H
MBT$E,C2J+*YTRFX6=>AZ>-@1?GO \VN=*YNJNG7 !?_N-8 )3[V+[;JWT'&[
MC((SQ/CP/,104F_BCH& 3B/O^ML=5O!!V]^G2?_/I33=%QQC+&'WNYU>'I:'
MP1_9=*A< S)O(K-NZ,T'*Q9? [JB +H:&MCRL)W&L+/)8M33:\"$TS7@J%"%
M>LHPY"OH#PIT]9O_XH7RR;+RQ>Y3HL87-BXQ^""M:T#(':4YX"4V!7].0R!$
M2[]<> W(F[H&;*BE_'_>_V_R_K?:7WWUOW@** _0W[SLY;Y-5PI>L03/<=6O
MPF;W'SVP_G>IV(^X!*P)3@.!\CXQFP]E<Y)+KO3'VP_^Q,:__MAFG^)CMH&&
M=1,I[V;B?*X!@,$@(1H"I,W?/0+]MYOPMIN1)POX/E0J?76XH30N<*I1W["?
M%,3P:B3GC%5@ZRAAG1:3$A7*MH\7;>YJ0>?'N/T.TG:8N09 >=JS]N%';J0M
M)[KY@IR"E5&PQV6R@X @QTO1VE[@.0^>Y<:]B6K]'65Y-G3$H(ZQT)G!@_Q!
M1JU=<] B=[[.29'I!ZYN=LH2T6JD5@-B-8'?TDQ#09BN2"3POO.",E6'JD])
M[.^/T7=!3=#J3^W/BK;,34<@GRF)^U:)[9+% /(;.#N;"-!OW4O9:T"X;<K?
M42U *EQVW[PR W>3V8+AI$&,J_78RL"T.4S<YRUKIE@H&A/A;3!"X@)7L$<L
M5H?R71HVS8@4MAQ;:+BQ@3L#WY@BI Q%CSG,5#^O?#TE_^E.D4Y*TAG6SW1Y
MHRM%-O")2T*:OZ-HOP^5^SL8(EH5=!!W1SUH>9!W2?FZ(>M/(_A_<,H817S+
M%/G^/"-59S!HXWU)9W9?FT36)_M9ZQ&Z5FKA>>I/"Z%:=NT2!-N@_^:*\U\R
MX<9UHQZ4[P>&)L#O>?@$V!<8(!AL,11SJ1R%,Y>?OSMXBC/]Z0.84@7  @I(
MN^%)H:1A4R+H'3Q!O/*_)I *CE^#96(&0N_%Z&'$K@'V.@'LL^2!I_W"4C5C
M8]L_R7<Z>4NJ5M31S;#TT0#R+$'Z9L*^A6=@ZH&9K@7DCQ,"S\X7U'X$*JQE
M_T"W;12#-3&:W4*S#;WEJAY!S7J/JN<K)*'+7PO%RB-_W,'4P^976G(WZS<I
MCH"X@X'[H9-LS+.TATFYZ]5B:\X1SOH%[.E+$(D6J*"Q9-*2A7?1966Z 6^X
M8CZ>86$SYHKZ&D 9MLE0_'=4=>X3V.$$$I\6PML0Q!,%BWI;K/?6T(V0.]5!
M!4#4X/ZS7F8%)N9SO! +K?:!ST<ANBD7P=WHS'WI?N,N RK<6RP"7/UPK03B
MEJ%V+'=D%"9TYVM**OGKIR13^?] ,"^O 2YF0^@8Q&H7_1QO^Y30;_DX00^N
MCO203-#K#Z/?C&U7(M_!0I_/T,+ING@P^;%*+#AF+?KED@]YE+H!DGRMG^>@
MGX4Y=83LS0C(#8%99=P1/GD?"'[7_J.M@S(?B>+KKUO<9Q-LND'.L&]@3N:#
MNZP.1F =:Z0M4;@2F^0P*J*83_*4W&-;LSK1'; Y29+\CPSU5^-3DJ1_]H2_
MK1OAC1?*Q'G<+-5\9U8\8!Q]%/-[@VS7/#2AV+2_=$\NF,S-V=']G5TT-^ A
M_R\ @,!<XC_6UX1TA/%)W6T#(K;?2QPZ=J)M H7[56+*#T-H"&C>3@ZLI'-K
MPJ0?AGOM:<][2J]'B(\'J,Z7%H5S2+U%1;Q,3'VDI#HSG;ID 5EU0P@-R1/[
M[SV?4KDG626\DL6PU-WQPJ'D7PYGBEO2"IO3IL4%OD+N)5>I[*E0&]IP@J\!
MS5H)$J!X2#XP?U,KMA1#^_N^M9E%33&5-!VF@9"?62[X_4*74S=+,*C<Q=PZ
M+J1V+] @_NAS$1LH[US\;<-#B'_3#L^'6_HD+H"CW2H1<MQ!?Y=$8V?;I&\[
MJ^WRB!^T%3+N^_'51Z5C49)HUMX:\-.K@BZ6O2ZRA6!+O-C4%AH;_<2%?M*J
M>(CH\S(7-ZC+X@Y]!?<=P.^' N._E9>YX/EQ$BV^%,I#<K1C5:/N(P<A(+8
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M%PPG;+S?F+K*)A"H')='G]W?%MV5-=;N-,^R:N.SQ3?"<)*2'<TJ/J[U5"/
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MH.]9_#%A''=1X3G'MG>S -MN[@KJ!;B4OG/74.&LXZ$!R',8>OTQ3]Z(/31
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M;=$W@/3OAXGOP;P0+'Z/K'O443BIB^R'>!8V<":UAXEMV@;+XTJX,L[Q.W_
MWF!/J! ,LPY#3P;L5F"XZ,>_V_05K'!ZE6%'ABF5K5\*3F7;8@^7D-$"XJRR
M _L]YUSO3Z27\3AM'VAQ/9.57O/W17E:S-'3A8IC>7<Y@X/S-LLEL]^<3%T(
M?MX5B8TX5'ZXK/:3.\KP58M%84U-S7&[1/Q*NF%Q/GBLV=+53=?^R@*W_PL?
M[Z.)0G357S@B3.<M[FX-L)1WR5"Q,G<%DMVIWMB/4*27DF6][=UOU[=M3)>4
M.-!5!&9K!&& @Z5<F*^##,7L?PZXD6CE:%5ZT \J;-? QP1\]&93].K'*UR/
M+MQQJC,MF69IXOT._9WOQ'YNH+(M0)X9[^N3:X\.:,FJ'X^G:EI*,9<KP2JO
M?'; CTI4!/:%EH@\(DWC1/9A'T<VK;6=E6JL(ZKJE A;3[L9?;+=>TQB%7/M
M)=[Y).L)6N:;D,FZL6KPPL"SE9 ^H.&M=W]M/Y*L:EG'3B+>@_DQCZ'R%/*6
MWOZV+*3>+-S%/^[RT>9(DJBLB@QK]%G! @92'WXK;;6\\#L4'73Z7;(EN[4)
M;#=UR\BE")CMA(?B8=VJT%>J*Z!6231T-5GL0%'VZ<B;>_+G4T]^O/ZDS#9Y
MJ@/O:"?%.2[#>W3\#LY\+55Z!UBU9HZU#4N8>;.TQK1^5XFF\DG&V>$G!AWJ
MQ7W"\1N,7[-M@^P]JT!>+B*%V\[7;+DO8H%U"]H$:B^+E-^U/^Z?"[:ER)'0
M*2E80)VA;@!3>=#4@2Q[*2Z8G^F?[%8()>+YVLE7VE?P.S1V2R>5S<O"78+N
M:+?\8K/MO D+ZQGH$<>4^]/ %QJ,2S:K3.=B)Q$_@JON:B[? ,B[OEG@O)]-
M"BZX\FRKT)F>>U>.'#E*,^<+F'I](J:<" -:UW6;4W8+L^">=RWP3-7=  B=
MR[_? %PJJTX\#L0K+@C;N<!?!O&VR+GCO#S\1A>N)BMD[,NH2K*JN ==D_U=
MW8-]]L ]F/Q.129L4;N_XW(NW7,T*4/%0D#E^LN_:NX\S<KRX5HI[27TU/V3
M,+C^N$-:053!T_H5F 3GO@2E7"$\CHQ?YF?_* O.86YL2'86O%_8DF?6&5_P
M8UAFR.Y28+)ND?"Z?^$1]D4.RYC$D/F(E0BJOM2EIDQ$A)"WD31998.Q['RR
MX,P00J+MNK\&:8EXU\)1-.'Z:W81#7=T:Z7\,AE.%IZT"[PFP"A"L>P]?FQL
MHP^I7>CC5/:E-2;(:AMWRF245JPU+M]BA,/![LN)4>>]T-+I2_GP;C96J5/_
MES_)=)X>Q/#,A65IS1UWQK1>R/RY)L+98]>1>K\O0:[+HQ5.AUVTR]W5'WD?
M<-YKP_;;FW!>S1FDB0332U<%#>V<!^Y(VT/?T,KT>\WSSUL#?19+AZU#!]B(
MJY-75)7HCK#+%P']R1WY<;Q?[FK9ABY!6"Y,TP.ZT!)5D:&D./Y>[);8B.\R
ML5V"MI0J5=>/AH&D_HO6*Q=KJM#A&\ #6VQDZ6O>"%_^F8CN&M@Y(C/0J-I=
M:EA)B-)*-]BWZM5$G9PP#9CP*L<G1,V:5Z]]*A[6'5:/9M+$]Y[EC+N8"-8T
M7 T=_RI5.9_Y![3S&H@2?MTW-AYREM=TTM96/-#F0K8V85LE7K'5P/WN/./J
M/N9@>@$<T((1SR7Q&70G^Y/V: >6]H.!("^QQ13$[_:0+"6U_P2K-#.E\T!!
MJN=$SY$NL<H2U.Y8@Z7[GG?5U!W.0_<[6?*[;8,M_RE"YDZ9])Y3HY>K8SM$
MA3O5:_CI26:C(+0BQ/7@#[C![,GJ)R(H24>D<M])55$HRY\3"&6;0L#>>"]*
ML+09#DO6.&;EU9(R83*4IA"2CV.-KGLO*MU!5"K1&3IN13W9(K%2SI^M<P3\
M")-CV!,4%I<3<:;]99LHLMS?E5.P0<3)ECK*HI*J2NI6M?W'TZAC()O>N#4[
M8W?<$E*Y\17G_JP9:_JQ;HBN0WYP2&5=SBG]JLA&-"3*<(=_3,DI\5W-)3'V
M;KHSZV5&968)\"M'2_(CQD,:].]W&DNT2FHGE2LGW!A7*"(.!F'>&NMP+@SP
MFRZSF)?62%M^J;:,"(-)01;?M,HM1[U?P\5?*(#H4@)J-;!5,?(*OI*UY,,I
M3YH%!':&J/"BV3FEV9KIQQI=EN=$GA!?E*L?W@ $%0]_=ZUM59(8,YW.SX5P
MKFU4S8'EA\M/OU"65E9IXUPKMMDICJN8@2&?_P2I=LY:I&<^V'?]@FI8#<4&
MGR-'VTE]CG"0"PGG4!%,\7N!2^_E>).SO%8INMXUZ K%-MPEON.9,0/#VH'+
M?E3H(\N9ZU_L-)5"\H\+-_TE@[JG1@IAC<;1Q3X"C)!6QL\11]-MJ=X] [LJ
M<IJ"ESM'8L7IG?V3.5BO446D^?&A^K"B(B8QXE(,W4ZR^"='.+Q;ZCRU-%._
M)OY.)E%G=G&.C$"#6ZC%D40WO;%ESSMK"ZSUBTO]"0%%E@#_)<J/KD?!C"VM
MTGK!Q+"XV.X#- 77RCJWMDW.A_564G,<"*T4$50<KR@2DJLW 98(+%+W_+8Y
MI@:E:FI@>??!EKE^R?;=[J;FFS..QA3_UI;Y79LTZUU>(9/D^*JVZ-[3R1O
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M7OP]>[($@(^@* !@^E5?UPAMJ%G07VQ>R#,O(Q$ZC-#_?JF/=8^\?*44?5N
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MC/";GS] S>O8>[+VM$#)L/6K212,&GODL@?G*R^;@LN_KN:L#:]GJ T^D-O
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MZXXO#WY-=TXVG*Q.01C> .Y(($957[SY5A'/;Y(:>#@RB#%15J4Q_N>]XW]
M;+4W #(@IODZS#\7QW0$Z:*[%+H!?+/<N+[;&@RE/818=$-&$*>YMVP.2S>
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MN0?R75/;[[;?EA6UWX?7"\O];P#]G]NUP2.?Y*G10[HCO6S\L?J8TX]Z/<[
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MYCC.Y?GG2Q5P4S\EE*+0I$0WTK?UJ<;]N5[2-].2 20,3RTPFHB'!N=05J7
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MQ41T8F+VC]*2YD 9!L0$I-.=V-MI2;L76X2P6XXN/*[M04A@K7S'1QP$*N+
M<Y>;5JWPS8G(%W#5L@G(E W]';VYE!G<E-:"WH683T:\M87;UX5IXQ+74A#K
M]UC,4JRFS6V:KJW6)J.A?+/2+E=4YEDX!RY9^EV_SG/>[!VQGK^2",%RRS94
M)R%J5]@1#K7U>K8BCR\<!#\P\I4Z%VP\<*:ZT[C=\Y9YD-]F7GGM'.: XZ'S
M?'..7=2PR:3-)427\';YYT$M5ER&^A\VU [O'<E3 %^!^(SC0 5R3  )73:$
MG*@EZR)>4@"K$ZT[=F@T'GWT:[OF,!L+:SP>RR"V:@?8L-R#9(&2_NTJVST
M@@*><0Z^@";=/^Q3<@NKTC\J4=HT'8FHK=D67Y#J^;*F_ICIC'I'R/WG*2M-
M!GX>#['-IBO?71O"ABPN<GRS%A ]? Z1"Q[@H_^NHG%$ U>%ZM^N'%/KQR84
MW71[:/'2K^Q\Z3:@#2D#K^"=]M1;5>?;#R+8?3YTZ*B#^_GA1.G<:/M=>-<"
M.H="GV-?47-?4?5SM:;Z*@20=B1Z$:S:P>RR%M40VM6QE-T8&6[_](FX)7L
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M//A*/;X)[$@04K+I2WEJY>=:QR@50S6UT4WK%75 JQZ-I0L>:.$?VX$PT5$
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MF'%P7FY$G(%?SM FEI]X)]]JP$NETL+"8E\NHR[&F\/>"X (%J;@1Q-B.M9
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ME/7&\Z-[<$6"9)1L*X/%2L.;@&\%C]E\]S%G/CC\]'>TO<'GR.C^45KO.D]
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M[Y&7C0$+U3_N]'H$GSA^?-I<ZR&V +'$:.;T/_RX8$)(U\Y)R#Y.CN;=VSF
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M7$38/1GDM W^D;\??&N9?)H([%3C(Y;M'>MH-7SZ1/Z&?L3<]^SRLL]!?F3
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MK.13 *5;B*4GR/4BR0,B9"PU^U:"U:VER=?YKUY0 -2R5,%1(IFG_GS5E9V
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MXZRZYQ1"P!*@*VO5(C]^S#3+(\L>AWL^7;UC#-T<:<J-3_*_+Q3!R5"/K>F
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M@?;;Q2;0O ?8\<&W0HVJ D$Y8=62DJ)LG0TG\3+8[V5>SR("?[$\+(7P*F#
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M/J"T/#H()>#H@>WJ,X8S""4"VV7*4P)$8+41?O@C]S1PDN";202:R4%/JXA
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MN,>PF>E#1S/WF.#+;;1;G3._P T?>)7Y@U731Q??"8OX?D<C2Z*Z]$**?[1
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M)H0P"0)SUF(0+(+D1EVFYC]-^GYU%>ZXNHF)OS73JVY,5HVS?E'>Q__ GZ[
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MFSXET(),LZTK6HM;33-&;LFY#-;UQ9DWFWS/N(#PE-+P^]+/"486RZA[%=@
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M(W8#(  @.TOV'P?POP^R,Z0Z4E*=.T]-0[J@@1$X0T9.?H:"_+=:DTJ#2.4
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MBB;;V.@J) ,WA)=E(EUSC-1L'IVXGA4FB7 [IMXBR]ZCX+%:FFL/&3E>/HD
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M%MFZ>_)I3GIX^6-[1 _GKTJLG$_2*G;K6N"SL"Q%4L-<+;T0M$:)"F%1XS[
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M?79JQ%%AD,T><P]*W3OTE@[4W+:U!5%XT]HVS(=5&F^WG]+-(FQ8C($KQ)+
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MS-:>75AQ_(&%G+"%M^LGFG],6));>,BE,EW1\IFI:R[A(%0G6FCB M8N*R+
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M%"7"PV90ZP:+ZU+)+-QV<V;$=Z@==BBQJKQ?,-JT.OD0QX61$TUL0SO"?/B
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M\U<U?U7SOZGFK-GN67[I+47XHBIH.$3N3X96>&?Q^E+M+$DPG)$.>YZ#K;N
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M3J@5[G#TNY^[NN 1>8P6%K26[B6?DB:.JG0+(++T&9ZYTN)YR'1.Q'YB$L4
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M\T<\7H%41/6>(7930]#-VQDKQ!C4!MO$#OAA&\*79H"5_<V!FS7/P$HD4%=
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M&^>9VGME*G=EU=-0NU20Y4S]+9:@O)^[CX4K4W;/RV,4351&9))\Q,N5R]7
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MH3'2Q0DA.:FN79Y>^ISY@,0)LS7US^K9A_XVWE.2_GT GW7]OY?D&*/X^MG
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M@ &B-)\S',%@!HEM$Z><=Y]F/8SVTWK.(69YZ%6N(L-D6QRS=TKNT3@4DTM
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M6,6WDAMCPX*/+8?!AWMG#UW%G:7A/9>&8(''=:'=R3R.I/>-JJK7TV]K4%(
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M=^JG\,"VFQLKM[,XD;8"I19'/(SH'8ZN'U42NS)O+?VL;DI4$D&[X_?J-]&
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MX^L(Q(WE1$=K24F,. >28F%(:F"58)Q\<GSG!I8J2D(>AG2LQJ]V*3[$C;9
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M!_KEY<7V/"S2,B*8,YW!")N2>S^M>\/;Y!@<RNZ!W+N,3, !Y[3'?O<N"'%
M%_LX:%M: ALW/='NZHDX6&M]%!4CUB#2DP>^=SF7+])]ZOJ(F)0Q/+YSCV7-
M"6E\E8 J0:_2SCC..R^#K7# L(_W86G%K QO.'9OD0:N.-V]I=ST*I>M !R1
M<JF5L]4+MUD9FE@43W>&;5'^0!C.&<QV0ME2!#(L:L)VZ0/\DF^;.0[S"+0O
M[R[1;E2NPJES1L62*EEO7"Q692/WR!7M[?/:G;,W$W[VN?FP#I=-%[D,W!AA
M^[TR-\SSD\A+ACT.)"\3K&!*;81.7!"D]H1VGIC=WE=N1*;,JFB4#E?$VX>(
M$8_D2MS2='?"BQ),T+?QC7ZHVFSP_IN?MAG159R2K#?QH(=R//MQP()@F,P]
MI$V/M&?")@Y0C\)'TD>:K?+*JBM*;[M'&B(_Y_GB9]YO/ D@Y0U'YRZ%EUQ;
M=]]?WU?T0CKJ04IMQ:N!K[W3A@A#_,^^>4-F*LV$@;]N_RPAC3X)08>6>%(^
M1UDE"@9N.V+$%DVEVYCZ(E<3G44VJ;0(9C18&\+=X5;/0RL-AR%)]8%2P'E.
M0^'"/.8+.&K^1&H:NBF;J3<1UB3C*[%/._8]-PSCMP@EG9]%9&^+>\^5.UJ+
MM+0%?N8L+M*)-Z]GZ(Z9G&"_D/(L5T1UALF)V_LSC[_# 3=MJLU$@G^/OJO/
MJJU.<7J?F>D00Z+7RON@>2&?50GP,:71EB?Z[_EVGM(!AE'R\EB:^A&Z>QS2
M9N2P0IQ$]R7W(;?3C7O2Q:JW'QZ.,<N]0*ZUVT^'@X(1O7HO>VSSYCOJ3.-[
M!9XWN[[;<B1,">:A4],.%U %/I, ;,G=W?.:Y1^&AZ_#'/F7#-(_T)"PV&22
M%F0&  #PZ'6EV;;@O-;6OM0\7)=K!)PR?7S1M9X1]GN=M!V5&PQ=?+COU/CC
M,G,[#9% 3P>RF8)W'UJ\F:WFD)S]]L::5<E16U."_MW3C*QO9KT'D*F]!4$,
MMQ^S7BD.^!2U988=K#&LJC![<G/'Q))C9M)]H'=JF<^"P$FK:$C)5#VVD$NJ
MOLI:.>+AT1B/^I""$HV>5?-_\G08./+XX@XX%;S?+B>( ]*#6T&GYULX(&9K
M73CY9_9 _XZ/?VXGZAI;,<>4C^3<Q"5E&G?)#_ABF"\8!RA2!D'WCB=P ,<0
M#B!_B;R*2 9?$1P +8:?L35]W'H'^GI&N8W1/_!7&:C0'_S+'G\<@#Y 02_)
MY1AQ 'P"C(E6&5^'/H1:(^%Q!W)^&4T?_DJ $=(*QP'KYOL#E]@Z'+#L+5>M
M>/;Q D2+28LYW*$]HO\+ >@OS![7L?>R3Z%+EC'1@G\^F!I- )6QASEBV;:\
M%>V;V"3HC;(#$:KW:B<+:?3#?F&7I.Z[=>"QB*LNR>S]9:=^R0*)Q,8_CK$>
M,B0R^'R7J2]?0_"N"Z)?I]'C@,'6Q;2+2[<K:'H$;:5!P[%![.0X8'ZK!*L"
M^T.("&@Y"MQUQBXW!%;X,T$FEB&W'0<</41;8W& *?1 EMTX'=-\F1:&U?I]
M=A)V3O97@K]H^WR6<O7_KCG<P217G]DV7I7_&Y4X(*>GX)CRS\HX'O*D/%%$
M:04?]Z3D'\]3JL?:>D?^,+"LY7HW_K(E]RLQ7A;AZ2])PGW7_+",1<[L0404
M 353J1.KOL4J+^OCK:<UU%,S?;:2>EKBQ-S3ANH_?Z\1J1&/4O&TVI^GG*54
M,E<=\H_W'4K[#@K,EK)Y*52^;;PVU$F["_WWXNL?%U!Z,?+=X'>D\^SUET&)
MZB?[(3S#]31@CP3O=KLU?I&M\.SX/>VN[=Q!3T![+1_9!S%..#!5,1P57&XX
MZ.N9-94)\OM(TE J7165M(%HK/[W1MKT+PUNW T[3Q4?7X%",=2MS.#1^=[9
MO-GJ)*<J2-+TZGOWG9##;HK"P'7Q*$F8=$G('%]3%/>NKS;,1(5J.])R]/ZK
M\,HX@&[!T</$6XBUSX?XWP?$((K!HU[^I^?D#OTI#FB6L5!!383*/!IBY6UC
M*O[Z.O1'Q-1<SXW?/7O<XC];$LY"-E*]1_M0S.W1ULXV<USC1N.+RPDV-]*%
MU$P/&Y,\7B7,N&B9?#LN,?\/W(6-@_S8T:_50,9!-_8/>=M!BP^O6"J-4\5.
MC\++M)G$?EZ8I#XN?&BES>:^\),PPD5>-+DZO'+^IJ'AU&;R>&:^D:' M+%/
M??Z]*+R AV%M@0R \R3IR<"_C;G<XV^R>^\$\RWXG?3_)K7 %GATKVGJY+OR
M[M).&=^$F</VG$^Q>_DRILW)@?IWUW%Q]#^#V1+MOPAH2A^( ]Z :&V-!,-A
MV1.^,GOYMK:VU"K\_;<"=XJF''Y)3I/=$'918>BZ):-)9JA1@!G*EKG!FWP0
M/H5]>N;T'\7Q%A@VB+7XOQO(?EM_@EE!?U9G23[<,BW0.ZT%&HP(BLF?FYPW
MT2Q0>U=FN\-Q^R4-#]Y<B.L7V=+?JPV]G;?4LXD9&IVB/>ZUZ&>&O\AGYA5!
M\+;A )L!?(Q,]:" KV4QAGO?(]I7V:I\Y%5<&Y-?E6E.3=3UMFIA!5Y..\NN
M.\8 "X'9E)GCA=*6OA%Q\\#-.2,;A%E=]\^LJO.5TMK2L/M)=!KA(4'D,8\#
MLRT)WRC[6V[*J5Y>/WNYX/\=";Z.'622052W0 *:J(8X46SIB[]W99BSU-AJ
M+=\FE/4Q4(O:,)J),5HJ\97$YG^C;.1M;Z#>CS8%AXS[RXT+RC'8>Y0K5!Y_
MI_[E8K@9US*T(Y^XD]?[V *R_Y/GH="W:-L?-XP[TT@QS"CU_KF)#CGJ(1E=
MHE*K:DU[S:!]^=Z'?0SQQK:W;ZC\*!$LO8QL8$ZW<4?<>%]@+\>\OV5[<FX%
MR]S@M:9MJB7G:_,K%&__6'5&T$!!+>D:Z]G9,"1_O>#6XSS2'Z\ 2=H5Z%_.
M/QOU_HRYGA,7#/WWDQI*-'@=GM/8^V8"^W*Q:4TX0"OE95T5I&9\T/AW^B0;
MLV7OR5-B3O$)@F6^QN_.,="VGJ5[$RD'.,#"YN%E&@3E5X74DH 6@\H7IR,L
MWB7U*\_U5Z:&\?9@20+Y3;)GL4;^MH$TVH;,@?^(P_Z3Z17I[>9[C&+6&7N6
MO9A&N?$H(IFS;FPFIJ] D<5%DU#[\4$,57<THSL/<7\1_I[D;T)W\_-4=Y%M
M3/]<V-D$TB-4[C9:RZ1FY*C/PVP4!Y2),APS0O@<*IH))-(DA>>R"E?+SISS
M+"OP0O5YPM3#IL<:M)%0F@VL#.I^.')*E!=,]ALUN3$T-=WCZ+5BK/+6;+V+
M,=$AU6KPKN?OIRS+J_5%L#X_VODN:?#>Y&'1V1?O>L$4_>I9.$9HYTC_XR3&
MOQQ%V0ZC5*U&Z<7D3"<Q/ZL9XJP+F!EP'U]];,A\&I:'-;&O*#XYQ"->*2[Y
M->*9JG43W:K)Q@VY96BD0*YWGI-N>=W8\4DH^>"G]Z\/[\H[]@^WO[=Z>>?V
MCM,-:1P 'D_SWE2/C:W#PDN&4E.4G*'7W1RU#/=?]!6!J_*A-]*A=A,0*N5A
M/GW7)Y\*>/*DM;UOC"%T*JW-KRRA2G:5IWX++V'K57# CT;=PG^Z](*T)C6H
M(#NO0&;Q5EO<_31G5X_K^YN(7X[I85)FW*C[S0]3A()>]_<DN%V7>U%65Z53
MI9*E;4:], MMKZH#M5Y>.5^'?O(H&\]G0U/;TZHJY\NDY0]J5,9Z8812BHS=
M7:OX6:FDA^FYK4OL56@$&26C9UR;N+?=]-2O^3?#3>-.-;'.3D]OML8PMP5T
M&RHR"I.8Z'VK/X.""RX&4Z/F)R!#EYWEVF:\6>AR8Q1Q $8JT\2N&H*4U3")
M>U9;P\V_NQ!$DI5@F=A-^D&;_+&X)]S=].!3_@N[ZA",8<[&>6($9;A3,8P/
MHRF0C&6OKZR@B[8_V2O[%#E,^U6=@/>!+0,=P^V@Q8,M>QQ@Y'_CG&2]Y !S
ME>E2-Y1\M^BC9)S%\XN%Y]$?& 0:% 0"+?U<Z;Z\*]2U'R)M4"\\R4FB=I\7
M9>B)\L#'.P61;3 E!.?*%N<6SWB&*?"*>E1_5J2YN,Z@?Z#-\?K&-JW2$O!!
MX76MWYC@5F;US*#&;%RT+M81O/=T(B.,1_Z/QYUXQK_C '9*'&!BB0.&''7M
M_OE:W5AX"7471J/]-.!O_SP94UZQ5"Q9DEH!843W: TA][&UA>@X350VYMQ!
M1*UHVO99PE ?!V>YX64\N8-PU ^MVL3E>ZJ+W_1%RN:UKNX,\PTN<_'A6+>[
MZ@0-"^P\ZLQ*+ KMJ.Q.O9\5.K\2(\F(DA+@>,'(."ZF0T[;$EN -_V-?,']
MB_MA^<4QO1MB:W?PBFEY6KL!K.P>="ODBL507;NQ-(S/' Z8N(4#,JERC&E9
MNRNT3>#ME#?-//47L;4%MAVB\ \S9Y0\>SHQ(;JO:YD#^&X(BT2\T;V^R5TB
MME]<"_-TA[+8)A>7.R-=,Y1H=RI7CAXJBG#\,FC#/K'Y1!P9\BI@\9=4AQ;A
M/+T8)&A<_)3M/LJM*<-MAV[\I-_4DG\;5E1B&6<NOQX> KR=;Q#8+)7H;2^H
M=3K3._=_4.]/;BJ5=EP +I +SFBXUH-4+D$*!C71-8XT&.;9N4?GS2#LV3CW
MJU)NY+MG@"2ZVVXI\$0N*\7>N8TOM[LPMLE^':/AMT09U,0V+G9['E)7J9^4
M3$WBO@'OD<G9=D)X6]/,&,$_E_BPNKG+7=GM\QOX\>155>4U^?-U91-!.1E&
MT;VAYR1F?RX7.? Q>3<ET^8FNO"%U0>#"N,4:=Z\$O=G4>;O&BT_\1+QF$8M
M$Y9]Z/YQ[NCEL2.2.5""H9]PX%^IN&9=164$!H<SN%W'#K$GO1F)Q?=+]W@L
M_/;I#S:2$LF3&UP+>Q]\1;+1:<I-P2=ZP8M!-:54YSN-T<&^A8SD;QX5C5<K
MN[^,?9]PY_-,(.'2NC<:!RR"/U;N4';X$PYEH9UQ &GADY$&W:(M<4TH-/M)
M;+,S;6=B+L+8<$;=L/OW&^= 70,2HIK.R?]58O3_\C#BL=%!R4?H@;:_-'1R
MS1$'Y)U$RK,5_D,+2MP/)6LBW12'5^1&8UR]D,:%7QT%YX9YWUCII?57AT%Y
M'.*^9JAEZ#SWLAEKDG^O-13?X7OO"N4875QU;1/8[P*%Y<7?E-1TTAI'M&J0
MS4.!3&9(=.,>'(R^NKN^$()&6PGXWYFT2"S?OE/<DM\C7GXS$LLHQ@0DH^.N
M954JB?YM&=<G/9R.'UIY?GWN?43%B^ -P+8VX(!4VZNF-PYC7_#I"\1C<J%=
M^44USZY70O:^8#.BK*6:+CG&8,>_;8NMVH^A]E-]K49 .66%DRTGG^6<L8^U
ME!C$!"V]*'C+;MB.ON[=W)L6(5<(!.I,E#V? &A5&*O<;9<#R"Y&(?&Z6@#I
MD>"V],#9:MKI&:@C^N_+>K\"+*3M\/(+#HB_[*# !EOFSQJ:F#PVLA?><=KB
MN!-11_-:/ ;#IU+M9)^\G]B, RC0S!JU(^_ .RG&9"%,D]-=)?.],1S6<JJQ
M[@?&G-]1.Z]\)M)Q@/D<=$#T"B1V846A?U^+R0W+=FZO88J6&J@76-D7=]-D
MH\*JNQQ%^]YN^>7/S*4)A5J_LH[IWGUML!"@QGF@5AQ6\J_N)3JKVFA,7Y9V
M *])5P+_HSYM_O'"UK6SYO+;E7@Q5W7K=D_T^0X[]L-QARV<W%<Z$YVP9%I>
M4?/AW/9-C4W@97,EM:H09Z'#FX,7RD1EF^^C3KO.4N0"DF4G1U8U0VNS'X.\
MOP-0J+/N%93? ZTE0^>7<0"3NK/FIL0S=XWX5*^K$&BBW7=*=_3)09A5C(<,
M(?BQA1X^K!G5Y+>CO$S-?R^=FGLNY=+Z0X*9")M8:@;'QY%S+3[Y@M\0<P.$
M2(^OO<-\ZTBEU]O/=(.)626+1RYN'&*]<B^Q6JC,OR\+3F)\?IOUYQZ4O]_'
M :VR@JV/5K)W0MY4E54DS"'FE+U,U$2;+-L.U+?[^&)IH_FF' JI.IW;].#$
MOKRV2((B6/9V-=C![XGQC%VUJV%V#U6'9:774YZ+KY^;\0B77_UK\XE>%LRG
MG,\\^S([$G[1I,+N]<?VIUBVT7=21ZC[27E:]\;:[NL3]AYXP>XV[?QNT4I2
M_ZP3H,] "VF5HQO!<.16)GP3B(#<25"#0.[7IZK<IA@0[3^0^O5<0NC7<V*
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MJP-3S[G:0,)[61]OFE1=>R1^R^<KBL?6^B8U#EB Y0Q^T@G[U5F0V*7F?NU
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M]X*_E]&N#6EIB@6"T@\Z?>8R@L3]O7W';.&MR \@\&7516YDR=RJ@X.T^XW
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M9$];FD/;(4CRC4-8]<G$3ZTPH=RF\N:FZ.W[><9F^6G0PQYN7>@>_]O-_=?
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M84_K,3%927MNO"<;_CI&6>:2OSD]HO'#4FVH4RBP^SAZECEOMLY> +"8@=/
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MP,L$,/N$7\18GYGAS0Y@Y7&V>!E%TOL+W,##3PID]>_51>@65L*5+!I#"M[
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M6#3[H\FZ%_DS<VIO\7(+[T3'F)80<L-V\4LFM*OYU-P2ABAW%</HDJ@<.=1
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M75-;U]S2VM;>\:NS:V!P:'AD=&Q\ H<GS"\L+BVOK)*V=W;W]@_(AT=_\V(
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M$F)PU"RP(Y AL*.MSCRBL'1J[%1MZF(_T#?J?@7;3X+_5%K C0;F=EN>/W3
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M(Q-SQ^_2K\C+/;'%C.),RPGAX,J#YKZX:G:W.:R L^7T-J-EEVJ5-</:0I6
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MV%R I2LM;) I#]1V$K'Z^ *Q'5"BT=:[5%2\!B^,M0S]J;PJ?M1NR879$-7
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M^K[%ZXHW<US%>]C(?EG7AZ2_4B&.TDK?)CRT9\7+3&G<*>'893GF-1HGHGF
M6$T]<Y6*:/Z^KXA(HK;3!H"_X\NB%\ XYT K6MA%.!:G1Y&6947\L6,?I8C_
M4Z6FC6N47ZMK,>3PXAZ72_T"SPTYDJ)6QU0Z!DYTPK^V6"O+%_C5@"0XLJ&T
MK9XI6,Y>K>%00].MS+_OHM\E,Q/A)ZG35E#1_I*B7@S_DZ& _>.V*3(($\[I
M*E^M_E EFA[5]P&8IV<Z!AG.$"1NIN,,N0?U!]R$?PQNV'.TG==FN$W#[,UA
M?[!30BGW=FGC4"H/5-?"7&1!S'NE35?MQ+,]X?]?N[W_N@!JN4;!#$GF<^\W
MXPV&WR)J:@B[X/304T5<=PM^,@'.$=G$J.QXO%0-\[%.Y!*2A/H&VJ%=MN[C
MLX1>+MBBPL;W:NF NN^[H\W?2JFP-R=>X@][XM\S4>/K';*\<T%@C/4P>OE4
MOW7/]<G):@>Q+23B_C8V&GIF"W89-#/.W## 2P>4,$GS5"#B0JT>I/)N7@O,
MU4E4%GCR^#G'LBM>KD$X!?^]+)9':G,BQ:K1;[.ASE>KXFSKYRFE:^8?%^-C
M4G)3W/OZMK28@^.*9[2D8<RN=V1*<;]BWV\//KE0N)F1/=%P0\=IK)BQY *+
M\ ?HV\4GMF(29<MV]NY]V3:#X.?=.U>T'/0M6KJHH^:KNL,KB',T!5LR]_,?
M#;)!.7*+U[W[0U!D2*JB7+$&MQ*&\0<J(D4J9<]Q6C"P1/2*'X\VAT ;'6 9
MA QVLMQ+>*<PYK&[%EY3]?[YK?U]X?+2<^24G^!+:&CDT1M#1XD0"S &[;-]
M#YQY@"K38"?$@3M2)5>Y3W]BJGJ<P^LTR=>!/0FS%[1;?>6C0E1#T!9KV%0Z
M0"82S[?$/M+EL"&\91*B-6-T-+1<D!5]S#3_C[6>9#RZQ)*,,*@9DK7N<&/<
M]&<2VRY((SR4\?$WL.B*=5 5;[/YT3,\9.&_;:01<UXNKD\X[;10SFCO+!=-
M3;_X;&4IPX0 ^"3TXG+WA<(.1Y5)ZO@-.B!>1FB"<235!)AX6@-;'XQTV?DX
M@V7#R]S,D/]Z-J7>=$WFQ^XZEF<>7O_!\[?G2"O!?&E DP<50+ZNREMQZ:%^
MP62I9MT@NR6E$YB563I21P=$(EC]H%$0G-N?IJ=QQVO50,F$.ZNAQ7ED4Z+N
M3KOIC<PBX?'E5>^SN,5]J$?P49A>__JNH!8(Q.I;517US/[.Z[VCT14-]>8D
M^0O6#^54!I;KNBDI2-OTOH@^E=2,,V286*-I\0IP!PY%V'?"G(^U5N)PZH&[
MXDHNR5#ES_"]WN"(@]U=E,T 3NG((>>!TJ=PSH0'XEPNT=04UN1GGN8.$/8+
MML\_&GCX[U/Z.DFJ\6)\]Q7*+RTNN.4=C(Q2_I[LCW;^'G-V)$UT@@ZP@]U-
MQ$M=?1$_#X33 5V-VS-0M1D)9KU'LY]1Y\DC>$);]R7J7I4YV.0A:+)R6&ZE
MJBBXY![[_(E% 6W[%'X[:^,6C1:W?-9\_)=>-S^T&J>%IXIG86]KW1//:NC#
M;\7 M+-<X1<'-, !KO9:Z,#]/B\_CR5)0'A%M;"FIBO_L#FO3_<1)F)7O*MA
M6*7> YM8N_()\IELU&%[]0=I;_9-PT.ILJWDGZO<=<D9$8I)3&Z2I$3_*J,R
MT$?BF6J2 9X[S*=L+#!%[XW*EEAU@E'MH#>O[CS@N<6OOH%:3*T@I]UDP*"A
M-!8J7[%ZN>)33J+%J)7ZS,B/T+JQ@R)0&-F1Q+_6-NA2IU6=+Y. #[W6;&O9
M?DSP _L_[O/U"-X"%:7?&XY.\U<I&DCGJS'RS&K(MB)!HGW9XS!"_0Y#I3(:
MX%*I#<$L2[=$#G['+[<"+L&35O<4UB3+]$'>]7!LH7E!G21;Y5#2<*,E]638
M2WO_EW($=8KL43H!DR#G$V39 A.-\S&-!0CGE=3PSDFNB1^O["\$3N57A8PV
MCAB]TQ#+)K<8'7.C\R9=_&NGA&MB;YJN:K+7E*X,&3^\-9Z&+KSO+A]VD#WK
MWM:)-@ %?8NV^B6<C*NZFR 9\:$\3;Q/#+"+$J*FHZ372RBATJVD)O[ Q/6*
M7[C;?%<277\0^YJ 3&1ULP23 0U-5]=0OM\^E-Y?P0X!E\,Z5\RVL([(R-3D
M0JUL/]Q7Y[)-4?G[ZUN1WM[Z N4CE;&%NK?"I]/K$$TWT^0N?9)\8@,UP&#\
MJ1>,FNL:L:U]$Q?66H,%!.*8M <O?+V1%78 N5R1+!E'N:/G92SE2#AHDP/)
M(1@#[Q,6H'-#LAT(WX3#T1\39,3#[_WQ'QV=N9*1"Y5W6<TYB@IY529C_0HT
MQ'":LC^/V*H2LBU+<\-KU(69Q3XFZF_J;YFMM=FTN22EK%+U'S^IUW5?P3@'
M86(&=\J-.F8T!V@"@:'H=!OW,QF)(M[Z'MPG M3KYPO!E*'1:(ICQ6 #F.!Q
MAKS6;)F?CG>#/(KH?TFHV<D>DD9&2'ZY"E#MFH,K[FKNQ545.BKFSG-,6_[.
M%8EP.!^?7\Y<Z@WG(:O.8<^X]!0NSPA5_,"J,OJ9/&%8Y1'9H,B9ZN9(K&XA
MF@YOD10D(0?FI7F-IC:0W?C>:/$R[3__>-TMST#!4V9%T!YJ<?4<@+05=]YB
MTJR#<IP!GKO1 )E#K!_@V'E@LOV*KG0 [QJ_WW37KP'+R57CCBN.OY^%FS3X
MHAS);3Y7]H/3WM<]R-!F^_4SH2X4U(IA@?=59\B17;-6+68YW!4R/46>/1.L
M-%J DR)N/32ZOTL0Y1+H['@8>3KM:Z7IGB8SC<_^)W87O#9+5HZA ]YE_[^_
M"UMIG(B<WT-@(J.D$?EYJ \MVCV;#GC%87YLB=@Y@@90.$)4$7UH*BR<#HAX
M3)2ELA\=T-CP= #>Z1^=T!\%+^>M LD,7$S[]T:9*4/3>G0 X'KVQ" =@!PX
MQLY%5J10CJ&CO\"X9!@K':!-:Z0#P@*QY-1:>^+H7V3OT4<K_!N;-3)7SV\$
M^7[\U/034,"[&CSBB_V14>I2FX)/6M<>,1#7VU%TU2-[S[+WK)L$%C8\W&D6
M"-&-LFL2!DIL(0=2TQRR"L7FZ0!<YZ?GR=_O!:R'T0% * <=L'X+>R0%Z4_:
M25B/O"5]T.KKS*DZ8A8NAMRSP\2C9!"7U7'$;UG1DJS_^4NW_S%HL.*3WF($
M24N3.)LL[Q2OZF)&)O;?[+V-D,?DL+SE&79#N#-GB]2=K%@AFU_'V:22V9BC
M\_SYX0[U09?X2GQNJ:<QJJ,(4-":&G4FE]]*8_/EW(OM3+$%ZXQ[1Z.$H&1[
M2+C7V.>!N&&_'J $%')(8UX)@C,B+SXK4(N?Z9RP=:U>(&>0B%O[;V*>#/%W
MV'),:/P WE@(O'T69S6X9CM0PJ<M\4OC#6C.7S3H"O\>,AQ\I0QVD^2<VJTY
MDI1>+ :)I.BA]=B]/F6-",@G#4X@*"F'U"6+@.8B??RM/<<1\ (-ZK5WFLO*
M:,@-[:I2MKYH$!.D.Y\H_U[G"6K<7E0DE\>WKVN!AWO0XID.ISD+Z!=<"L96
M1;K?7;A<D%R'F@G4.ZM,5MY!V68U3+7(M+SP%3S_P!W+>9S?GTZ^X@?#_"B-
M3$+.4;X0M?+SIE:4$R=LFO</.)1&X^^\83-U.0;AC9I#Y?%LV>J2$ZO1-?$K
M>F)_E M0*2@,_]J^ED3"G<1VHZI?Q_8_NVIH1*V,/?(9GY;/)7E%T0\]/U9:
M4I".A[M@KRYYBI*C?M6A(Y<_<K$!*Y,/SG7>*K3IN&ABJNJM?NYH"U<=W2#M
MD3WAS.\:ITEXE,6:D)1>GS[-^]$T$(R[$8/K8[V1XN/,-?_CV>8-OP6D8,(C
M9I<EBCY1E<_6AGO-WN]8L;,+^71:CP!U3IX?Q]Q.!K$_5+R2T@BL;/AXXC5K
MD7RICGSP -GBH;1,WD:@WN+HWFKP,-<.%1G=8$I<W0>Y#G\I;:(#$D*07YX@
MQH+W$\Z3BUK:@H.GQ@U.&I"^YH'EV[V.(8#ZOA]^2N?A>5@T<ZN?4D^#Z[7;
M_R@:$R\J+&S:$"TOU^&$#&2(&^MP OX5IL-^KH;<[0;UX\DLPGQ2';M">5D^
M<2JU/>/7LWF4LKG\NY-ZR!5M$Q=B7*6K"C6\OW 65AHWC@$?J<$5%^H.6DL#
MVOEC'B^_4VRLOR)B0;A5LV<_@2('S*4OK+'&N:^M=TU]ME.?]SCX6KT&/0N)
MDN-[FZLMEKFAIMI]#]%$JW0<-NV2>#I0_'EX?JT+([MV5(NSE2JOKAYV%RF/
MOE<BXFWWA$6J>.R*!5=HNE@+\ +FG5<>FY9BM,/$ .&68_E4R.AO(4FR:W$@
MHBU2)W[&X(NHQZY_'&)$U@Z,RH6;IWOVRDL:EX+T#:E)61[YAZ$=*T^T0B-^
MJQ:*=>'K]FSH@+XME86XW/?7)5[8O_KF[3J#N4QAFIU?I8E&A>/PY>[4)@2Q
M#(6#-H&,6#HN9!<53:^2ISBWWP,]3+=L2Z%>+6E"A=OX'=&  4%LV]+" 1*4
MX:5="%-B&/=+01CM'$=T\&OSY[AP<#Z5C 5(#!E#2Y%?_D?>."[RN#]][+IX
MYPL5 .0UQ8J\+[Q3F<#6_;'+$(8M,"*A@ H]W\<-@6Y1*5FKLRE[F:L+X^["
M"J7K!;*0_N!T2)M'W B<55^!JI"[6!XKM,)^/),_407G@CVL(H=E'B9R19I4
M6UNW_4%@-!-6H(*&\E/W!NZM;W:(?I[_:.%K S]N.3#2C&N9K+\6MW_%W;3)
M=-UUFU_#-?9H!V4.7UGY52<33Z7T#;L0([CF&L.5C]M0\JO'P4*S?M=(?:W?
M[ X)J<N2R*,7Z;0T8"\FTOS<MPNOGD(2*( !:0_?0S_J\H[2TWM#;^R ;4@?
M2G@(6R@=<.Z9BQZKAIM'?$,MQ@9L 0]!CB2,"(='MNA[4XYHKT]FYR12A@L/
MKKP1?Z*L8S "*VN(@-S*H[1HF?7GVXL)!WI)[NV-=16*1FS.J<.T]) 0IQ0>
M2UB$ZQ,!U7>_FH2)9=:&/+8?\^I137G^ST EBN;FNT8DPRL'85K<RS0FY='D
MOH""U5'C]9JA/8G?!Y<*EG,3[JP#RM3W78?<?&?#JWVFIUI<SP>7KFE\O,=A
M%A29:'1_7_=1UYUY(5 ?&(?4$J*6EWUM44+)JWZHED^2>J@/2N-O?AQDFB9Z
M!R2R.QD2I-5AJ/% TK3P_(/T>?QFTCXF%3VU0#E;:$ PBLZX24I^S5(W@/]N
M>*O7^>P]U V+J?M56LO" HUK?S2 Q8$MCQK2-?0R'SLK=7V)-C 85)=WS!30
M/0/*+2^O&I2^CJZLCA^9N(:^%LZ8E7";^7X&.CLR2>%K<K7;OAL=8//;%6]O
M7OFM]'G2EF_*%):I W.-#NC\"5.@ \J4L4< U+.2^JWS*ZG)Z&?%4Q,B=7&O
M_*IJ7F[&WFRQ7[-,\BVL\RD4VT^G TYAM=6&D^Z91A]+SL8@"HQUN :\_\W%
M!*XE*%>##G=8"5GFK)^T91-:T-A-V%!!U\1"6/W%;&\O.#*U!4/-W0T)V;HX
M;AD8TLJ/GHGT_#.C9^_RX^7M6P[3]0SP'*#+<MS9'C$NQ&J'2+E986>[^P@=
M ,K(#RI;F?"CIL<-[S6B%W @-P^I(I0<D\CUC\D_=XN'=SQ:MZ(L95 $5)BM
M-#I5OS)HH295Z=Z[]XO7&=?7ZKW:-5W[*\&QJ1YQTC##? %#^Y;@WB27P3['
M4,8VWW(N48<[B>P/Y3=2:Y\M\!:*KBV4QF;&YDMTL94J[?3+8X;\>L#WD@=
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M =F Y&[C0J!QH"YM5)$X0<>%1WKP,/)H?X<?12<X26)R)KX#>79V.GFIY"3
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M7#%O/5 ;:=+A-.']EQ5D2!AM</"6((O$1/>BDA[E3",> Z/FY] !1OVC S?
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M^K_A,:N!IA5_[WTPM\8 U"#C$>X=XV2%?M B 4P[AILK;Z/ZMM/GZ88[/2_
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M<9-27$Z%^?DI3VXQ-UN0E^:[L*M0[; V$(FSQ6>)30-VZD6K3!M/D&'WG:.
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M<N+#^-I])8V_"5_'Y C[ZJD"S,0'+/TZ _ ZQJKP'X#FZ#_HIU+TD=]@CQ@
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MN[L;<<[I-??%\_3H18Q*.4CG/5T0+<O<A]S7*8&D67W2F8R?H^K/RJWVDC.
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M-UXIPAO-Y:0T<:W*CC$G=Z;M4>:$SU19?O4QP+9*M"2A=2?- I>:]AQN54Q
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M'(PWT]63=)N.O:EWPX?J:3J[Q@@Z_\YRZ\B^W"\'ML(C<T_D1:MC0#$;7Z<
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M&=91[L)<0@9RZ*>'-6?< Q%^\_>5TMMAOY)66(T<)^*.S%X%7AG01;K(;9P
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MI15!K0[!.NW&W]%7#-I0O/U:NONR?B>=.Z-<:.!]VFEYL_=P!\+B!S@]0;>
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MBBD-.60Y8UDZ+"E:;8IY:Z*C5OZ.%P?%&HQOD<_UX=/V/?%"';F8Q+@ZA8;
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M*M0KD%M=Y)!!U"E(N#@>P66+9;.Z@#_Z)EJB]*7OY!,S75$IYC'>&X6 ^YP
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M\5^3H1WQWH]I]:Z=K<TFH38C,UPR#X<TN3YA^QZG^AN"!;P@PU)ZB>]%+T]
M#&\FVPJ5@/E,BQ+3'AW[H[-1^JAF!7DZ.G#0NB;IC-S/T2-6:3I*K<7+3^@E
MIHU1/XUIWS.A13R\T'#EUR$OK0O+KTUJ7PVS,2?2$>,/;*L7#R@J>$[JQ'GQ
M8D+%<50.Q2DTM)#"HE\_S#LZ;Z0"O.)2.[<F.>-S:0_1!CRYHH[WXI\6&UJO
M43P7\>MU^+CHR6T=^Z5WQP!,SU4!-C[B9]8^IY2YMG17UKTH4JN?W@>,HAX,
MZ/.VAQY6@6(Y\"C\M%1OU[_%$QL]LU]&>\CORF#[Z%6'61Q/7R/2"CSW2@_=
M,70-CE=( P66O#MTXLI>Q5^IS5?\',O1B$LKX -OG$+AWP=(NA!G&*WF!U[;
M#3FJ3OOXM[&)?XSMEMJ0N$*Y:-=PZ"3TIGV3'H,&VKLD_:&.FHVXM832_EL.
M^@!\,;?\@<@[D3_.#&&*Y9:FYSZ@W2W82?JPCW=!>3D.9N5XF V%'JS)ZK2<
MG&<PP7^,0G7^9L-]#VSXKAZ1A6%6]0VXO3>S)UNR'8+RY:7I3;?M ]BE/L?.
MJ=\*:>L32X:,9M?\;)V_HK[>TJFU,J=EU:%,];G8E&GR5();S+\_7"N$!'*S
MD7]&;&L-B6QJ&.F+JMZMN>>-7YH]5A="182LM>&U(K::^[BN=3N[_ !C.^1?
MVLNB7A Q>K5U0SF#_6WSPI A7QG_Y'6OFMRE;WGE:MJ/QE>MP@N.'1O2ZT-=
M@4H2T>WF+"M7O(2\D=@+M=[I4:_S(;;L)26N:D=9-V>8:,88VFF<$_!6$SK)
M3MGR1!98_, \9_?Z?R,H;3W<_F@?\9%<Q=YQ56"2Z\85KP6Z(=F/)-I9V.]
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M@.E)VR;2BC33[BV,6\^2"S1.^G 16@*)=$M>U.#R[X#XU%&=G#2N+H5(&'W
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MTY!>BD]6X.,+\4[&CQAG$A?RPXS*@"_@8A*DB!',2YJ#-SV&,"6Q:Q-DY;=
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MSN-4,ZCXZ",2$PGVHJ"[N$O1,VVTEA!0_/.*J TELI^).4MZP00NO.0Y+[A
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ML0*CL8/R4=Z$C!]U'#69[[ZHL@R--B*C#J23_ OM"] KB*X]L^HW$)\!-VH
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ML'H\?X-35TPU.&#'9-%/PN=TIQWGK;=:IF$J0I6=Q3W-SP&UZ@C[0 "T,>=
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M^O&&!1[D&"_!3K;7VN[:JT_-1QM^_A>(K_P7_LN":W_\_P%02P,$%     @
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MN=JWY6@3TVIR%DW&)&L?[L5K7LZ?DA+_Y&2\M.@5,/D%KDXUOT$2I'9PJ=.
M6SDA.F_!-XL_(7ADF"J2'TS?/]+2&WFL+IAA=Z_G%Y:5<4/WX9X8X-+R%;90
M9%_9=#QV*E&\]Z7,XP+"CCXFE&GP^H@VW?W %"9WZKS]]@L:( !;9Z<!AR*3
M,6OSU8-1,'S.RD@N^168_,6:!K1IUI3)Y!=UO'IN7QE^Z9?M5%=BUEM9B7=T
MY,8YZ9$%XGKF0?.;W?O5ZMA#=0A/R,F*NWQYP-)=0_RF)=$^3@45)<$[HFV2
M/ZLZ$5]JU17H^)JD;6!D>T/JU6NA9Z=>ZVI/=LZ_^L>VX$+6'!T1%M9HGG.A
MCO36PH[KVWB9WWG_2\47/.EKA/7O!N4]#KEOV"V$TB5A$IJEX&&+2A0.4+GD
M]QQ'%3$GS"6H%$Q\\$V]GQW3X^K"*!J:\N"&@,/H)]8EAC_U<KU(QV-+0OQD
M9+6K%@&;6CSC<FA[A)M9$S$IJ9Y0"&'6>A?KX13=PQF?8,C W)BQ:-B)BBTD
M5PT'\R$TFX?EO^XA67N^F/A_Q0FGWDYVBU'M?G"VR#7_KH.\H%>$-CMP^+T.
M&@4]I:VP8)W(>8/P"/'9I\Q*7-D$ZI"RZ+,8<26N )W1XI[]C:6D'U&X,!^5
M6X6.HEZ SR\DD]3?6MH19WUQ[^9/9=URR#*)VK_)/L7,_ERA85FA^@&$TT@U
M^B-U BI0=90+ 4TZU'$WP,);8+7S0I#+O='UD+![W])9WFD6(K]X @-S'P*'
M6.9V+7](2(/O2;&+2.R6&"B%O]24#Q?4)9Y%UXQ5]UN;:K[=WQ_I6O:_@GUX
MT2"V77UN\*^PAS ^C(M[U(EX"#X-RIF2!M[C$QD1]TDRI1Z%-,#Y#SJKR@3^
M6#377$NH!FN>]51:;;EU,92.[,I/3&RSGY&U& I6 M5;Y\Z 30O(N$-8;'F6
M6<)^NT7!CZ-;]3@K1:5SOI;AW=,-$9R&0\<_==D>K*O,F%Z<[_Y>'3$@WMG8
M &^[9'8O1#.S\C_'X?X%G]O9C]81 =./R(M$OX2\$9P9^T-0:=^D=JQQC$.\
M=[;T8Z"ZFW2)[!F'N>8W!2$ZST>IO.!W*,YA<2MZWM!GJ-$8[ZIE-H+2_DWR
MT7Y]J_R-GYN-P-UTP&NBP7YJL:5^JQTV'8E?":>8/L;9-16M%G TJ"=+7]'9
MU_([>Q$NE:^Z7G6')8DZ:<<V094./M'!/(@K^%Z!L;V?]XQ3Y@;Z;4_UGI5B
M%^Z^"R;;Z>%SX^>K#%(7FJ#M]>[K/7[,18X.3'&6A\6Q\C>_?#?XO&Q48N*Z
M>%6,W!\4>!- 3!/5R=>&=Y'A]0E9)'?389TS8'%'YM+<^<F/#56/-ICSSU]D
ME#N#=[A^1XR[;/0JZB6()*)/V@.[2D.\>FN.\$BC0O&L*3FZS#M+'YU@K!8^
M]R./?NJ!\"Y]?>9YAF54:#,C"=4.XPT>L3N3T?[=6 U-8/-QA[2N=""K'KCR
MWX%D+<VNH5=F#BS4\HDL'8=F%-ZNAZ"[<W'VC:Z C,A+(IO#S^-4#K-[54;+
MMZ^G+G<O>EQ=+ NR-<ZIHML>W#A+1&(EU(]3*#QX<=Z;*32@PRIH,G*IKN)1
MX3V1F48#K[J_+^#XZR4\L"Z?1JFB\$SH3(,%:='9K9DGM^7R[]7/_I^KRR<.
M/EYY]1-SEE5C)A$Q.23<97?!"4!%4J%_H"(TP)$&1-L+1[PGBMXG89,)B<*V
M:^F:1:@H>5>>?!_]N]\-%"C"*^(!EK-\=UA^Y')1>2D&8"^)T$Y8P4(@SE1(
MQ9#*3+QZ>S!7!$GQ5]1L/%I04*EDZE'A@1I*Z%I%^BZ7"=D2?(Z'0>"A^ZTP
M+H1J 9AC*K,],;!E.OH$_4'EFW;@@Q:AGPW.*_DHEY/L$C_.I4I1$* <T;Z5
MRI1+?C;A\ZA*7$=+IBFQ4]/;Y8H-I=5$S&<UU?X)"+$=IY@N',O=GVR\IAZN
M&EN"Z,T6"/Q[4V)XVZ!=&BGGJR%1C;D)P%G6+8DS';D<S<+P1!.20?JAZ?%D
MK&J0@9#=_:2FQDDF J*09T?QJG;"P@/H3&5+\"722?$VI8<R@2=M:4W3,J:J
MZ?%JTFRGVTBG^P4_NJ7'A7G0Q!OV!L.Z4#'$+3#[2)_RE B)TN8IH@Z4X:T3
M3SWL_]1<28#P3ILZ.XN5W%UR6NS58.\"N)N;+L8&=Q_FU"T.OLGE1ACF=Q$@
M82?ZDJ(N/3GI1[TW\Q)7:G#6J.]<;)I>O5[:3(\PJMKY/,/B%@Y)OD@\QK0'
M(D\A3H%!>4Y07H3ZE^DU*Y-5@:1I8\^A'QPMST0-)LQO"RVD\=_H..'+1):-
M1U\HID0:T.IJ@JU_T;2PH66:PA'T<J#_ZZ:Y0;K13)]7[>>S<*%=F>;A$[_#
MP&H") Y69;]. TAFK1DT@,$'QOA'L%[T4N:DU5[:5-.'[MPZ.J%76IXS?[_9
M'IN#@JM'-YR#(:,JXC#RT^;8N]45,3]$^V]TIM-/V]XYDZ);[#L;EZ31Q;\W
MSD=',EL_.I(%,?CR:J+#=1+G*=M5.P%;A\Z YGQGR>.TZH::[7QT-+<HSTWI
M#K4AY;U.'PQO(R])'0_9D/J"L 5]%L!@:6<=F>&RW6RO]M+/A@[^G!/KB-@H
M._OD#!?7Y]I[JGNF?'1+T,KJW$Z3+ @/&$OX.K2Z?_B3F&M*+/N:/"@1[O2%
M_XFR9**:@<:+5\D?',1BEO<@$<TR6>2M$>V 3&OTV\=$L4/]S(PLB?$&E_&D
MFY6^E'7&%;=K:[\USS.L;$6>)*])P8E2$-)V#"QJE!">5'$5F;P]QEEBX7_6
M\'3)G9F($<,Y0&(:Q3B).>$&T8)(H6KQ%U#.6X>O,")5\WSGNG"/@=7D1XV>
M-@[!KX7>H$7K%BSGW]UAZ<9-AE,5@@>0XCJ2<$P+%%((?L;#H,:N03JYS"CN
M7/]/]IV"Z1WOFRVC6U@2]+K^\AJ [Y"]P.E%=T90JJM^?0Y*<NQ$<H&A.];V
M[']<>$9AE9OW#0ZMC"L9"RYN)+<>?/=[S154=U(/WQ.[C,'<14PT51Q3#Y[%
M(T-S>$?$RU6%W9K;2_YHQF4A_?CKW@#A>DO=M^&$YLJ"&.#\?Y')18+3^!/2
M-8GWQ>3#93NNP,TZZM_2S\U8I:@AOS,_6=8,/[,U77MAD#$,UQ"S$*R%<!I"
M.LZ'6^TG4 P&O#<NBK>Q1NU<.O=4X.H]6$>?+GG C#Y$1_7X(^9%+CNU!P/9
MA4A0E":T]8H1UJ8N9M\K&W(?U=5E=:3V*DDGF?'6/6+(]SU[W\$U +/AL;!U
MBJ)(4HL\,H"+3+B4>;6?"LKJM!*O/%W?''?[^4& \-E?XTTL1V<L$Q#0XT(J
M%QS5I68OV*Q"L25NT(#XQ;ALCG:U3R]&&Q5Y$RPNW]M'2XMI=]6V$>E0]X\_
M:ON4!(] 3\MC'-TC#U-;GW@P!D0F(O1>F%%,=K'M"IG?5E5;SCB4W!L*G0+,
M0O?1L!HD5LL]SL_#UHHB2\SJ<5TH4UM0,31OPD[O:=P;YG:($UL(A9]9F=>!
M(1S0( MQ@ 9@]W&F6-0GYYV9LG7?[Q>U+_=<Q(YZC<D0C=;B)@>@[,_LI]P7
M1Q R8VYVBF%S&N_+&X4#_<X^']GCUM[0^)G(OA3Q5XXQ0TJ?RQ]4S!Q#%5A$
M'.RT.]5\Q]6G7VG1S!,9V1?_[O(^8^BU3L!_LG,+U]".9 U60"@2Q3<^[.\W
M:V7GHQO1R?H6L76GU5.UDS;Q!M>XS+X&C\T)$E<ZH-$BS&5\Z2+J(=XNKI;6
M),8$3A[M Z>--KK:[CMN+6M)0 \JI.J1MAZI=,&O$Q:M6?UA&$S$N\7G.0G$
M+:Y8]TMZ^ 4O_HR"%@5(SW-JFY'6R-Q@TV*9HEE]'0G6D1W4^( [BUM_>Y6\
M?Z6LZ?N>](' 4LE*NM":KL2!RY%7\P>R2%<L]12XV$(#(-5LA1$0P3\3)/]3
MT4+RYC9M7Y^AXZ/MW[_!XG.J?R*>'1<KG)"?4C.B7Z3VN3**,:E_ T4.&6K4
M_ISE8CISL[-CX+I^7,N7I5]1J+>JGT]B*@9*3IJ,ZIQ%N(!AA'CG@DH:$.[6
M?+8^96_Y!5U^CH;#]O"=T$<?-@X\E3M]<R4:&?")$32@.AZ+(AEVS&D2!4,H
M>O@RS=Y;)%BDZJ.RO)CE<6UT56,ZOX;TD['DN)1 (MTF]#3&J1<2!ZTT[+(]
MO:(W@>!8C&=IFT1]AKO;Q!EZ<7I:]_SJ%\V7DS<-B[PWYI6@7$A<)$=])\JV
MS;^98QS>#9P7A=, *^)$QN5AE0-^JX'1]>&MQOJTYH=/Q6,]5\(9)P=P!F'$
MD?T66)59;+#X2PD=4G9X<8ABU7N$.Z'I[N97=V51(]<RRO@CZ!.;=.CY64,2
MO1M%A-@0W!$L#EJ3(KC,[D[J0,$5@]%7"#^/S]TRJ::9#\>_;MVM2 M5EDVY
M=_7^S-@B()[;,A]/1'"9Q>$F2HMM7V9:Y).^K^C7UT6\%C0U2;P@@-_WB;?Y
MDJ1Q$!YDNHB,MPB&@.@%2&2%<X9(>26AU5_MM_0#$U$7>+OV]LJ7E!\AW!\G
M>S$,.J)3%$_0^L@:A/7'P*LQ$FMWK6T,6M->7+E.O%5<_(.@SC+U8&O*Q&:B
M&88P($$[!WEQINZ!>;]])1AK3,);K4ONF'ZN'=PO?B:\*Y0'*:-*(_2'3OB[
MH#4I,AJETYKO1-[P\M$9Z3B_P'2W5_DT']U8DMQ"[@P'^=.XSCGJ8*GC9X0"
MJ3CDE4^9@W&&_H0J_,X->,'V!?:>7Q4N?DZMSRVAEQD9D@=',&ATB,^):JF4
MC5I':#P^Q!8[>#A^B;]TV<2NR]5+;.0ZB^<#488ZP ^5C7QE-J.%1V('I_M^
MZYQJJINH[OUYPR3S3]>ZLM3O+QG?,EP*?@A("K&V#,JW<,9E H?VA)4-6_<%
M6)0#?O]M(R^*8DKJ\XU%!A8Y2:HDFJ'=:W<&S[*&8\(#/B2\%^X9A;EAZ(V)
MI9USER94^OW:#U%O-PFCU;EL=M,GK')B;M."@U%.Z"I2-;&[96$AY[)+?UFP
MK!/T.W(CG!1[!\Q5R1$G[G<PCJIR03HJK;O)*:*!7GPU*,FPBM8>]H"$P+B#
M3^C/\,!%M<]'-Q#V8PBF<A"S,%#A7.@TE,5J-;=Y[!JM],?BSY1GTNF/EX7/
M!# ##*L8.NI$YJ>*Q7Y(&U45U%M4C#1WZ2.M!B04B5FJI727-O2FX1V6ZL09
M$AI?U)K8XP+Q6RT8)LIK4DW60M.M'_,W24>KF=NQB\KV=D9#7>=FGTR'RHB;
MI=<>-7)FGO">"!A/Z@F5%](1_ST/4+7AN8L"R5]?DEI+0?6.4\8!-2(NSXMJ
M78KC_Y(P?Q-^59HT%19&4NYU?P.K!LX]@N%]6[@W#73&G2="=.J)N1N5[E\H
MMXF8\$83XFCG'.,HQ:8?&K'7[\DZ(:[7%G'?VT*!0^E#N)N_,/U7<(;\(]$8
M#$?!+5N17(V/2%<:E=:@4=402#LTN;A.-.ZB;63V99M4$:^9<H_8(^=3.B>R
MIVZ1>DD!18U*;]Q?0'6AF*G=.C(G+G2/U7S;+#A>WFA; L_XJ[&V*O/FQ-?-
MF$9W#LF:?9M7<I-7)6J!0QCYY7&AMSO.J[6^*WJ72VWG]JB\3VR\C"(:^'Y;
MDE6_(2#O\>(O-P-NEXFU)1@HDQ%UEN38-AB%^]445_^\N8C$\+ QX0><4G?F
MD8@:ZQI%GJY5/,%E[<=_6?/_YW:QB9SK\GGF;T6%_(:0I+^\L.*>FF(B%3<!
M!V2;,)X&'-(Y8T 6*&@17I[E_%QE9 ;7SEB9]!Q>R#[",U3!D(O].JS+CSJ1
MP<8.@K[??K+.&H4ZM6\\&8XP9)G[.GP3L$C\JS)"F) PPACC^R)=-?YZM_66
M@-!2SL&:^<Q,IS/[#49CSBOQG\5>\M\/ #394V* S]RI#NZ!YY8L+$BV/?N;
MI\^=5A^O2#6?>S3S1V"#:8QGMF4^0"-),[=$596/SM9[S6@]&%OSK2QG)->1
MYXW$Z)@K]LJ&?GW0QPE[AY0)87GRVR,M \Y 0SVT4!?_TQ@ KW,>CL0J+ 0V
MV(>C,R$1%!/Y[AZ?TD<J-:T!&A>$&9NOA'HJ,1M<1)U0;Z+;Z *L[:=<VQV[
MGB\_VT9L7XI\[*TQ6>OYT*.]KN7F>U4\A*$Z0($/>"!5X-Q/_C!EE5OUS9\&
M>&*:'GMR>.R<\E\N/W'/5M61K3E$<ALG6NN5>PG>7FZ(X+EG*')#I$ODBV3(
MER^7 7& [\]Y^J*$9(=/VBC'Y^Y.VQ^ZA_1+;(X6O,9&U.*+>\2&J^,K#55R
MO&.>F(O3@,9VL1P6V9R+O_CHN#JSFT:OC[:*]7,<)%=%"14B_;V&CF(.PCJA
M %7#*5B;)%"X (G&\>]'^C20QQQ&&WT^F93T%MR:FI7_"&E[S7HCW(8NX>.Q
MR4W /W%]BV@ #4%RTP \5+.S*VK/I7<MWMYBHKSPX=SA(7Z__U(GGNXJG<%K
M8&FR^#^]NV&SE: =E$_1',86E\\%I;,D/XGFY^A1B=^_>\JS+X@)\+YO*;J@
M&&LG!L:?VQ4Q[1N>?[@P.VW7,F0FDA/W(/)BT$V'55B5X9L]U&F]0JL_YN\O
MR:K53":ZK;EX7+XZE9)<]8&H)?&SA&&DI)RC*U>T48ZX==]4_7Y=;3JES>T9
MNJ+&?T[(4.)9EN$/C-W+^2@=1;AE>S#_*.6FQ^?HW9_Z7Z:R'N(>77I?+^_$
M;+RWNQ4#K)>4.[8@>;QAT2*O]C//]?Y0^'791D_%E&_("!8^'*%WS.4]]K]]
M-?9?F VL$Q)G)P&:N!2+V]C/O]3\6,:<7?B;;&XW/Z]9OL*C)R3?>E_@Q>_"
MSTN.]_ K'0H00L;;=8HA?N93_:B;2?'64Z>B&/VG*3>E7S%(1_WY\:/EE%X>
M=TK,MA8$E]%BE9$H26QJ&BB2S2[126:N.\Y2)^L?AJ[X9-JY;N.>5$<,!7RV
M67H:[T?^2!2,1'C(1KBY50N+S)$5E(X>HD=?9)A\:WQ7DH C;%CV)EA<"G/6
M%KSCD0GL_9#K")8)GC@A&V;^I>48/$3B4G91K4G\BYEV]=-38FETZ:_5OLFW
MZHD;MZ <1GP8QW<;M'X3,EDW\XTGY/[N\\Q[SLD_MOU5N?L:%V#]__B?C/^
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M)P$WV5UE*.&<?E]^9CS5V8U9:/*WS9M,-=96L;#JJ&Z62?YE#&LP'>B.MX]
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M$6$*0  :[8+:8:  K ;-"Z$\T81\X,9-B  :;9BH3(W)F*&ES3TCME&4MY:
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M@CNM3"FA/*$,I(N5E/73 D+N2^0\?OPRI9[[1T!CGPTCNJ*B_M1U,_RU[/E
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M/!M,"#\P?^ URS.RZ.;#O@U9]OE/Y(+\R!JMET6*P4I3N%S;5G*;F>GY5KD
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M2*=>5LO?\U_H7/]KB'YC_A502P,$%     @ $8>66%$,1C?]!@$ N#4* !4
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M<+?@RO'7$>P,M**!1K9.I&A'.F#$>P=)GZ=/S5NGAYX@P1\CD?3T*0J6<AJ
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M8I7F4)$D5@H5I!!6EI(?^9[53Q+%&;C\>GOKX.YQA]#"&]<K,&X:1[,"6EY
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M2<XA$B33$$D")54)4]J 121R\V2=")*7/RL,%G::\$3YW)1>2ZQ)PPM?8^.
M-*$*UNZ@,&RQVOTBOBI4>^#1$U)W=V^\6<I((4@,.6,%1'EFW%RI@E'$F"B(
M7I;8ZMQXG%3/2JI+N+59A%1C/E[\U2/E]A0SY2T,DYK.&3A?+.9CMEQ4>GHQ
M [>T\G'UTOAS*)/DO1@A[F9';X;&.H3WFVG',;N?FHKT=_3[!SG57_I%^67=
MC[**T+V3WQ<?M##_&,5%ELO85+[A2.D5+Q6D.8U@2C.,I"A8X59:WI^5OC5"
MPYB)5/TBS1QK"[ )<GPTM3W-'WZ:FPB4+N=53XB6=]_D!N=9L=0L@V#MIGFZ
M,._%$1C&0,-9DYP #'.@XJZ7/ 5?B(+G(S@S\D9Y![Z [<\O\!XQ:(F2NI7<
M[FH9"999DO $)AG/ZS ?0HH"IFF!*2(TYD(&J%%R@(6>M:!?D9(32DFYSP$K
M<,Q(CJ"*D-Z6HH1#PO5$Y%%"!2XB) K>MG!ZTUG8[-KD-@]MPG<+N1@48@?#
MM;<OK^.V$C!!H66WDZ/0>^D8"]#ZK1USB('W4#S& B#+ZC$V(YUJ9F]WCS&M
M[_CY5#1=9+:LN4@B?0"-D3Y51_I4S7@&J<I,&"G#),U)&@FGF U//@8TL'<U
M-ZIXJZ[)C[4Y"@J^JRG=&Z3^=K05F@.9T5[P!+>AW;AX(P/:"ZK]UK/?<'Z:
MK@ZEUS;ZQ6RZT$3EE+_4Z?6YD$(@Q6!$8U-X-37E<DD&698G<13)(LZ)BR[;
M2ZEO0[A.P3"GT@YEORH&^]&R4SY!,'!3+Y[B.RN.HZ(%4@W[Z0RZ^(^*N[V\
MC[\P< Y]]1]3CW]E3\4CHL_$),(",JH41"E5D$5<0)SA5 E&,$).:SXD<SVK
MB888J,LS5X>T%TGG@U54WC4=EA;-&X$\^+FN^@>T$Q7\/-<#C&^=*+Z+M3]&
M%O@!4(.E>!^BX1&T>Z-5!S5C51%K7TRF^(WZ5LKSQ]E\,?[O.C126U!1PN,8
MTLP4H"I(!#$1!:0YPQ1G7%!N51G1FF+/:O-Z-H6<E@]@UO)21^M67;.FI667
M/WO\#JO$7E!QTW,KZFTT:<4 O%'PF_FMRT1H;!R"<$-CY!=_&P(KM\A;%[D/
M!MU:#31<O*V+7!NAMDXO>BC%+_)93I?RDV9W7]&IR^]\LC1E;C>>G5;N\E_'
MBX>+9;G0IO-\E6MA*E2UV=J%4A++'.+4E,@0&86F6P@4<<85HT0;K5;U_ ;@
MM6=%_'DVO8?ZO4? &W[<$YR'F+%,*(QCD>EMSQPQH@A!++"",DOT)U06(HKM
M8O[>V9QYQ0ZN9^W)K#=M#E?NNO<\@18[\/N9%+>]N^$%&&; WF*,QJ_4, ^V
MWFCFS0@ 6@DV<OS64KR?"74P&][/Q/H9'.]B@MTLEF$@/VCK],S"<%;2,%AN
MV%<#D1SX[K".:;R:EHMYM0K+JA[MW0.=-HY8S>)SU?VS$_*CC36<2)0*&*6F
MGSTO*&0)3F%18,P*1:((NWE'!V6_[X-TU:NIBEG\^JU.,KHU/PUT_>@WHSU?
M4/8^3X-?839Y8QV1NJ6<5X$K*[G:-G'F>U&'.X#?NB&5(3V_;S)+;WU#ZL?\
M'^,.]:2)"7;+>AH7GAO;^'XZ5F-.-0^<FYAO<\4[FXRY/DIUPG5P)O*$<5C$
M,H5(\!0R\Q.-:1X12461Y$X;DA79OJ-SOOW\\_F7OX.;3^#KU4_75Y^N+LZO
M[\#YQ<7-M^N[J^N?P.W-YZN+J\NOCEN+'::66T)PI!Q5^9H^6#, 6@[ ;_T$
MUSA)'4HUVA$=5J4Y ?%*%;F]_4;MLE;!IU;ME7"<H#PK.$RCQ%08D!AB61 8
M,1I)%46BR-WBT0=EOV>5MB.&^DW;9KE-;2 C^<TF++R1;-T\:T< ]Q^I?Y;7
ME+R7%EINS+\OB[B7B0G>2,N/BQ.+BEY-GY:+\K-\EI.X*3V ,AQ'"*4P3>(<
MHC@E$*=8015E>89QA"EVZM9X@%;?3K#+7RX_@]BS<.@.:.QT=R"!W13MNFSH
M&:CIGH&*,HA[*-5@(6+HPJ$[*+U-W=#](N\M&WK@%;_U^U$J.9]7V93G92D7
MY;5<C%@D24*UT8AQIL^O+";ZZ*HR;4.F25%PA M3(M2^5ODN(DXKUKU:>4L2
M+.AW0"NB9V JJQQMTV^HMAWH9#+[W60SNJWLG:#9+>E3H7!;RRL43)CV>8/"
M=8W"+RL4SH^BX+RL#XD9:#WO)#'H0CXDY/8*/OBL1_S+[5QR_3=]6)V<3\5%
M\^/=?*Q_YWR^-,9#N2BKT^M+IUA#%N6%*!3,,TKU<1 SO<:3 A):4)EE>1*A
MR#JNQ8^'GK?J#E.5LZ-E"U1\@8HQ.G&)>_"$VB*>H7\ W=1%%[OS/=A5QR_-
M%/BM9LLJ72P8J XQ!?V#ZQ<KT!O(;O[_T^ YZ-?W''HX?_UILF_XX4\<RL]H
MNYV;J.C%R^W$7%5.Q:INZ7JA)(6@@B8,YI)I$RZ1$E)&$Y@BPG."DZB03G6X
MCI/LV_W026=MF5F5S'0H0.R H9U%%Q895X5=TSX#%?5-/'K-Y[67.I"Y9T%P
M4.//'H!M4]#A3=^R-7111P!5+E)SBS2;FGNC\^_C<I1C3+,BP1#Q7)N ,960
MF$N:+$Z2B',E<D>/P"%J/2N%)NQA31/\9JBZ]A _B)?E-7LH%-P4@#, 'N5(
M+ 0+5GGD$*V!BXQ8B/VZGHC-2T'Z-OP\FRX>)B]?-,%1D6-%1!K!-"(Y1$)(
MB%'!(4F3)%4)HRJW"C<X3JKO:];=_1D>:P; 7'-P4I>!+F@6Q[-@4+BMZ3W=
M QK:X$M(%$[JK^")1M">"E:HG-I%88>@CIT3NB.\9;>$'9(<Z9"PZPT_L^1B
M0LOR1OU*C2=K<3.ODL(V?%&K/Y;-7\MXI*((B32+(27&9D%205SD*4P(B6/3
M5)-E3L&]7ESTK/=:>N#WU@5-&Q?TJJ#>D^'LM/ $/_SMS)_>4753H14[YJ38
MT-3?TSH']&S+J=]YIEP]M/]RT-EZ.@F70%:5'P^#6ELGP;1MA9TVF(=U5E_H
MZY-<IRO$2H4:?;I54"Q5*$$T2:$0&8.H8 )22F*8H!0544(XIE9=7WR(#WA+
M\W7Y]#2IS&$Z 1_HI-JVOS[(JGVUFLT?:^_3)[WL-C9UE[MY5^@MK+X> 753
M8C4CU1WQ1M/=-5B&&Y=;GM/Q<[ 7>\31SX*TPS.0$>DI_4&STG7,X0Q-3VDW
M3$_?,09.46MBK'ZJMH\VP*JJ^CY*>$(3'G&8Y;GIF8@19"SA,(I$A$D6QQ);
M%0WHD<>>U7\;4'MO*)]4DKB'Z;&\R'M;T-VVB)!%C6O&NP&Q%?/O(!'L.+)O
MG>UU@,/W%<#J#W&PO"T+4FXJ7<CQZ'*Z&"]>OC[2R>3#LAQ/]88QRA,D4AH+
M$\460T2+ C*.&(R2HB TB2/)K1J3[!F_;]=&11%4)$%+TTZ)[@/DL (,(*:C
M[\))0FMU<T2.':JBE/PO][/G'_6;M9;0/ZR5P[[Q!EG81X1I%^6QQ]P7U&>-
M[^3V83:5=:+P*(FS'!<B@W&,36,+I-=556XG92*.,U(DA9638=?@?;L5##E0
MT6O2GNW7T2L<CB^B4Z1S]!38"^:T?/9)X+5V7@TVV,+9)T9WU>Q]QKOL]=S<
M87R4];]7TR:3L/PBN1P_5S6=*5<B+3(%"8U--7\204KR"$9QDBE<)"F.4=N?
MY,ZI$/91VE;?Q<VV)'?N"ZZE"^8KPL[UL(_#:&?/!T/%MTIV117\T-+_L[&P
M5P!].0Z03\5L:XG#%<\^3G+H.MK6(.PHJ6W_KK<W?[-"XOETNJ03XV5KJ8]2
MIHJ48PYCQ%.(9$P@PUIK1$K(A*9Y$<?VU\1V-'O>B+6MS\VUW;W4BZ!9&'HU
M,/-OU5:25AR!'V@)J/%SF:<M;PY<D+6X!0Z/E^/6WKB[7Y4RK9FH_-V@92,\
M0LYQ 2&1.BU X#3$?$(%;&6WB!DX.M30P0.VLNV((K!^U4.%_C]TJDE,.Z7/
M9M/S^[FL;AZ:',LTH3&AE$$B<6Q*'^C#"LX5S+$LTC3.1:KL2V);$.Q9>38<
M@ T6P(H'!QU@ YZ%B@P,B9M^/(+&\4Q5/U@<]&)@>/R4HN^7QDT-.HAZ4 ?:
MC#.< G20:D/[N;SGZ;R2$_W7^Y_D5&M8DW=R+A['T['I!&UJ0%[6)?++5@]B
M+'(F*,R4UGZHB"7$+,4P%H7*LCQ-$%9.;BD7ZGW'&]2\G('[FILJ X)N\./H
M>'*"UNX(VAM@;BISA=5/':PV60$M+SUD^GNA$,JQXT1[6)>-#RROG#%>@_B$
M.BT7#[.Y:;]<5XW\-)M_6BZ6<UEURZS\.^W:0"1.48ISF&&60"20-L0XB;3:
MP3&-B,@IHO913M9T>U8X:T:JAL>J8J+I=4PK-ERB;^S1M+#'^L'(3<=TX&G*
MBE;A735*%1^UW]E"P9P$ETN<4B^P>88HV<(7*DK)6?;# 4KVPPT8F^0LXV98
MDOOK?D;=W5S;C761B//%[6P\75Q-[\:/LOE&FTAW$O,4%JK((,HE@92G4>77
MIIQ3H>R\V7;D>M:B'>* +D!%WMP$&@;<[+4CJ-D9:.&P<-.6AV#HP0*S$S.0
MR76$V* VEIW@VT:5Y5M^J[T)0&^^IE(5C FA(,]D#A&6%))4K_4(:5.)"J(B
MA5P6]\;H/:_EB]GCXVS:F$"_-W'U;HMX$PR[->LMHML2;1-(PJ_&G0($6GR;
M8P^ZUG:*M;VT=C_DMY(VKYEW-:(A>:%0;DH=%8GI.!VGQI$F8,240BE)(WTD
M<5E=1RGV'L_2-G?:;H[8-G9Z<5M_QR&T6Y-!@7%;IZ^\/CWUSG$6-="*/DYO
MT%5N+?[VRK=_T?-JE)I.]Y5M?C&;EF,AZPO8VG,OQ:V<5_LZY=7),(]S4L0R
M@111TY@Z59#FF821_C N,D03S)WN1IW(][XS=SAH8G&TI6GR1Q=K)ASO1]WP
MM;P@[0TUQQM2VF2N&4[.P"9^+3,F/![<6>#G?D/J!4.H*U(WXL/>D7H!\^J2
MU&\43SW4)$)J@N;:@&T'RG^1Y6(^Y@LIZGN$J=CZY-MTO"C/-2O/6CUN)Y#F
MA$:,$D@S%D&4* $)CB5,<,PCF3 >"[?^(CTRV[<#J)-PNF:JN2NKV*I;7LEY
ME7&JOVZP$F_?PZT0CEJQS]FVU*'O9 X=->ZNQ*1NQ\17TV1F<^?<G:WFKM?"
M9T/@'$JE]\GJL!O  *"_VBZ&H.E9_[%>*66SFUV5Y=)HMJK2Y"A77'*"(ZB(
MHA"A)(%84@Y%E,2"2")I%'M$EQ^B::4?3HXJ;TD"7I5&->ZWY52#]OM\O%C(
M*7A:LLF8ZXU R;D^8#B6@SP$J9T&/ADAOQ*0#=65W0I6.%64 Y9\M) O5+''
M0Z2&+?-H(?2K H\V[_B6ZV>+=<N[:_HH/\X>Z7@Z2I,$%Q'/(8ZP-#5%,FWG
M$ I)) D77)@*<2XFX3Y"/9MSAFRGB^49,)3!;S5MQ[*.>[&R6\XA$'!;RI["
M>Q3G/RQ9L +]>\@,7*3_L+"O"_4?>=ZK6/^,2RE*TX'YMMJE;II-ZEHN;M2&
M@KB=RR<Z%FW(3M74\J*^&EM5R*@^K'\;Q4CEB D!LS0RQ81,7F9$"OV?)$N2
M-)$JM@^SZ9'1GA5'RSDPWX!M4\#LC;SCIEIU AEOF!1G)BMELA3Z6#'6YD0M
M'Y"-@&=@5G74;>XI5TU%S(&D_DO]B5,1_/Z^%X>5W'N:;4=[IYUHPS6HV08M
MWW5SDQNU90.=@8;]57SC6=,>N1$!=&H#U7\X?T]SZ=3UX%W,J6]KA/<PMZY]
M%'H'_$BSA?[H#]F1H7<4M]HV]$_/.X-\]BA7E:1-?GJ50&!*D6.:F[:M*41I
MSB'2!WJ(<1Q!GN?Z4)\QE-D5#K2@U?-V75,&*]*@I>U5P/T09G;&?B DW+8R
M;Q!\4L*/B1<N$WPOI:$3P(^)O"/O^^@K?HNZV[Q3:XOKV92N/^DXG=KPY5PF
M69K2#(J$Q1"IC$&:Y^;71*5%;&[3G((]'>GW[I=>948]RXU2955&2N?W>K]>
M/-"-#+9GWQL!UVFPTQT]@NNF3X; U5GU>*(32!VY4A]417E"LZVV?(?QN,C8
MZ>&8BHYWM7+E[7JL65(\Y47.9 YI%%%S3QE!BF(%BU0J_3FB$ED%W(1AIV=%
M%\ A[7 "/7UR+.X,!H7<3?WM\^AOH?WAD/O?(ROI=-@=CO>#PN]WB \1A1$N
MVCHL:@=/XJ=3&>Z\'0R1C5-UN%'=]J9ROM"TG\>E_I[>J-OY>#:ORXI^D=PT
M QBK<6/*B_]<EHM./0>,HJC VM#F@IIC-4DA(U)O1SQFF*DHP\0JDLJ;@P%V
MH/9TN29MI]W\43V\CPR"E>O64;-3-Y?4#*UJ(&_S=-:!,:":.AF30_:R'KQC
M*^O?UG:R/]U!=-7)L+3JZ?2!_ [^NRHAK8+>?Z:+Y?QUO%^2"*;MXAR21"B(
MB-9.F"441JG$*8[B/!9.,>D>/ P8M'G^:"KKG9F<1^.I,V;"-_V=F"_T,73Q
M8IZXH.4#^#29_=XX][92/=RN 'PFQ.X:H&>8W13:WF)HG;28Q0PP"6[I6*NY
MEK]>0R=/0"C0=8 /!X->"9P T?:UP"E#>39XTPO5-,'6_Y@&F,]T8JXDMENX
M%YF,1*8BR!32ZBVA6M'%L811HM(T3@F.F%,Y(BNJ?=]H&A5E5%?U0X<-QPYM
M5@#:J:/@L#C>1>Y#Y PT+>U[:6WO)7VH/FM6-(?MJ^8"PZL^:DXO>SI&5N96
M>3<[%V)L;# Z,9O2U?2"/HT7=+(*HI1B,RP7XR1-D@+!B&-D"N2FD"K!(2U2
M)1@O$%;8(]+Y%)[^?Q )?=*46'I,^D;8KW;1FBMC&ZWYJFPD$Q+6L';6";26
MVGCJ*^ Z!$RA_"BGL#*L4R4 :*\\+"'&/#F?N6Y0T*2CE VI:3?;%N7:@I(L
M@9E,4H@H+2 C*H6"J"1/8X:*R"H6U(=XWT?&NAQ6.9N<TE7,!4P[5=871&ZJ
M:RMQN>:D^J"&K6:F*BW4<^*R-0CATY:/DWZKI&5K4 ZD+-N/X7EXT\I*CZX)
MOCIPL)CD E,&*3+U4R(J(969@"+)\XAPD@GJ%(VRGU3O@2?EHK[BG8DE7X O
M\EE.EXXW2 > LCR9!1'?\3C62/[3;"9J7]Q7.7\V#;#[/88=%374V6L_H6$/
M7$<%?G7*.OZ&WX)NOMSE*,<D2B(<PR)#9OD2O9 3KG_B)%%IG@ED?%PS;</8
M+=]V8*?%NAK>^BM[9UX!\X:8VQI=R5Z()%,\RR#-$(<HE>:RJ6 PQSQ+4EI@
M)#,7U>4ENT=]Q!"RVVDC'XF<G6N'Q7!6*]L\!U(BJV$'51G;PFPKB%=_]\T<
MK4L9WM'OG0;+6['M(YG&*LE,SXS$],R(.-;KA7$89RHG3+(T25:MR>Q6C!5=
MCVL3MP5UNY7,Y9I):H.=W7H+AX=GCFE3;U33WVR#OIU&$S+?U$'D8,FG-C0'
MSD1U@.%U6JK+RQZAG9=*25.K0M91\)J.Z=7S11KA-+7*.:[IC.=MO8NJ\G'M
MO1WE*$VBK$@@0RJ!**F:[O(8YC))8I(AD=FUF#B9DY[WY8:L;[WWDS ^K%X&
M1<Y-Y:RX DW"BU$]53>N3<[.0 MOM]+Y61,A,!3,#L&80\'M%X?9,^QN$9@A
MH#H8?'D2@>'B+D/@L!%R&61 ]VC+Y@;%1'<V%PEE4UPCHY1@)"B,459 %!?Z
M[!4G&<PB1%)5<!%GQ#:B<B^5GM5\>S^T<4_BE'%T&*/#JCR8Y&YJVDMHIP#'
MHT*=$,2X?^S! A6/BM<-1CS^\*EU)\^GB[$83Y9&.7R5W(3[:(OQ\GM=X<(D
M/IMJ9LMZ5[E1EW0^'4_ORULYKZZ8._&(#!<I5@4L!,,0T2R'A,<<)EQP6N"B
MB!.K%=T?BP.&*]XL%^5"+Q$34G<[6^A=>4PGDQ?PL1$#K.4 K2!UV.(%G?#E
MI,[OU0-5+^B_F:(&GV=E6965K<3R+3T9;,(M/5]O.HV._K%NP&F'VP.SM>;8
MO-3RO)ZE@8I,AL8V>&G)8 R^44')T #O+R,9G))W@8FM[N97TV>MQV9SS<V(
MT2A5D>!05%W;$"X@8T;CXRP16/""9S[5(P\2'2AHJB'H6-KW,%QVJO)TZ7WK
M2]0]UG]H"?_9A !T: >M,'%<Q' U)@[0&KK*Q'&Q=]29L'C)U^M72OV2"=S\
M*)_E9/9D;@Z:"\(F/8L6@L<B4C"-D#ZB$6[ZH2 ,,2^8*!+.4)&X.<6.TNS9
M0FLYJ XO8LV#J^?L.':V3K6@B+CZVSI@=,BW-_L]]#)RD#>8K^XXQ8'=>-80
MO/;PV;_JIQ7T(<.$<>M#Y_-8VQH?7KZ5)GK(J)W2)(<T5:JU^CEGIFDL7XQB
MDI B0SE4J60012*!),UBB+"*5)K+/,N=E(0["SWKC!5E0%>D_^JF,#Q@M=,?
M_8+EID[, ;5*XFBY >P%_& 8TL;$G\$:QC53X+>6K8 ZQA^30"K'@X%!-9 _
M0-L*Z821/#R/G\?<*+H;=35=R,E$\L623C3M)SE?O'Q[FDU_'D\TW=E4D^,/
M8ZTA1;,9$X*2(DXPI+DB$%%!(2L8@2RB7&2\B$1J7_O6FXV>]53#E[F%Z'(&
M6M8 !$O-'7A<L:<56LV?@\_,?Q(L_)*#0.NFU5I4;_:A:M@":[Y RYA/B1A_
M<!V\D8. [.>*] 8[D/?Q9&@.NA[]1Q_.[W@R AM.Q]-'\\P6-,[+._UN5=DS
M9FE,&8\A3S,!4:%_PE%$(%=)PA/*\]0M+'UC])Z5>D4+&&)>!4\W@;"S*;W%
M<U.L]I*YY\/MDB!4@MO&V,-FK.T2ZU4*VLZ'/)?1:1?13: ,CHM4DCR#L5Z(
M$.6,09:B!$K&,\%1$<?<Z8 8A*N^EZWF$:Z<1^7:>22_KQL'+!XDX)O./M$X
M^TS;@8EQ]ID>G%4*FW\R6YA9M-0=0\^-H\X)X](+%_/4"VZA-%T0GH;5D"%A
M?*59@P[N&;5A1OJPW6&N4]CUP\OZD::]5+4CF,(,BY=UOYJZ.OW= YW>/%4U
M7W\R?=;+JVE=[6K$*"<427U8)N96CV,,F2(%C%*>1S$N>$3<^AT/Q'C/>KTB
M)D_)+!YJ NWT]7N<%C>5WFT,VI5AHXPU>P$[&X@:2<Y +4NGH5;9K7O=R',&
M:HG,QEW+%#"*8^!9"!7;,13;PT9\##P9K^) AJ;OV5I4K\).JSR*<Y3$*8%Q
M@O2F@8L8$B9BF%$2I7&&LY0[G;$WA^\[C%?_=DH#P2TL[%2OOX1N"M)!./=.
MGSME"-7;<W/P8;MY[A3L5?_.W4]YN#:^2A/2\;>+V?19SA=C-I&W\R:1JXK&
M;ZL0<YJQE"50*)Y!I$_/D*2)A%F69D6*,J%2JZ.T \V^0V8K)L#?0(<-L.*C
MSC1QN$"WQ-'"%1$>'4>[Q@(8'Q>#)4(._H3P2/DY#\(@YN8P<)/]H'? <JCA
M7 %NLFW<^SN^ZAFKHF6@Y</:V3P5G\93.N7ZYZN%?%S'4BBE\CS+%(Q1C/6)
M%L60,J7_4^0TRSA-L6).(2JVE'M6GIH/:!C19Y*M$)47UP 5:RSMC)M>$')3
MH T+G;@3$^:VX@)4;/03@.(J?*BX$VNZPX:;N,+Q*LK$>8"3"N'4-WF=9E>=
MLU=]VZ?I;CP[K:C_.EX\7"S+Q>Q1[Y^%)%(?B"*8FJLSQ% *"<("4DXPP2CA
M)%<CK1S9S+&B3 CN7!9=ET?KM==A<#9MR]-X5:<),QE%*O4\F.HDIGE'(14D
M,A(0HPQ+%1.$W$(4WV@J3NN@]QXFPF[S>"-XW;:7AG#K,=K34.\,K#@%6V_4
MS(+?-;>@93=XY:.0&(8MGA2$L[>HOQ02TCTEG(*2\-T+NX4!;M2WZ5Q_<C\=
M_W=56N:#G$HU7I0K;FKOEG%VF7X<^H.[V>5W^CB>5H]_D8OE?%I^T3)]FLW-
M9>6(R2C)&!<PB>-<;Y %AC@6,4P*;9^G),.H<++)^V:X9T7=91<LZ'? &H9=
ME77/TV:KP=_/9+BJ]2[GQOV_,3.F-$K+?5>W-P* M02F,G@K0UU1I98"_&;D
M (T@05-KAL$\V#;0,[L#[PW#@/]ZPQB(KM\N<OGX-)F]2-E4KMCMVKJ>50<[
M*>J2,U5)R^[?3>'3Z]GB[W+Q927;>J3ZI6U7UPA%C"#"%4Q18OQ1.(*4)#'D
MA/%4I!0GJ56_OC>7I.=]YU*?J!]-HC18=O5<%=O0M-[D7:]Z4Q>Q"H!XD73N
M&O_P=M\(NYWK#S'/CIZ$79$/W2/*2IQ50,1J7ZN9.ZL:5NCG%GK.%V M5/A
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M]?[[6),'/] 24.-#YUH G]K\0TRNI7_E'4Z9HT/F]"K\G2:C'6G.@)$'&(%
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M_/MTS6>.P6#K3FIV [V>Y$H0K0D"*#<%P#(O@-!NDYUC76HJC X[UCTO:NB
M9B]XOS=V9#,WV5Q[[J@\\/*<Z$E0")SC'0!V6Y(W-0"?>@ (G]P7;4LUK\\+
M&G=*7S3X:#9??B)N(O_*5]/5G;F5TF5"VXU"DSKR//NH0B07W'"@,50 6Z<"
M!"L+H J4,R8D%2*(O\I/[, 3O%;"1;Z?[8>V>_RP>>T)G]\<3P]*V'S?X;'7
M8)RDKC##$SD#3Z&C.H8P()X[B<"GATD&^V3EW/^A9S_T7ZVC^K::*%)5=CO
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M-H03E!<%UE@!4Y848"HA$!7!0%:YE C"G/$@WH@+\@;VUKLX:MDD7086BUW
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M;(74*?,+TUSCU"6&[E_3[5]<X>&J;G._JE4+O=7Q0]?SCB8Y9H$W+O5-5Z-
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MFB<QF$<W0ZG'CRSJF?'5ZL[\G3M.HO7=\LOTX=OZ[<*57TY<E4X!\Q+ 2FN
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M$21U:+?0Z-!MDQ5XP>\%G9^32 Y(F)/88K&3[U+RG>SL]_:_PW0."[$Z55Z
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MK>7>9'-]_OP\!C M55GQPK4\=>V1D1'6U1H,\IR1$FK"% RZ34X(6.PMRK"
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MVT9NT)O[%#"E"A2N467<L"(!:$=!2(HQX]SF;_.E'?QA[F@*K;0V'VHU,:K
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M).L)Q;FFL;Z/)VP0VVZT5V\WVO%BO[??L0G&LI(5)*"L4 XP-24059D#2)5
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M)%LVFF1VZ,>Z+,/U)/:MR@@ UL/Y)H<KS.=ND=I?V[2)EXT.6:M$YK1(#D^
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M#^9%R0NC@-9* 9Q;ST(9S('4I90E+2%70?5I9R4-[#XZ<K.%%9PYR<&%)F=
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M4,(R!P7A%<"5L;&44:[72\Y4@0I<,12T4SHC:.CP:2<V:^3&%TB=0\ISIY+
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MLK);$H4E(8+D& :5TP^HZ\#NKRNX4VX0E5DYY!OS\YVOY#V$N=?(5Q#L1$<
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M">Z==R1FX,B@CJ;:YNBR(S:%B[_*([]88-^P[O/5M_1A0[^E@_JIU^!6PKQ
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MT<.WMKE ]Z5:V-C!,="JQG* ZW3*-H3$]!6<K^0;.9=JNIY4G&.<80F$A!6
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M=T4<4JA@*=(<%+2HS'E<+V"<YR"EE".<2ZG<LACMR$9>S?NE-)Y:)ZE_ /P
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MMAMR+/,,:FF)5_7)'0VG)>J>(U\?<PWFW26!?_'H'BZ\)+S$,@.2,U-]LH2
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M G/3JC^<ME+HWZYL*U$%F!4+ V<TK-VTRC[,'6.'*1OZ&)/TN4L:]I*.O]&
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M"(J2P(P+* IA5>,J'$N1]Q1-/]$,U"K&! #QI133=3+;<N'@A \S!</[Q,L
MZ[8#;-GKTD5-:%'=0G>?Q9NDC_ZVQ%:RX_0F:7@=?1(<XB=&GPR_J(L1)\4M
M9B,H?H.1'F$HC1<?$A29O:B2L"-[5#5M*SA^G:_TACA54RDZ1R:K4BHYU=/'
M(("4,$"X4( 4J2A2C DJK8+2!JG$OAC=5O]T\E<. S.\+003U]'6MY;4K=+I
M)4FNJ79Z=NSQ*IY>$F^OZNG%AU_F,N-6:#M)_T!G[Z8K/ENL-LM>1D*>E2G3
M_P=Y;4<*I0#+]*IF2A A5($E'_4&8Y#;R.K@J [89VGFS^3]=<[C#9WI#5;)
M9#I/_EW2I6/P>=RY'.?B(M@,O=QMQ4Z$I"=#E"284=!^)7<2P[S^I2XBK& /
M??M@1_3<+M+_SG[4/_VO_])]HO\PW:G^UW_Y?U!+ P04    "  1AY98&,DM
MKF_.  "W> D %0   &-D='@M,C R,S$R,S%?<')E+GAM;.R]6W-;.9(N^CZ_
MHDZ?UX,NW"\3,[-#EN7:BG%);DGNGCXO#%P2-O=0I(>D7/;\^IT@)5EWD5Q8
M6I![(KI=LB03>?F0R 3R\B__Z]OYY)>O,%^,9]-__1/[,_W3+S"-LS2>?OK7
M/WT\>T?LG_[7O_W3/_W+_T/(?[PY>?_+VUF\.(?I\I?].?@EI%_^&"\__[+\
M#+_\;3;_S_%7_\N'B5_FV?R<D'];_;/]V9?O\_&GS\M?..7RZM>N?CK_Y^R5
MHXD#D50X_(-2$E(V1.6@G&%44Q[_OT__G*C1TFA!(M.12!4=L1P4L318"_@1
M5(K5AT[&T__\Y_)'\ OX!=F;+E9__=<_?5XNO_SSK[_^\<<??_X6YI,_S^:?
M?N64BE^O?OM/E[_^[=[O_R%6O\V<<[^N?GK]JXOQ0[^('\M^_8_?WY_&SW#N
MR7BZ6/II+ LLQO^\6'WS_2SZY4KJS]+URZ._4?Y&KGZ-E&\1QHE@?_ZV2'_Z
MMW_ZY9>U..:S"9Q _J7\]^/)X?62<9S\W/\YSLY_+3_Z=7^&4$ B5_]H^?T+
M_.N?%N/S+Q.X^M[G.>1__5-,RV^X&!>,KY?Z?]?_\-<?*WZ9PP)ALN+P/7[C
M\M^75;99';XM89I@S<O59T]F\=8O38HD9]?_<N(#3%;?'248CU:?NA<6R[F/
MRQ%%J#&3.5&0$I&"!>*9ED1'XRF'K%7,MYDMQ"Z0VI7@%Q#__&GV]5?\X%^+
M ,H7*TFLI'!ON;5$=J/[:J>=X>^.J&&,6AX) )6(?H&;!(0D)D)4DE&3J.I$
M]LW5;E-]4Y-[\_C+;)Y@CJ;B:CD_C[>T>A^DE[_QZQ<_QP\B\?-XDJ[^=9[/
MSFOH:CFK(+FU6I#</_V"7&>8SR&]7VOE4>96G"W1@,+J-VMH?&\ZO?"3$_@R
MFR]'5D5M6/#$NZ2(U(H13Z,D0F9%J:%.QCJ:O[GJ1@C@[2-@9TDV@H0/,!_/
MTL$TO<6S=A2,#-D@ R(;/"X5RL4*)XB,GANC+,V\F^UZ<-F-L"#:Q\+NLAP8
M#/L7\R*I=^-%])._@Y]?\1#1H@GTCX@+'GD(0A%O7"#.6:E##D)ZT^TL>V3E
MC2 AVX5$%8DV8B+.YGZZ&!?97YHYI#QFAHZ@XXH2"4P3SX4FW*M@J $1)*OC
M*MQ9>2-4J'91446B Z/B8+H<+[^_&T_@Z.(\P'P4E74B*(P)$+\876'$Y!D/
M^)5*X+UDPM!.:+B[XD8HT.VBH),$F]#^"7P:%R%,ET?^'&V:M#K2G$@6%@5A
MG2?!!DI$5"E1&AT#5P$!MU?=" 6F=11TD&032#B<QMD<3=A*\*<H?]B?74R7
M\^_[LP0CY2U0GM !CMGC81<%"=HQHDP,(7$AM. 5@/$D$1OAQ+:.DWIR;@(V
M9_[;84+QC?-X?45U:0DIMQ@N"T8<^LCH,WM%G, 3403K(K@H?/85 //(\AM!
MQ;4.E1JR;0(D>RFA"A:7_WD_G@(;*>U],-$0@') 0L2@RC-!DM.6<A,$4%L!
M( \LO=F5%6T='5V%VB@R^,AS&F36Z$0%*/!FCE@T?00,,$$#Q6!<]((,OADR
M&K[-K"/4EI"QCU\>S\]F?TQ''#&=3<HD"(>AE>-H %6YAN%)"<5-S@#U</%C
MX<U0T? -9PV!MH2)E==T//\PGWT=3R,Z3490HU@FWICB-*'7'91B1%!KF'34
M"Q7K >/.ZINAH^$[SVJB;0DB'V:+I9_\_^,O*Z_:&*X3]^45F&)8K@-'H!?_
MR:6<'7 0J:*O<6OMS>#1\/UG);$.?2]>>)B#7]'M!=<9W622O44OB2M)G+%
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M4<+6;CHS[ R^&YOD>HW;5. ZXXB$K#81GL%WOO-Q.D9JXG+\%??MG>@@&A$
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M_5:7>P@9>WE0&Q3\NB+C4)EW<%Q=,_'/^>*_W\S>+^8)E\M)J9[2D,.U6*?
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MCW>'2KI#M&RN?K4).:;,0;/$Z5"U$EQA 4R1QG$5*(YOG>/?3\FXB#E<PT]
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M!+]2T<D!=9AZ[WJ<PV0]=L;^D5)%7/Z?%_,9!?VK*9G0^RLR;GM1)8W/WG%
MXQ H940(4@>PF3M7MTS'?.>F^X&4?;O/&Q<HAZIT/JQ\>W POQZS7$J/J"DI
M+/2'""2JG!08'YEWCA)';%T;NU\P,U@"U0@U;43< T8NY?'/NF)GMGJW^##]
M_.6RZ21S@X+G DIG55L8!3BA&6B1$D5W.OK2?";K0\2,6P$Y5"331O:]@FAC
M72+*%+BS8(K%.O2Z-MGS#)GL1"=/Z4(8**2YCYPNCJQ#%;X-C/:0_MA!SBU?
MNN'E>CJQH/P0"Z02(M2%Q1"2R< -"X)Y9=.68<U#G] A*O;1W[RU,$=$Q'*Q
MFGP(L\^7_2LQ"%T\4:D]Q5QTJ$IPQA:HI;U)&,XLBFV<"/W66PZ$_G;C/'[Z
MP''G[K8^;_:790\ V.!6<.92I&B*%UGG.#D)WBL!F8GL@]&6V:U:_[:!P)A>
MX0!EW57W'I(;6>'_Q.K[,)]1&A:N&5 ,+48CR&516*Y$G3&=K029BA:::Q&V
M6[?TA.KO_?"10;"/"N<MY=E/=+GVA;]?UUQ+QB(/)4#6L39&FP2>UQ8D85RT
M.7)?6M=AW4O(5@ QIW)4M)-Y!\"Y_0!_49%/?_E"8EV^62XO,+^9W7J0GRAM
M,_>L@$LE@?+90.#>4H3DBM4ZBIA:I[N[T-=%B'H('!ZI[FNJF[YP]V(^6TY)
M-VM-?<"$T^^8W_W$7+ 4RV=10.LZ2S<+!LX+!]K5C5"4]PG1NF!F)P+[N:]K
MCKS&VAD[@7Z8LYI+3F>??V;->532%P_2TA]*,1*BHO BZ,2%ME)G?\?C/?1:
ML-/GCOLJV0Y/0XN\+T?V?C%-^!X7:R<]R2P$&:, CKK6B11+\D(&QF7B0:*(
MQ0SGLWZB9=RKX4'=T_XR[PL[][I9XNLG/^L"BI1T#59KS2)Q%W/18+WPRCKM
M,0V(J"TH'/=*Z/C'X 'ZZ0!]/S_?7D:69Q>K+_/%]'\Q3S &Z7,R$*V@?%II
M$IQG&6(01AMK4.;VRY@>HVC<++(]NAK*OSLTO0^+=XO+80#_".<7-QX:,W?)
M&[VN6@,5/"4LCEC#K*W5PEEI6@^\W(ZRK=!E3Q5=3?31<#K_(66%Q,YE OSR
MHC:'$"O3>;XTG\OBE"4I[5VY5:CR$1/]Z&J*RTF2)=<+84A8QT1FU)0P6P;%
M.,T$MSJ%K5Y)=JH]/(3BK7#I3@>71]1?!U[QP6JIVQ<Y?_\VG]UP/N%U8*6U
M#GRL=;[<$8O>9] 4O>J$3AK1^N#=@\RM<.E/!Y=#:VKLBX^'Z_;"OZ9?+[Z^
M^W-&'_1E^NUF>,_K^?GY_$\RT5LLI\Q5THI#?0,')6U=8^H=H#5&.^,=6>"6
M=08MZ-GNRI?U#\.Q=-2%C[PNP_@E"%;6!E<84@9/6;WBV=1AO!:*]))"$U%$
M:GWQ^P@YVZ'MA%X86HE^;.=V]3SRC_D*EZ]FJ^GJ?%T?_WJ^>!72ES5O_X'G
M>1*49TS53<DLQCJ%*H(7T@%)27,G4PIENQ$!VW[B=I Y@:>!X>0\-GAN&<'+
MZ?=IQEE>OB'U+# LEN\6+[&$B_/5Q!>%F24+BM6G8E$\!*X<T"FO2(ZB!.:W
M//FV^;SM@',J;P #R+B'D^N^JL1W%ZOE*LPRG<D3(1D=QLF#EZ(.I:?8T/F,
M(#(3%#/*A,WG4CY%TW:X.J''@*9*Z!54K_Y%$=]TB>OGCNMO+C??7?*)=T**
M:B\QKZ>7BT1&DQR002FME4&;6]^K[47H=O [H3>"X=4U^OEX/X??ID3'1 OM
MT/-8EQ&3<:F0Z: GCTTV);-UC"NEMSL5'_F4[4!S E?_;>79Q7WL%;;/9OD2
MW+==+SE7$?1:,E@S4:G!!TO<H W6:J/4W8E<!WNEQ^C9#D<G=,G?3/BG, SW
MX\77KV'Q8UYN!9,?Z&,6W\DXYHO7%ZN+!=9[NC!+V'1([EZ?W'QX[N'\#S-4
ME\F@G,H%7(SUH9+7^OM > Z$$B=8-.QTA^J6F$P).4+T1H"*I5[V"@V85) Y
M>XG-%_2=RE#=7?2^RU#=743>0;Q^]F=8Y.NEIDRD.GK!@L%(Y[<DSQM-O0)A
M)13+2[2E]6R3GPCH=WCN3FJ=MY)Q!P!9WXK]%I:X'H>)L^5&'8O:O%)OSY:_
M_;CYF??AQWJG8>7XANU9?G\>9K?6W3D?HBK"@BNNCM.W&IRV9(:&V9Q<3$*T
M=KI#\#$N7 ^ U5U_-K:..\#YSSVT4J#%VCL5; J4X1H+G@@'Z9TWF1G+3>MB
MQ8[ZE<?'P_V9PA[*&?OZ8<NY,V2\+*!FX',6]=$S4MXC259*9)X*>JW%4Y%_
MZ[D^PXVX[ 5>0VFH W>V*?N]$6\5UU5WJ#4RD%B("U;G41!3D:4ZZ8@%&T7,
MG/'6I^_#Y(P\PZX7++96W*C7:Y=CL:]?XR]?YU]?9?F7 ]^J^)8;QKA(Z!ER
M*+XNE PH(11%MA:+#5CKB"7;ROUM_YDC#QSJ!79#:JH#-_CJZ[?S^0_$VY[<
M!:FCDQP<+Z%:4;UCK'LKLK%9AI@S;^W^[B%CY $DO>"OE:(ZP-K]%^31,::0
M>W#!&&)">H@H(Z0091:!J1A:[R;:?XK!*%/-#[E:.5SF/0#GYD;\1?@V787S
M2S=\=3W^^N[U^(3SJ())#E!*4[M,!3@6"V ),96<"KGAX0H+MR.RQWD&.P'C
MX6K# ;34WQ/6Y;/-F[<O7KW]].8?K][_?O;V8^N-CCM_QH'/4H?QU.@!ZN5T
MF<[G2T)*;1.Y.7T_X'GM<'HQ7ZZ6:VC%6V?O\OKA(EKGT9M QR#6 1FIU!X[
M K+5N9Z7VI2MQF3M8/N'4=SP@6OOJ.7RI.$N2O2!U:*$" KKVC(=-3!7H@@)
M5;Z[\*CE<]AAQ(^\Z?MXF'WDL>V(ZN\@++B*KM?7^T*K$#0GLF4=D).T@A@P
M0&+%T3\[KEWKN<ZW/[^;A[EC0N!N3^J^^N@(2YM,K1#5QJ  IABQD(.%P+$
MA2BHN>"H3&M'V-/+V?Z:?  2>XAU[(>)3W_./WV97RS#+'_ZDV3VX\TL7Z2U
M#;V9U?:LZ7>L[)W5[U__Z.MI62'.+FLI?OJY3<Y>ZR:4C1YX(+-2CG,(63-
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M#\:!KFX!N4-IF^\0VIG*$[V 'Q#KPRKZT"K3+ES_K>O ZU);SNGP8RZ"DR&
MRL+25R4!LS&Y4&)DHIM2TH?9.-'+Z'Y=_Z%0>1;V\FO$6-_'4O(US^.&7$:=
MD"^<A:211:8""CW(_M&C)Q;]7=[V:RN'P>34"Z9_>FT^F]7MQ5A'RWR:UW^Z
M1S;2%DG_#R76R^;B- 16'YR"4)ESYK/MIH)J1][&34!.^!YK$/#TD'T<*)=-
MK%I'Y6P$D!5J;HEM0]$KJ+KP-5@G04:4*JF4H^^F"/DA)L;-74[83 Z#PS.P
MAUL.X<ZKYE56M]X*7@.#L@D,+&?%>(^ JE8U14T20A10LHV! EG*^GJ[VMJ=
MRW'3GQ.VJ($!]=<QN0F/QD;O'3#G3$T.,WB-'##[P%,I5JMN-F_OQMJS>8@9
M!.'C&.1.<#N=IYL'IR5N4]W_LX",5%8P@R#0B#I9D8-+20)7#+G1Q1=W]$"Q
M'7O/YJFG"YL<"7:G<#H^)9HK[K>3CE?18=VD'KFEI-6'S6:6Y# ([8OA4?9F
ME#MQ^&R>I4["+H<#WW,PS7N>,!Z5CTO!($D!HN8(JF0-H22DM$3%Y$Q0)AP]
M4VS,X[-Y)CL)\QP2@*=@H(U"?6.\-%PS4 +ICT!^RPLAP"J46432H7G.F>4I
MO,1U88XCP.TO\W;WJ,24\JDXK:'$I&O_BP87/8?$$P;%1"RJMSKTPS@>UVY/
M^+KUB$![!@?DK>>>1\6"7&?C@@.1$WDLKR,X@062*DQ+KP/ZHV>5;5C;RM#,
MOPWM*-!Y!A9UEO.T?A'.;W1[:_TBYNA2C)!3I.A$)8K$0Z)\.4H1.-?1--\=
M."A#6UF/_;?U# B37FPF/BV,N'/<_ 'KMC+Z]Q?SV5HT%^'\$RZ^BHF0$B./
M&B2O T-CMN"*%^!E*<FH()G!(2SIN&R>]L-@0Y#?9WX=(ZZ?.58'"&GG4/HA
MV?$)#]$:;PM867AM@S,0;.10L*3$E!(B#;+GJPON3_LEL5\C'@F?S^# ?3AV
M?UA$AK29:R^>]88RXSK QZ=8( NO&7G#'(9YNS@NFZ?]NMBOK0Z-N+'7'7^:
MK\+YV>?/BW5OT1OB9#I;3M-Z^,V[V\-3+BL=B/OK+,1EG80JH).B+,3)VE:2
M*#\65AAIG!'ISHS'!]8<[TW"5IAWSRB).Z+&>CDLVKQJ_"RE"5/)LZ096,4B
M*,8S!<.) F0G$\J2HP^]-78^R,PXF=8QD3C<8]<!L'@&]O%T&/J ;B<^6^%S
MD,"]]:!0U*4G7$ N+"I=,LO=M7KNS>PX2= )V]=Q8-6+_;4)+7\6!)]DXY+G
M:,&DNN2+1U$+7SRY(Y4IM:-X=YBZCD&X&2<U&=N"Q@=&,Q,YSBC*W\Y#^N^/
MZ0O]X/)2$/4=CMS%'_.,YV?+Y<772_$,-:!R9P*&'%MYF#0Z&6:IE,S6$UB-
MEZ"B*!"2UY YY3Z2LG>O6H?9(P^S3%\P7YQ7U[)W@>2G:O:3P&7*/--1:#4=
MA<QJ\!@,'8HH8D&C;?M=*JV(/^V1E3M@]A>_/XKZ.XB$WI^'V=OP%<_^-5U.
M6!;"(5&L6:X#/NK68(49<D@:B2F;>>LGD]N?/_++XS@0F#?21T=8>CFOUZL3
MB5B7?7IPPJDZ,\;7.90,/%$?G2O*Z-:]>C]3,"Z>]M?D Y#80ZRC7U'_.?_T
M97ZQI.3QTY\DLQ]O9ODBK6WHS2S1G]/O6-D[J]^__M'7T[)"G%W-@K_U<W_@
M>CY$U)$5413$(LG :CP=D'/"@^-:9Q2NE*?BR0'IZP-W^\!EWI?N.H+O%5^4
MJLQ_(*[SS_<7B_2%CH!;W/&28E9"@Y5)5H<?(/+D(+.4A4\>&?I=D;G=1X_[
MXC\ Z :0^(AX6BY6DP\U?E@?![ID&9AD@*EV8SB=P5LZ'8)@V>G@DC1;'8WT
M6V\=B_2WFR/QIP\<N1QDU,AJ?\GW )<-RIT7+'GIP C':XN1K/.)%6@MI<.4
MG+5;1>;; &;,0^P 9=U5]QZ2&UGA?TQGTZ\77S>$FR LDT77Z;W$/)/DV!RS
M8+-7')ES*+?J?WA"Y3]]Z,A*WT=E\Q;R&UOQX5^W")<Z8++,0V&4(2A%QUI=
MQ0Y91NWH#_0JM%#\[0\=YX!HIOB]Y==!UKSWH]WOTQF^6>%7RBZY<L5F50=&
MDMRR#> P%A Q,AU82!B[Z26^IGKDLK<N;GN.K/M31OOU7K=;#R@?ILO_?KW
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M;70^'UH!8U=@_%&WKW_[$A9?PQ^8IRF<OYA__19F5ZZ7L:(""0F2LKF.SA%
MAWX$ASH7R7))?+N=($]\T'@@&4BO\X&$/#9@_I,<,NGF_9J;A!>KRL[RS2Q=
M+9Q51B#G#EB=Z*'HW(80' -ME!+*E/I<MA5@GOB@<0ZV(P&FI9#'!LP?2/^\
M"I^^X")\6[-RBY&Z?)'.\P26!<HGC"+01PH44Z*_IZ*E%=M5RC_V*>.\ A[+
MM[02[\CQS?O%/%^DU;O%1UQ\GZ;+LSHI)HUG""&R4ML.&00,')*+-BG-=+@9
M)'9 *'/?9X_[=-Q1X'RP8OH 5I77AH/EQN92"))GJP"MJC;G>6TI-(!*.$\.
MU@:?VZ'K5P+&BWD.U^FO #E0P&,?4X\N$?[[M_EL;5%$U[NR^=&KX(T770JG
MN$VB)!\K.$3#-*3,I-4E9K]E=?&^%(P.HT,UO_4NYU9JZ!YKU^N*EYM]Q7G#
MI<MDB(I+,%$2JZ[D6N:/P(R2P6#ACFVW &IO$L:+N\= 6Q-%C VW%_2O-8%X
MN;CX_/'BV[?SJ[Q3>VZCKS>TM:Y1E2(@E**@&*]D%))"Q2UWVCWP">-%W@.
MI8D8>WC%F/\(Y]=WZ](I62AGI&,>:V45)HAH,Y3,4M#66L&:3]^Y3< X]6GM
M(7*X=,=V$Q](]/3I7T@>+\G3G<^_U43B2C17@V!R0%5R!JUD'>-N$GAI$Z!W
M/F8K8L[;'4#;?-HXO1X#N8_FXAT;+U?^\-(7WF'$U4S"! %)9F)$2 '.:9*:
MU$G;J)GEV]7$/O8IXZPL&_AX.5B<'1PQ5].>;X+UO\WG^>=TDV,2PM58/;M
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M"P806%=Q(7WE"G> #HWU]8HBM"XY;<I OX\\NZ#N02]^=!UW$+&^*A1$U1J
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M^M4?UUAC\1WKX-6SE!87X7RY[AQ8O\I\^A)N-UY.T&AIL[=@1 V&D\P0M&.
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M"/O5O]+YQ8UFEN]Q0=*O.JO!=/A*;F6]MP17%XO9\L/\_/SU9=@]X6B99L&
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M<_/SQRWX:H^3O7G; 2[>+?(WG*;-?CIZ7-]>?,F+6SR:.":3)C>A[F]%4*1
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MPP&H >M[P1">_SY??,2_\G+E.GS\@K/7LSC_FE=?NSI9L4&AY'0H4=>>YR+
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M,M&;+-H/!SZ]]28<-2?%Q$%[TAV*\0R.#&AZ!=$1@TJ((;8V"OYFZTUVP>$
MZTUVD7 'ELCCHX831Q\QL6I-Q3IJF('G@4&4ILC@-+U[?0W[[GD%RDZHV'K8
M]RXBZ@!K#TPKQNA35-)#XKGN!&$< ME2P+-#Y$R5:%K[W*<S['LG\3X_['L7
M7H]=G;3E,&H7L?!B Y#3&$ )J\ 'HZ%(ET/1W*F[FQM_K6'?.XETCV'?N_"W
M P5S6%^U%*2;>?&0F3>@DC%51[L:X)3:RQ"8:AVP&7[8=\\;, YY%(\GZ@YP
M??MNOL/%V\7JU4BK7 \=^<,7DMF$\Z!7V4#KZ950R6GP0BN0TFAA%/=&MMZ=
MN!UEISP<?">H/)G!;2*W+G)UM\^U.L3R[/+BRWPQ_7=.$\<22J\M<)[I7MN(
MY(L9":B4<\&F8OFP.+Q+T2E/^VB'OX/DU)T67)_F]7)Y22?!B-J0UP_115_[
M;#.$$"0X3"$);J+*K</ECU,S;D:X+[3M(9].D?;V\H+X-:N%\A-GD](HR!,3
MLH!R0@,&%< $*Z5 QC6V'JGW#$GCIHG[PMR^DNH >#<*+!ZU%DS*KC"'P*W(
MI+6S =29D_>7+$^R*)-;OZY;D#5NHGD\ +:66%\@O&<R1.9)6WL/-<1.]REG
M0&0!@K0B.<ME:IZ_>(*<<:N'NP#=01+J$6P;BR&GP'2=W"Q-=*#0T8$<\<@&
MK6W)WF?>?(_,PZ2,6_?0$<CVD$R/ +MI'LCB7<@N0)1UYCB& "[5[9H)6922
MZ<(&5V>[6G&#]4EW!+5]9?2+UMS\3!'-RZ93DKZ)M47I*U'XA?[^]'M>3Y[Z
M8[Z\KAD9NP#G4+I[J,9IRON12G-D<"((F\#*7-,X,=1=&0;("3+&>KJ@S3M0
M3Z\TQQC'C=0<F)5U5YH1$'A1@()'HW@N4K6>E/%W*\W9!8<#E.;L(N$1+9?E
MXF)R@_95*8!'E)PI!B:G6M_,,_CD,["@G,G.)QG$-N"DGWT#F/1OUZ!\X&-/
MONQF)XG/V["_'^1<;00O+@45R!X+=48@UPA!&4V25XQQ47Q.6S7\;H^=,<MJ
M#A;?PS#8@Y<C ^%#S#.D^_%ND;]/YY?+\Q_O\[<YZ>NT*>XH03)7IY'6+0-D
M6!L'WI0$T4;M!>H8L04NGJ.C"YCL(][Y0+P>78%\GRZ)^V_+#1W[/L=:?30M
MT[@6S4^=NSE@%H:74,<UUNYD9<A5\])S<-YSD^KZ=K[51K-GE<P>Q(V3_FV+
ML.&ETD&LYK (A+*RI%08E(*DY9.,X)%+0!:%"<%;5EH'<_[>]5O[6%?'%W4'
MN-Y,5KM>&B3([9':U<;6NK@EH  TQ$B;@M9191MBZ]5)=VDXY9JLG<1_K_?X
M %GT@Z46$_TF1:)*V41(.M'YBPJU?%A!G21B4TG!-)\FVY#\<1%\&(X>!N71
MA=I%->$S!_IY\+HMC?Y)'_&OB3*!8["V+E' 6IA.)HZW!F24)GM1-%E20R)W
M.S+'?>&'0^@ 0NI'L]945HHFB;I;34>RT4T ]&2C>QDR_1[HU6G="'#UV>/6
M#@Z!F-W8V0$,?LXBW:P?O^8&*]P[R8@'+I4ZLT*!Y]%#E E#(EX%UWIK]Z/$
MG'))\R'F6QOI] 2S%_/E:M[DU8$F)6OG58B@L0XE)W8 UJ&33-!=D4YQWWPY
M_*/$C&MC-1+V8Q ZB/,=0(@N5R8"OM 17I*R/9]_6QN*J]-,I.$FH^4@G;1U
M@8H'QPR'1*=@&3,KKG4XY$F"QM58PT"IG00Z@-.'?$[?^OP?>4:L.J<CG:6O
MT]FTLJGZ(E>G,L5@<N1::!]UK<<1X$5DX)PH 8ET:YK/C]V*LG%MIV$ -H!,
M.D#:/5Y-&!<^,R2GE=6=QH&3Y@U.@Y-*NJ2\-GRP_4@[O76#]5 ,_-;MQ>F>
MH')=8C7Q]$$^23(=-1)#)/WB,D<H+"E+3B=C8; E#==DG'*;5Q,+?$^)= "J
M-_/9_/8I-M?CYYWCSGM)1-=U0'0J3PK5\5"G*[C@BPO%J=;#;YXEZI1[O X!
M7%MI=0"_US/Z6<2E6X>Y><HW^6*2HN129%+,HH9>"J_#7PR"H)>>)V*98:UK
M-K>A:UR'L#$4Y@/+I8OP^FHU\:.,F\@H&,_5W0U.@(K%@(^Q@$V%5+C74OG6
M.'N:HG']Q&$1UE 67>BQ*P/@*BTPG5W2H:[KY'_+9;[(-W9BO_J+F$@RG,YP
M\6/U--0=3S6A,%\Y.E=7<))\=E:+!,;:6','M4I8D>\L U.R>!YTZQC\@,<Y
MY>[80Y[N7A#2S66A(VXN^V_DTI?IQ41'QK10!43)Q%[G:XI%(*1J16NK YK6
MHRL>(>64NVD/!^EADMD=8'X-L%G^7+N,/K;S;?+%#<=,*JT]DPK0^U@7-"+X
M0#?%)JU+L4HQWSJ7<(N 4VZ>/<AGV5L*7=B,#S2WT8G>EE567^=L(YF]=?(@
M78N@(0191P>AX9JA=*SU\),GR#GEEME# -9*0AV\C)]FJ0:TI^'RXGHE2+TW
M9^>K_YBTX_P=+BZF<?IM931_R/%RL9K2_QLNIW%B76;6) 2#=;I0E!F<B0JJ
MCO:)F,B:3T0YE.:M8.M_/=@>5=:'/LICH_OE]+S^1Y/ >$F>C-R40P+%Z!>O
MM8.(G#O+E2NVM2]T.-7;!8K8_T#\0(%W ?);YL[9=YR>UP:!C_,;@QTVBU36
MM]AYE^@=0F"VU&B')=9FZT&7X'WA+.C4VH;8D<3MX/L+UL</*<H.C(VK"WDU
MG&M]".(.V>%"@H_2@;*>06!TX;3%("SCT=C6&<4'"=D.=;]@6=_A8ND06U?J
MW''%Z!P>.#>EEI7E.C&)@14B80RR^-@ZQ/X(*=OAZQ=,6K<030<(^V>>?OY2
MET&1LX^?\YO+VN7YMMP;FK11S5*33N8&O*G5URX;<"IQR!DU,[6>4;5N[]F)
MP.W0^ MFM(<38[\8W=RX^_.],C)I$G%.V5#+FWP"M": E-)K19H_-Z_FV9'$
M[7#Z"Z9OAA3EKS^J[04NO_Q^/O^SRWELCQ/7V="U+;DXTF2UD'-VDAP?G54M
MO"T< A8/268ODB5'G?_/TL-00N'(+$CM204%*<#5.F5N,H\*@^:J=7SV[S99
M;1<<#C!9;1<)CS[>YO9LJ"B5LD+7D=RL+@WV]#[FDB!HP;Q@.J?M*CW_9I/5
M=I+X$Y/5=F%_/\BY6K^FDC9%<#!.R[IPFBQSF2)H@<%K'K.46W4MG.YDM9W$
M]^1DM5UXV?MD-18R8]IP8*8N-A/(R.9VQ)J2R!0VWKGM'.]?:++:3N+=9;+:
M+KP>78'L,\,+<_%.80+RWPQQSEE )31$;H)@#DG7;M7'^:M/5ML78<-+I8.@
MS&$Q!!VETUIS\)9E4)([\NLU@A$N2.^,SZ:UE_/WGJRVCW5U?%%W@.LW^:(&
M"-XMYM^GY/W_]N/3,J?7LY\]:F?$@^^KW/I/5RD5KD-4!:)GI"<B.GHP8B16
MFQB*C4DTKZ;8G<I3GLZV$X3N9Y^'E&<?B+W9.)D4U]DDJ"-R0!FC 7D0P +G
M7KM@@AJT$&+D=JZ!I?UD4>XNK.\ -S=NW<<YF2?S69R>YUM'^CC?E9M,8*V;
MTZ!+O:K697 Q&PB).,&M-"JTSA .<8Z16\:.B^+1@=#!9;BJ$<FK-2QYMEP)
M>R*%% 8S/36>WAL5:MT<\144YUAB5-KB5EL2=@DT/TC)N&IU?(3<C3 ?+JX1
M05>3<==3#_[(=([W-2_ZMA#7SK[.%Q?3?Z\/E(+5Q=$;@HF)NM\D00C<0M'!
M:>.QX-VIE/<3?5M_VKA*KQN,#2.=#G3<RTR?'*=KB<[2K:.@T-H*I4"+[$"5
MU11Y&2&&G'@M%3:!-U9T3Y S[B24;I#86G =8/ %?IM>X'E=+'HU];4.S;MU
M)%6"IFMD (UUU8XF=\_%.MZ3UPYYARHVWT?\/%GC#DOI#I.M!=D!-M_AE!CV
M?Z:S=-T2SIE*62)I^+K[UFH)3I@"WI4HG-**8>N1A_>I&+?7OSOD'2BF#H!&
MG%M4L^)E7O]^@U>;:_634:44GTW(]?8H4+7L+F1C@1RZ(@Q#F5SK<,[VU(W;
MW]\=, <2:Y> /8MQ?KF*U\8\_;Y*,0CKN")C!#QF<KE,;1+6)D%1=5UO8L&G
M]O.EGJ=K7,]Y*$P\"[T#!=3/^(G[1WL]^UX+.1=T;R="^<3J%'B&S(!2GHP-
M40HX1 RF<)FVRV4?!+H;!(WK0X^&MGU%TC/,WBWR-S(U7F[(NIK:-4NKF5MU
M+<7%<E*WAZL4Z)RLYE49UT >EP/I<_:ER&15ZP#A?I2.ZU*/!LSF0NRB._IQ
M=?\.?U1=7Z,$,2XNZ?.F&*;G*R-G4KPUI6 $'>H&#B$"N!("6#JA=R(I'N31
M7NBG*!W7UQ[]S6XFQ+%CW!OR7\_2M&;^/^)?-T_BA54R(@/EZD.A723_+7HH
MG$M1Y]I[_VP7R_,?,Z[W/#"6&G.Y2U?CU==OY_,?.;_/YRL%>N-L+AKRU9@C
MVT(0RPP9'8@\0O8^<)FCEFYXE^-Q^L;UCT=38XT$UB48'UI5=G7 'Q//R5K0
M68*NNQ)4+AH\$V0)&Q=5+(6GYAM2=B1QW/%YHT&RG=BZ1.7M;.7UP4QFH4@Z
M249,FU$J2EG0"9DR3 7'6R\UW)JX<>?LC8;$%J+J (/;ERA-)"LI,-+Y7%87
MRQ0/3EKB9&6>T!YU\V%ZVU,WKEM\_'+%(836+QQK6&KY"".%1XR.,7#":E">
M&(F!*3#)2D&>%/WO2+!\@LI37LHX0-5V*WEV@%CR\3>IJ[/XWY?DN-%9Z1Y>
M_'AWCK.+ND.0OKI:_C;QS!O',8-+F>YB\F0^1V% 6(;%8:2+W]K+V9ZZ+NN]
MF^'D7NIY$*%U$5/<GI43LE",90Y!L>+H9HLZ"=AHR'14$XTS6K>.(VY/79>E
MVT,!<B"A=: ?'SG99GK%@XR,B14>F0?&70!%E@L$60R$DDR(Q:--1^K#>H+*
M4U[R-L"+WDJ>'2"6CA9S3JO%)*^7RTLZ5WY;;DPYG01%;IQC'(*S#)1E"7Q(
M%A(O/@4>12RE]4/^'%%=OM_-4''W_6XJHK&S*\^>YO7LTXSD]^=B>G&19^\N
MP_DTOBU$:!VMEK!$[QV#&)@%1>YC#7I98JM./ 8N%+]3\?U(]N4@,KI\K5O#
M[\C2ZDP7K@[W]MOJO7GU5U[$*3%YDE%:Z8,!+NF.*:\0D#D.0L3H,WT/5?/*
MVN>(ZC(8= Q=>+B(>L#<QCE[6];7:7/':E7Z<A)M3+Z0:<V,)NM7UU8=0Z:+
M9$5;NEHA\=8NRU/TC%O@<&RDM1),/]5B[_.WGX?Z8S[[3#_YZ\L<+B;))(YD
M-H F]I"K)>KX9U'SG60N"^.Y=:W7CC]&R[B%#T?&6!.!]!R'>8!QDQ"BB<X4
MR"4(4$%'"+XDR,S7SH<0K3A2'.8!ZL8M?C@R_ 826@>O:CU6_7^-;'['\ZO8
MP&*Z&K5+WSB;I=M?N/$WUV&%^TG0>'Y9QSN_^BM^P=GG_)XNSRNR=$D(**16
M$15D3UZ7,L08E,2L&&S42@N&J?7\B..>\)1WKA\2_^D81Z=^RR9!FVQ3]I"%
M+G5B(4*P3H 6FGDFK>>E]3MP$,&GO+QXM#NPDY3WAO2W%1,^7.#BH@-@DSN@
M,D<&&7FMSK<2G*-WF=-7B_91F>9SOH<'=J<+C\<#]BY2/A#8KV9MC/0/E]^^
MG:\8B.=7^P1NS%/_:5-R3_ARJF;9B+-*9?)NBQ# >?(8I4 =6F]+WI*T4]ZC
M? A4AY!<!P;$52M\;8XG9V0B,#.7B=Y0R A2+M>Q((*!2C;FR%"&Y@-6[Y P
M\D#Z(<1\K[AS?YYW 9G-EOJ\O#J!8\B3+ J\PSJP@PE ;3WYP2'F))$[V3J#
M?I^*D6?M'@4X!W&^ ^R\F<\B,>>ZSF26?L8Z5CKZ)Y\P2.><(<980[HZ) &.
M)0\^AQI=L5JUGT>Z+7&GO.K]H%J,0:37 2PWI?NK+M\TO;@DB=)=NZR4_'9Y
M\69^\:^\TM83ASEJ+QV0/T4*6C.Z>")9,-$*&^EDLOE<GVUI&[D@8QAH/#P\
MJJV<.L#?C3F!M;/\;;A NK#I]>PJ0O7[?/%8 X@S4I,K3VY/*N3>\_H6Y,2!
M^^*]P124:^TJ'$#NR'4;1T'IL:39 7!7TQ"VYVK$F"W/"JPL%E24=5=%B9!2
M0588=PI;5Z3O1N%6\/2_WLL^H!P[0.G/\H&<7E[6LJ@U0_^!YY?YJNEX]7?>
M72[HABYS+<N?,#1,*>V ,2?(&3.,5( (@$$E[93(6K>V0/<B=-R'?TCDW W!
M#"[&O;'Z/2_"O$5M9JT]N%7H<F7?K$^\8?3;Q3M<7$SQ?//O'Q<X6^)*:52G
M,'J.DB<$5NJH#\4">%4T),8\O5W><+O=].<6U(S[XA\!GN/(K:<BXMLUIW22
MM^46+S;#E#9#E)8KF;RHW)E=K"<IW9FKQ!(R@<6!,?*J!\HR"R4P4[Q4)8BP
M%7X')'+<FL]CP;H7*?\-=G3/28RD&\)Y?G=UPM5CAK/U[U_FYX2I94V 7?QX
MF<LTD@/<XS[O)@?I;?=W>^F,M2<<-4:) H*IYE#F' +/$DS.TE@,Z+!U:OST
M]H3SK!FYX:)&CDA?^I3!URGD,7A1C(D:?>M\QM]N3_@..!Q@3_@N$N["@]U0
MOU8P=7G-?%8C :O=QTD)IDR18(/4U<5!<%H;\(C:V=HXKIMO&WJ*H)/?*;X3
M.NYYJ:U$U0'N[IQAL^#6!N.%, )RM,2CJ"P$$6MS>$GH&4\NN,9X>Y"0D7'6
M3M!W%Z<>S/4.H'.6R/8A4>#Y>O'")G>SV5ILO E<U;D%NH2Z LD <834O\HE
MV52B;QY<>Y*@D=><'B[P>[OY6G&_ RB]S^L,RBM<S,CU7%YMOC:AF&PM1*RC
M4KB19$QX#3Q$7W3()31?LO<P)2-/6VH.G@;\[@ UMQVUS1F216%U8J#0U%T&
MI@#*E"":@(8)$\3=Q7@-VH?OTS'R-(_FB#F8UQW@Y49+_>8 S@6#,A=B@:-3
M>*_H^29')1DBW@7IZ(EO7>UQEXB1^WZ:(^4P+G< DP^783E-4US\^(#5R5@=
M967R1<DB.I7 6>7KI*0,@0G"N[*^CD7D)K:&RZ/$C%P,.;(+UD1$/6#MFOPW
M^)7^>"-AM+F+*(@KI;;SJ)HSRJ@AT/6!H*THRB1=8NL%G,]3-78-=Q/QWP55
M6UF,G;][?&;,E8^08R"O-8+!6HL>-7&-.P.\H,@::R_R=DGDYSYI9+ T%NM\
M*!Z/#9@'#Q"59#8Y)+&[6LWN OA4.#B,-DJM9>9E*Y#L#8SAWK !@7$P+WMX
MFZ[>ZQ?GN%S>U++%.JL+=T 6?J*#2 U>9$:H5HXI[]"8UBFF1XD9U]$:VPYJ
M(J(.L':3_LW=R[H43IX!<%69$TH"7R)"]@6]0B8":UWV?)^*3@+0AXGWKH-V
M&*_'?J8^Y+I,\+\>3=AOE&U5STE) T(G!,45JZH[@]-.:4/'U5IO]7!M]WGC
M N50D<Z'Y6\'"N:PRNO(L]4V",@II+H'Q@'6/3"J;LKB04AG6B<S#B)XW)C2
MR(_B\43= :YOW\T/7TA R[>7%W2P61V ,U'1!Q8E)S5@9-WT5L#;0J?+R? 2
M!$-L/7;N&9)&3L0=#QQ/1M /DU0W4USNE\9-6'86/?&(YT0\<JGNH7$)0M(Z
M%,YMYJT'==VGXI37HQP"L@/ET0VN;B01[M^4$(+.(D?PU>I0A4<(K)"EX\DF
MU@J5,:TCHD_1<\J#^P_!6C,9=8.Z1_J/UJ=[D_]<?6LY,4*BX:B!KE6I(^08
M."\\E()%^.R$T\W30%M1=LHC! _6>FWEUH%I]U0WW/6AHLA<<BW!<:[(7 Z>
M^!8#1!N1&^=<RJT'%FQ%V"F/\AL BP=(K5\HKB_8PS/B"TIO++<@E>4U$^?H
MLB4#WELT40;+>6O'8W<J3WDLWV *\W!Y]HO8U35\^(!*HP[<:5 !Z8")S!:?
M<P8K;!:A&./:MX3L2N0IS^8;2JD>+LU^X;J^D-<#,M<)@#]QD5;=F;_/%R6O
MI^1,C(]!19[ 1>O(S9,1G(@>R//#C,XXLGR.J6^W(?J4QVP-IGZ;2[MW>#\Z
MV6$Y41B9J_D%Z;4')4(&3-Z 4;QP9M!J.4@L:7=23WFNS&!0;B39?@'\S&02
M'KG5V23(@=,CE",YG+$@J((8DC9:&79$D^+  3/L;X/>AF+M +LW&/AQ_DC;
MT.J^_H:K_OBO=;S#2OHW3:OW^;\OI\OI1?Z0%]^G,:\Y]3['^>?9ZB=.- O*
MHXV@91U/53  <IG!.5Z4,;[HYC-BCW2T[>['+YBSZA$Z'=PH,L?6DWK_F"^7
MD\)5(CXRB%@G^GEZU,@QKJ:9B-S9++ULW7%TBX#MT/D+)KOV%T,'&'HV'6R*
MDSP5('^5KH2E1\9+:X&YZ'U ZXH;MH]MS\3]+YCH:BFJ7M94/) G)NIC"84T
M+P^@T&4(3FL0A1<C#0M!#Q) V#UOSW_5%-;^ ND$5D^FA$76'.O<N_K:TS6A
MDX7BB%$RQ&+I,&A:=W,?G+;GOV"&JIF0FH*NW=RV3[]]>/6?GUZ]^?CJ'_3+
MAS>XJ(.8O^=#1J@]]S,/G6:V$\V-!HO5+CJRS.M\D^^KJ297DYL2=RJ4:$$Z
M[@E<1D"0C(-04695RS=":?T2/$)+BU[>&S]W75RJ8W+.UMF;6->Q!&G!)1T@
MI:!X6+D;S3,]#] Q?@_EP=)_J"_W('9W8)C?/0/]9ZN6"XL\JGJ"S%C=1ZU5
M+:CWP#EIWL*$M[%YH<7#I'0%G#UD_ QH]F%XG[C9M&)XR1Q+R8,,E3E6D%/J
M+"?_H*2BC?.Y-&^7>XR8OK"SEZB?A\\>?.\/0%?#,X(*D14+-M2.=J,38*E+
M:XE+(CEO#!M8[?30X-1(R$]#9P^.CPB;Y>+BND'P0\PS)*-Z,P3!8$%AP'G+
M:FY- 2:>(06GLO8J9K;5UE_ZA!MPH7^[ALJC'S[VCK9&;U,;YHZ-C@W=GV;+
M;SE.RS2GS:4I0DLBE$/6M3I;J%S+!R040P8>#S99N56LYSF$/$; .,JDD5#G
MK3D\,DS>+>:_USF^&_67@RR.J4+/<*J%?DD3Y>C!92ZLPZB8VFJ%SS/8N/VI
M(P*BC0CG3?C9GQ5R'7+B=:J;X)$>6F-!87" @2-$;86Q0H6@6N^2?XR6D6<^
M#.P [<?R'J!S+X;]9GZQKI_X\.U\>K%N*5^2F-Y78?%)U:O!&P06&:N)$V*?
M$Q)\P*1M2):E07H7=J"Q*[-W3V0\FVIH**8.8'@OOGUV>?%EOIC^.Z>)*2[0
ME8Q@BC&DD7T =(6N*>-6"R&]+(/G(*[)Z<I8;@.N5LSO$4?K0K%)#,RCE0%L
MSDCLR1&"]@Y*9LBYS%+JUN'Q1TCIZAT<"#][,+U'[-SJC8V:^SHV5[I4(^S)
M (JLP-&)N!6.T5E[2X0.-RSD*"C:E_T]0&D]V^>?-24XNWB[6"^?O7$>%XW(
M/%F02/=#I<A)K28!Q4G#HG*H5>ME#<_1-&[SYS"0:BF&7F%UU3_U;C&-^><W
MEYOO+OG$\<B2\A$8DG.C A('3=9@%&(I&17+K??[[D7HN(V=QP-@4X%UN(/O
M3EW$U62I>;G:7/ N+ZX*D*>1;N++Z?GE@>OR#OW,QK4@AYUY\%H1[3*7(D).
M*I'6XP9<8@5"7:;N><X"F[>X'+-6A#-?LJBZO-0M/UAK.^UJFZ6TQB!+*;>V
MU4ZI5F0'Z6]5*[(+N\?.KCR822C9<+3.@'"(Z[[CX(V#D(/0RGCT?JM)@8/E
MWHY;%[*3/)_-O>W"W+'1\6A:@;P/RW.(($R=Q\7H3\@S Y&RQ52LBVXK<_U7
MR;WM)-2M<F^[<+BOW%O2 9E1NNY>JM8:>:4^1P'&:9Y*D-K9K4)+)Y][VTF$
MC^?>=N%G!S[9$WY#-%FA(-M=U0Z3C."+J!MTBL_&RBQ2\]Z,0W)OQRWPV.>1
M:<KR#J!SNQ=.\:!5M PX]X*NCZ5C%"; V83,"YN8:CTW88^6Q!'<[QUD^F2S
MX2X,WAL=W_,BS-L%I.G#O^39<OH]KP^R&BKR$?^:9)D+*R5"DJ46.E@-02</
MA?'LN? LL=;3K9\@IRL%TP8[K9C?@9ZY&X/8Q!XFA=&3:L@3I+>Y3IF-N8ZV
MTV!29"AEM$XTWQC\,"G=)L7VQT\+IG>(G57\:N*<RRPI8HRJ,S2R=:1%;8&H
M0_&%1WK;6T>0'B2DVS18.]SLSO .4///7$/9.9W1<XB?\YO+:MF_+3>SP^MS
M69%X--$ LY+.982EVV ,.9(R&"FR":EUF\6VM'6;#]L?6X.(I5^X;53N_6PR
MBZ48<BJ!&2[JBC#B)D\(#+U)Y,/FQ%L;3SN2V&TNK#GXF@AI^"S8YAOUEX#+
M_+__U_\'4$L#!!0    ( !&'EEBAE31-/PD  &L_   5    97AH:6)I=#$P
M-3(P,C,M,3(N:'1M[5O=<]LV$G^_OP(7WZ7V#"5+LER[LNJ9G./KY"%I)^VT
MCS<@"9J(28(%0"N\O_YV 9 B)=)V+G9$W3D/<D3A8S]_NU@LE[%.D\MES&AX
M^9?E7T<C\E8$1<HR30+)J&8A*13/;L@?(5.W9#1RHZY$7DI^$VLRF\SFY \A
M;_D=M;]KKA-V6:VS/+;?E\=FDZ4OPO)R&?([PL,?7_%P,F&1?S:?G<_/Y\'\
MS ].HQ_\R9D_.PW"D\GL7]-7,!6&VSE*EPG[\57*LU',</_%V2S7%RL>ZG@Q
MG4S^_JHU3K//>D03?I,M#+7P:R2 -_=S(!(A%P<3\^\"?QE%-.5)N?CN-YXR
M13ZP%?DH4II]YRF:J9%BDD=VH.+_9HLI;FZ^KAPUL$[",U919TFZ_AQSGVLR
MG8Q/E\<XON)IB[,&Q0%(C\D=D7S%0RHI^2UFDN:LT#Q0'GF7!>,V_0.D_ U8
M70AV2[.0?&1*&R/^(++1=9HGHF2,O.62!5I(L.(T9YFBFHN,_"(2'I1+7UY6
M+#XM]9,-ZN>=U'^[_7NDE^=2W('$_)+\0U 9$A'5 E.O#T[/+\A;%K#49Y+,
M/73_DRV3L*2W>+G/7#X52O.H?'9[Z9;X-0UBDEJ&@%<=,])K_!TB(8<XXWE4
M5C-@5EQP#?(*'J'$UP?GL]GDPA!K_C^]>&8"[Y7P$5G%@G!%,J$)390@L- =
M1A6JP$T)JQP3Y-HO^L-!RMC2.P@A Z#1K$0A<JV(*GS%0TXEAST.&1JY*FI+
M]U#N@Q3H-4 "]Y,U2@]"MBN>) 3H8?R.&8@(FJ$#<J- <A]0DV?P*UCZH^,-
MB> YSL _@$ 68(Q_!. 0F0ECD4@2L4*'P:U#B&CP'ZKM5M3%N]RN!T\B+A4X
M6BAR;8$<9]F%#5@Y20]+_==1!$)"\;X%_G:I;6=P1V- (9#F6JZL)A%PRX6*
M-ME&6RDMB<]JO8">T"TUD&C-@Q$EP+Y##D;#C"FXM9R*< W8P"T#IB-2MY13
M9<N,X$O*M;;H6:]RM)VGW1>4=Y2I95E!$W)%5=SBZ<MSACU)-2"J@2T8I@-D
MN@4B-!4%DL0T8H*.0?G@]&AW.2TI(B)8#_L3)\.'A 0[ :O,(,%-$CQH09QL
M#*02CF^0G0AK<0D%1 BIB0XF%D1@?>N5<,8JYO#<F&>%/D%0P#+AF+R+R"$_
MZC)X!""+2$(C?@$NV1TM"+DMZ>9^@':''%:$P5N 3SX)8*OA$1C84%8==FZ\
MR_I68_\N1[V7'J\QI%.XM=QHG@,<&"D[38(/4]"TW-*<B1G@P9!0CZ0YA?A4
MP2<&#%HJ(^8J9%2;]ZNE!XG$ANZVI8GY/(<(U52M9S*OFA7/X)9D-T5")8F*
MI&EB8%3&O' ^V%0$3\?D#0QI6G+$8 ,J&;F#$Q<6#7+@TLW\,BBJ?#*G80@1
M;Y2P2"].O@?_VG9C^X@#-F9Z,<)!.W+LZ?CUP?3[R<7VY^X"F15.".%#&H!9
M%" GB:-JY+4N]*MS]X_.D'<;>^& ^54VL2,+H+T6@*ZRY97N)/VW^<0#NA['
ML*ET#=@)_%X17,642UB_#=V;=@<1 >(6,&S"H18=6+8YY<B)\>0+Q'B_W>Q)
M)C';3\!9)ZOO;<%EVP8R.#E5]G+T D5/"D7O6U6N-P6XVEHESI5^>"I/&@[\
MM-GN/CTY[L^\T_WD/G@D]Q]$RC/@'8MOD//]).Z8S&@6L"U1S+\-I.Y5GG>R
M[[!;1^*7I.]9D78SX^G&VNGY_Q[8;G)^+]Q.3_=5 /UXNRF QR/NDUG#X)+8
MGI+OGP77Y?]/Z8]9?EM5O[ZBT8VDF2FD()@_<"DYFTQ/B1,F/( @B96A7Q*:
M>8U"<E6/CJ1(;<4,CECF[W!O,)&'(=S_V(*7TB*X)2)'Q:DM#:T+=)4.X2B#
M[0<%G%S+]F0/QH#*L53YF<F *ZP28CC.L8X88R'-5GI!14A"A27_!&@A[ZF\
M!:OYG28%Z X4'+((2*XKB2BTHVJ&309*1!^LH*+%64+JJ];A7@E=68)_18*'
M<"%4%=-MN3NR%F!KIY1H)E,C=):1TI3>K:-MCB>'JO _L4"C;F%<PM%Z8+()
M$K #:#$068;U7?AF[:0U %:J*O2@?%?>;6G?6S\U]X2F&MN[2*-PCI>1(:,Z
M]O!ZBOH\04R!AP$M%+-5\EPH/6HNM39A$*\(:_.?S@BH3\<=DFA,[[BI^DK,
M7^MN/#D'!0/!IJ2TD"RA"(V][6*^T%JDB\EZ"O652 J]/657EMB=<TS[:NS?
MCL#S$Z"/O)"Q/V1T>%'S,Y;KS/.&C7S)Z.W(7/\L:+*BI6K[SD,MF0_L.<2<
M;=]N==YE %J0-/R$<6;G!WKR<SM:=MY.8FB=GETHB%Z6=I:XP(?):755X)G
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M_FZ#??62E/,!!^%9!R,O)=2O+Z'.7DJH+V0\<0GUV+[L?FQ>LO\/4$L#!!0
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M;7C?>&ML/-XX240&$45PS",8 -A '(;UPKC($N (:@7H$5DL"P8Z 24+X0H
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M\4/'OPH<\:4/7N=4YKJ(VGP*C8#/"KL\Y2O?R)8__1>[>^Y+X?\!4$L#!!0
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M.7\OVC1<F]5. [WNCZ@L'!%A+'D<0UDG1A %LZ(\>ZP)UB!6_[BZ8G/HA(Y
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MF,^>^T+ @G#L7(H"-F:B.:RB0#0R=;RP7\)'EY+D0?08D#(KKS]7*1J=8&A
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M+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( !&'EEA=">>5<A4  *ON   1
M          "  8.^! !C9'1X+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0    ( !&'
MEEA<&_(\7B(  -=6 0 5              "  234! !C9'1X+3(P,C,Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    "  1AY98^IXT6QV(  ""<P8 %0
M    @ &U]@0 8V1T>"TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ $8>6
M6$VX=08-50  ]%D  !0              ( !!7\% &-D='@M,C R,S$R,S%?
M9S$N:G!G4$L! A0#%     @ $8>66"JPN548Y $ K@(" !4
M ( !1-0% &-D='@M,C R,S$R,S%?9S$P+FIP9U!+ 0(4 Q0    ( !&'EEC#
M3G-_Z&P!  2O 0 5              "  8^X!P!C9'1X+3(P,C,Q,C,Q7V<Q
M,2YJ<&=02P$"% ,4    "  1AY98S2;553^M   3N   %0
M@ &J)0D 8V1T>"TR,#(S,3(S,5]G,3(N:G!G4$L! A0#%     @ $8>66&S,
MD"K1. 8 C=T( !4              ( !'-,) &-D='@M,C R,S$R,S%?9S$S
M+FIP9U!+ 0(4 Q0    ( !&'EECD8XY%K5($ /^M"0 5              "
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M &-D='@M,C R,S$R,S%?9S0N:G!G4$L! A0#%     @ $8>66%\L*/:F_0
M"#,! !0              ( !18P< &-D='@M,C R,S$R,S%?9S4N:G!G4$L!
M A0#%     @ $8>66/L'6.K?K@  0NX  !0              ( !'8H= &-D
M='@M,C R,S$R,S%?9S8N:G!G4$L! A0#%     @ $8>66 2GR#^.IP  /,,
M !0              ( !+CD> &-D='@M,C R,S$R,S%?9S<N:G!G4$L! A0#
M%     @ $8>66*Y;KM!6!@$ ;SH! !0              ( ![N > &-D='@M
M,C R,S$R,S%?9S@N:G!G4$L! A0#%     @ $8>66(XMC R4D   ]J4  !0
M             ( !=N<? &-D='@M,C R,S$R,S%?9SDN:G!G4$L! A0#%
M  @ $8>66%$,1C?]!@$ N#4* !4              ( !/'@@ &-D='@M,C R
M,S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( !&'EE@8R2VN;\X  +=X"0 5
M          "  6Q_(0!C9'1X+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4
M"  1AY98H94T33\)  !K/P  %0              @ $.3B( 97AH:6)I=#$P
M-3(P,C,M,3(N:'1M4$L! A0#%     @ $8>66,UX/.U4 P  \@L  !4
M         ( !@%<B &5X:&EB:70R,S$R,#(S+3$R+FAT;5!+ 0(4 Q0    (
M !&'EEA[2#G,.@@  # L   5              "  0=;(@!E>&AI8FET,S$Q
M,C R,RTQ,BYH=&U02P$"% ,4    "  1AY98P8KUZ&<(   J+0  %0
M        @ %T8R( 97AH:6)I=#,Q,C(P,C,M,3(N:'1M4$L! A0#%     @
M$8>66.$5N>/4!0  M!H  !4              ( !#FPB &5X:&EB:70S,C$R
M,#(S+3$R+FAT;5!+ 0(4 Q0    ( !&'EE@[B2'9ZP<   <I   4
M      "  15R(@!E>&AI8FET,S(R,#(S+3$R+FAT;5!+ 0(4 Q0    ( !&'
MEEAKNGW<\ 4  -<;   5              "  3)Z(@!E>&AI8FET,S(R,C R
M,RTQ,BYH=&U02P$"% ,4    "  1AY98K$R3$"T;  !!L   %0
M    @ %5@"( 97AH:6)I=#DW,3(P,C,M,3(N:'1M4$L%!@     = !T A0<
' +6;(@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>cdtx-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cdtx="http://cidara.com/20231231"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cdtx-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2024-04-12</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdtx:JanssenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-03</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-03</startDate>
            <endDate>2016-10-03</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:A2023UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-07</startDate>
            <endDate>2023-03-07</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-12</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-12</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandTwentyInducementIncentivePlanAndTwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-03</startDate>
            <endDate>2019-09-03</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-22</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:RDFundingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicenseOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponTransferOfLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponTransferOfLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponTransferOfLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicenseOfIntellectualPropertyUponMilestonesAchievedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-04-20</startDate>
            <endDate>2023-04-20</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-30</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ProFormaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-12</startDate>
            <endDate>2024-04-12</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cdtx:segment</measure>
    </unit>
    <unit id="obligation">
        <measure>cdtx:obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>cdtx:vote</measure>
    </unit>
    <unit id="claim">
        <measure>cdtx:claim</measure>
    </unit>
    <unit id="option">
        <measure>cdtx:option</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0001610618</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-64" id="f-404">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-123" id="f-535">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="c-369"
      decimals="INF"
      id="f-2597"
      unitRef="number">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36912</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">CIDARA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">46-1537286</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">6310 Nancy Ridge Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">752-6170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">&#x201c;CDTX&#x201d;</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">true</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentFinStmtRestatementRecoveryAnalysisFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtRestatementRecoveryAnalysisFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-31" unitRef="usd">100200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-32" unitRef="shares">91235020</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="c-1" id="f-37">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-38">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">35778000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-40" unitRef="usd">32731000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">16246000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-42" unitRef="usd">5833000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">6097000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-44" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">2734000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-46" unitRef="usd">6530000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">60855000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-48" unitRef="usd">45094000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">557000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-50" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">782000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-52" unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">3788000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-54" unitRef="usd">1099000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">1048000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">1072000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">67030000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-58" unitRef="usd">47487000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">3772000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-60" unitRef="usd">1447000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">14177000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">7672000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">18040000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">11534000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-65" unitRef="usd">5034000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-66" unitRef="usd">4922000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">25095000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">14614000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-69" unitRef="usd">218000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-70" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">1082000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-72" unitRef="usd">1211000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">67418000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">41400000</us-gaap:LiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">4245000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-76" unitRef="usd">20525000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">575000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-78" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">3002000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-81" unitRef="usd">75240000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-82" unitRef="usd">61925000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-83" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-84" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-85"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-86"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-87" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-88" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue contextRef="c-4" id="f-89" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-5" id="f-90" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-91"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-92"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-93" unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-94" unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-95" unitRef="shares">2156713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-96" unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-97" unitRef="shares">1870713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-98" unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-99" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-101"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-102"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-103" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-104" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-105" unitRef="shares">90601999</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-106" unitRef="shares">90601999</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-107" unitRef="shares">72470440</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-108" unitRef="shares">72470440</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-109" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">433212000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">404055000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-113" unitRef="usd">-441431000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">-418500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-115" unitRef="usd">-8210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">-14438000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-117" unitRef="usd">67030000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">47487000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">59570000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-8" decimals="-3" id="f-120" unitRef="usd">64448000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">4335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-122" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">63905000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-124" unitRef="usd">64448000</us-gaap:Revenues>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-1" decimals="-3" id="f-125" unitRef="usd">1523000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-8" decimals="-3" id="f-126" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">68532000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-128" unitRef="usd">77405000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">18333000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-130" unitRef="usd">20546000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">88388000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-8" decimals="-3" id="f-132" unitRef="usd">97951000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">-24483000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-8" decimals="-3" id="f-134" unitRef="usd">-33503000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">1995000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-8" decimals="-3" id="f-136" unitRef="usd">191000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-137" unitRef="usd">1995000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-8" decimals="-3" id="f-138" unitRef="usd">191000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">-22488000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-140" unitRef="usd">-33312000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-141" unitRef="usd">443000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-142" unitRef="usd">272000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-22931000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">-22931000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-8" decimals="-3" id="f-145" unitRef="usd">-33584000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-146" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-147"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-148"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-149"
      unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-150"
      unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-151" unitRef="shares">87427439</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-152" unitRef="shares">87427439</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-8" decimals="0" id="f-153" unitRef="shares">69857698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="0" id="f-154" unitRef="shares">69857698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-9" decimals="INF" id="f-155" unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-156" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-157"
      unitRef="shares">67863674</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-158" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-159" unitRef="usd">398013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-160" unitRef="usd">-384916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-161" unitRef="usd">13104000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-14"
      decimals="INF"
      id="f-162"
      unitRef="shares">3414926</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-163" unitRef="usd">2370000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-164" unitRef="usd">2370000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-17"
      decimals="INF"
      id="f-165"
      unitRef="shares">828244</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-17"
      decimals="INF"
      id="f-166"
      unitRef="shares">363596</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-18" decimals="-3" id="f-167" unitRef="usd">140000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-8" decimals="-3" id="f-168" unitRef="usd">140000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-18" decimals="-3" id="f-169" unitRef="usd">3532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-8" decimals="-3" id="f-170" unitRef="usd">3532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-19" decimals="-3" id="f-171" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-20" decimals="-3" id="f-172" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-173" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-174" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-175"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-176" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-177"
      unitRef="shares">72470440</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-178" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-179" unitRef="usd">404055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-180" unitRef="usd">-418500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-181" unitRef="usd">-14438000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-26"
      decimals="INF"
      id="f-182"
      unitRef="shares">286000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-27"
      decimals="INF"
      id="f-183"
      unitRef="shares">11086000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-184" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-185" unitRef="usd">17255000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-186" unitRef="usd">17256000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-30"
      decimals="INF"
      id="f-187"
      unitRef="shares">6219741</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-188" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-189" unitRef="usd">8698000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-190" unitRef="usd">8699000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-33"
      decimals="INF"
      id="f-191"
      unitRef="shares">25750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-34" decimals="-3" id="f-192" unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">21000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-33"
      decimals="INF"
      id="f-194"
      unitRef="shares">490520</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-33"
      decimals="INF"
      id="f-195"
      unitRef="shares">309548</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-34" decimals="-3" id="f-196" unitRef="usd">122000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">122000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-34" decimals="-3" id="f-198" unitRef="usd">3061000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">3061000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-200" unitRef="usd">-22931000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-22931000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-36"
      decimals="INF"
      id="f-202"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-37"
      decimals="INF"
      id="f-204"
      unitRef="shares">90601999</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-205" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-206" unitRef="usd">433212000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-207" unitRef="usd">-441431000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-208" unitRef="usd">-8210000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-22931000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-210" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">3061000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-8" decimals="-3" id="f-212" unitRef="usd">3532000</us-gaap:ShareBasedCompensation>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">1158000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-8" decimals="-3" id="f-214" unitRef="usd">981000</cdtx:OperatingLeaseRightOfUseAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">112000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-8" decimals="-3" id="f-216" unitRef="usd">143000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">77000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-8" decimals="-3" id="f-218" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">6000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c-8" decimals="-3" id="f-220" unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:PaidInKindInterest contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">5000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-8" decimals="-3" id="f-222" unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">10413000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-8" decimals="-3" id="f-224" unitRef="usd">477000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">6097000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-8" decimals="-3" id="f-226" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">-3735000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-8" decimals="-3" id="f-228" unitRef="usd">2440000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">8886000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-8" decimals="-3" id="f-230" unitRef="usd">-2371000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">6506000</cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes>
    <cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes contextRef="c-8" decimals="-3" id="f-232" unitRef="usd">3945000</cdtx:IncreaseDecreaseInAccrualForTaxesOtherThanIncomeTaxes>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">235000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-8" decimals="-3" id="f-234" unitRef="usd">203000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">-5799000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-8" decimals="-3" id="f-236" unitRef="usd">2646000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">-973000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-238" unitRef="usd">-1052000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">-22432000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-8" decimals="-3" id="f-240" unitRef="usd">-28473000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">505000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-242" unitRef="usd">118000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">-505000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-8" decimals="-3" id="f-244" unitRef="usd">-118000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">17256000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-8" decimals="-3" id="f-246" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">8707000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-8" decimals="-3" id="f-248" unitRef="usd">2362000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">21000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-8" decimals="-3" id="f-250" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-8" decimals="-3" id="f-252" unitRef="usd">720000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-8" decimals="-3" id="f-254" unitRef="usd">2593000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">25984000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-8" decimals="-3" id="f-256" unitRef="usd">-951000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">3047000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-8" decimals="-3" id="f-258" unitRef="usd">-29542000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-259" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-260" unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-261" unitRef="usd">35778000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-262" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-8" decimals="-3" id="f-264" unitRef="usd">40000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">797000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-8" decimals="-3" id="f-266" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">11000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-8" decimals="-3" id="f-268" unitRef="usd">69000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">788000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-8" decimals="-3" id="f-270" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">3847000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-272" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">122000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-8" decimals="-3" id="f-274" unitRef="usd">140000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">0</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-8" decimals="-3" id="f-276" unitRef="usd">8000</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-277">THE COMPANY AND BASIS OF PRESENTATION&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on developing targeted therapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company&#x2019;s first commercially approved product in the United States, or U.S., is REZZAYO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;(rezafungin for injection) which is indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Melinta Therapeutics, LLC, or Melinta, is commercializing REZZAYO in the U.S. The Company&#x2019;s proprietary Cloudbreak&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; platform enables development of novel drug-Fc conjugates, or DFCs, that inhibit specific disease targets while simultaneously engaging the immune system. The Company&#x2019;s most advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting multiple oncology and autoimmune indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December&#160;31, 2023, the Company had an accumulated deficit of $441.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company had cash and cash equivalents of $35.8 million. Based on the Company&#x2019;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s obligations for twelve months from the issuance of these financial statements. The Company&#x2019;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#x2019;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to estimated collaboration expenses related to the Company&#x2019;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;collaboration and license agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restatement of Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluated the indirect taxation consequences upon the first commercial sale of REZZAYO in 2023 and determined that it had a liability for indirect taxation in various tax jurisdictions outside of the U.S. based on its supply chain activities in 2023 and prior years. As a result, it was concluded that in prior years the Company did not appropriately account for indirect taxes which led to understatements of accrued liabilities and operating expenses during the impacted periods. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $11.5&#160;million, an increase in operating expenses of $3.9&#160;million, and an increase in beginning accumulated deficit of $7.6&#160;million, for 2022. The Company recorded an accrued liability for indirect taxes, and the related interest and penalties, of $7.6&#160;million, an increase in operating expenses of $3.7&#160;million, and an increase in beginning accumulated deficit of $3.9&#160;million, for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements (as restated) also include adjustments to correct certain other previously identified misstatements relating to fiscal year 2022 and the quarters within 2023 that the Company had determined to be immaterial, both individually and in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impact of Restatement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See below for reconciliation from the previously reported amounts to the restated amounts in the consolidated balance sheet, consolidated statement of operations and comprehensive loss, consolidated statement of convertible preferred stock and stockholders&#x2019; equity (deficit), and consolidated statement of cash flows as of and for the year ended December 31, 2022. The previously reported amounts were derived from the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 23, 2023. These amounts are labeled as "As Previously Reported" in the tables below. The amounts labeled "Restatement Adjustment" represent the effects of this restatement described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;61,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(406,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(418,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(14,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Statement of Operations and Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;20,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;94,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;97,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,857,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,857,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Additional Paid-In Capital&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;398,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;398,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance costs for underwritten public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;404,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;404,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Accumulated Deficit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(377,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(384,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(406,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(418,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(8,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;13,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance costs for underwritten public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(14,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.589%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The remainder of the notes to the Company&#x2019;s consolidated financial statements have been updated and restated, as applicable, to reflect the impacts from the restatement discussed above.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-278">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At December&#160;31, 2023, the Company had an accumulated deficit of $441.4 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company had cash and cash equivalents of $35.8 million. Based on the Company&#x2019;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s obligations for twelve months from the issuance of these financial statements. The Company&#x2019;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#x2019;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these consolidated financial statements are issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-279" unitRef="usd">-441400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-5" id="f-280" unitRef="usd">35800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-281">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-282">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to estimated collaboration expenses related to the Company&#x2019;s collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;collaboration and license agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-283">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-284"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-40" decimals="-5" id="f-285" unitRef="usd">11500000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:OperatingExpenses contextRef="c-41" decimals="-5" id="f-286" unitRef="usd">3900000</us-gaap:OperatingExpenses>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-40" decimals="-5" id="f-287" unitRef="usd">-7600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-42" decimals="-5" id="f-288" unitRef="usd">7600000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:OperatingExpenses contextRef="c-43" decimals="-5" id="f-289" unitRef="usd">3700000</us-gaap:OperatingExpenses>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-42" decimals="-5" id="f-290" unitRef="usd">-3900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="c-1" id="f-291">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following presents a reconciliation of the impacted financial statement line items as previously reported to the restated amounts as of and for the year ended December 31, 2022 (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;41,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;61,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(406,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(418,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(14,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;47,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Statement of Operations and Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;20,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;94,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;97,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,503)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,527)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,312)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,857,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,857,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Additional Paid-In Capital&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Statement of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;398,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;398,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance costs for underwritten public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;404,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;404,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Accumulated Deficit&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(377,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(384,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(406,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(418,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(8,469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;13,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Issuance costs for underwritten public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(11,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(14,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.442%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.589%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Corrected Consolidated Statement of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(29,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-44" decimals="-3" id="f-292" unitRef="usd">1205000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-45" decimals="-3" id="f-293" unitRef="usd">-106000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-294" unitRef="usd">1099000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-44" decimals="-3" id="f-295" unitRef="usd">47593000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-45" decimals="-3" id="f-296" unitRef="usd">-106000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-297" unitRef="usd">47487000</us-gaap:Assets>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-44" decimals="-3" id="f-298" unitRef="usd">0</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-45" decimals="-3" id="f-299" unitRef="usd">11534000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-5" decimals="-3" id="f-300" unitRef="usd">11534000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-44" decimals="-3" id="f-301" unitRef="usd">1317000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-45" decimals="-3" id="f-302" unitRef="usd">-106000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-303" unitRef="usd">1211000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-44" decimals="-3" id="f-304" unitRef="usd">29972000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-45" decimals="-3" id="f-305" unitRef="usd">11428000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-306" unitRef="usd">41400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities contextRef="c-44" decimals="-3" id="f-307" unitRef="usd">50497000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-45" decimals="-3" id="f-308" unitRef="usd">11428000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-309" unitRef="usd">61925000</us-gaap:Liabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-44" decimals="-3" id="f-310" unitRef="usd">-406966000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-45" decimals="-3" id="f-311" unitRef="usd">-11534000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-312" unitRef="usd">-418500000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-313" unitRef="usd">-2904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-314" unitRef="usd">-11534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-315" unitRef="usd">-14438000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-44" decimals="-3" id="f-316" unitRef="usd">47593000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-45" decimals="-3" id="f-317" unitRef="usd">-106000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-318" unitRef="usd">47487000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-46" decimals="-3" id="f-319" unitRef="usd">64288000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-47" decimals="-3" id="f-320" unitRef="usd">160000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-8" decimals="-3" id="f-321" unitRef="usd">64448000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-46" decimals="-3" id="f-322" unitRef="usd">64288000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-47" decimals="-3" id="f-323" unitRef="usd">160000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-3" id="f-324" unitRef="usd">64448000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-46" decimals="-3" id="f-325" unitRef="usd">75520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-47" decimals="-3" id="f-326" unitRef="usd">1885000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-327" unitRef="usd">77405000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-46" decimals="-3" id="f-328" unitRef="usd">18486000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-47" decimals="-3" id="f-329" unitRef="usd">2060000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-330" unitRef="usd">20546000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-46" decimals="-3" id="f-331" unitRef="usd">94006000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-47" decimals="-3" id="f-332" unitRef="usd">3945000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-8" decimals="-3" id="f-333" unitRef="usd">97951000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-46" decimals="-3" id="f-334" unitRef="usd">-29718000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-47" decimals="-3" id="f-335" unitRef="usd">-3785000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-8" decimals="-3" id="f-336" unitRef="usd">-33503000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-337" unitRef="usd">-29527000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-338" unitRef="usd">-3785000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-339" unitRef="usd">-33312000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-340" unitRef="usd">-29799000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-46" decimals="-3" id="f-341" unitRef="usd">-29799000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-47" decimals="-3" id="f-342" unitRef="usd">-3785000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-47" decimals="-3" id="f-343" unitRef="usd">-3785000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-344" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-8" decimals="-3" id="f-345" unitRef="usd">-33584000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-46"
      decimals="2"
      id="f-346"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-46"
      decimals="2"
      id="f-347"
      unitRef="usdPerShare">-0.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-348"
      unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-349"
      unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-46" decimals="0" id="f-350" unitRef="shares">69857698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-46" decimals="0" id="f-351" unitRef="shares">69857698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="0" id="f-352" unitRef="shares">69857698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-8" decimals="0" id="f-353" unitRef="shares">69857698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-354" unitRef="usd">398733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-355" unitRef="usd">-720000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-356" unitRef="usd">398013000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-50" decimals="-3" id="f-357" unitRef="usd">720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-51" decimals="-3" id="f-358" unitRef="usd">-720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-19" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-360" unitRef="usd">404055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-362" unitRef="usd">404055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-363" unitRef="usd">-377167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-364" unitRef="usd">-7749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-365" unitRef="usd">-384916000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-56" decimals="-3" id="f-366" unitRef="usd">-29799000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-57" decimals="-3" id="f-367" unitRef="usd">-3785000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-3" id="f-368" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-369" unitRef="usd">-406966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-59" decimals="-3" id="f-370" unitRef="usd">-11534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-371" unitRef="usd">-418500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-60" decimals="-3" id="f-372" unitRef="usd">21573000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-61" decimals="-3" id="f-373" unitRef="usd">-8469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-374" unitRef="usd">13104000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-62" decimals="-3" id="f-375" unitRef="usd">720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-63" decimals="-3" id="f-376" unitRef="usd">-720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-20" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-378" unitRef="usd">-29799000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-47" decimals="-3" id="f-379" unitRef="usd">-3785000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-380" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-381" unitRef="usd">-2904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-382" unitRef="usd">-11534000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-383" unitRef="usd">-14438000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-46" decimals="-3" id="f-384" unitRef="usd">-29799000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-47" decimals="-3" id="f-385" unitRef="usd">-3785000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-3" id="f-386" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-46" decimals="-3" id="f-387" unitRef="usd">1082000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-47" decimals="-3" id="f-388" unitRef="usd">-101000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-8" decimals="-3" id="f-389" unitRef="usd">981000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-46" decimals="-3" id="f-390" unitRef="usd">0</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-47" decimals="-3" id="f-391" unitRef="usd">3945000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-8" decimals="-3" id="f-392" unitRef="usd">3945000</cdtx:AccruedIndirectTaxLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-46" decimals="-3" id="f-393" unitRef="usd">2806000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-47" decimals="-3" id="f-394" unitRef="usd">-160000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-8" decimals="-3" id="f-395" unitRef="usd">2646000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-46" decimals="-3" id="f-396" unitRef="usd">-1153000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-47" decimals="-3" id="f-397" unitRef="usd">101000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-398" unitRef="usd">-1052000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-399">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, and product sales. The Company records accounts receivables net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#x2019;s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of December&#160;31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to materials, third-party contract manufacturing, freight-in and overhead. Inventory is stated at the lower of cost or net realizable value with cost based on the first-in-first-out method. The Company performs an assessment of recoverability of capitalized inventory during each reporting period based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life, and writes down any excess, obsolete or unsaleable inventory to its estimated realizable value in the period which the required reserve is first identified. Such write downs, should they occur, are charged to cost of product revenue in the consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the Company did not identify any excess, obsolete or unsaleable inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:f-404"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Codification&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC, 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#x2019;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#x2019;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in selling, general and administrative, or SG&amp;amp;A, expenses in the accompanying statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company reports deferred income taxes in accordance with ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indirect Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in research and development, or R&amp;amp;D, expenses, and the related interest and penalties are included in SG&amp;amp;A expenses. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#x2019;s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed in future periods. Indirect tax amounts on commercial sales (product revenue) that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included within inventory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company entered into a License Agreement with Melinta, or the Melinta License Agreement. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#x2019;s estimates have no impact on the Company&#x2019;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment and milestones achieved to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta are required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represents a distinct performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The transaction price to be recognized as revenue for each performance obligation under the Commercial Supply Agreements consists of variable consideration which is determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue are adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration is included in the transaction price only to the extent that it is considered probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections are recorded as indirect taxes liabilities. The transaction price will be fully allocated to the single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that the performance obligation is satisfied and product revenue is recognized when the customer obtains control of the product, which occurs at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#x2019;s product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Shipping and handling activities that are performed after a customer obtains control of the product are treated as activities to fulfill the promise to a customer and any amounts billed to a customer represent revenues for the product provided. Costs related to such shipping and handling billings are classified as cost of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or research and development expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#x2019;s stock, (c) the expected term of the award, and (d) the expected dividend yield.&#160;The Company computed the expected volatility data using the daily close prices for the Company&#x2019;s common stock during the equivalent period of the calculated expected term of the Company&#x2019;s stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#x2019;s losses. For all periods presented, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,044,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,764,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,323,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33,826,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40,025,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Update&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025 and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#x2019;s consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#x2019;s consolidated financial statements or related disclosures, or do not apply to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-401">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable is stated at the original invoice amount and consists of amounts due from customers related to milestones achieved, certain research and development and clinical supply costs subject to reimbursement under the collaboration and license agreements, royalties earned, and product sales. The Company records accounts receivables net of any allowances for doubtful accounts for potential credit losses. An allowance for doubtful accounts is determined based on the financial condition and creditworthiness of customers and the Company considers economic factors and events or trends expected to affect future collections experience. Any allowance would reduce the net receivables to the amount that is expected to be collected. The payment history of the Company&#x2019;s customers will be considered in future assessments of collectability as these patterns are established over a longer period of time. The Company did not record any credit losses as of December&#160;31, 2023 or 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-402">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company began capitalizing inventory for REZZAYO, which received approval by the U.S. Food and Drug Administration, or FDA, in March 2023. REZZAYO (rezafungin for injection) is approved for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Inventory is comprised of raw materials, work-in-process and finished goods, and includes costs related to materials, third-party contract manufacturing, freight-in and overhead. Inventory is stated at the lower of cost or net realizable value with cost based on the first-in-first-out method. The Company performs an assessment of recoverability of capitalized inventory during each reporting period based on an analysis of forecasted demand compared to quantities on hand and any firm purchase orders, as well as product shelf life, and writes down any excess, obsolete or unsaleable inventory to its estimated realizable value in the period which the required reserve is first identified. Such write downs, should they occur, are charged to cost of product revenue in the consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the Company did not identify any excess, obsolete or unsaleable inventory.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-403">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of laboratory equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:f-404"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-65" id="f-405">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-406">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Codification&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC, 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 842, the Company determines if a contract contains a lease at inception and recognizes finance lease right-of-use assets and finance lease liabilities based on the present value of the future minimum lease payments at the commencement date. The implicit rate within the Company&#x2019;s finance lease was determinable and therefore used in determining the present value of future payments at the commencement date. Lease agreements that have lease and non-lease components are accounted for as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes amortization of the right-of-use assets and interest on the lease liabilities for its finance lease. Finance lease right-of-use assets are amortized on a straight-line basis from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. However, if the lease transfers ownership of the underlying asset to the lessee or the lessee is reasonably certain to exercise an option to purchase the underlying asset, the right-of-use assets are amortized to the end of the useful life of the underlying asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 842 the Company determines if a contract contains a lease at inception and recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of the future minimum lease payments at the commencement date. As the Company&#x2019;s operating leases do not provide an implicit rate, management develops incremental borrowing rates based on the information available at the commencement date in determining the present &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;value of future payments. Lease agreements that have lease and non-lease components are accounted for as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-407">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <cdtx:PatentCostsPolicyPolicyTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patent Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in selling, general and administrative, or SG&amp;amp;A, expenses in the accompanying statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</cdtx:PatentCostsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-409">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company reports deferred income taxes in accordance with ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <cdtx:TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock contextRef="c-1" id="f-410">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indirect Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s purchases of clinical drug supplies and raw materials, inventory transfers, and sales of commercial drug product are subject to indirect taxation in various jurisdictions outside of the U.S. Indirect tax payable is included in accrued indirect tax liabilities, the related expense is included in research and development, or R&amp;amp;D, expenses, and the related interest and penalties are included in SG&amp;amp;A expenses. The accrual is for the indirect tax incurred in various tax jurisdictions outside of the U.S. as a consequence of the Company&#x2019;s supply chain activities or in connection with commercial sales of REZZAYO. To the extent that any accrued indirect taxes are determined to not be due and payable, then any associated liabilities and operating expenses will be reversed in future periods. Indirect tax amounts on commercial sales (product revenue) that can be billed to and recovered from our customers are included in accounts receivables. Indirect tax amounts related to inventory purchases and manufacturing are included within inventory.&lt;/span&gt;&lt;/div&gt;</cdtx:TaxesOtherThanIncomeTaxesPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-411">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational development milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company entered into a License Agreement with Melinta, or the Melinta License Agreement. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#x2019;s estimates have no impact on the Company&#x2019;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment and milestones achieved to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 9 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2022 and January 2023, the Company entered into separate Commercial Supply Agreements with Mundipharma and Melinta, respectively, for the batch supply of REZZAYO naked vials for commercial use. Under the Commercial Supply Agreements, Mundipharma and Melinta are required to submit purchase orders to the Company for batches of REZZAYO naked vials. The Company concluded that the delivery of each batch of REZZAYO naked vials and the related quality assessment certification represents a distinct performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The transaction price to be recognized as revenue for each performance obligation under the Commercial Supply Agreements consists of variable consideration which is determined based on the estimated per vial costs, plus the contractually stated margin rate. The amounts recognized as revenue are adjusted, as needed, each reporting period based on actual costs incurred for each batch. Variable consideration is included in the transaction price only to the extent that it is considered probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company has made an accounting policy election to exclude from the transaction price any indirect taxes collected from customers. As a result, any such collections are recorded as indirect taxes liabilities. The transaction price will be fully allocated to the single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that the performance obligation is satisfied and product revenue is recognized when the customer obtains control of the product, which occurs at a point in time, typically upon the later of (i) completion of a positive quality assessment, or (ii) shipment of the Company&#x2019;s product to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Shipping and handling activities that are performed after a customer obtains control of the product are treated as activities to fulfill the promise to a customer and any amounts billed to a customer represent revenues for the product provided. Costs related to such shipping and handling billings are classified as cost of product revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="c-66"
      decimals="INF"
      id="f-412"
      unitRef="obligation">3</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="c-67"
      decimals="INF"
      id="f-413"
      unitRef="obligation">1</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="c-68"
      decimals="INF"
      id="f-414"
      unitRef="obligation">3</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="c-69"
      decimals="INF"
      id="f-415"
      unitRef="obligation">3</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-416">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cost of product revenue consists primarily of costs related to materials, third-party contract manufacturing, freight-in and overhead. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-417">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses in preclinical development and certain manufacturing expenses before FDA approval, nonclinical and clinical trial costs, and indirect taxes on clinical supplies and development materials.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-418">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling, General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;SG&amp;amp;A expenses relate to selling, finance, human resources, legal and other administrative activities. SG&amp;amp;A expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning and support functions. Other SG&amp;amp;A expenses include facility and overhead costs not otherwise included in cost of product revenue or research and development expenses, consultant expenses, travel expenses, professional fees for auditing, tax, legal, and other services, the branded prescription drug fee, and any accrued interest and penalties on accrued indirect tax liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.&lt;/span&gt;&lt;/div&gt;</cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-420">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company&#x2019;s common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company&#x2019;s stock, (c) the expected term of the award, and (d) the expected dividend yield.&#160;The Company computed the expected volatility data using the daily close prices for the Company&#x2019;s common stock during the equivalent period of the calculated expected term of the Company&#x2019;s stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and does not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-421" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the treasury stock method or if-converted method. Under the two-class method, the net loss attributable to common stockholders is not allocated to the Series X Convertible Preferred Stock as the preferred stockholders do not have a contractual obligation to share in the Company&#x2019;s losses. For all periods presented, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-423">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of basic and diluted net loss per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,044,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,764,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,323,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33,826,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40,025,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-70" decimals="0" id="f-424" unitRef="shares">17331</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-71" decimals="0" id="f-425" unitRef="shares">12517328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-72" decimals="0" id="f-426" unitRef="shares">21044720</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-73" decimals="0" id="f-427" unitRef="shares">18184720</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-74" decimals="0" id="f-428" unitRef="shares">12764068</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-75" decimals="0" id="f-429" unitRef="shares">9323495</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-430" unitRef="shares">33826119</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-8" decimals="0" id="f-431" unitRef="shares">40025543</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 820-10, with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, accrued compensation and benefits, and lease liabilities. The carrying amount of these financial instruments are generally considered to be representative of their respective fair values because of their short-term nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-433">&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies that are adopted by the Company as of the specified effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Update&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, which requires public entities to disclose disaggregated information about their effective tax rate reconciliation as well as expanded information on income taxes paid by jurisdiction. The disclosure requirements will be applied on a prospective basis, with the option to apply them retrospectively. The standard is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company plans to adopt this guidance for the fiscal year ending December 31, 2025 and believes, based on its preliminary assessment, that this new guidance will not have a material impact on the Company&#x2019;s consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company believes, based on its preliminary assessment, that any other recently issued, but not yet adopted, accounting pronouncements will not have a material impact on the Company&#x2019;s consolidated financial statements or related disclosures, or do not apply to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-434">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company classifies investments in money market accounts within Level 1 as the prices are available from quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-435">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-436" unitRef="usd">35778000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-437" unitRef="usd">35778000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-77" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-4" decimals="-3" id="f-440" unitRef="usd">35778000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-441" unitRef="usd">35778000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-77" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-444" unitRef="usd">32731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-445" unitRef="usd">32731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-5" decimals="-3" id="f-448" unitRef="usd">32731000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-449" unitRef="usd">32731000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-452">INVENTORY&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s capitalized inventory consists of costs incurred subsequent to FDA approval of REZZAYO in March 2023. Prior to regulatory approval, all direct and indirect manufacturing costs were charged to research and development expense in the period incurred. There were no inventory write downs during the year ended&#160;December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-453">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-4" decimals="-3" id="f-454" unitRef="usd">2691000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-5" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c-4" decimals="-3" id="f-456" unitRef="usd">3406000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-5" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-4" decimals="-3" id="f-458" unitRef="usd">0</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-5" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-460" unitRef="usd">6097000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="INF" id="f-462" unitRef="usd">0</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-463">PROPERTY AND EQUIPMENT&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization of property and equipment of $0.1 million and $0.1 million were recorded for the years ended December&#160;31, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-464">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-82" decimals="-3" id="f-465" unitRef="usd">2817000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-83" decimals="-3" id="f-466" unitRef="usd">2415000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-84" decimals="-3" id="f-467" unitRef="usd">425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-85" decimals="-3" id="f-468" unitRef="usd">425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-86" decimals="-3" id="f-469" unitRef="usd">327000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-87" decimals="-3" id="f-470" unitRef="usd">305000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-88" decimals="-3" id="f-471" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-89" decimals="-3" id="f-472" unitRef="usd">93000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-90" decimals="-3" id="f-473" unitRef="usd">142000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-91" decimals="-3" id="f-474" unitRef="usd">142000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-475" unitRef="usd">3747000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-476" unitRef="usd">3380000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-477" unitRef="usd">3190000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-478" unitRef="usd">3158000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-479" unitRef="usd">557000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-480" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-481" unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-8" decimals="-5" id="f-482" unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-483">DEBT&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $10.0&#160;million&#160;from the Lender, or the Term A Loan. The Term A Loan bore interest at a variable annual rate equal to the greater of (i) 4.50%&#160;or (ii)&#160;the Lender&#x2019;s prime interest rate plus 0.75%, and matured on July 3, 2022. The Term A Loan had an interest-only period through April 3, 2020, which was followed by equal monthly principal payments and was paid in full on July 5, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-92" decimals="INF" id="f-484" unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-92"
      decimals="INF"
      id="f-485"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-93"
      decimals="INF"
      id="f-486"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-487">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Controlled Equity Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement, or the Sales Agreement, entered into on November 8, 2018 with Cantor Fitzgerald &amp;amp; Co, or Cantor. During the years ended December&#160;31, 2023 and 2022, the Company sold 6,219,741 and 3,414,926 shares of common stock for net proceeds of approximately $8.7 million and $2.4 million, respectively, after deducting placement agent fees. As of December&#160;31, 2023, the remaining capacity under the Sales Agreement is $37.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Underwritten Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On March 7, 2023, the Company completed concurrent but separate underwritten public offerings with Cantor, the underwriter, to issue and sell 11,086,000 shares of its common stock, including the exercise in full by Cantor of their option to purchase an additional 1,446,000 shares of common stock, and 286,000 shares of the Company&#x2019;s Series X Convertible Preferred Stock. Cantor agreed to purchase the shares of common stock at a price of $1.267 per share and the shares of Series X Convertible Preferred Stock at a price of $12.67 per share. The total gross proceeds from the offerings, including the full exercise by Cantor of its option to purchase additional shares of common stock, were approximately $19.5&#160;million, before deducting underwriting discounts and commissions and offering expenses. The Company received total net proceeds of approximately $17.3&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the amended and restated certificate of incorporation, the Company&#x2019;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On August 12, 2020, at the request of certain holders, 52,241 shares of the Company&#x2019;s Series X Convertible Preferred Stock were converted to an aggregate of 522,410 shares of the Company&#x2019;s common stock. As of December&#160;31, 2023 and 2022 shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The specific terms of the Series X Convertible Preferred Stock are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Conversion: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 10 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder&#x2019;s for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Dividends:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company&#x2019;s common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Liquidation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Upon the liquidation, dissolution, or winding up of the Company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Voting:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC 480, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company had 200,000,000 shares of common stock authorized as of December&#160;31, 2023. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#x2019;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#x2019;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, warrants to purchase 17,331 shares of the Company&#x2019;s common stock were outstanding with a weighted average exercise price of $11.54 per share. During the year ended December&#160;31, 2023, 12,499,997 common stock warrants expired unexercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, warrants to purchase 12,517,328 shares of the Company&#x2019;s common stock were outstanding with a weighted average exercise price of $6.82 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The warrants had no intrinsic value at December&#160;31, 2023 and 2022. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,044,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,764,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,323,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,411,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,469,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;987,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;806,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38,225,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,302,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-94"
      decimals="INF"
      id="f-488"
      unitRef="shares">6219741</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-95"
      decimals="INF"
      id="f-489"
      unitRef="shares">3414926</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-94" decimals="-5" id="f-490" unitRef="usd">8700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-95" decimals="-5" id="f-491" unitRef="usd">2400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cdtx:SaleOfStockConsiderationRemainingOnTransaction contextRef="c-96" decimals="-5" id="f-492" unitRef="usd">37100000</cdtx:SaleOfStockConsiderationRemainingOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-97"
      decimals="INF"
      id="f-493"
      unitRef="shares">11086000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-98"
      decimals="INF"
      id="f-494"
      unitRef="shares">1446000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-99"
      decimals="INF"
      id="f-495"
      unitRef="shares">286000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-100"
      decimals="3"
      id="f-496"
      unitRef="usdPerShare">1.267</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-101"
      decimals="2"
      id="f-497"
      unitRef="usdPerShare">12.67</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction contextRef="c-102" decimals="-5" id="f-498" unitRef="usd">19500000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-102" decimals="-5" id="f-499" unitRef="usd">17300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-500" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-501" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-103"
      decimals="INF"
      id="f-502"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-103"
      decimals="INF"
      id="f-503"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-104"
      decimals="INF"
      id="f-504"
      unitRef="shares">52241</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-105"
      decimals="INF"
      id="f-505"
      unitRef="shares">522410</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-506" unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-507" unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-103"
      decimals="INF"
      id="f-508"
      unitRef="shares">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion
      contextRef="c-106"
      decimals="INF"
      id="f-509"
      unitRef="number">0.0999</cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-510" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <cdtx:NumberOfVotesEntitlementForEachShareHeld contextRef="c-1" decimals="INF" id="f-511" unitRef="vote">1</cdtx:NumberOfVotesEntitlementForEachShareHeld>
    <cdtx:CommonStockDividendsInArrearsOrDefault contextRef="c-1" decimals="INF" id="f-512" unitRef="usd">0</cdtx:CommonStockDividendsInArrearsOrDefault>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-107"
      decimals="INF"
      id="f-513"
      unitRef="shares">17331</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-108"
      decimals="2"
      id="f-514"
      unitRef="usdPerShare">11.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdtx:ClassOfWarrantOrRightExpired
      contextRef="c-109"
      decimals="INF"
      id="f-515"
      unitRef="shares">12499997</cdtx:ClassOfWarrantOrRightExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-110"
      decimals="INF"
      id="f-516"
      unitRef="shares">12517328</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="2"
      id="f-517"
      unitRef="usdPerShare">6.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-107" decimals="INF" id="f-518" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c-110" decimals="INF" id="f-519" unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-520">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;21,044,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,764,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,323,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,411,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,469,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;987,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;806,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;38,225,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,302,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-112"
      decimals="INF"
      id="f-521"
      unitRef="shares">17331</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-113"
      decimals="INF"
      id="f-522"
      unitRef="shares">12517328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-114"
      decimals="INF"
      id="f-523"
      unitRef="shares">21044720</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-115"
      decimals="INF"
      id="f-524"
      unitRef="shares">18184720</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-116"
      decimals="INF"
      id="f-525"
      unitRef="shares">12764068</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-117"
      decimals="INF"
      id="f-526"
      unitRef="shares">9323495</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-118"
      decimals="INF"
      id="f-527"
      unitRef="shares">3411463</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-119"
      decimals="INF"
      id="f-528"
      unitRef="shares">4469969</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-120"
      decimals="INF"
      id="f-529"
      unitRef="shares">987756</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-121"
      decimals="INF"
      id="f-530"
      unitRef="shares">806968</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-531" unitRef="shares">38225338</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-5" decimals="INF" id="f-532" unitRef="shares">45302480</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-533">EQUITY INCENTIVE PLANS&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Inducement Incentive Plan and 2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company&#x2019;s board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company&#x2019;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by 4% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a &lt;span style="-sec-ix-hidden:f-535"&gt;three&lt;/span&gt;- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company&#x2019;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i) 1% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31, (ii) 490,336 shares, or (iii) such lesser number as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The ESPP allows substantially all employees to purchase the Company&#x2019;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#x2019;s payroll deductions under the ESPP are limited to 15% of the employee&#x2019;s eligible compensation.&#160;During the years ended December&#160;31, 2023 and 2022, 309,548 and 363,596 shares, respectively, were issued pursuant to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, total unrecognized compensation expense related to the ESPP was immaterial and is expected to be recognized over approximately 0.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PRSU activity during the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs and PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,223,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,515,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(490,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(151,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,098,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of RSUs and PRSUs granted by the Company during the year ended December&#160;31, 2022 was $0.83 per share. The total fair value of RSUs and PRSUs vested during the years ended December&#160;31, 2023 and 2022 was approximately $0.7 million and $1.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, estimated unrecognized compensation expense related to RSUs and PRSUs granted was approximately $1.7 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;br/&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,099,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,233,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(641,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,666,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,666,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,236,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted by the Company during the years ended December&#160;31, 2023 and 2022 was $0.72 and $0.51, respectively, per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, total unrecognized share-based compensation expense related to unvested stock options was approximately $2.4 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 1.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted to employees under the 2015 EIP and 2020 IIP and the shares purchasable under the 2015 ESPP during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2015 EIP and 2020 IIP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.58% - 4.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.39% - 4.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82% - 83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70% - 75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2015 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.29% - 5.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.57% - 2.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64% - 147%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75% - 98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.50 - 2.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.50 - 2.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage
      contextRef="c-122"
      decimals="INF"
      id="f-534"
      unitRef="number">0.04</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-124" id="f-536">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-122" id="f-537">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-122"
      decimals="INF"
      id="f-538"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold
      contextRef="c-122"
      decimals="INF"
      id="f-539"
      unitRef="number">0.10</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-125"
      decimals="INF"
      id="f-540"
      unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage
      contextRef="c-126"
      decimals="INF"
      id="f-541"
      unitRef="number">0.01</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-127"
      decimals="INF"
      id="f-542"
      unitRef="shares">490336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-126"
      decimals="INF"
      id="f-543"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c-128"
      decimals="INF"
      id="f-544"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-129"
      decimals="INF"
      id="f-545"
      unitRef="shares">309548</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-130"
      decimals="INF"
      id="f-546"
      unitRef="shares">363596</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-129" id="f-547">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-548">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PRSU activity during the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs and PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,223,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,515,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(490,520)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(151,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,098,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-131"
      decimals="INF"
      id="f-549"
      unitRef="shares">1223871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-131"
      decimals="2"
      id="f-550"
      unitRef="usdPerShare">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-132"
      decimals="INF"
      id="f-551"
      unitRef="shares">1515817</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-132"
      decimals="2"
      id="f-552"
      unitRef="usdPerShare">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-132"
      decimals="INF"
      id="f-553"
      unitRef="shares">490520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-132"
      decimals="2"
      id="f-554"
      unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-132"
      decimals="INF"
      id="f-555"
      unitRef="shares">151115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-132"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-133"
      decimals="INF"
      id="f-557"
      unitRef="shares">2098053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-133"
      decimals="2"
      id="f-558"
      unitRef="usdPerShare">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-134"
      decimals="2"
      id="f-559"
      unitRef="usdPerShare">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-132" decimals="-5" id="f-560" unitRef="usd">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-134" decimals="-5" id="f-561" unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-133" decimals="-5" id="f-562" unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-132" id="f-563">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-564">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;in Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;br/&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,099,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,233,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(641,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,666,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,666,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;7,236,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-565" unitRef="shares">8099624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-566"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-8" id="f-567">P6Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-568" unitRef="usd">48000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-569" unitRef="shares">3233558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-570"
      unitRef="usdPerShare">1.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-571" unitRef="shares">25750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-572"
      unitRef="usdPerShare">0.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-573" unitRef="shares">641417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-574"
      unitRef="usdPerShare">3.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-575" unitRef="shares">10666015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-576"
      unitRef="usdPerShare">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-577">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-578" unitRef="usd">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-4" decimals="INF" id="f-579" unitRef="shares">10666015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-581">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-3" id="f-582" unitRef="usd">57000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="INF" id="f-583" unitRef="shares">7236987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-584"
      unitRef="usdPerShare">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-585">P5Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-586" unitRef="usd">54000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-587"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-8"
      decimals="2"
      id="f-588"
      unitRef="usdPerShare">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-5" id="f-589" unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-135" id="f-590">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-591">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Black-Scholes option pricing model assumptions used to estimate the fair value of stock options granted to employees under the 2015 EIP and 2020 IIP and the shares purchasable under the 2015 ESPP during the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2015 EIP and 2020 IIP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.58% - 4.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.39% - 4.02%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82% - 83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70% - 75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.50 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2015 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4.29% - 5.43%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.57% - 2.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;64% - 147%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;75% - 98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.50 - 2.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.50 - 2.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-136" decimals="4" id="f-592" unitRef="number">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-136" decimals="4" id="f-593" unitRef="number">0.0461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-137" decimals="4" id="f-594" unitRef="number">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-137" decimals="4" id="f-595" unitRef="number">0.0402</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-136" decimals="2" id="f-596" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-137" decimals="2" id="f-597" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-136" decimals="2" id="f-598" unitRef="number">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-136" decimals="2" id="f-599" unitRef="number">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-137" decimals="2" id="f-600" unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-137" decimals="2" id="f-601" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-138" id="f-602">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-139" id="f-603">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-140" id="f-604">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-141" id="f-605">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-142" decimals="4" id="f-606" unitRef="number">0.0429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-142" decimals="4" id="f-607" unitRef="number">0.0543</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-143" decimals="4" id="f-608" unitRef="number">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-143" decimals="4" id="f-609" unitRef="number">0.0265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-142" decimals="2" id="f-610" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-143" decimals="2" id="f-611" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-142" decimals="2" id="f-612" unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-142" decimals="2" id="f-613" unitRef="number">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-143" decimals="2" id="f-614" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-143" decimals="2" id="f-615" unitRef="number">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-144" id="f-616">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-145" id="f-617">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-146" id="f-618">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-147" id="f-619">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-620">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for RSUs, PRSUs, stock options, and the ESPP has been reported in the consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-148" decimals="-3" id="f-621" unitRef="usd">1592000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-149" decimals="-3" id="f-622" unitRef="usd">1760000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-150" decimals="-3" id="f-623" unitRef="usd">1469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-151" decimals="-3" id="f-624" unitRef="usd">1945000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-625" unitRef="usd">3061000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-8" decimals="-3" id="f-626" unitRef="usd">3705000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-627">SIGNIFICANT AGREEMENTS AND CONTRACTS&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;.&#160;Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#x2019;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#x2019;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#x2011;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Mundipharma Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, at Mundipharma&#x2019;s sole cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;.&#160;Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#x2011;bearing license to develop, register and commercialize the Mundipharma Licensed Product in the Mundipharma Territory, subject to the Company&#x2019;s retained right as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#x2011;exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#x2019;s territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Retained Rights.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As of December&#160;31, 2023, the Company retained the exclusive right to develop, register and commercialize the Mundipharma Licensed Product, Subcutaneous Product and Other Products in Japan, or the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Mundipharma Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Terms&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;.&#160;As of the execution of the Mundipharma Collaboration Agreement, the parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#x2019;s Global Development Cost share of $31.2&#160;million. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible to receive double-digit royalties in the teens on tiers of annual net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;.&#160;Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSTORE Trial and the ReSPECT Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company&#x2019;s patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0 million, plus the research and development funding of $31.2 million, plus milestones achieved of $25.1 million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the revenue related to this performance obligation in the amount of&#160;$17.9 million&#160;in September 2019 as collaboration revenue in its consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company&#x2019;s initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;In November 2020, the Company achieved a $11.1 million milestone under the Mundipharma Collaboration Agreement, which is recorded as current contract liabilities as of December&#160;31, 2023 because the rights to consideration is expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. As of December&#160;31, 2023, the Company estimated the uncredited portion to be approximately $10.1&#160;million in December 2024. In December 2021, August 2022, and December 2023, the Company achieved milestones of $2.8&#160;million, $11.1&#160;million, and $11.1&#160;million, respectively, under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones achieved as of December&#160;31, 2023 in January 2022, September 2022, and February 2024, respectively. The Company determined that as of&#160;December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#x2019;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In January 2024, the Company achieved a milestone of $2.8&#160;million under the Mundipharma Collaboration Agreement for which the Company received payment in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur.&#160;No&#160;royalty revenue was recognized during the years ended&#160;December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs based on the Company&#x2019;s Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 clinical trial, or Phase 2 Study. Unless otherwise agreed by the parties, the Company is responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company is the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified CMC development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2023 Janssen delivered its Election to Proceed Notice for CD388 whereby Janssen will assume the future development, manufacturing and commercialization activities of CD388 under the Janssen Collaboration Agreement. The Company continues to work in collaboration with Janssen to complete the Phase 1 and Phase 2a clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Following Janssen&#x2019;s Election to Proceed Notice, Janssen, is obligated at its sole expense to diligently continue development and commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#x2019;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Compete Covenant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#x2019;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#x2019;s DFC technology more broadly. The Company&#x2019;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Terms&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company was eligible for reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting Research Plan activities. The Company was also be eligible to receive up to $695.0&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. In addition to the Company&#x2019;s right to terminate the Janssen Collaboration Agreement for Janssen&#x2019;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;prior to the completion of all Research Plan activities and the Company&#x2019;s delivery to Janssen of all Research Plan deliverables, upon 90 days&#x2019; written notice to the Company, provided that if any clinical trial under the Research Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;after completion of the Phase 2 Study and before expiration of the Election Period, immediately upon written notice to the Company; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;after delivery of the Election to Proceed Notice, upon 90 days&#x2019; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million, plus the research and development funding of $49.8&#160;million, plus milestones achieved of $10.0&#160;million. The transaction price includes the total estimated costs related to research and development and clinical supply services, which can increase or decrease as costs to continue the research and development efforts become known. No revenue was reversed due to the change in transaction price as revenue is recognized based on actual amounts billed. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $26.8&#160;million, as restated, in May 2021 as collaboration revenue in its consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The research and development services to be performed represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; In March 2022 and September 2023, the Company achieved milestones of $3.0&#160;million and $7.0&#160;million, respectively, under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in May 2022 and September 2023, respectively. The Company determined that as of December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#x2019;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur. No royalty revenue was recognized during the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Melinta License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Pursuant to the Melinta License Agreement, the Company granted Melinta an exclusive, royalty&#x2011;bearing license (including the right to sublicense through multiple tiers), to develop, register and commercialize the Melinta Licensed Product for all uses in humans and non-human animals in the Melinta Territory, subject to the Company&#x2019;s retained right, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Compete Covenant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Until the fifth anniversary of the first commercial sale of the first Melinta Licensed Product in the Melinta Territory, neither the Company nor Melinta, nor any of their respective majority-owned subsidiaries may, directly or indirectly, itself or in collaboration with any third party, develop, manufacture for development or commercialization, or commercialize any product in the echinocandin class of drugs in the Melinta Territory without the other party&#x2019;s prior written consent, subject to certain provisions in connection with a change of control of a party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercialization.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Melinta is solely responsible for the commercialization of rezafungin in the Melinta Territory, at its sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Retained Rights.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company retains the non-exclusive right to practice the intellectual property rights licensed to Melinta in the Melinta Territory solely for the purpose of performing its obligations under the Melinta License Agreement and Mundipharma Collaboration Agreement. The Company also retains the right to grant licenses under the intellectual property rights licensed to Melinta to third parties to which the Company has granted licenses or rights to market, promote and sell Melinta Licensed Product outside the Melinta Territory, to make and have made Melinta Licensed Product anywhere in the world solely to develop, register, use, sell, have sold, offer for sale, commercialize and import Melinta Licensed Product outside the Melinta Territory, subject to the terms of the Melinta License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Continued Development and Regulatory Activities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company is responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that includes, among other activities, (a) completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the FDA of a supplemental new drug application, or sNDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the Company&#x2019;s ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain CMC activities for the Melinta Licensed Product, and (f) all other development activities that are required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company will remain the holder of the rezafungin IND and new drug application, or NDA. Both regulatory applications will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated sNDA for the Prophylaxis Indication, after which Melinta will be responsible for performing all activities that may be necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta&#x2019;s sole expense, subject to Melinta&#x2019;s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket expenses incurred by Melinta.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supply and Transfer of CMC activities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Until Melinta assumes responsibility for the manufacture and supply of the Melinta Licensed Product for development and commercialization in the Melinta Territory, which it may do by direct purchase from the Company&#x2019;s contract manufacturing organizations for the Melinta Licensed Product or by having a manufacturing technology transfer to Melinta or its designee performed at Melinta&#x2019;s sole expense, which, in either case, will be no later than December 31, 2026, the Company will be responsible for the manufacture and supply of the Melinta Licensed Product for development and commercialization by Melinta in the Melinta Territory, and during such period, shall supply Melinta Licensed Product to Melinta pursuant to the terms of a supply agreement negotiated by the parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Terms.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Upon execution of the Melinta License Agreement, the total potential transaction value is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestone payments. In addition, the Company is eligible to receive tiered royalties on U.S. sales in the low double digits to mid-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Either party may terminate the Melinta License Agreement for uncured material breach by the other party. After July 26, 2023, Melinta may terminate the Melinta License Agreement at will. The Company may terminate the Melinta License Agreement if Melinta or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the patent rights licensed to Melinta by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million, plus a milestone achieved of $20.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company utilized discounted cash flows and developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022, therefore the Company recognized the revenue related to this performance obligation in the amount of&#160;$25.9&#160;million&#160;in August 2022 as collaboration revenue in its consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company is required to provide research and development services, at its sole expense, as described under the Melinta Development Plan, which represents a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company&#x2019;s obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services. Revenue related to the clinical supply services performance obligation recognized during the year ended December&#160;31, 2023 was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;In March 2023, the Company achieved a $20.0&#160;million milestone under the Melinta License Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as contract liabilities at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in April 2023. The Company determined that as of&#160;December&#160;31, 2023, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&#x2019;s control or are otherwise constrained under the variable consideration guidance. Therefore, these milestone payments have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize royalty revenue when the related sales occur. The Company recognized $0.2&#160;million in royalty revenue during the year ended December&#160;31, 2023 following the commercial launch of REZZAYO by Melinta in the U.S. on July 31, 2023. No royalty revenue was recognized during the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Costs to Obtain a Contract with a Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $2.0&#160;million upon execution of the Melinta License Agreement, and capitalized an additional $0.5&#160;million upon achievement of a milestone, in accordance with ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company incurred these costs in connection with all the performance obligations identified in the Melinta License Agreement and allocated the capitalized contract costs to performance obligations on a relative basis (i.e., in proportion to the transaction price allocated to each performance obligation) to determine the period of amortization. The Company recognized expense during the years ended December&#160;31, 2023 and 2022 of $0.5&#160;million and $1.8&#160;million, respectively, and is included within SG&amp;amp;A expenses in the Company&#x2019;s consolidated statements of operations and comprehensive loss. As of December&#160;31, 2023, the remaining balance of the asset recognized from costs to obtain the Melinta License Agreement was $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company&#x2019;s contract liabilities pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the year ended&#160;December&#160;31, 2023&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Opening balance, December&#160;31, 2022 (As Restated)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(9,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Closing balance, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total contract liabilities, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the aggregate transaction price allocated to performance obligations that are unsatisfied is $11.5&#160;million, $3.8&#160;million and $3.7&#160;million under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. These amounts are expected to be recognized over 2 years, 0.5 years, and 2 years which represent the remaining research periods under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the Company recorded $13.9&#160;million, $1.9&#160;million, and $0.4&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. As of December&#160;31, 2022, the Company recorded $0.2&#160;million and $5.6&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents our collaboration revenue disaggregated by collaborator and timing of revenue recognition (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon milestones achieved&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon transfer of license&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon milestones achieved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cdtx:CollaborativeArrangementCostSharingPercentage
      contextRef="c-152"
      decimals="INF"
      id="f-628"
      unitRef="number">0.50</cdtx:CollaborativeArrangementCostSharingPercentage>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost contextRef="c-152" decimals="-5" id="f-629" unitRef="usd">31200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <cdtx:CollaborativeArrangementTransactionPotentialValue contextRef="c-152" decimals="-5" id="f-630" unitRef="usd">568400000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-153" decimals="-5" id="f-631" unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost contextRef="c-153" decimals="-5" id="f-632" unitRef="usd">31200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-154" decimals="-5" id="f-633" unitRef="usd">25100000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-155" decimals="-5" id="f-634" unitRef="usd">17900000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability contextRef="c-156" decimals="-5" id="f-635" unitRef="usd">11100000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion contextRef="c-157" decimals="-5" id="f-636" unitRef="usd">10100000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-158" decimals="-5" id="f-637" unitRef="usd">2800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-159" decimals="-5" id="f-638" unitRef="usd">11100000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-160" decimals="-5" id="f-639" unitRef="usd">11100000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-161" decimals="-5" id="f-640" unitRef="usd">2800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-162" decimals="INF" id="f-641" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-163" decimals="INF" id="f-642" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-164" decimals="-5" id="f-643" unitRef="usd">27000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementTransactionPotentialValue contextRef="c-165" decimals="-5" id="f-644" unitRef="usd">58200000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:CollaborativeArrangementTransactionPotentialValue contextRef="c-166" decimals="-5" id="f-645" unitRef="usd">695000000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice contextRef="c-167" id="f-646">P90D</cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice>
    <cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice contextRef="c-167" id="f-647">P90D</cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-168" decimals="-5" id="f-648" unitRef="usd">27000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost contextRef="c-168" decimals="-5" id="f-649" unitRef="usd">49800000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-169" decimals="-5" id="f-650" unitRef="usd">10000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-170" decimals="-5" id="f-651" unitRef="usd">26800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-171" decimals="-5" id="f-652" unitRef="usd">3000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-172" decimals="-5" id="f-653" unitRef="usd">7000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-173" decimals="INF" id="f-654" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-174" decimals="INF" id="f-655" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:CollaborativeArrangementTransactionPotentialValue contextRef="c-175" decimals="-5" id="f-656" unitRef="usd">460000000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-176" decimals="-5" id="f-657" unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementTransactionPotentialValue contextRef="c-177" decimals="-5" id="f-658" unitRef="usd">430000000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:PaymentsRelatedToCollaborativeAgreements contextRef="c-178" decimals="-5" id="f-659" unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-179" decimals="-5" id="f-660" unitRef="usd">20000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-180" decimals="-5" id="f-661" unitRef="usd">25900000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-181" decimals="-5" id="f-662" unitRef="usd">20000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-182" decimals="-5" id="f-663" unitRef="usd">200000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-183" decimals="INF" id="f-664" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:CapitalizedContractCostGross contextRef="c-184" decimals="-5" id="f-665" unitRef="usd">2000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross contextRef="c-185" decimals="-5" id="f-666" unitRef="usd">500000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-186" decimals="-5" id="f-667" unitRef="usd">500000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-187" decimals="-5" id="f-668" unitRef="usd">1800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet contextRef="c-184" decimals="-5" id="f-669" unitRef="usd">200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock contextRef="c-1" id="f-670">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company&#x2019;s contract liabilities pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the year ended&#160;December&#160;31, 2023&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.124%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Opening balance, December&#160;31, 2022 (As Restated)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(9,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Closing balance, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term portion of contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total contract liabilities, December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;29,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents our collaboration revenue disaggregated by collaborator and timing of revenue recognition (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon milestones achieved&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;17,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;16,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon transfer of license&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property - upon milestones achieved&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;26,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability contextRef="c-188" decimals="-3" id="f-671" unitRef="usd">35139000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance contextRef="c-189" decimals="-3" id="f-672" unitRef="usd">1755000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable contextRef="c-190" decimals="-3" id="f-673" unitRef="usd">1488000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerPaymentReceivable>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized contextRef="c-189" decimals="-3" id="f-674" unitRef="usd">9042000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability contextRef="c-190" decimals="-3" id="f-675" unitRef="usd">29340000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-676" unitRef="usd">25095000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-677" unitRef="usd">4245000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-678" unitRef="usd">29340000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-191" decimals="-5" id="f-679" unitRef="usd">11500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-192" decimals="-5" id="f-680" unitRef="usd">3800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-193" decimals="-5" id="f-681" unitRef="usd">3700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-191" id="f-682">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-192" id="f-683">P0Y6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-193" id="f-684">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-194" decimals="-5" id="f-685" unitRef="usd">13900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-195" decimals="-5" id="f-686" unitRef="usd">1900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-196" decimals="-5" id="f-687" unitRef="usd">400000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-197" decimals="-5" id="f-688" unitRef="usd">200000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-198" decimals="-5" id="f-689" unitRef="usd">5600000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-199" decimals="-3" id="f-690" unitRef="usd">3252000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-200" decimals="-3" id="f-691" unitRef="usd">2347000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-201" decimals="-3" id="f-692" unitRef="usd">17257000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-202" decimals="-3" id="f-693" unitRef="usd">26000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-203" decimals="-3" id="f-694" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-204" decimals="-3" id="f-695" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-205" decimals="-3" id="f-696" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-206" decimals="-3" id="f-697" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-207" decimals="-3" id="f-698" unitRef="usd">168000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-208" decimals="-3" id="f-699" unitRef="usd">12303000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-209" decimals="-3" id="f-700" unitRef="usd">19011000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-210" decimals="-3" id="f-701" unitRef="usd">2441000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-211" decimals="-3" id="f-702" unitRef="usd">840000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-212" decimals="-3" id="f-703" unitRef="usd">1925000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-213" decimals="-3" id="f-704" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-214" decimals="-3" id="f-705" unitRef="usd">16421000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-215" decimals="-3" id="f-706" unitRef="usd">23283000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-216" decimals="-3" id="f-707" unitRef="usd">19866000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-217" decimals="-3" id="f-708" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-218" decimals="-3" id="f-709" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-219" decimals="-3" id="f-710" unitRef="usd">25885000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-220" decimals="-3" id="f-711" unitRef="usd">3252000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-221" decimals="-3" id="f-712" unitRef="usd">976000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-222" decimals="-3" id="f-713" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-223" decimals="-3" id="f-714" unitRef="usd">484000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-224" decimals="-3" id="f-715" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-225" decimals="-3" id="f-716" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-226" decimals="-3" id="f-717" unitRef="usd">9595000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-227" decimals="-3" id="f-718" unitRef="usd">18814000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-228" decimals="-3" id="f-719" unitRef="usd">811000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-229" decimals="-3" id="f-720" unitRef="usd">925000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-230" decimals="-3" id="f-721" unitRef="usd">3706000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-231" decimals="-3" id="f-722" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-232" decimals="-3" id="f-723" unitRef="usd">14256000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-233" decimals="-3" id="f-724" unitRef="usd">23496000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-234" decimals="-3" id="f-725" unitRef="usd">26696000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-726">INCOME TAXES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The tax provision for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current tax provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total current tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under ASC 740. Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation between income taxes computed at the federal statutory rate and the provision for income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21% for 2023 and 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nondeductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(19,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(10,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;162m deferred tax asset limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;382 NOL and tax credit limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expired stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Current year tax expense is primarily the result of capitalized Internal Revenue Code, or IRC, Section 174 research and development expenditures, effective January 1, 2022, creating taxable income which can be offset with net operating losses and credits that are limited in use by IRC Sections 382 and 383.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;84,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(83,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(76,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Capitalized inventory costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the Company had federal and state tax net operating loss carryforwards of approximately $153.8&#160;million and $131.2 million, respectively. The federal and state net operating loss carryforwards begin to expire in 2035 and 2029, respectively, unless previously utilized. The Company also has federal research and development credit and orphan drug credit carryforwards totaling $9.5 million and state research and development credit carryforwards totaling $5.3 million. The federal research and development credit and orphan drug credit carryforwards begin to expire in 2035, unless previously utilized. The state research and development credit carryforwards begin to expire in 2029, with the exception of $5.3&#160;million which have no expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Based on the weight of all evidence, including a history of operating losses, management has determined that it is more likely than not that the net deferred tax assets will not be realized. The valuation allowance increased by $6.4 million in 2023 and decreased by $19.7 million in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Future utilization of the Company&#x2019;s net operating loss and tax credit carryforwards to offset future taxable income may be subject to an annual limitation, pursuant to IRC Sections 382 and 383, as a result of ownership changes that may have occurred or that could occur in the future. An ownership change occurs when a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section 382/383 analysis regarding the limitation of net operating loss and research and development credit carryforwards through 2023 and has adjusted the attributes for their estimated limitation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more likely than not recognition at the effective date to be recognized.&#160;At December&#160;31, 2023 and 2022, the unrecognized tax benefits recorded were approximately $11.5&#160;million and $11.0 million, respectively.&#160;Approximately $9.7 million of the unrecognized tax benefits would reduce the Company&#x2019;s annual effective tax rates, if recognized, subject to the valuation allowance.&#160;The Company adjusted the uncertain tax position in the current year on certain attributes related to the IRC Section 382/383 analysis performed in the current year. The Company does not anticipate a significant change in the unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Decreases related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(13,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by the U.S. and state jurisdictions where applicable. There are currently no pending income tax examinations. The Company&#x2019;s tax years from inception in 2013 are subject to examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits. The Company&#x2019;s practice is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties since inception.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-727">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The tax provision for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current tax provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total current tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-728" unitRef="usd">393000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-729" unitRef="usd">248000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-730" unitRef="usd">50000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-731" unitRef="usd">24000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-732" unitRef="usd">443000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-733" unitRef="usd">272000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-734" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-735" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-736" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-737" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-738" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-739" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-740" unitRef="usd">443000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-741" unitRef="usd">272000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-742">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation between income taxes computed at the federal statutory rate and the provision for income taxes (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Federal income taxes at 21% for 2023 and 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(7,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Nondeductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(2,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(19,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Reserve for uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(10,423)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;162m deferred tax asset limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;382 NOL and tax credit limitation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;37,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Expired stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-743" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-8" decimals="INF" id="f-744" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-235"
      decimals="INF"
      id="f-745"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-746" unitRef="usd">-4723000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-8" decimals="-3" id="f-747" unitRef="usd">-7029000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-748" unitRef="usd">-186000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-8" decimals="-3" id="f-749" unitRef="usd">-247000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-1" decimals="-3" id="f-750" unitRef="usd">260000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-8" decimals="-3" id="f-751" unitRef="usd">415000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-1" decimals="-3" id="f-752" unitRef="usd">2076000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-8" decimals="-3" id="f-753" unitRef="usd">1877000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-754" unitRef="usd">-54000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-8" decimals="-3" id="f-755" unitRef="usd">491000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-756" unitRef="usd">6373000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-757" unitRef="usd">-19684000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-3" id="f-758" unitRef="usd">519000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-8" decimals="-3" id="f-759" unitRef="usd">-10423000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <cdtx:EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount contextRef="c-1" decimals="-3" id="f-760" unitRef="usd">128000</cdtx:EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount>
    <cdtx:EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount contextRef="c-8" decimals="-3" id="f-761" unitRef="usd">82000</cdtx:EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount>
    <cdtx:EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount contextRef="c-1" decimals="-3" id="f-762" unitRef="usd">0</cdtx:EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount>
    <cdtx:EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount contextRef="c-8" decimals="-3" id="f-763" unitRef="usd">37513000</cdtx:EffectiveIncomeTaxRateReconciliation382NOLAndTaxAssetLimitationAmount>
    <cdtx:EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount contextRef="c-1" decimals="-3" id="f-764" unitRef="usd">174000</cdtx:EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount>
    <cdtx:EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount contextRef="c-8" decimals="-3" id="f-765" unitRef="usd">1052000</cdtx:EffectiveIncomeTaxRateReconciliationExpiredStockAwardsAmount>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-766" unitRef="usd">28000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-8" decimals="-3" id="f-767" unitRef="usd">-21000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-768" unitRef="usd">443000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-3" id="f-769" unitRef="usd">272000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-770">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s net deferred tax assets are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.692%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;35,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;42,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;84,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;77,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(83,086)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(76,713)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Capitalized inventory costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-771" unitRef="usd">35506000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-772" unitRef="usd">42043000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-773" unitRef="usd">9747000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-774" unitRef="usd">9327000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-4" decimals="-3" id="f-775" unitRef="usd">136000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-776" unitRef="usd">160000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-777" unitRef="usd">25871000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-778" unitRef="usd">14706000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-779" unitRef="usd">1424000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-780" unitRef="usd">1385000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <cdtx:DeferredTaxAssetsLeasingArrangements contextRef="c-4" decimals="-3" id="f-781" unitRef="usd">1112000</cdtx:DeferredTaxAssetsLeasingArrangements>
    <cdtx:DeferredTaxAssetsLeasingArrangements contextRef="c-5" decimals="-3" id="f-782" unitRef="usd">275000</cdtx:DeferredTaxAssetsLeasingArrangements>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-4" decimals="-3" id="f-783" unitRef="usd">5951000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-3" id="f-784" unitRef="usd">5620000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <cdtx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes contextRef="c-4" decimals="-3" id="f-785" unitRef="usd">4114000</cdtx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes>
    <cdtx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes contextRef="c-5" decimals="-3" id="f-786" unitRef="usd">2617000</cdtx:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTaxesOtherThanIncomeTaxes>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-787" unitRef="usd">725000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-788" unitRef="usd">1018000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-789" unitRef="usd">84586000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-790" unitRef="usd">77151000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-791" unitRef="usd">83086000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-792" unitRef="usd">76713000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-793" unitRef="usd">1500000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-794" unitRef="usd">438000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-4" decimals="-3" id="f-795" unitRef="usd">214000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-5" decimals="-3" id="f-796" unitRef="usd">189000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts contextRef="c-4" decimals="-3" id="f-797" unitRef="usd">244000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts contextRef="c-5" decimals="-3" id="f-798" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-799" unitRef="usd">1042000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-800" unitRef="usd">249000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-801" unitRef="usd">1500000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-802" unitRef="usd">438000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-803" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-804" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <cdtx:NetOperatingLossCarryforwards contextRef="c-236" decimals="-5" id="f-805" unitRef="usd">153800000</cdtx:NetOperatingLossCarryforwards>
    <cdtx:NetOperatingLossCarryforwards contextRef="c-237" decimals="-5" id="f-806" unitRef="usd">131200000</cdtx:NetOperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-236" decimals="-5" id="f-807" unitRef="usd">9500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-237" decimals="-5" id="f-808" unitRef="usd">5300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-4" decimals="-5" id="f-809" unitRef="usd">5300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-810" unitRef="usd">6400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-8" decimals="-5" id="f-811" unitRef="usd">19700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-5" id="f-812" unitRef="usd">11500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-813" unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-4" decimals="-5" id="f-814" unitRef="usd">9700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-815">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits for 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;(As Restated)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;23,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Decreases related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(13,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-816" unitRef="usd">11015000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-3" id="f-817" unitRef="usd">23990000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-818" unitRef="usd">552000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-8" decimals="-3" id="f-819" unitRef="usd">497000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-820" unitRef="usd">47000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-8" decimals="-3" id="f-821" unitRef="usd">13472000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-822" unitRef="usd">11520000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-823" unitRef="usd">11015000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-824">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business. Management believes there are no claims or actions pending against the Company at December&#160;31, 2023 which will have, individually or in the aggregate, a material adverse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;effect on its business, liquidity, financial position or results of operations. Litigation, however, is subject to inherent uncertainties, and an adverse result in such matters may arise from time to time that may harm the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a finance lease for lab equipment which was entered into in November 2023. The finance lease has a term of 36 months, monthly lease payments of $25,009, and an option to purchase the lab equipment for $1 at the end of the finance lease term. As of December&#160;31, 2023, the Company was reasonably certain that it would exercise the option to purchase the lab equipment at the end of the finance lease term. The useful life of the lab equipment is estimated to be 10 years. The rate implicit to the finance lease used in measuring the Company&#x2019;s finance lease liability was 8.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#x2019;s finance lease as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted finance lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of finance lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company&#x2019;s finance lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net finance lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the weighted average remaining finance lease term was 3.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of finance lease liabilities was zero for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Finance lease costs were immaterial for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has an operating lease for laboratory and office space in San Diego, California which was entered into in June 2014. Amendments for additional space were entered into in February 2015, March 2015 and August 2015.&#160;On April 20, 2023, the Company entered into a seventh amendment to its operating lease with Nancy Ridge Technology Center, L.P. which extended the term of the operating lease by an additional 36 months and increases the base rent to $133,371 per month effective January 1, 2024, subject to 4% increases every January. The operating lease expires on December 31, 2026 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of December&#160;31, 2023, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total operating lease term for accounting purposes. The incremental borrowing rate used in measuring the Company&#x2019;s operating lease liability was 12.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#x2019;s operating lease as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company&#x2019;s operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the weighted average remaining operating lease term was 3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities was $1.3 million and $1.2 million for the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $1.6 million and $1.3 million for the years ended December&#160;31, 2023 and 2022, respectively. These costs are primarily related to the Company&#x2019;s operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber contextRef="c-4" decimals="INF" id="f-825" unitRef="claim">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LesseeFinanceLeaseTermOfContract1 contextRef="c-238" id="f-826">P36M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <cdtx:LesseeFinanceLeaseMonthlyRate contextRef="c-239" decimals="0" id="f-827" unitRef="usd">25009</cdtx:LesseeFinanceLeaseMonthlyRate>
    <cdtx:LesseeFinanceLeaseOptionPurchaseEquipment contextRef="c-239" decimals="0" id="f-828" unitRef="usd">1</cdtx:LesseeFinanceLeaseOptionPurchaseEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-82" id="f-829">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeFinanceLeaseDiscountRate contextRef="c-4" decimals="3" id="f-830" unitRef="number">0.080</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-831">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#x2019;s finance lease as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted finance lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of finance lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-832" unitRef="usd">275000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-833" unitRef="usd">300000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-834" unitRef="usd">300000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-835" unitRef="usd">25000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-836" unitRef="usd">900000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-837" unitRef="usd">107000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability contextRef="c-4" decimals="-3" id="f-838" unitRef="usd">793000</us-gaap:FinanceLeaseLiability>
    <cdtx:AssetsAndLiabilitiesFinanceLesseeTableTextBlock contextRef="c-1" id="f-839">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company&#x2019;s finance lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net finance lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term finance lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdtx:AssetsAndLiabilitiesFinanceLesseeTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-840" unitRef="usd">788000</us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-841" unitRef="usd">6000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-842" unitRef="usd">782000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-843" unitRef="usd">218000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-844" unitRef="usd">575000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability contextRef="c-4" decimals="-3" id="f-845" unitRef="usd">793000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-846">P3Y1M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="INF" id="f-847" unitRef="usd">0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-240" id="f-848">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cdtx:LesseeOperatingLeaseMonthlyRate contextRef="c-241" decimals="INF" id="f-849" unitRef="usd">133371</cdtx:LesseeOperatingLeaseMonthlyRate>
    <cdtx:LesseeOperatingLeaseAnnualRateIncrease contextRef="c-241" decimals="2" id="f-850" unitRef="number">0.04</cdtx:LesseeOperatingLeaseAnnualRateIncrease>
    <cdtx:NumberOfOperatingLeaseOptionsForExtension
      contextRef="c-241"
      decimals="INF"
      id="f-851"
      unitRef="option">2</cdtx:NumberOfOperatingLeaseOptionsForExtension>
    <cdtx:LesseeOperatingLeaseOptionRenewalTerm contextRef="c-241" id="f-852">P2Y</cdtx:LesseeOperatingLeaseOptionRenewalTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-4" decimals="3" id="f-853" unitRef="number">0.120</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-854">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company&#x2019;s operating lease as of December&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-855" unitRef="usd">1600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-856" unitRef="usd">1665000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-857" unitRef="usd">1731000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-858" unitRef="usd">4996000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-859" unitRef="usd">912000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-860" unitRef="usd">4084000</us-gaap:OperatingLeaseLiability>
    <cdtx:AssetsAndLiabilitiesOperatingLesseeTableTextBlock contextRef="c-1" id="f-861">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company&#x2019;s operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdtx:AssetsAndLiabilitiesOperatingLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-862" unitRef="usd">3788000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-863" unitRef="usd">1082000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-864" unitRef="usd">3002000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-865" unitRef="usd">4084000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-866">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-867" unitRef="usd">1300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-8" decimals="-5" id="f-868" unitRef="usd">1200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-869" unitRef="usd">1600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-8" decimals="-5" id="f-870" unitRef="usd">1300000</us-gaap:OperatingLeaseExpense>
    <cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost contextRef="c-1" id="f-871">P30D</cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="c-1" id="f-872">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restatement of Interim Financial Information (Unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Due to the misstatements described in Note 1 above, the Company has restated its unaudited condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders&#x2019; equity (deficit), and condensed consolidated statements of cash flows for the quarterly periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Balance Sheets (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity (deficit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Preferred stock (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(403,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(415,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(395,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(403,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at March 31, 2023 and March 31, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at March 31, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3) Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2023 and March 31, 2022; 90,024,562 shares issued and outstanding at March 31, 2023 and 69,049,247 shares issued and outstanding at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Balance Sheets (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity (deficit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Preferred stock (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(429,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(408,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(419,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at June 30, 2023 and June 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at June 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6) Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2023 and June 30, 2022; 90,251,746 shares issued and outstanding at June 30, 2023 and 69,238,508 shares issued and outstanding at June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Balance Sheets (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity (deficit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Preferred stock (7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock (8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock (9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(438,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(393,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(404,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at September 30, 2023 and September 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at September 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9) Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2023 and September 30, 2022; 90,415,944 shares issued and outstanding at September 30, 2023 and 71,181,197 shares issued and outstanding at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) and comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic net earnings (loss) per common share (10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted net earnings (loss) per common share (10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,640,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,640,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,189,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,189,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)  As the Company was in an income position for the three-months ended March 31, 2023, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,115,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,115,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,133,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,133,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84,409,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84,409,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,638,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,638,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) and comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic net earnings (loss) per common share (11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted net earnings (loss) per common share (11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,217,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,217,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,592,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,592,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)  As the Company was in an income position for the three-months ended September 30, 2022, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,390,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,390,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of costs to obtain a contract with a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from underwritten public offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal repayments of Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash investing activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of costs to obtain a contract with a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from underwritten public offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal repayments of Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash investing activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset obtained in exchange for lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase of shares pursuant to Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of costs to obtain a contract with a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from underwritten public offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuance costs for underwritten public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal repayments of Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash investing activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset obtained in exchange for lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase of shares pursuant to Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="c-1" id="f-873">the Company has restated its unaudited condensed consolidated balance sheets, condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders&#x2019; equity (deficit), and condensed consolidated statements of cash flows for the quarterly periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023.&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Balance Sheets (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity (deficit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Preferred stock (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;430,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(403,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(415,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(395,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(403,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at March 31, 2023 and March 31, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at March 31, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3) Common stock, $0.0001 par value; 200,000,000 shares authorized at March 31, 2023 and March 31, 2022; 90,024,562 shares issued and outstanding at March 31, 2023 and 69,049,247 shares issued and outstanding at March 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Balance Sheets (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity (deficit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Preferred stock (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock (5)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock (6)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(416,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(429,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(408,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(419,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2023 and June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at June 30, 2023 and June 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at June 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6) Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2023 and June 30, 2022; 90,251,746 shares issued and outstanding at June 30, 2023 and 69,238,508 shares issued and outstanding at June 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Balance Sheets (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity (deficit):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Preferred stock (7)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred stock (8)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Common stock (9)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;432,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(424,286)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(438,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(393,589)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(404,903)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,932)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity (deficit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7) Preferred stock, $0.0001 par value; 10,000,000 shares authorized at September 30, 2023 and September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8) Series X Convertible Preferred Stock, $0.0001 par value; 4,947,759 shares authorized at September 30, 2023 and September 30, 2022; 2,156,713 shares issued and 2,104,472 shares outstanding at September 30, 2023; 1,870,713 shares issued and 1,818,472 shares outstanding at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9) Common stock, $0.0001 par value; 200,000,000 shares authorized at September 30, 2023 and September 30, 2022; 90,415,944 shares issued and outstanding at September 30, 2023 and 71,181,197 shares issued and outstanding at September 30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,454)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) and comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(677)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(636)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic net earnings (loss) per common share (10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted net earnings (loss) per common share (10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,640,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,640,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,189,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,189,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,138,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10)  As the Company was in an income position for the three-months ended March 31, 2023, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,475)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,267)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,640)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,115,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,115,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,133,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,133,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income (expense), net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,462)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84,409,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84,409,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,638,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,638,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Income (Loss) (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) and comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic net earnings (loss) per common share (11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted net earnings (loss) per common share (11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,217,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,217,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,287,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,592,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88,592,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="36" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11)  As the Company was in an income position for the three-months ended September 30, 2022, the two-class method was used to compute basic net earnings per share and the Company calculated diluted net earnings per share based on the more dilutive of (1) the treasury stock method, reverse treasury stock method or if-converted method, as applicable, or (2) the two-class method.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:18pt;margin-top:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Operations and Comprehensive Loss (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,409)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,016)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other income, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,390,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86,390,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of costs to obtain a contract with a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,004)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from underwritten public offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal repayments of Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,111)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24,303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash investing activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(34,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of costs to obtain a contract with a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(483)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35,444)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from underwritten public offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal repayments of Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(37,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash investing activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset obtained in exchange for lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase of shares pursuant to Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuance costs incurred but not yet paid, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of costs to obtain a contract with a customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued indirect tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(670)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(778)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from underwritten public offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Issuance costs for underwritten public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(720)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Principal repayments of Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,615)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.820%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.389%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Corrected Condensed Consolidated Statement of Cash Flows (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Previously Reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restatement Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Supplemental disclosure of cash flows:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash investing activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchases of property and equipment, included in accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset obtained in exchange for lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-cash financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchase of shares pursuant to Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-242" decimals="-3" id="f-874" unitRef="usd">47976000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-243" decimals="-3" id="f-875" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-244" decimals="-3" id="f-876" unitRef="usd">47976000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-245" decimals="-3" id="f-877" unitRef="usd">36488000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-246" decimals="-3" id="f-878" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-247" decimals="-3" id="f-879" unitRef="usd">36488000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-242" decimals="-3" id="f-880" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-243" decimals="-3" id="f-881" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-244" decimals="-3" id="f-882" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-245" decimals="-3" id="f-883" unitRef="usd">1482000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-246" decimals="-3" id="f-884" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-247" decimals="-3" id="f-885" unitRef="usd">1482000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-242" decimals="-3" id="f-886" unitRef="usd">25826000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-243" decimals="-3" id="f-887" unitRef="usd">295000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-244" decimals="-3" id="f-888" unitRef="usd">26121000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-245" decimals="-3" id="f-889" unitRef="usd">8783000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-246" decimals="-3" id="f-890" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-247" decimals="-3" id="f-891" unitRef="usd">8783000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-242" decimals="-3" id="f-892" unitRef="usd">5686000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-243" decimals="-3" id="f-893" unitRef="usd">25000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-244" decimals="-3" id="f-894" unitRef="usd">5711000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-245" decimals="-3" id="f-895" unitRef="usd">5254000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-246" decimals="-3" id="f-896" unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-247" decimals="-3" id="f-897" unitRef="usd">5254000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-242" decimals="-3" id="f-898" unitRef="usd">79488000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-243" decimals="-3" id="f-899" unitRef="usd">320000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-244" decimals="-3" id="f-900" unitRef="usd">79808000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-245" decimals="-3" id="f-901" unitRef="usd">52007000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-246" decimals="-3" id="f-902" unitRef="usd">0</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-247" decimals="-3" id="f-903" unitRef="usd">52007000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-242" decimals="-3" id="f-904" unitRef="usd">270000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-243" decimals="-3" id="f-905" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-244" decimals="-3" id="f-906" unitRef="usd">270000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-245" decimals="-3" id="f-907" unitRef="usd">239000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-246" decimals="-3" id="f-908" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-247" decimals="-3" id="f-909" unitRef="usd">239000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-242" decimals="-3" id="f-910" unitRef="usd">917000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-243" decimals="-3" id="f-911" unitRef="usd">-81000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-244" decimals="-3" id="f-912" unitRef="usd">836000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-245" decimals="-3" id="f-913" unitRef="usd">2030000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-246" decimals="-3" id="f-914" unitRef="usd">-184000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-247" decimals="-3" id="f-915" unitRef="usd">1846000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-242" decimals="-3" id="f-916" unitRef="usd">1061000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-243" decimals="-3" id="f-917" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-244" decimals="-3" id="f-918" unitRef="usd">1061000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-245" decimals="-3" id="f-919" unitRef="usd">1019000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-246" decimals="-3" id="f-920" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-247" decimals="-3" id="f-921" unitRef="usd">1019000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-242" decimals="-3" id="f-922" unitRef="usd">81736000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-243" decimals="-3" id="f-923" unitRef="usd">239000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-244" decimals="-3" id="f-924" unitRef="usd">81975000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-245" decimals="-3" id="f-925" unitRef="usd">55295000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-246" decimals="-3" id="f-926" unitRef="usd">-184000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-247" decimals="-3" id="f-927" unitRef="usd">55111000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-242" decimals="-3" id="f-928" unitRef="usd">3980000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-243" decimals="-3" id="f-929" unitRef="usd">46000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-244" decimals="-3" id="f-930" unitRef="usd">4026000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-245" decimals="-3" id="f-931" unitRef="usd">2861000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-246" decimals="-3" id="f-932" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-247" decimals="-3" id="f-933" unitRef="usd">2861000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-242" decimals="-3" id="f-934" unitRef="usd">9078000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-243" decimals="-3" id="f-935" unitRef="usd">30000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-244" decimals="-3" id="f-936" unitRef="usd">9108000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-245" decimals="-3" id="f-937" unitRef="usd">9234000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-246" decimals="-3" id="f-938" unitRef="usd">720000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-247" decimals="-3" id="f-939" unitRef="usd">9954000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-242" decimals="-3" id="f-940" unitRef="usd">0</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-243" decimals="-3" id="f-941" unitRef="usd">11795000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-244" decimals="-3" id="f-942" unitRef="usd">11795000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-245" decimals="-3" id="f-943" unitRef="usd">0</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-246" decimals="-3" id="f-944" unitRef="usd">7942000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-247" decimals="-3" id="f-945" unitRef="usd">7942000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-242" decimals="-3" id="f-946" unitRef="usd">5843000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-243" decimals="-3" id="f-947" unitRef="usd">0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-244" decimals="-3" id="f-948" unitRef="usd">5843000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-245" decimals="-3" id="f-949" unitRef="usd">3079000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-246" decimals="-3" id="f-950" unitRef="usd">0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-247" decimals="-3" id="f-951" unitRef="usd">3079000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-242" decimals="-3" id="f-952" unitRef="usd">15761000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-243" decimals="-3" id="f-953" unitRef="usd">29000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-244" decimals="-3" id="f-954" unitRef="usd">15790000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-245" decimals="-3" id="f-955" unitRef="usd">14260000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-246" decimals="-3" id="f-956" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-247" decimals="-3" id="f-957" unitRef="usd">14260000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-242" decimals="-3" id="f-958" unitRef="usd">1001000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-243" decimals="-3" id="f-959" unitRef="usd">-81000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-244" decimals="-3" id="f-960" unitRef="usd">920000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-245" decimals="-3" id="f-961" unitRef="usd">1190000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-246" decimals="-3" id="f-962" unitRef="usd">-100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-247" decimals="-3" id="f-963" unitRef="usd">1090000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-242" decimals="-3" id="f-964" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-243" decimals="-3" id="f-965" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-244" decimals="-3" id="f-966" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-245" decimals="-3" id="f-967" unitRef="usd">1481000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-246" decimals="-3" id="f-968" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-247" decimals="-3" id="f-969" unitRef="usd">1481000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-242" decimals="-3" id="f-970" unitRef="usd">35663000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-243" decimals="-3" id="f-971" unitRef="usd">11819000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-244" decimals="-3" id="f-972" unitRef="usd">47482000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-245" decimals="-3" id="f-973" unitRef="usd">32105000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-246" decimals="-3" id="f-974" unitRef="usd">8562000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-247" decimals="-3" id="f-975" unitRef="usd">40667000</us-gaap:LiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-242" decimals="-3" id="f-976" unitRef="usd">19236000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-243" decimals="-3" id="f-977" unitRef="usd">150000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-244" decimals="-3" id="f-978" unitRef="usd">19386000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-245" decimals="-3" id="f-979" unitRef="usd">17229000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-246" decimals="-3" id="f-980" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-247" decimals="-3" id="f-981" unitRef="usd">17229000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-242" decimals="-3" id="f-982" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-243" decimals="-3" id="f-983" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-244" decimals="-3" id="f-984" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-245" decimals="-3" id="f-985" unitRef="usd">1004000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-246" decimals="-3" id="f-986" unitRef="usd">-84000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-247" decimals="-3" id="f-987" unitRef="usd">920000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-242" decimals="-3" id="f-988" unitRef="usd">54899000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-243" decimals="-3" id="f-989" unitRef="usd">11969000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-244" decimals="-3" id="f-990" unitRef="usd">66868000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-245" decimals="-3" id="f-991" unitRef="usd">50338000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-246" decimals="-3" id="f-992" unitRef="usd">8478000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-247" decimals="-3" id="f-993" unitRef="usd">58816000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-242" id="f-994" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-243" id="f-995" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-244" id="f-996" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-245" id="f-997" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-246" id="f-998" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-247" id="f-999" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-242" id="f-1000" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-243" id="f-1001" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-244" id="f-1002" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-245" id="f-1003" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-246" id="f-1004" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-247" id="f-1005" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-248" decimals="-3" id="f-1006" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-249" decimals="-3" id="f-1007" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-250" decimals="-3" id="f-1008" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-251" decimals="-3" id="f-1009" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-252" decimals="-3" id="f-1010" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-253" decimals="-3" id="f-1011" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-242" decimals="-3" id="f-1012" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-243" decimals="-3" id="f-1013" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-244" decimals="-3" id="f-1014" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-245" decimals="-3" id="f-1015" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-246" decimals="-3" id="f-1016" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-247" decimals="-3" id="f-1017" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-242" decimals="-3" id="f-1018" unitRef="usd">430585000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-243" decimals="-3" id="f-1019" unitRef="usd">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-244" decimals="-3" id="f-1020" unitRef="usd">430585000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-245" decimals="-3" id="f-1021" unitRef="usd">400398000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-246" decimals="-3" id="f-1022" unitRef="usd">-720000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-247" decimals="-3" id="f-1023" unitRef="usd">399678000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-242" decimals="-3" id="f-1024" unitRef="usd">-403757000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-243" decimals="-3" id="f-1025" unitRef="usd">-11730000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-244" decimals="-3" id="f-1026" unitRef="usd">-415487000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-245" decimals="-3" id="f-1027" unitRef="usd">-395448000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-246" decimals="-3" id="f-1028" unitRef="usd">-7942000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-247" decimals="-3" id="f-1029" unitRef="usd">-403390000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-242" decimals="-3" id="f-1030" unitRef="usd">26837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-243" decimals="-3" id="f-1031" unitRef="usd">-11730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-244" decimals="-3" id="f-1032" unitRef="usd">15107000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-245" decimals="-3" id="f-1033" unitRef="usd">4957000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-246" decimals="-3" id="f-1034" unitRef="usd">-8662000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-247" decimals="-3" id="f-1035" unitRef="usd">-3705000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-242" decimals="-3" id="f-1036" unitRef="usd">81736000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-243" decimals="-3" id="f-1037" unitRef="usd">239000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-244" decimals="-3" id="f-1038" unitRef="usd">81975000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-245" decimals="-3" id="f-1039" unitRef="usd">55295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-246" decimals="-3" id="f-1040" unitRef="usd">-184000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-247" decimals="-3" id="f-1041" unitRef="usd">55111000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-244"
      decimals="INF"
      id="f-1042"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-247"
      decimals="INF"
      id="f-1043"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-244"
      decimals="INF"
      id="f-1044"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-247"
      decimals="INF"
      id="f-1045"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-250"
      decimals="INF"
      id="f-1046"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-253"
      decimals="INF"
      id="f-1047"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-250"
      decimals="INF"
      id="f-1048"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-253"
      decimals="INF"
      id="f-1049"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-250"
      decimals="INF"
      id="f-1050"
      unitRef="shares">2156713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-250"
      decimals="INF"
      id="f-1051"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-253"
      decimals="INF"
      id="f-1052"
      unitRef="shares">1870713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-253"
      decimals="INF"
      id="f-1053"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-244"
      decimals="INF"
      id="f-1054"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-247"
      decimals="INF"
      id="f-1055"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-244"
      decimals="INF"
      id="f-1056"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-247"
      decimals="INF"
      id="f-1057"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-244"
      decimals="INF"
      id="f-1058"
      unitRef="shares">90024562</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-244"
      decimals="INF"
      id="f-1059"
      unitRef="shares">90024562</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-247"
      decimals="INF"
      id="f-1060"
      unitRef="shares">69049247</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-247"
      decimals="INF"
      id="f-1061"
      unitRef="shares">69049247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-254" decimals="-3" id="f-1062" unitRef="usd">50430000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-255" decimals="-3" id="f-1063" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-2" decimals="-3" id="f-1064" unitRef="usd">50430000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-256" decimals="-3" id="f-1065" unitRef="usd">24637000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-257" decimals="-3" id="f-1066" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-258" decimals="-3" id="f-1067" unitRef="usd">24637000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c-254" decimals="-3" id="f-1068" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-255" decimals="-3" id="f-1069" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-2" decimals="-3" id="f-1070" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-256" decimals="-3" id="f-1071" unitRef="usd">370000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-257" decimals="-3" id="f-1072" unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-258" decimals="-3" id="f-1073" unitRef="usd">370000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-254" decimals="-3" id="f-1074" unitRef="usd">5483000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-255" decimals="-3" id="f-1075" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-2" decimals="-3" id="f-1076" unitRef="usd">5483000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-256" decimals="-3" id="f-1077" unitRef="usd">4833000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-257" decimals="-3" id="f-1078" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-258" decimals="-3" id="f-1079" unitRef="usd">4833000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-254" decimals="-3" id="f-1080" unitRef="usd">1954000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-255" decimals="-3" id="f-1081" unitRef="usd">434000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-2" decimals="-3" id="f-1082" unitRef="usd">2388000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-256" decimals="-3" id="f-1083" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-257" decimals="-3" id="f-1084" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-258" decimals="-3" id="f-1085" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-254" decimals="-3" id="f-1086" unitRef="usd">4373000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-255" decimals="-3" id="f-1087" unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-2" decimals="-3" id="f-1088" unitRef="usd">4373000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-256" decimals="-3" id="f-1089" unitRef="usd">6706000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-257" decimals="-3" id="f-1090" unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-258" decimals="-3" id="f-1091" unitRef="usd">6706000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-254" decimals="-3" id="f-1092" unitRef="usd">62240000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-255" decimals="-3" id="f-1093" unitRef="usd">434000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-2" decimals="-3" id="f-1094" unitRef="usd">62674000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-256" decimals="-3" id="f-1095" unitRef="usd">36546000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-257" decimals="-3" id="f-1096" unitRef="usd">0</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-258" decimals="-3" id="f-1097" unitRef="usd">36546000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-254" decimals="-3" id="f-1098" unitRef="usd">297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-255" decimals="-3" id="f-1099" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-2" decimals="-3" id="f-1100" unitRef="usd">297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-256" decimals="-3" id="f-1101" unitRef="usd">201000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-257" decimals="-3" id="f-1102" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-258" decimals="-3" id="f-1103" unitRef="usd">201000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-254" decimals="-3" id="f-1104" unitRef="usd">4388000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-255" decimals="-3" id="f-1105" unitRef="usd">-81000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-2" decimals="-3" id="f-1106" unitRef="usd">4307000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-256" decimals="-3" id="f-1107" unitRef="usd">1764000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-257" decimals="-3" id="f-1108" unitRef="usd">-162000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-258" decimals="-3" id="f-1109" unitRef="usd">1602000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-254" decimals="-3" id="f-1110" unitRef="usd">1061000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-255" decimals="-3" id="f-1111" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-2" decimals="-3" id="f-1112" unitRef="usd">1061000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-256" decimals="-3" id="f-1113" unitRef="usd">1013000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-257" decimals="-3" id="f-1114" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-258" decimals="-3" id="f-1115" unitRef="usd">1013000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-254" decimals="-3" id="f-1116" unitRef="usd">67986000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-255" decimals="-3" id="f-1117" unitRef="usd">353000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-2" decimals="-3" id="f-1118" unitRef="usd">68339000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-256" decimals="-3" id="f-1119" unitRef="usd">39524000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-257" decimals="-3" id="f-1120" unitRef="usd">-162000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-258" decimals="-3" id="f-1121" unitRef="usd">39362000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-254" decimals="-3" id="f-1122" unitRef="usd">1899000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-255" decimals="-3" id="f-1123" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-2" decimals="-3" id="f-1124" unitRef="usd">1899000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-256" decimals="-3" id="f-1125" unitRef="usd">3091000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-257" decimals="-3" id="f-1126" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-258" decimals="-3" id="f-1127" unitRef="usd">3091000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-254" decimals="-3" id="f-1128" unitRef="usd">10022000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-255" decimals="-3" id="f-1129" unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-2" decimals="-3" id="f-1130" unitRef="usd">10022000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-256" decimals="-3" id="f-1131" unitRef="usd">8567000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-257" decimals="-3" id="f-1132" unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-258" decimals="-3" id="f-1133" unitRef="usd">8567000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-254" decimals="-3" id="f-1134" unitRef="usd">0</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-255" decimals="-3" id="f-1135" unitRef="usd">13431000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-2" decimals="-3" id="f-1136" unitRef="usd">13431000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-256" decimals="-3" id="f-1137" unitRef="usd">0</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-257" decimals="-3" id="f-1138" unitRef="usd">10582000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-258" decimals="-3" id="f-1139" unitRef="usd">10582000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-254" decimals="-3" id="f-1140" unitRef="usd">3582000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-255" decimals="-3" id="f-1141" unitRef="usd">0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-2" decimals="-3" id="f-1142" unitRef="usd">3582000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-256" decimals="-3" id="f-1143" unitRef="usd">3464000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-257" decimals="-3" id="f-1144" unitRef="usd">0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-258" decimals="-3" id="f-1145" unitRef="usd">3464000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-254" decimals="-3" id="f-1146" unitRef="usd">14975000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-255" decimals="-3" id="f-1147" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-2" decimals="-3" id="f-1148" unitRef="usd">14975000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-256" decimals="-3" id="f-1149" unitRef="usd">14730000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-257" decimals="-3" id="f-1150" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-258" decimals="-3" id="f-1151" unitRef="usd">14730000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-254" decimals="-3" id="f-1152" unitRef="usd">942000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-255" decimals="-3" id="f-1153" unitRef="usd">-81000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-2" decimals="-3" id="f-1154" unitRef="usd">861000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-256" decimals="-3" id="f-1155" unitRef="usd">1233000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-257" decimals="-3" id="f-1156" unitRef="usd">-104000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-258" decimals="-3" id="f-1157" unitRef="usd">1129000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-254" decimals="-3" id="f-1158" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-255" decimals="-3" id="f-1159" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-2" decimals="-3" id="f-1160" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-256" decimals="-3" id="f-1161" unitRef="usd">370000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-257" decimals="-3" id="f-1162" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-258" decimals="-3" id="f-1163" unitRef="usd">370000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-254" decimals="-3" id="f-1164" unitRef="usd">31420000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-255" decimals="-3" id="f-1165" unitRef="usd">13350000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-2" decimals="-3" id="f-1166" unitRef="usd">44770000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-256" decimals="-3" id="f-1167" unitRef="usd">31455000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-257" decimals="-3" id="f-1168" unitRef="usd">10478000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-258" decimals="-3" id="f-1169" unitRef="usd">41933000</us-gaap:LiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-254" decimals="-3" id="f-1170" unitRef="usd">17551000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-255" decimals="-3" id="f-1171" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-2" decimals="-3" id="f-1172" unitRef="usd">17551000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-256" decimals="-3" id="f-1173" unitRef="usd">15351000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-257" decimals="-3" id="f-1174" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-258" decimals="-3" id="f-1175" unitRef="usd">15351000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-254" decimals="-3" id="f-1176" unitRef="usd">3601000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-255" decimals="-3" id="f-1177" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-2" decimals="-3" id="f-1178" unitRef="usd">3601000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-256" decimals="-3" id="f-1179" unitRef="usd">679000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-257" decimals="-3" id="f-1180" unitRef="usd">-58000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-258" decimals="-3" id="f-1181" unitRef="usd">621000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-254" decimals="-3" id="f-1182" unitRef="usd">52572000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-255" decimals="-3" id="f-1183" unitRef="usd">13350000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-2" decimals="-3" id="f-1184" unitRef="usd">65922000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-256" decimals="-3" id="f-1185" unitRef="usd">47485000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-257" decimals="-3" id="f-1186" unitRef="usd">10420000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-258" decimals="-3" id="f-1187" unitRef="usd">57905000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-254" id="f-1188" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-255" id="f-1189" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-2" id="f-1190" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-256" id="f-1191" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-257" id="f-1192" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-258" id="f-1193" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-254" id="f-1194" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-255" id="f-1195" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-2" id="f-1196" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-256" id="f-1197" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-257" id="f-1198" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-258" id="f-1199" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-259" decimals="-3" id="f-1200" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-260" decimals="-3" id="f-1201" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-261" decimals="-3" id="f-1202" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-262" decimals="-3" id="f-1203" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-263" decimals="-3" id="f-1204" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-264" decimals="-3" id="f-1205" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-254" decimals="-3" id="f-1206" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-255" decimals="-3" id="f-1207" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-2" decimals="-3" id="f-1208" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-256" decimals="-3" id="f-1209" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-257" decimals="-3" id="f-1210" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-258" decimals="-3" id="f-1211" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-254" decimals="-3" id="f-1212" unitRef="usd">431519000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-255" decimals="-3" id="f-1213" unitRef="usd">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-2" decimals="-3" id="f-1214" unitRef="usd">431519000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-256" decimals="-3" id="f-1215" unitRef="usd">400599000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-257" decimals="-3" id="f-1216" unitRef="usd">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-258" decimals="-3" id="f-1217" unitRef="usd">400599000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-254" decimals="-3" id="f-1218" unitRef="usd">-416114000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-255" decimals="-3" id="f-1219" unitRef="usd">-12997000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-2" decimals="-3" id="f-1220" unitRef="usd">-429111000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-256" decimals="-3" id="f-1221" unitRef="usd">-408567000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-257" decimals="-3" id="f-1222" unitRef="usd">-10582000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-258" decimals="-3" id="f-1223" unitRef="usd">-419149000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-254" decimals="-3" id="f-1224" unitRef="usd">15414000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-255" decimals="-3" id="f-1225" unitRef="usd">-12997000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-2" decimals="-3" id="f-1226" unitRef="usd">2417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-256" decimals="-3" id="f-1227" unitRef="usd">-7961000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-257" decimals="-3" id="f-1228" unitRef="usd">-10582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-258" decimals="-3" id="f-1229" unitRef="usd">-18543000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-254" decimals="-3" id="f-1230" unitRef="usd">67986000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-255" decimals="-3" id="f-1231" unitRef="usd">353000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-2" decimals="-3" id="f-1232" unitRef="usd">68339000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-256" decimals="-3" id="f-1233" unitRef="usd">39524000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-257" decimals="-3" id="f-1234" unitRef="usd">-162000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-258" decimals="-3" id="f-1235" unitRef="usd">39362000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-2"
      decimals="INF"
      id="f-1236"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-258"
      decimals="INF"
      id="f-1237"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-2"
      decimals="INF"
      id="f-1238"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-258"
      decimals="INF"
      id="f-1239"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-261"
      decimals="INF"
      id="f-1240"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-264"
      decimals="INF"
      id="f-1241"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-261"
      decimals="INF"
      id="f-1242"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-264"
      decimals="INF"
      id="f-1243"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-261"
      decimals="INF"
      id="f-1244"
      unitRef="shares">2156713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-261"
      decimals="INF"
      id="f-1245"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-264"
      decimals="INF"
      id="f-1246"
      unitRef="shares">1870713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-264"
      decimals="INF"
      id="f-1247"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-258"
      decimals="INF"
      id="f-1248"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-2"
      decimals="INF"
      id="f-1249"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-2"
      decimals="INF"
      id="f-1250"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-258"
      decimals="INF"
      id="f-1251"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-2"
      decimals="INF"
      id="f-1252"
      unitRef="shares">90251746</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-2"
      decimals="INF"
      id="f-1253"
      unitRef="shares">90251746</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-258"
      decimals="INF"
      id="f-1254"
      unitRef="shares">69238508</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-258"
      decimals="INF"
      id="f-1255"
      unitRef="shares">69238508</us-gaap:CommonStockSharesIssued>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-265" decimals="-3" id="f-1256" unitRef="usd">48670000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-266" decimals="-3" id="f-1257" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-267" decimals="-3" id="f-1258" unitRef="usd">48670000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-268" decimals="-3" id="f-1259" unitRef="usd">53078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-269" decimals="-3" id="f-1260" unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-270" decimals="-3" id="f-1261" unitRef="usd">53078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-265" decimals="-3" id="f-1262" unitRef="usd">2855000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-266" decimals="-3" id="f-1263" unitRef="usd">323000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-267" decimals="-3" id="f-1264" unitRef="usd">3178000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-268" decimals="-3" id="f-1265" unitRef="usd">5042000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-269" decimals="-3" id="f-1266" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-270" decimals="-3" id="f-1267" unitRef="usd">5042000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-265" decimals="-3" id="f-1268" unitRef="usd">2467000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-266" decimals="-3" id="f-1269" unitRef="usd">434000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-267" decimals="-3" id="f-1270" unitRef="usd">2901000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-268" decimals="-3" id="f-1271" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-269" decimals="-3" id="f-1272" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-270" decimals="-3" id="f-1273" unitRef="usd">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-265" decimals="-3" id="f-1274" unitRef="usd">3712000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-266" decimals="-3" id="f-1275" unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-267" decimals="-3" id="f-1276" unitRef="usd">3712000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-268" decimals="-3" id="f-1277" unitRef="usd">5779000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-269" decimals="-3" id="f-1278" unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-270" decimals="-3" id="f-1279" unitRef="usd">5779000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-265" decimals="-3" id="f-1280" unitRef="usd">57704000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-266" decimals="-3" id="f-1281" unitRef="usd">757000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-267" decimals="-3" id="f-1282" unitRef="usd">58461000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-268" decimals="-3" id="f-1283" unitRef="usd">63899000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-269" decimals="-3" id="f-1284" unitRef="usd">0</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-270" decimals="-3" id="f-1285" unitRef="usd">63899000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-265" decimals="-3" id="f-1286" unitRef="usd">580000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-266" decimals="-3" id="f-1287" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-267" decimals="-3" id="f-1288" unitRef="usd">580000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-268" decimals="-3" id="f-1289" unitRef="usd">173000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-269" decimals="-3" id="f-1290" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-270" decimals="-3" id="f-1291" unitRef="usd">173000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-265" decimals="-3" id="f-1292" unitRef="usd">4131000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-266" decimals="-3" id="f-1293" unitRef="usd">-81000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-267" decimals="-3" id="f-1294" unitRef="usd">4050000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-268" decimals="-3" id="f-1295" unitRef="usd">1491000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-269" decimals="-3" id="f-1296" unitRef="usd">-137000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-270" decimals="-3" id="f-1297" unitRef="usd">1354000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-265" decimals="-3" id="f-1298" unitRef="usd">1053000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-266" decimals="-3" id="f-1299" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-267" decimals="-3" id="f-1300" unitRef="usd">1053000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-268" decimals="-3" id="f-1301" unitRef="usd">1295000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-269" decimals="-3" id="f-1302" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-270" decimals="-3" id="f-1303" unitRef="usd">1295000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-265" decimals="-3" id="f-1304" unitRef="usd">63468000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-266" decimals="-3" id="f-1305" unitRef="usd">676000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-267" decimals="-3" id="f-1306" unitRef="usd">64144000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-268" decimals="-3" id="f-1307" unitRef="usd">66858000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-269" decimals="-3" id="f-1308" unitRef="usd">-137000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-270" decimals="-3" id="f-1309" unitRef="usd">66721000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-265" decimals="-3" id="f-1310" unitRef="usd">3661000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-266" decimals="-3" id="f-1311" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-267" decimals="-3" id="f-1312" unitRef="usd">3661000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-268" decimals="-3" id="f-1313" unitRef="usd">4244000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-269" decimals="-3" id="f-1314" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-270" decimals="-3" id="f-1315" unitRef="usd">4244000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-265" decimals="-3" id="f-1316" unitRef="usd">11772000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-266" decimals="-3" id="f-1317" unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-267" decimals="-3" id="f-1318" unitRef="usd">11772000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-268" decimals="-3" id="f-1319" unitRef="usd">8162000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-269" decimals="-3" id="f-1320" unitRef="usd">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-270" decimals="-3" id="f-1321" unitRef="usd">8162000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-265" decimals="-3" id="f-1322" unitRef="usd">0</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-266" decimals="-3" id="f-1323" unitRef="usd">14689000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-267" decimals="-3" id="f-1324" unitRef="usd">14689000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-268" decimals="-3" id="f-1325" unitRef="usd">0</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-269" decimals="-3" id="f-1326" unitRef="usd">11314000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="c-270" decimals="-3" id="f-1327" unitRef="usd">11314000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-265" decimals="-3" id="f-1328" unitRef="usd">4457000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-266" decimals="-3" id="f-1329" unitRef="usd">0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-267" decimals="-3" id="f-1330" unitRef="usd">4457000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-268" decimals="-3" id="f-1331" unitRef="usd">4117000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-269" decimals="-3" id="f-1332" unitRef="usd">0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-270" decimals="-3" id="f-1333" unitRef="usd">4117000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-265" decimals="-3" id="f-1334" unitRef="usd">14679000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-266" decimals="-3" id="f-1335" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-267" decimals="-3" id="f-1336" unitRef="usd">14679000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-268" decimals="-3" id="f-1337" unitRef="usd">15249000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-269" decimals="-3" id="f-1338" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent contextRef="c-270" decimals="-3" id="f-1339" unitRef="usd">15249000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-265" decimals="-3" id="f-1340" unitRef="usd">1051000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-266" decimals="-3" id="f-1341" unitRef="usd">-81000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-267" decimals="-3" id="f-1342" unitRef="usd">970000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-268" decimals="-3" id="f-1343" unitRef="usd">1277000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-269" decimals="-3" id="f-1344" unitRef="usd">-108000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-270" decimals="-3" id="f-1345" unitRef="usd">1169000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-265" decimals="-3" id="f-1346" unitRef="usd">35620000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-266" decimals="-3" id="f-1347" unitRef="usd">14608000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-267" decimals="-3" id="f-1348" unitRef="usd">50228000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-268" decimals="-3" id="f-1349" unitRef="usd">33049000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-269" decimals="-3" id="f-1350" unitRef="usd">11206000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-270" decimals="-3" id="f-1351" unitRef="usd">44255000</us-gaap:LiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-265" decimals="-3" id="f-1352" unitRef="usd">16504000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-266" decimals="-3" id="f-1353" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-267" decimals="-3" id="f-1354" unitRef="usd">16504000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-268" decimals="-3" id="f-1355" unitRef="usd">24398000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-269" decimals="-3" id="f-1356" unitRef="usd">0</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent contextRef="c-270" decimals="-3" id="f-1357" unitRef="usd">24398000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-265" decimals="-3" id="f-1358" unitRef="usd">3306000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-266" decimals="-3" id="f-1359" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-267" decimals="-3" id="f-1360" unitRef="usd">3306000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-268" decimals="-3" id="f-1361" unitRef="usd">344000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-269" decimals="-3" id="f-1362" unitRef="usd">-29000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-270" decimals="-3" id="f-1363" unitRef="usd">315000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-265" decimals="-3" id="f-1364" unitRef="usd">55430000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-266" decimals="-3" id="f-1365" unitRef="usd">14608000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-267" decimals="-3" id="f-1366" unitRef="usd">70038000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-268" decimals="-3" id="f-1367" unitRef="usd">57791000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-269" decimals="-3" id="f-1368" unitRef="usd">11177000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-270" decimals="-3" id="f-1369" unitRef="usd">68968000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-265" id="f-1370" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-266" id="f-1371" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-267" id="f-1372" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-268" id="f-1373" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-269" id="f-1374" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-270" id="f-1375" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-265" id="f-1376" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-266" id="f-1377" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-267" id="f-1378" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-268" id="f-1379" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-269" id="f-1380" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-270" id="f-1381" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockValue contextRef="c-271" decimals="-3" id="f-1382" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-272" decimals="-3" id="f-1383" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-273" decimals="-3" id="f-1384" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-274" decimals="-3" id="f-1385" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-275" decimals="-3" id="f-1386" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-276" decimals="-3" id="f-1387" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue contextRef="c-265" decimals="-3" id="f-1388" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-266" decimals="-3" id="f-1389" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-267" decimals="-3" id="f-1390" unitRef="usd">9000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-268" decimals="-3" id="f-1391" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-269" decimals="-3" id="f-1392" unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-270" decimals="-3" id="f-1393" unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-265" decimals="-3" id="f-1394" unitRef="usd">432315000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-266" decimals="-3" id="f-1395" unitRef="usd">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-267" decimals="-3" id="f-1396" unitRef="usd">432315000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-268" decimals="-3" id="f-1397" unitRef="usd">402649000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-269" decimals="-3" id="f-1398" unitRef="usd">0</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-270" decimals="-3" id="f-1399" unitRef="usd">402649000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-265" decimals="-3" id="f-1400" unitRef="usd">-424286000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-266" decimals="-3" id="f-1401" unitRef="usd">-13932000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-267" decimals="-3" id="f-1402" unitRef="usd">-438218000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-268" decimals="-3" id="f-1403" unitRef="usd">-393589000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-269" decimals="-3" id="f-1404" unitRef="usd">-11314000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-270" decimals="-3" id="f-1405" unitRef="usd">-404903000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-265" decimals="-3" id="f-1406" unitRef="usd">8038000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-266" decimals="-3" id="f-1407" unitRef="usd">-13932000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-267" decimals="-3" id="f-1408" unitRef="usd">-5894000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-268" decimals="-3" id="f-1409" unitRef="usd">9067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-269" decimals="-3" id="f-1410" unitRef="usd">-11314000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-270" decimals="-3" id="f-1411" unitRef="usd">-2247000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-265" decimals="-3" id="f-1412" unitRef="usd">63468000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-266" decimals="-3" id="f-1413" unitRef="usd">676000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-267" decimals="-3" id="f-1414" unitRef="usd">64144000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-268" decimals="-3" id="f-1415" unitRef="usd">66858000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-269" decimals="-3" id="f-1416" unitRef="usd">-137000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-270" decimals="-3" id="f-1417" unitRef="usd">66721000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-270"
      decimals="INF"
      id="f-1418"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-267"
      decimals="INF"
      id="f-1419"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-267"
      decimals="INF"
      id="f-1420"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-270"
      decimals="INF"
      id="f-1421"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-276"
      decimals="INF"
      id="f-1422"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-273"
      decimals="INF"
      id="f-1423"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-276"
      decimals="INF"
      id="f-1424"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-273"
      decimals="INF"
      id="f-1425"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-273"
      decimals="INF"
      id="f-1426"
      unitRef="shares">2156713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-273"
      decimals="INF"
      id="f-1427"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-276"
      decimals="INF"
      id="f-1428"
      unitRef="shares">1870713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-276"
      decimals="INF"
      id="f-1429"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-270"
      decimals="INF"
      id="f-1430"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-267"
      decimals="INF"
      id="f-1431"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-267"
      decimals="INF"
      id="f-1432"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-270"
      decimals="INF"
      id="f-1433"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-267"
      decimals="INF"
      id="f-1434"
      unitRef="shares">90415944</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-267"
      decimals="INF"
      id="f-1435"
      unitRef="shares">90415944</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-270"
      decimals="INF"
      id="f-1436"
      unitRef="shares">71181197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-270"
      decimals="INF"
      id="f-1437"
      unitRef="shares">71181197</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-277" decimals="-3" id="f-1438" unitRef="usd">25990000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-278" decimals="-3" id="f-1439" unitRef="usd">117000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-279" decimals="-3" id="f-1440" unitRef="usd">26107000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-280" decimals="-3" id="f-1441" unitRef="usd">7109000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-281" decimals="-3" id="f-1442" unitRef="usd">160000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-282" decimals="-3" id="f-1443" unitRef="usd">7269000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-277" decimals="-3" id="f-1444" unitRef="usd">25990000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-278" decimals="-3" id="f-1445" unitRef="usd">117000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-279" decimals="-3" id="f-1446" unitRef="usd">26107000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-280" decimals="-3" id="f-1447" unitRef="usd">7109000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-281" decimals="-3" id="f-1448" unitRef="usd">160000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-282" decimals="-3" id="f-1449" unitRef="usd">7269000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-277" decimals="-3" id="f-1450" unitRef="usd">18715000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-278" decimals="-3" id="f-1451" unitRef="usd">154000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-279" decimals="-3" id="f-1452" unitRef="usd">18869000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-280" decimals="-3" id="f-1453" unitRef="usd">20166000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-281" decimals="-3" id="f-1454" unitRef="usd">215000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-282" decimals="-3" id="f-1455" unitRef="usd">20381000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-277" decimals="-3" id="f-1456" unitRef="usd">4298000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-278" decimals="-3" id="f-1457" unitRef="usd">159000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-279" decimals="-3" id="f-1458" unitRef="usd">4457000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-280" decimals="-3" id="f-1459" unitRef="usd">5204000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-281" decimals="-3" id="f-1460" unitRef="usd">138000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-282" decimals="-3" id="f-1461" unitRef="usd">5342000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-277" decimals="-3" id="f-1462" unitRef="usd">23013000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-278" decimals="-3" id="f-1463" unitRef="usd">313000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-279" decimals="-3" id="f-1464" unitRef="usd">23326000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-280" decimals="-3" id="f-1465" unitRef="usd">25370000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-281" decimals="-3" id="f-1466" unitRef="usd">353000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-282" decimals="-3" id="f-1467" unitRef="usd">25723000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-277" decimals="-3" id="f-1468" unitRef="usd">2977000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-278" decimals="-3" id="f-1469" unitRef="usd">-196000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-279" decimals="-3" id="f-1470" unitRef="usd">2781000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-280" decimals="-3" id="f-1471" unitRef="usd">-18261000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-281" decimals="-3" id="f-1472" unitRef="usd">-193000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-282" decimals="-3" id="f-1473" unitRef="usd">-18454000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-277" decimals="-3" id="f-1474" unitRef="usd">232000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-278" decimals="-3" id="f-1475" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-279" decimals="-3" id="f-1476" unitRef="usd">232000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-280" decimals="-3" id="f-1477" unitRef="usd">-20000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-281" decimals="-3" id="f-1478" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-282" decimals="-3" id="f-1479" unitRef="usd">-20000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-277" decimals="-3" id="f-1480" unitRef="usd">232000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-278" decimals="-3" id="f-1481" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-279" decimals="-3" id="f-1482" unitRef="usd">232000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-280" decimals="-3" id="f-1483" unitRef="usd">-20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-281" decimals="-3" id="f-1484" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-282" decimals="-3" id="f-1485" unitRef="usd">-20000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-277" decimals="-3" id="f-1486" unitRef="usd">3209000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-277" decimals="-3" id="f-1487" unitRef="usd">3209000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-278" decimals="-3" id="f-1488" unitRef="usd">-196000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-278" decimals="-3" id="f-1489" unitRef="usd">-196000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-279" decimals="-3" id="f-1490" unitRef="usd">3013000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-279" decimals="-3" id="f-1491" unitRef="usd">3013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-280" decimals="-3" id="f-1492" unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-280" decimals="-3" id="f-1493" unitRef="usd">-18281000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-281" decimals="-3" id="f-1494" unitRef="usd">-193000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-281" decimals="-3" id="f-1495" unitRef="usd">-193000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-282" decimals="-3" id="f-1496" unitRef="usd">-18474000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-282" decimals="-3" id="f-1497" unitRef="usd">-18474000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-277" decimals="-3" id="f-1498" unitRef="usd">677000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-277" decimals="-3" id="f-1499" unitRef="usd">677000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-278" decimals="-3" id="f-1500" unitRef="usd">-41000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-278" decimals="-3" id="f-1501" unitRef="usd">-41000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-279" decimals="-3" id="f-1502" unitRef="usd">636000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-279" decimals="-3" id="f-1503" unitRef="usd">636000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-280" decimals="-3" id="f-1504" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-280" decimals="-3" id="f-1505" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-281" decimals="-3" id="f-1506" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-281" decimals="-3" id="f-1507" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-282" decimals="-3" id="f-1508" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-282" decimals="-3" id="f-1509" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-277" decimals="-3" id="f-1510" unitRef="usd">2532000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-278" decimals="-3" id="f-1511" unitRef="usd">-155000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-279" decimals="-3" id="f-1512" unitRef="usd">2377000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-280" decimals="-3" id="f-1513" unitRef="usd">-18281000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-281" decimals="-3" id="f-1514" unitRef="usd">-193000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-282" decimals="-3" id="f-1515" unitRef="usd">-18474000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-277"
      decimals="2"
      id="f-1516"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-279"
      decimals="2"
      id="f-1517"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-280"
      decimals="2"
      id="f-1518"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-282"
      decimals="2"
      id="f-1519"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-277"
      decimals="2"
      id="f-1520"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-279"
      decimals="2"
      id="f-1521"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-280"
      decimals="2"
      id="f-1522"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-282"
      decimals="2"
      id="f-1523"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-277"
      decimals="0"
      id="f-1524"
      unitRef="shares">78640086</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-279"
      decimals="0"
      id="f-1525"
      unitRef="shares">78640086</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-280"
      decimals="0"
      id="f-1526"
      unitRef="shares">68138116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-282"
      decimals="0"
      id="f-1527"
      unitRef="shares">68138116</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-277"
      decimals="0"
      id="f-1528"
      unitRef="shares">101189396</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-279"
      decimals="0"
      id="f-1529"
      unitRef="shares">101189396</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-280"
      decimals="0"
      id="f-1530"
      unitRef="shares">68138116</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-282"
      decimals="0"
      id="f-1531"
      unitRef="shares">68138116</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-283" decimals="-3" id="f-1532" unitRef="usd">7614000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-284" decimals="-3" id="f-1533" unitRef="usd">-117000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-285" decimals="-3" id="f-1534" unitRef="usd">7497000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-286" decimals="-3" id="f-1535" unitRef="usd">6216000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-287" decimals="-3" id="f-1536" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-288" decimals="-3" id="f-1537" unitRef="usd">6216000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-283" decimals="-3" id="f-1538" unitRef="usd">7614000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-284" decimals="-3" id="f-1539" unitRef="usd">-117000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-285" decimals="-3" id="f-1540" unitRef="usd">7497000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-286" decimals="-3" id="f-1541" unitRef="usd">6216000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-287" decimals="-3" id="f-1542" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-288" decimals="-3" id="f-1543" unitRef="usd">6216000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-283" decimals="-3" id="f-1544" unitRef="usd">17135000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-284" decimals="-3" id="f-1545" unitRef="usd">421000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-285" decimals="-3" id="f-1546" unitRef="usd">17556000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-286" decimals="-3" id="f-1547" unitRef="usd">15255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-287" decimals="-3" id="f-1548" unitRef="usd">1375000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-288" decimals="-3" id="f-1549" unitRef="usd">16630000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-283" decimals="-3" id="f-1550" unitRef="usd">3310000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-284" decimals="-3" id="f-1551" unitRef="usd">729000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-285" decimals="-3" id="f-1552" unitRef="usd">4039000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-286" decimals="-3" id="f-1553" unitRef="usd">4074000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-287" decimals="-3" id="f-1554" unitRef="usd">1265000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-288" decimals="-3" id="f-1555" unitRef="usd">5339000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-283" decimals="-3" id="f-1556" unitRef="usd">20445000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-284" decimals="-3" id="f-1557" unitRef="usd">1150000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-285" decimals="-3" id="f-1558" unitRef="usd">21595000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-286" decimals="-3" id="f-1559" unitRef="usd">19329000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-287" decimals="-3" id="f-1560" unitRef="usd">2640000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-288" decimals="-3" id="f-1561" unitRef="usd">21969000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-283" decimals="-3" id="f-1562" unitRef="usd">-12831000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-284" decimals="-3" id="f-1563" unitRef="usd">-1267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-285" decimals="-3" id="f-1564" unitRef="usd">-14098000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-286" decimals="-3" id="f-1565" unitRef="usd">-13113000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-287" decimals="-3" id="f-1566" unitRef="usd">-2640000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-288" decimals="-3" id="f-1567" unitRef="usd">-15753000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-283" decimals="-3" id="f-1568" unitRef="usd">623000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-284" decimals="-3" id="f-1569" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-285" decimals="-3" id="f-1570" unitRef="usd">623000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-286" decimals="-3" id="f-1571" unitRef="usd">-6000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-287" decimals="-3" id="f-1572" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-288" decimals="-3" id="f-1573" unitRef="usd">-6000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-283" decimals="-3" id="f-1574" unitRef="usd">623000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-284" decimals="-3" id="f-1575" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-285" decimals="-3" id="f-1576" unitRef="usd">623000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-286" decimals="-3" id="f-1577" unitRef="usd">-6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-287" decimals="-3" id="f-1578" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-288" decimals="-3" id="f-1579" unitRef="usd">-6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-283" decimals="-3" id="f-1580" unitRef="usd">-12208000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-284" decimals="-3" id="f-1581" unitRef="usd">-1267000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-285" decimals="-3" id="f-1582" unitRef="usd">-13475000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-286" decimals="-3" id="f-1583" unitRef="usd">-13119000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-287" decimals="-3" id="f-1584" unitRef="usd">-2640000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-288" decimals="-3" id="f-1585" unitRef="usd">-15759000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-283" decimals="-3" id="f-1586" unitRef="usd">149000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-284" decimals="-3" id="f-1587" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-285" decimals="-3" id="f-1588" unitRef="usd">149000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-286" decimals="-3" id="f-1589" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-287" decimals="-3" id="f-1590" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-288" decimals="-3" id="f-1591" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-283" decimals="-3" id="f-1592" unitRef="usd">-12357000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-283" decimals="-3" id="f-1593" unitRef="usd">-12357000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-284" decimals="-3" id="f-1594" unitRef="usd">-1267000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-284" decimals="-3" id="f-1595" unitRef="usd">-1267000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-285" decimals="-3" id="f-1596" unitRef="usd">-13624000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-285" decimals="-3" id="f-1597" unitRef="usd">-13624000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-286" decimals="-3" id="f-1598" unitRef="usd">-13119000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-286" decimals="-3" id="f-1599" unitRef="usd">-13119000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-287" decimals="-3" id="f-1600" unitRef="usd">-2640000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-287" decimals="-3" id="f-1601" unitRef="usd">-2640000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-288" decimals="-3" id="f-1602" unitRef="usd">-15759000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-288" decimals="-3" id="f-1603" unitRef="usd">-15759000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-283"
      decimals="2"
      id="f-1604"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-283"
      decimals="2"
      id="f-1605"
      unitRef="usdPerShare">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-285"
      decimals="2"
      id="f-1606"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-285"
      decimals="2"
      id="f-1607"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-286"
      decimals="2"
      id="f-1608"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-286"
      decimals="2"
      id="f-1609"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-288"
      decimals="2"
      id="f-1610"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-288"
      decimals="2"
      id="f-1611"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-283"
      decimals="0"
      id="f-1612"
      unitRef="shares">90115859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-283"
      decimals="0"
      id="f-1613"
      unitRef="shares">90115859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-285"
      decimals="0"
      id="f-1614"
      unitRef="shares">90115859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-285"
      decimals="0"
      id="f-1615"
      unitRef="shares">90115859</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-286"
      decimals="0"
      id="f-1616"
      unitRef="shares">69133700</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-286"
      decimals="0"
      id="f-1617"
      unitRef="shares">69133700</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-288"
      decimals="0"
      id="f-1618"
      unitRef="shares">69133700</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-288"
      decimals="0"
      id="f-1619"
      unitRef="shares">69133700</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-289" decimals="-3" id="f-1620" unitRef="usd">33604000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-290" decimals="-3" id="f-1621" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-291" decimals="-3" id="f-1622" unitRef="usd">33604000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-292" decimals="-3" id="f-1623" unitRef="usd">13325000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-293" decimals="-3" id="f-1624" unitRef="usd">160000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-294" decimals="-3" id="f-1625" unitRef="usd">13485000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:Revenues contextRef="c-289" decimals="-3" id="f-1626" unitRef="usd">33604000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-290" decimals="-3" id="f-1627" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-291" decimals="-3" id="f-1628" unitRef="usd">33604000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-292" decimals="-3" id="f-1629" unitRef="usd">13325000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-293" decimals="-3" id="f-1630" unitRef="usd">160000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-294" decimals="-3" id="f-1631" unitRef="usd">13485000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-289" decimals="-3" id="f-1632" unitRef="usd">35850000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-290" decimals="-3" id="f-1633" unitRef="usd">575000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-291" decimals="-3" id="f-1634" unitRef="usd">36425000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-292" decimals="-3" id="f-1635" unitRef="usd">35421000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-293" decimals="-3" id="f-1636" unitRef="usd">1590000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-294" decimals="-3" id="f-1637" unitRef="usd">37011000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-289" decimals="-3" id="f-1638" unitRef="usd">7608000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-290" decimals="-3" id="f-1639" unitRef="usd">888000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-291" decimals="-3" id="f-1640" unitRef="usd">8496000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-292" decimals="-3" id="f-1641" unitRef="usd">9278000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-293" decimals="-3" id="f-1642" unitRef="usd">1403000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-294" decimals="-3" id="f-1643" unitRef="usd">10681000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-289" decimals="-3" id="f-1644" unitRef="usd">43458000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-290" decimals="-3" id="f-1645" unitRef="usd">1463000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-291" decimals="-3" id="f-1646" unitRef="usd">44921000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-292" decimals="-3" id="f-1647" unitRef="usd">44699000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-293" decimals="-3" id="f-1648" unitRef="usd">2993000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-294" decimals="-3" id="f-1649" unitRef="usd">47692000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-289" decimals="-3" id="f-1650" unitRef="usd">-9854000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-290" decimals="-3" id="f-1651" unitRef="usd">-1463000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-291" decimals="-3" id="f-1652" unitRef="usd">-11317000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-292" decimals="-3" id="f-1653" unitRef="usd">-31374000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-293" decimals="-3" id="f-1654" unitRef="usd">-2833000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-294" decimals="-3" id="f-1655" unitRef="usd">-34207000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-289" decimals="-3" id="f-1656" unitRef="usd">855000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-290" decimals="-3" id="f-1657" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-291" decimals="-3" id="f-1658" unitRef="usd">855000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-292" decimals="-3" id="f-1659" unitRef="usd">-26000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-293" decimals="-3" id="f-1660" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-294" decimals="-3" id="f-1661" unitRef="usd">-26000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-289" decimals="-3" id="f-1662" unitRef="usd">855000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-290" decimals="-3" id="f-1663" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-291" decimals="-3" id="f-1664" unitRef="usd">855000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-292" decimals="-3" id="f-1665" unitRef="usd">-26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-293" decimals="-3" id="f-1666" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-294" decimals="-3" id="f-1667" unitRef="usd">-26000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-289" decimals="-3" id="f-1668" unitRef="usd">-8999000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-290" decimals="-3" id="f-1669" unitRef="usd">-1463000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-291" decimals="-3" id="f-1670" unitRef="usd">-10462000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-292" decimals="-3" id="f-1671" unitRef="usd">-31400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-293" decimals="-3" id="f-1672" unitRef="usd">-2833000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-294" decimals="-3" id="f-1673" unitRef="usd">-34233000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-289" decimals="-3" id="f-1674" unitRef="usd">149000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-290" decimals="-3" id="f-1675" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-291" decimals="-3" id="f-1676" unitRef="usd">149000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-292" decimals="-3" id="f-1677" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-293" decimals="-3" id="f-1678" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-294" decimals="-3" id="f-1679" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-289" decimals="-3" id="f-1680" unitRef="usd">-9148000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-289" decimals="-3" id="f-1681" unitRef="usd">-9148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-290" decimals="-3" id="f-1682" unitRef="usd">-1463000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-290" decimals="-3" id="f-1683" unitRef="usd">-1463000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-291" decimals="-3" id="f-1684" unitRef="usd">-10611000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-291" decimals="-3" id="f-1685" unitRef="usd">-10611000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-292" decimals="-3" id="f-1686" unitRef="usd">-31400000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-292" decimals="-3" id="f-1687" unitRef="usd">-31400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-293" decimals="-3" id="f-1688" unitRef="usd">-2833000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-293" decimals="-3" id="f-1689" unitRef="usd">-2833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-294" decimals="-3" id="f-1690" unitRef="usd">-34233000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-294" decimals="-3" id="f-1691" unitRef="usd">-34233000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-289"
      decimals="2"
      id="f-1692"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-289"
      decimals="2"
      id="f-1693"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-291"
      decimals="2"
      id="f-1694"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-291"
      decimals="2"
      id="f-1695"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-292"
      decimals="2"
      id="f-1696"
      unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-292"
      decimals="2"
      id="f-1697"
      unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-294"
      decimals="2"
      id="f-1698"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-294"
      decimals="2"
      id="f-1699"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-289"
      decimals="0"
      id="f-1700"
      unitRef="shares">84409667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-289"
      decimals="0"
      id="f-1701"
      unitRef="shares">84409667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-291"
      decimals="0"
      id="f-1702"
      unitRef="shares">84409667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-291"
      decimals="0"
      id="f-1703"
      unitRef="shares">84409667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-292"
      decimals="0"
      id="f-1704"
      unitRef="shares">68638651</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-292"
      decimals="0"
      id="f-1705"
      unitRef="shares">68638651</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-294"
      decimals="0"
      id="f-1706"
      unitRef="shares">68638651</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-294"
      decimals="0"
      id="f-1707"
      unitRef="shares">68638651</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-295" decimals="-3" id="f-1708" unitRef="usd">11250000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-296" decimals="-3" id="f-1709" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-297" decimals="-3" id="f-1710" unitRef="usd">11250000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-298" decimals="-3" id="f-1711" unitRef="usd">40744000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-299" decimals="-3" id="f-1712" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-300" decimals="-3" id="f-1713" unitRef="usd">40744000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-295" decimals="-3" id="f-1714" unitRef="usd">1468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-296" decimals="-3" id="f-1715" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-297" decimals="-3" id="f-1716" unitRef="usd">1468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-298" decimals="-3" id="f-1717" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-299" decimals="-3" id="f-1718" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-300" decimals="-3" id="f-1719" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-295" decimals="-3" id="f-1720" unitRef="usd">12718000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-296" decimals="-3" id="f-1721" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-297" decimals="-3" id="f-1722" unitRef="usd">12718000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-298" decimals="-3" id="f-1723" unitRef="usd">40744000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-299" decimals="-3" id="f-1724" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-300" decimals="-3" id="f-1725" unitRef="usd">40744000</us-gaap:Revenues>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-295" decimals="-3" id="f-1726" unitRef="usd">387000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-296" decimals="-3" id="f-1727" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-297" decimals="-3" id="f-1728" unitRef="usd">387000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-298" decimals="-3" id="f-1729" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-299" decimals="-3" id="f-1730" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-300" decimals="-3" id="f-1731" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-295" decimals="-3" id="f-1732" unitRef="usd">17330000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-296" decimals="-3" id="f-1733" unitRef="usd">59000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-297" decimals="-3" id="f-1734" unitRef="usd">17389000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-298" decimals="-3" id="f-1735" unitRef="usd">20041000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-299" decimals="-3" id="f-1736" unitRef="usd">242000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-300" decimals="-3" id="f-1737" unitRef="usd">20283000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-295" decimals="-3" id="f-1738" unitRef="usd">3556000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-296" decimals="-3" id="f-1739" unitRef="usd">876000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-297" decimals="-3" id="f-1740" unitRef="usd">4432000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-298" decimals="-3" id="f-1741" unitRef="usd">5780000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-299" decimals="-3" id="f-1742" unitRef="usd">490000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-300" decimals="-3" id="f-1743" unitRef="usd">6270000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-295" decimals="-3" id="f-1744" unitRef="usd">21273000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-296" decimals="-3" id="f-1745" unitRef="usd">935000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-297" decimals="-3" id="f-1746" unitRef="usd">22208000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-298" decimals="-3" id="f-1747" unitRef="usd">25821000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-299" decimals="-3" id="f-1748" unitRef="usd">732000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-300" decimals="-3" id="f-1749" unitRef="usd">26553000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-295" decimals="-3" id="f-1750" unitRef="usd">-8555000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-296" decimals="-3" id="f-1751" unitRef="usd">-935000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-297" decimals="-3" id="f-1752" unitRef="usd">-9490000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-298" decimals="-3" id="f-1753" unitRef="usd">14923000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-299" decimals="-3" id="f-1754" unitRef="usd">-732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-300" decimals="-3" id="f-1755" unitRef="usd">14191000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-295" decimals="-3" id="f-1756" unitRef="usd">613000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-296" decimals="-3" id="f-1757" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-297" decimals="-3" id="f-1758" unitRef="usd">613000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-298" decimals="-3" id="f-1759" unitRef="usd">55000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-299" decimals="-3" id="f-1760" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-300" decimals="-3" id="f-1761" unitRef="usd">55000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-295" decimals="-3" id="f-1762" unitRef="usd">613000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-296" decimals="-3" id="f-1763" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-297" decimals="-3" id="f-1764" unitRef="usd">613000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-298" decimals="-3" id="f-1765" unitRef="usd">55000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-299" decimals="-3" id="f-1766" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-300" decimals="-3" id="f-1767" unitRef="usd">55000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-295" decimals="-3" id="f-1768" unitRef="usd">-7942000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-296" decimals="-3" id="f-1769" unitRef="usd">-935000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-297" decimals="-3" id="f-1770" unitRef="usd">-8877000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-298" decimals="-3" id="f-1771" unitRef="usd">14978000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-299" decimals="-3" id="f-1772" unitRef="usd">-732000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-300" decimals="-3" id="f-1773" unitRef="usd">14246000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-295" decimals="-3" id="f-1774" unitRef="usd">230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-296" decimals="-3" id="f-1775" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-297" decimals="-3" id="f-1776" unitRef="usd">230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-298" decimals="-3" id="f-1777" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-299" decimals="-3" id="f-1778" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-300" decimals="-3" id="f-1779" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-295" decimals="-3" id="f-1780" unitRef="usd">-8172000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-295" decimals="-3" id="f-1781" unitRef="usd">-8172000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-296" decimals="-3" id="f-1782" unitRef="usd">-935000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-296" decimals="-3" id="f-1783" unitRef="usd">-935000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-297" decimals="-3" id="f-1784" unitRef="usd">-9107000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-297" decimals="-3" id="f-1785" unitRef="usd">-9107000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-298" decimals="-3" id="f-1786" unitRef="usd">14978000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-298" decimals="-3" id="f-1787" unitRef="usd">14978000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-299" decimals="-3" id="f-1788" unitRef="usd">-732000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-299" decimals="-3" id="f-1789" unitRef="usd">-732000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-300" decimals="-3" id="f-1790" unitRef="usd">14246000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-300" decimals="-3" id="f-1791" unitRef="usd">14246000</us-gaap:NetIncomeLoss>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-295" decimals="-3" id="f-1792" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-295" decimals="-3" id="f-1793" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-296" decimals="-3" id="f-1794" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-296" decimals="-3" id="f-1795" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-297" decimals="-3" id="f-1796" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-297" decimals="-3" id="f-1797" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-298" decimals="-3" id="f-1798" unitRef="usd">3081000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-298" decimals="-3" id="f-1799" unitRef="usd">3081000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-299" decimals="-3" id="f-1800" unitRef="usd">-150000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-299" decimals="-3" id="f-1801" unitRef="usd">-150000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-300" decimals="-3" id="f-1802" unitRef="usd">2931000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-300" decimals="-3" id="f-1803" unitRef="usd">2931000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-295" decimals="-3" id="f-1804" unitRef="usd">-8172000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-296" decimals="-3" id="f-1805" unitRef="usd">-935000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-297" decimals="-3" id="f-1806" unitRef="usd">-9107000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-298" decimals="-3" id="f-1807" unitRef="usd">11897000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-299" decimals="-3" id="f-1808" unitRef="usd">-582000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-300" decimals="-3" id="f-1809" unitRef="usd">11315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-295"
      decimals="2"
      id="f-1810"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-297"
      decimals="2"
      id="f-1811"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-298"
      decimals="2"
      id="f-1812"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-300"
      decimals="2"
      id="f-1813"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-295"
      decimals="2"
      id="f-1814"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-297"
      decimals="2"
      id="f-1815"
      unitRef="usdPerShare">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-298"
      decimals="2"
      id="f-1816"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-300"
      decimals="2"
      id="f-1817"
      unitRef="usdPerShare">0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-295"
      decimals="0"
      id="f-1818"
      unitRef="shares">90287441</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-297"
      decimals="0"
      id="f-1819"
      unitRef="shares">90287441</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-298"
      decimals="0"
      id="f-1820"
      unitRef="shares">70217985</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-300"
      decimals="0"
      id="f-1821"
      unitRef="shares">70217985</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-295"
      decimals="0"
      id="f-1822"
      unitRef="shares">90287441</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-297"
      decimals="0"
      id="f-1823"
      unitRef="shares">90287441</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-298"
      decimals="0"
      id="f-1824"
      unitRef="shares">88592568</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-300"
      decimals="0"
      id="f-1825"
      unitRef="shares">88592568</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-301" decimals="-3" id="f-1826" unitRef="usd">44854000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-302" decimals="-3" id="f-1827" unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-303" decimals="-3" id="f-1828" unitRef="usd">44854000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-304" decimals="-3" id="f-1829" unitRef="usd">54069000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-305" decimals="-3" id="f-1830" unitRef="usd">160000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer contextRef="c-306" decimals="-3" id="f-1831" unitRef="usd">54229000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-301" decimals="-3" id="f-1832" unitRef="usd">1468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-302" decimals="-3" id="f-1833" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-303" decimals="-3" id="f-1834" unitRef="usd">1468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-304" decimals="-3" id="f-1835" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-305" decimals="-3" id="f-1836" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-306" decimals="-3" id="f-1837" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues contextRef="c-301" decimals="-3" id="f-1838" unitRef="usd">46322000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-302" decimals="-3" id="f-1839" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-303" decimals="-3" id="f-1840" unitRef="usd">46322000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-304" decimals="-3" id="f-1841" unitRef="usd">54069000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-305" decimals="-3" id="f-1842" unitRef="usd">160000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-306" decimals="-3" id="f-1843" unitRef="usd">54229000</us-gaap:Revenues>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-301" decimals="-3" id="f-1844" unitRef="usd">387000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-302" decimals="-3" id="f-1845" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-303" decimals="-3" id="f-1846" unitRef="usd">387000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-304" decimals="-3" id="f-1847" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-305" decimals="-3" id="f-1848" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-306" decimals="-3" id="f-1849" unitRef="usd">0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-301" decimals="-3" id="f-1850" unitRef="usd">53180000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-302" decimals="-3" id="f-1851" unitRef="usd">634000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-303" decimals="-3" id="f-1852" unitRef="usd">53814000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-304" decimals="-3" id="f-1853" unitRef="usd">55462000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-305" decimals="-3" id="f-1854" unitRef="usd">1832000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-306" decimals="-3" id="f-1855" unitRef="usd">57294000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-301" decimals="-3" id="f-1856" unitRef="usd">11164000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-302" decimals="-3" id="f-1857" unitRef="usd">1764000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-303" decimals="-3" id="f-1858" unitRef="usd">12928000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-304" decimals="-3" id="f-1859" unitRef="usd">15058000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-305" decimals="-3" id="f-1860" unitRef="usd">1893000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-306" decimals="-3" id="f-1861" unitRef="usd">16951000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-301" decimals="-3" id="f-1862" unitRef="usd">64731000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-302" decimals="-3" id="f-1863" unitRef="usd">2398000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-303" decimals="-3" id="f-1864" unitRef="usd">67129000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-304" decimals="-3" id="f-1865" unitRef="usd">70520000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-305" decimals="-3" id="f-1866" unitRef="usd">3725000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-306" decimals="-3" id="f-1867" unitRef="usd">74245000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-301" decimals="-3" id="f-1868" unitRef="usd">-18409000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-302" decimals="-3" id="f-1869" unitRef="usd">-2398000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-303" decimals="-3" id="f-1870" unitRef="usd">-20807000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-304" decimals="-3" id="f-1871" unitRef="usd">-16451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-305" decimals="-3" id="f-1872" unitRef="usd">-3565000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-306" decimals="-3" id="f-1873" unitRef="usd">-20016000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-301" decimals="-3" id="f-1874" unitRef="usd">1468000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-302" decimals="-3" id="f-1875" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-303" decimals="-3" id="f-1876" unitRef="usd">1468000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-304" decimals="-3" id="f-1877" unitRef="usd">29000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-305" decimals="-3" id="f-1878" unitRef="usd">0</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-306" decimals="-3" id="f-1879" unitRef="usd">29000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-301" decimals="-3" id="f-1880" unitRef="usd">1468000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-302" decimals="-3" id="f-1881" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-303" decimals="-3" id="f-1882" unitRef="usd">1468000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-304" decimals="-3" id="f-1883" unitRef="usd">29000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-305" decimals="-3" id="f-1884" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-306" decimals="-3" id="f-1885" unitRef="usd">29000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-301" decimals="-3" id="f-1886" unitRef="usd">-16941000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-302" decimals="-3" id="f-1887" unitRef="usd">-2398000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-303" decimals="-3" id="f-1888" unitRef="usd">-19339000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-304" decimals="-3" id="f-1889" unitRef="usd">-16422000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-305" decimals="-3" id="f-1890" unitRef="usd">-3565000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-306" decimals="-3" id="f-1891" unitRef="usd">-19987000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-301" decimals="-3" id="f-1892" unitRef="usd">379000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-302" decimals="-3" id="f-1893" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-303" decimals="-3" id="f-1894" unitRef="usd">379000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-304" decimals="-3" id="f-1895" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-305" decimals="-3" id="f-1896" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-306" decimals="-3" id="f-1897" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-301" decimals="-3" id="f-1898" unitRef="usd">-17320000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-301" decimals="-3" id="f-1899" unitRef="usd">-17320000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-302" decimals="-3" id="f-1900" unitRef="usd">-2398000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-302" decimals="-3" id="f-1901" unitRef="usd">-2398000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-303" decimals="-3" id="f-1902" unitRef="usd">-19718000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-303" decimals="-3" id="f-1903" unitRef="usd">-19718000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-304" decimals="-3" id="f-1904" unitRef="usd">-16422000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-304" decimals="-3" id="f-1905" unitRef="usd">-16422000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-305" decimals="-3" id="f-1906" unitRef="usd">-3565000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-305" decimals="-3" id="f-1907" unitRef="usd">-3565000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-306" decimals="-3" id="f-1908" unitRef="usd">-19987000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-306" decimals="-3" id="f-1909" unitRef="usd">-19987000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-301"
      decimals="2"
      id="f-1910"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-301"
      decimals="2"
      id="f-1911"
      unitRef="usdPerShare">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-303"
      decimals="2"
      id="f-1912"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-303"
      decimals="2"
      id="f-1913"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-304"
      decimals="2"
      id="f-1914"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-304"
      decimals="2"
      id="f-1915"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-306"
      decimals="2"
      id="f-1916"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-306"
      decimals="2"
      id="f-1917"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-301"
      decimals="0"
      id="f-1918"
      unitRef="shares">86390446</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-301"
      decimals="0"
      id="f-1919"
      unitRef="shares">86390446</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-303"
      decimals="0"
      id="f-1920"
      unitRef="shares">86390446</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-303"
      decimals="0"
      id="f-1921"
      unitRef="shares">86390446</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-304"
      decimals="0"
      id="f-1922"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-304"
      decimals="0"
      id="f-1923"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-306"
      decimals="0"
      id="f-1924"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-306"
      decimals="0"
      id="f-1925"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-277" decimals="-3" id="f-1926" unitRef="usd">3209000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-278" decimals="-3" id="f-1927" unitRef="usd">-196000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-279" decimals="-3" id="f-1928" unitRef="usd">3013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-280" decimals="-3" id="f-1929" unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-281" decimals="-3" id="f-1930" unitRef="usd">-193000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-282" decimals="-3" id="f-1931" unitRef="usd">-18474000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-277" decimals="-3" id="f-1932" unitRef="usd">640000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-278" decimals="-3" id="f-1933" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-279" decimals="-3" id="f-1934" unitRef="usd">640000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-280" decimals="-3" id="f-1935" unitRef="usd">1338000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-281" decimals="-3" id="f-1936" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-282" decimals="-3" id="f-1937" unitRef="usd">1338000</us-gaap:ShareBasedCompensation>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-277" decimals="-3" id="f-1938" unitRef="usd">288000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-278" decimals="-3" id="f-1939" unitRef="usd">-26000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-279" decimals="-3" id="f-1940" unitRef="usd">262000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-280" decimals="-3" id="f-1941" unitRef="usd">258000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-281" decimals="-3" id="f-1942" unitRef="usd">-24000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-282" decimals="-3" id="f-1943" unitRef="usd">234000</cdtx:OperatingLeaseRightOfUseAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-277" decimals="-3" id="f-1944" unitRef="usd">32000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-278" decimals="-3" id="f-1945" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-279" decimals="-3" id="f-1946" unitRef="usd">32000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-280" decimals="-3" id="f-1947" unitRef="usd">39000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-281" decimals="-3" id="f-1948" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-282" decimals="-3" id="f-1949" unitRef="usd">39000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-277" decimals="-3" id="f-1950" unitRef="usd">475000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-278" decimals="-3" id="f-1951" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-279" decimals="-3" id="f-1952" unitRef="usd">475000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-280" decimals="-3" id="f-1953" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-281" decimals="-3" id="f-1954" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-282" decimals="-3" id="f-1955" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:PaidInKindInterest contextRef="c-277" decimals="-3" id="f-1956" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-278" decimals="-3" id="f-1957" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-279" decimals="-3" id="f-1958" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-280" decimals="-3" id="f-1959" unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-281" decimals="-3" id="f-1960" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-282" decimals="-3" id="f-1961" unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-277" decimals="-3" id="f-1962" unitRef="usd">19993000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-278" decimals="-3" id="f-1963" unitRef="usd">295000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-279" decimals="-3" id="f-1964" unitRef="usd">20288000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-280" decimals="-3" id="f-1965" unitRef="usd">3427000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-281" decimals="-3" id="f-1966" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-282" decimals="-3" id="f-1967" unitRef="usd">3427000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-277" decimals="-3" id="f-1968" unitRef="usd">-872000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-278" decimals="-3" id="f-1969" unitRef="usd">24000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-279" decimals="-3" id="f-1970" unitRef="usd">-848000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-280" decimals="-3" id="f-1971" unitRef="usd">1120000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-281" decimals="-3" id="f-1972" unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-282" decimals="-3" id="f-1973" unitRef="usd">1120000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-277" decimals="-3" id="f-1974" unitRef="usd">3116000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-278" decimals="-3" id="f-1975" unitRef="usd">76000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-279" decimals="-3" id="f-1976" unitRef="usd">3192000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-280" decimals="-3" id="f-1977" unitRef="usd">657000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-281" decimals="-3" id="f-1978" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-282" decimals="-3" id="f-1979" unitRef="usd">657000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-277" decimals="-3" id="f-1980" unitRef="usd">0</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-278" decimals="-3" id="f-1981" unitRef="usd">261000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-279" decimals="-3" id="f-1982" unitRef="usd">261000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-280" decimals="-3" id="f-1983" unitRef="usd">0</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-281" decimals="-3" id="f-1984" unitRef="usd">353000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-282" decimals="-3" id="f-1985" unitRef="usd">353000</cdtx:AccruedIndirectTaxLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-277" decimals="-3" id="f-1986" unitRef="usd">921000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-278" decimals="-3" id="f-1987" unitRef="usd">0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-279" decimals="-3" id="f-1988" unitRef="usd">921000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-280" decimals="-3" id="f-1989" unitRef="usd">-1953000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-281" decimals="-3" id="f-1990" unitRef="usd">0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-282" decimals="-3" id="f-1991" unitRef="usd">-1953000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-277" decimals="-3" id="f-1992" unitRef="usd">-142000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-278" decimals="-3" id="f-1993" unitRef="usd">178000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-279" decimals="-3" id="f-1994" unitRef="usd">36000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-280" decimals="-3" id="f-1995" unitRef="usd">-844000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-281" decimals="-3" id="f-1996" unitRef="usd">-160000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-282" decimals="-3" id="f-1997" unitRef="usd">-1004000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-277" decimals="-3" id="f-1998" unitRef="usd">-316000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-278" decimals="-3" id="f-1999" unitRef="usd">26000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-279" decimals="-3" id="f-2000" unitRef="usd">-290000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-280" decimals="-3" id="f-2001" unitRef="usd">-276000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-281" decimals="-3" id="f-2002" unitRef="usd">24000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-282" decimals="-3" id="f-2003" unitRef="usd">-252000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-277" decimals="-3" id="f-2004" unitRef="usd">-10898000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-278" decimals="-3" id="f-2005" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-279" decimals="-3" id="f-2006" unitRef="usd">-10898000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-280" decimals="-3" id="f-2007" unitRef="usd">-23608000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-281" decimals="-3" id="f-2008" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-282" decimals="-3" id="f-2009" unitRef="usd">-23608000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-277" decimals="-3" id="f-2010" unitRef="usd">94000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-278" decimals="-3" id="f-2011" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-279" decimals="-3" id="f-2012" unitRef="usd">94000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-280" decimals="-3" id="f-2013" unitRef="usd">84000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-281" decimals="-3" id="f-2014" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-282" decimals="-3" id="f-2015" unitRef="usd">84000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-277" decimals="-3" id="f-2016" unitRef="usd">-94000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-278" decimals="-3" id="f-2017" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-279" decimals="-3" id="f-2018" unitRef="usd">-94000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-280" decimals="-3" id="f-2019" unitRef="usd">-84000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-281" decimals="-3" id="f-2020" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-282" decimals="-3" id="f-2021" unitRef="usd">-84000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-277" decimals="-3" id="f-2022" unitRef="usd">17593000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-278" decimals="-3" id="f-2023" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-279" decimals="-3" id="f-2024" unitRef="usd">17593000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-280" decimals="-3" id="f-2025" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-281" decimals="-3" id="f-2026" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-282" decimals="-3" id="f-2027" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-277" decimals="-3" id="f-2028" unitRef="usd">8630000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-278" decimals="-3" id="f-2029" unitRef="usd">0</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-279" decimals="-3" id="f-2030" unitRef="usd">8630000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-280" decimals="-3" id="f-2031" unitRef="usd">500000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-281" decimals="-3" id="f-2032" unitRef="usd">0</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-282" decimals="-3" id="f-2033" unitRef="usd">500000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-277" decimals="-3" id="f-2034" unitRef="usd">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-278" decimals="-3" id="f-2035" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-279" decimals="-3" id="f-2036" unitRef="usd">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-280" decimals="-3" id="f-2037" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-281" decimals="-3" id="f-2038" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-282" decimals="-3" id="f-2039" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-277" decimals="-3" id="f-2040" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-278" decimals="-3" id="f-2041" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-279" decimals="-3" id="f-2042" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-280" decimals="-3" id="f-2043" unitRef="usd">1111000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-281" decimals="-3" id="f-2044" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-282" decimals="-3" id="f-2045" unitRef="usd">1111000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-277" decimals="-3" id="f-2046" unitRef="usd">26237000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-278" decimals="-3" id="f-2047" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-279" decimals="-3" id="f-2048" unitRef="usd">26237000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-280" decimals="-3" id="f-2049" unitRef="usd">-611000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-281" decimals="-3" id="f-2050" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-282" decimals="-3" id="f-2051" unitRef="usd">-611000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-277" decimals="-3" id="f-2052" unitRef="usd">15245000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-278" decimals="-3" id="f-2053" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-279" decimals="-3" id="f-2054" unitRef="usd">15245000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-280" decimals="-3" id="f-2055" unitRef="usd">-24303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-281" decimals="-3" id="f-2056" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-282" decimals="-3" id="f-2057" unitRef="usd">-24303000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-2058" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-45" decimals="-3" id="f-2059" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-2060" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-60" decimals="-3" id="f-2061" unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-61" decimals="-3" id="f-2062" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-2063" unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-242" decimals="-3" id="f-2064" unitRef="usd">47976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-243" decimals="-3" id="f-2065" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-244" decimals="-3" id="f-2066" unitRef="usd">47976000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-245" decimals="-3" id="f-2067" unitRef="usd">37970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-246" decimals="-3" id="f-2068" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-247" decimals="-3" id="f-2069" unitRef="usd">37970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-277" decimals="-3" id="f-2070" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-278" decimals="-3" id="f-2071" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-279" decimals="-3" id="f-2072" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-280" decimals="-3" id="f-2073" unitRef="usd">25000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-281" decimals="-3" id="f-2074" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-282" decimals="-3" id="f-2075" unitRef="usd">25000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-277" decimals="-3" id="f-2076" unitRef="usd">55000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-278" decimals="-3" id="f-2077" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-279" decimals="-3" id="f-2078" unitRef="usd">55000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-280" decimals="-3" id="f-2079" unitRef="usd">16000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-281" decimals="-3" id="f-2080" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-282" decimals="-3" id="f-2081" unitRef="usd">16000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-277" decimals="-3" id="f-2082" unitRef="usd">337000</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-278" decimals="-3" id="f-2083" unitRef="usd">0</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-279" decimals="-3" id="f-2084" unitRef="usd">337000</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-280" decimals="-3" id="f-2085" unitRef="usd">0</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-281" decimals="-3" id="f-2086" unitRef="usd">720000</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-282" decimals="-3" id="f-2087" unitRef="usd">720000</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <us-gaap:NetIncomeLoss contextRef="c-289" decimals="-3" id="f-2088" unitRef="usd">-9148000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-290" decimals="-3" id="f-2089" unitRef="usd">-1463000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-291" decimals="-3" id="f-2090" unitRef="usd">-10611000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-292" decimals="-3" id="f-2091" unitRef="usd">-31400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-293" decimals="-3" id="f-2092" unitRef="usd">-2833000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-294" decimals="-3" id="f-2093" unitRef="usd">-34233000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-289" decimals="-3" id="f-2094" unitRef="usd">1435000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-290" decimals="-3" id="f-2095" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-291" decimals="-3" id="f-2096" unitRef="usd">1435000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-292" decimals="-3" id="f-2097" unitRef="usd">2016000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-293" decimals="-3" id="f-2098" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-294" decimals="-3" id="f-2099" unitRef="usd">2016000</us-gaap:ShareBasedCompensation>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-289" decimals="-3" id="f-2100" unitRef="usd">664000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-290" decimals="-3" id="f-2101" unitRef="usd">-25000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-291" decimals="-3" id="f-2102" unitRef="usd">639000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-292" decimals="-3" id="f-2103" unitRef="usd">523000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-293" decimals="-3" id="f-2104" unitRef="usd">-47000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-294" decimals="-3" id="f-2105" unitRef="usd">476000</cdtx:OperatingLeaseRightOfUseAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-289" decimals="-3" id="f-2106" unitRef="usd">57000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-290" decimals="-3" id="f-2107" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-291" decimals="-3" id="f-2108" unitRef="usd">57000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-292" decimals="-3" id="f-2109" unitRef="usd">77000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-293" decimals="-3" id="f-2110" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-294" decimals="-3" id="f-2111" unitRef="usd">77000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-289" decimals="-3" id="f-2112" unitRef="usd">40000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-290" decimals="-3" id="f-2113" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-291" decimals="-3" id="f-2114" unitRef="usd">40000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-292" decimals="-3" id="f-2115" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-293" decimals="-3" id="f-2116" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-294" decimals="-3" id="f-2117" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:PaidInKindInterest contextRef="c-289" decimals="-3" id="f-2118" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-290" decimals="-3" id="f-2119" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-291" decimals="-3" id="f-2120" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-292" decimals="-3" id="f-2121" unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-293" decimals="-3" id="f-2122" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-294" decimals="-3" id="f-2123" unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-289" decimals="-3" id="f-2124" unitRef="usd">-350000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-290" decimals="-3" id="f-2125" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-291" decimals="-3" id="f-2126" unitRef="usd">-350000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-292" decimals="-3" id="f-2127" unitRef="usd">-524000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-293" decimals="-3" id="f-2128" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-294" decimals="-3" id="f-2129" unitRef="usd">-524000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-289" decimals="-3" id="f-2130" unitRef="usd">1954000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-290" decimals="-3" id="f-2131" unitRef="usd">434000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-291" decimals="-3" id="f-2132" unitRef="usd">2388000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-292" decimals="-3" id="f-2133" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-293" decimals="-3" id="f-2134" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-294" decimals="-3" id="f-2135" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-289" decimals="-3" id="f-2136" unitRef="usd">-2120000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-290" decimals="-3" id="f-2137" unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-291" decimals="-3" id="f-2138" unitRef="usd">-2120000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-292" decimals="-3" id="f-2139" unitRef="usd">2567000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-293" decimals="-3" id="f-2140" unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-294" decimals="-3" id="f-2141" unitRef="usd">2567000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-289" decimals="-3" id="f-2142" unitRef="usd">2870000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-290" decimals="-3" id="f-2143" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-291" decimals="-3" id="f-2144" unitRef="usd">2870000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-292" decimals="-3" id="f-2145" unitRef="usd">-483000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-293" decimals="-3" id="f-2146" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-294" decimals="-3" id="f-2147" unitRef="usd">-483000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-289" decimals="-3" id="f-2148" unitRef="usd">0</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-290" decimals="-3" id="f-2149" unitRef="usd">1897000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-291" decimals="-3" id="f-2150" unitRef="usd">1897000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-292" decimals="-3" id="f-2151" unitRef="usd">0</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-293" decimals="-3" id="f-2152" unitRef="usd">2993000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-294" decimals="-3" id="f-2153" unitRef="usd">2993000</cdtx:AccruedIndirectTaxLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-289" decimals="-3" id="f-2154" unitRef="usd">-1277000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-290" decimals="-3" id="f-2155" unitRef="usd">0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-291" decimals="-3" id="f-2156" unitRef="usd">-1277000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-292" decimals="-3" id="f-2157" unitRef="usd">-1324000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-293" decimals="-3" id="f-2158" unitRef="usd">0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-294" decimals="-3" id="f-2159" unitRef="usd">-1324000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-289" decimals="-3" id="f-2160" unitRef="usd">-2613000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-290" decimals="-3" id="f-2161" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-291" decimals="-3" id="f-2162" unitRef="usd">-2613000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-292" decimals="-3" id="f-2163" unitRef="usd">-2252000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-293" decimals="-3" id="f-2164" unitRef="usd">-160000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-294" decimals="-3" id="f-2165" unitRef="usd">-2412000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-289" decimals="-3" id="f-2166" unitRef="usd">-620000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-290" decimals="-3" id="f-2167" unitRef="usd">25000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-291" decimals="-3" id="f-2168" unitRef="usd">-595000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-292" decimals="-3" id="f-2169" unitRef="usd">-559000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-293" decimals="-3" id="f-2170" unitRef="usd">47000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-294" decimals="-3" id="f-2171" unitRef="usd">-512000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-289" decimals="-3" id="f-2172" unitRef="usd">-8076000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-290" decimals="-3" id="f-2173" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-291" decimals="-3" id="f-2174" unitRef="usd">-8076000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-292" decimals="-3" id="f-2175" unitRef="usd">-35444000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-293" decimals="-3" id="f-2176" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-294" decimals="-3" id="f-2177" unitRef="usd">-35444000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-289" decimals="-3" id="f-2178" unitRef="usd">201000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-290" decimals="-3" id="f-2179" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-291" decimals="-3" id="f-2180" unitRef="usd">201000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-292" decimals="-3" id="f-2181" unitRef="usd">100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-293" decimals="-3" id="f-2182" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-294" decimals="-3" id="f-2183" unitRef="usd">100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-289" decimals="-3" id="f-2184" unitRef="usd">-201000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-290" decimals="-3" id="f-2185" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-291" decimals="-3" id="f-2186" unitRef="usd">-201000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-292" decimals="-3" id="f-2187" unitRef="usd">-100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-293" decimals="-3" id="f-2188" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-294" decimals="-3" id="f-2189" unitRef="usd">-100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-289" decimals="-3" id="f-2190" unitRef="usd">17256000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-290" decimals="-3" id="f-2191" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-291" decimals="-3" id="f-2192" unitRef="usd">17256000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-292" decimals="-3" id="f-2193" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-293" decimals="-3" id="f-2194" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-294" decimals="-3" id="f-2195" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-289" decimals="-3" id="f-2196" unitRef="usd">8706000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-290" decimals="-3" id="f-2197" unitRef="usd">0</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-291" decimals="-3" id="f-2198" unitRef="usd">8706000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-292" decimals="-3" id="f-2199" unitRef="usd">500000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-293" decimals="-3" id="f-2200" unitRef="usd">0</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-294" decimals="-3" id="f-2201" unitRef="usd">500000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-289" decimals="-3" id="f-2202" unitRef="usd">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-290" decimals="-3" id="f-2203" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-291" decimals="-3" id="f-2204" unitRef="usd">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-292" decimals="-3" id="f-2205" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-293" decimals="-3" id="f-2206" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-294" decimals="-3" id="f-2207" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-289" decimals="-3" id="f-2208" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-290" decimals="-3" id="f-2209" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-291" decimals="-3" id="f-2210" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-292" decimals="-3" id="f-2211" unitRef="usd">2222000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-293" decimals="-3" id="f-2212" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-294" decimals="-3" id="f-2213" unitRef="usd">2222000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-289" decimals="-3" id="f-2214" unitRef="usd">25976000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-290" decimals="-3" id="f-2215" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-291" decimals="-3" id="f-2216" unitRef="usd">25976000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-292" decimals="-3" id="f-2217" unitRef="usd">-1722000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-293" decimals="-3" id="f-2218" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-294" decimals="-3" id="f-2219" unitRef="usd">-1722000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-289" decimals="-3" id="f-2220" unitRef="usd">17699000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-290" decimals="-3" id="f-2221" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-291" decimals="-3" id="f-2222" unitRef="usd">17699000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-292" decimals="-3" id="f-2223" unitRef="usd">-37266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-293" decimals="-3" id="f-2224" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-294" decimals="-3" id="f-2225" unitRef="usd">-37266000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-2226" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-45" decimals="-3" id="f-2227" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-2228" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-60" decimals="-3" id="f-2229" unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-61" decimals="-3" id="f-2230" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-2231" unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-254" decimals="-3" id="f-2232" unitRef="usd">50430000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-255" decimals="-3" id="f-2233" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-2" decimals="-3" id="f-2234" unitRef="usd">50430000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-256" decimals="-3" id="f-2235" unitRef="usd">25007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-257" decimals="-3" id="f-2236" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-258" decimals="-3" id="f-2237" unitRef="usd">25007000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-289" decimals="-3" id="f-2238" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-290" decimals="-3" id="f-2239" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-291" decimals="-3" id="f-2240" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-292" decimals="-3" id="f-2241" unitRef="usd">38000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-293" decimals="-3" id="f-2242" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-294" decimals="-3" id="f-2243" unitRef="usd">38000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-289" decimals="-3" id="f-2244" unitRef="usd">588000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-290" decimals="-3" id="f-2245" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-291" decimals="-3" id="f-2246" unitRef="usd">588000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-292" decimals="-3" id="f-2247" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-293" decimals="-3" id="f-2248" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-294" decimals="-3" id="f-2249" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-289" decimals="-3" id="f-2250" unitRef="usd">3847000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-290" decimals="-3" id="f-2251" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-291" decimals="-3" id="f-2252" unitRef="usd">3847000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-292" decimals="-3" id="f-2253" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-293" decimals="-3" id="f-2254" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-294" decimals="-3" id="f-2255" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-289" decimals="-3" id="f-2256" unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-290" decimals="-3" id="f-2257" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-291" decimals="-3" id="f-2258" unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-292" decimals="-3" id="f-2259" unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-293" decimals="-3" id="f-2260" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-294" decimals="-3" id="f-2261" unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-289" decimals="-3" id="f-2262" unitRef="usd">0</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-290" decimals="-3" id="f-2263" unitRef="usd">0</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-291" decimals="-3" id="f-2264" unitRef="usd">0</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-292" decimals="-3" id="f-2265" unitRef="usd">720000</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-293" decimals="-3" id="f-2266" unitRef="usd">0</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet contextRef="c-294" decimals="-3" id="f-2267" unitRef="usd">720000</cdtx:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransactionNet>
    <us-gaap:NetIncomeLoss contextRef="c-301" decimals="-3" id="f-2268" unitRef="usd">-17320000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-302" decimals="-3" id="f-2269" unitRef="usd">-2398000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-303" decimals="-3" id="f-2270" unitRef="usd">-19718000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-304" decimals="-3" id="f-2271" unitRef="usd">-16422000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-305" decimals="-3" id="f-2272" unitRef="usd">-3565000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-306" decimals="-3" id="f-2273" unitRef="usd">-19987000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-301" decimals="-3" id="f-2274" unitRef="usd">2231000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-302" decimals="-3" id="f-2275" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-303" decimals="-3" id="f-2276" unitRef="usd">2231000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-304" decimals="-3" id="f-2277" unitRef="usd">2859000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-305" decimals="-3" id="f-2278" unitRef="usd">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-306" decimals="-3" id="f-2279" unitRef="usd">2859000</us-gaap:ShareBasedCompensation>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-301" decimals="-3" id="f-2280" unitRef="usd">921000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-302" decimals="-3" id="f-2281" unitRef="usd">-26000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-303" decimals="-3" id="f-2282" unitRef="usd">895000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-304" decimals="-3" id="f-2283" unitRef="usd">796000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-305" decimals="-3" id="f-2284" unitRef="usd">-72000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization contextRef="c-306" decimals="-3" id="f-2285" unitRef="usd">724000</cdtx:OperatingLeaseRightOfUseAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-301" decimals="-3" id="f-2286" unitRef="usd">79000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-302" decimals="-3" id="f-2287" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-303" decimals="-3" id="f-2288" unitRef="usd">79000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-304" decimals="-3" id="f-2289" unitRef="usd">114000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-305" decimals="-3" id="f-2290" unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-306" decimals="-3" id="f-2291" unitRef="usd">114000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-301" decimals="-3" id="f-2292" unitRef="usd">53000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-302" decimals="-3" id="f-2293" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-303" decimals="-3" id="f-2294" unitRef="usd">53000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-304" decimals="-3" id="f-2295" unitRef="usd">1772000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-305" decimals="-3" id="f-2296" unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-306" decimals="-3" id="f-2297" unitRef="usd">1772000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:PaidInKindInterest contextRef="c-301" decimals="-3" id="f-2298" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-302" decimals="-3" id="f-2299" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-303" decimals="-3" id="f-2300" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-304" decimals="-3" id="f-2301" unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-305" decimals="-3" id="f-2302" unitRef="usd">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest contextRef="c-306" decimals="-3" id="f-2303" unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-301" decimals="-3" id="f-2304" unitRef="usd">-2978000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-302" decimals="-3" id="f-2305" unitRef="usd">323000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-303" decimals="-3" id="f-2306" unitRef="usd">-2655000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-304" decimals="-3" id="f-2307" unitRef="usd">-314000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-305" decimals="-3" id="f-2308" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-306" decimals="-3" id="f-2309" unitRef="usd">-314000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-301" decimals="-3" id="f-2310" unitRef="usd">2467000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-302" decimals="-3" id="f-2311" unitRef="usd">434000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-303" decimals="-3" id="f-2312" unitRef="usd">2901000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-304" decimals="-3" id="f-2313" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-305" decimals="-3" id="f-2314" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-306" decimals="-3" id="f-2315" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-301" decimals="-3" id="f-2316" unitRef="usd">-2776000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-302" decimals="-3" id="f-2317" unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-303" decimals="-3" id="f-2318" unitRef="usd">-2776000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-304" decimals="-3" id="f-2319" unitRef="usd">1662000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-305" decimals="-3" id="f-2320" unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-306" decimals="-3" id="f-2321" unitRef="usd">1662000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-301" decimals="-3" id="f-2322" unitRef="usd">6204000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-302" decimals="-3" id="f-2323" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-303" decimals="-3" id="f-2324" unitRef="usd">6204000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-304" decimals="-3" id="f-2325" unitRef="usd">-1037000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-305" decimals="-3" id="f-2326" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-306" decimals="-3" id="f-2327" unitRef="usd">-1037000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-301" decimals="-3" id="f-2328" unitRef="usd">0</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-302" decimals="-3" id="f-2329" unitRef="usd">3155000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-303" decimals="-3" id="f-2330" unitRef="usd">3155000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-304" decimals="-3" id="f-2331" unitRef="usd">0</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-305" decimals="-3" id="f-2332" unitRef="usd">3725000</cdtx:AccruedIndirectTaxLiabilities>
    <cdtx:AccruedIndirectTaxLiabilities contextRef="c-306" decimals="-3" id="f-2333" unitRef="usd">3725000</cdtx:AccruedIndirectTaxLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-301" decimals="-3" id="f-2334" unitRef="usd">-402000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-302" decimals="-3" id="f-2335" unitRef="usd">0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-303" decimals="-3" id="f-2336" unitRef="usd">-402000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-304" decimals="-3" id="f-2337" unitRef="usd">-670000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-305" decimals="-3" id="f-2338" unitRef="usd">0</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-306" decimals="-3" id="f-2339" unitRef="usd">-670000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-301" decimals="-3" id="f-2340" unitRef="usd">-3956000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-302" decimals="-3" id="f-2341" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-303" decimals="-3" id="f-2342" unitRef="usd">-3956000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-304" decimals="-3" id="f-2343" unitRef="usd">7314000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-305" decimals="-3" id="f-2344" unitRef="usd">-160000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-306" decimals="-3" id="f-2345" unitRef="usd">7154000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-301" decimals="-3" id="f-2346" unitRef="usd">-807000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-302" decimals="-3" id="f-2347" unitRef="usd">26000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-303" decimals="-3" id="f-2348" unitRef="usd">-781000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-304" decimals="-3" id="f-2349" unitRef="usd">-850000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-305" decimals="-3" id="f-2350" unitRef="usd">72000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-306" decimals="-3" id="f-2351" unitRef="usd">-778000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-301" decimals="-3" id="f-2352" unitRef="usd">-9710000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-302" decimals="-3" id="f-2353" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-303" decimals="-3" id="f-2354" unitRef="usd">-9710000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-304" decimals="-3" id="f-2355" unitRef="usd">-7471000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-305" decimals="-3" id="f-2356" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-306" decimals="-3" id="f-2357" unitRef="usd">-7471000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-301" decimals="-3" id="f-2358" unitRef="usd">327000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-302" decimals="-3" id="f-2359" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-303" decimals="-3" id="f-2360" unitRef="usd">327000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-304" decimals="-3" id="f-2361" unitRef="usd">109000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-305" decimals="-3" id="f-2362" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-306" decimals="-3" id="f-2363" unitRef="usd">109000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-301" decimals="-3" id="f-2364" unitRef="usd">-327000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-302" decimals="-3" id="f-2365" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-303" decimals="-3" id="f-2366" unitRef="usd">-327000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-304" decimals="-3" id="f-2367" unitRef="usd">-109000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-305" decimals="-3" id="f-2368" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-306" decimals="-3" id="f-2369" unitRef="usd">-109000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-301" decimals="-3" id="f-2370" unitRef="usd">17256000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-302" decimals="-3" id="f-2371" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-303" decimals="-3" id="f-2372" unitRef="usd">17256000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-304" decimals="-3" id="f-2373" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-305" decimals="-3" id="f-2374" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-306" decimals="-3" id="f-2375" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-301" decimals="-3" id="f-2376" unitRef="usd">8706000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-302" decimals="-3" id="f-2377" unitRef="usd">0</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-303" decimals="-3" id="f-2378" unitRef="usd">8706000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-304" decimals="-3" id="f-2379" unitRef="usd">1698000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-305" decimals="-3" id="f-2380" unitRef="usd">0</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering contextRef="c-306" decimals="-3" id="f-2381" unitRef="usd">1698000</cdtx:ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-301" decimals="-3" id="f-2382" unitRef="usd">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-302" decimals="-3" id="f-2383" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-303" decimals="-3" id="f-2384" unitRef="usd">14000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-304" decimals="-3" id="f-2385" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-305" decimals="-3" id="f-2386" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-306" decimals="-3" id="f-2387" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-301" decimals="-3" id="f-2388" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-302" decimals="-3" id="f-2389" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-303" decimals="-3" id="f-2390" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-304" decimals="-3" id="f-2391" unitRef="usd">720000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-305" decimals="-3" id="f-2392" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-306" decimals="-3" id="f-2393" unitRef="usd">720000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-301" decimals="-3" id="f-2394" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-302" decimals="-3" id="f-2395" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-303" decimals="-3" id="f-2396" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-304" decimals="-3" id="f-2397" unitRef="usd">2593000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-305" decimals="-3" id="f-2398" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-306" decimals="-3" id="f-2399" unitRef="usd">2593000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-301" decimals="-3" id="f-2400" unitRef="usd">25976000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-302" decimals="-3" id="f-2401" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-303" decimals="-3" id="f-2402" unitRef="usd">25976000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-304" decimals="-3" id="f-2403" unitRef="usd">-1615000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-305" decimals="-3" id="f-2404" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-306" decimals="-3" id="f-2405" unitRef="usd">-1615000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-301" decimals="-3" id="f-2406" unitRef="usd">15939000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-302" decimals="-3" id="f-2407" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-303" decimals="-3" id="f-2408" unitRef="usd">15939000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-304" decimals="-3" id="f-2409" unitRef="usd">-9195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-305" decimals="-3" id="f-2410" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-306" decimals="-3" id="f-2411" unitRef="usd">-9195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-44" decimals="-3" id="f-2412" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-45" decimals="-3" id="f-2413" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-2414" unitRef="usd">32731000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-60" decimals="-3" id="f-2415" unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-61" decimals="-3" id="f-2416" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-2417" unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-265" decimals="-3" id="f-2418" unitRef="usd">48670000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-266" decimals="-3" id="f-2419" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-267" decimals="-3" id="f-2420" unitRef="usd">48670000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-268" decimals="-3" id="f-2421" unitRef="usd">53078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-269" decimals="-3" id="f-2422" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-270" decimals="-3" id="f-2423" unitRef="usd">53078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-301" decimals="-3" id="f-2424" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-302" decimals="-3" id="f-2425" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-303" decimals="-3" id="f-2426" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-304" decimals="-3" id="f-2427" unitRef="usd">40000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-305" decimals="-3" id="f-2428" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-306" decimals="-3" id="f-2429" unitRef="usd">40000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-301" decimals="-3" id="f-2430" unitRef="usd">651000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-302" decimals="-3" id="f-2431" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-303" decimals="-3" id="f-2432" unitRef="usd">651000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-304" decimals="-3" id="f-2433" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-305" decimals="-3" id="f-2434" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-306" decimals="-3" id="f-2435" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-301" decimals="-3" id="f-2436" unitRef="usd">178000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-302" decimals="-3" id="f-2437" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-303" decimals="-3" id="f-2438" unitRef="usd">178000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-304" decimals="-3" id="f-2439" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-305" decimals="-3" id="f-2440" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-306" decimals="-3" id="f-2441" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-301" decimals="-3" id="f-2442" unitRef="usd">3847000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-302" decimals="-3" id="f-2443" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-303" decimals="-3" id="f-2444" unitRef="usd">3847000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-304" decimals="-3" id="f-2445" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-305" decimals="-3" id="f-2446" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-306" decimals="-3" id="f-2447" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-301" decimals="-3" id="f-2448" unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-302" decimals="-3" id="f-2449" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-303" decimals="-3" id="f-2450" unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-304" decimals="-3" id="f-2451" unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-305" decimals="-3" id="f-2452" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-306" decimals="-3" id="f-2453" unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-301" decimals="-3" id="f-2454" unitRef="usd">0</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-302" decimals="-3" id="f-2455" unitRef="usd">0</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-303" decimals="-3" id="f-2456" unitRef="usd">0</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-304" decimals="-3" id="f-2457" unitRef="usd">10000</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-305" decimals="-3" id="f-2458" unitRef="usd">0</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets contextRef="c-306" decimals="-3" id="f-2459" unitRef="usd">10000</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesOtherCurrentAssetsAndOtherAssets>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-22"
      decimals="INF"
      id="f-2460"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-2461" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-2462"
      unitRef="shares">72470440</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-2463" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-2464" unitRef="usd">404055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-2465" unitRef="usd">-418500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-2466" unitRef="usd">-14438000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-307"
      decimals="INF"
      id="f-2467"
      unitRef="shares">286000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-308"
      decimals="INF"
      id="f-2468"
      unitRef="shares">11086000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-308" decimals="-3" id="f-2469" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-309" decimals="-3" id="f-2470" unitRef="usd">17255000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-310" decimals="-3" id="f-2471" unitRef="usd">17256000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-311"
      decimals="INF"
      id="f-2472"
      unitRef="shares">6158799</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-311" decimals="-3" id="f-2473" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-312" decimals="-3" id="f-2474" unitRef="usd">8621000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-313" decimals="-3" id="f-2475" unitRef="usd">8622000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-314"
      decimals="INF"
      id="f-2476"
      unitRef="shares">16250</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-315" decimals="-3" id="f-2477" unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-279" decimals="-3" id="f-2478" unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-314"
      decimals="INF"
      id="f-2479"
      unitRef="shares">293073</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-315" decimals="-3" id="f-2480" unitRef="usd">640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-279" decimals="-3" id="f-2481" unitRef="usd">640000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-316" decimals="-3" id="f-2482" unitRef="usd">3013000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-279" decimals="-3" id="f-2483" unitRef="usd">3013000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-317"
      decimals="INF"
      id="f-2484"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-317" decimals="-3" id="f-2485" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-318"
      decimals="INF"
      id="f-2486"
      unitRef="shares">90024562</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-318" decimals="-3" id="f-2487" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-319" decimals="-3" id="f-2488" unitRef="usd">430585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-320" decimals="-3" id="f-2489" unitRef="usd">-415487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-244" decimals="-3" id="f-2490" unitRef="usd">15107000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-321"
      decimals="INF"
      id="f-2491"
      unitRef="shares">60942</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-322" decimals="-3" id="f-2492" unitRef="usd">76000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-323" decimals="-3" id="f-2493" unitRef="usd">76000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-324"
      decimals="INF"
      id="f-2494"
      unitRef="shares">4875</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-324"
      decimals="INF"
      id="f-2495"
      unitRef="shares">161367</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-325" decimals="-3" id="f-2496" unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-285" decimals="-3" id="f-2497" unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-325" decimals="-3" id="f-2498" unitRef="usd">795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-285" decimals="-3" id="f-2499" unitRef="usd">795000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-326" decimals="-3" id="f-2500" unitRef="usd">-13624000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-285" decimals="-3" id="f-2501" unitRef="usd">-13624000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-327"
      decimals="INF"
      id="f-2502"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-327" decimals="-3" id="f-2503" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-328"
      decimals="INF"
      id="f-2504"
      unitRef="shares">90251746</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-328" decimals="-3" id="f-2505" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-329" decimals="-3" id="f-2506" unitRef="usd">431519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-330" decimals="-3" id="f-2507" unitRef="usd">-429111000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-2" decimals="-3" id="f-2508" unitRef="usd">2417000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-331"
      decimals="INF"
      id="f-2509"
      unitRef="shares">164198</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-332" decimals="-3" id="f-2510" unitRef="usd">796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-297" decimals="-3" id="f-2511" unitRef="usd">796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-333" decimals="-3" id="f-2512" unitRef="usd">-9107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-297" decimals="-3" id="f-2513" unitRef="usd">-9107000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-334"
      decimals="INF"
      id="f-2514"
      unitRef="shares">2104472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-334" decimals="-3" id="f-2515" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-335"
      decimals="INF"
      id="f-2516"
      unitRef="shares">90415944</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-335" decimals="-3" id="f-2517" unitRef="usd">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-336" decimals="-3" id="f-2518" unitRef="usd">432315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-337" decimals="-3" id="f-2519" unitRef="usd">-438218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-267" decimals="-3" id="f-2520" unitRef="usd">-5894000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-9"
      decimals="INF"
      id="f-2521"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-2522" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-2523"
      unitRef="shares">67863674</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-2524" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-2525" unitRef="usd">398013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-2526" unitRef="usd">-384916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-2527" unitRef="usd">13104000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-338"
      decimals="INF"
      id="f-2528"
      unitRef="shares">644265</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-339" decimals="-3" id="f-2529" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-340" decimals="-3" id="f-2530" unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-341"
      decimals="INF"
      id="f-2531"
      unitRef="shares">541308</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-342" decimals="-3" id="f-2532" unitRef="usd">1165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-282" decimals="-3" id="f-2533" unitRef="usd">1165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-343" decimals="-3" id="f-2534" unitRef="usd">-18474000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-282" decimals="-3" id="f-2535" unitRef="usd">-18474000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-344"
      decimals="INF"
      id="f-2536"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-344" decimals="-3" id="f-2537" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-345"
      decimals="INF"
      id="f-2538"
      unitRef="shares">69049247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-345" decimals="-3" id="f-2539" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-346" decimals="-3" id="f-2540" unitRef="usd">399678000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-347" decimals="-3" id="f-2541" unitRef="usd">-403390000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-247" decimals="-3" id="f-2542" unitRef="usd">-3705000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-348"
      decimals="INF"
      id="f-2543"
      unitRef="shares">5042</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-348"
      decimals="INF"
      id="f-2544"
      unitRef="shares">184219</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-349" decimals="-3" id="f-2545" unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-288" decimals="-3" id="f-2546" unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-349" decimals="-3" id="f-2547" unitRef="usd">852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-288" decimals="-3" id="f-2548" unitRef="usd">852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-350" decimals="-3" id="f-2549" unitRef="usd">-15759000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-288" decimals="-3" id="f-2550" unitRef="usd">-15759000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-351"
      decimals="INF"
      id="f-2551"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-351" decimals="-3" id="f-2552" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-352"
      decimals="INF"
      id="f-2553"
      unitRef="shares">69238508</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-352" decimals="-3" id="f-2554" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-353" decimals="-3" id="f-2555" unitRef="usd">400599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-354" decimals="-3" id="f-2556" unitRef="usd">-419149000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-258" decimals="-3" id="f-2557" unitRef="usd">-18543000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-355"
      decimals="INF"
      id="f-2558"
      unitRef="shares">1664170</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-356" decimals="-3" id="f-2559" unitRef="usd">1208000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-357" decimals="-3" id="f-2560" unitRef="usd">1208000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-358"
      decimals="INF"
      id="f-2561"
      unitRef="shares">278519</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-359" decimals="-3" id="f-2562" unitRef="usd">842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c-300" decimals="-3" id="f-2563" unitRef="usd">842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c-360" decimals="-3" id="f-2564" unitRef="usd">14246000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-300" decimals="-3" id="f-2565" unitRef="usd">14246000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-361"
      decimals="INF"
      id="f-2566"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-361" decimals="-3" id="f-2567" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-362"
      decimals="INF"
      id="f-2568"
      unitRef="shares">71181197</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-362" decimals="-3" id="f-2569" unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-363" decimals="-3" id="f-2570" unitRef="usd">402649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-364" decimals="-3" id="f-2571" unitRef="usd">-404903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-270" decimals="-3" id="f-2572" unitRef="usd">-2247000</us-gaap:StockholdersEquity>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-2573">SUBSEQUENT EVENTS&lt;div style="margin-top:15pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the Company&#x2019;s special meeting of stockholders held on April 4, 2024, the Company&#x2019;s stockholders approved a proposal to (i) amend the Company&#x2019;s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company&#x2019;s outstanding common stock at a ratio in the range of 1-for-10 to 1-for-30, inclusive; and (ii) if and only if the reverse stock split is approved and implemented, a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the reverse stock split ratio, with such ratio to be determined in the discretion of the Company&#x2019;s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company&#x2019;s board of directors in its sole discretion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On April 12, 2024, the Company&#x2019;s board of directors approved a reverse stock split of all outstanding shares of the Company&#x2019;s common stock at a ratio of 1-for-20, or the Reverse Stock Split. The Company&#x2019;s board of directors also approved a reduction in the number of authorized shares of common stock, at a ratio that is equal to half of the Reverse Stock Split ratio. On April 22, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Amended and Restated Certificate of Incorporation to effect the Reverse Stock Split. As of the date of this filing, the Reverse Stock Split was not effective as trading on the Nasdaq Capital Market did not reflect the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;All shares and per share information presented in these consolidated financial statements does not reflect the upcoming Reverse Stock Split. As of December 31, 2023, adjusting for the Reverse Stock Split will decrease the total number of the Company&#x2019;s authorized shares of common stock from 200,000,000 to 20,000,000; will decrease the number of issued and outstanding shares of common stock from 90,601,999 to approximately 4,530,099; and will decrease the number of outstanding warrants from 17,331 to 866 and will change the exercise price on these warrants from $11.54 to $230.95.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information presents the Company&#x2019;s basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(22,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(9.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,371,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,492,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-365"
      decimals="INF"
      id="f-2574"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-366"
      decimals="INF"
      id="f-2575"
      unitRef="shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-365"
      decimals="INF"
      id="f-2576"
      unitRef="shares">90601999</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-365"
      decimals="INF"
      id="f-2577"
      unitRef="shares">90601999</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-366"
      decimals="INF"
      id="f-2578"
      unitRef="shares">4530099</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-366"
      decimals="INF"
      id="f-2579"
      unitRef="shares">4530099</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-365"
      decimals="INF"
      id="f-2580"
      unitRef="shares">17331</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-366"
      decimals="INF"
      id="f-2581"
      unitRef="shares">866</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-365"
      decimals="2"
      id="f-2582"
      unitRef="usdPerShare">11.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-366"
      decimals="2"
      id="f-2583"
      unitRef="usdPerShare">230.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-2584">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma financial information presents the Company&#x2019;s basic and diluted net loss per share upon effectiveness of the Reverse Stock Split for the periods indicated (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;As Restated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net loss and comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(22,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(33,584)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(5.25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(9.61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Shares used to compute basic and diluted net loss per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;4,371,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,492,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-367" decimals="-3" id="f-2585" unitRef="usd">-22931000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-367" decimals="-3" id="f-2586" unitRef="usd">-22931000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-368" decimals="-3" id="f-2587" unitRef="usd">-33584000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-368" decimals="-3" id="f-2588" unitRef="usd">-33584000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-367"
      decimals="2"
      id="f-2589"
      unitRef="usdPerShare">-5.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-367"
      decimals="2"
      id="f-2590"
      unitRef="usdPerShare">-5.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-368"
      decimals="2"
      id="f-2591"
      unitRef="usdPerShare">-9.61</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-368"
      decimals="2"
      id="f-2592"
      unitRef="usdPerShare">-9.61</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="c-367"
      decimals="0"
      id="f-2593"
      unitRef="shares">4371371</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-367"
      decimals="0"
      id="f-2594"
      unitRef="shares">4371371</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="c-368"
      decimals="0"
      id="f-2595"
      unitRef="shares">3492884</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-368"
      decimals="0"
      id="f-2596"
      unitRef="shares">3492884</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:AuditorFirmId contextRef="c-1" id="f-2598">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
